<SEC-DOCUMENT>0001367644-23-000088.txt : 20230510
<SEC-HEADER>0001367644-23-000088.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230509175112
ACCESSION NUMBER:		0001367644-23-000088
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		103
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emergent BioSolutions Inc.
		CENTRAL INDEX KEY:			0001367644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				141902018
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33137
		FILM NUMBER:		23903611

	BUSINESS ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-631-3200

	MAIL ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ebs-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:da57861a-e185-4b6f-8b91-f9335b77a88a,g:0a9819bf-1d2f-49f0-b0b7-eedd5e464486,d:9481dacf30bb4098a06bd54f3af5a34a--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ebs="http://emergentbiosolutions.com/20230331" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ebs-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80L2ZyYWc6NjIzNTdjZjQ5MzAwNDBlZGEwZTQ3NjdjOWYwMDQ4MzAvdGFibGU6OTUyYzg0MTY5OGJlNGQ4OGE0MmFmNmExMzc4Mjc0MDYvdGFibGVyYW5nZTo5NTJjODQxNjk4YmU0ZDg4YTQyYWY2YTEzNzgyNzQwNl8zLTEtMS0xLTE3NDA5MA_4e6be801-969e-4031-97e0-fb751bbba7f9">0001367644</ix:nonNumeric><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80L2ZyYWc6NjIzNTdjZjQ5MzAwNDBlZGEwZTQ3NjdjOWYwMDQ4MzAvdGFibGU6OTUyYzg0MTY5OGJlNGQ4OGE0MmFmNmExMzc4Mjc0MDYvdGFibGVyYW5nZTo5NTJjODQxNjk4YmU0ZDg4YTQyYWY2YTEzNzgyNzQwNl80LTEtMS0xLTE3NDA5MA_b1574acf-4f73-4a58-a0a6-320ba05a1c22">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80L2ZyYWc6NjIzNTdjZjQ5MzAwNDBlZGEwZTQ3NjdjOWYwMDQ4MzAvdGFibGU6OTUyYzg0MTY5OGJlNGQ4OGE0MmFmNmExMzc4Mjc0MDYvdGFibGVyYW5nZTo5NTJjODQxNjk4YmU0ZDg4YTQyYWY2YTEzNzgyNzQwNl8xMC0xLTEtMS0xNzQwOTA_207dabbb-f7b4-4983-813d-bfee17679a9f">false</ix:nonNumeric><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80L2ZyYWc6NjIzNTdjZjQ5MzAwNDBlZGEwZTQ3NjdjOWYwMDQ4MzAvdGFibGU6OTUyYzg0MTY5OGJlNGQ4OGE0MmFmNmExMzc4Mjc0MDYvdGFibGVyYW5nZTo5NTJjODQxNjk4YmU0ZDg4YTQyYWY2YTEzNzgyNzQwNl8xMi0xLTEtMS0xNzQwOTA_7e2eaf7b-d491-486c-8300-6582a6ce2f4e">2023</ix:nonNumeric><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80L2ZyYWc6NjIzNTdjZjQ5MzAwNDBlZGEwZTQ3NjdjOWYwMDQ4MzAvdGFibGU6OTUyYzg0MTY5OGJlNGQ4OGE0MmFmNmExMzc4Mjc0MDYvdGFibGVyYW5nZTo5NTJjODQxNjk4YmU0ZDg4YTQyYWY2YTEzNzgyNzQwNl8xMy0xLTEtMS0xNzQwOTA_c8920cb3-0219-43f5-bb31-09fb8a0114ca">Q1</ix:nonNumeric><ix:nonNumeric contextRef="icaeda5c9c6b540f5bb7a60baecd1d9b2_D20200807-20200807" name="ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82MS9mcmFnOjUyNjNkM2U4ZmNhNzQ2YjhhN2MzMmFhYTFmYjBkMDUzL3RleHRyZWdpb246NTI2M2QzZThmY2E3NDZiOGE3YzMyYWFhMWZiMGQwNTNfMzIx_94f7ee9f-d39f-4471-866a-c9cf1baa9a9e">12</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i7bb83926187b4279b16006f3f7fb2ab1_D20230101-20230331" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMS0xLTEtMS0xNzQwOTA_ee155303-6849-458c-bc9a-064105f232e8">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i2f45a7313b224629804838fb75fad240_D20230101-20230331" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMS0yLTEtMS0xNzQwOTA_a833e2e6-4527-4de4-8c37-aa1d810060d2">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i1fad61803b4d40fbab45263d09fa943a_D20230101-20230331" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMi0xLTEtMS0xNzQwOTA_ac4f06c7-9998-43a5-8151-9b36b165dc9c">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i2b14f3e18ba4492ba6a39464c8dbffda_D20230101-20230331" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMi0yLTEtMS0xNzQwOTA_9bceb940-1c10-4600-95c7-7d1a14cf1da1">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i147235e355704bc1902c80160146ae9b_D20230101-20230331" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMy0xLTEtMS0xNzQwOTA_fb817a40-687a-4aa9-b42e-6a53fcad4690">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i72844a727a4940a0a5b4f18cc4afb0ec_D20230101-20230331" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMy0yLTEtMS0xNzQwOTA_b4356db1-881d-4671-87bd-afada4e061e4">33.33</ix:nonFraction><ix:nonNumeric contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_2bbfbc2c-d247-4e2c-8c4a-1c01ee6c8aa2">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_7baa0cdf-0d92-4228-afaa-c3228f02be7a">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_1145e4f7-1aec-4074-98e1-3ac124493f0e">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_d44d3959-2bf6-46da-bfab-b74e748a5df1">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_3c68e61a-e113-4e32-8721-bdace66fd926">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_9da09783-cbaa-40ca-9a98-b6bc1f730f8f">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ebs-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88874a031ee64129abddf35ef51b22ec_I20230502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i960cf41acb8b4188a01129fbd602dc88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8bac9a933b6d4e1f906de2a6a7325d62_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96983ae20d1a4fd892a5f1444783a570_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e052da12c34e0e91cf56a39cd08cd1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i513c1b52eb2e4d47828f3ec0440d9a1a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79e134d107e94e148da24dade40b12b6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8373489620694e8096c4d7cb76a601a2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i282b3d80373a44448dcd835b4ec3dd02_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fcbd10db46849358e569878c1ae8ae0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5222cf971340bab0614a17ebbf5ed8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d4fc9a55e4b49afb88321e52246a468_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a099fddd1d84c7d879062f83fca8e8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i953f447150654f76b7cc01b3726027f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if638389216994724b23bca4d31679eb8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e44cdd29cc9499e9a66348b41656de5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i849666feb2a44d2fa12bc7967461f166_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8b4fd4e61c64973a212a85c54c0ebfd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if51069b7c708450e883968233c7b1100_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i082e5f03a9d2471da47571c1adea47c0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e9d567e96ac4140ac247d74d68d020a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i497afa8d2afd4248a986014e9fa76586_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7692443ac57041479453a23b16bf3759_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d0eaabe911a4ba4b4d72bc7370d9dc9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i613917f0ad0b475e99daeb4f7102a659_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d83f154114044a1bbe6ae3c214f52d4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54a6e4454a964795b8edeb5a00bdfc7a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c1de96d7b3145dfbc133d2bb6a68cf5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie210714807324475943299c21e7d8fbc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife892d5886074c32ab62a900867615d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id730fb1f570643e09406bfe6aebe15ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0c52e66b26e4a1896b467cc5a122d9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdfa38102e80436a8a1a8bf7681229d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ce03bb85346406d822354b0c6ab920f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf01802184ad4612ab0690e8efff37c0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31244a3a054948c88dabb06cdf5a93c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03aa139c772549d8844c18ac3d48d451_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4912cf676c54fd1a8050521892e67c6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1caaf133e6f74cabaebe862b712e4d3f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i974ccd2c2487469c941cfc01885a5b62_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9426132f4f814179b20fee2cb4d853f7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b10b20be474bf0bb98ab88bd4310f2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="category"><xbrli:measure>ebs:category</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>ebs:product</xbrli:measure></xbrli:unit><xbrli:unit id="productcandidate"><xbrli:measure>ebs:productCandidate</xbrli:measure></xbrli:unit><xbrli:unit id="category2"><xbrli:measure>ebs:Category</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ebs:segment</xbrli:measure></xbrli:unit><xbrli:context id="i822b4db8d3a940d2a307f01f1a9c52ed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b4a69b4f7e640dc9de146fd74f4ac6a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7237bcbb75b9405287fe50d45561e97f_D20230401-20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>ebs:employee</xbrli:measure></xbrli:unit><xbrli:context id="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i81c28e226ee545b286e49388a057533c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c9842bc063446586bea2405cf33206_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff2f736d0b84c82b69da3ae149c3877_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90160f3d0ce54037a7e491254512bf65_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4f9663fd12b4d8484ab91cd3165ab5f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d94d342fe9f478da83d206f54833e08_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i624499c702f2496996732d4f547a1882_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic516a1f410604d7db3e1ff143e87a7b1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd5bdd8d49c244448c14a689d71f1025_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84af060aae1748fbbaa67887f4b7dbcd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3d2e8509aab4186a3c6aa464c1d4d74_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i469c99f1aa3e49068c75ef98b7a985dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75626974e4ff4354ae25be0a61b75c46_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad162e2c548e417d957ea777b298e0d2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32b120655ff64d55a24337355f419f4f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89d77487aec94b21a79a891c0bdda7bc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4331c0bdb2464807b4afa3f5612e3dad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib52346ef764e49d7ae1d0de332535d80_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0029254369834e77ba355f9f9212091d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04382820c4b94237b445c43c5180113d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib46720b3fc2644378640e7ecb3eaff6c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6246980b9314b79820f3539a51fe388_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e4c69e4ac943b990497e0161be6d0a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0622ee9b0854a68821bf3319e45908f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id84508c19f22426e8d7a7d283878a833_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i338e967572ba42808fef537a31e71be4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f4212f3132341cf84f6c7de6e063ded_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4232914f6124a5e9828197daee03b72_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ad12ca119f497ab07833d15fda564a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie47c273b662b4a1892d60f7abfa2f3ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f1b2dc03074501a7307fb35e98698e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2cfce5e9fe14623a73853fac221b591_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i949bce8b04694470a4528f867f0e10cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa639b8052ec4dfd86c079463f947791_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i941ca3dc089c4dac89d3aced14c53f5b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fa7094242a244a5b9b80db78bdbc0d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d248c38e3394ed5bd6f6e4cda0f9c56_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb147a1d8ee745288cc6b591771da65f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db14af93756495bb396ad2850eb791d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iced1288bc5d94738bdeb41c7ef631b5a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2678670ef0614327a8e6d3ba7f775ffe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i312fc4d3fa3d40a8b8d40b165fac9f23_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe6faf4ab404b7eaeb1185f253fdc6d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237d46bcc69045b68b66b29364f7c338_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575796b9fe234a88851410d4452a2542_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b9542ada7984655be665a722b9ac8b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c9b39689c8b4daabd9ce8b4ca48f1fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i087f2351596c4d7aaa0c69f2847ad606_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a4bf125ea1426898eefe90abf2468b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b76ca7b5a934284bb3f69ae4eac313f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63a4559b34534083bbc78a87767ff732_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6de70121c46438aa85618bf326f814d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676d5ac2770d4880b80e8f9affcc0405_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab0b615be15c41e492c20d99095ebd67_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846c202a9d2c465a8eaa59bba8fb61d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa141f63b241430bb8414182bb967b11_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecb9b277674f497f94bb0ad15086a2d1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9da03b4151704bc0b9cd5c7932118c29_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07bc53a7e37d4103b284a544dfaee08f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10bc8bb2a2354813ac6212066587b081_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28872533ff2f45f8afc92cc4728820d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8dd4d6dd4734137a3740ddea65d8249_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c6e639de504e66bd14ca1b9f011604_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba6b2f3fd2d4feba5acceb8d159572c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2adc9adb687d4dc4a6c4288252be0818_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityOfPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a1c5f04948a4ba69680ad3fa0b5fe08_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityOfPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i542cdb35121f4951af58b7c4d099cc0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib979976208634b5c8e0a9ae50b18d4cb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8751da105fac4730bbdbaffce144fb47_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c80cc2623ec43ee87f691cd40d2b03c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="instrument"><xbrli:measure>ebs:instrument</xbrli:measure></xbrli:unit><xbrli:context id="i1f157297decc4c27a1eb9955ddfbb47b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48a3c046c3a04962bc32bb21e900d52f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i263ac071f3a94b6cb410cb5275bfd042_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa715f99b2c046f29b82294c4c8cf1bd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id194daf24cf04654893b13c8dd06a8ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52702739ed104778bc9a6b44dbd6a56c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacaf8ffa11674dc59342790fd0bd5b42_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb39b7b0e50a41899b13e8e7a176cb73_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b6cd7196060498f8905b788318223e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a4e68384fff4fba80f54b1741dcdea3_I20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b6c423aa64e4e4896e0475d47d5f2cb_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78876bbef2be40f0b38c6232f78ff57d_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf16d55ed5643cb9ac1bebbf0f1c165_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b04150f100345e5b7d1dba860fc021b_I20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3e55eef26f54a4894de8f45425d8253_I20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4918ce9801c5412b8cd5dd6bf028c13e_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i254adee00af34c94bbc5984b0bfbe52e_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedb6ef8e0b6b46208f6e01be5daa2b80_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d8a56f631634a619610a599c7700384_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if513d33ee9754a8db7bc70bffe5355a8_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2890fd9ac6bc4bceb48adb41f2e0e88c_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide27297d8c9443f09185ce0447397db4_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c8865dca0b4780ad587e383427e48b_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaeda5c9c6b540f5bb7a60baecd1d9b2_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1dc2e31750040a4aeea787dbc908607_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cc418bd58f7472abd99705c9a2a8c70_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c48770f38cc4b868dfb8e4164c70c6d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f2abaf2d65647afabbaad4036b4002b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a17055fb3844751ba1ee5905c41696a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c648afc26c64c1cb1d06fba7976dd3e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i052a8c8b494f4d23ba4683eec555cd78_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7b2c1680b344a52a7479ff1cb61e234_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i352e9c64d26145bd8c991621254ab36d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f4af96e200044a4bde5f4e7858cea4c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3820b0b0d3c345288eeffbe32298f81f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a35abf804794f0cb7a12ca90e436e2b_I20211111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a932e200f934b2e8d7602dfc0339fbe_D20211111-20221111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-11</xbrli:startDate><xbrli:endDate>2022-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib39593e9eeaa410eb010f609006439d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i571387e1e87d4c0ca79fba6168341392_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8456a4beddae4620b224ffe90a753930_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e2cc2fa38f451983e4495ebddf4541_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96351882c9cf4a119573f21d2fd9c69c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia07411d977084f2bb9e23d05b7a3e72f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8cf4c3b78864ea8b78309b616ed410d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i004ed59fdb204528af83813c202f2349_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied3e0a962bf84f89a49887476428ac94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f133842273b47d8a0e0c8008c0debc9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1df6434f4c741debcb5c66e3f358e12_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecaf90f0f80546248e7c187071884007_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691f830478c747349de4e41c45528d98_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eb60b9b64b04e06af66a990c3c77632_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bb83926187b4279b16006f3f7fb2ab1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f45a7313b224629804838fb75fad240_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fad61803b4d40fbab45263d09fa943a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b14f3e18ba4492ba6a39464c8dbffda_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i147235e355704bc1902c80160146ae9b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72844a727a4940a0a5b4f18cc4afb0ec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f98df3f96494ca3af0b6134b79f6e6c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i732a446dfeda451387df581fcd0cfb6e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id50de4745d3a466eafedae511bbe57f3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ed128aa8d4847bd8d098b42c1c2112a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a7228c4c4da4a3daa277c2e60ff556d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc9f8df6d25942899d6f3695ef5c6172_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i987753cf494a4b45ace898c7942aef7c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5383a292c962418f9b059d0b06839b4e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie421a9cb2b954cbca8c8c507c55fd2bd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95813f0ec62d4d0c9fcc5789b0837330_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d187bce987143dc92586a3d08ecacd6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id10f475f516846bcae44f6b46b3bbd0b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab03b11d81254786a5977fced794e6b1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i871dc7a154524d879334cb879c7ddfd0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3379cc28cb04ee5bececd01664b6872_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4efd920943c8420a8281d18b9639ad0e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib83a1dda4ddc4ccdad92792fb6b17c46_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c77354994dd4d71ac100d180641d494_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9415e748067844bfbe9ef3caeb28bad0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f4207af8e54989a266f7659a215b5e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff58dd309a0441e3b97192aae2d95c4f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd7432d9b0914c74aee8b459bf887d15_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f3699777f34efe88b689e5c3e48b90_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39d08b46e2f94f58a5f1e2935eeece69_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4294703259534cdcbbf6f3c0f104718b_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id18cb2b8881b4956ac5446f313a06aa4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae2ab95b86444d45b4d488934aae7ce6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide9ab2059eb245668f1987b63208f7e7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib40925538fdf41e1b15aa28d2dffd833_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e936994b3b439dae281f549affd0f1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dd32b195d7e4239a60662ca51d6ee42_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsAndServicesSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i918438631165446c9ba9921f135d6a33_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsAndServicesSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81a432e8a0bd409aabe9374107df1be3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i994e594bda11477a97c710abd0cf5e86_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODMz_8f142fad-fbe7-461b-9d0a-a3885510031b">10-Q</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:0.1%"></td><td style="width:2.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NjgwNjIzMWM5M2ViNDA2NWEwNDZmMjk0ZWU1Mzk1YmMvdGFibGVyYW5nZTo2ODA2MjMxYzkzZWI0MDY1YTA0NmYyOTRlZTUzOTViY18wLTAtMS0xLTE3NDA5MA_95dbc491-53b2-4711-a5a2-13c9bde6ab1e">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8yMTk5MDIzMjYxMjc5_700ae287-09b9-4702-bc15-82e47f4a744a">March&#160;31, 2023</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.194%"><tr><td style="width:0.1%"></td><td style="width:2.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NzhkZmUwMWI4MDRkNDUwZGJiZWU0ZGNmN2I0ODU5NDMvdGFibGVyYW5nZTo3OGRmZTAxYjgwNGQ0NTBkYmJlZTRkY2Y3YjQ4NTk0M18wLTAtMS0xLTE3NDA5MA_acde85d3-331d-4812-8a52-e383ce6c7713">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from    to        </span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission file number: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM2_18289c08-917c-4e49-8087-e879c123deed">001-33137</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><img src="ebs-20230331_g1.jpg" alt="emergent logo gray + carmine  r.jpg" style="height:20px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM3_01d17204-9280-4089-93d3-95e5523f1a2a">EMERGENT BIOSOLUTIONS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF8wLTAtMS0xLTE3NDA5MA_265e3fb2-8a80-46c8-898d-b35dbc3e2263">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF8wLTItMS0xLTE3NDA5MA_e0e4c2c0-863d-47bf-9b36-8d39fc5d4118">14-1902018</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF8zLTAtMS0xLTE3NDA5MA_4f78440f-9e3f-44f1-a060-f5a49ed33403">400 Professional Drive Suite 400</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF80LTAtMS0xLTE3NDA5MA_3da4fa25-b438-419f-8e4b-fb4f9f86e782">Gaithersburg,</ix:nonNumeric>  </span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF80LTEtMS0xLTE3NDA5MA_e4d9ba2f-bbdc-47ea-aa8f-8355f3fc11af">MD</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF80LTItMS0xLTE3NDA5MA_644d2057-25d0-469f-ad85-093ca15af9a0">20879</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address and zip code of Principal Executive Offices)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM0_f85cbc3c-c58b-4770-9a27-13f77781423d">240</ix:nonNumeric>) <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM4_84cb19af-f607-4716-8909-d82338cdbd97">631-3200</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant's Telephone Number, Including Area Code)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.963%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6MWJhNjAzYjMwNzEwNGRlMGE1N2EyMTViNzcwMGYxZDEvdGFibGVyYW5nZToxYmE2MDNiMzA3MTA0ZGUwYTU3YTIxNWI3NzAwZjFkMV8yLTAtMS0xLTE3NDA5MA_b100b3e5-a250-453d-a08a-aecb1020b023">Common Stock, Par Value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6MWJhNjAzYjMwNzEwNGRlMGE1N2EyMTViNzcwMGYxZDEvdGFibGVyYW5nZToxYmE2MDNiMzA3MTA0ZGUwYTU3YTIxNWI3NzAwZjFkMV8yLTEtMS0xLTE3NDA5MA_1f2fa359-2ab9-47d8-aebd-54c60e7a6f7a">EBS</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6MWJhNjAzYjMwNzEwNGRlMGE1N2EyMTViNzcwMGYxZDEvdGFibGVyYW5nZToxYmE2MDNiMzA3MTA0ZGUwYTU3YTIxNWI3NzAwZjFkMV8yLTItMS0xLTE3NDA5MA_7f3c3179-1690-40f5-8e2e-efd2e6d0f9b6">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#9746; <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM1_9eeeb979-cdb3-4f02-b9d1-a44cbb874fff">Yes</ix:nonNumeric> &#9744; No</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#9746; <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM5_b77c30fd-f44f-453a-be02-b4235d71a912">Yes</ix:nonNumeric> &#9744; No</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"></td><td style="width:41.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NzA2NGYxZDkzMjVlNGI4NGI2ZGMyMGFhNGJmNzJmMWYvdGFibGVyYW5nZTo3MDY0ZjFkOTMyNWU0Yjg0YjZkYzIwYWE0YmY3MmYxZl8wLTAtMS0xLTE3NDA5MA_89315657-22a2-4965-991a-ad0e22bc0e61">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NzA2NGYxZDkzMjVlNGI4NGI2ZGMyMGFhNGJmNzJmMWYvdGFibGVyYW5nZTo3MDY0ZjFkOTMyNWU0Yjg0YjZkYzIwYWE0YmY3MmYxZl8xLTMtMS0xLTE3NDA5MA_7b1b445c-0058-459e-9e45-447913a07b41">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NzA2NGYxZDkzMjVlNGI4NGI2ZGMyMGFhNGJmNzJmMWYvdGFibGVyYW5nZTo3MDY0ZjFkOTMyNWU0Yjg0YjZkYzIwYWE0YmY3MmYxZl8yLTMtMS0xLTE3NDA5MA_cf73bf73-6ee2-45ff-a071-cb216c9d94c0">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODQw_3525ff26-c2f1-46db-b1d1-207f5b617b7a">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;2, 2023 the registrant ha</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="i88874a031ee64129abddf35ef51b22ec_I20230502" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml81NDk3NTU4MTU3NTE_defe86b8-81cd-4365-b6e9-0005e6064b8b">50,447,918</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares of common stock outstanding.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form 10-Q</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_10">Part I. Financial Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_13">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_16">Condensed Consolidated Balance Sheets&#8212;</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_16">March</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_16"> 3</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_16">1</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_16">, 202</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_16">3</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_16"> and December 31, 202</a>2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_19">Condensed Consolidated Statements of Operations&#8212;Three</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_19"> Months Ended </a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_19">March 31</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_19">, 202</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_19">3</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_19"> and 202</a>2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_22">Condensed Consolidated Statements of Comprehensive Income (Loss)&#8212;Three</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_22"> </a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_22">Months Ended </a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_22">March</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_22"> 3</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_22">1</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_22">, 202</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_22">3</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_22"> and 202</a>2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_22">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_25">Condensed Consolidated Statements of Cash Flow</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_25">s</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_25">&#8212;</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_25">Three</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_25"> Months Ended</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_25"> </a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_25">March 31</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_25">, 202</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_25">3</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_25"> and 202</a>2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_28">Condensed Consolidated Statements of Changes in Stockholders' Equity&#8212;Three </a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_28">Months Ended </a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_28">March 31</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_28">, 202</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_28">3</a><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_28"> and 202</a>2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_31">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_94">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_94">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_94">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_118">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_118">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_118">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_121">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_121">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_121">41</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_124">Part II. Other Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_127">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_127">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_127">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_130">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_130">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_130">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_133">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_133">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_133">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_136">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_136">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_136">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_139">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_139">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_139">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_142">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_142">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_142">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_145">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_145">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_145">73</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9481dacf30bb4098a06bd54f3af5a34a_151">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9481dacf30bb4098a06bd54f3af5a34a_151">75</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding our future performance, business strategy, operations, financial position, revenues and earnings, projected costs, prospects, plans and objectives of management and the ongoing impact of the Coronavirus Disease 2019 ("COVID-19") pandemic, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," should," "will," "would," and similar expressions or variations thereof, the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. You should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. You are, therefore, cautioned not to place undue reliance on any forward-looking statement contained herein. Any forward-looking statement speaks only as of the date on which such statement is made and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others:</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the availability of U.S. Government ("USG") funding for contracts related to procurement of our medical countermeasures, including AV7909 (Anthrax Vaccine Adsorbed (AVA), Adjuvanted), BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed) and ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Smallpox (Vaccinia) Vaccine, Live) among others, as well as contracts related to development of medical countermeasures; </span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to meet our commitments to quality and compliance in all of our manufacturing operations;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to negotiate additional USG procurement or follow-on contracts for our medical countermeasures ("MCM") products that have expired or will be expiring;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the commercial availability, including the timing of availability, of over-the-counter NARCAN&#174; (naloxone HCI) Nasal Spray;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the impact of a generic marketplace on NARCAN&#174; (naloxone HCI) Nasal Spray and future NARCAN sales;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to perform under our contracts with the USG, including the timing of and specifications relating to deliveries;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to provide contract development and manufacturing ("CDMO") services for the development and/or manufacture of product and/or product candidates of our customers at required levels and on required timelines;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to negotiate new CDMO contracts and the negotiation of further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing under our existing CDMO contracts;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to collect reimbursement for raw materials and payment of service fees from our CDMO customers;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the results of pending shareholder litigation and government investigations and their potential impact on our business;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to comply with the operating and financial covenants required by our senior secured credit facilities ("Senior Secured Credit Facilities") and the amended and restated credit agreement related to such facilities (as amended, the "Credit Agreement") and our 3.875% Senior Unsecured Notes due 2028 ("Senior Unsecured Notes");</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to refinance our Senior Secured Credit Facilities prior to their maturity in October 2023;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the procurement of our product candidates by USG entities under regulatory authorities that permit government procurement of certain medical products prior to FDA marketing authorization, and corresponding procurement by government entities outside of the U.S.;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the full impact of the COVID-19 pandemic on our markets, operations and employees as well as those of our customers and suppliers;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the impact on our revenues from and duration of declines in sales of our vaccine products that target travelers due to the reduction of international travel caused by the COVID-19 pandemic;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the ability of the Company and Bavarian Nordic to consummate the transactions contemplated under the Purchase and Sale Agreement (the "Sale Agreement") pursuant to which we agreed to sell our travel health business, to meet </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expectations regarding the conditions, timing and completion of the transactions, and to realize the potential benefits of the transactions; </span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the impact of the organizational changes we announced in January 2023;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the impact of cyber security incidents, including the risks from the interruption, failure or compromise of our information systems or those of our business partners, collaborators or other third parties;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the success of our commercialization, marketing and manufacturing capabilities and strategy; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the accuracy of our estimates regarding future revenues, expenses, capital requirements and needs for additional financing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. When evaluating our forward-looking statements, you should consider this cautionary statement along with the risk factors identified elsewhere in this document, including in the sections entitled "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for our fiscal year ended December 31, 2022 and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures about Market Risk" in this Quarterly Report on Form 10-Q, as well as the risks identified in our other reports filed with the SEC. New factors may emerge from time to time, and it is not possible for management to predict all such factors, nor can it assess the impact of any such factor on the business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY REFERENCES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Emergent BioSolutions Inc. and its consolidated subsidiaries.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING TRADE NAMES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BioThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BaciThrax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RSDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trobigard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Anthrasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CNJ-016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ACAM2000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TEMBEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_13"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div><span><br/></span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_16"></div><div><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions, except per share amounts)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">(unaudited)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNC0yLTEtMS0xNzQwOTA_3ed92bbe-effa-49fe-993f-4b7ad70f070f">430.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNC00LTEtMS0xNzQwOTA_a3d7392a-ae95-4329-a2eb-9ff18ee9f7cb">642.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNi0yLTEtMS0xNzQwOTA_75db1f84-7253-4620-8e75-e04c5fa4c193">155.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNi00LTEtMS0xNzQwOTA_8227d196-ae95-411f-ac2c-2976787296df">158.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNy0yLTEtMS0xNzQwOTA_56983838-b673-4fc8-9179-ffe8b853fa2e">367.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNy00LTEtMS0xNzQwOTA_dd72abd6-01da-428c-9de2-4a6a921e1528">351.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOC0yLTEtMS0xNzQwOTA_43dafef6-ce77-400b-81c1-d7ee699394cd">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOC00LTEtMS0xNzQwOTA_d5f4c01a-3656-4147-8b62-aed1fb335fc1">57.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets held for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOS0yLTEtMS0xNzcyNDQ_c510561c-1ec5-4cb1-af58-0419714b0d03">225.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOS00LTEtMS0xNzcyMzA_03a138f2-c7ac-407e-bf0d-d189e947f09d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOS0yLTEtMS0xNzQwOTA_2477c057-46c5-4703-b0c1-a676ee264975">1,221.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOS00LTEtMS0xNzQwOTA_f8b2a541-b203-4f63-bbda-96f96af281bc">1,210.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTEtMi0xLTEtMTc0MDkw_7d1268b6-48f0-43a7-9ffe-ed2d576e7ae7">716.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTEtNC0xLTEtMTc0MDkw_b4d17c15-27c7-4c91-8644-6cca1a8e3bab">817.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTItMi0xLTEtMTc0MDkw_d1bc11e0-97e6-4ba8-ae16-8e01e1c518b0">608.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTItNC0xLTEtMTc0MDkw_0406c878-8273-47ea-b452-842bd0b79b81">728.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTMtMi0xLTEtMTc0MDkw_d6b924e3-92a7-4b38-a990-f3f6f4778f55">218.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTMtNC0xLTEtMTc0MDkw_6c54423c-f7df-4892-a38c-5a26ec50bddd">218.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTQtMi0xLTEtMTc0MDkw_e258ef54-fdd0-4f33-8aee-7ab0b9a5c9fc">184.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTQtNC0xLTEtMTc0MDkw_3d5b8ad2-d144-4a1d-aa2b-81be1af3f90f">191.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTUtMi0xLTEtMTc0MDkw_1ced4ea9-5a29-42bd-8925-c2cbe37687ac">2,949.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTUtNC0xLTEtMTc0MDkw_7a7cbe54-21df-4c67-8e12-228ad2d91e5d">3,166.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTktMi0xLTEtMTc0MDkw_f1da97a6-1622-4006-93bb-182aea691271">124.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTktNC0xLTEtMTc0MDkw_7a71e13c-5905-40ad-bdcc-5afdec09bffe">103.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjAtMi0xLTEtMTc0MDkw_6110cf3a-e45f-4c3b-ae0b-42a9b523b0ad">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjAtNC0xLTEtMTc0MDkw_4099e514-8f26-44ac-b787-660e05489191">34.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjEtMi0xLTEtMTc0MDkw_2035c0b0-389a-4da1-9bf9-c6ab1075a3ab">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjEtNC0xLTEtMTc0MDkw_19079e65-2cb4-4fb9-9369-35d232428d51">88.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt, current portion</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjItMi0xLTEtMTc0MDkw_13963a58-9629-427e-ab81-fa58d6d5a905">950.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjItNC0xLTEtMTc0MDkw_a3781426-e3bf-4bf0-8136-3dea5534816a">957.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjMtMi0xLTEtMTc0MDkw_2ef8f9cd-9ac0-43f6-bd47-472065314808">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjMtNC0xLTEtMTc0MDkw_cfe90234-0cd0-4a7d-bbe3-2e6b306b467d">45.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities held for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjUtMi0xLTEtMTgzNzIy_8151f9a7-e18c-4fc2-9757-f7f4ade18f5e">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjUtNC0xLTEtMTgzNzIy_942a568d-8d9b-4e94-b20d-7c627786e7db">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjQtMi0xLTEtMTc0MDkw_31a1f323-f5bb-45a8-86d4-b42bf99cfece">1,215.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjQtNC0xLTEtMTc0MDkw_0878c9e8-c1a4-4758-8e89-51fb83cb4e80">1,229.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt, net of current portion</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjYtMi0xLTEtMTc0MDkw_e99f557f-5fa4-4137-9f4e-561e97e0dd93">447.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjYtNC0xLTEtMTc0MDkw_7693c437-48b5-4bef-a97f-86cd84ebffde">448.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjctMi0xLTEtMTc0MDkw_e56914a4-5e4b-43d3-abc4-7c1896cf3acc">59.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjctNC0xLTEtMTc0MDkw_9b7e7b29-5c2e-4a58-8567-a6f7a4361c24">71.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjgtMi0xLTEtMTc0MDkw_96f70e8d-6b13-4719-a0eb-867068dcaa11">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjgtNC0xLTEtMTc0MDkw_24635fcd-8137-4c05-9528-4198c2152b66">33.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjktMi0xLTEtMTc0MDkw_253c026c-0216-4256-8205-84330b233296">1,747.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjktNC0xLTEtMTc0MDkw_f5124eba-e8d8-48cd-a10c-676416ba1f2e">1,783.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders' equity:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg2NQ_29f9a2d1-37dd-4c9a-814e-1e293d1e0ae5"><ix:nonFraction unitRef="usdPerShare" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg2NQ_653c9e94-a11b-4ca9-beba-1cfab4892871">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg2OQ_01113c94-5ac1-4106-9331-b05b41b944df"><ix:nonFraction unitRef="shares" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg2OQ_f2cabb4b-8362-4625-9214-f4677c9cf75b">15.0</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg3Mw_0915c235-3524-4f97-8429-749488ff2751"><ix:nonFraction unitRef="shares" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg3Mw_587e9d34-c625-4b66-938a-aaf07518da36"><ix:nonFraction unitRef="shares" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg3Mw_74884d0a-d863-4e32-a90d-d4869ac1c866"><ix:nonFraction unitRef="shares" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg3Mw_edd7eb33-6d26-45bb-a60e-1b49a55a9091">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMi0xLTEtMTc0MDkw_1b1ea12c-c14b-4b52-89ea-b36f1e53f32a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItNC0xLTEtMTc0MDkw_761f8042-0cda-4956-9425-e27f3558a7f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzg5OQ_29b78270-a5a6-48ec-a186-48a2660fed16"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzg5OQ_aa6bdcaa-58c6-4ee0-9b78-3885bb58a109">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkwMw_a8561c9b-5aef-429b-a27a-99796c8baefb"><ix:nonFraction unitRef="shares" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkwMw_b2fde3b6-813b-46bc-bd52-6ffdbd4ea9b4">200.0</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkxNQ_702d2e9b-4133-414e-87dd-761a0970b59b">56.0</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkwNw_473f4723-32a7-4761-9daa-54e23ada144d">55.7</ix:nonFraction> shares issued; <ix:nonFraction unitRef="shares" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkxOQ_cf0b6d8f-279a-4c05-89f0-8328bddc87d3">50.4</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkxMQ_0e574fd8-7b18-4810-93e7-f1520192a1ec">50.1</ix:nonFraction> shares outstanding, respectively</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMi0xLTEtMTc0MDkw_64dc9ecb-f505-4d3c-8ff1-804dfbc7d090">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtNC0xLTEtMTc0MDkw_31e57edb-45f2-4fc2-bb45-6836987096a2">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzQtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZThiMTcwNjZlYWIzNGU5NDllYjEwYTBjY2FlNDY1YjBfMTA5OTUxMTYyNzg0Mw_21b1155e-078c-4a93-97d2-bbadd8767538">5.6</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzQtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZThiMTcwNjZlYWIzNGU5NDllYjEwYTBjY2FlNDY1YjBfMTA5OTUxMTYyNzg1MQ_3c3715ed-f058-4389-89a1-a86f1462e3e2">5.6</ix:nonFraction> common shares, respectively</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzQtMi0xLTEtMTc0MDkw_73e2f59b-82b4-4e17-b17b-53fd0d708f69">227.7</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzQtNC0xLTEtMTc0MDkw_58ac306c-9c36-4e6c-bb92-c5f68bf5a014">227.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzUtMi0xLTEtMTc0MDkw_afd49b66-ded6-4ac2-9455-96c96b845f24">878.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzUtNC0xLTEtMTc0MDkw_8f7e0857-6d62-4610-a78c-83880bda3e8a">873.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzYtMi0xLTEtMTc0MDkw_625fb869-125f-43c4-aa6d-d4657e912e47">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzYtNC0xLTEtMTc0MDkw_6a027b05-d61e-41d1-a411-25a89356c18b">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzctMi0xLTEtMTc0MDkw_273a2ab0-68be-4a0d-ac65-3e638aadeeac">551.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzctNC0xLTEtMTc0MDkw_ce4a9b3d-af14-439f-b058-a04f3f31e2c3">734.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzgtMi0xLTEtMTc0MDkw_b37ede72-1bc2-4252-9608-617122023c08">1,202.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzgtNC0xLTEtMTc0MDkw_08f42409-7cc0-4ba5-96f8-52c0d7559587">1,383.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzktMi0xLTEtMTc0MDkw_4bb9f49e-b254-461d-b90d-f41c849b8d14">2,949.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzktNC0xLTEtMTc0MDkw_8c93e810-6278-45c9-a1c7-5e4f8a0d11e1">3,166.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_19"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.851%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8bac9a933b6d4e1f906de2a6a7325d62_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMy0xLTEtMS0xNzQwOTA_47f1d220-02fb-40c4-a5a5-364a7adb4ba2">143.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i96983ae20d1a4fd892a5f1444783a570_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMy0zLTEtMS0xNzQwOTA_220d741f-af4d-4c3c-aa7a-ff740b026ef9">237.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i18e052da12c34e0e91cf56a39cd08cd1_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNS0xLTEtMS0xNzQwOTA_89376ba8-f089-49c4-bcd6-8a3b8091a3da">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i513c1b52eb2e4d47828f3ec0440d9a1a_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNS0zLTEtMS0xNzQwOTA_47754fce-5f19-4c93-93e6-0a8df75ef925">51.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i79e134d107e94e148da24dade40b12b6_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNi0xLTEtMS0xNzQwOTA_bb9292b7-733e-488e-ae5c-fdbb2229ec8a">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8373489620694e8096c4d7cb76a601a2_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNi0zLTEtMS0xNzQwOTA_86dad9c2-80b9-4f22-af2b-0dd5c71d26a2">9.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total CDMO revenues</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i282b3d80373a44448dcd835b4ec3dd02_D20230101-20230331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNy0xLTEtMS0xNzQwOTA_d186d78f-8167-4346-9987-e2f3f1cecba5">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6fcbd10db46849358e569878c1ae8ae0_D20220101-20220331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNy0zLTEtMS0xNzQwOTA_5ddaf273-1da8-4610-9a20-e87b8da47dab">60.8</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0e5222cf971340bab0614a17ebbf5ed8_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfOC0xLTEtMS0xNzQwOTA_856608bd-1b52-4468-a6f7-f2469fe8e3c9">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0d4fc9a55e4b49afb88321e52246a468_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfOC0zLTEtMS0xNzQwOTA_05117b5e-7fab-46c0-a363-f3d5b0427568">9.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 20.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfOS0xLTEtMS0xNzQwOTA_df516f92-db37-42ea-90a0-b2abd3e3cc61">165.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfOS0zLTEtMS0xNzQwOTA_79fe4717-b7a1-49de-8c56-17bae9a49637">307.5</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8bac9a933b6d4e1f906de2a6a7325d62_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTItMS0xLTEtMTc0MDkw_219d70c1-470a-4aec-85ae-1ce7f22be030">102.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i96983ae20d1a4fd892a5f1444783a570_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTItMy0xLTEtMTc0MDkw_4c266433-ce12-47ce-9b02-b3e4e129d787">80.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i282b3d80373a44448dcd835b4ec3dd02_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTMtMS0xLTEtMTc0MDkw_fbb3cbad-fa86-472f-bf39-14b7e16b930c">52.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6fcbd10db46849358e569878c1ae8ae0_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTMtMy0xLTEtMTc0MDkw_2b3251b8-4166-4e5e-8a44-2aaa9bdcd110">75.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTQtMS0xLTEtMTc0MDkw_14628469-53cb-4309-b566-067c3ae1c8f2">40.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTQtMy0xLTEtMTc0MDkw_cabd71cf-2412-4d62-bdf2-1fd271809532">46.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTUtMS0xLTEtMTc0MDkw_b798cafd-3d9d-41c4-82d8-3285c5c063af">100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTUtMy0xLTEtMTc0MDkw_0becac56-44d1-478e-b6a2-d1bc041709f1">84.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTYtMS0xLTEtMTc0MDkw_c905d190-f8c2-44b8-8ec5-1441158a0291">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTYtMy0xLTEtMTc0MDkw_b873614f-01bd-4c91-bd29-26e904e6db38">14.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTctMS0xLTEtMTc0MDkw_e6f62788-5538-458b-ab77-9bd3366827be">313.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTctMy0xLTEtMTc0MDkw_9be15efe-3cdb-4f14-930f-64479e6b1469">301.1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTktMS0xLTEtMTc0MDkw_80ce2ea8-f4bb-44ad-be72-5e276a88aafb">148.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTktMy0xLTEtMTc0MDkw_3481de83-e918-46e0-b071-8da477ebf33a">6.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjItMS0xLTEtMTc0MDkw_2d0352d0-8342-4383-b5fa-8678a9f600b8">17.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjItMy0xLTEtMTc0MDkw_340b0204-a869-4bcb-b5e9-6dc3181b38fb">8.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjMtMS0xLTEtMTc0MDkw_1dc2e9e5-4fc5-4261-a4df-3af55624026b">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjMtMy0xLTEtMTc0MDkw_27758d59-e55d-4987-b965-91c3f630ad7f">2.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjQtMS0xLTEtMTc0MDkw_52cde439-391b-4b29-8e9f-0bf8753e1ee0">13.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjQtMy0xLTEtMTc0MDkw_94733124-186b-474b-b840-7b39dbabe835">10.2</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjYtMS0xLTEtMTc0MDkw_2ae179df-b78f-46cd-9921-e0f01d49de64">161.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjYtMy0xLTEtMTc0MDkw_db419477-a718-42b1-87e4-c3839dfa05f6">3.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjctMS0xLTEtMTc0MDkw_622a8cf8-4470-45d8-a3f7-ffa009ecfea0">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjctMy0xLTEtMTc0MDkw_0556864f-299a-4b77-9fb8-33056a391b86">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjgtMS0xLTEtMTc0MDkw_b9d147c4-e9cd-49bb-8e39-4aef3a15b632">183.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjgtMy0xLTEtMTc0MDkw_d88b4ef6-53c7-435b-bc59-7e028c5909a3">3.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per common share</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzEtMS0xLTEtMTc0MDkw_9ec1226c-99d0-41b5-93dd-1803f5de3eb3">3.65</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzEtMy0xLTEtMTc0MDkw_698382dc-c236-4c26-8f88-a1b0a5b7c617">0.07</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzItMS0xLTEtMTc0MDkw_dd3e9f52-16e1-4f96-bdc6-cb239c04030d">3.65</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzItMy0xLTEtMTc0MDkw_52c24f6c-16a4-4004-8061-3a390d717c1e">0.07</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average shares outstanding</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzUtMS0xLTEtMTc0MDkw_e026564f-26cf-4b05-8d8a-a9809fce1e2e">50.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzUtMy0xLTEtMTc0MDkw_a1321d9d-aff7-4c91-89c9-e41a4ec4ddbf">50.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzYtMS0xLTEtMTc0MDkw_d72d0325-c113-4175-8265-6cf149410704">50.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzYtMy0xLTEtMTc0MDkw_ec35f0de-e6de-4622-a82d-b7e553fb2b4b">50.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_22"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc.  and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.851%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfMi0xLTEtMS0xNzQwOTA_df104032-7d34-4670-8046-d6c357ddb78d">183.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfMi0zLTEtMS0xNzQwOTA_e0ce7220-39f1-447f-b468-d7f22ea03887">3.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNC0xLTEtMS0xNzQwOTA_d9c3cc8a-eaf5-4558-ba70-7d29311e1867">0.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNC0zLTEtMS0xNzQwOTA_87b37586-8f18-4c2f-9014-828b00b76150">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains (losses) on hedging activities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNS0xLTEtMS0xNzQwOTA_c46e0275-e807-45c9-9d58-15a7310f1305">2.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNS0zLTEtMS0xNzQwOTA_cb0682b6-b025-4389-8e4f-49ac0ff73cb9">6.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNy0xLTEtMS0xNzQwOTA_f4dd3ef1-f661-4ea9-b073-1de3a0be2dfe">2.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNy0zLTEtMS0xNzQwOTA_50f98a87-bb7a-4966-8e67-fd60428a68de">6.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive income (loss), net of tax</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfOC0xLTEtMS0xNzQwOTA_fef392f5-9035-4b64-866d-31f9523af979">185.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfOC0zLTEtMS0xNzQwOTA_bc9954ec-fe95-4fc6-a19e-d80445a6e7bb">3.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.163%"><tr><td style="width:1.0%"></td><td style="width:63.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Activities</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMy0xLTEtMS0xNzQwOTA_459e0bf4-3819-4f61-a393-2416c5b11df4">183.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMy0zLTEtMS0xNzQwOTA_53ac25be-3e7d-4b07-8125-61b33459c9e3">3.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNS0xLTEtMS0xNzQwOTA_8d018c1a-bbe6-48ec-b8c1-c6d2a819fcf9">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNS0zLTEtMS0xNzQwOTA_baefcc11-6e40-4a3a-a4d7-901ea756278f">9.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNi0xLTEtMS0xNzQwOTA_79269be5-9e58-4346-a121-1bab48ce348e">34.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNi0zLTEtMS0xNzQwOTA_27914552-03ff-4957-89ef-2e492b3a2978">30.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of contingent obligations, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfOC0xLTEtMS0xNzQwOTA_ba69ecde-a56d-4e52-b45a-8a454e2bbcfa">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfOC0zLTEtMS0xNzQwOTA_b744ae5f-b243-4835-9238-939b6fdd1e2a">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfOS0xLTEtMS0xNzQwOTA_01ce6143-3c57-458e-afb8-81e3679ce644">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfOS0zLTEtMS0xNzQwOTA_b113ebd0-1ca1-41ba-afe2-2c67620ca27a">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTAtMS0xLTEtMTc0MDkw_7e7e19a8-a6b8-4a9b-be58-612e468551d7">8.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTAtMy0xLTEtMTc0MDkw_7a235d39-7133-4612-98a4-3e17a8044303">1.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTEtMS0xLTEtMTc0MDkw_0e5752e9-7669-4d37-a661-d22b61794c56">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTEtMy0xLTEtMTc0MDkw_273220b5-7b6d-4f9a-8eba-a0e9ca6cf5f9">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTMtMS0xLTEtMTc0MDkw_706f97a0-03f4-472c-8f23-894bdfcf3d25">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTMtMy0xLTEtMTc0MDkw_1300a881-92b3-4a53-ab13-02bdcfee3675">93.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTQtMS0xLTEtMTc0MDkw_fcccd691-551f-4123-80c9-63f0228a8eaf">29.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTQtMy0xLTEtMTc0MDkw_75e9239a-78db-479c-8211-2b28b274df06">50.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTUtMS0xLTEtMTc0MDkw_fbc9c76f-0fef-46d0-a990-dd84a67752d7">4.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTUtMy0xLTEtMTc0MDkw_eb14b6c3-a2cb-4ceb-891f-dc3d46914c98">16.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTYtMS0xLTEtMTc0MDkw_8494490b-9415-4b1a-a755-c34e06f537a2">31.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTYtMy0xLTEtMTc0MDkw_6ebe8ced-69e9-4c5d-8cae-d736e20e6ddd">14.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTctMS0xLTEtMTc0MDkw_53f8bb59-b386-41d9-9474-b9792695be31">14.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTctMy0xLTEtMTc0MDkw_50ba7e38-8e6f-4985-8b86-2ced9109ba8d">51.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTctMS0xLTEtMTgyODQ0_98b5f773-42d0-4e7c-a6ea-7aedb7e69a66">25.3</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTctMy0xLTEtMTgyODQ0_9c7d5913-dadf-4cd4-beac-247dcced242b">32.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes receivable and payable, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTgtMS0xLTEtMTc0MDkw_c6dce842-ed1a-48ad-a312-b6a097b9e04c">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTgtMy0xLTEtMTc0MDkw_0d16dd7f-7528-42d6-babc-5b150931c6b7">5.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTktMS0xLTEtMTc0MDkw_bcac86cb-be88-4706-a33d-56df92ab5f81">8.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTktMy0xLTEtMTc0MDkw_3e427445-4f65-4a7b-8d53-ca129fd0401b">2.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Net cash used in operating activities   </span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjAtMS0xLTEtMTc0MDkw_b83ceb2f-f9a6-4bfc-9eab-84917647aa61">184.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjAtMy0xLTEtMTc0MDkw_89c2fc09-e742-420f-9e2d-1d68a318cf26">37.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing Activities</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjItMS0xLTEtMTc0MDkw_f66caa83-bb1d-4db0-9a6b-690e780d8ec5">15.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjItMy0xLTEtMTc0MDkw_a82854ef-8ede-4641-a7df-b11691ed7bdd">32.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Net cash used in investing activities</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjQtMS0xLTEtMTc0MDkw_cb7b7e45-5f1d-45f0-9982-e06a3b24743d">15.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjQtMy0xLTEtMTc0MDkw_5085e114-2a82-423b-8664-222ab95d0364">32.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Activities</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjctMS0xLTEtMTc0MDkw_c4ff27c5-c847-43e1-8030-b5d9cf3b7591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjctMy0xLTEtMTc0MDkw_e4132bc7-4696-46e9-8c22-52a00bf597e7">57.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments on term loan facility</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:RepaymentsOfMediumTermNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjgtMS0xLTEtMTc0MDkw_9d6ff9dd-0a01-4287-b835-a97d84b3f6b1">8.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:RepaymentsOfMediumTermNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjgtMy0xLTEtMTc0MDkw_861ed073-270d-4424-9574-a539256de58d">8.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from stock-based compensation activity</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzAtMS0xLTEtMTc0MDkw_5aa6fb6a-c8dd-4cbf-a7bc-dce74a5b315d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzAtMy0xLTEtMTc0MDkw_3f2e5b17-52fa-4abb-82d8-0f1d82255678">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes paid for stock-based compensation activity</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzEtMS0xLTEtMTc0MDkw_b82558de-083e-4536-9be6-ee1733eb3118">2.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzEtMy0xLTEtMTc0MDkw_538c0f62-23a1-45e8-ae14-b06f367be520">5.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash used in financing activities:</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzMtMS0xLTEtMTc0MDkw_eb68c2b1-8940-4edc-9f74-c1d4da680aa6">10.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzMtMy0xLTEtMTc0MDkw_5bce7b44-4867-4e2e-9cac-74988562b839">70.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzQtMS0xLTEtMTc0MDkw_795988de-1d6d-407f-8e3a-98c81912893d">0.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzQtMy0xLTEtMTc0MDkw_018227da-164b-4be9-aac4-8a0cef32e7ff">0.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net change in cash, cash equivalents and restricted cash excluding cash classified within assets held for sale</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzUtMS0xLTEtMTc0MDkw_bb63a328-da2e-4dd1-b6b3-1960354e3096">209.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzUtMy0xLTEtMTc0MDkw_32ef88b8-86de-4ca9-bfb3-502844d5ca10">140.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Add: Net change in cash, classified within current assets held for sale</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzYtMS0xLTEtMjAwMjMw_4619f1fd-25ec-445e-b864-5839a458602c">2.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzYtMy0xLTEtMjAwMjM5_18a3c769-b7ec-4426-9d73-483ab716d080">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzYtMS0xLTEtMTc0MDkw_951b2a9f-c8b0-4052-99ef-4f4275c32cd1">642.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7a099fddd1d84c7d879062f83fca8e8e_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzYtMy0xLTEtMTc0MDkw_c899160e-85c8-427b-90e9-94839fbe6458">576.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzctMS0xLTEtMTc0MDkw_c70a1a82-164a-4c3c-b5bc-b3f89884bf0d">430.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzctMy0xLTEtMTc0MDkw_8d0abbcb-4c87-4b8a-af7c-8210261fb093">436.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cash paid for interest</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzktMS0xLTEtMTc0MDkw_188108a0-a44a-4426-b0ab-0f4db7434500">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzktMy0xLTEtMTc0MDkw_a88987df-f76e-431c-8e83-654a78c8118b">11.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cash paid for income taxes</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDAtMS0xLTEtMTc0MDkw_b45bcae9-d633-4cb4-a9f6-a259c8ab24db">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDAtMy0xLTEtMTc0MDkw_c6d2f692-187f-439d-8867-506f9f1f193e">4.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental information on non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property, plant and equipment unpaid at period end</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDItMS0xLTEtMTc0MDkw_45fb7a6b-9972-4cb2-bf96-1d60fbb5f21f">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDItMy0xLTEtMTc0MDkw_bec5d681-0f3d-4f25-ac74-beba4e8d19dd">13.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of treasury stock unpaid at period end</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="ebs:NoncashPurchasesOfTreasuryStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDMtMS0xLTEtMTgyOTc1_17d399e6-37d9-4e18-867d-ed2dbc168064">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="ebs:NoncashPurchasesOfTreasuryStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDMtMy0xLTEtMTgyOTc1_7442e80f-722f-47b6-8ab9-8d730b394956">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of cash and cash equivalents and restricted cash at March&#160;31, 2023 and December&#160;31, 2022:</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDQtMS0xLTEtMTc0MDkw_dd31dfd9-39f9-46f0-9859-3822d818ddb1">430.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDQtMy0xLTEtMTc0MDkw_b43b1785-ae4e-42e4-85fa-f6de3d643fd7">642.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents included in assets held for sale</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDYtMS0xLTEtMTkzNDQ3_71537194-c3d6-4060-9a76-869be4484c41">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDYtMy0xLTEtMTkzNDU1_44cd4275-e1fb-47f7-a98f-a747119c6506">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDYtMS0xLTEtMTc0MDkw_7931fa71-ba0d-4c08-b1a3-9049c5cebe53">432.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDYtMy0xLTEtMTc0MDkw_1f419a45-8ce9-4b05-af05-778468acabbd">642.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_28"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergent BioSolutions Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:5pt;margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.616%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMC0yLTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjphMmY2NDNlMjUzNjQ0NDlkOTQ3MmE5MWU0MmZkNTZiNV81_9466289d-8f0c-4276-9d09-703111df8758"><ix:nonFraction unitRef="usdPerShare" contextRef="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMC0yLTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjphMmY2NDNlMjUzNjQ0NDlkOTQ3MmE5MWU0MmZkNTZiNV81_b904d2af-6ace-4437-b0a7-03cf8cab6595">0.001</ix:nonFraction></ix:nonFraction> Par Value </span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Common Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Treasury Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Retained Earnings</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i953f447150654f76b7cc01b3726027f2_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi0yLTEtMS0xNzQwOTA_3d72b3b7-132a-4cef-8c59-19165bcd9dc9">55.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i953f447150654f76b7cc01b3726027f2_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi00LTEtMS0xNzQwOTA_53d9642b-7a11-4c90-9ec0-a80c872378a6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="if638389216994724b23bca4d31679eb8_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi02LTEtMS0xNzQwOTA_3a433911-6b95-4db5-a34d-2c21d1f402ff">5.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if638389216994724b23bca4d31679eb8_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi04LTEtMS0xNzQwOTA_fa74bc3d-df51-4d0f-9bcf-bd57ccb8a9e3">227.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9e44cdd29cc9499e9a66348b41656de5_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi0xMC0xLTEtMTc0MDkw_e7b2110d-86af-4b3e-8976-f27dd43e803d">873.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i849666feb2a44d2fa12bc7967461f166_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi0xMi0xLTEtMTc0MDkw_2cc47609-0994-4237-bbd3-566af4428ca6">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic8b4fd4e61c64973a212a85c54c0ebfd_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi0xNC0xLTEtMTc0MDkw_18706970-6dd2-4ce9-a8e4-5cd5deeb8ee9">734.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi0xNi0xLTEtMTc0MDkw_17201e07-0203-48f1-8f9a-9ea6ae28d6ec">1,383.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if51069b7c708450e883968233c7b1100_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMy0xNC0xLTEtMTk1MzIw_05791a84-badc-4ee6-8c39-add1b7a0f0bb">183.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMy0xNi0xLTEtMTk1MzIw_16975cbb-d541-48fa-b947-0265d34f5493">183.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i082e5f03a9d2471da47571c1adea47c0_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMy0yLTEtMS0xNzQwOTA_6a82ff62-0058-4539-b7cc-4b3d1651c829">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9e9d567e96ac4140ac247d74d68d020a_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMy0xMC0xLTEtMTc0MDkw_b01b0412-422e-428e-b3ee-a05ab38bae5c">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMy0xNi0xLTEtMTc0MDkw_cd713548-0487-47da-a990-97f79d97ed5d">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i497afa8d2afd4248a986014e9fa76586_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNi0xMi0xLTEtMTc0MDkw_c5853f77-24b6-459b-982d-9713503f0f60">2.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNi0xNi0xLTEtMTc0MDkw_179599aa-55ea-4fc9-9cdd-604f85ba86ad">2.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7692443ac57041479453a23b16bf3759_I20230331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy0yLTEtMS0xNzQwOTA_7f435787-eb8b-4629-9d66-1217b849778f">56.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7692443ac57041479453a23b16bf3759_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy00LTEtMS0xNzQwOTA_3ddd3c5c-739c-47a2-8a32-cd307a4987d8">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i8d0eaabe911a4ba4b4d72bc7370d9dc9_I20230331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy02LTEtMS0xNzQwOTA_6457213f-7da4-475c-ae94-71fce469ea9c">5.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d0eaabe911a4ba4b4d72bc7370d9dc9_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy04LTEtMS0xNzQwOTA_a89b70ba-7002-41f5-9a24-aaf8a3017258">227.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i613917f0ad0b475e99daeb4f7102a659_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy0xMC0xLTEtMTc0MDkw_6917c70c-c242-4e97-923d-6cdbf88d3f87">878.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d83f154114044a1bbe6ae3c214f52d4_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy0xMi0xLTEtMTc0MDkw_6d3ed94d-87ff-4194-b0e4-9441adbc3def">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a6e4454a964795b8edeb5a00bdfc7a_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy0xNC0xLTEtMTc0MDkw_2f919d30-29f7-4ca2-b07b-e67364d48f46">551.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy0xNi0xLTEtMTc0MDkw_f3f66e58-5449-4872-922e-9a419e6f5159">1,202.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:2pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.616%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMC0yLTEtMS0xODU2NjIvdGV4dHJlZ2lvbjpjOWRlM2RjNTFmMmQ0MDEwYjk4YmViYmVjMmViNjQ0MF81_9466289d-8f0c-4276-9d09-703111df8758"><ix:nonFraction unitRef="usdPerShare" contextRef="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMC0yLTEtMS0xODU2NjIvdGV4dHJlZ2lvbjpjOWRlM2RjNTFmMmQ0MDEwYjk4YmViYmVjMmViNjQ0MF81_b904d2af-6ace-4437-b0a7-03cf8cab6595">0.001</ix:nonFraction></ix:nonFraction> Par Value </span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Common Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Treasury Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Retained Earnings</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0c1de96d7b3145dfbc133d2bb6a68cf5_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi0yLTEtMS0xODU2OTE_79c51dfe-be3b-4fa7-9140-6330254e2b64">55.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c1de96d7b3145dfbc133d2bb6a68cf5_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi00LTEtMS0xODU2OTE_e1e78158-3bc5-4163-a719-8ff2064c5b9b">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ie210714807324475943299c21e7d8fbc_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi02LTEtMS0xODU2OTQ_22d3d722-1c0b-42cb-a536-b04e1762898f">3.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie210714807324475943299c21e7d8fbc_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi04LTEtMS0xODU2OTQ_ade6aa72-581b-45b3-ae20-ace29229eec6">152.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife892d5886074c32ab62a900867615d9_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi0xMC0xLTEtMTg1Njk3_f9ec8ad8-29c3-48c5-b4ce-18af91611897">829.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id730fb1f570643e09406bfe6aebe15ba_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi0xMi0xLTEtMTg1NzAw_29133cc8-5260-4241-80ef-60366c66ab09">16.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie0c52e66b26e4a1896b467cc5a122d9f_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi0xNC0xLTEtMTg1NzAw_7861c6ad-bcd8-4346-bbcf-e75c57a2877d">957.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7a099fddd1d84c7d879062f83fca8e8e_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi0xNi0xLTEtMTg1NzAw_66b031e1-c2ad-4a34-ae14-4a96bd3d6939">1,619.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icdfa38102e80436a8a1a8bf7681229d4_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMy0xNC0xLTEtMTk1MzEw_27c0b7c2-836b-40d4-8321-5c0c4cf428cc">3.7</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMy0xNi0xLTEtMjAwMDkx_f72b62ba-2384-4c6c-aabe-8611495e851e">3.7</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2ce03bb85346406d822354b0c6ab920f_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMy0yLTEtMS0xODU3MDM_1dd2f4fd-d323-473d-a2d5-6f2e861306ef">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaf01802184ad4612ab0690e8efff37c0_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMy0xMC0xLTEtMTg1NzE3_862955f3-8ee0-4e41-abca-148260c2426c">5.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMy0xNi0xLTEtMTg1NzEw_ba28cc62-18b0-4544-91b8-327e325a5208">5.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i31244a3a054948c88dabb06cdf5a93c8_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNS02LTEtMS0xODU3MDc_d8ce2f90-0a62-46aa-b8a5-0e7d74e8fbd6">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i31244a3a054948c88dabb06cdf5a93c8_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNS04LTEtMS0xODU3MDc_78a5c9c4-383c-48f0-b50d-49f5fe305ff3">52.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNS0xNi0xLTEtMTg1NzEw_abce7a09-c339-4753-9460-f9be718161bf">52.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03aa139c772549d8844c18ac3d48d451_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNi0xMi0xLTEtMTg1NzEw_b11b0c84-6745-40c3-b1cb-5f92991c53b1">6.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNi0xNi0xLTEtMTg1NzEw_e024e49d-6d26-45a2-894b-a4b32f98c8f4">6.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie4912cf676c54fd1a8050521892e67c6_I20220331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy0yLTEtMS0xODU2NzA_f65e9a81-82ec-4e18-9ae2-9170e02f790c">55.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie4912cf676c54fd1a8050521892e67c6_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy00LTEtMS0xODU3MDM_b74c52e5-edd4-450c-b35a-3dd7ed5a6890">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i1caaf133e6f74cabaebe862b712e4d3f_I20220331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy02LTEtMS0xODU3MDc_f4d97ade-bc3c-4960-8822-d24439861ce3">4.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1caaf133e6f74cabaebe862b712e4d3f_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy04LTEtMS0xODU3MDc_121bb979-e413-4449-b5d8-c9521db94d6c">204.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i974ccd2c2487469c941cfc01885a5b62_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy0xMC0xLTEtMTg1NzE3_d4ef5700-f38e-42f1-875d-b0a32ea54fcf">834.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9426132f4f814179b20fee2cb4d853f7_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy0xMi0xLTEtMTg1NzEw_62617511-e8c0-44b0-82cc-3788bf4b3875">9.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i92b10b20be474bf0bb98ab88bd4310f2_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy0xNC0xLTEtMTg1NzEw_2bffc073-2237-4166-b0db-6adffcd9de4c">954.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy0xNi0xLTEtMTg1NzEw_11bd7ccf-7873-4c21-b7cb-d458a5b39732">1,575.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_31"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EMERGENT BIOSOLUTIONS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, dollar and share amounts in tables in millions, except per share data)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_34"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.   <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfNzYwNw_bb02f848-d884-4a5b-8d84-9bb2c1586bb5" continuedAt="ib526f44736874495b18e5e685f2ebb8b" escape="true">Nature of the business and organization</ix:nonNumeric></span></div><ix:continuation id="ib526f44736874495b18e5e685f2ebb8b" continuedAt="id5511e7ff0c8403db350d4141f0cb897"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc., including its consolidated subsidiaries (&#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats ("PHTs"). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following <ix:nonFraction unitRef="category" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="INF" name="ebs:NumberOfCategoriesOfPublicHealthThreats" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfMTY0OTI2NzQ2NzA1Nw_b2dd703d-c0f8-4fe5-9fa2-d2cdf05223f7">five</ix:nonFraction> PHT categories: chemical, biological, radiological, nuclear and explosives ("CBRNE"); emerging infectious diseases ("EID"); travel health, which we have agreed to sell to Bavarian Nordic; emerging health crises; and acute/emergency care. The Company has a product portfolio of <ix:nonFraction unitRef="product" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="INF" name="ebs:NumberOfRevenueGeneratingProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfMTY0OTI2NzQ2NzA2MQ_cb7167d2-4f09-49e1-8d3b-c12193c27b5c">thirteen</ix:nonFraction> products (vaccines, therapeutics, and drug-device combination products). The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company has <ix:nonFraction unitRef="productcandidate" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="INF" name="ebs:NumberOfProductCandidates" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfMTA5OTUxMTY0MjYzMQ_f57f5272-1ec5-46d7-a52f-64218d271e7d">one</ix:nonFraction> product candidate that is procured under special circumstances by the United States government ("USG"), although it is not approved by the United States Food and Drug Administration ("FDA"). The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following <ix:nonFraction unitRef="category2" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="INF" name="ebs:NumberOfProductAndServiceCategories" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfNDk0NzgwMjM2Mjc4Ng_775d5c05-4970-4395-8092-2235af9e6fec">four</ix:nonFraction> product and service categories: Anthrax - Medical Countermeasures ("MCM") Products, NARCAN, Smallpox - MCM Products and CDMO Services. The Company operates as <ix:nonFraction unitRef="segment" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfMTA5OTUxMTY0MjY1Nw_25904a2e-c7fd-4897-92f6-57fb9e4dbb42"><ix:nonFraction unitRef="segment" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfMTA5OTUxMTY0MjY1Nw_e1785b3d-d453-4476-864e-65e5ac7806fb">two</ix:nonFraction></ix:nonFraction> operating segments: (1) a products segment ("Products") consisting of the Anthrax - MCM products, NARCAN products, Smallpox - MCM products and Other products and (2) a services segment ("Services") focused on CDMO services (Note 17, "Segment information</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anthrax - MCM Products</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Anthrasil&#174; (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">AV7909 (Anthrax vaccine adsorbed (AVA), adjuvanted) procured product candidate being developed as a next-generation anthrax vaccine for post-exposure prophylaxis. AV7909 has not been approved by the FDA, but is procured by certain authorized government buyers for their use;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BioThrax&#174; (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">NARCAN</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone approved by the FDA (including in over-the-counter form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Smallpox - MCM Products</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">ACAM2000&#174;, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">CNJ-016&#174; (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">TEMBEXA&#174;, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BAT&#174; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="id5511e7ff0c8403db350d4141f0cb897"><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Ebanga&#8482; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics ("Ridgeback"), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#8482;;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">RSDL&#174; (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA that is intended to remove or neutralize chemical warfare agents from the skin, including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Trobigard&#174; atropine sulfate, obidoxime chloride auto-injector, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It was approved in Belgium in 2021 but has not been approved by the FDA. Trobigard is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure outside of the U.S.;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the first vaccine approved by the FDA for the prevention of cholera, which we have agreed to sell as part of our travel health business (Note 3, "Assets and liabilities held for sale"); and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), a live attenuated vaccine for oral administration for the prevention of typhoid fever, which we have agreed to sell as part of our travel health business (Note 3, "Assets and liabilities held for sale").</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services - Contract Development and Manufacturing</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's services line focused on CDMO offerings cover development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided to customers from across the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale.&#160;Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms.</span></div></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_37"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.  <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfODI3Ng_3de520fd-c78d-4bf2-8678-6793369d9b73" continuedAt="i48b0081ea8b84f2cbf6ac0f6120662a9" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="i48b0081ea8b84f2cbf6ac0f6120662a9" continuedAt="i4895f2ee961d4e4caee6429ec8c5448b"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation and consolidation</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfODI4Nw_d99eb0f6-44db-48a5-b438-2d0b20d5c208" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of March&#160;31, 2023. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there is $<ix:nonFraction unitRef="usd" contextRef="i822b4db8d3a940d2a307f01f1a9c52ed_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfMTY0OTI2NzQ2MjEwNA_14b02ab2-a098-4840-b71f-6249911e591c">598.0</ix:nonFraction>&#160;million outstanding on the Revolving Credit Facility (defined below) and $<ix:nonFraction unitRef="usd" contextRef="i9b4a69b4f7e640dc9de146fd74f4ac6a_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfMTY0OTI2NzQ2MjExMQ_3018234d-f860-456c-98fb-1563e7e4cfd8">354.4</ix:nonFraction>&#160;million on the Term Loan Facility (defined below) that matures in October 2023, which is within one year of the date that the consolidated financial statements are issued for the quarter ended March&#160;31, 2023. The Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation considered the potential mitigating effect of management&#8217;s plans that have not been fully implemented. Management may evaluate the mitigating effect of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i4895f2ee961d4e4caee6429ec8c5448b" continuedAt="i2dedf00d700f47808301b99d010e2e29"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's plan to alleviate the substantial doubt includes amending its existing Revolving Credit Facility and Term Loan Facility that are due October 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company is in the process of and expects to replace the current credit facility before it matures, management cannot make the assumption that it is probable that the Company will be able to obtain such debt refinancing on commercially reasonable terms or at all until the new credit facility is in place. The Company is currently working with its lenders and expects to refinance the credit facility with revised terms and conditions. The extent to which the Company will be able to affect such refinancing, replacement or maturity extension on terms that are favorable or at all is dependent on a number of uncertain factors, including then-prevailing credit and other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, disruptions or volatility caused by factors such as COVID-19, regional conflicts, inflation, and supply chain disruptions. In addition, rising interest rates could limit our ability to refinance our existing credit facility when it matures or cause us to pay higher interest rates upon refinancing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the replacement of the Company&#8217;s current debt facility is conditional upon the execution of agreements with new or existing third parties, which are considered outside of the Company&#8217;s control, until such time as they are completed, the refinancing cannot be considered to be probable to occur as of the date of this report. The Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pre-launch inventory</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfMjE5OTAyMzI4MTkzNg_7869a1b0-9455-42ee-b27b-460dd8d9d240" escape="true">Within our Products segment, costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, we consider a number of specific facts and circumstances, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a CDMO contract as CDMO pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract.</ix:nonNumeric></span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of the policy on pre-launch inventory discussed above, there have been no significant changes to the Company's summary of significant accounting policies during the three months ended March&#160;31, 2023, contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC that have materially impacted the presentation of the Company's financial statements.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value measurements</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfNDk0NzgwMjM0MjQxOQ_8f11fbfe-467b-40b0-b728-a8e7b551764e" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:</span></div><div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable inputs for identical assets or liabilities such as quoted prices in active markets;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs other than quoted prices in active markets that are either directly or indirectly observable; and</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company&#8217;s long-term variable interest rate debt arrangements (Level 2) approximate their fair values.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i2dedf00d700f47808301b99d010e2e29"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board that the Company adopts as of the pronouncement's specified effective date. There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#8217;s 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.</span></div></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_1560"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGV4dHJlZ2lvbjoyOWExMjNmZjA2ZDg0YjczOGZlZTAxYjhkMjY4MDQ1Ml80OTQ3ODAyMzQ3ODQy_f9bcfae0-fcdd-4ba4-ba0b-0b44d7751961" continuedAt="i11d00ea0f70146f8b19ed083aaec4c58" escape="true">Assets and liabilities held for sale</ix:nonNumeric></span></div><ix:continuation id="i11d00ea0f70146f8b19ed083aaec4c58"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the Company entered into a definitive agreement with Bavarian Nordic, under which we agreed to sell our travel health business, including rights to Vaxchora and Vivotif, as well as our development-stage chikungunya vaccine candidate CHIKV VLP, the Company&#8217;s manufacturing site in Bern, Switzerland and certain of its development facilities in San Diego, California. Additionally,  approximately <ix:nonFraction unitRef="employee" contextRef="i7237bcbb75b9405287fe50d45561e97f_D20230401-20230630" decimals="INF" name="ebs:DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGV4dHJlZ2lvbjoyOWExMjNmZjA2ZDg0YjczOGZlZTAxYjhkMjY4MDQ1Ml8yMTk5MDIzMjg1ODM4_7897e4eb-bf6a-476d-8088-04fa5b3a98d3">280</ix:nonFraction> employees are expected to join Bavarian Nordic as a result of the transaction. The transaction is expected to close in the second quarter of 2023, subject to certain customary closing conditions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the accompanying Condensed Consolidated Balance Sheet as of March 31, 2023, the assets and liabilities of our travel health business are classified as held for sale and are measured at the lower of (i) the carrying value of the disposal group and (ii) the fair value of the disposal group, less costs to sell. Effective with the designation of the travel health business as held for sale on February 15, 2023, we suspended recording depreciation of property, plant and equipment and amortization of finite-lived intangible assets and right-of-use assets while these assets are classified as held for sale. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of sale. Gains and losses recognized from a sale of a disposal group will be recognized in income (loss) from operating activities.</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGV4dHJlZ2lvbjoyOWExMjNmZjA2ZDg0YjczOGZlZTAxYjhkMjY4MDQ1Ml8yMTk5MDIzMjg0Mzc5_824fb1df-0197-4cf5-ac62-e9a28e73bc42" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities classified as held for sale in the Condensed Consolidated Balance Sheets as of March&#160;31, 2023 consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;March&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets held for sale:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xLTEtMS0xLTE5MjI1Mw_3d97f6c7-35fd-4a23-b489-6278b8e9c587">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8zLTEtMS0xLTE5NDc0OA_8ab52129-4274-400a-a6f4-261bc364c3c7">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV80LTEtMS0xLTE5NDc0OA_784f8f40-6352-40db-b7d5-d6e9f685be79">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV81LTEtMS0xLTE5NDc0OA_079db1f3-6790-432b-b13b-0bd95ea1cddb">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV82LTEtMS0xLTE5NDc0OA_ae4884ba-2b1e-46db-84c8-718c5768e80f">97.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV83LTEtMS0xLTE5NDc0OA_0d828002-5ca5-4c14-ab53-8df8d93546de">102.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV84LTEtMS0xLTE5NDc0MA_90e76648-5d2b-4f89-9ac5-6c9ac22282a8">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets held for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV85LTEtMS0xLTIwMDM2MA_a4790c3b-17c1-4bf6-9f31-ae79c14643ff">225.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities held for sale:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xMi0xLTEtMS0xOTQ3NjQ_5617d978-02b8-47a9-a0ce-c741434635dc">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xMy0xLTEtMS0xOTQ3NjQ_404b893e-3118-4c99-aba1-d173d2794052">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="ebs:DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xNC0xLTEtMS0xOTQ3NjQ_cc65dca8-9c2c-44b0-b45f-6a8f6a6676ce">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xNS0xLTEtMS0xOTQ3NjQ_f6501364-eed9-4037-9ae3-432a3cca19fd">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xNi0xLTEtMS0xOTQ3NjQ_2ef93252-ba2d-418c-a197-e148d6befd75">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xNy0xLTEtMS0xOTQ3NjQ_d733ca4e-bffc-43e0-bf03-1ddeb37361fd">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities held for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xOC0xLTEtMS0yMDAzNjE_aaaa5ad1-4ca6-490f-9a57-f4725856f67b">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_1594"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGV4dHJlZ2lvbjpkY2NkZDk2NWI2ZDk0MTEyYjI5YTgwZTEwMDJjNDYyM180OTQ3ODAyMzI2Nzcw_2335c064-53b7-4d9e-81d6-16cba082d2ab" continuedAt="i1f3ea4d6417141ec9c3afce96108b358" escape="true">Restructuring costs</ix:nonNumeric></span></div><ix:continuation id="i1f3ea4d6417141ec9c3afce96108b358"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company initiated an organizational restructuring plan (the &#8220;2023 Plan&#8221;) intended to reduce operating costs, improve operating margins, and continue advancing the Company&#8217;s ongoing commitment to profitable growth. As part of the 2023 Plan, the Company eliminated approximately <ix:nonFraction unitRef="number" contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGV4dHJlZ2lvbjpkY2NkZDk2NWI2ZDk0MTEyYjI5YTgwZTEwMDJjNDYyM18xMDk5NTExNjI4MTU0_86c4a2ba-1f1f-4746-a1fe-9262201282c6">five</ix:nonFraction> percent of its total headcount. The Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGV4dHJlZ2lvbjpkY2NkZDk2NWI2ZDk0MTEyYjI5YTgwZTEwMDJjNDYyM18xMDk5NTExNjMyMjIw_196bb922-6b4c-48ad-b397-0e59a8a32b56">9.7</ix:nonFraction>&#160;million in charges in connection with the 2023 Plan during the three months ended March&#160;31, 2023. These charges consist primarily of charges related to employee transition, severance payments and employee benefits. All activities related to the 2023 Plan were substantially completed during the first quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGV4dHJlZ2lvbjpkY2NkZDk2NWI2ZDk0MTEyYjI5YTgwZTEwMDJjNDYyM18yMTk5MDIzMjYwMDA2_78f8eb6c-add0-4129-ad63-153f1cea03f4" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs associated with the Company&#8217;s segments as well as unallocated corporate and research and development ("R&amp;D") charges for the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.216%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81c28e226ee545b286e49388a057533c_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV8xLTMtMS0xLTE5NTUwMw_24f168bd-77c6-491a-b012-4c47d53dd59e">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i73c9842bc063446586bea2405cf33206_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV8yLTMtMS0xLTE5NTUwMw_45f74f2e-9b76-4643-9a5e-9546eef4984a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs by segment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icff2f736d0b84c82b69da3ae149c3877_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV8zLTMtMS0xLTE5NTUwMw_0ec952a9-3c07-4d91-9a1f-9544ca049bd5">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i90160f3d0ce54037a7e491254512bf65_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV80LTMtMS0xLTE5NTUwMw_5854298e-2d26-444b-8099-5f40afbf0616">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie4f9663fd12b4d8484ab91cd3165ab5f_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV81LTMtMS0xLTE5NTUyNw_e727ed04-9275-40bf-86ec-b40b51b1b27d">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV82LTMtMS0xLTE5NTUwMw_196bb922-6b4c-48ad-b397-0e59a8a32b56">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs, by function, for the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.216%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee transition</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d94d342fe9f478da83d206f54833e08_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6MDk4ZDcyOTFiMGNhNDc1NDlhODc4YjY2NGZjNzhlNDgvdGFibGVyYW5nZTowOThkNzI5MWIwY2E0NzU0OWE4NzhiNjY0ZmM3OGU0OF8xLTMtMS0xLTE5NTU0MQ_1e4b431b-1274-4ade-9d02-3c35e87935fa">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance payments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i624499c702f2496996732d4f547a1882_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6MDk4ZDcyOTFiMGNhNDc1NDlhODc4YjY2NGZjNzhlNDgvdGFibGVyYW5nZTowOThkNzI5MWIwY2E0NzU0OWE4NzhiNjY0ZmM3OGU0OF8yLTMtMS0xLTE5NTU0MQ_57a15749-80c7-436b-ac8f-d34efd000373">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic516a1f410604d7db3e1ff143e87a7b1_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6MDk4ZDcyOTFiMGNhNDc1NDlhODc4YjY2NGZjNzhlNDgvdGFibGVyYW5nZTowOThkNzI5MWIwY2E0NzU0OWE4NzhiNjY0ZmM3OGU0OF8zLTMtMS0xLTE5NTU0MQ_ab959174-9bb8-4f29-865e-3677923c2066">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6MDk4ZDcyOTFiMGNhNDc1NDlhODc4YjY2NGZjNzhlNDgvdGFibGVyYW5nZTowOThkNzI5MWIwY2E0NzU0OWE4NzhiNjY0ZmM3OGU0OF80LTMtMS0xLTE5NTU1Mg_ec7ec4f8-5594-4a78-af90-f8089c491436">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGV4dHJlZ2lvbjpkY2NkZDk2NWI2ZDk0MTEyYjI5YTgwZTEwMDJjNDYyM18yMTk5MDIzMjYwMDA1_85557146-9d28-497c-8a41-5067055b50db" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of and changes in the Company's restructuring accrual during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icd5bdd8d49c244448c14a689d71f1025_I20221231" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8xLTEtMS0xLTE5NTY0Nw_0e346128-7938-4d2b-8fdb-234eacb68b65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i84af060aae1748fbbaa67887f4b7dbcd_I20221231" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8xLTMtMS0xLTE5NTY0Nw_d3eeac5d-623e-4b91-9f44-5a6321a4b040">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3d2e8509aab4186a3c6aa464c1d4d74_I20221231" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8xLTUtMS0xLTE5NTY0Nw_5007e520-006b-4a36-944c-db762f11d64f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i469c99f1aa3e49068c75ef98b7a985dc_I20221231" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8xLTEtMS0xLTE5MjI5NQ_20e5c72f-d857-4fcf-843c-78f544f8efca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d94d342fe9f478da83d206f54833e08_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8yLTEtMS0xLTE5NTY0Nw_2f91ff4a-0437-4d09-8ef9-504d063344a2">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i624499c702f2496996732d4f547a1882_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8yLTMtMS0xLTE5NTY0Nw_489d938b-5842-4eea-986d-1389a334040f">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic516a1f410604d7db3e1ff143e87a7b1_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8yLTUtMS0xLTE5NTY0Nw_717057c0-ded9-4073-9558-df15dc6e08ac">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8yLTEtMS0xLTE5MjI5NQ_a193fa1a-3210-437c-ab3f-440e87af5e1d">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d94d342fe9f478da83d206f54833e08_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8zLTEtMS0xLTE5NTY0Nw_c68e61a9-8182-483a-a0ee-d8ef3fcb6b84">0.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i624499c702f2496996732d4f547a1882_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8zLTMtMS0xLTE5NTY0Nw_a3e2dae4-4626-471e-aa41-92011e77b20d">2.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic516a1f410604d7db3e1ff143e87a7b1_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8zLTUtMS0xLTE5NTY0Nw_a2e21926-3e79-44a5-ab0f-33b9cb18b708">0.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8zLTEtMS0xLTE5MjI5NQ_38c470f3-5f10-4ec8-a6ff-f0454b88870a">2.3</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i75626974e4ff4354ae25be0a61b75c46_I20230331" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl81LTEtMS0xLTE5NTY0Nw_1f5b6288-20fa-45b4-8f4b-c300c898225f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad162e2c548e417d957ea777b298e0d2_I20230331" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl81LTMtMS0xLTE5NTY0Nw_a3bce0d5-4313-4373-b656-68aa4b0a88bb">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32b120655ff64d55a24337355f419f4f_I20230331" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl81LTUtMS0xLTE5NTY0Nw_e468d030-5137-45d2-bce0-12e1c456b232">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i89d77487aec94b21a79a891c0bdda7bc_I20230331" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl81LTEtMS0xLTE5MjI5NQ_c26f3f84-e247-4ed9-86e9-99e2d4e906f1">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_40"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RleHRyZWdpb246YmI3MTgwZTM1YjliNGNlOWI5ODcwZDY3YTMxMmMwYjNfMzc0_b735f9f0-d1d3-4693-8583-ca77de60b4e4" continuedAt="i2ecb48f6475948e5a790996921d2898f" escape="true">Inventories, net</ix:nonNumeric></span></div><ix:continuation id="i2ecb48f6475948e5a790996921d2898f"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RleHRyZWdpb246YmI3MTgwZTM1YjliNGNlOWI5ODcwZDY3YTMxMmMwYjNfMzcy_81cffc2e-99a0-41a9-9f09-d2e853773c55" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.148%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMS0xLTEtMS0xNzQwOTA_e14fd035-2542-49a2-839c-9784705a44bd">148.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMS0zLTEtMS0xNzQwOTA_675cd823-229a-4a63-83ff-1b95593e39e3">143.4</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMi0xLTEtMS0xNzQwOTA_17d22196-4300-453c-8c1c-46dbadd34246">122.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMi0zLTEtMS0xNzQwOTA_2d2b9ac6-cca3-4733-8129-35994380eb4f">116.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMy0xLTEtMS0xNzQwOTA_78ced56d-5962-4c45-9910-79a4f6b0d81e">96.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMy0zLTEtMS0xNzQwOTA_716b6178-27ae-4ee7-a87d-76fccf0bc4d0">92.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfNC0xLTEtMS0xNzQwOTA_cc9c7c4a-28be-412d-8991-c2bd65282806">367.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfNC0zLTEtMS0xNzQwOTA_9bedf4aa-bc60-4aec-b3b6-dc2a3e9eb795">351.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is stated at the lower of cost or net realizable value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_43"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RleHRyZWdpb246NWFkY2RkZjg4MzE1NDU4YThkY2EyYzU5M2NhZTgwNjNfNzAw_152937f2-1890-452c-9f75-bbd9a8c83fa3" continuedAt="i61725225822c42f4933e4b3bd4d5d3d8" escape="true">Property, plant and equipment, net</ix:nonNumeric></span></div><ix:continuation id="i61725225822c42f4933e4b3bd4d5d3d8"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RleHRyZWdpb246NWFkY2RkZjg4MzE1NDU4YThkY2EyYzU5M2NhZTgwNjNfNzAx_557aa7c6-56be-492c-acd2-b470cee1a894" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.148%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land and improvements</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4331c0bdb2464807b4afa3f5612e3dad_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMS0xLTEtMS0xNzQwOTA_b6b79082-ced6-4fd8-8d06-a76ab92ddced">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib52346ef764e49d7ae1d0de332535d80_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMS0zLTEtMS0xNzQwOTA_289a7b5b-6e92-4b31-a19e-61a849eb2f17">54.9</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0029254369834e77ba355f9f9212091d_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMi0xLTEtMS0xNzQwOTA_f4784736-5667-4a11-a3ef-4d531d36ec9e">305.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i04382820c4b94237b445c43c5180113d_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMi0zLTEtMS0xNzQwOTA_03c04164-33e6-463d-a6cb-613897c5a059">327.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib46720b3fc2644378640e7ecb3eaff6c_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMy0xLTEtMS0xNzQwOTA_03b18bdc-d9b5-4721-b4ff-35893b23e5bb">515.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if6246980b9314b79820f3539a51fe388_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMy0zLTEtMS0xNzQwOTA_4b2df4c2-594b-45bd-9983-1046de121e74">567.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia4e4c69e4ac943b990497e0161be6d0a_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNC0xLTEtMS0xNzQwOTA_af5a70f8-766f-49ba-9a92-e6cd66370e2e">64.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia0622ee9b0854a68821bf3319e45908f_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNC0zLTEtMS0xNzQwOTA_fb77e182-c490-4414-a8e8-3302b5ea1db9">65.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84508c19f22426e8d7a7d283878a833_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNS0xLTEtMS0xNzQwOTA_feddb399-6618-4dee-9808-c6615ebabcd9">174.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i338e967572ba42808fef537a31e71be4_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNS0zLTEtMS0xNzQwOTA_9243ab6b-f843-41d5-b544-ebb783f2d9a0">185.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNi0xLTEtMS0xNzQwOTA_61402ad2-d713-4465-b84f-1e218464566f">1,092.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNi0zLTEtMS0xNzQwOTA_273b29c1-b073-4d55-b038-c603d40d83ae">1,201.4</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation &amp; amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNy0xLTEtMS0xNzQwOTA_904f17c3-4fa3-4426-a199-4ead9ddab02f">375.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNy0zLTEtMS0xNzQwOTA_760bbf76-5748-467b-a444-7fd328d840ed">383.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property, plant and equipment, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfOC0xLTEtMS0xNzQwOTA_3f077017-3eab-4004-b647-b928b5cc3112">716.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfOC0zLTEtMS0xNzQwOTA_10fe1a15-60ed-4843-95a8-7f4b161e36a9">817.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, construction-in-progress primarily included costs incurred related to construction to advance the Company's CDMO capabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. During the year ended December&#160;31, 2022, the Company recorded accelerated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i3f4212f3132341cf84f6c7de6e063ded_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RleHRyZWdpb246NWFkY2RkZjg4MzE1NDU4YThkY2EyYzU5M2NhZTgwNjNfNDEy_5d67a234-d300-44d2-a7f4-9bee3ee80bc4">12.7</ix:nonFraction>&#160;million reflecting a shortening of the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement with Janssen (the "Agreement"). For additional information related to the termination of the Agreement, refer to Note 13, "Revenue recognition".</span></div></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_49"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTcxMw_67222899-ce40-4b8c-b4cf-40f76b1ad387" continuedAt="i54aec122a635485abdc50e4c0c7eb133" escape="true">Intangible assets and goodwill</ix:nonNumeric></span></div><ix:continuation id="i54aec122a635485abdc50e4c0c7eb133" continuedAt="if2ba2c6018e4490bbb212d741ee096ae"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTcyMA_96e8d888-5499-4c1a-9f31-fdfbe09f172e" continuedAt="i061ebc772ec34a048a8c1753c75854b5" escape="true">The following table summarizes the Company's Intangible assets, net:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><ix:continuation id="i061ebc772ec34a048a8c1753c75854b5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:14.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Weighted Average Useful Life in Years</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if4232914f6124a5e9828197daee03b72_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi0xLTEtMS0xNzQwOTA_79b6da73-d932-4d2d-a9b1-124a5e91d803">13.6</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95ad12ca119f497ab07833d15fda564a_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi0zLTEtMS0xNzQwOTA_6f72234b-75b7-4cb7-9219-ac53e4de6e5f">849.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95ad12ca119f497ab07833d15fda564a_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi00LTEtMS0xNzQwOTA_9de99303-35fe-46d8-85c1-9db399a0a880">240.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95ad12ca119f497ab07833d15fda564a_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi01LTEtMS0xNzQwOTA_7527921c-5e54-44d4-ae26-c559ae054f92">608.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie47c273b662b4a1892d60f7abfa2f3ef_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi03LTEtMS0xNzQwOTA_4fdef5ae-8fa7-4f33-aa21-cc378e132cc3">982.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie47c273b662b4a1892d60f7abfa2f3ef_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi04LTEtMS0xNzQwOTA_f60dd355-b8e4-464a-84fc-35855e954aaa">253.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie47c273b662b4a1892d60f7abfa2f3ef_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi05LTEtMS0xNzQwOTA_f8c46b42-3126-48b1-ba91-eaccea13f2af">728.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id2f1b2dc03074501a7307fb35e98698e_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy0xLTEtMS0xODQwNDU_633cf24d-44d0-4d25-a82a-8a578176ab51">0.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib2cfce5e9fe14623a73853fac221b591_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy0zLTEtMS0xODQwMjQ_738924a5-a9e1-4229-b406-fa5f25efea32">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib2cfce5e9fe14623a73853fac221b591_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy00LTEtMS0xODQwMzA_2d998b38-e016-4a35-92bb-97f2d6ae50ed">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib2cfce5e9fe14623a73853fac221b591_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy01LTEtMS0xODQwMzk_9ee86a37-9dde-46d0-b725-29aa8e66e039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i949bce8b04694470a4528f867f0e10cd_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy03LTEtMS0xODM5Nzk_d90b4e60-fea8-4021-81ce-cb3790b89927">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i949bce8b04694470a4528f867f0e10cd_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy04LTEtMS0xODQwMDg_2c0d1adb-3d66-4113-a967-0bb8b120ddb3">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i949bce8b04694470a4528f867f0e10cd_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy05LTEtMS0xODM5Nzk_4f18d56e-c56c-44fe-a341-2bc404645100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifa639b8052ec4dfd86c079463f947791_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy0xLTEtMS0xNzQwOTA_1f1ad782-2524-4338-89ff-91d060cc6274">0.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i941ca3dc089c4dac89d3aced14c53f5b_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy0zLTEtMS0xNzQwOTA_2f7ef425-9a5a-498d-89de-057062cf2181">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i941ca3dc089c4dac89d3aced14c53f5b_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy00LTEtMS0xNzQwOTA_36139904-514f-4273-ae7d-55e18303f8dc">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i941ca3dc089c4dac89d3aced14c53f5b_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy01LTEtMS0xNzQwOTA_fa8b79eb-cc3e-4049-a489-6ec8ea164a7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2fa7094242a244a5b9b80db78bdbc0d8_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy03LTEtMS0xNzQwOTA_e44f6c06-1250-4f05-a983-2aadc5ee9bc9">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2fa7094242a244a5b9b80db78bdbc0d8_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy04LTEtMS0xNzQwOTA_b4f011fd-e722-4638-a8b5-6ce8804ebbbc">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2fa7094242a244a5b9b80db78bdbc0d8_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy05LTEtMS0xNzQwOTA_4a1aa1fc-696d-4c5f-b233-5b0c90b9ac04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC0zLTEtMS0xNzQwOTA_6b11a530-2eeb-413c-9c7f-fd27efe8326b">883.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC00LTEtMS0xNzQwOTA_5f028852-6d71-42e7-b6cb-2ba099c53da5">274.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC01LTEtMS0xNzQwOTA_9d5afb0e-4bee-4bac-82a5-f54218b71e64">608.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC03LTEtMS0xNzQwOTA_16d74c6a-da08-4062-b74a-a010b05151a5">1,016.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC04LTEtMS0xNzQwOTA_5e873476-4aec-4a63-8895-2d8d592d740a">287.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC05LTEtMS0xNzQwOTA_6c0068da-e1fe-4d42-9ca5-f4b09bccf279">728.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The net carrying value of intangible assets as of March&#160;31, 2023 excluded $<ix:nonFraction unitRef="usd" contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNi0wLTEtMS0xOTgwNzQvdGV4dHJlZ2lvbjphMjNjNjZhNjVjODM0YTJmYjU3YWE5YTA3ZDBhNjJhN18xNjQ5MjY3NDQ2MDIw_0d828002-5ca5-4c14-ab53-8df8d93546de">102.9</ix:nonFraction>&#160;million of assets related to our travel health business, which were reclassified as assets held for sale in anticipation of the sale of the travel health business to Bavarian Nordic (see Note 3, "Assets and liabilities held for sale").</span></div></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="if2ba2c6018e4490bbb212d741ee096ae"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, the Company recorded amortization expense for intangible assets of $<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTA5OTUxMTYzMTM2NQ_107ff77b-e155-4e38-a397-9b5e1771e2aa">17.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTA5OTUxMTYzMTM3MA_31c680c8-869e-4fbd-ad23-7df19f99c302">14.0</ix:nonFraction> million, respectively, which is included in "Amortization of intangible assets" on the Condensed Consolidated Statements of Operations.</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTcxNA_ac9c0536-3a81-4c9e-9fd1-b729cb51294b" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the changes in the carrying amount of goodwill by reportable segment:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Products </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Services </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2d248c38e3394ed5bd6f6e4cda0f9c56_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNC0xLTEtMS0xOTMwNjg_356d2c8e-08cc-43e1-ad2e-987c9727b209">218.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb147a1d8ee745288cc6b591771da65f_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNC0zLTEtMS0xOTMwNjg_7897984a-c8a6-448a-9505-8d415bd71983">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNC01LTEtMS0xOTMwNjg_d34320c9-64be-4a04-9aaa-61dbeefc0e50">218.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7db14af93756495bb396ad2850eb791d_I20230331" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNy0xLTEtMS0xOTMwNjg_3ed4b941-42f5-44d4-94a4-943557f7f2cf">218.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iced1288bc5d94738bdeb41c7ef631b5a_I20230331" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNy0zLTEtMS0xOTMwNjg_4b5ea3f6-f38b-4079-a387-ab5fa0e694c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNy01LTEtMS0xOTMwNjg_b59e24ef-8a8b-4298-a5bd-17a732dde857">218.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts for the Company's Products segment include gross carrying values of $<ix:nonFraction unitRef="usd" contextRef="i7db14af93756495bb396ad2850eb791d_I20230331" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfOS0wLTEtMS0xNzc4OTAvdGV4dHJlZ2lvbjpiNDkwMWRlMjE0YWI0ZjA4YjJhYjVkODViZTQ2MzY2ZV84NQ_1cabbd19-d520-410a-9a11-b1a9bb0ead3e"><ix:nonFraction unitRef="usd" contextRef="i2d248c38e3394ed5bd6f6e4cda0f9c56_I20221231" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfOS0wLTEtMS0xNzc4OTAvdGV4dHJlZ2lvbjpiNDkwMWRlMjE0YWI0ZjA4YjJhYjVkODViZTQ2MzY2ZV84NQ_2f78384e-c0c3-4c58-82b2-38b15604d1c2">259.9</ix:nonFraction></ix:nonFraction>&#160;million as of March&#160;31, 2023 and December&#160;31, 2022 and accumulated impairment losses of $<ix:nonFraction unitRef="usd" contextRef="i2d248c38e3394ed5bd6f6e4cda0f9c56_I20221231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfOS0wLTEtMS0xNzc4OTAvdGV4dHJlZ2lvbjpiNDkwMWRlMjE0YWI0ZjA4YjJhYjVkODViZTQ2MzY2ZV8xNTk_236dbc5e-3986-4a8d-8756-0f08fd163049"><ix:nonFraction unitRef="usd" contextRef="i7db14af93756495bb396ad2850eb791d_I20230331" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfOS0wLTEtMS0xNzc4OTAvdGV4dHJlZ2lvbjpiNDkwMWRlMjE0YWI0ZjA4YjJhYjVkODViZTQ2MzY2ZV8xNTk_6117fff6-2087-4568-9e5c-c470618836c2">41.7</ix:nonFraction></ix:nonFraction>&#160;million.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts for the Company's Services segment include gross carrying values of $<ix:nonFraction unitRef="usd" contextRef="iced1288bc5d94738bdeb41c7ef631b5a_I20230331" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfMTEtMC0xLTEtMTc3ODkwL3RleHRyZWdpb246MmM1NGRmYjA4YzlmNGE0MTlmOTZkMmNlNjRlZWMzYjhfMTA5OTUxMTYyODAzNw_8c18f10e-551e-48ec-b4bf-1d14e57dd29b"><ix:nonFraction unitRef="usd" contextRef="idb147a1d8ee745288cc6b591771da65f_I20221231" decimals="-5" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfMTEtMC0xLTEtMTc3ODkwL3RleHRyZWdpb246MmM1NGRmYjA4YzlmNGE0MTlmOTZkMmNlNjRlZWMzYjhfMTA5OTUxMTYyODAzNw_c678415c-f3cb-4eea-8f04-0704c6c3d0de">6.7</ix:nonFraction></ix:nonFraction>&#160;million as of March&#160;31, 2023, December&#160;31, 2022, and accumulated impairment losses of $<ix:nonFraction unitRef="usd" contextRef="idb147a1d8ee745288cc6b591771da65f_I20221231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfMTEtMC0xLTEtMTc3ODkwL3RleHRyZWdpb246MmM1NGRmYjA4YzlmNGE0MTlmOTZkMmNlNjRlZWMzYjhfMTY0OTI2NzQ0Mjc4Nw_2d33c51f-8ed8-4a84-ad45-7a7816bdb34a"><ix:nonFraction unitRef="usd" contextRef="iced1288bc5d94738bdeb41c7ef631b5a_I20230331" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfMTEtMC0xLTEtMTc3ODkwL3RleHRyZWdpb246MmM1NGRmYjA4YzlmNGE0MTlmOTZkMmNlNjRlZWMzYjhfMTY0OTI2NzQ0Mjc4Nw_504ffc1a-31fa-4b83-9dc2-4c90d174e812">6.7</ix:nonFraction></ix:nonFraction>&#160;million.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has $<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTY0OTI2NzQ0Mzc1OQ_a0e875e8-0294-4478-8f8f-82cee7a9bcb0">218.2</ix:nonFraction>&#160;million of total goodwill which is attributable to our Products segment. There is the risk of future impairments in our reporting units as any further deterioration in their performance compared to forecast, changes in order volumes or delivery schedules for major customers, as well as any changes in economic forecasts and expected recovery in the biopharmaceutical industry, may require the Company to complete additional impairment tests in future quarters and could result in the reporting unit&#8217;s fair value falling below carrying value in subsequent quarters. In the event the Company experiences factors that it believes indicate a decline in fair value, including negative changes to long-term growth rates or if discount rates increase, we may be required to record impairments of goodwill and other identified intangible assets. Further, if the composition of the Company&#8217;s reporting unit&#8217;s assets and liabilities were to change and result in an increase in the reporting unit&#8217;s carrying value, it could lead to additional impairment testing and further impairment losses.</span></div></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_52"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMjE4MQ_ee532109-cca2-4fca-8e61-dd4b15e6fda4" continuedAt="i50b8283079d048ba91a9bf902f1d3dfc" escape="true">Fair value measurements</ix:nonNumeric></span></div><ix:continuation id="i50b8283079d048ba91a9bf902f1d3dfc" continuedAt="i6544cafba1fd495488d63f6557f34bec"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMjE4Mg_6218fd19-4d84-4dbe-898f-0d516cb840cd" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2678670ef0614327a8e6d3ba7f775ffe_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy0xLTEtMS0xNzQwOTA_ef6e2bd9-7839-4286-aad5-0d48c21734bc">176.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i312fc4d3fa3d40a8b8d40b165fac9f23_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy0yLTEtMS0xNzQwOTA_35342256-33ea-4c6e-886b-95c1f44933a6">176.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0fe6faf4ab404b7eaeb1185f253fdc6d_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy0zLTEtMS0xNzQwOTA_866e3575-dba0-4d53-90ee-8744e6f04cd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i237d46bcc69045b68b66b29364f7c338_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy00LTEtMS0xNzQwOTA_fc5a084a-12e2-4edc-bb68-71304ff07a0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i575796b9fe234a88851410d4452a2542_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy02LTEtMS0xNzQwOTA_b2d54314-8946-4e3b-8b08-f928f5745a82">320.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9b9542ada7984655be665a722b9ac8b4_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy03LTEtMS0xNzQwOTA_93fd6dc0-d4e2-4ae4-826e-f399d91a6e3d">320.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7c9b39689c8b4daabd9ce8b4ca48f1fc_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy04LTEtMS0xNzQwOTA_b5a6af43-a11d-4d51-8a8d-6e21520bd695">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i087f2351596c4d7aaa0c69f2847ad606_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy05LTEtMS0xNzQwOTA_02791a64-964c-4526-aa4d-51cdd890216f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia4a4bf125ea1426898eefe90abf2468b_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC0xLTEtMS0xNzQwOTA_dfccbf59-d85c-4b4f-ab8b-250b1f98bddb">125.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b76ca7b5a934284bb3f69ae4eac313f_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC0yLTEtMS0xNzQwOTA_771b9652-40f1-4c94-85f7-a9105d36f5a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i63a4559b34534083bbc78a87767ff732_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC0zLTEtMS0xNzQwOTA_9ac96e31-cff4-4f7f-99a9-5faa2ca9273a">125.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib6de70121c46438aa85618bf326f814d_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC00LTEtMS0xNzQwOTA_10ff3ed6-0c8f-4b13-b56e-71220a173da8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i676d5ac2770d4880b80e8f9affcc0405_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC02LTEtMS0xNzQwOTA_eb3365eb-b31b-4711-9a5c-81b3bae05b26">170.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iab0b615be15c41e492c20d99095ebd67_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC03LTEtMS0xNzQwOTA_d0ac618a-0b2b-40d6-a000-9f114a8a78fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i846c202a9d2c465a8eaa59bba8fb61d3_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC04LTEtMS0xNzQwOTA_d9967170-ed10-4519-9ec4-a873c263a59e">170.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaa141f63b241430bb8414182bb967b11_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC05LTEtMS0xNzQwOTA_890c2784-7225-44a3-b0d6-54228b3e3942">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS0xLTEtMS0xNzQwOTA_cab1b2da-935a-4f49-ae31-bb945b9b84c8">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iecb9b277674f497f94bb0ad15086a2d1_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS0yLTEtMS0xNzQwOTA_198673a0-e068-4280-bfe4-0f3aad71ecc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9da03b4151704bc0b9cd5c7932118c29_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS0zLTEtMS0xNzQwOTA_e2603b83-fd6a-4d72-a806-d1e93b94c2a3">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i07bc53a7e37d4103b284a544dfaee08f_I20230331" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS00LTEtMS0xNzQwOTA_e60fb92b-7300-46d1-899a-73fd893661da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS02LTEtMS0xNzQwOTA_ae37f93c-14b8-4bac-980d-5f26c7dd99a2">8.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i10bc8bb2a2354813ac6212066587b081_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS03LTEtMS0xNzQwOTA_d3e4ef61-3f08-4a70-94a6-ec1eb2454d81">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28872533ff2f45f8afc92cc4728820d6_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS04LTEtMS0xNzQwOTA_c59eecb7-735f-4a64-9dfd-608c9f189bc5">8.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if8dd4d6dd4734137a3740ddea65d8249_I20221231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS05LTEtMS0xNzQwOTA_15975293-429c-494c-ab11-507ebee29bb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi0xLTEtMS0xNzQwOTA_17fb54de-145d-4c7e-a641-0958f4c6a60f">308.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iecb9b277674f497f94bb0ad15086a2d1_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi0yLTEtMS0xNzQwOTA_22557a0b-42f2-4512-a36a-167b85a8fd7c">176.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9da03b4151704bc0b9cd5c7932118c29_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi0zLTEtMS0xNzQwOTA_54607e30-be06-46f4-a1a9-351f0c8edae5">131.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i07bc53a7e37d4103b284a544dfaee08f_I20230331" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi00LTEtMS0xNzQwOTA_968e8707-9d93-45ec-a25c-e691c6065069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi02LTEtMS0xNzQwOTA_65bf5cb9-81b2-4ee6-b1da-181fd7f632b9">500.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i10bc8bb2a2354813ac6212066587b081_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi03LTEtMS0xNzQwOTA_2c8925ba-dd8d-4932-b1a9-640d795e115e">320.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28872533ff2f45f8afc92cc4728820d6_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi04LTEtMS0xNzQwOTA_5876b6a1-78f0-4f8e-bc55-93de58b66815">179.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if8dd4d6dd4734137a3740ddea65d8249_I20221231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi05LTEtMS0xNzQwOTA_23a70a3d-52bc-4e64-b87d-9d2046c8e524">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC0xLTEtMS0xNzQwOTA_21c16600-541d-463e-bdc9-13897520677d">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iecb9b277674f497f94bb0ad15086a2d1_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC0yLTEtMS0xNzQwOTA_49c058a9-b5a4-4b5a-86cd-e1d7f2fc1b9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9da03b4151704bc0b9cd5c7932118c29_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC0zLTEtMS0xNzQwOTA_3c284638-e76c-4b58-87ae-a8e320497996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i07bc53a7e37d4103b284a544dfaee08f_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC00LTEtMS0xNzQwOTA_ceb83e43-f933-4700-8ffe-2422eff72d3c">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC02LTEtMS0xNzQwOTA_043bb4b4-1577-46b3-9b4b-6b9bb5f3364d">6.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i10bc8bb2a2354813ac6212066587b081_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC03LTEtMS0xNzQwOTA_1fe2a7b3-ba23-4cbd-af25-d9647269cfe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28872533ff2f45f8afc92cc4728820d6_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC04LTEtMS0xNzQwOTA_1df2089f-4b18-41c1-9b12-e5b3c390a627">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if8dd4d6dd4734137a3740ddea65d8249_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC05LTEtMS0xNzQwOTA_6b6ce65a-1e9a-4252-85e2-4a5907ec04bd">6.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtMS0xLTEtMTc0MDkw_5ef43d63-f92b-4ac0-ac72-3916b7b1cc33">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iecb9b277674f497f94bb0ad15086a2d1_I20230331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtMi0xLTEtMTc0MDkw_15fec32b-6b04-4d72-b83a-b7a8ded09bca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9da03b4151704bc0b9cd5c7932118c29_I20230331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtMy0xLTEtMTc0MDkw_ecbd11b8-0ce1-4e17-b4b2-5c9183b48576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i07bc53a7e37d4103b284a544dfaee08f_I20230331" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtNC0xLTEtMTc0MDkw_b59bfe41-6a4d-4ce1-9038-8bc0ab56d946">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtNi0xLTEtMTc0MDkw_528b376f-ce1e-4e71-9458-d60827d57a3f">6.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i10bc8bb2a2354813ac6212066587b081_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtNy0xLTEtMTc0MDkw_f3797ed8-38c0-4343-bd3c-7391d432c805">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28872533ff2f45f8afc92cc4728820d6_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtOC0xLTEtMTc0MDkw_3f43a170-25d8-4c1b-b232-6f2412290879">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if8dd4d6dd4734137a3740ddea65d8249_I20221231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtOS0xLTEtMTc0MDkw_7846ede3-3e15-4f6b-83f2-a8a34b7af870">6.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contingent consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#8217;s products are classified in the Company's statement of operations as cost of product sales. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i6544cafba1fd495488d63f6557f34bec"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMjE4Mw_536c77ac-e172-41b7-819c-65c6a83a8caf" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a reconciliation of the beginning and ending balance of the Company's contingent consideration liability: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjlkYmI0MWM0ZjdjMjQwMWM4OWQ4MzQxYWFiYmRjM2ZmL3RhYmxlcmFuZ2U6OWRiYjQxYzRmN2MyNDAxYzg5ZDgzNDFhYWJiZGMzZmZfMS0yLTEtMS0xNzQwOTA_d90b302a-c0ed-4498-b31a-1ab93fb13e3c">6.8</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjlkYmI0MWM0ZjdjMjQwMWM4OWQ4MzQxYWFiYmRjM2ZmL3RhYmxlcmFuZ2U6OWRiYjQxYzRmN2MyNDAxYzg5ZDgzNDFhYWJiZGMzZmZfMi0yLTEtMS0xNzQwOTA_9570ec56-f746-41ee-8fb0-4ec4c14fc558">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjlkYmI0MWM0ZjdjMjQwMWM4OWQ4MzQxYWFiYmRjM2ZmL3RhYmxlcmFuZ2U6OWRiYjQxYzRmN2MyNDAxYzg5ZDgzNDFhYWJiZGMzZmZfMy0yLTEtMS0xNzQwOTA_e83ae70a-eff4-43ec-814d-b7309456c4c2">0.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjlkYmI0MWM0ZjdjMjQwMWM4OWQ4MzQxYWFiYmRjM2ZmL3RhYmxlcmFuZ2U6OWRiYjQxYzRmN2MyNDAxYzg5ZDgzNDFhYWJiZGMzZmZfNC0yLTEtMS0xNzQwOTA_17808f0b-cb5b-4c07-9b22-c17068e74f88">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the current portion of the contingent consideration liability was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTA5OTUxMTYzMDA1MQ_59a27e95-a194-43be-86ae-637661a2f241">3.4</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTA5OTUxMTYzMDA1NQ_edf6702b-3b42-4558-8436-5e0379ffd99d">3.1</ix:nonFraction>&#160;million, respectively, and was included in "Other current liabilities" on the Condensed Consolidated Balance Sheets. The non-current portion of the contingent consideration liability is included in "Other liabilities" on the Condensed Consolidated Balance Sheets.</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMjE3OA_41dbcb98-a076-4051-9790-912eeef6b8d7" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurement for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:18.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.066%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Contingent Consideration Liability</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Fair Value as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Range</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty based</span></td><td colspan="3" rowspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i20c6e639de504e66bd14ca1b9f011604_I20230331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjhjZjcyNjhmYjJmNzQ1M2ZhZjdmNjUwOTRjMzMyNzAyL3RhYmxlcmFuZ2U6OGNmNzI2OGZiMmY3NDUzZmFmN2Y2NTA5NGMzMzI3MDJfMS0xLTEtMS0xNzQwOTA_c9f40416-989a-460e-b66e-886b423e4ba4">7.6</ix:nonFraction> million</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounted cash flow</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ifba6b2f3fd2d4feba5acceb8d159572c_I20230331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjhjZjcyNjhmYjJmNzQ1M2ZhZjdmNjUwOTRjMzMyNzAyL3RhYmxlcmFuZ2U6OGNmNzI2OGZiMmY3NDUzZmFmN2Y2NTA5NGMzMzI3MDJfMS00LTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjowYmNhYzE1YWU0NzU0NzQwYjFiNzMxNGQyMDU0MzNkM18xMDk5NTExNjI3Nzgz_b0e2c255-f644-41da-a903-a8a88e68ae0a">9.6</ix:nonFraction>%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2adc9adb687d4dc4a6c4288252be0818_I20230331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjhjZjcyNjhmYjJmNzQ1M2ZhZjdmNjUwOTRjMzMyNzAyL3RhYmxlcmFuZ2U6OGNmNzI2OGZiMmY3NDUzZmFmN2Y2NTA5NGMzMzI3MDJfMi00LTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjoyMDg2Yzg3NjIzY2Y0YjgxODRmNjhjZTFjMmMyZjFmOV8xMDk5NTExNjI3Nzg4_5ce7e246-55a6-45a1-be12-10fd5e14a394">25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6a1c5f04948a4ba69680ad3fa0b5fe08_I20230331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjhjZjcyNjhmYjJmNzQ1M2ZhZjdmNjUwOTRjMzMyNzAyL3RhYmxlcmFuZ2U6OGNmNzI2OGZiMmY3NDUzZmFmN2Y2NTA5NGMzMzI3MDJfMi00LTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjoyMDg2Yzg3NjIzY2Y0YjgxODRmNjhjZTFjMmMyZjFmOV8xMDk5NTExNjI3Nzkz_607c5748-2b18-4230-9be1-de47b268e60d">50</ix:nonFraction>%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projected year of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 - 2028</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative instruments</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9, "Derivative instruments and hedging activities</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information about the Company's derivative instruments.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Non-variable rate debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2022, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he fair value of the Company's <ix:nonFraction unitRef="number" contextRef="i542cdb35121f4951af58b7c4d099cc0e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTg3OQ_096fde69-bc82-4ef5-9ded-709772e40ba7"><ix:nonFraction unitRef="number" contextRef="ib979976208634b5c8e0a9ae50b18d4cb_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTg3OQ_f8e7cecd-8154-4ef9-bf67-f7fc4e558231">3.875</ix:nonFraction></ix:nonFraction>% Senior Unsecured Notes was $<ix:nonFraction unitRef="usd" contextRef="ib979976208634b5c8e0a9ae50b18d4cb_I20230331" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTA5OTUxMTYzMDA3NQ_60486a3c-434e-4b88-b725-5a71002efd24">220.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i542cdb35121f4951af58b7c4d099cc0e_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTA5OTUxMTYzMDA3OQ_24650aae-68a6-444e-89e8-f04820603eb0">225.1</ix:nonFraction>&#160;million, respectively. The fair value was determined through market sources, which are Level 2 inputs and directly observable. The carrying amounts of the Company&#8217;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 10, "Debt").</span></div></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_55"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMjk4Mw_e6d08c54-d645-4589-8013-91e7f28dcf6c" continuedAt="i3a6f1939110740f89c9a361fce628db3" escape="true">Derivative instruments and hedging activities</ix:nonNumeric></span></div><ix:continuation id="i3a6f1939110740f89c9a361fce628db3" continuedAt="i2938648668bb4b778f58decaafb9abc5"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risk management objective of using derivatives</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from payments of variable interest rate debt associated with the Company's senior secured credit agreements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If current fair values of designated interest rate swaps&#160;remained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;$<ix:nonFraction unitRef="usd" contextRef="i8751da105fac4730bbdbaffce144fb47_D20230101-20230331" decimals="-5" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMTA5OTUxMTYzMDgzOQ_34dc0212-c31a-4462-9da0-5921062ade43">5.9</ix:nonFraction>&#160;million of net deferred gains from&#160;accumulated other comprehensive income&#160;into the Condensed Consolidated Statement of Operations over the next&#160;twelve-month period. All outstanding cash flow hedges mature in October 2023.</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMjk4MQ_a9066ca6-3685-497b-bbb1-fa96c276e85d" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Number of Instruments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Notional</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="instrument" contextRef="i8c80cc2623ec43ee87f691cd40d2b03c_I20230331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmYwYjhkMTZjYjFlZTQwYjg4YzBlNDMxZWVlOWQzZTAzL3RhYmxlcmFuZ2U6ZjBiOGQxNmNiMWVlNDBiODhjMGU0MzFlZWU5ZDNlMDNfMS0xLTEtMS0xNzQwOTA_e79f52c4-172d-47c8-9e79-1bf2ff07918f">7</ix:nonFraction></span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i8c80cc2623ec43ee87f691cd40d2b03c_I20230331" decimals="INF" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmYwYjhkMTZjYjFlZTQwYjg4YzBlNDMxZWVlOWQzZTAzL3RhYmxlcmFuZ2U6ZjBiOGQxNmNiMWVlNDBiODhjMGU0MzFlZWU5ZDNlMDNfMS0zLTEtMS0xNzQwOTA_95b897ca-a531-4a56-b193-51a1fb23d7a9">350.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i2938648668bb4b778f58decaafb9abc5"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMjk4OA_553d97a5-39d4-4164-959e-f914c96e62ba" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.143%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Fair Value of Asset Derivatives</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1f157297decc4c27a1eb9955ddfbb47b_I20230331" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmEwMjA0MmZmNTVmODQxZTJiMmFiMDkzMDAzNGFiZDE4L3RhYmxlcmFuZ2U6YTAyMDQyZmY1NWY4NDFlMmIyYWIwOTMwMDM0YWJkMThfMy0yLTEtMS0xNzQwOTA_a7a223d5-ee7a-4d57-8f20-8200509ce77d">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i48a3c046c3a04962bc32bb21e900d52f_I20221231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmEwMjA0MmZmNTVmODQxZTJiMmFiMDkzMDAzNGFiZDE4L3RhYmxlcmFuZ2U6YTAyMDQyZmY1NWY4NDFlMmIyYWIwOTMwMDM0YWJkMThfMy00LTEtMS0xNzQwOTA_5ff51d8f-658d-4333-9c9b-b738fc0959b7">8.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMjk4NQ_68f7dffd-1610-412c-94aa-82be929b09de" escape="true">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMjk5Mw_cc3bd8d3-77c4-4cba-bd22-a26a77cdd8ef" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:15.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.162%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivatives</span></td><td colspan="3" rowspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Location of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)</span></td><td colspan="9" style="background-color:#19415e;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Amount of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)</span></td></tr><tr style="height:15pt"><td colspan="9" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8751da105fac4730bbdbaffce144fb47_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmFlZTIzYzc0ZDQzOTQ0NWE4MjVlYTc2MWYyOWEzYWFlL3RhYmxlcmFuZ2U6YWVlMjNjNzRkNDM5NDQ1YTgyNWVhNzYxZjI5YTNhYWVfMy0xLTEtMS0xNzQwOTA_1cc69f18-93fa-4019-ad34-23403dc049b4">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i263ac071f3a94b6cb410cb5275bfd042_D20220101-20221231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmFlZTIzYzc0ZDQzOTQ0NWE4MjVlYTc2MWYyOWEzYWFlL3RhYmxlcmFuZ2U6YWVlMjNjNzRkNDM5NDQ1YTgyNWVhNzYxZjI5YTNhYWVfMy0yLTEtMS0xNzQwOTA_ef6ae263-4a43-489a-9d20-5559b1098387">8.5</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifa715f99b2c046f29b82294c4c8cf1bd_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmFlZTIzYzc0ZDQzOTQ0NWE4MjVlYTc2MWYyOWEzYWFlL3RhYmxlcmFuZ2U6YWVlMjNjNzRkNDM5NDQ1YTgyNWVhNzYxZjI5YTNhYWVfMy00LTEtMS0xNzQwOTA_4fadf90b-1080-49a7-b69a-d8636a273a83">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id194daf24cf04654893b13c8dd06a8ab_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmFlZTIzYzc0ZDQzOTQ0NWE4MjVlYTc2MWYyOWEzYWFlL3RhYmxlcmFuZ2U6YWVlMjNjNzRkNDM5NDQ1YTgyNWVhNzYxZjI5YTNhYWVfMy01LTEtMS0xNzQwOTA_294f397d-52e5-4ca1-b245-ebd3572231d4">1.4</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_58"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjg1NA_463e2ad9-047d-495f-83db-5447c6eecf6a" continuedAt="i411f4603406b49af835aea1759d56f30" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i411f4603406b49af835aea1759d56f30" continuedAt="i7706de06348b4b24aba57b261e2453dd"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjg1NQ_ccccf922-3dea-47d3-be50-1019a5dc9f6b" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the components of the Company&#8217;s debt:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.148%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement - Term loan due 2023</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9b4a69b4f7e640dc9de146fd74f4ac6a_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMS0xLTEtMS0xNzQwOTA_3018234d-f860-456c-98fb-1563e7e4cfd8">354.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i52702739ed104778bc9a6b44dbd6a56c_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMS0zLTEtMS0xNzQwOTA_3ad634d1-ff9f-4c42-9969-2e07c9260584">362.8</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement - Revolver loan due 2023</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i822b4db8d3a940d2a307f01f1a9c52ed_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMi0xLTEtMS0xNzQwOTA_14b02ab2-a098-4840-b71f-6249911e591c">598.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iacaf8ffa11674dc59342790fd0bd5b42_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMi0zLTEtMS0xNzQwOTA_c76d9bf9-83f6-4d2a-8f6d-1cdb573f96d8">598.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib979976208634b5c8e0a9ae50b18d4cb_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMy0wLTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjpiODRhM2JlNmM4MWI0YWY3YWFkNGVlNTY2NDYxZDRiMV80_4f5eb469-c53c-4f1d-9ca7-0b3a04b92d0c">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib979976208634b5c8e0a9ae50b18d4cb_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMy0xLTEtMS0xNzQwOTA_aa66eb08-ae83-48d5-a145-2889d4076beb">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i542cdb35121f4951af58b7c4d099cc0e_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMy0zLTEtMS0xNzQwOTA_0928451c-0630-455a-ab07-9c1310b99861">450.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icb39b7b0e50a41899b13e8e7a176cb73_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNC0xLTEtMS0xNzQwOTA_43ff796f-8251-43ba-9029-5bd44f37995a">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1b6cd7196060498f8905b788318223e9_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNC0zLTEtMS0xNzQwOTA_e056ee5e-ac3f-499b-8665-cde8164b27f0">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNS0xLTEtMS0xNzQwOTA_017927ad-24dd-4184-a881-fcf09e26a93c">1,405.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNS0zLTEtMS0xNzQwOTA_88d80998-14c0-472d-a404-2bcd9709a854">1,413.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNy0xLTEtMS0xOTcyMDQ_7e738f91-fa42-423f-b8e7-1d58096cf64d">7.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNy0zLTEtMS0xOTcxOTA_d2376b43-eb43-4672-8eb1-d46e77079ed9">8.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion of long-term debt, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNy0xLTEtMS0xNzQwOTA_d2f2b919-3565-4cbe-95a3-401e2eeb963f">950.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNy0zLTEtMS0xNzQwOTA_0a69bebd-3549-4e14-b252-c2b352b06a86">957.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of debt, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfOS0xLTEtMS0xNzQwOTA_b6546187-ca79-4aa6-b4d1-4f6c5e5a68bc">447.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfOS0zLTEtMS0xNzQwOTA_80881d78-ab8d-4b8d-b962-a3a61912e4fa">448.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company reclassified the debt issuance costs associated with the revolver loan to a contra account to directly offset the loan balance in other current liabilities on the Company's consolidated balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMTA5OTUxMTYzNDcwOQ_2c53aa42-7784-457c-9a92-342cc1567aa2">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMTA5OTUxMTYzNTUwMw_d34a3705-8a47-475c-93ed-b20751e01a8a">1.3</ix:nonFraction>&#160;million of debt issuance costs associated with the revolver loan that were classified as an offset to other current liabilities, respectively. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i2a4e68384fff4fba80f54b1741dcdea3_I20200807" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjU4_b42e5a5b-e790-40d5-a75e-c0d237a5e0f2">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028 </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company completed its offering of $<ix:nonFraction unitRef="usd" contextRef="i2a4e68384fff4fba80f54b1741dcdea3_I20200807" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNzUx_74d1f613-1e2c-4d86-8138-d89141d23905">450.0</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i2a4e68384fff4fba80f54b1741dcdea3_I20200807" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNzg0_0b88d814-0fc1-4ef5-abdf-d9ca9c394851">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028 (the 2028 Notes) of which the majority of the net proceeds were used to pay down the Revolving Credit Facility. Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i7706de06348b4b24aba57b261e2453dd" continuedAt="i2b7a45c7643b4997be54748ae1277ba5"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related Indenture, plus accrued and unpaid interest. Prior to August 15, 2023 the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i2b6c423aa64e4e4896e0475d47d5f2cb_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMTQyNw_f748de2b-4a4c-4f05-af1e-793d6504b0d0">100</ix:nonFraction>% of the principal amount of the 2028 Notes plus a &#8220;make-whole&#8221; premium and accrued and unpaid interest. Prior to August 15, 2023, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i78876bbef2be40f0b38c6232f78ff57d_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMTU4OA_fe315d3a-58fb-45eb-805f-5ad963b06a9a">40</ix:nonFraction>% of the aggregate principal amount of the 2028 Notes using the net cash proceeds of certain equity offerings at the redemption price set forth in the related Indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of <ix:nonFraction unitRef="number" contextRef="iacf16d55ed5643cb9ac1bebbf0f1c165_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMTg3OA_b9cbbe3c-0392-4e19-9c66-6a7aeccb5ce6">101</ix:nonFraction>% of the principal amount of such 2028 Notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative covenants in the Indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior secured credit agreement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on August 7, 2020, the Company entered into a Second Amendment (the &#8220;Credit Agreement Amendment&#8221;) to its senior secured credit agreement, dated October 15, 2018, with multiple lending institutions relating to the Company&#8217;s senior secured credit facilities (the &#8220;Credit Agreement,&#8221; and as amended, the &#8220;Amended Credit Agreement&#8221;), consisting of a senior revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and senior term loan facility (the &#8220;Term Loan Facility,&#8221; and together with the Revolving Credit Facility, the &#8220;Senior Secured Credit Facilities&#8221;).  The Credit Agreement Amendment amended, among other things, the definition of incremental facilities limit, the consolidated net leverage ratio financial covenant by increasing the maximum level, increased the permissible applicable margins based on the Company&#8217;s consolidated net leverage ratio and increased the commitment fee that the Company is required to pay in respect of the average daily unused commitments under the Revolving Credit Facility, depending on the Company&#8217;s consolidated net leverage ratio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement includes (i) a Revolving Credit Facility of $<ix:nonFraction unitRef="usd" contextRef="i4b04150f100345e5b7d1dba860fc021b_I20200807" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMzQxMw_7db51448-178d-4f09-b1f1-b6c2220870b1">600.0</ix:nonFraction>&#160;million and (ii) a Term Loan Facility with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="ic3e55eef26f54a4894de8f45425d8253_I20200807" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMzQ3Mw_92093dd2-4c54-4b43-ab3a-f6b078ce643d">450.0</ix:nonFraction>&#160;million. The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as certain requirements involving the Company's net leverage ratio will be maintained on a pro forma basis. Borrowings under the Revolving Credit Facility and the Term Loan Facility bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from <ix:nonFraction unitRef="number" contextRef="i4918ce9801c5412b8cd5dd6bf028c13e_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMzg5Mw_74ac84df-7528-4c82-bfd5-434b022c5f0e">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i254adee00af34c94bbc5984b0bfbe52e_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMzg5OQ_10ace0a2-d213-4f93-b75e-82e3d9c90982">2.25</ix:nonFraction>% per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="iedb6ef8e0b6b46208f6e01be5daa2b80_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDA2MA_a4d84db8-38ba-4311-b3ab-79b261c10dd3">0.50</ix:nonFraction>%, and a eurocurrency rate for an interest period of one month plus <ix:nonFraction unitRef="number" contextRef="i8d8a56f631634a619610a599c7700384_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDEyOQ_16c7ccb2-b4b6-43b1-a400-d5c3bd1386cc">1</ix:nonFraction>% plus a margin ranging from <ix:nonFraction unitRef="number" contextRef="if513d33ee9754a8db7bc70bffe5355a8_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDE1OQ_55443674-1b14-4421-adfb-77e3f43329f2">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i2890fd9ac6bc4bceb48adb41f2e0e88c_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDE2NQ_35c40d76-24ce-47ff-8c12-20d10f2524c6">1.25</ix:nonFraction>%, depending on the Company's consolidated net leverage ratio). The Company is required to make quarterly payments on the last business day of each calendar quarter under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from <ix:nonFraction unitRef="number" contextRef="ide27297d8c9443f09185ce0447397db4_D20200807-20200807" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDU0NA_374c7668-c847-4f18-aa0b-7e84471efc08">0.15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id5c8865dca0b4780ad587e383427e48b_D20200807-20200807" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDU1MA_808f88aa-fab5-498e-922d-db9baddace77">0.35</ix:nonFraction>% per annum, depending on the Company's consolidated net leverage ratio, for the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments on the last business day of each calendar quarter based on an annual percentage equal to <ix:nonFraction unitRef="number" contextRef="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807" decimals="INF" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDkwMA_5f046927-b6fa-4f01-b242-df87821172bc">2.5</ix:nonFraction>% of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, <ix:nonFraction unitRef="number" contextRef="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807" decimals="INF" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNTAyNA_2b48fd26-1f7b-47c0-8fdd-d9e920635dce">5</ix:nonFraction>% of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and <ix:nonFraction unitRef="number" contextRef="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807" decimals="INF" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNTEzOA_87026b75-a356-4408-b3f4-f826caa013ce">7.5</ix:nonFraction>% of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature on October 13, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of $<ix:nonFraction unitRef="usd" contextRef="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807" decimals="-5" name="ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNTg1Ng_baa11a6d-32d9-473d-93bc-4609277e6372">100.0</ix:nonFraction>&#160;million during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights. The financial covenants under the Amended Credit Agreement currently require the quarterly presentation of a minimum consolidated <ix:nonNumeric contextRef="icaeda5c9c6b540f5bb7a60baecd1d9b2_D20200807-20200807" name="ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjE1Nw_3a2441b9-4243-445b-bd94-c36e989a406c">12</ix:nonNumeric>-month rolling debt service coverage ratio of <ix:nonFraction unitRef="number" contextRef="ide27297d8c9443f09185ce0447397db4_D20200807-20200807" decimals="INF" name="ebs:DebtInstrumentCovenantDebtServiceCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjIwNQ_9097b04f-224c-4a4a-b22f-8d0c7622935a">2.50</ix:nonFraction> to 1.00, and a maximum consolidated net leverage ratio of <ix:nonFraction unitRef="number" contextRef="id5c8865dca0b4780ad587e383427e48b_D20200807-20200807" decimals="INF" name="ebs:DebtInstrumentCovenantNetLeverageRatioOne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjI2NA_0608e792-b150-45fb-9c1b-410c5f34bf32">4.50</ix:nonFraction> to 1.00 (subject to an increase to <ix:nonFraction unitRef="number" contextRef="id5c8865dca0b4780ad587e383427e48b_D20200807-20200807" decimals="INF" name="ebs:DebtInstrumentCovenantNetLeverageRatioTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjMwMA_2538d838-d989-4dcb-b738-5d81bc4deced">5.00</ix:nonFraction> to 1.00 for an applicable four quarter period, at the election of the Company, in connection with a permitted acquisition having an aggregate consideration in excess of $<ix:nonFraction unitRef="usd" contextRef="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807" decimals="-5" name="ebs:DebtInstrumentCovenantConsiderationThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjQ3MA_fecb1840-0a45-40ab-970a-5f8f2a518db5">75.0</ix:nonFraction>&#160;million). Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i2b7a45c7643b4997be54748ae1277ba5"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2023, the Company entered into a Consent, Limited Waiver, and Third Amendment (the "Third Credit Agreement Amendment") to the Amended Credit Agreement relating to the Senior Secured Credit Facilities. Pursuant to the Third Credit Agreement Amendment, the requisite lenders consented to our sale of our travel health business to Bavarian Nordic substantially in accordance with the terms of the Purchase and Sale Agreement with Bavarian Nordic (the "Sale Agreement"). The proceeds from the transaction will be deposited into a cash collateral account with the Administrative Agent and will, unless otherwise agreed to by the Company and the requisite lenders, be used to repay the outstanding Term Loan Facility on the expiration of the Limited Waiver (as described below). We currently expect the transaction to close in the second quarter of 2023, but we can provide no assurance that the transaction will close prior to the October 2023 maturity of the Term Loan Facility, or at all.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Third Credit Agreement Amendment the requisite lenders have agreed to a limited waiver of any defaults or events of default that was extended on April 17, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Company entered into a First Amendment (the &#8220;Waiver Amendment&#8221;) to the Third  Credit Agreement Amendment. The lenders agreed to extend the limited waiver (the &#8220;Extended Limited Waiver&#8221;) of any defaults or events of default that result from (a) any violation of the financial covenants set forth in the Amended Credit Agreement with respect to the fiscal quarters ending December&#160;31, 2022 and March&#160;31, 2023 and (b) any going concern qualification or exception contained in the audited financial statements for the fiscal year ending December&#160;31, 2022. The Extended Limited Waiver expires on the earlier to occur of (i) any other event of default under the Amended Credit Agreement and (ii) May 17, 2023. During the period of the Limited Waiver, the Company is working with lenders under the Amended Credit Agreement in connection with replacing the current credit facility before it matures with revised terms and conditions. The Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to the Amended Credit Agreement. See Note 2, "Summary of significant accounting policies" for Going Concern considerations related to noncompliance with our debt covenants and the limited waiver.</span></div></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_76"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTU4Nw_047264c7-3e6a-4630-861b-ff5df0a81023" continuedAt="i3cc484d40efe42f79e201301907135b6" escape="true">Stock-based compensation and stockholders' equity</ix:nonNumeric></span></div><ix:continuation id="i3cc484d40efe42f79e201301907135b6" continuedAt="ic105a4e31b994fae8c0e06f6487ff1df"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock-based compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company granted stock options to purchase <ix:nonFraction unitRef="shares" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYyOTUyMA_ae6e50a7-c7dd-414d-980f-dd321247783b">0.3</ix:nonFraction>&#160;million shares of common stock, <ix:nonFraction unitRef="shares" contextRef="ib1dc2e31750040a4aeea787dbc908607_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYyOTUxNg_736d1625-a095-45e1-89d5-2f78061e79f3">0.6</ix:nonFraction>&#160;million restricted stock units and <ix:nonFraction unitRef="shares" contextRef="i3cc418bd58f7472abd99705c9a2a8c70_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYzNDkwNA_11d68da9-6968-4e4d-9557-75affe13b47b">0.1</ix:nonFraction>&#160;million performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Performance stock units are presented at the target payout percentage of <ix:nonFraction unitRef="number" contextRef="i7c48770f38cc4b868dfb8e4164c70c6d_I20230331" decimals="2" name="ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMjE5OTAyMzI2MjgyOA_20b2ebf7-d478-471f-8fa2-a5d67d130742">100</ix:nonFraction>% of target shares granted. Typically, the stock options and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the <ix:nonNumeric contextRef="i3cc418bd58f7472abd99705c9a2a8c70_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTU4OQ_0093a074-1952-4da5-83ee-62947315f2af">three-year</ix:nonNumeric> performance period based on the Company's results compared to the performance criteria. During the three months ended March&#160;31, 2023 <ix:nonFraction unitRef="shares" contextRef="ib1dc2e31750040a4aeea787dbc908607_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYzNTAxMQ_3a698424-7548-4887-bb46-e3890a6712b7">0.2</ix:nonFraction>&#160;million shares of restricted stock units and <ix:nonFraction unitRef="shares" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfNTQ5NzU1ODIxNzM0_6d23b045-b77c-496f-b982-e7f48d387e1d">0.2</ix:nonFraction>&#160;million of stock options were forfeited prior to the completion of the applicable vesting requirements or expiration. Additionally, an immaterial amount of performance stock units were forfeited during the three months ended March&#160;31, 2023, as the award targets were not achieved. </span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTU4Mg_9783b3f4-058d-46a8-b26f-5e8eb642b775" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense, net of forfeitures was recorded in the following financial statement line items:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.861%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6f2abaf2d65647afabbaad4036b4002b_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfMi0xLTEtMS0xNzQwOTA_b5cc5436-06fd-4887-93aa-18d9dc5518b9">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a17055fb3844751ba1ee5905c41696a_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfMi0zLTEtMS0xNzQwOTA_b0ba09fa-2b28-4165-b755-d253653a615a">1.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7c648afc26c64c1cb1d06fba7976dd3e_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfMy0xLTEtMS0xNzQwOTA_e4fe42ad-3681-4f5f-917d-d09072878f53">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i052a8c8b494f4d23ba4683eec555cd78_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfMy0zLTEtMS0xNzQwOTA_b595e0dd-03d8-4e3a-98bb-f0092d0f73d4">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7b2c1680b344a52a7479ff1cb61e234_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNC0xLTEtMS0xNzQwOTA_e04fccd5-0e4d-4062-9093-1d24a56ec0cb">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i352e9c64d26145bd8c991621254ab36d_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNC0zLTEtMS0xNzQwOTA_4b44c8e2-4652-4cf5-aed8-b573916f805b">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2f4af96e200044a4bde5f4e7858cea4c_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNS0xLTEtMS0xNzQwOTA_ae731148-d273-471f-9965-46466a879f0c">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3820b0b0d3c345288eeffbe32298f81f_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNS0zLTEtMS0xNzQwOTA_3bd76de4-25a1-4f74-b22b-26d3233757b5">6.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNi0xLTEtMS0xNzQwOTA_f3874ba8-0993-48f4-b36b-aea9028aeb20">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNi0zLTEtMS0xNzQwOTA_ad7d8f7b-f9b4-460f-b0dd-10ba87d1d99b">9.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ic105a4e31b994fae8c0e06f6487ff1df"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 Share Repurchase Program</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2021, the Company announced that its Board of Directors authorized a stock repurchase program of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i5a35abf804794f0cb7a12ca90e436e2b_I20211111" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfNjkzNg_8c749c8b-30e9-4a66-b18d-9c78dfd48867">250.0</ix:nonFraction>&#160;million of Common Stock ("the Share Repurchase Program"). The Share Repurchase Program expired on November 11, 2022. The Company utilized $<ix:nonFraction unitRef="usd" contextRef="i6a932e200f934b2e8d7602dfc0339fbe_D20211111-20221111" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMzg0ODI5MDcwMzIxNw_8cf03ccc-1cfd-4dc7-86c2-77035a80e07d">187.9</ix:nonFraction>&#160;million to purchase <ix:nonFraction unitRef="shares" contextRef="i6a932e200f934b2e8d7602dfc0339fbe_D20211111-20221111" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMzg0ODI5MDcwMzIzMw_f6b6aad3-a7e9-48d2-be76-44cced4c2e98">4.4</ix:nonFraction>&#160;million shares as of the program's expiration date. During the three months ended March&#160;31, 2022, the Company utilized $<ix:nonFraction unitRef="usd" contextRef="i31244a3a054948c88dabb06cdf5a93c8_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYzNDczNA_a7017509-35e3-4ea2-a61d-bb3ab43c7bb7">52.2</ix:nonFraction>&#160;million to purchase <ix:nonFraction unitRef="shares" contextRef="i31244a3a054948c88dabb06cdf5a93c8_D20220101-20220331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYzNDc2OQ_30029cf9-022a-492e-bc7c-654a7eb4d33e">1.1</ix:nonFraction> million shares. Repurchased shares are available for use in connection with the Company's stock plans and for other corporate purposes.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accumulated other comprehensive income (loss), net of tax</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTU4Ng_8ebdc34a-2757-49ae-9bfa-633ddacd1aff" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.110%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Defined Benefit Pension Plan</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2022</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib39593e9eeaa410eb010f609006439d3_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMi0yLTEtMS0xNzQwOTA_f49b9060-99df-4728-a0b4-f64218fa6c05">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i571387e1e87d4c0ca79fba6168341392_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMi00LTEtMS0xNzQwOTA_1071e7a1-49e7-4d58-af92-a38dc5120974">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8456a4beddae4620b224ffe90a753930_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMi02LTEtMS0xNzQwOTA_611d90c3-b987-436c-84db-b1f3a38bd766">6.6</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i849666feb2a44d2fa12bc7967461f166_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMi04LTEtMS0xNzQwOTA_52e60d9b-393a-4a54-9c28-37582edd08d2">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i38e2cc2fa38f451983e4495ebddf4541_D20230101-20230331" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMy0yLTEtMS0xNzQwOTA_bee9a092-be19-4fd5-93e3-64e37e11ae7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMy00LTEtMS0xNzQwOTA_4b51c467-0c6a-4823-8313-da3a60dd4a7b">4.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMy02LTEtMS0xNzQwOTA_c40e80ba-e209-4a3c-a4b4-2b2981f491d4">0.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMy04LTEtMS0xNzQwOTA_8680bb34-b3f5-498f-b6c2-e49bb4dda7da">4.5</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i38e2cc2fa38f451983e4495ebddf4541_D20230101-20230331" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNC0yLTEtMS0xNzQwOTA_c44d03e8-0ca3-4e11-b107-4a4e6fe4562d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNC00LTEtMS0xNzQwOTA_8cc53540-fe58-4826-803a-16fe4f5202d4">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNC02LTEtMS0xNzQwOTA_a1e77a55-0270-4ac5-a65a-ec68765c0b5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNC04LTEtMS0xNzQwOTA_ba6ef5ee-629b-4509-b3fe-e433df49285b">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net current period other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i38e2cc2fa38f451983e4495ebddf4541_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNS0yLTEtMS0xNzQwOTA_4c9d7b48-d723-49b9-bac6-bbc1c3460b87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNS00LTEtMS0xNzQwOTA_2bf1aee5-6dde-44f9-9767-b3a44e7f6d58">2.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNS02LTEtMS0xNzQwOTA_09d7c775-2c8b-4933-9d78-075580e72225">0.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNS04LTEtMS0xNzQwOTA_740dc91c-7276-4da4-b16f-c6d527556dca">2.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i96351882c9cf4a119573f21d2fd9c69c_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNi0yLTEtMS0xNzQwOTA_dd8cd0e5-173e-48bf-b1c1-4c56f20ea5d1">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia07411d977084f2bb9e23d05b7a3e72f_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNi00LTEtMS0xNzQwOTA_7367ba9d-d4f2-4ee3-aa55-14871572bf15">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id8cf4c3b78864ea8b78309b616ed410d_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNi02LTEtMS0xNzQwOTA_2f626608-33c0-474a-94c6-c7ecf89cc165">6.7</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d83f154114044a1bbe6ae3c214f52d4_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNi04LTEtMS0xNzQwOTA_56ff55bc-738f-4386-8565-2540d9b81d23">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i004ed59fdb204528af83813c202f2349_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTQtMi0xLTEtMTc0MDkw_2b9351aa-f510-4b79-ac53-f5c28d2605d7">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ied3e0a962bf84f89a49887476428ac94_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTQtNC0xLTEtMTc0MDkw_666794b7-5807-4105-9eb0-4f1f0a8133f4">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9f133842273b47d8a0e0c8008c0debc9_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTQtNi0xLTEtMTc0MDkw_6ce5d660-67cb-4fc5-b776-108747e1c06b">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id730fb1f570643e09406bfe6aebe15ba_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTQtOC0xLTEtMTc0MDkw_fbd47516-34e2-4a41-8457-c32b5c25d13a">16.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1df6434f4c741debcb5c66e3f358e12_D20220101-20220331" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTUtMi0xLTEtMTc0MDkw_a57c324c-bc64-4b72-a509-8d587d38ba85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTUtNC0xLTEtMTc0MDkw_f3b3b30d-6fcf-4b40-a177-67e10dd2fa87">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTUtNi0xLTEtMTc0MDkw_2f4cf8ed-df56-45e7-a023-7f176ce9664e">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTUtOC0xLTEtMTc0MDkw_a8c126af-b9e3-4311-b09d-633e644f6666">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1df6434f4c741debcb5c66e3f358e12_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTYtMi0xLTEtMTc0MDkw_c7fbab28-8a5a-4b3b-97b6-b85cd586b011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTYtNC0xLTEtMTc0MDkw_e44e490e-3d91-4f55-b601-a32cca846cb9">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTYtNi0xLTEtMTc0MDkw_62d2792d-8ed5-4b80-a1a3-e0797490a157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTYtOC0xLTEtMTc0MDkw_f61cf93f-a096-4b40-b6b8-f1bae69f32a0">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net current period other comprehensive income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1df6434f4c741debcb5c66e3f358e12_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTctMi0xLTEtMTkyODM1_a5a67026-f478-49e7-aabf-e97f7a6a80ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTctNC0xLTEtMTc0MDkw_acfc2cd6-1366-45ab-a95e-2bcbe5b09212">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTctNi0xLTEtMTc0MDkw_1bc788a1-f579-4742-bdad-7f19ab3e7bbf">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTctOC0xLTEtMTc0MDkw_0de38a40-0289-41b6-bcb8-2fe23a33e04c">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iecaf90f0f80546248e7c187071884007_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTgtMi0xLTEtMTc0MDkw_6d291410-5c71-4b7d-b32a-7853369e9a17">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i691f830478c747349de4e41c45528d98_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTgtNC0xLTEtMTc0MDkw_fce76ee0-62b6-4244-a8ea-0f8b658b1bc8">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4eb60b9b64b04e06af66a990c3c77632_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTgtNi0xLTEtMTc0MDkw_95745bab-50a3-43d9-b890-9128e1b2f31c">7.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9426132f4f814179b20fee2cb4d853f7_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTgtOC0xLTEtMTc0MDkw_9df949a4-51eb-4ed2-b86f-d81f09fea5de">9.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTU5MA_c7bd1d3f-3c3d-41b2-bcf2-14a600475d1a" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the tax effects related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="33" style="background-color:#19415e;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS0xLTEtMS0xNzQwOTA_d06fde2f-f686-4512-bc99-533e0921213a">2.6</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS0zLTEtMS0xNzQwOTA_8e19494f-321c-45a9-9307-74c07b700ee2">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS01LTEtMS0xNzQwOTA_ac45b056-cff3-45a9-a947-72c1a0c13577">2.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS03LTEtMS0xNzQwOTA_dd8ccbc9-a83c-402e-a955-4933c30af906">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS05LTEtMS0xNzQwOTA_c02c8075-02c7-4441-bc3b-445db5197762">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS0xMS0xLTEtMTc0MDkw_c8b168ce-71fc-4df9-9719-9c05e38ca8e6">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi0xLTEtMS0xNzQwOTA_6370bdf8-6e08-4315-bb33-61b6806571aa">0.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi0zLTEtMS0xNzQwOTA_ca983b86-35fb-48f4-a4f6-ef5448facf81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi01LTEtMS0xNzQwOTA_3da0bdfe-3e64-4a1c-8bd0-c1a4ebee6b50">0.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi03LTEtMS0xNzQwOTA_d37c0d19-a7d9-4409-a9d0-ee76dbb9b09b">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi05LTEtMS0xNzQwOTA_d9022670-469f-437f-8d79-991ee40f3a31">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi0xMS0xLTEtMTc0MDkw_9f25b2fa-1707-4b6e-bc94-181d77291296">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy0xLTEtMS0xNzQwOTA_902afdbc-4ea0-44c3-ac96-7049e7dfb646">2.7</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy0zLTEtMS0xNzQwOTA_2abd920e-ea07-40c1-b369-adb764695c23">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy01LTEtMS0xNzQwOTA_f0357417-03c9-49d3-af7e-f5d0f83fa92e">2.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy03LTEtMS0xNzQwOTA_ce5b509f-cfe8-458c-94ed-7a277ee41921">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy05LTEtMS0xNzQwOTA_0dd88ee3-9b70-4a72-ac46-2d16d605b665">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy0xMS0xLTEtMTc0MDkw_18bae771-172a-4f50-94be-187242bcf379">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RleHRyZWdpb246Y2Q0M2ZlNGRmODU5NGVmN2E3MTU5ZmRkNjNiZDRjZjRfMTMwNQ_5f849070-8080-418f-9230-f8cb090725f4" continuedAt="idab4235ac4de4c898bb8bc7bdd75905c" escape="true">Earnings (loss) per common share</ix:nonNumeric></span></div><ix:continuation id="idab4235ac4de4c898bb8bc7bdd75905c"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share adjusts basic loss per common share for the effects of potentially dilutive common shares and is calculated using the treasury stock method. Potentially dilutive common shares include the dilutive effect of shares issuable under our equity compensation plans, including stock options, restricted stock units, and performance stock units. Diluted loss per share excludes anti-dilutive securities, which represent the number of potential common shares related to shares issuable under our equity compensation plan that were excluded from diluted loss per common share because their effect would have been antidilutive.</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RleHRyZWdpb246Y2Q0M2ZlNGRmODU5NGVmN2E3MTU5ZmRkNjNiZDRjZjRfMTMwNA_c572b2a3-9292-4463-9b17-9e37aa68c590" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted loss per share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.287%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMy0xLTEtMS0xNzQwOTA_0fbe4725-1c9d-45dc-8c18-24654d55d61b">183.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMy0zLTEtMS0xNzQwOTA_0d567eb1-d823-4f66-a8ed-cef1a0048697">3.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfNi0xLTEtMS0xNzQwOTA_a09bf8f8-4dc8-4491-88e5-37df65ef1d0f">50.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfNi0zLTEtMS0xNzQwOTA_795bdb3c-137e-4654-9a1e-6a7a0f976cd6">50.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-diluted</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfOC0xLTEtMS0xNzQwOTA_3e13913d-d859-4c8d-86d2-3210fb19e5a8">50.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfOC0zLTEtMS0xNzQwOTA_2ba4a9b3-e266-47dc-8270-56e38f2a4976">50.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per common share - basic</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTAtMS0xLTEtMTc0MDkw_8713f992-7487-40aa-a5d4-371a68594f04">3.65</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTAtMy0xLTEtMTc0MDkw_4ba25c4e-59cb-4c8e-96f9-6efde373ecd8">0.07</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per common share - diluted</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTEtMS0xLTEtMTc0MDkw_82316647-8db5-4b8e-9e90-c571b7803b1b">3.65</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTEtMy0xLTEtMTc0MDkw_6d78697a-99ad-4d95-b4a3-1bcb117622ff">0.07</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTEtMS0xLTEtMTkyODUy_13201276-0b06-4f08-ab93-41af499ca966">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTEtMy0xLTEtMTkyODUy_d1b79200-383d-425a-8f29-224e68da7bbd">1.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_64"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfODIzMA_9cb55893-1dfd-4dbb-b672-4f012ca594b6" continuedAt="ic54d2c64c77e46ddbb013e7b3a441746" escape="true">Revenue recognition </ix:nonNumeric></span></div><ix:continuation id="ic54d2c64c77e46ddbb013e7b3a441746" continuedAt="i4dc77b2084724807a550f95e69960677"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0NTg1MA_25904a2e-c7fd-4897-92f6-57fb9e4dbb42"><ix:nonFraction unitRef="segment" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0NTg1MA_e1785b3d-d453-4476-864e-65e5ac7806fb">two</ix:nonFraction></ix:nonFraction> operating segments (see Note 17, "Segment information"). <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfODIzMg_101807eb-b2e0-4666-a34f-7322ac0f9237" continuedAt="ic5898e02a99b4e52b537d16a0bebab8c" escape="true">The Company's revenues disaggregated by the major sources were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="ic5898e02a99b4e52b537d16a0bebab8c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6f98df3f96494ca3af0b6134b79f6e6c_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi0xLTEtMS0xNzQwOTA_b2c32862-3672-4443-b28c-01e794fdf6fd">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i732a446dfeda451387df581fcd0cfb6e_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi0zLTEtMS0xNzQwOTA_e273f1a0-b36f-4475-9542-cce7bbf4e43d">117.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8bac9a933b6d4e1f906de2a6a7325d62_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi01LTEtMS0xNzQwOTA_446c9ab0-462f-41d8-992e-9e725292e861">143.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id50de4745d3a466eafedae511bbe57f3_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi03LTEtMS0xNzQwOTA_956029b1-13ef-4c31-8db8-5f8f638cdb64">103.4</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1ed128aa8d4847bd8d098b42c1c2112a_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi05LTEtMS0xNzQwOTA_73812005-ab6e-4e2b-b1d6-1cf519be11f8">133.7</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i96983ae20d1a4fd892a5f1444783a570_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi0xMS0xLTEtMTc0MDkw_f3c015d2-02bb-46e3-8cfd-5319ac683b35">237.1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a7228c4c4da4a3daa277c2e60ff556d_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC0xLTEtMS0xNzQwOTA_de7fbf35-9407-4801-b55b-7378d36bf500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifc9f8df6d25942899d6f3695ef5c6172_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC0zLTEtMS0xNzQwOTA_72b08603-fc90-477a-8eaa-1f5c2df39562">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i18e052da12c34e0e91cf56a39cd08cd1_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC01LTEtMS0xNzQwOTA_72234573-1869-4776-beb7-098e451ca577">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i987753cf494a4b45ace898c7942aef7c_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC03LTEtMS0xNzQwOTA_233c1547-00ac-4df7-b9d1-5b66b9c1dbfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5383a292c962418f9b059d0b06839b4e_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC05LTEtMS0xNzQwOTA_6c4eb278-974a-47bf-99b1-5576a7076d07">51.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i513c1b52eb2e4d47828f3ec0440d9a1a_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC0xMS0xLTEtMTc0MDkw_4e0ef9e5-59b4-43c8-89bd-9530dc691504">51.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie421a9cb2b954cbca8c8c507c55fd2bd_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS0xLTEtMS0xNzQwOTA_94d58a35-3e7c-4805-9483-86eb0c3882b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95813f0ec62d4d0c9fcc5789b0837330_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS0zLTEtMS0xNzQwOTA_7fc665f4-195e-4908-a93e-41034c1c6e44">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i79e134d107e94e148da24dade40b12b6_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS01LTEtMS0xNzQwOTA_76957a9c-7b79-42a8-b58f-cad423dabbeb">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d187bce987143dc92586a3d08ecacd6_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS03LTEtMS0xNzQwOTA_42ff9b75-d116-4603-85b0-db41e9629ea2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id10f475f516846bcae44f6b46b3bbd0b_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS05LTEtMS0xNzQwOTA_2e2a9439-9598-40a7-b63f-f0ea4e346930">9.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8373489620694e8096c4d7cb76a601a2_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS0xMS0xLTEtMTc0MDkw_0cd08138-94e0-42e4-aaba-c260f50e7770">9.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total CDMO</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iab03b11d81254786a5977fced794e6b1_D20230101-20230331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi0xLTEtMS0xNzQwOTA_f1c8244b-d7cd-4b49-a949-22b01e108cfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i871dc7a154524d879334cb879c7ddfd0_D20230101-20230331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi0zLTEtMS0xNzQwOTA_c1fb4172-3fdb-4c17-a274-672e8e60c9c5">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i282b3d80373a44448dcd835b4ec3dd02_D20230101-20230331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi01LTEtMS0xNzQwOTA_c751a1eb-bd29-4ac8-8cdd-ffcf550196a3">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3379cc28cb04ee5bececd01664b6872_D20220101-20220331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi03LTEtMS0xNzQwOTA_d23ff47d-295d-4036-9c8e-d2be38b39486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4efd920943c8420a8281d18b9639ad0e_D20220101-20220331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi05LTEtMS0xNzQwOTA_9cdbb73d-5210-46dc-9db8-41498e8382a6">60.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6fcbd10db46849358e569878c1ae8ae0_D20220101-20220331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi0xMS0xLTEtMTc0MDkw_9ed84912-5525-4954-8c06-4d44a0ff2e9b">60.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib83a1dda4ddc4ccdad92792fb6b17c46_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy0xLTEtMS0xNzQwOTA_e3cf7f73-1c3d-4cbd-a080-3587826c2ef7">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2c77354994dd4d71ac100d180641d494_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy0zLTEtMS0xNzQwOTA_4bda558f-0c5e-4560-a8f7-8865a8784fad">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0e5222cf971340bab0614a17ebbf5ed8_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy01LTEtMS0xNzQwOTA_1ec0538a-f79d-4269-952e-1f112f4cd4e4">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9415e748067844bfbe9ef3caeb28bad0_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy03LTEtMS0xNzQwOTA_f81e9dc0-6455-4dff-af50-77741a010d09">9.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id3f4207af8e54989a266f7659a215b5e_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy05LTEtMS0xNzQwOTA_e8940d1a-7eb4-457e-ab6c-786b5195509b">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0d4fc9a55e4b49afb88321e52246a468_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy0xMS0xLTEtMTc0MDkw_4ad383f2-c832-47a0-b0be-0d6b8dab6d01">9.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iff58dd309a0441e3b97192aae2d95c4f_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC0xLTEtMS0xNzQwOTA_60a9ce6c-a76c-436f-b6d7-4810576f6352">31.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idd7432d9b0914c74aee8b459bf887d15_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC0zLTEtMS0xNzQwOTA_662b33e9-9926-43e4-a3b9-e363232924c7">134.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC01LTEtMS0xNzQwOTA_9310d7b6-97cc-4d74-a12d-35d2d99f695c">165.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i04f3699777f34efe88b689e5c3e48b90_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC03LTEtMS0xNzQwOTA_40a7f55f-9428-4d3a-a64f-434e601794e8">112.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i39d08b46e2f94f58a5f1e2935eeece69_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC05LTEtMS0xNzQwOTA_d4622aa7-f7ee-4b19-9017-6626bb5c686f">195.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC0xMS0xLTEtMTc0MDkw_8772a568-038c-40b6-acdc-3e7f306c3d35">307.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/><br/></span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2020, the Company, through its wholly-owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into the Agreement with Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, for large-scale drug substance manufacturing of Johnson &amp; Johnson&#8217;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#8220;Product&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, the Company provided to Janssen a notice (the &#8220;Notice&#8221;) of material breach of the Agreement for, among other things, failure by Janssen (i) to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Agreement and (ii) to confirm Janssen&#8217;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Agreement and instead, wind-down the Agreement ahead of fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#8220;Janssen Notice&#8221;) of the Agreement for asserted material breaches of the Agreement by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices ("cGMP") or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the Company&#8217;s breaches were not curable and that, therefore, termination of the Agreement would be effective as of July 6, 2022. The Company disputes </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i4dc77b2084724807a550f95e69960677" continuedAt="i993874037a634741bf9398dee1159ffc"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result of the Company's alleged failure to perform under the Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process through arbitration.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, there were no impacts on previously recognized revenue or depreciation related to the conclusion of the Agreement. As of March&#160;31, 2023, the Company has no billed or unbilled net accounts receivable related to the Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the fourth quarter of 2022, because the arbitration process may extend longer than one year, the Company reclassified amounts related to the Janssen Agreement from "Inventories, net" and from "Prepaid expenses and other current assets" to "Other assets", resulting in $<ix:nonFraction unitRef="usd" contextRef="i4294703259534cdcbbf6f3c0f104718b_D20221001-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY2NTE3Ng_f79c8848-c8bc-4de6-bbd5-cdc850c1f3fb">152.7</ix:nonFraction>&#160;million in long-term assets related to the Janssen Agreement on the Condensed Consolidated Balance Sheet as of December&#160;31, 2022. The long-term asset balance within "Other Assets" related to the Agreement as of March&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="id18cb2b8881b4956ac5446f313a06aa4_I20230331" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY2NTE2OA_1089175f-d1b4-47d6-a486-5620b57d398e">153.9</ix:nonFraction>&#160;million. These assets include termination penalties, certain inventory related items and raw materials inventory representing materials purchased for the Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of the inventory as of March&#160;31, 2023, concluding that because the Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for any reason, the Company is entitled to payment from Janssen for these raw materials. Additionally, the Company has $<ix:nonFraction unitRef="usd" contextRef="id18cb2b8881b4956ac5446f313a06aa4_I20230331" decimals="-5" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY2NjE3Nw_b1e43019-4b55-476a-97fb-20c47ba8ddb5">5.4</ix:nonFraction>&#160;million of non-cancelable orders as of March&#160;31, 2023 which have not been received and Janssen has not reimbursed.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CDMO operating leases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain multi-year CDMO service arrangements with commercial customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates <ix:nonNumeric contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY2NTIwMQ_d2054332-3edb-4607-bac4-118309db60bd">2.5</ix:nonNumeric> years. The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components. Excluding future amounts related to the Agreement as discussed above, the Company estimates future operating lease revenues to be $<ix:nonFraction unitRef="usd" contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTQ5MQ_34c1536c-510e-4ef6-8af6-837650c64b63">3.3</ix:nonFraction>&#160;million in the remainder of 2023, $<ix:nonFraction unitRef="usd" contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTQ5NQ_ab3ba185-4c3f-4a6e-919f-43537d581c5e">0.9</ix:nonFraction>&#160;million in 2024, $<ix:nonFraction unitRef="usd" contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTQ5OQ_5ec43c44-6ec8-4b44-a0f1-881f8f0cc54e">0.9</ix:nonFraction>&#160;million in 2025, $<ix:nonFraction unitRef="usd" contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfNTQ5NzU1ODUyNTQ1_9930e150-ce4b-4bb1-8a8e-00c53cee9758">0.9</ix:nonFraction>&#160;million in 2026, $<ix:nonFraction unitRef="usd" contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfNTQ5NzU1ODUyNTU5_b76b7011-3e68-48a3-89bf-8132976c70ea">0.9</ix:nonFraction>&#160;million in 2027 and $<ix:nonFraction unitRef="usd" contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331" decimals="-5" name="ebs:LessorOperatingLeasePaymentToBeReceivedAfterYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTUwMw_3edd7ce8-d5b0-4fb3-9e33-a1d160ac2e68">0.9</ix:nonFraction>&#160;million in years beyon</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d 2027.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction price allocated to remaining performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company has future contract value on unsatisfied performance obligations of approximately $<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTY0OQ_f8d0e914-30d3-4d0e-aa69-721573932253">331.1</ix:nonFraction>&#160;million associated with all arrangements entered into by the Company. The Company expects to recognize a majority of the $<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTY1Mw_f8d0e914-30d3-4d0e-aa69-721573932253">331.1</ix:nonFraction>&#160;million of unsatisfied performance obligations within the next <ix:nonNumeric contextRef="ide9ab2059eb245668f1987b63208f7e7_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfNjMyOQ_55c0679a-b10c-4e79-a0fb-ce2c69fd368c">24</ix:nonNumeric> months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associated with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#8217;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of March&#160;31, 2023 and December&#160;31, 2022, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had $<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTY3NQ_eb7a1ed4-b886-496e-8aa5-77305bb3a019">27.1</ix:nonFraction> million an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTY2Ng_31847546-dfa8-4037-b25c-74a7c3953bfa">34.8</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, of contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded within "Accounts receivable, net" on the Condensed Consolidated Balance Sheets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i993874037a634741bf9398dee1159ffc"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the Condensed Consolidated Balance Sheets and is deferred until control of these performance obligations is transferred to the customer. <ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfODIzNA_efbc1fe7-968a-4ed5-9fc9-1c0b0d4e4fc2" continuedAt="i53a5498f62be493cb58d1a1300055c40" escape="true">The following table presents the roll forward of the contract liability balances:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="i53a5498f62be493cb58d1a1300055c40"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmNkYWUwNmIxODI5NTQ2Yjg5NWFhYzE5ZjBlMGZkOTM5L3RhYmxlcmFuZ2U6Y2RhZTA2YjE4Mjk1NDZiODk1YWFjMTlmMGUwZmQ5MzlfMS0yLTEtMS0xNzQwOTA_f560edb0-da2d-4d0a-9dff-44bd47615767">31.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="ebs:ContractWithCustomerLiabilityAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmNkYWUwNmIxODI5NTQ2Yjg5NWFhYzE5ZjBlMGZkOTM5L3RhYmxlcmFuZ2U6Y2RhZTA2YjE4Mjk1NDZiODk1YWFjMTlmMGUwZmQ5MzlfMi0yLTEtMS0xNzQwOTA_99bff6ab-e34f-4518-b7f7-d54c1e06502c">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="ebs:ContractWithCustomerLiabilityDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmNkYWUwNmIxODI5NTQ2Yjg5NWFhYzE5ZjBlMGZkOTM5L3RhYmxlcmFuZ2U6Y2RhZTA2YjE4Mjk1NDZiODk1YWFjMTlmMGUwZmQ5MzlfMy0yLTEtMS0xNzQwOTA_bb06064a-cc96-4d85-b4a0-34deb7e4334b">18.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmNkYWUwNmIxODI5NTQ2Yjg5NWFhYzE5ZjBlMGZkOTM5L3RhYmxlcmFuZ2U6Y2RhZTA2YjE4Mjk1NDZiODk1YWFjMTlmMGUwZmQ5MzlfNC0yLTEtMS0xNzQwOTA_506884c1-3965-4387-9ac0-eae3d473c89f">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the current portion of contract liabilities was $<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTYzMw_134f70f7-a02a-4576-9934-ea57229d313e">12.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTYzNw_0dfbcab2-9778-4f1c-a9b4-8082a321594d">26.4</ix:nonFraction>&#160;million, respectively, and was included in "Other current liabilities" on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable and allowance for expected credit losses</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="ebs:ScheduleOfAccountsReceivableNetTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfODIzNQ_69a06eda-54ac-44f1-a451-c4a9f57cb694" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:61.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billed</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMS0yLTEtMS0xNzQwOTA_4470c064-83f9-4981-bd0e-4da21fad3d67">106.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMS00LTEtMS0xNzQwOTA_7296ea4f-a719-4da9-9b3c-d87639948fd2">102.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMi0yLTEtMS0xNzQwOTA_c6490ac5-d852-4abe-9820-610a7524589b">49.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMi00LTEtMS0xNzQwOTA_4036a607-b686-4fab-8538-60b11196612c">56.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for expected credit losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMy0yLTEtMS0xODEyMzA_6f796635-5c41-4994-85f3-024c93a3771c">0.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMy00LTEtMS0xODEyMzA_fdc27700-5733-4a44-9500-72a95e5cf51a">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMy0yLTEtMS0xNzQwOTA_38cadded-a2c1-4138-99c3-dca3fe35279a">155.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMy00LTEtMS0xNzQwOTA_c96dd31a-51ba-4763-8184-d297b16fa912">158.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_46"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RleHRyZWdpb246ZTM1ZjU1YjdkOWJiNDBjYzllMDgzNmEyZWFkYTAyNjlfMTA2Nw_94766212-45cd-4601-83e6-b1559fc2a4a4" continuedAt="ic22531da3f73403aae15b990bce11776" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ic22531da3f73403aae15b990bce11776" continuedAt="i41e3003370d74383a39bdaf56b93d222"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the lessee for operating leases for offices, R&amp;D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets and liabilities. For a discussion of lessor activities, see Note 13, "Revenue recognition".</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RleHRyZWdpb246ZTM1ZjU1YjdkOWJiNDBjYzllMDgzNmEyZWFkYTAyNjlfMTA2OQ_c126c478-8630-43e5-98b9-52ac49707f27" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.149%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfMy0xLTEtMS0xNzQwOTA_acb077ba-70e1-4580-a89e-f892f7b90c8d">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfMy0zLTEtMS0xNzQwOTA_a97dc804-7913-478c-82fb-8ceb8aa5037c">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfNC0xLTEtMS0xNzQwOTA_893686a7-60dd-4838-840e-39ba48c08b55">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfNC0zLTEtMS0xNzQwOTA_f812ee3f-4574-4b71-a47b-cdd9c06d0f30">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfNS0xLTEtMS0xNzQwOTA_28ff7392-5918-429f-b22b-9430d5bacd6b">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfNS0zLTEtMS0xNzQwOTA_603ac74d-8a44-42ca-a481-7af7ef44d6b5">1.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are reflected as components of cost of product sales, cost of contract development and manufacturing, R&amp;D expense and selling, general and administrative expense.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i41e3003370d74383a39bdaf56b93d222"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="ebs:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RleHRyZWdpb246ZTM1ZjU1YjdkOWJiNDBjYzllMDgzNmEyZWFkYTAyNjlfMTA1Ng_d015f8f6-82bf-40eb-a55e-7adb14e23419" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.863%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Leases</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_2bbfbc2c-d247-4e2c-8c4a-1c01ee6c8aa2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_7baa0cdf-0d92-4228-afaa-c3228f02be7a">Other assets</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0zLTEtMS0xNzQwOTA_d5589068-c8f2-4d06-be6b-0a6e64999145">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS01LTEtMS0xNzQwOTA_f1d597d4-c7b6-4f07-b75a-526ef22743b5">19.4</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_1145e4f7-1aec-4074-98e1-3ac124493f0e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_d44d3959-2bf6-46da-bfab-b74e748a5df1">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0zLTEtMS0xNzQwOTA_88a600e6-9857-40f1-aefa-118d5c81937c">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy01LTEtMS0xNzQwOTA_8e98b242-6681-4033-91eb-20a4ac8a06d6">5.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_3c68e61a-e113-4e32-8721-bdace66fd926"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_9da09783-cbaa-40ca-9a98-b6bc1f730f8f">Other liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0zLTEtMS0xNzQwOTA_56bdf365-500b-4ce0-b963-29bca834811f">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC01LTEtMS0xNzQwOTA_ef1e491b-57a1-4e5e-a06c-8be492cd016e">14.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNS0zLTEtMS0xNzQwOTA_f3af4c4b-5d52-411c-828b-61601d7d514e">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNS01LTEtMS0xNzQwOTA_2100886d-3d47-494f-9ab7-543d9ffb8272">20.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfOC0zLTEtMS0xNzQwOTA_a9723521-e222-4501-b732-1720d9480a5c">6.6</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfOC01LTEtMS0xNzQwOTA_fb990bbe-cc93-4f0d-b65d-1843649d56d0">5.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfOS0zLTEtMS0xNzQwOTA_6df6907d-0226-4a2e-b549-bbc32274468a">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfOS01LTEtMS0xNzQwOTA_60f67b4d-898b-4c87-82c5-d4c5a4a4c674">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_70"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfMTgzMg_5afc8605-adaf-4594-8697-291351347ea5" continuedAt="idd6f924d485e4db0b5e27c5a6fb76b2a" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="idd6f924d485e4db0b5e27c5a6fb76b2a" continuedAt="ie12cfa22da7846e9b44fdf59dc3efdcc"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated effective annual tax rate for the years ended December&#160;31, 2023 and 2022, excluding the impact of discrete adjustments, was (<ix:nonFraction unitRef="number" contextRef="ib40925538fdf41e1b15aa28d2dffd833_D20230101-20231231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfMTA5OTUxMTYzMjAwNQ_81f509f9-eb23-4cbb-9231-f0d2bfdb0328">13</ix:nonFraction>)% and <ix:nonFraction unitRef="number" contextRef="i92e936994b3b439dae281f549affd0f1_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfMTA5OTUxMTYzMjAwOQ_b934bace-efd5-4107-af61-09ee5244a85b">25</ix:nonFraction>%, respectively. The decrease in the estimated effective annual tax rate is primarily due to a valuation allowance charge. The Company recorded a discrete tax expense of $<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfMTA5OTUxMTYzMjAxNw_a9bd7e0a-aab1-41b3-96fa-7ef6de308da2">0.0&#160;million</ix:nonFraction> for the three months ended March&#160;31, 2023, and $<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfMTA5OTUxMTYzMjAxMw_576c79f9-d6b7-4740-a4d4-c453995162cd">0.4</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2022. The discrete tax expense in 2023 was due to share-based compensation activity which was entirely offset by a valuation allowance charge. The net discrete expense in 2022 was primarily due to share-based compensation activity and return to provision adjustments.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. At each reporting period, the Company considers the scheduled reversal of deferred tax liabilities and assets, available taxes in carryback periods, tax planning strategies and projected future taxable income in making this assessment.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie12cfa22da7846e9b44fdf59dc3efdcc">In 2022, the Company determined that it was more likely than not that certain deferred tax assets would not be realized due to reductions in estimates of future profitability and disclosure related to substantial doubt about the Company's ability to continue as a going concern. Accordingly, the Company recorded an additional valuation allowance charge of $<ix:nonFraction unitRef="usd" contextRef="ib40925538fdf41e1b15aa28d2dffd833_D20230101-20231231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfNTQ5NzU1ODE5Mjgz_0ba35470-aecf-430c-8dec-78aba25a8124">65.2</ix:nonFraction> million in calculating the estimated annual tax rate for the year ended December&#160;31, 2023.</ix:continuation> </span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_88"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84OC9mcmFnOjNiODllYzBmOWFjMDQ1NDM4NjM3OWU0ZjAwZTBmNzkxL3RleHRyZWdpb246M2I4OWVjMGY5YWMwNDU0Mzg2Mzc5ZTRmMDBlMGY3OTFfNzY0Mw_735a328c-a944-4a5f-b555-8900c08e55b9" continuedAt="idfa0b9618ecf4679a134ef6eea814248" escape="true">Litigation</ix:nonNumeric></span></div><ix:continuation id="idfa0b9618ecf4679a134ef6eea814248" continuedAt="ib899ba6f55fb4ffab4f4d9c5b5024573"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities and shareholder litigation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock, seeking to pursue remedies under the Securities Exchange Act of 1934. These complaints were filed by Palm Tran, Inc. &#8211; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth; and Stephen M. Weiss, respectively. The complaints allege, among other things, that the defendants made false and misleading statements about the Company's manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as "CDMO Manufacturing Capabilities"). These cases were consolidated on December 23, 2021, under the caption In re Emergent BioSolutions Inc. Securities Litigation, No. 8:21-cv-00955-PWG (the "Federal Securities Class Action"). The Lead Plaintiffs in the consolidated matter are Nova Scotia Health Employees&#8217; Pension Plan and The City of Fort Lauderdale Police &amp; Firefighters&#8217; Retirement System. The defendants filed a motion to dismiss on May 19, 2022 and the Lead Plaintiff filed an opposition to that motion on July 19, 2022. A hearing on the motion to dismiss was conducted on April 19, 2023 and a decision on the motion is expected in the coming months. The defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ib899ba6f55fb4ffab4f4d9c5b5024573"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the consolidated action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, Lincolnshire Police Pension Fund (&#8220;Lincolnshire&#8221;), and on August 16, 2021, Pooja Sayal, filed putative shareholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, the cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-PWG. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022 the Court approved the parties joint stipulation to and stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action. The defendants believe that the allegations in the complaints are without merit and intend to defend the matter vigorously.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, September 16, 2021 and November 12, 2021, putative shareholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp; Police Officers Pension Fund, respectively, in The Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption In re Emergent BioSolutions, Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#8217; filed a motion to dismiss the complaint. Ruling on this motion is stayed pursuant to a March 29, 2022 order staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, December 22, 2021 and January 18, 2022, putative shareholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the federal securities laws, each allegation related to the CDMO Manufacturing Capabilities. The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings and Discovery, pursuant to which the parties agreed to stay all proceedings until 30 calendar days after a ruling on the defendants&#8217; motion to dismiss the Federal Securities Class Action. The Court approved the Joint Stipulation on March 14, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above actions, the Company has received inquiries and subpoenas to produce documents related to these matters from the Department of Justice, the SEC, the Maryland Attorney General&#8217;s Office, and the New York Attorney General&#8217;s Office. The Company produced or is producing documents as required in response and will continue to cooperate with these government inquiries. The Company also received inquiries and subpoenas from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis and Senator Murray of the Committee on Health, Education, Labor and Pensions. The Company produced documents and provided testimony and briefings as requested in response to these inquiries.</span></div></ix:continuation><div id="i9481dacf30bb4098a06bd54f3af5a34a_82"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMTg0OQ_82c03852-4682-4563-b7eb-c021a52f39ba" continuedAt="if101bd0b07e244f6970b5a6ce74d7342" escape="true">Segment information</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if101bd0b07e244f6970b5a6ce74d7342" continuedAt="icc3632ef4047464397cd68cf31df083e"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMjE5OTAyMzI2NTU5MA_1df719f6-f136-40cc-b463-0bb81910537f" escape="true">The Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. We manage our business with a focus on <ix:nonFraction unitRef="segment" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMTA5OTUxMTYzMjk2NQ_25904a2e-c7fd-4897-92f6-57fb9e4dbb42"><ix:nonFraction unitRef="segment" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMTA5OTUxMTYzMjk2NQ_e1785b3d-d453-4476-864e-65e5ac7806fb">two</ix:nonFraction></ix:nonFraction> reportable segments. Our Products segment, which includes the Anthrax - MCM products, NARCAN products, Smallpox - MCM products and Other products, and our Services segment consisting of our CDMO services. The Company evaluates the performance of these reportable segments based on revenue and Adjusted Gross Margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but it does not include inter-segment services. The Company defines Adjusted Gross Margin as segment revenue less segment cost of sales reduced for significant events, inventory step-up provisions and changes in fair value of contingent consideration. The Company does not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the chief operating decision maker ("CODM"). The accounting policies for segment reporting are the same as for the Company as a whole.</ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="icc3632ef4047464397cd68cf31df083e" continuedAt="i6d4931bc7c0145058ee740a9c21af5cc"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its assets on a total company basis, not by operating segment, as the Company's operating assets are shared or commingled. Therefore, the Company's CODM does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment.</span></div><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMTg1MQ_f43026ca-9393-4ace-9ab9-02eb12f5b8eb" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes segment revenues and a reconciliation of the Company's segment adjusted gross margin to the consolidated statement of operations for each of the Company's reporting segments:</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:63.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#ededed;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMy0xLTEtMS0xODEzNzM_4d29865b-18a4-4c6e-96d9-d15b528b2da2">143.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMy0zLTEtMS0xODEzNzM_e0773961-d651-4eb1-a2f0-4c9efa9bfc97">237.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNC0xLTEtMS0xODEzNzM_8232c18b-e547-4acb-aeb2-88c74b0717d2">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNC0zLTEtMS0xODEzNzM_69d6ae88-ae2b-47bd-bfa1-31ab9ba942fa">60.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total segment revenues</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4dd32b195d7e4239a60662ca51d6ee42_D20230101-20230331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNS0xLTEtMS0xODEzNzM_f8c222ed-b0a1-4b23-91c2-c02764b918bb">158.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i918438631165446c9ba9921f135d6a33_D20220101-20220331" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNS0zLTEtMS0xODEzNzM_60d3da21-b8da-4296-bda0-5045161a9835">297.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants revenues</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0e5222cf971340bab0614a17ebbf5ed8_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNi0xLTEtMS0xODEzNzM_644dfb1c-faf2-4a71-9286-86d31f2cf1f9">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0d4fc9a55e4b49afb88321e52246a468_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNi0zLTEtMS0xODEzNzM_f392a211-6e64-4c0d-9e95-13d1d7c9df95">9.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNy0xLTEtMS0xODEzNzM_63dff80d-c83b-45fc-b157-2893a31473ba">165.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNy0zLTEtMS0xODEzNzM_667e0104-65fc-4d68-af62-a372295d4018">307.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Less: Cost of sales:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTAtMS0xLTEtMTgxMzcz_61fe0bc7-30d1-4bff-bd2f-422cea89a0e5">102.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTAtMy0xLTEtMTgxMzcz_1cc4f77e-e81b-45e8-87b8-c04bf891719d">80.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTEtMS0xLTEtMTgxMzcz_a25107ad-f0da-4375-bec3-f6dc3c1907ba">52.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTEtMy0xLTEtMTgxMzcz_40c19f7d-8024-4c73-af6f-c83cd5ad1430">75.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost of sales</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTItMS0xLTEtMTgxMzcz_e8992f3f-eb10-4431-b1ba-a2e82e85a3e7">155.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTItMy0xLTEtMTgxMzcz_ff277aa5-c3b6-428b-86c1-961693f48fb9">155.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTQtMS0xLTEtMTgxMzcz_0ea8da0e-9d23-42f0-abe8-5e64c0e8173c">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTQtMy0xLTEtMTgxMzcz_f4408481-9758-4d15-8f9f-1bf92b9e56e7">156.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTUtMS0xLTEtMTgxMzcz_3c710224-3feb-4d40-b3f7-6a6f5190ed69">37.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTUtMy0xLTEtMTgxMzcz_bb81ddc8-ffcf-4521-8217-de9ffc4c7d42">14.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated gross margin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTYtMS0xLTEtMTgxMzcz_62bb9c09-ef56-4b65-9262-750390bf9c17">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTYtMy0xLTEtMTgxMzcz_ac810ef1-29dd-4c70-b834-05c9e64e8153">142.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"></td><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments to gross margin:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value of contingent consideration</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjAtMS0xLTEtMTgxMzcz_9028b5e3-5acb-4be5-ab9d-92d40dbf2722">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjAtMy0xLTEtMTgxMzcz_adb575c0-00f1-4a8a-91b8-e5027a97090c">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331" decimals="-5" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjEtMS0xLTEtMTk2OTU1_7f25c10d-bd1d-4d05-bcf7-e518e22dffdf">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331" decimals="-5" name="us-gaap:RestructuringCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjEtMy0xLTEtMTk2OTk5_8992a726-4f25-4fc0-8d2a-537031561d1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjMtMS0xLTEtMTgxMzcz_0cab0778-04e0-454d-b7dd-7283abe3c398">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjMtMy0xLTEtMTgxMzcz_dea1d33a-e24b-4075-bbe3-57fdf63c4a26">157.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331" decimals="-5" sign="-" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjQtMS0xLTEtMTgxMzcz_7af5996a-eb01-4d39-bf15-c064681a287d">37.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331" decimals="-5" sign="-" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjQtMy0xLTEtMTgxMzcz_0a96210f-0ace-4138-8500-9bd66d8b8a77">14.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated adjusted gross margin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjUtMS0xLTEtMTgxMzcz_cefa5ffa-1020-4168-bf9a-4eb7340e84aa">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjUtMy0xLTEtMTgxMzcz_95b73068-a188-4c16-bee5-ae1ffeb8e4ba">142.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt;text-indent:-9pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other reconciling items</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants revenue</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0e5222cf971340bab0614a17ebbf5ed8_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjgtMS0xLTEtMTgxMzcz_7ee241f4-f875-4a2f-98f9-99113802f867">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0d4fc9a55e4b49afb88321e52246a468_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjgtMy0xLTEtMTgxMzcz_abb3da47-0b32-4e48-9c37-8843ce438caf">9.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to gross margin</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="ebs:GrossProfitAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjktMS0xLTEtMTgxMzcz_65d53a15-23bf-45a8-8810-548fe7cfca0d">3.5</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="ebs:GrossProfitAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjktMy0xLTEtMTgxMzcz_7748c301-d0a8-4929-9630-70a7393c22ca">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzAtMS0xLTEtMTgxMzcz_6e53c64f-0c8b-4a8c-950d-71b339f9d1ee">40.6</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzAtMy0xLTEtMTgxMzcz_cceb609e-8e56-45a1-a5de-8b74f3f75a65">46.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzEtMS0xLTEtMTgxMzcz_1a2245f4-7e46-483d-8e70-3e9d7f2b8a1e">100.5</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzEtMy0xLTEtMTgxMzcz_87907465-994c-46c5-a82b-c0d7bb2db802">84.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzMtMS0xLTEtMTgxMzcz_ad3a0303-5ad2-439f-9019-4cd047a8e786">17.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzMtMy0xLTEtMTgxMzcz_83d0a765-f54f-4476-b567-776615adb385">14.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzQtMS0xLTEtMTgxMzcz_2f1f5813-3cbb-4056-83c6-a0e3d7ff35bc">17.9</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzQtMy0xLTEtMTgxMzcz_ea258a52-646a-4aea-8c83-9df170d43d8c">8.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzUtMS0xLTEtMTgxMzcz_692a4dbe-0687-459e-ae6a-3abf7871dde5">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzUtMy0xLTEtMTgxMzcz_307813de-0238-44c6-be63-d60c8fd1d17a">2.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzYtMS0xLTEtMTgxMzcz_0e78c6d6-eb53-44ea-978c-d2490a37da60">161.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzYtMy0xLTEtMTgxMzcz_95c10e75-8885-4264-8da5-b1f28963cf3d">3.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 10pt 0 1pt;text-indent:-9pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total segment revenues less total cost of sales.</span></div></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consolidated gross margin plus adjustments to gross margin.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i6d4931bc7c0145058ee740a9c21af5cc"><ix:nonNumeric contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMTg1Mg_0b502681-e2c4-40bb-8d79-7d7ac1b500a1" escape="true"><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each segment:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:61.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.361%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation:</span></td><td colspan="3" style="background-color:#ededed;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfMy0xLTEtMS0xNzQwOTA_a198cf1f-3531-4875-9d68-983f47780356">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfMy0zLTEtMS0xNzQwOTA_343b9279-fab0-48d8-a59f-c4942c3f831b">7.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNC0xLTEtMS0xNzQwOTA_89ee2d58-6b1d-445f-92fa-f1128751f939">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNC0zLTEtMS0xNzQwOTA_92072a32-84ce-415f-b6e8-49d70603dfe4">7.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81a432e8a0bd409aabe9374107df1be3_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNS0xLTEtMS0xNzQwOTA_7d5f86a9-ddb2-4395-9334-80eac87aa966">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i994e594bda11477a97c710abd0cf5e86_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNS0zLTEtMS0xNzQwOTA_179ff750-9cd8-4073-8d81-74252eb96dab">1.4</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNi0xLTEtMS0xNzQwOTA_c1221e59-de64-40eb-9f5e-6c9f7663e330">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNi0zLTEtMS0xNzQwOTA_0536db05-6ae6-4a15-82d5-eac21ce41896">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_94"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes and other financial information included elsewhere in this quarterly report on Form 10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this quarterly report on Form 10-Q, includes information with respect to our plans and strategy for our business and financing, as well as forward-looking statements that involve risks and uncertainties. You should carefully review the "Special Note Regarding Forward-Looking Statements" section of this Quarterly Report on Form 10-Q and the "Risk Factor Summary" and "Risk Factors" sections in Part I, Item 1A of our Annual Report on Form 10-K for our fiscal year ended December 31, 2022 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_97"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS OVERVIEW</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (&#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats ("PHTs"). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently focused on the following five PHT categories: chemical, biological, radiological, nuclear and explosives ("CBRNE"); emerging infectious diseases ("EID"); travel health, which we have agreed to sell to Bavarian Nordic; public health crises; and acute, emergency and community care. We have a product portfolio of thirteen products that contribute a substantial portion of our revenue and are sold to government and commercial customers. We also have a product candidate, AV7909, which is procured under special circumstances by the United States ("U.S.") Government ("USG"), although it is not approved by the U.S. Food and Drug Administration ("FDA"). Additionally, we have a development pipeline consisting of a diversified mix of both pre-clinical and clinical stage product candidates. Finally, we have a fully integrated portfolio of CDMO services. Our CDMO service offerings cover development services, drug substance manufacturing and drug product manufacturing and packaging. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures ("MCM") Products, NARCAN, Smallpox - MCM products and CDMO Services. The Company operates as two operating segments: (1) a products segment ("Products") consisting of the Anthrax - MCM, NARCAN, Smallpox - MCM and Other products and (2) a services segment ("Services") consisting of our CDMO services.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products Segment:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our product revenue comes from the following products and procured product candidates:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anthrax - MCM Products</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Anthrasil&#174; (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">AV7909 (Anthrax vaccine adsorbed (AVA), adjuvanted) procured product candidate being developed as a next-generation anthrax vaccine for post-exposure prophylaxis. AV7909 has not been approved by the FDA, but is procured by certain authorized government buyers for their use;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BioThrax&#174; (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">NARCAN</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone approved by the FDA (including in over-the-counter form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Smallpox - MCM Products</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">ACAM2000&#174;, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">CNJ-016&#174; (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">TEMBEXA&#174;, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BAT&#174; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Ebanga&#8482; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics ("Ridgeback"). Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#8482;;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">RSDL&#174; (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA that is intended to remove or neutralize chemical warfare agents from the skin, including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Trobigard&#174; atropine sulfate, obidoxime chloride auto-injector, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It was approved in Belgium in 2021 but has not been approved by the FDA. Trobigard is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure outside of the U.S;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the first vaccine approved by the FDA for the prevention of cholera, which we have agreed to sell as part of our travel health business (Note 3, "Assets and liabilities held for sale"); and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), a live attenuated vaccine for oral administration for the prevention of typhoid fever, which we have agreed to sell as part of our travel health business (Note 3, "Assets and liabilities held for sale").</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services Segment:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services - Contract Development and Manufacturing</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our services revenue consists of distinct but interrelated CDMO services: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations. These services, which we refer to as "molecule-to-market" offerings, employ diverse technology platforms (mammalian, microbial, viral and plasma) across a network of nine geographically distinct development and manufacturing sites operated by us for our internal products and pipeline candidates and third-party CDMO services. We service both clinical-stage and commercial-stage projects for a variety of third-party customers, including government agencies, innovative pharmaceutical companies, and non-government organizations.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Strategic Activities</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company initiated an organizational restructuring plan (the &#8220;2023 Plan&#8221;) intended to reduce operating costs, improve operating margins, and continue advancing the Company&#8217;s ongoing commitment to profitable growth. As part of the 2023 Plan, the Company eliminated approximately five percent of its total headcount.  The Company incurred approximately $9.7&#160;million in charges in connection with the 2023 Plan during the three months ended March&#160;31, 2023. These charges consist primarily of charges related to employee transition, severance payments and employee benefits. All activities related to the 2023 Plan were substantially completed during the first quarter of 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_103"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL OPERATIONS OVERVIEW</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenues from the sale of our marketed products and procured product candidates. The USG is the largest purchaser of our Government - MCM products and primarily purchases our products for the Strategic National Stockpile ("SNS"), a national repository of medical countermeasures including critical antibiotics, vaccines, chemical antidotes, antitoxins, and other critical medical supplies. The USG primarily purchases our products under long-term, firm fixed-price procurement contracts, generally with annual options. Our opioid overdose treatment product, NARCAN&#174; Nasal Spray, and our travel health products, Vivotif and Vaxchora, are sold commercially through wholesalers and distributors, physician-directed or standing order prescriptions at retail pharmacies and to state and local community healthcare agencies, practitioners and hospitals.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also generate revenue from our CDMO services, which is based on our established development and manufacturing infrastructure, technology platforms and expertise. Our services include a fully integrated molecule-to-market CDMO services business offering across development </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services, drug substance and drug product for small to large pharmaceutical and biotechnology industry and government agencies/non-governmental organizations. From time to time, clients require suite reservations at our various manufacturing sites, which may be considered leases depending on the facts and circumstances.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received contracts and grant funding from the USG and other non-governmental organizations to perform research and development ("R&amp;D") activities, particularly related to programs addressing certain CBRNE threats and EIDs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue, operating results and profitability vary quarterly based on the timing of production and deliveries, the timing of manufacturing services performed and the nature of our business, which involves providing large scale bundles of products and services as needs arise. We expect continued variability in our quarterly financial results.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cost of product sales and CDMO services</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The primary expenses that we incur to deliver our products consist of fixed and variable costs. We determine the cost of product sales for products sold during a reporting period based on the average manufacturing cost per unit in the period those units were manufactured. Fixed manufacturing costs include facilities and utilities costs. Variable </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs primarily consist of costs for materials and personnel-related expenses for direct and indirect manufacturing support staff, contract manufacturing operations, sales-based royalties, shipping and logistics. In addition to the fixed and variable manufacturing costs described above, the cost of product sales depends on utilization of available manufacturing capacity. For our commercial sales, other associated expenses include sales-based royalties (which include fair value adjustments associated with contingent consideration), shipping, and logistics.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The primary expenses that we incur to deliver our CDMO services consist of fixed and variable costs, including personnel, equipment, and facilities costs. Our manufacturing process includes the production of bulk material and performing drug product work for containment and distribution of biological products. For drug product customers, we receive work in process inventory to be prepared for distribution. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D expenses</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense R&amp;D costs as incurred. Our R&amp;D expenses consist primarily of:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">personnel-related expenses;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">fees to professional service providers for, among other things, analytical testing, independent monitoring or other administration of our clinical trials and obtaining and evaluating data from our clinical trials and non-clinical studies;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of CDMO services for our clinical trial material; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of materials intended for use and used in clinical trials and R&amp;D.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many cases, we seek funding for development activities from external sources and third parties, such as governments and non-governmental organizations, or through collaborative partnerships. We expect our R&amp;D spending will be dependent upon such factors as the results from our clinical trials, the availability of reimbursement of R&amp;D spending, the number of product candidates under development, the size, structure and duration of any clinical programs that we may initiate, the costs associated with manufacturing and development of our product candidates on a large-scale basis for later stage clinical trials, and our ability to use or rely on data generated by government agencies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Selling, general and administrative expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel-related costs and professional fees in support of our executives, sales and marketing, business development, government affairs, finance, accounting, information technology, legal, human resource functions and other corporate functions. Other costs include facility costs not otherwise included in cost of product sales and CDMO services or R&amp;D expense.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty in income taxes is accounted for using a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We recognize in our financial statements the impact of a tax position if that position is more likely than not of being sustained on audit, based on the technical merits of the position.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the assumptions and estimates related to the provision for income taxes are critical to the Company&#8217;s results of operations. </span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_106"></div><div style="margin-bottom:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and exp</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enses. Actual results may differ from these estimates. There have been no significant changes to our critical accounting policies and estimates contained in "Critical Accounting Policies and Estimates" in the Management's Discussion and Analysis, in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC.</span></div><div style="margin-bottom:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please see Note 2, "Summary of significant accounting policies", in Part I item 1, of this Quarterly Report on Form 10-Q. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_109"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.099%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="21" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions, except %)</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product sales, net:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax MCM</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(87.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smallpox MCM</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 20.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Products sales</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 38.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total product sales, net</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(93.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(74)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total CDMO revenues</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(45.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 38.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165.1&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(142.4)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">301.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(148.1)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(154.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17.9)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13.0)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(161.1)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(157.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit)</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(183.0)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(179.3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="24" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM - Not meaningful</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023 Compared with Three Months Ended March 31, 2022</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues and gross margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues decreased $142.4 million, or 46%, to $165.1 million for the three months ended March&#160;31, 2023. The decrease was due to declines in Total product sales of $93.7 million, Services revenue of $45.6 million and contracts and grants revenue of $3.1 million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated gross margin decreased $138.5 million, or 98%, to $3.5 million for the three months ended March&#160;31, 2023. Consolidated gross margin percentage decreased 45 percentage points to 2% for the three months ended March&#160;31, 2023. Consolidated gross margin percentage excludes contracts and grants revenues because the related costs are R&amp;D expenses. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Segment Results" for an expanded discussion of revenues and gross profit margin.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unallocated corporate operating expenses</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D expenses</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses decreased $5.8&#160;million, or 13%,  to $40.6&#160;million for the three months ended March&#160;31, 2023. The decrease was primarily due to a reduction in R&amp;D spend related to the next phase of the development program for Company's development-stage chikungunya vaccine candidate CHIKV VLP, which have agreed to sell to Bavarian Nordic (Note 18, "Subsequent events").</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selling, general and administrative expenses </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $15.7&#160;million, or 19%, to $100.5&#160;million for the three months ended March&#160;31, 2023. The increase was primarily due to higher professional services fees and severance costs related to our 2023 Restructuring Plan. Selling, general and administrative costs as a percentage of total revenue increased 33% to 61% for the three months ended March 31, 2023.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amortization of intangible Assets</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets increased $3.0&#160;million, or 21%, to $17.0&#160;million for the three months ended March&#160;31, 2023. The increase was primarily due to amortization expense for recently acquired intangible assets related to TEMBEXA, which was acquired in the third quarter of 2022. The increase was partially offset by a decrease in amortization expense resulting from the held for sale intangibles related to our Travel Health business, which we have agreed to sell to Bavarian Nordic.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased $9.7&#160;million, or 118%, to $17.9&#160;million for the three months ended March&#160;31, 2023. The increase was primarily due to an increase in new borrowings and rising interest rates, partially offset by a decrease in interest expense related to our interest rate swaps.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other, net</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net increased $6.9&#160;million to $4.9&#160;million in income for the three months ended March&#160;31, 2023. The increase was primarily due to an increase in interest income due to higher cash balances and higher interest rates, coupled with other income increases resulting from favorable foreign exchange revaluations.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax provision (benefit)</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision increased $22.0&#160;million to $21.9&#160;million for the three months ended March 31, 2023. The increase was largely due to the decline in income before income taxes and a valuation allowance charge. The effective tax rate was (14)% for the three months ended March 31, 2023 as compared with 3% in 2022. The effective annual tax rate decreased largely due to a valuation charge.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEGMENT RESULTS</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCTS SEGMENT</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.277%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;&#160;</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Products Segment</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Restructuring costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79.8&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjusted gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjusted gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Adjusted cost of sales, which is a non-GAAP financial measure, is calculated as cost of sales less restructuring costs and other special items and non-cash items related to changes in fair value of contingent consideration. The Company's management utilizes Adjusted cost of sales for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP operating measure, when reviewed collectively with our GAAP financial information, provides useful supplementary information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin is calculated as revenues less cost of sales. Gross margin % is calculated as gross margin divided by revenues. </span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Adjusted gross margin, which is a non-GAAP financial measure, is calculated as revenues less Adjusted cost of sales. Adjusted gross margin %, which is a non-GAAP financial measure, is calculated as Adjusted gross margin divided by revenues. The Company&#8217;s management utilizes Adjusted gross margin and Adjusted gross margin % for purposes of evaluating our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP operating measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance.</span></div></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM - Not meaningful</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023 Compared with Three Months Ended March 31, 2022</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anthrax MCM </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax MCM sales decreased $87.5&#160;million, or 80%, to $21.9 million for the three months ended March&#160;31, 2023. The decrease was primarily due to timing of sales related to AV7909 and BioThrax during the first quarter of 2022, partially offset by an increase in Anthrasil sales. Anthrax vaccine product sales are primarily made under annual purchase options exercised by the USG. Fluctuations in revenues result from the timing of the exercise of annual purchase options and the USG purchases and Company delivery of orders that follow. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">NARCAN</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN sales increased $7.3&#160;million, or 8%, to $100.4&#160;million for the three months ended March&#160;31, 2023. The increase was primarily driven by an increase in branded NARCAN sales as well as an increase in Canadian public sales, partially offset by a decline in authorized generic NARCAN sales resulting from the cessation of shipments related to the relationship with Sandoz and a reduction in commercial retail sales in the U.S.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Smallpox MCM</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smallpox MCM sales decreased $16.1&#160;million, or 69%, to $7.2&#160;million for the three months ended March&#160;31, 2023. The decrease was primarily due to the timing of ACAM2000 international sales during the first quarter of 2022. Fluctuations in revenues result from the timing of the exercise of annual purchase options and the USG purchases and Company delivery of orders that follow.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Products sales increased $2.6&#160;million, or 23%, to $13.9&#160;million for the three months ended March&#160;31, 2023. The increase was primarily due to increases in Vivotif and Vaxchora product sales, partially offset by decreases in RSDL and BAT product sales.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Sales and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales increased $22.6&#160;million, or 28%, to $102.9&#160;million for the three months ended March&#160;31, 2023. The increase was primarily due to lower overhead absorption coupled with higher allocations to product COGS at our Bayview facility, partially offset by lower period costs at our Bern facility and lower NARCAN royalty fees.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin decreased $116.3&#160;million, or 74%, to $40.5&#160;million for the three months ended March&#160;31, 2023. Product gross margin percentage decreased 38 percentage points to 28% for the three months ended March&#160;31, 2023. The decrease was largely due to decreased sales volumes and increases in shutdown related costs combined with a less favorable sales mix weighted more heavily towards lower margin products. Product adjusted gross margin excludes the impacts of restructuring costs of $2.0 million and non-cash items related to the changes in the fair value of contingent consideration of $1.5 million.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SERVICES SEGMENT</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:51.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Services Segment</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO revenues</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of services</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross margin % </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(243)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross margin is calculated as revenues less cost of services. Gross margin % is calculated as gross margin divided by revenues. </span></div></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023 Compared with Three Months Ended March 31, 2022</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CDMO revenues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO services revenues decreased $38.4&#160;million, or 74%,  to $13.4&#160;million for the three months ended March&#160;31, 2023. The decrease was primarily due to $19.2&#160;million less revenue related to reduced production activities at the Company's Bayview facility as a result of a halt in manufacturing under the Janssen Agreement in 2022. Additionally, the decrease also reflects reduced production at the Camden facility. The decreases were slightly offset by an increase in production at the Company's Canton facility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO lease revenues decreased $7.2&#160;million, or 80%, to $1.8&#160;million for the three months ended March&#160;31, 2023. The decrease was primarily due to a reduction of lease revenues related to the Janssen Agreement termination in 2022.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Services and Gross Margin</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services decreased $23.4&#160;million, or 31%, to $52.2&#160;million for the three months ended March&#160;31, 2023. The decrease was primarily due to reduced production activities across our CDMO network, partially offset by increased costs at our Camden </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facility for additional investments in quality enhancement and improvement initiatives and increased costs associated with production activities at the Company's Canton Facility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Services gross margin decreased $22.2&#160;million to $37.0&#160;million for the three months ended March&#160;31, 2023 Services gross margin percentage decreased 219 percentage points to (243)% for the three months ended March&#160;31, 2023. The decrease was primarily due to reduced production activities across our CDMO network including the halt in manufacturing under the Janssen contract and the decrease in margins at the Company's Camden facility due to additional investments in quality enhancement and improvement initiatives.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER REVENUE</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023 Compared with Three Months Ended March 31, 2022</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contracts and Grants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract and grants revenue decreased $3.1&#160;million, or 32%, to $6.5&#160;million in 2023. The decrease was primarily due to the conclusion of COVID-19 related studies in the fourth quarter of 2022.</span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_115"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(dollars in millions)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Change %</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets:</span></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">430.2&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">642.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt, current portion</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">957.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt, net of current portion</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">447.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">448.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total borrowings</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,398.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,405.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working capital:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,221.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,210.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,215.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,229.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total working capital</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(129)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Principal Sources of Capital Resources</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operating and capital expenditures through existing cash and cash equivalents, cash from operations, development contracts and grant funding and borrowings under our senior revolving credit facility (the "Revolving Credit Facility") and senior term loan facility (the "Term Loan Facility", and together with the Revolving Credit Facility, the "Senior Secured Credit Facilities") and other lines of credit we have established from time to time. We also obtain financing from the sale of our common stock upon exercise of stock options. As of March&#160;31, 2023, we had unrestricted cash and cash equivalents of $430.2&#160;million and remaining capacity under our Revolving Credit Facility of $1.1&#160;million.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Going Concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared on the going concern basis of accounting, which assumes the Company will continue to operate as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there is $598.0&#160;million outstanding on our Revolving Credit Facility and $354.4&#160;million on our Term Loan Facility that mature in October 2023, which is within one year of the date that the consolidated financial statements for the quarter ended March&#160;31, 2023 are issued. The Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued as a result of these pending </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maturities. This evaluation considered the potential mitigating effect of management&#8217;s plans that have not been fully implemented. Management may evaluate the mitigating effect of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern. The Company's plan to alleviate the substantial doubt includes amending its existing Senior Secured Credit Facilities that are due October 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2023, the Company entered into a Consent, Limited Waiver, and Third Amendment (the "Third Credit Agreement Amendment") to the Amended and Restated Credit Agreement relating to the Senior Secured Credit Facilities (the "Credit Agreement"). Pursuant to the Third Credit Agreement Amendment, the requisite lenders consented to our sale of our travel health business to Bavarian Nordic substantially in accordance with the terms of the Sale Agreement. The proceeds from the transaction will be deposited into a cash collateral account with the Administrative Agent and will, unless otherwise agreed to by the Company and the requisite lenders, be used to repay the outstanding Term Loan Facility on the expiration of the Limited Waiver (as described below).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Third Credit Agreement Amendment the requisite lenders agreed to a limited waiver of any defaults or events of default that was extended on April 17, 2023 and described below.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Company entered into a First Amendment (the &#8220;Waiver Amendment&#8221;) to the Third Credit Agreement Amendment. The lenders agreed to extend the limited waiver (the &#8220;Extended Limited Waiver&#8221;) of any defaults or events of default that result from (a) any violation of the financial covenants set forth in the Credit Agreement with respect to the fiscal quarters ending December&#160;31, 2022 and March&#160;31, 2023 and (b) any going concern qualification or exception contained in the audited financial statements for the fiscal year ending December&#160;31, 2022. The Extended Limited Waiver expires on the earlier to occur of (i) any other event of default under the Credit Agreement and (ii) May 17, 2023. During the period of the Limited Waiver, the Company is working with lenders under the Credit Agreement in connection with replacing the current credit facility before it matures with revised terms and conditions. The Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to the Credit Agreement. See Note 2, "Summary of significant accounting policies" in the Notes to Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for Going Concern considerations related to noncompliance with our debt covenants and the limited waiver.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company is in the process of replacing and expects to replace the Senior Secured Credit Facilities before they mature, management cannot make the assumption that it is probable that the Company will be able to obtain such debt refinancing on commercially reasonable terms or at all until a new credit facility is in place. The Company is currently working with its lenders to refinance the Senior Secured Credit Facilities with revised terms and conditions. The extent to which the Company will be able to affect such refinancing, replacement or maturity extension on terms that are favorable or at all is dependent on a number of uncertain factors, including then-prevailing credit and other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, disruptions or volatility caused by factors such as COVID-19, regional conflicts, inflation, and supply chain disruptions. In addition, rising interest rates could limit our ability to refinance the Senior Secured Credit Facilities when they mature or cause us to pay higher interest rates upon refinancing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has $430.2 million of cash on hand at March&#160;31, 2023. On January 9, 2023, the Company announced the 2023 Plan intended to reduce operating costs, improve operating margins, and continue advancing the Company&#8217;s ongoing commitment to profitable growth. The Plan includes a reduction of the Company&#8217;s current workforce by approximately five percent. These actions, in combination with other cost reduction initiatives, are expected to result in annualized savings of over $60.0&#160;million when fully implemented.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in:</span></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(184.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(209.8)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(140.3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $184.0&#160;million in 2023 was due to net loss excluding non-cash items of $147.2&#160;million coupled with negative working capital changes of $36.8&#160;million, primarily due an increase in payments for taxes and compensation and an accumulation of inventory, partially offset by an increase in our accounts payable.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities increased $146.7&#160;million from 2022 to 2023. The increase is due to a decrease in net loss excluding non-cash items of $188.3&#160;million, partially offset by an increase in working capital changes of $41.6&#160;million.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities of $15.1&#160;million in 2023 relates to the purchases of property, plant and equipment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities decreased $17.1&#160;million from 2022 to 2023. The decrease is largely due to lower product development activities, including our chikungunya facility redesign project.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities:</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities of $10.5&#160;million in 2023 was primarily related to payments on our Term Loan Facility of $8.4&#160;million. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities decreased $60.0&#160;million from 2022 to 2023. The decrease is largely due to the repurchases of stock of $57.5&#160;million in the first quarter of 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company has $1.4&#160;billion of fixed and variable rate debt with varying maturities, with $953.4&#160;million payable within 12 months (see Note 10, "Debt" in the Notes to Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q).</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Uncertainties and Trends Affecting Funding Requirements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to fund our short-term and long-term anticipated operating expenses, capital expenditures and debt service requirements from the following sources:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">existing cash and cash equivalents;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">net proceeds from the sale of our products and CDMO services;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">development contracts and grant funding; </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.21pt">proceeds from the sale of our travel health business to Bavarian Nordic (see Note 3, "Assets and liabilities held for sale" in the Notes to Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q); and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our Senior Secured Credit Facilities and any replacement or other lines of credit we may establish from time to time.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous risks and uncertainties associated with product sales and with the development and commercialization of our product candidates. We may seek additional external financing to provide additional financial flexibility. Our future capital requirements will depend on many factors, including (but not limited to):</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the level, timing and cost of product sales and CDMO services;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the payment obligations under our indebtedness;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the scope, progress, results and costs of our development activities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the costs of commercialization activities, including product marketing, sales and distribution.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans, collaboration and licensing arrangements, cost reductions, assets sales or a combination of these options. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds by issuing equity securities, our stockholders may experience dilution. Public or bank debt financing, if available, may involve agreements that include covenants, like those contained in our 3.875% Senior Unsecured Notes due 2028 (the "Senior Unsecured Notes") and the Senior Secured Credit Facilities, which could limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities, buying back shares or declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions, including market volatility and adverse impacts on financial markets as a result of the COVID-19 pandemic, may make it more difficult to obtain financing on attractive terms, or at all. Any new debt funding, if available, may be on terms less favorable to us than our Senior Secured Credit Facilities or the Senior Unsecured Notes. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Unused Credit Capacity</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available room under the Revolving Credit Facility as of March&#160;31, 2023 and December&#160;31, 2022 was:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Capacity</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">600.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">600.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></div></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding Letters of Credit</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding Indebtedness</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">598.0&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">598.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unused Capacity</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_118"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET&#160;RISK</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of additional risks arising from our operations, see &#8220;Item&#160;1A-Risk Factors&#8221; of this Quarterly Report on Form 10-Q. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have interest rate and foreign currency market risk. Because of the short-term maturities of our cash and cash equivalents, we believe that an increase in market rates would likely not have a significant impact on the realized value of our investments.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest rate risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have debt with a mix of fixed and variable rates of interest. Floating rate debt carries interest based generally on the eurocurrency rate, as defined in our Amended Credit Agreement, plus an applicable margin. We manage the impact of interest rate changes on our variable debt through derivative interest rate swap arrangements. Increases in interest rates could result in an increase in interest payments for debt that we have not hedged through our interest rate swap arrangements. See Note 10, "Debt" in Part I, item 1, of this Quarterly Report on Form 10-Q. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assessed our exposure to changes in interest rates by analyzing the sensitivity to our operating results assuming various changes in market interest</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> rates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A hypothetical increase of one percentage point in the eurocurrency rate as of March&#160;31, 2023 would increase our interest expense by approximately $6.0&#160;million annually.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency exchange rate risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exposure to foreign currency exchange rate fluctuations worldwide and primarily with respect to the Euro, Canadian dollar, Swiss franc and British pound. We manage our foreign currency exchange rate risk primarily by either entering into foreign currency hedging transactions or incurring operating expenses in the local currency in the countries in which we operate, to the extent practical. We currently do not hedge all of our foreign currency exchange exposure and the movement of foreign currency exchange rates could have an adverse or positive impact on our results of operations.</span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_121"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2023. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act"), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2023, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in internal control over financial reporting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, we identified and disclosed a material weakness in our internal control over financial reporting related to our assessment of pre-launch materials meeting the criteria for capitalization, which requires those materials to have economic value and a high probability of regulatory approval. To remediate the material weakness, we designed and implemented controls and enhanced and revised the design of existing controls and procedures to properly assess pre-launch inventory.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March&#160;31, 2023, we successfully completed the testing necessary to conclude that the material weakness has been remediated. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except those noted above, there have been no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during the three months ended March&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_124"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_127"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16, "Litigation" in Part I, item 1, of this Quarterly Report on Form 10-Q. </span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_130"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risk factors and other information included in this Quarterly Report on Form 10-Q should be carefully considered. The occurrence of any of the following risks or of unknown risks and uncertainties may adversely affect our business, operating results and financial condition. </span></div><div style="margin-bottom:3pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of government contracting risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Reduced demand for and/or funding for procurement of AV7909 and/or BioThrax vaccines or ACAM2000 and discontinuation of funding of our other USG procurement and development contracts.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Inability to secure follow-on product procurement contracts with the USG upon the expiration of any of our existing procurement contracts.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Inability to receive FDA licensure of AV7909 and realize the full value of our contract for development and procurement of AV7909.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of manufacturing risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Our inability to maintain quality and manufacturing compliance at our manufacturing facilities for our products and for product candidates for our CDMO customers.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Disruption at, damage to or destruction of our development and/or manufacturing facilities may impede our ability to manufacture our products, as well as deliver our CDMO services.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Our operations, including our use of hazardous materials, chemicals, bacteria and viruses expose us to significant potential liabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of product development and commercialization risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Clinical trials of product candidates are expensive and time-consuming, and their outcome is uncertain. </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">We may fail to capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of regulatory and compliance risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Failure to comply with complex laws and regulations pertaining to government contracts and resources required for responding to related government inquiries.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Conditions associated with approvals and ongoing regulation of products may limit how and the extent to which we manufacture and market them.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Failure to comply with various health care laws could result in substantial penalties.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Failure to comply with obligations under USG pricing programs may require reimbursement for underpayments and the payment of substantial penalties, sanctions and fines.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">The extent to which we may be able to lawfully offer to sell and sell unapproved products in many jurisdictions may be unclear or ambiguous and such activities may subject us to regulatory enforcement actions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of competitive and political risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Development and commercialization of pharmaceutical products are subject to evolving private and public sector competition.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">NARCAN Nasal Spray is currently subject to branded and generic competition in the U.S. and may be subject to branded and generic competition in Canada. In addition, the success of NARCAN Nasal Spray is subject to our ability to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Biologic products may be affected by the approval and entry of follow-on biologics, or biosimilars in the United States and other jurisdictions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to our intellectual property that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Challenges in obtaining or maintaining intellectual property rights and defense or enforcement of such rights, including against current or potential infringers.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Potential discrepancies or challenges with respect to licenses, including our failure to comply with obligations under such licenses.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Potential loss of proprietary information and know-how, which carries the risk of reducing the value of our technology and products.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Entry of competing generic drugs upon patent and/or regulatory expires or with patents no longer in force.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to reliance on third parties that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">The loss of sole-source suppliers or an increase in the price of inventory.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">If other parties do not perform as contractually required or as expected, we may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of legal and reputational risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Unfavorable results of legal proceedings and government investigations could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Our work on PHTs has exposed us to criticism and may expose us to further criticism, from the media, government personnel and others, which could further harm our reputation, negatively affect our share price, operations and our ability to attract and retain talent.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">The potential for cyber security incidents involving us, our business partners, collaborators or other third parties to harm our ability to operate our business effectively in light of our heightened risk profile, including the impact of a recent cyber security incident at one of our business partners.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">We could face product liability exposure associated with the use of our medical products. There can be no assurance that the SAFETY Act, PREP Act, or other liability protections will be sufficient to limit or avoid product liability, and defending such cases requires significant resources.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of financial risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Our ability to maintain sufficient cash flow from our operations to pay our substantial debt, both now and in the future.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Our ability to obtain additional funding and be able to raise capital when needed, including in order to be able to continue as a going concern.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Our ability to comply with the covenants under our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revolving Credit Facility and Term Loan Facility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other debt agreements, and to refinance our Senior Secured Credit Facilities prior to their maturity in October 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to our strategic acquisitions, divestitures and collaborations that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Our failure to successfully integrate acquired businesses and/or assets into our operations and our ability to realize the benefits of such acquisitions.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Our failure to consummate the sale of our travel health business to Bavarian Nordic and to realize the anticipated benefits of the transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks associated with our common stock, including, but not limited to:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Our business or our share price could be negatively affected as a result of the actions of shareholders.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">The price of our common stock has been and remains subject to extreme volatility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factors below contain more detailed descriptions of the risks identified above, as well as additional risks that may materially harm our business, financial condition or results of cash flows.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT CONTRACTING RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently derive a substantial portion of our revenue from USG procurement of the AV7909 vaccine and the TEMBEXA</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (brincidofovir), oral antiviral and have historically derived a substantial portion of our revenue from USG procurement of the ACAM2000 vaccine and of BioThrax. If the USG&#8217;s demand for and/or funding for procurement of AV7909, BioThrax and/or ACAM2000 vaccines and/or TEMBEXA</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(brincidofovir), oral antiviral are substantially reduced, our business, financial condition, operating results and cash flows would be materially harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive a substantial portion of our current and expected future revenues from USG procurement of AV7909. As AV7909 is a product candidate, there is a higher level of risk that we may encounter challenges causing delays or an inability to deliver AV7909 than with BioThrax, an approved product, which may have a material effect on our ability to generate and recognize revenue.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The success of our business and our future operating results are significantly dependent on anticipated funding for the procurement of our anthrax vaccines and the terms of such procurement by the USG, including the price per dose, the number of doses and the timing of deliveries. We have no certainty that funding will be made available for the procurement of our anthrax vaccines. If priorities for the SNS change generally, or as a result of the conclusion of the USG&#8217;s audit of the SNS, or with respect to the level of procurement of our anthrax vaccines, funding to procure future doses of AV7909 or BioThrax vaccines may be delayed, limited or not available, BARDA may never complete the anticipated full transition to stockpiling AV7909 in support of anthrax preparedness, and our future business, financial condition, operating results and cash flows could be materially harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past we have derived a substantial portion of our revenues from sales of ACAM2000 vaccine to the USG. If priorities for the SNS change with respect to ACAM2000 vaccine or the USG decides not to exercise additional options under our ACAM2000 contract, our future business, financial condition, operating results and cash flows could be materially harmed. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not receive FDA approval of AV7909 in a timely manner or at all. Delays in our ability to achieve a favorable outcome from the FDA, or lack of approval from the FDA, could prevent us from realizing the full potential value of our BARDA contract for the advanced development and procurement of AV7909.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with us, the CDC filed with the FDA a pre-EUA submission package related to AV7909, which enables FDA review of data in anticipation of a request for an EUA. Following this submission, BARDA began procuring AV7909, exercising its first contract option in July 2019 to procure 10 million doses of AV7909, its second contract option in July 2020 and, most recently, funding another procurement commitment in October 2021 for inclusion of additional doses into the SNS in support of anthrax preparedness.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we completed the rolling submission of a Biologics License Application ("BLA") filing with the FDA related to AV7909 and the application has been accepted for review. There can be no guarantee on the outcomes of the FDA review. The FDA may decide that our data are insufficient and may require additional pre-clinical, clinical or other studies. If we are unsuccessful in obtaining FDA licensure, in a timely manner or at all, we may not be able to realize the full potential value of the USG contract for AV7909, which could have a material adverse effect on our future business, financial condition, operating results and cash flows. Furthermore, prior to FDA licensure, the EUA could be terminated if the emergency determination underlying the EUA terminates. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our USG procurement and development contracts require ongoing funding decisions by the USG. Any reduction or discontinuation of funding of any of these contracts could cause our business, financial condition, operating results and cash flows to suffer materially.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USG is the principal customer for our MCMs and the primary source of funds for the development of most of our product candidates in our development pipeline, including our AV7909 procured product candidate. We anticipate that the USG will also be a principal customer for any MCMs that we successfully develop from within our existing product development pipeline, as well as those we acquire in the future. Additionally, a significant portion of our revenue comes from USG development contracts and grants. Over its lifetime, a USG procurement or development program, such as for AV7909 under our development and procurement contract with BARDA, may be implemented through the award of many different individual contracts and subcontracts. The funding for such government programs is subject to Congressional appropriations, generally made on a fiscal year basis, even for programs designed to continue for several years. These appropriations can be subject to a number of uncertainties, including political considerations, changes in priorities due to global pandemics, the results of elections and stringent budgetary constraints.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our government-funded development contracts typically give the USG the right, exercisable in its sole discretion, to extend these contracts for successive option periods following a base period of performance. The value of the services to be performed during these option periods may constitute the majority of the total value of the underlying contract. For example, the September 2016 contract award from BARDA for the development and delivery to the SNS of AV7909 for post-exposure prophylaxis of anthrax disease consists of a five-year base period of performance and includes options for the delivery of additional doses of AV7909 to the SNS and options for an additional clinical study and post-marketing commitments. This contract was extended in September 2021 through 2025 and provides for additional procurement of AV7909 for the SNS over 18 months. If levels of government expenditures and authorizations for public health countermeasure preparedness decrease or shift to programs in areas where we do not offer products or are not developing product candidates, or if the USG otherwise declines to exercise its options under our existing contracts, our revenues would suffer, as well as our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">There can be no assurance that we will be able to secure follow-on product procurement contracts with the USG upon the expiration of any of our existing procurement contracts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue is substantially dependent upon product procurement contracts with the USG and foreign governments for our MCMs. Upon the expiration of a procurement contract, we may not be able to negotiate a follow-on procurement contract for the particular product on similar terms. We intend to negotiate follow-on procurement contracts for most of our MCMs upon the expiration of a related procurement contract, but there can be no assurance that we will be successful obtaining any follow-on contracts. Even if we are successful in negotiating a follow-on procurement contract, it may be for a lower product volume, over a shorter period of performance or be on less favorable pricing or other terms. An inability to secure follow-on procurement contracts for our approved products or product candidates could materially and adversely affect our revenues, and our business, financial condition, operating results and cash flows could be harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The government contracting process is typically a competitive bidding process and involves unique risks and requirements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business involves government contracts and grants, which may be awarded through competitive bidding. Competitive bidding for government contracts presents many risks and requirements, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the possibility that we may be ineligible to respond to a request for proposal;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the commitment of substantial time and attention of management and key employees to the preparation of bids and proposals;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the need to accurately estimate the resources and cost structure that will be required to perform any contract that we might be awarded;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the submission by third parties of protests to our responses to requests for proposal that could result in delays or withdrawals of those requests for proposal; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">in the event our competitors protest or challenge contract or grant awards made to us through competitive bidding, the potential that we may incur expenses or delays, and that any such protest or challenge could result in the resubmission of bids based on modified specifications, or in the termination, reduction or modification of the awarded contract.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USG may choose not to award us future contracts for either the development of our new product candidates or for the procurement of our existing MCM products and may instead award such contracts to our competitors. If we are unable to secure particular contracts, we may not be able to operate in the market for products that are provided under those contracts. Additionally, if we are unable to consistently win new contract awards over an extended period, or if we fail to anticipate all of the costs or resources that we will be required to secure and, if applicable, perform under such contract awards, our growth strategy and our business, financial condition and operating results and cash flows could be materially and adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The amounts we are paid under our fixed price government procurement contracts are based on estimates we have made of the time, resources and expenses required for us to perform under those contracts. If our actual costs exceed our estimates, we may not be able to earn an adequate return or may incur a loss under these contracts, which could harm our operating results and materially reduce our net income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current procurement contracts with the U.S. Department of Health ("HHS") and the U.S. Department of Defense ("DoD") are generally fixed price contracts. We expect that any future procurement contracts we successfully secure with the USG would likely also be fixed price contracts. Under a fixed price contract, we are required to deliver our products at a fixed price regardless of the actual costs we incur. Estimating costs that are related to performance in accordance with contract specifications is difficult, particularly where the period of performance is over several years, and when factoring in higher levels of inflation. Our failure to anticipate technical problems, estimate costs accurately or control costs during performance of a fixed price contract could reduce the profitability of such a contract or cause a loss, which could harm our operating results and materially reduce our net income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unfavorable provisions in government contracts, some of which may be customary, may subject our business to material limitations, restrictions and uncertainties and may have a material adverse impact on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government contracts customarily contain provisions that give the USG substantial rights and remedies, many of which are not typically found in commercial contracts, including provisions that allow the USG to:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">terminate existing contracts, in whole or in part, for any reason;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">unilaterally reduce or modify contracts or subcontracts;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">decline, in whole or in part, to exercise an option to purchase product under a procurement contract or to fund additional development under a development contract;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">decline to renew a procurement contract;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">claim certain rights to facilities or to products, including intellectual property, developed under the contract;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">require repayment of contract funds spent on construction of facilities in the event of contract default;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">take actions that result in a longer development timeline than expected;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">direct the course of a development program in a manner not chosen by the government contractor;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">suspend or debar the contractor from doing business with the government or a specific government agency;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">pursue civil or criminal remedies under acts such as the False Claims Act and False Statements Act; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">control or prohibit the export of products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, government contracts contain provisions permitting unilateral termination or modification, in whole or in part, at the USG&#8217;s convenience. Under general principles of government contracting law, if the USG terminates a contract for convenience, the government contractor may recover only its incurred or committed costs, settlement expenses and profit on work completed prior to the termination. If the USG terminates a contract for default, the government contractor is entitled to recover costs incurred and associated profits on accepted items only and may be liable for excess costs incurred by the government in procuring undelivered items from another source. All of our development and procurement contracts with the USG are terminable at their convenience with these potential consequences.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our USG contracts grant the USG the right to use technologies developed by us under the government contract or the right to share data related to our technologies, for or on behalf of the USG. Under our USG contracts, we may not be able to limit third parties, including our competitors, from accessing certain of these technology or data rights, including intellectual property, in providing products and services to the USG.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An inability to maintain manufacturing compliance at our manufacturing facilities, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts periodic inspections of our manufacturing facilities for compliance with cGMP and QSR requirements relating to quality control. The Company's failure to regain or maintain compliance with cGMP standards at our manufacturing facilities has hindered and could continue to hinder our ability to continue manufacturing for our own products and for CDMO customers, which could adversely affect our business, financial condition, operating results and cash flows. For example in April </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, we temporarily stopped manufacturing bulk drug substance material for Johnson &amp; Johnson&#8217;s COVID-19 vaccine at our Baltimore Bayview facility after issues were identified in a viral vaccine drug substance batch. Additionally</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in February 2022, FDA inspected Emergent&#8217;s Camden facility and issued a Form FDA 483. In August 2022, FDA issued a warning letter to Emergent, related to the February 2022 inspection. The warning letter included issues pertaining to equipment cleaning and maintenance; aseptic sterilization technique and procedures; and quality systems. Emergent has responded to the warning letter and continues to make significant progress implementing the corrective and preventive action commitments in the company&#8217;s warning letter responses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disruption at, damage to or destruction of our manufacturing facilities could impede our ability to manufacture anthrax vaccines, our ACAM2000 vaccine or our other products or product candidates, as well as impact the delivery of CDMO services, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any interruptions in our manufacturing operations could result in our inability to produce products and product candidates for delivery to satisfy the demands of our customers in a timely manner, which would reduce our revenues and materially harm our business, financial condition, operating results and cash flows. A number of factors could cause interruptions, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">equipment malfunctions or failures;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">technology malfunctions;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">cyber-attacks;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">work stoppages or slowdowns, particularly due to the impact of COVID-19;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">civil unrest and protests, including by animal rights activists;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">injunctions;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">damage to or destruction of our manufacturing equipment, or of one or more of our facilities; </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">findings and recommendations of health authorities or qualified persons in connection with facility inspections;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">ongoing supply chain interruptions from the COVID-19 pandemic, including lower available plasma levels caused by the pandemic (which has the potential to impact our plasma based products); and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">product contamination or tampering.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors listed above could cause disruptions at any of our manufacturing facilities. We do not have any redundant manufacturing facilities for any of our products. Accordingly, any damage to, or disruption or destruction of one or more of our facilities could impede our ability to manufacture our products, and our product candidates and our ability to provide manufacturing and development services for external customers, result in losses and delays, including delays in the performance of our contractual obligations or delays in our clinical trials, any of which could be costly to us and materially harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providers of MCMs could be subject to an increased risk of terrorist activities. The USG has designated both our Lansing, Michigan and our Bayview bulk manufacturing facility in Baltimore, Maryland as facilities requiring additional security. Although we continually evaluate and update security measures, there can be no assurance that any additional security measures would protect these facilities from terrorist efforts determined to disrupt our manufacturing activities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Problems may arise during the production of our products and product candidates, as well as those we produce for our CDMO customers, due to the complexity of the processes involved in their development, manufacturing and shipment or other factors. Significant delays in product manufacturing or development and our ability to ramp up production to meet the needs of our customers could cause delays in recognizing revenues, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our products and product candidates are biologics. Manufacturing biologics, especially in large quantities, is complex. The products must be made consistently and in compliance with a clearly-defined manufacturing process. Problems during manufacturing may arise for a variety of reasons, including problems with raw materials, equipment malfunction and failure to follow specific protocols and procedures. Slight deviations anywhere in the manufacturing process, including obtaining materials, maintaining master seed or cell banks and preventing genetic drift, seed or cell growth, fermentation, contamination including from particulates among other things, filtration, filling, labeling, packaging, storage and shipping, potency and stability issues and other quality control testing, may result in lot failures or manufacturing shut-downs, delays in the release of lots, product recalls, spoilage or regulatory action. Such deviations may require us to revise manufacturing processes or change manufacturers. Additionally, as our equipment ages, it will need to be replaced, which has the potential to result in similar consequences. Success rates can also vary dramatically at different stages of the manufacturing process, which can reduce yields </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and increase costs. From time to time, we may experience deviations in the manufacturing process that may take significant time and resources to resolve and, if unresolved, may affect manufacturing output and could cause us to fail to satisfy customer orders or contractual commitments, lead to a termination of one or more of our contracts, lead to delays in our clinical trials, result in litigation, or other restrictions on the marketing or manufacturing of a product, any of which could be costly to us, damage our reputation and negatively impact our business. Regulatory action, including the issuance of Forms FDA 483 and warning letters can also have an impact.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if changes are made to the manufacturing process, we may be required to provide the FDA with pre-clinical and clinical data showing the comparable identity, strength, quality, purity or potency of any impacted products before and after the changes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are contractually required to ship our biologic products at a prescribed temperature range and variations from that temperature range could result in loss of product and could significantly and adversely impact our revenues, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may not be able to ramp up our manufacturing processes to meet the rapidly changing demand or specifications of our customers on the desired timeframe, if at all. Our inability to ramp up manufacturing to meet the demand or specifications of our customers or the inability to timely obtain regulatory authorization to produce the products or product candidates of our customers could also harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products and product candidates procured by the USG and other customers require us to perform tests for and meet certain potency and lot release standards prescribed by the FDA and other agencies, which may not be met on a timely basis or at all.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to sell any products and product candidates that fail to satisfy such testing specifications. For example, we must provide the FDA with the results of certain tests, including potency tests, before certain lots are released for sale. Potency testing of each applicable lot is performed against qualified control lots that we maintain. We continually monitor the status of such reference lots for FDA compliance and periodically produce and qualify a new reference lot to replace the existing reference lot. If we are unable to satisfy USG requirements for the release of our products or product candidates, our ability to supply such products and product candidates to authorized buyers would be impaired until such time as we become able to meet such requirements, which could materially harm our future business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operations, including our use of hazardous materials, chemicals, bacteria and viruses, require us to comply with regulatory requirements and expose us to significant potential liabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve the use of hazardous materials, including chemicals, bacteria and viruses, and may produce dangerous waste products. Accordingly, we, along with the third parties that conduct clinical trials and manufacture our products and product candidates on our behalf, are subject to federal, state, local and foreign laws and regulations that govern the use, manufacture, distribution, storage, handling, exposure, disposal and recordkeeping with respect to these materials. Under the Federal Select Agent Program, pursuant to the Public Health Security and Bioterrorism Preparedness and Response Act, we are required to register with and be inspected by the CDC and the Animal and Plant Health Inspection Service if we have in our possession, or if we use or transfer, select biological agents or toxins that could pose a threat to public health and safety, to animal or plant health or to animal or plant products. This legislation requires stringent safeguards and security measures for these select agents and toxins, including controlled access and the screening of entities and personnel and establishes a comprehensive national database of registered entities. We are also subject to a variety of environmental and occupational health and safety laws. Compliance with current or future laws and regulations in this area can require significant costs and we could be subject to substantial fines and penalties in the event of noncompliance. In addition, the risk of contamination or injury from these materials cannot be completely eliminated. In such event, we could be held liable for substantial civil damages or costs associated with the cleanup of hazardous materials. From time to time, we have been involved in remediation activities and may be so involved in the future. Any related cost or liability might not be fully covered by insurance, could exceed our resources and could have a material adverse effect on our business, financial condition, operating results and cash flows. In addition to complying with environmental and occupational health and safety laws, we must comply with special regulations relating to biosafety administered by the CDC, HHS, U.S. Department of Agriculture and the DoD, as well as regulatory authorities in Canada and Switzerland.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCT DEVELOPMENT AND COMMERCIALIZATION RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The product candidates that we work on for our CDMO customers may not be safe or effective and even if they are, we may be unable to manufacture sufficient quantities to meet demand.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may provide CDMO services for the development and/or manufacture of various product candidates. There can be no assurance that these product candidates will be safe or effective or that they will be authorized for emergency use or approved by the FDA or any other health regulatory authority. Even if product candidates are found to be safe and/or effective and receive authorization or approval by a health regulatory authority or we receive authorization to produce drug substance or drug product at our facilities, the manufacturing processes for our CDMO programs are under development and are complex. There can be no assurance that we will be able to produce sufficient clinical or commercial quantities of any product candidate in a timely basis or at all. Difficulties manufacturing COVID-19 product candidates for certain CDMO customers and the November 2021 termination of the termination of the Center for Innovation in Advanced Development and Manufacturing (&#8220;CIADM&#8221;) agreement with BARDA for COVID-19 vaccine development and manufacturing (the &#8220;BARDA COVID-19 Development Public Private Partnership&#8221;) caused us to suffer considerable reputational and financial damage and resulted in the instigation of shareholder litigation and government investigations described elsewhere in this Annual Report. Any future failure to satisfy manufacturing commitments could adversely affect our reputation, subject us to potential legal liability and harm our business, financial condition, operating results and cash fl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ou</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">r growth depends on our success in developing and commercializing our product candidates. If we are unable to commercialize these product candidates or experience significant delays or unanticipated costs in doing so, our business would be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested significant efforts and financial resources in the development of our vaccines, therapeutics and medical device product candidates and the acquisition of additional product candidates. In addition to our product sales, our ability to generate revenue is dependent on a number of factors, including the success of our development programs, the USG's interest in providing development funding for or procuring certain of our product candidates, and the commercial viability of our acquired or developed product candidates. The commercial success of our product candidates can depend on many factors, including accomplishing the following in an economical manner:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">successful development, formulation and cGMP or QSR scale-up of manufacturing that meets FDA and/or foreign regulatory requirements;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">successful program partnering;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">successful completion of clinical or non-clinical development;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">receipt of marketing approvals, clearances, or other authorizations from the FDA and equivalent foreign regulatory authorities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">establishment of commercial manufacturing processes and product supply arrangements;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">training of a commercial sales force for the product;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">successful registration and maintenance of relevant patent and/or other proprietary protection;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">competitive pricing and market access; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">acceptance of the product by potential government and other customers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, the success of NARCAN Nasal Spray, including in over-the-counter form, is subject to our ability to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trials of product candidates are expensive and time-consuming, and their outcome is uncertain. We must invest substantial amounts of time and financial resources in these trials, which may not yield viable products. Failure to obtain regulatory approval for product candidates, particularly in the United States, could materially and adversely affect our financial resources, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval or other authorization of our product candidates, we and our collaborative partners, where applicable, must conduct pre-clinical studies and clinical trials to establish proof of concept and demonstrate the safety and efficacy of our product candidates. Pre-clinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. Success in pre-clinical testing and early clinical trials does not ensure that later clinical trials will be successful, and interim results of such trials do not necessarily predict final results. An unexpected result in one or more of our clinical trials can occur at any stage of testing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience unforeseen events or issues during, or as a result of, pre-clinical testing, clinical trials or animal efficacy studies. These issues and events, which could delay or prevent our ability to receive regulatory approval for a product candidate, include, among others:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our inability to manufacture sufficient quantities for use in trials;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the unavailability or variability in the number and types of subjects for each study;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">safety issues or inconclusive or incomplete testing, trial or study results;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">drug immunogenicity;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">lack of efficacy of product candidates during the trials;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">government or regulatory restrictions or delays; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">greater than anticipated costs of trials</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical and clinical testing for certain of our MCM product candidates may face additional difficulties and uncertainties because they cannot ethically or feasibly be tested in human subjects. In the U.S. we expect to rely on the Animal Rule to obtain regulatory approval for some of our MCM product candidates. The Animal Rule permits, for certain limited diseases and circumstances, the use of animal efficacy studies, together with human clinical safety and immunogenicity trials, to support an application for marketing approval. For a product approved under the Animal Rule, certain additional post-marketing requirements apply. For example, to the extent feasible and ethical, applicants must conduct post-marketing clinical studies, such as field studies in the event of an outbreak or act of bioterrorism, to assess the drug's safety and effectiveness. It is possible that results from the animal efficacy studies used to support approval under the Animal Rule may not be predictive of the actual efficacy of our product candidates in humans.</span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the PHSA and the FDCA, the Secretary of HHS can contract to purchase MCMs for the SNS prior to FDA approval, clearance, or other authorization of certain MCM product candidates. If the USG does not provide funding for and procure our MCM product candidates, they generally will have to be approved by the FDA through traditional regulatory mechanisms prior to sale and distribution in the United States. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our product development strategy and, as a result, may modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product candidates or may delay or halt the development of various product candidates. We may change or refocus our existing product development, commercialization and manufacturing activities based on government funding decisions and other factors. This could require changes in our facilities and our personnel. Any product development changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates or choose candidates for which government development funds are not available. Our decisions to allocate our R&amp;D, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources from better business opportunities. Similarly, our decisions to delay or terminate product development programs could also cause us to miss valuable opportunities.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGULATORY AND COMPLIANCE RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">There are a number of complex laws and regulations that pertain to government contracts and compliance with those laws and regulations require significant time and cost, which could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a manufacturer and supplier of MCMs to the USG addressing PHTs, we must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts. These laws and regulations govern how we transact business with our government clients and, in some instances, impose additional costs and related obligations on our operations. For a detailed description of the most significant regulations that affect our government contracting business, see the prior discussion under &#8220;Regulation - Government Contracting.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to government investigations of compliance with government acquisition regulations. USG agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. Even though we take significant precautions to identify, prevent and deter fraud, misconduct and non-compliance, we face the risk that our personnel or outside partners may engage in misconduct, fraud or improper activities. If we are audited or investigated and such audit or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigation were to uncover improper or illegal activities, we could be subject to civil and criminal fines and penalties, administrative sanctions, including suspension or debarment from government contracting, and suffer significant reputational harm. The loss of our status as an eligible government contractor or significant fines or penalties associated with contract non-compliance or resulting from investigations could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our long-term success depends, in part, upon our ability to develop, receive regulatory approval for and commercialize product candidates we develop or acquire and, if we are not successful, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with them are subject to extensive FDA regulation and oversight. This includes, but is not limited to, laws and regulations governing product development, product labeling, product testing, manufacturing, storage, product distribution, record keeping, and advertising and promotion. In limited circumstances, governments may have the authority to procure products that have not obtained regulatory approval to stockpile for emergency preparedness and to respond to public health emergencies. In other circumstances, failure to obtain regulatory approval for a product candidate will prevent us from selling and commercializing the product candidate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, to obtain authorization from FDA to market and sell any of our future drug, biologic, or vaccine products, we will be required to submit an NDA or BLA to the FDA. Under the FDCA, the PHSA, and FDA&#8217;s implementation of those statutes, a company must support an NDA or BLA with substantial evidence that the product candidate is effective and evidence that the product is safe. Ordinarily, FDA requires data from adequate and well-controlled clinical trials, including Phase 3 trials conducted in patients with the disease or condition being targeted, to demonstrate that a drug meets the statutory standards for approval. Once an NDA or BLA is submitted, the FDA has substantial discretion and may refuse to accept our application or may decide that our data are insufficient to support approval and require additional pre-clinical, clinical or other studies. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed, or to conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. Likewise, the data in our device submissions may be insufficient to support approval, de novo classification or clearance where required, and we may not be able to demonstrate to the satisfaction of the FDA that our devices are safe or effective for their intended uses or, for a 510(k) device, that they are substantially equivalent to the predicate. Even if we are granted 510(k) clearances, de novo authorizations, or PMA approvals, they may include significant limitations on the indications for use for the device.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can market a new medical device, or an existing medical device for a new use, or make significant modifications to an existing product, we must first receive either clearance under Section 510(k) of the FDCA, de novo authorization, or approval of a PMA from the FDA, unless an exemption applies. These marketing submissions must also be supported by appropriate data, including in many cases clinical data. Likewise, changes to our combination products, including changes to the device constituent part, may also require a new submission to, and approval from, FDA.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, our MCM product candidates may be eligible for approval under the FDA's &#8220;Animal Rule,&#8221; under which findings from adequate and well controlled animal efficacy studies may serve as the basis of an approval when it is not feasible or ethical to conduct efficacy trials in humans. We cannot guarantee that the FDA will permit us to proceed with approval or licensure of any of our MCM product candidates under the Animal Rule. Even if we are able to proceed under the Animal Rule, product development can take a considerable amount of time, and the FDA may decide that our data are insufficient to support approval and require additional pre-clinical, clinical or other studies, refuse to approve our products, or place restrictions on our ability to commercialize those products. Furthermore, products approved under the Animal Rule are subject to certain additional post-marketing requirements. We cannot guarantee that we will be able to meet this regulatory requirement even if one or more of our product candidates are approved under the Animal Rule.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining these regulatory approvals is expensive, often takes many years if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidate involved. Changes in the regulatory approval process may cause delays in the approval or other marketing authorization, or rejection of an application. There is a high rate of failure inherent in the medical product development process, and potential products that appear promising at early stages of development may fail for a number of reasons, and positive results from pre-clinical studies may not be predictive of similar results in human clinical trials. Similarly, promising results from earlier clinical trials of a product candidate may not be replicated in later clinical trials.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to successfully develop future product candidates may materially adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unapproved and investigational stage products are also subject to the FDA's laws and regulations governing advertising and promotion, which prohibit the promotion of both unapproved products and unapproved uses of approved products. There is some risk that the FDA could conclude that our communications relating to unapproved products or unapproved uses of approved products constitute the promotion of an unapproved product or product use in violation of FDA laws and regulations.&#160;There is also a risk that a regulatory authority in another country could take a similar position under that country's laws and regulations and conclude that we have violated the laws and regulations related to product development, approval, or promotion in that country.&#160;If the FDA or any foreign regulatory authority determines that any of our communications constitute pre-approval promotion or promotion of an off-label use, FDA could request that we modify our promotional materials, issue an untitled letter or warning letter, or subject us to regulatory or enforcement actions, including injunction, seizure, civil fine or criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Even if we or our collaborators obtain marketing approvals for our product candidates, the conditions of approvals and ongoing regulation of our products may limit how we manufacture, market and sell our products, which could materially impair our ability to generate revenue.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once marketing authorization has been granted, we and our business partners will remain subject to ongoing regulatory oversight of our medical products, including with respect to labeling; safety surveillance and reporting; registration and listing requirements; cGMP and QSR requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents; advertising and promotional activities; requirements regarding the distribution of samples to physicians and related recordkeeping; medical device design, development and manufacturing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other agencies, including the U.S. Department of Justice (&#8220;DOJ&#8221;) and the HHS Office of Inspector General (&#8220;OIG&#8221;), closely regulate and monitor the marketing and promotion of medical products to ensure that they are marketed in a manner consistent with the FDA-approved label. For drugs products, we must promote the product in a manner consistent with the full prescribing information or, for 510(k) cleared devices, consistent with the cleared indication. The FDA, DOJ, and OIG impose stringent restrictions on manufacturers&#8217; communications regarding unapproved/uncleared products and unapproved/uncleared uses of approved/cleared products. If we market unapproved/uncleared products or market our approved/cleared products for unapproved/uncleared indications, we may be subject to enforcement action. Violations of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are subject to post marketing requirements (&#8220;PMRs&#8221;), which we are required to conduct, and post marketing commitments, which we have agreed to conduct. The FDA has the authority to take action against sponsors who fail to meet the obligations of a PMR, including civil monetary penalties and/or misbranding charges.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, discovery of previously unknown adverse events or other problems with our products, manufacturing partners or manufacturing processes, or failure to comply with regulatory requirements, may result in various penalties and sanctions. For all FDA-regulated products, if the FDA finds that a manufacturer has failed to comply with applicable laws and regulations, or that a product is ineffective or poses an unreasonable health risk, it can institute or seek a wide variety of enforcement actions and other remedies, including but not limited to:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">restrictions on the labeling or marketing of a product;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">restrictions on distribution or use of a product;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">warning letters or untitled letters;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">refusal to approve pending applications or supplements to approved applications that are submitted;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">delay in or refusal to approve/clear/authorize pending PMA applications, 510(k) premarket submissions, or de novo authorization requests;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">fines, restitution or disgorgement of profits or revenues; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">refusal to permit the import or export of our products;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">product seizure; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and our collaborators are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market and sell any products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condit</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we or our collaborators obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Likewise, non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU and other legal and regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions. Non-compliance with similar requirements in other foreign jurisdictions can also result in enforcement actions and significant penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and may affect the prices we, or our collaborators, may obtain.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other health care reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we, or any collaborators, may receive for any approved products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the "ACA"), passed in 2010 and substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry. However, some provisions of the ACA have yet to be fully implemented and certain provisions have been subject to legal and political challenges, as well as efforts by the last Presidential administration to repeal or replace certain aspects of the ACA. On January 28, 2021, however, the President issued an executive order to strengthen implementation of the ACA. Concurrently, Congress considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA, such as removing penalties as of January 1, 2019 for not complying with the ACA&#8217;s </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">individual mandate to carry health insurance, delaying the implementation of certain ACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, the current Presidential administration issued an executive order initiating a special enrollment period during 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare. It is unclear how healthcare reform measures enacted by Congress or implemented by the current Presidential administration or other challenges to the ACA, if any, will impact the ACA or our business. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there has been recent heightened federal governmental scrutiny over the manner in which manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries and has been proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), was signed into law on August 16, 2022. While the IRA is still subject to rulemaking (with more information to come via guidance documents from the responsible federal agencies), the IRA, as written, will, among other changes, give the U.S. Department of Health and Human Services (the &#8220;HHS&#8221;) the ability and authority to directly negotiate with manufacturers the price that Medicare will pay for certain high-priced drugs. The IRA will also require manufacturers of certain Part B and Part D drugs to issue to HHS rebates based on certain calculations and triggers (i.e., when drug prices increase and outpace the rate of inflation). At this time, we cannot predict the implications the IRA provisions will have on our business. These types of laws may have a significant impact on our ability to set a product price we believe is fair and may adversely affect our ability to generate revenue and achieve or maintain profitability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program ("SIP"), to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation. At least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada, and at least three states (Colorado, Florida, and New Mexico) have submitted SIPs to FDA for review and approval.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, and wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we fail to comply with foreign, federal, state and local health care laws, including fraud and abuse and health information privacy and security laws, and antitrust laws, we could face substantial&#160;penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, certain of our products are reimbursed under federal and state health care programs such as Medicaid, Medicare, TriCare, and/or state pharmaceutical assistance programs. Many foreign countries have similar laws. Federal and state laws designed to prevent fraud and abuse under these programs prohibit pharmaceutical companies from offering valuable items or services to customers or potential customers to induce them to buy, prescribe, or recommend our product (the so-called &#8220;anti-kickback&#8221; laws). Exceptions are provided for discounts and certain other arrangements if specified requirements are met. Other federal and state laws, and similar foreign laws, not only prohibit us from submitting any false information to government reimbursement programs but also prohibit us, our employees, or any third party acting on our behalf from doing anything to cause, assist, or encourage our customers to submit false claims for payment to these programs. We are also subject to various federal, state and foreign antitrust and competition laws that prohibit certain activities that may have an impact against potential competitors. Violations of the various fraud and abuse and antitrust laws may result in severe penalties against the responsible employees and us, including jail sentences, large fines, and the exclusion of our products from reimbursement under federal and state programs. Some of the laws that may affect our ability to operate include:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the federal Anti-Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay remuneration, directly or indirectly, overtly or covertly, to induce, or in return for, either the referral of an individual, or the purchase, lease, prescribing or recommendation of an item, good, facility or service reimbursable by a federally funded health care program, such as the Medicare or Medicaid program. The term &#8220;remuneration&#8221; has been interpreted broadly and may constrain our marketing practices, educational programs, pricing policies and relationships with health care providers or other entities, among other activities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal health care program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability, including mandatory treble damages and significant per-claim penalties.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statement, in connection with the delivery of, or payment for, health care benefits, items or services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">HIPAA, as amended by HITECH, and their respective implementing regulations mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common health care transactions, as well as standards relating to the privacy, security and transmission of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA's security standards directly applicable to &#8220;business associates,&#8221; or independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the Physician Payments Sunshine Act and its implementing regulations require certain manufacturers of drugs, biologics, medical devices and medical supplies for which payment is available under Medicare, Medicaid or the Centers for Medicare &amp; Medicaid Services (CMS) to report certain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments and transfers of value made to U.S. physicians, other healthcare providers and teaching hospitals, and ownership or investment interests held by physicians, other healthcare providers and their immediate family members; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; state, local and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, obtain pharmaceutical agent licensure, and/or otherwise restrict payments that may be made to health care providers and entities; and state, local and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to health care providers or entities, or marketing expenditures.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under the federal Anti-Kickback Statute, it is possible that some of our business activities could be subject to challenges under one or more of such laws. Moreover, recent health care reform legislation has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal health care fraud statutes, so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or otherwise, we may be subject to penalties, including civil and criminal penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from funded health care programs and the curtailment or restructuring of our operations. Any such penalties could adversely affect our financial results. We continue to improve our corporate compliance program designed to ensure that our development, marketing, and sales of existing and future products and product candidates are in compliance with all applicable laws and regulations, but we cannot guarantee that this program will protect us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from government funded health care programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If a third party fails to comply with applicable laws and regulations while acting on our behalf, we may also be subject to criminal, civil, and administrative penalties, including those listed above.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States government, state governments and private payors regularly investigate the pricing and competitive practices of pharmaceutical companies and biotechnology companies, and many file actions alleging that inaccurate reporting of prices has improperly inflated reimbursement rates. We may also be subject to investigations related to our pricing practices. Regardless of merit or eventual outcome, these types of investigations and related litigation can result in:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Diversion of management time and attention;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Significant legal fees and payment of damages or penalties;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Limitations on our ability to continue certain operations;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Decreased product demand; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Injury to our reputation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, an adverse outcome, or the imposition of penalties or sanctions for failing to comply with the fraud and abuse and antitrust laws, could adversely affect us and may have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we fail to comply with our obligations under U.S. governmental pricing programs, we could&#160;be required to reimburse government programs for underpayments and could pay penalties, sanctions and fines.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of regulations and coverage expansion by various governmental agencies relating to the Medicaid rebate program will continue to increase our costs and the complexity of compliance and will be time-consuming. Changes to the definition of average manufacturer price (AMP), and the Medicaid rebate amount under the ACA, the issuance of final regulations implementing those and other changes has affected and could further affect our 340B &#8220;ceiling price&#8221; calculations. Because we participate in the Medicaid rebate program, we are required to report average sales price (ASP), information to CMS for certain categories of drugs that are paid for under Part B of the Medicare program. Future statutory or regulatory changes or CMS binding guidance could affect the ASP calculations for our products and the resulting Medicare payment rate and could negatively impact our results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary among products and programs, involve complex calculations and are often subject to interpretation by us, governmental or regulatory agencies and the courts. The Medicaid rebate amount is computed each quarter based on our submission to CMS of our current AMP and &#8220;best price&#8221; for the quarter. If we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due. Any such revisions could have the impact of increasing or decreasing our rebate liability for prior quarters, depending on the direction of the revision. Such restatements and recalculations would increase our costs for complying with the laws and regulations governing the Medicaid rebate program. Price recalculations also may affect the &#8220;ceiling price&#8221; at which we are required to offer our products to certain covered entities, such as safety-net providers, under the 340B/Public Health Service ("PHS") drug pricing program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we are found to have made a misrepresentation in the reporting of ASP, we are subject to civil monetary penalties for each such price misrepresentation and for each day in which such price misrepresentation was applied. If we are found to have knowingly submitted false AMP or &#8220;best price&#8221; information to the government, we may be liable for civil monetary penalties per item of false information. Any refusal of a request for information or knowing provision of false information in connection with an AMP survey verification would also subject us to civil monetary penalties. In addition, our failure to submit monthly/quarterly AMP or &#8220;best price&#8221; information on a timely basis could result in a civil monetary penalty per day for each day the information is late beyond the due date. Such failure could also be grounds for CMS to terminate our Medicaid drug rebate agreement, under which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, no federal payments would be available under Medicaid or Medicare Part B for our covered outpatient drugs. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot ensure that our submissions will not be found by CMS to be incomplete or incorrect.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for our products to be reimbursed by the primary federal governmental programs, we must report certain pricing data to the USG. Compliance with reporting and other requirements of these federal programs is a pre-condition to: (i)&#160;the availability of federal funds to pay for our products under Medicaid and Medicare Part B; and (ii)&#160;procurement of our products by the Department of Veterans Affairs ("DVA"), and by covered entities under the 340B/PHS program. The pricing data reported are used as the basis for establishing Federal Supply Schedule ("FSS"), and 340B/PHS program contract pricing and payment and rebate rates under the Medicare Part B and Medicaid programs, respectively. Pharmaceutical companies have been prosecuted under federal and state false claims laws for submitting inaccurate and/or incomplete pricing information to the government that resulted in increased payments made by these programs. Although we maintain and follow strict procedures to ensure the maximum possible integrity for our federal pricing calculations, the process for making the required calculations is complex, involves some subjective judgments and the risk of errors always exists, which creates the potential for exposure under the false claims laws. If we become subject to investigations or other inquiries concerning our compliance with price reporting laws and regulations, and our methodologies for calculating federal prices are found to include flaws or to have been incorrectly applied, we could be required to pay or be subject to additional reimbursements, penalties, sanctions or fines, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, we also must participate in the DVA FSS pricing program. To participate, we are required to enter into an&#160;FSS contract with the DVA, under which we must make our innovator &#8220;covered drugs&#8221; available to the &#8220;Big Four&#8221; federal agencies-the DVA, the DoD, the PHS (including the Indian Health Service), and the Coast Guard-at pricing that is capped under a statutory federal ceiling price ("FCP") formula set forth in Section&#160;603 of the Veterans Health Care Act of 1992 ("VHCA"). The FCP is based on a weighted average wholesale price known as the Non-Federal Average Manufacturer Price ("Non-FAMP"), which manufacturers are required to report on a quarterly and annual basis to the DVA. Under the VHCA, knowingly providing false information in connection with a Non-FAMP filing can subject us to significant penalties for each item of false information. If we overcharge the government in connection with our FSS contract or Section&#160;703 Agreement, whether due to a misstated FCP or otherwise, we are required to disclose the error and refund the difference to the government. The failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government&#160;investigation or enforcement action, can be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">From time to time, we sell unapproved MCMs to government entities under certain circumstances. While this is permissible in some cases, the extent to which we may be able to lawfully offer to sell and sell unapproved products in many jurisdictions may be unclear or ambiguous. Such sales could subject us to regulatory enforcement action, product liability and reputational risk.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain and narrow circumstances, MCMs may be procured by government entities prior to approval by the FDA or other regulatory authorities, a practice which we follow in connection with certain MCMs, including AV7909 and TROBIGARD in the United States. In the United States, the Secretary of HHS has the authority to contract to purchase MCMs for the SNS prior to FDA approval of the relevant MCM in specified circumstances. FDA also has the authority to permit the emergency use of medical products that have not yet been approved by the FDA under an EUA. An EUA terminates when the EUA is revoked or the emergency declaration underlying the EUA terminates. An EUA is not a long-term alternative to obtaining FDA approval, licensure, clearance, or other marketing authorization for a product. An EUA has not been granted for TROBIGARD or AV7909. Absent an applicable exception, our MCM product candidates generally will have to be approved, licensed, or cleared by the FDA or other regulatory authorities in the relevant country through traditional pathways before we can sell those products to governments. Additionally, the laws in certain jurisdictions regarding the ability of government entities to purchase unapproved product candidates can be ambiguous, and the permissibility of exporting unapproved products from the United States and importing them to foreign countries may be unclear in some instances. Nevertheless, government bodies, such as U.S. federal entities other than HHS, state and local governments within the United States, and foreign governments have sought and may further seek to procure our MCM product candidates that are not yet approved. In this situation, we would expect to assess the permissibility and liability implications of supplying our product candidates to such entities on a case-by-case basis, which presents certain challenges, both in the case of U.S. and foreign governments, and particularly under emergency conditions. In addition, agencies or branches of one country&#8217;s government may take different positions regarding the permissibility of such sales than another country&#8217;s government or even other agencies or branches of the same government. If local enforcement authorities disagree with our conclusion that such activities are permissible, they may take enforcement action against us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the sale of unapproved products also could give rise to product liability claims for which we may not be able to obtain adequate indemnification or insurance coverage. For example, despite liability protections applicable to claims arising under U.S. law and resulting from the use of certain unlicensed or unauthorized MCMs, such as a declaration issued under the PREP Act, plaintiffs still may bring lawsuits, among other things, that their claims are not barred under the PREP Act.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a user of one or more of our products experiences an adverse event, we may be subject to additional reputational risk if the product has not been approved by the FDA or the corresponding regulatory authority of another country, particularly because we will not have approved labeling regarding the safety or efficacy of those products. In addition, legislatures and other governmental bodies that have oversight responsibility for procuring agencies may raise concerns after the fact, even if procurement was permissible at the time, which could result in negative publicity, reputational risk and harm to our business prospects.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that our communications with governments about our unapproved/uncleared products, such as in the procurement context, could be considered promotion of an unapproved/uncleared product or unapproved/uncleared use of an approved product. Therefore, there is a risk that we could be subject to enforcement actions if found to be in violation of such laws or regulations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Even after regulatory approval is received, if we fail to comply with regulatory requirements, or if we experience unanticipated problems with our approved products, they could be subject to restrictions, penalties or withdrawal from the market.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any vaccine, therapeutic product or medical device for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to the continual requirements of and review by the FDA and other regulatory bodies. Our approved products are subject to these requirements and ongoing review. For drugs and vaccines, these requirements include submissions of safety and other post-marketing information and reports, plasma donor testing, registration requirements, cGMP, requirements relating to potency and stability, quality control, quality assurance, restrictions on advertising and promotion, import and export restrictions and recordkeeping requirements. Requirements for medical devices are similar and include QSR compliance, establishment registration and device listing; record keeping; restrictions on advertising and promotion; post-market surveillance, and restrictions on import and export. In addition, various state laws require that companies that manufacture and/or distribute drug products within the state obtain and maintain a manufacturer or distributor license, as appropriate. Some states have similar requirements for devices. Because of the breadth of these laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government regulators enforce cGMP, QSR, and other requirements through periodic unannounced inspections of manufacturing facilities. The FDA is authorized to inspect domestic and foreign manufacturing facilities without prior notice at reasonable times and in a reasonable manner. Health Canada may conduct similar inspections of our domestic and foreign facilities where products offered and sold in Canada are produced, or related formulation and filling operations are conducted. The FDA, Health Canada, and other foreign regulatory agencies conduct periodic inspections of our facilities. Following several of these inspections, regulatory authorities have issued inspectional observations, some of which were significant, but all of which are being, or have been, addressed through corrective actions. If, in connection with any future inspection, regulatory authorities find that we are not in substantial compliance with all applicable requirements, or if they are not satisfied with the corrective actions we take, our regulators may undertake enforcement action against us, which may include:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">warning letters, untitled letters, and other communications;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">product seizure or withdrawal of the product from the market;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">restrictions on the marketing or manufacturing of a product;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">suspension or withdrawal of regulatory approvals or refusal to approve pending applications or other marketing submissions, or supplements to approved applications;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">fines or disgorgement of profits or revenue; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar action may be taken against us should we fail to comply with regulatory requirements, or later discover previously unknown problems with our products or manufacturing processes. For instance, our products are tested regularly to determine if they satisfy potency and stability requirements for their required shelf lives. Failure to meet potency, stability or other specification requirements could result in delays in distributions, recalls or other consequences. In November 2022, a specific batch of our RSDL kits was recalled due to leakage, which could cause the product not to perform as effectively as intended. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if regulatory approval, clearance, or other marketing authorization of a product is granted, the approval, clearance, or marketing authorization may be subject to limitations on the indicated uses for which the product may be marketed or sold or to the conditions of approval. Regulatory approval or other authorization may also contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. If we experience any of these post-approval events, our business, financial condition, operating results and cash flows could be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, companies may not promote unapproved products or unapproved uses of approved products (i.e. &#8220;off-label&#8221; uses or uses that are not described in the product&#8217;s approved labeling and/or that differ from the uses approved or cleared by the applicable regulatory agencies). A company that is found to have improperly promoted an unapproved/uncleared product or an unapproved/uncleared use of an approved/cleared product may be subject to significant liability, including civil and administrative remedies (such as entering into corporate integrity agreements with the USG), as well as criminal sanctions. If our employees or agents engage in marketing of an unapproved/uncleared product or the unapproved/uncleared use of an approved/cleared product, we could be subject to civil or criminal investigations and monetary and injunctive penalties, which could adversely impact our ability to conduct business in certain markets, negatively affect our business, financial condition, operating results and cash flows, and damage our reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failure to obtain or maintain regulatory approval in international jurisdictions could prevent us from marketing our products abroad and could limit the growth of our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently sell certain of our products outside the United States and intend to expand the countries in which we sell our products and have received market authorization under the mutual recognition procedure to sell BioThrax in France, Italy, the Netherlands, Poland, and the United Kingdom. To market or sell our products in foreign jurisdictions under normal circumstances, we generally need to obtain separate regulatory approvals and comply with numerous and varying requirements or use alternative &#8220;emergency use&#8221; or other exemptions from general approval and import requirements. Approval by the FDA in the United States or the mutual recognition procedure in the European member states does not ensure approval by all foreign regulatory authorities. The approval procedures in foreign jurisdictions can vary widely and can involve additional clinical trials and data review beyond that required by the FDA or under the mutual recognition procedure. There is also a risk that a regulatory authority in another country could conclude that we have violated the rules and regulations related to product development, approval or promotion in that country. Therefore, there is a risk that we could be subject to a foreign enforcement action if found to be in violation of such laws and regulations. We and our collaborators may not be able to obtain foreign regulatory approvals on a timely basis, if at all, and we may be unable to successfully commercialize our products in desired jurisdictions internationally if no alternate procurement pathway is identified for authorized government customers in a particular jurisdiction. We have limited experience in preparing, filing and prosecuting the applications necessary to gain foreign regulatory approvals and expect to rely on third-party contract research organizations and consultants to assist us in this process. Our reliance on third parties can introduce additional uncertainty into the process.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency (the "MHRA"), became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to European Union rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended) (the "HMR"), as the basis for regulating medicines. The HMR has incorporated into the domestic law of the body of European Union law instruments governing medicinal products that pre-existed prior to the United Kingdom's withdrawal from the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain products outside of the United States, require us to develop and implement costly compliance programs, and if violated, can lead to financial and other impacts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our commercialization activities outside of the United States, we are subject to an increased risk of violating, and must dedicate additional resources towards avoiding inadvertently conducting activities in a manner that violates, the FCPA, the U.K. Bribery Act, Canada's Corruption of Foreign Public Officials Act, and other similar foreign anti-bribery laws that prohibit corporations and individuals from corruptly paying, offering to pay, or authorizing the payment of anything of value, directly or indirectly, to any foreign government official, government staff member, political party or party official, or political candidate in an attempt to influence a person working in an official capacity or otherwise obtain an improper advantage. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the Company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Some anti-bribery laws also apply to private sector bribery. Compliance with the FCPA and other anti-bribery laws is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals and other parts of the health system are operated by the government, and doctors, hospital employees, and other health care providers are considered foreign officials. Certain payments to hospital employees and other health care professionals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including the U.S., also have various lobbying laws and regulations governing the conduct of individuals and companies who interact with government officials. These laws and regulations typically include certain restrictions and disclosure obligations. If we, our employees, or third parties acting on our behalf do not comply with these laws and regulations, we may be subject to civil and criminal penalties. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including the United States, restrict the export or import of products to or from certain countries through, for example, bans, sanction programs, and boycotts. Such restrictions may preclude us from supplying products in certain countries, which could limit our growth potential. Furthermore, if we, or third parties acting on our behalf, do not comply with these restrictions, we may be subject to civil and criminal penalties. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we continue to expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties, suspension or debarment from government contracting, and other sanctions, and can cause reputational harm. The SEC also may bring enforcement actions against issuers for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITIVE AND POLITICAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development and commercialization of pharmaceutical products, including for PHT preparedness, are routinely subject to evolving private and public sector competition. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new biopharmaceutical and medical technology products is highly competitive and subject to rapid technological advances. We will continue to face future competition from other companies and governments, universities and other non-profit research organizations in respect to our products, any products that we acquire, our current product candidates and any products we may seek to develop or commercialize in the future. The market for products can be subject to development of safer, more effective, more convenient or less costly products. The market for current products can also depend on what resources can be devoted to marketing or selling products, or how companies are positioned to adapt more quickly to new technologies, respond to scientific advances or patient preferences and needs, initiate or withstand substantial price competition and/or procure third-party licensing and collaborative arrangements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of companies with products or product candidates addressing PHT preparedness that are competing with us for both USG procurement and development resources. Factors to consider include competitors' financial, technical, marketing and selling resources as well as potential leverage that their intellectual property estates may offer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in demand for our products or reduction or loss of development funding for our products or product candidates in favor of a competing product could lead to a loss of market share for our products and cause reduced revenues, margins and levels of profitability for us, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our biologic products may face risks of competition from biosimilar manufacturers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biological products and product candidates, which we refer to as &#8220;Biologic Products,&#8221; can be affected by the approval and entry of &#8220;biosimilars&#8221; in the United States and other jurisdictions. Biosimilar products are licensed through an abbreviated pathway based on a showing that they are &#8220;highly similar&#8221; to a previously licensed product (known as the reference product) notwithstanding minor differences in clinically inactive components, and there are no clinically meaningful differences from the reference product in terms of safety, purity, and potency. Biologic Products in our current pipeline include AV7909, BioThrax, and ACAM2000. If a biosimilar version of one of our Biologic Products were approved, it could have a material adverse effect on the sales and gross profits of the affected Biologic Product and could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NARCAN&#174; (naloxone HCI) is currently subject to generic competition and may be subject to additional branded and generic competition in the future.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN currently faces generic competition. In 2016, Teva Pharmaceuticals Industries Limited and Teva Pharmaceuticals USA (collectively, Teva) filed an Abbreviated New Drug Application (ANDA) seeking regulatory approval to market a generic version of NARCAN. In patent litigation related to Teva&#8217;s ANDA filing, a trial Court decided in favor of Teva, and this decision was subsequently affirmed by the Court of Appeals for the Federal Circuit.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA approved Teva's ANDA on April 19, 2019. On December 22, 2021, Teva commenced the launch of its generic naloxone nasal spray. As part of recent state settlements, including in Florida, Texas, Rhode Island, and West Virginia, Teva has agreed to supply Medication- Assisted Treatment (MAT) and generic opioid overdose reversal agents, like naloxone, to states at no cost in lieu of additional monetary compensation. The terms of these product donation agreements stretch 10 to 15 years. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN also faces generic competition from Perrigo UK FINCO Limited Partnership (Perrigo, now Padagis), which filed its own ANDA in 2018. Emergent settled with Perrigo on February 12, 2020 providing for a license effective upon the Teva litigation decision. In June 2022, the FDA approved the Padagis ANDA and Padagis launched its generic naloxone nasal spray.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of generic versions of NARCAN at prices lower than our branded product or provided at no cost by Teva have the potential to erode our sales and could impact our product revenue related to NARCAN. For example, certain U.S. state laws allow for, and in some instances in the absence of specific instructions from the prescribing physician, mandate the dispensing of generic products rather than branded products where a generic version is available. In addition, in January 2019, the FDA released new proposed template Drug Facts Labels to assist sponsors of investigational naloxone nasal sprays and auto-injectors seeking approval from the FDA for over-the-counter naloxone products. In November 2022, the FDA announced its preliminary assessment that naloxone nasal spray products up to 4mg and naloxone auto-injector products for intramuscular or subcutaneous use up to 2mg have the potential to be approvable as safe and effective for nonprescription use.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasal Spray</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> also faces branded competition Kloxxado</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (naloxone HCI) nasal spray 8mg, a branded product developed by Hikma Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc.'s naloxone injection product, Teleflex Medical Inc.'s Intranasal Mucosal Atomization Device and Zimhi</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone), a branded injectable product developed by Adamis.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Harm Reduction Therapeutics has announced filing of an NDA application for a 3mg naloxone nasal spray formulation intended for OTC use in opioid overdose reversal. NARCAN may face additional generic and branded competition in the future.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Political or social factors may delay or impair our ability to market and sell our products and may require us to spend significant management time and financial resources to address these issues.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products developed to counter the potential impact of PHTs are subject to changing political and social environments. The political responses and social awareness of the risks of these threats on military personnel or civilians and the level of emphasis placed on such risks by the USG may vary over time. If the threat of terrorism were to decline, then the public perception of the risk on public health and safety may be reduced. This perception, as well as political or social pressures (including as a result of negative publicity we have received based on our longstanding ties to the USG), could delay or cause resistance to bringing our products in development to market or limit pricing or purchases of our products, any of which could negatively affect our revenues and our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, substantial delays or cancellations of purchases could result from protests or challenges from third parties. Lawsuits brought against us by third parties or activists, even if not successful, could require us to spend significant management time and financial resources defending the related litigation and could potentially damage the public's perception of us and our products. Any publicity campaigns or other negative publicity may adversely affect the degree of market acceptance of our MCMs and thereby limit the demand for our products, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to obtain orphan drug exclusivity for product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or foreign regulatory authorities from approving other competing products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same rare disease or condition for that time period. The applicable period is seven years in the United States. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for the FDA to grant orphan drug designation to one of our products, the agency must find, among other requirements, that the product is being or will be investigated for a condition or disease with a patient population of fewer than 200,000 individuals in the United States, or, for a vaccine, diagnostic drug, or preventive drug, it will be administered to fewer than 200,000 persons per year in the United States. Alternatively, FDA may determine that there is no reasonable expectation that the costs of research and development of the drug can be recovered from sales of the drug in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug designation does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In addition, even after a product receives orphan drug exclusivity, the FDA can subsequently approve the same product for the same condition if the FDA or such authorities conclude that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care; if the FDA determines that the holder of orphan drug exclusivity cannot ensure the availability of sufficient quantities of the product to meet the needs of patients with the rare disease or condition; or if the holder of orphan drug exclusivity consents to the approval of such subsequent product. Additionally, the FDA may revoke orphan drug designation if the FDA determines that the request for designation contained an untrue statement of material fact, omitted material information, or the FDA subsequently finds that the drug in fact had not been eligible for orphan drug designation at the time of submission of the request for designation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face similar risks in the EU and other foreign jurisdictions that have comparable regulations concerning orphan drug exclusivity.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Protection of our intellectual property rights is an important tool for sustaining our business and the failure to do so could impact our financial condition, operating results, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek to protect intellectual property rights related to our Company's assets, including patent rights, trademark rights, trade secrets and proprietary confidential information, through defense and enforcement of existing rights and pursuit of protection on new and arising innovations. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining, maintaining and defending our intellectual property rights in the United States and other countries remains a critical component of the development and commercialization of our Company's assets. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the risks associated with procurement, maintenance and enforcement of intellectual property rights include changes in patent laws or administrative patent office rules, evolving criteria and eligibility of obtaining patent protection on particular subject matter, the validity and enforceability of our intellectual property rights, the potential scope of coverage of our intellectual property rights, and/or the availability or strength of legal remedies in a particular country to defend and enforce intellectual property rights.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks include associated costs, such as costs of patent prosecution and maintenance and costs associated with post-grant challenges. For example, such costs include </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes review</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proceedings in the United States and oppositions in Europe, as well as costs associated with litigating and enforcing patent and trademark rights. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional risks include limitations on our extent or ability to procure, maintain or defend intellectual property rights associated with in-licensed or acquired intellectual property, where, for example, other parties (e.g., licensors) may have the first right to maintain or defend intellectual property rights in which we have an interest, or may pursue strategies that are divergent to the interest of our Company.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third party claims of for patent infringement could impact our business, financial condition, operating results, and cash flows. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Claims by other parties of alleged patent infringement could delay, stop or affect the development and commercialization of our products and product candidates. Such challenges, while ongoing, could be costly, requiring and utilizing company resources. Such challenges, if successful, may impact marketing or launch of products, or require ongoing license and/or royalty fees associated with potential settlement agreements. These may have the potential to materially harm our business, financial condition, operating results, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intellectual property licenses with third parties carry risks of challenges, which may be costly and time consuming and could impact the commercialization of our products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of license agreements and expect to enter into additional license agreements in the future. Such license agreements or collaboration arrangements can be subject to challenges if interests or expectations under such license agreements diverge. Such challenges may be costly, risk time and resources, and could delay or impact development, commercialization or launch of our products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential loss of proprietary information and know-how generally carries the risk of reducing the value of our technology and products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented proprietary technology, processes, and know-how, particularly as to our proprietary manufacturing processes. These types of confidential information and trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants, and third parties, as well as confidentiality policies and audits, although these may not always be successful in protecting our trade secrets and confidential information.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One or more of our products could be subject to early competition from generic drugs and biosimilars.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our products is approved as a drug product under the provisions of the FDCA, which may render it susceptible to potential competition from generic manufacturers via the Hatch-Waxman Act and ANDA process. Other of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products may be susceptible to challenges by entry of biosimilars through the route established under the Biologics Price Competition and Innovation Action of 2009. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we intend to vigorously enforce our intellectual property rights, there can be no assurance that we will prevail in our enforcement or defense of our patent rights. Our existing patents could be invalidated, found unenforceable, or found not to cover a generic form of our product.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO RELIANCE ON OTHER PARTIES </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The loss of any of our non-exclusive, sole-source or single source suppliers, a shortage of related supplies or an increase in the price of inventory supplied to us could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase certain supplies used in our manufacturing processes from non-exclusive, or single sources due to quality considerations, costs or constraints resulting from regulatory requirements. We depend on certain single-source suppliers for key materials and services necessary to manufacture the majority of our products and certain product candidates. For example, we rely on a single-source supplier to provide us with Alhydrogel in sufficient quantities to meet our needs to manufacture AV7909 and BioThrax vaccines and the specialty plasma in our hyperimmune specialty plasma products and certain ingredients for the ACAM2000 vaccine. We also rely on single-source suppliers for the materials necessary to produce NARCAN, such as the naloxone active pharmaceutical ingredient and other excipients, along with the vial, stopper and device. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where a particular single-source supply relationship is terminated, we may not be able to establish additional or replacement suppliers for certain components or materials quickly. This is largely due to the FDA approval system, which mandates validation of materials prior to use in our products and product candidates, and the complex nature of manufacturing processes. In addition, we may lose a sole-source supplier due to, among other things, the acquisition of a supplier by a competitor (which may cause the supplier to stop selling its products to us) or the bankruptcy of such a supplier, which may cause the supplier to cease operations. Any reduction or interruption by a sole-source supplier of the supply of materials or key components used in the manufacturing of our products or product candidates, a reduction in quality or an increase in the price of those materials or components could adversely affect us. If we are unable to locate or establish alternative suppliers, our ability to manufacture our products and product candidates could be adversely affected and could harm our revenues, cause us to fail to satisfy contractual commitments, lead to a termination of one or more of our contracts or lead to delays in our clinical trials, any of which could be costly to us and otherwise materially harm our business, financial condition, operating results and cash flows. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend on third parties to conduct many of our clinical and non-clinical trials. If these third parties do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or commercialize our product candidates and, as a result, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on third parties, such as independent clinical investigators, contract research organizations and other third-party service providers to conduct the clinical and non-clinical trials of our product candidates and expect to continue to do so. We rely heavily on these third parties for successful execution of our clinical and non-clinical trials, but do not exercise day-to-day control over their activities. Our reliance on these service providers does not relieve us of our regulatory responsibilities, including ensuring that our trials are conducted in accordance with good clinical practice regulations and the plan and protocols contained in the relevant regulatory application. In addition, these organizations may not complete these activities on our anticipated or desired timeframe. We also may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the work of a contract research organization or other third party may lead us to seek to terminate the relationship and use an alternative service provider, which may prove difficult, costly and result in a delay of our trials. Any delay in or inability to complete our trials could delay or prevent the development, approval and commercialization of our product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, government entities and NGOs conduct studies of our product candidates, and we may seek to rely on these studies in applying for marketing approval for certain of our product candidates. These government entities and NGOs have no obligation or commitment to us to conduct or complete any of these studies or clinical trials and may choose to discontinue these development efforts at any time. Furthermore, government entities depend on annual Congressional appropriations to fund their development efforts, which may not be approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain any necessary third-party services on acceptable terms or if these service providers do not successfully carry out their contractual duties or meet expected deadlines, our efforts to obtain regulatory approvals for our product candidates may be delayed or prevented.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL AND REPUTATIONAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our financial condition and operating results could be adversely impacted by unfavorable results of legal proceedings or government investigations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various claims, legal proceedings and government investigations that have not yet been fully resolved, including stockholder derivative and putative class action lawsuits, and new matters may arise in the future. In addition, agreements entered into by us sometimes include indemnification provisions which can subject us to costs and damages in the event of a claim against an indemnified third party. The number of claims, legal proceedings and government investigations involving us, and the alleged magnitude of such claims, proceedings and government investigations, has generally increased over time and may continue to increase. Certain of these actions include, and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other actions adverse to us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, multiple purported class action lawsuits have been filed against us and certain of our current and former senior officers in the United States District Court for the District of Maryland seeking unspecified damages on behalf of a putative class of persons who purchased or otherwise acquired shares of our common stock during various date ranges. The complaints, allege, among other things, that we made materially false and misleading statements regarding our procedures and quality controls relating to vaccine production, in violation of federal securities laws. As another example, multiple stockholder derivative lawsuits were filed in The Court of Chancery of the State of Delaware and the United States District Court for the District of Maryland on behalf of the Company against certain current and former officers and directors for breach of fiduciary duties, waste of corporate assets, unjust enrichment and insider trading, each allegation related to the Company&#8217;s capabilities to manufacture COVID-19 vaccine bulk drug substance. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of merit, litigation can be both time-consuming and disruptive to our operations and cause significant expense and diversion of management&#8217;s attention. The outcome of litigation or government investigations is also inherently uncertain. If one or more legal matters were resolved against us or an indemnified third party in a reporting period for amounts above management&#8217;s expectations, our financial condition and operating results for that reporting period could be materially adversely affected. Further, such an outcome could result in significant compensatory, punitive or trebled monetary damages, disgorgement of revenue or profits, remedial corporate measures or injunctive relief against us and could require us to change our business practices or limit our ability to offer certain products and services, all of which could materially adversely affect our financial condition and operating results. While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely significantly on information technology systems and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm our ability to operate our business effectively or result in data leakage of proprietary and confidential business and employee information.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. We previously contracted with the USG and pharmaceutical companies for the development and manufacture of a significant quantity of COVID-19 vaccines, which raised our security profile and heightened potential risks that malicious actors may seek to disrupt our systems or misappropriate our information. The size and complexity of our computer systems and those of many of our business partners, collaborators and other third parties make them potentially vulnerable to interruption, invasion, computer viruses, destruction, malicious intrusion and additional related disruptions, which may result in the impairment of production and key business processes. Our systems and information are also potentially vulnerable to cyber security incidents through employee error, phishing scams and malfeasance, as well as cyber security incidents involving our business partners, collaborators and other third parties, any of which may expose sensitive data to unauthorized persons. Our systems and those of our business partners and collaborators have in the past been, and in the future likely will be subject to computer viruses, malicious codes, unauthorized access and other cyber security incidents. We are not aware of any significant impact on our operations or financial results from such incidents although, as of the date of this report, we are assessing the potential impact of a cyber security incident involving a business partner of which we were made aware in early May 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No system of protection is adequate to protect against all such threats, even if they are deemed to be industry standard, and there can be no assurance that we will be able to repel any such attacks. Cyber security incidents could lead to the loss of trade secrets or other intellectual property or the public exposure of personal information, including sensitive personal information, of our employees, clinical trial patients, customers and others. Responding to any such threats may also be expensive and time-consuming. Any such unauthorized access to our information, whether through an incident involving our information technology </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">systems or those of our business partners, collaborators or other third parties, could disrupt our business operations, result in the loss of assets, and have a material adverse effect on our reputation, business, financial condition, or results of operations. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant business disruption or a breach in security resulting in misappropriation, theft or sabotage with respect to proprietary and confidential business and employee information could result in significant financial losses, legal, business or reputational harm to us, compromise our business prospects and our commitments to the USG or other customers, any of which could materially and adversely affect our business, financial condition and operating results.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e face</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> product liability exposure, which could cause us to incur substantial liabilities and negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the sale of our products, any other products that we successfully acquire or develop and the testing of our product candidates in clinical trials.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One measure of protection against such lawsuits is coverage under the PREP Act, which was signed into law in December 2005. The PREP Act creates liability protection for manufacturers of biodefense countermeasures when the Secretary of HHS issues a declaration for their manufacture, administration or use. A PREP Act declaration is meant to provide liability protection from all claims under federal or state law for loss arising out of the administration or use of a covered countermeasure under a government contract. The Secretary of HHS has issued PREP Act declarations covering countermeasures for smallpox, mpox, and other orthopox; anthrax; and botulinum toxin. These declarations apply to certain of our products, namely BioThrax, ACAM2000, raxibacumab, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthrasil</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAT and VIGIV products, as covered countermeasures.</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers are not entitled to protection under the PREP Act in cases of willful misconduct or for cases brought in non-U.S. tribunals or under non-U.S. law. We cannot predict whether the Secretary of HHS will renew the declarations when they expire, whether Congress will fund the relevant PREP Act compensation programs, or whether the necessary prerequisites for immunity would be triggered with respect to our products or product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain of our products, namely BioThrax and RSDL, are under the SAFETY Act, which provides certain product liability limitations for qualifying anti-terrorism technologies for claims arising from or related to an act of terrorism. Although BioThrax and RSDL are designated and certified under the SAFETY Act, the law may not provide adequate protection from claims made against us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against future claims that our products or product candidates caused injuries and if we are not entitled to indemnity by the USG, or the USG does not honor its obligations to us under the PREP Act or SAFETY Act, or if the liability protections under the PREP Act and SAFETY Act are not adequate to cover all claims, we may incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">decreased demand or withdrawal of a product;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">injury to our reputation;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">costs to defend the related litigation;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">loss of revenue; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">an inability to commercialize products that we may develop.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. Further product liability insurance may be difficult and expensive to obtain. We may not be able to maintain insurance coverage at a reasonable cost and we may not be able to obtain insurance coverage that will be adequate to satisfy all potential liabilities. For example, we may not have sufficient insurance against potential liabilities associated with a possible large-scale deployment of BioThrax vaccine as a countermeasure to a bioterrorism threat. We rely on PREP Act protection for BioThrax, raxibacumab, ACAM2000, Anthrasil, BAT and VIGIV products, and SAFETY Act protection for BioThrax and RSDL products in addition to our insurance coverage to help mitigate our product liability exposure for these products. Additionally, potential product liability claims related to our commercial products, including NARCAN, Vivotif and Vaxchora, may be made by patients, health care providers or others who sell or consume these products. Such claims may be made even with respect to those products that possess regulatory approval for commercial sale. Claims or losses in excess of our product liability insurance coverage could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL RISKS</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have incurred significant indebtedness in connection with our acquisitions and servicing our debt requires a significant amount of cash. We may not have sufficient cash flow from our operations to pay our substantial debt.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled payments of the principal of, to pay interest on or to further refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing can have significant adverse consequences for our business, including:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">requiring us to dedicate a substantial portion of cash flows from operations to payment on our debt, which would reduce available funds for other corporate initiatives;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">increasing the amount of interest that we have to pay on debt with variable interest rates, if market rates of interest increase, to the extent we are unable to offset such risk through our hedging instruments;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">subjecting us, as under our Senior Secured Credit Facilities and the indenture governing the Senior Unsecured Notes, to restrictive covenants that reduce our ability to take certain corporate actions, acquire companies, products or technology, or obtain further debt financing; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">requiring us to pledge our assets as collateral, which could limit our ability to obtain additional debt financing; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">limiting our flexibility in planning for, or reacting to, general adverse economic and industry conditions; and </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">placing us at a competitive disadvantage compared to our competitors that have less debt, better debt servicing options or stronger debt servicing capacity.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient funds or be able to obtain additional financing to pay the amounts due under our indebtedness. In addition, failure to comply with the covenants under our Senior Secured Credit Facilities and other debt agreements, including the maintenance of a specified consolidated net leverage ratio and debt service coverage ratio under our Senior Secured Credit Facilities, could result in an event of default under those agreements. An event of default could result in the acceleration of amounts due under a particular debt agreement and a cross default and acceleration under other debt agreements, and we may not have sufficient funds to pay or be able to obtain additional financing to make any accelerated payments. We were not in compliance with the net leverage ratio and debt service coverage ratio covenants under our Senior Secured Credit Facilities as of December 31, 2022. We received a limited waiver from compliance with these covenants for the quarter ended December 31, 2022 and the quarter ending March 31, 2023. The Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to the Credit Agreement. If we default under the Credit Agreement or our other debt arrangements, our lenders could seek to enforce security interests in our assets securing our indebtedness.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current indebtedness restricts and any additional debt financing may restrict the operation of our business and limit the cash available for investment in our&#160;business operations. If we are unable to refinance our Senior Secured Credit Facilities prior to their maturity in October 2023, our results of operations and financial condition may be adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities include a $450.0&#160;million Term Loan Facility which had an outstanding principal balance of $354.4 million as of March&#160;31, 2023 and the ability to borrow up to $600.0&#160;million under our Revolving Credit Facility of which we had $598.0 million of outstanding borrowings as of March&#160;31, 2023. On August 7, 2020, we completed an offering of $450.0&#160;million aggregate principal amount of Senior Unsecured Notes, of which $353.0&#160;million of the net proceeds were used to pay down our Revolving Credit Facility. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing can have significant adverse consequences for our business, including:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the level, timing and cost of product sales and CDMO services;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the payment obligations under our indebtedness;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the scope, progress, results and costs of our development activities;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the extent to which we repurchase common stock under any future share repurchase program; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the costs of commercialization activities, including product marketing, sales and distribution.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Senior Secured Credit Facilities mature in October 2023. If we are unable to refinance our Senior Secured Credit Facilities prior to their maturity, we will be required to immediately repay the entire amount outstanding thereunder, which could adversely affect our results of operations and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Senior Secured Credit Facilities and our Senior Unsecured Notes each contain cross-default provisions whereby a default under one agreement would likely result in cross defaults under agreements covering other indebtedness. The occurrence of a default under any of these arrangements would permit the holders of the notes or the lenders under our Senior Secured Credit Facilities to declare all amounts outstanding under those borrowing arrangements to be immediately due and payable, and there is no assurance that we would have sufficient funds to satisfy any such accelerated obligations. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company was not in compliance with the debt service charge ratio and consolidated net leverage ratio covenants under the Credit Agreement. Pursuant to the Credit Agreement Amendment (as defined below) the requisite lenders have agreed to a limited waiver of any defaults or events of default that result from (a) any violation of the financial covenants set forth in the Senior Secured Credit Facilities with respect to the fiscal quarter ending December 31, 2022 and the fiscal quarter ending March 31, 2023 and (b) the going concern qualification or exception contained in the audited financial statements for the fiscal year ending December 31, 2022. This limited waiver will expire on the earlier to occur of (i) any other event of default and (ii) April 17, 2023. During this period the Company is working with lenders under the Senior Secured Credit Facilities in connection with replacing such facilities before their October 2023 maturity with revised terms and conditions. The Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to the Credit Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our hedging program is subject to counterparty default risk. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our interest rate risk in part by entering into interest rate swaps with a number of counterparties to swap a portion of our indebtedness that is based on variable interest rates to a fixed rate. As a result, we are subject to the risk that the counterparty to one or more of these contracts defaults on its performance under the contract. During an economic downturn, the counterparty's financial condition may deteriorate rapidly and with little notice and we may be unable to take action to protect our exposure. In the event of a counterparty default, we could incur losses, which may harm our business and financial condition. In the event that one or more of our counterparties becomes insolvent or files for bankruptcy, our ability to eventually recover any losses suffered as a result of that counterparty's default may be limited by the liquidity of the counterparty.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We require significant additional funding to be able to continue as a going concern and we may be unable to raise capital when needed or on acceptable terms, which would harm our ability to grow our business, and our results of operations and financial condition. In addition, any capital we raise may result in dilution to our current stockholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had unrestricted cash and cash equivalents of $642.6 million and remaining capacity under our Revolving Credit Facility of $0.7 million. Also as of December 31, 2022, there was $598.0 million outstanding under our Revolving Credit Facility and $362.8 million under our Term Loan Facility that mature in October 2023, which is within one year of the date that the Company&#8217;s consolidated financial statements are issued for the year ended December 31, 2022. As a result, the Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. We will need to obtain substantial additional funding in connection with our continuing operations, which cannot be assured.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans or collaboration and licensing arrangements. In August 2021, we filed an automatic shelf registration statement, which immediately became effective under SEC rules. For so long as we continue to satisfy the requirements to be deemed a &#8220;well-known seasoned issuer&#8221; under SEC rules, this shelf registration statement, effective until August 9, 2024, allows us to issue an unrestricted amount of equity, debt and certain other types of securities through one or more future primary or secondary offerings. If we do not file a new shelf registration statement prior to the expiration of our automatic shell registration statement (whether by lapse of time due to us no longer qualifying as a "well-known seasoned issuer"), the existing shelf registration statement will expire, and we will not be able to publicly raise capital or issue debt until a new registration statement is filed and becomes effective. There can be no assurance that we will be eligible to file an automatically effective shelf registration statement at a future date when we may need to raise funds publicly.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds by issuing equity securities, our stockholders may experience dilution. Debt financing, if available, may involve agreements that include covenants, like those contained in our Senior Secured Credit Facilities and the indenture governing the Senior Unsecured Notes, limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities or declaring dividends. If we raise funds through collaboration </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us. </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Senior Secured Credit Facilities as well as the indenture governing the Senior Unsecured Notes restrict our ability to incur additional indebtedness.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions may make it difficult to obtain financing on attractive terms, or at all. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not maintain profitability in future periods or on a consistent basis.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have been profitable on an annual basis since becoming a public company, we have not been profitable for every quarter during that time. Our profitability has been substantially dependent on product sales, which historically have fluctuated significantly from quarter to quarter, and we expect that they will continue to fluctuate significantly based primarily on the timing of our fulfillment of orders from the USG. We may not be able to achieve consistent profitability on a quarterly basis or sustain or increase profitability on an annual basis.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill impairment charges in the future could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded a significant amount of goodwill on our consolidated balance sheet as a result of acquisitions. We review the recoverability of goodwill annually and whenever events or circumstances indicate that the carrying value of a reporting unit may not be recoverable. As of March&#160;31, 2023, the only reporting unit that has goodwill associated with it is our MCM reporting unit.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impairment tests require us to make an estimate of the fair value of our reporting units. An impairment could be recorded as a result of changes in assumptions, estimates or circumstances, some of which are beyond our control. Since a number of factors may influence determinations of fair value of goodwill, we are unable to predict whether impairments of goodwill will occur in the future, and there can be no assurance that continued conditions will not result in future impairments of goodwill. The future occurrence of a potential indicator of impairment could include matters such as (i) a decrease in expected net earnings, (ii) adverse equity market conditions, (iii) a decline in current market multiples, (iv) a decline in our common stock price, (v) a significant adverse change in legal factors or the general business climate, and (vi) an adverse action or assessment by a regulator. Any such impairment would result in us recognizing a non-cash charge in our consolidated balance sheets, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The expansion of our international operations increases our risk of exposure to credit losses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our business activities with foreign governments in certain countries that have experienced deterioration in credit and economic conditions or otherwise, our exposure to uncollectible accounts will rise. Global economic conditions and liquidity issues in certain countries have resulted and may continue to result in delays in the collection of accounts receivable and may result in credit losses. Future governmental actions and customer specific actions may require us to re-evaluate the collectability of our accounts receivable and we may potentially incur credit losses that materially impact our operating results.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A substantial portion of our indebtedness bears interest at variable interest rates based on LIBOR and certain of our financial contracts are also indexed to LIBOR. Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness and may otherwise adversely affect our financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the Financial Conduct Authority, the authority that regulates the London Inter-bank Offered Rate (LIBOR) announced that it intended to stop compelling banks to submit rates for the calculation of LIBOR after 2021. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the International Exchange (ICE) Benchmark Association, which administrates LIBOR, ceased (i) entering into new contracts that use LIBOR as a reference rate and (ii) publication of two LIBOR rates (one-week and two-month) and has announced that the remaining LIBOR rates (overnight, one-month, three-month, six-month and 12-month) will be retired on June 30, 2023. It is unclear if LIBOR will cease to exist at that time or if new methods of calculating LIBOR will be established such that it continues to exist after 2023. We have certain financial contracts, including the Amended Credit Agreement and our interest rate swaps, that are indexed to LIBOR. Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness. Any transition process may involve, among other things, increased volatility or illiquidity in markets for instruments that rely on LIBOR, reductions in the value of certain instruments or the effectiveness of related transactions such as hedges, increased </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrowing costs, uncertainty under applicable documentation, or difficult and costly consent processes. The transition away from LIBOR may result in increased expenses, may impair our ability to refinance our indebtedness or hedge our exposure to floating rate instruments, or may result in difficulties, complications or delays in connection with future financing efforts, any of which could adversely affect our financial condition and results of op</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">erations.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO STRATEGIC ACQUISITIONS, DIVESTITURES AND COLLABORATIONS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our strategy of generating growth through acquisitions may not be successful.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes growing our business through acquisition and in-licensing transactions. For example, in September 2022, we completed the acquisition from Chimerix, Inc. of its exclusive worldwide rights to brincidofovir, including TEMBEXA</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#174;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and related assets. We may not be successful in identifying, effectively evaluating, structuring, acquiring or in-licensing, and developing and commercializing additional products on favorable terms, or at all. Competition for attractive product opportunities is intense and may require us to devote substantial resources, both managerial and financial, to an acquisition opportunity. A number of more established companies are also pursuing strategies to acquire or in-license products in the biopharmaceutical field. These companies may have a competitive advantage over us due to their size, cash resources, cost of capital, effective tax rate and greater clinical development and commercialization capabilities. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition efforts can consume significant management attention and require substantial expenditures, which could detract from our other programs. In addition, we may devote significant resources to potential acquisitions that are never completed. Even if we are successful in acquiring a company or product, it may not result in a successfully developed or commercialized product or, even if an acquired product is commercialized, competing products or technologies could render a product noncompetitive, uneconomical or obsolete. Moreover, the cost of acquiring other companies or in-licensing products could be substantial, and in order to acquire companies or new products, we may need to incur substantial debt or issue dilutive securities. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in our efforts to acquire other companies, products, or in-license and develop additional products, or if we acquire or in-license unproductive assets, it could have a material adverse effect on the growth of our business, and we could be compelled to record significant impairment charges to write-down the carrying value of our acquired intangible assets, which could materially harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our failure to successfully integrate acquired businesses and/or assets into our operations could adversely affect our ability to realize the benefits of such acquisitions and, therefore, to grow our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to integrate any acquired business successfully or operate any acquired business profitably. In addition, cost synergies, if achieved at all, may be less than we expect, or may take greater time to achieve than we anticipate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issues that could delay or prevent successful integration or cost synergies of an acquired business or products include, among others:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">retaining existing customers and attracting new customers;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">retaining key employees;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">diversion of management attention and resources;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">conforming internal controls, policies and procedures, business cultures and compensation programs;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">consolidating corporate and administrative infrastructures;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">successfully executing technology transfers and obtaining required regulatory approvals;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">consolidating sales and marketing operations;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">identifying and eliminating redundant and underperforming operations and assets;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">assumption of known and unknown liabilities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">coordinating geographically dispersed organizations; </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">managing tax costs or inefficiencies associated with integrating operations; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">risks associated with intellectual property rights related to an acquisition or collaboration.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully integrate pending and future acquisitions with our existing businesses, or operate any acquired business profitably, we may not obtain the advantages that the acquisitions were intended to create, which may materially adversely affect the growth of our business, financial condition, operating results and cash flows.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our proposed sale of our travel health business to Bavarian Nordic may not be consummated and if the transaction is consummated we may not realize the benefit of the proposed transaction.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, we entered into the Sale Agreement with Bavarian Nordic, under which we [agreed to sell] [sold] our travel health business, including rights to Vaxchora and Vivotif, as well as our development-stage chikungunya vaccine candidate CHIKV VLP, our manufacturing site in Bern, Switzerland and certain of our development facilities in San Diego, California for a cash purchase price of $270.0 million, subject to certain customary adjustments. In addition, we may receive milestone payments of up to $80.0 million related to the development of CHIKV VLP and receipt of marketing approval and authorization in the U.S. and Europe, and sales-based milestone payments of up to $30.0 million based on aggregate net sales of Vaxchora and Vivotif in calendar year 2026. The transaction is expected to close during the second quarter of 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to close the sale of our travel health business to Bavarian Nordic. If we are unable to consummate the transaction or do not realize the expected strategic, economic, or other benefits of the transaction, it could adversely affect our business and financial position.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have incurred, and will continue to incur, significant expenses in connection with the proposed sale of our travel health business to Bavarian Nordic. These expenses include fees and expenses for investment bankers, attorneys, accountants and other advisers in connection with our efforts and will be incurred whether or not an acquisition is consummated. The incurrence of these costs could adversely affect our financial results for particular quarterly or annual periods.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business or our share price could be negatively affected as a result of the actions of shareholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, some shareholders have placed increasing pressure on publicly traded companies in our industry and others to effect changes to corporate governance practices, executive compensation practices, social and environmental practices and to undertake certain corporate actions. This may be true even if they only hold a minority of shares. In addition, many institutional investors are increasingly focused on ESG factors. These investors may be seeking enhanced ESG disclosures or to implement policies adverse to our business. There can be no assurances that shareholders will not publicly advocate for us to make corporate governance changes or engage in certain corporate actions. Responding to challenges from shareholders, such as proxy contests, media campaigns or other public or private means, could be costly and time consuming and could have an adverse effect on our reputation and divert the attention and resources of management and our board, which could have an adverse effect on our business and operational results. Any such shareholder actions or requests, or the mere public presence of shareholders with a reputation for taking such actions among our shareholder base, could also cause the market price of our common stock to experience periods of significant volatility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and by-laws and under Delaware law may discourage acquisition proposals, delay a change in control or prevent transactions that stockholders may consider favorable.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and by-laws may discourage, delay or prevent a merger, acquisition or other changes in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions include:</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the classification of our directors;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">limitations on changing the size of our Board of Directors;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">limitations on the removal of directors;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">limitations on filling vacancies on the Board of Directors;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">advance notice requirements for stockholder nominations of candidates for election to the Board of Directors and other proposals;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the inability of stockholders to act by written consent;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the inability of stockholders to call special meetings; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the ability of our Board of Directors to designate the terms of and issue a new series of preferred stock without stockholder approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative vote of a majority of our Board of Directors or the holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal the above provisions of our certificate of incorporation or by-laws. The affirmative vote of either a majority of the directors present at a meeting of our Board of Directors or holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal our by-laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to Section 203 of the Delaware General Corporation Law (Section 203). In general and subject to certain exceptions, Section 203 prohibits a publicly-held corporation from engaging in a business combination with an interested stockholder, generally a person which, together with its affiliates, owns or within the last three years has owned 15% or more of the corporation's voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Accordingly, Section 203 may discourage, delay or prevent a change in control of us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Board of Directors may implement a new stockholder rights plan without stockholder approval, which could prevent a change in control of us in instances in which some stockholders may believe a change in control is in their best interests.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors may implement a stockholder rights plan without stockholder approval, which may have anti-takeover effects, potentially preventing a change in control of us in instances in which some stockholders may believe a change in control is in their best interests. This could cause substantial dilution to a person or group that attempts to acquire us on terms that our Board of Directors does not believe are in our best interests or those of our stockholders and may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our stock price is volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been, and is likely to continue to be, volatile. The market price of our common stock could fluctuate significantly for many reasons, including in response to the risks described in this &#8220;Risk Factors&#8221; section, or for reasons unrelated to our operations, such as reports by industry analysts, investor perceptions or negative announcements by our customers, competitors or suppliers regarding their own performance, as we</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ll as industry conditions and general financial, economic and political instability. From November 15, 2006, when our common stock first began trading on the New York Stock Exchange, through May&#160;2, 2023, our common stock has traded as high as $137.61 per share and as low as $4.17 per share. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be influenced by many factors, including, among others:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">contracts, decisions and procurement policies by the USG affecting our anthrax vaccines and our other products and product candidates;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">CDMO contracts related to COVID-19 with collaboration partners;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the success of competitive products or technologies;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">results of clinical and non-clinical trials of our product candidates;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">announcements of acquisitions, financings or other transactions by us;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">litigation or legal proceedings;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">public concern as to the safety of our products;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">termination or delay of a development program;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">variations in our product revenue and profitability; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because we currently do not pay dividends, investors will benefit from an investment in our common stock only if it appreciates in value.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not pay dividends on our common stock. Our Senior Secured Credit Facilities and the indenture governing our Senior Unsecured Notes limit and any future debt agreements that we enter into may limit our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders based on current expectations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future issuances </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of our common stock or securities convertible into common stock could result in dilution of our stockholders and could cause our share price to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> decline.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations or for general corporate purposes. To the extent we raise additional capital by issuing equity securities or securities convertible or exchangeable into common stock, our stockholders may experience substantial dilution. We may sell common stock, and we may sell convertible or exchangeable securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell such common stock, convertible or exchangeable securities or other equity securities in subsequent transactions, existing stockholders may be materially diluted.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISK FACTORS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accuracy of our financial reporting depends on the effectiveness of our internal control over financial reporting. Any material weakness in our internal control over financial reporting could have an adverse effect on our business and financial results and our ability to meet our reporting obligations could be negatively affected, each of which could negatively affect the trading price of our common stock.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements and may not prevent or detect misstatements. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Failure to maintain effective internal control over financial reporting, or lapses in disclosure controls and procedures, could impact our financial information and disclosures, require significant resources to remediate, and expose us to legal or regulatory proceedings.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review and update our internal controls and disclosure controls and procedures. In addition, we are required under the Sarbanes-Oxley Act of 2002 to report annually on our internal control over financial reporting. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our success is dependent on our continued ability to attract, motivate and retain key personnel, and any failure to attract or retain key personnel may negatively affect our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the specialized scientific nature of our business, our ability to develop products and to compete with our current and future competitors largely depends upon our ability to attract, retain and motivate highly qualified managerial and key scientific and technical personnel (including quality and manufacturing personnel). If we are unable to retain the services of one or more of the principal members of senior management or other key employees, our ability to implement our business strategy could be materially harmed. We face intense competition for qualified employees from biopharmaceutical companies, research organizations and academic institutions. Attracting, retaining or replacing these personnel on acceptable terms may be difficult and time-consuming given the high demand in our industry for similar personnel. We believe part of being able to attract, motivate and retain personnel is our ability to offer a competitive compensation package, including equity incentive awards. If we cannot offer a competitive compensation package to attract and retain the qualified personnel necessary for the continued development of our business, we may not be able to maintain our operations or grow our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_133"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent sales of unregistered securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of proceeds</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of equity securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_136"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_139"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_142"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.&#160;&#160;&#160;&#160;</span></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_145"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits hereto.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_148"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 &#8224;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">Form of 2023-20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">5 Performance</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">B</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">a</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">e</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">d</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">c</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">k</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">U</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">n</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">i</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">w</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">a</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">d</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm"> Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exc_compmins2-9x23v1x202.htm">.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a311-kramercert033123.htm">Certification of the Chief Executive Officer, pursuant to Exchange Act Rule 13a-14(a).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a312-lindhalcert033123.htm">Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a321-kramercert033123.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a322-lindhalcert033123.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial information related to the Company&#8217;s Quarterly Report on Form </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the quarter ended March&#160;31, 2023, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statement of Changes in Stockholders' Equity; and (vi) the related Notes to the Condensed Consolidated Financial Statements.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101.<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because of the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management or compensatory plan or arrangement.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i9481dacf30bb4098a06bd54f3af5a34a_151"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.195%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ROBERT G. KRAMER</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert G. Kramer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May 9, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/RICHARD S. LINDAHL</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard S. Lindahl</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President, Chief Financial Officer and Treasurer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May 9, 2023</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>exc_compmins2-9x23v1x202.htm
<DESCRIPTION>EX-10
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exc_compmins2-9x23v1x202</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exc_compmins2-9x23v1x202001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exc_compmins2-9x23v1x202001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 1 -   Certain portions of this exhibit were omitted by means of marking such portions with asterisk because  the identified confidential portions would be competitively harmful if publicly disclosed and they are  the type of information that the registrant treats as private or confidential.   Double asterisk denotes omissions.    Form of 2023-2025 Performance-Based Stock Unit Award Agreement      1. Grant of PSUs. In consideration of services rendered to the Company by  the Participant, the Company has granted to the Participant, subject to the terms and  conditions set forth herein and in the Company&#8217;s Stock Incentive Plan (the &#8220;Plan&#8221;),  an award of performance-based stock units (individually, a &#8220;PSU&#8221; and collectively,  the &#8220;PSUs&#8221;), representing the number of PSUs set forth under the Participant&#8217;s  account in the Company&#8217;s third-party electronic stock administrative platform (the  &#8220;Grant Summary&#8221;). The PSUs entitle the Participant to receive, upon and subject to  the vesting of the PSUs (as described in Section 2 below), one share of common  stock, $0.001 par value per share, of the Company (the &#8220;Common Stock&#8221;) for each  PSU that vests. The shares of Common Stock that are issuable upon vesting of the  PSUs are referred to herein as the &#8220;Shares.&#8221;    2. Vesting of PSUs and Issuance of Shares.    (a) General. Subject to the other provisions of this Section 2, the PSUs shall vest as  set forth on Schedule 1 to this Agreement, based on the achievement of the  performance goal for the performance period set forth on Schedule 1, as certified  by the Compensation Committee promptly following the performance period.  Such date on which PSUs vest under this Agreement may be referred to herein as  the &#8220;Vesting Date.&#8221; Subject to Section 4, as soon as administratively practicable  after the Vesting Date shown on Schedule 1, the Company will issue to the  Participant, in certificated or uncertificated form, such number of Shares as is  equal to the number of PSUs that vested on such Vesting Date. In no event shall  the Shares be issued to the Participant later than 30 days after the Vesting Date.    (b) Service Termination. Except as set forth in Section 2(c) below and on Schedule  1, upon the cessation of the Participant&#8217;s services with the Company for any  reason, all unvested PSUs shall be automatically forfeited as of such cessation of  services. For purposes of this PSU award, services with the Company shall  include services as an employee or director of, or consultant or advisor to, the  Company or to a parent or subsidiary of the Company, or any successor to the  Company.    (c) Change in Control Event. Upon a Change in Control Event (as defined in the  Plan), the acquiring or succeeding entity (or an affiliate thereof) shall assume each  outstanding PSU such that, following the consummation of the Change in Control  Event, the PSU confers the Participant with the right to receive, for each Share  subject to the award, the consideration (whether cash, securities or other property)  received by each holder of Common Stock immediately prior to the Change in  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exc_compmins2-9x23v1x202002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exc_compmins2-9x23v1x202002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 2 -   Control Event (the &#8220;Replacement Award&#8221;), provided that (i) such Replacement  Award shall vest solely based on the Participant&#8217;s continued provision of services  with the Company (as described on Section 2(b) hereof) until the last day of the  performance period set forth on Schedule 1 and shall not, for the avoidance of  doubt, be subject to achievement of the performance goals set forth on Schedule 1  and (ii) the amount of cash, securities or other property subject to such  Replacement Award shall be determined assuming that the number of shares  subject to the PSU is equal to the target number of Shares issuable under this  Agreement (as set forth on Schedule 1) for the performance period. In the event  that the Participant&#8217;s employment is terminated by either the Company or its  successor without Cause or by the Participant for Good Reason (as such terms are  defined in the Plan) within eighteen (18) months following a Change in Control  Event, the remaining unvested portion of the Replacement Award shall become  vested as of the date of the Participant&#8217;s termination of employment.  Notwithstanding the foregoing, in the event that the acquiring or succeeding entity  (or an affiliate thereof) refuses to assume the PSUs and grant Replacement  Awards in connection with a Change in Control Event, this PSU award shall  become vested, immediately prior to the Change in Control Event, with respect to  the target number of Shares (as set forth on Schedule 1) for the performance  period.    3. Dividends. At the time of the issuance of Shares to the Participant  pursuant to Section 2, the Company shall also pay to the Participant an amount of  cash equal to the aggregate amount of all dividends paid by the Company, between  the grant date and the issuance of such Shares, with respect to the number of Shares  so issued to the Participant.    4. Withholding Taxes. Upon vesting, the Company shall, in accordance with  the terms of the Plan, withhold such number of Shares from the PSU award as is  sufficient to satisfy the required federal, state, and local and other income and  employment tax withholding obligations of the Company associated with the PSUs.    5. Restrictions on Transfer. Neither the PSUs, nor any interest therein  (including the right to receive dividend payments in accordance with Section 3),  may be transferred by the Participant except to the extent specifically permitted in  Section 10(a) of the Plan.    6. Provisions of the Plan. This PSU award is subject to the provisions of the  Plan. The Participant acknowledges receipt of the Plan, along with the Prospectus  relating to the Plan.    7. Section 409A. This PSU award is intended to comply with or be exempt  from Section 409A of the Internal Revenue Code of 1986, as amended, and the  guidance issued thereunder (&#8220;Section 409A&#8221;) and shall be interpreted and construed  consistently therewith. In no event shall either the Participant or the Company have  the right to accelerate or defer delivery of the Shares to a date or event other than as  set forth herein except to the extent specifically permitted or required by Section  409A. In the event that the Participant is a &#8220;specified employee&#8221; within the  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exc_compmins2-9x23v1x202003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exc_compmins2-9x23v1x202003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 3 -   meaning of Section 409A and the Shares are to be delivered in connection with the  termination of the Participant&#8217;s employment, the delivery of the Shares and any  dividends payable under Section 3 in connection with such delivery shall be  delayed until the date that is six months and one day following the date of the  Participant&#8217;s termination of employment if required to avoid the imposition of  additional taxes under Section 409A. Solely for purposes of determining when the  Shares (and any dividends payable under Section 3) may be delivered in connection  with the Participant&#8217;s termination of employment, such termination of employment  must constitute a &#8220;separation from service&#8221; within the meaning of Section 409A.  Solely to the extent necessary to comply with Section 409A, any Change in Control  Event must also constitute a &#8220;Change in Control Event&#8221; as described in Treasury  Regulation Section 1.409A-3(i)(5).    8. Miscellaneous.    (a) No Rights to Employment. The Participant acknowledges and agrees that the  grant of the PSUs and their vesting pursuant to Section 2 do not constitute an  express or implied promise of continued employment for the vesting period, or for  any period.    (b) Entire Agreement. These terms and the Plan constitute the entire agreement  between the parties, and supersede all prior agreements and understandings,  relating to the subject matter of this PSU award; and, with respect to this PSU  award, these terms shall, for the avoidance of doubt, supersede the terms in any  separate employment or severance plan or agreement between the Company and  the Participant relating to the acceleration of vesting of equity awards.    (c) Governing Law. This PSU award shall be construed, interpreted and enforced in  accordance with the internal laws of the State of Delaware without regard to any  applicable conflict of law principles.    (d) Interpretation. The interpretation and construction of any terms or conditions of  the Plan or this PSU award by the Compensation Committee shall be final and  conclusive.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exc_compmins2-9x23v1x202004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exc_compmins2-9x23v1x202004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 4 -   COMPANY CONFIDENTIAL  SCHEDULE 1  VESTING CRITERIA FOR PSUs    A. Performance Measure    PSUs shall vest based upon the Company&#8217;s achievement of a specific target, as described  in Section B below (the &#8220;Performance Objective&#8221;), of two equally-weighted performance targets  of (i) Revenue and (ii) Adjusted EBITDA (as defined below) as a percentage of total Revenue (as  defined below) (such percentage, &#8220;Adjusted EBITDA Margin&#8221;) calculated on a cumulative basis  for the three-year performance period described below (the &#8220;Performance Period&#8221;). The number  of Shares issuable upon vesting of the PSUs shall be determined based upon the extent to which  the Performance Objective is achieved, as certified by the Compensation Committee following  the end of the Performance Period.    &#8220;Adjusted EBITDA&#8221; is defined as Adjusted Earnings Before Interest, Taxes,  Depreciation and Amortization as reported by the Company.    &#8220;Revenue&#8221; is defined as revenue, determined in accordance with GAAP.    The Performance Period and the Threshold Number of Shares, Target Number of Shares  and Maximum Number of Shares that can vest at the end of the Performance Period are as  follows:    Performance  Period  Threshold Number  of Shares for  Performance Period  Target Number  of Shares for  Performance Period  Maximum Number  of Shares for  Performance Period  January 1, 2023 to  December 31, 2025  50% of Target  Number of Shares  100% of Target  Number of Shares  200% of Target  Number of Shares    B. Performance Objective Target    The Performance Objective at Target Performance is achieved for Revenue when equal to  [**] and is achieved for Adjusted EBITDA Margin when equal to [**] %, each of Revenue and  Adjusted EBIDTA is calculated on a cumulative basis for the three years in the Performance  Period.     The Performance Objective at Threshold Performance is achieved for Revenue when  equal to [**] and is achieved for Adjusted EBITDA Margin when equal to [**] %.      The Performance Objective at Maximum Performance is achieved for Revenue when  equal to [**] and is achieved for Adjusted EBITDA Margin when equal to [**] %.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exc_compmins2-9x23v1x202005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exc_compmins2-9x23v1x202005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 5 -   For the avoidance of doubt, the calculation of Adjusted EBITDA Margin on a cumulative  basis shall equal the sum of Adjusted EBITDA for each year in the performance period divided  by the sum of Revenue for each year in the performance period.  Revenue caluclated on a  cumulative basis shall equal the sum of all Revenue for the Performance Period.    If, at the end of the Performance Period, the Company is required to make periodic  reports under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), the  Company&#8217;s consolidated financial statements filed with the Securities and Exchange  Commission on Form 10-K shall constitute its &#8220;Public Company Financial Statements&#8221; and shall  apply for the Performance Period. If, at the end of the Performance Period, the Company is not  required to make periodic reports under the Exchange Act, the Company&#8217;s regularly prepared  annual audited financial statements prepared by management shall be its &#8220;Private Company  Financial Statements&#8221; and shall apply for the Performance Period. The applicable financial  statements may be referred to herein as the &#8220;Financial Statements.&#8221; The Compensation  Committee shall certify the level of achievement of the Performance Objective promptly  following the end of the Performance Period.    Notwithstanding anything herein to the contrary, the Compensation Committee shall have  the discretion to determine the level of payout at the end of the Performance Period in  recognition of broader performance outcomes and otherwise in its discretion.    C. Calculation of Number of Shares Issuable    The number of Shares issuable at the end of the Performance Period upon certification of  the extent of achievement of the Performance Objective by the Compensation Committee shall  be equal to the product of (i) the Target Number of Shares for the Performance Period and (ii)  the Payout Factor for the Performance Period.    The table below sets forth the Payout Factor based on the level of achievement of the  Performance Objective for the Performance Period:    Threshold  Performance Payout  Factor  Target Performance  Payout Factor  Maximum  Performance Payout  Factor  50% 100% 200%    In measuring the achievement of the Performance Objective for the Performance Period  and calculating the related Payout Factor, achievement will be linearly interpolated between the  percentages that constitute Threshold Performance and Target Performance and the percentages  that constitute Target Performance and Maximum Performance based on actual results as  determined and certified by the Compensation Committee. If the Adjusted EBITDA Margin and  the cumulative Revenue achieved is below Threshold Performance, the Payout Factor for the  Performance Objective shall be 0% and this award shall be terminated without the issuance of  any Shares and the Participant shall have no further rights with respect to the Award.    In no event may the number of Shares issuable at the end of the Performance Period  exceed the Maximum Number of Shares for the Performance Period.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exc_compmins2-9x23v1x202006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exc_compmins2-9x23v1x202006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 6 -   E. Effect of Death or Disability; Retirement    If the Participant dies or is disabled (within the meaning of Section 409A) prior to the end  of the Performance Period, then the PSUs shall vest as to a number of Shares equal to the greater  of (i) the Target Number of Shares and (ii) such number of Shares as the Compensation  Committee shall determine in its sole discretion exercised in good faith based upon the projected  level of achievement of the Performance Objective for the Performance Period, in either case  prorated based on the portion of the Performance Period during which the Participant performed  services with the Company. The Shares of Common Stock represented by such vested PSUs  shall be delivered to the Participant or the Participant&#8217;s estate within 30 days following such  death or disability.    In the event of the Retirement (as defined below) of the Participant, the Participant shall  be entitled to receive, following the end of the Performance Period, a prorated number of Shares  that the Participant would have earned had the Participant remained employed through the end of  the Performance Period based on the Compensation Committee&#8217;s certification of the level of  achievement of the Performance Objective, such proration based on the portion of the  Performance Period during which the Participant performed services with the Company ending  on the date of the Participant&#8217;s Retirement. &#8220;Retirement&#8221; means attainment of age 60 and  completion of 5 years of service with the Company or a parent or subsidiary of the Company, or  any successor of the Company, with &#8220;services&#8221; including service to the Company or a parent or  subsidiary of the Company, or any successor to the Company as an employee or director of, or  consultant or advisor to such entity.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a311-kramercert033123.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i675818b622844162903fd756450d1f73_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert G. Kramer, certify that&#58;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Emergent BioSolutions Inc.&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; May&#160;9, 2023 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47;ROBERT G. KRAMER</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Robert G. Kramer</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></div><div style="height:69.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a312-lindhalcert033123.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iac59841eb0ee443db0463b38277b5a37_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard S. Lindahl, certify that&#58;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Emergent BioSolutions Inc.&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;May&#160;9, 2023</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47;RICHARD S. LINDAHL</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard S. Lindahl</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a321-kramercert033123.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0853e73ccfde456397da3470baf9aaf2_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form&#160;10-Q&#160;of Emergent BioSolutions Inc. (the &#34;Company&#34;) for the period ended&#160;March&#160;31, 2023&#160;as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned, Robert G. Kramer, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-indent:-13.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;May&#160;9, 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47;ROBERT G. KRAMER</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert G. Kramer</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>a322-lindhalcert033123.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7fed812729074cdf81f2fbe0150868f9_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Emergent BioSolutions Inc. (the &#34;Company&#34;) for the period ended&#160;March&#160;31, 2023&#160;as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned, Richard S. Lindahl, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Date&#58;&#160;May&#160;9, 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%;text-decoration:underline">&#47;s&#47;RICHARD S. LINDAHL</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Richard S. Lindahl</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Financial Officer</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ebs-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:da57861a-e185-4b6f-8b91-f9335b77a88a,g:0a9819bf-1d2f-49f0-b0b7-eedd5e464486-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ebs="http://emergentbiosolutions.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://emergentbiosolutions.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://emergentbiosolutions.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical">
        <link:definition>0000008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Natureofthebusinessandorganization" roleURI="http://emergentbiosolutions.com/role/Natureofthebusinessandorganization">
        <link:definition>0000009 - Disclosure - Nature of the business and organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>0000010 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Assetsandliabilitiesheldforsale" roleURI="http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale">
        <link:definition>0000011 - Disclosure - Assets and liabilities held for sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuringcosts" roleURI="http://emergentbiosolutions.com/role/Restructuringcosts">
        <link:definition>0000012 - Disclosure - Restructuring costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventoriesnet" roleURI="http://emergentbiosolutions.com/role/Inventoriesnet">
        <link:definition>0000013 - Disclosure - Inventories, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipmentnet" roleURI="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet">
        <link:definition>0000014 - Disclosure - Property, plant and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassetsandgoodwill" roleURI="http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill">
        <link:definition>0000015 - Disclosure - Intangible assets and goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurements" roleURI="http://emergentbiosolutions.com/role/Fairvaluemeasurements">
        <link:definition>0000016 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Derivativeinstrumentsandhedgingactivities" roleURI="http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities">
        <link:definition>0000017 - Disclosure - Derivative instruments and hedging activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://emergentbiosolutions.com/role/Debt">
        <link:definition>0000018 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockbasedcompensationandstockholdersequity" roleURI="http://emergentbiosolutions.com/role/Stockbasedcompensationandstockholdersequity">
        <link:definition>0000019 - Disclosure - Stock-based compensation and stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Earningslosspercommonshare" roleURI="http://emergentbiosolutions.com/role/Earningslosspercommonshare">
        <link:definition>0000020 - Disclosure - Earnings (loss) per common share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenuerecognition" roleURI="http://emergentbiosolutions.com/role/Revenuerecognition">
        <link:definition>0000021 - Disclosure - Revenue recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://emergentbiosolutions.com/role/Leases">
        <link:definition>0000022 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://emergentbiosolutions.com/role/Incometaxes">
        <link:definition>0000023 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://emergentbiosolutions.com/role/Litigation">
        <link:definition>0000024 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://emergentbiosolutions.com/role/SegmentInformation">
        <link:definition>0000025 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>0000026 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandliabilitiesheldforsaleTables" roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables">
        <link:definition>0000027 - Disclosure - Assets and liabilities held for sale (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringcostsTables" roleURI="http://emergentbiosolutions.com/role/RestructuringcostsTables">
        <link:definition>0000028 - Disclosure - Restructuring costs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetTables" roleURI="http://emergentbiosolutions.com/role/InventoriesnetTables">
        <link:definition>0000029 - Disclosure - Inventories, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentnetTables" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables">
        <link:definition>0000030 - Disclosure - Property, plant and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillTables" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables">
        <link:definition>0000031 - Disclosure - Intangible assets and goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsTables" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables">
        <link:definition>0000032 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesTables" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables">
        <link:definition>0000033 - Disclosure - Derivative instruments and hedging activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://emergentbiosolutions.com/role/DebtTables">
        <link:definition>0000034 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationandstockholdersequityTables" roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTables">
        <link:definition>0000035 - Disclosure - Stock-based compensation and stockholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningslosspercommonshareTables" roleURI="http://emergentbiosolutions.com/role/EarningslosspercommonshareTables">
        <link:definition>0000036 - Disclosure - Earnings (loss) per common share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionTables" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionTables">
        <link:definition>0000037 - Disclosure - Revenue recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://emergentbiosolutions.com/role/LeasesTables">
        <link:definition>0000038 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://emergentbiosolutions.com/role/SegmentInformationTables">
        <link:definition>0000039 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofthebusinessandorganizationDetails" roleURI="http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails">
        <link:definition>0000040 - Disclosure - Nature of the business and organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesDetails" roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails">
        <link:definition>0000041 - Disclosure - Summary of significant accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandliabilitiesheldforsaleNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails">
        <link:definition>0000042 - Disclosure - Assets and liabilities held for sale - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails">
        <link:definition>0000043 - Disclosure - Assets and liabilities held for sale - Schedule of Assets and Liabilities Held for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringcostsNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails">
        <link:definition>0000044 - Disclosure - Restructuring costs - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringcostsRestructuringandRelatedCostsDetails" roleURI="http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails">
        <link:definition>0000045 - Disclosure - Restructuring costs - Restructuring and Related Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails" roleURI="http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails">
        <link:definition>0000046 - Disclosure - Restructuring costs - Schedule of Restructuring Reserve by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetScheduleofInventoryDetails" roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails">
        <link:definition>0000047 - Disclosure - Inventories, net - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>0000048 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails">
        <link:definition>0000049 - Disclosure - Property, plant and equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails">
        <link:definition>0000050 - Disclosure - Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails">
        <link:definition>0000051 - Disclosure - Intangible assets and goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsandgoodwillGoodwillRollForwardDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails">
        <link:definition>0000052 - Disclosure - Intangible assets and goodwill - Goodwill Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails">
        <link:definition>0000053 - Disclosure - Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsContingentConsiderationRollForwardDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails">
        <link:definition>0000054 - Disclosure - Fair value measurements - Contingent Consideration Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsAdditionalInformationDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails">
        <link:definition>0000055 - Disclosure - Fair value measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails">
        <link:definition>0000056 - Disclosure - Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails">
        <link:definition>0000057 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails">
        <link:definition>0000058 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails">
        <link:definition>0000059 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails">
        <link:definition>0000060 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleDetails" roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails">
        <link:definition>0000061 - Disclosure - Debt - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails">
        <link:definition>0000062 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationandstockholdersequityNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails">
        <link:definition>0000063 - Disclosure - Stock-based compensation and stockholders' equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails" roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>0000064 - Disclosure - Stock-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails">
        <link:definition>0000065 - Disclosure - Stock-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails">
        <link:definition>0000066 - Disclosure - Stock-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningslosspercommonshareDetails" roleURI="http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails">
        <link:definition>0000067 - Disclosure - Earnings (loss) per common share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails">
        <link:definition>0000068 - Disclosure - Revenue recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionNarrativeDetails_1" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1">
        <link:definition>0000068 - Disclosure - Revenue recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionDisaggregationofRevenueDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails">
        <link:definition>0000069 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionContractLiabilitiesDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails">
        <link:definition>0000070 - Disclosure - Revenue recognition - Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionAccountsReceivableDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails">
        <link:definition>0000071 - Disclosure - Revenue recognition - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>0000072 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>0000073 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesDetails" roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails">
        <link:definition>0000074 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails">
        <link:definition>0000075 - Disclosure - Segment Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails">
        <link:definition>0000076 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>0000077 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" abstract="false" name="LessorOperatingLeasePaymentToBeReceivedAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" abstract="false" name="PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_ProductsAndServicesSegmentsMember" abstract="true" name="ProductsAndServicesSegmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ServicesSegmentMember" abstract="true" name="ServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AdjustedGrossMargin" abstract="false" name="AdjustedGrossMargin" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_RestructuringPlan2023Member" abstract="true" name="RestructuringPlan2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_EmployeeBenefitsMember" abstract="true" name="EmployeeBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_UnallocatedResearchAndDevelopmentMember" abstract="true" name="UnallocatedResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" abstract="false" name="PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" abstract="false" name="CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ProductsSegmentMember" abstract="true" name="ProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_NumberOfProductAndServiceCategories" abstract="false" name="NumberOfProductAndServiceCategories" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_EmployeeTransitionMember" abstract="true" name="EmployeeTransitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_GrossProfitAdjustments" abstract="false" name="GrossProfitAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_NumberOfRevenueGeneratingProducts" abstract="false" name="NumberOfRevenueGeneratingProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" abstract="false" name="DebtInstrumentCovenantDebtServiceCoverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_ScheduleOfAccountsReceivableNetTableTextBlock" abstract="false" name="ScheduleOfAccountsReceivableNetTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" abstract="false" name="PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_OtherLongTermDebtFacilityMember" abstract="true" name="OtherLongTermDebtFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ebs_ContractWithCustomerLiabilityDeductions" abstract="false" name="ContractWithCustomerLiabilityDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ContractWithCustomerLiabilityAdditions" abstract="false" name="ContractWithCustomerLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_SeniorUnsecuredNotesDueAugust2028Member" abstract="true" name="SeniorUnsecuredNotesDueAugust2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" abstract="false" name="OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantConsiderationThreshold" abstract="false" name="DebtInstrumentCovenantConsiderationThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioOne" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_ContractsAndGrantsMember" abstract="true" name="ContractsAndGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_TravelHealthBusinessMember" abstract="true" name="TravelHealthBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ContractDevelopmentAndManufacturingMember" abstract="true" name="ContractDevelopmentAndManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ChangeinContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeinContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_JansenPharmaceuticalsIncMember" abstract="true" name="JansenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ProductsSegmentAbstract" abstract="true" name="ProductsSegmentAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioTwo" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_ContractDevelopmentAndManufacturingLeasesMember" abstract="true" name="ContractDevelopmentAndManufacturingLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_NonUnitedStatesGovernmentMember" abstract="true" name="NonUnitedStatesGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioRollingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_NumberOfCategoriesOfPublicHealthThreats" abstract="false" name="NumberOfCategoriesOfPublicHealthThreats" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_NoncashPurchasesOfTreasuryStock" abstract="false" name="NoncashPurchasesOfTreasuryStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_UnitedStatesGovernmentMember" abstract="true" name="UnitedStatesGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_MeasurementInputProbabilityOfPaymentMember" abstract="true" name="MeasurementInputProbabilityOfPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ebs-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:da57861a-e185-4b6f-8b91-f9335b77a88a,g:0a9819bf-1d2f-49f0-b0b7-eedd5e464486-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_efe575eb-8e29-44ab-a0f6-e1d8f1fddadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48bc07ed-f879-40dd-99c7-d461752af645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_efe575eb-8e29-44ab-a0f6-e1d8f1fddadf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48bc07ed-f879-40dd-99c7-d461752af645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b29fba97-291c-4c81-a610-cdbde9c95e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_efe575eb-8e29-44ab-a0f6-e1d8f1fddadf" xlink:to="loc_us-gaap_InventoryNet_b29fba97-291c-4c81-a610-cdbde9c95e32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72a4cbf1-da2f-4c2c-bb90-b4c0b950157e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_efe575eb-8e29-44ab-a0f6-e1d8f1fddadf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72a4cbf1-da2f-4c2c-bb90-b4c0b950157e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ea3bea4d-6d7b-4e27-b777-bebeae6ed406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_efe575eb-8e29-44ab-a0f6-e1d8f1fddadf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ea3bea4d-6d7b-4e27-b777-bebeae6ed406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_71094609-7789-42b5-9f63-da44e6f6470a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_efe575eb-8e29-44ab-a0f6-e1d8f1fddadf" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_71094609-7789-42b5-9f63-da44e6f6470a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d6e85ac6-4349-484a-a530-56e3851f15cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c2f3bc41-45c7-4085-8d1f-38a73df97866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d6e85ac6-4349-484a-a530-56e3851f15cb" xlink:to="loc_us-gaap_PreferredStockValue_c2f3bc41-45c7-4085-8d1f-38a73df97866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_20ef30c3-b742-4b21-b5e7-3933427ec9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d6e85ac6-4349-484a-a530-56e3851f15cb" xlink:to="loc_us-gaap_CommonStockValue_20ef30c3-b742-4b21-b5e7-3933427ec9f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_747765cf-6d2d-41b5-9ba8-fed01d3a7978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d6e85ac6-4349-484a-a530-56e3851f15cb" xlink:to="loc_us-gaap_TreasuryStockValue_747765cf-6d2d-41b5-9ba8-fed01d3a7978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a61dab12-9735-4eb0-b020-fe55ace3cea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d6e85ac6-4349-484a-a530-56e3851f15cb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a61dab12-9735-4eb0-b020-fe55ace3cea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dd2ae963-384a-48df-80fa-d73b486f3d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d6e85ac6-4349-484a-a530-56e3851f15cb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dd2ae963-384a-48df-80fa-d73b486f3d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15127f7e-d474-4398-967d-86eecf66ea79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d6e85ac6-4349-484a-a530-56e3851f15cb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15127f7e-d474-4398-967d-86eecf66ea79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5176fdea-7265-475b-8228-e5092909b9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_eb205eea-5fbb-4958-a49b-3b426a050449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5176fdea-7265-475b-8228-e5092909b9ff" xlink:to="loc_us-gaap_AssetsCurrent_eb205eea-5fbb-4958-a49b-3b426a050449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6a1775a8-e426-4cdb-bb62-48446394bd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5176fdea-7265-475b-8228-e5092909b9ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6a1775a8-e426-4cdb-bb62-48446394bd07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_91a090c1-f1f3-4bd9-8c0e-4479d822239c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5176fdea-7265-475b-8228-e5092909b9ff" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_91a090c1-f1f3-4bd9-8c0e-4479d822239c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_806e8301-604c-4136-92f5-7e0f6245de5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5176fdea-7265-475b-8228-e5092909b9ff" xlink:to="loc_us-gaap_Goodwill_806e8301-604c-4136-92f5-7e0f6245de5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c354974c-f69e-4b4e-90e3-f1ffd10f169c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5176fdea-7265-475b-8228-e5092909b9ff" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c354974c-f69e-4b4e-90e3-f1ffd10f169c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e68eb595-dd45-4366-ac08-d1270e4233ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b68c2842-2aeb-449b-bc7c-5ded04a7b2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e68eb595-dd45-4366-ac08-d1270e4233ed" xlink:to="loc_us-gaap_LiabilitiesCurrent_b68c2842-2aeb-449b-bc7c-5ded04a7b2a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0014ad12-c604-4ed8-b0af-015b89e9cf95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e68eb595-dd45-4366-ac08-d1270e4233ed" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0014ad12-c604-4ed8-b0af-015b89e9cf95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_044ee26d-2fff-4298-8203-3641afeba552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e68eb595-dd45-4366-ac08-d1270e4233ed" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_044ee26d-2fff-4298-8203-3641afeba552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_871c2206-777b-43cd-a66c-08d56d562fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e68eb595-dd45-4366-ac08-d1270e4233ed" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_871c2206-777b-43cd-a66c-08d56d562fa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a2efb056-2db9-4fd7-84f6-d00a5b1e94b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_34d75dbd-27a9-4b6d-a9a3-e4abe8b69139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a2efb056-2db9-4fd7-84f6-d00a5b1e94b0" xlink:to="loc_us-gaap_NotesPayableCurrent_34d75dbd-27a9-4b6d-a9a3-e4abe8b69139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ec3893a1-f83a-4c75-a60a-8db7b91c9390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a2efb056-2db9-4fd7-84f6-d00a5b1e94b0" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ec3893a1-f83a-4c75-a60a-8db7b91c9390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fbb1e5e1-5627-4453-ac6c-2f686c4e9f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a2efb056-2db9-4fd7-84f6-d00a5b1e94b0" xlink:to="loc_us-gaap_AccountsPayableCurrent_fbb1e5e1-5627-4453-ac6c-2f686c4e9f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2b5b9461-0ca3-408e-a985-f54735bc4a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a2efb056-2db9-4fd7-84f6-d00a5b1e94b0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2b5b9461-0ca3-408e-a985-f54735bc4a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_db98d537-c772-49ca-ab31-d3c322782177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a2efb056-2db9-4fd7-84f6-d00a5b1e94b0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_db98d537-c772-49ca-ab31-d3c322782177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e804f45f-ac07-4424-9712-641a9b0ba3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a2efb056-2db9-4fd7-84f6-d00a5b1e94b0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e804f45f-ac07-4424-9712-641a9b0ba3ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd64594c-5c27-480e-8a2b-485994c725cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6fd2a335-1c40-44eb-8a5d-fa5dc04e0b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd64594c-5c27-480e-8a2b-485994c725cf" xlink:to="loc_us-gaap_StockholdersEquity_6fd2a335-1c40-44eb-8a5d-fa5dc04e0b7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6039c476-a0e1-42e5-922c-df1bf5bf54dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd64594c-5c27-480e-8a2b-485994c725cf" xlink:to="loc_us-gaap_Liabilities_6039c476-a0e1-42e5-922c-df1bf5bf54dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3f80e21a-1a66-4381-810a-a226404672b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_cabea80a-b87e-4609-8bae-f0a2683aa67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_3f80e21a-1a66-4381-810a-a226404672b0" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_cabea80a-b87e-4609-8bae-f0a2683aa67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_771151eb-f90e-4b3c-8060-4ed0ed730bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_3f80e21a-1a66-4381-810a-a226404672b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_771151eb-f90e-4b3c-8060-4ed0ed730bfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_afc8b348-e188-4adf-9f11-c147d4b4672c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b9b7e5f2-1805-466a-9ab7-966df7f3fdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_afc8b348-e188-4adf-9f11-c147d4b4672c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b9b7e5f2-1805-466a-9ab7-966df7f3fdb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_48dd1348-c301-4c6a-adc1-41da001c8154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_afc8b348-e188-4adf-9f11-c147d4b4672c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_48dd1348-c301-4c6a-adc1-41da001c8154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2733d15f-444c-4bce-b6b9-ca3b9395774d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_493f7c51-7e2f-472c-8cab-805c5b5004c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2733d15f-444c-4bce-b6b9-ca3b9395774d" xlink:to="loc_us-gaap_InterestExpense_493f7c51-7e2f-472c-8cab-805c5b5004c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_53f23932-0214-439d-b75d-0dacb43b489d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2733d15f-444c-4bce-b6b9-ca3b9395774d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_53f23932-0214-439d-b75d-0dacb43b489d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_d2115395-ac77-4574-b5e2-0068445578f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0116206a-7e38-46cc-a344-e640981b46c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_d2115395-ac77-4574-b5e2-0068445578f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0116206a-7e38-46cc-a344-e640981b46c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f334fd2e-bff0-46d0-b42a-fcc868d5f500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_d2115395-ac77-4574-b5e2-0068445578f5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f334fd2e-bff0-46d0-b42a-fcc868d5f500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a7884145-140f-4b1a-a893-6cd6a226bfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_d2115395-ac77-4574-b5e2-0068445578f5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a7884145-140f-4b1a-a893-6cd6a226bfd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3fdd813d-093d-4808-8861-57683de17276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_d2115395-ac77-4574-b5e2-0068445578f5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3fdd813d-093d-4808-8861-57683de17276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_35a414a9-4d29-4f00-8180-0ba514c9cbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9c12b350-dc3b-45af-8ad1-fed173c9ff20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_35a414a9-4d29-4f00-8180-0ba514c9cbdb" xlink:to="loc_us-gaap_Revenues_9c12b350-dc3b-45af-8ad1-fed173c9ff20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_8eb0ed95-f510-464e-a14e-893596a1229c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_35a414a9-4d29-4f00-8180-0ba514c9cbdb" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_8eb0ed95-f510-464e-a14e-893596a1229c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_029abcd9-0bef-45d1-b805-983edeea34a1" xlink:href="ebs-20230331.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_9df4afe9-130f-4935-b2f4-cd821513e189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_029abcd9-0bef-45d1-b805-983edeea34a1" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_9df4afe9-130f-4935-b2f4-cd821513e189" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f8c64d62-e7d5-4853-b136-4e9bc1ae5242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_029abcd9-0bef-45d1-b805-983edeea34a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f8c64d62-e7d5-4853-b136-4e9bc1ae5242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d7a0709-7e38-46bc-ba59-a1f445b404b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b13abac-3920-4b07-bae9-c8cb6faed0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d7a0709-7e38-46bc-ba59-a1f445b404b9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b13abac-3920-4b07-bae9-c8cb6faed0bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f32878fc-3158-4249-9830-9f6bd135436b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d7a0709-7e38-46bc-ba59-a1f445b404b9" xlink:to="loc_us-gaap_OperatingIncomeLoss_f32878fc-3158-4249-9830-9f6bd135436b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c4dc6287-9a3b-4200-a9ba-ea17a290b73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8401d7d1-add2-435c-87ca-c67f1bd02da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c4dc6287-9a3b-4200-a9ba-ea17a290b73b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8401d7d1-add2-435c-87ca-c67f1bd02da5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_604b6e74-1f06-4ca2-9b72-b61cbc17e406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c4dc6287-9a3b-4200-a9ba-ea17a290b73b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_604b6e74-1f06-4ca2-9b72-b61cbc17e406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_37c74048-f903-4652-bde5-ac4bb03cbd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2be22459-a587-413e-a926-b6d7a32b80d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_37c74048-f903-4652-bde5-ac4bb03cbd3e" xlink:to="loc_us-gaap_NetIncomeLoss_2be22459-a587-413e-a926-b6d7a32b80d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_40b89611-7441-46e7-8bd3-3ffe685d6aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_37c74048-f903-4652-bde5-ac4bb03cbd3e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_40b89611-7441-46e7-8bd3-3ffe685d6aae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca6ebf35-b2af-49fb-be30-c541536d4a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_547263db-3443-47b1-bd18-4243da320908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca6ebf35-b2af-49fb-be30-c541536d4a2d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_547263db-3443-47b1-bd18-4243da320908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_924da6c1-d3b8-4f37-aac0-a647ce3ae90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca6ebf35-b2af-49fb-be30-c541536d4a2d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_924da6c1-d3b8-4f37-aac0-a647ce3ae90c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_d04d623a-8680-4669-a66c-e505dba9f373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca6ebf35-b2af-49fb-be30-c541536d4a2d" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_d04d623a-8680-4669-a66c-e505dba9f373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_285522b9-b78b-4a93-89a1-acd5c2bd4ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca6ebf35-b2af-49fb-be30-c541536d4a2d" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_285522b9-b78b-4a93-89a1-acd5c2bd4ce5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_81f361b1-3a4a-4ffd-8305-cd704ff2876e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_ef055945-4089-4c95-95fb-abcf174abc22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_81f361b1-3a4a-4ffd-8305-cd704ff2876e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_ef055945-4089-4c95-95fb-abcf174abc22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ee33c9f-41a6-4397-aa86-8cda803c6ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_81f361b1-3a4a-4ffd-8305-cd704ff2876e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ee33c9f-41a6-4397-aa86-8cda803c6ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_6a664751-d87c-44bd-a1e4-ad8fb233cbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_6a664751-d87c-44bd-a1e4-ad8fb233cbb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0acd31c1-03be-4e44-9373-0f877c22422e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0acd31c1-03be-4e44-9373-0f877c22422e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cc90e257-c2b1-461b-a639-a6868c8b9fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cc90e257-c2b1-461b-a639-a6868c8b9fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_9e2c4967-5da0-4136-86d2-2b2d94b2c728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_9e2c4967-5da0-4136-86d2-2b2d94b2c728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b37e5199-0f35-4a4a-bebb-956abb60bbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_ShareBasedCompensation_b37e5199-0f35-4a4a-bebb-956abb60bbc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f06a11b8-12c3-489e-b974-f9c02eb8c8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f06a11b8-12c3-489e-b974-f9c02eb8c8b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5de495bf-d4df-4dcb-96e6-4f8857fcd33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5de495bf-d4df-4dcb-96e6-4f8857fcd33f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_96caa365-edc0-4a9d-b79e-e80778b94404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_NetIncomeLoss_96caa365-edc0-4a9d-b79e-e80778b94404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_173bd83f-073a-4c7e-ab47-8b12cb08f069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_173bd83f-073a-4c7e-ab47-8b12cb08f069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_84030461-045c-4aff-87b8-987ed776ab00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_84030461-045c-4aff-87b8-987ed776ab00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c10723f5-eb65-4d8e-8665-be06b10a8a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c10723f5-eb65-4d8e-8665-be06b10a8a0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5cc0f658-678f-455d-a8c9-e3a18876dca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5cc0f658-678f-455d-a8c9-e3a18876dca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f3e4423c-9f6d-4af7-afb8-603575c7b29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f3e4423c-9f6d-4af7-afb8-603575c7b29c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_75e82fcb-f58f-4a52-9fc0-106d61bbe133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_75e82fcb-f58f-4a52-9fc0-106d61bbe133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fcb067e3-dbfc-4325-b36b-5ed964da1eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6072c0f-ca1c-414f-b9ec-9e445451242a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fcb067e3-dbfc-4325-b36b-5ed964da1eaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_545f4320-0dc4-4ed6-ae2c-b3485d25ecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_439d8e56-9fbc-4b7a-b6a4-bc0b4ff749d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_545f4320-0dc4-4ed6-ae2c-b3485d25ecd1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_439d8e56-9fbc-4b7a-b6a4-bc0b4ff749d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a8c8eb0-2aed-4ad9-b55f-57b0fbe76409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c63e882-7b74-4ed1-b269-08a4cb695a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a8c8eb0-2aed-4ad9-b55f-57b0fbe76409" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c63e882-7b74-4ed1-b269-08a4cb695a06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f1f9874-89ac-4c4d-b5bc-ff0cd74ee3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a8c8eb0-2aed-4ad9-b55f-57b0fbe76409" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f1f9874-89ac-4c4d-b5bc-ff0cd74ee3c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2d73be6e-c842-4bf3-bbd6-6612d40810ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a8c8eb0-2aed-4ad9-b55f-57b0fbe76409" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2d73be6e-c842-4bf3-bbd6-6612d40810ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bbe6166-c523-43aa-a508-28c43df751e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a8c8eb0-2aed-4ad9-b55f-57b0fbe76409" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bbe6166-c523-43aa-a508-28c43df751e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6bb5ec3e-531b-4770-b421-ecc71b1771f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_c3427dd5-4ba3-41aa-9085-4e70b132d4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6bb5ec3e-531b-4770-b421-ecc71b1771f9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_c3427dd5-4ba3-41aa-9085-4e70b132d4c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_55ee6033-92f0-44d5-a529-9e9a7af23a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6bb5ec3e-531b-4770-b421-ecc71b1771f9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_55ee6033-92f0-44d5-a529-9e9a7af23a9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c4c8b6cf-17dd-4403-8c9e-fc2010c0c7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6bb5ec3e-531b-4770-b421-ecc71b1771f9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c4c8b6cf-17dd-4403-8c9e-fc2010c0c7e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_451f07f4-b894-41ab-b9bd-95d53f45b86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6bb5ec3e-531b-4770-b421-ecc71b1771f9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_451f07f4-b894-41ab-b9bd-95d53f45b86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_7e939ce7-04a8-4887-b203-d2d1844af597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6bb5ec3e-531b-4770-b421-ecc71b1771f9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_7e939ce7-04a8-4887-b203-d2d1844af597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_59e86ccc-8b31-43cc-8e2a-a1645ee0cdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6bb5ec3e-531b-4770-b421-ecc71b1771f9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_59e86ccc-8b31-43cc-8e2a-a1645ee0cdfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_5d9133a9-8b55-40c5-8ee6-e7b42b734b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6bb5ec3e-531b-4770-b421-ecc71b1771f9" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_5d9133a9-8b55-40c5-8ee6-e7b42b734b36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c9f44e87-835d-4177-aece-18a74ce567c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_f7538397-bf7b-4120-ad77-149acbca483d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c9f44e87-835d-4177-aece-18a74ce567c6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_f7538397-bf7b-4120-ad77-149acbca483d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_8c956f77-2994-4777-8eb0-0f78c87e2557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c9f44e87-835d-4177-aece-18a74ce567c6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_8c956f77-2994-4777-8eb0-0f78c87e2557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_5680f401-d6d5-44a5-a8d4-8ad94f178a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c9f44e87-835d-4177-aece-18a74ce567c6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_5680f401-d6d5-44a5-a8d4-8ad94f178a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_68aa5f80-3e45-4815-be69-80483cb67e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c9f44e87-835d-4177-aece-18a74ce567c6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_68aa5f80-3e45-4815-be69-80483cb67e26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_ce36d75e-e365-46db-8ee1-bf90552a4cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c9f44e87-835d-4177-aece-18a74ce567c6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_ce36d75e-e365-46db-8ee1-bf90552a4cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent_cf500aef-299d-435f-96da-1f5db36e8101" xlink:href="ebs-20230331.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c9f44e87-835d-4177-aece-18a74ce567c6" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent_cf500aef-299d-435f-96da-1f5db36e8101" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#InventoriesnetScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6642d3b3-7ecb-42ae-b6bb-1407c390c9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2a515470-2bf9-4d0f-a27d-96e301676bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6642d3b3-7ecb-42ae-b6bb-1407c390c9b5" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2a515470-2bf9-4d0f-a27d-96e301676bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9dfd3e71-78a3-49a5-9b95-3eac04912113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6642d3b3-7ecb-42ae-b6bb-1407c390c9b5" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9dfd3e71-78a3-49a5-9b95-3eac04912113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8182549e-8a3d-47e0-a188-2c6c2c13b9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6642d3b3-7ecb-42ae-b6bb-1407c390c9b5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_8182549e-8a3d-47e0-a188-2c6c2c13b9db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fb367762-1a31-48f4-b985-de51885a6e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_875459ed-b4b7-4cfd-976b-410e3d2a9095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fb367762-1a31-48f4-b985-de51885a6e00" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_875459ed-b4b7-4cfd-976b-410e3d2a9095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bd5d9ce7-b349-47e6-890f-0608cac01a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_fb367762-1a31-48f4-b985-de51885a6e00" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bd5d9ce7-b349-47e6-890f-0608cac01a5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_02b572d6-080c-4b9e-b4af-dae3d46d94e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f86229f8-f2c8-4a0b-ad01-e6ee6e619e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_02b572d6-080c-4b9e-b4af-dae3d46d94e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f86229f8-f2c8-4a0b-ad01-e6ee6e619e14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a7fff475-9067-44b7-8f92-75bcd7c4b6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_02b572d6-080c-4b9e-b4af-dae3d46d94e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a7fff475-9067-44b7-8f92-75bcd7c4b6e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b811625c-9738-41f8-b5e9-e824ef2452f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_606a40dc-e9e1-4295-a7a1-17cf10d81e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b811625c-9738-41f8-b5e9-e824ef2452f3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_606a40dc-e9e1-4295-a7a1-17cf10d81e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_1f41e710-45a1-4252-92b0-7defbbffba60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b811625c-9738-41f8-b5e9-e824ef2452f3" xlink:to="loc_us-gaap_DerivativeAssets_1f41e710-45a1-4252-92b0-7defbbffba60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d8c8aaec-b458-4754-8da3-28250347a26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47bcd202-9ff2-4fe3-b872-e60b7d92d1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d8c8aaec-b458-4754-8da3-28250347a26a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47bcd202-9ff2-4fe3-b872-e60b7d92d1fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_83f491d4-e911-446c-afb9-f86dcaa9fc66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_282cdcb0-8b73-487f-bf5e-d08f1b2282f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_83f491d4-e911-446c-afb9-f86dcaa9fc66" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_282cdcb0-8b73-487f-bf5e-d08f1b2282f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_1b879011-cc5d-442b-83b7-e7138f0b616a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_83f491d4-e911-446c-afb9-f86dcaa9fc66" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_1b879011-cc5d-442b-83b7-e7138f0b616a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_54a697f5-0626-4bf3-8743-611dd95642d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_86174e05-19b7-4211-94ee-31503f49d51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_54a697f5-0626-4bf3-8743-611dd95642d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_86174e05-19b7-4211-94ee-31503f49d51f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_2b2d40a3-0c07-44c2-9b4f-368ba19c7de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_54a697f5-0626-4bf3-8743-611dd95642d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_2b2d40a3-0c07-44c2-9b4f-368ba19c7de9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#EarningslosspercommonshareDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_16d16a7f-ef6a-45fc-821a-03dc2691b368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6e7e3472-fbb2-491f-85b5-4eade15c1cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_16d16a7f-ef6a-45fc-821a-03dc2691b368" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6e7e3472-fbb2-491f-85b5-4eade15c1cdc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RevenuerecognitionAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_572d52d0-384f-47f3-a800-b65bfe0524c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_3552e941-ad6f-47f4-a76f-c25ca4afd03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_572d52d0-384f-47f3-a800-b65bfe0524c3" xlink:to="loc_us-gaap_UnbilledContractsReceivable_3552e941-ad6f-47f4-a76f-c25ca4afd03d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_cd8d56fc-95be-452f-972c-684dc46c2179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_572d52d0-384f-47f3-a800-b65bfe0524c3" xlink:to="loc_us-gaap_BilledContractReceivables_cd8d56fc-95be-452f-972c-684dc46c2179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_95317379-a4a0-4277-9607-c45fc386f498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_572d52d0-384f-47f3-a800-b65bfe0524c3" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_95317379-a4a0-4277-9607-c45fc386f498" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fffadf2e-8e3e-4c3a-890b-daab6b221ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fa39397e-cda0-4ecc-a27c-6ad60fd7104e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_fffadf2e-8e3e-4c3a-890b-daab6b221ba4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fa39397e-cda0-4ecc-a27c-6ad60fd7104e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_10a6f567-894a-49f1-8360-a9e0d03dd264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_fffadf2e-8e3e-4c3a-890b-daab6b221ba4" xlink:to="loc_us-gaap_OperatingLeaseExpense_10a6f567-894a-49f1-8360-a9e0d03dd264" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4d466a3b-924f-4a4c-a511-8847a678e8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ec0d035b-1173-487a-9241-a48f8eb6388f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_4d466a3b-924f-4a4c-a511-8847a678e8b5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ec0d035b-1173-487a-9241-a48f8eb6388f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a15522de-2ea3-4483-b214-a181dd207a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_4d466a3b-924f-4a4c-a511-8847a678e8b5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a15522de-2ea3-4483-b214-a181dd207a52" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ebs-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:da57861a-e185-4b6f-8b91-f9335b77a88a,g:0a9819bf-1d2f-49f0-b0b7-eedd5e464486-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="ib9ec7970e507491d88a425b68ff10050_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39a10edc-62b6-477b-ab0f-0b148186b143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39a10edc-62b6-477b-ab0f-0b148186b143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_12775a49-b8c6-4ea8-9399-1632234940e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_12775a49-b8c6-4ea8-9399-1632234940e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_a0ae287f-1728-4c79-a542-b984628714bb" xlink:href="ebs-20230331.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_a0ae287f-1728-4c79-a542-b984628714bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c5d60447-f7d4-432d-a277-fa029347336a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:to="loc_us-gaap_Revenues_c5d60447-f7d4-432d-a277-fa029347336a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_dfc4c768-188a-40b4-afb0-d3d217c1dac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_dfc4c768-188a-40b4-afb0-d3d217c1dac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5f5db02b-26bd-4424-92c3-b31ae1061cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5f5db02b-26bd-4424-92c3-b31ae1061cd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_aa4ef061-b908-4855-b67f-32c28aa06909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_aa4ef061-b908-4855-b67f-32c28aa06909" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_aeae0661-81d6-4460-ad8b-b796242e95c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_aeae0661-81d6-4460-ad8b-b796242e95c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_fb401b75-f8d3-4632-b2ce-6d019a37b78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_fb401b75-f8d3-4632-b2ce-6d019a37b78c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_84a5da11-b89c-432c-bf96-c233d93c8baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_OperatingIncomeLoss_84a5da11-b89c-432c-bf96-c233d93c8baf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9862e550-9aff-465a-ad94-eb585598841a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9862e550-9aff-465a-ad94-eb585598841a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dca5f707-71e0-4158-8abb-993a09281d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9862e550-9aff-465a-ad94-eb585598841a" xlink:to="loc_us-gaap_InterestExpense_dca5f707-71e0-4158-8abb-993a09281d7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_01cccfb0-ff15-4006-b19f-522cc7157d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9862e550-9aff-465a-ad94-eb585598841a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_01cccfb0-ff15-4006-b19f-522cc7157d24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e108c846-5f59-4fab-90c2-70ba18703394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9862e550-9aff-465a-ad94-eb585598841a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e108c846-5f59-4fab-90c2-70ba18703394" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a519240f-84db-4ba7-919c-18bb0519dfd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a519240f-84db-4ba7-919c-18bb0519dfd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ccd3c4bc-ef75-4067-8034-e842cf3ec4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ccd3c4bc-ef75-4067-8034-e842cf3ec4c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_99f86de4-e124-4458-a8f8-0eee2070ed13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_NetIncomeLoss_99f86de4-e124-4458-a8f8-0eee2070ed13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_2ac343c7-ee8c-4cad-88d4-d69fea57f9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_2ac343c7-ee8c-4cad-88d4-d69fea57f9cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_96ee7438-dcf2-46b9-9199-4eab8d02d169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2ac343c7-ee8c-4cad-88d4-d69fea57f9cf" xlink:to="loc_us-gaap_EarningsPerShareBasic_96ee7438-dcf2-46b9-9199-4eab8d02d169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_63d6faa2-f173-448b-a31a-f42132f1ec32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2ac343c7-ee8c-4cad-88d4-d69fea57f9cf" xlink:to="loc_us-gaap_EarningsPerShareDiluted_63d6faa2-f173-448b-a31a-f42132f1ec32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c97c9f9d-4115-4b03-bc73-aac7358dea81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c97c9f9d-4115-4b03-bc73-aac7358dea81" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b8696ce6-3857-4a11-8fea-5e1302d9e93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c97c9f9d-4115-4b03-bc73-aac7358dea81" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b8696ce6-3857-4a11-8fea-5e1302d9e93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f95a2af0-69ea-48db-bc64-3589bf905285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c97c9f9d-4115-4b03-bc73-aac7358dea81" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f95a2af0-69ea-48db-bc64-3589bf905285" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d1e0577d-792f-4d18-b651-2d673d76d9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_StatementTable_d1e0577d-792f-4d18-b651-2d673d76d9e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4940aca8-a222-4e85-86ae-5c72492f6a81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d1e0577d-792f-4d18-b651-2d673d76d9e2" xlink:to="loc_srt_ProductOrServiceAxis_4940aca8-a222-4e85-86ae-5c72492f6a81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4940aca8-a222-4e85-86ae-5c72492f6a81_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4940aca8-a222-4e85-86ae-5c72492f6a81" xlink:to="loc_srt_ProductsAndServicesDomain_4940aca8-a222-4e85-86ae-5c72492f6a81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9750ca6f-c7c3-4a30-aa55-86ee880387ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4940aca8-a222-4e85-86ae-5c72492f6a81" xlink:to="loc_srt_ProductsAndServicesDomain_9750ca6f-c7c3-4a30-aa55-86ee880387ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_987dab52-f4d9-474e-80ec-6247b3cbe4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9750ca6f-c7c3-4a30-aa55-86ee880387ba" xlink:to="loc_us-gaap_ProductMember_987dab52-f4d9-474e-80ec-6247b3cbe4ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_f78845a8-9486-44c0-9f16-0f77896343a2" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9750ca6f-c7c3-4a30-aa55-86ee880387ba" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_f78845a8-9486-44c0-9f16-0f77896343a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_83211c23-1b1e-496b-8923-3837a88732c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_f78845a8-9486-44c0-9f16-0f77896343a2" xlink:to="loc_us-gaap_ServiceMember_83211c23-1b1e-496b-8923-3837a88732c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_10c4149f-0204-454c-9c9d-06dc4308abf7" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_f78845a8-9486-44c0-9f16-0f77896343a2" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_10c4149f-0204-454c-9c9d-06dc4308abf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_34e3a412-a7bf-4d25-b898-f326c9653366" xlink:href="ebs-20230331.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9750ca6f-c7c3-4a30-aa55-86ee880387ba" xlink:to="loc_ebs_ContractsAndGrantsMember_34e3a412-a7bf-4d25-b898-f326c9653366" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended" id="ia526db765e87477b88b4483b5f485dcf_CondensedConsolidatedStatementsofChangesinStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1cb1d875-4c29-4db6-af16-2d583b182fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1cb1d875-4c29-4db6-af16-2d583b182fdc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2cd6ef02-e912-4cea-9c68-7f120e17a30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_CommonStockSharesIssued_2cd6ef02-e912-4cea-9c68-7f120e17a30c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4c55c532-224c-4dde-9325-8420bd1cbcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_StockholdersEquity_4c55c532-224c-4dde-9325-8420bd1cbcaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_420c6243-766e-4f0d-98ba-05ceff417161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_NetIncomeLoss_420c6243-766e-4f0d-98ba-05ceff417161" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bdf5c769-d871-4c1b-b0f3-1ed66de05655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bdf5c769-d871-4c1b-b0f3-1ed66de05655" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_506b2f83-d6b1-44d2-8c14-d2201abf1fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_506b2f83-d6b1-44d2-8c14-d2201abf1fa8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_a659a683-3eff-4bcd-b10f-119a88cf8200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_a659a683-3eff-4bcd-b10f-119a88cf8200" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_217472a2-16d5-4509-a776-06d928e04e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_217472a2-16d5-4509-a776-06d928e04e49" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e87dd7e6-8079-4a6d-8514-c56436854029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e87dd7e6-8079-4a6d-8514-c56436854029" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d3da33c1-4aff-4b15-9d4d-85b486424794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_daa7a54c-5527-4956-9fc5-61274b286517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d25742e5-9815-4036-bd12-e6795c6941e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1cb1d875-4c29-4db6-af16-2d583b182fdc" xlink:to="loc_us-gaap_StatementTable_d25742e5-9815-4036-bd12-e6795c6941e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51db47b9-e5ce-4d70-8607-b06e1b780822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d25742e5-9815-4036-bd12-e6795c6941e3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51db47b9-e5ce-4d70-8607-b06e1b780822" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_51db47b9-e5ce-4d70-8607-b06e1b780822_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51db47b9-e5ce-4d70-8607-b06e1b780822" xlink:to="loc_us-gaap_EquityComponentDomain_51db47b9-e5ce-4d70-8607-b06e1b780822_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51db47b9-e5ce-4d70-8607-b06e1b780822" xlink:to="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eb9ff9a9-dab4-4428-9839-804e0e6cd475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:to="loc_us-gaap_CommonStockMember_eb9ff9a9-dab4-4428-9839-804e0e6cd475" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_d74289ab-77f1-4c42-b346-18610da203e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:to="loc_us-gaap_TreasuryStockCommonMember_d74289ab-77f1-4c42-b346-18610da203e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dcdccb8c-cb37-4330-8740-d65de27943a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dcdccb8c-cb37-4330-8740-d65de27943a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6847cbb-c1ab-4be5-94f7-1405f8e2b8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6847cbb-c1ab-4be5-94f7-1405f8e2b8d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_752cc641-12fc-411a-95de-a88a1baf2820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:to="loc_us-gaap_RetainedEarningsMember_752cc641-12fc-411a-95de-a88a1baf2820" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#SummaryofsignificantaccountingpoliciesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails" xlink:type="extended" id="i4752e94b0adf4d5a84bebd61a639c2a1_SummaryofsignificantaccountingpoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6516a328-dd10-4535-9ce2-ce148a0e8b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_240bee78-0123-48f4-8e17-78514b330fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6516a328-dd10-4535-9ce2-ce148a0e8b63" xlink:to="loc_us-gaap_LongTermDebt_240bee78-0123-48f4-8e17-78514b330fcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_64b7a8a6-9e34-4b80-bee5-dfc09b6b2f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6516a328-dd10-4535-9ce2-ce148a0e8b63" xlink:to="loc_us-gaap_DebtInstrumentTable_64b7a8a6-9e34-4b80-bee5-dfc09b6b2f2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4b181551-f1dc-410f-9768-fe14020551a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_64b7a8a6-9e34-4b80-bee5-dfc09b6b2f2e" xlink:to="loc_us-gaap_CreditFacilityAxis_4b181551-f1dc-410f-9768-fe14020551a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4b181551-f1dc-410f-9768-fe14020551a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_4b181551-f1dc-410f-9768-fe14020551a8" xlink:to="loc_us-gaap_CreditFacilityDomain_4b181551-f1dc-410f-9768-fe14020551a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_53218515-5b33-4aff-903c-e8e5f5157e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_4b181551-f1dc-410f-9768-fe14020551a8" xlink:to="loc_us-gaap_CreditFacilityDomain_53218515-5b33-4aff-903c-e8e5f5157e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4515a3f6-2766-4d60-b59e-18dc190034f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_53218515-5b33-4aff-903c-e8e5f5157e26" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4515a3f6-2766-4d60-b59e-18dc190034f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bdeb27d2-12fa-4447-a0f3-97f70a6f6dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_64b7a8a6-9e34-4b80-bee5-dfc09b6b2f2e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bdeb27d2-12fa-4447-a0f3-97f70a6f6dbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bdeb27d2-12fa-4447-a0f3-97f70a6f6dbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bdeb27d2-12fa-4447-a0f3-97f70a6f6dbe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bdeb27d2-12fa-4447-a0f3-97f70a6f6dbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f322aba4-a309-41ad-a51c-ab4ecca69c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bdeb27d2-12fa-4447-a0f3-97f70a6f6dbe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f322aba4-a309-41ad-a51c-ab4ecca69c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ada3e473-1ca7-4a4f-89f1-444be4ac082c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f322aba4-a309-41ad-a51c-ab4ecca69c96" xlink:to="loc_us-gaap_LineOfCreditMember_ada3e473-1ca7-4a4f-89f1-444be4ac082c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_1ea89bc8-cefc-4020-8830-83d1608f2e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f322aba4-a309-41ad-a51c-ab4ecca69c96" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_1ea89bc8-cefc-4020-8830-83d1608f2e73" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#AssetsandliabilitiesheldforsaleNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails" xlink:type="extended" id="i33b6b68673d54d4a95b9f72fce43e006_AssetsandliabilitiesheldforsaleNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_30c2a206-1ed6-4d2a-ab39-6b869afcd6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated_baf0d7d2-a42f-4076-ad48-228886eb4d3e" xlink:href="ebs-20230331.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_30c2a206-1ed6-4d2a-ab39-6b869afcd6d7" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated_baf0d7d2-a42f-4076-ad48-228886eb4d3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35a51f55-19eb-4c9b-b085-343fe39211b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_30c2a206-1ed6-4d2a-ab39-6b869afcd6d7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35a51f55-19eb-4c9b-b085-343fe39211b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59e8e33d-22e7-4392-9fab-356fee3ad166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35a51f55-19eb-4c9b-b085-343fe39211b0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59e8e33d-22e7-4392-9fab-356fee3ad166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_59e8e33d-22e7-4392-9fab-356fee3ad166_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59e8e33d-22e7-4392-9fab-356fee3ad166" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_59e8e33d-22e7-4392-9fab-356fee3ad166_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55dd0d8c-b739-47b6-9b6d-a8fb82e31028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59e8e33d-22e7-4392-9fab-356fee3ad166" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55dd0d8c-b739-47b6-9b6d-a8fb82e31028" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_63168f9b-3e73-43e5-803d-f9351d5f7f8a" xlink:href="ebs-20230331.xsd#ebs_TravelHealthBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55dd0d8c-b739-47b6-9b6d-a8fb82e31028" xlink:to="loc_ebs_TravelHealthBusinessMember_63168f9b-3e73-43e5-803d-f9351d5f7f8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d88a01a3-1f4f-4cf2-b02b-c24021c4a348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35a51f55-19eb-4c9b-b085-343fe39211b0" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d88a01a3-1f4f-4cf2-b02b-c24021c4a348" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d88a01a3-1f4f-4cf2-b02b-c24021c4a348_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d88a01a3-1f4f-4cf2-b02b-c24021c4a348" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d88a01a3-1f4f-4cf2-b02b-c24021c4a348_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_dc6a3a6b-29bb-491d-b4f1-4ea8b9a84d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d88a01a3-1f4f-4cf2-b02b-c24021c4a348" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_dc6a3a6b-29bb-491d-b4f1-4ea8b9a84d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b705e50f-fc74-471b-a404-38cc2b91182c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_dc6a3a6b-29bb-491d-b4f1-4ea8b9a84d26" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b705e50f-fc74-471b-a404-38cc2b91182c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5edc6e16-777d-4893-a9a5-24aad416c31f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35a51f55-19eb-4c9b-b085-343fe39211b0" xlink:to="loc_srt_StatementScenarioAxis_5edc6e16-777d-4893-a9a5-24aad416c31f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5edc6e16-777d-4893-a9a5-24aad416c31f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_5edc6e16-777d-4893-a9a5-24aad416c31f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5edc6e16-777d-4893-a9a5-24aad416c31f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bb4e174d-fb2d-4a8b-8a39-b417878f9bf8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_5edc6e16-777d-4893-a9a5-24aad416c31f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bb4e174d-fb2d-4a8b-8a39-b417878f9bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e79943a4-fd23-4eed-8032-c7abdd4d9cb4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bb4e174d-fb2d-4a8b-8a39-b417878f9bf8" xlink:to="loc_srt_ScenarioForecastMember_e79943a4-fd23-4eed-8032-c7abdd4d9cb4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="extended" id="i5566cd9021124cbcb17469032e30d68c_AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a7df6696-0ea4-4bc4-929a-4f79abb6226f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a7df6696-0ea4-4bc4-929a-4f79abb6226f" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_e9b64a65-6668-4b88-a791-23f8925f9282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_e9b64a65-6668-4b88-a791-23f8925f9282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_abf21deb-a1a1-4019-8140-d46e02e0416a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_abf21deb-a1a1-4019-8140-d46e02e0416a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_68dfdc19-61e7-44a7-9480-5d339444aa8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_68dfdc19-61e7-44a7-9480-5d339444aa8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_ff9cfbf1-e1ec-43d5-b941-d58bc1c1bc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_ff9cfbf1-e1ec-43d5-b941-d58bc1c1bc4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_b66288eb-a8af-4d64-98a3-4f518c64b544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_b66288eb-a8af-4d64-98a3-4f518c64b544" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_de4d40c9-d5c2-4a5f-8fef-22c614cbd678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_de4d40c9-d5c2-4a5f-8fef-22c614cbd678" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_e98c4a3a-50a0-4713-a725-7cd141a17bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_e98c4a3a-50a0-4713-a725-7cd141a17bb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5cd5135b-7a9e-4de6-92a7-f0457f94bf07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5cd5135b-7a9e-4de6-92a7-f0457f94bf07" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a7df6696-0ea4-4bc4-929a-4f79abb6226f" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_f2174ee2-8411-427e-9542-0c9c1ade358c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_f2174ee2-8411-427e-9542-0c9c1ade358c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_649b0ee7-6e15-4329-8b08-10140a5f2a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_649b0ee7-6e15-4329-8b08-10140a5f2a88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent_16ce65cb-e53f-4874-85ee-77e7859398c6" xlink:href="ebs-20230331.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent_16ce65cb-e53f-4874-85ee-77e7859398c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_93e3fdaa-9248-49ad-855a-fd8dc1f0fcab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_93e3fdaa-9248-49ad-855a-fd8dc1f0fcab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_6d07a746-c73c-42f9-9fc7-135e4be70f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_6d07a746-c73c-42f9-9fc7-135e4be70f9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_7124eb11-9110-4ff9-846c-03db878afa91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_7124eb11-9110-4ff9-846c-03db878afa91" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_921e6fbf-a2bb-4824-99e8-d96959159678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_921e6fbf-a2bb-4824-99e8-d96959159678" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fdaee9b1-3846-4035-a7e9-9b2b493dcc18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a7df6696-0ea4-4bc4-929a-4f79abb6226f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fdaee9b1-3846-4035-a7e9-9b2b493dcc18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_22fb272c-0b52-4a92-9687-55cc4389a258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fdaee9b1-3846-4035-a7e9-9b2b493dcc18" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_22fb272c-0b52-4a92-9687-55cc4389a258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_22fb272c-0b52-4a92-9687-55cc4389a258_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_22fb272c-0b52-4a92-9687-55cc4389a258" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_22fb272c-0b52-4a92-9687-55cc4389a258_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5d496446-26ef-4d63-9018-b5e7899ebe79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_22fb272c-0b52-4a92-9687-55cc4389a258" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5d496446-26ef-4d63-9018-b5e7899ebe79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d2bece2b-22da-4831-827b-31792c92b3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5d496446-26ef-4d63-9018-b5e7899ebe79" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d2bece2b-22da-4831-827b-31792c92b3c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_688a48d9-186d-4c23-a1bc-1b20c03db493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fdaee9b1-3846-4035-a7e9-9b2b493dcc18" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_688a48d9-186d-4c23-a1bc-1b20c03db493" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_688a48d9-186d-4c23-a1bc-1b20c03db493_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_688a48d9-186d-4c23-a1bc-1b20c03db493" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_688a48d9-186d-4c23-a1bc-1b20c03db493_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2b400a10-283b-408c-bcdc-f9cf9eac4c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_688a48d9-186d-4c23-a1bc-1b20c03db493" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2b400a10-283b-408c-bcdc-f9cf9eac4c3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_91f7f0b5-aac7-41b4-8d29-6d9708cd778b" xlink:href="ebs-20230331.xsd#ebs_TravelHealthBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2b400a10-283b-408c-bcdc-f9cf9eac4c3b" xlink:to="loc_ebs_TravelHealthBusinessMember_91f7f0b5-aac7-41b4-8d29-6d9708cd778b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RestructuringcostsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails" xlink:type="extended" id="i9ffcedf5a5284449a0cf1edd11e14579_RestructuringcostsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1746bba0-d1ad-4335-9304-e54c4286cf97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_6b0523ae-a064-449d-abd1-35378cb2292d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1746bba0-d1ad-4335-9304-e54c4286cf97" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_6b0523ae-a064-449d-abd1-35378cb2292d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_558d56f6-5e89-4aa1-8d47-f657c4a15f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1746bba0-d1ad-4335-9304-e54c4286cf97" xlink:to="loc_us-gaap_RestructuringCharges_558d56f6-5e89-4aa1-8d47-f657c4a15f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9f531d8d-2abb-4640-bb77-936b28f54afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1746bba0-d1ad-4335-9304-e54c4286cf97" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9f531d8d-2abb-4640-bb77-936b28f54afb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_446cb6cb-d630-486e-b77b-4258d8c00593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9f531d8d-2abb-4640-bb77-936b28f54afb" xlink:to="loc_us-gaap_RestructuringPlanAxis_446cb6cb-d630-486e-b77b-4258d8c00593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_446cb6cb-d630-486e-b77b-4258d8c00593_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_446cb6cb-d630-486e-b77b-4258d8c00593" xlink:to="loc_us-gaap_RestructuringPlanDomain_446cb6cb-d630-486e-b77b-4258d8c00593_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b93c6a48-9c46-4278-97fe-0e33da2c757f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_446cb6cb-d630-486e-b77b-4258d8c00593" xlink:to="loc_us-gaap_RestructuringPlanDomain_b93c6a48-9c46-4278-97fe-0e33da2c757f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlan2023Member_a5fd0642-79b7-420f-8ee8-9c6f5b85d472" xlink:href="ebs-20230331.xsd#ebs_RestructuringPlan2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_b93c6a48-9c46-4278-97fe-0e33da2c757f" xlink:to="loc_ebs_RestructuringPlan2023Member_a5fd0642-79b7-420f-8ee8-9c6f5b85d472" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RestructuringcostsRestructuringandRelatedCostsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails" xlink:type="extended" id="i0cc78c84b720422ebb353a8dff1bf36b_RestructuringcostsRestructuringandRelatedCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0eb2c319-e505-41b7-9c37-268b3db0417c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_29e134a7-773e-4fd8-8853-6f836122e3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0eb2c319-e505-41b7-9c37-268b3db0417c" xlink:to="loc_us-gaap_RestructuringCharges_29e134a7-773e-4fd8-8853-6f836122e3c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0eb2c319-e505-41b7-9c37-268b3db0417c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_806733bc-3445-4e04-9556-083c7b5a26ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_806733bc-3445-4e04-9556-083c7b5a26ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_806733bc-3445-4e04-9556-083c7b5a26ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_806733bc-3445-4e04-9556-083c7b5a26ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_806733bc-3445-4e04-9556-083c7b5a26ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_806733bc-3445-4e04-9556-083c7b5a26ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedResearchAndDevelopmentMember_8a148b5f-5735-4672-bb75-cb4274e0043b" xlink:href="ebs-20230331.xsd#ebs_UnallocatedResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:to="loc_ebs_UnallocatedResearchAndDevelopmentMember_8a148b5f-5735-4672-bb75-cb4274e0043b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember_8c4e8121-143a-45d5-97ed-d278ef7aa8af" xlink:href="ebs-20230331.xsd#ebs_EmployeeTransitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:to="loc_ebs_EmployeeTransitionMember_8c4e8121-143a-45d5-97ed-d278ef7aa8af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_9ff7b1ce-72db-464e-a570-51f23d9497fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:to="loc_us-gaap_EmployeeSeveranceMember_9ff7b1ce-72db-464e-a570-51f23d9497fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_683122b9-72ee-4ec3-8fc7-a9580a369344" xlink:href="ebs-20230331.xsd#ebs_EmployeeBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:to="loc_ebs_EmployeeBenefitsMember_683122b9-72ee-4ec3-8fc7-a9580a369344" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8a939c8f-a70d-454e-9a51-634133247ac1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:to="loc_srt_ConsolidationItemsAxis_8a939c8f-a70d-454e-9a51-634133247ac1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8a939c8f-a70d-454e-9a51-634133247ac1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_8a939c8f-a70d-454e-9a51-634133247ac1" xlink:to="loc_srt_ConsolidationItemsDomain_8a939c8f-a70d-454e-9a51-634133247ac1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a445a344-97fc-4349-a969-d7173b7df3e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_8a939c8f-a70d-454e-9a51-634133247ac1" xlink:to="loc_srt_ConsolidationItemsDomain_a445a344-97fc-4349-a969-d7173b7df3e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9373faf1-b150-4e77-b7a9-b4250919011c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a445a344-97fc-4349-a969-d7173b7df3e2" xlink:to="loc_us-gaap_OperatingSegmentsMember_9373faf1-b150-4e77-b7a9-b4250919011c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a3ecdfd8-1308-4f0c-854b-1049f63467b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a445a344-97fc-4349-a969-d7173b7df3e2" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a3ecdfd8-1308-4f0c-854b-1049f63467b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_03f43a2b-6c52-4dc1-a4af-d572e69018f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_03f43a2b-6c52-4dc1-a4af-d572e69018f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_03f43a2b-6c52-4dc1-a4af-d572e69018f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03f43a2b-6c52-4dc1-a4af-d572e69018f2" xlink:to="loc_us-gaap_SegmentDomain_03f43a2b-6c52-4dc1-a4af-d572e69018f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dcf32d61-7ffa-49bb-b605-a2414255445c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03f43a2b-6c52-4dc1-a4af-d572e69018f2" xlink:to="loc_us-gaap_SegmentDomain_dcf32d61-7ffa-49bb-b605-a2414255445c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_5274133d-9dd2-4087-8173-1b521e47bfc1" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dcf32d61-7ffa-49bb-b605-a2414255445c" xlink:to="loc_ebs_ProductsSegmentMember_5274133d-9dd2-4087-8173-1b521e47bfc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_94759856-4647-4695-b898-8ee3e3c067be" xlink:href="ebs-20230331.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dcf32d61-7ffa-49bb-b605-a2414255445c" xlink:to="loc_ebs_ServicesSegmentMember_94759856-4647-4695-b898-8ee3e3c067be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_f6b42ccd-f6a1-49ed-8724-e1bf66b831ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:to="loc_us-gaap_RestructuringPlanAxis_f6b42ccd-f6a1-49ed-8724-e1bf66b831ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_f6b42ccd-f6a1-49ed-8724-e1bf66b831ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_f6b42ccd-f6a1-49ed-8724-e1bf66b831ad" xlink:to="loc_us-gaap_RestructuringPlanDomain_f6b42ccd-f6a1-49ed-8724-e1bf66b831ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_149fbe5c-f0c2-4838-b8ec-f41db13e2117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_f6b42ccd-f6a1-49ed-8724-e1bf66b831ad" xlink:to="loc_us-gaap_RestructuringPlanDomain_149fbe5c-f0c2-4838-b8ec-f41db13e2117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlan2023Member_e47f32f8-5269-4a37-bf14-1d45cfb8af34" xlink:href="ebs-20230331.xsd#ebs_RestructuringPlan2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_149fbe5c-f0c2-4838-b8ec-f41db13e2117" xlink:to="loc_ebs_RestructuringPlan2023Member_e47f32f8-5269-4a37-bf14-1d45cfb8af34" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended" id="i4af6b8010cc242b3881d61c4dae153f1_RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_cfa5539c-76e1-4318-b15b-a6a9981c1bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_0c2d4ed8-78aa-4de1-a433-01ecf6fea939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_cfa5539c-76e1-4318-b15b-a6a9981c1bf3" xlink:to="loc_us-gaap_RestructuringReserveRollForward_0c2d4ed8-78aa-4de1-a433-01ecf6fea939" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_340f1e5b-a649-4278-913b-15e2537c1f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0c2d4ed8-78aa-4de1-a433-01ecf6fea939" xlink:to="loc_us-gaap_RestructuringReserve_340f1e5b-a649-4278-913b-15e2537c1f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_66875efb-b3ad-42d6-8bdd-55c3570fa189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0c2d4ed8-78aa-4de1-a433-01ecf6fea939" xlink:to="loc_us-gaap_RestructuringCharges_66875efb-b3ad-42d6-8bdd-55c3570fa189" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_89a864d7-9ad0-4ba0-9b72-564f8264f75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0c2d4ed8-78aa-4de1-a433-01ecf6fea939" xlink:to="loc_us-gaap_PaymentsForRestructuring_89a864d7-9ad0-4ba0-9b72-564f8264f75c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_db5a750e-d361-43ee-a259-cf1b92b62024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_321d3f19-b566-47f6-a809-6de9fd15f7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_cfa5539c-76e1-4318-b15b-a6a9981c1bf3" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_321d3f19-b566-47f6-a809-6de9fd15f7c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_131f0427-9dcb-477d-a09c-34b64fb33cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_321d3f19-b566-47f6-a809-6de9fd15f7c3" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_131f0427-9dcb-477d-a09c-34b64fb33cc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_131f0427-9dcb-477d-a09c-34b64fb33cc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_131f0427-9dcb-477d-a09c-34b64fb33cc1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_131f0427-9dcb-477d-a09c-34b64fb33cc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_960be083-c7cb-4ce0-8686-e56b65ba0b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_131f0427-9dcb-477d-a09c-34b64fb33cc1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_960be083-c7cb-4ce0-8686-e56b65ba0b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember_448857ee-31e7-4184-b94c-93af265cb8ea" xlink:href="ebs-20230331.xsd#ebs_EmployeeTransitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_960be083-c7cb-4ce0-8686-e56b65ba0b1e" xlink:to="loc_ebs_EmployeeTransitionMember_448857ee-31e7-4184-b94c-93af265cb8ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_c2c56b1e-74eb-476d-81b7-8e1c4caa8f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_960be083-c7cb-4ce0-8686-e56b65ba0b1e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_c2c56b1e-74eb-476d-81b7-8e1c4caa8f54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_dd6aca34-7151-4ef3-b511-38ffa281038a" xlink:href="ebs-20230331.xsd#ebs_EmployeeBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_960be083-c7cb-4ce0-8686-e56b65ba0b1e" xlink:to="loc_ebs_EmployeeBenefitsMember_dd6aca34-7151-4ef3-b511-38ffa281038a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_8522ab19-1b84-4cff-a963-18ecd6fc7e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_321d3f19-b566-47f6-a809-6de9fd15f7c3" xlink:to="loc_us-gaap_RestructuringPlanAxis_8522ab19-1b84-4cff-a963-18ecd6fc7e60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_8522ab19-1b84-4cff-a963-18ecd6fc7e60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_8522ab19-1b84-4cff-a963-18ecd6fc7e60" xlink:to="loc_us-gaap_RestructuringPlanDomain_8522ab19-1b84-4cff-a963-18ecd6fc7e60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0e72bf5e-500f-46f7-9e52-9de34b158692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_8522ab19-1b84-4cff-a963-18ecd6fc7e60" xlink:to="loc_us-gaap_RestructuringPlanDomain_0e72bf5e-500f-46f7-9e52-9de34b158692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlan2023Member_366ff6f8-e46f-4afa-be53-dd9a7ab1de4a" xlink:href="ebs-20230331.xsd#ebs_RestructuringPlan2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0e72bf5e-500f-46f7-9e52-9de34b158692" xlink:to="loc_ebs_RestructuringPlan2023Member_366ff6f8-e46f-4afa-be53-dd9a7ab1de4a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i17fee7d9a9e44aacb7a91a027d23b292_PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b442a30-48c5-4dc3-a9d6-98e53b622955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_096b416f-b9a7-4215-8ec3-da2ba343df4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b442a30-48c5-4dc3-a9d6-98e53b622955" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_096b416f-b9a7-4215-8ec3-da2ba343df4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_adf80359-8fee-4244-83cf-75eb7bc49c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_096b416f-b9a7-4215-8ec3-da2ba343df4b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_adf80359-8fee-4244-83cf-75eb7bc49c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_800d1c24-65e6-4fff-9953-65c5dfb6aba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_096b416f-b9a7-4215-8ec3-da2ba343df4b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_800d1c24-65e6-4fff-9953-65c5dfb6aba3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7e7c0591-a61b-40ca-8319-1741e8ea8e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_096b416f-b9a7-4215-8ec3-da2ba343df4b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7e7c0591-a61b-40ca-8319-1741e8ea8e2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ccf96b7-cb7a-4033-a9bf-acdea1e97567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b442a30-48c5-4dc3-a9d6-98e53b622955" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ccf96b7-cb7a-4033-a9bf-acdea1e97567" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a2db6161-2fb0-47fb-aa96-d8bf0c99bfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ccf96b7-cb7a-4033-a9bf-acdea1e97567" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a2db6161-2fb0-47fb-aa96-d8bf0c99bfa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a2db6161-2fb0-47fb-aa96-d8bf0c99bfa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a2db6161-2fb0-47fb-aa96-d8bf0c99bfa5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a2db6161-2fb0-47fb-aa96-d8bf0c99bfa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a2db6161-2fb0-47fb-aa96-d8bf0c99bfa5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_72d08317-2319-4aad-9fcb-bba90c82beb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_72d08317-2319-4aad-9fcb-bba90c82beb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_ec3d421d-27c4-43af-8748-67447f3decb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_ec3d421d-27c4-43af-8748-67447f3decb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_47c47105-332a-4a1c-bbf3-b767b78dc1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_47c47105-332a-4a1c-bbf3-b767b78dc1c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7573e91b-306e-4590-9cd4-ea96a26cf3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7573e91b-306e-4590-9cd4-ea96a26cf3f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b52310e4-3ab7-41a3-8de1-00afce9f6825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:to="loc_us-gaap_ConstructionInProgressMember_b52310e4-3ab7-41a3-8de1-00afce9f6825" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#PropertyplantandequipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="extended" id="iac179cb09c1e4d44ad2276d1eea4869d_PropertyplantandequipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f1f926fe-d7a7-4c92-bb84-8e5d480f6109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ba46c83f-6225-4688-9f19-29fc26e55490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f1f926fe-d7a7-4c92-bb84-8e5d480f6109" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ba46c83f-6225-4688-9f19-29fc26e55490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b074ea47-17ca-48a8-a645-4b809ec91df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f1f926fe-d7a7-4c92-bb84-8e5d480f6109" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b074ea47-17ca-48a8-a645-4b809ec91df7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_47776746-6c32-4844-93b5-1b8718f27182" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b074ea47-17ca-48a8-a645-4b809ec91df7" xlink:to="loc_srt_MajorCustomersAxis_47776746-6c32-4844-93b5-1b8718f27182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_47776746-6c32-4844-93b5-1b8718f27182_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_47776746-6c32-4844-93b5-1b8718f27182" xlink:to="loc_srt_NameOfMajorCustomerDomain_47776746-6c32-4844-93b5-1b8718f27182_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_40d631e4-4f5b-4d3c-815e-2ce8b42a6abf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_47776746-6c32-4844-93b5-1b8718f27182" xlink:to="loc_srt_NameOfMajorCustomerDomain_40d631e4-4f5b-4d3c-815e-2ce8b42a6abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_035ee5cc-bd4c-434a-890d-582618d74920" xlink:href="ebs-20230331.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_40d631e4-4f5b-4d3c-815e-2ce8b42a6abf" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_035ee5cc-bd4c-434a-890d-582618d74920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2d6b44a1-6c5b-48f4-98bf-97ea57641ee3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b074ea47-17ca-48a8-a645-4b809ec91df7" xlink:to="loc_srt_ProductOrServiceAxis_2d6b44a1-6c5b-48f4-98bf-97ea57641ee3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2d6b44a1-6c5b-48f4-98bf-97ea57641ee3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2d6b44a1-6c5b-48f4-98bf-97ea57641ee3" xlink:to="loc_srt_ProductsAndServicesDomain_2d6b44a1-6c5b-48f4-98bf-97ea57641ee3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b828c2b-777f-4326-a226-14c40d9fa4c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2d6b44a1-6c5b-48f4-98bf-97ea57641ee3" xlink:to="loc_srt_ProductsAndServicesDomain_3b828c2b-777f-4326-a226-14c40d9fa4c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1d810602-0d63-4b2d-b7c6-6d0a8cb9373c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b828c2b-777f-4326-a226-14c40d9fa4c4" xlink:to="loc_us-gaap_ServiceMember_1d810602-0d63-4b2d-b7c6-6d0a8cb9373c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended" id="i1a3b9dc23c8744aba6934b905a335265_IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fcb5eb25-0c65-4bf0-92be-b8583aadd1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fcb5eb25-0c65-4bf0-92be-b8583aadd1fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_24c60690-d68f-413f-a721-38e138d0f8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_24c60690-d68f-413f-a721-38e138d0f8b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e45d1872-bb1c-4443-b118-7d3cef2a38f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e45d1872-bb1c-4443-b118-7d3cef2a38f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1a31f103-a0c1-46a6-a428-a9c664b24977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1a31f103-a0c1-46a6-a428-a9c664b24977" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_19133e3f-aff2-4125-a612-127ec3c412d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_19133e3f-aff2-4125-a612-127ec3c412d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d10ff3a2-77d3-4257-8430-a17afbf0c883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d10ff3a2-77d3-4257-8430-a17afbf0c883" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3553c953-92a8-46fb-a494-d2e969bc2bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d10ff3a2-77d3-4257-8430-a17afbf0c883" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3553c953-92a8-46fb-a494-d2e969bc2bd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3553c953-92a8-46fb-a494-d2e969bc2bd6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3553c953-92a8-46fb-a494-d2e969bc2bd6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3553c953-92a8-46fb-a494-d2e969bc2bd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_915ed944-cb75-4334-bffc-863463c8fcbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3553c953-92a8-46fb-a494-d2e969bc2bd6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_915ed944-cb75-4334-bffc-863463c8fcbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a869eccd-62c6-4658-a0c7-b17a20133a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_915ed944-cb75-4334-bffc-863463c8fcbf" xlink:to="loc_us-gaap_ProductMember_a869eccd-62c6-4658-a0c7-b17a20133a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_4bd6b962-d0df-434b-8922-119341fd54bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_915ed944-cb75-4334-bffc-863463c8fcbf" xlink:to="loc_us-gaap_CustomerRelationshipsMember_4bd6b962-d0df-434b-8922-119341fd54bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_6123d1e8-f90b-493e-abd9-3d974146a836" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_915ed944-cb75-4334-bffc-863463c8fcbf" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_6123d1e8-f90b-493e-abd9-3d974146a836" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_40db4562-35a5-439c-9ce7-dfd03db4a2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d10ff3a2-77d3-4257-8430-a17afbf0c883" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_40db4562-35a5-439c-9ce7-dfd03db4a2dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_40db4562-35a5-439c-9ce7-dfd03db4a2dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_40db4562-35a5-439c-9ce7-dfd03db4a2dc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_40db4562-35a5-439c-9ce7-dfd03db4a2dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_91e1929a-e447-49cb-9a33-e1e24b7055a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_40db4562-35a5-439c-9ce7-dfd03db4a2dc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_91e1929a-e447-49cb-9a33-e1e24b7055a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33fa1e26-c55e-4fbc-bcd4-30df2c9b13d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_91e1929a-e447-49cb-9a33-e1e24b7055a5" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33fa1e26-c55e-4fbc-bcd4-30df2c9b13d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2de08901-8fe2-4f3a-9a63-f06946bffc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d10ff3a2-77d3-4257-8430-a17afbf0c883" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2de08901-8fe2-4f3a-9a63-f06946bffc49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2de08901-8fe2-4f3a-9a63-f06946bffc49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2de08901-8fe2-4f3a-9a63-f06946bffc49" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2de08901-8fe2-4f3a-9a63-f06946bffc49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0670c640-a672-44cf-af92-85a7f983f11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2de08901-8fe2-4f3a-9a63-f06946bffc49" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0670c640-a672-44cf-af92-85a7f983f11f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_5fb75cab-786f-45d7-ab37-55cc23678915" xlink:href="ebs-20230331.xsd#ebs_TravelHealthBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0670c640-a672-44cf-af92-85a7f983f11f" xlink:to="loc_ebs_TravelHealthBusinessMember_5fb75cab-786f-45d7-ab37-55cc23678915" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#IntangibleassetsandgoodwillGoodwillRollForwardDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails" xlink:type="extended" id="idd67857e6c2845f58efb599715dc26de_IntangibleassetsandgoodwillGoodwillRollForwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_aa22f942-365f-40fa-af4f-211eada00c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_5d300c99-2f86-4718-abc7-0d802b542a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_aa22f942-365f-40fa-af4f-211eada00c5c" xlink:to="loc_us-gaap_GoodwillRollForward_5d300c99-2f86-4718-abc7-0d802b542a0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9d3e8889-6977-451f-9bfd-ecf7ecf3c908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5d300c99-2f86-4718-abc7-0d802b542a0d" xlink:to="loc_us-gaap_Goodwill_9d3e8889-6977-451f-9bfd-ecf7ecf3c908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_49561a61-1558-40ff-93a5-49d5aef9dc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_aa22f942-365f-40fa-af4f-211eada00c5c" xlink:to="loc_us-gaap_GoodwillGross_49561a61-1558-40ff-93a5-49d5aef9dc12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c4532154-80e8-458d-9b13-49f9f65fdd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_aa22f942-365f-40fa-af4f-211eada00c5c" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c4532154-80e8-458d-9b13-49f9f65fdd5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_8b155331-9e28-4b4c-8b98-d004661d007c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_aa22f942-365f-40fa-af4f-211eada00c5c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_8b155331-9e28-4b4c-8b98-d004661d007c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ed6133e9-a83d-4c50-ae36-bf76bec4f508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8b155331-9e28-4b4c-8b98-d004661d007c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ed6133e9-a83d-4c50-ae36-bf76bec4f508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ed6133e9-a83d-4c50-ae36-bf76bec4f508_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ed6133e9-a83d-4c50-ae36-bf76bec4f508" xlink:to="loc_us-gaap_SegmentDomain_ed6133e9-a83d-4c50-ae36-bf76bec4f508_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_70584296-9b25-4c59-a215-4d37fa674c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ed6133e9-a83d-4c50-ae36-bf76bec4f508" xlink:to="loc_us-gaap_SegmentDomain_70584296-9b25-4c59-a215-4d37fa674c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_78c59cff-0c39-43aa-9319-9bc23cfa690b" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_70584296-9b25-4c59-a215-4d37fa674c98" xlink:to="loc_ebs_ProductsSegmentMember_78c59cff-0c39-43aa-9319-9bc23cfa690b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_d3ea5ee7-c3e4-4776-8e26-7afaa823d06b" xlink:href="ebs-20230331.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_70584296-9b25-4c59-a215-4d37fa674c98" xlink:to="loc_ebs_ServicesSegmentMember_d3ea5ee7-c3e4-4776-8e26-7afaa823d06b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended" id="id153becd910346c28fc528ae8211136c_FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9449732d-73cf-4a04-b0bd-7d5be1fab29b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9449732d-73cf-4a04-b0bd-7d5be1fab29b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_405a0053-912c-4c23-803f-d0bc7f6c0e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:to="loc_us-gaap_DerivativeAssets_405a0053-912c-4c23-803f-d0bc7f6c0e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b2c1b0a2-3306-479b-a34c-9f4c34b564b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b2c1b0a2-3306-479b-a34c-9f4c34b564b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2c91f1fc-9518-4db8-ac4b-524299fdb800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2c91f1fc-9518-4db8-ac4b-524299fdb800" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_45cf2ee2-4703-4994-b7e2-f654fcf03213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_45cf2ee2-4703-4994-b7e2-f654fcf03213" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1adef9e1-4c63-4cd4-8553-ce168ba0b586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1adef9e1-4c63-4cd4-8553-ce168ba0b586" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_35a56d8a-3161-4930-9a06-d587e9d764d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1adef9e1-4c63-4cd4-8553-ce168ba0b586" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_35a56d8a-3161-4930-9a06-d587e9d764d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35a56d8a-3161-4930-9a06-d587e9d764d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_35a56d8a-3161-4930-9a06-d587e9d764d2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35a56d8a-3161-4930-9a06-d587e9d764d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_534409e3-3607-457a-8b90-d55b91e5a1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_35a56d8a-3161-4930-9a06-d587e9d764d2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_534409e3-3607-457a-8b90-d55b91e5a1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c0c4ca5b-f9c3-4a19-9a17-06e9d799a627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_534409e3-3607-457a-8b90-d55b91e5a1fd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c0c4ca5b-f9c3-4a19-9a17-06e9d799a627" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_125afed6-53f0-4478-ad50-4247a92d9b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_534409e3-3607-457a-8b90-d55b91e5a1fd" xlink:to="loc_us-gaap_BankTimeDepositsMember_125afed6-53f0-4478-ad50-4247a92d9b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0bbfb60-cefb-4e6d-8d1b-ff0f33930b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1adef9e1-4c63-4cd4-8553-ce168ba0b586" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0bbfb60-cefb-4e6d-8d1b-ff0f33930b24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0bbfb60-cefb-4e6d-8d1b-ff0f33930b24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0bbfb60-cefb-4e6d-8d1b-ff0f33930b24" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b0bbfb60-cefb-4e6d-8d1b-ff0f33930b24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b2d4b67-149c-4f85-b402-5a0fd0f8f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0bbfb60-cefb-4e6d-8d1b-ff0f33930b24" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b2d4b67-149c-4f85-b402-5a0fd0f8f0c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a5a3177f-69b9-4b54-b68c-e844a596777c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b2d4b67-149c-4f85-b402-5a0fd0f8f0c7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a5a3177f-69b9-4b54-b68c-e844a596777c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_82f44020-5f68-4a50-b60e-9efff7c18ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b2d4b67-149c-4f85-b402-5a0fd0f8f0c7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_82f44020-5f68-4a50-b60e-9efff7c18ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f4ca6481-b253-4536-9ac1-2dd2f8201698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b2d4b67-149c-4f85-b402-5a0fd0f8f0c7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f4ca6481-b253-4536-9ac1-2dd2f8201698" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#FairvaluemeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="extended" id="if80021db88ee469285f351e2da0ef3ac_FairvaluemeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_14c39d8b-ecef-464d-bc18-41ed797832d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2f556733-4735-4c49-9e5e-b537511038b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14c39d8b-ecef-464d-bc18-41ed797832d6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2f556733-4735-4c49-9e5e-b537511038b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1c79bb5-afd4-41f4-a075-dee4d17af5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14c39d8b-ecef-464d-bc18-41ed797832d6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1c79bb5-afd4-41f4-a075-dee4d17af5fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_d499b494-99b7-40bc-84cb-3b1cda67f267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14c39d8b-ecef-464d-bc18-41ed797832d6" xlink:to="loc_us-gaap_LongTermDebtFairValue_d499b494-99b7-40bc-84cb-3b1cda67f267" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d47988d0-2334-408c-871a-3355173f0cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14c39d8b-ecef-464d-bc18-41ed797832d6" xlink:to="loc_us-gaap_DebtInstrumentTable_d47988d0-2334-408c-871a-3355173f0cd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e9d560ce-4160-488b-94a1-753a3a54b73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d47988d0-2334-408c-871a-3355173f0cd1" xlink:to="loc_us-gaap_DebtInstrumentAxis_e9d560ce-4160-488b-94a1-753a3a54b73f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9d560ce-4160-488b-94a1-753a3a54b73f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9d560ce-4160-488b-94a1-753a3a54b73f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9d560ce-4160-488b-94a1-753a3a54b73f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9be679f4-bfec-48af-a5a0-c66045d6133c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9d560ce-4160-488b-94a1-753a3a54b73f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9be679f4-bfec-48af-a5a0-c66045d6133c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_1a6da9d0-965a-420a-a503-91543ec80c92" xlink:href="ebs-20230331.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9be679f4-bfec-48af-a5a0-c66045d6133c" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_1a6da9d0-965a-420a-a503-91543ec80c92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_358955cf-106d-4e58-b96b-0ac459719590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d47988d0-2334-408c-871a-3355173f0cd1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_358955cf-106d-4e58-b96b-0ac459719590" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_358955cf-106d-4e58-b96b-0ac459719590_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_358955cf-106d-4e58-b96b-0ac459719590" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_358955cf-106d-4e58-b96b-0ac459719590_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f747680a-51b0-4bba-99ca-a7221ac97bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_358955cf-106d-4e58-b96b-0ac459719590" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f747680a-51b0-4bba-99ca-a7221ac97bf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_dfcb8f72-c7c1-47bf-9cf7-08422a116c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f747680a-51b0-4bba-99ca-a7221ac97bf5" xlink:to="loc_us-gaap_SeniorNotesMember_dfcb8f72-c7c1-47bf-9cf7-08422a116c41" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="extended" id="i25af732f458c4b6da0c796900cbbb895_FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d187419b-766d-4e9d-8d9b-d5a32281faf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b005e796-7142-4691-a2a1-1025f1112ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d187419b-766d-4e9d-8d9b-d5a32281faf6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b005e796-7142-4691-a2a1-1025f1112ac0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_78ebb423-e237-4f9c-9243-ac3a17288dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d187419b-766d-4e9d-8d9b-d5a32281faf6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_78ebb423-e237-4f9c-9243-ac3a17288dde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d187419b-766d-4e9d-8d9b-d5a32281faf6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_20955c40-57da-400b-b1a7-d33f3c4fb811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:to="loc_us-gaap_ValuationTechniqueAxis_20955c40-57da-400b-b1a7-d33f3c4fb811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_20955c40-57da-400b-b1a7-d33f3c4fb811_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_20955c40-57da-400b-b1a7-d33f3c4fb811" xlink:to="loc_us-gaap_ValuationTechniqueDomain_20955c40-57da-400b-b1a7-d33f3c4fb811_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_07c701bb-7b3e-4f05-920b-63e4aa39b845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_20955c40-57da-400b-b1a7-d33f3c4fb811" xlink:to="loc_us-gaap_ValuationTechniqueDomain_07c701bb-7b3e-4f05-920b-63e4aa39b845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_d1814a15-63fd-46e3-b983-da4eb551d678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_07c701bb-7b3e-4f05-920b-63e4aa39b845" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_d1814a15-63fd-46e3-b983-da4eb551d678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_396ce5bd-7bc6-41d8-b50f-53551cb35ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_396ce5bd-7bc6-41d8-b50f-53551cb35ea6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_396ce5bd-7bc6-41d8-b50f-53551cb35ea6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_396ce5bd-7bc6-41d8-b50f-53551cb35ea6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_396ce5bd-7bc6-41d8-b50f-53551cb35ea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6e8ef06-0f61-4f65-8e95-87af146da258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_396ce5bd-7bc6-41d8-b50f-53551cb35ea6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6e8ef06-0f61-4f65-8e95-87af146da258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_899ae8a2-cf72-42c3-93c7-bfb9e81ae4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6e8ef06-0f61-4f65-8e95-87af146da258" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_899ae8a2-cf72-42c3-93c7-bfb9e81ae4e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb911cf0-cbdb-48df-bf67-7cc26ba8d6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb911cf0-cbdb-48df-bf67-7cc26ba8d6e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb911cf0-cbdb-48df-bf67-7cc26ba8d6e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb911cf0-cbdb-48df-bf67-7cc26ba8d6e4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb911cf0-cbdb-48df-bf67-7cc26ba8d6e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1762fa10-a13b-4445-8a73-29c4caaa111e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb911cf0-cbdb-48df-bf67-7cc26ba8d6e4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1762fa10-a13b-4445-8a73-29c4caaa111e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6b554c9f-e0de-4c36-9960-3da360e64333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1762fa10-a13b-4445-8a73-29c4caaa111e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6b554c9f-e0de-4c36-9960-3da360e64333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e9ffec7c-10e8-4b45-b1f2-083225ae42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e9ffec7c-10e8-4b45-b1f2-083225ae42ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e9ffec7c-10e8-4b45-b1f2-083225ae42ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e9ffec7c-10e8-4b45-b1f2-083225ae42ae" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e9ffec7c-10e8-4b45-b1f2-083225ae42ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_94fe4f7c-c95f-42b8-8d16-027ce34f1a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e9ffec7c-10e8-4b45-b1f2-083225ae42ae" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_94fe4f7c-c95f-42b8-8d16-027ce34f1a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cca33928-fb7f-4c94-bfc8-fd38c8fa442d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_94fe4f7c-c95f-42b8-8d16-027ce34f1a89" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cca33928-fb7f-4c94-bfc8-fd38c8fa442d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityOfPaymentMember_f31b72f1-d06e-443b-8958-17d853e2ed0f" xlink:href="ebs-20230331.xsd#ebs_MeasurementInputProbabilityOfPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_94fe4f7c-c95f-42b8-8d16-027ce34f1a89" xlink:to="loc_ebs_MeasurementInputProbabilityOfPaymentMember_f31b72f1-d06e-443b-8958-17d853e2ed0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cf89c059-2f1e-48cf-aa46-ba5d5be4a2da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:to="loc_srt_RangeAxis_cf89c059-2f1e-48cf-aa46-ba5d5be4a2da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cf89c059-2f1e-48cf-aa46-ba5d5be4a2da_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cf89c059-2f1e-48cf-aa46-ba5d5be4a2da" xlink:to="loc_srt_RangeMember_cf89c059-2f1e-48cf-aa46-ba5d5be4a2da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08d295af-e55f-476e-91dc-8717a5db006b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cf89c059-2f1e-48cf-aa46-ba5d5be4a2da" xlink:to="loc_srt_RangeMember_08d295af-e55f-476e-91dc-8717a5db006b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f99abb48-9e9c-4c67-9d7d-fe8e17c1fac8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_08d295af-e55f-476e-91dc-8717a5db006b" xlink:to="loc_srt_MinimumMember_f99abb48-9e9c-4c67-9d7d-fe8e17c1fac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_adaf839b-90f9-4003-96ea-a2c877f3bba8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_08d295af-e55f-476e-91dc-8717a5db006b" xlink:to="loc_srt_MaximumMember_adaf839b-90f9-4003-96ea-a2c877f3bba8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="extended" id="i9a47dab0b38a433eb64b1d348326f89a_DerivativeinstrumentsandhedgingactivitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_943a429e-5bbc-425e-b288-4cf9bc0e4912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_94129525-f48d-4996-9b22-edebe73eb3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_943a429e-5bbc-425e-b288-4cf9bc0e4912" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_94129525-f48d-4996-9b22-edebe73eb3e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d817cc05-5c23-425f-aac2-d8bf86b0a525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_943a429e-5bbc-425e-b288-4cf9bc0e4912" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d817cc05-5c23-425f-aac2-d8bf86b0a525" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c10bc006-0ce2-4ccc-8db6-02fc0adb7969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d817cc05-5c23-425f-aac2-d8bf86b0a525" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c10bc006-0ce2-4ccc-8db6-02fc0adb7969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c10bc006-0ce2-4ccc-8db6-02fc0adb7969_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c10bc006-0ce2-4ccc-8db6-02fc0adb7969" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c10bc006-0ce2-4ccc-8db6-02fc0adb7969_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3f17d132-9554-4fef-80d5-678184104c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c10bc006-0ce2-4ccc-8db6-02fc0adb7969" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3f17d132-9554-4fef-80d5-678184104c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_15078101-0db9-4551-8444-94005310fc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3f17d132-9554-4fef-80d5-678184104c1c" xlink:to="loc_us-gaap_InterestRateSwapMember_15078101-0db9-4551-8444-94005310fc00" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="extended" id="iec590c5192004451bf35c3fa8d880f37_DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_dc1d7b4e-0711-4dd9-95a3-6c914fee1387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6d0c7e39-4d5d-4dbb-90a4-9d90643d938f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_dc1d7b4e-0711-4dd9-95a3-6c914fee1387" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6d0c7e39-4d5d-4dbb-90a4-9d90643d938f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_95b685fe-55cc-4606-8f86-276541463315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_dc1d7b4e-0711-4dd9-95a3-6c914fee1387" xlink:to="loc_us-gaap_DerivativeNotionalAmount_95b685fe-55cc-4606-8f86-276541463315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_490c8749-344b-42b5-937b-2758f2813c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_dc1d7b4e-0711-4dd9-95a3-6c914fee1387" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_490c8749-344b-42b5-937b-2758f2813c0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_325ddbbc-82ba-4035-a436-00fa33a96da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_490c8749-344b-42b5-937b-2758f2813c0e" xlink:to="loc_us-gaap_HedgingDesignationAxis_325ddbbc-82ba-4035-a436-00fa33a96da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_325ddbbc-82ba-4035-a436-00fa33a96da4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_325ddbbc-82ba-4035-a436-00fa33a96da4" xlink:to="loc_us-gaap_HedgingDesignationDomain_325ddbbc-82ba-4035-a436-00fa33a96da4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_49399abb-1d50-4cbd-a942-a6e1a402f102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_325ddbbc-82ba-4035-a436-00fa33a96da4" xlink:to="loc_us-gaap_HedgingDesignationDomain_49399abb-1d50-4cbd-a942-a6e1a402f102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6facd443-c9a8-410c-99e0-75fbb87d94c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_49399abb-1d50-4cbd-a942-a6e1a402f102" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6facd443-c9a8-410c-99e0-75fbb87d94c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_820c16d5-9240-482c-ba50-895de94bb342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_490c8749-344b-42b5-937b-2758f2813c0e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_820c16d5-9240-482c-ba50-895de94bb342" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_820c16d5-9240-482c-ba50-895de94bb342_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_820c16d5-9240-482c-ba50-895de94bb342" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_820c16d5-9240-482c-ba50-895de94bb342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_253ef945-8089-45f7-b38e-af0878dd162d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_820c16d5-9240-482c-ba50-895de94bb342" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_253ef945-8089-45f7-b38e-af0878dd162d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_99dda1cd-efa7-4a56-a45f-45d631837959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_253ef945-8089-45f7-b38e-af0878dd162d" xlink:to="loc_us-gaap_InterestRateSwapMember_99dda1cd-efa7-4a56-a45f-45d631837959" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="extended" id="ie6c5dd338b7e43bea6719ad9b15ece50_DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ddb2df5b-507e-4ba0-aaa9-846ca8aac7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_e5c6bd7e-caa7-45f5-8e61-dbd91e218a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ddb2df5b-507e-4ba0-aaa9-846ca8aac7e2" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_e5c6bd7e-caa7-45f5-8e61-dbd91e218a4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_965deb82-6451-49d6-9580-18fde8ddf3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ddb2df5b-507e-4ba0-aaa9-846ca8aac7e2" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_965deb82-6451-49d6-9580-18fde8ddf3f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b2522bf6-eb06-4b33-b7a2-6c68c5efe95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_965deb82-6451-49d6-9580-18fde8ddf3f3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b2522bf6-eb06-4b33-b7a2-6c68c5efe95a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b2522bf6-eb06-4b33-b7a2-6c68c5efe95a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b2522bf6-eb06-4b33-b7a2-6c68c5efe95a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b2522bf6-eb06-4b33-b7a2-6c68c5efe95a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_780c5f3e-385b-4256-9305-0fa84a33e12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b2522bf6-eb06-4b33-b7a2-6c68c5efe95a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_780c5f3e-385b-4256-9305-0fa84a33e12c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_a7a2f100-99ed-4de6-afc6-bcc79182bb26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_780c5f3e-385b-4256-9305-0fa84a33e12c" xlink:to="loc_us-gaap_InterestRateSwapMember_a7a2f100-99ed-4de6-afc6-bcc79182bb26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0131b461-1938-48a2-b2b6-08bca2ee3539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_965deb82-6451-49d6-9580-18fde8ddf3f3" xlink:to="loc_us-gaap_HedgingDesignationAxis_0131b461-1938-48a2-b2b6-08bca2ee3539" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0131b461-1938-48a2-b2b6-08bca2ee3539_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_0131b461-1938-48a2-b2b6-08bca2ee3539" xlink:to="loc_us-gaap_HedgingDesignationDomain_0131b461-1938-48a2-b2b6-08bca2ee3539_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6dd67639-43e1-4634-8912-0f6d2a734ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_0131b461-1938-48a2-b2b6-08bca2ee3539" xlink:to="loc_us-gaap_HedgingDesignationDomain_6dd67639-43e1-4634-8912-0f6d2a734ef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_28876d33-7af9-4654-b2e6-66bcc9832c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_6dd67639-43e1-4634-8912-0f6d2a734ef8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_28876d33-7af9-4654-b2e6-66bcc9832c11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_dd45794a-71df-4001-aae5-360a8a78d1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_965deb82-6451-49d6-9580-18fde8ddf3f3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_dd45794a-71df-4001-aae5-360a8a78d1ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_dd45794a-71df-4001-aae5-360a8a78d1ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dd45794a-71df-4001-aae5-360a8a78d1ee" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_dd45794a-71df-4001-aae5-360a8a78d1ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cf156dba-7d39-41cd-98ea-cecde893b366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dd45794a-71df-4001-aae5-360a8a78d1ee" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cf156dba-7d39-41cd-98ea-cecde893b366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_d0433b7b-662e-4114-9dd8-4269b069f3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf156dba-7d39-41cd-98ea-cecde893b366" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_d0433b7b-662e-4114-9dd8-4269b069f3b9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="extended" id="i37d3485b990748ecbb60c4cf22195563_DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_cc621163-74a8-4436-9295-510641a79d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_6986173f-7cc1-4366-bb3a-b295d55eb7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_cc621163-74a8-4436-9295-510641a79d13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_6986173f-7cc1-4366-bb3a-b295d55eb7e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_2e258293-7518-4aa2-91df-6278f60b6f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_cc621163-74a8-4436-9295-510641a79d13" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_2e258293-7518-4aa2-91df-6278f60b6f00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_fe8e5852-5c7b-4891-8d2a-583df3918048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_2e258293-7518-4aa2-91df-6278f60b6f00" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_fe8e5852-5c7b-4891-8d2a-583df3918048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_fe8e5852-5c7b-4891-8d2a-583df3918048_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_fe8e5852-5c7b-4891-8d2a-583df3918048" xlink:to="loc_us-gaap_HedgingRelationshipDomain_fe8e5852-5c7b-4891-8d2a-583df3918048_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ed7f5bc6-a8cf-4c6c-a75e-af874a23ff58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_fe8e5852-5c7b-4891-8d2a-583df3918048" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ed7f5bc6-a8cf-4c6c-a75e-af874a23ff58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9107546c-f741-4178-afac-907ba34a7f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ed7f5bc6-a8cf-4c6c-a75e-af874a23ff58" xlink:to="loc_us-gaap_CashFlowHedgingMember_9107546c-f741-4178-afac-907ba34a7f6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4705ef77-529e-4753-9a7e-a9b1c5b06df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_2e258293-7518-4aa2-91df-6278f60b6f00" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4705ef77-529e-4753-9a7e-a9b1c5b06df0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4705ef77-529e-4753-9a7e-a9b1c5b06df0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4705ef77-529e-4753-9a7e-a9b1c5b06df0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4705ef77-529e-4753-9a7e-a9b1c5b06df0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6eacee1d-01ec-4076-931f-bd86bfdc3e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4705ef77-529e-4753-9a7e-a9b1c5b06df0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6eacee1d-01ec-4076-931f-bd86bfdc3e9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_c7bf3e7c-89c7-4a31-ad6e-1f849cb8b86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6eacee1d-01ec-4076-931f-bd86bfdc3e9d" xlink:to="loc_us-gaap_InterestExpenseMember_c7bf3e7c-89c7-4a31-ad6e-1f849cb8b86a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3cc2b3a2-d17f-46b1-b639-ceac47582422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_2e258293-7518-4aa2-91df-6278f60b6f00" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3cc2b3a2-d17f-46b1-b639-ceac47582422" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3cc2b3a2-d17f-46b1-b639-ceac47582422_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3cc2b3a2-d17f-46b1-b639-ceac47582422" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3cc2b3a2-d17f-46b1-b639-ceac47582422_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c3a60435-dd61-4302-86a2-bbd0599955b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3cc2b3a2-d17f-46b1-b639-ceac47582422" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c3a60435-dd61-4302-86a2-bbd0599955b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_984990b3-23d5-4fad-9d5b-072af95e5898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c3a60435-dd61-4302-86a2-bbd0599955b5" xlink:to="loc_us-gaap_InterestRateSwapMember_984990b3-23d5-4fad-9d5b-072af95e5898" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DebtScheduleDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended" id="i2e6175ff001149db832b4a308ed219ec_DebtScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a147750c-d67e-4f24-8d7a-adfcf2f139d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a147750c-d67e-4f24-8d7a-adfcf2f139d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_74e17f51-b2ab-4461-b560-622a304ce442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:to="loc_us-gaap_LongTermDebt_74e17f51-b2ab-4461-b560-622a304ce442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_d8ab6e8f-faa8-4140-9664-6bcc9d9e2e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_d8ab6e8f-faa8-4140-9664-6bcc9d9e2e33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b87463f2-71c1-48c7-b4bc-e399b91d0b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:to="loc_us-gaap_LongTermDebtCurrent_b87463f2-71c1-48c7-b4bc-e399b91d0b87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_91a4385d-d6fe-4314-8873-3e05a411026d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_91a4385d-d6fe-4314-8873-3e05a411026d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1307cbe0-11bd-4210-a4fc-a7bd279b1b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:to="loc_us-gaap_DebtInstrumentTable_1307cbe0-11bd-4210-a4fc-a7bd279b1b72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4617e4e5-6105-4f95-ba16-beaeb28b5e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1307cbe0-11bd-4210-a4fc-a7bd279b1b72" xlink:to="loc_us-gaap_DebtInstrumentAxis_4617e4e5-6105-4f95-ba16-beaeb28b5e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4617e4e5-6105-4f95-ba16-beaeb28b5e58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4617e4e5-6105-4f95-ba16-beaeb28b5e58" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4617e4e5-6105-4f95-ba16-beaeb28b5e58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_62df5273-d2b1-4d6a-8ced-2453f80a28c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4617e4e5-6105-4f95-ba16-beaeb28b5e58" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_62df5273-d2b1-4d6a-8ced-2453f80a28c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_592cc8c1-4753-438e-a9f9-4bb500da803c" xlink:href="ebs-20230331.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62df5273-d2b1-4d6a-8ced-2453f80a28c1" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_592cc8c1-4753-438e-a9f9-4bb500da803c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_02f5c5fc-7fd2-4c6c-bb0a-7f5d48427f17" xlink:href="ebs-20230331.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62df5273-d2b1-4d6a-8ced-2453f80a28c1" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_02f5c5fc-7fd2-4c6c-bb0a-7f5d48427f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8032107c-3cb0-40a9-a5e3-db0b4324e040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1307cbe0-11bd-4210-a4fc-a7bd279b1b72" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8032107c-3cb0-40a9-a5e3-db0b4324e040" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8032107c-3cb0-40a9-a5e3-db0b4324e040_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8032107c-3cb0-40a9-a5e3-db0b4324e040" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8032107c-3cb0-40a9-a5e3-db0b4324e040_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2d2e7aed-e71c-40eb-936a-b78a840c80e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8032107c-3cb0-40a9-a5e3-db0b4324e040" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2d2e7aed-e71c-40eb-936a-b78a840c80e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_711d387f-771d-45da-be46-8637428f8217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d2e7aed-e71c-40eb-936a-b78a840c80e8" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_711d387f-771d-45da-be46-8637428f8217" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_dc3a1744-6fe8-43e1-9867-7bb947dee9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d2e7aed-e71c-40eb-936a-b78a840c80e8" xlink:to="loc_us-gaap_LineOfCreditMember_dc3a1744-6fe8-43e1-9867-7bb947dee9be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_6b855e34-e749-45aa-a3be-328e20e98c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d2e7aed-e71c-40eb-936a-b78a840c80e8" xlink:to="loc_us-gaap_SeniorNotesMember_6b855e34-e749-45aa-a3be-328e20e98c8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_315607c2-9dc5-4d69-8d54-272977cf4973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1307cbe0-11bd-4210-a4fc-a7bd279b1b72" xlink:to="loc_us-gaap_CreditFacilityAxis_315607c2-9dc5-4d69-8d54-272977cf4973" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_315607c2-9dc5-4d69-8d54-272977cf4973_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_315607c2-9dc5-4d69-8d54-272977cf4973" xlink:to="loc_us-gaap_CreditFacilityDomain_315607c2-9dc5-4d69-8d54-272977cf4973_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ef25da80-3a29-4f3e-9dd2-3847b256a7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_315607c2-9dc5-4d69-8d54-272977cf4973" xlink:to="loc_us-gaap_CreditFacilityDomain_ef25da80-3a29-4f3e-9dd2-3847b256a7ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_b83e21ea-ae26-41fb-a184-2c9625066378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ef25da80-3a29-4f3e-9dd2-3847b256a7ed" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_b83e21ea-ae26-41fb-a184-2c9625066378" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended" id="i2934ad648a36427aab36a0ac18614684_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_41977bc0-171f-4f43-ac07-39c5ce28f115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_41977bc0-171f-4f43-ac07-39c5ce28f115" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_409bae67-7f1c-4c61-8f17-21d41d4387f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_409bae67-7f1c-4c61-8f17-21d41d4387f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5cc63b55-564e-418f-9e2c-a5efc2e50be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_LongTermDebt_5cc63b55-564e-418f-9e2c-a5efc2e50be4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_73a06dfe-16b5-4487-9bbb-045e7cff3938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_73a06dfe-16b5-4487-9bbb-045e7cff3938" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_ad9c4f69-39b1-49b8-a23d-285b67db5e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_ad9c4f69-39b1-49b8-a23d-285b67db5e28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_394a21e3-0e16-43fa-a9ea-4891dec322cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_394a21e3-0e16-43fa-a9ea-4891dec322cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7448da32-b998-4ae8-8a89-5a52c42dc2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7448da32-b998-4ae8-8a89-5a52c42dc2a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_4c67ceca-e121-4c70-b239-a2a03f7301e0" xlink:href="ebs-20230331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_4c67ceca-e121-4c70-b239-a2a03f7301e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_10113d33-95e9-4d90-a0e7-1b3ae5a518bd" xlink:href="ebs-20230331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_10113d33-95e9-4d90-a0e7-1b3ae5a518bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_98fb54d0-4206-4c26-906c-482c9fdd7b08" xlink:href="ebs-20230331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_98fb54d0-4206-4c26-906c-482c9fdd7b08" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_8d8e6365-ee56-4fec-b8d7-522e1df35e63" xlink:href="ebs-20230331.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_8d8e6365-ee56-4fec-b8d7-522e1df35e63" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_14c45e03-8727-44ff-a0e8-31f45196a624" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_14c45e03-8727-44ff-a0e8-31f45196a624" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_3a372c5e-07fa-4a55-8ffa-606592570484" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_3a372c5e-07fa-4a55-8ffa-606592570484" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_6c99f5ad-80ae-47d7-b109-fdec18bd68bc" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_6c99f5ad-80ae-47d7-b109-fdec18bd68bc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_e0b7fe25-32d6-4239-a260-9923c85f6e32" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_e0b7fe25-32d6-4239-a260-9923c85f6e32" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_7e7ede33-5075-45a3-9231-ebb10abdf60c" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_7e7ede33-5075-45a3-9231-ebb10abdf60c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_400e7e44-66cd-44a1-8356-8b2a2910ff28" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_400e7e44-66cd-44a1-8356-8b2a2910ff28" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a5ca98ea-f486-4077-93db-9e4da01243f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_us-gaap_CreditFacilityAxis_a5ca98ea-f486-4077-93db-9e4da01243f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a5ca98ea-f486-4077-93db-9e4da01243f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_a5ca98ea-f486-4077-93db-9e4da01243f6" xlink:to="loc_us-gaap_CreditFacilityDomain_a5ca98ea-f486-4077-93db-9e4da01243f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d133a9e0-baff-4cb8-9b28-0eb971774734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_a5ca98ea-f486-4077-93db-9e4da01243f6" xlink:to="loc_us-gaap_CreditFacilityDomain_d133a9e0-baff-4cb8-9b28-0eb971774734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_636773ef-e19e-4dd9-8246-1669fbeca997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d133a9e0-baff-4cb8-9b28-0eb971774734" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_636773ef-e19e-4dd9-8246-1669fbeca997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember_cd76bd54-e8e7-4e32-94c8-e25b4f600ad7" xlink:href="ebs-20230331.xsd#ebs_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d133a9e0-baff-4cb8-9b28-0eb971774734" xlink:to="loc_ebs_TermLoanFacilityMember_cd76bd54-e8e7-4e32-94c8-e25b4f600ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_939291ab-71f7-40f9-864c-a36cadf54b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_us-gaap_DebtInstrumentAxis_939291ab-71f7-40f9-864c-a36cadf54b45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_939291ab-71f7-40f9-864c-a36cadf54b45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_939291ab-71f7-40f9-864c-a36cadf54b45" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_939291ab-71f7-40f9-864c-a36cadf54b45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a0c51351-d569-4e5d-a88c-3900f30b4efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_939291ab-71f7-40f9-864c-a36cadf54b45" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a0c51351-d569-4e5d-a88c-3900f30b4efb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_32415a97-91db-4d13-8780-8b5a53bb4f50" xlink:href="ebs-20230331.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0c51351-d569-4e5d-a88c-3900f30b4efb" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_32415a97-91db-4d13-8780-8b5a53bb4f50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember_3b1c03bf-812a-4dec-8d70-6b5f4879b2cf" xlink:href="ebs-20230331.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0c51351-d569-4e5d-a88c-3900f30b4efb" xlink:to="loc_ebs_AmendedCreditAgreementMember_3b1c03bf-812a-4dec-8d70-6b5f4879b2cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_127e5b0b-e032-44f5-bdb6-159ed2c8dbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_us-gaap_VariableRateAxis_127e5b0b-e032-44f5-bdb6-159ed2c8dbf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_127e5b0b-e032-44f5-bdb6-159ed2c8dbf9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_127e5b0b-e032-44f5-bdb6-159ed2c8dbf9" xlink:to="loc_us-gaap_VariableRateDomain_127e5b0b-e032-44f5-bdb6-159ed2c8dbf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_098f5448-a0a6-4f53-83f1-1be09a3c6611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_127e5b0b-e032-44f5-bdb6-159ed2c8dbf9" xlink:to="loc_us-gaap_VariableRateDomain_098f5448-a0a6-4f53-83f1-1be09a3c6611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_b7cb1df4-9dff-458a-b231-27527fd27849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_098f5448-a0a6-4f53-83f1-1be09a3c6611" xlink:to="loc_us-gaap_EurodollarMember_b7cb1df4-9dff-458a-b231-27527fd27849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_1c877d16-df0b-4915-a0c7-070ac0abcfca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_098f5448-a0a6-4f53-83f1-1be09a3c6611" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_1c877d16-df0b-4915-a0c7-070ac0abcfca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_4f503282-dad1-4104-990f-b168c8ee3837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_098f5448-a0a6-4f53-83f1-1be09a3c6611" xlink:to="loc_us-gaap_BaseRateMember_4f503282-dad1-4104-990f-b168c8ee3837" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_52d962a4-6450-449a-bef3-3aaa6a9e5e1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_srt_RangeAxis_52d962a4-6450-449a-bef3-3aaa6a9e5e1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52d962a4-6450-449a-bef3-3aaa6a9e5e1f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_52d962a4-6450-449a-bef3-3aaa6a9e5e1f" xlink:to="loc_srt_RangeMember_52d962a4-6450-449a-bef3-3aaa6a9e5e1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c157b6b-0c8d-4bce-9fc3-877e5a69cffd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_52d962a4-6450-449a-bef3-3aaa6a9e5e1f" xlink:to="loc_srt_RangeMember_2c157b6b-0c8d-4bce-9fc3-877e5a69cffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f96291ca-014e-43af-a818-71fd79ffc65d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c157b6b-0c8d-4bce-9fc3-877e5a69cffd" xlink:to="loc_srt_MinimumMember_f96291ca-014e-43af-a818-71fd79ffc65d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_91338353-1b12-4041-9daa-69b5346bfac1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c157b6b-0c8d-4bce-9fc3-877e5a69cffd" xlink:to="loc_srt_MaximumMember_91338353-1b12-4041-9daa-69b5346bfac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6fd4b386-4e16-401c-901a-48e7217d1397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6fd4b386-4e16-401c-901a-48e7217d1397" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6fd4b386-4e16-401c-901a-48e7217d1397_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6fd4b386-4e16-401c-901a-48e7217d1397" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6fd4b386-4e16-401c-901a-48e7217d1397_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6e89478b-22bf-44cc-93f2-bd09f1424628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6fd4b386-4e16-401c-901a-48e7217d1397" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6e89478b-22bf-44cc-93f2-bd09f1424628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8cc22855-2b68-455d-abb6-5bd999fc165a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6e89478b-22bf-44cc-93f2-bd09f1424628" xlink:to="loc_us-gaap_SeniorNotesMember_8cc22855-2b68-455d-abb6-5bd999fc165a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b254fb47-6a3c-46f0-b17f-ad54e795fc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b254fb47-6a3c-46f0-b17f-ad54e795fc93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b254fb47-6a3c-46f0-b17f-ad54e795fc93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b254fb47-6a3c-46f0-b17f-ad54e795fc93" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b254fb47-6a3c-46f0-b17f-ad54e795fc93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dd45400f-0ed4-4796-a636-2f9c0c1d6699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b254fb47-6a3c-46f0-b17f-ad54e795fc93" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dd45400f-0ed4-4796-a636-2f9c0c1d6699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b101f83e-7d7a-422c-9dec-5865d9623314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dd45400f-0ed4-4796-a636-2f9c0c1d6699" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b101f83e-7d7a-422c-9dec-5865d9623314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_6ac68ed2-f9ba-47c1-8fad-81760a7e7e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dd45400f-0ed4-4796-a636-2f9c0c1d6699" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_6ac68ed2-f9ba-47c1-8fad-81760a7e7e62" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#StockbasedcompensationandstockholdersequityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails" xlink:type="extended" id="ie44725efe8434d8fa51250a4c8432964_StockbasedcompensationandstockholdersequityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f4c56d99-2f0d-4570-94fd-ba08a0aa6975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f4c56d99-2f0d-4570-94fd-ba08a0aa6975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e3256cce-64cb-44cb-bf93-f02d788adb46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e3256cce-64cb-44cb-bf93-f02d788adb46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_43a17033-c747-4bf6-b991-551468007e6a" xlink:href="ebs-20230331.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_43a17033-c747-4bf6-b991-551468007e6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6f0bc333-e2b5-4390-8082-b9644cea6a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6f0bc333-e2b5-4390-8082-b9644cea6a7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_53a7daa7-56bc-4fb6-b5b4-ccb7fb399756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_53a7daa7-56bc-4fb6-b5b4-ccb7fb399756" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0464162d-eec4-4d03-aee4-f9d1cbaeb483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0464162d-eec4-4d03-aee4-f9d1cbaeb483" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_8f2e6209-f798-4fba-b0d2-277917dca44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_8f2e6209-f798-4fba-b0d2-277917dca44e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6c92f8b4-d99b-412a-9a59-d70ace792164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6c92f8b4-d99b-412a-9a59-d70ace792164" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_dcd01264-b8db-49ad-816e-789576fdb4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_dcd01264-b8db-49ad-816e-789576fdb4ec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_78b26c5f-c847-4b0f-8e23-3ebe52e21e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_78b26c5f-c847-4b0f-8e23-3ebe52e21e08" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8719d3bb-3808-42bc-891f-a12893d5ec8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8719d3bb-3808-42bc-891f-a12893d5ec8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7a6ccc86-4ecd-4aca-84f4-b5958e3159d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8719d3bb-3808-42bc-891f-a12893d5ec8e" xlink:to="loc_us-gaap_VestingAxis_7a6ccc86-4ecd-4aca-84f4-b5958e3159d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7a6ccc86-4ecd-4aca-84f4-b5958e3159d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_7a6ccc86-4ecd-4aca-84f4-b5958e3159d0" xlink:to="loc_us-gaap_VestingDomain_7a6ccc86-4ecd-4aca-84f4-b5958e3159d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5f7f6c93-aab8-498c-bbff-37d453debb44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_7a6ccc86-4ecd-4aca-84f4-b5958e3159d0" xlink:to="loc_us-gaap_VestingDomain_5f7f6c93-aab8-498c-bbff-37d453debb44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f2dc610a-45de-454d-9681-249c23bc4af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5f7f6c93-aab8-498c-bbff-37d453debb44" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f2dc610a-45de-454d-9681-249c23bc4af4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c1a9eefc-b842-4a73-9504-114fd5be22d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5f7f6c93-aab8-498c-bbff-37d453debb44" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c1a9eefc-b842-4a73-9504-114fd5be22d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_b94d0456-f29a-4f8d-8571-157d14c5b19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5f7f6c93-aab8-498c-bbff-37d453debb44" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_b94d0456-f29a-4f8d-8571-157d14c5b19d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e26068f5-d980-4a10-8081-6d843e5a7661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8719d3bb-3808-42bc-891f-a12893d5ec8e" xlink:to="loc_us-gaap_AwardTypeAxis_e26068f5-d980-4a10-8081-6d843e5a7661" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e26068f5-d980-4a10-8081-6d843e5a7661_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e26068f5-d980-4a10-8081-6d843e5a7661" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e26068f5-d980-4a10-8081-6d843e5a7661_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af6c754e-c329-404c-8ddb-8232a77fb8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e26068f5-d980-4a10-8081-6d843e5a7661" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af6c754e-c329-404c-8ddb-8232a77fb8ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0a7b00b7-7463-4d83-b9cf-25dfbe3aa981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af6c754e-c329-404c-8ddb-8232a77fb8ad" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0a7b00b7-7463-4d83-b9cf-25dfbe3aa981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1c3ba098-8f6a-43d6-9477-dfad1b214223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af6c754e-c329-404c-8ddb-8232a77fb8ad" xlink:to="loc_us-gaap_PerformanceSharesMember_1c3ba098-8f6a-43d6-9477-dfad1b214223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6eaf038d-2406-4e54-a6e2-2f686f13162a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af6c754e-c329-404c-8ddb-8232a77fb8ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6eaf038d-2406-4e54-a6e2-2f686f13162a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4258b256-6152-492e-b762-fa826ef1ed05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8719d3bb-3808-42bc-891f-a12893d5ec8e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4258b256-6152-492e-b762-fa826ef1ed05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4258b256-6152-492e-b762-fa826ef1ed05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4258b256-6152-492e-b762-fa826ef1ed05" xlink:to="loc_us-gaap_EquityComponentDomain_4258b256-6152-492e-b762-fa826ef1ed05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc01b025-6d6c-4277-a4f5-a1d8e632d14a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4258b256-6152-492e-b762-fa826ef1ed05" xlink:to="loc_us-gaap_EquityComponentDomain_fc01b025-6d6c-4277-a4f5-a1d8e632d14a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_25c79539-d6e7-482b-93cb-4919bd1730f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fc01b025-6d6c-4277-a4f5-a1d8e632d14a" xlink:to="loc_us-gaap_TreasuryStockCommonMember_25c79539-d6e7-482b-93cb-4919bd1730f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i217abdab57324c69b453600c1f40493d_StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69a55fc6-a5e7-4c42-a2ea-8288b2b5d4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e4eefed-197e-456e-a8a7-304063e12eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69a55fc6-a5e7-4c42-a2ea-8288b2b5d4ad" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e4eefed-197e-456e-a8a7-304063e12eb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb2a4ca-4dc3-43ea-a373-d76395ee40ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69a55fc6-a5e7-4c42-a2ea-8288b2b5d4ad" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb2a4ca-4dc3-43ea-a373-d76395ee40ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0ba8bd41-ad3c-45b3-ab57-2ad790956d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb2a4ca-4dc3-43ea-a373-d76395ee40ea" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0ba8bd41-ad3c-45b3-ab57-2ad790956d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0ba8bd41-ad3c-45b3-ab57-2ad790956d1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0ba8bd41-ad3c-45b3-ab57-2ad790956d1e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0ba8bd41-ad3c-45b3-ab57-2ad790956d1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_38f5ed6a-52dd-4076-874c-13c89c202426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0ba8bd41-ad3c-45b3-ab57-2ad790956d1e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_38f5ed6a-52dd-4076-874c-13c89c202426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_15ddeac9-ff0a-4b0b-bd24-990e6367b75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_38f5ed6a-52dd-4076-874c-13c89c202426" xlink:to="loc_us-gaap_CostOfSalesMember_15ddeac9-ff0a-4b0b-bd24-990e6367b75b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b503b6a2-13bf-4cba-bb67-4860b91fc536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_38f5ed6a-52dd-4076-874c-13c89c202426" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b503b6a2-13bf-4cba-bb67-4860b91fc536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bc638a44-18b0-4eb3-a04c-342d9150bcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_38f5ed6a-52dd-4076-874c-13c89c202426" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bc638a44-18b0-4eb3-a04c-342d9150bcdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aed504b1-4bd7-4c31-a906-b768e33e57e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb2a4ca-4dc3-43ea-a373-d76395ee40ea" xlink:to="loc_srt_ProductOrServiceAxis_aed504b1-4bd7-4c31-a906-b768e33e57e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aed504b1-4bd7-4c31-a906-b768e33e57e2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_aed504b1-4bd7-4c31-a906-b768e33e57e2" xlink:to="loc_srt_ProductsAndServicesDomain_aed504b1-4bd7-4c31-a906-b768e33e57e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef1d9eb9-7c0e-4e3c-b165-ea7dd7fdcd70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_aed504b1-4bd7-4c31-a906-b768e33e57e2" xlink:to="loc_srt_ProductsAndServicesDomain_ef1d9eb9-7c0e-4e3c-b165-ea7dd7fdcd70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5a02f291-63cc-4ab5-a749-a98e6c307a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ef1d9eb9-7c0e-4e3c-b165-ea7dd7fdcd70" xlink:to="loc_us-gaap_ProductMember_5a02f291-63cc-4ab5-a749-a98e6c307a6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_7909ecd2-25b4-4d60-9eaa-3268de1cf69b" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ef1d9eb9-7c0e-4e3c-b165-ea7dd7fdcd70" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_7909ecd2-25b4-4d60-9eaa-3268de1cf69b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="id53d24e2d9b34e94aac8cc5bd1c4cbb9_StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c8dfa2b0-9805-4a77-ab98-7c4600a47d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c8dfa2b0-9805-4a77-ab98-7c4600a47d62" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4d15590a-1609-44c7-b9e0-723c36d14500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:to="loc_us-gaap_StockholdersEquity_4d15590a-1609-44c7-b9e0-723c36d14500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_8c924253-c9df-408c-9c8a-22acd9b3e4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_8c924253-c9df-408c-9c8a-22acd9b3e4e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_aaba27b5-c2b8-45dd-99cd-176163c8fb81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_aaba27b5-c2b8-45dd-99cd-176163c8fb81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3661a94-93e3-4f35-8197-a53c4b8f2ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3661a94-93e3-4f35-8197-a53c4b8f2ce2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1b6eba65-8dba-4af8-9f33-5149f814e0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_60d1c971-f698-4c4a-91d6-e93c51c1c1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c8dfa2b0-9805-4a77-ab98-7c4600a47d62" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_60d1c971-f698-4c4a-91d6-e93c51c1c1b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1338016d-ad98-4734-abb6-b740d360a93d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_60d1c971-f698-4c4a-91d6-e93c51c1c1b4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1338016d-ad98-4734-abb6-b740d360a93d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1338016d-ad98-4734-abb6-b740d360a93d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1338016d-ad98-4734-abb6-b740d360a93d" xlink:to="loc_us-gaap_EquityComponentDomain_1338016d-ad98-4734-abb6-b740d360a93d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6e0267f7-d651-4693-b2eb-f775beb5cbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1338016d-ad98-4734-abb6-b740d360a93d" xlink:to="loc_us-gaap_EquityComponentDomain_6e0267f7-d651-4693-b2eb-f775beb5cbcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f5c4f18-f523-490b-b0e7-d7690e8d2c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6e0267f7-d651-4693-b2eb-f775beb5cbcd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f5c4f18-f523-490b-b0e7-d7690e8d2c4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_fd42cef6-dfd4-44bc-80e7-0a5169ce661d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f5c4f18-f523-490b-b0e7-d7690e8d2c4d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_fd42cef6-dfd4-44bc-80e7-0a5169ce661d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7b004410-3d62-4fc4-a64b-8ee06ffac078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f5c4f18-f523-490b-b0e7-d7690e8d2c4d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7b004410-3d62-4fc4-a64b-8ee06ffac078" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_de5c6a22-d2ed-473b-93bf-b1a213dc1621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f5c4f18-f523-490b-b0e7-d7690e8d2c4d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_de5c6a22-d2ed-473b-93bf-b1a213dc1621" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended" id="ide47d1c2bbae4237b757999ea41fc6e5_StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2a331ce2-d95e-4924-99cd-4681f1fd65ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_6defd214-21c3-4aa7-9522-6f8ecd1584ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2a331ce2-d95e-4924-99cd-4681f1fd65ee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_6defd214-21c3-4aa7-9522-6f8ecd1584ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_777d3876-8b9c-482d-859a-13438b48fb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2a331ce2-d95e-4924-99cd-4681f1fd65ee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_777d3876-8b9c-482d-859a-13438b48fb18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2490f963-fd96-4eea-96e5-ce718a487a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2a331ce2-d95e-4924-99cd-4681f1fd65ee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2490f963-fd96-4eea-96e5-ce718a487a36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dee8154b-cfac-4f4e-a6d6-8b7dc8704aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2a331ce2-d95e-4924-99cd-4681f1fd65ee" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dee8154b-cfac-4f4e-a6d6-8b7dc8704aea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0185ef62-d7eb-4216-b4ce-9f79c98465b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dee8154b-cfac-4f4e-a6d6-8b7dc8704aea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0185ef62-d7eb-4216-b4ce-9f79c98465b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0185ef62-d7eb-4216-b4ce-9f79c98465b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0185ef62-d7eb-4216-b4ce-9f79c98465b9" xlink:to="loc_us-gaap_EquityComponentDomain_0185ef62-d7eb-4216-b4ce-9f79c98465b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b240043-11fc-44bb-941b-8fb0ffc78334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0185ef62-d7eb-4216-b4ce-9f79c98465b9" xlink:to="loc_us-gaap_EquityComponentDomain_7b240043-11fc-44bb-941b-8fb0ffc78334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_b3ea7dd6-8463-40bd-9cb2-51f056aa0475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b240043-11fc-44bb-941b-8fb0ffc78334" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_b3ea7dd6-8463-40bd-9cb2-51f056aa0475" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_cc198d21-c6a3-488c-a87c-86ea33b6fff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b240043-11fc-44bb-941b-8fb0ffc78334" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_cc198d21-c6a3-488c-a87c-86ea33b6fff4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RevenuerecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="extended" id="ibf990456975f40c8b86a06206c4ec6d3_RevenuerecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_585ee28a-5a2d-4201-84ed-1dc347ff3c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_NumberOfOperatingSegments_585ee28a-5a2d-4201-84ed-1dc347ff3c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7d39a552-918d-4eaf-a566-532f6b0c2173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7d39a552-918d-4eaf-a566-532f6b0c2173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_78442bbb-b08c-47a7-b587-b2db751e4d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_78442bbb-b08c-47a7-b587-b2db751e4d66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_05153f4c-c3cd-44ac-85cc-43102dec2497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_05153f4c-c3cd-44ac-85cc-43102dec2497" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_0dee98ea-e894-410e-9333-49c84bf3f2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_0dee98ea-e894-410e-9333-49c84bf3f2ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_351d8789-09f5-48d0-925b-8ee0fac51b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_351d8789-09f5-48d0-925b-8ee0fac51b6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_0fcf208e-0550-4af9-a18b-dea4d914432e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_0fcf208e-0550-4af9-a18b-dea4d914432e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_6c0138bd-348d-45ca-a014-be7c8ef390fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_6c0138bd-348d-45ca-a014-be7c8ef390fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_278b0eda-5f8e-4907-83e0-e8ccea61a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_278b0eda-5f8e-4907-83e0-e8ccea61a7a9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_b73d495d-44fa-4ae1-b0b1-96d188c0c57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_b73d495d-44fa-4ae1-b0b1-96d188c0c57b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_33c080a3-a603-4fae-9f1a-5e91f0d1282b" xlink:href="ebs-20230331.xsd#ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_33c080a3-a603-4fae-9f1a-5e91f0d1282b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b31290c2-c817-45d2-adf9-8d66f937a585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b31290c2-c817-45d2-adf9-8d66f937a585" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c55d9906-093e-45b9-a771-f07565d37848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c55d9906-093e-45b9-a771-f07565d37848" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_f56c8954-edb7-4f2f-bb22-fed36529a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_f56c8954-edb7-4f2f-bb22-fed36529a0f8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b1f3cd76-7991-4b69-b0f8-471df1bdaf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b1f3cd76-7991-4b69-b0f8-471df1bdaf3a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_361b738d-2752-4edb-b96f-58ef8ab5a86d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:to="loc_srt_MajorCustomersAxis_361b738d-2752-4edb-b96f-58ef8ab5a86d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_361b738d-2752-4edb-b96f-58ef8ab5a86d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_361b738d-2752-4edb-b96f-58ef8ab5a86d" xlink:to="loc_srt_NameOfMajorCustomerDomain_361b738d-2752-4edb-b96f-58ef8ab5a86d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b0e0b4d4-e993-4b04-9a63-f9e37ceb6b45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_361b738d-2752-4edb-b96f-58ef8ab5a86d" xlink:to="loc_srt_NameOfMajorCustomerDomain_b0e0b4d4-e993-4b04-9a63-f9e37ceb6b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_0da9b125-a96c-4ea6-8b7a-216f9a95f8fb" xlink:href="ebs-20230331.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b0e0b4d4-e993-4b04-9a63-f9e37ceb6b45" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_0da9b125-a96c-4ea6-8b7a-216f9a95f8fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:to="loc_srt_ProductOrServiceAxis_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2" xlink:to="loc_srt_ProductsAndServicesDomain_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_09561f04-e37a-4eda-9709-0fcc145d4fd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2" xlink:to="loc_srt_ProductsAndServicesDomain_09561f04-e37a-4eda-9709-0fcc145d4fd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_59d31d16-d984-448b-b973-2953a2f04907" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_09561f04-e37a-4eda-9709-0fcc145d4fd7" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_59d31d16-d984-448b-b973-2953a2f04907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fd0d7cac-4b90-43ac-b79f-bf01d0ffb3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fd0d7cac-4b90-43ac-b79f-bf01d0ffb3b0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1" xlink:type="simple" xlink:href="ebs-20230331.xsd#RevenuerecognitionNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1" xlink:type="extended" id="i111fd2bde9d04cae87ed93f6edb3212a_RevenuerecognitionNarrativeDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_585ee28a-5a2d-4201-84ed-1dc347ff3c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_NumberOfOperatingSegments_585ee28a-5a2d-4201-84ed-1dc347ff3c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7d39a552-918d-4eaf-a566-532f6b0c2173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7d39a552-918d-4eaf-a566-532f6b0c2173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_78442bbb-b08c-47a7-b587-b2db751e4d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_78442bbb-b08c-47a7-b587-b2db751e4d66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_05153f4c-c3cd-44ac-85cc-43102dec2497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_05153f4c-c3cd-44ac-85cc-43102dec2497" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_0dee98ea-e894-410e-9333-49c84bf3f2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_0dee98ea-e894-410e-9333-49c84bf3f2ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_351d8789-09f5-48d0-925b-8ee0fac51b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_351d8789-09f5-48d0-925b-8ee0fac51b6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_0fcf208e-0550-4af9-a18b-dea4d914432e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_0fcf208e-0550-4af9-a18b-dea4d914432e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_6c0138bd-348d-45ca-a014-be7c8ef390fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_6c0138bd-348d-45ca-a014-be7c8ef390fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_278b0eda-5f8e-4907-83e0-e8ccea61a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_278b0eda-5f8e-4907-83e0-e8ccea61a7a9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_b73d495d-44fa-4ae1-b0b1-96d188c0c57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_b73d495d-44fa-4ae1-b0b1-96d188c0c57b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_33c080a3-a603-4fae-9f1a-5e91f0d1282b" xlink:href="ebs-20230331.xsd#ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_33c080a3-a603-4fae-9f1a-5e91f0d1282b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b31290c2-c817-45d2-adf9-8d66f937a585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b31290c2-c817-45d2-adf9-8d66f937a585" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c55d9906-093e-45b9-a771-f07565d37848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c55d9906-093e-45b9-a771-f07565d37848" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_f56c8954-edb7-4f2f-bb22-fed36529a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_f56c8954-edb7-4f2f-bb22-fed36529a0f8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b1f3cd76-7991-4b69-b0f8-471df1bdaf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b1f3cd76-7991-4b69-b0f8-471df1bdaf3a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_361b738d-2752-4edb-b96f-58ef8ab5a86d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:to="loc_srt_MajorCustomersAxis_361b738d-2752-4edb-b96f-58ef8ab5a86d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_361b738d-2752-4edb-b96f-58ef8ab5a86d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_361b738d-2752-4edb-b96f-58ef8ab5a86d" xlink:to="loc_srt_NameOfMajorCustomerDomain_361b738d-2752-4edb-b96f-58ef8ab5a86d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b0e0b4d4-e993-4b04-9a63-f9e37ceb6b45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_361b738d-2752-4edb-b96f-58ef8ab5a86d" xlink:to="loc_srt_NameOfMajorCustomerDomain_b0e0b4d4-e993-4b04-9a63-f9e37ceb6b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_0da9b125-a96c-4ea6-8b7a-216f9a95f8fb" xlink:href="ebs-20230331.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b0e0b4d4-e993-4b04-9a63-f9e37ceb6b45" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_0da9b125-a96c-4ea6-8b7a-216f9a95f8fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:to="loc_srt_ProductOrServiceAxis_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2" xlink:to="loc_srt_ProductsAndServicesDomain_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_09561f04-e37a-4eda-9709-0fcc145d4fd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2" xlink:to="loc_srt_ProductsAndServicesDomain_09561f04-e37a-4eda-9709-0fcc145d4fd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_59d31d16-d984-448b-b973-2953a2f04907" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_09561f04-e37a-4eda-9709-0fcc145d4fd7" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_59d31d16-d984-448b-b973-2953a2f04907" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RevenuerecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="i018d4f53ba78461b8ff01ddaca526f54_RevenuerecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a51ec5d-d093-4316-9b2f-e7202ce40b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a51ec5d-d093-4316-9b2f-e7202ce40b29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_22f138ec-6ede-425b-9bd9-6cde9642c755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_22f138ec-6ede-425b-9bd9-6cde9642c755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_aff38a69-58c2-4953-8505-3d660c37213c" xlink:href="ebs-20230331.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_aff38a69-58c2-4953-8505-3d660c37213c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cff2ad7c-f488-4f8f-8e90-1f6814f7f3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:to="loc_us-gaap_Revenues_cff2ad7c-f488-4f8f-8e90-1f6814f7f3bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f7d376ca-d089-4585-9241-c88ee0024ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f7d376ca-d089-4585-9241-c88ee0024ade" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_196b8d6c-1880-41df-b0da-0f5e794580a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7d376ca-d089-4585-9241-c88ee0024ade" xlink:to="loc_srt_ProductOrServiceAxis_196b8d6c-1880-41df-b0da-0f5e794580a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_196b8d6c-1880-41df-b0da-0f5e794580a5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_196b8d6c-1880-41df-b0da-0f5e794580a5" xlink:to="loc_srt_ProductsAndServicesDomain_196b8d6c-1880-41df-b0da-0f5e794580a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_61058d65-f6d3-4acc-9937-52b22e41eb91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_196b8d6c-1880-41df-b0da-0f5e794580a5" xlink:to="loc_srt_ProductsAndServicesDomain_61058d65-f6d3-4acc-9937-52b22e41eb91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d2693aaf-1ade-4f79-946f-a334710d9a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61058d65-f6d3-4acc-9937-52b22e41eb91" xlink:to="loc_us-gaap_ProductMember_d2693aaf-1ade-4f79-946f-a334710d9a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_54c2ccf4-08b4-49b8-9c97-b8f09ca6ab80" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61058d65-f6d3-4acc-9937-52b22e41eb91" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_54c2ccf4-08b4-49b8-9c97-b8f09ca6ab80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_f67c13c7-9d2a-4f5a-98ca-74aceba15105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_54c2ccf4-08b4-49b8-9c97-b8f09ca6ab80" xlink:to="loc_us-gaap_ServiceMember_f67c13c7-9d2a-4f5a-98ca-74aceba15105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_ba1a21c1-7f3b-43b9-b11e-c795a85d7818" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_54c2ccf4-08b4-49b8-9c97-b8f09ca6ab80" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_ba1a21c1-7f3b-43b9-b11e-c795a85d7818" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_5068bdba-9974-4c1e-8a84-7554914effc8" xlink:href="ebs-20230331.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61058d65-f6d3-4acc-9937-52b22e41eb91" xlink:to="loc_ebs_ContractsAndGrantsMember_5068bdba-9974-4c1e-8a84-7554914effc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cf45a778-844a-4c6a-84af-460eb54a88d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7d376ca-d089-4585-9241-c88ee0024ade" xlink:to="loc_srt_MajorCustomersAxis_cf45a778-844a-4c6a-84af-460eb54a88d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cf45a778-844a-4c6a-84af-460eb54a88d4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_cf45a778-844a-4c6a-84af-460eb54a88d4" xlink:to="loc_srt_NameOfMajorCustomerDomain_cf45a778-844a-4c6a-84af-460eb54a88d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_abdb0db1-907f-4045-92a7-70b2ff7a249c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_cf45a778-844a-4c6a-84af-460eb54a88d4" xlink:to="loc_srt_NameOfMajorCustomerDomain_abdb0db1-907f-4045-92a7-70b2ff7a249c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember_884b5321-11f2-4461-b465-451346e29174" xlink:href="ebs-20230331.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_abdb0db1-907f-4045-92a7-70b2ff7a249c" xlink:to="loc_ebs_UnitedStatesGovernmentMember_884b5321-11f2-4461-b465-451346e29174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NonUnitedStatesGovernmentMember_48df2edc-2101-460c-8d76-584689a1b6c8" xlink:href="ebs-20230331.xsd#ebs_NonUnitedStatesGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_abdb0db1-907f-4045-92a7-70b2ff7a249c" xlink:to="loc_ebs_NonUnitedStatesGovernmentMember_48df2edc-2101-460c-8d76-584689a1b6c8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#IncometaxesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="extended" id="i90a61bd3f4424222839dc39855f72d07_IncometaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesLineItems_d5958265-ff48-4ad2-ac7b-3690872cc7a5" xlink:href="ebs-20230331.xsd#ebs_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4faa097b-f028-4a5a-a18a-4b6bce52f87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_IncomeTaxesLineItems_d5958265-ff48-4ad2-ac7b-3690872cc7a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4faa097b-f028-4a5a-a18a-4b6bce52f87d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_21c24ce3-84be-42a0-ac10-21cb32c69346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_IncomeTaxesLineItems_d5958265-ff48-4ad2-ac7b-3690872cc7a5" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_21c24ce3-84be-42a0-ac10-21cb32c69346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_387a4c73-6d2f-4917-ae97-6294acce04f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_IncomeTaxesLineItems_d5958265-ff48-4ad2-ac7b-3690872cc7a5" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_387a4c73-6d2f-4917-ae97-6294acce04f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesTable_f316d3ed-5acb-4de8-9573-82b7fcac43d0" xlink:href="ebs-20230331.xsd#ebs_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ebs_IncomeTaxesLineItems_d5958265-ff48-4ad2-ac7b-3690872cc7a5" xlink:to="loc_ebs_IncomeTaxesTable_f316d3ed-5acb-4de8-9573-82b7fcac43d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4d697ddf-a535-4acd-a6af-825936b60080" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ebs_IncomeTaxesTable_f316d3ed-5acb-4de8-9573-82b7fcac43d0" xlink:to="loc_srt_StatementScenarioAxis_4d697ddf-a535-4acd-a6af-825936b60080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4d697ddf-a535-4acd-a6af-825936b60080_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_4d697ddf-a535-4acd-a6af-825936b60080" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4d697ddf-a535-4acd-a6af-825936b60080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_82e4d018-2dc1-41d5-8931-4dea33bcc52d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_4d697ddf-a535-4acd-a6af-825936b60080" xlink:to="loc_srt_ScenarioUnspecifiedDomain_82e4d018-2dc1-41d5-8931-4dea33bcc52d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3bc98b93-05bd-4bc8-8917-735b9cae2e2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_82e4d018-2dc1-41d5-8931-4dea33bcc52d" xlink:to="loc_srt_ScenarioForecastMember_3bc98b93-05bd-4bc8-8917-735b9cae2e2f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended" id="ib6a277a8d21b43c6bd88e695586f581b_SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_dd29381d-75fc-433f-97bf-84dc0f50ed95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_RevenuesAbstract_dd29381d-75fc-433f-97bf-84dc0f50ed95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e90d7c2-de60-4da2-90ce-7e8db12b3416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_dd29381d-75fc-433f-97bf-84dc0f50ed95" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e90d7c2-de60-4da2-90ce-7e8db12b3416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_213eacc3-a6c1-4ec4-8174-ee727fe9e4f0" xlink:href="ebs-20230331.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_dd29381d-75fc-433f-97bf-84dc0f50ed95" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_213eacc3-a6c1-4ec4-8174-ee727fe9e4f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f1536fd8-fec0-4909-b533-3776c5569a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_dd29381d-75fc-433f-97bf-84dc0f50ed95" xlink:to="loc_us-gaap_Revenues_f1536fd8-fec0-4909-b533-3776c5569a60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_77582c6f-a813-4b35-bbd9-eafffbb8612f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_77582c6f-a813-4b35-bbd9-eafffbb8612f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5af15a3a-4897-453c-8478-c68002bfd948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_77582c6f-a813-4b35-bbd9-eafffbb8612f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5af15a3a-4897-453c-8478-c68002bfd948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_4d5a9878-d374-47d3-8645-cf0518bd6541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_GrossProfit_4d5a9878-d374-47d3-8645-cf0518bd6541" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract_66989830-ebde-4af2-9ab4-6e335b61dbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfitAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_GrossProfitAbstract_66989830-ebde-4af2-9ab4-6e335b61dbd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentAbstract_fdf32c30-16c5-4ea9-b8d5-71ddd4e10ac1" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GrossProfitAbstract_66989830-ebde-4af2-9ab4-6e335b61dbd6" xlink:to="loc_ebs_ProductsSegmentAbstract_fdf32c30-16c5-4ea9-b8d5-71ddd4e10ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a4047f3f-5b12-4858-9fdb-172285517282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ProductsSegmentAbstract_fdf32c30-16c5-4ea9-b8d5-71ddd4e10ac1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a4047f3f-5b12-4858-9fdb-172285517282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_2e5fa101-3f65-40c9-ae8a-122a1324f379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ProductsSegmentAbstract_fdf32c30-16c5-4ea9-b8d5-71ddd4e10ac1" xlink:to="loc_us-gaap_RestructuringCosts_2e5fa101-3f65-40c9-ae8a-122a1324f379" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin_8d3a7bc7-b800-4075-a2f1-1c83ec9fff4f" xlink:href="ebs-20230331.xsd#ebs_AdjustedGrossMargin"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_ebs_AdjustedGrossMargin_8d3a7bc7-b800-4075-a2f1-1c83ec9fff4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_GrossProfitAdjustments_d8ab6f04-1ea0-42e3-862b-d92e1c93d22f" xlink:href="ebs-20230331.xsd#ebs_GrossProfitAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_ebs_GrossProfitAdjustments_d8ab6f04-1ea0-42e3-862b-d92e1c93d22f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3d369c32-cbcb-43e4-ad84-b183ecc6800a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3d369c32-cbcb-43e4-ad84-b183ecc6800a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_01385716-ba8d-41c2-9e8f-3548155d2a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_01385716-ba8d-41c2-9e8f-3548155d2a67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d4e1aa7e-65e4-47e3-9de9-8f436e7b9a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d4e1aa7e-65e4-47e3-9de9-8f436e7b9a36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d45082b2-b945-402f-a510-81f6b138d0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_us-gaap_InterestExpense_d45082b2-b945-402f-a510-81f6b138d0c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_03d8b2c2-9cd1-4d52-a07d-289019017b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_03d8b2c2-9cd1-4d52-a07d-289019017b5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39710f26-1873-43f6-8bcb-b33d406e96b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39710f26-1873-43f6-8bcb-b33d406e96b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_79756e30-72b8-4afc-857b-d32183172122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_79756e30-72b8-4afc-857b-d32183172122" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_99c9666d-05bb-43af-bccd-4be2d9973957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_79756e30-72b8-4afc-857b-d32183172122" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_99c9666d-05bb-43af-bccd-4be2d9973957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_99c9666d-05bb-43af-bccd-4be2d9973957_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_99c9666d-05bb-43af-bccd-4be2d9973957" xlink:to="loc_us-gaap_SegmentDomain_99c9666d-05bb-43af-bccd-4be2d9973957_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_772c399d-7e90-4f56-8919-83a4a210fd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_99c9666d-05bb-43af-bccd-4be2d9973957" xlink:to="loc_us-gaap_SegmentDomain_772c399d-7e90-4f56-8919-83a4a210fd7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsAndServicesSegmentsMember_8cffaaac-eaa5-44db-b919-69fb31f3f85c" xlink:href="ebs-20230331.xsd#ebs_ProductsAndServicesSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_772c399d-7e90-4f56-8919-83a4a210fd7a" xlink:to="loc_ebs_ProductsAndServicesSegmentsMember_8cffaaac-eaa5-44db-b919-69fb31f3f85c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_25ed91d1-93ef-463d-a9b3-65dfd1edfc70" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ProductsAndServicesSegmentsMember_8cffaaac-eaa5-44db-b919-69fb31f3f85c" xlink:to="loc_ebs_ProductsSegmentMember_25ed91d1-93ef-463d-a9b3-65dfd1edfc70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_60ccb474-399f-410a-9c7a-79f62a7039f7" xlink:href="ebs-20230331.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ProductsAndServicesSegmentsMember_8cffaaac-eaa5-44db-b919-69fb31f3f85c" xlink:to="loc_ebs_ServicesSegmentMember_60ccb474-399f-410a-9c7a-79f62a7039f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_327cb601-c66a-4c2c-acf0-d8acc2ae3446" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_79756e30-72b8-4afc-857b-d32183172122" xlink:to="loc_srt_ProductOrServiceAxis_327cb601-c66a-4c2c-acf0-d8acc2ae3446" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_327cb601-c66a-4c2c-acf0-d8acc2ae3446_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_327cb601-c66a-4c2c-acf0-d8acc2ae3446" xlink:to="loc_srt_ProductsAndServicesDomain_327cb601-c66a-4c2c-acf0-d8acc2ae3446_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_334a43f0-d379-449b-94dc-311b31d8192e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_327cb601-c66a-4c2c-acf0-d8acc2ae3446" xlink:to="loc_srt_ProductsAndServicesDomain_334a43f0-d379-449b-94dc-311b31d8192e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_d8ceb474-e4ea-4bb4-9191-838cf6ee167c" xlink:href="ebs-20230331.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_334a43f0-d379-449b-94dc-311b31d8192e" xlink:to="loc_ebs_ContractsAndGrantsMember_d8ceb474-e4ea-4bb4-9191-838cf6ee167c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended" id="id10134e6ae434c1488d0a9ab651cdc0b_SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_26f8be2b-b851-4162-8c57-8b8179f14612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract_4f76097f-dc27-4cb8-baea-36c4966db012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_26f8be2b-b851-4162-8c57-8b8179f14612" xlink:to="loc_us-gaap_DepreciationAbstract_4f76097f-dc27-4cb8-baea-36c4966db012" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_097fae5a-fb61-4d33-bf35-08c4bdb99e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DepreciationAbstract_4f76097f-dc27-4cb8-baea-36c4966db012" xlink:to="loc_us-gaap_Depreciation_097fae5a-fb61-4d33-bf35-08c4bdb99e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e0a3594-4f66-4df7-a10a-545fc37d2309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_26f8be2b-b851-4162-8c57-8b8179f14612" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e0a3594-4f66-4df7-a10a-545fc37d2309" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_69945f3a-f8f0-48ea-a9a6-15fa902a633c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e0a3594-4f66-4df7-a10a-545fc37d2309" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_69945f3a-f8f0-48ea-a9a6-15fa902a633c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_69945f3a-f8f0-48ea-a9a6-15fa902a633c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_69945f3a-f8f0-48ea-a9a6-15fa902a633c" xlink:to="loc_us-gaap_SegmentDomain_69945f3a-f8f0-48ea-a9a6-15fa902a633c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_995b6b6b-da19-4077-95cd-57e6eb749721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_69945f3a-f8f0-48ea-a9a6-15fa902a633c" xlink:to="loc_us-gaap_SegmentDomain_995b6b6b-da19-4077-95cd-57e6eb749721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_9cac6171-d6bb-4120-bca8-7c77362b7ae0" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_995b6b6b-da19-4077-95cd-57e6eb749721" xlink:to="loc_ebs_ProductsSegmentMember_9cac6171-d6bb-4120-bca8-7c77362b7ae0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_b366e3fb-df07-4623-b07b-86bbe0795a69" xlink:href="ebs-20230331.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_995b6b6b-da19-4077-95cd-57e6eb749721" xlink:to="loc_ebs_ServicesSegmentMember_b366e3fb-df07-4623-b07b-86bbe0795a69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d198526a-d0db-42a6-8682-76edd4d601dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e0a3594-4f66-4df7-a10a-545fc37d2309" xlink:to="loc_srt_ConsolidationItemsAxis_d198526a-d0db-42a6-8682-76edd4d601dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d198526a-d0db-42a6-8682-76edd4d601dd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_d198526a-d0db-42a6-8682-76edd4d601dd" xlink:to="loc_srt_ConsolidationItemsDomain_d198526a-d0db-42a6-8682-76edd4d601dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_61f7718d-3bb1-48e9-ae53-5891f1ef7199" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_d198526a-d0db-42a6-8682-76edd4d601dd" xlink:to="loc_srt_ConsolidationItemsDomain_61f7718d-3bb1-48e9-ae53-5891f1ef7199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_5f6fa6fb-d6d2-40fd-bb77-1db2e2faba77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_61f7718d-3bb1-48e9-ae53-5891f1ef7199" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_5f6fa6fb-d6d2-40fd-bb77-1db2e2faba77" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ebs-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:da57861a-e185-4b6f-8b91-f9335b77a88a,g:0a9819bf-1d2f-49f0-b0b7-eedd5e464486-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_42c62a95-e4b6-4882-ba32-4f9ddaecac57_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable orders</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1070f7a6-3ad8-48ae-ad8b-a403d95cbd09_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ServicesSegmentMember_91699cb6-a429-463a-982f-03af841a5fdc_terseLabel_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_ebs_ServicesSegmentMember_label_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Segment [Member]</link:label>
    <link:label id="lab_ebs_ServicesSegmentMember_documentation_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember" xlink:href="ebs-20230331.xsd#ebs_ServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ServicesSegmentMember" xlink:to="lab_ebs_ServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c2115ac0-c32c-4ddd-a977-0cd05d9d67c4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d6e31e4e-966c-482d-9b4d-f509652313a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_d5a12e08-ebd3-4f1e-839e-95b9215c78b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_86e4b940-df4c-4916-86cc-821f0b56d8ef_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_988461bf-1b9a-4dd9-b5cd-cd6f223f83b6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted cash flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_734330b6-d105-4947-bc18-22f85e37da9b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_db74cdd1-0a87-4801-9ded-130b38f643eb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_da7dd385-7065-4dc4-be02-7dbab75e830f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_4915b049-5a5a-4921-b5fd-ea4e76ce7a13_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_ea75e4ae-b147-478f-a1b9-ed5c952bc906_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_b21fb7a6-2bec-4655-8a83-b816179c1ea2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_391ce9c8-1a4c-43d6-9965-8f992bb65eea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_033fea52-8b6f-4fb4-af83-f357e528bb18_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_aebeacf2-4af2-4ae6-985b-234ff8fb8837_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_bad43963-4e77-4062-bfc6-5cae1b16aafb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a8acf39-c4df-4276-9ac8-e4b00a912172_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_60cf9436-0c85-46a2-b319-735ee94d2c87_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_b3501ea6-0ba0-451c-b0ad-2787a0d3793a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_63b35ee7-7dc7-48a1-aad9-e735c6954449_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_dd49a828-7923-4c3e-9fe9-d22cd384b777_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_0cfd6eb2-4214-4eaf-8019-28acecfefc64_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_e02dcd55-c9d5-4124-9d88-4b46558b98b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_da73a9ec-abec-41ae-b7f3-4dbcd3d05235_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a92b1117-fb8f-4412-b5e8-0f4095b82fed_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3f8dbd83-fa2e-49d3-8549-38ec0e84ce45_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_f2c71067-1a89-4388-945b-740fd8a852c6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_10e3f4b1-f97c-433b-9226-257331c72c48_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6ff9bdc2-f04a-4aec-a4ae-1b58073c4984_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_48486ebb-67cb-4146-82ab-66d06d9d9c83_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0f0df559-a1eb-4f61-8e52-c8dcdb292ff8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_69b2095b-b3cf-4e3f-ad12-fe9a24623420_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_7ac755b3-d227-4643-80ea-bbb2166b0b9e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_50725eae-6e57-4e8e-ae9e-b08b5529ab5c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_d880dbfd-61a9-400d-a06f-0343570dcc1b_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_ae2f9971-b4ca-49d7-b367-dd49ff40d634_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractsAndGrantsMember_3f29bfc5-1099-4f34-b4ab-04a235d3861c_terseLabel_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracts and grants</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_label_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracts and Grants [Member]</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_documentation_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember" xlink:href="ebs-20230331.xsd#ebs_ContractsAndGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractsAndGrantsMember" xlink:to="lab_ebs_ContractsAndGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_df8ee4e3-81de-432c-95e2-c86e1c5814d9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_12fe8804-f3e6-4903-8a60-34e0643b1c53_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b23bf4ee-2878-455b-b0ed-9c4f561e24b0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_c29f3596-5a8a-4724-8eb7-acd5e5b1cff9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_e2427c42-e3ba-4b7c-b1ba-e4c039ad1810_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Instruments</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_a2688c21-eb9c-4dac-81f7-bf24f0957914_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a6ab067d-e3d0-43be-a08b-6f3e9397ab6c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAbstract_f30aa830-47bb-4f7b-8bdb-9acdc94219fc_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation:</link:label>
    <link:label id="lab_us-gaap_DepreciationAbstract_label_en-US" xlink:label="lab_us-gaap_DepreciationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAbstract" xlink:to="lab_us-gaap_DepreciationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_f092366a-fd7b-4c50-8029-89f2735c71f5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_161296a4-f29c-4406-bc77-4a9a4a71f851_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_c715d68b-8ce5-451d-8fba-5b52db62fe85_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_b53bc4e5-f9f5-43a0-901a-5222ef71e779_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ca4b7baa-fe56-4804-a629-557feae193db_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_25c2078b-8ff7-4460-8d1b-756981fd7746_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_fe050401-4445-4df3-a2b2-52b4db3a4af4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e8dc76fc-a71c-4e09-ab98-765ab1e758e3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7f269e2a-ddae-4b2a-b314-da84d5eaac23_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f27dbf99-5ac4-41c7-8036-a47e8990918b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7cf286b4-5f00-442a-9896-b0ed21125a83_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d3413a12-3b9e-41ad-bdcd-9f9608cc790e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_fb57ec15-8138-4ca4-b53e-e26d09ce5141_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_dddc4422-c343-46b5-9401-b03a64d72d91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_700dc380-e428-4650-b92d-19b97df0518b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4f5c986f-8bd4-4c18-abf4-b209c2b0ab15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_ab8524a4-d537-4dcc-b77f-d21d84d4c6bb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_9e558aac-917c-4142-bf7f-3a9c791d6197_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_635b6006-036d-4361-bb62-29dc0a34a024_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_6b86a668-2d98-429c-ad11-a1bc73b96ecc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_e3326ca0-b755-46fd-8a93-79871d822938_verboseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, consolidated debt service coverage ratio, minimum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:to="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_00752564-33ef-48ab-b018-2e24869d98ad_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c4582461-5509-45d3-9924-712127a43ca1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c3f00dca-27b9-4799-8e1b-c36e884001ea_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_4b24e3df-ba0c-4fab-b28b-8279f81f8614_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e55f543b-1279-455f-8fcf-81fd857fec40_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9011292b-f575-4c56-a0d6-1a42ba65cfe4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f15ae0a7-5207-4a8c-a4a7-db02434f650e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a6e3bfb0-7d39-4ade-af6d-d0f236af1aa1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_610a3fe1-9aab-429c-b46f-ad97bf34dd2c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_08886707-8389-46e5-90bc-5ffffac5c73a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_4151dabd-a3c0-4a09-8ad1-7c43d1ae5128_terseLabel_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_label_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_documentation_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember" xlink:href="ebs-20230331.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OtherLongTermDebtFacilityMember" xlink:to="lab_ebs_OtherLongTermDebtFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_e6861da2-591e-4566-8d0c-7057b4a2b4fe_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_e95f536f-db52-4674-904d-1c7db7e848d5_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0f528b49-4cd0-40bc-ad9b-58c01571d748_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2dfffa50-1131-4163-9494-366dde37c8b0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ea5f5d0d-0897-4a95-bc9a-e5d50ec0f36c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_eb1154b8-fda3-4e81-bdb6-f0e1e0c400b3_terseLabel_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of revenue generating products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_label_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Revenue Generating Products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_documentation_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to the number of revenue generating products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts" xlink:href="ebs-20230331.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfRevenueGeneratingProducts" xlink:to="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5035bb2-50f5-47ea-b603-91988641c28a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_0106de33-37ca-4e19-b469-f5b84ee40972_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_a45cf037-0431-47ba-8d3f-21475bfdfcc0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_8d3e28e7-500e-4c46-b750-de8862593c9c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_7bc25ea4-9426-438d-9cf2-c11317c00046_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_58e4e10e-8cdc-433e-a962-6b6ed57ade23_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_144c17c8-c48b-4689-8e50-bdd340afc4c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_74a611bc-782f-4d37-af90-77e79dce665d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_3bf00075-c692-4c00-9563-436ad353d232_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_b70dbb96-c2bb-428c-9aee-187062ad5881_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, consideration threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Consideration Threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Consideration Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:to="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_09d67569-ed52-4e2d-b564-714039630125_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_259e31f3-a761-4386-bc76-0d8f592900d8_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_004b6fec-ea54-43f4-8bb3-c27b02f530ac_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rollforward of Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f8d86fe2-7d01-4b8e-868d-6ab8bd86a4a7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_05ec85da-a3eb-4ada-ae19-4737b00472ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NoncashPurchasesOfTreasuryStock_ea960c46-cf52-4135-8057-3a2a108e1d18_terseLabel_en-US" xlink:label="lab_ebs_NoncashPurchasesOfTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock unpaid at period end</link:label>
    <link:label id="lab_ebs_NoncashPurchasesOfTreasuryStock_label_en-US" xlink:label="lab_ebs_NoncashPurchasesOfTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Purchases Of Treasury Stock</link:label>
    <link:label id="lab_ebs_NoncashPurchasesOfTreasuryStock_documentation_en-US" xlink:label="lab_ebs_NoncashPurchasesOfTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Purchases Of Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NoncashPurchasesOfTreasuryStock" xlink:href="ebs-20230331.xsd#ebs_NoncashPurchasesOfTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NoncashPurchasesOfTreasuryStock" xlink:to="lab_ebs_NoncashPurchasesOfTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_e5940b3c-ce88-4832-9669-1effe6f85261_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_90f4127a-a3d8-48be-bc38-55304862848c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_23cb59a0-b794-4dee-a740-362990a8f7e3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_c041376e-3dc7-432d-b795-f8632ef4ad15_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e79e8405-c8d1-4ca2-ba53-0ebb40ebad9c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1c2bb917-01c0-4925-b1bf-392d51f342a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0250d06a-c817-4990-b669-5186371395a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_f93c34b7-60ff-442b-8dd9-12e6d63251d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_1c87721d-bbb6-4be7-8618-ea57ea0c8f3b_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_993fe9b1-8234-4fdb-ab23-0d09c830d4fe_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1f99f4de-b91b-4f2d-acd4-62b6ecc29ebd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_ba200cd4-4ecc-48f9-bcf5-2e7d883796f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Expense</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44b33f2c-2677-4063-9810-6df384174a44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_258ced9c-b9ad-4b46-883b-969e87e2b94a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_68fc8fdf-a16e-47ee-b559-47085eb27433_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b91f3168-7182-4917-a017-d13e97781e09_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_e306c2b7-2727-4b8a-b38f-05deb84ec8c1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ff20027e-40b8-4b9a-a016-39dff374b48e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1c807e2e-3579-44b8-9ef1-4d9655df9566_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_a928d166-6833-4eb3-ab50-0238e49c05fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6cf582c5-8d16-449d-9786-2fb4badd7504_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f0df8e54-6f52-4d96-9bee-e4692549fe0c_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_1da6e542-0a56-4910-8dae-d16898ee907d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1b754ab5-3c3c-4262-a0a2-24226b107323_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_66720712-7346-4ccd-bc1f-9608c60fc524_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e584e8f1-8266-4397-ad5b-92a7e3889ee1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_5b270dfd-1cab-4468-b597-9809af6c668f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_f30a013a-8818-4416-af4a-87d27bd6ef48_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5b05265c-8a9a-43dc-96e8-486f6f0b299d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8bd2edbc-e6db-4afd-ae49-b0b710d72199_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_38f15dd9-20dd-464e-a28d-6612c086d2f8_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NonUnitedStatesGovernmentMember_71333517-1708-4ba3-92b6-68a60d5de8e2_terseLabel_en-US" xlink:label="lab_ebs_NonUnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-USG</link:label>
    <link:label id="lab_ebs_NonUnitedStatesGovernmentMember_label_en-US" xlink:label="lab_ebs_NonUnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-United States Government [Member]</link:label>
    <link:label id="lab_ebs_NonUnitedStatesGovernmentMember_documentation_en-US" xlink:label="lab_ebs_NonUnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-United States Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NonUnitedStatesGovernmentMember" xlink:href="ebs-20230331.xsd#ebs_NonUnitedStatesGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NonUnitedStatesGovernmentMember" xlink:to="lab_ebs_NonUnitedStatesGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_408eb82d-e72d-432a-85b2-634dd77fc9ac_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d215e958-68e4-45f6-bb9d-4cf58668aad3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_595835a8-5166-451e-84ec-2f1a7fec827b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0cb8ea08-b520-46c0-98da-488561ac2dae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_a47b442f-16da-49a2-b816-3d428bcfd797_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_bde5bc19-d9c1-4c48-9467-8cfe601c8fc6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_310cc49d-815e-49b8-88dd-852298a7b475_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AdjustedGrossMargin_90690c23-7f1b-48bd-9e3b-2e66c62f97f8_terseLabel_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Gross Margin</link:label>
    <link:label id="lab_ebs_AdjustedGrossMargin_label_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Gross Margin</link:label>
    <link:label id="lab_ebs_AdjustedGrossMargin_documentation_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Gross Margin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin" xlink:href="ebs-20230331.xsd#ebs_AdjustedGrossMargin"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AdjustedGrossMargin" xlink:to="lab_ebs_AdjustedGrossMargin" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_63b0fa76-3d65-40aa-84d4-cf3f7c566db7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_e710a6dc-068f-40b6-88d0-2464fda402d5_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_3310c908-b073-4d5c-863f-f7a9ef01371c_terseLabel_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable, Net</link:label>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_label_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_documentation_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:href="ebs-20230331.xsd#ebs_ScheduleOfAccountsReceivableNetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:to="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5e0fa0cd-716b-446c-bbcb-aa8bd6eaca98_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_1cde78cc-ea5b-40b4-ab23-086e3a497864_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_64be9777-75db-4e08-b263-289385f93a63_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_6734bca8-33fc-4ec0-af6c-caac99211d54_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_22781a62-9526-4d91-93a9-79c3fcbf79f7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_550146fb-2158-4b7c-a55d-9af44a6689ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_520a6248-7483-4927-b483-225cdc79f1a5_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_29cac70e-c8a8-4bc9-aec9-d912594fbdf4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a22855cf-fe71-4af7-a675-1e429e43a848_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4f162154-e60e-49db-bce8-fb69342d13fe_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ProductsSegmentMember_c66f16da-16b7-485f-8edc-b4a48969f9a5_terseLabel_en-US" xlink:label="lab_ebs_ProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products</link:label>
    <link:label id="lab_ebs_ProductsSegmentMember_label_en-US" xlink:label="lab_ebs_ProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Segment [Member]</link:label>
    <link:label id="lab_ebs_ProductsSegmentMember_documentation_en-US" xlink:label="lab_ebs_ProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ProductsSegmentMember" xlink:to="lab_ebs_ProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_77336e3f-8f01-40bb-8485-d85c1de341ff_verboseLabel_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDMO</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_e33923be-ca91-4f70-a015-0a0da35531ec_terseLabel_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Development And Manufacturing [Member]</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_label_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Development And Manufacturing [Member]</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_documentation_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue earned during the period arising from manufacturing sale under the terms of a contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember" xlink:to="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9c2b0630-8975-4f81-bf0e-cb15eb142f46_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_94f2504d-e261-4038-b84c-b5c5f6eb9c3d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d8bce8b5-b23c-4047-b1ea-c4f3e097d72c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_0d61703a-2c68-44b6-a014-d111dc822275_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, payment to be received, year four</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_70e9ac18-d04c-4133-891a-9ff8dbc7c09d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_008c4c3a-0b07-4b69-b1f3-686d1c8150ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_c350f9b8-6450-4608-8497-a55e8ede0c16_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d9dc31ed-4473-4c0f-95b0-0ab8463e4d79_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6e7b84d6-7795-4a1f-9c3a-06f2601b8b33_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1206bb12-df93-47a8-975e-05059a48f80b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_16b3c082-8f52-4095-92ab-1d45d4a015dd_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfProductCandidates_6ebd2db8-212d-439f-99c8-f620ece295d8_terseLabel_en-US" xlink:label="lab_ebs_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates</link:label>
    <link:label id="lab_ebs_NumberOfProductCandidates_label_en-US" xlink:label="lab_ebs_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:label id="lab_ebs_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_ebs_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductCandidates" xlink:href="ebs-20230331.xsd#ebs_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfProductCandidates" xlink:to="lab_ebs_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_7c4c8c71-17c6-42cf-a218-6c3271a12b26_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ab83181e-b0c7-4cb9-8c09-93618b60ea6b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5a84cef2-9827-4ea0-a9f9-aa8224fae7a6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_95f8ed34-bb29-4e9d-a383-f46e19502d5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_7ad2d65a-3649-4b65-98a8-1c3684d433aa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_dc6a6505-f4bd-4dae-aa2e-550b07d22280_terseLabel_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of categories of public health threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_label_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Categories Of Public Health Threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_documentation_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to the number of categories of public health threats.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:href="ebs-20230331.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:to="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_c85d6257-13df-4736-9bde-2ccaa0b7daee_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_538f6f94-bbfc-462a-8d78-710c40560ab2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b359608b-505d-40c4-bca2-d553dcc6255e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments other than options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_facb866f-dc67-405c-9150-ee89d25fc28a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d4aed3d0-5139-4264-b753-6c528a001de3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective annual tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_42db1ef9-f35f-42ee-95d1-c4eb11941539_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_f551855f-8651-42e6-977a-80310fde660e_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e83333e3-7e88-4f6f-80de-379b07bcfd7e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4a812935-8d76-4eb6-aa2b-b1b2bff092f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ba3cecfb-a08f-48fb-ab9a-04f4fa85bc95_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d32aa0cc-501a-474b-b2f8-7bb1ea38f4d7_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eed6c6a7-0a88-443c-92a1-f0ea2ea90dae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_ef90dcfa-7cac-40e2-8e17-378784b820d5_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_cdc8180e-9a1b-4607-bacd-6bb1bb4d7526_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_577e52f6-6630-47e1-8f75-e16f4db3743c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on hedging activities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1c4107ed-91be-404b-a88e-2777fb31c86c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_952e731c-4dd1-4436-8c82-5d198935cd11_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_ccd29b91-8c93-4a4d-b2e8-80b189aaf7a9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_69490a38-6288-4853-97e3-2f34e362d9a8_terseLabel_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jansen Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jansen Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jansen Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember" xlink:href="ebs-20230331.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_JansenPharmaceuticalsIncMember" xlink:to="lab_ebs_JansenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6d4b8d16-9ee8-4421-a081-7f4f43d79991_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e9f67915-dcce-465d-b4d3-4fa12436a498_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_50731c2e-0ec6-47d4-b40f-79ac3277af02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_1d20cf53-d486-4ac9-8737-fe41ab4d9f86_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_4a64b811-d4d2-4fa9-a5d7-40041c9a322a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_df56bd5d-dd36-4ad1-b1ef-6cf9314a0403_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2627436a-9751-44ef-bd3e-71b23e20f3c0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_22ddccd9-0eeb-4d0b-96ef-7e8cc0c510db_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_6e924fea-aa50-4362-ad1f-770eb4807fe5_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_35dae634-85fa-443e-a383-8488fa94bf34_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_ce817f1a-b1b7-4b07-ac71-213c119bf9ab_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-launch inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_361bf8af-8a1e-4a57-8fda-d721a3e8fefd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_94a294bc-d2fd-4721-b148-ea6d42b813b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1a801a7b-f2ff-4c06-b16b-e83c1edfa1f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_694c8757-7e46-4db6-95d3-16daae705ea7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments and hedging activities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_4e123bf2-f112-4150-ab68-81570f0d731b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_fd42ab43-b1d0-48f2-8f69-a2ee4fee2469_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_b8285594-2d3b-444f-8a44-dd0d17dd3526_terseLabel_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:href="ebs-20230331.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:to="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_15063382-cf20-42f7-8f4e-7b8d924b20fb_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_2a145f2c-d43b-4f0a-a35f-8d713aa318c5_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, payment to be received, year one</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ad70808f-7d60-46ac-afef-2529ce2feb20_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c738d70e-ac04-471c-b88e-3ed4b3288c88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_297d5754-d54a-4a38-8470-35ebc360a327_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_518f2d1b-f3be-4a1a-987a-cb33d3f71c0d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_d9a2d89c-d684-4cc5-b6d4-d22a57e781c7_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market accounts</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7fb9ac36-60f9-4bb7-8ca0-132b44b9f476_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_ae1caa6b-e84d-4fd5-a5c5-710058ac79f1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_0b3f314e-5958-43ba-9f69-3b6a94753c38_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, payment to be received, year three</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_0b05a5a6-9672-4680-9c5c-21787c333aea_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_d9c406e1-b7ef-4f11-89ba-c47f6769a184_terseLabel_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferral of revenue</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_label_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Additions</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_documentation_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityAdditions" xlink:href="ebs-20230331.xsd#ebs_ContractWithCustomerLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractWithCustomerLiabilityAdditions" xlink:to="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9fd23dac-5b2a-445b-a598-b675218f16ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$0.001 Par Value Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9aedf4be-8fd5-44ef-a026-8b64a5405d56_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0e3c1618-5196-4302-88c6-c642e1fb0658_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c3b0f128-7381-429a-a825-f1e66145b9cb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_204dc34b-275e-405a-8f85-f1454652a883_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation activity</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f79a2a54-4b0b-48ef-b438-ba4e7e7c1bd3_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss before reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_0774215d-ec04-449c-baba-bee972c1901b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_9e529749-cfe9-43f0-8448-8ebcd43e907e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1dfb3164-09fd-4267-92d8-568a04a35de7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_30729f05-a441-44a2-827a-16e3fbe519c8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b26142c5-53f1-4bca-b48e-33a0bbfc2bb2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_08db436c-758f-482a-8940-59c5affc2741_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_UnitedStatesGovernmentMember_e2a9afa8-7bbe-456b-ba24-3e8a7a5fa51e_terseLabel_en-US" xlink:label="lab_ebs_UnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USG</link:label>
    <link:label id="lab_ebs_UnitedStatesGovernmentMember_label_en-US" xlink:label="lab_ebs_UnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States Government [Member]</link:label>
    <link:label id="lab_ebs_UnitedStatesGovernmentMember_documentation_en-US" xlink:label="lab_ebs_UnitedStatesGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember" xlink:href="ebs-20230331.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_UnitedStatesGovernmentMember" xlink:to="lab_ebs_UnitedStatesGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_11e1c050-87e3-4b62-a54a-226837cf587b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember_7ff078db-6944-41e3-afab-77df4a458229_terseLabel_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember_label_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Development And Manufacturing, Leases [Member]</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember_documentation_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Development And Manufacturing, Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:to="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_fef874e7-f392-4b7b-b3b9-743102bfc2e6_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_91e7eaf6-08b8-4983-a980-8fc56de14ca2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5e274213-4023-4963-9969-086c5480c264_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_af5fce6b-f541-4cfd-ab88-fdd190dc5128_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_00232428-26b6-4073-996d-8bbb62670cc7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_b7b9a7ab-75bb-4127-930c-62279abadd99_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, asset, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ead70851-a1fc-48c6-beaf-0c7330c730e8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_68878d1b-4662-4e02-9cb6-0a10ec9343f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_410ef1c2-4916-4f45-b0d4-3ce4f5d78a24_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6e25c073-aa70-4d77-9861-178b65780f8f_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f298ac8a-2eba-4edb-8168-fc8e000c71e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0b6b2946-9a3b-4630-b9e0-5b8e69c10058_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_8817900d-7994-44d4-bf8b-2b0f12e32f82_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d61e4558-5ce9-4b11-b7c5-84b49999e54d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_be0f9a2e-77f8-4b28-95e3-61e72eacc347_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_72fc6bdc-960a-4d70-99bc-659426706a7b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f9008439-0c2c-4ab7-8ae1-50870ad70861_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_43fc0d54-6583-4318-8368-c32a06021690_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_270eb388-c992-4be7-a07c-e6e48fae5517_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, liability, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_73ef513f-2c1c-456d-9a24-b3d23dd6d0c1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_66ae6e09-8a92-4752-9fe1-052b22aa17ac_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_07a6f506-b04a-4822-8d16-e72661d1612f_terseLabel_en-US" xlink:label="lab_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, payment to be received, after year four</link:label>
    <link:label id="lab_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_label_en-US" xlink:label="lab_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment To Be Received, After Year Four</link:label>
    <link:label id="lab_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_documentation_en-US" xlink:label="lab_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment To Be Received, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:href="ebs-20230331.xsd#ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:to="lab_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_667f08a3-87ff-4171-af74-72366bbf65f4_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_120a1f41-ad64-47d9-92f2-bb057d53f490_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5e6cd605-e8d6-429b-8611-f5833ce866fe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_026f5ef1-5531-45f1-ab3f-72cd43208bd4_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_b579e466-04a4-4acc-989e-dd05304123ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b2e66c1d-0f08-47d9-be50-45e798666376_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent obligations, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9575bfdb-8b7b-4be9-849d-afe395e99d6c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_cbbbcc69-c99b-41ee-9c25-6ff633d2ad1c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_9f9bce68-a8d5-41ee-856d-9fce4450edec_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_bf931567-9f64-4cfa-86c5-2aa08974df85_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_2ca54d17-2b17-4241-bd8b-1d6618910bcd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_8b414e03-8247-430a-9928-6cbdaabc43bf_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during period, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9f9ca9e5-fd82-4b08-9d14-ee58684807bd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8345d810-69b3-45ca-996a-53bf3c413cc1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_b482fd7b-4946-455f-9f1a-cf43bf21280d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_29a6206b-8b5d-45c1-951d-078ac5ceb817_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_40cee564-75b8-4eb5-862c-7343a0d3d6f1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_bb5af065-0f4d-486d-b660-874d8c0b07d5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_52ffb72e-3bc7-4c32-a0e5-c19617b1fcd6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e51567b6-4e45-48de-9ad7-e2454ed7dc36_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_16239b5b-613a-4bf6-8c05-ab152fc89b3e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_GrossProfitAdjustments_115bab32-5107-452d-a1df-15af737e355f_terseLabel_en-US" xlink:label="lab_ebs_GrossProfitAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to gross margin</link:label>
    <link:label id="lab_ebs_GrossProfitAdjustments_label_en-US" xlink:label="lab_ebs_GrossProfitAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit, Adjustments</link:label>
    <link:label id="lab_ebs_GrossProfitAdjustments_documentation_en-US" xlink:label="lab_ebs_GrossProfitAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit, Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_GrossProfitAdjustments" xlink:href="ebs-20230331.xsd#ebs_GrossProfitAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_GrossProfitAdjustments" xlink:to="lab_ebs_GrossProfitAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_b4102ac9-8a39-4506-ace1-15397e393655_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1a1ff447-1512-4dc4-8889-5893b95b7f0b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_05b28a3f-b09c-4dcf-81ae-88d146d81cb1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2564d731-30d3-406a-8bcd-77c68c1e21ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_957c8cbc-bb96-4460-a0b6-f0e8e93646e8_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_0f0f0cdb-10c7-4aee-9601-7f55e95f957a_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_8a927ab4-98e5-465d-b945-bf98c66a918b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b49dd83f-867b-4e68-9d04-046f104a0029_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_f5e1f367-c995-4430-a760-a02b29c339c7_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_29e59873-46b6-44da-850f-c7dd29dcc0ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during period, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_4603acf8-ec81-478a-9da0-9cfda800193b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, current, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_497d37b2-c010-4cad-b469-aa16bdb60bf6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income, Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ded1bb02-8ce2-4df4-9db6-195f3c4dcf75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf4f05a1-da8c-4e4d-ae41-5ac0256d32e0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9719ccd5-2c34-4220-b365-86224267dca6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_d1cafc06-bf9b-4baa-a742-f7f9f28dd510_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_dde7755f-a637-4eb5-b6ce-38bbb6c8063d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3f07acaf-d735-44ab-8a9b-431e8600da77_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_95f62a9d-9d8f-46ff-bfde-6f76dcfcf6c1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_26941eaf-c390-48cf-878a-503954442375_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2bcb0bb3-99f9-4638-80af-3a9904e9444d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_edca4d1d-974d-4bb9-bdb6-a486b6c1a680_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_4ee2d3b2-7494-4bd5-a960-bc335bae9f7a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods and services sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_267a1bc9-0b72-438b-b7ee-225832ff3e1f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3fd4a4c1-f6a5-44cb-82ee-f781744d4cd5_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares outstanding-diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5c0ba2de-8474-4ee5-ae7d-1cc9aa1e2f21_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation &amp; amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c4fc6135-3ecc-43be-b9a5-a17a602e5ef1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityDeductions_8f50ffe0-d444-41fa-9e36-03bd3aa48881_negatedTerseLabel_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityDeductions_label_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deductions</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityDeductions_documentation_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityDeductions" xlink:href="ebs-20230331.xsd#ebs_ContractWithCustomerLiabilityDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractWithCustomerLiabilityDeductions" xlink:to="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledContractReceivables_57e9911a-4659-4c5c-9596-e9ea2f90431a_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables" xlink:to="lab_us-gaap_BilledContractReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_28735ec4-0978-4575-b435-cdf05e6709f7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_e8558bdd-62eb-4ba7-9ccc-988927eb0a70_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, current portion</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_4bc71455-a713-4dba-9072-b38ab8af4e17_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings, building improvements and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_7a3a2f5d-8d77-4375-9e35-ed715ae263f1_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MeasurementInputProbabilityOfPaymentMember_45c769a8-eda2-4909-802c-9f8badd9a456_terseLabel_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of payment</link:label>
    <link:label id="lab_ebs_MeasurementInputProbabilityOfPaymentMember_label_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Payment [Member]</link:label>
    <link:label id="lab_ebs_MeasurementInputProbabilityOfPaymentMember_documentation_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:href="ebs-20230331.xsd#ebs_MeasurementInputProbabilityOfPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:to="lab_ebs_MeasurementInputProbabilityOfPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_520c00dd-be56-4a14-806e-e16234a7963e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200.0 shares authorized, 56.0 and 55.7 shares issued; 50.4 and 50.1 shares outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b5190a39-271c-4186-96b3-3b3599a58f07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_8d6398eb-a3c3-4cb7-8e34-bad983f6c08c_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_25853bba-65cc-4dab-86c0-829bb5e8ae7b_terseLabel_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Leases Supplemental Balance Sheets</link:label>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="ebs-20230331.xsd#ebs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_7303a7ff-1ef5-44e1-878e-c71112faa713_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring costs by segment</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_0b4af9c7-8996-4738-8899-dfbdf5cf5313_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred losses from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_ab3c6733-0fdf-4590-b3f8-911928a4bdd4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c8d5bc94-3b8f-461b-9942-82d2967d62c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_55e238af-46cf-4f8b-9b18-aa8353ca1389_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c9d9dd82-bfc2-48e4-9426-873f8689fbd5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1868e2c2-6150-40ea-87ea-56073aa94206_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b8604476-7777-4c80-9e72-a065c4cacccf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impaired, accumulated impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_bc89963a-9383-44c8-83b0-0ed3387dd617_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ProductsAndServicesSegmentsMember_23d84ffd-ae16-4e2d-9c29-e870fdf2832d_terseLabel_en-US" xlink:label="lab_ebs_ProductsAndServicesSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products And Services Segments</link:label>
    <link:label id="lab_ebs_ProductsAndServicesSegmentsMember_label_en-US" xlink:label="lab_ebs_ProductsAndServicesSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products And Services Segments [Member]</link:label>
    <link:label id="lab_ebs_ProductsAndServicesSegmentsMember_documentation_en-US" xlink:label="lab_ebs_ProductsAndServicesSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products And Services Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsAndServicesSegmentsMember" xlink:href="ebs-20230331.xsd#ebs_ProductsAndServicesSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ProductsAndServicesSegmentsMember" xlink:to="lab_ebs_ProductsAndServicesSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_39dd93fc-a5ca-4ea2-8fde-b8392230a44b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_dc08044b-af11-4b7a-804f-fac4bbc30ce9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9f9fafbd-02cc-4e9e-ac63-ede89cc1a075_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_62d7e5e0-a77b-4ebd-bfe9-052abf4a76df_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1d45dc51-5536-490c-8775-ce059a8b6a8a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_48ac5b39-3934-427a-ad3d-022b82d0d4ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discrete tax expense (benefits)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_cef0443f-6891-4e6a-8aac-1c239485b69c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c01c4fff-b374-4994-a99c-69ea41418487_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment unpaid at period end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfitAbstract_b11fb6ac-53a0-4b4d-8dfe-f17e4b9312ee_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to gross margin:</link:label>
    <link:label id="lab_us-gaap_GrossProfitAbstract_label_en-US" xlink:label="lab_us-gaap_GrossProfitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfitAbstract" xlink:to="lab_us-gaap_GrossProfitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_466f1204-807c-4aef-b422-1338f847377a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_c4de5492-4f2e-42e2-8508-8b806c295966_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ba17681b-4bfe-443b-a002-b735adfc508c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_20a253f3-32fd-4fc7-b532-5ef422ef6eda_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_893eb301-988d-4ec8-9df8-19bb81411e90_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3f2aeb61-be2b-477c-bccd-d0a190914f80_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Useful Life in Years</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_68f60670-a37f-4d43-8e87-4ef2acc9ef2f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e387295c-a422-4ede-8e89-86e3c1a78aea_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_0eb3fd83-633b-40ef-b685-78acd1a1eb70_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio adjustment period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_753e0a62-08ec-4686-8bbb-5266b2428b9f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock-based compensation activity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_28a61f82-694d-488c-920a-464c7d58e86d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_e3a6b718-c79a-46d3-a110-70aefeaafa5b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reconciling items</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Other Significant Reconciling Item, Consolidated [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_a9a446b1-2be6-4f80-aa92-ca4a985ab5c4_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a883272a-a3fa-46c0-b883-45d37fcadce9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4504d7f7-1d49-4da1-939e-efc6e8db85bb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_771b8822-c102-40c7-aa3d-d93275a188c3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e5502e4f-215d-4297-bdd1-3568147f5b1d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_3fae2304-6102-4b8f-bcaf-f388186f9e9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_cede9ade-b1d0-4dad-ae8f-5a81296cb6f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_2418e4b3-acf3-473a-9db3-20e8767ff501_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original principal amount required to repay in the first two years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay in First Two Years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in the first two years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:href="ebs-20230331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ce13fab6-01e8-4722-81a9-f787161cac3a_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_543ed19a-c58b-4d8c-b9db-90986baddbca_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_2e26579a-8b55-40d5-907a-313a86325f59_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_33ce45ff-9f7b-472f-a689-dbbdddb526e5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance payments</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_6b8594c7-5931-4e47-bb0c-e6ddf063bfd3_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, payment to be received, remainder of fiscal year</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8a87da46-8ccd-4081-a275-ac327055a79f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_7ee56029-0847-4544-9d6a-f37eb6f47fb0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_cfd8b5cb-f7fb-4113-a518-3e31b6b531bf_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_4eea7d2d-5840-4a8e-89c4-7bf6c9f9e41f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba9bcec9-a75b-4707-b4da-8811927f3608_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a0d27598-c000-4b20-b158-3ef2c2f6d288_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_eb7a0d9a-8a58-440c-8e56-6842890944a8_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a52a97ee-39fd-490d-9e35-14db3cb6e96a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3626c661-8522-41d2-9dea-0b4d8118295c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_083bee2b-1288-4ebc-9b7d-5f4b045377bd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_f1ff8baa-ae6d-469c-8642-6d3e269a14c1_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 5.6 and 5.6 common shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_970b8f72-0e66-4a84-8289-3d4c9608a42a_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_a760af10-37d4-4a42-a034-3527fd2f729e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent_76dc0aac-0cb7-469b-9922-763319a1a0c3_terseLabel_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent_label_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Compensation, Current</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent_documentation_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Compensation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent" xlink:href="ebs-20230331.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent" xlink:to="lab_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ProductsSegmentAbstract_7e2bd24a-4770-43e7-be1a-c3f8782aad2b_terseLabel_en-US" xlink:label="lab_ebs_ProductsSegmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_ebs_ProductsSegmentAbstract_label_en-US" xlink:label="lab_ebs_ProductsSegmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Segment [Abstract]</link:label>
    <link:label id="lab_ebs_ProductsSegmentAbstract_documentation_en-US" xlink:label="lab_ebs_ProductsSegmentAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentAbstract" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ProductsSegmentAbstract" xlink:to="lab_ebs_ProductsSegmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c1f40cf2-92b0-4d1a-b704-2aefc55cfd5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments other than options, forfeited in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_5ac7aebf-2661-4b9e-aa7b-259606701bba_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_faf62c7b-b87f-471c-88d1-ffb1451a2936_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_13b8c646-9f89-4b6d-877d-f7fb989daeff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_d3d3c23e-c8aa-42eb-98f8-61eac6479ae3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_77eedb8a-fbe9-4cf7-ad70-79f28a44f736_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_20b8440e-dae3-44fd-944e-7314b31f7d8b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_47239c18-e008-4a77-9b93-ea82982a5139_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_004cbe78-dba2-4a44-a4ff-02a2b41e20a4_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_b42904e8-5e83-4e9c-ab76-4de0f4c80a3a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_54422685-073d-41e7-b32d-51e1cb962668_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_UnallocatedResearchAndDevelopmentMember_4e158754-c55e-452d-9344-75c8ef16ac31_terseLabel_en-US" xlink:label="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_ebs_UnallocatedResearchAndDevelopmentMember_label_en-US" xlink:label="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unallocated Research And Development [Member]</link:label>
    <link:label id="lab_ebs_UnallocatedResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unallocated Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedResearchAndDevelopmentMember" xlink:href="ebs-20230331.xsd#ebs_UnallocatedResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_UnallocatedResearchAndDevelopmentMember" xlink:to="lab_ebs_UnallocatedResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5b6b918f-854e-4a63-b5a3-b1a9c8ee8acc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_85f009a9-26e1-4f44-aa54-15378bd0876f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7d84db38-d8d1-41ed-9d17-cf4c43c4bac6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_d54925b4-6f25-42a1-8712-ba5c2c222c90_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfProductAndServiceCategories_d2574389-067b-4a3a-997b-a0e64f7d402a_terseLabel_en-US" xlink:label="lab_ebs_NumberOfProductAndServiceCategories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product and service categories</link:label>
    <link:label id="lab_ebs_NumberOfProductAndServiceCategories_label_en-US" xlink:label="lab_ebs_NumberOfProductAndServiceCategories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product And Service Categories</link:label>
    <link:label id="lab_ebs_NumberOfProductAndServiceCategories_documentation_en-US" xlink:label="lab_ebs_NumberOfProductAndServiceCategories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product And Service Categories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductAndServiceCategories" xlink:href="ebs-20230331.xsd#ebs_NumberOfProductAndServiceCategories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfProductAndServiceCategories" xlink:to="lab_ebs_NumberOfProductAndServiceCategories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_59b7544a-046c-4642-9891-fe0ee2bd66b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated_b9c81d59-b32d-4867-9f4c-a2b6dc354063_terseLabel_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees expected to join Bavarian Nordic</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated_label_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Expected Number Of Positions Eliminated</link:label>
    <link:label id="lab_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated_documentation_en-US" xlink:label="lab_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Expected Number Of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated" xlink:href="ebs-20230331.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated" xlink:to="lab_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a2901ec4-1408-428b-9d9d-a240bd52604c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_bb8bae5d-616d-4e79-b0b5-a938f37396cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_20aa632d-18c4-4ce7-a37e-70812a83298e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6b6dc11e-2184-4534-a44c-aaba4c9258a5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_13027906-4914-4dcc-9219-1237a14f6951_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9629636f-02d3-4926-94db-8568c12293f8_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_356262b9-95e2-4e45-b397-fec1bba26ab4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_2a1f3827-dd1a-4db1-85a4-6fa7f5c01e07_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_73138e79-922e-4de8-9f4f-7eb9dcf54941_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_8a01d483-f162-48c9-a927-fb067583d76c_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a82de45b-1d55-4935-9e0d-d3476efb935d_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_f2cfd5ca-c91a-4568-8def-9c7a794f0542_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_01a24b53-5fa5-41b8-a331-5d4296e06490_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_27c1663b-adfa-4939-8b5b-ff0bc79d8837_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7ae2e485-ce80-471c-9a80-282bfa81c4bb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of the business and organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_EmployeeBenefitsMember_ccb6d4ed-c70c-423e-9b02-b99f2554c652_terseLabel_en-US" xlink:label="lab_ebs_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_ebs_EmployeeBenefitsMember_label_en-US" xlink:label="lab_ebs_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits [Member]</link:label>
    <link:label id="lab_ebs_EmployeeBenefitsMember_documentation_en-US" xlink:label="lab_ebs_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember" xlink:href="ebs-20230331.xsd#ebs_EmployeeBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_EmployeeBenefitsMember" xlink:to="lab_ebs_EmployeeBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9c200f80-eaf7-4d99-af82-c8a125f6e970_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_bed79439-a763-4b85-b0d8-8be973752864_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_804eb4f4-f3c6-4857-a33e-1d1fc93e485b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation activity (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5d06a231-26a8-4871-9676-33ee9ae88f66_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_8ad59a11-da32-4b51-b840-263b95064e4e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_eee6ce3b-93ca-4781-89f8-b68b0ebc4db1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aefdf997-9756-408c-8dbc-4f327a3d419e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9ed403fa-6471-4c91-943a-43a4a9c04817_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1b1e15ae-8584-46c2-8afa-aac3b5220970_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_86a9ed32-2b7f-4a64-a2fc-482ebf6701cd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_bcec63ff-e37d-4fe7-8c16-47d07c074c9e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c0594204-e5ab-4555-bdfe-b492d95d0821_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_f4912230-ce1d-4810-8540-a8a6fd5b4afa_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8e086d7e-87b1-4e1d-84bb-f8b7f312ad98_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_b1e2f968-3007-4a67-ad9f-2d46f89fc382_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_8cff1406-7779-40d5-94b8-8a04d4835fdc_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_d54d77d3-cd9c-4b52-a272-efcb526ae1c4_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_b5ae208f-9aa6-423a-9950-153abd68e85e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_29d321ed-381a-4944-8a12-ec58132cc5ad_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eb407083-b320-495b-84ed-3e710c76d3f1_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f8a7552c-0bb4-4724-a992-d14a907b9dd7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares outstanding-basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0dfac621-cab2-4735-b9aa-c6039ded3c7f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_IncomeTaxesLineItems_c49609bb-cb3d-456b-bf37-76bace310905_terseLabel_en-US" xlink:label="lab_ebs_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_ebs_IncomeTaxesLineItems_label_en-US" xlink:label="lab_ebs_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_ebs_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_ebs_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesLineItems" xlink:href="ebs-20230331.xsd#ebs_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_IncomeTaxesLineItems" xlink:to="lab_ebs_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6962e29f-be79-4110-b527-e7647df098fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_a65770f7-da46-4a65-ac64-e0612bd8ad7c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on term loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Medium-term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:to="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_TravelHealthBusinessMember_15c830e7-ad44-459f-a3d7-9cfc026f3624_terseLabel_en-US" xlink:label="lab_ebs_TravelHealthBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Travel Health Business</link:label>
    <link:label id="lab_ebs_TravelHealthBusinessMember_label_en-US" xlink:label="lab_ebs_TravelHealthBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Travel Health Business [Member]</link:label>
    <link:label id="lab_ebs_TravelHealthBusinessMember_documentation_en-US" xlink:label="lab_ebs_TravelHealthBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Travel Health Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember" xlink:href="ebs-20230331.xsd#ebs_TravelHealthBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TravelHealthBusinessMember" xlink:to="lab_ebs_TravelHealthBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1e7fe24c-ea9a-4730-89d9-7ddcc8cdcfe6_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_06b3c277-e2c4-45f1-8662-ca3c1ba0db83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents included in assets held for sale</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_de4553bf-c9a7-43ed-b6a5-642590197e05_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents included in assets held for sale</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4afe6954-2ea7-4bf6-8e45-2bbfafec0f32_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_f9b7f1d9-4e8f-4c16-a77f-40a03461539b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_071a3adb-6c64-4f82-8d44-17732a7fe8bb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ec73def1-d834-405b-839d-d567c352577f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_cb97d8bc-5133-4ecb-a658-b9d1e916d543_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_f79a29bf-6954-4ff3-b815-d405ec8b9cc6_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_11594ac5-d348-44e9-b3a3-0908395bbfb9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_2692c93d-5c88-4da4-b00b-370afa7b8dcd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4d0aa976-db65-4c68-8096-77c74cdc5ee0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a66717bc-c1fe-42ec-aab1-a839f8bababf_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ca4d1921-dfc8-4535-8c5f-344debbe4f8d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4dc00611-114f-4a6e-aa69-58ee56e3141c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_02db6bd0-069d-4807-9a6e-0fd2ed87054b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_1cd8ed14-d4ed-4d96-aa8a-07f5413f46c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for expected credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_68441b54-2dfd-4216-80fc-0e1dcc478102_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_359c6ebf-878a-4ca1-89da-bff336062832_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plan</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_8a3512fd-b331-4b49-b659-e061f9c5460f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_b43c7af6-6f08-4738-8e6e-a9c19df64a76_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio, maximum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, One</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_ee617652-95d8-433c-8b8a-4cef0f84efff_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_TermLoanFacilityMember_15c6b291-db90-46d0-9979-866f18ff91cc_verboseLabel_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_label_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan dated December 2013.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember" xlink:href="ebs-20230331.xsd#ebs_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TermLoanFacilityMember" xlink:to="lab_ebs_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_1c758363-d95d-49e5-8e3b-107f6b933ab1_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original principal amount required to repay during the third year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay During the Third Year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in the third year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:href="ebs-20230331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_e0a1cd1d-5226-4fe6-bc3e-73ecc064edb4_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, payment to be received, year two</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_74aab19a-30d8-4845-8f97-ba4384510d5a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon the occurrence of a change in control</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_af4673f1-90d8-448c-864b-121315f6c134_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract_9a1d4abd-5849-4ca0-bb07-18ae8e649061_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cost of sales:</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3143faab-a122-41e5-b575-80feaddb8a0c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid for stock-based compensation activity</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b73d68f7-3af6-466a-844a-4d1e38e68a7d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_4c840e9b-5cb4-471c-a04b-6759a8e3de81_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_dd1f4f9b-f53f-4c27-bbde-f0276324dd02_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurocurrency</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_476a320e-4109-41f6-8c20-6be3a1f3ded4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_09269e6e-c95b-4026-821a-98ea6cf61b87_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ee16f528-5bd4-46f7-8fcf-2388b92b48a1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_edcd0ce9-d016-4176-91fa-7067ab61cf9d_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio, adjustment</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Two</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_ab3e2946-e7fc-44a7-88e2-e2dd5f1eb293_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_babf3fc1-3529-40f2-aad1-61acc7daf8ca_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_255c3976-7966-4fc4-92be-1a7756c915fb_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_896cd333-9b7b-4928-9ef3-1287feac7d26_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_64d089d1-df32-434f-b73d-5a71182f3ad7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_30842937-40fd-44b9-81b5-af71cf1a5b5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_2691b580-36d1-477d-b7cc-59b3686744f4_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_59817a66-d4cf-4691-b44f-862a7974e296_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to August 15, 2023</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f16ab2df-9532-455d-917e-25bda99fb1fc_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_c65653c0-ad8e-48ee-8baa-ad7ab6f1774e_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_d48dba85-aa85-435b-8665-a0a21b297c78_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3c23c92b-3b41-4782-bab9-c8065db6d556_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_aaeb675b-4649-4e7a-bf0c-245d9d13630e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5f7949b0-6bb5-4904-8375-13348bce39fd_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_405598ab-0209-478a-8ecb-ffca1f93f7ee_terseLabel_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target payout percentage</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_label_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Target Payout Percentage</link:label>
    <link:label id="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_documentation_en-US" xlink:label="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Target Payout Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:href="ebs-20230331.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:to="lab_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9f2ea45a-8278-4333-964a-d16c91af1c5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5c037ab4-4b4d-4503-af78-10b4c08340ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_29453ec1-2c9d-4f1a-8c69-d33eb27418a6_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f9e2355f-b189-411d-89cc-c4873d99a8e6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_ae7dc7d6-ac63-480b-9d45-9ee1e1920a5f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities held for sale:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_1ec41fbb-ff49-434e-9ba2-aeb63f07f42c_terseLabel_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Senior Unsecured Notes due 2028</link:label>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_label_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due August 2028 [Member]</link:label>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_documentation_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due August 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:href="ebs-20230331.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:to="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_24130e5e-8ee4-4cf3-adcd-b8eba19e4cdb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_37dd2607-d9d3-4b70-8256-f160baf634d3_totalLabel_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CDMO</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_7da827cc-671c-4079-8995-be274ded9b00_terseLabel_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_documentation_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="ebs-20230331.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RestructuringPlan2023Member_27efce51-77c6-448a-a076-bf6d010dd330_terseLabel_en-US" xlink:label="lab_ebs_RestructuringPlan2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Restructuring Plan</link:label>
    <link:label id="lab_ebs_RestructuringPlan2023Member_label_en-US" xlink:label="lab_ebs_RestructuringPlan2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan 2023 [Member]</link:label>
    <link:label id="lab_ebs_RestructuringPlan2023Member_documentation_en-US" xlink:label="lab_ebs_RestructuringPlan2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlan2023Member" xlink:href="ebs-20230331.xsd#ebs_RestructuringPlan2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RestructuringPlan2023Member" xlink:to="lab_ebs_RestructuringPlan2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6226cc32-56a3-4279-9be3-e27ef4d31909_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_030ecfc4-0584-48b3-8f9c-377379d1c85a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_36feb317-75f5-49d2-a703-c0acd24c82cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_a46d1b89-24f4-42b7-bf77-3aaa8a22e826_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_06fbb49b-f20c-4e57-a5cc-fcb10e86878c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_5e2ddbbd-9c19-4673-9e9a-2864b3baea3a_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_b5f6bcbb-dfc3-4703-967f-3db0bd7e35b7_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original principal amount required to repay remaining year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay Remaining Years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in remaining years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:href="ebs-20230331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_e4fc55c6-f541-4fd5-a6c5-bf1f302f2ce0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Asset Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_531386d5-e4b4-44c5-a3d9-6d4a5cc91ee9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable and payable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_032b2932-f4f5-4aa7-b60a-dbc47e5e9cf8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_dc26992c-a602-4ae9-b88c-2b47bad9dab6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_8d7b02b4-543f-4e95-883f-d0262815870a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_88fec212-ae02-4b2e-9128-31232b7bd4ee_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_fafebf92-9693-4b3d-992d-a625001fc4da_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_5478cde1-45e5-4414-8cdd-d600301ebb70_verboseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3520b617-4ca9-4ff6-8f7c-5e92b763b357_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, deferred tax asset, increase, amount</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_7a81baa4-0025-4389-aa91-fd41d9f69787_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_8f912a7f-ff2c-4522-961c-4a79e28c0030_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_ef4d96e4-519e-4b59-ab15-53677f9827f7_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_7cf0eafa-4892-48b2-ab8e-2b4081ce8a09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_86d9ded3-0df9-4350-8482-f07401122057_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_458b9b12-b26d-4e82-b1cc-2e8693fc3204_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_025b20f3-7417-478d-b95f-7d64b076d408_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_892da985-d415-4383-a877-037792668567_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash and cash equivalents and restricted cash at March&#160;31, 2023 and December&#160;31, 2022:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842e9978-26b4-4918-9b40-a6ab09ffee56_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_dc4ab038-38bf-4450-80c9-c575a79731b3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f2f9f156-9277-4b12-b3d6-7ae4129f0505_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_10c1802b-e29b-4ecd-8ab5-241dee17d5d9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_EmployeeTransitionMember_06448f0a-c3b9-4eaa-9fa2-9b7ca38144ef_terseLabel_en-US" xlink:label="lab_ebs_EmployeeTransitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee transition</link:label>
    <link:label id="lab_ebs_EmployeeTransitionMember_label_en-US" xlink:label="lab_ebs_EmployeeTransitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Transition [Member]</link:label>
    <link:label id="lab_ebs_EmployeeTransitionMember_documentation_en-US" xlink:label="lab_ebs_EmployeeTransitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Transition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember" xlink:href="ebs-20230331.xsd#ebs_EmployeeTransitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_EmployeeTransitionMember" xlink:to="lab_ebs_EmployeeTransitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_8ca7fe5e-b8c4-4f2c-aef0-32efb8ac4b6e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_60c4c172-2767-42b0-8064-d462641cf34b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_59cd781c-d473-4bff-9b8e-e2fe93ea08cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_47a57ba9-3059-4cc3-be02-4e08bf3af964_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash excluding cash classified within assets held for sale</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_40c0149a-f63c-480f-a6da-597b16222b81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_fb18b341-77b8-48ec-88d1-01be3e612ec6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_357ac042-e586-4062-807e-754fb8268dff_terseLabel_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended credit agreement dated October 15, 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember" xlink:href="ebs-20230331.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AmendedCreditAgreementMember" xlink:to="lab_ebs_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_348a6c08-c315-493f-8933-cc6f5ab80827_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_e4343fe7-a9cd-4da8-9394-c13bac94a4d1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_37ab6320-7b93-45e1-b31d-773ba16a5843_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a5ca8790-24e3-4d96-ba0f-49d8b08cc08b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65c4c027-a461-4270-9312-88a693c56359_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c985905-e3dd-464a-bd3a-900d3c415977_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_IncomeTaxesTable_3a804362-6094-4fb8-9f45-86d694545a70_terseLabel_en-US" xlink:label="lab_ebs_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_ebs_IncomeTaxesTable_label_en-US" xlink:label="lab_ebs_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_ebs_IncomeTaxesTable_documentation_en-US" xlink:label="lab_ebs_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesTable" xlink:href="ebs-20230331.xsd#ebs_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_IncomeTaxesTable" xlink:to="lab_ebs_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_fbc1ce78-40fc-4cbe-823d-562e1628464c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_34b4c52e-60b7-4c09-a1a0-89c9a30a3b91_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3a9a166e-346d-402d-ac4b-80835744539d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_96fc4127-1d35-4fb4-913b-7ebd4a4c30b1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_eceb049e-4179-491b-91bb-bfc6fe4effbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_63ef316f-d577-440b-bf24-9c8e6465c7de_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3b3de9f4-f8bf-4a41-b419-494785dd2cc8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_622cdb23-be6a-4f0e-809d-9f4b005ee702_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_975fe4e1-d747-45b9-97b4-99c07715c685_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_1fae3118-0289-43a9-b9cd-172f21d2b4d9_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio rolling period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b54c97c3-4468-4dfb-bc69-06e5d68cdf54_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental information on non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3641f397-5b12-45db-b49d-c8fbcffdb04d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_9362a64c-3fc9-4235-a567-ecfcbf407882_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4ca2e46b-cf47-4259-a20b-b00d961d21c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_997b2bce-8e48-42ca-8e33-a4ea613f9950_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_401322c7-033d-465a-b761-ea7efb4a7f2b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_391bd39c-732b-40ec-8aaf-516bdd19c9ac_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4164cdae-45c8-430d-ab1c-b1963c93d7bb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0b2f84ac-dd01-4bcf-b899-ad69fcef35e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Income per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_e5785d19-3d26-4343-9138-8f43b3d57c9e_terseLabel_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right</link:label>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_label_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Proceeds Excess Amount from Dispositions of Property or Casualty Events Subject to Certain Reinvestment Right</link:label>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_documentation_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:href="ebs-20230331.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:to="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_8c46da29-02f8-4be1-9124-22349b86a34a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_6061cde0-0cd9-4550-95ee-d1963487f8f9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated, percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_ed700ee9-b16a-40a3-abe2-613c13531511_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ebs-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:da57861a-e185-4b6f-8b91-f9335b77a88a,g:0a9819bf-1d2f-49f0-b0b7-eedd5e464486-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPage" xlink:type="simple" xlink:href="ebs-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_64dfd153-9667-4816-b920-cf38adea56de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_DocumentType_64dfd153-9667-4816-b920-cf38adea56de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0b7602c2-9d3b-44cb-a87a-b9640c0aaaa5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_DocumentQuarterlyReport_0b7602c2-9d3b-44cb-a87a-b9640c0aaaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e2bece45-bb42-4878-b43b-4e74f755e845" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_DocumentPeriodEndDate_e2bece45-bb42-4878-b43b-4e74f755e845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_78b96b27-31a5-498a-a63d-b965d939df62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_DocumentTransitionReport_78b96b27-31a5-498a-a63d-b965d939df62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_85b4440f-e335-4c99-b5bd-5ceb192e27f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityFileNumber_85b4440f-e335-4c99-b5bd-5ceb192e27f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ee09343c-cc86-4bfa-b4c1-0a2a71e68b91" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityRegistrantName_ee09343c-cc86-4bfa-b4c1-0a2a71e68b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_96225970-6bca-4fe1-ac31-86d0a566c1e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_96225970-6bca-4fe1-ac31-86d0a566c1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_123742cd-2cea-4474-b504-61ff726decdd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityTaxIdentificationNumber_123742cd-2cea-4474-b504-61ff726decdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_15e70279-4e36-4b3a-84fd-9fce625eb76a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityAddressAddressLine1_15e70279-4e36-4b3a-84fd-9fce625eb76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f02377ad-8073-40d8-951e-a1bcf1d5ff92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityAddressCityOrTown_f02377ad-8073-40d8-951e-a1bcf1d5ff92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a7724ba6-2f90-4306-adec-a9efd1d316bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityAddressStateOrProvince_a7724ba6-2f90-4306-adec-a9efd1d316bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b94813b1-e3b2-4cfd-a468-f54d872c4a33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityAddressPostalZipCode_b94813b1-e3b2-4cfd-a468-f54d872c4a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_08fe2d17-e4d6-4cf8-8237-eb81b9b7870b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_CityAreaCode_08fe2d17-e4d6-4cf8-8237-eb81b9b7870b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_44c1a5b6-33e2-4fcb-95f9-d907bba9a371" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_LocalPhoneNumber_44c1a5b6-33e2-4fcb-95f9-d907bba9a371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d3fbdda6-bb0b-4a12-b75b-c20a08d8a856" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_Security12bTitle_d3fbdda6-bb0b-4a12-b75b-c20a08d8a856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_89db8164-6ac7-4382-83f0-1079049c31fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_TradingSymbol_89db8164-6ac7-4382-83f0-1079049c31fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_283cdedc-9578-40c0-8fde-3a01f22fa004" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_SecurityExchangeName_283cdedc-9578-40c0-8fde-3a01f22fa004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0aad5579-036b-4933-9b8f-3947fa21210d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityCurrentReportingStatus_0aad5579-036b-4933-9b8f-3947fa21210d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9785406f-d5a2-4f1d-8983-157a72f7ff00" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityInteractiveDataCurrent_9785406f-d5a2-4f1d-8983-157a72f7ff00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_82124dc7-e235-4ff1-ac08-23f4536119e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityFilerCategory_82124dc7-e235-4ff1-ac08-23f4536119e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e9254e2b-15b1-4b7a-9b34-7fb91974b196" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntitySmallBusiness_e9254e2b-15b1-4b7a-9b34-7fb91974b196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_094023a6-285c-4cb3-90a3-ba69f3fc5ad6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityEmergingGrowthCompany_094023a6-285c-4cb3-90a3-ba69f3fc5ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f9f0b44d-ffba-4d01-aad4-2a093256684b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityShellCompany_f9f0b44d-ffba-4d01-aad4-2a093256684b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ed341f00-ea2d-4419-919b-1097423c691a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ed341f00-ea2d-4419-919b-1097423c691a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_43c13f62-49b2-4e35-8425-1041e62bdff6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_EntityCentralIndexKey_43c13f62-49b2-4e35-8425-1041e62bdff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9a770fc1-7ed7-4a83-aea7-7f308eb2d447" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_CurrentFiscalYearEndDate_9a770fc1-7ed7-4a83-aea7-7f308eb2d447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b56dae16-44ef-456a-8ecb-de9ebd44531d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_AmendmentFlag_b56dae16-44ef-456a-8ecb-de9ebd44531d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_326cf85c-2235-4bb7-872f-5dd659c0f533" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_DocumentFiscalYearFocus_326cf85c-2235-4bb7-872f-5dd659c0f533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_db0958d0-516b-44fa-b238-b228d701f362" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6daf400b-3ab4-4c22-85d5-988715666a7f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_db0958d0-516b-44fa-b238-b228d701f362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e47ae1a4-507c-4c1e-9aa6-a3c6400a5290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ac1b57e8-5da7-4959-897f-1a2787247043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e47ae1a4-507c-4c1e-9aa6-a3c6400a5290" xlink:to="loc_us-gaap_AssetsAbstract_ac1b57e8-5da7-4959-897f-1a2787247043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1f08789c-e5b3-45ef-87de-59984e6c0abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac1b57e8-5da7-4959-897f-1a2787247043" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1f08789c-e5b3-45ef-87de-59984e6c0abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e4951b38-3a43-4df7-9b96-8386378ca697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f08789c-e5b3-45ef-87de-59984e6c0abb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e4951b38-3a43-4df7-9b96-8386378ca697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_43fd6fad-60bf-4d3a-b307-c62685d9101d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f08789c-e5b3-45ef-87de-59984e6c0abb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_43fd6fad-60bf-4d3a-b307-c62685d9101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c770b76c-0041-46b2-b8a2-3a4d4edfd2af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f08789c-e5b3-45ef-87de-59984e6c0abb" xlink:to="loc_us-gaap_InventoryNet_c770b76c-0041-46b2-b8a2-3a4d4edfd2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f58ac16e-3b10-4e11-971d-1705ef245218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f08789c-e5b3-45ef-87de-59984e6c0abb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f58ac16e-3b10-4e11-971d-1705ef245218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d8813d6f-46be-4855-9b40-b907280e78c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f08789c-e5b3-45ef-87de-59984e6c0abb" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d8813d6f-46be-4855-9b40-b907280e78c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ee79870c-ab81-4640-99c1-8a103b17193f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1f08789c-e5b3-45ef-87de-59984e6c0abb" xlink:to="loc_us-gaap_AssetsCurrent_ee79870c-ab81-4640-99c1-8a103b17193f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4a55a24b-8e19-479a-94f1-16d5b8a5d56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac1b57e8-5da7-4959-897f-1a2787247043" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4a55a24b-8e19-479a-94f1-16d5b8a5d56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_74f9f8d9-3506-422a-9f57-166c19ca0462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac1b57e8-5da7-4959-897f-1a2787247043" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_74f9f8d9-3506-422a-9f57-166c19ca0462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_432d5160-6cb7-4b15-bde3-a8b16e63ff41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac1b57e8-5da7-4959-897f-1a2787247043" xlink:to="loc_us-gaap_Goodwill_432d5160-6cb7-4b15-bde3-a8b16e63ff41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_84e2e7de-1850-490f-a311-81774d71cc29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac1b57e8-5da7-4959-897f-1a2787247043" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_84e2e7de-1850-490f-a311-81774d71cc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3c8e7c23-df84-4f77-9149-658995ccbabd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ac1b57e8-5da7-4959-897f-1a2787247043" xlink:to="loc_us-gaap_Assets_3c8e7c23-df84-4f77-9149-658995ccbabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18a44b37-a332-4687-8d7b-fa9d7e4b6eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e47ae1a4-507c-4c1e-9aa6-a3c6400a5290" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18a44b37-a332-4687-8d7b-fa9d7e4b6eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_69a9b5a7-e84d-4603-9de3-f9bf7c9f7e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18a44b37-a332-4687-8d7b-fa9d7e4b6eee" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_69a9b5a7-e84d-4603-9de3-f9bf7c9f7e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3e72749d-c914-4cb9-8273-393dadda68b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69a9b5a7-e84d-4603-9de3-f9bf7c9f7e88" xlink:to="loc_us-gaap_AccountsPayableCurrent_3e72749d-c914-4cb9-8273-393dadda68b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a97cb239-dd3e-46e3-bafa-2445a81b6c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69a9b5a7-e84d-4603-9de3-f9bf7c9f7e88" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a97cb239-dd3e-46e3-bafa-2445a81b6c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_383eb845-c432-464b-a0ec-b52ea8aa652b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69a9b5a7-e84d-4603-9de3-f9bf7c9f7e88" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_383eb845-c432-464b-a0ec-b52ea8aa652b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_7ea295cb-769e-4e94-a8be-a66a94752139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69a9b5a7-e84d-4603-9de3-f9bf7c9f7e88" xlink:to="loc_us-gaap_NotesPayableCurrent_7ea295cb-769e-4e94-a8be-a66a94752139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_13b8c2e5-56a3-430c-92f3-d7f35f4e2c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69a9b5a7-e84d-4603-9de3-f9bf7c9f7e88" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_13b8c2e5-56a3-430c-92f3-d7f35f4e2c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_4ffdffcf-0931-43b3-8562-c53b55838b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69a9b5a7-e84d-4603-9de3-f9bf7c9f7e88" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_4ffdffcf-0931-43b3-8562-c53b55838b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4a090241-22f9-4451-8f90-9abd87e57463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_69a9b5a7-e84d-4603-9de3-f9bf7c9f7e88" xlink:to="loc_us-gaap_LiabilitiesCurrent_4a090241-22f9-4451-8f90-9abd87e57463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_56c14f6c-3553-4069-877c-729b0208318e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18a44b37-a332-4687-8d7b-fa9d7e4b6eee" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_56c14f6c-3553-4069-877c-729b0208318e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7993995c-d8ec-4fe1-ac06-d61ec9fece20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18a44b37-a332-4687-8d7b-fa9d7e4b6eee" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7993995c-d8ec-4fe1-ac06-d61ec9fece20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e7c98ff9-19f8-412f-9cf5-54f2da0f1439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18a44b37-a332-4687-8d7b-fa9d7e4b6eee" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e7c98ff9-19f8-412f-9cf5-54f2da0f1439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e5ab50df-116f-49f2-a6a2-f15229dd67f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18a44b37-a332-4687-8d7b-fa9d7e4b6eee" xlink:to="loc_us-gaap_Liabilities_e5ab50df-116f-49f2-a6a2-f15229dd67f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_682209d5-20da-453c-8b36-1e38c0e702cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18a44b37-a332-4687-8d7b-fa9d7e4b6eee" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_682209d5-20da-453c-8b36-1e38c0e702cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_30f59770-d2b6-4eac-a377-c70fd2f52436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_682209d5-20da-453c-8b36-1e38c0e702cd" xlink:to="loc_us-gaap_PreferredStockValue_30f59770-d2b6-4eac-a377-c70fd2f52436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_daadc3b7-2171-4ce9-8253-b70616594689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_682209d5-20da-453c-8b36-1e38c0e702cd" xlink:to="loc_us-gaap_CommonStockValue_daadc3b7-2171-4ce9-8253-b70616594689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f1e1fa0f-22fd-4fae-b554-23f1b8a5eb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_682209d5-20da-453c-8b36-1e38c0e702cd" xlink:to="loc_us-gaap_TreasuryStockValue_f1e1fa0f-22fd-4fae-b554-23f1b8a5eb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e608cc8f-33b1-467d-b889-1ece411dd519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_682209d5-20da-453c-8b36-1e38c0e702cd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e608cc8f-33b1-467d-b889-1ece411dd519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aa547a52-f600-45a6-8bc5-2ba0bccf8c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_682209d5-20da-453c-8b36-1e38c0e702cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aa547a52-f600-45a6-8bc5-2ba0bccf8c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9dc9c82-1261-4f9f-bef4-fe77d78a811d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_682209d5-20da-453c-8b36-1e38c0e702cd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9dc9c82-1261-4f9f-bef4-fe77d78a811d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_20f6352c-73ea-4fae-bc93-51f0afc51e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_682209d5-20da-453c-8b36-1e38c0e702cd" xlink:to="loc_us-gaap_StockholdersEquity_20f6352c-73ea-4fae-bc93-51f0afc51e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e18fae91-4adb-4642-b7ae-da679820d359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18a44b37-a332-4687-8d7b-fa9d7e4b6eee" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e18fae91-4adb-4642-b7ae-da679820d359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ac810070-2264-4716-9767-cdc8624c8889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6c7782b-a533-4062-ba68-ab24ce6bcbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ac810070-2264-4716-9767-cdc8624c8889" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6c7782b-a533-4062-ba68-ab24ce6bcbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56a9e134-a8c2-4e32-9f51-01e69a12d46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6c7782b-a533-4062-ba68-ab24ce6bcbc4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56a9e134-a8c2-4e32-9f51-01e69a12d46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_982c0325-b446-4432-810f-395ba2da1f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56a9e134-a8c2-4e32-9f51-01e69a12d46d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_982c0325-b446-4432-810f-395ba2da1f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d242e515-e127-4247-8485-65ab403935f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56a9e134-a8c2-4e32-9f51-01e69a12d46d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d242e515-e127-4247-8485-65ab403935f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_81aded52-f367-4efa-a025-60b289bb483a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56a9e134-a8c2-4e32-9f51-01e69a12d46d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_81aded52-f367-4efa-a025-60b289bb483a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_42cce2f4-ece3-4c5b-b1a6-062828eed752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56a9e134-a8c2-4e32-9f51-01e69a12d46d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_42cce2f4-ece3-4c5b-b1a6-062828eed752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5a010f25-4989-4aa3-ae00-b4e586b7142f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56a9e134-a8c2-4e32-9f51-01e69a12d46d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5a010f25-4989-4aa3-ae00-b4e586b7142f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a81488f3-6e11-4f3f-afa5-416cd8d30e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56a9e134-a8c2-4e32-9f51-01e69a12d46d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a81488f3-6e11-4f3f-afa5-416cd8d30e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_02c5ffca-cba8-4bf1-b7b4-a5276e1171c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56a9e134-a8c2-4e32-9f51-01e69a12d46d" xlink:to="loc_us-gaap_CommonStockSharesIssued_02c5ffca-cba8-4bf1-b7b4-a5276e1171c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b8f78dfb-7c1a-44e9-b1d5-61c5d60780f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56a9e134-a8c2-4e32-9f51-01e69a12d46d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b8f78dfb-7c1a-44e9-b1d5-61c5d60780f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b1f21735-438a-4c98-a92e-4d353016df55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_56a9e134-a8c2-4e32-9f51-01e69a12d46d" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b1f21735-438a-4c98-a92e-4d353016df55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ed051737-48bf-45a5-bb00-86a50727b1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d1e0577d-792f-4d18-b651-2d673d76d9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ed051737-48bf-45a5-bb00-86a50727b1d2" xlink:to="loc_us-gaap_StatementTable_d1e0577d-792f-4d18-b651-2d673d76d9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4940aca8-a222-4e85-86ae-5c72492f6a81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d1e0577d-792f-4d18-b651-2d673d76d9e2" xlink:to="loc_srt_ProductOrServiceAxis_4940aca8-a222-4e85-86ae-5c72492f6a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9750ca6f-c7c3-4a30-aa55-86ee880387ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4940aca8-a222-4e85-86ae-5c72492f6a81" xlink:to="loc_srt_ProductsAndServicesDomain_9750ca6f-c7c3-4a30-aa55-86ee880387ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_987dab52-f4d9-474e-80ec-6247b3cbe4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9750ca6f-c7c3-4a30-aa55-86ee880387ba" xlink:to="loc_us-gaap_ProductMember_987dab52-f4d9-474e-80ec-6247b3cbe4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_f78845a8-9486-44c0-9f16-0f77896343a2" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9750ca6f-c7c3-4a30-aa55-86ee880387ba" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_f78845a8-9486-44c0-9f16-0f77896343a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_83211c23-1b1e-496b-8923-3837a88732c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_f78845a8-9486-44c0-9f16-0f77896343a2" xlink:to="loc_us-gaap_ServiceMember_83211c23-1b1e-496b-8923-3837a88732c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_10c4149f-0204-454c-9c9d-06dc4308abf7" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_f78845a8-9486-44c0-9f16-0f77896343a2" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_10c4149f-0204-454c-9c9d-06dc4308abf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_34e3a412-a7bf-4d25-b898-f326c9653366" xlink:href="ebs-20230331.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9750ca6f-c7c3-4a30-aa55-86ee880387ba" xlink:to="loc_ebs_ContractsAndGrantsMember_34e3a412-a7bf-4d25-b898-f326c9653366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d1e0577d-792f-4d18-b651-2d673d76d9e2" xlink:to="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39a10edc-62b6-477b-ab0f-0b148186b143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39a10edc-62b6-477b-ab0f-0b148186b143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_12775a49-b8c6-4ea8-9399-1632234940e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_12775a49-b8c6-4ea8-9399-1632234940e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_a0ae287f-1728-4c79-a542-b984628714bb" xlink:href="ebs-20230331.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_a0ae287f-1728-4c79-a542-b984628714bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c5d60447-f7d4-432d-a277-fa029347336a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0152d98d-8fb7-4b95-abc5-07be3c872ddb" xlink:to="loc_us-gaap_Revenues_c5d60447-f7d4-432d-a277-fa029347336a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_dfc4c768-188a-40b4-afb0-d3d217c1dac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_dfc4c768-188a-40b4-afb0-d3d217c1dac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5f5db02b-26bd-4424-92c3-b31ae1061cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5f5db02b-26bd-4424-92c3-b31ae1061cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_aa4ef061-b908-4855-b67f-32c28aa06909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_aa4ef061-b908-4855-b67f-32c28aa06909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_aeae0661-81d6-4460-ad8b-b796242e95c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_aeae0661-81d6-4460-ad8b-b796242e95c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_fb401b75-f8d3-4632-b2ce-6d019a37b78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5691d16b-4141-4e54-9dc4-8be2bccfe6b7" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_fb401b75-f8d3-4632-b2ce-6d019a37b78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_84a5da11-b89c-432c-bf96-c233d93c8baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_OperatingIncomeLoss_84a5da11-b89c-432c-bf96-c233d93c8baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9862e550-9aff-465a-ad94-eb585598841a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9862e550-9aff-465a-ad94-eb585598841a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dca5f707-71e0-4158-8abb-993a09281d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9862e550-9aff-465a-ad94-eb585598841a" xlink:to="loc_us-gaap_InterestExpense_dca5f707-71e0-4158-8abb-993a09281d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_01cccfb0-ff15-4006-b19f-522cc7157d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9862e550-9aff-465a-ad94-eb585598841a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_01cccfb0-ff15-4006-b19f-522cc7157d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e108c846-5f59-4fab-90c2-70ba18703394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9862e550-9aff-465a-ad94-eb585598841a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e108c846-5f59-4fab-90c2-70ba18703394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a519240f-84db-4ba7-919c-18bb0519dfd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a519240f-84db-4ba7-919c-18bb0519dfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ccd3c4bc-ef75-4067-8034-e842cf3ec4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ccd3c4bc-ef75-4067-8034-e842cf3ec4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_99f86de4-e124-4458-a8f8-0eee2070ed13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_NetIncomeLoss_99f86de4-e124-4458-a8f8-0eee2070ed13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_2ac343c7-ee8c-4cad-88d4-d69fea57f9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_2ac343c7-ee8c-4cad-88d4-d69fea57f9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_96ee7438-dcf2-46b9-9199-4eab8d02d169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2ac343c7-ee8c-4cad-88d4-d69fea57f9cf" xlink:to="loc_us-gaap_EarningsPerShareBasic_96ee7438-dcf2-46b9-9199-4eab8d02d169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_63d6faa2-f173-448b-a31a-f42132f1ec32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2ac343c7-ee8c-4cad-88d4-d69fea57f9cf" xlink:to="loc_us-gaap_EarningsPerShareDiluted_63d6faa2-f173-448b-a31a-f42132f1ec32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c97c9f9d-4115-4b03-bc73-aac7358dea81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_772a4755-be35-47c1-9554-57261ff99e22" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c97c9f9d-4115-4b03-bc73-aac7358dea81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b8696ce6-3857-4a11-8fea-5e1302d9e93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c97c9f9d-4115-4b03-bc73-aac7358dea81" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b8696ce6-3857-4a11-8fea-5e1302d9e93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f95a2af0-69ea-48db-bc64-3589bf905285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c97c9f9d-4115-4b03-bc73-aac7358dea81" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f95a2af0-69ea-48db-bc64-3589bf905285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1fe6abe5-ca68-458d-ad80-3feb190f8b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a94b6260-5ed4-4f6a-afb4-0a8cc2153093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1fe6abe5-ca68-458d-ad80-3feb190f8b51" xlink:to="loc_us-gaap_NetIncomeLoss_a94b6260-5ed4-4f6a-afb4-0a8cc2153093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f212ec4c-83d4-4446-9aae-2b7e707a7ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1fe6abe5-ca68-458d-ad80-3feb190f8b51" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f212ec4c-83d4-4446-9aae-2b7e707a7ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9b91d875-30cc-4f5e-9c08-51becd619433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f212ec4c-83d4-4446-9aae-2b7e707a7ba8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9b91d875-30cc-4f5e-9c08-51becd619433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_66233cb5-4f72-4433-8cce-aff81bda06f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f212ec4c-83d4-4446-9aae-2b7e707a7ba8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_66233cb5-4f72-4433-8cce-aff81bda06f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9db0c38f-ab3f-4d2c-904c-c055726a5dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f212ec4c-83d4-4446-9aae-2b7e707a7ba8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9db0c38f-ab3f-4d2c-904c-c055726a5dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b964e6a9-6cf6-485d-ba33-399f861b4919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1fe6abe5-ca68-458d-ad80-3feb190f8b51" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b964e6a9-6cf6-485d-ba33-399f861b4919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fc92e6bf-06d9-49d5-9f5e-73d71fb1df64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fc92e6bf-06d9-49d5-9f5e-73d71fb1df64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e8db9f94-8eb3-4d35-8f27-52399b885b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fc92e6bf-06d9-49d5-9f5e-73d71fb1df64" xlink:to="loc_us-gaap_NetIncomeLoss_e8db9f94-8eb3-4d35-8f27-52399b885b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb25f87c-0307-4d89-a2ee-8d3accd66c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fc92e6bf-06d9-49d5-9f5e-73d71fb1df64" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb25f87c-0307-4d89-a2ee-8d3accd66c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1049ad62-8dbf-42fb-83fc-4badfe7529d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb25f87c-0307-4d89-a2ee-8d3accd66c24" xlink:to="loc_us-gaap_ShareBasedCompensation_1049ad62-8dbf-42fb-83fc-4badfe7529d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8d27f246-497d-4714-941a-ed164464c692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb25f87c-0307-4d89-a2ee-8d3accd66c24" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8d27f246-497d-4714-941a-ed164464c692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6055062f-c816-40c8-9bf7-34de3cfedc68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb25f87c-0307-4d89-a2ee-8d3accd66c24" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6055062f-c816-40c8-9bf7-34de3cfedc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ce451b59-592c-4cca-bd31-840fd47bf2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb25f87c-0307-4d89-a2ee-8d3accd66c24" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ce451b59-592c-4cca-bd31-840fd47bf2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_fbd6b771-331e-4421-8d0b-86d9626e75ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb25f87c-0307-4d89-a2ee-8d3accd66c24" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_fbd6b771-331e-4421-8d0b-86d9626e75ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f877b0a8-2b19-4dd2-b7e5-c2f92143f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb25f87c-0307-4d89-a2ee-8d3accd66c24" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f877b0a8-2b19-4dd2-b7e5-c2f92143f6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26e29aaf-b0cc-4940-8fb2-1ea83f381d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fb25f87c-0307-4d89-a2ee-8d3accd66c24" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26e29aaf-b0cc-4940-8fb2-1ea83f381d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c6676f00-70e7-48f2-821e-0457a91908be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26e29aaf-b0cc-4940-8fb2-1ea83f381d41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c6676f00-70e7-48f2-821e-0457a91908be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_870200ae-1880-4141-b66a-acdc621b9037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26e29aaf-b0cc-4940-8fb2-1ea83f381d41" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_870200ae-1880-4141-b66a-acdc621b9037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_be799a33-94f5-4fff-b547-046e8ac22f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26e29aaf-b0cc-4940-8fb2-1ea83f381d41" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_be799a33-94f5-4fff-b547-046e8ac22f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_edce4350-fbd6-4d84-8556-cc8cde4d7ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26e29aaf-b0cc-4940-8fb2-1ea83f381d41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_edce4350-fbd6-4d84-8556-cc8cde4d7ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eb46b098-65f2-4b5b-8556-ef074843632f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26e29aaf-b0cc-4940-8fb2-1ea83f381d41" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eb46b098-65f2-4b5b-8556-ef074843632f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_df3652e8-a9ad-4d0b-83b5-76ed586775db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26e29aaf-b0cc-4940-8fb2-1ea83f381d41" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_df3652e8-a9ad-4d0b-83b5-76ed586775db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_4557bdca-5b83-4ef4-a772-757556579c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26e29aaf-b0cc-4940-8fb2-1ea83f381d41" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_4557bdca-5b83-4ef4-a772-757556579c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a80bf70b-1c90-4726-8cc1-712ea1bb6045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26e29aaf-b0cc-4940-8fb2-1ea83f381d41" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a80bf70b-1c90-4726-8cc1-712ea1bb6045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5e528b0-ad86-460c-9057-911157052a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fc92e6bf-06d9-49d5-9f5e-73d71fb1df64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5e528b0-ad86-460c-9057-911157052a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12a7a3e4-32d6-43ab-817e-2a2ef8c5c783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12a7a3e4-32d6-43ab-817e-2a2ef8c5c783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ff8e24e1-5eb9-408c-9e39-aeb517349b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12a7a3e4-32d6-43ab-817e-2a2ef8c5c783" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ff8e24e1-5eb9-408c-9e39-aeb517349b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9f5d79f5-6baf-4245-9b76-e76f5b6b06d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12a7a3e4-32d6-43ab-817e-2a2ef8c5c783" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9f5d79f5-6baf-4245-9b76-e76f5b6b06d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_223da6ce-0cf3-4da7-9586-fc0bb0bb47dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_223da6ce-0cf3-4da7-9586-fc0bb0bb47dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fa2b21df-cbaf-4aae-8de9-6a5c0473d539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_223da6ce-0cf3-4da7-9586-fc0bb0bb47dc" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fa2b21df-cbaf-4aae-8de9-6a5c0473d539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_13823a95-f651-42e8-992f-e2a5b80f0110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_223da6ce-0cf3-4da7-9586-fc0bb0bb47dc" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_13823a95-f651-42e8-992f-e2a5b80f0110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b42dffe0-fe48-4fdf-a61b-b2161e75a9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_223da6ce-0cf3-4da7-9586-fc0bb0bb47dc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b42dffe0-fe48-4fdf-a61b-b2161e75a9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0b039829-d88d-472c-8587-52a680f9c481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_223da6ce-0cf3-4da7-9586-fc0bb0bb47dc" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0b039829-d88d-472c-8587-52a680f9c481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29a8f690-e903-4103-a31b-14e38e141314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_223da6ce-0cf3-4da7-9586-fc0bb0bb47dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29a8f690-e903-4103-a31b-14e38e141314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b651276-727d-47e1-8054-34ed354a2250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b651276-727d-47e1-8054-34ed354a2250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e3809798-4dc2-4d7c-abb9-ef338fa0f649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e3809798-4dc2-4d7c-abb9-ef338fa0f649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_421c5777-42a9-4e50-82b9-fcf2f38d98e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_421c5777-42a9-4e50-82b9-fcf2f38d98e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8e20ca8-bffc-4ad6-b1ce-b8c0d3b33467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8e20ca8-bffc-4ad6-b1ce-b8c0d3b33467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33510abf-d216-4a42-b33d-688a3f44e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33510abf-d216-4a42-b33d-688a3f44e74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ae4a73ba-1dc9-4561-94f2-4ca4e331dcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ae4a73ba-1dc9-4561-94f2-4ca4e331dcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_830aaf10-e541-4a2f-b091-c3b4c487971f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ae4a73ba-1dc9-4561-94f2-4ca4e331dcc0" xlink:to="loc_us-gaap_InterestPaidNet_830aaf10-e541-4a2f-b091-c3b4c487971f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_c337f03f-a46a-475a-8900-f465a5291d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ae4a73ba-1dc9-4561-94f2-4ca4e331dcc0" xlink:to="loc_us-gaap_IncomeTaxesPaid_c337f03f-a46a-475a-8900-f465a5291d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ee30c602-00b5-4bf7-a68e-fc5ee5c7cbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ee30c602-00b5-4bf7-a68e-fc5ee5c7cbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_616c0056-c869-4b54-b77a-937931ad600f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ee30c602-00b5-4bf7-a68e-fc5ee5c7cbf2" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_616c0056-c869-4b54-b77a-937931ad600f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NoncashPurchasesOfTreasuryStock_7b670df1-6782-4877-84a2-b55af1345e9d" xlink:href="ebs-20230331.xsd#ebs_NoncashPurchasesOfTreasuryStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ee30c602-00b5-4bf7-a68e-fc5ee5c7cbf2" xlink:to="loc_ebs_NoncashPurchasesOfTreasuryStock_7b670df1-6782-4877-84a2-b55af1345e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_898cc2f5-ee9c-43bc-8923-0c0ed1e1ca05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e039366b-8e93-4d4d-a6b8-d65f6276dc00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_898cc2f5-ee9c-43bc-8923-0c0ed1e1ca05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_df976c17-6958-4d45-b93c-a78b48ece4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_898cc2f5-ee9c-43bc-8923-0c0ed1e1ca05" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_df976c17-6958-4d45-b93c-a78b48ece4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_97dc32d5-d3f9-499d-b844-8ca453eb5072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_898cc2f5-ee9c-43bc-8923-0c0ed1e1ca05" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_97dc32d5-d3f9-499d-b844-8ca453eb5072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_8e49250b-5679-4c7a-83c6-ca4d1f2bf5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_898cc2f5-ee9c-43bc-8923-0c0ed1e1ca05" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_8e49250b-5679-4c7a-83c6-ca4d1f2bf5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a7ae9f92-b124-4561-b1f4-4200d736d83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d25742e5-9815-4036-bd12-e6795c6941e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a7ae9f92-b124-4561-b1f4-4200d736d83d" xlink:to="loc_us-gaap_StatementTable_d25742e5-9815-4036-bd12-e6795c6941e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51db47b9-e5ce-4d70-8607-b06e1b780822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d25742e5-9815-4036-bd12-e6795c6941e3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51db47b9-e5ce-4d70-8607-b06e1b780822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51db47b9-e5ce-4d70-8607-b06e1b780822" xlink:to="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eb9ff9a9-dab4-4428-9839-804e0e6cd475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:to="loc_us-gaap_CommonStockMember_eb9ff9a9-dab4-4428-9839-804e0e6cd475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_d74289ab-77f1-4c42-b346-18610da203e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:to="loc_us-gaap_TreasuryStockCommonMember_d74289ab-77f1-4c42-b346-18610da203e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dcdccb8c-cb37-4330-8740-d65de27943a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dcdccb8c-cb37-4330-8740-d65de27943a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6847cbb-c1ab-4be5-94f7-1405f8e2b8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d6847cbb-c1ab-4be5-94f7-1405f8e2b8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_752cc641-12fc-411a-95de-a88a1baf2820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cbee03a8-375d-49ab-8b65-49a74c9dd255" xlink:to="loc_us-gaap_RetainedEarningsMember_752cc641-12fc-411a-95de-a88a1baf2820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1cb1d875-4c29-4db6-af16-2d583b182fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d25742e5-9815-4036-bd12-e6795c6941e3" xlink:to="loc_us-gaap_StatementLineItems_1cb1d875-4c29-4db6-af16-2d583b182fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1cb1d875-4c29-4db6-af16-2d583b182fdc" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2cd6ef02-e912-4cea-9c68-7f120e17a30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_CommonStockSharesIssued_2cd6ef02-e912-4cea-9c68-7f120e17a30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4c55c532-224c-4dde-9325-8420bd1cbcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_StockholdersEquity_4c55c532-224c-4dde-9325-8420bd1cbcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_420c6243-766e-4f0d-98ba-05ceff417161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_NetIncomeLoss_420c6243-766e-4f0d-98ba-05ceff417161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bdf5c769-d871-4c1b-b0f3-1ed66de05655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bdf5c769-d871-4c1b-b0f3-1ed66de05655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_506b2f83-d6b1-44d2-8c14-d2201abf1fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_506b2f83-d6b1-44d2-8c14-d2201abf1fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_a659a683-3eff-4bcd-b10f-119a88cf8200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_a659a683-3eff-4bcd-b10f-119a88cf8200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_217472a2-16d5-4509-a776-06d928e04e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_217472a2-16d5-4509-a776-06d928e04e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e87dd7e6-8079-4a6d-8514-c56436854029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e87dd7e6-8079-4a6d-8514-c56436854029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d3da33c1-4aff-4b15-9d4d-85b486424794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_CommonStockSharesIssued_d3da33c1-4aff-4b15-9d4d-85b486424794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_daa7a54c-5527-4956-9fc5-61274b286517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4fbb330-83f4-4fef-9075-f8272daa7853" xlink:to="loc_us-gaap_StockholdersEquity_daa7a54c-5527-4956-9fc5-61274b286517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ebs-20230331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_05f0f6f7-155d-4fb0-89fd-3f9d005e8526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_93670a4a-e210-4b7e-a3b1-ac7331c8a4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_05f0f6f7-155d-4fb0-89fd-3f9d005e8526" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_93670a4a-e210-4b7e-a3b1-ac7331c8a4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Natureofthebusinessandorganization" xlink:type="simple" xlink:href="ebs-20230331.xsd#Natureofthebusinessandorganization"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Natureofthebusinessandorganization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f83646a-700e-4eae-9d88-0f1ceb33d2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9c40da35-7f39-4909-a74d-15e54890f515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5f83646a-700e-4eae-9d88-0f1ceb33d2d7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9c40da35-7f39-4909-a74d-15e54890f515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="ebs-20230331.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_556b5642-c6f4-457b-b7af-c79633f41200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_94bec58f-445b-434e-a5e1-ed9986f03214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_556b5642-c6f4-457b-b7af-c79633f41200" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_94bec58f-445b-434e-a5e1-ed9986f03214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale" xlink:type="simple" xlink:href="ebs-20230331.xsd#Assetsandliabilitiesheldforsale"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9f8efd52-5607-4568-98f2-4b298ef2de8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_51d8898e-2e9a-4ee2-ad0b-ae2ee87209da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9f8efd52-5607-4568-98f2-4b298ef2de8b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_51d8898e-2e9a-4ee2-ad0b-ae2ee87209da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Restructuringcosts" xlink:type="simple" xlink:href="ebs-20230331.xsd#Restructuringcosts"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Restructuringcosts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ce17a4f8-6af1-4c51-949a-ac5358df5ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_ecb2949e-84c3-48e8-9dd8-bec366664a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ce17a4f8-6af1-4c51-949a-ac5358df5ad4" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_ecb2949e-84c3-48e8-9dd8-bec366664a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Inventoriesnet" xlink:type="simple" xlink:href="ebs-20230331.xsd#Inventoriesnet"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Inventoriesnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6aaf8853-4a2c-4dd2-b5fd-fd75ccafd551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_cd003a9e-84c2-4d87-b171-7fcfe392043a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6aaf8853-4a2c-4dd2-b5fd-fd75ccafd551" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_cd003a9e-84c2-4d87-b171-7fcfe392043a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet" xlink:type="simple" xlink:href="ebs-20230331.xsd#Propertyplantandequipmentnet"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_e8c662a6-fc2e-4a9c-bebe-6dd50970562b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_44209720-1d1c-43b5-9d52-b3617b8e6183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_e8c662a6-fc2e-4a9c-bebe-6dd50970562b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_44209720-1d1c-43b5-9d52-b3617b8e6183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill" xlink:type="simple" xlink:href="ebs-20230331.xsd#Intangibleassetsandgoodwill"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bf52edc1-f8b8-491e-8acc-fefdf9328eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_983949bf-14f1-48b2-889f-5aac9201960f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bf52edc1-f8b8-491e-8acc-fefdf9328eb1" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_983949bf-14f1-48b2-889f-5aac9201960f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Fairvaluemeasurements" xlink:type="simple" xlink:href="ebs-20230331.xsd#Fairvaluemeasurements"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Fairvaluemeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3593eff1-a99c-41fe-a716-6f90a5a6c64d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7e493ed1-cbe6-4a26-a9e6-007fefe1ca65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3593eff1-a99c-41fe-a716-6f90a5a6c64d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7e493ed1-cbe6-4a26-a9e6-007fefe1ca65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities" xlink:type="simple" xlink:href="ebs-20230331.xsd#Derivativeinstrumentsandhedgingactivities"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a62dc95d-8f9e-4bd5-90b5-968ded8c4a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f04f3108-de31-4bfa-a3ea-70b9d1a25703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a62dc95d-8f9e-4bd5-90b5-968ded8c4a5d" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f04f3108-de31-4bfa-a3ea-70b9d1a25703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Debt" xlink:type="simple" xlink:href="ebs-20230331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d416edb7-2ca0-4717-a4ce-514fc228c606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_0ce3eddc-7f16-43cf-8f18-88d06de3d015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d416edb7-2ca0-4717-a4ce-514fc228c606" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_0ce3eddc-7f16-43cf-8f18-88d06de3d015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Stockbasedcompensationandstockholdersequity" xlink:type="simple" xlink:href="ebs-20230331.xsd#Stockbasedcompensationandstockholdersequity"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Stockbasedcompensationandstockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6387006f-df67-4f6d-a3ae-bda694992637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2565d526-4d84-440d-b45c-7d96d31396d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6387006f-df67-4f6d-a3ae-bda694992637" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2565d526-4d84-440d-b45c-7d96d31396d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Earningslosspercommonshare" xlink:type="simple" xlink:href="ebs-20230331.xsd#Earningslosspercommonshare"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Earningslosspercommonshare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4f5ecf27-2648-4e15-bd6a-b366ec1187da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_85652f59-ba08-490b-b82b-ed89157c38bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4f5ecf27-2648-4e15-bd6a-b366ec1187da" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_85652f59-ba08-490b-b82b-ed89157c38bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Revenuerecognition" xlink:type="simple" xlink:href="ebs-20230331.xsd#Revenuerecognition"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Revenuerecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ada1ea6d-865b-443b-9ae1-757f3a13dcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_401495ab-02f1-4927-98be-95eef1260bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ada1ea6d-865b-443b-9ae1-757f3a13dcbc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_401495ab-02f1-4927-98be-95eef1260bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Leases" xlink:type="simple" xlink:href="ebs-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f435be51-f5d9-460f-934c-50b42b4b63cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_86759a5c-0e32-499d-99f1-269ef790f837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f435be51-f5d9-460f-934c-50b42b4b63cb" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_86759a5c-0e32-499d-99f1-269ef790f837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Incometaxes" xlink:type="simple" xlink:href="ebs-20230331.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0759db49-a547-43fa-bb99-48fccb3fae70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a5d2d4ca-c0ca-4966-b087-65d2c2e3af04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0759db49-a547-43fa-bb99-48fccb3fae70" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a5d2d4ca-c0ca-4966-b087-65d2c2e3af04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Litigation" xlink:type="simple" xlink:href="ebs-20230331.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_16e9d121-84c5-4610-9804-a2c0cbe7d507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_24a53b98-bbcf-440b-bca8-c702b5bc01ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_16e9d121-84c5-4610-9804-a2c0cbe7d507" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_24a53b98-bbcf-440b-bca8-c702b5bc01ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformation" xlink:type="simple" xlink:href="ebs-20230331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ca426353-8e04-4142-8443-05e9ca716f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1d69d7bb-24f1-4fc6-9c72-37618dd87b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ca426353-8e04-4142-8443-05e9ca716f3e" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1d69d7bb-24f1-4fc6-9c72-37618dd87b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="ebs-20230331.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f4352902-b915-447d-ad4b-259c39a37c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_026658ec-e1fd-431b-95c1-6d2be40de21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4352902-b915-447d-ad4b-259c39a37c8c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_026658ec-e1fd-431b-95c1-6d2be40de21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_b2deaff4-c3a3-4000-b172-ba7839468610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4352902-b915-447d-ad4b-259c39a37c8c" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_b2deaff4-c3a3-4000-b172-ba7839468610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_356bcaaf-f124-4ce4-8374-8274b88cc1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4352902-b915-447d-ad4b-259c39a37c8c" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_356bcaaf-f124-4ce4-8374-8274b88cc1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_14e8da8d-77d9-4698-af7e-71c7d03c551f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4352902-b915-447d-ad4b-259c39a37c8c" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_14e8da8d-77d9-4698-af7e-71c7d03c551f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0c2a4d37-f07c-4a7f-a7af-6f9dbdfd4f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4352902-b915-447d-ad4b-259c39a37c8c" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0c2a4d37-f07c-4a7f-a7af-6f9dbdfd4f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#AssetsandliabilitiesheldforsaleTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fa2bf5a9-b074-424d-a635-de600daaf457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6e7a53dc-fe75-45ef-ae1b-3d018ac06bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fa2bf5a9-b074-424d-a635-de600daaf457" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6e7a53dc-fe75-45ef-ae1b-3d018ac06bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RestructuringcostsTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#RestructuringcostsTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RestructuringcostsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6dc9e4ef-6fc8-4065-8992-03305c0dbd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_89ee49ae-208a-4bd7-92be-57448f8995a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6dc9e4ef-6fc8-4065-8992-03305c0dbd7a" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_89ee49ae-208a-4bd7-92be-57448f8995a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_4be7c96c-77d0-42f4-9501-d58b7b752162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6dc9e4ef-6fc8-4065-8992-03305c0dbd7a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_4be7c96c-77d0-42f4-9501-d58b7b752162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#InventoriesnetTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d11ef0dc-ef51-4161-9b83-ecba39532f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fb9cffd4-2731-4ad5-aed2-6714be7afb24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d11ef0dc-ef51-4161-9b83-ecba39532f81" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fb9cffd4-2731-4ad5-aed2-6714be7afb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#PropertyplantandequipmentnetTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_a7176e6f-8967-4af7-8246-120b499bf891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e62751d0-d79d-4fbe-98b5-54dbeaa9f324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_a7176e6f-8967-4af7-8246-120b499bf891" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e62751d0-d79d-4fbe-98b5-54dbeaa9f324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#IntangibleassetsandgoodwillTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d7b91843-ac7d-43bf-8589-3dbe2670e28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_763b95ab-fe0c-458f-88fb-0ae4f6252c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d7b91843-ac7d-43bf-8589-3dbe2670e28c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_763b95ab-fe0c-458f-88fb-0ae4f6252c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_d8508993-4407-4be2-b9a8-b94436281ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d7b91843-ac7d-43bf-8589-3dbe2670e28c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_d8508993-4407-4be2-b9a8-b94436281ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#FairvaluemeasurementsTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8b3c3e5f-fdd0-4ebc-b51e-8cfdebe0e73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_14f8525d-da06-4531-b975-540e36f186cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8b3c3e5f-fdd0-4ebc-b51e-8cfdebe0e73c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_14f8525d-da06-4531-b975-540e36f186cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b03b55e4-33ef-4815-a47b-8508f3d3e4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8b3c3e5f-fdd0-4ebc-b51e-8cfdebe0e73c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b03b55e4-33ef-4815-a47b-8508f3d3e4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_c1eda115-7f0f-4540-812a-5ce735c97f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8b3c3e5f-fdd0-4ebc-b51e-8cfdebe0e73c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_c1eda115-7f0f-4540-812a-5ce735c97f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#DerivativeinstrumentsandhedgingactivitiesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8e4fbfcc-da38-4e6d-90d4-c9bdd74091f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_2f4267cc-1e98-4b92-9d0d-f7fb0a1572d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8e4fbfcc-da38-4e6d-90d4-c9bdd74091f5" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_2f4267cc-1e98-4b92-9d0d-f7fb0a1572d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ba886ff8-d2cd-41f8-9782-6bd9371b4fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8e4fbfcc-da38-4e6d-90d4-c9bdd74091f5" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ba886ff8-d2cd-41f8-9782-6bd9371b4fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e6f2d673-7026-454a-9cd0-0b067974560f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8e4fbfcc-da38-4e6d-90d4-c9bdd74091f5" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e6f2d673-7026-454a-9cd0-0b067974560f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3f019ce5-0552-4087-bd44-b24a2bc0a4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_ee5024d9-45db-42de-91c6-e5af1ce0b428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3f019ce5-0552-4087-bd44-b24a2bc0a4a0" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_ee5024d9-45db-42de-91c6-e5af1ce0b428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#StockbasedcompensationandstockholdersequityTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_09d592f3-b31d-4a3c-89c8-727096beabd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_08887c31-67f2-4fd7-acfe-c9fc7f42fb27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_09d592f3-b31d-4a3c-89c8-727096beabd5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_08887c31-67f2-4fd7-acfe-c9fc7f42fb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_9abe9eb3-e37e-44bb-80be-c2abcd1ffba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_09d592f3-b31d-4a3c-89c8-727096beabd5" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_9abe9eb3-e37e-44bb-80be-c2abcd1ffba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_85c96e17-570a-41c6-b04a-d01c4a8bc1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_09d592f3-b31d-4a3c-89c8-727096beabd5" xlink:to="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_85c96e17-570a-41c6-b04a-d01c4a8bc1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EarningslosspercommonshareTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#EarningslosspercommonshareTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EarningslosspercommonshareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a9d1f0b4-0e3e-40a6-b623-b66c5d9bfba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d698ee19-6c8d-4842-b27b-33fa40e10261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a9d1f0b4-0e3e-40a6-b623-b66c5d9bfba8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d698ee19-6c8d-4842-b27b-33fa40e10261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#RevenuerecognitionTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6b21357-d108-4d13-acef-c0e59a106f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_cf7fe883-1f76-41ca-9174-8cf84f065df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6b21357-d108-4d13-acef-c0e59a106f21" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_cf7fe883-1f76-41ca-9174-8cf84f065df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_81476e08-babf-4caf-ba5d-d4a028ea5281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6b21357-d108-4d13-acef-c0e59a106f21" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_81476e08-babf-4caf-ba5d-d4a028ea5281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_9429d736-9470-40fb-a228-1d7b3927fafb" xlink:href="ebs-20230331.xsd#ebs_ScheduleOfAccountsReceivableNetTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6b21357-d108-4d13-acef-c0e59a106f21" xlink:to="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_9429d736-9470-40fb-a228-1d7b3927fafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_00144057-7902-44ac-8d69-339421f3414e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_03f3e9c2-69ab-4cae-acb4-919f01c75a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_00144057-7902-44ac-8d69-339421f3414e" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_03f3e9c2-69ab-4cae-acb4-919f01c75a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_ed9110fa-6765-479a-952a-551f163a27ec" xlink:href="ebs-20230331.xsd#ebs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_00144057-7902-44ac-8d69-339421f3414e" xlink:to="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_ed9110fa-6765-479a-952a-551f163a27ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="ebs-20230331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_45afbefe-778a-40d5-a450-0122c74b7220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_04919a1b-3462-4336-94d8-b30fa3f8e9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_45afbefe-778a-40d5-a450-0122c74b7220" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_04919a1b-3462-4336-94d8-b30fa3f8e9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_73c76ec1-0879-42b8-abed-1a2e9d8327d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_45afbefe-778a-40d5-a450-0122c74b7220" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_73c76ec1-0879-42b8-abed-1a2e9d8327d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#NatureofthebusinessandorganizationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e353493a-1900-4e03-9dc3-54bbe1f5a1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_7667c2c4-3876-4e06-afb9-5c43b5e9e266" xlink:href="ebs-20230331.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e353493a-1900-4e03-9dc3-54bbe1f5a1c3" xlink:to="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_7667c2c4-3876-4e06-afb9-5c43b5e9e266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts_30bd1a7f-d1ff-4093-bb5e-8f86c54f1888" xlink:href="ebs-20230331.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e353493a-1900-4e03-9dc3-54bbe1f5a1c3" xlink:to="loc_ebs_NumberOfRevenueGeneratingProducts_30bd1a7f-d1ff-4093-bb5e-8f86c54f1888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductCandidates_605d30f5-fd21-4f50-81a7-dd061332d8a9" xlink:href="ebs-20230331.xsd#ebs_NumberOfProductCandidates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e353493a-1900-4e03-9dc3-54bbe1f5a1c3" xlink:to="loc_ebs_NumberOfProductCandidates_605d30f5-fd21-4f50-81a7-dd061332d8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductAndServiceCategories_e7b5e8aa-d8c5-4058-bd91-1ccfb424ef19" xlink:href="ebs-20230331.xsd#ebs_NumberOfProductAndServiceCategories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e353493a-1900-4e03-9dc3-54bbe1f5a1c3" xlink:to="loc_ebs_NumberOfProductAndServiceCategories_e7b5e8aa-d8c5-4058-bd91-1ccfb424ef19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a60813ad-d276-4933-8d08-7ad1c2a8dbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e353493a-1900-4e03-9dc3-54bbe1f5a1c3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a60813ad-d276-4933-8d08-7ad1c2a8dbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#SummaryofsignificantaccountingpoliciesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b0bfd050-2f40-4287-93ca-0a12dbb9d1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_64b7a8a6-9e34-4b80-bee5-dfc09b6b2f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b0bfd050-2f40-4287-93ca-0a12dbb9d1ec" xlink:to="loc_us-gaap_DebtInstrumentTable_64b7a8a6-9e34-4b80-bee5-dfc09b6b2f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4b181551-f1dc-410f-9768-fe14020551a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64b7a8a6-9e34-4b80-bee5-dfc09b6b2f2e" xlink:to="loc_us-gaap_CreditFacilityAxis_4b181551-f1dc-410f-9768-fe14020551a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_53218515-5b33-4aff-903c-e8e5f5157e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_4b181551-f1dc-410f-9768-fe14020551a8" xlink:to="loc_us-gaap_CreditFacilityDomain_53218515-5b33-4aff-903c-e8e5f5157e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4515a3f6-2766-4d60-b59e-18dc190034f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_53218515-5b33-4aff-903c-e8e5f5157e26" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4515a3f6-2766-4d60-b59e-18dc190034f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bdeb27d2-12fa-4447-a0f3-97f70a6f6dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64b7a8a6-9e34-4b80-bee5-dfc09b6b2f2e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bdeb27d2-12fa-4447-a0f3-97f70a6f6dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f322aba4-a309-41ad-a51c-ab4ecca69c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bdeb27d2-12fa-4447-a0f3-97f70a6f6dbe" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f322aba4-a309-41ad-a51c-ab4ecca69c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ada3e473-1ca7-4a4f-89f1-444be4ac082c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f322aba4-a309-41ad-a51c-ab4ecca69c96" xlink:to="loc_us-gaap_LineOfCreditMember_ada3e473-1ca7-4a4f-89f1-444be4ac082c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_1ea89bc8-cefc-4020-8830-83d1608f2e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f322aba4-a309-41ad-a51c-ab4ecca69c96" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_1ea89bc8-cefc-4020-8830-83d1608f2e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6516a328-dd10-4535-9ce2-ce148a0e8b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_64b7a8a6-9e34-4b80-bee5-dfc09b6b2f2e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6516a328-dd10-4535-9ce2-ce148a0e8b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_240bee78-0123-48f4-8e17-78514b330fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6516a328-dd10-4535-9ce2-ce148a0e8b63" xlink:to="loc_us-gaap_LongTermDebt_240bee78-0123-48f4-8e17-78514b330fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#AssetsandliabilitiesheldforsaleNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b82dc1ef-4824-46fa-84ea-64cb62c0b12a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35a51f55-19eb-4c9b-b085-343fe39211b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b82dc1ef-4824-46fa-84ea-64cb62c0b12a" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35a51f55-19eb-4c9b-b085-343fe39211b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59e8e33d-22e7-4392-9fab-356fee3ad166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35a51f55-19eb-4c9b-b085-343fe39211b0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59e8e33d-22e7-4392-9fab-356fee3ad166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55dd0d8c-b739-47b6-9b6d-a8fb82e31028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_59e8e33d-22e7-4392-9fab-356fee3ad166" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55dd0d8c-b739-47b6-9b6d-a8fb82e31028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_63168f9b-3e73-43e5-803d-f9351d5f7f8a" xlink:href="ebs-20230331.xsd#ebs_TravelHealthBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_55dd0d8c-b739-47b6-9b6d-a8fb82e31028" xlink:to="loc_ebs_TravelHealthBusinessMember_63168f9b-3e73-43e5-803d-f9351d5f7f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d88a01a3-1f4f-4cf2-b02b-c24021c4a348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35a51f55-19eb-4c9b-b085-343fe39211b0" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d88a01a3-1f4f-4cf2-b02b-c24021c4a348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_dc6a3a6b-29bb-491d-b4f1-4ea8b9a84d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d88a01a3-1f4f-4cf2-b02b-c24021c4a348" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_dc6a3a6b-29bb-491d-b4f1-4ea8b9a84d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b705e50f-fc74-471b-a404-38cc2b91182c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_dc6a3a6b-29bb-491d-b4f1-4ea8b9a84d26" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b705e50f-fc74-471b-a404-38cc2b91182c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_5edc6e16-777d-4893-a9a5-24aad416c31f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35a51f55-19eb-4c9b-b085-343fe39211b0" xlink:to="loc_srt_StatementScenarioAxis_5edc6e16-777d-4893-a9a5-24aad416c31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bb4e174d-fb2d-4a8b-8a39-b417878f9bf8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_5edc6e16-777d-4893-a9a5-24aad416c31f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bb4e174d-fb2d-4a8b-8a39-b417878f9bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e79943a4-fd23-4eed-8032-c7abdd4d9cb4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bb4e174d-fb2d-4a8b-8a39-b417878f9bf8" xlink:to="loc_srt_ScenarioForecastMember_e79943a4-fd23-4eed-8032-c7abdd4d9cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_30c2a206-1ed6-4d2a-ab39-6b869afcd6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35a51f55-19eb-4c9b-b085-343fe39211b0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_30c2a206-1ed6-4d2a-ab39-6b869afcd6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated_baf0d7d2-a42f-4076-ad48-228886eb4d3e" xlink:href="ebs-20230331.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_30c2a206-1ed6-4d2a-ab39-6b869afcd6d7" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated_baf0d7d2-a42f-4076-ad48-228886eb4d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_f20ecfcf-7db8-45f2-abe1-de358e52c65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fdaee9b1-3846-4035-a7e9-9b2b493dcc18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_f20ecfcf-7db8-45f2-abe1-de358e52c65d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fdaee9b1-3846-4035-a7e9-9b2b493dcc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_22fb272c-0b52-4a92-9687-55cc4389a258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fdaee9b1-3846-4035-a7e9-9b2b493dcc18" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_22fb272c-0b52-4a92-9687-55cc4389a258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5d496446-26ef-4d63-9018-b5e7899ebe79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_22fb272c-0b52-4a92-9687-55cc4389a258" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5d496446-26ef-4d63-9018-b5e7899ebe79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d2bece2b-22da-4831-827b-31792c92b3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5d496446-26ef-4d63-9018-b5e7899ebe79" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d2bece2b-22da-4831-827b-31792c92b3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_688a48d9-186d-4c23-a1bc-1b20c03db493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fdaee9b1-3846-4035-a7e9-9b2b493dcc18" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_688a48d9-186d-4c23-a1bc-1b20c03db493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2b400a10-283b-408c-bcdc-f9cf9eac4c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_688a48d9-186d-4c23-a1bc-1b20c03db493" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2b400a10-283b-408c-bcdc-f9cf9eac4c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_91f7f0b5-aac7-41b4-8d29-6d9708cd778b" xlink:href="ebs-20230331.xsd#ebs_TravelHealthBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2b400a10-283b-408c-bcdc-f9cf9eac4c3b" xlink:to="loc_ebs_TravelHealthBusinessMember_91f7f0b5-aac7-41b4-8d29-6d9708cd778b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a7df6696-0ea4-4bc4-929a-4f79abb6226f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_fdaee9b1-3846-4035-a7e9-9b2b493dcc18" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a7df6696-0ea4-4bc4-929a-4f79abb6226f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a7df6696-0ea4-4bc4-929a-4f79abb6226f" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_e9b64a65-6668-4b88-a791-23f8925f9282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_e9b64a65-6668-4b88-a791-23f8925f9282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_abf21deb-a1a1-4019-8140-d46e02e0416a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_abf21deb-a1a1-4019-8140-d46e02e0416a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_68dfdc19-61e7-44a7-9480-5d339444aa8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_68dfdc19-61e7-44a7-9480-5d339444aa8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_ff9cfbf1-e1ec-43d5-b941-d58bc1c1bc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_ff9cfbf1-e1ec-43d5-b941-d58bc1c1bc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_b66288eb-a8af-4d64-98a3-4f518c64b544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_b66288eb-a8af-4d64-98a3-4f518c64b544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_de4d40c9-d5c2-4a5f-8fef-22c614cbd678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_de4d40c9-d5c2-4a5f-8fef-22c614cbd678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_e98c4a3a-50a0-4713-a725-7cd141a17bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_e98c4a3a-50a0-4713-a725-7cd141a17bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5cd5135b-7a9e-4de6-92a7-f0457f94bf07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_c083eed8-6705-463e-901b-a58eb9e89b9e" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5cd5135b-7a9e-4de6-92a7-f0457f94bf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_a7df6696-0ea4-4bc4-929a-4f79abb6226f" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_f2174ee2-8411-427e-9542-0c9c1ade358c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_f2174ee2-8411-427e-9542-0c9c1ade358c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_649b0ee7-6e15-4329-8b08-10140a5f2a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_649b0ee7-6e15-4329-8b08-10140a5f2a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent_16ce65cb-e53f-4874-85ee-77e7859398c6" xlink:href="ebs-20230331.xsd#ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent_16ce65cb-e53f-4874-85ee-77e7859398c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_93e3fdaa-9248-49ad-855a-fd8dc1f0fcab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_93e3fdaa-9248-49ad-855a-fd8dc1f0fcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_6d07a746-c73c-42f9-9fc7-135e4be70f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_6d07a746-c73c-42f9-9fc7-135e4be70f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_7124eb11-9110-4ff9-846c-03db878afa91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_7124eb11-9110-4ff9-846c-03db878afa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_921e6fbf-a2bb-4824-99e8-d96959159678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5eed5e7e-b4ce-408d-a655-e88b9759ad4e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_921e6fbf-a2bb-4824-99e8-d96959159678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RestructuringcostsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_eb61d450-74a7-47a4-a171-a9a94c3501e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9f531d8d-2abb-4640-bb77-936b28f54afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_eb61d450-74a7-47a4-a171-a9a94c3501e9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9f531d8d-2abb-4640-bb77-936b28f54afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_446cb6cb-d630-486e-b77b-4258d8c00593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9f531d8d-2abb-4640-bb77-936b28f54afb" xlink:to="loc_us-gaap_RestructuringPlanAxis_446cb6cb-d630-486e-b77b-4258d8c00593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b93c6a48-9c46-4278-97fe-0e33da2c757f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_446cb6cb-d630-486e-b77b-4258d8c00593" xlink:to="loc_us-gaap_RestructuringPlanDomain_b93c6a48-9c46-4278-97fe-0e33da2c757f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlan2023Member_a5fd0642-79b7-420f-8ee8-9c6f5b85d472" xlink:href="ebs-20230331.xsd#ebs_RestructuringPlan2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_b93c6a48-9c46-4278-97fe-0e33da2c757f" xlink:to="loc_ebs_RestructuringPlan2023Member_a5fd0642-79b7-420f-8ee8-9c6f5b85d472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1746bba0-d1ad-4335-9304-e54c4286cf97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9f531d8d-2abb-4640-bb77-936b28f54afb" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1746bba0-d1ad-4335-9304-e54c4286cf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_6b0523ae-a064-449d-abd1-35378cb2292d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1746bba0-d1ad-4335-9304-e54c4286cf97" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_6b0523ae-a064-449d-abd1-35378cb2292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_558d56f6-5e89-4aa1-8d47-f657c4a15f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1746bba0-d1ad-4335-9304-e54c4286cf97" xlink:to="loc_us-gaap_RestructuringCharges_558d56f6-5e89-4aa1-8d47-f657c4a15f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RestructuringcostsRestructuringandRelatedCostsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bf6dea32-b907-48eb-bbf5-a83b5af52db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bf6dea32-b907-48eb-bbf5-a83b5af52db6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_806733bc-3445-4e04-9556-083c7b5a26ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_806733bc-3445-4e04-9556-083c7b5a26ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_806733bc-3445-4e04-9556-083c7b5a26ac" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnallocatedResearchAndDevelopmentMember_8a148b5f-5735-4672-bb75-cb4274e0043b" xlink:href="ebs-20230331.xsd#ebs_UnallocatedResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:to="loc_ebs_UnallocatedResearchAndDevelopmentMember_8a148b5f-5735-4672-bb75-cb4274e0043b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember_8c4e8121-143a-45d5-97ed-d278ef7aa8af" xlink:href="ebs-20230331.xsd#ebs_EmployeeTransitionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:to="loc_ebs_EmployeeTransitionMember_8c4e8121-143a-45d5-97ed-d278ef7aa8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_9ff7b1ce-72db-464e-a570-51f23d9497fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:to="loc_us-gaap_EmployeeSeveranceMember_9ff7b1ce-72db-464e-a570-51f23d9497fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_683122b9-72ee-4ec3-8fc7-a9580a369344" xlink:href="ebs-20230331.xsd#ebs_EmployeeBenefitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_11860bc4-3370-4438-823f-3e935a5aa75a" xlink:to="loc_ebs_EmployeeBenefitsMember_683122b9-72ee-4ec3-8fc7-a9580a369344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8a939c8f-a70d-454e-9a51-634133247ac1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:to="loc_srt_ConsolidationItemsAxis_8a939c8f-a70d-454e-9a51-634133247ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a445a344-97fc-4349-a969-d7173b7df3e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_8a939c8f-a70d-454e-9a51-634133247ac1" xlink:to="loc_srt_ConsolidationItemsDomain_a445a344-97fc-4349-a969-d7173b7df3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9373faf1-b150-4e77-b7a9-b4250919011c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a445a344-97fc-4349-a969-d7173b7df3e2" xlink:to="loc_us-gaap_OperatingSegmentsMember_9373faf1-b150-4e77-b7a9-b4250919011c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a3ecdfd8-1308-4f0c-854b-1049f63467b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a445a344-97fc-4349-a969-d7173b7df3e2" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a3ecdfd8-1308-4f0c-854b-1049f63467b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_03f43a2b-6c52-4dc1-a4af-d572e69018f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_03f43a2b-6c52-4dc1-a4af-d572e69018f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dcf32d61-7ffa-49bb-b605-a2414255445c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03f43a2b-6c52-4dc1-a4af-d572e69018f2" xlink:to="loc_us-gaap_SegmentDomain_dcf32d61-7ffa-49bb-b605-a2414255445c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_5274133d-9dd2-4087-8173-1b521e47bfc1" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dcf32d61-7ffa-49bb-b605-a2414255445c" xlink:to="loc_ebs_ProductsSegmentMember_5274133d-9dd2-4087-8173-1b521e47bfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_94759856-4647-4695-b898-8ee3e3c067be" xlink:href="ebs-20230331.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dcf32d61-7ffa-49bb-b605-a2414255445c" xlink:to="loc_ebs_ServicesSegmentMember_94759856-4647-4695-b898-8ee3e3c067be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_f6b42ccd-f6a1-49ed-8724-e1bf66b831ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:to="loc_us-gaap_RestructuringPlanAxis_f6b42ccd-f6a1-49ed-8724-e1bf66b831ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_149fbe5c-f0c2-4838-b8ec-f41db13e2117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_f6b42ccd-f6a1-49ed-8724-e1bf66b831ad" xlink:to="loc_us-gaap_RestructuringPlanDomain_149fbe5c-f0c2-4838-b8ec-f41db13e2117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlan2023Member_e47f32f8-5269-4a37-bf14-1d45cfb8af34" xlink:href="ebs-20230331.xsd#ebs_RestructuringPlan2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_149fbe5c-f0c2-4838-b8ec-f41db13e2117" xlink:to="loc_ebs_RestructuringPlan2023Member_e47f32f8-5269-4a37-bf14-1d45cfb8af34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0eb2c319-e505-41b7-9c37-268b3db0417c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24e61323-1205-4ead-b994-5c855b659aa6" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_0eb2c319-e505-41b7-9c37-268b3db0417c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_29e134a7-773e-4fd8-8853-6f836122e3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0eb2c319-e505-41b7-9c37-268b3db0417c" xlink:to="loc_us-gaap_RestructuringCharges_29e134a7-773e-4fd8-8853-6f836122e3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2e1f8153-8d51-497a-a6cc-303a4623fa1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_321d3f19-b566-47f6-a809-6de9fd15f7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2e1f8153-8d51-497a-a6cc-303a4623fa1a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_321d3f19-b566-47f6-a809-6de9fd15f7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_131f0427-9dcb-477d-a09c-34b64fb33cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_321d3f19-b566-47f6-a809-6de9fd15f7c3" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_131f0427-9dcb-477d-a09c-34b64fb33cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_960be083-c7cb-4ce0-8686-e56b65ba0b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_131f0427-9dcb-477d-a09c-34b64fb33cc1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_960be083-c7cb-4ce0-8686-e56b65ba0b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeTransitionMember_448857ee-31e7-4184-b94c-93af265cb8ea" xlink:href="ebs-20230331.xsd#ebs_EmployeeTransitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_960be083-c7cb-4ce0-8686-e56b65ba0b1e" xlink:to="loc_ebs_EmployeeTransitionMember_448857ee-31e7-4184-b94c-93af265cb8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_c2c56b1e-74eb-476d-81b7-8e1c4caa8f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_960be083-c7cb-4ce0-8686-e56b65ba0b1e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_c2c56b1e-74eb-476d-81b7-8e1c4caa8f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_EmployeeBenefitsMember_dd6aca34-7151-4ef3-b511-38ffa281038a" xlink:href="ebs-20230331.xsd#ebs_EmployeeBenefitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_960be083-c7cb-4ce0-8686-e56b65ba0b1e" xlink:to="loc_ebs_EmployeeBenefitsMember_dd6aca34-7151-4ef3-b511-38ffa281038a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_8522ab19-1b84-4cff-a963-18ecd6fc7e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_321d3f19-b566-47f6-a809-6de9fd15f7c3" xlink:to="loc_us-gaap_RestructuringPlanAxis_8522ab19-1b84-4cff-a963-18ecd6fc7e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0e72bf5e-500f-46f7-9e52-9de34b158692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_8522ab19-1b84-4cff-a963-18ecd6fc7e60" xlink:to="loc_us-gaap_RestructuringPlanDomain_0e72bf5e-500f-46f7-9e52-9de34b158692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RestructuringPlan2023Member_366ff6f8-e46f-4afa-be53-dd9a7ab1de4a" xlink:href="ebs-20230331.xsd#ebs_RestructuringPlan2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0e72bf5e-500f-46f7-9e52-9de34b158692" xlink:to="loc_ebs_RestructuringPlan2023Member_366ff6f8-e46f-4afa-be53-dd9a7ab1de4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_cfa5539c-76e1-4318-b15b-a6a9981c1bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_321d3f19-b566-47f6-a809-6de9fd15f7c3" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_cfa5539c-76e1-4318-b15b-a6a9981c1bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_0c2d4ed8-78aa-4de1-a433-01ecf6fea939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_cfa5539c-76e1-4318-b15b-a6a9981c1bf3" xlink:to="loc_us-gaap_RestructuringReserveRollForward_0c2d4ed8-78aa-4de1-a433-01ecf6fea939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_340f1e5b-a649-4278-913b-15e2537c1f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0c2d4ed8-78aa-4de1-a433-01ecf6fea939" xlink:to="loc_us-gaap_RestructuringReserve_340f1e5b-a649-4278-913b-15e2537c1f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_66875efb-b3ad-42d6-8bdd-55c3570fa189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0c2d4ed8-78aa-4de1-a433-01ecf6fea939" xlink:to="loc_us-gaap_RestructuringCharges_66875efb-b3ad-42d6-8bdd-55c3570fa189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_89a864d7-9ad0-4ba0-9b72-564f8264f75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0c2d4ed8-78aa-4de1-a433-01ecf6fea939" xlink:to="loc_us-gaap_PaymentsForRestructuring_89a864d7-9ad0-4ba0-9b72-564f8264f75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_db5a750e-d361-43ee-a259-cf1b92b62024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_0c2d4ed8-78aa-4de1-a433-01ecf6fea939" xlink:to="loc_us-gaap_RestructuringReserve_db5a750e-d361-43ee-a259-cf1b92b62024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#InventoriesnetScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_46a8ce8e-fc62-4f11-908b-e3503a29cd89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_8ff9ffaa-63de-4c9e-b12c-1c4679866000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_46a8ce8e-fc62-4f11-908b-e3503a29cd89" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_8ff9ffaa-63de-4c9e-b12c-1c4679866000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_28f4cb3b-b73a-4c37-8b3a-f820ba3e207f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_46a8ce8e-fc62-4f11-908b-e3503a29cd89" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_28f4cb3b-b73a-4c37-8b3a-f820ba3e207f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_6df2c736-35c9-4f98-86ce-fe6c7f96c468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_46a8ce8e-fc62-4f11-908b-e3503a29cd89" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_6df2c736-35c9-4f98-86ce-fe6c7f96c468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_04b0752f-5f6f-4f78-aa85-40c6d2e9fa25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_46a8ce8e-fc62-4f11-908b-e3503a29cd89" xlink:to="loc_us-gaap_InventoryNet_04b0752f-5f6f-4f78-aa85-40c6d2e9fa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_012117fc-729a-4f2b-a96b-d70c1c22f169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ccf96b7-cb7a-4033-a9bf-acdea1e97567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_012117fc-729a-4f2b-a96b-d70c1c22f169" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ccf96b7-cb7a-4033-a9bf-acdea1e97567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a2db6161-2fb0-47fb-aa96-d8bf0c99bfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ccf96b7-cb7a-4033-a9bf-acdea1e97567" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a2db6161-2fb0-47fb-aa96-d8bf0c99bfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a2db6161-2fb0-47fb-aa96-d8bf0c99bfa5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_72d08317-2319-4aad-9fcb-bba90c82beb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_72d08317-2319-4aad-9fcb-bba90c82beb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_ec3d421d-27c4-43af-8748-67447f3decb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_ec3d421d-27c4-43af-8748-67447f3decb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_47c47105-332a-4a1c-bbf3-b767b78dc1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_47c47105-332a-4a1c-bbf3-b767b78dc1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7573e91b-306e-4590-9cd4-ea96a26cf3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7573e91b-306e-4590-9cd4-ea96a26cf3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b52310e4-3ab7-41a3-8de1-00afce9f6825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db2dd39d-d2fc-443b-bcd6-da13787cd18c" xlink:to="loc_us-gaap_ConstructionInProgressMember_b52310e4-3ab7-41a3-8de1-00afce9f6825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b442a30-48c5-4dc3-a9d6-98e53b622955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ccf96b7-cb7a-4033-a9bf-acdea1e97567" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b442a30-48c5-4dc3-a9d6-98e53b622955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_096b416f-b9a7-4215-8ec3-da2ba343df4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3b442a30-48c5-4dc3-a9d6-98e53b622955" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_096b416f-b9a7-4215-8ec3-da2ba343df4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_adf80359-8fee-4244-83cf-75eb7bc49c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_096b416f-b9a7-4215-8ec3-da2ba343df4b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_adf80359-8fee-4244-83cf-75eb7bc49c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_800d1c24-65e6-4fff-9953-65c5dfb6aba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_096b416f-b9a7-4215-8ec3-da2ba343df4b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_800d1c24-65e6-4fff-9953-65c5dfb6aba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7e7c0591-a61b-40ca-8319-1741e8ea8e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_096b416f-b9a7-4215-8ec3-da2ba343df4b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7e7c0591-a61b-40ca-8319-1741e8ea8e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#PropertyplantandequipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aa694fb7-14dc-44e0-afef-a0136753e08d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b074ea47-17ca-48a8-a645-4b809ec91df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_aa694fb7-14dc-44e0-afef-a0136753e08d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b074ea47-17ca-48a8-a645-4b809ec91df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_47776746-6c32-4844-93b5-1b8718f27182" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b074ea47-17ca-48a8-a645-4b809ec91df7" xlink:to="loc_srt_MajorCustomersAxis_47776746-6c32-4844-93b5-1b8718f27182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_40d631e4-4f5b-4d3c-815e-2ce8b42a6abf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_47776746-6c32-4844-93b5-1b8718f27182" xlink:to="loc_srt_NameOfMajorCustomerDomain_40d631e4-4f5b-4d3c-815e-2ce8b42a6abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_035ee5cc-bd4c-434a-890d-582618d74920" xlink:href="ebs-20230331.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_40d631e4-4f5b-4d3c-815e-2ce8b42a6abf" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_035ee5cc-bd4c-434a-890d-582618d74920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2d6b44a1-6c5b-48f4-98bf-97ea57641ee3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b074ea47-17ca-48a8-a645-4b809ec91df7" xlink:to="loc_srt_ProductOrServiceAxis_2d6b44a1-6c5b-48f4-98bf-97ea57641ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b828c2b-777f-4326-a226-14c40d9fa4c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2d6b44a1-6c5b-48f4-98bf-97ea57641ee3" xlink:to="loc_srt_ProductsAndServicesDomain_3b828c2b-777f-4326-a226-14c40d9fa4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1d810602-0d63-4b2d-b7c6-6d0a8cb9373c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b828c2b-777f-4326-a226-14c40d9fa4c4" xlink:to="loc_us-gaap_ServiceMember_1d810602-0d63-4b2d-b7c6-6d0a8cb9373c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f1f926fe-d7a7-4c92-bb84-8e5d480f6109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b074ea47-17ca-48a8-a645-4b809ec91df7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f1f926fe-d7a7-4c92-bb84-8e5d480f6109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ba46c83f-6225-4688-9f19-29fc26e55490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f1f926fe-d7a7-4c92-bb84-8e5d480f6109" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ba46c83f-6225-4688-9f19-29fc26e55490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bb191a5-829f-470b-b8ba-089f022da037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d10ff3a2-77d3-4257-8430-a17afbf0c883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bb191a5-829f-470b-b8ba-089f022da037" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d10ff3a2-77d3-4257-8430-a17afbf0c883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3553c953-92a8-46fb-a494-d2e969bc2bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d10ff3a2-77d3-4257-8430-a17afbf0c883" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3553c953-92a8-46fb-a494-d2e969bc2bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_915ed944-cb75-4334-bffc-863463c8fcbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3553c953-92a8-46fb-a494-d2e969bc2bd6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_915ed944-cb75-4334-bffc-863463c8fcbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a869eccd-62c6-4658-a0c7-b17a20133a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_915ed944-cb75-4334-bffc-863463c8fcbf" xlink:to="loc_us-gaap_ProductMember_a869eccd-62c6-4658-a0c7-b17a20133a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_4bd6b962-d0df-434b-8922-119341fd54bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_915ed944-cb75-4334-bffc-863463c8fcbf" xlink:to="loc_us-gaap_CustomerRelationshipsMember_4bd6b962-d0df-434b-8922-119341fd54bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_6123d1e8-f90b-493e-abd9-3d974146a836" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_915ed944-cb75-4334-bffc-863463c8fcbf" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_6123d1e8-f90b-493e-abd9-3d974146a836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_40db4562-35a5-439c-9ce7-dfd03db4a2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d10ff3a2-77d3-4257-8430-a17afbf0c883" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_40db4562-35a5-439c-9ce7-dfd03db4a2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_91e1929a-e447-49cb-9a33-e1e24b7055a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_40db4562-35a5-439c-9ce7-dfd03db4a2dc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_91e1929a-e447-49cb-9a33-e1e24b7055a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33fa1e26-c55e-4fbc-bcd4-30df2c9b13d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_91e1929a-e447-49cb-9a33-e1e24b7055a5" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_33fa1e26-c55e-4fbc-bcd4-30df2c9b13d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2de08901-8fe2-4f3a-9a63-f06946bffc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d10ff3a2-77d3-4257-8430-a17afbf0c883" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2de08901-8fe2-4f3a-9a63-f06946bffc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0670c640-a672-44cf-af92-85a7f983f11f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2de08901-8fe2-4f3a-9a63-f06946bffc49" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0670c640-a672-44cf-af92-85a7f983f11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TravelHealthBusinessMember_5fb75cab-786f-45d7-ab37-55cc23678915" xlink:href="ebs-20230331.xsd#ebs_TravelHealthBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0670c640-a672-44cf-af92-85a7f983f11f" xlink:to="loc_ebs_TravelHealthBusinessMember_5fb75cab-786f-45d7-ab37-55cc23678915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d10ff3a2-77d3-4257-8430-a17afbf0c883" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fcb5eb25-0c65-4bf0-92be-b8583aadd1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fcb5eb25-0c65-4bf0-92be-b8583aadd1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_24c60690-d68f-413f-a721-38e138d0f8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_24c60690-d68f-413f-a721-38e138d0f8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e45d1872-bb1c-4443-b118-7d3cef2a38f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e45d1872-bb1c-4443-b118-7d3cef2a38f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1a31f103-a0c1-46a6-a428-a9c664b24977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1a31f103-a0c1-46a6-a428-a9c664b24977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_19133e3f-aff2-4125-a612-127ec3c412d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_959a052d-70cc-4bfd-8b61-af4269942da0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_19133e3f-aff2-4125-a612-127ec3c412d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#IntangibleassetsandgoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c09404d6-0d17-4d50-b6e6-e1bc47466fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a572d523-be6e-47b8-af44-264f3ed1e1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c09404d6-0d17-4d50-b6e6-e1bc47466fde" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a572d523-be6e-47b8-af44-264f3ed1e1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c8828203-5db5-43ce-a291-a7a84b47e8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c09404d6-0d17-4d50-b6e6-e1bc47466fde" xlink:to="loc_us-gaap_Goodwill_c8828203-5db5-43ce-a291-a7a84b47e8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#IntangibleassetsandgoodwillGoodwillRollForwardDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_87b47bbe-9dfc-48f0-bd71-9222126cfa78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_bf27b6da-1360-49a6-9665-453bf0282e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_87b47bbe-9dfc-48f0-bd71-9222126cfa78" xlink:to="loc_us-gaap_GoodwillRollForward_bf27b6da-1360-49a6-9665-453bf0282e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_8b155331-9e28-4b4c-8b98-d004661d007c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_87b47bbe-9dfc-48f0-bd71-9222126cfa78" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_8b155331-9e28-4b4c-8b98-d004661d007c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ed6133e9-a83d-4c50-ae36-bf76bec4f508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8b155331-9e28-4b4c-8b98-d004661d007c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ed6133e9-a83d-4c50-ae36-bf76bec4f508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_70584296-9b25-4c59-a215-4d37fa674c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ed6133e9-a83d-4c50-ae36-bf76bec4f508" xlink:to="loc_us-gaap_SegmentDomain_70584296-9b25-4c59-a215-4d37fa674c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_78c59cff-0c39-43aa-9319-9bc23cfa690b" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_70584296-9b25-4c59-a215-4d37fa674c98" xlink:to="loc_ebs_ProductsSegmentMember_78c59cff-0c39-43aa-9319-9bc23cfa690b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_d3ea5ee7-c3e4-4776-8e26-7afaa823d06b" xlink:href="ebs-20230331.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_70584296-9b25-4c59-a215-4d37fa674c98" xlink:to="loc_ebs_ServicesSegmentMember_d3ea5ee7-c3e4-4776-8e26-7afaa823d06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_aa22f942-365f-40fa-af4f-211eada00c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8b155331-9e28-4b4c-8b98-d004661d007c" xlink:to="loc_us-gaap_GoodwillLineItems_aa22f942-365f-40fa-af4f-211eada00c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_5d300c99-2f86-4718-abc7-0d802b542a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_aa22f942-365f-40fa-af4f-211eada00c5c" xlink:to="loc_us-gaap_GoodwillRollForward_5d300c99-2f86-4718-abc7-0d802b542a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9d3e8889-6977-451f-9bfd-ecf7ecf3c908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5d300c99-2f86-4718-abc7-0d802b542a0d" xlink:to="loc_us-gaap_Goodwill_9d3e8889-6977-451f-9bfd-ecf7ecf3c908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_49561a61-1558-40ff-93a5-49d5aef9dc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_aa22f942-365f-40fa-af4f-211eada00c5c" xlink:to="loc_us-gaap_GoodwillGross_49561a61-1558-40ff-93a5-49d5aef9dc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c4532154-80e8-458d-9b13-49f9f65fdd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_aa22f942-365f-40fa-af4f-211eada00c5c" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c4532154-80e8-458d-9b13-49f9f65fdd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_595b6e5a-befc-4622-8a7a-34724df206f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1adef9e1-4c63-4cd4-8553-ce168ba0b586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_595b6e5a-befc-4622-8a7a-34724df206f3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1adef9e1-4c63-4cd4-8553-ce168ba0b586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_35a56d8a-3161-4930-9a06-d587e9d764d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1adef9e1-4c63-4cd4-8553-ce168ba0b586" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_35a56d8a-3161-4930-9a06-d587e9d764d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_534409e3-3607-457a-8b90-d55b91e5a1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_35a56d8a-3161-4930-9a06-d587e9d764d2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_534409e3-3607-457a-8b90-d55b91e5a1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c0c4ca5b-f9c3-4a19-9a17-06e9d799a627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_534409e3-3607-457a-8b90-d55b91e5a1fd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c0c4ca5b-f9c3-4a19-9a17-06e9d799a627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_125afed6-53f0-4478-ad50-4247a92d9b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_534409e3-3607-457a-8b90-d55b91e5a1fd" xlink:to="loc_us-gaap_BankTimeDepositsMember_125afed6-53f0-4478-ad50-4247a92d9b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0bbfb60-cefb-4e6d-8d1b-ff0f33930b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1adef9e1-4c63-4cd4-8553-ce168ba0b586" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0bbfb60-cefb-4e6d-8d1b-ff0f33930b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b2d4b67-149c-4f85-b402-5a0fd0f8f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b0bbfb60-cefb-4e6d-8d1b-ff0f33930b24" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b2d4b67-149c-4f85-b402-5a0fd0f8f0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a5a3177f-69b9-4b54-b68c-e844a596777c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b2d4b67-149c-4f85-b402-5a0fd0f8f0c7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a5a3177f-69b9-4b54-b68c-e844a596777c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_82f44020-5f68-4a50-b60e-9efff7c18ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b2d4b67-149c-4f85-b402-5a0fd0f8f0c7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_82f44020-5f68-4a50-b60e-9efff7c18ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f4ca6481-b253-4536-9ac1-2dd2f8201698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0b2d4b67-149c-4f85-b402-5a0fd0f8f0c7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f4ca6481-b253-4536-9ac1-2dd2f8201698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1adef9e1-4c63-4cd4-8553-ce168ba0b586" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9449732d-73cf-4a04-b0bd-7d5be1fab29b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9449732d-73cf-4a04-b0bd-7d5be1fab29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_405a0053-912c-4c23-803f-d0bc7f6c0e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:to="loc_us-gaap_DerivativeAssets_405a0053-912c-4c23-803f-d0bc7f6c0e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b2c1b0a2-3306-479b-a34c-9f4c34b564b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b2c1b0a2-3306-479b-a34c-9f4c34b564b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2c91f1fc-9518-4db8-ac4b-524299fdb800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2c91f1fc-9518-4db8-ac4b-524299fdb800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_45cf2ee2-4703-4994-b7e2-f654fcf03213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78b2a596-0633-4176-8d35-dcfc46c56a8c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_45cf2ee2-4703-4994-b7e2-f654fcf03213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#FairvaluemeasurementsContingentConsiderationRollForwardDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3b58f75a-e103-465d-a873-e83cfd56e222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_59f62d40-13b3-48db-af7e-90555a71b352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3b58f75a-e103-465d-a873-e83cfd56e222" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_59f62d40-13b3-48db-af7e-90555a71b352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ca002f35-4a2f-4534-a603-6ffc5d8ff226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_59f62d40-13b3-48db-af7e-90555a71b352" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ca002f35-4a2f-4534-a603-6ffc5d8ff226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b8bf1536-bfb0-475a-95dc-75fa9d2e53cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_59f62d40-13b3-48db-af7e-90555a71b352" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b8bf1536-bfb0-475a-95dc-75fa9d2e53cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_35b0b79c-7fbe-4ebf-83af-de2b2a78cae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_59f62d40-13b3-48db-af7e-90555a71b352" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_35b0b79c-7fbe-4ebf-83af-de2b2a78cae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0937601d-302d-4eac-aebe-08a25ff3c8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_59f62d40-13b3-48db-af7e-90555a71b352" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0937601d-302d-4eac-aebe-08a25ff3c8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#FairvaluemeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_64717920-66c4-48d8-a318-5b08f8b60827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d47988d0-2334-408c-871a-3355173f0cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64717920-66c4-48d8-a318-5b08f8b60827" xlink:to="loc_us-gaap_DebtInstrumentTable_d47988d0-2334-408c-871a-3355173f0cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e9d560ce-4160-488b-94a1-753a3a54b73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d47988d0-2334-408c-871a-3355173f0cd1" xlink:to="loc_us-gaap_DebtInstrumentAxis_e9d560ce-4160-488b-94a1-753a3a54b73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9be679f4-bfec-48af-a5a0-c66045d6133c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9d560ce-4160-488b-94a1-753a3a54b73f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9be679f4-bfec-48af-a5a0-c66045d6133c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_1a6da9d0-965a-420a-a503-91543ec80c92" xlink:href="ebs-20230331.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9be679f4-bfec-48af-a5a0-c66045d6133c" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_1a6da9d0-965a-420a-a503-91543ec80c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_358955cf-106d-4e58-b96b-0ac459719590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d47988d0-2334-408c-871a-3355173f0cd1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_358955cf-106d-4e58-b96b-0ac459719590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f747680a-51b0-4bba-99ca-a7221ac97bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_358955cf-106d-4e58-b96b-0ac459719590" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f747680a-51b0-4bba-99ca-a7221ac97bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_dfcb8f72-c7c1-47bf-9cf7-08422a116c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f747680a-51b0-4bba-99ca-a7221ac97bf5" xlink:to="loc_us-gaap_SeniorNotesMember_dfcb8f72-c7c1-47bf-9cf7-08422a116c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_14c39d8b-ecef-464d-bc18-41ed797832d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d47988d0-2334-408c-871a-3355173f0cd1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_14c39d8b-ecef-464d-bc18-41ed797832d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2f556733-4735-4c49-9e5e-b537511038b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14c39d8b-ecef-464d-bc18-41ed797832d6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2f556733-4735-4c49-9e5e-b537511038b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1c79bb5-afd4-41f4-a075-dee4d17af5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14c39d8b-ecef-464d-bc18-41ed797832d6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a1c79bb5-afd4-41f4-a075-dee4d17af5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_d499b494-99b7-40bc-84cb-3b1cda67f267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_14c39d8b-ecef-464d-bc18-41ed797832d6" xlink:to="loc_us-gaap_LongTermDebtFairValue_d499b494-99b7-40bc-84cb-3b1cda67f267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bc07662b-b4e0-4585-be71-c1917877d3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bc07662b-b4e0-4585-be71-c1917877d3d8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_20955c40-57da-400b-b1a7-d33f3c4fb811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:to="loc_us-gaap_ValuationTechniqueAxis_20955c40-57da-400b-b1a7-d33f3c4fb811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_07c701bb-7b3e-4f05-920b-63e4aa39b845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_20955c40-57da-400b-b1a7-d33f3c4fb811" xlink:to="loc_us-gaap_ValuationTechniqueDomain_07c701bb-7b3e-4f05-920b-63e4aa39b845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_d1814a15-63fd-46e3-b983-da4eb551d678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_07c701bb-7b3e-4f05-920b-63e4aa39b845" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_d1814a15-63fd-46e3-b983-da4eb551d678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_396ce5bd-7bc6-41d8-b50f-53551cb35ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_396ce5bd-7bc6-41d8-b50f-53551cb35ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6e8ef06-0f61-4f65-8e95-87af146da258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_396ce5bd-7bc6-41d8-b50f-53551cb35ea6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6e8ef06-0f61-4f65-8e95-87af146da258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_899ae8a2-cf72-42c3-93c7-bfb9e81ae4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f6e8ef06-0f61-4f65-8e95-87af146da258" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_899ae8a2-cf72-42c3-93c7-bfb9e81ae4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb911cf0-cbdb-48df-bf67-7cc26ba8d6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb911cf0-cbdb-48df-bf67-7cc26ba8d6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1762fa10-a13b-4445-8a73-29c4caaa111e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb911cf0-cbdb-48df-bf67-7cc26ba8d6e4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1762fa10-a13b-4445-8a73-29c4caaa111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6b554c9f-e0de-4c36-9960-3da360e64333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1762fa10-a13b-4445-8a73-29c4caaa111e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6b554c9f-e0de-4c36-9960-3da360e64333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e9ffec7c-10e8-4b45-b1f2-083225ae42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e9ffec7c-10e8-4b45-b1f2-083225ae42ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_94fe4f7c-c95f-42b8-8d16-027ce34f1a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e9ffec7c-10e8-4b45-b1f2-083225ae42ae" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_94fe4f7c-c95f-42b8-8d16-027ce34f1a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cca33928-fb7f-4c94-bfc8-fd38c8fa442d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_94fe4f7c-c95f-42b8-8d16-027ce34f1a89" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cca33928-fb7f-4c94-bfc8-fd38c8fa442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityOfPaymentMember_f31b72f1-d06e-443b-8958-17d853e2ed0f" xlink:href="ebs-20230331.xsd#ebs_MeasurementInputProbabilityOfPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_94fe4f7c-c95f-42b8-8d16-027ce34f1a89" xlink:to="loc_ebs_MeasurementInputProbabilityOfPaymentMember_f31b72f1-d06e-443b-8958-17d853e2ed0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cf89c059-2f1e-48cf-aa46-ba5d5be4a2da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:to="loc_srt_RangeAxis_cf89c059-2f1e-48cf-aa46-ba5d5be4a2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08d295af-e55f-476e-91dc-8717a5db006b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cf89c059-2f1e-48cf-aa46-ba5d5be4a2da" xlink:to="loc_srt_RangeMember_08d295af-e55f-476e-91dc-8717a5db006b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f99abb48-9e9c-4c67-9d7d-fe8e17c1fac8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_08d295af-e55f-476e-91dc-8717a5db006b" xlink:to="loc_srt_MinimumMember_f99abb48-9e9c-4c67-9d7d-fe8e17c1fac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_adaf839b-90f9-4003-96ea-a2c877f3bba8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_08d295af-e55f-476e-91dc-8717a5db006b" xlink:to="loc_srt_MaximumMember_adaf839b-90f9-4003-96ea-a2c877f3bba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d187419b-766d-4e9d-8d9b-d5a32281faf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e53cabff-7687-46c6-a507-fa76f9648f48" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d187419b-766d-4e9d-8d9b-d5a32281faf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b005e796-7142-4691-a2a1-1025f1112ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d187419b-766d-4e9d-8d9b-d5a32281faf6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b005e796-7142-4691-a2a1-1025f1112ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_78ebb423-e237-4f9c-9243-ac3a17288dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d187419b-766d-4e9d-8d9b-d5a32281faf6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_78ebb423-e237-4f9c-9243-ac3a17288dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1a770167-4a9f-45ae-a615-801af326d058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d817cc05-5c23-425f-aac2-d8bf86b0a525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1a770167-4a9f-45ae-a615-801af326d058" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d817cc05-5c23-425f-aac2-d8bf86b0a525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c10bc006-0ce2-4ccc-8db6-02fc0adb7969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d817cc05-5c23-425f-aac2-d8bf86b0a525" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c10bc006-0ce2-4ccc-8db6-02fc0adb7969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3f17d132-9554-4fef-80d5-678184104c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c10bc006-0ce2-4ccc-8db6-02fc0adb7969" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3f17d132-9554-4fef-80d5-678184104c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_15078101-0db9-4551-8444-94005310fc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3f17d132-9554-4fef-80d5-678184104c1c" xlink:to="loc_us-gaap_InterestRateSwapMember_15078101-0db9-4551-8444-94005310fc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_943a429e-5bbc-425e-b288-4cf9bc0e4912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d817cc05-5c23-425f-aac2-d8bf86b0a525" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_943a429e-5bbc-425e-b288-4cf9bc0e4912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_94129525-f48d-4996-9b22-edebe73eb3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_943a429e-5bbc-425e-b288-4cf9bc0e4912" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_94129525-f48d-4996-9b22-edebe73eb3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_247848d5-199e-45ff-9cac-f7653f7c039a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_490c8749-344b-42b5-937b-2758f2813c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_247848d5-199e-45ff-9cac-f7653f7c039a" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_490c8749-344b-42b5-937b-2758f2813c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_325ddbbc-82ba-4035-a436-00fa33a96da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_490c8749-344b-42b5-937b-2758f2813c0e" xlink:to="loc_us-gaap_HedgingDesignationAxis_325ddbbc-82ba-4035-a436-00fa33a96da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_49399abb-1d50-4cbd-a942-a6e1a402f102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_325ddbbc-82ba-4035-a436-00fa33a96da4" xlink:to="loc_us-gaap_HedgingDesignationDomain_49399abb-1d50-4cbd-a942-a6e1a402f102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6facd443-c9a8-410c-99e0-75fbb87d94c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_49399abb-1d50-4cbd-a942-a6e1a402f102" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6facd443-c9a8-410c-99e0-75fbb87d94c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_820c16d5-9240-482c-ba50-895de94bb342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_490c8749-344b-42b5-937b-2758f2813c0e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_820c16d5-9240-482c-ba50-895de94bb342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_253ef945-8089-45f7-b38e-af0878dd162d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_820c16d5-9240-482c-ba50-895de94bb342" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_253ef945-8089-45f7-b38e-af0878dd162d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_99dda1cd-efa7-4a56-a45f-45d631837959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_253ef945-8089-45f7-b38e-af0878dd162d" xlink:to="loc_us-gaap_InterestRateSwapMember_99dda1cd-efa7-4a56-a45f-45d631837959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_dc1d7b4e-0711-4dd9-95a3-6c914fee1387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_490c8749-344b-42b5-937b-2758f2813c0e" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_dc1d7b4e-0711-4dd9-95a3-6c914fee1387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6d0c7e39-4d5d-4dbb-90a4-9d90643d938f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_dc1d7b4e-0711-4dd9-95a3-6c914fee1387" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6d0c7e39-4d5d-4dbb-90a4-9d90643d938f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_95b685fe-55cc-4606-8f86-276541463315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_dc1d7b4e-0711-4dd9-95a3-6c914fee1387" xlink:to="loc_us-gaap_DerivativeNotionalAmount_95b685fe-55cc-4606-8f86-276541463315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4fb18196-809a-481c-bdb0-71d6cc7586aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_965deb82-6451-49d6-9580-18fde8ddf3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4fb18196-809a-481c-bdb0-71d6cc7586aa" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_965deb82-6451-49d6-9580-18fde8ddf3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b2522bf6-eb06-4b33-b7a2-6c68c5efe95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_965deb82-6451-49d6-9580-18fde8ddf3f3" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b2522bf6-eb06-4b33-b7a2-6c68c5efe95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_780c5f3e-385b-4256-9305-0fa84a33e12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b2522bf6-eb06-4b33-b7a2-6c68c5efe95a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_780c5f3e-385b-4256-9305-0fa84a33e12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_a7a2f100-99ed-4de6-afc6-bcc79182bb26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_780c5f3e-385b-4256-9305-0fa84a33e12c" xlink:to="loc_us-gaap_InterestRateSwapMember_a7a2f100-99ed-4de6-afc6-bcc79182bb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0131b461-1938-48a2-b2b6-08bca2ee3539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_965deb82-6451-49d6-9580-18fde8ddf3f3" xlink:to="loc_us-gaap_HedgingDesignationAxis_0131b461-1938-48a2-b2b6-08bca2ee3539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6dd67639-43e1-4634-8912-0f6d2a734ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_0131b461-1938-48a2-b2b6-08bca2ee3539" xlink:to="loc_us-gaap_HedgingDesignationDomain_6dd67639-43e1-4634-8912-0f6d2a734ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_28876d33-7af9-4654-b2e6-66bcc9832c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_6dd67639-43e1-4634-8912-0f6d2a734ef8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_28876d33-7af9-4654-b2e6-66bcc9832c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_dd45794a-71df-4001-aae5-360a8a78d1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_965deb82-6451-49d6-9580-18fde8ddf3f3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_dd45794a-71df-4001-aae5-360a8a78d1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cf156dba-7d39-41cd-98ea-cecde893b366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dd45794a-71df-4001-aae5-360a8a78d1ee" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cf156dba-7d39-41cd-98ea-cecde893b366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_d0433b7b-662e-4114-9dd8-4269b069f3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf156dba-7d39-41cd-98ea-cecde893b366" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_d0433b7b-662e-4114-9dd8-4269b069f3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ddb2df5b-507e-4ba0-aaa9-846ca8aac7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_965deb82-6451-49d6-9580-18fde8ddf3f3" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_ddb2df5b-507e-4ba0-aaa9-846ca8aac7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_e5c6bd7e-caa7-45f5-8e61-dbd91e218a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ddb2df5b-507e-4ba0-aaa9-846ca8aac7e2" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_e5c6bd7e-caa7-45f5-8e61-dbd91e218a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d8a8d9a2-f77a-4b41-ae79-ee3edb2d21ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_2e258293-7518-4aa2-91df-6278f60b6f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d8a8d9a2-f77a-4b41-ae79-ee3edb2d21ac" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_2e258293-7518-4aa2-91df-6278f60b6f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_fe8e5852-5c7b-4891-8d2a-583df3918048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_2e258293-7518-4aa2-91df-6278f60b6f00" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_fe8e5852-5c7b-4891-8d2a-583df3918048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ed7f5bc6-a8cf-4c6c-a75e-af874a23ff58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_fe8e5852-5c7b-4891-8d2a-583df3918048" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ed7f5bc6-a8cf-4c6c-a75e-af874a23ff58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_9107546c-f741-4178-afac-907ba34a7f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ed7f5bc6-a8cf-4c6c-a75e-af874a23ff58" xlink:to="loc_us-gaap_CashFlowHedgingMember_9107546c-f741-4178-afac-907ba34a7f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4705ef77-529e-4753-9a7e-a9b1c5b06df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_2e258293-7518-4aa2-91df-6278f60b6f00" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4705ef77-529e-4753-9a7e-a9b1c5b06df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6eacee1d-01ec-4076-931f-bd86bfdc3e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4705ef77-529e-4753-9a7e-a9b1c5b06df0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6eacee1d-01ec-4076-931f-bd86bfdc3e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_c7bf3e7c-89c7-4a31-ad6e-1f849cb8b86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6eacee1d-01ec-4076-931f-bd86bfdc3e9d" xlink:to="loc_us-gaap_InterestExpenseMember_c7bf3e7c-89c7-4a31-ad6e-1f849cb8b86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3cc2b3a2-d17f-46b1-b639-ceac47582422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_2e258293-7518-4aa2-91df-6278f60b6f00" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3cc2b3a2-d17f-46b1-b639-ceac47582422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c3a60435-dd61-4302-86a2-bbd0599955b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3cc2b3a2-d17f-46b1-b639-ceac47582422" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c3a60435-dd61-4302-86a2-bbd0599955b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_984990b3-23d5-4fad-9d5b-072af95e5898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c3a60435-dd61-4302-86a2-bbd0599955b5" xlink:to="loc_us-gaap_InterestRateSwapMember_984990b3-23d5-4fad-9d5b-072af95e5898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_cc621163-74a8-4436-9295-510641a79d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_2e258293-7518-4aa2-91df-6278f60b6f00" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_cc621163-74a8-4436-9295-510641a79d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_6986173f-7cc1-4366-bb3a-b295d55eb7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_cc621163-74a8-4436-9295-510641a79d13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_6986173f-7cc1-4366-bb3a-b295d55eb7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DebtScheduleDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dc66f2ab-a28b-49c9-8930-ac31ce4c6df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1307cbe0-11bd-4210-a4fc-a7bd279b1b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dc66f2ab-a28b-49c9-8930-ac31ce4c6df3" xlink:to="loc_us-gaap_DebtInstrumentTable_1307cbe0-11bd-4210-a4fc-a7bd279b1b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4617e4e5-6105-4f95-ba16-beaeb28b5e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1307cbe0-11bd-4210-a4fc-a7bd279b1b72" xlink:to="loc_us-gaap_DebtInstrumentAxis_4617e4e5-6105-4f95-ba16-beaeb28b5e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_62df5273-d2b1-4d6a-8ced-2453f80a28c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4617e4e5-6105-4f95-ba16-beaeb28b5e58" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_62df5273-d2b1-4d6a-8ced-2453f80a28c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_592cc8c1-4753-438e-a9f9-4bb500da803c" xlink:href="ebs-20230331.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62df5273-d2b1-4d6a-8ced-2453f80a28c1" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_592cc8c1-4753-438e-a9f9-4bb500da803c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_02f5c5fc-7fd2-4c6c-bb0a-7f5d48427f17" xlink:href="ebs-20230331.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_62df5273-d2b1-4d6a-8ced-2453f80a28c1" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_02f5c5fc-7fd2-4c6c-bb0a-7f5d48427f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8032107c-3cb0-40a9-a5e3-db0b4324e040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1307cbe0-11bd-4210-a4fc-a7bd279b1b72" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8032107c-3cb0-40a9-a5e3-db0b4324e040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2d2e7aed-e71c-40eb-936a-b78a840c80e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8032107c-3cb0-40a9-a5e3-db0b4324e040" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2d2e7aed-e71c-40eb-936a-b78a840c80e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_711d387f-771d-45da-be46-8637428f8217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d2e7aed-e71c-40eb-936a-b78a840c80e8" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_711d387f-771d-45da-be46-8637428f8217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_dc3a1744-6fe8-43e1-9867-7bb947dee9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d2e7aed-e71c-40eb-936a-b78a840c80e8" xlink:to="loc_us-gaap_LineOfCreditMember_dc3a1744-6fe8-43e1-9867-7bb947dee9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_6b855e34-e749-45aa-a3be-328e20e98c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2d2e7aed-e71c-40eb-936a-b78a840c80e8" xlink:to="loc_us-gaap_SeniorNotesMember_6b855e34-e749-45aa-a3be-328e20e98c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_315607c2-9dc5-4d69-8d54-272977cf4973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1307cbe0-11bd-4210-a4fc-a7bd279b1b72" xlink:to="loc_us-gaap_CreditFacilityAxis_315607c2-9dc5-4d69-8d54-272977cf4973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ef25da80-3a29-4f3e-9dd2-3847b256a7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_315607c2-9dc5-4d69-8d54-272977cf4973" xlink:to="loc_us-gaap_CreditFacilityDomain_ef25da80-3a29-4f3e-9dd2-3847b256a7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_b83e21ea-ae26-41fb-a184-2c9625066378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ef25da80-3a29-4f3e-9dd2-3847b256a7ed" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_b83e21ea-ae26-41fb-a184-2c9625066378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1307cbe0-11bd-4210-a4fc-a7bd279b1b72" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a147750c-d67e-4f24-8d7a-adfcf2f139d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a147750c-d67e-4f24-8d7a-adfcf2f139d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_74e17f51-b2ab-4461-b560-622a304ce442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:to="loc_us-gaap_LongTermDebt_74e17f51-b2ab-4461-b560-622a304ce442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_d8ab6e8f-faa8-4140-9664-6bcc9d9e2e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_d8ab6e8f-faa8-4140-9664-6bcc9d9e2e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b87463f2-71c1-48c7-b4bc-e399b91d0b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:to="loc_us-gaap_LongTermDebtCurrent_b87463f2-71c1-48c7-b4bc-e399b91d0b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_91a4385d-d6fe-4314-8873-3e05a411026d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cac8ab97-4dc0-4d31-b4e2-2f30624bd2e3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_91a4385d-d6fe-4314-8873-3e05a411026d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_06cf92b0-01e5-49fa-8fe4-6009b8342cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_06cf92b0-01e5-49fa-8fe4-6009b8342cab" xlink:to="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a5ca98ea-f486-4077-93db-9e4da01243f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_us-gaap_CreditFacilityAxis_a5ca98ea-f486-4077-93db-9e4da01243f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d133a9e0-baff-4cb8-9b28-0eb971774734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_a5ca98ea-f486-4077-93db-9e4da01243f6" xlink:to="loc_us-gaap_CreditFacilityDomain_d133a9e0-baff-4cb8-9b28-0eb971774734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_636773ef-e19e-4dd9-8246-1669fbeca997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d133a9e0-baff-4cb8-9b28-0eb971774734" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_636773ef-e19e-4dd9-8246-1669fbeca997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember_cd76bd54-e8e7-4e32-94c8-e25b4f600ad7" xlink:href="ebs-20230331.xsd#ebs_TermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d133a9e0-baff-4cb8-9b28-0eb971774734" xlink:to="loc_ebs_TermLoanFacilityMember_cd76bd54-e8e7-4e32-94c8-e25b4f600ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_939291ab-71f7-40f9-864c-a36cadf54b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_us-gaap_DebtInstrumentAxis_939291ab-71f7-40f9-864c-a36cadf54b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a0c51351-d569-4e5d-a88c-3900f30b4efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_939291ab-71f7-40f9-864c-a36cadf54b45" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a0c51351-d569-4e5d-a88c-3900f30b4efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_32415a97-91db-4d13-8780-8b5a53bb4f50" xlink:href="ebs-20230331.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0c51351-d569-4e5d-a88c-3900f30b4efb" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_32415a97-91db-4d13-8780-8b5a53bb4f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember_3b1c03bf-812a-4dec-8d70-6b5f4879b2cf" xlink:href="ebs-20230331.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a0c51351-d569-4e5d-a88c-3900f30b4efb" xlink:to="loc_ebs_AmendedCreditAgreementMember_3b1c03bf-812a-4dec-8d70-6b5f4879b2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_127e5b0b-e032-44f5-bdb6-159ed2c8dbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_us-gaap_VariableRateAxis_127e5b0b-e032-44f5-bdb6-159ed2c8dbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_098f5448-a0a6-4f53-83f1-1be09a3c6611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_127e5b0b-e032-44f5-bdb6-159ed2c8dbf9" xlink:to="loc_us-gaap_VariableRateDomain_098f5448-a0a6-4f53-83f1-1be09a3c6611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_b7cb1df4-9dff-458a-b231-27527fd27849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_098f5448-a0a6-4f53-83f1-1be09a3c6611" xlink:to="loc_us-gaap_EurodollarMember_b7cb1df4-9dff-458a-b231-27527fd27849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_1c877d16-df0b-4915-a0c7-070ac0abcfca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_098f5448-a0a6-4f53-83f1-1be09a3c6611" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_1c877d16-df0b-4915-a0c7-070ac0abcfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_4f503282-dad1-4104-990f-b168c8ee3837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_098f5448-a0a6-4f53-83f1-1be09a3c6611" xlink:to="loc_us-gaap_BaseRateMember_4f503282-dad1-4104-990f-b168c8ee3837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_52d962a4-6450-449a-bef3-3aaa6a9e5e1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_srt_RangeAxis_52d962a4-6450-449a-bef3-3aaa6a9e5e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c157b6b-0c8d-4bce-9fc3-877e5a69cffd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_52d962a4-6450-449a-bef3-3aaa6a9e5e1f" xlink:to="loc_srt_RangeMember_2c157b6b-0c8d-4bce-9fc3-877e5a69cffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f96291ca-014e-43af-a818-71fd79ffc65d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2c157b6b-0c8d-4bce-9fc3-877e5a69cffd" xlink:to="loc_srt_MinimumMember_f96291ca-014e-43af-a818-71fd79ffc65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_91338353-1b12-4041-9daa-69b5346bfac1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2c157b6b-0c8d-4bce-9fc3-877e5a69cffd" xlink:to="loc_srt_MaximumMember_91338353-1b12-4041-9daa-69b5346bfac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6fd4b386-4e16-401c-901a-48e7217d1397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6fd4b386-4e16-401c-901a-48e7217d1397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6e89478b-22bf-44cc-93f2-bd09f1424628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6fd4b386-4e16-401c-901a-48e7217d1397" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6e89478b-22bf-44cc-93f2-bd09f1424628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8cc22855-2b68-455d-abb6-5bd999fc165a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6e89478b-22bf-44cc-93f2-bd09f1424628" xlink:to="loc_us-gaap_SeniorNotesMember_8cc22855-2b68-455d-abb6-5bd999fc165a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b254fb47-6a3c-46f0-b17f-ad54e795fc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b254fb47-6a3c-46f0-b17f-ad54e795fc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dd45400f-0ed4-4796-a636-2f9c0c1d6699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_b254fb47-6a3c-46f0-b17f-ad54e795fc93" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dd45400f-0ed4-4796-a636-2f9c0c1d6699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b101f83e-7d7a-422c-9dec-5865d9623314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dd45400f-0ed4-4796-a636-2f9c0c1d6699" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b101f83e-7d7a-422c-9dec-5865d9623314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_6ac68ed2-f9ba-47c1-8fad-81760a7e7e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_dd45400f-0ed4-4796-a636-2f9c0c1d6699" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_6ac68ed2-f9ba-47c1-8fad-81760a7e7e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_160a7f0f-acab-4707-bc5f-6a1397dfb659" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_41977bc0-171f-4f43-ac07-39c5ce28f115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_41977bc0-171f-4f43-ac07-39c5ce28f115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_409bae67-7f1c-4c61-8f17-21d41d4387f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_409bae67-7f1c-4c61-8f17-21d41d4387f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5cc63b55-564e-418f-9e2c-a5efc2e50be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_LongTermDebt_5cc63b55-564e-418f-9e2c-a5efc2e50be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_73a06dfe-16b5-4487-9bbb-045e7cff3938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_73a06dfe-16b5-4487-9bbb-045e7cff3938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_ad9c4f69-39b1-49b8-a23d-285b67db5e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_ad9c4f69-39b1-49b8-a23d-285b67db5e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_394a21e3-0e16-43fa-a9ea-4891dec322cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_394a21e3-0e16-43fa-a9ea-4891dec322cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7448da32-b998-4ae8-8a89-5a52c42dc2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7448da32-b998-4ae8-8a89-5a52c42dc2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_4c67ceca-e121-4c70-b239-a2a03f7301e0" xlink:href="ebs-20230331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_4c67ceca-e121-4c70-b239-a2a03f7301e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_10113d33-95e9-4d90-a0e7-1b3ae5a518bd" xlink:href="ebs-20230331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_10113d33-95e9-4d90-a0e7-1b3ae5a518bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_98fb54d0-4206-4c26-906c-482c9fdd7b08" xlink:href="ebs-20230331.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_98fb54d0-4206-4c26-906c-482c9fdd7b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_8d8e6365-ee56-4fec-b8d7-522e1df35e63" xlink:href="ebs-20230331.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_8d8e6365-ee56-4fec-b8d7-522e1df35e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_14c45e03-8727-44ff-a0e8-31f45196a624" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_14c45e03-8727-44ff-a0e8-31f45196a624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_3a372c5e-07fa-4a55-8ffa-606592570484" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_3a372c5e-07fa-4a55-8ffa-606592570484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_6c99f5ad-80ae-47d7-b109-fdec18bd68bc" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_6c99f5ad-80ae-47d7-b109-fdec18bd68bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_e0b7fe25-32d6-4239-a260-9923c85f6e32" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_e0b7fe25-32d6-4239-a260-9923c85f6e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_7e7ede33-5075-45a3-9231-ebb10abdf60c" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_7e7ede33-5075-45a3-9231-ebb10abdf60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_400e7e44-66cd-44a1-8356-8b2a2910ff28" xlink:href="ebs-20230331.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0e636f62-7423-46dc-b287-1ec66c5ef020" xlink:to="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_400e7e44-66cd-44a1-8356-8b2a2910ff28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#StockbasedcompensationandstockholdersequityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_3f1d24bf-19bd-47c7-9b02-69c69f3aea9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8719d3bb-3808-42bc-891f-a12893d5ec8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3f1d24bf-19bd-47c7-9b02-69c69f3aea9b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8719d3bb-3808-42bc-891f-a12893d5ec8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7a6ccc86-4ecd-4aca-84f4-b5958e3159d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8719d3bb-3808-42bc-891f-a12893d5ec8e" xlink:to="loc_us-gaap_VestingAxis_7a6ccc86-4ecd-4aca-84f4-b5958e3159d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5f7f6c93-aab8-498c-bbff-37d453debb44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_7a6ccc86-4ecd-4aca-84f4-b5958e3159d0" xlink:to="loc_us-gaap_VestingDomain_5f7f6c93-aab8-498c-bbff-37d453debb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f2dc610a-45de-454d-9681-249c23bc4af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5f7f6c93-aab8-498c-bbff-37d453debb44" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f2dc610a-45de-454d-9681-249c23bc4af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c1a9eefc-b842-4a73-9504-114fd5be22d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5f7f6c93-aab8-498c-bbff-37d453debb44" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c1a9eefc-b842-4a73-9504-114fd5be22d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_b94d0456-f29a-4f8d-8571-157d14c5b19d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5f7f6c93-aab8-498c-bbff-37d453debb44" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_b94d0456-f29a-4f8d-8571-157d14c5b19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e26068f5-d980-4a10-8081-6d843e5a7661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8719d3bb-3808-42bc-891f-a12893d5ec8e" xlink:to="loc_us-gaap_AwardTypeAxis_e26068f5-d980-4a10-8081-6d843e5a7661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af6c754e-c329-404c-8ddb-8232a77fb8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e26068f5-d980-4a10-8081-6d843e5a7661" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af6c754e-c329-404c-8ddb-8232a77fb8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0a7b00b7-7463-4d83-b9cf-25dfbe3aa981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af6c754e-c329-404c-8ddb-8232a77fb8ad" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0a7b00b7-7463-4d83-b9cf-25dfbe3aa981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1c3ba098-8f6a-43d6-9477-dfad1b214223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af6c754e-c329-404c-8ddb-8232a77fb8ad" xlink:to="loc_us-gaap_PerformanceSharesMember_1c3ba098-8f6a-43d6-9477-dfad1b214223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6eaf038d-2406-4e54-a6e2-2f686f13162a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af6c754e-c329-404c-8ddb-8232a77fb8ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6eaf038d-2406-4e54-a6e2-2f686f13162a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4258b256-6152-492e-b762-fa826ef1ed05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8719d3bb-3808-42bc-891f-a12893d5ec8e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4258b256-6152-492e-b762-fa826ef1ed05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc01b025-6d6c-4277-a4f5-a1d8e632d14a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4258b256-6152-492e-b762-fa826ef1ed05" xlink:to="loc_us-gaap_EquityComponentDomain_fc01b025-6d6c-4277-a4f5-a1d8e632d14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_25c79539-d6e7-482b-93cb-4919bd1730f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fc01b025-6d6c-4277-a4f5-a1d8e632d14a" xlink:to="loc_us-gaap_TreasuryStockCommonMember_25c79539-d6e7-482b-93cb-4919bd1730f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8719d3bb-3808-42bc-891f-a12893d5ec8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f4c56d99-2f0d-4570-94fd-ba08a0aa6975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f4c56d99-2f0d-4570-94fd-ba08a0aa6975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e3256cce-64cb-44cb-bf93-f02d788adb46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e3256cce-64cb-44cb-bf93-f02d788adb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_43a17033-c747-4bf6-b991-551468007e6a" xlink:href="ebs-20230331.xsd#ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage_43a17033-c747-4bf6-b991-551468007e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6f0bc333-e2b5-4390-8082-b9644cea6a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6f0bc333-e2b5-4390-8082-b9644cea6a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_53a7daa7-56bc-4fb6-b5b4-ccb7fb399756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_53a7daa7-56bc-4fb6-b5b4-ccb7fb399756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0464162d-eec4-4d03-aee4-f9d1cbaeb483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0464162d-eec4-4d03-aee4-f9d1cbaeb483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_8f2e6209-f798-4fba-b0d2-277917dca44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_8f2e6209-f798-4fba-b0d2-277917dca44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6c92f8b4-d99b-412a-9a59-d70ace792164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6c92f8b4-d99b-412a-9a59-d70ace792164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_dcd01264-b8db-49ad-816e-789576fdb4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_dcd01264-b8db-49ad-816e-789576fdb4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_78b26c5f-c847-4b0f-8e23-3ebe52e21e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a013a0f6-dfbc-4618-8091-063da8e921e0" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_78b26c5f-c847-4b0f-8e23-3ebe52e21e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6fa24772-2c74-4ba3-a508-52672115eef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb2a4ca-4dc3-43ea-a373-d76395ee40ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6fa24772-2c74-4ba3-a508-52672115eef9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb2a4ca-4dc3-43ea-a373-d76395ee40ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0ba8bd41-ad3c-45b3-ab57-2ad790956d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb2a4ca-4dc3-43ea-a373-d76395ee40ea" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0ba8bd41-ad3c-45b3-ab57-2ad790956d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_38f5ed6a-52dd-4076-874c-13c89c202426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0ba8bd41-ad3c-45b3-ab57-2ad790956d1e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_38f5ed6a-52dd-4076-874c-13c89c202426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_15ddeac9-ff0a-4b0b-bd24-990e6367b75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_38f5ed6a-52dd-4076-874c-13c89c202426" xlink:to="loc_us-gaap_CostOfSalesMember_15ddeac9-ff0a-4b0b-bd24-990e6367b75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b503b6a2-13bf-4cba-bb67-4860b91fc536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_38f5ed6a-52dd-4076-874c-13c89c202426" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b503b6a2-13bf-4cba-bb67-4860b91fc536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bc638a44-18b0-4eb3-a04c-342d9150bcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_38f5ed6a-52dd-4076-874c-13c89c202426" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bc638a44-18b0-4eb3-a04c-342d9150bcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aed504b1-4bd7-4c31-a906-b768e33e57e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb2a4ca-4dc3-43ea-a373-d76395ee40ea" xlink:to="loc_srt_ProductOrServiceAxis_aed504b1-4bd7-4c31-a906-b768e33e57e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef1d9eb9-7c0e-4e3c-b165-ea7dd7fdcd70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_aed504b1-4bd7-4c31-a906-b768e33e57e2" xlink:to="loc_srt_ProductsAndServicesDomain_ef1d9eb9-7c0e-4e3c-b165-ea7dd7fdcd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5a02f291-63cc-4ab5-a749-a98e6c307a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ef1d9eb9-7c0e-4e3c-b165-ea7dd7fdcd70" xlink:to="loc_us-gaap_ProductMember_5a02f291-63cc-4ab5-a749-a98e6c307a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_7909ecd2-25b4-4d60-9eaa-3268de1cf69b" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ef1d9eb9-7c0e-4e3c-b165-ea7dd7fdcd70" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_7909ecd2-25b4-4d60-9eaa-3268de1cf69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69a55fc6-a5e7-4c42-a2ea-8288b2b5d4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb2a4ca-4dc3-43ea-a373-d76395ee40ea" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69a55fc6-a5e7-4c42-a2ea-8288b2b5d4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e4eefed-197e-456e-a8a7-304063e12eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_69a55fc6-a5e7-4c42-a2ea-8288b2b5d4ad" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0e4eefed-197e-456e-a8a7-304063e12eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4489e452-2c5c-413d-99c5-3a2808c2c930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_60d1c971-f698-4c4a-91d6-e93c51c1c1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4489e452-2c5c-413d-99c5-3a2808c2c930" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_60d1c971-f698-4c4a-91d6-e93c51c1c1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1338016d-ad98-4734-abb6-b740d360a93d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_60d1c971-f698-4c4a-91d6-e93c51c1c1b4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1338016d-ad98-4734-abb6-b740d360a93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6e0267f7-d651-4693-b2eb-f775beb5cbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1338016d-ad98-4734-abb6-b740d360a93d" xlink:to="loc_us-gaap_EquityComponentDomain_6e0267f7-d651-4693-b2eb-f775beb5cbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f5c4f18-f523-490b-b0e7-d7690e8d2c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6e0267f7-d651-4693-b2eb-f775beb5cbcd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f5c4f18-f523-490b-b0e7-d7690e8d2c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_fd42cef6-dfd4-44bc-80e7-0a5169ce661d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f5c4f18-f523-490b-b0e7-d7690e8d2c4d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_fd42cef6-dfd4-44bc-80e7-0a5169ce661d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7b004410-3d62-4fc4-a64b-8ee06ffac078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f5c4f18-f523-490b-b0e7-d7690e8d2c4d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7b004410-3d62-4fc4-a64b-8ee06ffac078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_de5c6a22-d2ed-473b-93bf-b1a213dc1621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f5c4f18-f523-490b-b0e7-d7690e8d2c4d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_de5c6a22-d2ed-473b-93bf-b1a213dc1621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c8dfa2b0-9805-4a77-ab98-7c4600a47d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_60d1c971-f698-4c4a-91d6-e93c51c1c1b4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c8dfa2b0-9805-4a77-ab98-7c4600a47d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c8dfa2b0-9805-4a77-ab98-7c4600a47d62" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4d15590a-1609-44c7-b9e0-723c36d14500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:to="loc_us-gaap_StockholdersEquity_4d15590a-1609-44c7-b9e0-723c36d14500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_8c924253-c9df-408c-9c8a-22acd9b3e4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_8c924253-c9df-408c-9c8a-22acd9b3e4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_aaba27b5-c2b8-45dd-99cd-176163c8fb81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_aaba27b5-c2b8-45dd-99cd-176163c8fb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3661a94-93e3-4f35-8197-a53c4b8f2ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3661a94-93e3-4f35-8197-a53c4b8f2ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1b6eba65-8dba-4af8-9f33-5149f814e0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_11b88375-7cfc-44bc-85ce-b8308702f447" xlink:to="loc_us-gaap_StockholdersEquity_1b6eba65-8dba-4af8-9f33-5149f814e0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_275687ec-8236-4510-94c1-2a1c396b1c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dee8154b-cfac-4f4e-a6d6-8b7dc8704aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_275687ec-8236-4510-94c1-2a1c396b1c27" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dee8154b-cfac-4f4e-a6d6-8b7dc8704aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0185ef62-d7eb-4216-b4ce-9f79c98465b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dee8154b-cfac-4f4e-a6d6-8b7dc8704aea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0185ef62-d7eb-4216-b4ce-9f79c98465b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b240043-11fc-44bb-941b-8fb0ffc78334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0185ef62-d7eb-4216-b4ce-9f79c98465b9" xlink:to="loc_us-gaap_EquityComponentDomain_7b240043-11fc-44bb-941b-8fb0ffc78334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_b3ea7dd6-8463-40bd-9cb2-51f056aa0475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b240043-11fc-44bb-941b-8fb0ffc78334" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_b3ea7dd6-8463-40bd-9cb2-51f056aa0475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_cc198d21-c6a3-488c-a87c-86ea33b6fff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b240043-11fc-44bb-941b-8fb0ffc78334" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_cc198d21-c6a3-488c-a87c-86ea33b6fff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2a331ce2-d95e-4924-99cd-4681f1fd65ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dee8154b-cfac-4f4e-a6d6-8b7dc8704aea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2a331ce2-d95e-4924-99cd-4681f1fd65ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_6defd214-21c3-4aa7-9522-6f8ecd1584ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2a331ce2-d95e-4924-99cd-4681f1fd65ee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_6defd214-21c3-4aa7-9522-6f8ecd1584ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_777d3876-8b9c-482d-859a-13438b48fb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2a331ce2-d95e-4924-99cd-4681f1fd65ee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_777d3876-8b9c-482d-859a-13438b48fb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2490f963-fd96-4eea-96e5-ce718a487a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2a331ce2-d95e-4924-99cd-4681f1fd65ee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2490f963-fd96-4eea-96e5-ce718a487a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#EarningslosspercommonshareDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_527d2ba3-2e1c-4b7d-adb0-c499f48fd6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7bff6d00-2bab-46fc-bbc7-7a3f31d1e97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_527d2ba3-2e1c-4b7d-adb0-c499f48fd6d4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7bff6d00-2bab-46fc-bbc7-7a3f31d1e97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_867089c0-bf10-4827-94fd-ae9326d525a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_7bff6d00-2bab-46fc-bbc7-7a3f31d1e97e" xlink:to="loc_us-gaap_NetIncomeLoss_867089c0-bf10-4827-94fd-ae9326d525a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92a6bb79-243d-4aec-b6f0-ede395965430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_527d2ba3-2e1c-4b7d-adb0-c499f48fd6d4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92a6bb79-243d-4aec-b6f0-ede395965430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4435b10d-1ed7-4d73-b82b-2ecb5a08f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92a6bb79-243d-4aec-b6f0-ede395965430" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4435b10d-1ed7-4d73-b82b-2ecb5a08f5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_479551e0-a232-4fca-8f6d-40af19576388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92a6bb79-243d-4aec-b6f0-ede395965430" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_479551e0-a232-4fca-8f6d-40af19576388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9e3f91d0-5315-4841-9172-e5148f9d225f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_527d2ba3-2e1c-4b7d-adb0-c499f48fd6d4" xlink:to="loc_us-gaap_EarningsPerShareBasic_9e3f91d0-5315-4841-9172-e5148f9d225f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e978ee45-882e-42eb-a07e-5cc3994e8883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_527d2ba3-2e1c-4b7d-adb0-c499f48fd6d4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e978ee45-882e-42eb-a07e-5cc3994e8883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_78c928d5-b2f4-4b02-a882-099c8e50e10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_527d2ba3-2e1c-4b7d-adb0-c499f48fd6d4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_78c928d5-b2f4-4b02-a882-099c8e50e10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RevenuerecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a1fddf85-1230-4a86-aeb8-db659862e422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a1fddf85-1230-4a86-aeb8-db659862e422" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_361b738d-2752-4edb-b96f-58ef8ab5a86d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:to="loc_srt_MajorCustomersAxis_361b738d-2752-4edb-b96f-58ef8ab5a86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b0e0b4d4-e993-4b04-9a63-f9e37ceb6b45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_361b738d-2752-4edb-b96f-58ef8ab5a86d" xlink:to="loc_srt_NameOfMajorCustomerDomain_b0e0b4d4-e993-4b04-9a63-f9e37ceb6b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_0da9b125-a96c-4ea6-8b7a-216f9a95f8fb" xlink:href="ebs-20230331.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b0e0b4d4-e993-4b04-9a63-f9e37ceb6b45" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_0da9b125-a96c-4ea6-8b7a-216f9a95f8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:to="loc_srt_ProductOrServiceAxis_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_09561f04-e37a-4eda-9709-0fcc145d4fd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7bf89aa1-3073-4146-b5b4-0d72e9b99eb2" xlink:to="loc_srt_ProductsAndServicesDomain_09561f04-e37a-4eda-9709-0fcc145d4fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_59d31d16-d984-448b-b973-2953a2f04907" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_09561f04-e37a-4eda-9709-0fcc145d4fd7" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_59d31d16-d984-448b-b973-2953a2f04907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fd0d7cac-4b90-43ac-b79f-bf01d0ffb3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fd0d7cac-4b90-43ac-b79f-bf01d0ffb3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b5c2ca53-68b5-4e37-bd98-1dfb1cb71602" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_585ee28a-5a2d-4201-84ed-1dc347ff3c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_NumberOfOperatingSegments_585ee28a-5a2d-4201-84ed-1dc347ff3c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7d39a552-918d-4eaf-a566-532f6b0c2173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7d39a552-918d-4eaf-a566-532f6b0c2173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_78442bbb-b08c-47a7-b587-b2db751e4d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_78442bbb-b08c-47a7-b587-b2db751e4d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_05153f4c-c3cd-44ac-85cc-43102dec2497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_05153f4c-c3cd-44ac-85cc-43102dec2497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_0dee98ea-e894-410e-9333-49c84bf3f2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_0dee98ea-e894-410e-9333-49c84bf3f2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_351d8789-09f5-48d0-925b-8ee0fac51b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear_351d8789-09f5-48d0-925b-8ee0fac51b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_0fcf208e-0550-4af9-a18b-dea4d914432e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_0fcf208e-0550-4af9-a18b-dea4d914432e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_6c0138bd-348d-45ca-a014-be7c8ef390fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_6c0138bd-348d-45ca-a014-be7c8ef390fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_278b0eda-5f8e-4907-83e0-e8ccea61a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_278b0eda-5f8e-4907-83e0-e8ccea61a7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_b73d495d-44fa-4ae1-b0b1-96d188c0c57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_b73d495d-44fa-4ae1-b0b1-96d188c0c57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_33c080a3-a603-4fae-9f1a-5e91f0d1282b" xlink:href="ebs-20230331.xsd#ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour_33c080a3-a603-4fae-9f1a-5e91f0d1282b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b31290c2-c817-45d2-adf9-8d66f937a585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b31290c2-c817-45d2-adf9-8d66f937a585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c55d9906-093e-45b9-a771-f07565d37848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c55d9906-093e-45b9-a771-f07565d37848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_f56c8954-edb7-4f2f-bb22-fed36529a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_f56c8954-edb7-4f2f-bb22-fed36529a0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b1f3cd76-7991-4b69-b0f8-471df1bdaf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5b0b45b2-5eea-44b5-8b8a-4843701ab914" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b1f3cd76-7991-4b69-b0f8-471df1bdaf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1" xlink:type="simple" xlink:href="ebs-20230331.xsd#RevenuerecognitionNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RevenuerecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b54ab72-02e5-4820-9eb0-c4d71947a268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f7d376ca-d089-4585-9241-c88ee0024ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2b54ab72-02e5-4820-9eb0-c4d71947a268" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f7d376ca-d089-4585-9241-c88ee0024ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_196b8d6c-1880-41df-b0da-0f5e794580a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7d376ca-d089-4585-9241-c88ee0024ade" xlink:to="loc_srt_ProductOrServiceAxis_196b8d6c-1880-41df-b0da-0f5e794580a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_61058d65-f6d3-4acc-9937-52b22e41eb91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_196b8d6c-1880-41df-b0da-0f5e794580a5" xlink:to="loc_srt_ProductsAndServicesDomain_61058d65-f6d3-4acc-9937-52b22e41eb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d2693aaf-1ade-4f79-946f-a334710d9a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61058d65-f6d3-4acc-9937-52b22e41eb91" xlink:to="loc_us-gaap_ProductMember_d2693aaf-1ade-4f79-946f-a334710d9a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_54c2ccf4-08b4-49b8-9c97-b8f09ca6ab80" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61058d65-f6d3-4acc-9937-52b22e41eb91" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_54c2ccf4-08b4-49b8-9c97-b8f09ca6ab80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_f67c13c7-9d2a-4f5a-98ca-74aceba15105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_54c2ccf4-08b4-49b8-9c97-b8f09ca6ab80" xlink:to="loc_us-gaap_ServiceMember_f67c13c7-9d2a-4f5a-98ca-74aceba15105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_ba1a21c1-7f3b-43b9-b11e-c795a85d7818" xlink:href="ebs-20230331.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_54c2ccf4-08b4-49b8-9c97-b8f09ca6ab80" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_ba1a21c1-7f3b-43b9-b11e-c795a85d7818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_5068bdba-9974-4c1e-8a84-7554914effc8" xlink:href="ebs-20230331.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61058d65-f6d3-4acc-9937-52b22e41eb91" xlink:to="loc_ebs_ContractsAndGrantsMember_5068bdba-9974-4c1e-8a84-7554914effc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cf45a778-844a-4c6a-84af-460eb54a88d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7d376ca-d089-4585-9241-c88ee0024ade" xlink:to="loc_srt_MajorCustomersAxis_cf45a778-844a-4c6a-84af-460eb54a88d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_abdb0db1-907f-4045-92a7-70b2ff7a249c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_cf45a778-844a-4c6a-84af-460eb54a88d4" xlink:to="loc_srt_NameOfMajorCustomerDomain_abdb0db1-907f-4045-92a7-70b2ff7a249c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_UnitedStatesGovernmentMember_884b5321-11f2-4461-b465-451346e29174" xlink:href="ebs-20230331.xsd#ebs_UnitedStatesGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_abdb0db1-907f-4045-92a7-70b2ff7a249c" xlink:to="loc_ebs_UnitedStatesGovernmentMember_884b5321-11f2-4461-b465-451346e29174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NonUnitedStatesGovernmentMember_48df2edc-2101-460c-8d76-584689a1b6c8" xlink:href="ebs-20230331.xsd#ebs_NonUnitedStatesGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_abdb0db1-907f-4045-92a7-70b2ff7a249c" xlink:to="loc_ebs_NonUnitedStatesGovernmentMember_48df2edc-2101-460c-8d76-584689a1b6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7d376ca-d089-4585-9241-c88ee0024ade" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a51ec5d-d093-4316-9b2f-e7202ce40b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a51ec5d-d093-4316-9b2f-e7202ce40b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_22f138ec-6ede-425b-9bd9-6cde9642c755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_22f138ec-6ede-425b-9bd9-6cde9642c755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_aff38a69-58c2-4953-8505-3d660c37213c" xlink:href="ebs-20230331.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_aff38a69-58c2-4953-8505-3d660c37213c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cff2ad7c-f488-4f8f-8e90-1f6814f7f3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a2ca11ec-d315-4133-a1e5-e7fc75ac34c9" xlink:to="loc_us-gaap_Revenues_cff2ad7c-f488-4f8f-8e90-1f6814f7f3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RevenuerecognitionContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3ddf4d37-6d86-47c8-9749-7ecb6129de49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_93d482bf-1c50-4193-bd33-b62ac65dd26a" xlink:href="ebs-20230331.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3ddf4d37-6d86-47c8-9749-7ecb6129de49" xlink:to="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_93d482bf-1c50-4193-bd33-b62ac65dd26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e77736d2-3e1d-4a98-8fd1-4e977572a499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_93d482bf-1c50-4193-bd33-b62ac65dd26a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e77736d2-3e1d-4a98-8fd1-4e977572a499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityAdditions_13b79bbd-7b76-409f-9b32-a15931fa2bed" xlink:href="ebs-20230331.xsd#ebs_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_93d482bf-1c50-4193-bd33-b62ac65dd26a" xlink:to="loc_ebs_ContractWithCustomerLiabilityAdditions_13b79bbd-7b76-409f-9b32-a15931fa2bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityDeductions_2e8dcf62-b18d-409f-8439-67f8f179b99c" xlink:href="ebs-20230331.xsd#ebs_ContractWithCustomerLiabilityDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_93d482bf-1c50-4193-bd33-b62ac65dd26a" xlink:to="loc_ebs_ContractWithCustomerLiabilityDeductions_2e8dcf62-b18d-409f-8439-67f8f179b99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c54d2c60-f6ea-4a5a-9f6a-01db8081b3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_93d482bf-1c50-4193-bd33-b62ac65dd26a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c54d2c60-f6ea-4a5a-9f6a-01db8081b3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#RevenuerecognitionAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cb4cd011-a009-4feb-83ce-ea85d993d106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_b5bee2b8-f0ae-4f38-b39f-5795948baa83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cb4cd011-a009-4feb-83ce-ea85d993d106" xlink:to="loc_us-gaap_BilledContractReceivables_b5bee2b8-f0ae-4f38-b39f-5795948baa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_846fde1c-d549-4129-83d2-914d070c6af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cb4cd011-a009-4feb-83ce-ea85d993d106" xlink:to="loc_us-gaap_UnbilledContractsReceivable_846fde1c-d549-4129-83d2-914d070c6af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c15e2140-6556-42dc-b7e4-f259fa78680b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cb4cd011-a009-4feb-83ce-ea85d993d106" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c15e2140-6556-42dc-b7e4-f259fa78680b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7a184254-6105-44db-9bd7-59764e2227c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cb4cd011-a009-4feb-83ce-ea85d993d106" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7a184254-6105-44db-9bd7-59764e2227c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_51ce41eb-b66c-4f34-8983-32cae3efe824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_f29caa8d-b20d-42ff-b0bd-9ef8c112d06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_51ce41eb-b66c-4f34-8983-32cae3efe824" xlink:to="loc_us-gaap_LeaseCostAbstract_f29caa8d-b20d-42ff-b0bd-9ef8c112d06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e4b1990d-6dbc-413a-ac28-addc338da1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_f29caa8d-b20d-42ff-b0bd-9ef8c112d06d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e4b1990d-6dbc-413a-ac28-addc338da1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_4ce3f00c-d764-4da6-9714-70c440c866e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_f29caa8d-b20d-42ff-b0bd-9ef8c112d06d" xlink:to="loc_us-gaap_OperatingLeaseExpense_4ce3f00c-d764-4da6-9714-70c440c866e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_56502918-b620-4a25-a03e-efffdc4a78be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_f29caa8d-b20d-42ff-b0bd-9ef8c112d06d" xlink:to="loc_us-gaap_LeaseCost_56502918-b620-4a25-a03e-efffdc4a78be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fc86cb45-4b9a-4d3f-ab57-9a327e548bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c00b1acc-1850-4f16-9ccb-343af28c281b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc86cb45-4b9a-4d3f-ab57-9a327e548bbf" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c00b1acc-1850-4f16-9ccb-343af28c281b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a9a5dd3d-5910-41c3-836d-3adc1acb0e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c00b1acc-1850-4f16-9ccb-343af28c281b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a9a5dd3d-5910-41c3-836d-3adc1acb0e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8f26b785-c348-43ec-af22-67dc868b4295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c00b1acc-1850-4f16-9ccb-343af28c281b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8f26b785-c348-43ec-af22-67dc868b4295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_4d407c82-5ebc-4615-99e4-8cc22e113715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c00b1acc-1850-4f16-9ccb-343af28c281b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_4d407c82-5ebc-4615-99e4-8cc22e113715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_babe0895-30b5-4ec6-8c79-f0b1c69536d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c00b1acc-1850-4f16-9ccb-343af28c281b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_babe0895-30b5-4ec6-8c79-f0b1c69536d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_a10e6431-cb24-4d7b-9ef2-f89dc9baa125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c00b1acc-1850-4f16-9ccb-343af28c281b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_a10e6431-cb24-4d7b-9ef2-f89dc9baa125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dfb451a0-bbf0-4872-9c62-ba0cf89637e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c00b1acc-1850-4f16-9ccb-343af28c281b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dfb451a0-bbf0-4872-9c62-ba0cf89637e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a90e3ad2-6ecf-4298-8d52-3ac4b8217e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c00b1acc-1850-4f16-9ccb-343af28c281b" xlink:to="loc_us-gaap_OperatingLeaseLiability_a90e3ad2-6ecf-4298-8d52-3ac4b8217e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_b343978d-7fec-4b58-b36e-81c18ffccad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fc86cb45-4b9a-4d3f-ab57-9a327e548bbf" xlink:to="loc_us-gaap_LeaseCostAbstract_b343978d-7fec-4b58-b36e-81c18ffccad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_88456d34-5fff-4c38-842a-05947d3fde10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_b343978d-7fec-4b58-b36e-81c18ffccad1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_88456d34-5fff-4c38-842a-05947d3fde10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5d8ffb6c-c81d-439f-a6ce-2bc17675cbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_b343978d-7fec-4b58-b36e-81c18ffccad1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5d8ffb6c-c81d-439f-a6ce-2bc17675cbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#IncometaxesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ff7417ad-9f8b-4993-b09e-24b243afebf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesTable_f316d3ed-5acb-4de8-9573-82b7fcac43d0" xlink:href="ebs-20230331.xsd#ebs_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ff7417ad-9f8b-4993-b09e-24b243afebf3" xlink:to="loc_ebs_IncomeTaxesTable_f316d3ed-5acb-4de8-9573-82b7fcac43d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4d697ddf-a535-4acd-a6af-825936b60080" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesTable_f316d3ed-5acb-4de8-9573-82b7fcac43d0" xlink:to="loc_srt_StatementScenarioAxis_4d697ddf-a535-4acd-a6af-825936b60080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_82e4d018-2dc1-41d5-8931-4dea33bcc52d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_4d697ddf-a535-4acd-a6af-825936b60080" xlink:to="loc_srt_ScenarioUnspecifiedDomain_82e4d018-2dc1-41d5-8931-4dea33bcc52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3bc98b93-05bd-4bc8-8917-735b9cae2e2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_82e4d018-2dc1-41d5-8931-4dea33bcc52d" xlink:to="loc_srt_ScenarioForecastMember_3bc98b93-05bd-4bc8-8917-735b9cae2e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesLineItems_d5958265-ff48-4ad2-ac7b-3690872cc7a5" xlink:href="ebs-20230331.xsd#ebs_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesTable_f316d3ed-5acb-4de8-9573-82b7fcac43d0" xlink:to="loc_ebs_IncomeTaxesLineItems_d5958265-ff48-4ad2-ac7b-3690872cc7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4faa097b-f028-4a5a-a18a-4b6bce52f87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesLineItems_d5958265-ff48-4ad2-ac7b-3690872cc7a5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4faa097b-f028-4a5a-a18a-4b6bce52f87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_21c24ce3-84be-42a0-ac10-21cb32c69346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesLineItems_d5958265-ff48-4ad2-ac7b-3690872cc7a5" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_21c24ce3-84be-42a0-ac10-21cb32c69346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_387a4c73-6d2f-4917-ae97-6294acce04f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesLineItems_d5958265-ff48-4ad2-ac7b-3690872cc7a5" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_387a4c73-6d2f-4917-ae97-6294acce04f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_08e8961f-ef62-4ab1-acc6-4aa233828047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_3eb666ad-a653-4169-8ce5-aee82eef3825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_08e8961f-ef62-4ab1-acc6-4aa233828047" xlink:to="loc_us-gaap_NumberOfReportableSegments_3eb666ad-a653-4169-8ce5-aee82eef3825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1a52c3d1-adff-48bc-ab44-7341d3642ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_79756e30-72b8-4afc-857b-d32183172122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1a52c3d1-adff-48bc-ab44-7341d3642ea7" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_79756e30-72b8-4afc-857b-d32183172122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_99c9666d-05bb-43af-bccd-4be2d9973957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_79756e30-72b8-4afc-857b-d32183172122" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_99c9666d-05bb-43af-bccd-4be2d9973957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_772c399d-7e90-4f56-8919-83a4a210fd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_99c9666d-05bb-43af-bccd-4be2d9973957" xlink:to="loc_us-gaap_SegmentDomain_772c399d-7e90-4f56-8919-83a4a210fd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsAndServicesSegmentsMember_8cffaaac-eaa5-44db-b919-69fb31f3f85c" xlink:href="ebs-20230331.xsd#ebs_ProductsAndServicesSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_772c399d-7e90-4f56-8919-83a4a210fd7a" xlink:to="loc_ebs_ProductsAndServicesSegmentsMember_8cffaaac-eaa5-44db-b919-69fb31f3f85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_25ed91d1-93ef-463d-a9b3-65dfd1edfc70" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ProductsAndServicesSegmentsMember_8cffaaac-eaa5-44db-b919-69fb31f3f85c" xlink:to="loc_ebs_ProductsSegmentMember_25ed91d1-93ef-463d-a9b3-65dfd1edfc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_60ccb474-399f-410a-9c7a-79f62a7039f7" xlink:href="ebs-20230331.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ProductsAndServicesSegmentsMember_8cffaaac-eaa5-44db-b919-69fb31f3f85c" xlink:to="loc_ebs_ServicesSegmentMember_60ccb474-399f-410a-9c7a-79f62a7039f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_327cb601-c66a-4c2c-acf0-d8acc2ae3446" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_79756e30-72b8-4afc-857b-d32183172122" xlink:to="loc_srt_ProductOrServiceAxis_327cb601-c66a-4c2c-acf0-d8acc2ae3446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_334a43f0-d379-449b-94dc-311b31d8192e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_327cb601-c66a-4c2c-acf0-d8acc2ae3446" xlink:to="loc_srt_ProductsAndServicesDomain_334a43f0-d379-449b-94dc-311b31d8192e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_d8ceb474-e4ea-4bb4-9191-838cf6ee167c" xlink:href="ebs-20230331.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_334a43f0-d379-449b-94dc-311b31d8192e" xlink:to="loc_ebs_ContractsAndGrantsMember_d8ceb474-e4ea-4bb4-9191-838cf6ee167c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_79756e30-72b8-4afc-857b-d32183172122" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_dd29381d-75fc-433f-97bf-84dc0f50ed95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_RevenuesAbstract_dd29381d-75fc-433f-97bf-84dc0f50ed95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e90d7c2-de60-4da2-90ce-7e8db12b3416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_dd29381d-75fc-433f-97bf-84dc0f50ed95" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e90d7c2-de60-4da2-90ce-7e8db12b3416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_213eacc3-a6c1-4ec4-8174-ee727fe9e4f0" xlink:href="ebs-20230331.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_dd29381d-75fc-433f-97bf-84dc0f50ed95" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_213eacc3-a6c1-4ec4-8174-ee727fe9e4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f1536fd8-fec0-4909-b533-3776c5569a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_dd29381d-75fc-433f-97bf-84dc0f50ed95" xlink:to="loc_us-gaap_Revenues_f1536fd8-fec0-4909-b533-3776c5569a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_77582c6f-a813-4b35-bbd9-eafffbb8612f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_77582c6f-a813-4b35-bbd9-eafffbb8612f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5af15a3a-4897-453c-8478-c68002bfd948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAbstract_77582c6f-a813-4b35-bbd9-eafffbb8612f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5af15a3a-4897-453c-8478-c68002bfd948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_4d5a9878-d374-47d3-8645-cf0518bd6541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_GrossProfit_4d5a9878-d374-47d3-8645-cf0518bd6541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract_66989830-ebde-4af2-9ab4-6e335b61dbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfitAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_GrossProfitAbstract_66989830-ebde-4af2-9ab4-6e335b61dbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentAbstract_fdf32c30-16c5-4ea9-b8d5-71ddd4e10ac1" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GrossProfitAbstract_66989830-ebde-4af2-9ab4-6e335b61dbd6" xlink:to="loc_ebs_ProductsSegmentAbstract_fdf32c30-16c5-4ea9-b8d5-71ddd4e10ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a4047f3f-5b12-4858-9fdb-172285517282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ProductsSegmentAbstract_fdf32c30-16c5-4ea9-b8d5-71ddd4e10ac1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a4047f3f-5b12-4858-9fdb-172285517282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_2e5fa101-3f65-40c9-ae8a-122a1324f379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ProductsSegmentAbstract_fdf32c30-16c5-4ea9-b8d5-71ddd4e10ac1" xlink:to="loc_us-gaap_RestructuringCosts_2e5fa101-3f65-40c9-ae8a-122a1324f379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin_8d3a7bc7-b800-4075-a2f1-1c83ec9fff4f" xlink:href="ebs-20230331.xsd#ebs_AdjustedGrossMargin"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_ebs_AdjustedGrossMargin_8d3a7bc7-b800-4075-a2f1-1c83ec9fff4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_GrossProfitAdjustments_d8ab6f04-1ea0-42e3-862b-d92e1c93d22f" xlink:href="ebs-20230331.xsd#ebs_GrossProfitAdjustments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_ebs_GrossProfitAdjustments_d8ab6f04-1ea0-42e3-862b-d92e1c93d22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3d369c32-cbcb-43e4-ad84-b183ecc6800a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3d369c32-cbcb-43e4-ad84-b183ecc6800a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_01385716-ba8d-41c2-9e8f-3548155d2a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_01385716-ba8d-41c2-9e8f-3548155d2a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d4e1aa7e-65e4-47e3-9de9-8f436e7b9a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d4e1aa7e-65e4-47e3-9de9-8f436e7b9a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d45082b2-b945-402f-a510-81f6b138d0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_us-gaap_InterestExpense_d45082b2-b945-402f-a510-81f6b138d0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_03d8b2c2-9cd1-4d52-a07d-289019017b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_66efcc62-43fd-4204-aa0c-d741841cc93e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_03d8b2c2-9cd1-4d52-a07d-289019017b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39710f26-1873-43f6-8bcb-b33d406e96b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b54ad608-12e3-4d8f-ba57-c60dad1b01a5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_39710f26-1873-43f6-8bcb-b33d406e96b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="ebs-20230331.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6436ebc5-9f2a-4137-aea3-58d64ab288b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e0a3594-4f66-4df7-a10a-545fc37d2309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6436ebc5-9f2a-4137-aea3-58d64ab288b7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e0a3594-4f66-4df7-a10a-545fc37d2309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_69945f3a-f8f0-48ea-a9a6-15fa902a633c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e0a3594-4f66-4df7-a10a-545fc37d2309" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_69945f3a-f8f0-48ea-a9a6-15fa902a633c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_995b6b6b-da19-4077-95cd-57e6eb749721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_69945f3a-f8f0-48ea-a9a6-15fa902a633c" xlink:to="loc_us-gaap_SegmentDomain_995b6b6b-da19-4077-95cd-57e6eb749721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_9cac6171-d6bb-4120-bca8-7c77362b7ae0" xlink:href="ebs-20230331.xsd#ebs_ProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_995b6b6b-da19-4077-95cd-57e6eb749721" xlink:to="loc_ebs_ProductsSegmentMember_9cac6171-d6bb-4120-bca8-7c77362b7ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_b366e3fb-df07-4623-b07b-86bbe0795a69" xlink:href="ebs-20230331.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_995b6b6b-da19-4077-95cd-57e6eb749721" xlink:to="loc_ebs_ServicesSegmentMember_b366e3fb-df07-4623-b07b-86bbe0795a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d198526a-d0db-42a6-8682-76edd4d601dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e0a3594-4f66-4df7-a10a-545fc37d2309" xlink:to="loc_srt_ConsolidationItemsAxis_d198526a-d0db-42a6-8682-76edd4d601dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_61f7718d-3bb1-48e9-ae53-5891f1ef7199" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_d198526a-d0db-42a6-8682-76edd4d601dd" xlink:to="loc_srt_ConsolidationItemsDomain_61f7718d-3bb1-48e9-ae53-5891f1ef7199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_5f6fa6fb-d6d2-40fd-bb77-1db2e2faba77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_61f7718d-3bb1-48e9-ae53-5891f1ef7199" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_5f6fa6fb-d6d2-40fd-bb77-1db2e2faba77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_26f8be2b-b851-4162-8c57-8b8179f14612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4e0a3594-4f66-4df7-a10a-545fc37d2309" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_26f8be2b-b851-4162-8c57-8b8179f14612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract_4f76097f-dc27-4cb8-baea-36c4966db012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_26f8be2b-b851-4162-8c57-8b8179f14612" xlink:to="loc_us-gaap_DepreciationAbstract_4f76097f-dc27-4cb8-baea-36c4966db012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_097fae5a-fb61-4d33-bf35-08c4bdb99e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DepreciationAbstract_4f76097f-dc27-4cb8-baea-36c4966db012" xlink:to="loc_us-gaap_Depreciation_097fae5a-fb61-4d33-bf35-08c4bdb99e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ebs-20230331_g1.jpg
<TEXT>
begin 644 ebs-20230331_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M &22I"I>1@BCJS$ #MR3P* &PSQW"[X761<XRC!AGTR"1F@"6@ H * "@ H
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MT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_\<H
M/^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_
M\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\
M@7!_\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@">V\3Z1>RK
M!;7UG-*YPL<=Q"[L<9PJJY8G )X'2@#<H * "@ H * "@ H * "@ H * "@#
M.U#6+'2=OV^Y@M/,SL\^6.+?MQNV[V7=MW+G&<9&>HH S?\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H ?'XLT64X34+)CUPMU 3C\'H U;;4+:]_P"/::*;
MC/[MU?CIGY2>,]Z += !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!0U'5;/2(_.OYX;
M6/\ OS2)&OT!<@$^PYH \OU;XY>%=+RJ3R7K#JMM$S?^/R&*,Y_V7(I7 \WU
M+]I51E=.TXGT>>?'YQQH?TE'XT7 XF^_:%\2W/$"6=J.VR%F;\3+(X/X*/IW
MI#.:N?C-XNN>&U!D .0(X;=.V.JPAB/8DC- &+)\2?$\G!U.]&/[LSK_ .@D
M4 1?\+#\2_\ 04O_ /P)E_\ BJ )(_B/XFBY74[WG^].[?\ H1.* -:U^,'B
MVS^YJ,C< ?O(X)>!_P!=(F.?4YS[T =%9?'_ ,46I!E:UNAZ2P;<]?\ GBT7
M^0/?(!V>G?M*SIQJ&G1R=/F@G:/'K\DB29SV^=<>_6G<1Z'I7Q_\,WY"W)N;
M%CU,T6] ?0- TK8SQDHOJ<#."X'J6C^)]*\0 '3+NWNB1G;'(I<#_:CSO7_@
M2@]^],#=H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * ,>]\1:7ILA@O+RUMY0 3'+/%&X!Y!*NX.".AQS0!4_X3'0O^@C8?
M^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@ _X3'0O^
M@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@ _X3
M'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_ !R@
M _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X%P?_
M !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"-A_X
M%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,="_Z"
M-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #_A,=
M"_Z"-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\ '* #
M_A,="_Z"-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\
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M_BJ #^U;+_GXA_[^I_\ %4 ']JV7_/Q#_P!_4_\ BJ #^U;+_GXA_P"_J?\
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MT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_\<H
M/^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_
M\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\
M@7!_\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C
M8?\ @7!_\<H /^$QT+_H(V'_ (%P?_'* 'Q^+=%E81QZA9.[D*JK=0$DDX
M#Y))X ')- '04 % !0 4 % !0 4 % $4T\=LAEF98XUY9G(50/<D@#\30!A'
MQ?H:D@ZC8@C@@W4&0?\ OY0!JV6IVFI*6LYX;E1U,,B2 ?4H2* +M !0 4 ?
ME;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?8G[-O_()OO^OM?_1*4T!]'4P"@ H * "@ H * "@ H *
M/,OC)_R*.H_[D/\ Z4PTF!\C_#'XB3^ K_+[I-.N2!<PCDCL)8P<#S$],@.N
M5.#M94,^^[&^@U*".[M'6:"90\<B'*LI&00?Z=0>#@U0BU0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'AWQA^)X\(VYTK3'!U2Y3EA@_9HV&-Y])6_Y9*1P/WAX
M"!T!X)\"6+^+868DL8;DDDY))C.23W)[FD,^[*H04 % !0 4 % !0 4 % !0
M 4 % !0!\9_M'_\ (=M/^O!?_1\]2QGSS0(* "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79O_14
ME S]#:H04 % !0 4 % !0 4 % !0 4 % 'RM^TS_ ,PG_M^_]LZ3 ^5J0!0
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MWQ-X=VI%=M=0KC]U=CSUPO10S$2HN.,)(HQCT& 9[QX:_:)TZ]VPZY;O8N<
MS19FASW8K@2H/91,?>G<1[WI.M6.NP"ZTV>*ZA/\<3A@#UVM@Y5O56 8=P*8
M&G0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY
M_P"1LG_ZX6__ *+%2,\;H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0![)\!O^1L@_ZX7'_HLT#/NZJ$% !0 4
M % !0 4 % !0 4 % !0!\V?&C_D*6_\ UZC_ -&RUX6,^-?X?U9]GE'\&?\
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M9^T;_P C';?]@V+_ -*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5=3PRGD?0@FA&O0!^5M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!]B?LV_P#()OO^OM?_ $2E- ?1U, H
M * "@ H * "@ H * "@#S+XR?\BCJ/\ N0_^E,-)@?GU2 ]W^#?Q0/A6X&CZ
MF_\ Q++A_D=CQ:RL?OY_YXN?]8,@(?W@Q\^XV&?;2L' 92"",@CD$'H0>X-4
M(6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M 4 % !0 4 % !0 4 % !0 4 % !0  XY% 'JGA/XQ>(/"I6(S&^M%X\BY)?
MZ8CE_P!:F!]T;C&/^>9H&?5/@OXOZ)XP*V^\V-ZW'V><@;SZ0R\))[+\DA[1
MX&:8CU6F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H ]D^ W_(V0?]<+C_ -%F@9]W50@H * "@ H
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M315(SR.@04 % !0 4 % !0!]<_LU?\>6H_\ 7>#_ - >FAGTS3$% !0 4 %
M!0 4 % !0!\6?M&_\C';?]@V+_TINZE@> 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;?AK_D+67_ %]V
M_P#Z.2@9^F]4(* "@ H * "@#Y=^/WCV2WQX8L'*%T$EZRD@[6YC@^C+B23'
M52B]"P*8S6^#/PJATRWB\0:O&)+R=1);1. 5MXSRDA4\><XPRG_EFI&,.6V@
M$&N_M"_V)J-UIO\ 9?F_8KF:W\S[9MW^3(T>_;]E;;NVYV[FQG&3UHN(RO\
MAIC_ *A/_D]_]QT7 V]$_:-TV]F$6IV<M@C''FI*+A5SW<>7$X7U*JY]C1<#
MTCQMX'TSXCZ<K IYYC#VEXF"0&&Y/F'WX7SEEY&#N7#8- 'RO\/?%-[\,/$#
MZ;J>8[9YOL][$3\J,#M6X7J#LR&W+D20DXSE"%L,^[001D<@U0C\K:D H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#[$_9M_Y!-]_P!?:_\ HE*: ^CJ8!0 4 % !0 4 % !0 4 % 'F7QD_
MY%'4?]R'_P!*8:3 _/JD 4 ?5'P1^*6/+\,ZQ)Q]VQG<\^UL['_R 2>/]5G'
MEJ&AGU53$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!ROC+Q?9>"M.?4KXYQ\L40.'FE()6-
M>#C.,LV"$4%B#@ @'YZ^)?$E[XKOY-3U!]\LIX49V1H/NQQ@D[44=!U)RS$L
M23(S!H$>R? ;_D;(/^N%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % '
MQG^T?_R';3_KP7_T?/4L9\\T""@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H ]%^$O\ R-FF_P#79O\ T5)0,_0V
MJ$% !0 4 % !0 4 % !0 4 % !0!\K?M,_\ ,)_[?O\ VSI,#Y6I % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %  #CD4 >\_
M#[XX7_API9:T7O[ 84.3NN(1_LLQ'FH/[CG(  1U VD&?8VC:U9:_:I?:=*E
MQ;R#Y70]^ZL.JL/XE8!AW%4(TZ "@ H * "@ H * "@ H * "@ H * "@ H
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M /A'X\_\C9/_ -<+?_T6*D9XW0(* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#V3X#?\C9!_P!<+C_T6:!GW=5"
M"@ H * "@ H * "@ H * "@ H ^;/C1_R%+?_KU'_HV6O"QGQK_#^K/L\H_@
MS_Q_^VQ/':\T^C"@#3TG5[K0[E+RR<QRQG\&'=6'1E;H0?T(!JX2=-J4'9HP
MJTH5X.G45XO\/-=F?5W@WQK:^+(/EQ%=QC][!GD=MZ9^]&2?JI.UNQ;Z&C65
M9=I+=?JO+\CX+%X.>$EKK3?PR_1]G^>Z\NTKK/-"@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!EZUK-KX?LY=1OW$5O;KN=C^051W9F(55'+,0!UH _/OQ_XZN_'>HM
M>3YCMH\K;09^6*,GOS@R/@&5NY  PBJ!(SA:!!0![)\!O^1L@_ZX7'_HLT#/
MNZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/-
M@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /1?A+_R-FF_]=F_]%24#/T-JA!0 4 % !0 4 % !0 4 % !0 4 ?
M*W[3/_,)_P"W[_VSI,#Y6I % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 =KX(\>:CX%N_M-BVZ%R//MV)\J91ZC^%P,
M[) -RYQRI96!GWIX0\8:?XTL5O\ 3FR/NR1-@20OW2103CU5@2K#E3UQ0CJ:
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H AN;F*RB:>X=8
MHHU+.[L%55'4LQP !ZF@#Y,^(WQWENR^F^&&:&'E7O<%9'['[.#S&O\ TT($
MAX*B/&6D9\T.[2,7<EF8DDDY))Y))/))/4T"&T % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0![?\.?C/?>$REAJF^^TT84 G,UN.
MG[IF/SH!_P LG( P-C)R&!GVAHVM66OVJ7VG2I<6\@^5T/?NK#JK#^)6 8=Q
M5"-.@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /A'X\_\C9/_ -<+
M?_T6*D9XW0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M3=U+ \ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H V_#7_ "%K+_K[M_\ T<E S]-ZH04 % !0 4 4M3S]
MDGVYW>3)C'7.PXQ[^E 'Q+\ ]G_"51[^OV:XV=?O;1GI_L[NO'XXJ4,^YZH1
M^;/CK_D8M5_["-[_ .E,E2!O6GQ,\6:/8165O=26]G&@CA_T> 80#@+*8-YX
M[[RWO0,Y_1=$U7QYJ9MK8FZO9]TDDDTF#@8WR2.YR0,C.-S'HJDX% 'WSX%\
M)1>"=(ATJ-A(ZY>:0 CS)GY=@#T48"*.NQ5S\V2:$>0?M(X_LJQ]?M;?^BFI
M,#R_P=]O_LF#R/-\O]YMV[MO^NDSC'OG\:12/"Z"0H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#[$_9M_P"0
M3??]?:_^B4IH#Z.I@% !0 4 % !0 4 % !0 4 >9?&3_ )%'4?\ <A_]*8:3
M _/JD 4 % %JRO9]-GCN[5VAG@</&ZG#*RG((/L?P/0\4 ??7PP^(L'CRP_>
M%8]2M@!<PCC/831CO&_<=8WRIX*,[ ].I@% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $-Q<16D33SLL44
M2EW=R%55499F)P  .23P!0!\(?%?XER>.+S[-:%DTNU8^2AX,K\@SN.N2,B-
M3]Q.P9FJ1GD5 @H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H *
M"@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Z+\)?^1LTW_KL
MW_HJ2@9^AM4(* "@ H * "@ H * "@ H * "@#Y6_:9_YA/_ &_?^V=)@?*U
M( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H ZWP7XQO?!&H)J%D<K]V:$DA)H^Z-CN.J-@E&P<$9!!GZ#^&?$EGXK
ML(M3T]]\4HY4XWQN/O1R#^%U/4=""&4E64FA&]0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!DZYKMEX;LWU#4I5@MXARQY))Z*JC)9V/"JH)/T
MS0!\,?$?XJ7WCJ4P1YM=,C;,=N#RY'22<CAW[J@^2/@ %LNTC/*J!!0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 =KX(\>
M:CX%N_M%BVZ%R//MV)\N91ZC^%P,[) -R]]REE(,^\?!OC/3_&UD+[3GY7"S
M0M_K(7(SM<=P>=CCY7 .#D,!0CK* "@ H * "@ H * "@ H * "@ H * "@
MH * "@#X1^//_(V3_P#7"W_]%BI&>-T""@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@
M9]W50@H * "@ H * "@ H * "@ H * /FSXT?\A2W_Z]1_Z-EKPL9\:_P_JS
M[/*/X,_\?_ML3QVO-/HPH * "@">WN)+.19X&:.6-@R.IPRL.001T---IW6C
M1$HJ:<))--6:>S1].> OB''XB5;&^(COU'!X5)P.Z]A)CED'!P63C*K[U#$*
MI[D])_@_^#Y?<?$8W /#-U:6M+\8^3\NS^3[OU*O0/#"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /@GXY?\ (W7G^Y;?^DT52,\CH$%
M!0 4 % !0 4 ?7/[-7_'EJ/_ %W@_P#0'IH9],TQ!0 4 % !0 4 % !0 4 ?
M%G[1O_(QVW_8-B_]*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M='P Z$' .5%".NH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MS%55F !\">/O']]X\O3<7),5K$2+>V!RD2GN>FZ5N-\A&3]U0J!5$C.#H$%
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MJ?%T??U\_P _7?XS'9>Z-ZV'5X;RCUCYKO'\O3;V*O4/G0H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /@GXY?\ (W7G^Y;?^DT52,\CH$%
M!0 4 % !0 4 ?7/[-7_'EJ/_ %W@_P#0'IH9],TQ!0 4 % !0 4 % !0 4 ?
M%G[1O_(QVW_8-B_]*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!]B?LV_\ ()OO^OM?_1*4T!]'4P"@ H * "@ H * "@ H * /
M,OC)_P BCJ/^Y#_Z4PTF!^?5( H * "@ H [;P'XWN_ FHK?6V9(7PEQ 3A9
MH\Y([A77K&^,J<@Y5F5@9^@^AZW:>(K*+4=/<2V\Z[E(Z@]U8?PNIRK*>001
M5"-6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H ^:/C;\4?L"/X;T>3_ $AQMO)D/^J4]8$(_P"6CC_6D?<0[/OL
MVQ#/D2D(* "@ H * /9/@-_R-D'_ %PN/_19H&?=U4(* "@ H * "@ H * "
M@ H * "@ H ^,_VC_P#D.VG_ %X+_P"CYZEC/GF@04 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'HOPE_Y&S3?^
MNS?^BI*!GZ&U0@H * "@ H * "@ H * "@ H * /E;]IG_F$_P#;]_[9TF!\
MK4@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /L'X >.CJ-LWAN]?,UFN^U+'EH,_-%GN86(*CD^6V  L5-
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH ]D^ W_ "-D'_7"X_\ 19H&?=U4(* "@ H * "@ H * "@ H * "@#YL^-'
M_(4M_P#KU'_HV6O"QGQK_#^K/L\H_@S_ ,?_ +;$\=KS3Z,* "@ H * "@!0
M<<C@B@1[_P##_P")?F;-+UE\-]V*Y=OO>B3$]^RR$_-P'Y^8^QA\3M3JOTD_
MR?\ G]Y\GCLOM>OAEIO*"6WG'R[KITTT7NM>N?+!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!\$_'+_D;KS_<MO\ TFBJ1GD= @H * "@ H *
M "@#ZY_9J_X\M1_Z[P?^@/30SZ9IB"@ H * "@ H * "@ H ^+/VC?\ D8[;
M_L&Q?^E-W4L#P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(C<<46 ^NM"T*R\-V<>G:;&(+>(<*.I)ZL['EG8\LQY/T %4(UZ /RMJ0"@
MH * "@ H * "@#[@^&O@+P_JGANPN[RPMIYY8B7D>,%F/F.,D]S@ 4QG<_\
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M H * "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@
MH * /4_@WI%GK?B2&TU"%+F!HIR8Y!N4E8R5./4'D4#/L;_A67A?_H&6G_?H
M4Q!_PK+PO_T#+3_OT* #_A67A?\ Z!EI_P!^A0 ?\*R\+_\ 0,M/^_0H /\
MA67A?_H&6G_?H4 '_"LO"_\ T#+3_OT* #_A67A?_H&6G_?H4 '_  K+PO\
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MD\,["I&>/4""@ H * "@ H * "@ H * "@#MO#'P\UWQ<0VFVKF$G!N)/W<
M]?WC8#XSRL8=O]F@9[_X?_9OMX@)-<O'E;O%:J$0'T\V0,S#Z11GWIV$>Q:1
M\,?#.AX-KI]NS #YYE-PV1W!G,FT_P"[M]L#BBP'<11)"HCC4(B\!5   ] !
MP/PI@/H * "@!KQK*I1P&5A@@@$$>A!X(H X76/ACX9UL'[3I]NK$'YX%^SO
MD]R83'N(Z_/N'J".*5@/'/$/[-\#@R:%>-&W:*[&Y3])HE#*!Z&*0^]%@/GS
MQ-X"UOP@W_$TM7CBS@3+B2$YZ#S4RH)[*Q5_]FD,X^@04 % !0 4 % !0 4
M% !0 4 >A?#CQ[<> ]2%PNY[*<JEW"/XT!X=02!YL>2R$XSED)"N30,_06PO
MX-3MX[RT=9H)T#QNO1E89!'<>X(!!R" 015"+= !0 4 % !0 4 % !0 4 %
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M!EI_WZ% !_PK+PO_ - RT_[]"@ _X5EX7_Z!EI_WZ% !_P *R\+_ /0,M/\
MOT* #_A67A?_ *!EI_WZ% !_PK+PO_T#+3_OT* )(?AQX:MI%FBTZU22-@ZL
M(QE64Y4CW! (I@=K0 4 % !0 4 % !0 4 1RPI.ACE571N"K ,I'N#D'\: ,
M)O"&AL<MIUB2>I-K 3_Z+H U;+3;735*6<,5LIQE8HTC!QTR$ '';TH N4 %
M !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?_1DE- >B4P"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MV_\ (6OO^O1?_1JT(9]AU0@H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^5OVF?^83_ -OW_MG2
M8'RM2 * "@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@9]W50@H * "@ H * "@
MH * "@ H * "@ H X/QQ\.]+\=0;+Q/*ND&(KJ,#S8_0'IYD>>3&QQR2I5CN
MI ?"?B_P??\ @J^;3]17!^]%*N?+F3/#H2!]&4_,IX(Z90SE:!!0 4 % !0
M4 % !0!]@?LZ^*#=V-QH,S9>S;SX 2<^3*<2*!V5)3N^LU- ?25, H * "@
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M * "@ H * "@ H * "@#Z/\ @1\0SI=P/#>H/_HMTV;5F/$4[=8L]DF/W1G
MEZ#]XQ AGV'5""@ H * "@ H * "@ H * "@ H * "@#X1^//_(V3_\ 7"W_
M /18J1GC= @H * "@ H * "@#ZP_9H_U.J?[]I_*XIH9]14Q!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!\V?&C_D*6_\ UZC_ -&RUX6,^-?X?U9]GE'\&?\ C_\ ;8GCM>:?
M1A0 4 % !0 4 % !0 4 >M^ /B,^A%=.U(E['HC\EX,]!ZM%ZKU7.5X&T^C0
MQ'L_<G\'XK_@>7W'S^.P"KWK4-*G5;*7^4O/KU[GTM#,DZ++$P=' 964@JRD
M9!!'!!'((KW4TU=;'Q33BW&2LUHT]TR2F(* "@ H * "@ H * "@ H * "@
MH * "@ H * /@GXY?\C=>?[EM_Z315(SR.@04 % !0 4 % !0!]<_LU?\>6H
M_P#7>#_T!Z:&?3-,04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % 'SC^TE_R";'_K[;_T2])@?'=( H * "@ H * "@#U7X)_\CCI_P#V]?\
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M@SZ\TW3;72+=+.QB2W@B&$CC4*H'T'4GJS'+,<EB22:H1=H * "@ H * "@
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M]FC_ %.J?[]I_*XIH9]14Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\Y_&FWE%_;7&UO*-OL
M#X.W>)'8KGINVD''7'->'C$^>+Z<MK^=V?8Y1)>SG"ZYN:]NMK)7]+GBU>8?
M2A0 4 % !0 4 % !0 4 % 'I?@3X@3>&7%I=[IK!SRO5H2>KQ_[/=H^AZKAL
M[NZAB'1?++6'Y>:_R/%QN!CB5[2G:-5?=+R?GV?WZ;?45I=PW\*7%LZRQ2#<
MCJ<@CV/Z$=000<$5[\6I)2B[I['PTHRIR<)IJ2T:>Z+%40% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?!/QR_Y&Z\_W+;_ -)HJD9Y'0(* "@ H * "@ H
M ^N?V:O^/+4?^N\'_H#TT,^F:8@H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /G']I+_ )!-C_U]M_Z)>DP/CND 4 % !0 4 % !0!ZK\$_^
M1QT__MZ_]([B@#[]J@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#\K:D H * "@ H * "@ H _0[X2_\BGIO_7 _P#HR2F@
M/1*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 >9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 %
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M * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[9TF!\K4@"@ H * "@ H
M* /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H * "@ H * "@ H * "@
M H ^6_VB/!X9(?$MLN&4K;W6!U!_U,IP.QS$S$Y.8E' I,#Y1I % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /RMJ0"@ H *
M"@ H * "@#]#OA+_ ,BGIO\ UP/_ *,DIH#T2F 4 % !0 4 % !0 4 % !0
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M&?/- @H * "@ H * "@#Z/\ V;?^0M??]>B_^C5H0S[#JA!0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!\K?M,_\PG_ +?O_;.DP/E:D 4 % !0 4 % !0![)\!O^1L@_ZX7'_H
MLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 87B?1(_$>E76ER@$7
M4+HN>BOC,;_\ D"N/=><CB@#\S9(VB8QN-K(2I!Z@@X(_ U(#* "@ H * "@
M H * /NKX":B;[PM'$?^7.XG@'T)$X_+S\?3%- >T4P"@ H * "@ H * "@
MH * "@#R/XS^,#X4T)XK=MMYJ)-O"1U1"/WT@X_A0[ 005>1&'0T@/@FD 4
M% !0 4 % !0 4 % 'V'\&?A0-(2/Q#K,?^FN-UK X_U"$<2NI_Y;,"=JG_5+
M@G]X?W;0SZ/IB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /DKXS
M_"867F>(]$3]R27O+9!_J^I:XC _Y9D\RH/]63O7]WN$:&?,5(04 % 'L?@3
MX,:MXNVW5T#IVGMR)9%_>2#K^YB)!(.1B1]J8.5WD%:!GV%X3\$:3X+@\C2X
M0C,,23/AIY>_SR8!QGD(H5 >0HJA'6T % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'PC\>?^1LG_ .N%O_Z+%2,\;H$% !0 4 % !0 4 ?6'[-'^IU3_
M '[3^5Q30SZBIB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H K7EG#J$+VURBRPRJ5=&&00?Y
M$=01@@@$$$ U,HJ2<9*Z?0N$Y4Y*<&U).Z:Z'RYX[\ 3>&'-U:YET]V^5NK0
MD]$D]L\(_?HV&QN^?KX=T7S1UA^7D_\ ,^YP6.CB5[.>E5+;I+S7GW7W:;>;
M5Q'M!0 4 % !0 4 % !0 4 % '7^$?&%WX2N-\/[RWD(\Z GY7']Y?[L@'1A
M]&!'%=%*M*B[K;JN_P#P?,\[%82&+C:6DU\,NJ\GW7E]Q]8:+K=IX@M5O+%]
M\;<$'AD8=4=?X6'IT(P02I!/T<)QJ1YH;?EY,^"K49X>;IU59K[FNZ?5?UN:
MU:'.% !0 4 % !0 4 % !0 4 % !0 4 % 'P3\<O^1NO/]RV_P#2:*I&>1T"
M"@ H * "@ H * /KG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@#YQ_:2_P"038_]?;?^B7I,#X[I % !0 4
M% !0 4 >J_!/_D<=/_[>O_2.XH ^_:H H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _*VI * "@ H * "@ H * /T.^$O_(I
MZ;_UP/\ Z,DIH#T2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_TIAI,#\^J0!0
M4 % !0 4 % !0 4 % '1>%?$][X/U"/4]/;$D?#(<[)8R1NBD (RC8'N&"LN
M&4$ S]"_"7BJS\8Z='J=@?E?Y9(S]^*0 ;HW]USP>C*0PX(JA'2T % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?'_QK^*?]J._AW1Y/]%C8K=S(
M?]<ZGF%"/^62$'>>1(PP/D7,DC/FV@04 % !0 4 % !0 4 % !0![)\!O^1L
M@_ZX7'_HLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7
M_P!'SU+&?/- @H * "@ H * "@#Z/_9M_P"0M??]>B_^C5H0S[#JA!0 4 %
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MP)\9?%1\3^(9EB;=:Z?FUAP<J2A/FN,<'?)N 8?>14YXJ1GE% @H * "@ H
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M-'^IU3_?M/Y7%-#/J*F(* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H CFA2X1HI5#HX*LK
M%64C!!!X((X(-)I-6>PTW%J479K5-;IGS/X^^'+Z"6U#30TEB>73JT&3^;1>
MC<E>C_WCX-?#NE[\-8?E_P #S^_N_M<#CU7M1K653H]E/_*7EUZ=CR:O//H
MH * "@ H * "@ H * "@#H_#/B>[\+70N;0Y4\21,3LD7T([$?PL.5/J"0=J
M=25&7-'YKHSBQ&&ABH<E3?I);I_Y=UU/K/PYXDL_$UJ+JS;D8$D9^_$Q'W6'
MY[6'RL!D'J!]'3J1JQYH_-=4? XC#SPL_9U%Z/I)=U^JW1OUL<@4 % !0 4
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M: ]$I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!YE\9/\ D4=1_P!R'_TIAI,#\^J0!0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M6.-!T"J,#ZD]68\LQ+$DDFJ$7: "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H S=7T>TUZTDT_48EGMI@ \;$@'!##!4AE(8 AE(((!!% $F
MFZ9:Z/;I9V$4=M!$,+'&H51[X'4GJS'+,>6))S0!>H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /A'X\_P#(V3_]<+?_ -%BI&>-T""@ H *
M "@ H * /K#]FC_4ZI_OVG\KBFAGU%3$% !0 4 % !0 4 % !0 4 % !0 4
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M!0 4 % !0 4 % !0 4 % !0 4 ?!/QR_Y&Z\_P!RV_\ 2:*I&>1T""@ H *
M"@ H * /KG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#YQ_:2_Y!-C_U]M_Z)>DP/CND 4 % !0 4 % !0!Z
MK\$_^1QT_P#[>O\ TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@#]#OA+_ ,BGIO\
MUP/_ *,DIH#T2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_ -*8:3 _/JD 4 %
M!0 4 % !0 4 % !0 4 % 'LOPC^)K^"KO[#?,S:5=-\XZ^1(>!,@_NG $JCD
MJ P!90K S[JBE2=%EB8.C@,K*0RLK#(92,@@@@@C@CD50A] !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 >/?%GXFQ^"+3[)9%7U6Z4^4O!\A#QY[KZ_\\E88
M9@2051E* ^$YIGN)&FE8O)(Q9V8Y9F8Y+$GDDDY)/4T@(J "@ H * "@ H *
M "@ H * "@#V3X#?\C9!_P!<+C_T6:!GW=5""@ H * "@ H * "@ H * "@
MH * /C/]H_\ Y#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4 ?1_[-O\ R%K[
M_KT7_P!&K0AGV'5""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#Y6_:9_YA/_;]_P"V=)@?*U(
MH * "@ H * "@#V3X#?\C9!_UPN/_19H&?=U4(* "@ H * "@ H * "@ H *
M "@ H * "@ H * /B_\ :."CQ!:D'YCI\8(]A<7.#^))_*I8'S[0 4 % !0
M4 % !0!]'_LV_P#(6OO^O1?_ $:M"&?8=4(* "@ H * "@ H * "@ H ^4?V
MD?$!,EEH<9.%#7<HSP2Q:*'\5 F//9@:3 ^6Z0!0 4 % !0 4 % !0!]P_ O
MP6/#VCC5+A<7FI@2<CE+?K$GMYG^M;U#1@C*4T![C3 * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /A'X\_P#(V3_]<+?_ -%BI&>-T""@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _*VI *
M"@ H * "@ H * /T.^$O_(IZ;_UP/_HR2F@/1*8!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?&3_
M )%'4?\ <A_]*8:3 _/JD 4 % !0 4 % !0 4 % !0 4 % !0!]*?!/XI?V8
MZ>'-8DQ:R';:3.>(7)XA<G_EFY/R$G$;?*?D;* SZ^JA!0 4 % !0 4 % !0
M 4 % !0 4 % !0!P?Q"\>6O@+3C=2XDNI<K;09P9'[DXY$:9!=N.R@[F6D!^
M?>L:O=:]=RZA?R&:XN&+NQ]3T '154855&%50%  %(9FT""@ H * "@ H *
M"@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@9]W50@H * "@ H * "@ H * "@ H
M * "@#XS_:/_ .0[:?\ 7@O_ */GJ6,^>:!!0 4 % !0 4 % 'T?^S;_ ,A:
M^_Z]%_\ 1JT(9]AU0@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H ^5OVF?^83_V_?\ MG28'RM2
M * "@ H * "@ H ]D^ W_(V0?]<+C_T6:!GW=5""@ H * "@ H * "@ H *
M"@ H * "@ H * "@#X?_ &@[L7/B<1C'^C6<$1Q[M+-S[XE'3MCOFI \-H *
M "@ H * "@ H ^D_V;(B=2OY.RVT:X_WI,_IL_6A#/K^J$% !0 4 % !0 4
M% !0 4 ?G7\3]:_M[Q+?W0.Z-)C!'CIL@Q"I'LVPO]6-2,X&@04 % !0 4 %
M !0!VGP^\,'Q=KEKIC F%G\R<CC$$?SR<\X+ ;%./ONM S]'$18U"( JJ
M,  <  #@ #@ =*H0Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^
M$?CS_P C9/\ ]<+?_P!%BI&>-T""@ H * "@ H * /K#]FC_ %.J?[]I_*XI
MH9]14Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!\M?&/Q=J'@SQ597^FOM86*"2,Y\N9/M$^8
MY%R,@]CPR'YD(89I#/</ _CO3_'5D+JR/ES)@3VS,#)"WOTW(?X)  &'!"L&
M501VM, H * "@#QOQ_\ #9=4WZGI*A;OEI81PLWJR=EE]1P).O#\MY>(PW->
MI3^+JN_FO/\ /UW^CP.8>RM0Q#]S:,NL?)_W?R]-OG%T:-BC@JRD@@C!!'!!
M!Y!!X(->)L?9)WU6PR@84 % !0 4 % !0 4 % %NRO9]-F2ZM7:*:([E93@@
MC^8/0@Y!&000:I-Q:E%V:V,YPC4BX32<7HTSZF\#>/H/%,8MY]L-^@.Z/HL@
M'5X\^W+)DLO)Y7D>_0Q"JKEEI/MW\U_D?"XS RPKYX7=)[/K'RE^CV?J>B5W
M'CA0 4 % !0 4 % !0 4 % 'P3\<O^1NO/\ <MO_ $FBJ1GD= @H * "@ H
M* "@#ZY_9J_X\M1_Z[P?^@/30SZ9IB"@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H ^<?VDO^038_]?;?^B7I,#X[I % !0 4 % !0 4 >J_!
M/_D<=/\ ^WK_ -([B@#[]J@"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@#\K:D H * "@ H * "@ H _0[X2_P#(IZ;_ -<#
M_P"C)*: ]$I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0!YE\9/^11U'_<A_P#2F&DP/SZI % !0 4
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M H ^N?V<?#@@M+O79 -]PXM83SD1QX>4CMM=R@Z]8CT[M ?3-, H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /A'X\_\C9/_ -<+?_T6*D9XW0(*
M "@ H * "@ H ^L/V:/]3JG^_:?RN*:&?45,04 % !0 4 % !0 4 % !0 4
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MWK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /RMJ0"@ H * "@ H * "@#[0^'7Q/\-:)X=L;"^O5AN((BLB&
M*=BI+N<96)E/!!X)IC.U_P"%R>$?^@BG_?FY_P#C-%Q!_P +D\(_]!%/^_-S
M_P#&:+@'_"Y/"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3P
MC_T$4_[\W/\ \9HN ?\ "Y/"/_013_OS<_\ QFBX!_PN3PC_ -!%/^_-S_\
M&:+@'_"Y/"/_ $$4_P"_-S_\9HN ?\+D\(_]!%/^_-S_ /&:+@'_  N3PC_T
M$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\ OS<__&:+
M@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/"/\ T$4_
M[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\ \9HN ?\
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MN%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_ ,AVT_Z\%_\
M1\]2QGSS0(* "@ H * "@ H ]N^!WBK2_"FHW<^KSBUCEMPB,5D;+"16QB-'
M(X!.2 />@9]+_P#"Y/"/_013_OS<_P#QFG<0?\+D\(_]!%/^_-S_ /&:+@'_
M  N3PC_T$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\
MOS<__&:+@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/
M"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\
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M7.I$@2JAC@!_BGD!6( =]I.]A_<1CVI ?G S%B23DGDD]2:0"4 % !0 4 %
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M  N3PC_T$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\
MOS<__&:+@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/
M"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\
M\9HN ?\ "Y/"/_013_OS<_\ QFBX!_PN3PC_ -!%/^_-S_\ &:+@'_"Y/"/_
M $$4_P"_-S_\9HN ?\+D\(_]!%/^_-S_ /&:+@'_  N3PC_T$4_[\W/_ ,9H
MN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\ OS<__&:+@>CV]Q'=Q)/"
M=T<JJZ-R,JP#*<'!Y!!Y -,":@ H * "@ H * "@ H * "@ H * "@ H ^,_
MVC_^0[:?]>"_^CYZEC/GF@1H:5JMUH=U'?V$C07$#;D=>H/<$="K#(92"K*2
MK @D4#/NGX9_%.T\=0BVGVVVJ1+F2$9"R =9(,DDKW9"2Z=]RX8L1ZS3 * "
M@ H X3QCX"L_%2-* (+Y5PDPX#$=%E ^\O& ?O(.A(&T\=:A&MJM)='_ )_U
M?\CU<)C9X1J/Q4[ZQ[><>S_!]>Y\KZMI-SH=R]G>H8Y8SR.Q'9E/1E(Y!'\\
MBOGY1=-N,E9H^ZI585XJI2=XO\/)]F9M0;A0 4 % !0 4 % !0 4 /1VC8.A
M*LI!!!P01R"".00>011L)J^CV/HWX?\ Q(74]FF:LVV[^[%,<!9O17Z 2]@<
M8DZ</]_V\/B>:U.I\71]_)^?Y^N_QN.R_P!E>OAU[F\H]8^:_N_EZ;>RUZA\
MX% !0 4 % !0 4 % 'P3\<O^1NO/]RV_])HJD9Y'0(* "@ H * "@ H ^N?V
M:O\ CRU'_KO!_P"@/30SZ9IB"@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H ^<?VDO^038_\ 7VW_ *)>DP/CND 4 % !0 4 % !0!ZK\$_\
MD<=/_P"WK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /1?A+_ ,C9IO\ UV;_ -%24#/T-JA!0 4
M% !0 4 % !0 4 % !0 4 % 'F7QD_P"11U'_ '(?_2F&DP/SZI % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!IZ-K%UH%Y%J-@YAN+=@R,/R((/#*PRK*>&4D
M'@T#/T&^'_CFU\=Z<+R#$=Q%M2Y@SS%(1U'.3&^"8V/4 @_,K ,1W-, H *
M"@ H * "@ H ;)(L2EW(5%!9F8@  #)))X  Y)/ % 'PY\8/B<WC"Y.FZ<Y&
ME6S<$<?:9%X\UAU\M3D1*>H_>, S!4D9XE0(* "@ H * "@ H * "@ H * "
M@ H * "@#V3X#?\ (V0?]<+C_P!%F@9]W50@H * "@ H * "@ H * "@ H *
M "@#XS_:/_Y#MI_UX+_Z/GJ6,^>:!!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z,_#+_D5],_Z](OY4P.YI@% !0
M4 % !0 4 % !0 4 % !0 4 % 'RM^TS_ ,PG_M^_]LZ3 ^5J0!0 4 % !0 4
M % 'LGP&_P"1L@_ZX7'_ *+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'Q+\=?'*^(M272+-MUGII8,RG*R7)X=N#@K$/W:G^\92"0PJ1G@] @H
M * "@ H * "@ H _2/P!I!T+P_86+ J\=M&S@C!$D@\V08]I'8?X4P.OI@%
M!0 4 % !0 4 % !0!\Z?M(7IBT>SM!_RVNS(?I%$XQ^<H/3L.1W3 ^.*0!0
M4 % !0 4 % '1^#],&LZU8V#?<N+N!'_ -PR+O\ R3<:!GZ7U0@H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#X1^//_(V3_\ 7"W_ /18J1GC
M= @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#]./#7_ "";+_KTM_\ T4E4!M4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'QG^T?_P AVT_Z\%_]'SU+&?/- @H LV=Y/I\R75K(\,T3!DD1BK*PZ%2,
M$&@#[;^%GQ<@\8(NFZF4M]50 #HJ70 Y>,=%EX)>(<?Q1_+N5&![=3 * "@
MH Y?Q3X3M/%5MY%R-LJ F&8#YHV/Y;D/\2'@CD88!ASU:4:RL]^C[?\  \CN
MPV)GA)\T-8OXH]&OT?9_IH?)_B#P]>>&KIK2]7:1DHXSLD7^\C8&1ZCJIX8
MU\[4IRI/EDO\GYH^^H5X8F"J4GZKK%]FOZOT,*LCJ"@ H * "@ H * "@ H
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M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % !0
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M 4 % !0 4 % !0!\K?M,_P#,)_[?O_;.DP/E:D 4 % !0 4 % !0![)\!O\
MD;(/^N%Q_P"BS0,^[JH04 % !0 4 % !0 4 % !0 4 % !0 4 % '@WQC^**
M>&+=M&TMP=3N$Q(ZGFUC8?>..DSJ?W8R"@/F''R;D!\3$YY-( H * "@ H *
M "@ H Z_P%H)\2Z]9:<5+1RSJTH'_/&/]Y+ST'[M6 )[D#DG% S](ZH04 %
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M !N@ _X6UXL_Z"4W_?,7_P ;H ^Y/ ]U<WV@Z?=7SF6XGM(99'.,L9$#AC@
M9(89P.M4(ZF@ H * "@ H * "@ H * "@#X1^//_ "-D_P#UPM__ $6*D9XW
M0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H _3CPU_R";+_ *]+?_T4E4!M4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'QG^T?\ \AVT_P"O!?\ T?/4L9\\T""@ H DAF>W=98F:.2-@RLI*LK Y#*1
M@@@\@CD&@#[(^$_QB37PFC:ZXCU #;#<,0J7..BMT"SXZ?PRGIAR%9@?0U,
MH * "@#$\0>'K3Q):FTO5W#DHXX>-L8#H>Q]1T8<,"*QJ4XU5RR^3ZKT.JA7
MGAI^TI.W==&NS_K3H?)WBKPG=^%+GR;@;X7)\F8#"R ?GM<9&Y"<@]"5(8_.
MU:4J+M+;H^C_ *ZH^]PV*ABX\T-)+XH]4_U79_KH<M6!WA0 4 % !0 4 % !
M0 4 % 'M7P_^))T_9IFKL6M_NQ3L<F+T20]X_1NJ=#E/N>IA\3R6IU/AZ/MZ
M^7Y>FWS..R_GO7PZ][>45]KS7GW77UW^BE8. RD,K $$'((/0@CJ#V->WOJC
MY!JVCW%H$% !0 4 % 'P3\<O^1NO/]RV_P#2:*I&>1T""@ H * "@ H * /K
MG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@#YQ_:2_P"038_]?;?^B7I,#X[I % !0 4 % !0 4 >J_!/_D<=
M/_[>O_2.XH ^_:H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H _*VI * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H ]%^$O_ "-FF_\ 79O_ $5)0,_0VJ$% !0 4 %
M!0 4 % !0 4 % !0 4 >9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'I7PS^(=QX"OP[;I-/N"%N80>W02QCH)(^O^VN4
M)&0RFPS[]L+^WU2WCO+-UF@G0/&Z]&5AD'U'N" 0<@@$$50BW0 4 % !0 4
M?/?QH^*/_"/Q-H.DOC4)E_?RJ>;:-AG:I'2:13P>L:'<,,R,J ^,:0!0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0![)\!O^1L@_ZX7'_HLT#/NZJ$% !0
M 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/- @H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]&?A
ME_R*^F?]>D7\J8'<TP"@ H * "@ H * "@ H * "@ H * "@#Y6_:9_YA/\
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MKD#W,I!/X[1^52QGS=0(* "@ H * "@ H ]Z_9UB63Q),S=8]/F9?J9[9/\
MT%C_ #H0'VQ5 % !0 4 % !0 4 % !0 4 ?,W[2O_'EIW_7>?_T!*3&?(U(0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z5>!T,
M?A[2T/5=.LP?J+>,50'44 % !0 4 % !0 4 % !0 4 ?"/QY_P"1LG_ZX6__
M *+%2,\;H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 ?IQX:_Y!-E_UZ6__HI*H#:H * "@ H * "@ H * "@ H *
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MD@(W5K?GMW:+U3JO5.ZMZ%#$.E[D]8?^D_\  \ON\_ QV 5>]6BDJG5;*?\
ME+SZ]>Z^F89H[A%EA97C<!E92"I!Z$$<$?2O>335UL?%-.+<9)IK=/1HDIDA
M0 4 % 'Q=\?/">H6FL2:^4WV%V(4$B9/END2Q[)1CY2Q3*'E6!QG<"*D9\_4
M""@ H * "@ H * /KG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#YQ_:2_Y!-C_U]M_Z)>DP/CND 4 % !0
M4 % !0!ZK\$_^1QT_P#[>O\ TCN* /OVJ * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /1?A+_R-FF_]=F_]%24#
M/T-JA!0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_ -*8:3 _/JD
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M\D(#URSD N0 9X?0(* "@ H * "@ H ]D^ W_(V0?]<+C_T6:!GW=5""@ H
M* "@ H * "@ H * "@ H * /C/\ :/\ ^0[:?]>"_P#H^>I8SYYH$% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?HS\
M,O\ D5],_P"O2+^5,#N:8!0 4 % !0 4 % !0 4 % !0 4 % !0!\K?M,_\
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M - 2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!^F'@\8T/3@?^?&U_P#1$=4!T5 !0 4 % !0 4 % !0 4 % 'PC\>?\
MD;)_^N%O_P"BQ4C/&Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % 'Z<>&O^039?]>EO_Z*2J VJ "@ H * "@ H *
M"@ H * "@ H * "@#XS_ &C_ /D.VG_7@O\ Z/GJ6,^>:!!0 4 % !0 4 ?3
M'PF^,QTX1Z'XADS; !+>[<DM%V6*8\YB[))UCX5LQX,8,^N58. RD$$9!'((
M/0@]P:H0M !0 4 5KRSAU"%[:Y19895*NC#((/\ (CJ",$$ @@@&IE%23C)7
M3Z%PG*G)3@VI)W370^7/'7P_F\,.;JUW36#GANKQ$_PR8'3LK]#T;#8W?/U\
M.Z+YHZP[]O7_ #/N<%CHXE>SG[M5=.DO./GW7W:;>;5Q'M!0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 ?./[27_()L?\ K[;_ -$O28'QW2 * "@
MH * "@ H ]5^"?\ R..G_P#;U_Z1W% 'W[5 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y6U(!0 4 % !0 4 % !0 4 %
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M^-<UN[\17LNHZA(9;B=MS$]!Z*H_A1!A44<*H I#,J@04 % !0 4 % !0 4
M.1&D8(@+,Q   R23P  .22>@H ^X_@_\,5\'VHU+44!U6Z3D$?\ 'M&W/E+_
M --&&#*W&#^['"L78'%?M+_ZG2_]^[_E;T,9\GTA!0 4 % !0 4 % 'LGP&_
MY&R#_KA<?^BS0,^[JH04 % !0 4 % !0 4 % !0 4 % !0!\9_M'_P#(=M/^
MO!?_ $?/4L9\\T""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /T9^&7_(KZ9_UZ1?RI@=S3 * "@ H * "@ H * "@
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M_P"/+3O^N\__ * E)C/D:D(* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#].?#BE-*LU8$$6MN"#P01$F01ZU0&S0 4 % !0 4 %
M!0 4 % !0!\(_'G_ )&R?_KA;_\ HL5(SQN@04 % !0 4 % !0 4 % !0 4
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M(X- 'QQ\6/@X^@&36="0R6!)::W4%FMNY9>I:#U[Q#KE,LLC/GB@04 % !0
M4 ?7/[-7_'EJ/_7>#_T!Z:&?3-,04 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?
M_(XZ?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0!^5M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!Z+\)?^1LTW_KLW_HJ2@9^AM4(* "@ H *
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M7GC;47U&\.T?=AB!.R&(?=1<]_XG;JSDG@8 D9R5 @H * "@ H * "@ H *
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M &_?^V=)@?*U( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /0/AQX%G\=ZHMJH9+.';)=RC^"//"*3QYDI!5!R
M1\SX*HU S]";*SATZ".TMD$4,"+'&B]%10 H'T [\^O-4(LT % !0 4 % !0
M 4 % !0 4 % 'S!^TM;EK?3+C'$<ERF>>LBPL!Z<^6??CCO28'R92 * "@ H
M * "@ H ]'^$>H#3?%>G2GI),T!_[;QO"/R9P?P[]*!GZ%U0@H * "@ H *
M"@ H * "@#YF_:5_X\M._P"N\_\ Z E)C/D:D(* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#]0]*_P"/*W_ZXQ?^@+5 7Z "@ H
M* "@ H * "@ H * /A'X\_\ (V3_ /7"W_\ 18J1GC= @H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]./#7_()LO\
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M0@H * "@#ZY_9J_X\M1_Z[P?^@/30SZ9IB"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H ^<?VDO^038_]?;?^B7I,#X[I % !0 4 % !0 4
M>J_!/_D<=/\ ^WK_ -([B@#[]J@"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#\K:D H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79O_14E S]#:H04
M % !0 4 % !0 4 % !0 4 % !0!YE\9/^11U'_<A_P#2F&DP/SZI % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH _1GX9?\BOIG_7I%_*F!W-, H * "@ H * "@ H * "@ H * "@ H ^5OVF
M?^83_P!OW_MG28'RM2 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * -[PUX;O?%=_'IFG)OFE/).0D:#[TDC ':BCJ
M<9)PJ@L0"#/T(\%^#[/P3IJ:;9C)'S32D8::4@;G;T'&$7G:@"Y)R36PCK*
M"@ H * "@ H * "@ H * "@ H \)_:&LOM/AI)@.;:\A<GC(5DEB(SUP6=,@
M8R0">E)@?$=( H * "@ H * "@"[IMZ^F74-Y$2)+:6.92."&C<.I!['(% S
M]/K2YCO88[F$[HYD61#ZJZAE/X@BJ$3T % !0 4 % !0 4 % !0!\S?M*_\
M'EIW_7>?_P! 2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % #D4NP5>K$ ?4\4 ?J7;PK;1)"F2L:J@SUPH &<8&<#G@50$M
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M=( H * "@ H * "@#U7X)_\ (XZ?_P!O7_I'<4 ??M4 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4
M % 'VO\ #CX<>'-8\.6-[>V,4UQ-$6DD8R L?,<9.' Z #@4QG;_ /"I?"?_
M $#8/SD_^.46$'_"I?"?_0-@_.3_ ..46 /^%2^$_P#H&P?G)_\ '*+ '_"I
M?"?_ $#8/SD_^.46 /\ A4OA/_H&P?G)_P#'*+ '_"I?"?\ T#8/SD_^.46
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MD]N=:TM/^)E;)^\1>MS$HZ8[S1@?N\<NN8_F(C 0'Q000<'@BD E !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!Z3\,_A]/X\U#RSNBL+<AKJ8#H.T2'
MIYDF,#^XNYR#@*P,^_K"PM]+MX[.SC6&"!0D<:C"JHZ ?U)R2<DDDDU0BW0
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M_P#'*+ =S86$&EV\=G:((8(%"1HN<*HZ 9)/'N:8%N@ H * "@ H * "@ H
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M)[>5CRO?_4-%^.:: ]5I@% !0 4 % !0 4 % !0!\S?M*_\ 'EIW_7>?_P!
M2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &
M]X6LO[2UBQL_^>]W;Q_0/*BDG@\ ')X/':@9^FE4(* "@ H * "@ H * "@
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M?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?\ T9)30'HE, H
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M *-6A#/L.J$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'RM^TS_P PG_M^_P#;.DP/E:D 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'J?@
M'X3ZIXW=9R#9Z=GYKF13\X!P1 AP96R""V1&N#EMP"D&?;?A?PGIO@ZS%CI<
M7EIP7<_-)*X&-\KX&YCZ !5Z(JKQ5".DH * "@ H * "@ H * "@ H * "@
MH * (YH4N(VAE 9)%*LIZ%6&"#[$'% 'YAZSILFC7UQI\O#VL\D+?6-RN?H<
M9![CFI&9M @H * "@ H * "@#Z%_9Y\3#3=6FT:8XCU&/='GM/"&8#DC&^(R
M9ZDLB"A#/LVJ$% !0 4 % !0 4 % !0!Y'\6OA]>^/[>UAL98(&M9)'8S%P"
M'50-NQ'Y&.<XI >'_P##-^N_\_=A_P!]3_\ QBE88?\ #-^N_P#/W8?]]3__
M !BBP!_PS?KO_/W8?]]3_P#QBBP!_P ,WZ[_ ,_=A_WU/_\ &*+ '_#-^N_\
M_=A_WU/_ /&*+ '_  S?KO\ S]V'_?4__P 8HL ?\,WZ[_S]V'_?4_\ \8HL
M ?\ #-^N_P#/W8?]]3__ !BBP!_PS?KO_/W8?]]3_P#QBBP!_P ,WZ[_ ,_=
MA_WU/_\ &*+ '_#-^N_\_=A_WU/_ /&*+ '_  S?KO\ S]V'_?4__P 8HL ?
M\,WZ[_S]V'_?4_\ \8HL ?\ #-^N_P#/W8?]]3__ !BBP!_PS?KO_/W8?]]3
M_P#QBBP'B?B/1'\-ZC/I<LD<\EJ_EN\6[86 !8+O56^4DJ<J/F!QD8) ,6@0
M4 % !0 4 % !0!ZA\&M._M+Q98J?NP-).WMY43LG_D38/Q_"@9^@54(* "@
MH * "@ H * "@ H * /A'X\_\C9/_P!<+?\ ]%BI&>-T""@ H * "@ H * /
MK#]FC_4ZI_OVG\KBFAGU%3$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MO3>TOT?9_@^G9=S78>6% !0 4 >,?%'X2V_C2,W^GA+?5D'WNB7( P(Y<='
M "2XR/N/E=I1 ?#]_87&ESO:7D;03PL5>-QAE8=B/U!'!&""0<T@/J[]FK_C
MRU'_ *[P?^@/30SZ9IB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H ^<?VDO^038_P#7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_ .1QT_\
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M0 4 % !0 4 % !0 4 7]+TRYUFZBL;*-IKBX<)&B]23[] !U9B0JJ"S$ $T
M?H%\.? 5MX"TX6R8DO)]KW4V/ON!PB]_*CR0@/7+.0"Q >P'H-, H * "@#Y
M=_:7_P!3I?\ OW?\K>DQGR?2$% !0 4 % !0 4 >R? ;_D;(/^N%Q_Z+- S[
MNJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_R';3_KP7_T?/4L9\\T""@
MH * "@ H * /H_\ 9M_Y"U]_UZ+_ .C5H0S[#JA!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\
MK?M,_P#,)_[?O_;.DP/E:D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!U7AKP3K'BZ3R]*MI)ESAI2-D*>N^5L(#CG:"7/\*D
M\4#/JCP3\ ].T0K=ZXRZC=+R(@"+5#_ND!IC[R!4YP8B0#3L(]^1%C4(@"JH
M   P !P  .  . !TI@.H * "@ H * "@ H * "@ H * "@ H * "@ H ^%_C
MSH7]D^)6ND&(M1B2<8& '4>5(/\ >)02-_UTJ1GBM @H * "@ H * "@"[IN
MH3:3=0WULVR:VD26-O1D8,/PR.1W'% 'Z4>&=>@\3Z9;ZK;?ZNZC#;<YV/TD
MC/NCAD)[D9'!J@-V@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H Q_$&LP^'M.N-3N/]7:1/(1G&XJ/E0>[MA%]V% 'YGWMY+J%Q+=W
M#%YKB1Y9&/5G=BS'\6)-2!5H * "@ H * "@ H ^E?V;=)\W4+[4R.+>!(%)
M_O3/O./<+#@GKAL=":$!]>U0!0 4 % !0 4 % !0 4 % !0!\(_'G_D;)_\
MKA;_ /HL5(SQN@04 % !0 4 % !0!]8?LT?ZG5/]^T_E<4T,^HJ8@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M % !0 4 % !0 4 % !0!\X_M)?\ ()L?^OMO_1+TF!\=T@"@ H * "@ H *
M/5?@G_R..G_]O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_
M -&24T!Z)3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?GU2 * "@ H *
M "@ H GM?]='_OK_ #%(9^I=6(* "@ H * ,[5M*MM<M)=/OD$MO<(4=#W!Y
M!'HRD!E8<JP# @@&@#\^OB%X$NO >HFTES):RY>UGQQ)'GH<<"2/(61>W# ;
M'4F=AG!T""@ H * "@ H * "@ H * "@ H <JER%4$L2  !DDGH .Y/84 ?<
M7P>^&*^#[8:GJ* ZI=(.#_R[1-SY0_Z:-QYK=O\ 5J<!B[ ]NI@% !0 4 %
M'R[^TO\ ZG2_]^[_ )6])C/D^D(* "@ H * "@ H ]D^ W_(V0?]<+C_ -%F
M@9]W50@H * "@ H * "@ H * "@ H * "@#XS_:/_P"0[:?]>"_^CYZEC/GF
M@04 % !0 4 % !0!]'_LV_\ (6OO^O1?_1JT(9]AU0@H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MQGO@9Q^63^9H 6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* /G']I+_D$V/_7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_Y''3_ /MZ_P#2
M.XH ^_:H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _*VI * "@ H * "@ H * /T.^$O\ R*>F_P#7 _\ HR2F@/1*8!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 >9?&3_D4=1_W(?\ TIAI,#\^J0!0 4 % !0 4 % $]K_ *Z/
M_?7^8I#/U+JQ!0 4 % !0 4 <IXS\(6?C739--O!@GYH90!NAE ^5U_DZ\;D
M)7(R" #\]/$?AZ\\*W\NF:@NR:!L9'W74_=D0\91QRIP#V8!@0)&8= @H *
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M "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@ H *
M/9/@-_R-D'_7"X_]%F@9]W50@H * "@ H * "@#,UK1[;Q!93:;?+YEO<H4=
M>A]0RGLRL R'LP![4 ?G3XR\*77@S4Y=+N^?+.Z*3&%EB;[DB_4<, 3M<,N2
M5J1G+4""@ H * "@ H * "@#V+X0?$9O!5_]DO6/]EWK 2YY$,GW5G ]!PLH
M'+)AL,T:@@S[N1UD4,A#*P!!!R"#R""."".AJA#J "@ H * "@ H * "@ H
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M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^,_VC_\
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M_E\U_=\NGIM[57JGS04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!\X_M)?\@FQ_P"OMO\ T2])@?'=( H * "@ H * "@#U7X)
M_P#(XZ?_ -O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_T9
M)30'HE, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /,OC)_R*.H_P"Y#_Z4PTF!^?5( H * "@ H *
M"@">U_UT?^^O\Q2&?J75B"@ H * "@ H * /+OBC\.H?'=AF$+'J5J";:0X&
M[N8)#_<<]"?]6_S#@N&0'P-=VDUA,]M<HT4T+,DB.,,C*<,K ]"",4@*] !0
M 4 % !0 4 % !0 4 >[?!OX8'Q5<#5]30_V9;/\ *C#BZE4_<YZPH?\ 6'D,
M1Y0S\Y4&?;:J%  & . !T JA"T % !0 4 % !0!\N_M+_P"ITO\ W[O^5O28
MSY/I""@ H * "@ H * /9/@-_P C9!_UPN/_ $6:!GW=5""@ H * "@ H *
M"@ H * "@ H * /C/]H__D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?1_P"S
M;_R%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[9TF!
M\K4@"@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H *
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M 009^AGA[Q!9^)[&+4]/<203+G_:1A]Z-Q_"Z'AA^()4@FA&U0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 R65($:65@B("S,Q"JJJ,EF)P  !
MDD\ <F@#X.^+GQ&;QO?BWM"1IEFS"$=/-?HT[#@\CB,'[J9. SN*D9Y#0(*
M"@ H * "@ H * /H?]GGPQ_:&JRZW,O[K3T*1'L9Y@5XXYV1;\]""\9H0S[+
MJA!0 4 % !0 4 % !0 4 % !0 4 ?"/QY_Y&R?\ ZX6__HL5(SQN@04 % !0
M 4 % !0!]8?LT?ZG5/\ ?M/Y7%-#/J*F(* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /C/]H_\
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M>DP/CND 4 % !0 4 % !0!ZK\$_^1QT__MZ_]([B@#[]J@"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\K:D H * "@ H *
M "@ H _0[X2_\BGIO_7 _P#HR2F@/1*8!0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?&3_D4=1_W(
M?_2F&DP/SZI % !0 4 % !0 4 3VO^NC_P!]?YBD,_4NK$% !0 4 % !0 4
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MP"@ H * "@ H * "@ H * "@ H ^$?CS_P C9/\ ]<+?_P!%BI&>-T""@ H
M* "@ H * /K#]FC_ %.J?[]I_*XIH9]14Q!0 4 % !0 4 % !0 4 % !0 4
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M0>001P01R".M>WOJCXYJVCT:'4Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'SC^TE_R";'_ *^V_P#1+TF!\=T@"@ H * "@ H * /5
M?@G_ ,CCI_\ V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M5O28SY/I""@ H * "@ H * /9/@-_P C9!_UPN/_ $6:!GW=5""@ H * "@
MH * "@ H * "@ H * /C/]H__D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?1
M_P"S;_R%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[
M9TF!\K4@"@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@
MH * "@""ZM8KZ%[:X1989D:.1&&59&!5E(]""0: /SW^)?@67P)JC6P#-93[
MI+24\[H\\HQZ&2+(5^F05? #BI&>>4""@ H * "@ H * "@#IO"/BF[\&ZE%
MJED?FC.V2,G"RQ-C?$_LP&0<':P5Q\RB@9^B7A[7[3Q/80ZG8-O@G7(S]Y&'
M#1N.SHV58<C(R"5()H1M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '
MS+^T#X&^U0KXFLU_>0!8KP*/O19Q',<#),9/EN3D[&3HL9I,#Y'I % !0 4
M% !0 4 % !0!Z#X!^(NH> KKS+<^=9R$>?:LQ"..,LG7RY0!A7 /HRLO% S[
MJ\*>+]-\96@O=,D#@8$D;8$L+'^&1,G:>#@\JP!*L15".GH * "@ H * "@
MH * "@ H * "@ H * "@"O=W<-A"]S<NL,,2EGD=@JJHZEF. !0!\;?%/XRR
M>) ^D:&6AT[[LLW*R7..J@<%(3_=/SR#[VU24,C/GZ@04 % !0 4 % !0 4
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MO9^_3^'JNW_ _(^SP.8*K:C7=JG26REZ]I?@_70\>KS3Z(* "@ H * "@ H
M* "@ H ]4\!?$23P\5L;\M)8$_*>KP$]U[F//+)VR63G*MWT,0Z7N3UA^7IY
M>7W>?@XW +$7JT;*KUZ*7KV?9_)]U].6]Q'=1K-"RR1R*&5E.593R"".H->^
MFFKK9GQ,HN#<9*S6C3W3):9(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?_(XZ
M?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?\ T9)30'HE
M, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /,OC)_R*.H_[D/\ Z4PTF!^?5( H * "@ H * "@">U_
MUT?^^O\ ,4AGZEU8@H * "@ H * "@ H * (Y8DG1HI55XW4JRL RLK##*RG
M((()!!&".#0!\(_%KX:/X(O/M=FI;2KISY3<GR7.6,#DY/0$Q,3ET!!)9&-3
ML,\?H$% !0 4 7M,TVYUBZBL;*-IKB=PD:+U)/Z  9+,<!5!8D $T ?H%\./
M -MX"TX6Z[9+R?#W4X'WGQPBGKY4>2$'&3N<@%B ]@/0J8!0 4 % !0 4 %
M!0 4 ?+O[2_^ITO_ '[O^5O28SY/I""@ H * "@ H * /9/@-_R-D'_7"X_]
M%F@9]W50@H * "@ H * "@ H * "@ H * "@#XS_ &C_ /D.VG_7@O\ Z/GJ
M6,^>:!!0 4 % !0 4 % 'T?^S;_R%K[_ *]%_P#1JT(9]AU0@H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H ^5OVF?\ F$_]OW_MG28'RM2 * "@ H * "@ H ]D^ W_ "-D'_7"
MX_\ 19H&?=U4(* "@ H * "@ H * "@ H XOQ[X,M_'&E2:=-A)A^\MY2/\
M53 ':3CG8V2L@'52<?,%(0'YWZGIMQH]U+8WB&*XMW:.1#V93@\C@@]589#
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MOXF:KXZDVW#?9[)6S':1D^6,=&D/!ED _B8 #G8B9(*&>=4""@ H * "@ H
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M'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_ -&24T!Z)3 * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?GU2 * "@ H * "@ H GM?]='_OK_
M #%(9^I=6(* "@ H * "@ H * "@ H R]:T:U\064NG7Z"6WN%*NO?U#*>S*
M0&5NS 'M0!^>_CWP1=^!-2:QN,O ^7MI\866+. >,@.O21,Y4X(RK*QD9Q-
M@H <JER%4$L2  !DDGH .Y/84 ?<7P>^&*^#[8:GJ* ZI=(.#_R[1-SY0_Z:
M-QYK=O\ 5J<!B[ ]NI@% !0 4 % !0 4 % !0 4 ?+O[2_\ J=+_ -^[_E;T
MF,^3Z0@H * "@ H * "@#V3X#?\ (V0?]<+C_P!%F@9]W50@H * "@ H * "
M@ H * "@ H * "@#XS_:/_Y#MI_UX+_Z/GJ6,^>:!!0 4 % !0 4 % 'T?\
MLV_\A:^_Z]%_]&K0AGV'5""@ H * "@ H * "@ H * "@ H * "@ H * "@
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M!F[JFU?E)D6F@/?J8!0 4 % !0 4 % !0 4 % !0 4 % !0!\(_'G_D;)_\
MKA;_ /HL5(SQN@04 % !0 4 % !0!]8?LT?ZG5/]^T_E<4T,^HJ8@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?0W[-__
M "';O_KP;_T?!0AGV95""@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M *"E_P#^!,O_ ,50 ?\ "P_$O_04O_\ P)E_^*H /^%A^)?^@I?_ /@3+_\
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M9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 3VO^NC_P!]?YBD,_4NK$%
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M4+R>"64AXY)Y&1AY;G#*6((R >>XH ^YJH04 % !0 4 % !0 4 % !0 4 %
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M,^@*,!TYZTK@>3Z[\1O$7B/*WU].T;<&*-A#$1Z&.((K?\"#'OG- SB:!!0
M4 % !0 4 % !0 4 % !0 4 ?0GP4^&)U^==>U6/_ $"W?,$;CBXF4_>(/WH8
MB.<_+(_R?,JR+0,^SJH04 % !0 4 % !0 4 % !0 4 % !0 4 % 'PC\>?\
MD;)_^N%O_P"BQ4C/&Z!!0 4 % !0 4 % &UI/B/4]!#C3+JXLQ+M+B"5X]^W
M.W=M(SC<<9Z9/K0,U_\ A8?B7_H*7_\ X$R__%4 '_"P_$O_ $%+_P#\"9?_
M (J@ _X6'XE_Z"E__P"!,O\ \50 ?\+#\2_]!2__ / F7_XJ@ _X6'XE_P"@
MI?\ _@3+_P#%4 '_  L/Q+_T%+__ ,"9?_BJ #_A8?B7_H*7_P#X$R__ !5
M!_PL/Q+_ -!2_P#_  )E_P#BJ #_ (6'XE_Z"E__ .!,O_Q5 !_PL/Q+_P!!
M2_\ _ F7_P"*H /^%A^)?^@I?_\ @3+_ /%4 '_"P_$O_04O_P#P)E_^*H /
M^%A^)?\ H*7_ /X$R_\ Q5 !_P +#\2_]!2__P# F7_XJ@ _X6'XE_Z"E_\
M^!,O_P 50 ?\+#\2_P#04O\ _P "9?\ XJ@ _P"%A^)?^@I?_P#@3+_\50 ?
M\+#\2_\ 04O_ /P)E_\ BJ #_A8?B7_H*7__ ($R_P#Q5 !_PL/Q+_T%+_\
M\"9?_BJ #_A8?B7_ *"E_P#^!,O_ ,50 ?\ "P_$O_04O_\ P)E_^*H ]6^#
M'B_6M8\2PVM_?75S T,Y,<LTCH2L9()5F(R#R/2@#[+JA!0 4 % !0 4 % !
M0 4 % !0 4 ?&?[1_P#R';3_ *\%_P#1\]2QGSS0(* "@ H * "@ H ^AOV;
M_P#D.W?_ %X-_P"CX*$,^S*H04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!Y;X\^'<7B%6OK +%?J.1PJ3@=G])/[K]#]U^,,OGU\.JGOPTG^#_X
M/G]Y[N"Q[PS5*K=TOO<?3R[KYKL_F.XMI;.5H)U:.6,E71AAE(Z@@]*\%IQ=
MGHT?;1DII2@TT]4ULT04BPH * "@ H * "@#Z(^"G_'K>?\ 76/_ - :O9P6
MT_5?J?'YO\=/_"_S1[;7K'S(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?_(XZ
M?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M-&5./W<;#][D89AY7/S[4,^U54*  , < #H!5"%H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H ]D^ W_(V0?]<+C_ -%F@9]W50@H * "@ H
M* "@ H * "@ H * /C/]H_\ Y#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4
M?0W[-_\ R';O_KP;_P!'P4(9]F50@H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H X#QOX#M_%47G1;8;Y!A)>S@?P2XZKZ-@LG;(RIXJ]!5E=:3
M[]_)GK8/&RPCY7K2>\>WG'S\MG^)\K:AIUQI4[VEVC131G#*W\P>A4]0PR".
M02*^?E%P;C)6:/NZ=2-6*J4VG%[-?UH^Z*52:A0 4 % !0 4 ?1'P4_X];S_
M *ZQ_P#H#5[."VGZK]3X_-_CI_X7^:/;:]8^9"@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H ^<?VDO\ D$V/_7VW_HEZ3 ^.Z0!0 4 % !0
M4 % 'JOP3_Y''3_^WK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /L3]FW_D$WW_7VO_HE
M*: ^CJ8!0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_TIAI,#\^J0!0 4 %
M!0 4 % $]K_KH_\ ?7^8I#/U+JQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!\N_M+_ .ITO_?N_P"5O28SY/I""@ H * "
M@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H * "@ H * "@ H
M^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 % !0 4 % !0 4 % !0
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M&2QXMYCPLH[!'X27T 5\_(0QL,^Y 01D<@U0@H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /GOXL?!U?$6_6=#41ZA]Z: 85+GU=>@2?U)^67OA\LR
M^-IH9+9VAF5HY$)5D8%65@<$,#@@@\$'D4@(J "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /8OA?\ "FY\;3+>W@:W
MTF-OFDZ/.5ZQPY[=GDQM7D#+\ &?<>G:=;:1;1V5E&L%O H2.-!A54?J23DL
MQ)9F)9B6)-4(NT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY_Y&R?
M_KA;_P#HL5(SQN@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % 'LGP&_P"1L@_ZX7'_ *+- S[NJA!0 4 % !0
M4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/- @H * "@ H * "@#Z
M&_9O_P"0[=_]>#?^CX*$,^S*H04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % '(>+O!MIXL@V2XBN8Q^ZG RR]]K#C<A/52>"25(.<\M:C&LM
M=)+9_IZ'HX7%SPDKQU@_BCT?FNS\_O/E#6M$N_#]RUG>H8Y%Y!_A=<D!T/\
M$IQP?P(!! ^>G"5-\LU9_P!:H^]HUH8B"J4G=?BGV:Z,R*S.@* "@ H * /H
MCX*?\>MY_P!=8_\ T!J]G!;3]5^I\?F_QT_\+_-'MM>L?,A0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?./[27_ "";'_K[;_T2])@?'=(
MH * "@ H * "@#U7X)_\CCI__;U_Z1W% 'W[5 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y6U(!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'V)^S;_R"
M;[_K[7_T2E- ?1U, H * "@ H * "@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?
MGU2 * "@ H * "@ H GM?]='_OK_ #%(9^I=6(* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /EW]I?\ U.E_[]W_ "MZ3&?)
M](04 % !0 4 % !0![)\!O\ D;(/^N%Q_P"BS0,^[JH04 % !0 4 % !0 4
M% !0 4 % !0!\9_M'_\ (=M/^O!?_1\]2QGSS0(* "@ H * "@ H * "@ H
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M[."VGZK]3X_-_CI_X7^:/;:]8^9"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H ^<?VDO^038_P#7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_
M .1QT_\ [>O_ $CN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@H * "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@
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M?8_P[^"UAX2*7^I%;[4EPRDC]Q W_3)6^^X/25QD$ HJ$9+L(]OI@% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY_P"1LG_ZX6__ *+%2,\;
MH$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MKV<%M/U7ZGQ^;_'3_P +_-'MM>L?,A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?./[27_()L?^OMO_ $2])@?'=( H * "@ H * "@#U7X
M)_\ (XZ?_P!O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?8G[-O_ "";[_K[7_T2E- ?
M1U, H * "@ H * "@ H * "@#S+XR?\ (HZC_N0_^E,-)@?GU2 * "@ H *
M"@ H GM?]='_ +Z_S%(9^I=6(* "@ H * "@ H * "@ H * "@ H * "@ H
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M^P\-6PLM+@2VA7G:@Y8_WG8Y9V/=G).,#. !5"-B@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H ^$?CS_ ,C9/_UPM_\ T6*D9XW0(* "@ H
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M'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?E;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?8G[-O_()OO^OM?_1*4T!]'4P"@ H * "@ H *
M "@ H * /,OC)_R*.H_[D/\ Z4PTF!^?5( H * "@ H * "@">U_UT?^^O\
M,4AGZEU8@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M % !0 4 % !0 4 % 'QG^T?_ ,AVT_Z\%_\ 1\]2QGSS0(* "@ H * "@ H
M^AOV;_\ D.W?_7@W_H^"A#/LRJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 07-M%>Q-;W"+)%("KHPRK ]014M*2Y9*Z?0J,
MG!J<&TUJFMT?,?CSX=R^'6:]L0TM@QR>[09/"MW*<X5^WW7YPS>#7P[I>]#6
M'Y>OEY_?Y_;X+'K$)4JME5Z=I^:[/NOFNR\MK@/=/HCX*?\ 'K>?]=8__0&K
MV<%M/U7ZGQ^;_'3_ ,+_ #1[;7K'S(4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'SC^TE_R";'_ *^V_P#1+TF!\=T@"@ H * "@ H * /5
M?@G_ ,CCI_\ V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!\C_\,U7O_01A_P"_#_\ Q=*PP_X9JO?^@C#_
M -^'_P#BZ+ '_#-5[_T$8?\ OP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-
M5[_T$8?^_#__ !=%@#_AFJ]_Z",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718
M_P"&:KW_ *",/_?A_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\
MWX?_ .+HL ?\,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7
MO_01A_[\/_\ %T6 /^&:KW_H(P_]^'_^+HL ?\,U7O\ T$8?^_#_ /Q=%@#_
M (9JO?\ H(P_]^'_ /BZ+ '_  S5>_\ 01A_[\/_ /%T6 /^&:KW_H(P_P#?
MA_\ XNBP!_PS5>_]!&'_ +\/_P#%T6 /^&:KW_H(P_\ ?A__ (NBP!_PS5>_
M]!&'_OP__P 718 _X9JO?^@C#_WX?_XNBP!_PS5>_P#01A_[\/\ _%T6 /\
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M_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\ %T6
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M^"USX*UB/5I;R.X6..1/+6)E)\Q2N<ER.,YZ46 ^@:8@H * "@ H * "@ H
M* "@ H * "@ H * "@ H \)^(OP4A\97XU2PG2QGD7%P&C+K*PX60!67:^/E
M?J& 4\-N+*P'GO\ PS5>_P#01A_[\/\ _%T6&'_#-5[_ -!&'_OP_P#\718
M_P"&:KW_ *",/_?A_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\
MWX?_ .+HL ?\,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7
MO_01A_[\/_\ %T6 /^&:KT?\Q&'_ +\/_P#'*+ ?37AFPO\ 2].AL]4G6]N8
M%V&=5*F15X0N&+$OMP';/SD;CR33$;U !0 4 % !0 4 % !0 4 % !0 4 %
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M,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\
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M_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\ %T6
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M>/DQC'>@1[?3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * &NBRJ4<!E8$,I (((P00>""."#P12WT8TVG=:-;'SEX_^&S:9
MOU/25+6O+2PCDP^K(.IB[D=8QSROW?$KX;DO.G\/5=O^!^1]C@<P52U#$.T]
MHR_F\GVE^?KOT7P4_P"/6\_ZZQ_^@-6V"VGZK]3CS?XZ?^%_FCVVO6/F0H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /,OB?X E^(%G!:0SI
M:FWF,I9T+@@H5P &7!YSFD!XI_PS5>_]!&'_ +\/_P#%T6&'_#-5[_T$8?\
MOP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-5[_T$8?^_#__ !=%@#_AFJ]_
MZ",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718 _P"&:KW_ *",/_?A_P#XNBP'
M7>!/@?<^#];MM9EO8ITMO-S&L3*6\R"6(88N0,&3=TY Q181]%4P"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H Q-)T&TT6:X>R3RA=,LCH/N
M!AN!*+CY0>I . ?N@#BL84XTW)PTYK-KIUV.JK6G6C!5'?D32?6VF[Z_GW-N
MMCE"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
+* "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exc_compmins2-9x23v1x202001.jpg
<TEXT>
begin 644 exc_compmins2-9x23v1x202001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BB@G R: "BFI)'(H9'5@3@%3FG4 %%%
M% !113(IHIXQ)#(DB$D!D8$9!P>1[T /HHHH **** "BBFR2)%&TDCJB*"S,
MQP !U)- #J*165U#*P92,@@Y!%+0 4444 %%%% !14,MW;0S1PRW$4<LIQ&C
MN S_ $'>IJ "BF"6-I6B61#(@!9 >5!Z$CWP?RHDFBAV>;(B;V"+N8#<QZ >
MIH ?1110 4444 %%,\V/SA#YB>:5W!,_-CIG'IR*)9HH(S)-(D: @%G8 #)P
M.3[T /HIGFQ^=Y/F+YI7=LS\V.F<>E$LT4$9DFD2.,8RSL !VZF@!]%%% !1
M110 4444 %%%% !1110 44R6:*")I9I$CC499W8  >Y-/H **** "BF2RQPQ
MF2618T'5G. /QIY.!DT %%,CECFC62)U=&&593D'\:?0 4444 %%%% !1110
M 4444 %%%% !14,5W;3RR10W$4DD1Q(B."4/N!TJ:@ HHHH ***8LL;2O$LB
MF1 "R \J#TR.V<'\J 'T4R2:*+9YDB)O8(NY@-S'L/4T^@ HHHH **** "BB
MCI0 44R*6.:-9(G61&Z,IR#^-/H **** "BBB@ HID<T4V_RY$?8Q1MK [6'
M4'T-/H **** "BBB@ HH)P,FF12QSQ++#(DD;C*NAR"/4$4 /HIGFQ^<8?,3
MS0N[9GG'KCTI] !1110 4444 %%%,2:*1Y$21&>,X=58$J<9P?3B@!]%(S!5
M+,0% R23P*1'26-9(V5T8!E93D$'H0: '44V26.&)I976.-1EF8X 'J33@<C
M(Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7GMQ<'Q3\6+KP_>?/I&C623R6I^Y<3
MR8*EQ_$JJ>%/&>:]"KB=6T#5-+\=+XNT.V6]^T6PM-1L?,$;R*#E9(V;Y=PQ
MC!(!'>@#:E\*Z:-7TW4K.WBLY[*5G/D($653&Z;6 X.-^03TQQU-8=Y\3--M
M([>]V0R:7-<BV\^.Z4RKEMHD,779D=<YQSBNCM;S4=0D3=ID^G0#F3[4\;2/
MZ*HC9@/<D]L <Y'(>%;/QCX=M$\+-H]O/96SLEMK/VE HA+$C=%]XN <8Z'C
MGO0!J?\ ";7L^OZEI%AX:O;F;3IX(YV\^) $D&X/R><#!P.>N<51T+QIJ;Z'
MX@U;5-,9TL=0FMTALW\QR498Q&HP,\\EO<G K1\/:=J5IX[\5:A=6$D-GJ+6
MS6\IDC.?+BV-D!B1D\CCIZ5@+HGC#3_#OBC3],M%BN;C5)KRUN%NE4SQ22JQ
M13U1MFX9.,'&/4 '5V/B:2?Q!?:%=:?Y6H6MJEV%@F$BRHQ( #$+ALC&"!VY
MKG]/\:Z;I/@+3]7T_P /36]C<WS6PM82@\IFG9"QP><MDX4'K^-.T71M6L?'
MTFL)X>CLM.GTE+<HES&7219&;# =7.1SDCN6SQ61%X7\0I\--.T4Z1)]N@U8
M73H)XL>6+DS9!WXS@XQZ_G0!VFE>*);WQ/=:#?:5-I]W%;+=P[Y4D$L)8KGY
M>%((P1D_6G>)_%*^&6TP/IUU=B_NUM$,!7Y78$@8)R20I[8]2*HIIVI-\4_[
M:.GR+IYT<6?FF2/(D\W?]T-G&.,^OYU3^)DDD7_"(R0PF:1?$=L1&K %OW<O
M )XS]<4 6M/\>PG4=5T[7=-FT6[TZU-\ZS2+(LEOWD5EX.#P1Z^M3/XS-F=(
MGU+3'M-/U:1(K>X\T,8W<9195Q\F[ID%@#P<5E:UX.N?%^JZO?7<3Z<D^C-I
M=LLC*SDL^\R-L)  (4 9R?FZ<4DNBZWXB\/:%H>JZ8UF]E<V\EY<^=&T<@AY
M_=[6+9<@?> P"?09 -"/QM>W>MZAI=AX9O;B33[N*WN6,\2!%=0P?KR,$' R
M<=<=#DZ=XKO=1\"^(M4U[1DNK.WDNTEMX958&.,E63# <!5//4^G:MGPQIVI
M6?B_Q5>7=A)!:ZC<12V\ADC;<$B5#D*Q(.1D>U8EKH&OVW@;Q;H#:4&DO'OO
MLDJW"8F\\ML."1M W<YP>. : .D@\16\5MH>GZ=9*;J_LQ/;V@?8D,*JN2S
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M*VQ-VTY.0>1G. .>N,57T[Q3K][X]BTJXT=;. :4EV\#W*LZEY-I)(&"5VD
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MG?@8'7W]:T_%WAR?Q))/(_A^ZCU&&!6TO4[6YBBF@DV_=<AP=H;G^(8)QSU
M.]:23[,9(HPTFS<J,VW)QTSCBN+;XC*GA&W\1-I3) ][]CN(GN &M7\SR\OQ
MC&[KCH".O;L-/CN8=-M8KV59KI(46:51@.X W$?4Y-<1/X DOM<\16ETR?\
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MW4FNZ1I]WHC6L.L0/)93FX#$LB!RKJ!\HV\@Y/N!TH ZQW2&)I)'"HBDL['
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MQL&4\XX(KCM,U;5=6\<^)]&OK.S?3+..WC"&8MA71VW;2F&+< C( P.O?F_
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MAD;FVMG&0-PY.,UVESX>TV[URUUF:.4W]JK)#(+B10BMC<-H;;@X&>.<5J4
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M4K::>;[:OES)$K+N4 $C.>A&03T/;L_%EKJ][X3U&VT*<6^J20X@DW;<-D9
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MM5U8@@J5ZCK7=44 5M/%X+&+[>T9NB"TGE?=4DYV@]P.F>,XS5FBB@ HHHH
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MD@K]T8(P/KGM7+V6@^);#7_$&HVVFZ5%'J%E;)!;B<E$:(,/+(V 8(;DXX[
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MP=R/@C(89YZCTJG-X*\0ZI;^*Q-]DL)]0O8+^PE2<R>7+$$*AAM'&4QGZ\4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLX+C;M\V-7VYSC(SBIJ "BBB@ HJ%[J".ZBM7E43RJSQQ]V"XW'\-P_,5-0
M4452L[J]GO;Z*YT\VT$,BK;S&97^T*5!+;1RN#D8/IF@"[7.)X#\,173W$>D
M0H78N\:,PB8GJ3&#L/Y5IZ[JAT70;[5!;/<BT@><Q(P4L%!)Y/L*?H^H?VMH
MEAJ/E^5]KMHY_+W9V[U#8SWQF@"X    , = *6BL+4/$9L/%NCZ$UB[#4TF9
M;GS %7RU#$;>IZCTH W:*** "BBFRR)#$\LKJD:*69F. H'4F@!U%,AFCN((
MYHFW1R*'5O4$9!I] !1110 4444 %%4M5NKVSLO-T_3S?S^8B^2)EB^4L S;
MFXX&3COC%7: "BBJ4EU>KK$%JFGE[)XG>2\\Y1Y;@C:FSJ<@DY'3% $-]H&F
MZEJ5GJ-U#(]W9$FWD6>1?+)&"0%8#D<'U%:=%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1137
M4LC*'*$C 9<9'N,\4 <'\+/^/7Q9_P!C-??S6N2U36KG0_&OQ)\0:,@>.TTZ
MWBD8#*?:L* 3V)4$Y^G->B6'@;3M,CNX[.^U2&.[G>XG5+QEWR/]YLCD$^Q%
M:=EX<T?3]&ETBUT^%+"8,)8<;A+NX8L3RQ/<DDT <CKS77AMO"NIZ9J%[<?;
M+^"QNXYKAY4N8Y0<OAB0K C<"N.XZ<506\OAX1^))_M&^WZ==W7V20W4F^$+
M KJ%;.< DG&<5V>G>$=/T[[$HFN[B'3SFRAN9=ZV_!4;>,DA20"Q) /&*JWW
M@'1K^ZU661[U(]50K=V\5RRQ.Q79OV=-V,>V0#C(H Y:XMI-9\8>"XYKV[B:
M?09FEF@EV2-D0D_/U&3W&#[UGW\E_9^#OB5X>NK^YO[72XA]EN;I]\FR6'>4
M9OXMN>IYYKT!_!NF8TM[>6\MKC3(C#:W$=PS2+&0 5._<&!P.&!Z<8J6X\)Z
M9<Z#>:,XF%M?,S7;B3]Y.6^\68\Y. /8  8 Q0!SDE_=7WB33/#B8\@:(EYY
M?VR2V,K%MGWD!8[0.G ^;)S@8Z#PC9:KIND26.KZDE_<0SN$D#EW6,X9$=B
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M+*^9)@5V\D8QA> !@#M0!RAN)K>_\+^'+9Y/(O-.DNF$U_+&TKJ(P$$GS,
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MQ26652,%BN.,*HP !@<8H WJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9>&L".*:ZRTJC8,9 XX0<\]:]6_X1K0?^@)IO_@)'_A1_P (UH/_ $!--_\
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MQ1\,]-D-SIE]X8M[L*0CQF*(\]MRC(%=3_PC6@_] 33?_ 2/_"C_ (1K0?\
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M+W?_  G.@&71KK[7*SS;1,V]6VJ!G:HVX&23CKG&3ZG_ ,(UH/\ T!--_P#
M2/\ PH_X1K0?^@)IO_@)'_A0!Y7I%UX7L_%WBO5KKQGH36VO1&+RXKCYX1C
MZ\'@UT/PB%EI>A-X?M?$FE:N+0O(@LB=P5G)W/DGN<8'YFNS_P"$:T'_ * F
MF_\ @)'_ (58L])TW3W9[+3[6V=AAFAA5"1Z' H N4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1156[U*RL9+>.[NX()+B010I(X4R
M.>@4=S]* +5%%% !1110 4444 %%%% !116;=Z_I-C=FTN+^%;E5#-"#N=0>
MA*C) ]S0!I455L=2L=3B:6PO(+J)6V,\,@<!L XR.^"/SJU0 4444 %%%% !
M1165;^)='NM4338;Z-KN1&>-""!*JG#%&(P^.^TG% &K161>>*?#^G7C6E[K
M5A;7*C<8IKA48#UP3T]ZNQZE82Z<=0CO;9[((7^TK*ICVCJ=V<8]Z +5%95G
MXET2_N8[:UU2UDN)/N1"0!W&"<A3R1@$Y''%26>OZ1J%[+96>IVEQ=0_ZV&*
M4,Z?[P'(_&@#1HJD=7TX:D---[ +XKO%OY@\PKZ[>N/>KM !115>^O[/3+5[
MJ^N8K:W3[TLKA57ZD]* +%%5[&_M-3M5NK&YBN;=_NRQ.&5OH1UJQ0 4444
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M#*3@\XQ_.JG@7Q#ING>&[K2=5L$UO1K3["_FQ/\ 9[F A?D;!W#!4'([]A0
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M**0I/? ).!^-/HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-%M(VJ^=ISC!S@]#7":I<>+XO&/A*RO=2TM&N+F\;;;6LAC8)"VTL"X).&/
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M.I/L.:RO">JZOJ=K>+K-@;::VN6BBF$+1)<Q_P ,BH_S+GN"3C%<UHTS:O\
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M3 QDZ;WVK7/Q;L+>"^A2P;0WN5@>W+8!FB#9(<98X&#T [')- '=T45QFO\
MB^33?$[:)]LLM-EDM%ELI;^)C'=RDL"@<,H7&%XZG=[<@'9UGZIK>FZ*+8ZC
M=+!]IF6"$$$EY&.   /4BL:#7M4/CT>'YUM1$^C_ &\.L;;TD\P(5)W8*\D\
M8KCM>UZ_U_P-8W=S%;?:X/$\-LJQ;D1_+N=H/)8C..>M 'K54M*U:QUNR^V:
M=/YUOYCQ[]I7YE8JPP0#P0:Y>R\0>(K+QHGA[78M.D%]:R7%A<V:N@#)C=&X
M8DG (.1^7/%73/'=Y-X2LK^\@@74+W5)=.B6")W12KN-VT$LV%C8X'4^F<@
M[^BN"E\:ZMHL.N7&K:<\]E9PQRV=VEK):K.SL$\IED)((9E^8<8.<<5N1MXK
MCU=+>8:?-8S6K,;J.(K]FG'0%"^9%.>V.G6@#H:*XOX67>IZAX&M;[4KR.Y>
M>2=P1$58-Y\F[<=Q!R>@ &!QS41N]7/QAELSJ$ L(='6X6%K<G:K3889WCYC
ML'S'C'\/J =S17G\GC36)O!$GC2QBM)--C+S"R>-O->W1RI;S-V ^ 6QM([>
M]=M%<_VCI4=U8RJGVB$20R2)N W#*DKD9ZCC(H AUC7--T&S%WJETMM"7"!F
M!.6)P   3U-:%>*3W>IW_P"S^;_4;J.ZEGNXY 1$4;=]N^;<=Q!R>F ,#CFN
MZA\2:KI_C.XTC6S8M:MICZE%):QNK1!'"LC;B=_!!W +]* .QI&570HRAE88
M((X(K@[;Q=KUV-#U"TTYKJQU&2/S[9+"9'MHI!D2><QV/MR,X'.>*O?%"[O[
M#X<:U=:=="VFC@.7V;CM/!"\C:>>O./U !T>GZ3INDI(FFZ?:V:R-O<6\*QA
MF]3@#)JY7)7GB"]LM0LM#\Z)KZ2T>ZEN(K"6540,%4"-6)R2>I;'R^XK&NO&
M?BFS\/V5S/I-O#>/K4>FN)XY(UN(W<!98U)RH8'^+.#ZT >C57O;"SU*T>TO
M[6"ZMGQOAGC#HV#D9!X/(KC;O7/%VEZ[H&E78T6:35+BYC\R))5"JD9=#@GK
MZCG.,9&<U7A\1>+YW\3:<KZ,+[0W5C<F"3RYT:(2*HCWY4XX+;CCT- 'H$<<
M<,211(J1H JHHP% Z #L*=7 2_$(+IGA>]NI+?2K;6;0S/>7$320Q2X0B(D%
M0N=S'<3T3WR.RTF6[GTJWEOC;M<LN7:W/[MN>"O)X(P>O>@"XRAE*L 01@@]
MZKV&G6.E6HM=.L[>TMP21%;Q+&H)ZG  %<1K?C/6=$D>:XCL8PNJ1VHL,&25
MK9W"+,75L(3G(#+[=:N3ZYXDNO&VJ>'M/_LN%+>RBN8;B>-W(WLPPRAAG[O8
MC'OTH [2L^VUO3;S5[O2K>Z62]M%5IXE!_=ALXR<8[&N2TOQY=ZKX>\,,EO;
MQ:QKLLL(4@F*+R=WFOC()'R<+GJPYIOAQ+U/BWXF6^E@ED&GV>UX8R@9<R8R
M"3@]1U[=NE '?T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<Q#X>U*Q\::MKEG>6QMM2AA66"6-MX>)65<,#@*=V3P3QQZUT
M]% 'GD/@'5(? 6C>&Q>V9DTZ\CN?M!5L2!)?, V]LDXZ]JN3>%?$>G>)[[5/
M#FKV-O;:H5DO;6]MVE6.4*%,D>TKR0!P>./R[>B@""V@>VLHX?->>2- IDE/
M+G'4GW/I7.^$O#>H>'[_ %V>ZN+::/5+Y[T"(,#$6 &WGJ, <\?2NIK.UC7=
M.T&&"74IS"D\RP1D1LVYV( ' ..3WH R=7\/ZK<>,=/U[3K^UC$%K):R074+
M2*H9@V],,,-P ?45@0?#[6;?POIFC#4[*3^S]7&HQR-"PW!9FE"G!ZDMR>,8
MZ'K7<C5K-M;?1Q(_VU+<7)3RVQY98J#NQMSD=,YI=4U.TT;2[C4;UV2UMUWR
M,J,Y ^B@DT 8WB'P]?ZIK&@:M87=O;W6ER2L5FC,B,LD>QNA!R.HJJW@^:[\
M0^(;N_FADL-9L4LGB3(D555AG/3)WGZ<=:ZU'$B*Z_=89'&*=0!Q_ACP]XGT
MF&UT[5-<M;K2[$!8##;LD\RKP@D8L1@<=!DX&3US@>)]!O-$\ ^/[BZFMY$U
M,RWBB/(,9*JNTYZ\*.>/I7I]5[RQM-1MS;WUK!<PDY,<\8=2?H>* .:MM"O=
M8/AZYU:2V^SZ7MN8D@W$S3>7M5VR/E #,=HW<D<\<X<7P^\01:+IVF?VU8,N
MFZLNHP3/:N7F(D9R93NY/S'IC/K7HL%O#:P)!;PQPPH,)'&H55'L!TJ2@#D;
M;PSJEOK'BB_-Q:/_ &U'$B+AAY12/R\GUSG/;T]ZHP^!]4M=(\)0V^H6:WOA
MYBJO)$S1S(8S&3M!!!P<]:[RB@#GM,FUS_A+-2@NKFVN=)6)# 8XBKPOP"K-
MT8GYC@=..F:;XF\/7NK:GH>I:==P076EW#R@7$1='5T*,, @YP<CFK^K^(M-
MT-6-[+)E(C.ZPPO*R1C@N0@)"CU/O5ZTNX+^S@O+659;>>-9(I%Z,I&01]0:
M .8M?#6IVNO>)=2^T6L@UB&&-%.X&,QH4!)QSG=GC&.GO60OP_UBRT3PX=+U
M:VM];T&)H(YFB+0W,38W(Z]1T'3IC\O1*AN[N"QM);JX?9#$I=V"DX [X'-
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MIMO)(*JA)!W;L$G<>U95KX#N[3PS<^$TU*(^'YG8)F,_:(H6;<T0.<'J0&[
M]#0!'=>(O$NI>+I-&T.?3(H)='CU*VGN8'8KND*@, W/ [8QGH<5!HLVL3^)
MO',=]J,4\5J(HM@@*X4V^\!3N^4 L>N<^M=!!X9N;?QU_;\5S;K:#35TY;00
MG*HKEPV[=CJ<8QTJ!?"NH6WB#Q!J%IJ4"V^L(A:&2W+,DBQ>7G<&'RXYQC.>
MX[@'(^%=:UO0O!W@*;S+)]+OWM]/:V$3>:N]6VR>9NQG*_=V]#U/6O0/&/\
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M\WS,2MO^;DGI@].>U;]CX<U&R\5ZOK?V^VE-_;0P"-H"-AC#88D-SG<<C H
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M:-EW$\@ [L\')QV#K_P%!KEIKW]KSAKO6(HXGD@7:+=8^8PF3DD-\Q)ZGL*
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MC'O^%=99VYM+.*!II)F1<-+(?F<]V/;D\\<>E3T ></=36GQRU"2&QN+QO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:ZMX7U@:/<Q6B64L3VXGAFA3[@*DC!7L<^U==!:6UKN^SV\46[KY:!<_E4U
M')WWA"^N[O0+D:TIETJX>Y=Y[7>UQ(ZE6Z.H488X !QQZ59USPW>:MXDT/5H
M-1AMQI3RNL+VID\PNA0Y;>,<$]JZ.B@#EX_"]YIOB+4M5T74(+==4"M=6]Q;
MF11*HP)$PZX)'4'.?453?P"8+?PY;Z;J*6\.BW!N?WUL96N)&#!BQ#KC.]CP
M.I_"NTHH YZ[\.7-SXVL?$*:A$B6MK);"V-L6+!R"3OWC!RH[5E+X%O1X?\
M$^E-K,!&NW$T[2BR(\GS5"L /,YP ,=/QKMJ* .-B\%ZE;:W:ZE;ZZB,NF)I
MMROV/.]$)(:/+G8W/?</:J5E\.[^RT7PUIHUZ)UT.[%S&S6/^LP& 7B08X8\
M\\_E7?T4 <==>!%U+4O$LVHWR36>NV\5O)!';E&B$8(5@Y<Y/S9^[U J?0/#
M.LV44=OKOB'^UK:WC,4$8M1"6!4KF0[B7.TD=ASDY.,;^HZC#INF7-_(DLL5
MNA=DMT,CG'4!1R35B*030I*H8!U# ,I!&?4'H: .+\/^"=7T$QZ<OB>2;P]
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MHRO<DG)]L6=-\*7>D>*KS5K+4X8K._"O>:>+4['F'65#O^1CWX.>^3S7444
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M:S6AD*3,NUGC8.,%NX(8<5U&E:K::UIT.H6+R/:S+NC=XFCW ]" P!Q[U=H
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MY;,85><CG.,C.0GA6>Y@U:VBTGQ5HFN6DKXN8+#3HXC&FT_.7B8A2.,!ASG
MH TOBH]W'X/5[6]EMLWMLDGE@?O%:9%(.1TYSQUZ'C(JGJUM?GXJZ+;V]^%N
M3HMR#=21!B!YL?(48&?T]CTKJ?%?AY?$_A^;3#=-:NTD<L<ZH'V.CAU.T]1E
M>E4QX8O3XJL->EU9)9K6T>U*-:XWAV#,<AACD# QP.N>M '/6'C35D\/>1=%
M;K5/[?DT19XXU7S-I8^9M)"AMBGC.,X^E=!X?F\3+KU_;:I;3/I/EK):7=P8
M%E#]&C81-@CN#@=P<UF/\.%N-#U+3[C59/-NM4;5K>Z@A\M[6X)SE?F.0/Y$
M\]QO:!HVJ:?NFUK77U:[V^6DGV=8$1>IPB]R0,DGL,8[@&7XFU76[3QEX9TO
M3KNVAMM3-RLOF0;R#'$6!SG]..G7%8%WXJ\0:=X4\:&34$FU#P_< 077V=5$
MJ%%<!TZ<;B,C':NPU?P[-J?B;1-92^2'^RC*5A,&[S/,38V3N&..G'7UK-D\
M!BZM_%-O>:CYD7B#YI!'!L,+! @()8YP #SWH DO]:U&V\:^&=/BG7[+J=M<
MO-&T8.&C12I!Z]6Y&>W:N6G\3>+/^$-\2:XNJVJ2Z)J-S$L:V8VSI$P&ULG*
M@C/3G/>NDA\&:F^LZ%JM_P"(C<7.E1RQ@)9K&DBNJKTW'!^7DY.>V*C/@*=O
M"VOZ&VKH4UFZFN9)1:8,?FG+ #?^7I[T )_;&N6/C7P];75]#<6.N0SDVRP!
M/LS1QAQM;.6X.#GZ\=!RNDOXFLO"WB?5M#U*T@2PUC4+@VDMMO\ M(60LP9\
MY7@8&!^//'=W/A:ZN=:\.ZD^I1!]&210@M3B;>FQL_/QP./?UZ54B\$7$%GJ
M^EQZQC2-4N9IYX_L_P"_7S3F1%DW8 .2/N$@$\YY !4@\67_ (EN1;Z3'>6R
MKIEM>N]LL+N'G5F53YI V@+S@9.>JXYISZ]XUA3PA;7RV>FZAJ-Q+;7D9C$H
MRJ.0X(8C! !V^O&<5KZMX'F?6K75_#FLOH=Y#;+9R!;=9HI85^ZI0D<CL:FO
M/!]Q<W6A7"ZN3+I4[W+/-!O:XD8%6+890!AC@ <<8X&* -O3DO=/T6,:O?)>
M74*,9KE(?*#X).=@)QQC\JX>7Q5KDOPZ_P"$ZM+A-J@W7]FM&OEFW#D%=V-P
M?:,[LXS_  XKT<@,I! (/!![UQ=MX :UT&X\-1ZIGP[-(Q%J8/WT<;-N:)9=
MV-I.1RN0"1GH0 9NL_:-1^)?@ZYMM1FABN;&[EB'EH?+!2(]QSG/?/M7=ZM_
MR!K[_KWD_P#0361?^&9[OQ7I.MPW\4":9#+#%;?9MP99  V3N']T8P/SK9U*
MVEO-.N+6&9(7FC9!(T>\+D8SC(S^= 'C^E:!JOC/X+^'/#]K:);V\GER37\T
MJXC17)RBC+%NW.![UT^OZ9XH\/>*+WQ1X62'58;J.)-1TJ5]LC&-<*T;=FVG
MH?7H<C'3^$M ?POX:L]%:\%W':+LCD\KRR5R3R,GGGVIC:+JUOK&H7^G:Q%&
MEZR.UM<VIEC0JBIE=KJ<G:,\XZ<=Z .(\1:_IGB7X)^)K_3+>:V8[UN[:9=L
MD,^Y2ZL/7G/XUZ5I/.C6)_Z=X_\ T$5C67@NPAT'5M,O7:[.L2RS7\NW9YCR
M#!*@?=    YQCJ3S4=GX>\06FE1:1_PDD36448A686.+KRP, ;_,V[L<;MGO
MC- &#_PD,WAWP'X0GD-U!I4EI$M[>VT(E:W7R@4)!#84GJ<'&/>NR\-WC7^A
M073:C!J(D:0I=0 !9$WMLZ< A=H/N#4<^C7,7]FII%Y'9P64+0?9Y(#+')&0
MH (W*1C:,'-+X:\/6_AK2WLK=@PDN);A]J;$#NQ8A5YVJ,X R< =Z .8NO%M
MQ'XNN-%O-2?2+O[9$+"*X@7[/>6_R;MLA7ESEQ@,,' P>:=>Z[XBUC^W3X=C
MN!-IMRUK;(B0&*:5%4L)3(P8 EL?+C YR<X&EJ_@^?7+:YT_4-2BFTV:[%RJ
M-:_OH<,&VI)OP.1UVY )]L5[CP1J$'B2]U70?$D^E0ZBP>]M1;),KN!C>A;[
MC$#DX- &=#)K%W\5M)%W=S6;MX?:XELEV.D+F6(.@.#G)'WLYXX-=/XT25_!
M6M>3<- RV4S%E4$D"-N.?6J\_A(_\)+IFL6.I2VS6=F;&2,QB0RPEE;&XGAL
MJ.>:UM;T^35M$O=.CN%MS=0O 93'OVAE*D@9'.#0!P^CZO>:5X9\#:-#>%KG
M6H(DCFDC7%O$EN'?: ,$X  SGDY.<8-R?Q!K.E^)-6\.RW4=Q(-*;4["\EA&
MY0K;6215VAN<$$8X/.:N3^!S/X>T.Q.I;+_0S&UC?1P8*[%"X="QW!@,,,C/
MM5MO"\T]S?ZC=WL,FJ75E]A29+<K'#%DDA4WDDDG));L/2@#@M;O?%6H_!NZ
M\0W>OHD=UI$;FWM[548,Q&X[_1E)R !CL?7<\16]\GC?P'#%>A[HB_ N)H@=
MN8!SM7 .!TK:_P"$*67X<'P=<WY>+[*+5+E(MK!1C:2N3DC [C/M2R>%+^XU
MGP_JESK233Z0)>MH )C(NQNC?* !QUYZYH 3P7JVI7L^O:;JMREW/I=^;=+E
M8A&9$**ZY4<9&XCBG76KW\'Q)L-&6<&QNM.FN&0HN5=&100<9Q\QX.:M:!X=
MFT75=:OI+Y+C^U+@7#((-GEL%"X!W'(PHJ/7/#-SJ/B#3=;T[5!87MG') Q:
MW$RRQ/@D8R,$%00?T- '(W_C#Q#;^!_$>I0W<!NM,UQ[&-Y( =T0EC09QP&^
M<G.#]*VEUS5]&\=/IVK7\5WI\VE2WXV6XC,#1NH(7DDJ0W<DY%0R_#>:3PYK
M.C?V](8]4U$W[R26RED/F*^!@C)RBY/3K@"MFY\+RWOBNVUNXO876*Q>R>V%
ML=LB.06.=_'('X>M '#^*[W5-?\ A7::_->^7%>W5I,;%8U*)$TZ; &QNWCY
M23G!YX'&.EU'6];U35-=L-#6YCDTO9%&\*0,))FC$GS^:P.WYE&% /!.?2FW
MPTOO^$7?PS'XF<:.DR2VJ/9JTT*K() A?=A@".. >G) Q6C?^"M0'B277-#\
M23:7<W<:1WZ&U29+@H,*^TX"MCC/Z=<@&;=:UXQEUOPQI4DEII5UJEC</=1F
M$3>1+&J\@[B&&6R!D8[D]*[:*WOAHB6]Q?9OA $DNXH@N7QRX4Y YYQR*QI?
M"4K>(M$U6+4B!I44L0CEAWM-YH&]F?<.25!X'7-=.1D8H \35KV?X$:-=W%X
M]S-<7MI(/- X8W0)Y R<DY).:[(>(=5T'Q?JNGZM>QW]G%HS:LA2W$31;'*L
M@P3D$<C))]Z9'\.;B+P;;^&EUXM:VMQ'+ SV@)54D\Q5.&&3G@GN , =]B?P
MHUWXM?6[J\BECDTUM-EM/LY >-FW$[M_!S[=/SH R+'5/&%W+H.HV]I-/9WI
M1K^&3[.L4,3KD/$P?>=N1PV<CL*WO''_ "('B/\ [!ES_P"BFK*\.^"=2T$P
M63^*+J[T.U8-:V+VZ*Z '*JTH^9E4XP,#H!TXKH/$&ER:WH%]I4=RML+R!X'
ME,>_:K*5.!D<X- 'G4/A_5?&'@?P'81VBV=E9)97LU[+*I8B.(8$:KDY.>IQ
MCWK0\5^*=:T*UUB_6^B\ZQO(A#901"6,V[,@_?MMRCMN8@;AT& :[7P]I4FA
M^'[#2I+E;D64"6Z2B/861%"C(R><"N4U#X;W%[I_B#34\0RQ6&K7AO?*^RJS
M12EE8Y8G++E1@<$<<^H!)JU_XGNOB#<>'=,U6ULH&T@7D4K6GF-&_F[.06^;
MI[#!/&>:A\+QZK)X]\91RZQ),UL]K&GF0J4^:#<!M&" "QP 1GN2<FMRW\,W
M<7C)/$4NJK,XL!8/$UMC<N_?NW!N#N]L8_.G6OAF>Q\5ZMK=KJ91-2$;2VKP
M!@)(X_+5MV0=N,'''(Z]J .:T+QIJE_X2\+FXEB_M76[V:V:<1@+&J-(68+T
MSM0  ]R"<]#L:A+XHT;1?$]S)?6L\5K;M<:;<2Q RG;&6=9%4*O##@CL>15)
M?AJ!X,L-"_MB1+K3+HW=CJ$4(5XI"S-DJ20P^<C'&1BM;_A&=2N/#^I66I:Z
M;R^O[=K9[HVH1(T((PD:G@_,3DDY..P H P9O$7B.:7P)!:7EI&=<M&>Y>6W
MW$.+</N&"!C)SM&.G7%,M/$7BFSF\5:#=W>GW.IZ9#%<V>H3H((FBDSDR <#
M;@_7%5M<LY-'\3?#?2(]4MUN;,7$*321<,JVX4;DW=P,<$<GBM_5/ 2:QINM
M)=:BRZCJK0E[N*+"Q"$@QJJ$GY00202<ECTXP 5])\0:E<>,-1T.*_>YMQI:
M7MM<W=IL97+LAX 3<AP"#@?4BL+3O%GBA_"GA/Q+<ZC;/'J%]#:W-HMJ &62
M0INW9R&'!&,#USU/4V_A'4HO$_\ ;\OB RW;Z?\ 8I$-FHC;#%@0 <@9/3)/
MOCBJ<?P^GB\(:+X>36$\O2KN.YCF-IRYC?>H(W^IY_I0 WP^+Z3XJ^+5EU.>
M2&WCL@L+*FW:R2,%'&0 23QR<\YK<UL76A>']7U#2;:6\U)P9MN-SN>!P!C.
MU1PO?'J22VV\,RVGC&^UZ'4F6._BA2YM?)&':,$*0Q.0,-R/UK4U:SN+_39+
M>UO&LYRR,DZIOV%6#=,C(.,$>] &%X.\06_B%KRXLM<_M&T18U$4T2QW%O)E
M]ZR*%7'\...QZUU58.E^&Q9^(KS7KF:&2_NK>.W<V\'DH54DY(+,2QSC)/0
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M;O,&TC !WG'IQ5Q/"<UAKE_J>C:H;,ZBJ_;(I(!*K.HP)4Y&U\=>H/<5TU%
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M6!!(['_ZU71X<:WFMI;#4[NV,,#0LK;95FW-N+/N&2^<G.1U/7-;M(2 "2<
M=2: .5/@'3H[+0[>RN[RR;1I))+>:$IO/F B0-N4CYMQZ 8[8JVGA2.+7]2U
MB/4KU9[^W2V=/W95%3.TKE<Y&X\DGK52V\=VMW(98=-OY--*1.E\BH599'=
M^S=O"93KCOD@#DZ=]XBAM-3;3;>TNK^]2#[1+#;!,QQYP"Q9E&20< ')P>*
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M%W-H@F,PL) F#E]^PL%W%-QS@GGH21Q2ZOX%AU#Q"==L-7U+2+Z6-8KEK)U
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MGJ-@Y>UO[5@LJ$C#=L$-CD8K1T;2!I%HT;7ES>W$C;YKJZ8&20XQV    P
M!^.364WC2!K.YU"VTK4KO3+=I%>]@2-E;82'*J7#L 01D+VXR.:W8+^">VLY
MMX07:@Q*YP6)4OCZX!/X&@#)NO"\;^(FUZPO9["_EA$%P8E5DG0?=W*P/S+V
M8?3D56U'P+I]_P"$9/#:W5W;VDTGFSRQ%#+*Y?S"S,RD9+<G 'IP*ZBB@".%
M'CA5))6E8#EV !;\@!7)0?#VTM-5NY[35=2M]-O9C<7.EQR*())#][MN"MW
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M>TN+B)IHX3Y)7Y"[!03DCC)'3- &U1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>;ZWX@N-*\375OKLVHZ;:S747]F:
MI Q-H$PF8I .%8L'!+#^+@@ 5Z17.WWA"WU%+ZVNM0O9-/O9A-/9L4,9((.
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M8RM8R6^ T!5=O&0005)!!!!!J?2M%MM):[EC>2:ZO)?-N;F4@O*P 49P
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M')XKUJTF-Q9P3, #)&KD#W&:\X_L<'1-:TEM#\7FVUBXDN+HEK'=N?&_:=_
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MN6E5III$(*EBRD8!5>  .* *.G3:AIGQ2DT:35;N]L[K2#>E;DJ?+E68)\F
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M.ISCKWZ4 ='H7B-=<U#6+,64UL^F7(MW\UE)<E0V1M) &".];E>22V=Q-/\
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M:_@N$F598I6R6((7&#N.00>M3Q^ M&C36XV>]ECUF/9=I+<LP/RA2PS_ !$
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M.LPUX?W0P1L& /EPQ'][WKLJ* ,;2/#=OHVI:E?075U+)J,@EN%E92I<  $
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MU,H8-!,,/&RL593]"#6C0!B:%X7L_#MQ?26%Q="&\G:X>V9E,2.QR2@"C;]
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M5+H[D/"KL7;\G&%X_P#K\U2N_AUH]WHNE:<;G4(7TD8L;V"<1W$"XQ@.!TP
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M,WEK^\8L>IX^7IR<UO$VFW3V_@-=8OVN]075XK:XGM;B2-'*I*"P"D -D<D
M'J.G%=7K7@72-;UF/5WEO[+4%C\IY["Z:!I8_P"ZY7J/U]ZLZAX2T[4%TM&:
MXACTN19;2.&3:J.H(#'@YX)'.1S0!S<SW^O^(_$6@VTLB)I<4$,!&IS02)OB
MW^:2JDN<G&6)^Y[G-&\M]<;Q!X*TC4/$5RTMU;WL-_)83%%E:)  PXX;DY/4
M'.,<5U&M>!-)UO5H=6DFO[348XQ"UU8W30/*G]URO4?E5J3PEIKZEI-\C7$,
MFE(R6BQR85 P ;((^;( SG/YT <>=$NY_B!-X9;Q+KRV,>@PRAUO")?,\YEW
M;L=<*,G'/?C(I8UUSQA:Z[_9]\;6]L]2FL[:<:C+']G\I@%W1*NU]P&X[LYW
M>@&.U7P[:+XG?Q")KG[<]N+8_.-AB!+!=N/4DYZ^]9E[\/=$O=>FU<-?6TUS
MC[7%:7;Q176./WBJ?FX^F>] &=I5]/XE\9:MI5_>2"'2K*TPME</$L\DR%WE
M#*02!@!><#D]:?\ "6,Q>!5C+M(4OKM2[G);$[\GWK8U#P=IE]K<.L1R7=C?
MQQ>0TME,8O-B[(X'! [=QZU:\/>'+#PQ8/9:=Y_DO*TI\Z9I#N8DG&3QR>U
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M=FX<C<0!D=L^M4_(?2?BA!I%EYG]DZIIDLMS:!SLB=& $BC/R;@VTXQGKUH
MTXO$VIZC<R2:-I45Y8V^I-87!:XV2C:0KR*",$*<\9R0.*NZIX@DM==M-#T^
MUCN=2N(7N=LTWE1QQ*0I8L%8DDL   >_3%<[\+M/MK>QUN>-&$@UJ]B!+L?E
M$O P3CMUZU>\7^%;+Q5?VPM]2N-+\06$?G6EY;G#(K$@@C^)<CD?X\@$MWXK
MU*RTK7[BXT-8[G1[;[08S=92==K,2CA<XPI'*@YR,#K6]I%\VIZ+87[($:ZM
MXYB@.0I90<?K7FS:YKTGAKQQX;\3Q6TFJ:?HTLBWUL,)<Q-%)M)'8@@\<=3Q
MZNLK0:1JGPYO+6XNO-U" P76^X=EE3[+N *D[0 0", 4 >J45Y!J=TPMM/UC
M3+FXN0_B6.,ZI+*4>56G*-$BC.8@,IS@';D#O6O9:)#K7Q)\6VMY>ZB;>U.G
MSPQ)>R*$<J[<?-TR#\O3D\=, 'I%%>3Z3;:CXO\ "5OXACUJWT_48KEYY;O$
MC/ 4D.Z%EW ;-HQMQC&#@DY-C5KRXT;Q%-<:]92SZ3/J<3VNMV4I8VN'4""5
M,Y5-RE3C@[N1F@#U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE]0^'GAK5
M=2GU"\L[F2ZG(,D@O[A<XZ<!P !V X%=110!B+X2T5+;2K9+1DATJ;S[11,_
MR/SR3G+?>/WLYS6W110 4444 %%%% !1110!!>R7,5I(]G;I<7  V1/+Y8;G
MNV#CCVKF;]-<U-[1[SPII\S6<ZW,!;5#\D@! 8?NO<UUM% ',7<_B&_LYK2[
M\*Z=/;S(4DB?4\JRG@@CRJP='\*3Z%;W,%CX.M5CN(F@82:Y))MC;JBED.T'
MVQT'H*]%HH XFQT_6-/N8+B+PS!)+;Q&&!KC7))3$AQD+NC.,[1SUX'-4!X3
ME70[C11X-M1IUP^^2 :],!]XM@?)E5W$G:,#)Z5Z+10!Q!TS5FUBWU9O"\)O
MK>$P1RG7Y<B,]1C9@YP,Y':L36?#VK1:!=65IX+BGM;N]6\O8$UMWDF.[<Q0
MN!M8L%R0<XSCG!'J5% 'DWAG3/$%MJ,.H:;X4U+2TB<B6#4/$#R).A5AMV$/
MC#%3GCI[UU.KV^M:[9"TU'PI8S1*ZRH1J[*T;KRK*RQ JP]0<UV%% '&V=MK
MEB;AXO#5NTUPH6:>36W:5P,X&\QY &3@# &3ZFFZ'8ZOX<LC9Z7X6MH;?<7\
MMM;DD ).21OC.,DDUVE% '#7VE:IJ6M6FL77A:!K^S#"WE77I4\K<,-A50#D
M<'CFKVI'7]6T^:POO"UA-:SKMDC.JD!AZ'$5=710!P<>BZJD]M))X;2X6U<2
M6\5SK\LL<3#HP5D(R.Q.<=L5-JVGZOK-Q;7-UX7M5N[7/D7,&M/%+'GJ RQ@
MX/<'@^E=M10!QNG6NN:9-+/#X;@EN90%>>XUMYI"HZ+N:,X'L,"JUOHVIVTD
M+)X7@9(9S<Q0R:[(\:2DD[PK1D Y)([ G(Q7=T4 <=K5KK/B'3'T[5/"EC/;
M.RMM&KLI# Y!#+&""#W!K.C\,W,5W-=IX0M_M$]O]FEE.OS%Y$Y^\VS);!(W
M'YL'&:]"HH \_/AR\.GZ;8?\(E!]FTR59K.,>()AY3K]T@[,G&3C/3-,O/#-
MW?:G=:A)X3@CN+R/R[KR->EB6X7&!YBJ@#\>HKT.B@#DM*37=$TR#3M/\+64
M5K H2-#K#/M [9:,FJ-OHNHVNKWNJQ>%8!>WJ!+F0Z_*WFJ!@ @IC@=..*[N
MB@#A+/1]4LC;^7X7@<6L30VZSZ[)*(488(7=&<<<9ZXXZ4[3])U739+1X/#$
M#?8T,=J)]<DE$"D8(7=&<<<9ZXX'%=S10!YI+X+::*ZAD\&VS07,_P!H: Z]
M+Y:R;@Y9%V80EASMQGITJQ=>%Y[V]N[NX\&VCR7D @N1_;DH290NT;U"89@.
MC$9'KFO0Z* . M_#][:W&F7$/A*W673(VBM&_MZ;]VI ##&S!R ,YSG I4\/
MW:VNJ6K>#K.6#5',EY'-K<DBRL<?-AD.#P.1CH/2N^HH X+1-"O_  ];36]A
MX1LRDR>7(;C6GF)3LF7C/R\GY>E0:%X5G\-WK76E^#;.&3YM@;6Y'2+=UV*T
M9"Y]A[=*]$HH Y'5HM:US3I+#4O">GW%LY!*G52""#D$$19!!Z$'(J*RM-<L
M)99H_#<$EQ+&(GN)];>238,X4,T9(')/&.>>M=G10!Q6BV&K^'XYTTWPM;Q)
M/*TTBOKDD@9V.6;YT/)I-0T_6-2U"/4)_#,"7D4?E1SP:Y)$Z*3D@%8QP3U!
MX.!7;44 <&-$U'[!J%F_A6WE341MO))-=D,LXQMPS^7NQC(QG !/%!T/4&.E
M$^%(2=*_X\O^)_-^ZXQ_<YXXYSQQ7>44 >:OX++Q31'P7:^5+<"Z\L:],%CE
MW;MT8"8C.>NW%:=AIFJZ9JUUJEIX5MH[NZ5$F;^W)&5U084;2FT8' P.*[>B
M@#SA?",B:_)K2>"K%+N2032!=:D$3R Y#F/R]I;/.<=>>O-7&T;4WEF9_"\#
M1S7'VJ6!M=D,3RA@P8H8\=0#C&,@<5W=% &=I^C65A?W^HP0F.[U%D>Z/FLP
M9E7:, G P/0#-:-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !116;JFKK83V=E$HEOKYREO$3@8499V/95'7W(
M'4T :5%(N=HW$%L<D# K,OM7&F:G9P7:*MK>R""&<'[LQ!(1A_M8.#Z\=QD
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MP!P ,DD=.M.T_4]6;7)-,U+3X(E6W\Z.Z@F+I+\V",%05([CGJ.: -NBBB@
MHJI'J5I+JL^F)*&NX(DFE0?P*Q8+GZ[33=,;4WMY#JL5K'-YSB,6SLRF//R$
MY ^;'6@"[1110 45%<SK:VLUPRNRQ(7*HN6( S@#N:XT^,==TS7M,M?$'AZ*
MSL-5G^SVUQ!=^<T4I!*I(-H&3@\J2!CO0!V]%%5+O4K2RN;.VGE"S7LIB@3N
M[!2Q_(*: +=%<YHOB"\U'Q=XBT:YMH(H]+^S&)XW+&02JS9.0,=!Q]>371T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M) QOXHS$DPE<%4/50 <8/I51/!VA1P20I9,J277VQMMQ(#Y_/[P'=D-SU'-
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M,\"10I-*EI<^+GLKR;S#N2V,[!LMG(!P%)ST->K2^']*GUH:Q)91G41%Y0N
M2&V\XZ'J,G!ZCM4,'A30[?2KO2TT^-K&[8O/!(S2*[$Y)(8GDGG/KS0!S-[8
M+HWQ/T.TTB(6]CJUG=+J%M;_ +N,",*4DPN-K9?;N&#S7$VNG00?"/2->1IC
MJEKJR^3<M,Q9 ;TH0,GH03D=\\U['9:!IVG[S;Q2^8\8A,LEQ))($'10[,6
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M>(=(\-:=X@:QL3J&A73:G/-!=N[RAR3<+M,8 4@G^+@*!SB@#UPG R>E("&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB%D&67<,K]?2A)8Y(Q(DBM&1D,IR/SH IQ:)ID.CG2$LH?[.*&/[,R[H]O\
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M\FMF65(8S))(B*/XG; 'XUSO@W7K[78];^WK;A[#59K*,VZD*R(%P3DGDY-
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MRBB61!&Y Y*CHN3S@9.!T&: /*O#/AG19O@Q=:K+IT$M]%9:BD<[KN95\R7
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M3_#^CZ3<2W&GZ9:6LTP DDBB"LP   )'..!6E0 4444 %%%% !1110 4444
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M^%6KS4K'3E1KZ]MK57.%,\JH&/H,GFI);RUA:-9;F&-I 2@9P"P R2/7 YH
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M5U!'3 (XJ:SL[73[2.TL[>*WMXAMCBA0(JCT ' IEK<[M+@NKAU4&%9)'8X
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M>;*L#\G[I"F<==QQZ&NTM=+T^QFDFL["UMY9?]8\,*HS_4@<T >5>&O^$?\
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M)I8K=5:3/7<0,G\: /,O#FC6P\%^+K_3-/MVUBTU#5!82I&#)"PW!1&>J]>
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M9KG0;C?.J]9+5_EE7\L'VP:WM'M[Q?#EU>A"FIZB)+LJW5'9<1H?]U0B_P#
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M*:TNZ20A57,,F,D]*A\-WD4WC[QC;:HT9>=+>6V\W&V6R\O VYZJ&+9[98T
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M?:E]@:(2VLN[RK<D-AU!POS8P",YSCH<><//8W'[,T2"2"2:VA@WC(+1-]H
MY]#P: /:;W4;'38A)?WEO:QL<!IY50$_4FD?4["*TCNY+ZV2VE($<S2J$?/3
M#9P<]JY".[>'XSW$.H$+'/I"#36;[K8<F55_VONDCK@#TKA]3L4B\%Z^"D9T
MO_A*H_[.SC:J&>,2>6>R[MXXXX- 'LUIJNG7\]Q!9W]K<S6[;9HX9E=HCZ,
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M7A&*[C22S;Q=LL?-&2;0M+L'/52.0.A!':NWT"."V^+?BF"W2.)&L+)V2,
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M?(4L6'4= <=<A_A'Q/%>W=YH-WK5KJ.IZ>_ER3QA8C.3N/"#J57;N(XSGTH
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M!O*^F>N/:J \2:$;>XN!K6G>1;/LGD^U)MB;T8YPI]C4YUC2U2V<ZE9A;O\
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MI,@'0,<<CZTDVD:;<3)-/IUI+*F-KO"K,N.F"1QT%/L-1LM4M5NK"[ANH&)
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M:=-#)%)86KQ22&5T:%2&<]6(QR?>LJ"Q\2M8BXGUB!-19-WV9;93:HV/N_\
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M_OK&:;%IMA#>R7L5E;1W<@P\ZQ*)''NV,FK5% !1110 4444 %%%% !1110
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MIJMJ/B1X;OKE!IT=YX9*PP3M@AVEB(B&?O,!QCK67.UI_8/Q;0&':LDQ"Y&
M?LP _'=G\:]<:&-Y$D>-&=,E&*@E<]<>E0_V?988?8[?#=?W0Y_2@#S=Q96V
MK_"QH/(CW)* 4P,AK4Y_-L?C61?3Z7/8^-/"DVOZ1#_:&K22?:+Z[6)X=Q0N
M"C<G85PI'!QV S7L'V"S^7_1(/E^[^[''.>.*XZV\+^(('EM[G_A'M2A>5Y!
M>WEHS3D,Q/S+T;&<##*, #B@#L[184LX1;LK0A!L92,,,=1CCFO._ NK:;:^
M)/';7&H6D(_M<MF295X" $\GID&N^TO38-*TFWTZ  PP1A "  1]!P/H.!3Q
MIUBI!6SMP1T(B7_"@#RZ22+6O%_B3QN;.:X\/6&A26$14%3?=7<QGJ5QE=PX
M[BHM-U:PD\:> 9H]3LFA;3[F&."V8&.W!CCV1;B2S/T')R<#Y1FO7\<8J".S
MM81&(K:%!&24"H!MSUQZ9H \=:]9/ /C.UM',EY;^(+BXN;6$@R_9Q<HS_+Z
M%,]1@C/6NOT&X\+Z]XHL]:TO6I]6U%+1HRR.N(H2<XD"J,?-C ;G.>.#CMUA
MC1W=(T5Y#EV"@%OKZTRWM+:T#"VMX80[;F$:!=Q]3CO0!R_C2TDO+W1EL-:7
M2]:CDEDL'E0/%,=N'C93URI[<C!(KC-3U/\ M;PWX775+"TM)E\7)!<1Q-N@
MF</)YCIGJK,3U[Y%>MW%I;7D?EW-O%.G]V5 P_(TC6-HZ(C6L#)&-J*8P0H]
M!Z4 >5>(DNG\2?$*UT0@7TNAVQ6.$_.Q'F X _BVG [\BKNLSVFN^'O DV@2
M1F[74+5[81$;HHU4B8$#D*%!##V ]*])2TMHY?-2WB60_P :H ?SI(;*UMYI
M)H;:&.67F1TC 9_J1UH \[UC3Y;3QKJNA10,UCXOM-VX+E894PD[>@)B8,,]
M6 '>K?P^:^OX([;5HV\SPZLFF,[CY9I0<;QG_IDL?/\ TT:N_**7#E06 (!Q
MR,]?Y4GE1X<;%P_+#'WN,<^M 'ALRV"? SQ#/&+=7&KR,)%QG(O!MY^G3VKV
M?5?M4NB7O]G,/M;6TGV=@?X]IVG\\5)_9]EMV_8[?:3G'E+C/Y5.B+&@1%"J
MHP%48 H \=N9(-6^ ^F6-@0-;A:V@@B!Q-'?)*H;CJ&SO8^Q)Z5T6EPV+_%O
MQ7YZ6S.NG6FXL%XR)-WZ8S^%=VME:I=-=+;0K<L,-,(P'(]SUH-C:,[.;6 L
MV=S&,9.>N: .1^$D@D^%NA%7#;8F7@YQAV&*I^(-'\)^.=1O[>[G6PUS2)?+
M2\@G$5Q$-H=7![K\W?(!!Z&N]A@AMU*PQ)&I.2$4 9_"N;N_#6K7K'S]9LI4
M#EE6728WVG\6Z^] 'GZZ]J\7A+PUJOB"=KS3=/UYH[B^5.)X%WI%<,!U7<0<
M]\*>36_XKN_#=]X,\;:GHLEO/+<Z=MN[V"3='(RH51-V=I8 ]!ZC/45TS:+X
MA>(Q-XC@:,C:4.F(01Z8W=*B7PYK26RVRZ[9K OW8AI484?0;L4 <W-]CM_%
MWPR^S^1&&M[I1LP,J;<'''O^M8FCW6A:MX9G\.^)M7O(]7M[Z3S],#(DTL_G
M%T:+Y=S;B0<@]^3BN^'AO605(URSRGW3_9,?'?CYJ<?#VN&[%T=>M#<@;1-_
M92;P/3.[.* .:TC6+*T\2>.[#7[B&"^EGWQ+<L%\VT\H+&%S]X#YL@=V/K7/
MZ)?V<'A;X5WTMU"EK;W+PS3,X"1N89 %8] <^M>BR^'M<GFCFFUZTDECSL=]
M*0LOT);BDD\.ZW+:BUDUZT>W  $3:4A08Z<;L4 <KI^J6%SXC^)SPW<+J]M;
MR(0X^9!:XW#U7/<<=/6LR#58])T+X:7][>RVFCC3F@FNX@I6"=HHPA;((' D
M7..,GWKOSH&ND2 Z_:D28+C^RT^;  &?FYX _*D/AW6S;-;'7K0P-]Z(Z4FT
M_4;L4 -\'6VB(^JWFA7DM[#>7/G3W7F!HI9L88H5 'ID@8S[@XH?%B6.+P0?
M,=4S?V>-QQTG0G]*U(M%\0P1+%#XCMXXU&%1-,0 #V :FS:#KUQCS_$%M+MZ
M;]+1L?FU &KJVO:5H=O!/JE]#:Q3S+!$\C8#.V<#/X&K-\I;3[E5!),3  =^
M#6.?#MQ>Z;)I^KW\-[;.5^5;-8]J@$%1R<9SC/4#.,9R.@H \16^T^[^"_@^
MW^TV\OEZAI\4Z;@0I\WE6]\ Y![5N>($F_X3[Q-;:.52^E\)'R4A(#&0/(%Q
MCO@@#\*]*-C9LH5K6 J"6 ,8QD]3^-.6SM4E$J6T*R#HX0 CMUH \U\-WOA3
MQ*/#,\.KW-SJEA@V]@K(LEJVT+('55!"  @YX.!C)(K6^+.C7VK>#5ETZ!KB
MYTZ\AOQ;H,M*$)W*!W."3CVKM(K.V@GDGBMX8Y9>9)$0!G^I[U-0!C:?XLT'
M4]*CU*VU2U-NZ@\R ,I_NE>H;MCKFN:N=0>W^+VE7&H*\&GW>C/#9&<;0MQY
MH9U]F*!??C%=HNFV"WAO%LK871ZS")=__?6,U+<6UO=PF&Y@BFB/)21 RG\#
M0!XKXGMEB\'_ !,N(RG]D3WT+6?389OW?G,G_ ^,CNI]*Z[6X-.'Q8\&HD=M
MC[%>!5 7& (RF![')'XUW;6EL\*0M;Q-$GW4* JOT':FBQM ZN+6#<N-I\L9
M&.F* /%==-L? 7Q-13$4CUP.%7'RY,&2/3D']:Z[6-.L/^%A>#KO0X8!)!%<
M23M:*,&T\O W;>H+$!?<G'>MOQKX7EU[PE>Z/I45E;S7>P&60% H5U;^%23]
MW';K7065I%;1EDM+>VED^:40 8+?7 S]2* /%X]<TF?3/ UW:W=I964>M@K8
M))N-HA$V?-=B6W$_0<D8.,UN6\6G2:I\4V9+8XC522!PIM1D>PR.?<5Z<+.U
M7.VVA&9/-.(Q]_\ O?7WI/L%G\W^B0?-][]V.><\\4 >:R6D\OPH\)>)=-7S
MM4T*QM[N/:<F6,1!9HL_[2;OQ KM/"N;RQFUR1&2359/M"*XPR0X"Q*?3Y &
M([%VJ+6='UB^N8[&PNK"TT*:)H[R,0-YYR>?+((497C)'&2>>,=$JJB!%4*J
MC  ' % '$>/=VB:CH?B^&*23^S[C[->)$N6>VFPIX'4J^P@?6L31++4]/\4W
MWA6\B)MM6E36G9!\D2DYGBSW'F*BX[JY->I,BNNUU##(.",].12;%WA]HW@8
M#8YQZ?I0!PX:!?CHRAHQ(WASD C)/VC_  KE1/"WPA^(165"#J6I<AAWDX_/
M(KUXVEL9C,;>(RGJY09].M-%A9!"@M( K$$CRQ@XZ=J (M(=9-%L71@RFWC(
M(.0?E%>:6<>F7-G\0[6ZO_L-L^M(IN(2,P,1$%?TP'QGZ&O5HXTB0)&BH@Z*
MHP!4*V-FH8+:P -PP$8Y^M 'FCW%Y/;>(]"\6W5LDD=M:_\ $^L!L#(TI$1D
M4\*RL2Q'3!/;K'?7.N2:%XVT768K2^OXM#+IJ=DI47,1678KIT5P=QP.H->G
MQ6%G!;M;PVD$<+')C2,!2?7 XIUM:6UG$8K6WB@C)R5B0*"?7 H \N?7M)NM
M<^&3P:C;2K&)5D9) 0C-:E0K'H"3Q@\U0TZZT'4]"U3PSXJU>[AU*/4)O/T[
M<B23N9C)&T7R[VSE<8/Z8KUZ&QL[<((+6"+825V1A=I/7&.F:<UG;/=+=-;P
MFX4;5E*#>!Z ]: (=01CHUT@#%C;N #R2=I_6O(;'5H4\!_#JZ6XCETNPNK=
M=3*-E8&V%4,GH%<@G/0[3Z5[542VT"PM"L,8B;.Y HVG/7(]Z .,BA,WQD-[
MISJUN-&V7[1G*LYDS$#CC=C<1WQ[&D^(T\-I=>#[JYE2&WBUZ(R2R,%5!Y4H
MR2>!7:6]K;V<(AMH(H(@<A(D"C\A3I8HYTV2QI(N0=KJ",CI0!P6FO87GQAU
MR5C!*/['M2I;!PI9\]>G!&?K7%Z'JJZ7X)^'NH75Y-;Z-#/=PW-S" P@D8NL
M3-D$ ?>7..-U>VFQM&=G-K 7;.YC&,G/7- LK40/ +:'R7^_'Y8VM]1WH YS
MP?!H7VW6-0T.^EOQ>RH]S=>8KQ22@$?(5 7(&-V/4=\UU5,AABMX5A@B2*)1
MA410H ]@*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7 Q7_ (@O_B'KN@P:V;>VLK2&> FU
MC<[GSD-P,@8]C[UWU>7V4>F:M\:/$]K-=L=VGVR!;>\>(L1G<,HP)QD<=LT
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MV^PUO>VXWE2#G(/+C(XY&<9Y[W1KAKO0]/N6M6M6FMHY#;OUB)4':?<=/PH
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M]CDT =>T4;1M&T:E&X*D<'\*5$2) D:JB*,!5& *YS0O&^E:UX6TO6S(8%U
M%8X,%Y#(N=Z*JC+$%6Z#H,TFM>.='TGPN==BG%U SB&+R@3ND+;=K<?+@]<]
M/KQ0!T2011ERD2*7.7*J!N/OZT\*J_=4#Z"LZ?7M,MK6*XEN<)*&:,+&S.P7
M[Q" ;L#N<<5:L+^TU2QBO;&YBN;69=T<L3!E8>QH F>-)4*2(KHW!5AD&A8T
M2,1JBA ,!0.!^%.KB;_4]6B^*^F:+%J<J:;<V$MU)"(HC\RM@ ,5SCGU[=:
M.U"JOW0!]!3);>&="DT,<B,<E74$'\ZPKCQUX6MHY9)==L@D4Q@D82;@KC&0
M<>FX9/09YK?WH8_,#+LQG=GC'KF@ $:! @10HX"XX%'EID'8N1[5@/X[\+1J
MK-KMEL:8P!A)E=X(&,C@#) STSWK4O\ 5K'361;J?;)("R1HC.[ =2%4$D#(
MR<8&10!:$48SB-!EMWW1U]?K3@B@Y"@'U J"QO[34[**\L;F*YMI1E)8F#*W
MXU6U/7M,T<$WUT(MJ>8P"LQ1/[S!0=J^YP* +WDQ>=YWEIYN-N_:-V/3-)Y$
M/G";RH_- P'VC</QK//B/1Q?65D+^%KB^3S+5%);SEQG<A'!&.<CH*G.KV"R
MW<3W2(UFH>XWY41J1D$D\8Q0!=(!&#R*8L4:A0L:@*,+@=!Z"LN'Q1HDWVL?
MVC#&UF@DN%GS$T:'HQ#@':?7I45KXR\.WM[:6=MJ]K)<7B;[=%;_ %@QGCWQ
MSCKB@#82"&)W>.)$9_O,J@%OK3RJM]X _45S^E>+]/U?Q+J>C6Y?S; HC,R,
M-[E2S8XZ 8Y[YXK7O=1M=/$9N9"K2MMC1$9W<XR=JJ"3P">!0!,]O!(5+PQL
M4.5+*#M/M4E<-XJ\1M&WA;4-+U<II]WJZVUQM"B.2,"3=DD9&"F#R.^:Z33O
M$NBZK;7=Q9:E;RPV9(N7W;1%@9RV<8&.<]* -6BLRQU_2]5N6M+.\!N/)$PC
M*%&,9X$BA@-RY_B&17 C7=<_X5GXQO\ ^U[C[?IM_>QP7.R/=LB;"C&W;T]
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MF] ,BO;) 2A*JI< E=W3-<_X-\/7/AK0#IEW/#<XGEE#QH5!\QV<@@YZ%L4
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M4Y!^4=ZOT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)91]H+"&+[/)YLA'7$>W><8STZ<US_Q6AEN/ACK:0Q/(_EHVU%).!(I)P/0
MFLV\U:*W^)6D>(YI2/#]YI4EE#=R*5CBF\T/EB<;0ZJ ">#B@#N-,U6QUBT^
MU:?<I/$',;%<@HPX*L#RK#N" :R+WQ?9V?C&U\.-%<&>:V>=I%@=E7#*J@$
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MXGTBUA\Z6XDV" 7#%;>1O+B.<.^%.P'!Y;'0^AK51UDC5U.58 @^U>:^,_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'.LK0.L#(LI
M&%9U+ 'W (S^=244 8/@WP_-X5\*V6B2W:7?V12BS)$8]P))Y&X\\^M;U%%
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M-,4!P6('"_B<#\: -*BN/\+Z;=ZWX>LM9UR_OGOK^%;GR[>[D@B@5QN5%1&
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MVM?V/*;I[\VYN5AAM9',B @?)@?,<GMG&#G&* &?\(F?^A@U[_P,_P#L:/\
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MZ1[6:3<1C[H(&#SN&.]>HZG9OJ&EW5FDPA-Q$T1DV[MH88) R.<&J_A[2/[
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M!2=N =JDX/(Z'!XKOJ* /._"FAIK7A/Q3HVIV=U;PWVJWK 7%N\1*2.2CKN
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M 4.&XPV,9'H0+5@FK:#X\FU?5K*>2VU?3+9)9+.%YA;7$0.Z,J@)"G<2#TH
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M<_M?PI=ZUI^K21SVMU:V8N2C"-8VB<?PCY1@GCFIM=T*WGFLQ%9ZEX?U*TL
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M#[2L4T-K'N9(MC?,!Z A>/P')H P_#G]DZS=V>L>&=<N+G3!&Z7%J;R20!F
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M,#AT\LG<.O*DX[XK';Q=;:-H?A"+1[*^NK+5'BAAED.YUCV%L$LV2Y"_SYZ
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M@)@C&6P,?AF+58[G0O'-QJ6K>&9]9T[4[.!/,L;7[0;6:,,"NWJ$.[.?_KT
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MPB>)"C1L$!(SU!QCWS7.ZIX>U*R^$FNVB6%W)>ZKJ;WL-E#"TCQ(]PKA2%R
M0BY/N2* ._T/1;2RN[G4K5;^V%VBJ]G<2DHK*3\X4DX8]SGG [UNTR&59X5E
M0.%89 ="A_$$ BGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 445AMXHMOM$B0V=Y/!'>+8R7,00HDI95P1NW8!8
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MWT'5-5:UU"+^RI-E_:2PJL]OGH64MR#VP36S<>([2UUW3](EAN!-?PR36[A
M481@%AP<@@,.W>@#8HKD+7XBZ9>/)]GTW698HIIH)IDLF9(7B!+!\'(SC X^
MN,BH8/B?H<W]E2M:ZG#8ZFRQP7TMMM@$C=$9L\'MQD=>>#@ [6BL*^\46UK-
M?1P6=Y?G3U!O#:(K>3D;L'<P+-MYPN3@CU%*OBK3KF/3FT[S-0;48&N+9+<J
M"T:[=S?.R@8+J,9SD].#@ W**QE\26TEI9R16MV]S>;_ ";/:JS'8</D%@J@
M<9)(Z@=2!5.T\;Z7>61EBCN1<K?'3VLG55F6X&24.6V] 3G=C ZT =+15'3-
M2&I)<?Z+<6TEO,89(YPH8-M5LC:2",,.<U7O-?AMM0DT^VM+J_O(81/+#:A,
MQH20I)=E&3@X&<G!XH UJ*X#QEXT$GPMOM=\/-._FQ^6LZ (ULQ<(VX,058$
MD< D'\ZZ'0]#LK&\N-3M+.[T][I%26TDD&S*DX?:K%=Q[G//?G- &]17G%WX
MFN_$?A7QU%-I]Y9)IPNH89%E52AC@4X)1\[MQ)XR,8&:T/"GBZS33_#&CSVU
M]'+>6$2V]U)#B&9TB#,H;.<X!.2,''!- ';T5R-CKWAZSU#Q7?(MW!+9/&VI
M/.&P2(_EV*3Q\N.@&<CK6Y8ZN;R^FLY-/N[2:*))?WX0JRL2!@HS G*G(^GK
M0!I45Y_\4V:"/PQ(EW<VPGUZUM9V@N7AWPMNW*2I'''6JFGWU]9_%6[T30K^
M>_TO^RS//%<7#7"6EQN(0!V)(W#'RY[DT >ET5X_X<O].\2:--HMWJ6H:7XZ
MC1EN%N+J2*5YNORC.UHS_= X'0#@UT'B57'Q:\(6ZW-VEO=Q7C7$,=RZQR%(
MP4RH.#@F@#T"BN=\66XF723YL\9.HP(?)G>/<I/*G:1D'T-;5Y=V^F:?/>74
MGEVUM$TLKG)VHHR3Z]!0!8HKG;#QA:7VH6UC]BO8)[NS-[:"94Q/&,9VD,<'
MYEX;'6JC?$+3$\-2:^UEJ LHKHVLP,:!XG#[#N&_@;CC_P"MS0!UM%95WK]M
M8730W4,\:1V;WDTV%*0QKUW8.<_0'.#CH:I:?XQLKZ_L[-K2]MI+ZT-Y:&9%
M(GC&"=NUF(.&4X(!YH Z*BN4TSQ]INKW0BM;'5/*$\T$UR]KMAMWB!+>8V?E
MZ'&?QQD5SOC+7DU4^#[JUMM2BMKC7K0P71.R*>,MGE0V<$8(W*.!Q0!Z;116
M;?ZS%8WUO8)!-=7EQ&\J00E VQ"H9LNRC +J.N>?8X -*BL9?$EM):64D5K=
MR7%X',-F%59B$X<D,P50.,DD<D#J0*RI?B/HD&C2:E+'>HL-[]@N(3#F2WFW
M!=KX.!U'()![9H ZZJNI6;:AIMS9I=W%HTT903V[;9(\]U/8US__  G=HEU9
MP7&CZQ:F\O#90-<VRQAI ,CJW0CD'O@CJ,5?U76K.--6M+JUO&@M;3S;B2%<
M@HP887:=V[ ;L,=<C(H LZ+HT6B6)@2XN+J5V\R:YN7WRS/@#<QX[ #@< "M
M*N:TK7-)M/#.@#3H;IXKZW3^S[3.Z9T"!N2S8X7J2V/?)&9+/QEIEY97,ZI<
MQS6UX;"2TD0>:+C(P@ )!SD'(.,<Y !P =#17-+XXTM'U6&]CN;&ZTN-9;BW
MN%7>4;[K*59E8$\<'KP<5J6&K&]OKFSDL+NTF@CCD(G"897+ ;2C,#RASZ<>
MM &C16/?>(K;3_$.G:+-;W/GZ@'-O*JKY9*#<P)+9! YQCGMWJK:>,;*[M-:
MN!:7D8T9WCNDD5 VY5W':-W/!!!Z'MF@#HJ*Y:34M)E\;Z;#-9ZA'K)T^62$
M-E46/*EE/S;2V=OKCUKE=9\37?B;X;>,IIK&\L?L37,43+*J[3%A=I*/DMG)
M(^[VR: /4Z*Y31/%MG)=Z5HDMK?03W-GYEM/-#MBN-BKO"'.<@'/(&1R,U/X
M[\17'A7PA?:M:VCW$T2A5P5"QEB%#-DC(!(X&2?U !TE%>=^(+]K;XC^$;U[
M;4(S-;WP:SW;V8JJ!<(K%<\GG/0\D8XZ/3O&6F:AH]SJ'EW5N;:Z-E-;3QXF
M6?( CV@D$DLN,$@Y% '0T5B:=XGM;_7+G1);:ZLM3@A6X-O<A,O$3@.I1F!&
M>.N0:Q?&NMWB^(/#OA33KA[6?6)9&GN8_OQ01KN<*>S-T![<^U ':T5S>H^$
M8'TUX]*N;NRNQADF6ZD)<@@XDR3N!Q@DY/-6;WQ+!;75Y;6UE>:A+8HKW2VB
MJ?*##(!W,,L1SM7)QCCD9 -NBN9G\>:)%;:-<Q/<7-OK#[+26W@9U)P3@^AX
M(V]<CI4$?CZTE?4;>/1]9;4-/*^?8BV4RA6&X./FV[2,X^;/M0!UM%<K+\0=
M#BL-%O5^URP:Q_QZF*W9LG:3M/\ M<$;1DY[4EC\0=&NK?6)+F.\TZ72$\V\
MM[V'9*B8R& !.0<<8_J* .KHK LO%EK=ZH=-DL[VUNS9_;HXYD5C+#G!*[&;
MD$@8.#R.*RX/B9H]Q866H+9ZH+"YN?LQNFML1POYAC&\YR 6'8'&1G% '9T5
MC6WB6VN?%-UX>^S745Y;PBX9I%4(\9. RG=DC/'3COBK6E:I'J]O+/%!-$D<
M\D&90OSE&*L1@GC((S[4 7Z*PY_%%M%<7*16=W<Q6MREK<30!"L<C;>""P8X
MWJ20"!GV..1M-8&@_$3QPYMM2OU6&QE$%N#*RC9*6(W, H]LCV% 'I5%<^/&
M.F2VVC2V:SW;ZRADLH8E4.ZJNYB=Q 7 QG)ZG%<OX]URU\0_!_6]1L7NH&@)
MB9"QCDCE20*R-M.#WXR0: /2**X?7P8_BEX*99)0)8[X.GF-L.V)<';G&>3S
MCO7<4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5YCJ.CWB^(9=7\.V^J:9K;:BJ7-OY;FROH1
M( 97)&P'R^<@AL@\$D&O3J* /+;>UGT'Q#K>GZGX*FUN&_OI+NRO8+:.5"LI
MR8Y6<C9M.1D]OUV;2TNK?XJ6]RVGR1VB: MD98(&$"S"7=L4XX&.AZ=NM=S1
M0!P_BO0=3D\6Z9JFC*1]NA?2]393@I P+K*/]I2& /JP%/\ &EG,U]X12RL;
MB6&RU6.>7R(698HEC=<\#L6''6NUHH \ZTRYUGPCXDU_3YO#VHZE:ZG?O?V5
MU9JK)F0 -'(20$P5ZGM^%0ZM;7VB>-I=6U'PP^O:?J5G!'(;*W6=[6>/<" K
M<[&W=?:O2Z* //-9T*QU&TTFWO-"O=)*+-/:W.D1D2Z>Y9<*?*!Y8')P"N5/
ML:UO#NHZ[8:%H5MK=C=WM_=2R137$42@1("Q2249^4E0N?<GO76T4 %<''#=
M?\+KEU,V-X+ Z*+(7/D-L,PFWXSCICOT]Z[RB@#C/'>AWD^E:3<Z-:^=)I.J
MQ:B;1" 9U!;>JYXW?.2*;+;/K?CO2?$,=M>066E64X=IK9XWEDEV@($(#':
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MX_\ !M_#97CVMM'=_:)?L[XB\R-53=QQD@_3OBNVHHH **** "BBB@ HHHH
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MGUXKCDTK58_ ?@.P.E7GVO3-1M);R(1\Q)'NW-Z'J.F<UHZ3+K_A/7]=T_\
MX1Z\U.TU*_DO[&[MF0(IDQN24L1L"D=<'CL: +%\\;_%OP]=P&1UGTFZ<#<?
MF&8]N 3@=?:M&3Q]IT7A;4?$#65_]ETZYDMKF,+'YB,C;6.-^",^AJM>VFH-
M\3- OGM)9(+?3YX+BYBC/EK(Y0@>N/E/TXS7):EI6O+X+\9^&H=!O9KF[U"X
MN;>==OE21R2!UPV<ENV,<=\4 >DWVNPQ:@FEV]M<7E[) 9VA@*J8XLX#,S,
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MR2-9 Q']\# (QCT^8=\<<UGQO-I6O?#"*ZLKI9K;2KJ">)8RSQLL,*M\HY8
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M^\J@)%Y/+;'SA]Q&!MSP<G%,BL=0"_$3.FW8_M,L;+]U_KOW CX]/F'?''-
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MBU]M4O$@&];>-_,XST.W>HP,YP<4 >D:3J;ZII:7K:=>V3L6!MKM DHVDCD
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M\<XR0#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8;LYRK#C/3WH ["BN:B\6F1(89-(N[;4I1(PLKEXT941MN]FW%<$D8P3G/'
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M[UPQ'.TD8.,CGH:S-/\ %2ZFUG+::?/+8WDTL,5TCH0"@<DL,Y4'80/J,XH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMM+))M"O&X)&.@P>F.I%=Q10!Y99^$M6T.W\%6Z6$ERUC?SWM\T#IMA\T/\
M*-Q!."X' [9KU.BB@#R?_A$_$%UX(U/14L&M[ZTU>34+2665/*NB)S(@&"2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<",=!\O)Y^E./C_4O#MWX@L?%=O:-/IMB-1MY; ,J7$1;8%PQ)5M^%Z]_;D
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M6\S(#A9  2N3UX8=*=-JUC;ZM;:5+.%O;J-Y(8MI^=4QN.<8&,CJ:Y'X9"Y
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M&6!X3!.X@%LD=A5=?"&JC3O&%J9[//B!Y71@6_<;XQ'@\?-@#/:NF&NZ<WB
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M/F^8TI+>1P>#C8"W0;6/3FO0+RV6\LI[5V*K-&T9(Z@$8_K0!Y)<2:A)\,O
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MIMAI"Z@#%"5?[S!LDL<\(>F.M9M]XNUK3/ ^G^-I7@DLI1#/=6"Q_P"K@E(
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MZ?X<AF15U#6;1[US;6Q!AB4)\H5W.6S(/F)Q@'Y: .^JD^JVR:U'I)\W[5)
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MZUX<_L"_OYX+NSU*YBM+N)(=GD/*/E:,YR5!X(;).>M+X8_Y*=X[^MA_Z(-
M';4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M54Y#C/#'/ YZ8Z4 8^G^--0UG3/"\,,,BWNK6#WEPUJ(]R!-@.P2$+RS]\X
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MCKZ@$NL:EXEN/'[>'M+U.TLX)=(:\CE>T\QHW$JKSEOF_08)X)Q5?PRFKO\
M$7Q='<:PTS6T=F@#0KL^:)V "CD*&8G .3GDUMP^&+V/QC;^(9=625XK V+Q
M&UQO4N'+9#<'(XXZ>O6I(/#-Q9^+]3UVUU,I'J,<0FM6@##?&I56W9SC!Y'4
MD=10!S>C^-=4N?"&AR7,D#:KJVJRV F$>$C"R298+GG"1X SU(SGFMRY;Q/I
M5EXAEDO;6>V@MO.TZXFB!E#!"7615"J1D#!&.O.:S5^&P/@V#0I-8<7%I>M?
MV5_#!L>"8NSYVEB&&788XX_.M>'P[JLFC7]OJ>O?;;^[MVMQ<&U$<<2$$';&
MK=3G));G [#% '.MXG\1S6'@)K6ZLUEUV$?:6EMR?G,!?<,$<9YV@#.,9%.M
M?$'BFPU+Q+X?O+BPOM1LK);[3[V5!;QNC9!$H!P-I'KSBJ.NZ=)H-[\.-%35
M+?S[.X>&.>2+ *K 5&Y-W?@'!'7C%=%JO@--<L-<6_U _;]6BCA:YABVK#'&
M=R*JDG(W9)R><GIQ@ K:/XAU&X\:RZ%%J!N[:32!>PW5Q:[=L@D"';M";XSD
M$']36%8>+?%+^"_#OBBYU"T9+F_CMKFT2U $B/.8R=V<@CC&/3G-=3;^$=4C
M\3P>()_$(FO4L&LI%^Q*L;C>'! #9 R.1DD]B*I1_#RYB\$Z;X:76H_+L;I+
ME9S9G<VV3S "/,Q]X]?2@ T8:A)\6_$R2:G,\$%K9E(2B[0K>:=HXXP<G/4Y
MYK2\>:IJ6@Z+#K%C/LMK6YB-^GEAR;<L [+GHR@Y],9XJ>'PS/;^,KG7X=3*
M+>6\45U;" $.8]VTAB?E'S'(P?K6U?V4&I:=<V%TF^WN8FAD7U5A@_H: .-7
MQ9+9_$'4M+OM0SI:V!NK9Q$H"LH#2H6Q\Q5&1ACLW.:74=7\0Z3_ ,(>EQ=1
M%]2OD@O4: ;AN1GV@@X&-N.F3UR.E3K\.[ Z-X=L);F6231IUG-P?O7!VD.K
M<_=;(R.> !TK2\1^'9]=O=&N([Y+8:9>"[56@,GF,%*X)W# PQH P- &H2?$
M?QHL^IS2PVPM56)D7&QH68*.. "QZ=>^:YOPGJFMZ%X \#7L5[ ;"ZNH+"2R
M\C)*2NR[]^<[@><  =N>I[Y/"US;>*=7UFSU7REU..,2V[VX<!XT**V[<#C!
MY''(Z]JRH_A]<1>$M"T!-9CV:1>174<QLSF0QMN52/,]3R?Y4 ='XJ>YB\)Z
MM+9W3VMQ':2R),@!92JD\9X[5YS=QWB^ /AJWVH332:CIK1M,@PF8&P#C!('
MYGUKU2_LDU'3+FQF8A+B%H79>#AE()'YUR(\"7YT3P]ILFO)(-$NH;B%VL@-
MXB4JBD!Q@8/)R23Z=* *3^+]5\.7/B^#5KB/41I-I#>6SK$(2?,##8V#C 91
MSUP3UK4L[CQ=%XET]9+6>XTF>-Q>O<"WC^S.!E6C".6*DY&#N(X.:?<^"$U#
M6==N]0O$FM-8LTLYK9("A15W;2'W'GYB>GI3O#GA?6=(:"/5/%$^JVEH,6L+
M6RQ$<8!D<$F0@' Z>IR<8 #Q_K.JZ%HEK=Z3+ DKWUO XFCW;E>0+@'/R]>N
M#5#6+_Q/X=DT&.YU:TO!J&N):R%;+RR(75B%'S$<;2,]3D>G.WXM\.S>)M,A
MLHKY;,1W,5R7,'F$F-@RC&X8Y'--\1^'+G7VT9AJ$5NVFWL=]_Q[EQ(Z @#[
MXPOS'U/3F@#(U'Q#J4VM>*[*"[73QHEE%<6Y:-6$Y9&<NVX?<!4+\N.AYZ8P
MM1O=8U:U^'.H7C6\>HWE[YV/(9$BW6[G!4L2<9]1GVJ'6KNUO_&FKO+XNTS1
MIK=X[=+36;"*0D*H.^(R,I"LS'IG)&?0#I(=%UCQ)%H6HW^I6R3:7=O/'(ED
MRK=##(K;2X* J3QSV/0XH RK[6=>&B_$'2[C5=UUHMJ)[>^AA6-RKP&3:1R
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M %%%% !117GW_"5W/_"72Z-J&I3Z3??V@HM+>X@06]Y;!A]R0J27*YXW?>.
M* /0:RKKQ#96?B+3]#E$_P!LOED>$B(["$&6^;IZ<#/45R\.NZNT7CN)K]BV
MCL39R^4FY1Y DP?EP>3CITK(N[G4M:UKX9W:7<<&H7FFW,KW!B#!6:"(L0O
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M$2%V  S]T<]*N5Y;I<=VUE\27N-4N[D17%S$$E$>"!;)@\*",#@ $# Z9YH
M]'TO4(-7TFSU*V#B"[@2>/>,-M90PR/7!JW7ENA:CK>BZ9\/7.I)+I^IPP6<
MEEY"@(#;[E8/][<-O/.#GH*O3:YXIUVPU&_\.1W'GVU]+;VT!%O]GE$4FQA(
M7;S,MACD;<9'7J0#T2BLS5M6.C^&;S6+F AK2T>YDA#9.50L5S^&,UD::GB6
MY.AZFNJ03VES%YFH6TD:JJAD#+Y)5=W!X^9CD>] '545YPGB76]7^'MYXUTV
M_$7E>?<06#1(8GAA=AM<XW[F5"<AA@D<<<S1>(-;USQAIEG8:BMEIVI:!_:2
MK]F5Y(F+Q@<GJ<-W&.3P: /0:I:MJ2:1IDU]);75RL6,Q6L1ED;) X4<GKGZ
M9K@;7Q;KR>"7O)Q/>36.L2V-_=65NIE\B-V!E6/!7/"Y&#P2<4NL^++V/X9:
MIXAT'Q%#?B*X0V]R8$+JA:-2CK@!6!9NJ^G% 'I)8*I8YP!G@9/Y5F:%X@LO
M$5K<7%B)@EO<R6KB:,HV]#AN#SU]<5E3ZO=:IXXN/#MG=O916-DES<31(C2.
M\C$*HWA@  "3QDDCI@YXWPSK-YH>@7=LC-/?W_BNZLO-14!R69F<*Q"Y(0X!
M.,D=>A /6Z*\^OM0\9:5I7BBYD+K9VM@]W87=XD#2JZ(2T;+$=I''!QQSG-/
MBN?%$/AJUU>Y\168CO4LV<26RQ_94;'FF,X/F2," H(QNZ#G% '=/!#(P:2)
M&8=V4$U5U#58K"&UE\BYN4N9XX5-K$9-N_H[8Z(.[=J\_GU[5KS1_B#8'4;Q
M/[)M1-:730I%<;6@,FUAM '(Z[0V#V/-2OJ&K:#X)\$O9ZDS+=W>GVTXFA1F
M\J0*"BD  # ZD$\]: /2:*Y"WU2_\1^(_$&FV6HR:=%I)B@1XHHW:25DWEFW
MJ?E&0 !@G!YZ8YN'QMXAU+2O#$T,UM:7=SK#Z5?IY&]&= ^67)SCY <#!YQF
M@#U.H+R]M["V:XN9-D8(7H268G 4 <DDD  <DFN7\+:EJI\5^)-"U._^WKI_
MV:6"X:%8WVRJQ*D* #@KP<9YJ#6[I[KXK>&M)8G[/;VMQJ!7L\@'EH3_ +H9
MC^- ':(Q>-6*,A(!*MC(]CBG5Q]_JNH:;\08-.N]2:/2=2L)7M6\N,>5/'@N
M-Q7D;/F&?0]:R?"WB;5M<\.16DVH2IKO]IFUF<P1J5C'[S=L*\ P],_Q$<]J
M .QTSQ#8ZMJNJ:;;"<7&FNB7'FQ%!EUW#&>3QSG'<5JUY=Y>JGQC\19=+U3^
MSY(%M)1((%E9F6UR!\V0%XYXSZ$=]*R\8:CK-OX:M8(YTNM2TG^T;E[,1;UQ
ML7">:=H!9R3G)P!QSD '?,ZHI9V"J.I)P*RQXAL3XI_X1T"?[=]E-WDQ$)Y8
M8+PQZG+#IGO7GOB63Q4?"5O'K5Q<6DJ:_;PQ2Q&$-=6[2KL:0*&4,/08!(Y!
M'%:=_:7S_%VRMK;4GBG_ .$=E#7;Q([X^T)R!@+NZ=L>U 'HE%>;:;XSU8^'
M+*WN7-SJD^M3:0;B*-%9A&7)D"L0@8JF #QDYP>AFU'4O&>D:+XINI6=+6TL
MFNM/N[Q(&F#*I+1LL1VD9'!Q]<T >AT5SWA6/6I+--0U75DNX[RV@DCMTMEC
M$#%<M\PY;.1U';C&<"BVI:IK^M^(M,TO43I[:2L<43+&C>9,\>_+[E;Y!E1@
M '[W/3 !UC11NRLR*S+]TD9(^E/KC[R\UZ*?2;74-2@M))+)C<+IJ>;/-<C:
M/W:.C?NAEB20,$C) K"M?&^KR?#WP]K]ZER(9Y9$U2ZL+=7DA12ZAPA#  LJ
M[C@X&<=J .XUKQ#8Z#)I\=X)]U_=QVD)CB+#S'.!N/0#ZGM6K7EWB._;5/"_
MA2[M=7@U/S?$ML8+P(-I7S'V!E4#D# (XY!Z5T/A_4=6B\<:UH&I:A]OBAM8
M+NWE:%(V0.65D^4 $94$9Y]S0!V%%%>?+XKN3XMET;4-2GTF_P#[0 M+:X@0
M6]Y;!A_JY"I)<KG^+.XX ] #T&BO/;G7/$^N6NKW/AU+E9[*^EM;:(+;FWE,
M3;6$I=O,^8AON[< KUY)T(=5U;Q#K6L:5;79TF;3+:#<(UCD8W$L9?YBRL-B
M\#@9//- '945Q+:KXAL/%/@[3=1NK<R:C!<B_B@0&,R11@@H2 PY/-8VJ^*O
M$%IX:\=W%OJ"?:-%N_+M99+=&(38C8(  )RQY(- 'H6JZDFDV)NY+:ZN%#HG
MEVL)D?YF"YVCL,Y/M5PNH<(6&X@D+GD@=?YC\Z\^\37OBGP[X7GU8Z]#,\MU
M:A(Q9*ODH[JCH#GD?-G)&:F>.\D^-GE?VI=K NAB=80(R@S. R@%>AVC)^][
MXP* .OT_4DU"2\1+:ZA-K<&!C/"4$A !W)G[R\]?8U=KSBW\9:M9:'XHN;R6
M.ZN;+71IMIB((JA_*5<C(S@R$\MSTR.VG%/XRM=7NC':W%YIK6+O%]O-NLB7
M*@[5'E'E&X'(R#WH [2BN&\%^)_[>U 1-J]P;N"U(OM*OK=(9X)LIA@ H)7[
MPZGJM:?B'7)[?Q+H/AZTE\B75&F=[@*&:..)-Q"@@C<25&2" ,\=* .FHKSN
M^\2:YI5[XJT-[Q9KBPTHZI87LD"[BF&!1U7"DAEX( XZBMWP;_;MWIEGJVJZ
MNEU'>V%O*MLEJL8B<J"QW#ELY'!'7.,#B@#IZ1G5!EF"C(&2<<DX'ZURB:M>
M:]XPUS0[2_DT^+2(H \D,:,\DLJEP?G5AM"@< 9))YKB]2U_5?$'A[11=7DM
MI>V?BR'2KW[*%$<S)*,/A@?12!TSU!XH ]+B\0V,OB>7P\HG%]%:BZ;=$53R
MRVT88]>?3C@UJUYU=6E_-\7VMK34WMYO^$;0-=M$CR?\?#<@8"9)]L=>/2/2
M?&NK77AK0(9B9M5U"_N+&2>!(U8B$R9=58A Q"#@\#).#C% 'I-%>;ZQJOC3
M1?#'BJ[F<Q16<2SZ;>74<#3,,?.CK&=G!Z''3J*Z[P_;ZPD<MUJNJI>)<I')
M#"ELL8M_E^8!@<L"<<GTH VJ*\_^U>*]9\7^*=%LM>@L(K!;5[>5;)793(C-
M@AB01D<D^@QCFLFT\:>)=4T;PE,EQ;6EW?:E)IU\H@#J602 L,GI\@.!CGC.
M* /5J*XBRO\ 6)/$Z>$KC6WDN+2P-Y=:A%;1QR3%Y"J*$(95 4<G')QTYK!U
M'QIXBM/#FN0K<P#5-%U6&S>X, Q<12.@1L=%;:_. 1QQB@#U6BO/I]<\0>%?
M&UE9ZSJ4>IZ7JEK<RQ[+58FMI(4\Q@,'E2O3<2??U+#5O%^IVN@:U803RP7K
M12WEM+]F6!;>09)C8-YFY<C&3SSP.E 'H-(KJX)5@P!(.#GD=:X#1+CQ3KVM
MZY WB&.UM],U7R,162%I(O+4E<MG;C=D'DYZY'%8_AI?$O\ PJ2ZU'1]9N9=
M52>[EC2>.*02%;B3</N9W,,]^N,8'% 'J[$JC,%+$#(4=3[<U7L;ZWU&V\^V
MDW(&*,""&1@<%6!Y!!Z@US^FZ\WB&[T272;Z0V4EE]MNB50EE;"QJW'#%A)G
M&/\ 5L*I:==/9?&/6-*0_P"CWVE0ZBR]A*KF(GZE0N?]T4 =M1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<M?>$)=4
MC^R:CJ2W-@+\7T:-;XEC(D\P(LF[A<\?=SC(R.W4T4 <?>^!YI]3UVXM=;FM
M;36X@MU;+ K?.(_+W*YY (QD=^Q%*O@=[>W\-FTU>47N@0M!;S3P*Z2(R*A#
MH-IZ*,$,#]:Z^B@#S_Q&NEZ+I'B*RN;]9O$6NV$[@,A5K@K$42.->G&0 N2Q
MR3SDFK-QX&FO]&\-RP:G/I&NZ1:)#'=PJL@ V*KHRGAE)%=O5*^U'[#<64/V
M.[N/M4WD[X(MZP\$[I#GY5XQGU(H Y[4_ HU?08[2]UB[?58KE;R/5%55DCG
M485E4#:% XV_UYJ?_A$IKWP_J6G:WK-QJ-QJ%NUM)=>4D7EH01A$48')R>I)
MZ\  =/10!0T73Y]+TF"SN;Y[V2) IF:-4R  !A1TX%8:^!K9KCQ EQ>S3:9K
M;-)/9%% 5V0(S!^O100.QKJZR(_$5I+XJE\.B*X%Y':"[+-'B,QEMO!SR<Y[
M=C0!FVGA&80Z3:ZIJAU"TTF19;53 $=G0%4,K;CO*@\8"Y(!.:U_$&C0^(O#
MU_H]Q(\<5Y"T3.G5<CJ*BU?Q%::+?:7:7,5PSZE<"VA:./*AR"?F)(QP#[\5
MKT <HWA"[EO_  _>SZTTT^C%V4O;*!*73RSD C V],=^234%Q\/[?4%\21:C
M>M-#KKQRR+''Y;0/& $9&R>FU3SW'X5V5% '.^'O#NIZ8ZR:OXCN=9>)=EOY
ML*1",=R=O+-CC<3TSZG*Z]X9EU?6M)U>TU.6PO-.\U5*Q+(KI( &!#=#\HP?
MYUT-% '.^&_"B^'H=4@;4)KZ"_NY;DQSHHVF0Y8<#G/Y>PK-'PTTC_A$K+P^
MTLSPVEVETLS'+MM;[I/H8_W?^[CTKM*R+#Q%::AXAU/18HKA;K3DC>9I(]JL
M'W;=ISD_=/:@"KX@\,R:QJND:I:ZG)87FF-+Y;+$LBNDBA74J>^ ,'M6)/\
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MPD[MCKE3P>001^-<=\1=+M-!^'NH![U1>ZCJ=O<3W#[59Y/.CR5!Z!548'.
MO.>2?4:* ,"'0!?:K;ZQJ=W#?O#;O#:B*'9$JR8WMC<VYF  SG&.@Y-96@^
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M_6]&L_$&BW>DZA&7M;J,I( <$=P0>Q!P1[B@#GK7_A*[;Q"&#32:1):OYO\
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M&]O<V.I6\FISB6]U+^U$N4C59+6X^7YHSVX4#G/>NRM8YHK6..>?SY57#2E
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M<5U;Q2(%6-V=QRP&2/E'>J:_#:0:/9Z.?$NH'3K"ZCN+.,Q1%XA&VY5+E3N
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M+V946-'\Y5G8LGS*>2,XQWQ78>'_  G>:,8_MGB._P!56V4I9I=*@$/&,G:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !114-Y<&TLI[A8);@Q1LXAA
M+R8&=J@D D]!R* )JQ_$_B"+POX?NM8GM;BYBMDWND &['KR0,4FA:_+K33K
M)H6K:9Y04@W\2(),Y^[M=NF.>G45E_%#_DF/B+_KS>@#JH91-!'*!@.H;'ID
M4^J]C_R#[;_KDO\ (5CZIXGFTS4Q9)X;UN]4A3]IM(8VBY]RX/'?B@#H****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L[7=%M?$.D3Z7>M*+2X7;*
ML3;2Z^F>H'TK1HH AM+<6EK%;B2218U"AI""Q Z9P!4U%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exc_compmins2-9x23v1x202002.jpg
<TEXT>
begin 644 exc_compmins2-9x23v1x202002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNJV2ZG<W=Q#$C,D32[)F0!$SD\ >M=/?ZOIFE;/[0U&TM-_W?M$RQ[OID^]
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M='3Q4OATWL OO)\UE,@&TEE54]V;)..N![BMR@ HHHH **** "BBB@ HHHH
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M$:)\C?5?-P:3_A&=;%FEG_:FB_98^4A_L,;%^B^;@4 9]Y;6=C\7?#:6D4,
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M9)-BMK5H,[MI^^<X/;BNXCT^RBN3<QV=NDYZRK$H;\\9HN=/LKTJ;JSMYRO
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MJ,^HKAK?6[?0]4\ ZCJLZQ:+)H?V>*Y<_NH;EDC.6;HN54J"??WJ3QP?#_\
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M6T@61G$C.(P"6'\1..O)YK(U'Q?I>F>)K'09YE6ZNHWE)8X"*N,9/J21@?\
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MODNS.&!X#9X'WN: .N%G:B[-T+:$7)&#-Y8WX],]:>UO"\PF:&-I0I4.5!8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_3;JYL%OK5=,M(Y(&)"9^12S;>=JM\QQZ5Z969I>D)I*SVUNR_8)':5("O\
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MC/7% '*?"^>*?X9^'S%(K[+-$;!Z,!R*YS0[VTMM%\;Z/XBDCCO3?7<LL4Q
M:>&1?W;*#]X%<*,>@%>H !5"J  . !VIK0Q/(DCQ(SI]UBH)7Z'M0!Y)I<#V
M&O\ PML=:DC_ +0@TZ[$B3,-Z,8X]@.>XQCZ@UT?P[N;:75_&D<$T3C^W)'V
MHP/!CCR>/4@\^H-=T54G) SZXH"JO0 ?04 <AXJ_X1;7-1;PQXFAMBKVRW%N
M\[;/F+.I"/QM8;0>#D@GL#7"QVNM6WA'QOH>EW]SK>DV @_L^=FWNRY#30!Q
M]_"C;QZX]A[/)#%*K+)&CJPPP9001[TJ1I$@2-%1%& JC % 'FEM>>'/%DT>
MI>'=1N[_ %V*PG6W8RL#:;XR/W@P /FV@ ]^1P":/!FO>&-8\.>&M)F@276]
M,\J/[ R$36T\8V/(1V ^9LG@_7BO2HX8XBQCC1-QW-M4#)]30L4:R-(L:!W^
M\P7D_4T >;^'M0LK5OB%8W-Q%'<_VE<SM$YP1$88\.1V4^O2L32+W['H?PLU
M2:53HMM')#=R9RD,SP[(V?L,$L,GINKV78N2=HR>IQUI#&C(4**5/!4C@T >
M7:TD3^(_&^K6DT7]E-X=\BZE5AY<EUA\#/0L$P#Z;@*J_:M/@T7X3F.>VC(E
MASM=1C-LP;\V.#[UZTD4<<8C1%5!T51@#\*78O\ ='Y4 4M9UG3_  _I4^IZ
MG<I;VD"Y=V/Y >I/0"N2\-^+_#.L^(1<QZM;7>M7J>3#;0$N;>$9;;D#'8LS
M="0 ,X%=V0",$ _6@*H.0H!^E ' ?#"*6'X?7EG,#]KM[V]BG'?S/-8G^8KD
MK>UL=6^"&@Z/I_V=]=\V 6\46/-AG64%W('*[5#%B>U>MVVDK8ZM=7EHX2.\
M(>YA(X:0  2+Z$@ 'UP#P0<WUAB21I%C19'^\P4 GZF@#B/'4;W'BWP+#!GS
MQJCR\=HTB8O^&"/SI_Q=ECB^%NN>9(J;XE5=QQD[UX'O731Z4K:VVK7+"2X2
M,P6X XAC)!;'^TQ"Y/\ L@=B3H$ ]0#]: //-3N;)?BEX32SN+5"^EW<<>QE
MQ@B,H..W!P/8USOAB[\.ZMX;TSP_KEU?G7]/N%5]*:1EE^THQPZ@#IGYBV<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG- '<P^)='GOXK*._C,\Q80C!"S%?O!&(VN1W )Q1<^)=&L[Q+2XOXXY7E$
M+ [/,/1"^-H;_9)S7&^#O$?AS7-(\/:8;+S-;TQ(XVLY(&$EE(B['8DC"@ '
M![\#K7/Z1=>'KG1KKPAXJ34'UN.[E#Z=YLX^UL9FD1X]IQ@D@YX Y)XYH ]@
MO+RVT^TDN[RXBM[>)=TDLK!54>I)K(M?&WAF]U*VTZVUJTDN[F-9(8@_+J1N
M&/<@@XZX[5:\1C_BE=7'_3E-_P"@&O,%BL-<^&?@73=*>"358IK&6-82-\!3
M!ED8#E0!NR3U)'<B@#T[4/$NCZ5*8[Z^C@VLJNS [(RWW0[ 83.1C<14&I>,
MO#FD3SP7^LVD$L$8DE1GRR*3@$@?7I7GL5_H$&H^)?#7C%[Z.YN]0FEA@#S[
M;V"0Y38$X8XPN!SP/PU[$:>GQAAM&2)/+\,1VZPR.'9")CF,DYRVW&>Y'- '
M5:7?65[XCU3[+KWVTI'#OL4962U^]@Y SEO0GM5B#Q+HUS>0VD5_&99RP@R"
M%F(ZB-B-KX_V2:X&\$U_XN^(]CI4Z?VA<:1;Q6X5P"9!'*"![C('MD5#?7-K
MXE^'?AC3-)=5UJ"YL@EL.);.2(@2%EZH%4/DG';U% '=>)M>L].TS4(1J36M
MY%;-+OBCWF#@[6?Y6502.K<=:/ ]]<ZEX%T.^O)FFN;BRBDED;JS%02:XK3]
M:M=)O/'FD:].MOJ5U=SW-L)^#=6[1!8Q'_?P%Q@9Q75?#25)?AMX>V$G98Q(
MV01@A0"* -=O$&EI>+:M=#S6F\A3L;89?[@?&W=[9R*;?>)='TVX\F\OXX6#
MK&S,#L1VQM5GQM4G(P"1U%>>I<S:5KZR:#JD.I:;>:VT=WH=R 9K:8S'?+$1
M\P 8%\$8QD]ZJ6E[X>!U[PIXP^WB_EU&>1;0/-B^CDD+QM&$.#U QVQ0!Z"G
MB_3Y/&4OAM=_VB&!97<HV-S-@*#CGH<GIVZYI_C/Q"/"_A/4=5 #30P.T"LI
M(:0*2H..V:YRSG@TSXORP7 :!KG0[:.W1LN7*R/E0>^,C)].36G\4)HXOAIK
MXDD53):.B G&YCT ]30 FCW7V;RM9N/$EQ<6-S D)M)X<EKG@[H\ -R,_( 1
MW'2ME?$^B'3+C43J=NEI;,4GDD;9Y3#JK X*M[$9KC-5OUM?$?@?7))D?0HX
M)K>6X5@8X)9(U",YZ '!7)Z9[9K.UV..2?XBZS:S1_V7=:*MMYJL-EQ<B-Q\
MIZ,0"J\=SCJ#0!U6K_$KPYIVGW,]O?QWD\)B0PP@L093A,X' ]?ICK@54U#Q
M*;+XAZ:9-6:/1)]+GG:*10J!U=%!'RAB3G&"3STK*\3_ &8_!+3[FU6-HHH]
M.:1XAG:B21ELX_N\Y].:NW6IZ;>_%[P]<1W,#QG2KGRW) Y+IM(SZ@-CU'(X
MH [;2M6L-;T^._TRZCN;60D+)&>,@X(]B#V-)?ZQ8:8ZI=3[9&4N(T1I'VCJ
MVU03M&1DXP,UR?PRN()8O%"PRQN!XAO'4(P/RLP((]CS@U'#?+H?Q9UJ36ID
MM[74K&W_ +/N)V"QXBW>9&&/ ;+;L>G- '43>)]#@LK.\DU:T%M>NL=K)YH(
MF9C@!?7G\N].TKQ'H^N3W,.F:A#=2VQ F6,\KGH?<'!P1P:\EN[5+#PD#<E(
M["]\9K=6,4O ^RF8?, >B'#-Z8.>]=E:W5JWQONUBGB)?0(EPK#YF$SG'U"D
M'Z4 7O'WB23PY:Z43<FQM+R^6WN=0"!_LR%6.0"" 20!D@@9)Q5[3(=4CUJ&
M1=9;4]%FM'='=(RRR;DVG>@ 92I;''8\GC"^)]3TNS2TLM:@BDT[4':"8S)N
MC3Y2P+]@O&,G@$BN%T'1TT/QQ+IW@C5&GT.ZL9I+JV6?SH;*;CRRK<X+$_=S
MG )Z8P >B'Q+HXOXK(W\8FEE,,>0=CR#JBOC:6&#\H.>.E<GH_C"#2=8\4Q>
M(]< @M=16&V:X"@JAC1L851P"W)QW&36=X(U[0KWPSH?AO4;(R>(-+DC1M/F
M@)DAGC./.SC ');=GOZG%5TNK!K3XK,9[<M(9 #N&7'V8*,>OS9'UH ]-O-6
ML;&&.6><;91F,1J9&D&,DJJ@DC'/ J*/Q!I,VCIJT6H0/8/@+.K95B3M"C_:
MSQCKGC&:\OBUFST:Z\(ZKK-Q<Q:'<>'HK-;V"1PL%P-K,KE.1N  Y[K['$NI
M'2M#/AK6]+MKF/PLFLS75Y-(9'#/)%M6X(;+! Q;GIW'49 .@TSQ3O\ B!XA
MCFU2:32K.PAF\J6'9]F8LV[*[0PX /S<X.>E=4?$.DA-.D^W1>7J146;\[9B
MPR IZ$D<XK@8[^RUCXA^*?[,GCNA=Z!&D+P?,LK#S.C#@]0.OMVK%@U[3;CP
M?\-;>&Y$DMEJ5G'=*BDF!UA=2K\?*<YX/.!GI0!WNA:A?R?$3Q7I]S?23V=K
M#9O;QN% BWK(6 P!GH.N3QUK9M?$NCWFH1V$%]&US*ADB0@J)E'4QDC#@>JD
MUY_>B74?%'Q+L=,F5K^XTFWBMT5QN9Q%*"![@D#VR*L>&=3\)>*+C0VA2_FU
MO3R&%I++/NL6"[7W@G: ,8YZ\"@#TN0.8V$;*KD?*S+D ^XR,_G7+^ -6U'6
M-"NY]4N%GN8M1N;?>L80;4D*C 'L/>NH=UC1G=@J*,LS'  ]37#_  LN8)]!
MU-8IHW8:O>.0K G:TK%3]".10!V%_J-IID"S7DZQ(SB-,Y)=ST50.6)]!S5$
M^*M"72[C4I-3MXK2VD,4\DIV&)QU1@V"&]B,UC>/]5MM*70GNX8%C?45 O[A
M2T=DVQL2?[QY49X!.3TQ7 7=]:CPU\4;8W4LLDK^9&T\>QI T*!3]T#D], 9
MQD4 >LV?BC0]0U5M,M-3MYKT)YGDJW)4=2.QQWQT[USGQ(\51Z7X.UAM-U9[
M74;5,"2&,,%DX_=LQ4JK$'ID-TQ6?>W=@/&OPX\FXMP@MKI1L<8 ,"A1QT!(
MP/<5RCZS:P_!/Q!X<U698_$EN;@75K*/WLLC3%Q(!U92"#N''% 'N%LQ>UA9
MCEBBDG\*H0Z]IE].EI;WI\Z=6\EEC($@'5D8C:P'J,BK%C/%<:1!,A+1-"".
M",C%>:^$[N72M6T&RTW5H-:\-7,4CP+,!]ITI5C)PS#^ ?<^;!!(% &KX*\:
MVJZ'!%X@UR-]1GU"XMXVFPK/B9D0': %SC Z XXKK=1\1Z1I,LD=[>K&T48E
ME 5F\I"<!GV@[%X/+8'!]*\?ENK/_A16L!)H/.;6&< ,-Q/VU6!]?NC/T'I6
M[XIUJRN-2\9Z=&Z64[Z2I1H8M\NJ PN00<$>6NXJ=HSU)( H Z?Q-J=[;>*/
M!XLM0=;*_NWCFB0*4E7RF93G&>PZ'%.T#4+^7XB>*].N;V6>TM8K-[:-U4"+
M>LA8# &>0.N3QUKE#J=E):_"MQ<H%5DW%CMQBV*D\]MW&?6M[P[=0-\6_&4:
MS1EV@L0JAADE5DW ?3(SZ9H ZK4=>TG2)[>'4-0M[:6X)$22R %L#)./0 'G
MI3=*\0Z1K<-Q-IM_#<);N4F*G'EG&>0>G'.:Y;XA36J:[X+6XDB&W65D(D(X
M41N,G/;)'/KBN9\017&J:G\4K#1I5>^N+*R$<<3#=)M1O,4 =3M^7\0* /3K
M3Q'I%]>1VEO?(T\J&2%2"OG(.K1D@!Q[KD52T#Q?I_B'4]4LK3?FQN#!ED8;
M\*I8\C@9;'OC/2N6UF]LO%T7@I]!FC>\@U."Z=(C\]K J-YH<=4'1"#C)(%2
M^&-:T_0]9\=C49S T.I/>R*48D0>3'\^ #QP?K0!Z+7 W>OOX@\8ZKX=M=7N
M=-%K:Q?9YK>/YC<.7R6R.54*HP< Y/MCL]+U2SUK3+?4M/G$UI<)OBD (R/H
M>1]#7#Z==Q3?%3Q?!:WD*W,FG6L<)WC_ %BB3/U(++GZT =1;^(M,M_LUE=Z
MK%+=%A;-/L*1RS@8*AON!B0?DSD=*;J7C/PWI$]Q#?ZS:02VX4S(SY*;C@9
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MWB!2VX?[. 3GI7!ZGKMC/X@O;)6%C-+HD9BN$A+3Z@I#XC3(/RJ<Y !8[NH
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MVOCH6;  //!]#3O U]:S^,/&RQ7,3L^HHR!7!W 0H"1ZC((_"@#O1TYHHHH
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MVI_V:EP3>&V^U"+RV!:+(&\<<C) X[UR?C/Q,LOAJSU30]7DBBCU>"VG:,;
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M(V8-+YR-MX'7 )^E<E+-;R?#CXE(KQM)<:K>-$H^](&V["H[@X.".N#7L]%
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M*@#RNVGDTC4M+T#5%DM;V/P]#$U[# 9)KQQPT"O@\*02<?,<YR,<X]G>0_\
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MXYW7J<!L^N"*]';PYJ!8D>+M<&3T"VG'_D"D_P"$;U#_ *'#7?\ OFT_^,4
M<MXKU71=:^'_ (KU'1K92MW9>6U\(#&;N0 A4&0&?:.,].<#H<.O+JU/C/X<
MM%-$8TMKI6*D84- H4'TR1@>I&*Z?_A&]0_Z'#7?^^;3_P",4?\ "-ZA_P!#
MAKO_ 'S:?_&* /.M FT.;1CX0\3V6ISZ_;W#J; RW.RY;S"R2J5.P*<@EN .
M36OINKPZ%K_C72]=9X;R^NGNK-GC8BZ@,0550@'<5VXVCGGZUUW_  C>H?\
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M1Z;H:O(H8:W9R$9Y"+("S?0#J>U=PCJZ*Z,&5AD,#D$5S_\ PC>H?]#AKO\
MWS:?_&*T],L)["%TGU2\U!F;(>Z$0*^P\M%&/J* +U%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5AW/B_0[.>6*:\8"
M&X6UEE$+M%'*V,(T@&U3\R]3QD9ZUN5XIXLOWU'P[XKM38W=K=6^JHPL;6S8
M)(BS1_Z1(P7YRP!/7' XR,T >G7WC'0M/U*?3I[QOML,0F>WC@DD<J3CY0JG
M<>O R>#Z5/#XFT>XT&#6X;Y'T^? BE56)=BVT*%QN+;N-N,YXQ7,6UW!)\8I
M[WYD@;P_&@DE0H PF9BIR!AMI!(/(':N-TY[K3_"_A?5#;7$EAI6NW4U_ D3
M%XTD>4)*4QD@!\\#O0!VFB:U+?\ Q6U>TCO;U[.+3(9/LUPC1B*0R,#A& _A
M"\\]>M;OB;6Y-,_LVPM"!J&JW0MH"1GRQ@L\F.^U03CUQ7.:-J-OJ/Q>O;RT
M6XDM9]%A1+C[/((V(E<GYBN.A_'I5CQA#)'\0? >I,#]EBNKJV<]@\L)"?F5
M(H V+R?3K;Q-H-A+K-[%?8F,%HKL4NQL^8R\$':!D<C!INFRZ?J>J^((;'6[
M^:X62)9XMY"V;A?E$65QSC<1\P/?@XK*\4.H^)?@EN2L37GF, 2(]T.U=Q[9
M/ SUH\)NI^(7C=AD++/:M&Q! D"PA6*GO@\'% &WX5UU]:L;J.Y""_TZ[DLK
ML(,*70_> [!E*L!VSCM4%QXM@B\<1>&?L]WYC637#3+;2, =Z*H!"D8^9LL?
ME& ,]:RO 4#MXB\:WX!%O/JYBC]"8T"N1_P+(_ T:A+_ &?\8[&[GAG^SW&B
M/:QR)"SJ9?/5MI(&!\O.3@8H S_"_C2RTBVUQ/$&KW$AAUVYMDEF1Y?*C#A4
MWLJD1KV!.!G/O7<:CK=CI9VW#3/)L,GEV\#S.$'5BJ D#WKRJXQ)\,/B% J.
M9KG5[QX(]AW2AW4H5&,L#@X(]#Z5IW^IVVA^-3J6LIJ1T;5-.MDM[VS:?;%)
M'OS&XB.>=^1D>OO0!Z3IVI6>KZ=!J&GW"7%I.N^.5#D,*S;CQ?H=K<20S7C
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MWA;4(=2AFFLI(PDRP E]I(!*XYR,YX]*X:VAUN73/%.AQZC_ ,)#8/HKBSU
MH/.#LKJ+=W'#MW]1GGK0!WS>(]*6;3(3=$/JB[K(^4^)1MW<'& =O.#@UQ'A
M_P <6&@R^)8O$6M7#^3KDT,3RH\IBB"Q[<[%(1<DX)P,Y]ZSHM8@O_\ A6QM
M8+V464@CN2+23]TXMBA4_+U!ZXR!WQQ6AI=S;:=%X[TW4;>0W5[J5S+!9M"Q
M>[C>)%78,?."01QT[XH ZS4-1TJ7Q'X?B.M7$5S/YLEK;6[GRKQ?+)._ ((
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBO.H/M5W\3O$6F3:UJ-OI
M]K8P3Q*ER5$3/G<<G/'&>>* /1:*XCX:^(-1UKPU?7.K7"W$5K?306^H,H07
M4"8Q*<8'KR../K6U%XNTB74+>R,L\4MU&TMJ9;=T6X51EMA(^8@<XZXY'% &
M[534M.MM5LFM;I24)5E93AD=2"K*>S @$'U%<U)\3_"<<,<[:A+]G:8PM/\
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M:[,PLYBGEJ<$Y"]02,CJ,\U9'CWP_P#;;>U>YGC>YB,MN[VL@2<  D1MMP[
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M#?Q\OS<<XKTFB@#S1&9=<^)<A@N-ES;PB!O(?$Q%N4(3CYCNP.,U2A$BZ/\
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M6%G%Y%*!A4(!RPQM*]N.U>D44 >33Z3>Z#X-^'>DW<<\UW8ZI;37(BC:3R4
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M_9/)!+_,0 3_  K@G.[(XR1U?C6SN-0\"Z]9VL32W$^GSQQ1J,EV*$ #W)H
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MF:\2_7?:I;KN:4 9) [ =R<8. >3BLZ3X@^'HM(.IRW$\<*W?V*56MWW0SY
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M2,*P!SR2/IQFIXGT/6=+U._@\&WP@>R-O<^?9M%<3*S#,2#[S8Y/'&0,'.<
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M@YK'@N[TG4WUNV66-?+LY)$N0TI<2+(!M(.[USD=* /5KK7;?3T6$Q7-U<K
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MV!XA87]W%LFD4J2RL2!OVG W8YR?3 [*@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***YKQM-J+Z$^
ME:-+Y6K:D&@MI,X\L;2SOGMA00#_ 'F6@#I:*Y[P/XA/B?P?8:E(-MT4\JZ0
MC!29#M<$=N03]"*BN_'>CV5K)?2+=/IT=T;1KV*'?&)0=NW .X_-\N0N,\9H
M MZYX?EUMVB?5KJ"PFMWMKFTC5"LR/P3DC*G&1D&MB&&.W@CAB0)'&H1%'0
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MR9#<,21@X/  /'% 'I-%<U'XSTJ*&PDD^UKI]Y(L%MJ,J#RIG/"\YR-V.&(
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MPOOV#S"?NY;\1D9 R*LKXJF?X@R^'!IUQY4-FMPTV%PQ9]H;KPHVL/4GMQR
M=11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK6XU#XE6,T5M>+:OHMQ;-=?9I D;R,I4$D<' )]J[RB@#RKPA$([#3?#NJ>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_M9VCM(8U D9E!+@[B NT*<Y/;C/%85AJ4=C\6O%326]W(CV-D08+=Y<$"3
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MGPY]GM9)86$3W*R.ZH2<>HZX';.: -RP\:6-_>:;;"TO8#JELUU8/,J;;A%
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M "BBB@ KS.^T*\;Q&=7T&SU'2=<.I!;E4!^QWUN),&23JN?+Y[-GMT->F44
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MEB,CGMEH\<XX->J44 <SH'B#6-8$9O?#EYI(A0FZ-UM.]\?=B"DEAGG<0.F
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M]37#Q>&M6M/"GAG7=(LI(?$VB6,5K<6DGR?;(54"2$GH>F5/(!_3U(D $DX
MZF@$$9!R#0!YQXDBU&37M(\50^&9]2M5M9+.]TR:-#/$&97#HK':Q!&#@_\
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M(S @J2.A% '6T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 445Y5Y&B1?&37XM1TZ.> Z?;ND8LFG <DY;:JG!/
MKWH ]5HKBK?5=*\/^$=3\2:)I,SV/G2RS6L*>40(B8W=48#'^KR1QW/6MY=<
M\TZ/Y%N)AJ2>8"DHQ''M#%SQR.0..[+ZYH UZ*XJ[^).F6B6MXT:OI5Q<BV%
MREPA=26*AS'UV$CKG..<4^Y\>3)>:]:6GAV_N9]%V&=?,C0%63?N!W8^[T')
M/H* .RHKAM1\:7DNI>#?['LO.L=;#SEGD",RB!G"8/3J"3[8[UW R0,C!]*
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MWYA\V< <?A7HF@:E?^'?AQI=SXLD=M22-(I0S N\C-MC4DG&[E023UR2>IH
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M;2!,<;\G&TYQG\:ZNXO;2T:-;FZAA:5ML8DD"ESZ#/4U/0!Q;^%KV/XB2ZA
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MFWN$R[L"2_0XY)]0M>F@AE#*001D$=Z6@#SSP;;^+O#VFP>%)]'1X+-S'#K
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MCV #_P"\5(Z5/IFC^*;'X;WB":+_ (2N:W*K)D$!T4(F">,[5!YXW,37<T4
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M')(IFN6.N3^-;2==.BU+0Q9E!!)<*B0W._/F.ISN&W & 2.<#FL#1?"NHQ^
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MX!DD:YD"J.P'!)/8 UOC2KS4O&UMXAN;&6UATZRD@@A=XS++)(06/RL5  4
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M:4^IK;1VMRVF#-S')>+#(QVARL:D'>P4@\X&3@$G.&#Q\MUJ>F66F:1<W?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW<KJ!\APP/!85FS?$RTC2QO8H;:XTR[N1 &AO UPBL2%D,(7[G&?O9 (..H
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MJY4A!<$"-"A=FSMYP!@\#D@=Z .BHHHH **** "BBB@ HHHH **** "BBB@
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MAU@SD P[>7 X'('3KCGT&B@"KJ0E;3+I8(3-,T3*B!@,DC Y/ KSZ/P;K1\
M>&;-(HH=:\/3PW$:/*#%.4R"FX9P&4GDC@_G7I=4;_6=+TIHUU#4K2T:0@(+
MB=8]Q/'&3SS0!S[:3?:GXJM?$=UI[VW]GV4L%O:M*C2222$;B2I*A0%P.<G)
MZ8YR=/\ !>JS?!R'PI<LEEJEO&OE2APZ"1)/,1LCMD#/'KUKT3.1D44 <KH^
MI>*'@:X\3Z?8:3;6<3//)'="43D#EL8_=H.3R2>G;.>)T>+6M)T/3[J^\'?:
M=,L&;4(A!JR>5"3N;?'$Z@\!CM5F..W->NS0Q7,$D$\:2PR*4>-URK*1@@@]
M017.V_@[POH8^U):K;P0D.%FNI#!'@\$(S%%P>G'% %#3M*U;PYXHUR\LK(Z
MAINL.MTJK*L<EO/MVL&#$94X!R,D8Q@UER^"=2T[POX:TRSB2ZGLM9CU.\=9
M B\.SN%SUY; Z<#G%=_8ZC8ZI;?:=/O+>[@W%?,@D#KD=1D=ZLT <A8Z9JEK
MX\\0:P]@S6E[:V\4&V5-Q:,/G(SP#NX^G.*Y1=%U;2_!7A'PZVG6T^MV=TTZ
MPB\$3[8]S&2*0 @8+H#N'.XC'.:]:K*UKPWI'B$0?VG9K,\!+0RAVCDC)Z[7
M4AAGV- '+Z+>:Q82ZK&WA0VNM7<#WJ23:BDRWCH%0!W4#9C<@ P!C.,<UU?A
M_4;C5M!L[ZZMEMIYH]SQ*^Y0<XRI[J<9!]"*-/T#2],MY(+:T&V4 2&9VE:0
M#H&9R21R>">]:0&!@=* //)/#NMO9^/XA8 -KH<6?[Y/XH/*^?GCGGOQ4\NA
M:P\_@9Q8<:,/],_?)Q^Y,7R\\\G/;CWXKO** .<\>Z)=^(_ ^J:58>7]JGC7
MRA(V%)5U;!/;.W%9]YIVMZAXS\+ZS-IJ116$5TMRB7"N4,JJ% SC=C;STZ\9
MKLZ* /,IO!FNWFG^)!$L=E?3ZTFKZ;+(X9=R!-JN%SC.P^O6NM\/W7B>^?S=
M=TRUTM(TV^3#<B<S/Q\V<#:HP<#))SSC'/044 <=XKTG7HO$6F>)?#D,%W<V
ML,EK<V,\OEB>%RK?*_16#*#S_P#KUH+*]UO0;RV\16T,(OD:-[2&3S!%&RXV
ME\#<W4YQ@9P.F3MT4 <;X>\)7L7@>[T?7+H37MW;/92SISB$(8H\?\!^;_>9
MJC\++XWM+:TT;5[&Q2"R"QMJ<5SO-S&G "Q%?E8@ $DCOCG%=M10!YH_A?79
M/!7C/2OL %UK-_<W%M^^3:$EQC<<\$8Y'/;&:UGT;6H_%^@ZU;V<+QQ:8]A<
MI).%,)+(V[@'</E/ _2NU) !). .]06E]::A"9K*ZAN8@Q0O#('4,.HR.XH
MPO'VB7GB+P3J.EZ?Y9NY1&T8D;:K%)%?&>V=N*H76G:W?>-O#FM3::D4-E;W
M,=PJ7"L4,NW;C.-V-O/3KQFNSHH \R?PYXIBTOQ"EE;K')?:Z-0$/VD)]HMC
ML#1%U^XQ"<]L'&:N:=X8UE/$'B*9M.L;&QU;38K>)8I\^0R+(NW:%&?O@DC
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MM)+<^4UK*J!&W#!W*0 >*[BJE_=65M J7UW';).PB0O-Y19F. JG(.2>F.:
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MEPY\T* 5&.<;>>1UH J77C>ZABNH4LK%-2L8$>[M9[W;^]9 _E1D*=QP1\W
MR1UYQD^)]>O]7MO ][86:QVU]JD$AANI6C?S DA\MUV' !4'//(''>M&ZTGQ
M5H?C'4=5\/P6&H6&K^6UQ;74YA:"9%";U8*<J5 R,9XJQXBT37-1E\,/&L%S
M)IVH)>W<AD\L-A74J@P?[_&>P&3WH ET?4?L_B[5]#AT6SM+HV\>HRRP3DK/
M)(2IW?("#\G7G/I52S^(D=UX;T/4Y[:WL9-7NI;51<7'[F)D,@Y?:,Y\O@8&
M2:GNM)URU^(#:[IUI:W%M>Z?':3":<QFW='9@V IW##=!CD=167H7A;6-/\
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MD *IP3QZ9_"J=CH/C&Q^&/AR66P?4+K2[XW<FDW#_/);_,$0GNRY# 'I@<9
M%=GX>T35K#Q_XFUFZMH4L]6%L(=LVYT\J,K\PQWSV)K:UI-:%UI\^D);RK%(
MQNH9Y3&)(RN,*0#\V<$9&.#TS0!SGA#7/"_BOQ#+J^F(;/6HK5K:^LIX?*G
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M+7,:,<+*8PN-O<C.0"/I4LOC/6I+OQ):V.@V\DVB,A<RWNU95,?F<80G<1C
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M0OO$>K:%JUE;6]W8I%.CVTS2))')NQRRJ<@J0>.: .DCC2*-8XT5$0!551@
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M?I^([@'HU%<?IOC&[UKPWH.J6.F;/[3W>?)*V8;((&W,Y'497:.F<]16;/\
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MX=M/%?AN]T6]++#<IC>O5&!RK#W! -9^DOXOL[**QO[/3;N:)0@OTNV190.
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M3S2!K>5G4AY&?NJXQNQ^%4=8T+7I_B'IGB&RM]/DM;*TEMS'-=/&[ESG/$;
M8Q7:44 9%C_;LVJF6_@LK6R2(A8[>X:5I)"1RQ*+@ #  SG/L*R]!\)2:-XK
MUC4!.&T^YE-Q:6P_Y8RR!?./XE%(],MZUT%CJ=EJ:SM9745P+>9K>4QMG9(O
MWE/N*MT <%::%XO\/:YJ<6B2:5<:/J5V]XK7C.)+21SE\*HPZYY R/J.M:$6
MA:M!\0FUW%M-9C2%T\%YR)7=9"^X@)@ YQUKK:RU\2:&UP8%UBP,H;85%PF=
MW]WKU]J .(B\$:_%X)M--_XE_P#:%EK0U2)?/?RI0)S+L+;,J<-C.#TKJ4U+
M7X_%UK87%OIS:=-:&1VA=S+'*.I.1C9T4'@DG/J!OQ2QSPI-$ZO&ZAD=3D,#
MR"#3@JABP4 GJ<=: .<\;:'?:]HUM'II@^UVE];WD:3L51_+<-M+ $C([X-5
M8]%UL_$&+Q#-%8?9QI)LF1+A]V\R"3(!3E1C&<Y/7 Z5UU% 'F4W@CQ#+\.M
M5\/!=.%W>:BUVC_:7V*AG$V"?+SGC'3WK8\5^&KSQ/#=6=]I.G7=N\ ^QRM.
M4EM)\'+!MF=N=IR#G@Y&*[6HY[B&U@>>XECAAC&YY)&"JH]23TH KZ;:SV&C
M6EI-.;NX@MTC>9S@RNJ@%CUZD9_&N<\$Z!J^@W?B!]12S\O4]3EOXC;SLY0/
M@;2"B],=:Z>PO[74[&*]L9TN+:8;HY8SE6'J#5.X\2Z#9W+6USK>FP3I]Z*6
M[167Z@G- $&IQZ['K=K>:8MK/9K \=Q;SS-&68LI5E(4C(PW7KGJ*S]%\.7$
M?C/4O%%Y!;VDUW;1VJVT#[\A229)&P 6/ XZ!>ISQOV&K:=JJR-IVH6MX(R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *\LTV[\16>N>.9?#^GV-TT6IB21;J9D,F($^1 H/S'U)
MZ=><>IUQUKH.O:3K'B&;3SI\L.KSBXCFFE=7MW\M4Y0*0X&W/WESTXZT 16G
MQ AUFST@Z9'Y4VH637K&6&280*&"8*Q\L=^1U ^4GT!33_&]]=65E;W.D/::
MS=ZA)8113*Z1/L4NTZ[@&,>P9 ZD\9[U4F\!ZGH']A7?@^[M1=Z99FQEAU#<
M([J$L&))4$JV_+<#O^=K7/"WB'5]/T[4%U&SB\2:?=_:X,*WV8978T/][:5Z
MMUR3P,X !9O/%6IZ!IVL7&N:8F+26**RF@;:E\9,!0%))0AB <Y]1FI;CQ'J
M.C>)-+TK5X;62+50Z6UQ;[E$<RKN\MP<Y!'1AW'W:JZMX7UGQ7X5O;+7;RUM
M;Z;RWMA8AFBMGC;<K9;!8D]>!Q@#U-EM#U76=5T6^UR.QB.DEYECM9FD$TY3
M:&RR+M4 DXY.2/3D P9O'WB%?#&LZZFDZ<(M'OIK>XB:X<M(D;!6V';UZG)_
M*MM/$^JP>+M(TR_L;1++6(IGM6BE9I8FC4/B3(P<J>W0]SUK);P5KC^"/$^A
MLVG"XUB]N+B.03N5C65MV#\F<C]?:M:\\/ZO=>)/"NIA;%8](299T\]R7,D8
M3Y?D[8SSC/M0!G3^/[][&#5],TR2^T][GRS;0VLS3M%O*^:K@;#TW;<=/XLU
MVNHO>1Z=</I\<4EVJ%HHY20KL.BDCIGIGM7%Z%X9\7>'3)H=GJ&FMX=\UV@G
MD#_:[>-F+% !\I(R<,3QUP>E=]0!R.C^*[K6_#&AZC:QVXO-1F$<D+!L1%=W
MF@\YR@1NO4@#C-4M3\<WZVVH7NC:>;V.QNFM_LJVTSR7.QMLA1U!52"&P#G.
M.V:TO#_A(Z)XEUG4!<!K.[F,UI;C_E@T@4S'_@3(I]N?4UF6?ASQ=H&L:C#H
ME]I3:)J%T]V/MBN9K1Y#E]@7AQG) )'^(!8N?&D\VM7FDV'V2#4(+:.>"ROP
MR2WF]=V$Y&,?=Q@G(.<=::FIZPWQ8O-/>XMAIUOI<=PL95AA6D(8DYY;Y.O0
M#\26>*?!]]XEM;[3[FVTZXA(7^SK^65EN+-@B@MPG)W MPPSG!]KA\-:G#XY
M76(9[6:RFTR.PNA.6\WY'9MR@#!W!B.2,=>>E &<OCW4)X-+U2RTN2[TV^G1
M#!%:3&:*%C\LV_&PC&"5QQG[QJ36M=OM<\/^*_[)CM?L>G)<6;F?<6N)%C_>
M!2#A ,X!(.2#P!S3/#7ASQAX?ACT :CILN@6[X@NB'^UK#G(CQ]W..-V>!VJ
M-/"7B+2F\2Z?I4FG3Z3K4D]RAN9'26VEE7#C 4AUSR.1B@#H? G_ "3[PY_V
M#+;_ -%K5GQ3J,VD>%=4U*&UANFM;629H9G*JZJI)!X/8=._M6!I\?B7PW:^
M$M&4Z5<010K:WJJ9/-(50H>/M@ $DMCL!R170>*-.N=8\+:II=F81/>6LENK
M3,55=ZE<G )XSGI0!@7'BW4X;KPC:VNFVCKKENS$M,R>6RP^9@#:<+TYY. >
M*JQ>+/%$Z>(;--.TH:CH;YED:9_)E0QB10HQNW$'!R<#CKVLGPQK)OO!EQ_H
M&-"B=+@>>_[PM#Y7R?)^/./3WJ2V\.:Q!J?B^[(L"-:">0HG?Y"L0C^;Y.^,
M\9]/>@"%_'-_.?![V&F6[Q>(8F?][.0T3"$R;>%Z?[7/0\5%#XJ\4W$GB'3D
MT[2O[1T5E:25IG\F5&C\Q HQNW$9!R<#WIECX.URUB\$(QTYO^$>5EF(G?\
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MBZP1A"[=7/=C[DY)]S7&7+WT?QMD:QAMYC_PCR;TFE,?'VA\$$*W?MC_ .N
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M$\?GD!3YQBW)QSG&1DC&>]%AX0\2::?"K1S:9.-(L39RP322&,-A0)X\+R^
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M$DGB_<R'_EG*/F1OP8 _A6%+X#>35?#]^;S]]:*ZZF^,&\#,)?R\Y0V/0D4
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MGEB3@=<8XH WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1"%@0C+*P .[@Y/)(.>.F*;\76NT^'.I-;31QIF)90R$E@94& 01CKSD'(H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC^&F:_!+HGPKL]!OKK3X;J2.WTN.68%X)#\J_-G&T%5;)[=LG%=\S!5+,0%
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MV+,B$':>2<,>F<X/2N]HH S/$G_(K:O_ ->4W_H!KB_#>AW_ (B^'WA&SO\
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M;SQY:N%&",,<_>Z=..X]#KSCPXFK2>)_'D>FO:*)-05/,F+9A;R$^8 #Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:-"JMG?\W7)'%,;P?=3:Q>ZV;RVL]6GTU[%9[. J-Q(/FN"V6((&!G@9Y/8
MIZ1XLEUK2K^_TK6[2[2WLGD>-[?9-;SCG:Z9!V\$#Z'DTS_A+]6/A[P/J@^S
M!M;N;:"[C\HX DC9B4^;C!7OGK6I#X/\[Q#/K>H/:BZFT]K"7['$8Q*K$$N^
M2<G@ #G'/)XQCP> -;72?#^G3>(+4Q:%>13VQ2Q(WI&K !_GY;! XP.O4XP
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M.#@@]* *%AKFJ#QAJ/A.\FA:Y6S6^LKU8?O1%MC!TSC<&]",@]!5'X1QW3>
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MV2)8(GC@\H>6HPN1N;)P.3G'L* -NBBB@ HHHH **** "BBB@ HHHH ****
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M"#N9F"\8..< U1N?&^OI\.M>U:":#[;I6JO8B2:V*F6,2HH)7(V/A^>,<=*
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MUJ+9:7*SBX-D<MME\T KYG][OGI573#>R_%OQ4ECJ%G',+*R61983(&.U^0
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MIY1"JH54B2,'JIZ]SUXXQ73:-H::7<7][)+Y]_J$JRW4^S8&VJ%557)PJJ,
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M9V\0EC\@E ?/8KE';<V &'&W /-=[I=@VG62PRW4MW.27FN)<!I7/4X& /0
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MBFY2& XR&% %[Q+?VOA_2+[Q)+;^9-86<FW!P6!P=N?=E7Z5S>J:[K?A[3=
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MQZ5H>*_"?_"1M87=KJ4VF:KITC26E["H<IN&&5E/#*0!D>U &$?$/BG1]/\
MLVKVCFXN]52RTZX/D^9)$X+;F56V!P%8=0"2..H+KO4/&6F67B2:17%C;:>]
MW8W=ZD#2K*BDM&RQ-@CC(; QSG-:-_X'.L^'9+'5M9NKG46E2X34D18GAE3[
MAC5>% R>/]H\Y-.3PGJMQH6H66K>))-0N[RU>T%RUHD:Q1N,-MC4@%CZDGH.
M/4 QK/7?$5M?>"KJ\U.*YMM<C$=Q;"V5 C&#S ZL.<Y'/;G@"O1:Y)_!MP\?
MAA/[40?V"5,9^R_Z[$?E_-\_'RGMWY]JZV@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *BEN(XED)RS1KO*(-S8YQP.><'\
MJEK@]!ANG^+7BS?JEX\4,%D5A;RRNUA*=GW<A022,$'DY)H ZGP]KUIXFT*V
MU>P65;:XW;!*NUOE8J<C)QRIK3KQ;PU?ZSH7PR\,:O::H5MO[06VDL?(0I)'
M)<LC98@MNYR""!['K76WNL:[K=[XAM=$:]@ETV46UNUNMN4:7RU?,OFG=M)8
M#"@< G))X .\HJEI$E_+H]G)JL,<&H&)?M$<;;E63'S8/IFO.)O%?B"Y\+QZ
MK;7[0:NVLFQ?2_)C8(OG%-F"-VX)A\Y]>U 'JE%>?WDWBB\\>W?AVT\1BSB7
M2(KM)ULHW99#*R'@]<[>Y[\>M4O$_B37-%LM6OX]5$T]EJ$*);VL*O;I SQK
MMF8KD2'<20K9&5P,9H ],VKG.!GUQ2.Z1KN=E49 RQQR3@#\ZXF\N]>N_B5=
M:!;ZT;2Q.D)>*8[:-GC8RLGRE@1GY>X(Y/'<<O>ZMJVN^ _"MU>:G/'=_P#"
M1PV=P]NJ()MER5#E2I&?D#8^[GJ#Q0![!63KWB*S\.QV;WB7#"[NH[6,PQ[@
M'=@HW'H!D_\ ZZGU"]70] N[^Y>2=+*V>:1FP&<(I8] !DX[ 5YMXD;4]2\'
M>$];O-3=VO=4T^XDM5C01()'5E53MW?+D#)8YY]L 'K%-+HKJA90S9V@GDXZ
MXKSGQIXAUK2+;Q'>6NJ@2Z>D<MI:VD*R*B;06^T%E^4L=V &!Q@@5/=B[N_B
MYHI74[N&*31IIA"GEE%/F1Y !4]>YZ\<$4 >@T5YPNM^*_$&B-K/AU+GSQ=N
ML%L_V86LD22E"KDGS 2JDY&,'@#%=SJTUU#H=[/:/;0W:6[O$]TV(D<*2"Y'
M\(/7VH O45Y_H^O:H_C2QTHZE<7EI>:2]QYT]NB#SD91OCPJDH=W<8/!!K"'
MB3Q5'\/G\4R:YOELM2:%K<6L82XC^U>40YQD<'C;CISD\T >MR.(XV<AB%!)
M"@DGZ =:S?#VOVGB;1HM4L5F6WD>1%$R;6RCE#D9XY4UCQ:I>:]XQUO1K6_E
ML+?1XH%=H41GEEE4OD[U8!54#C'))]*I_",.OPZLUD8/(+F[#,!@$_:),G%
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MGMMQCG)JU9:OJFM^*?[!N;@V+V.F0W-[]D()DGDS\JL0?D7:3QR21V&#-=^
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MTER/+@C=HI!*J@J2/?OG@G&"01!X6LKT?$;QA'+K5],T"62[G$>&W0L>FW@
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MO(C6*6.28HV<+NW=,$$ 8''<]I;^#)(?$$6N2:_J$^H+9&S=W6(+(N[<,J%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 445E^(M?LO#&A76KZ@S>1;H6VH,LY_NJ.Y_\
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M):2O<V8FM67[IC<3#&,G&<\<=*M6]C<PZ3-9OHWC2XN)7B=K^>[LWN!Y;AT
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MXQG-=M;^%K>UU^;6HK^^^U2VJVAW.C*(UR5ZJ22"2<DG.><UF-\-M&?PM;:
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M-?W\^OZ%J<JWHCE(:YMHSYC,P[*8BN".Y&.IKV"""*VMXX(4"11*$1%Z*H&
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MFC2N>K-C!)]SUKBIH]3O4^(/F>(=73^RY&>S\JX\O8PMQ(/N@?+G^'H>X/8
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M(=7BM=.N;*6"*&<(/FCWLIXP4)R"O<'G.!C:\?:W<Z+H]@MK(87U#4K:P:X
M&84D?#.,\9V@@'L2* .JKFKKQ7-]HO%TO2)M3AL+I+2\,,@$BN0K'8A'SA0Z
MYY'?K@UEWDEWH'Q#T'3;:ZNYM-UJ&YCG@GN'E,3Q('$B,Q++D'! ..AZU!\.
M-.A@U3Q=*LET6BUV>-0]S(ZD>7%R06(8_P"T<GWH ZK6-=BTF>QM%@DNKZ_=
MDMK>,@%MJ[F8DD *!U/N, DU!:>(II[^[T^;1KR"\MK<3[&:,K*"2!L8-@\@
M]<8JEXS\,0^)OL"6^J3:9K=F7N=/NH>63&U7R.ZG<H(^GN*R_"GB+75\33>&
M/%MC;#5XK,W%OJ%K_J[J$,%/'\)SCCCZ#C(!TWA77T\4>&;+6HK=K=+I698G
M;<5 8KR?PK8KQ'P_]LTGX:^"=9M=4ODD.HP6S6ZRX@:*2=E92@X/7.3D@]".
ME;GC;4;VWL?%M]I^JWT]SIXC:%K:5H8; JJDHPW8E9B22-K8# ''% 'J5%>=
MZNFH:K\0M-TP:WJ5G9WNBS32QVDHCVL&0!E..#SUY/;O4<:ZQXCD\1:99W\R
M3Z7*MC:SMJ4D$D9$*$2NJ)B0LQ).[@@8P.20#TBBO--=U/6]'^Q76N)>7^E+
MIR1W=WHD[*UM<@MOF**060C'J%VGCGGO=&FBN=#L)H+O[9%);QLMSS^]!4?-
MSSSUH R-1\530W.H0Z5I$NJ-ICQK>)#(%D!<!L1J1\Y"D$C*]>,G..E'(KS+
MPUI:1:[X]:"[OXI(+H+'(+N1B/\ 1U.2&)#'W8$CMTK+M]2U71_A78>+7UW4
MKC4+RT@M6$\H>"$R2J/.V$??4$\D\]Z /8:*X76'O/#/B_PTEC>WLMGJDTEE
M=6]Q</-SL++*I<G:1@YQP1VKE;B75F\ >+M6/B'5A>:/JMXMHZW!4 12  ,!
MPPP,8/'H!S0![)45S<PV=K+<W$BQ01(7D=C@*H&237".]]IGC_PH5U6^GCUF
M&Y%W!-,6BRD0=2B=$P>..W6IOC! LWPSU1F:53&8F79(R9_>H.<$9&">#D=^
MU &]>^(Q9>+M+T!K*4G4(II$N=Z[!Y8!(QUS\P].O>MRO//$>FK_ ,+%\&6,
M-U=Q)]FU &43,\N"L9(WN2?;/4#ICC&7;^(M3T?0=8L?M\\Y@\3+I4%U=S$O
M% YC/S2$$Y 9@&(.,@\XH ]7KG_%/BJ/PK#933Z?=727=U':1_9RF1(^=H.Y
MAQQUJIHVE:YIWBF:::]C&D7%M@64E]+=2+.K<NC2*"%VG!7/7!K*^+6_^Q_#
M_E[=_P#PD%EMW=,[CC- &]8>,+.Y\02:#>6EUINIK!]H2&Z"8ECS@LC(S*<=
MQD'VXJF_CG_B0R:_!H=_<:.J-(EQ$T>]T&?G$98'8<9SUQSBB/PG<7/C9?%.
MLW4#M:VC6MK:V\9"(K9W,S$Y8D$C&  /6N0N=.\0?#G2IK_09H]>\%^69I=,
MN3^]MX6&6,3]UP2<'MV/)H [O5O%B:3XETG0VTVZFGU7S/LTD;)L_=J&?=E@
M1@'TJ]K6L-HT5O)]AGNA/<1VX$+("K.P52=Q'&37&Z_>PW_Q%^&>HPD_9[A+
MV2,L,</;J5S[UU/BGFTTY1]YM3M,#UQ*I/Z G\* -Q22H)&"1R/2EJGJTWV?
M1[V;[7'9F.!V%S(,K#A3\Y'<#KCVKS_2KV^@\8>%K5;K4Y+/4M-N//DNYW/V
MID5")50L3%DL3_"><8&!0!Z917D-_<ZS!HGB?PY!J6I2>(;*^$FG2"Z?S)H'
M7S$!.>0$213[KZFNITW68?$-K_;UCJ,EI86VE ^9),S1I,Z;R9%)PQC7:3GK
MO.>@P =K17F.E7]_;^+/"$$5[J4EKJ=C<BXFNIF(NV2-&$RQ,3Y?)) P.#C&
M!4.BS:A%I7B7Q%>:YJUR=!U+4/)M?/Q',D:G"2#'S#ICIC''?(!W'B7Q&/#B
M:<[64MPM[?0V6Y'51&9&"ACGD_@/RK<KR37;:2[\(>"=:GU&[N+N[U739YRT
M[&)S(X8@1YVJ 3Q@ X'N:]*U^X-KX>U&<7\>GLEM(PO)%W+ =IPY'?!YQWH
MT:*\YT6^OK;Q]I-BLVH_8KS1Y)76^G9S-(C)B4(S,8\[CQD=>0,5'X8UJYC\
M0Z;I/B(ZG8Z[^\.YYWEL]3&TY:(YVJ1PVW P./H =[JUW=V.ESW-CI[ZA<H
M4M4D6,R<@?>;@<9/X5='(&1CVKC_ (I75Y8_#K5KRPO;BSN8$1DE@;:WWU!&
M>HX)Z8JAXSU._P!(U?[7>6VIS^'C9!7GTN=EELI=S;I'12"RE=O)R!M/'/(!
MW]%4M'GBN=$L9X+K[7%);QLEQS^]!48;GUZU=H **** "BBB@ HHHH ****
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MLESOAN2RLQ.[:&7:$.[*^F,YJUHFL:[?ZE/;:EX;;3H(58?:OM:R)(X8 !
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\R\2:K=:-KU_+KJ:BFC3W$7V35["X<QV> @,<T:L,*6!R<'._'ICTV
ML&Z\)V%X]Z)YKM[6^D$MU:&7,4K  =",@?*,A2 <<YH Q=+DGF\?>--/DO+Q
MK2.VLWBC-S)B(NLA8ISE,D#ICI7(7YEUCX&>'+^_NKN>Z:XM-\K7,@+[KA02
MV&^8^A.2.V*])O?"&F7VNMJ[M=17$D(@G6&X9([A%SM$BC[V,G\#@Y%5/^$
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MLOE$L(^>1T.#C %9ERE_)X+\<ZD=<U<7.D:K=_8F6\<>7Y80J#@_,.V&R/0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\O.S VC!QGC.2>:MSZ5'J.M?$R22YO(FMS%)%]GN'AVR"T4AOD()((Z'(]J
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MR*BWN'B.X0/AB5()QCH3CU!XJ+2->U'5[/P-IMU<*_\ :.E27$IGE9/M,J!
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M21\= 68]!DX P!DX'-:%% &'I_A/3---CY7VB1-/!%G'/.TBP97;\NXYSM)
MSG ) Q5S2-&L]#M9;>R$@CEG>=O,E9SO<Y/+$\>U:%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSQ=I$,DILK+4$^SQR2,_EAX49@"Q)QDDX]Z[B@ HHHH **** "BBB@ HHHH
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M,\-L=<E:&*0DG<D9BVJ<DD8'!Y&*F32=6CU#4+]/"]JMUJ*JEU(OB"<>8%&
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MMNY=-FX[3D@'.W&:RAX@N_\ A8?_  CCVL*VQTQKY)Q(2[$2*FTC  ZGN>U
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_:Y>SG\/%Y(5N9%5F\\#/!X[=,<@&K.CV[VWQ.\4VUI-(N-,M#%YTK2!&/F
M'YB>.!Q76'0--;71K9@?^T1%Y(F\Y_\ 5YSMQG&W/.,8SS52]T"&%]4U72K:
M/^W+FV:-9+B5S'(P!V*XR1M![8XYH \_TS1KS6]"\(B.VNTU..[WZM?*[QB>
M#YO,/G*1Y@<["NTGJ.@%76T2QUGQO\08;Y'EB2VLBJ"1E&[R'PW!Y(QP3TJK
MIO@6W>UBMH/!VI:+J2(%&H#50(HGQ_K%$<I+<\A=@!Z' KT-?#.DI>:A=K!*
MMQJ"A;J07$@,H P ?F[#(&.@.!0!YE9P0ZU'\*+K4XDNIYXI8Y9)AN9P+=B
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M2[.H);;Y>W/TR<?4UA7>D6E_I?Q/NK@2--:7<\UN5E91%(MLC*X (^;('/\
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M.*YBD1B7;>S#YLX ^[T_6NDKSBZT'3?$'Q:UFTU6V^TVW]CVQ,+.P5CYDG)
M(SCMGI7-Z;?W6GZ;H^CW5ZHT,^(;RQAN+U3+')#&&$*/\PW*7! R<?*.PQ0!
M[6"",CI5,ZI:#64TGS0;UK=KGRQU$88+D^F2W'K@^E87A;0(] UC64AU&*1+
MHQ7!L+>#RH;4D$$HNYL;\9(]1FL>73-.E^.+O-96S,= 6;>T:Y\P7& ^>NX
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M ^9<X(QCCIP/2K_PLRG@Y[8,QBM=0N[>$,2=L:S,%7)[ <4 =K1110 4444
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MP-:Y90I8D!0,Y)XQ2(ZR('1@RGH5.0: .;\11ZUJER^@P:5"='O+?9<ZB]R
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MW<P(:6)2" >NW^[G_9Q4T_A;1+G1AH\]@DFGB3S/L[NQ7=G=GKZDGZ\UL44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM+NU&CV8M[R3S+B(1 +*V<Y8=^230!S+3B\^*>G:5J4:26(T+S[.*5<H\_F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M06][:7;2+;74,S1G#B.0,5/H<=*J:[KMAX=TN34-1F6*)2%4$@%W)P%'J2:
M-*BN4N_$5W!X_P!,TM9[1M)N[&>Y+A?F#1E1]_=C'S>@KIXKB&>!9X9HY(6&
M1(C J1ZY'% $E%0VUY:WL9DM;F&= =I:)PP!],BG23Q0D"65$)!(W,!G R?R
M% $E%0)>6LEK]JCN86ML$^<L@*8'4YZ4JW=LXE*W$3>3_K,.#LXSSZ<<\T 3
M457BO[.>V-S#=P20 X,J2 J/Q'%+]MM/)\[[5#Y6=N_S!MSZ9H GHK/MVO3K
M=V)+RT>R\J,P0(I\U#SN9CGD'C''8U8@O[.Z=DM[N"9T)#+'(&(QUSB@"Q16
M=H\EX-'1]4O;.YN5+^9/:KLB(#'& 2<8& >>H-6[:[MKR+S;6XBGCSC?$X89
M^HH FHJNM_9O+%&MW TDH)C42 EP.I [XHEO[."X6WENX(YV&5C>0!B/4#K0
M!8HHJ"&]M+B:2&&ZAEEBXD1) S)]0.E $]%<=?\ B*^U+Q%J6@Z%?6-M=V5K
M'*LEPOF++*Y;$> 1A0$Y(R?F]N=G4-?M]!TZPEUJ:"&YNI8;;9&_RM,[!2%S
M@E023GT&: -BBN37Q'=1_$672)[BS_LD:/\ V@DH7:0?-V?,Y8@C )R .M=0
M+B$V_P!H$T9@V[_,W#;M]<],4 245%;W5O>0B:VGBGB/1XG#*?Q%2T %%%%
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M\'A)I+H;;ASI#DS#T<^;\P^M36.B>(]-W_89/#5OO #>5ILJY Z#B7H.P[4
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M+^1!% &+<$?\*UE.>/['/_HFN!M=.LK'0OA7J%M;117LMQ;1R7"J/,=7MFW
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M;NPLO ^LSZF+AK(6S+*MLVV1@WRX4]LYQFM#3M#TK27=]/TZUMG< .\405F
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MH.D6MU]J@TRSBGWF3S$A53O/5N!]XY.3UH \OEDM+?P1\58)FAC;^T;PK&Q
MY:!-I ]R./I5\6=AJWC3P5!>PP7=LV@2GRY '1R/*QD'AO7!],]J[ZX\-Z'=
MWL][<:/8RW4\1AEF>W4O(A&"I.,D8X^E/N= T>[MX+>XTNSDAM^8$:!<1?[O
M'R_A0!Y1?Z/;6?@_XGV=K;I_8<$A>QCQE(IA$#+L],.<<=""*W+S4(H/&^@V
M>IWZV-G-H8^QR2JAC:?</,7+@@-LV?AD=^>@\2Z+J6I:7<^&].L;"WT>[LS
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M(V4-'Q<D#Y>AQ7):;J":7X4\-1W-S]ET2/Q!>032;0R1 /+Y(8,"-H?!YX&
M>PKU\:%I"W8NQI5B+D1^4)A;IOV8QMW8SC':D3P_HL>GS:?'I%@EE.<RVZVR
M".0_[2@8- &)X6TO2K'7M:N]-U9[V2]\J6ZCC,?DQN 0" @ #,!D^O!/45UE
M5--TO3]'LQ::996]G; DB*WC"+D]3@=ZMT %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MER&VC@>VFCLW7.YRKJ5,C<C*D'IR>*[6&_L[BZFM8+N"6X@QYL22!GC_ -X
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ME\S*&\J0*?\ KB!(?]Y?2NF\919^#_B7494V3ZE"UT^X8(5MHC4^XC" ^X-
M'>2:C:V5A%=7]W!;1LHS)-($7)&>IXJ9KRU6T^UM<PBVV[_.+C9M]=W3'O7G
MNIZI!9_$;3X-5U5M-L[C1E%E.WEB-I=Y\U=TBD E?+],X%9+II/AR_\ !EE:
M7\UQX6;5+IGN+AU,/G[,Q %0%V"0OCMN&>U '8>'_$=SJWCC7].^V6EUIUI!
M;2VKVRC^/?NRV3N/R@=OI71Q:II\\SPPW]K)*GWD292R\XY /K7G2&Q?QY\0
MH8+^"R>XTFWW7",,QMY<H9^.<J,$U5T.SL?$R^!$D.E#^QH/WJ_:(I?._=!
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MZG81);O)>VR+<D"!FE4"4GIMY^;/M0!%#H>D6ZPK#I=E&( RQ!+=!Y8;[P7
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MR+Y9XZY8C]:[EE#J58 J1@@C@B@#S&35H3XB^'UPUQ%)HY@DA\U6!C2[,*[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@\YXPX1-PWG:>IVY ]S7&VE[XCN?B!JGAS^WBL-I8Q7*2_8XRQ9R001C&.*
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M 0.EW%&RA5=C&UP(AN##Y=RY;IFNVL->TC5+NYM+#4K6ZN+8XFCAE#-']0*
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M]W%Y\'A-8[R&"XN"Q2&61@5D)/16 8*3V8] :[6;P_KER@2?Q*)5!R ^FPL
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M"021LJ>(;S:J," I8$=.W6CQ%IGBU+S6=1LKG1&M9+8QQBZAE:6*()\R@JP
MRV3G'/&>@QK)H.O1Y\OQ/MSUVZ=$*<=&\1$8/BIO_!?%0!YQI]GJB_#WP!K5
M\;9[;2KRVF)MU8>7:,@3>^2<E2<DCC'/:NKEL(?$GQ6>Y"I<Z79:*]I<,#E'
MDF?F//?Y!D^FX>M;8T3Q %VCQ20N,8_L^+%,3P_KD<'DIXE"Q8(V#380N#UX
MH X^Z\)_;;K2/".E:K?WNC:==I<WGG-&T5M'&<I '"AF8G& 6.U1SVKI[BX?
MQ#XQ-OINI6J?V(FYPR>=F>0$?=##!5,C/_34CM5N/0M?AC6.+Q/L1> JZ=$
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MX$GSWH,>(95)YR!M4CM@>M1^&+_PIXCM/#49O[N;5].:,QZ<6V26LB*%?<H
MP@ .<\$<=2!7J7E1B3S/+3?_ 'MO/YTB6\"2O*D,:R2??<* 6^I[T >.!]/;
MX<?%!@]L2VIW_.5R>%*?KT]ZVKR:QB\2_# Q2VZ*4N -K*!M:U(_(MC\:](^
MS0 $>3'@]1M%!MXL96&,LH^7*@?TXH \BL(M#F\'?$:WO4M6F;5K]2A ,A.?
MW04=<[ONX[].:OZ<SZ%XR\%1:W.L-Q_PC;6K-*W+S@Q90?WFXZ#DUU7A/PS<
M:*^J2:@EE+)=ZE/?Q2199H_-()3E1TQU'7T%=.R(S*S*I*G*DCI]* '4444
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M2(H)SYT9>;&,D<8W=\'MR=#6-2L;KXI>"IH;F-D:VOL-G&0RIMZ_WL''KVH
MZN[\2Z-8SM%=7\<91UCD<@^7&YQA7?&U2<C@D'D>M)?>)]#TV]:RO-4MH;I8
MC,T+/\P3(&<>Y( ]<\5YSI5W;V_PX\3^&M<91K:R7JR6TG^MNGE9FC>->K[M
MP ([BK6EQG3O'W@ZRU2>)K^T\./#,SN"1+^[&,^IPWU&: /1M*U:PUO3X[_3
M;J.YM9,A9(SQD'!'L0>QJAXGU>?2],D2P59-2EC<VZMRJA5RTC?[*C'U)4=Z
MP/AE/!+#XG6&6-@/$%XZA6!^5F!!'L><&E\1:)XH%QK>HV6KZ8MO/;%%BGL7
MDDCC5#\@82 <G<>G4]\"@"K'XNU%/ 'A&3SP^L:\UM;"X9!\A=<R2[1P<*"0
M.F2.U6[SQ5<>%]>U33-0FDOX(='?5K:60*LA\O(DC.T 'HI!QW/7BN2T_3-5
MC^'W@/6;R2.>+2;JWN&6&$J8;1HPA+#)W%<Y)&.,\<5T_P!DM_$?Q/DU1#%<
MZ-9:,UG+,"&BDDE<ED!Z$!!SZ;A0!%=>(M6T?PWX>\47&HFZ@OI+<7UJ8T$:
M).!@QD#<"A88R3D9SSS74^*M1N]-T"=M-02:G/BWLD/\4S<*?H.6/LIKA9?"
M5OJ5[I'AW1;^^N?#^G7:W=RTLP>")4.4MXV RY)Z@EM@'8D"NDEG3Q)XR>"P
MU9(1HL?2,)(6FD!#'!S]U<#([R,.U &AX)\0CQ1X0T_56&VXDCV7"8P4F7Y7
M&.WS _ABMNXN(+2VDN+F9(8(E+/)(P55 ZDD]!7FWABZB\(?$W6?#-S?I+;Z
MJ%U*W<[5VSL2)(R!P&; 8#C@>];?Q0BO7\(I/:0R3QVE];W5U!&-S20)(&<
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M\?[)->>:C>KKWCCQ+'HDYEFO/"OE6<L8.V1]TN"K=",GKT_*IO"^I>$_$O\
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M&28@)!<&4.0YZ*64*.O)&.:Y77;.^6V\6ZUIT4EQH4VM6-TT4(W">*(*;AU
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M1*&F9(7D6%3T,A4$(#ZMBJ^H^-/#FE2F*\U>WCD%N;K:N7/E<?,-H.>HQZT
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M5!_$P0$A?<\4 :.**S6U_2UL;6\6[6:&[&;8P*96FXS\BJ"6XYX'%8NK^/\
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MLJG#-L52P /!)'6J&I^/=)LUT-[5WO(M7F"0S6\3R)MP2QRH//RD;>N>W!H
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MEJ6J6OAWX@:C)XJ^VV]EJEK;_9;NV><1;T5@\1\L]<DD9'<^M=?_ ,(UJ/\
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M5054OU )PNUN1CC.#0!U.AZSH\.BW-[;ZS=W]JU])'YMP&=Q*SX\I!M!(!.
M #47B'QW8:-X9U+5H8;J=[*00-";612LK!2H<$#"_.ISTYXR2!7':3!IUYX,
MU2UU-KVVBE\1W$D=S;;DEMB96>*8<<+P.<8P3Z5'K UZ]^&OBZPNI5UA;:6
MVNI6\&UKQ T;,2%X8H!@L.#CV- 'ILVOV$$$,C_:MTP9HX!:2F9@IPQ\O;O
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MVC02^4QC8)YF\EP-HQD=2* *?@#QO9)X1T6#6]5GEU&[GE@\Z9'<&0S.$5I
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M$KVR,X/%9H^(GA8VT%R-3)MIIC )Q;R^6K[MN';;A,D8&[&?I67>-!XB\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !117+VOBJ+5/%^L>&Q;WD0LXH1YXA<99]Y)W 85<*N"<9.<9H
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MM)YFM[!WCN2]M(AC=!EEVLH)([X%:EG=17UG#=0;_*F0.F]&0X/3*L 1^(H
MFHK!D\8Z+$T;27$BVTD_V9+LPMY!DSMV^9C;U!&>F>,YK$\2Z\#XXTGP])_:
M"V4MO<2W/V:*96D8! @5HQDJ-Q)VG&<9H [FBN9O[W_A O MQ=7$]_JWV")V
M$DW[R63DE0S = , L>PYYKG]<\0/_;?@?4?M=[:VUS-*MS!MDC23]PS#]V1E
MOFQC@YXQF@#T:BL73?%>CZI8WUW%</#'8.4NUN8FA>$@9^97 (X(/2G67B;3
M;W5SI0:>"^\KSTAN8'B:2/.-R[@,C/7N.XH V**XWXC:[/H&EZ=<F2Y@TR2^
M2/4KJV4F2& @\C'(!;:"1R >.2*LZ+;"YU"+4-(UZXOM!GLY$V&Z\X)*63:R
MN<OG&\8).,=LT =317FG@CQI9:=X:ACUK4+R:9]2N+?[3+')*J$SLJ+))@A<
M\  D=NU=AJ?BS2=)FNXKB69VLH5GN_)A:3[/&<X9]H./NDXZX!.,4 ;=%8&H
M^--"TN>SAN;J0R7L+36PB@DD\U NX[2H()P1P.>1Q2MXPTD:?'>QFZFC:V%T
M5BM9'>.(YPSJ!E>AX/)P< X- &]16.OB?2Y8;26TF>\6[A-Q"+6-I"T0QE\
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M:X>6"ZE,$*K$WF/("04V$9##:V<]-I)X%7=.U.WU2*62W$H\F4PR++$T;*X
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M#D8^4MROS\FNW\"2ZR^FWT6L3K>>3>-';7XA\HWD05<2%?7.5ST.WOU/544
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M8P#R6YP&XZ9R_"NFWOAF75O [PW;V<D)EL-52T?RQO7:8W< @,N!CD_+@9X
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MNWM9%@WGHAD(P&/IV[XKJ[G_ (]9O]QOY5XYI<'_  D_P+T7PY9V]PU]<"!
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MT3/+!O9'639U(^7!]*S=;LY!I^D>(-#\-7$%E9ZRE]<6:6^RXN(]A5IC'U+
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M@/V96!/.XC/W6X&3@=* .FHKF[[QQHUC)I*$W<YU:)IK,P6SN)5";^#CJ1C
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M#CKVS7+6.FZEI/ASP1JESX<N]1@TVTFLM1T\VQ:>/>5(=(V'S8*#IV->ST4
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M_GN;.]CLTEAGCE<N%D=N$()(.[M^OJ-M'Y-K%%LC38@7;&,*N!T [#TJ6B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[7/!UA
MX@U"&]NKS5(9H8S'']DO9( H/7A2.3QGZ#TKH:* ,K0O#]IX?MI8;66[F,TG
MF/+=W#32,<  ;F). !T^M:M%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exc_compmins2-9x23v1x202003.jpg
<TEXT>
begin 644 exc_compmins2-9x23v1x202003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$L/(WV5Q.L=_/VMQ+N6'/IEU;)[!?>NQH **IWVK:=I84ZA?VMH&!*^?,J9
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MR+'?ZE:6KL,A9YU0D9QGD^O% %VBJEUJNG6+*MW?VMNS(SJ)9E0E5&21D]
M234,^OZ-:VD-W<:M8Q6TZ[H9I+A%21?523@CD=/6@#1HJI=:II]E%'+=WUM!
M'(,H\LJJ&[\$GFIX9XKF".>"5)89%#)(C!E8'H01U% $E%46UK2UOQ8-J5F+
MPML%N9U\PMC.-N<YQSBDN==TBRDDCNM4LH'C*AUEN$4J6X4$$\9P<>N* +]%
M4I]9TNUO8[*XU*TBNY" D$DZJ[$] %)R<U8N;F"RM9;FZF2&")2\DDC!54#J
M230!+16+H/BK2?$&B?VM:7</V8 LY:09C7) +_W<@9P:T++4[#4E=K"]MKI8
MVVN8)5?:?0X/!H M45ROC'6-1T:^\-_9+B*.VO=5CM+E6C!)1E=CAB>/N>G?
MK6]I^K:=JT;R:;?VMY'&VQVMYED"MZ$J3@T 7**I6NLZ7>W<EI::E:3W,8R\
M,4ZLZC.,D Y'-6I98X8GEE=8XT!9G<X"@=23VH ?17&6?B>6_P#B<-)L]3L[
MO2CI+W.VWVL5E$J+\S GL>G'6NFCUG2Y=0.GQZE:/>C.;=9U,@QU^7.>* +M
M%<AH.M:E>:UXOLK^^@6/39XX[>7R@BQ*T0?)R><$]SV[5JZ?J]G::7IT>I:_
M87-U/$NVY$B1"Z/]Y%SC!/IF@#:HJ#[;:F\-F+F'[4%WF#S!O"^NWKCWJ"UU
MK2KZ>6"TU*SN)8ANDCBG5V0>I / H O450M];TF[N([>VU2RFFE5FCCCG5F<
M*2&( /(!!!]"*=::SI=_<R6UGJ5I<3QC+Q0SJ[*.F2 <B@"[17%?$'Q8=#T"
M=]*U:QCU*&>%&@8J\A#R(I 7/! ;/0UVA(4$D@ <DF@!:*Q=*U&*VT5)]2\0
M6-]NG=!>*4BC8ER%08)&1PO7)(]:OV>JZ=J$UQ#97]K<RV[;9DAF5VB/HP!X
M/!ZT 6Z*CN+B&U@>>XFCAA09:21@JJ/<GI4-IJ5C?VS7-G>V]Q I*M)#*KJI
M'4$@X&* +5%4K+5]-U)I%L=0M+IHP"X@F5RH/3.#Q41\0Z('A0ZQIX:>0Q1#
M[2F9'!P57GD@]A0!I452NM9TNQ>5+O4K.W:*/S9%EG52B9 W')X&2!GWJ1=1
MLGT\7ZWEN;(KO%P)1Y97UW9QCWH LT55LM3L-2MVN+&]MKJ%6*M)#*KJ".H)
M!ZU73Q#HLD%S/'JUC)%:KOG=+A6$2^K8/ H TJ*Y1?%%GXB\(G4M'UZSTTNR
M[;F?8XB&_HRDC!90>#R,^U=#>ZE8Z9&LE_>V]JC' :>54!_,T 6J*JR:G816
ML5U)?6R6\Q412M*H1RW3:<X.>V*2SU73M1FGALK^UN9;=MLR0S*YC/HP!X/!
MZT 6Z*JW6I6%C+#%=WMM;R3'$22RJA<^B@GG\*;%JVFSW,UM#J%I)/ "98DF
M4M&!UW '(_&@"Y16+<ZA'=W>DRV&OV,5O),VZ,;)/M@"GY$;/!!YXSTJB_C+
M3]1EUO3M(U&U_M#3XR 68.#)M+$!<@MM &<=S[4 =117+>#/%$&K>'-#_M#4
MK1M9O;)+AH/,19'R,DA!SCZ"MW5-4LM%TR?4=1N$M[6!"\DCG  _J?0=Z +E
M%<)J?C&:X3PC?Z1>VPLM4OXK>ZC 61E#1-(5+9PI& ",9YKL+#5-/U6)Y=.O
MK:\C1BCO;RK(%8=02"<&@"W15*TUG2]0N)+>RU*TN9XAEXX9U=E'J0#D5=H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/
M]'L=/F^+/C%9;:V?_0[(L&13]Y9-Q_$8S7H%5#I>GF624V-J9),AW\E<MGKD
MXYH \7LH+2+X'>%;Q8X5G&J6K"; W9%SMSNZ\*,?05ORZAI;>*O&.B>*-<.F
M?:V1HUF:%(Y[0PJH"M(AZ$/P#U)(&<UZ.='TLQ"(Z;9^6#N">0N ?7&*=<:7
MI]VT#7-C:S-!S"9(58Q_[N1Q^% 'G<=UHVGZ]9Z5:S?8Y8= 5%O=3<F1[4N0
ML:(2 6XR21D<#![<YI7]GZAX&^&"2?9[AEU2."4-AB!LERA_\=X]Q7M<MG:S
M7$5Q+;0R3PY\N1T!9,]<'J*A.D:88XT.G6A2/.Q3 N%R<G'''- '"V$%HGCG
MXA6WE0B V5F[Q;1MSY4F21T[#]*YV&"TN?A_\+!/'#)OU&VC.\ [E\N3*^XS
MC(KUXZ5IQ>1S86I>7(D;R5R^>N>.::='TLHJ'3;,HA)5?(7"GVXH X 6]LGC
M'XBVD=PMA%)I-L7EB&/*)BE!DP.X&#^ JAH']F^)&\#))?:,KZ+ 0\:7D4KS
MDQ!%5$!R!P&.0"" ,'K7H.M:"+W2K^+2S!I^HW,3(MXL +*3UR1@\].N>:Y^
MV\(7=Z8H]5T/PO:)&Z/]HT^(M*2I!&S<B^6>.N6(_6@"U\4OMP^&^L'3TD>4
M1J9%C^\8MZ^8!_P#=^&:S_$9@U+Q!X$O]!DC>8W197AQ@V1C)DSC^'[@^I'>
MO0*JVFF6%@TC6=C;6S2'+F&)4+'WP.: .1\*O&WQ,\=JK*6$ECD ]/W%;/BN
MXT/[%::;XAB@DL-3N/LA%P0$#[&=<GL<I@'CDBM6'3;"WG,\-E;1S'.9$B4-
MS[@5--;PW";)X8Y5]'4,.F._L30!YEHNE7W@CQ_9>'M%U2:^T*_M9YFLKA_,
M.GE -K!NH1F(4#Z]3S69X;GT#7O".E:=K6NW::S8W:M)IH:)+D7BN>5&S><L
M2<Y[G)X./6;+2]/TQ76PL;:T#G+""%8]Q]\#FE&FV*WYOQ96PO"-IN!$OF$>
MF[&: /-M+U3P]-_PFF@>,)X(KB75)6E@N9"CW%N=ODE,$,WRA0 O/ ]:TDN+
M6T^,D(G9;99O#<4<,<S ,6^T'Y.3RW(XYKN)=.L9[R*\FL[>2ZBXCF>)2Z?1
MB,BI'M;>6>.>2")YH@1'(R LF>N#VS0!XQ>>=!X#^( TZ/,47B60W,4(Y^SC
MR?,  [;0V?;-==XA2'4?&G@F\T=XI9&:8R/$05:R,?S;L=5SLQGC)%=M;V%G
M:%S;6D$)?[WEQA=WUP.:9::7I]@)!9V-K;B7_6"&%4W_ %P.: /&+NRL!\(O
M'TZ6]N)$U>\"2!1E=LXV 'MC/&/6O:)S=2:3*UBT7VMH"8&ESLW[?E+8YQG&
M<=J8-'TL1M&--LQ&Q#,OD+@D="1CW-6HHHX8ECB18XU&%5!@ >PH \>\0V?C
M'37\(VL\&@EEUE&A=)YF,LYCD):0E!P<L21W[8KI] C?1OB;XM;46CA&I6UI
M>Q.6PC+&ACEP3_=;'T#"NZDABE*&2-',;;D+*#M/J/0U%=6-I?*BW=K!<!&W
M*)8P^T^HST- 'F7A7PA'J?@N'5+RYFTRZ_M6XUBRNEP&@5V."P;@JR $@]B*
MTO"=I/<>*=:\:ZE=NUC]E6RLKBX18]\"'>\N !A"WW<\D#/<5WMQ:6UVJK<V
M\4P0[E$B!MI]1FG300W,+0SQ1RQ-U210RG\#0!Y[<^&=2\9>$-4=KVQCBUX?
M:HUDM':2-<#R!O$H (54/W>"6Z]]SX=^)?\ A*/!EE=S.#?PC[->KG)69.&S
M]<!OQKI([6WAM_L\5O$D!!'E*@"X/7CI3+;3[*R9FM;.W@+<,8HE7/UP* .(
M\0:GIR^.KVS,EO97PT8"6[NGSYD+.V(XD)"DYR2W/88/;D-+_L_4?"?PL63[
M/<,MZL$@.&QB)\H?_'>/<5[1)9VLUS%<RVT+SQ9$<K("R9ZX/45"='TPI&AT
MZT*1?ZM?(7"<YXXXYH \G\1&ZLYOBM'HB[)Q:V+[(!@@&,B1@!T.S/-:NN:O
MX>NM;^'5UIUW9?9ENF$)611Y<9@8!?\ 9Y"C'J,5Z1%I]E!<-/%:01S/G=(D
M8#-GKDXS44&C:7:N'M]-LX6#F0-' JD,>"W Z^] &!\3E+?#+Q$ ,G[$YK!U
MJ;3M5\4_#H));W5NTMR."'1B+8_@><?C7I#HLB,CJ&1AAE89!'H:J_V3IO[K
M_B7VG[D!8_W*_(!T XX_"@#R75GDLK3XDK8(WDP:E9S3PVZC/E;8C-A<8Y4-
MG(P><UUVB-X:UGQ79ZWINORZKJ(LVB_=21;4@)S^]5%7'S8P&YSVX..OAT^R
MMI'D@M+>*1QAV2,*6^I YHL].L=.5UL;*WMA(VYQ!$J;CZG Y- &1XKFT*2V
MM-)\10V\EEJDQMP)SA=^TLO/8_*<'(.<8KDO#NF7O@OXA6OAO3-5GU#0+NTE
MG-I</YCZ?M(VD-V5B< ?7TS7I$UO!<IMGACE7!&'4,.>O6H+32M.L(9(;/3[
M6VBE_P!8D,*HK_4 <T >,206:_ _4KY8X1<+K+.)\#<"+X8(;KT/Y&MWQ;J>
MG27GCVSADM[*Z72D2Z>=]TEW^Y=HUB0G"@;L$@$DGH,9KTG^QM+\HQ?V;9^6
M3NV>0N,^N,4_^S; RK*;*V\Q8_*#^4N0G]W..GMTH \NA73-4UWX6M(+6Z63
M3KA7)VN'9;>/@^N#G@]"*M27>DZ5X\U[1-7U--$LI[.W6P0K#'!);!"'12Z$
M##EOE!'6O1?[)TW=$W]GVN8@%C/DK\@'0#CC%/O--L=0\O[;96]SY9W)YT2O
MM/J,C@T ><KI$ME'HO\ PA6L*MY8Z?(MO::L-R7MHTF>HP5Y5<,!T*YKLO!>
MH1:IX-TJ\AL38QR6X"VV<B,#Y< ]UXX/<8K3N],T^_*F\L;:X*_=\Z)7Q],B
MK*JJ*%4 *!@ #@"@#Q'5]8TRYT"*>RN+:QMT\4)*UH\FZ?>+G]Y+(6/R \G
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MEVL;6Q\0VXE$N-A!CE&#GC';FN?\2:5/;^)_%<_A6 19\-M'=+:+M!N2^4
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M#736ME:65L+:TMH;> 9Q%%&$49]AQ3;/3[+3HVCL;.WMD9MS+!$J GU( ZT
M>,S7%A<_LV6BK+;R36T=H&P03$WVE!@^AP#7;6]T\/QFOH-0(5+C28O[,9_N
MLJN3*J_[62I(ZX ["NN.E:<T)A:PM3$7,A0PKMW'JV,=?>BYTO3[RWCM[JQM
MIX(\;(Y8595QTP","@#QB_L8XO!FJATC.E_\)<G]F[L;5B,Z!]A[)NW]/0UV
M]M!;6?QM:&UBB@5_#@+1QJ%!Q<8!P/0<5V4VGV5Q%'%/9V\L<?"(\2L%^@(X
MI$TVQCN!<)96ZS*,"01*& QCKC/2@#G?B)ID][X4DO;)-VHZ3*FHVGN\1W%?
M^!+N7\:Y$ZIJ$'BBW\2Z= ZVOBZ#[%;KY>#%*BY@E?UROF-_NX]*]:(R,'I4
M8MX0L2B&,+#_ *L!1A.,<>G!(X[&@#@O$]A9Z;XF^'MO!&B""\>",G&[8(&
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M*\2TNM3M(+AV"+'),JL6/08)ZGL.],N_$>B6#W"7>KV,#6RAYUDN%4Q@G +
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MN=7O+*33K69I-/M[:%E<94J#(Q)!*J6  '4Y[ #H:** "BBB@ HHHH ****
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M^JY'0U*T$+R+(\2,ZG*L5!(^AIMVLSVDJP!#*RD*)&(7/N0#0!XE:VNGZM\
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MK8O]T?E2@ #  'TH \IT76M!BM?$?A7Q:BMJ$FJ3R-9RH2]ZCONB:,?Q9 4
M#IM'2M?2+]=)^)_B6+6I([07MM:RV#S.%1H8T(=%8\?*[$D>^:[TQ1M*LIC0
MR*,!RHR!]:)88I@!+&D@4Y 90<'UH \2-M%I_A/PY#>F*.QG\9":QAGP +0R
M/MX/\)!)^C#UKHKN]L8_B#XU!N;=0V@P[P9 ,D"4'/N 1^8KTTJK=0#]12;%
M_NC\J /&XKG3X/ 7PL*3VT;+J5F6PR@C]TX?/XD9]SS4\6H:#]L\4^&_%]_=
MVT]QJ,TJVQ9@+R"0@QF/ RQP N!S\HKUW8G]U?RI&AB>1)&C1G3[K%02OT-
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MSUX(XZG%:_PW_LV[N_%KQ_99IE\17,@(VLP&% 8>W+8/N:[Y88ED:18T#O\
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M3QC.A0C#':01*[$$'H0""0>0* -'X=:C?:IX7DGU&[>ZN%OKJ(RN "525E'
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M'FQX!W*2,'@CZ9H TPH!)  )Z^]+7.:GXBT6\\-:M,-<>P@MV>UN+M 4DMI
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M]P_$.G7"N9%*[&,$:C.1QD@@>N.,UF:M_IG@_P"*$-H#,[ZCYR)&-Q= L66
M'4?*W(]#7M5% %;3[^WU.QBN[1R\$@RCE"NX>H! .*\W\8DV>M:UJ>AZPMKJ
MT4"+=:5>()(-40)E55>NX@E/EYS@<9S7J-% $-K))-90RS0F&5XU9XB<[&(Y
M'X=*\6TZ>>'X2^'&CM;Z;^PM2675+:!9$E2,/*&QC!++N5L \8!.*]OHH \N
MOKGPOJGA?Q3K.A)<SO/HTUM)?SO/^\)0[(E\T_,V?3IP.],\426K_ [3(XS&
M=T6GH$4<Y22(L,>P#9';!KU2B@#@KRYM&^,ND2B:$J-&G4.&! 9I$*C/J1DC
MVKD;R>&3X7_$:)'5GFUF[:%!R9 SH5*CN#@X(ZX->UT4 >>WEW:3?%+PI,LT
M3H-,N1O# @%O+VC/8D!L?C7.0ZO;Z?H?B28VL%S&WBXN99(C*EM&S)BYVC[P
M!!P1P37LM% 'D=K(+G6_B)!;O>WDE]I$)MY98&!GQ#*"1A0,9( P #QC-)J6
MI6ES\,/!/ER',%]IBR;D*[3'M\SJ.B\Y/05Z[10!Y_INH1Z!\2?$S:U.EO;:
MHEM/I]U,P6.1$C*M&&/&X'G;U.<URHL&TGPSX7BNU\F*7Q<+V"WE&##;%Y"I
M*G[HP0>>FX9Q7M5% '"Z-/"WQ@\1[)$/F:?:*"#PS*9-P'J0",^F:/%TDNE^
M//"VMW6[^QH%N;>XEQ\MM)(H"._HIQMW'@9]Z[JB@#@=+6+_ (3CQ3XCAF1=
M'EL[>$W ;]W/*@;+*>C!057([DCL:M?">1&^&>B0AAYL,&R1/XD.X\$=17:4
M4 >7ZMJ6G^'_ (B:S_PDYOX-/U2& V-U \XC;8A5XF\H]<Y(!'\1]>26#3--
M\4?#JVLK0V%E U\T=O,S%HD>,["V[E2Q/ /()QVKU"B@#S"QN;1=6^)KF6$+
M*$*G(PX%L%./7YLCZ\5EZ?>6=LWPDEO)8TBALKB.1I.D;BV08;/W2#QSTKV.
MN=U?P[=ZEXLT/6HKZ&)-*\[$+0%C+YJ!3\VX8P!QP: .*U"UC*_$S6[0J-.O
M]-6WAD7[MS.L+ABG][EE7(ZG/I4D%T=-U?P)K=R__$E72#923_P6LS(A!<_P
MYV[<GH1SBO4Z* ."T/1X=7\6^,K[8LNAZK%;VV1]RY98RLC+ZC#!=PZD'TJ+
MP);ZHUTVG:NK%/#!>R@G<\7!8 I)[%82@_[:-79:W::E>Z7)!I.IC3;PE2ER
M;=9@H!!(V-P<C(_&G:1IHTJP$!G>XF9VEFG< -+(QRS$#@>P[  =J /*?.MG
M^&WQ(17C+SZG?M$O>3=C85'?..".N*VK^ZM3XG^&SQS1;(TGW%2,(#;[1GTR
MW'UXKTJB@#QK1YM#?2KGP?XILM3GUJ.ZE_T'S+G9>$RF1)$VG8%)()8X P2:
MZ/2[FSB^)7C>2:6%5-G9J'=A@[4DW@$]<97/X9KT*B@#Q72IUM? OPTNY]XA
MLM0"W+!"WDDQR* P R.2!^(KV4W$2VWVB1O+BV;RTGR[1C/.>GXU+10!XDLT
M8_9E>VW?Z08WC$/\>[[03MV]<XYQZ<U[/:W$-U:QS6\J2Q.N5=&R#^-344 >
M>>#3'=:CX[BM98Q=3ZD[0N.I'E(JN#W ;/([YK#\)W7AW4M(T7P]JFGZHWB+
M2WA5M/FDN<12Q<"8'.P*!EL],< '(!]?HH \=CUV'3?"'CGPYJJSQZV3J,VP
MPN?M$<BL5E4@8V[2!G/ %7C>0:1JGPXU2^<PV(TB2W:<J2JR-%$54D="<''K
MBO0O$&FRZSX>U#2X9T@:\MY+<RO&7"!U*DXR,G!]:?H=A+I6A6.G33),]K D
M'F(A0,%4 '!)QT]: /*C=QR^!/B<A29&GO[IHEEB92^Z) H&1U)!XZ^U;%S=
MV<GC3X<R>=$RQV5T&;((0M#&%R>Q)! ]P17IE% 'EVIZCIOA_P"(.MQ^)_M]
MOI^J1P-87,#SB)PL>QXB(CUSD@$?Q>XS&LEGX0\8^'+Z6RFT[PRVE36=MYN]
MEM)6E#@R$Y*%E Z].G8UZK10!P7P^NX;CQ#XR:$2;)=4$J,8F564Q(,@D8Z@
M_P Z?KMPFG_%CP_=W"R""73KFW1UC9@TA>,A> >2 :[JB@#RG2+J+3_!OBKP
MUKG&K-/>D0.,O?"7<4>,=7W;L<9P1SBN]\)6%WI7@[1["_8M=VUG%%+SG#!0
M",]\=/PK9HH \/?68+[2/"]T(IK,VOB.-I]+M[1ECL1ODR&PN2Y)!//.3@"N
MP\36VHZ3XVL=6T:&0_V[ =+N2H_U4@!>&<C_ &1OS[#%>@44 >?Z]$/#GCCP
MIJ$BF/0+:TFL#*?N6KL%V,Y[ A0NX\#OUJA<0*]Y\1-=@D7^RKW34@BD!^2X
MF6%@S+_>^\JY'4Y':O3Z* /(;?4!H_\ PKC6KTM_8MOI1M)YE4LMK.T2 %\?
M=^Z5R>G.<5O^#;ZWO/B+XVFMM[0SO9/'((F".!  2&(P>WU!R.*[^B@#A?%T
MZ6'Q$\&7]PL@MD6]B:1(V<!WC3:O /)P<>M8L-S:F7XI,98OWRX0DC]X/LP7
MCU^;(X[\5ZI10!XU!J4&BCP;J^KF]&B/X?CL9+FUDE'V6X&PD2>6<@'&/JOM
M7HG@^WTB'3+B?1+.:WLKNZ>X#S&3=<,P&Z7$GS $COUQGO70T4 <''=6\?QJ
MOY'FC1%T*-"[,  RS.Q&?4*0<>E<4DEO_P ,_P!E;,4\X:@I:(CYO^/W<<KU
M^YS]*]QHH X2>ZMV^-.FNDT;*VARQ[E8$%C*C*N?4@$@>G-<1IHL=:^ ,/A^
MT\J;5[B1D@M5QYHE^T$A\=0 .2W3 /->WRB0Q,(659,?*7&0#[@$5A^#/#T_
MA7PQ:Z+->1W?V8OME2$QY#.6Y&X_WO6@#G-&O1X;^('B:+7[A8$U 6\]E=SG
M:DR)'L9 QXW*?X>O.:Y_3="2S\,:/!=ZK<^'KXWE[=Z5=$ +;(S_ "QR*W&&
M5L[3CTZ\5[%10!Y%J^IWUYX"T9]7CMH[I/$4/[VW7;'<HEQEIU'96&6STYST
M(KH8KN*R^,EZT^]4O='MUMW"%ED*R/NP0,< @GT'-=Y10!XH4NKKP3K\NG1O
M<_9/%DE_-;1#+36ZS!^!_$"!N'KMXKK+^:U\1^/?"FJZ-=13V^GQW4MY<Q-E
M8XGC"JCGL2W.T\C:3CBN_HH \/EF@/P,UF%&7SWU5W6,??;-X&! ZGY1GZ"O
M8-7CFU'P[?Q:=,HGN+21;>56X#,A"L#]2.:T** /'KAX]>^#>G>%[53%XBA%
MI:"S(Q-;S12(&D*]54!6;=TP>O-=+-=VZ?&ZUW3H,:#)"6)X\PSH0F?[Q )Q
MUKO** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8_,"?WOND'&?3O6Y?>(;#7_'G@;4-.2[F@C-YYK"TD_=%H0 &^7@YP#Z=^*
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M;X@(U*H/E)QT['(JI>6EUJOB?XBV5@Q2YOM*MX+9S\H>01R!E#=,@L <=,T
M=M#XLT6>ZM($NV!O"1:R/"Z17!ZX20@*W'(P>1R,U5N_'OANRDOHY=08R6!
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M/;>6C2>:@&XE=H.>,<=3D#O447C_ ,-3E5@U!Y9&MENUBCMI6=HVZ$*%R3[
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MZ6DKBP5CY,B97+N,8R.,<]S7FEU^\^#WC*W2-S<3ZK<O%"(SOD#3AE*KC)!
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M8WD,>X2%ML:+D#@9...YKL1X@TQ],M-1BNA-;7@!MC"C.TV1D;5 +$X!.,<
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M\#QBX5>6*%@ <#G'7'/2K.JZYI^B&T^WRO$+NX2VA81.X,CG"J2H.W)[G H
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MGN+\_NBRIN>XDY.55?4 G X !Z 4 2Z#H\NDVTAO-0EU&_G(:XNY$5#(0
MJ\*H Z#U)ZDUK5B6OBW1KJPO+P71B2RE\FZ2:-DDBDXPI0C.3D8P#G(QFH)O
M&NE0Q:GE;LW6G6_VF:T-NZS&,CAE4CD''7H.^* .BHKAW\4:9K'@[0]1U2ZU
M'3#>RVK*;:.6/=,VU@F[;RA)QGH1WKI;_7K*PN6M6\^>Y2+SGAMH6E=$R0&(
M4'&<''<X.,X- &G7/:UX<N=5\1Z)JT5_% -*DDD6)K<OYA="ARV\8X/''6EN
M/&WAZVT[3M0?45-GJ,JPVTZ(S([$XP2!A>ASNQC!]*L:/XFTS7;J\M;-YUN;
M,KYT-Q;O"ZALE6VN <'!P: -BBLK7=.?4;8(VKW6FVJ!FEDM7$;GT^<@[5')
M..O'.,@X?@I=3U3P6RWNKR7+&XF6RU&-QYDD*N1%(V."2!G!X(QD=: .MG65
MX'6%T20C"LZ%@#[@$9_,5C>#_#\GA7PQ9Z*]XMVMJ"J2B'RR023R-QYYH\):
M\WB#13/,BI>VT\EG>1IT6:-BK8]C@$>Q%,NO&NBVFH7VGF2ZEO;)%>:W@M)9
M'PV<$ +\PX/(X'K0!T%%<Q'\0?#<J:?+%>R26U^R1PW*VTAA#MPJ.^W:C$\8
M)!'?%6M3\7Z/I,UY'<S2G["B27C10O(MNK?=+E0<<#/KCGI0!NT5D/XFTJ/7
M;31C/(;V[B,UNH@<I(@&20X&WCZ]ZMVNJ6MY?7EG TAFLV5)]T3*JL5# !B,
M'@@\$]10!<HKSR\\0IH'Q3U)+Z]OI;,Z/%-':1K)-AS*X)2-0>RC)Q]3756?
MBK1=0T2WUBSO!/9W#>7"8T8N[YQL"8W;N#QC(P>U &S167I/B#3]:ENX+21Q
M<V;B.YMYHVCDB)&1E2.A'(/0T_4-8M+&XCLW::2[F1G2"WC,DFT=6P!P!D<G
MC) ZT :-%<!\/M>0^&]7OKZ_N9X5UJYA@>XWO(4WA8T"D;L] %QGVK8O?$-E
MJ^CZ]9V5S<VNH6-LS2QLC0S190LK#(Z''!'% '3T5Y_I>J6;>!/ [ZSJVHPW
M-T;,Q20N^ZYF*C"2, <JQ)R&(SBNKM?$6FWNNW>BPR3&_M$#S1M;R*%4]"&(
M"D'M@F@#5HK)3Q)ILEFERCSLLD[V\<?V=Q))(I(8*I&3C:W/3@G.*H2>/?#T
M.D7&IS7<D<%K/]FN%>WD#PRY VNN,KR1R>.>M '2T5A6WB_2+N*5X)+AC'<?
M9A&;:0/))MW812,L-O.1QCG.*=:^+=%NM-O;\7?E16,ABNEFC9'A<?PLI&<G
M(QQSD8S0!MT5P"ZU)=_%_3K6*?48H&TJ:62TN%>-,[T"N%/!.,\]1R.*Z#Q?
M>:;9Z/'_ &IJ%[80R7$2K-9EPY?>-J[E!P"< YX(- &_7-7_ (<U0^()]7TG
MQ UD]S%'%/!/:K<1D)G;MY4K]YN^.>E3WWC'1M/U:72II;AM0B@^T&WAM9)'
M9,X!4*IW<YZ9Q@YQBM#1M8L=?TF#4]-F\ZTG!*/M*G@D$$'D$$$$'TH --TX
MV*RR37#W5W.0TT[J%W8&  !P !T'ZDDFKU8NJ^*M*T<W7VJ64K:()+IH87D%
MNIY!<J#CCG'7'.,5-/X@TZ$VRQRO<R7,/GPQVJ&5GCX^?"]%Y')X.0.M &I1
M7/3>./#T&A1ZR]__ *"\OD>8(GRDF[;M<8RASP=V,5+8^+M(U#4+NPAEN!<V
MT(G:.2UD0O%G&] 5&]<\97- &Y17*VWQ%\-7:6$L%Y,T%_-Y$,_V601>86*A
M6?;A6)' )!Z'O6EJOB;3='%P;EIW%L@DN3! \H@0\[GV@XX&?7'/2@#8HK*F
M\1:;'':M%,UTUW%Y\$=JAE:2/@[P%_AY')XY ZFL/4?B'ID5GH5WIRS7MOJU
MVMO'-% [!!D[@0!G?\K#;C.>W% '8T5SUOJ&EW/CAH8[^_\ [2730[6+B1(1
M$7&)-K #?D[<YS@$=J>_C'18VB9[B1;:6?[/'=F%_(:3.-OF8V]01G.,\9S0
M!O45S]YXUT6QU*ZTUY;F2^M8Q+);PVDLCE3G!4*OS=#R,@=ZU-*U6RUO2K;4
M].G$]I<IOBD (R/H>0>V* +E%%% !1110 4444 %%%% !1110 4444 %%%%
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MP!Z$'\:[2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2"!U[=Z /8))!%$\A5F"J6P@R3CT'<URWAGQO!K7AV;6+NWGLXEN)(U$D1Y
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MF :>1E^\!G((/% '1ZAK5OI\WD>5<7-R(S,8+:/>X3.-Q';G('<X.,X-9?\
MPGWATVNDW,=W))#JK%;1X[>1@[ '*GCAAM(V_>SVKG?$);0OB%-JFI:)>ZGH
M^HV44*S6<#3-;2QL_P K*O.U@^<^M,U*T6"Z\%FP\/W-C:Q:H]R]O!9L?(C:
M-P&DV A22P)';//0T ="OQ!T9TO@D&IM=6+8GLQ8R&= 1N#%,9"D<Y/'XU-<
M>._#]M;:3<O=R-#JJ[K-TMY&$@VEL9 ^]Q]W[V>,5D:2TEO\0_&MU+9WRV\]
MO9B&4V<NV4QHX<*=OS8+#IU[5R&F-+I7AWX7QWUI>036M[(DT,ELXD0^5)_
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M3$C>>+8.5<$J5.<'(4]Z -BBL"T\7Z=J&FZ9>6*7%S_::L]K"BA9'5?O'YB
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M):6-2,A@%SN4CNI(]ZII\1-%8Z6[Q:A%;ZF@:UN7M6\MV*;Q&",DN1T !R>
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MG(^< _[39KK/#XNM+\:^+A=:;?"&[N(KF&X2 M&R"%5.".K;AC:,GVQ7<44
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MH3(YVC<,<JY/U%=5I,\-]97U]:^#Y]' M'B)GLDCN)7/1%5,DJ,<D]21CH:
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M!F4-G.< G)&#C@FM/5/&VG:3;S7L]O=OIMO/]GN+^)%,4+[MIS\VX@,<$JI
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M@BN7\$>*(?#WPL\/7.H17MPES<26_G)A]KM.X7>688!/<\>IK;BLGU#XB?\
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M'P\^+O3T&JW(&?FBB<$1\?WR&/N(V'>E\/\ A&&W\3R>)9=.^PV]K;&VTZS
M+RJG5I'QD[CT503A?<X%S1=(CUPW^K:E#JEK=W<[*8#<36^R%"5C7"L <K\Q
MZ\NPH Z/2=3M]:T>SU.T;=;W<*S1GV89P?>KE><^ S?^%M/UW1)-)U*2PT^>
M:;26\ELSP'+")<_Q Y SC.X5VF@:PNO:+!J(M9[0R%U>WN%Q)&Z,492/9E-
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M]"P) #J20/SP< &]17*:5XGOM0\>:YHCZ9/':V"6X67?&0"XD8NWS9PP"@
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M$C2'*_._+, P'.!GDC KJ[;Q-%<:]<:*=/O8;Z"S2\*2>7AD8E0 0Y&<@CG
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M5C>=(8DY5U+;E+,!C Z'!.> ><7!XPTR73M%N[;S9VUK'V*%  [_ "ESG)
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M N?7OTH U+#P5'8PK:'7=:N=.1=BV4\Z&/9T"E@@<KCC!;IP<UU     P!T
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M_+Y8#E@J_>SN^5N,?S%7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7E>M?V%:?&J0:U+:V^G-X>\]A<2B.,S?:
M,;N2!NVYYZUZI7!76C7E[\6Y=0N=&EET2;0CIDDKF,HS&;>05W;MNWOB@!OP
MUDU!+;7IKB2Z_L#[:SZ2]Z6W^1C)(+_-Y?3;GM6E_P )_8)=:3YUM-'9:M*L
M%G=%T(9V&4#(#N4,.F1]<5G:%HVM:1::GX.NK>XN-$>)X]-U)71C%$ZD>5("
MP;*9X(!R,=*@\(1Z_:6UAH6H^$8(+BQV12:KNC:&2-, .N/G+L!TQP3DXZ4
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MN\8,F63YMO\ &."1WKI)M+U*]^)8OYM.GBL)=!:QDG5T(25I ^.N3@9YQC-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUZUK5R?A^PUCPKX:\/:-'9#4"C^3=2_:0OV6([B"-PRX7A0!@G%=90 4444
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MDCZF4B2ZNU\VTLF/!=N0Y7'W03P0,\4 =K1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7O;&TU*SDM+ZVBN;:
M0 /%,@96P<\@\'D"L;_A O"'_0L:1_X!Q_X5T-% '/?\(%X0_P"A8TC_ , X
M_P#"C_A O"'_ $+&D?\ @''_ (5T-% '/?\ "!>$/^A8TC_P#C_PH_X0+PA_
MT+&D?^ <?^%=#10!SW_"!>$/^A8TC_P#C_PH_P"$"\(?]"QI'_@''_A70T4
M<]_P@7A#_H6-(_\  ./_  H_X0+PA_T+&D?^ <?^%=#10!SW_"!>$/\ H6-(
M_P# ./\ PH_X0+PA_P!"QI'_ (!Q_P"%=#10!SW_  @7A#_H6-(_\ X_\*/^
M$"\(?]"QI'_@''_A70T4 <]_P@7A#_H6-(_\ X_\*T],T72]%B>+2]/M;*.1
MMSI;Q+&&/3) %7J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSK=,3$7$C'G9AF) !Z !1C-+HOC"T7PN+Z+1HK*:XU62PALH7 $MP9"N2P4
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M9'0Y# \@@]Q7ETVJZOKO@;XA_P!KV]FT5J]]!'LE9_+,<*@*JE!QU;=D')/
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M:I=JRE7G+C)'(QG!.*[=#;W_ (QB\1W<]I;K963VUK;&ZC:1W=@78D-M PH
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MZC:VZ,YF*R1M%OX"XPV=PYR,5SB^!]??P;]EC-O:ZQ9:V^KV1:3?$[%V8(Q
MR.'(/%>GT4 <U:MXFU'2KR35-/M;.9K=HH;*"Y\W<Y'+LY4 #T S@9R3P!Q5
M]I^I:#H7PWTV>VC>^LM22%HUE&U]L,F<-CN.F<<_G7K59NIZ!INL7-I<7T+R
M2V;^9;LLSIY;_P!X!2!GDC- '*:UX8UW5[G7=:LI1INJ7&F+IU@ID^9%#EV9
MV7(4L3@8)P!G.3PS3- UVU\8Z=K0T?3K.TBTN2SDM8+K<T;&17R#M 8G;C]2
M>U>@44 >7CP?X@'PLB\-?9(/MZ7WV@M]H'E[?M/G]<9SCCIUKI+?2-7MOB+=
MZS'!;M8:A9012L\V)(6C+$C: 0V0W7(_QZRB@#F/&FF:QJ5OIG]EQPW,,%XL
MMY932^6MU%@C:6P> 2#@\''/I7+W'@/7=2M?%MI-]ALAJ<\%Y930REQ%+&J;
M5(VCY04P3^0KT^B@#F='N/%MU"9-;TVRLVAB*^3:W/FFYDQC=DJ B=>,D\]>
M.>0\*^"/$/A"#1+O3K:W%XL9M=8MO/ BNHP24D4X_P!8N<#(Y&1]?5:* .-L
M=(U>W\5^*M4>R7R-4@MTME$R[MT:,IW=ADMV)Z5B:1X+US1K+PC?Q10/J6AP
M26=U:^=\MQ"_4HV.&!P0#C/(S7H-]J^FZ88QJ&H6EH9.$%Q,L>[Z9(S5F*:*
M=-\,J2)G&Y&!&?PH YW1M"F'B;5_$5_$L4U_%%;QV^X,8XD!^\1P68L>!D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEQC[1MB5BY;9UP1P1VQFK5IXOU,Z]H-GJ&E6\%IK<+M;21W)>1'2,2$.NT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!SP1T8>GW:K>%O$_B'Q'.)FTJPM]/AO+FTN7%RS2 QDA2@VX89&"3@\]!CD
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MBN+BY95'[S9\X"Y'?@9SD<CFJ6F_$5[G1_\ 3=/%MK2:FVE2VH9G19E4N6!
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M=;U"T@TC3X[?3M3^R74C73$F/8K;D^7EN<X.!T'/) !VM%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PEOX>\7:#KVJ
M?V#=:5+H^IW37C"]\SS;65_OE0O#@GG!(_#J>[HH Y36O"TWB..?3M6\N;3$
MM0EKB=A*T^,>:_RX!'&W&<$DX.1CF/%$/B*T\(>%;;69+*XU:'7K%!/%(Q28
MASM9LJ"">,X![GVKU*J&I:+IVL"$:C:)<B!Q)$'SA''1A[CL>M &(^@ZA>^(
MI-?NHK5+B&P>SL[99F9<N<N[OMXZ*  #QD]\#-M? U]+\*(/"5[=06][;QH(
M;JV9G57C<.C\@'J!D?K7=J JA1T QUI: .3TVW\<3V,XUBYTB"YCMW2W-D78
M2S%<*[[A\J@\[0#^F*H0>#K^/Q%+K]I;:?I&H/8303"TE9H[J=L;'8;  %()
MS@DYYZ<]W10!QFE^$9H/&4/B)K.QTR;[+)%>I8RLRWCL5(9@54 +ACGDG//3
MFYXH\.WFHZOHFNZ5)"NI:3+(5CG8K'/%(NV1"0"5. "#@X(Z5TS,J(SL0%49
M)/856TW4K/5].@U#3[A+BTG7='*G1ATH Y6^\*:AJ4GB#5)5M$U/4M,_LRWB
M\YC'#'ALEGVY)+/GA?X0/>N@\-6-UI?AG3-.O1#]HM+6.!S"Y96V*%R"0#SC
M/2M2J-[K&G:;<VEM>7L,,]W((K>)F^:1CV ZF@#%GT/4V^(T/B&,6ALH],>R
MV-,PD+-(K[L;",?+CKWS[5STG@?7I?AOK/ALMIHNK^[EG23SW**KR^9S^[SD
M=.G/M7I-% '*WVAZM>^-?#^M;+)+?3X)XID\]RY,H4?+\F#C;W(SGM7)>$].
MU77/A[JVBPK:Q6E]?WL#732G?'&TS!_DVX+8SCY@.1GISZJZ"1&1L[6!!P<?
MK5/2]&T[18'@TVTCMHG8NR1\*6/4X]30!@'PU>P>.-)U.T6U&F6&G/8A&E82
M8)4@@;<<; .O.:R3X#U.\T+Q/I]U<VUK-J>J'4[.XMY&<P.-A3<"HZ&,9QZF
MO0Z* ..@T?Q1KVC7NF^+)M-AAGM9+8C32[&4NNTNQ<#& 20HSR>O&*QG\*^,
MKG0-!T>Z;1V_L:^MITNA-)FXCA/RY39\K8QGDY/I7I5% ',_$'/_  K;Q'NQ
MG^S9\X_W#6;9Z)J/B#3?"O\ :,=K#:::8+[]U*SM-(D>(Q@J-HRVX\GD >]=
M=J&G6FJV4EG?0+/;2##Q/]UAZ$=Q[5):6D%C:QVMM&(X(EVH@)PH[ >U '+^
M'?#-]9Q^)K;5EM6M=8O9KD"WF9F5)$5"IR@YPO4>M9D/@S69?!$?@K4);.33
M(V2$WR2-YKVRN&"^7MP'P N=Q Z\]*]!HH Y6ST/5+3QWJVMA+(VEU9PV\,8
MG8.#&6()&S !W=B<8[USZ^!M?7X86OA?=IINX;M9S+]H?85%QYW_ #SSGMT]
M_:O2J* .4;0M7;XA'Q !9I;'2?L&T3,9 _F;]V-F,9XZ^_M6=:^"KFY\2:=K
M=_::?97L4$L6HRV,K$7^]-N&7:O&?FR<D$ <]:[RB@#@_#&@>,M!@@T&6_TR
M70[5@L-X-_VHP@\1E<;0<?+NSP.V:WO&/AM?%?ABZTK[0;>5RLD$X&?+D1@R
MG'<9'/M6]10!RAT/5=;U71+W78K*#^R7:?9:S-()IBNT-RJ[5&2<<G./3EWA
MW1-5TWQ1XBU*\6S^SZK/%+&(9F9TV1A,$% .< ]:ZFB@#DO%WAW5K[5=(U_P
M_<6T>JZ89$$5WN$5Q%( &1BH)!X!!QUJ#6_"VM^(M"MY+V]M(-;M+V*_M!"&
M-O"\?1#GYF!RV6P.O3C%=I10!RXT74=1\2V.OZG!:0S:;;2Q6MM%.T@,DNT.
MS.4&!A0 ,'J3[5SL?@;7T^&MAX:W::;JVO5N&E^T/L*B<S8'[O.><?K[5Z51
M0!RL6A:O:^/KO7(&LC9WUG##.CN_F1O&6/RX7!!W8R2,>AZ5S\_@;7YO 6MZ
M!NTT7.H:D]XDGVB38BM,)<']WG(QC\<UZ510!RUQHFJW'C_3->*6:VMM8RVT
MB>>Q?+LK9 V8(&W'49SVKEY? OBC_A#+GPM#+I0M8[\7-M</)(7D3[0)L.NW
M"D<\@MGIQUKU&B@#AKK0/%>E^++S6O#TVERQ:HD7VZTOFD54E10HDC903]T
M$'T_)VH>&->M_$VF>)M+N;2[U&*T:ROH;IFACGC9]^4*ABA#= 0>,#/KV]%
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MCT]Z@TSPYXO\/7U[IVDWNEOH-U<R7$4MP'^T6?F,6=54#:^"21DCKSZ5WU%
M'*V>A:K:>.M5UL+9R6MU90VT2FX?S,QECEODQSN]3C'>L"U\"Z]:>"?#>F+)
MIS:AHFIK>C,S^5,H:0D;MF5.)/0]*])HH B7SUM1N$;W 3D E5+8_$@9^M>?
M6_P_U*X^'5QX;U"XM8+L73WEM=6TC2!)#*95R&5>A.#[5Z-10!RC:)JNLZOH
MVHZU#90-I.^5(K>=I!-.R;0<E!M4 DXY.2/3F7P3H>I:!IU];:C]E+3W\]TA
MMY6<8D<M@[E7D9Q[UTU% ',>*M"U+4]3T#4M+:U\_2[MI6CN695='C9#@J"<
MC.>E5K+P_K5KXF\3ZHZV#QZK!!'"!.ZE6C1ERPV' .[/!.,=Z["B@#S2W\#>
M)-*T+PQ-I=WIR:YH4+VS)(SM;W4+XW*3M#*?E!''6NYT6/5Q;--K4EL;N0Y\
MJUW&*)1T +<L>I)('7&.*TJ* .8\8^%9/$G]ES6EU]DO+*YSYPX;R'!29 ?4
MH>/<"HO%OAO4K]](U+P[<6UKJFD2,;=+A3Y,D;KM>-MO(! &".F/Q'644 <P
M+7Q5<:69+W^R9+R25!)9!G^S>2,AEW%22S9Z[<< 8X.>=F^&\[>%_%6EV'V;
M3DU=XY+:R1V>"W9-I)S@8WD<@# XQFO2:* .0U/1->U36?"^I2KIJMIDTDUR
MBSO@[T*;4.SG .<G&?056C\+ZT@\:9%AG7<FWQ</^[S$(OG_ '?MGC/I[UW%
M% 'EU_IVJHWA'P[:G1Y=8TFP,LD<US+%D*JQ*\<J .,_/E0,'OT&>F\'27UK
M)>Z1?Z5864L&V<O8W33K(TA8DN7 ;?D9.<YR*V-7\.Z-KPC&K:7:7IB_U;3Q
M!BGT/459L-.LM*M%M=/M(+6W4Y$<,81<^N!WH XJ]>]C^-J-900S-_PCOSI+
M*8^/M'4$*><XXIEY\/\ 49-)DN[*^M[?Q&=7.L)*06A$A&SRCQDIL^4G&2<G
M SBNR_L33?[8_M?[(G]H;/+^T9._9G.W/]W/..E:% '%W^D>+->\(ZO9:H^E
M17M[:/:Q0V\DGDQ[@079BI)/3 QQCKS3O$?AK5]:^&G_  CL7V*._>"&)W>9
M_*78RDD'9DYV^@ZUV5% '(W'A_5;7QHGB?35M7DN;,6E_9RS,JG:<JZ.%/(Y
M&"!D>AK)U'X>7MSIDUW;7=O#X@;6%UF-VW&$2*-JQ$XR4V\$XR3DX[5Z)10!
MQ5MHWB67QQ!XDO8M*MU32GLG@CN)),,9 ^X,47C*CZ9[UL^$[_5]0T02ZW'9
MK>+*Z%[(L89%!X9-W..WOC(X(K<(!!!&0:.E ''V/A_6/#WB'6[K2%L[FQU:
M471BN)FB:"?&&/"MN5L ]B,5GQ>!+_2XO"%MIKVDT.B3R7%P\\C1M,\BL'V@
M*V.7)&3Z#WKT"B@!#G:=H!/8$XK@K7P-?7GA[Q7HNL-:I!K=]/=QR6TK.T6_
M;M!#*N<%0>O-=]10!QA\/:UK5MH5IKXLECTJYCNI);>5G-S)$"$^4J-@)(8\
MGICOFKGA70]3TC5O$-Q?"T\G4KXW<7D2LS+\BKM8%!_=SD'O73T4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P?B
M7QKJGAZ#4+Z>VLH8+6[CBBLYB3/=PED5I5(;Y1ES@%3]WD\UWE>:ZMX#\17^
MF>*--CO]-:'5KT7D-Q,KF8 .K+$V. J[< C/'89H V[WQ#KQ\=3>&]/M-/ _
MLT7L=Q/(YQF39\R@#T/ ]>HZ5E/X\UC_ (0&V\2K96:^1=M;ZHA#N(E64QO*
MF""0,;L'L>O'.S#H6L+X\_X2&9K%XSI0L3&CNI+B0R;ONG R<8R?7VJIH>FV
MOA;PG<Z1XHO=,C@NY[EOFN-JR+*S.R_.!T#$<9XYH WUU*YG\2I8VS6[V<=H
M)[B3:2P9B1&%.<8(5CTXVC^]QG>+?$>I:#>Z)!86-M<_VE>"T)EE*%6*LPZ#
MI\O)YQZ&F?#S1'T7PE;)/---/.!(7G&'$8 6)2.Q6-4!'KFL_P"(IG&I>#3:
MB,SC7$*"4D*?W4G!(!(^N#CT- $4?C[4-%O]=T[Q396J7.G6(U&"2P9BEQ"3
MMP W(;=A?Q_._;^)->'B&RL9-+-S:7D4A,\5E<0+:2J,A9&<$,K= P Y[4W4
M/!!\1W.LW>M/%%-?Z<--B2V8N((@Q?=N(7<Q<@] !M YJ?P]8>-+<10Z]J.E
MW$-HI$;VJR+)=$ A3*3PH[G:#DX],$ H>&?$WBKQ#IJ:H-.TF.T5KJ*1#/('
M+QNRJ5^4C;Q@YY[\4:3XXEOO#7A5X[6WBU/7RRPQ#/E0JH9G;'4A57ID9)'(
M[:/A'0-4\/>%9]+N#9RW'G3RQ-'(VT^8[/ALKD8+8XS6+:> -3M/"_AB&.ZM
M%UKP[*7MY,L89D;(=&XRNY3C(!QCO0!H2>-VT/5M8TSQ"D0>PT_^TXKBV4JL
M\ .TC82=KAN,9.<CI6-XHN-9O)O EW?I9I!<:W;R^3$K;X&,<A"EB</P3DX7
MD=.>-K4/!+>)+G5KS6C%#/>Z9_9D<=LYD$,98N6W,J[F+;3T  4=<UG2>%?&
M%]8>'+2^N]'W:+?PW'VA/,+7"1HR@E< *V&&1D@YSD8P0#T2BL^Q75QJ.H&_
MDLVLBZ?8A K"0+M^;S,\9W=,=JT* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JE]I6G:F8#
M?V-M=&!_,A\^)7\MO[RY'!]ZMT4 %4;[1M,U.:":^L+:YD@;="\T88QGU4GH
M?<5>HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD+*6)C(J^<802P;[^<-C'0X]ZO7VN^+9/&%QX<TT:,LR:7'>I-.DA4,9"A!
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M+K=\;L2&W93&6V%LC<<_<  [9))/2@#737]9L/'-MI&K?8&LKZSFN83;HX:
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M1LPPRK>8YVNH/!X'J,=*L_\ "'W#^(_$%U->0/I>NV\<5W;^41)E8C'A6S@
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M&X?/TXZ=: .UHKSI?'6JZ=X)\2:A?Q6USJ&BZBUAYD:%(Y/FC"R,N20 ) 2
M?X3S6JFL:Y!\0(/#YGM+FSDT\WS2FW(D&'"%,AL '.02#W'/6@#L**X7PCXO
MG\27=NGV^V2[3>-2TF6$QSVK ' 7)RR@X!.#G(/'2NZH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:0[G.!G .![]*M22+$C,V3M4L0JEC@>@')_"@#CE\%Z@-/\ %EJ=2MC_ ,)
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M"[TO1K:RO;U;R:%%3S4A\I2  !A<GT]3R3T&  #C'UOQ5>3^,8+?4;"W.BR
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MGQZ>QXQ%I/A9+2ZUF^U":.[O=8V+=E(O+CV(FQ45<DX )R223GMT !%\.O\
MDF_AO_L'0_\ H JSX1_Y DW_ &$;_P#]*Y:SM&\-:]X>TJ/1M-UNT;3X<K;/
M<V3/-%'GA<B0*V.@) ]P:Z/2].BTK38;*%G=8P<O(<L[$DLQ]R22?<T 6Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9B0 I7 YYK(A\::YXA?P3+I=Q;V,.O0W/GH\'F&-XXR202>0&!P..@R<<4
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MKZ.^L?[&DU1?+MQ$83&X5D7!.00>Y)XZU:TF?Q-JECX?URWOK9H+Y4GO;.1
M$CA=-P\I@NXNN0/F.#STH ["BO.G\0>*];TB76/#EK/*Z7DD=O:M]G%O-%'*
M8V#LS"0,0K'(P!P,'J>TUK5DT3P]?:O<1,4M+9[AXP>3M4G;G\,4 :-96JZ_
M:Z2_DM%<7-SY+7'V>VCWR>6I 9L9'&2!ZGL#7):EXCUO0_#6B^*;B\2ZM[E[
M?[=9B)0D:38&8B!NRI8?>)S[4JVMVWQOGQJ4P4:)')M\M/N?:&_=].GOU]Z
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MX ?Y^N,<?=K<&IZ]8>.M)TR]U&*XM-8L[AQ'';JAMI(PARK<E@0W\7<9XZ4
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MFA2'88O+7:A5MQY[\CJ!]*?H_A36+.W,.J^*KG5$BB:*UW6ZQ&/*E=[D',C
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MC72T4 <'I8T/QGXWM/%6D2/<06%H\+7 5D261F^1<,!DH/,/MY@KO*0 *,
M#T%95IXALKWQ%?Z'$LXN[*))92\952') VD]>AYZ>] &M1110 4444 %%%%
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M9+<;?D)4JWR9SD@$C ]:SQXHN9(?#UA8ZBVIOJQNI5O[-80[0Q'("A\(&PZ
MY'&UN,\CJ=1T^]N;ZTN[+4!:O LB-&\/F1RA]OWAD'C;P01UKF[GX:V3Z/9V
M]CJ%QI^HV=W+>V]_;J 8Y9"2X"=-ASC;Z <GG(!3O9?'MOX5U^4321W=DYGT
MZ61(&DN80,LDBH"H8 $ KC.1[ULV_B :E]BU*QO96TV+3/M]R J$R!A^[4\<
M'Y9"<8Q@>M:VB:3<:;;N;[4YM3O9<>;<RHJ9 Z*J* %49/'J2<U6\->%-/\
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M55G)D(547>&  .XDX)^[TYIL^K>(M*30]#U&9+G5;^>=6N;%4#&&-2P($FU
MY!7/&!\V!TIUS\/I-FBW.G:Y/I^K:5:BR2]B@5A-  !LDC;(/3/UR?3%G5_
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M06L:I(DDI0DMC<&'&,$#CD'J>NM_!]Y%XDCU^7Q!<37XL392;K>,(XW;@=H
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M<H]H8K>+<"8/,VG*D%<GGC)]:KSW=_KVM_#._?4KJU?4+2:>1(-FQ9/LVXL
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M3 'S<J6.[YNF, C'()*W>K:QK6M:YI6G2W4,FFQPHDEF80#-)'YF]O,R2O(
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MEW80@9XR1P>E<[J6M^)O"-AK^IWJ-<:7'!&UA]L>,RI.S!-K>7U3+ YZCD4
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M8/GV>2^WG *'[P)((.:]$H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPUR^XIF*0E264[>3E%//''&.<W[KPI)>7^AWMQK%U)<:2[RH[QI^^=U*L6
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MS.3R2=QSTY)-4IO (3Q!>:EI>O:GI<.H/YE]:6Q39,_0LI8$HQ[E>?I78T4
M<_;^%H[;Q;_;T5Y(I%DM@+4(OEB)6W#'?()ZY_"L:\^&D%W8:QIXUS48K#4K
MLWOV=1&1%,7#D@E<D;EZ$XKN:* .>;PHO_"46VO1ZI>)<QV:V<R_(1<(KEQN
M^7@[B<[<>G JDGP_L)-&US2KZZGNK;5[M[V7(5&BE8@Y0@<8*J1G/3O7744
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MMK,6LRR+&J2@,6!PJC&,G@8]\\YE7P;I(O\ 7KIHV<ZW&([E"?E V;&VCMN
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'ZUC>&/%-KXKL7O;&TNX;=)&BWW"HN64X8 !B>#6VH*J 6+$#&3U-<%\'_\
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M9QT)!QZ&L6X\2ZWX0D\4:3<:E)J2V:V<EC>707S(EN)/+(D( !VG+ D=OPH
M]7HKDM-L?$MGXJCFDN0=%F@*307-WYT@F'(>,[!C(SE<X[@5-XEU>:#Q#X=T
M*&=K==5FF\V9/O!(H]^Q3V+$@9ZX!QS@@ Z>BN U^_UCP?I-TIU?[2+[4K>V
ML'E7=)9QRL%8L3]_&&*D^V<]*L:A=:AX>\=:#IT-]=7&GZTD\,B3,)'@EC3>
M)$8COR"#Q[4 =O17C9U;Q#%\.+CQ._B*]>\T_4WC2/;&(Y4%UY9$@"\Y4]L
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M">6 QSXW@HQ4YP2.H]:P-.U.^\1>+=0T:ZNFM4TJQMFF6RE*^;/,I8L'ZE%
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MYY0K12*3C&Y20''=3]>16S7$W5]/#XKT+PK'>W2PW-K->7$[/^\D"X"QJP'
MR23CG@<]:P=7UW7-+M/'>D1ZI<;](LTOK"\PC2*CHQ\MR5(."IP?O8[T >J4
M5YW/=:KHZ:&LNO7<\GB*ZMX&>54"VH$3._E<<%L!1G..O)JWK]UJW@S2-;U
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M%6#+R0>X!_"HO^$:A_X25=?-]>?;5L_L?6/88]V[ILZ[N<_TXH \RO)[S5?
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M5,3PA"N-JX)^]GG(Z5<UG5;H^(O$]GJ%_<V"6]A%+H_D2LGF,5;>PQ_K'\P
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M*8U(+(<J03D +TY.0#TVBJVG317&F6D\,XN(I(4=)ATD4J"&_$<U9H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N0O/AOH5[%JT,DFH+;:I,;F>WCNF6,3$AC(J^I(!YR/:NOHH \\&E3O\6VD
MA?5K:WCT1+5+U8F97D$K,59Y%96."#D_G3?'&@Q6F@:%IFFVE](BZW;W,[VT
M4DL@&\M)*S*"=V23GUZ5Z+10!DV>AP07DVHM<W-Q?SPB'[5/MWI&.0J@*%49
M.?N\GKG K+_X0#2?^$2;PQY][_99D\PIYHW9W^9C=C.-_P W_P!;BNJHH YK
M6O!&FZYJ%IJ4MUJ%KJ5M'Y(O;*X,,KQ]2K%1@C//3Z4ZZ\$Z3<7&F7$;7EK-
MIR/'%);7+([(_+*[=6R>22<YYSFNCHH Y6/X?:%%H]SI:B\^SS7?VQ?])?=#
M*&WAD.?EPQS[]\UJV6A06EU)>O<W%U?R1"#[7.5+J@.=J@*% SSP.3C.<"M6
MB@#EA\/]#/A>?P[.MQ<:?+*TP663YXY"Q8LK  @[B3_]:M#0/#5KX?C<17=_
M>S. K7%_<M/)M'103T R>!6S10!@^(_".F^)GM)[I[JVO+-BUM>6<QBFBSP0
M&'8]Q27/@W2+K1(M+F6X989A<QW)G8W"S@Y$OF'G?[^G'3BM^B@#&C\-VR_;
M)9;JZGO+N$6\MY(5\WRQG"KA0JCDG@=3GK5'_A!=-&D:1I8N;T6NDSI<6@$B
MY1T^YD[><9/!]><UT]% &*GAJVC\3R>(!=79OI(!;-EEV&(-N"[=OJ2<]>>M
M5X?!MA!9:S:+=7OE:R[R7F77+,XVL1\ORY4 <?ABNBHH Y>_\!:1J.CZ7I\L
MM[&VE "QNX9_+N(  %PK@>@ Y'.!WJ>Y\&:5=^''T6=KMX7D69[AKAFG:52"
M)#(>2V5'X #IQ70T4 16UNMK;1P(TCJ@QND<LS>Y)Y)KGX? VDV\4UI$]RNE
MS3_:'TWS!]GW[MQP,;@I;G:&V^U=+10!C7GANVO?$5GKCW-TEY9QO' $=0BJ
M^-PP5YS@=?3BM#4+)-2TZXL97D2.XC,;M&0&VD8."0<<59HH Y<^ M*\K1D2
MXU")]'C,-I-%<;)!$0 8R0.5P![\=:OZ#X8T[PY'>QV'GF.[G>>1)IFD 9CD
M[0>@R?J>Y-;-% '/1^"=!CT"QT1;,?8;&X2Y@0GI(K[P3ZY)(/L2*Z&BB@#S
MKP]H\U_XK\9M,^KV-O>W2;2(FB2XB$2J2&=.#G<,J0??I73S>$=-DOM'NHFG
MMCHZ,EE% P5(U9=I&,'.5&.:WJ* ,>X\.VUQXD@UXW%RMY! UO'M9=@1B"PP
M1SD@'/M6:W@'2G\/7^AO<7S6-_.UQ<*95W,[-N;YMN0"V#Q_C7544 <QJW@7
M3=7U&UU)[O4;74H(O(-Y97)AEECZ[7*C!&?859O?"6G7BZ4F^X@32I1-:K$X
MXD (W,2"6."<YSG)SS6]10!YWHFE7%[X]\9S-)J]A!>26XCD2%HTG180K89T
M/(.1E2#[]*Z6[\(:9=6^D6\?G6L&D2++9Q6[!51U!"DY!SP2.?6M^B@#E=1^
M'^D:AKTFLK/J-E=3JJW0L;MX%N@. ) O7CCC%7KGPO:SRW#17=Y:Q7%NMM-!
M ZB-HU!  !4[>"1E<'WX%;E% &5!X>L[74[.\MWN(5M+/['#;),1 (\C'R="
M1@#/I6K110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$_AQCC /7JND>9XQMO%DMW>75O=VFI7%E:F&X>,VBQJ-C* 0,DY8D]<XZ#%
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M<*.@D"X##M].*T+G3[ZZUFSU9_"+)=VD7D1M%JPC4QY#;&5<!E! .#Q7<44
M>8KX,5+9+9?!]RL$5T+N",:ZP6WD#%LQC/R<D],=:U5TZ_CUV;68O"<D5[-$
ML4ACU<*C!054E/NE@"0"1Q7<T4 >>P^'IHO#LN@_\(<TFG22&7RY-7#%7+;M
MRL?F4[N<@]:MVUIK%M)+,?#EQ-=20^0;J;5E:41YSM4X^49YXZGDYQ7;US/B
M?Q:NB^$M4US3H(K_ /L]F22,RE!N4[6&<')!/3V/- '/KX:G70['1E\*7 L+
M&99[>(:U]QU.Y3GJ<'D FNSL-'M[;4[G5]DR7M[%$DZM.74;!@ #H.IY YK1
MC;?$CXQN -5-/FU"9KS[?:16X2X9+<QR[_-B&-KG@;2>>.<8H NUBWOA?3K_
M %^TUN?[3]OLU9;=UG91&&&& 4''(ZY%;5<QXC\4W6A:UH^FP:9'=-JLKPPN
MUUY85E7<=WR'C'IF@#2U;P]8:U=6-Q>>>9+&7SK<QS,@1\$;L \G!(Y]:B3P
MKI2:CJEZT,DLNJ1K%>++(SI*@!4 J>  "1QZUF6OCVS%WK=CJUK+IU]H]N;N
MXB+"17AQG?&P^\/J <FG#Q/K"Z?8:E+H$9L;V2!5,-[OEB65E56==@&!N!.U
MFQ].: +'A[P-HGAB;S=.CN<J"L2SW,DJP*>HC#$A?PY]ZOZYH%AXBM([741*
MT,<JS*L<K1_.IRIRI'0\UFR>*;F/Q[%X6&FQDR69O1<_:>!&'V$;=GWL]LX]
MZT-5U6[L-2TNU@LHITOYFA\QIRGED1O(21M.1A#WZX^M #5\-6"Z])K8:Y&H
M26XM6E\]O]6#D#;TZDG..M4E\!Z$N@+HHBN19)<"ZC'VF3?%*&W[U?.X'<2>
MO>NEHH YG5_ 6@ZS=6EW/%<PW=K'Y,=S;74D4IC_ +K.IRP^ISR>>35J;PEI
M$MWI5R(IHGTH$68BF95BR,-P#SD<'.<UN44 <%/I<][\7Y;XQZC;VPT=+5+N
M%'1#()69ESC!&T@Y/'H<UO77@S1;O2K737AF2UMIQ<QK'.ZL90V[>S Y9MQ)
MR3U.:WZ* ,/Q#X2TCQ1:VT.IPR.]JV^WN(Y6CEB;U5UP1G'/_P!:F2^#=%F\
M.G0Y()FM#(LQ<SOYID!!$ADSN+9 YSVQTI-<\0SZ1X@T'3ELXY8=4N'@:8RD
M-&51G^[CG./6G>,]?G\+^%+[6K>S2[:T3>8GE,>1G&<X/KT_6@"*7P-H4VH_
M;GAN?.:W%M-MNY0+B,9P)1N_>=3RV<YYS35\!:"FEZ;IZ0W*Q:;)YEJZW<JR
M1G&T_.&W8V\8SC'%='&V^-'QC< :=0!D0>&].MM=GUF-9?MD\*P2$RL4,:]%
MV] !D]JK67@O1K!8HH(YOL<,WVB"R:9F@BDSG*H3V)R!T!Y !KH*Y?Q3XP&B
M>#[[7]-@BU!+20Q.IE*#(D\ML'!SANW'0\T 7T\,:?%JNHZG&UREWJ*+'<N+
MAOF500H S@8!.,8ZU9T31;+P]I,.EZ<LB6D (B1Y"^T>@)YQ6A10!R<OPX\-
MRPW,#6]T()[G[5Y2WDJI%+NW%HU#80DCJ,5I0>%].M=7N-4@-S'=W$*V\CBX
M;&Q?N@ G QDX/6M6ZNH+*TFN[J58K>%#))(YP%4#))_"L#3/$&JZY81ZGINC
M1#3YAOMVN[HQ2S)V8($8 $<C+ D$9Q0!$?A]X>.@6FC""X6VLIO/M'6Y<2V[
MY)RDF=PY)[U>TKPII>CZK<ZI;?:FO;E$CFFFNI)#(%&!D$X)Y/TSQ@5:T+5&
MUG24O7LY;-VDEC:"8@NA21D(..,_+GC(]SUK1H P_$/A+2?$YM7U"*5;BT8M
M;W-O,T4L1/7:ZD'!]*6?PEHMSH<6D26K&UAD$T3>:WFI*#D2"3.[?G)W9R<F
MMNB@#(B\.6,<=WN:XEGO(A#/<R3$RL@SA0W\(Y/ QR2>IS5/_A!]&_LS2]."
MW0M=+F6>S07+_NG7[ISG)QDX!SUKHZ* ,)_">FR/,)#<R6\UR+J6U>=FB>4,
M&#;3T&X [1@$CD&G2>$]*DUB]U4)<1W=[&L=PT=PZJ^%VAMH.-P4XSC(%;=%
M &+:>%=)L_##>'$@=]*:)H?(EE9\(W50Q.<?CQ5.T\!Z):7FFW@^W376FAUM
MIIKV5W4, ""2W*X& O3D\<FNFJO?WUMIEA/?7DJQ6\"&21VZ "@# @\ >'K;
M6Y=5@MIHY)9OM$ENMPXMVESGS#%G:6SSTZ\]:O\ _",Z8-?N-;1)H[ZXC6.5
MDG=5?:"JL4SM+ $@$CBK=W-J$=_8QVEI%-:R.PNI7EVM$H7*E5Q\V3QVJ[0!
MSL7@?08O#C:!]FD?3C(95CDG=F1RV[<K9W*=Q)R#UJ[:^'[.VDFF\RYFNI81
M UU-,6E$8Y"@_P (R<\8R>3FM6B@#F5\!Z&NAV6BJET+"QF6>WB%R_R.IW*<
MYR<'D FN@GM8+NSDM+F-9H)4,<B2#(=2,$'UR*RM<\20Z1>V.FPP/>:K?EA;
M6J,%R%&6=V/W4'<\GT!-1SZUJVGW%DE_H\7E75PD'G6ET95A+="^Y%(&> 1G
MDC.* 'Z;X3TS3&M/*^TRI8@BSCN)VD6W!&/D!/H2 3D@$@$ U+:>&["QUZ\U
MJ W O;P*MPS3L5<*"%&TG QDXP*UZ* ,C6_#6F^('LY+U9EFLI#+;S6\[PR1
MDC!PRD'!'!K-D^'GAR2QU.R-M<"VU.42W4:W4@#MQS][C)4$XY.!G.*ZFB@#
M%G\.6+:K9ZP_VN:^L(FCMSY[?=(&X8S@YP.M9VAQSZ_KL?B34-#FTN2VM6M;
M>.ZV^<=S NQVDX7Y5"]^6XP>>KJE>3:A'?6*6EI%-:R.PNI7EVM$NTE2HQ\V
M3@=J +A 92K#((P0:YD?#[PW_P (W)X?>RDDTUV#+'+<2.8B"2NQB<H 2< 8
MZGU-;T5_:SW5U;1S*TMKM\\ _<+#(!]\<_B*6QO;?4;&"]M)!+;SH)(W'1E/
M0B@#"A\"Z+%H5WI!%W+;WBA+F2:ZD>651P%+DYVC)X&!R?4U:O\ PIIFI:-:
M:5=?:7M+5D>(?:'#90Y0E@<G&!U]*VZ* ,@^&[ Z^NN%KG^T%M_LHD\]L>7G
M.W;TZ\].M4X/!.D6MOY-NUY%B]:_5UNGW+.P8,X.>X9LCH<]*Z.N?\0>(I]%
MU?0K-+..:'5+S[*TIE(,1VLV=N.>%]10!I:;I-KI8N#;JQEN9?.GED;<\KX
MR3] !@< #BJEWX8T^ZU=M54W%K?/$(99K69HS*@Z!L<''8]1V-;-(Q8*2H!;
M' )P": ,.Z\'Z-=6^EVYAEAATN19;2."9HQ&XSAN#R>3USG)]:W1P*X1O'UX
M/ .L>)/[)A\[3;B>%[;[2<$1OM)W[>?7&!7;0RM-:1S*HWO&&"DX&2,XS0!S
MMCX \/:;K#ZC:6TT9>;S_LPN'^SB7KO$6=N[N...V*M7'A'2Y]1O+U1<6\E\
MH2\6WG:-;@ 8&X ]<<9&#CO3?"/B&;Q)IES=3VB6LD%[/:&-)/,'[MMN<X&<
MX]*WZ ,:?POI<^HZ7?>5)'+I:LEFL4A1(E*[2 HXP0 .>U0?\(5H;1:O#-;R
M7$6KG=>QS3,ZR-@ '!/RD8&",8P/2N@KG-3\0WHU:\TC1+*&\U"SM$NI$GF,
M:MN+!8U.#\QVMR>!QZ\ #+3P'HUI>Z;>;]0GN--#K:R3WTKF,, "/O=,#&.G
MKFIX?!NC0V6KV?DS26^KN\EZDL[,)&<89N3\I( Z8Z"KFA7>K7MBTVL:9'IT
MYD.R!)Q*?+XP6(&-W7(&>G6M.@#GG\%Z1);Z9"_VQETV43VS-=R,PD P&))R
MQ XYR,<=*FN?"NFW&JW&I(;FVNKJ,1736T[1_:%' W@'J!D!AA@.];=<_I'B
M*?4O%>OZ+-9I"-+%N4E64OYHE5FR1@;<!1QSWYH EN/"FDW$^E2B&2'^R?\
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M@8_O<\<<YXXK)\5>&+6/P_XINM,L[F75M7L9+=PDLC^<WELJ#:6V@#.,\8H
MYB[TV?0QX&\0:=?W[WU]=VEG>I+<NZ7$4J?-E"=HV@9& ,=:DM+74/&N@ZEJ
M":Q!I^I6^HSK]KR_F67E2G"8W!0OE@9!&#N).377>&/#UI;Z3HUQ/!=?:K2V
M5(X[J5V^SOL"MM5B0#U&1VX'!I;CX?\ AFZU]]:DT[_3)6#S;)G6.9AT+Q@[
M6/U'/>@#GH=*CUGXE:]87UW>RV;:9:RF%+N5$W,7R0 V5'&=H./;I69HUQX@
MU'X;>%+ZVC36I8/.:ZT^XGV/>1(S1@ACPQ7Y3AN"<=\5Z(OAO3$UFZU=(YUO
MKJ,132K<R#<@Z#&[ QDXP.,U5M?!6B6%G96ME%<VT=BSM;>7>2@Q[_O8.[D'
MT.1[4 <E::KI6JZ3X?M[.74\R:C<K_9%QQ)*Z[V>*8L>$C+ ]3P%&"<"N<UA
M)+GX4>-;>]RPT_76CMX_.9U@7S(2%4G!*C>V,COT%>H7/@G0+NWM(I+20&UG
M>YAFCN)(Y1(_WV\Q6#$MGG)YIJ^!?#:66J6:Z8HMM4;==1^8^'/'(Y^4_*#E
M<<@>E &-XAMQI_CCP-#:2W$<+W-RCQ"=RCCR'894G!()//6J6DJ/%^E^+;F_
MGFBO[74;FUMW25D:R6( 1E,'Y3_$3WSSD<5UK>$M'>;39FAG:732S6KF[ERC
M-PQ)W?,2"02V2:2Y\):/=7]W>-!+'+>J$NQ#</&EP ,#>JD!N.,]<<=* //;
M"[O_ !'??#>YU*ZO8I-2L;LW:17#QK-MC7:V <*2"3E<'YNM=1\/0UK=>*=+
M669[2QU9H[9)9&<QHT:-M!8DXR3^==!<>&]*N=3T_47MW%SIRLEH8YG18E(P
M0%4A<$ #IVI^E^'].T>ZO;FRBE26]D\VX9YY'WOC&[#$@'  X]* .+FW6G[0
M=M+>'$-YH30V3-T,BRAG4>^,GZ&O0YI(HU4S,H4NJC=W8GC\<XJCK.@Z9X@M
M4M]3M5F6-Q)$P8H\3CHR.I#*?<$4ECH-I82I*)+NXE3A'N[J28IQCC<2 <<9
M'- ' Z>6\4^!_$FLW=Q/#J\%S>"*9)65K(Q$^6BX/R@ *2/XLG.<U':3W>O^
M)/ \^HSWD3:GHDTUW!%</&CL%C.0H/RYW'I@\XKN)O!^BSW=Y<&WD3[<0;N*
M.=TBN#C&70':<C@\<C@YJS/X=TRXUJTU>2&3[;:(8X'6=U5%.,@*#MP<#MVH
M \O72DD\&^/5:\U KHEY=_V:!>2#[-LB61<$-DX8_P 6<#ZG.Q/YVJ>+? OV
MB\O FH:3/)=1QW+HLC".,YP#P?F/(P:ZY?!NB)9ZG:+;S^1JCL]ZINY3YS,,
M,3\W&1P<8XIT7A'1H;S3;M()_.TR(PVC&[E/E(0 5P6P00 .<]!0!YU'I,<G
MACQ] ]WJ!BT6YN3IRB\D'V<B%9!@ALG#'C=G';J<[$]W=7.K?#*\DNKCS+Q&
M-PHE8)(3:ELE,[2<D\XS76)X/T5+?5(%@N/*U4LUZOVN4^<6&"3\W&1QQCCB
ME_X1#1<Z2?(GSI(Q9?Z7+^Y&-O\ >YXXYSQQ0!P^EZ+8/>_$E6@)"SD8\QN<
MVZL<\\Y/K5?2KC^SO!OP\TZ&1;>WU=8UN7E=]KL("4C)!R S8X!&<8Z$BO18
M_#.D1:S>:LMIB[O%"W!,C%),+MR4SMSMXSC./K5(^ ?#3^'&T!]-\S32P98I
M)I'*$=-K%BRXR< $8R?4T <EK4>H^"=*UB1=:C6SO+NSQ;H'"Z=%)($E96+$
MA6^;&,8.<5T>D^'[K2O%@OTU.WBL[JU,;:="'*2.ISYPW,<'!P2!SD9YK2LO
M!^A6.B7.D)8B6SNABX6XD:5I>,?,S$DX[<\=L4GA[P=HGA8/_95J\;.NS=+.
M\I5.RJ7)VK["@#.\;QZOYNF7&FV46JPVYD>ZTIYO+:X3  9<\$H3T/'S#OBN
M2O+JPUK3/ QT^2_B@;7I$9;ABMQ"VV;=&Q))!4DKG.< <UZ7J&BVFI75M=3&
M=+BU#B&6&=XRH;&X?*0"#M'!STJE)X.T.1;%3:RC[#.UQ 5N9%*RL26<D-\S
M$L<DY/)H XA)8="N?B)IW]KWFG:9:PVLL4PD:9[9I8VW%-Q)R6 P,]3QBM#0
MOM-C\4X[%;9[&SGT$SFU,^_<ZS(H=P/E#X8@X)SZFNEN/!F@W<NJR7-F\S:M
M&L=Z'N)")57[O&[ QV(QCM3;3P3H-EJ%M?PVLIO+:$P)/)=2NY0D'#%F.[!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114-Y<&TLI
M[A8);@Q1LXAA +R8&=J@D D]!R* )JQ];UB]TU0FG:+=:K<;2[1PND85?=G(
M&3V R>*30M?EUIIUDT+5M,\H*0;^)$$F<_=VNW3'/3J*NZI#?7&G30Z;>1V=
MVZD1SR0^:$/KMR,T 5O#>OVOB?0+76+-)8X;@-^[E7:Z,K%64CU!!%:M<A\-
MKBZ;PHUA>VT,%SI=U-82&#.R4QMS(,\_-G)]\U?U3Q/-IFIBR3PWK=ZI"G[3
M:0QM%S[EP>._% '04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9.
MH:"E_J<5^-2U.UDCC\HQVUR5C=<D\H<C//7K[UK44 5[&QMM-M$M;2(1PID@
M9))).223R22223R2<FK%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exc_compmins2-9x23v1x202004.jpg
<TEXT>
begin 644 exc_compmins2-9x23v1x202004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH_W<DD08#YMN!N&Y3D=<G/3GFO"GCWQ!X2\3VFE^-KV2YTK68(Y[&_EQB/<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***;)M\MMYPN#DYZ
M"@#GO^$VT@V]Q>)]KDTVW=DDOX[=GA!4X;D#) ((+ %>#S5_4/$6DZ5H:ZSJ
M%[':V#(KB67C(89  ZDGT'->)(_C;X.P.D=O'K_@IF+JPY,<;G/)'*9SSD%3
MGWH\;ZK:Z[X[^&D$08>')TMYX(I.A+2!=K>I 51WZGUH ]9D\>Z3;Z6VIWMO
MJ=G8!=XN+BQD56'8],KGMN SD4_6/'>AZ%K5GI%_)<QWMZ5%M&MN[^:2<#!
MQUXK>O+2#4+*>SNHQ+;SQM%(C=&5A@C\J\8^+'G)\7/ /V:.-YEF3RTD<HI/
MFK@%@"0/?!^E 'I.L^.]$T#5K+2]2>ZBO+XJMM&+=W\TD@  @$9R0*36?'FB
M:!JUEI>HM=17M[@6T2VSN922  "H(SD@8KR_XE2:G)\5OA[_ &E:6ENPOH]@
MMKEI@1YT><[HTQ^M6?BZ95^*_P /S B/,+E2B.Y16;SDP"0#@>^#]* /4;3Q
M5I]YK']DK#?0WI@:X6.XLY(MZ*0"5+  \L.A[UFV_P 2/#UUJ5]I]N=0EN[
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M] 'QM\?X&/F3^= 'KU%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6DB01!)?G(&75?FX&>"*@^.OA;4]:T?2M8TJW>YGTB9I'@C&69&VDL!WP4'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444      P!1110 A (P1D&D\N/S/,V+YF,;L<X^M.HH **** "BBB@ P
M,YQS3)(HYEVRQHXZX89I]% " !0   !T I:** &"*-9#((T#GJP49/XT^BB@
M HHHH **** "BBB@ HHHH **** "BBB@ IABC,HE,:>8!C=M&?SI]% !1110
M 4444 & <9'3I34CCC+%$52QRQ QD^].HH 9)%'*NV1%=>N&&13L#;MP,8QB
MEHH 14522J@%CDX'4TM%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^'_PN#1VV'U"Q#9"_-F%@X/KDXS^M:&KW>GZ=XQ\>/<6OVFU&@0/<6L+;&E
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M-S$8Z'KNZ'..O%>XQNLL:R+G:P!&00<?0\BG44 %%%% !1110 4444 %%%%
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MEHSC8,( -W.W ')Z#FL?Q#/X;URYU'0?%EE$MK R&"XN8V2-MR G;+T5P2>
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MP!D9ZUSGPZU*74KGQ4SWEW<10ZP\</VHMNC41I\F&P5P2>,"@#7_ .$7N?\
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MYPSD XX!/K@$]* (_P#A%[G_ *&G7O\ OY#_ /&J/^$7N?\ H:=>_P"_D/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPG. IV]> !S6'H.JZ6=*\+VVMR:M;V>CR)<6XFTB9 K!2L?F3#*E5#?> 4'
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M*RHC1$[LRLD:KC.]N "!W-:-GXJTN[N-0MI))+.YT]!+=0W:^6T<9&0^>A7
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M2 $8@<G(.0*S[-;RVL?AA?R:5J7E:;"UO=(MHYDC8VOE@E -P&[C) '?I@T
M=WJOBW3-(2YEN!<O!:$"[FAA9TM\@'YR/8@D#) ()QFI[O7[%)(;:$RW<]Q
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M%X9+XJ]J'MW03A85!V$@!CE2.*T&U%]7\:^![^VTO5!:6\%W'-++92((V:-
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M-.NO&FEV;V[SK<K8SW'V6._\L>09<E<9SD#((W8V^] "_P#"(V__ $%]=_\
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M6\TL.88D0(C."&VD<#G&/QJ;_A#-/_Y_]>_\'=W_ /'*/^$,T_\ Y_\ 7O\
MP=W?_P <H Q/#=]9:I=VMU_P@D^E7MHK-<3W.G+'Y)VD%86 W.2>/E'W<Y[
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MOKQVZUQFBWEO;Z%HEKJVB^)8])TNY%_ %T_S(XL%F3=,C$O&@;((49P">.*
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MFC:)G3)1B,J2.AQQ^5 ')>&_'"ZCX,M->U.TFMC=N%@0;6\YG<A$C .2>@Y
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M_M((LW$!^5@P0X)^9<''89J]XN;4]9T+2)ET:\C8:U:W0MQ$6EC@C<%FD"Y
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MEV49;:V![=A67+\0]&CT;3-5CCO)K:_NULE\N'+PREMI61<Y!!!X&3QQG(H
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MD!2V,@_*.];/@;2]1TBZU6U^U7\^@@Q'3AJ.?.C.#YBC=AM@^4#=[X]3V5%
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M'_++:<DL?7  )Y)QFQ\/[/4-*T/48=0TZXMI6U&YN41BC%TDD++C:Q&<'H:
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M]"L["TD::^M5>SLT(!2)44Y8DX"J"HSSR1C-,@\;Z6;'5Y[T2V4VCL$OK>8
MO&2,IC:2&#9&W'7/K7/1Z-K&FZGX2\01Z?/,+/3/[-U"S4KYL8(4AU&<-AEY
M .<8QFJGB#P3JVOP>*]5M(OLU[J#6;65M.P!<6Q#?/@X&XY !/&!G'( !9U6
MYFN?BQX)DN-*GLI&CO2&D=6W+Y/W3M)PP[CI\W!/->D5Y[/)K>N>,?"&K'PS
MJ%I#8_:A=B:2+]V9(PHQA_F /?J1T%=EI5]>7PNS>:9+8F&Y>&(22*WG1C&)
M!CH#Z'GB@#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[AC'A1C\N*Z*\C-[X$\1/8>%Y=,-]92006WV54N)G,;*"ZIG RP R>.2<9%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***XWXJY3X:ZU<1L\<\$&^*6-BK(
MVX<@CD4 =E17%7'A%;GPI#+H][?:=JJVJR07$-U(09-N0'4DJZD]00:;X/\
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M35)I 3YF(B4*KN/\ '89S0!V%%<[9>+8KO55TQ]-O;>\EL?M\$<GEGSH\@$
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M1[KBTD9!P8_,5@P8@J5YXYX/&: .LHK@[G7K*\\->%;GQ'I%Z\EY>V8@92H
MN6"E)3L?A<DG!].5Z5T5WXCCBO[NQLK"ZU&YLHUDN4MM@\O<"57YF&6(!( [
M8SC(R ;5%<G+\0M&73M%U"".\NK75YQ;P/!#G;)S\K#.01M88 /(J_H/B>'7
M+_4M/:QO+"^T]D\^WN@F[:X)1@49@00#WXQ0!NT5DZIKT6FZE8Z:EM/=7UZL
MCPPQ;1\L8!9BS$ #YE'KS]:HVOC73KW1K#4((;C=?7364-LX59/.7?N0Y;:,
M>6QSGMQDD"@#I**HZ9J)U&.<M:7%K)!,87CGVYR #D;20001@YK"U'QU;V&M
MWND1:-J][>VD*3M':P*V]&8KN7+#.,?X9H ZNBN8U;QO9:3:75\]G=S:=9S>
M3=7<(0K$V0K?*6#,%)P< XYZX.(KOQ[:0ZM=Z7::3JFH7EO EP$M85(EC?.&
M4E@,<=\=L9- '645S-CXZT?4M"L-4L_/E-_-]F@M=@$QF&=R$$X!4*223@ 9
MSTIZ>,;3S=4M;BSO(+_381<36C*K.\1Z/&0Q5EX(Z\$8.* .CHKSK6?B;*O@
MN\UO2= U,H+!;J"ZN(T2$;SCD[LDJ3R .<<<<UUDFOF+[-;G3KHZA/&\JV>Z
M+>$4@%F;?M R5QSGGIP< &S17,6?CO2;W1EOXDN?.:\.G_8BJ^?]I!P8L9VY
M'7.<8YS6)H,SS?&36R]G<6C_ -DP%XYG#9/F-\RD$C!&/RZ4 >A4R5/-B>/<
MR[E*[D.",]P?6N$\?R)9^*?!=Z8YY&34)%\N$%F<>2Y "]"<XY_7%7[;X@VD
M]MK&_2-5@O\ 24$MSI\D:"?RR,AU^?:PP#T/],@&MHWAR#2)C<O>7FH7A@6W
M^U7KJTGE*2P7*J >6)R1D]R<"MFL*/Q1;3Z/H^I06EU+'JK1K;QIY9<;U+ G
MYL8"@DX)P :;XVUVY\->#]2U>TM3<S6T)95W !3_ 'FR>0/09)H WZ*\U\07
MKGQAX!U.>RO$G9[H-!E6=_\ 1SC"JQ7DGKD8SS@5TVG^-;"\T[4[JYM[JPDT
MR?[/=6UPJF17.-H&PL&W;EQ@\DT =)16!9^*[>X\1_V#=6=S8W[6_P!IA68H
MRS1@X.UD9AD'J#^HK(\?ZY>VMWX?\/:=</:W.N7GDO<I]^*% #(4]&P0 >V:
M .VHKF=3\%:=<:+<VFG"2QO'B98[R&9UEW8X+OG<X]0V<U=NO$*1:C<:?9V5
MSJ%W:Q++<1VY0>6&SM!+LHW'!('MSC(R ;-%<G+\0M'72=(U.&.\N+;5+I;.
M(Q0Y,<I)&UUSD$%6X )X^E$7CE9=0O\ 3%\/ZO\ VI:*DGV,I%NDC;.'#;]@
M'!ZL#GC!- '645R#?$72!H>C:N+:_>VU:X%M"$@RR2Y8%6&>H*,,#.<<4^P\
M?Z;<W&K6M]9W^EW6F6QNYH+V(!F@ )\Q=I8,..W?B@#K*KWUE!J6GW-C=)OM
M[F)H94R1N5A@C(Y'!K$L/&%O>:G:6$FGWEK->V9O;7S0A$L8QD?*QPPW#@^O
M6LO_ (6=IW]EMJG]DZL-/BNS:W-PT2!;=@_EY;Y\D;C_  YQWQTH T;'P9':
M1K;2Z[K-[8JNT6=S.C1[?[I(0.P[8+$$<'-=-6(GB:!O%[>&WL[N.Z%L;I)G
M">5)&"%)4[LDY.,8JYI>JIJJW31VT\207#V^Z7;B1D.UBNTG@$$<XY!H OT4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% $*6L,=S+<JG[Z0 ,Y))P
M.@&>@Z\#C))[U-110 4444 %%%% !4-S:PW<:QSIO0,&VDG!(Z9'<>QXJ:B@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y
M/XE6=YJ?@#5M.T^TFNKRZB\N**(=3N'4G@#'K7644 <=<ZEKTGAF/3]&T*[3
M4GMUA$UV4BBMVVX+L=Q)QUPH.?:N:N_!%UX0TWPI)IFEKKT&CQSP7MH57?,)
MBK-(@;C(9<XZX('O7JU% 'EGC1Y#\/)KQ/#_ /922:A9&*S*1I,^)TY?:=H)
M/ &>,<GG Z&ZLIM:\<Z-KBVES!::-;7)9I8BKRR2A5"*IY( #$GIDC&><;?B
M/P[;>)M.6QN[FYAA65)3Y!4$LC!ER2IZ$ UJHI5%4NSD#!9L9/N<<4 >::1X
M8U6_^"ESX:EMI+'4R)]B7 &"QF:5.1D8/ /IDU>T5+K7;<VEQX*&@W'D21W5
MU)%$%#,A7$)4[FY.<G P".<UW]% ' >";WQ+8:3I_AB_\.W$-SIZI;OJ!=#:
MO"G 93NW%BH  QUY.*KO;>([;5?B#?:1I\J7=ZENVFR3(-LK1PA&QGC.<X#=
M>.U>CT4 >:Z38:B/B!H^L)X?U*&V?2Y;:XGO)4:42%T;=(=Y., @?H *J6^D
MZU#\)_$'AQ]%NQ>DW<<)!0K.99792F#TPPR3C\:]5HH \^_L_4],\6Z%XF2Q
MN9[1M'&EWL")F6W(8.'V=6&X8.,GH>:R?$GAC5+WP_X[OK;3YVNO$#VZ6MF
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[^UHM,>38!)Y)AWKD@?=9LD= 3U% '245QZ_$O0'LH[Y4U#[$;DVTER;1Q'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK*S+_7->C44 9[ZILUZ+2OL-ZWF6[3_:UB_<+A@-A?/#'.<>E:%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\L\\LD* 6\@&^,$LI)7"G@]<9QQ6OJ&J6FF+$;J0AIG\N&-$+O(V"<*J@D\
MGV )- %RBLBV\3:9>6=Y<6TDTALG\NX@%O)YT3>ACV[N^>F,<]*Y;P)+<>*=
M,TCQ)+J>JPWF'DNX#YBVTX<MM4*XV87 P4YXY/- 'H%%>>ZQXC@B^(SZ'KVI
MW.E6+VL;Z<T<IA2XD).\M(.X^4!2<=>#D5%XU77-$^&6OS/KEXUS!.KVUXC+
M'(8BT8 )0#& 6!QC)&>] 'H]%8UAXJT?4M9DTFVN7-XD7G!'A=!)'G&]&8 .
MN3U4D5';>,=$O+JT@ANG/VUWCM93"XBG9,[@CD;3T/?G'&: -VBN;/CSPY_:
M1T\7SM<K=)9LBV\AVRM]T$[> <CD\>]6)?%VBPW=O;RW+H+B?[-#.T+B%Y<D
M;!)C;G((Z\D$=: -RBLF7Q+ID5SY!DF;%PMJ9$MW:,2L0 A<# .2!UP#QUK6
MH **YS7]-O7&H:BFL7MM%%9GR;>W=54.H8ECE223E1U[5C>!8-5U;PKX=UZ?
M7K^2>6,2W44K*8Y00P(QMR,<$8/:@#O**PK3QAHE[=V=O!=.?MK.MI*876.<
MIG<$<C:>A[\XXS4"^//#CZE_9Z7SO<B[6S9%MY#ME8< G;@ YZGCWX- '245
M@7/C30;-/-FO'%O]H-J+A8)&B,P."@8 @G((^HQUXJQ?>)M,T^(R2R3N%A%P
MX@MI)6CB.<.P525'!Z^A]#0!KT5RE]X[L+?6=!LK5)[J'5DDF2Y@@>1#&J%O
MEV@[CDKTS@9SCBM7Q-'*_AS4'@NY[6>*WDDCF@;#*P4D=<@_0B@#6HK@_ ?B
MN]U))/#?B7]SXAM85<NIVB\@8?+,A&/QQT/IT%[1]<MM'T*&?6=0N7:YU":T
MCFE5Y,L)WCC4E1A> !DXS0!UU%9;^(=,CU:XTMYW6]M[?[5)$87_ -5G&X'&
M&&>.,UE1_$7PO+#8SKJ+?9KU_+AN6MY!#NR0%9RNU2<' 8@]Z .IHK!MO$NE
M:[/?:797=Q%>0P^8RM \+[#P)$WJ-RYXW#(_2N3\!?$'2E\)>'K76=6E?4KQ
M-AGG21E:4L<*TN-H;'8G/3VH ]*HK'U7Q/I>C"<W<LVVW027#0V[RB!3W<J#
MM&.>>W/2JNH>.?#NF31PW&H9DDMC=QB*%Y/,B !W+M!W<$' [<]* .BHJO;W
MUM<Z=%?QRC[++$)ED<%1L(R"<XQQZUFV_BS1[F\M+9;B1'O03:-+ \:7  S\
MC, &XYP#R.1D4 ;5%>?WNK?\)#XZU+PX]SJUG;06,?DR6<<\+K.[N#(64#Y0
M%7!;Y#SUJYXXU6^\+>#;*9;JZDCCN+>#4+^.,-+'!TDE  P&.!VXW<4 =I17
M*:-%]LO;'4M#\0SW^ARQ2+)&TXF <@;6#GY@1R"I)&2.!BL#PMXTLM'L]:37
MM4NY?)UVZMEFE2280QAPB;V4$1KV&<#K[T >E45D:GXFTO2;B2WN996FB@-S
M+'! \K1Q XWL%!P.#]<''2H+SQGH%BNG-/J VZDGF6A2-W$R[=W& >W0=3P!
MS0!O45A1>+]'N-.@OK>2YGCGB:9$AM97DV D%B@7<!D$<CG'&:EB\4:1<V5E
M=VET;N*^1GMOL\;2-(J_>.T#( R <]"0.IQ0!L456T_4+;5+&.\M'9H),[2R
M,AX)!R& (Y!ZBK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F
M^()4A\/:BSD\VT@  )))4X  ZGVK2HH X[X8MY'PTT:*=7AEMK;;,DJE&C()
MSD'D5PKK(?@?=V@M[C[6=5+K!Y+>81]M$F=N,XV<Y]*]KHH \NO[ZUT3QYK3
MZ]:ZI)I>L)!+8W5EY[QMB((T3+$>N1D<=Z[[0+6WL- M8+:P_LZV1"8[4GF)
M220#Z'!Y'8Y%:=% 'F'A#2=+U;Q7XS_M/3(KA)]162#[5;965 H&5W###(]Q
M5SQHQT+Q9HFM7%G?2Z%':364YL#(&M2S(RN5C(.T[,<>@]J]#HH \G\1Q:8W
MA&*XTC2;J&WN]<M;HF2*4RW(612\S(P+@8!Y;DXSW&=_XD2J^G: 8EDEQK5G
M.1$A<B-7RSG X '>NYHH X)KAM%^*=UJE^6_LG5--BBMKS!,<3QL28V(^[NW
M%@3P?K7*ZGID]KX;U.Z:WG$&I^*HKZWMQ"Q;R1(FZ0IC(!VEN1TQZU[/10!P
M_C"17\7>"94#/''>RRR.B%E1#"RAF(Z D@9-5=,FCB\<>/YY%=8IH;7RY#&=
MLFV%E;:<?-@D#BO0J* /'] U"73O#O@.SN;*YMXOLLL4U]'9-+/;R  >2ORD
MQ[^YQD@#'J,]ED7X;ZIIYLK]9U\2^8(Y;>0L4^U*^<D'=A1DGGW/->X44 ><
MZU#)J/Q+N8[-F4W/A>>UBN IV"9Y 5&[IG'./2G>"_$%M>Z+HF@76A72ZWIB
M10S07%FP2V,:[#*)"-HX!Q@Y.<>]>B44 >/Z2VGV]M?^$?$VBZM=ZC]KF,4(
M\][>^5Y6D1P0?+4989+8 QD\YKUF:6.TLFDE(2.-.3R<?XU/10!YG\)- TQ_
M &CM?Z1!_:=H\K-]IML2Q,97*M\PR#MQ@^E,U.[M] ^(.MGQ#::JVFZLD#V=
MS9^>Z96,1O$RQ'J2,CCN:]/HH \TEMK6Q\8^ 8[73)+&SMHK[]QL9A;"1!L#
MGD*3SP3UR*TK[<WQCLF7S%7^Q)H/."$JLC2HRJ6Z9P"<5W-% 'C]E',?@W>^
M"KRSE_X2"*.6S%J8R3*[2$I*IQ@IR&+]!@YK5TN>;P?\0=137!<R6VHV%G%9
MWJ0O*I>%"KQG:"0Q9BP'?->ET4 <1\*RZ^$98I+>X@=;^Z;;-"T>0TS,"-P&
M1@]JY/QI=3ZEI?CK3FT^\M[I3^XMK2S8"[0(O[^215^<\$8)P H&":]CHH \
M]ANXY_BGH]Z(YTM_[!DC,DL+(%<R(0IR/E) )P<'%<J8[Z/0)M0M[.ZGAT[Q
MG+J5S;I$V^2VWL0ZKC+#D,,>F>U>V44 >>6>JV^J_%ZSU"RCNI;.30GA%Q]D
ME5-YG5@"2HQP#R>,\=:O?$8/''X9O!#-)!9Z[;S3F*)I#''M<%B%!.,L/SKM
M:* .#L+J,_%O4[QTEB@?1H$$DD;*-P=V9<D?> ()'6N+TM;O3?!/@_5);#4)
MK/2[R\74+:V$B3Q)*[A9-HPV "#]&KW"B@#F/"/]CW4M_JNC:?<Q17?E^9>7
M2RK)=,H(Z2?,0H( )ZY('2G?$)O^+?:]$JL\L]C-%%&BEF=V0@  <DUTM% '
M-^'+B-/AWIK.67R=-B2164AD81@%2.N<\8KSVV5XOA=X MV@F6>UU:T>>+RF
MWQ!'8NS#&0 #R3ZU[-10!PWAAU/Q.\9R;'"7 LO)D,9"R;(B&VMC!P3@XKEM
M _L]-+?P?XDT35KK6()W5;=O/:WN_P!X624,#Y:KR"2<8P3UKV*B@#RO78[B
MQUO4=4\,WEQ'J37J)=Z'<QEX-0.57S(P1\IVX)=>!MYQ@FM/3Y4B^('CJ:57
M6*6UM%CD:,[9"D;A@IQAL$@$#UKT&B@#QKP\EYI>G?#K6;BWN/[/L+:>SOE\
MIMUJ\@ 5V7&0,C!/8'WK?>U,_B#QEXBMPXTZXTI+6-PIQ<RJK991_$ "J@CJ
M20.E>C44 >/VDMSH^G_#;6KBVN7TS3K)[6^"0LS6LCQ*H=D S@$$$XXS[UT?
MA*[2Z^)/B^ZBANA;W4=B89GMI$23;&P;!( [CKUSQ7>T4 <[K=U%%XH\/(S'
M(EF+$*2%!B8 L>@R3@9ZUR7B/PKJ.A^)K?4O#\>[2=6U*T.JV2CB*19T87"#
MMG;AOKGZ>GT4 <%<W:Z+\7;BZO(;GR+[2(H;9XK=Y!)(DKDI\H.#A@><<5R&
MG^:OPV\'6\MI=QS6_B1)I8WMW!6,7,CE^G*A6!W#CGK7ME% '#031K\9+^Y.
MX0'0XHO.*'8765V*[L8R%(.*X^RBG3X?^'I&M;G;8>*?M5ROD.6BA\^5MY7&
M=N&!SCO7M-% 'F?B#1KCQ;K^K:AHG^J_X1V?3UN0-JSS2'*HI/4 #D] 6QU!
MPOAC4=%UU]*2;1-576]/PTT=\+C98LHPS!W)7G!  Y.1P!G'I=% '$?#,A=/
MUQ3&\;OK=Y, \90LCR95AD<@CH:3Q:MSIWCCPOK[QRR:3;"XMKIHU+?9S*H"
MR$#^'*X)[5W%% '":9 &\;^)?$T99-*ELH+=9-IQ<2(&)9?[P *J".I) Z59
M^%>8_AMHMM*CQ7$$&R6*1"KH=QX(/(KLJ* ..U^YT'5[K4=!\4Z<IL8]C0W$
M\#")MR@D++T5P?0@X(QWK@[G3+^Q^#WBG3(VOKK3FO!'HJ3QLTSP!T. N,[<
MAL<= 3TQ7MM% '!:K<!_BEH%U;1O-$NF72[E4[=S%"BEL8!.#C-<E%?O>V_@
MR^:PU"&6UU;_ $FR@T^2."QRD@\M4"\\D<_,?< XKVJB@#A/")W^+_&^T21F
MXNXGAD:,@.HA52RDC# ,".*YKPHVG2:-8>%==T+59=>L'6(VTOGM;LR'Y9P^
M?+"8^;/UP#QGV"B@#RN[CN-/\03:AX9O+@33ZL$O] NHR\<Y\T*T\61E.!YF
MX?+Q[8KO=-\26.J:SJ6DP+<)=:>RB42PE%8'NA/WAVS6O5>&RBANYKKYGGF
M5G8]%&<*/0#)_.@"KXAE2+P[J+.3S;2*  222IP !U/M7/?#9I(/A?I$7D2&
MZMK3:]NZE'#C/RD'IFNSHH \6M[]KL>"+]K'4(Y+;42+FS@T^2*"R)CD C1
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MH'))-7JY7QY?7=AIFG26]G)/$=0A6XGBM?M$EI'SF5$P?F!P <'&<X- %O\
MX3+1TL-4NYI)X5TIMM]&]NYD@^7=DJ 21M.<C(QWIECXVT74-3LK"&6X$M]$
M9;5Y+9TCG 7<P1R-K$ Y(!K@7CG2/XFPQZ=JY74+%/LC3V\KM-FU*#D@G)8_
M=ZCT&,#5G\TW?PU<6EX1:@_:"+63]SFV*?/\OR_-QS0!I?$#Q);Q^#O$*65Q
M?+/9P.C75FK@0S;<JI=>^2,XZ9YQ74Z*S2^'M.:1F9GM8RS$G))09.?6O*XY
M[O3/AYXN\*:AI^H-J_\ IKPM':22)=K*699%=05_BP<G/'KQ7J/A]R?#.FL\
M4L3+:QADEC9'4A0""I&0>* .%\-:[J>E_$B^T;5+V:XTO4Y)AIC3N6,4D+'=
M%D\G*D'GT%.^)FOZG!J.C:?I5Y+:P#4;6._EA;:S"9BJQ@]OE5V/?[GK4>MZ
M3<:[X4U:?3(;B/6=+U:74M/,D#H696R NX#<&7(XX.14'BZQOD\,Z#)/97,V
MJ7.NVVI7R6T#R^4,Y()4'A%"I_P$4 =WJ'B73-&FELY&N)IK:V^TS)#&TK10
M\C>QZ]CZDX/%,N_&.BV2:3)+<2&'5FC6RF2%VCE9^5&X#"DCGG%<OXAO;F[\
M2:O82:??I;S:6OV*2RM7S>N0^5DE494*2,*2H^8YSD"J^GVBZ_\ #'P]X3N+
M"\@FN;**.26>UD3[+Y2C+@D##[AA<XR>>1U .QN]>TRYT35YI)KR*SM1+!<3
MQ0R!DVY#E"!D[<'YES@CVJI;^*M!TC2O#\#WMV\>H6Z"RDFCDD>9?+W LV.7
M('0\DGI6#I.HWK_#C6M$U#3[F/4=-M9[/=':2!+L!2J21_+\V[C('.<U119U
MT[X7J;.]W67E_:A]EDS!BV*'?\OR_,<<T =4OQ!T-H;UE&H-/9/MN+06$OGQ
MC&[<8]N0N.=QX_&KZ>+=&D?1Q'<LZZP,V,BQ,4E^4MC./E. 3@XKG-*=H/'O
MCFYEMKI8)X+3RI#;2;9=D3A@IV_-@D#BN9TV*ZTWP9\.KZZL+Y8]*NBMZ@M9
M#)"&C=<E -V,D<@=Z /1IO&.BVRZPTTTZ?V.%-Z/LTA,09=P. O(P,Y'%5E\
M?Z ;NTMWFN8_MD1EMI'M9!'/A=Q5&VX9L'H,\\#GBN+O'N+J7XGR+IFI*NHV
M$*VFZSDS,?LI7 P.N2ORGD9Y P<:%YYC/\-V6TO"+5PUQBUD_<C[.4^?Y?E^
M8XYH [71/$FG^(#=I9F=)K.01W$%Q T,D9(R,JP!P1R#7-_$(:_9RZ1?>&+F
M;^T3=,K6;RGR;E%ADD*%3P"1'@$8Y/XB3PT)!\2_&<K6]PD-P+/R97@=4DV1
M%6VL1@X) XK4\07"QZ]X<4QSN$O7DD:.!W5%-O,H+$ @?,RCGUH RI_$EKXK
M\"1:OI=S<VKFX@BD2.5HY(',R+)&X'?!(Y]<CM711:YIZZS+H2-.;ZWMA<F)
MHW):+.T,&/WN1CKFN(\7^$M1T[7X]<\.)FVU&[MTUBR49#XE4B=1V88^;V)/
MJ:T=2G;1_BW%J5S:7CVEWHHM(I+>V>4&99BVP[0=I(.<G ]Z -=O'GA]-'MM
M5:ZE6SN;K[)'(UO(/WN_85;CY>0>6P.*:OCO16O+JR OQ>VZ"06IL91+*AR
MT:;<L.#R!QCG%>=PQ7@^'&GVKZ9J*7,?B43O$;.0L(Q=%RW .5"GJ.*[+>W_
M  N0WGD7/V7^P/)\_P"SOY?F>=OV[L8SMYQ0!1\8>);74?#/A_7=*U*XAM&U
MJUCE97:'*>;MD21>.F#D'TKI]'\9:-K>HW6G6TL\5Y;)YCP7=N\#F/LX#@$K
M[UYS#9WI\#JPTZ^S:^+!?2Q_99 X@^T%]X3&6&WG@&NAUS2)O%_B22^TH/%#
M#HEU9B[>-HQ++,,(HR 2%P6)Z D#KG !TT?C#2'O[*U:2>/[>#]CFD@98[C
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M<LENZH64N67=C;D;AWH V]2\8:1I/F27<DRVL,P@GNUA9H87) PS@8') )Z
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ME0R3K<RPF: RV[HDZ#&XQN0 ^,CI5G7_ !!I_AG3&U+5'ECM$8*\D<+2;<G
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M[6=/6SN85L+@0*TD##<=@8DGH,YX!YQSWKDS:W5CXD%]X9EOX7N=7*:CHEU
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*\Q\5>*/%?AKQIX5T :Q#.NK2+'<3&S52I+A24'X]\T >@?:O$__ $"-(_\
M!I)_\CT?:O$__0(TC_P:2?\ R/7(^-]:\5^#O!NMZH=0@GDMIX#9RFV4!HW*
MJRNOJ"2<C':NE\-^,-)UN*SLUU6SFU=K2.:>WCD&X$J"W'L3T[4 6?M7B?\
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M$(1V/I4=AXGT/5+I;:QU2VGF<,R*C_ZP*<,4_O 'J1G% $?VKQ/_ - C2/\
MP:2?_(]'VKQ/_P! C2/_  :2?_(]<QX,\6:KJOC[Q=HNH3Q26>E2*+=A&%8
MEOO$=> *S/'GQ,&G_P!CR>%]8L[G[1?K:W$8"R J3RRGZC&02* .Z^U>)_\
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MVDZ[:O<Z7J%O=PQL4=HG!V,.H;T/UH K?:O$_P#T"-(_\&DG_P CT?:O$_\
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M<9QWJG+XX\+00W,LNOZ>B6LBPSYF&8W.<*1U!^5N/8^E $OVKQ/_ - C2/\
MP:2?_(]'VKQ/_P! C2/_  :2?_(];((8 @@@\@BEH Q?M7B?_H$:1_X-)/\
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M%I$%O/J&K6=M#<C=!)+* L@QGY3T/'I0!']J\3_] C2/_!I)_P#(]'VKQ/\
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M_:KN6VW2IYA*D.I;(8## 8RN>.O%>B^"+'1DU#6]7T?6YM5&IR1RW$N4,(D
M(PNT ;L$;AU'&:ZYH(F@\AHD,1&WRRHVX],>E+%#%;Q+%#&D<:\*B* !] *
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M*** "BBB@ HHHH Q?%'_ "#[/_L)6?\ Z4)6U6+XH_Y!]G_V$K/_ -*$K:H
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M!U( '05')!#*H62)'4'(#*",^M9>I>*M$TBXL(;_ %".!]08+:DABLI) &&
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M.GW=WXO:YMK>:1]5,B"5 V4#,58 ]LG(-9%O;7.J>,OBK9Z:^;J\M"EMM/\
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M %35?^0/??\ 7O)_Z":CT/\ Y &F_P#7K%_Z"*DU7_D#WW_7O)_Z":CT/_D
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M *"*DU7_ ) ]]_U[R?\ H)J/0_\ D :;_P!>L7_H(H OT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BS_ /([V/\
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M-_T#=(_\#Y/_ (S63)J=[X=\8Z)I%U?37]MK$,RJ\RH&CGB4-D;0!M92>.Q
MQBLGQ&?%WAR*S\0#7C=L]Y!#<:1]G00E97";(R!OW L.23G&?:@#K//\3?\
M0-TC_P #Y/\ XS1Y_B;_ *!ND?\ @?)_\9JAXQM=6;3+R^M/$<ND1VD#21"&
M*-@[@$YD+J<CH JX^IS@;&@3:A<>'M.FU:)8=1DMHVN8UZ+(5&X?G0!6\_Q-
M_P! W2/_  /D_P#C-'G^)O\ H&Z1_P"!\G_QFJ]GXOL[WQAJ/A^.*<264<1:
M1H'"EWWY&<8  4<G@YXSBK47BG19[NWMDO1ON6*6[M&RQSL.HCD(VN>#PI/2
M@!OG^)O^@;I'_@?)_P#&://\3?\ 0-TC_P #Y/\ XS6U10!QWB.;Q$;&U\W3
M]+4?VA:8VWTA^;STP/\ 5#C./_KUK^?XF_Z!ND?^!\G_ ,9H\4?\@^S_ .PE
M9_\ I0E;5 &+Y_B;_H&Z1_X'R?\ QFCS_$W_ $#=(_\  ^3_ .,UM44 8OG^
M)O\ H&Z1_P"!\G_QFCS_ !-_T#=(_P# ^3_XS6U10!B^?XF_Z!ND?^!\G_QF
MCS_$W_0-TC_P/D_^,UR-QXINO$'C6[T71?&-AI4EI)Y'V*:Q\V2<J,NRLQ Z
MDK@9^[GO6]=:S=ZCXX;PU8W3VD=K8B[N[F-%9RS-M2,;@5' +$X/8#'- &AY
M_B;_ *!ND?\ @?)_\9H\_P 3?] W2/\ P/D_^,UREOXUU&_MM/T_<L%^==DT
M:^N8T&%,:L^Y V0"X5<9SC<?2M?0/%-S/X7GNKU/M%[#?3V$(0!3=NDK(A '
M SCD]!ACP!0!J>?XF_Z!ND?^!\G_ ,9H\_Q-_P! W2/_  /D_P#C-:5C'<Q6
M427DXGN0N99%4*I8\G [ =!WP!DD\TV]U&STY$>[N$B#MM0$\N<9PHZDX!.!
MZ4 9_G^)O^@;I'_@?)_\9H\_Q-_T#=(_\#Y/_C-+>>)M+M_#EQK<-Y!/:11N
MP=) 0S*#\F>QR,8K%\'76HZ[;:5KH\0">&>R5KZP\I"B3.H8;& !3;DC!SD8
M[\T ;/G^)O\ H&Z1_P"!\G_QFCS_ !-_T#=(_P# ^3_XS7,^/+_Q+X;\(ZUX
M@@UD(]O(&M[46T;(J&14 8D9)P<]1UQVKH[.'5-/N_M6H:TMSI@M6:7SXHXC
M$X*D-N4#Y=N_.>F* '^?XF_Z!ND?^!\G_P 9H\_Q-_T#=(_\#Y/_ (S5BT\0
MZ1>O,EOJ$#-#&)I%+;2L9Z/@X^4_WNE0V7BK0-1NH;:RUFRN)YHWEC2*96+H
MI*LPQU (/Y&@!OG^)O\ H&Z1_P"!\G_QFCS_ !-_T#=(_P# ^3_XS3U\5: 9
M8HSK%FC3#,/F2A!*,XRA. XSW7-27?B'1["Z6VN]1MX9F=8\.^ &;[JD] 3V
M!ZT 0>?XF_Z!ND?^!\G_ ,9H\_Q-_P! W2/_  /D_P#C-0Q^,-+E\7S>'$G7
M[5#"LCDG W,<!!ZG )/IQ[UT% &+Y_B;_H&Z1_X'R?\ QFCS_$W_ $#=(_\
M ^3_ .,UM44 8OG^)O\ H&Z1_P"!\G_QFLCQ1-XB/AZY$VGZ6J;H\E+Z0G_6
M+V,0KL:Q?%O_ "+5U_O1?^C%H //\3?] W2/_ ^3_P",T>?XF_Z!ND?^!\G_
M ,9K:HH Q?/\3?\ 0-TC_P #Y/\ XS1Y_B;_ *!ND?\ @?)_\9K:HH Q?/\
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M_$W_ $#=(_\  ^3_ .,UM44 8OG^)O\ H&Z1_P"!\G_QFCS_ !-_T#=(_P#
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M\5P6'B;1M &HI9K>><]U.K+OB5(P5 W @%BPYQT!K5BL-?@\-_8_[:2YU/S
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8ND?\C!X@_Z^(O\
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M "#[/_L)6?\ Z4)6U0 4444 %%%% ";5R3@9/)XI:** "D*AL9 .#D9I:*
MC(P:0 *    .@%+10 4FT%@V!D=#BEHH *.M%% "!%4DJH!/4@=:6BB@ HHH
MH 0@,"& (/8T$ C! (]*6B@   & ,"BBB@ K%\6_\BU=?[T7_HQ:VJQ?%O\
MR+5U_O1?^C%H VJ*** "BBB@ HHHH 3:N2<#)Z\4M%% !2%0PPP!'O2T4 %(
M%"C"@ >@I:* "D*@D$@$CH<=*6B@ HZT44 ($4,6"@,>IQR:6BB@ HHHH "
M001D'M28&,8&/2EHH 0 *    .@%+110 4444 5-5_Y ]]_U[R?^@FH]#_Y
M&F_]>L7_ *"*DU7_ ) ]]_U[R?\ H)J/0_\ D :;_P!>L7_H(H OT444 %%%
M% !2;5'0#KGIWI:* "BBB@!"H)!(!(Z9[4$ @@C(/4&EHH  ,# Z4444 (5!
M() )'0XZ4M%% !UI-B[]VT;@,9QS2T4 %'6BB@ H(R,'I110 @  P  .F*
MH 4  =A2T4 %%%% !6+/_P CO8_]@VY_]&05M5BS_P#([V/_ &#;G_T9!0!M
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &+I'_(P>(/^OB+_P!$)6U7/FVUVQUG4KBQL].N;>[=)%,]
MZ\+*5C52"!$X_A]:E^U>*/\ H#Z/_P"#67_Y'H VZ*Q/M7BC_H#Z/_X-9?\
MY'H^U>*/^@/H_P#X-9?_ )'H VZ*Q/M7BC_H#Z/_ .#67_Y'H^U>*/\ H#Z/
M_P"#67_Y'H VZ*Q/M7BC_H#Z/_X-9?\ Y'H^U>*/^@/H_P#X-9?_ )'H VZ*
MQ/M7BC_H#Z/_ .#67_Y'H^U>*/\ H#Z/_P"#67_Y'H VZ*Q/M7BC_H#Z/_X-
M9?\ Y'H^U>*/^@/H_P#X-9?_ )'H VZ*Q/M7BC_H#Z/_ .#67_Y'H^U>*/\
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MF:/%O*G?_:<IQA@W3[/[4 =116)]J\4?] ?1_P#P:R__ "/1]J\4?] ?1_\
MP:R__(] &W16)]J\4?\ 0'T?_P &LO\ \CT?:O%'_0'T?_P:R_\ R/0!MT5B
M?:O%'_0'T?\ \&LO_P CT?:O%'_0'T?_ ,&LO_R/0!MT5B?:O%'_ $!]'_\
M!K+_ /(]'VKQ1_T!]'_\&LO_ ,CT ;=%8GVKQ1_T!]'_ /!K+_\ (]'VKQ1_
MT!]'_P#!K+_\CT ;=%8GVKQ1_P! ?1__  :R_P#R/1]J\4?] ?1__!K+_P#(
M] &W16)]J\4?] ?1_P#P:R__ "/1]J\4?] ?1_\ P:R__(] &W16)]J\4?\
M0'T?_P &LO\ \CT?:O%'_0'T?_P:R_\ R/0!MT5B?:O%'_0'T?\ \&LO_P C
MT?:O%'_0'T?_ ,&LO_R/0!MT5B?:O%'_ $!]'_\ !K+_ /(]'VKQ1_T!]'_\
M&LO_ ,CT ;=%8GVKQ1_T!]'_ /!K+_\ (]'VKQ1_T!]'_P#!K+_\CT ;=%8G
MVKQ1_P! ?1__  :R_P#R/1]J\4?] ?1__!K+_P#(] &W16)]J\4?] ?1_P#P
M:R__ "/1]J\4?] ?1_\ P:R__(] &AJO_('OO^O>3_T$U'H?_( TW_KUB_\
M016==OXHNK.>W_LG1U\V-DW?VI*<9&,_\>]-L3XHL]/MK7^RM'?R8ECW?VI*
M,X &<?9_:@#HJ*Q/M7BC_H#Z/_X-9?\ Y'H^U>*/^@/H_P#X-9?_ )'H VZ*
MQ/M7BC_H#Z/_ .#67_Y'H^U>*/\ H#Z/_P"#67_Y'H VZ*Q/M7BC_H#Z/_X-
M9?\ Y'H^U>*/^@/H_P#X-9?_ )'H VZ*Q/M7BC_H#Z/_ .#67_Y'H^U>*/\
MH#Z/_P"#67_Y'H VZ*Q/M7BC_H#Z/_X-9?\ Y'H^U>*/^@/H_P#X-9?_ )'H
M VZ*Q/M7BC_H#Z/_ .#67_Y'H^U>*/\ H#Z/_P"#67_Y'H VZ*Q/M7BC_H#Z
M/_X-9?\ Y'H^U>*/^@/H_P#X-9?_ )'H VZ*Q/M7BC_H#Z/_ .#67_Y'H^U>
M*/\ H#Z/_P"#67_Y'H VZ*Q/M7BC_H#Z/_X-9?\ Y'H^U>*/^@/H_P#X-9?_
M )'H VZ*Q/M7BC_H#Z/_ .#67_Y'H^U>*/\ H#Z/_P"#67_Y'H VZ*Q/M7BC
M_H#Z/_X-9?\ Y'H^U>*/^@/H_P#X-9?_ )'H VZ*Q/M7BC_H#Z/_ .#67_Y'
MH^U>*/\ H#Z/_P"#67_Y'H VZQ9_^1WL?^P;<_\ HR"D^U>*/^@/H_\ X-9?
M_D>FV=KK$_B*+4=1M;&VBAM)8%6WNWF9F=XVR=T:8 V'UZT ;M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRDT>P&G[MQM?LZ^63ZE<8)]Z .&^(/A_1M-^$^N7-GIUK#--;PO)*J#<[!E
M8GJ3R>>IR?6K^J-%:_$_PQI\T,46E26=P]L@0"-KOCMTW!-V/]XUU]QHFE7>
MGII]QIMG-9)C;;R0*T:XZ84C%+<:+I=W8I8W&G6LEK&P9(6B4JA'0@=B/44
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ME^>.0 ;B!@EL],$UZ9698^'-$TN_FOK#2;*UNY\^;-# J.^>3D@>M:1 92I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU!H 6BJ-T=3&IV'V7[']A)?[9YI;S?N_)Y>..O7/;I5W<NXKN&1VS0 M%!(
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MXQ\-Z3%#;M9ZH\Z2R,6\Q3'$SC:.G4#KGO71@AAD$$>HH 6BD5E895@1TX-
M92<!@3C/7M0 M%%(K*XRI!'J#0 M%(&4D@,#@XX/>EH **0LH8*6 )Z GK7.
M3:_?1?$2U\/F&W^Q3Z?)="7+&3<KJN/0#YCZT =)15+4=5L]*%M]KE"-<W"6
MT*]W=S@ #]3[ U<+*N,D#)P,GK0 M%%% !1110 4444 %%%% !1110 4444
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M\R/]XLPP3)T+'/0@D]ZX-]-T^/\ 9XU*>.U@CN?/F)>-0KG;>%1DCD@ XYZ
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M=L85^>(EQCYBQ) SG;D\"H=*TC38_B3H2320ZH(_#TC"^N(E+3,DT860D]2
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M/>Q6:QW,\8BEEC9E9D P%.#T'8=NU5Y?!OAV;0QHDND6SZ8K;TMF7*(WJO\
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M.M6=)\*Z7I%W)>11>;=M+,ZW$H!>-97WM&I &$!Z#M65X;_Y*+XV_P!^R_\
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M >I+/"S[%E0MMWX##.WU^E.\Q-N[>N/7->5QZ58:?KGPVN[2UBBN+N*2*YE
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MMI6WR0BT38[>I7&"?>FP>%O#UK+'+;Z#I<,D9S&T=G&I0^Q XH X?5;RXO\
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MM+::V%M)!$\ VXC9 5&T@CCIP0/RHNK2VOK62UN[>*XMY1MDBE0,K#T(/!H
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M0,  < 51M=#TBQNY+NTTNRM[F3[\T-NB.WU8#)H X/7[;3?"&I^#-'AD73-
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M/J:OUSOA?5=.'AWP[:?;K?[3<Z?&88O-&Z0+&N[:.^._I714 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD VJ0PRK;NQVGGJ,TO@CQC%=Z#9KK^M6?]JW-W<0Q)(Z1-*%F=%"H,=@!_\
M7J;X52QO\+M *NI"VH#$'H03G->>DV2? F\N4, E_MDOY@QNW"^&#GUV_I0!
M[-J.M:7I !U'4+:T!&1YTH3CUY[>]7$=)8U>-PR,,JRG((/0BO,+W5].LO'_
M (ET_P 2:R^EV]_! UI)(T:Q7$ BVN@9U/1B_&?XC7=>%[.ST_PS86FG"X%C
M%'MM_M!)?R\G:3GG&,8!Y Q0!REAJOBG4_$?BW3;75;5/['>);7S[0,)-\>_
M$A!'TR,>M:_@WQK;^(_ UCXBOA%8>=N217?"[U8J=I/7)' Z]JYCP]IVGZ[\
M0_B%:W%Q,T;S6JLEO=O%O7R<,#L89'!'YBK7BMK+PAKOA++OI7AV!+BV\ZW5
M=EO*P386RI R XS[GGDT =J/$6BG3TU :M8_8W?RTG\]=C-G&T'/7/&.M8/B
MGQ[I>E^'Y;K3=5T^>Y-TEFNV=6".757)&?X VXCZ9KC?%MMX<C^'^N7FE7AO
M+>]U2UFFNGD5HI93-'O,9  Z#YBO'Y''1_$R/3].\'P&!+:V275;-SL"H'(E
M3)XZ_*.OH* -S3KTZ8;F[U'Q/;7VF7+*;!Y!&KK@'>NY %<9&1@9'.<UJ/KN
MD1:;'J+ZI9K92X\NX,Z^6^>F&S@_A7*3WALOC- VH.$L[K1S#I\KG"&42[I$
M!_O%=I]PHKB?$-M'!X&\>3 QC2)];@>RR1M)\Z'SF3VW;NG]UJ /6X_$^@2R
M>7'K6GN_GFWVK<H3YHZIC/7VJ,>+_#;6,]\NO::;6!_+EF%TFU&[*3GK7*^/
M;+2;>[\'B.VLHTFU^ L%10)!Y;C)]?X1^52:5'8'XP^*"R6Y8:=:%LA<_P 8
M;]-N?;% '9R:OIL-C#>R7]LMK/M\J;S1MDSR-I_BSVQ41\0Z,NF?VDVJV0L2
M2OV@SJ$W X(SG&<\8ZUY/X6UC3K+P;X CG-K%.\]X+?4+F0B&T*F0'(# %F5
MMJ@G'.>V#0OKNRD^%WQ!@-Y'/(NO/("^T,5:6'#X &-W)' S@XH ]JM-;TJ_
MO[BPL]2M+B[MO]?!%,K/'V^8 Y'-)_;FD_V@NG_VE:?;&8HL/G+N+ 9*@9ZX
MYQUKC-66&W^*NB1:<;>&9]$NXX@F #\R%!@=LY(_&L[P7K'AC5/!^@:/J8CD
MUS3KE,Z?(Q%REXC',A7.>I9BQXP3F@#T2[UW2;"Z2VO-2M()W(58Y9E4Y/0<
MGOV]:N3SQ6MO+<3.$BB0N['HJ@9)_*O(H+W0KM?%'AKQ=K%Q9W,FISM)9,44
MW43/NB:/Y"S?+M "DGY1[5Z;>Z;_ &CX5N-*!DB^T636P,IRR[DV_,>Y&>:
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M#XCT2>*YEBU:R:.U -PWGKB('H6YX!]34@UO23IZ:@-3LS92,%2Y\]?+8DX
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBHKBY@L[=[BYF2&%!EG=@
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M2::MY";V./SGM]XWJF<;L>F>,U6C\2:-*7$>HPL4A:XQGK$, N/[R\CD9'-
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M+(@8 ^N#3HXHX0PCC1 S%CM4#)/4_6L?Q/XHL/"NGPW-Z_,\Z01)_>9F S[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYK=]:)\</#4;74*NNG7*E2X!!., ^YP?RH^+=[:VUCX9$]S#$1X@LY#O<+A
M6RQSV'<UZ&44G)49]<4I56ZJ#]10!P'Q UZUUGPM>>'O#\L6JZKJ:?9XXK1Q
M((U8X9Y&&0B@9Y-2W$$4:>'? EMJ=NES:6T4UP6PQ*0! @V9!^9]IQZ(U=T
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MUO4K!;G[.4(+X4%STP.N<?X5TU-**7#E064$!L<@&G4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5SVMC7XY+V[L]0M[6RM[3
M?'&UL)&DD&XL2=PP,;1C'K70UGZ\ZQ^'M3=V"J+64DDX ^0T <MX2O\ Q3K_
M (<T37'U*T*7B;[BW%IC:I# %6W=CM..XS3O!'C".\T&T&OZS9C5;F[N(8DD
M=(FE"3,BA4XSP *F^%3H_P +O#Y5@0+4 D'H03FO/2MFGP*O+M! )AK)<2C&
M[<+X8.?7;^E 'LNH:SIFDA3J.HVMH&&09YE3(]>3T]ZN*ZR1JZ,&5AE64Y!'
MJ*\QO-6TZS^('B;3O$>LMI<%]! UH\IC6*>W\O:ZAG4]'+\9'WC7<>%K.RT_
MPQ86FG?:/L,4>VW-P<N8\G:3GG&,8SVQ0!RMAJWBK4_$?BS3+34[)/['>);;
MS[3<)=\>_#D,,>F1]:V/!WC6V\2>![+Q%>B+3Q-N2022 ('5BIP3U!(X_*N8
M\/Z;8ZY\1/B':SW$_EM-:HZ6]T\6]?)PP.PCT(_.K/BIK'P?KGA%?,;2?#L"
MW%OYT"KLMY6"^66W*P&0)!NZ_,<GDT =N/$&C-IZ:@-6L39NVQ9_M"[&;.-H
M.<9SQCK6!XJ\>:7I'A^:ZT_5-/GNOM*6B 7",$<NJN2 ?X VXCZ9KC/%MIX=
MC^'^O7FE7AO8+O4[6::[:16B>8S1[S&5 'W?O%>/Q!QT?Q+M]/TWP;']GAMK
M5)=4LW;RU5 Y$R<G'4[5Z^@H W-.O3IQN;S4O%%I?:5<LIL99/+1E(!WKN3"
MN,CC R.<YK5?6]*CTY-1?4[-;&3&RY,Z^6V>F&S@UREQ=M9_&>V_M!@EI<Z,
M8M/D<X0S"7=(H/\ >*A3[A17$>(K5(?!'C^4;!I$NM0-9$GY=WFQ><4/INW#
MCN&H ]=3Q)H<DGEIK.GL_GFWVK<H3YHZIC/WO;K48\6>'6L9[U=>TPVL#^7+
M,+I"B-V4G. ?:N2\>Z=I%M<>$1%9V42S^(+?>$C51(/+<<XZ\;1^53:7;V!^
M,?B4-#;EAIMH2"HZ_."?RP/IB@#LY-6TZ&QBOI+^V6TFV^5.95V29Z;3G!SV
MQUJ(Z_HXTS^TCJMD+')'VDSKY>1P1NSC.>U>3^%]7TZR\&> HY_LT=P]U>"U
MOKF0B&T*F4'(# ,Q4[5!('.>W.??W5E+\+_B+";N*XD76Y)0S;0Q#/#A\#&
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MMX+#_A0OAF0QV^3J=N2V!R?M)!Y]=N1]*[E%M[?XX1Q0B*/=X<(*)@9Q<#'
M]!F@"[\2=<U+PUX.N-8TN:-)X)(EV2QAU8/(J<]#QNSUJM<^(]8\/>.=#T+4
MY;:_L]96589HH3%+#)& 3N&XAE((]"/PJM\:I(T^%VHAW"[IK<#)QG]\AX_
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MUNDDNG6X>6- &<! >6')Y)Z]R: ,S7]7UJV^(6AZ'97T4-KJ4$\KE[<.R&,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***BN+B"TMWGN9DAA099Y&"JH]R: ):*HZ?K.FZJLQL;V&?R&VS!&YC/7##J
M./6J\/B?0KB[BM(=6M'N)L^5&)1F7 ))3^\, \C/2@#6HK,_X2+1?L$]_P#V
MK9_9+>0Q33^<NR-QU5CG (R.#3[W7=+T](VNK^"(21F5,MDL@QE@!_",C)Z#
M- &A17'^,M;N[2T\.WNCZBHM[S5[2"1HU1UFAD;G#$'@CN/6NIO+RWL+.:[N
MI5B@A4N[MT % $],EABGC\N:))$/\+J"/R-8FA>+M*USPZFM1W4,-L5W/YD@
M'E GY=WH2,<>]:-AJVGZH9A97<4[0L%E1&^:,GD!AU&1ZT 3QVEM#&\<5O$D
M;_>54 #?4=ZC_LRPV[?L-MMSG'E+C/Y5@^,]1O[$Z!!87CVAO]6CM9I(T1F\
MLQR,0-ZL <J.<5F>//$FH^&=*BLK2[22ZN+6?;<.RFY5T7(D$80*RC^(\8'-
M '93:?97"1+/9V\JPG,8>,,$/MD<?A5FN*M_&MQ-X+U772NFQ/93M$L<]V5"
MA2HVS';^[D.3\H!Y*C/-4_!GC'4-:UB;3;LHGF&XN$-PPCG5/,(1$0+AE0<%
MB<Y[<4 =S%86<$@DAM((W'1DC /YBI)X(;J%H;B*.6)QADD4,I^H-<QH-[J*
M^-]=T:[U*:]MK2UM9H3-'&K*TADW<HJY'RCM70WVI66FK&UY<QP^8VV,,>7;
M&<*.I. 3QZ4 .-A9F". VD!ACX2,QC:OT':EDLK25$22UA=(QA%:,$*/;TJD
MWB31%T^#4&U:R%I.VR*8S+MD;.-JG/)SQCK3]/U_2-6NKFUT[4[6ZGMCB:.&
M4,4^N* +,UA9W%L+:>T@EMQTB>,,H_ C%*]G:R1)%);0M&GW$9 0OT':N+\=
M^+5L+*T72-9BBN_[2@MY(T"OY@,BJZ9(/(!.0.17<32QP0O+-(L<: LSN0 H
M]230!$]A9RJBR6D#J@P@:,$*/0>E(=/LB[.;.WWMG<WEC)SUSQ67HVI6UMX:
MM;FZU^+5$9F1=0 51.VYL!0G!(QCCKMK4LM0M-2@,]E<QW$08H7C;(##@CZ@
M\$4 ']G6)B$7V.W\L,'V>4N-PZ'&.OO2O8VDF_?:P-O;>VZ,'<V,9/OCO56_
M\0:1IDS17VHVUNZA6<2.!L#' +?W03T)QFI[W4[+3HT>[N8X0YP@8\OQDX'4
M\<\4 /%A9K(L@M( Z8VL(QD8Z8.*5;*U2[>[6VA6Y<;6F$8#L/0MU-<CXI\1
M2PGPK?:/JT1T^_U6*WF:/8Z2Q,KL?FYQ]SL1WK?M/$>BZI8W=S8:Q9R06^5F
MGCF4K"<=6/0>O/% %^2RM)KF.YEM87GB_P!7*T8+)]#U%3UC:1?V]MX8L[J[
MUR+4(]@!U$A46<DX! 7CGH .M./BG0%TUM1;6+)+-)/*>=YE54?^ZQ/1O8\T
M 7;K3+"^='O+*VN&3[AFB5ROTR.*L@     #@ 56?4[&.2UC>[A5[OBW4N 9
M>,_+Z\<U7/B#2!J*:>=2MA=NY1(C(,LXZJ/5AZ=: $NM/DM+"[;0+;3[;4)!
ME6EAQ&S9_CV8)[U6T#1)=.O-5U.[:+[=JDR2S)"24CV1JBJI(!/W2<D#K[5%
MXK\06NE:+J*IJL-GJ$5JTL9.UBAP=I(.0 2,#/7M5CPC>W&I>#-$OKN0RW-S
M802RR$ ;G9 2<#CJ: -*WLK2T>1[:UAA:4[I#'&%+GU..M"65K'=/=1VT*W$
M@P\JQ@.P]SU-<1/XCD\1>*=9T#2_$,>F2V4, M98A'(9IWWELA@=RJ%4;1CJ
M>>F.H@U[35G@L)]5M'OF/E$*P422@?,JC/7K\N210!H-:6SM(SV\3-( KDH"
M6 Z ^M.AMX;=-D$4<2DYVHH49_"LN]\6>'M.EFBO-;L()(&595>X4%"Q(4$9
MX)P>/8UL4 -1$C14C5511A548 'M44%E:6TLLMO:PQ22G,CQQA2Y]21UKD-4
M\:3Z?\1=,T@PC^R+@M9S7)Z+>,HDC3/^[^?F#TKL;FY@L[:2YNIHX8(QN>21
M@JJ/4D]* %G@AN8C%<11RQMU210P/X&A;>%'=TAC5W 5F"@%@.@/KBN,LO$[
MW?Q0N=/BU5)M)CT<W31%57R9?-"DL<;A\N#SZYK5TC6M/M-%@FO/$]KJ"3W$
MD<5ZS1QK(Q<@1KM^4D?=XZXH WXH8K>)8H8TCC7HB* !^ J..SM893+%;0I(
M<Y=8P"?QJ-=4L'U*33EO(#>QQ^:]OY@WJF<;BO7&>]5H_$FBREQ'J5NQ2$SD
M!^L8P"X]5Y'(XYH O2VEM.JK-;Q2*OW0Z @?3--^PV>(A]E@Q$VZ,>6/D/J/
M0UD>'_&&D^(=!.L0744=LI8MYC@%%WLJEL_=R%S@^M:.GZSINJB<V-[#.8&V
MS*C<QGKAAU''K0!/]AM,@_98.'+C]V.&/)/U]Z1K&S>5I6M8&D;(9C&"3D8.
M3]*XW5_%@D\:>%;/2-8BDM;VXE2Y@C"L)4$3LK!L9QD=5..*Z7Q+<7-GX9U.
M\M)S#<6UK+-&P4,-RH2 00>,B@"W_9MAL"?8K;:#G'E+C/Y4O]GV6_?]CM]^
M,;O+&<8QZ>E<AHTVOZOX%T_61X@\F^O+2.55>VB\KS7 VK]W."Q ZYYIWB#5
M-7M_B'X>T6TU)H+/5(;EY0(8V9#$H(VDCOGG.: .N%A9+#)"MI (I1B1!&-K
MCT(QS0MA9HNU+2!5\L18$8 V#HOTY/%<I:>(-3L?B*OA6^FBOH;BQ-Y#<)'L
MEAPVTK(!\I![$ >F*JZ/JOB'4O$/C32X]25FTORXK O"@ >2(L&? &[!QTQT
MH [/^S;#8$^Q6VT'(7REQG\J<MC:)*)5M8%D7HXC (XQU^E<->WOB.T\?:1X
M=&OEH;VSFGDE^R1!@R8P!QC!S2>*]2\3>'=*TC&KHUU=:S%8/-]F3:T,C'#;
M>S 8'7''3F@#O)[2VN=OVBWBEV]/,0-C\Z?'%'#&(XD5$'15& /PKB_%.J^(
MO!FF_P!N?:8M7TRW9?MMO) (YEC) +QLI"G&>A7IWKJ)=8LHM";6?-W60M_M
M(=1]Y-NX$#W% %@65H+PW@M8?M17:9O+&_'INZXHCL[6&4RQ6T,<AZNJ $_C
M7,^ ?$U[XATV^AU>!;;6-/O)+>Z@'\'.Y"/;:0,]]I-=3,CRPNB2M"Y&!(@!
M*_F"* (XK&T@D\R&U@C?^\D8!_,41V%G#=2745I EQ)]^58P';ZGJ:XGX9^,
M-2\06]YI^O&,:M:^7.IC3:);>50R.!^8./:F:QXLU1OBGH?ARPE6#3)S/'<S
M!%9VECB\TJI((  9,G_:([4 =TEE:1R-)':PH[ AF6, G/7)I@TVP"%!96VT
MD$CREP2.G;W-5KGQ#H]E=FUN=2MHI@ZHRO(!M9ONJQZ GL#UIE_XHT'2IIH;
M_6+&WE@C\V5))U#(N0 2,\9+ >^: +O]GV09&%G;Y3[I\I?E[\<<4OV"S&_%
MI!\[B1OW8^9QT8^I]ZJW7B#2++FYU&VC'EK*6,@PJ-PK,>BJ>Q. :I7^KV%W
M+I)L_$]I;"2[&U(WCD^V 9!B&3ZD<KR,4 :QTZR+.QL[<E_O'RE^;OSQS0VG
MV3VK6K6=NUNQRT1C!0_48Q6?=^+O#MC]I^U:W81?965)]TZ_NV;.%//!^4\=
M>#6M#-%<0QS0R))%(H='0Y5E(R"#W% """$0>0(D$.W9Y84;=OICIBFVUK;V
M<(AM;>*"('(2) JC\!6>/%&@FUN;K^V+'[/:OY=Q+YZ[8F_NL<_*?8U8;5M/
M=+54U"!6O01:L'!\TXS\G][CF@"Q+9VUPX>:WAD=> SH"1^=,&G62W?VL6=N
M+GG]\(EW\]?FQFN,\%^,X)-&AC\0ZY;?VG/?W%O")F2-I LS(H"C'ICW-=;J
M6MZ9I"AM0OH+8;2W[QL84=6/H!Z]* +KHLB,CJ&1A@JPR"/2HX[.VA,9BMH8
MS&I1-J ;%/4#T%4I_$6BVLD,<^K6,;S1&:,-.HW1@;BXY^[@9STJ;2]7T[6[
M,7FEWL%W;[BGF0N&&X=1QWH FCLK6*YDN8[:%+B08>58P&;ZGJ:8--L "!96
MP#=1Y2\_I3=0U6PTJ,/?7<4"L"5WGD@=2!U.._I2'5]-&FIJ7V^V-C( 4N!(
M"CYX&#T.3TQ0!)_9UCE#]CM\I]W]TOR\YXXXYISV5I)=)=26L+W$8PDK1@NH
M]CU%9\?BC098;J9-7LS': &Y8R@>0#G&_/W?NMUQTJR=9TP36<)U"V$MZNZU
M3S1F<8SE/[W'/% %QT20 .JL 0<$9Y!R#^=)+#%/$T4T:21N,,CJ""/<&L^3
MQ#H\5\+*34K9;@RB#89!_K",A,]-Q'\/6L9-3U%?BP^D-=E].;1OM:P;%&V3
MS@F<XR>!W/<T =/%;06]N+>&".. # C1 % ],#BH[?3K*TV_9K.WAV9"^7$J
M[<]<8'? _*LWQ/XHT_PK80W-]( 9YT@B3.-S,P&?8#.2?;Z5;GUS2[:WAGEO
MX%CF!:(AL[P.I4#D@=R.E %R:WAN4"3PQRJ#D*ZAAG\:8;*T-JUL;6$V[?>B
M,8V'ZCI2VEW;7]K'=6=Q%<6\HW1RQ.&5AZ@C@US#WFI7GQ(N=)34Y[:QMM-@
MNA%#'$=[M)(K;BR,<84="* .E6QM$M5M5M8%MUZ1",!!^'2I8H8H(Q'#&D:#
MHJ* /R%>:^)O'^H:5XD>V@%N]O83-YJPR[DD5H&*K.Q7,15@&.,_*#Z<Z'C+
MQA?:3X;LI;22Q%SJ-C*ZR03[W1Q$&$D2E<21J3DDXPN#[4 =K)86<LIEDM('
MD)R7:,$G\<4^6UMYW5YH(I&3[I= 2/IFN:\.:Q=^*M(NR;K[#+!<F#=;.CS+
MM R)5="J.3DE<' (YJ7P%JE[K/@^UO=1G\^Z::XC:0HJ[@DSHO"@#HHZ"@#>
M^Q6GVS[9]EA^U;=OG>6-^/3=UQ4K(CE2RJQ4Y4D9P<8R/S->?:CXNU6#4=2N
M8WVV^GZU:Z8+/RU/G)((]SDXW;LRY7! PO0Y-==->SW6MQV%D^V.VQ)>RX!Q
MD?+$,_Q'[Q]% _O T :%Q;07<#0W,$<T3?>21 RGZ@TQ[&TDBCB>U@:.,81#
M&"%'L.U6** ($L;2.82I:P+(.CB, CC'7Z4U=.LD9F2SMU9I/-8B)02_]X\=
M?>K-% $$UE:7,T4T]K#++$<QN\88H?4$]*GHHH ;L4.7"C>0 6QR0.@_4_G3
M6MX6A,+0QF(]4*C:><]/K4E% %4Z98%0IL;8J.@\I<#]*?+96DUQ%<2VL,D\
M7^KD>,%D^AZBIZ* *[6-H\IE>U@:1NKF,$GC'7Z4^"UM[8$0011!NHC0+G\J
MEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KB/B;<RZ?I.D:B?M'V"SU2&:_
M: 99(<,-^,'(5BC?A7;TA (((!!Z@T >1>)/[(U'PQXGUGPI=W6JWTUE%'>7
M$4A96B5U+)P "WE[^G('7&16CJ'B'0_$/C#P#-HMY!=1+<W'^IY\H&V;"M_=
M/^R<'CI7I44,5O&(X8DC0=%10 /P%<UK?ARZO/$/A^_L%LXK?2YY9WC8E3(7
M0H0,+@=<Y[T >?7NIV-EX/\ B=I5Q<QQZA)J%[*EJ3^]9'C0JX7J5QDYZ<5M
M#7M*?Q#I]LMQ;V4\N@1E=0)WO<H6XAA4Y4D,"3PQ.< =Z]*:V@=V=H8V=UVL
MQ0$L/0^U/,:,ZNR*73.UB.1]* /$;'4;-OA'\/Q]JBS%K5DCY<#:5D)(_ =?
M2O:;P&2PN GS%HFQCG/%/\B':%\I-HZ#:,"I ,# Z4 >):=JD:_#GP!=QSK+
MIVEWT']JA#D6_#!3)Z!6()!Z?*?2NT2-;WXP0:CIDJ26T>CM%?2Q,&1B9 8E
M)'&[[Q]<?6NW$:!"@10ISD8X.>M-A@BMXQ'#$D2#HJ*%'Y"@#D_'?_'YX0_[
M#\/_ **EKH]4TFRUG3[BQOX!+;SQ-%(,E24;J 1R.@Z5G>)]"N=;&DO:7,4$
MVG7Z7J^;&75]J.NT@$'^/K[5LVXG%N@N6C:;'SF-2%)]@230 "VA$9C$2;"0
M2"N<D8Y/J>!^55M/TBPTL3?8[<1F:>2X<DEB7D;<YR>F3V'%7J1MVT[<;L<9
MZ9H Y#1_^2J^*/\ KPL/YS5#XPU>PT_Q;X<ANFMK.>1;DPZG=-A(!M4,B@D*
M78$8W<#'0YQ6IHN@W]GXFU76[^ZMI9+Z""$1V\3($$>_GDG.=_Z5T#QI)MWH
MK;3N7<,X/J* /");VP;X6ZU:R7*2/'XG.Y9@%;!NU/S+@8)7)(P.,\"NOU>;
M'Q4GBTJ6%;U_"<R6P1@,R>:#&!_,>U>C&"(@@Q(<G)^4=?6E$,08,(T##H=H
MS0!XE=:_HD_P>\.6@N[=+VRO+%+FVD8"6&5)5$K,IY'.XDG^][U[898O(\XR
M)Y.W=O)&W'KGTI/LMOYC2>1%O8@LVP9)'0D^U2$!@00"#U!H \;\,1VM]\*_
M"$<&NC2=2CO)C870"N@F!F^1U)P0R%AC_)[SP)J5]J6E7QU*TM8;RWOY8)I;
M0DPW+*%S*F>QS@^ZFND:V@>,QM!&R'JI0$'\*>B)&BI&JHBC 51@ 4 >0^,]
M7T^9?B#81R0Z?=K9@2Q_>GOR(,JP#9 C4<?*,\$DBK5IXFL-'\8Z'J6JW:1:
M/>^'X[>SOG/[E9E?,B[N@) 7GOM%>IF&)G+M&A8KM+%1DCT^E));PS1"*6&-
MXQC",H(XZ<4 >7^)3H$>G>#8M-@@M],E\21RQHXPLJE9"T@#?PECP>AR"."*
MT+"ZLX_B9XX5IX%4Z?:-("X )59 2?H",_A7H+11OC?&K8Z9&:3R(LD^4F3U
M.T<T >*:9J<>F>!/ASJES<31Z-;>;%>W%O\ -]G=D*HS<' !+ GMNKL]-T+P
MQXDT[Q*FF7$M[;ZPBI=WIDWQO(%(!3H-R_*21WQW!KN?)B,;1^6GEM]Y=HP?
MPI8XTAC6.-%1%& JC 'X4 <+X'N=5UO3UGU*)HK[2(9-,)<</<J=LDGN"%CP
M?]IQ7+>%[OPYK'AO2-#UF]OCKVGW"!M*9RLJW4;'YP ,XSEBV< $Y/6O9 JK
MG: ,G)P.],$$(G,XB03$;3)M&XCTS0!Y38ZU9VEA\0])URYA@U:6[NY%BN&"
MM/ \86$H#]X;0  ,X_&NU^'L\5Q\._#K0R+(%TZ!&*G.&$:@CZ@UT$EM!+()
M)(8W< J&902 >HSZ5( %    '  H \[TRY\_XB?$&"PNH?MSV=FMN XSY@BD
M_D2,^E<]++!JWP(M-'MB%UZ$PVT=KG$\=XDHR<=0V0S$^A)Z5[&(8E;<(T#>
MH49I!;PB<SB&,3$8,@4;B/3/6@#@--33[KXQZ]!<_9;B;^R;52K!6W$,Y;@_
M\!/Y5VFMZQ9Z!HUUJE_*L=O;QEV)(&[ X4>I/0"K@BC#[Q&H;^]CFE9%<8=0
MP]",T >9:_X2U2_^'5T9-9LQ<#.J*Z0?=N0?,^67?C /R@X^[BJNM>,8=>\&
M>$/$H<-IL>IV\NKI'\P@P"#O _A63!Y]%->K[$V;-J[?[N.*00Q!&01H%888
M;1@_6@#SZSU;2K[XW"6ROK2=9O#VQ9(9%8.PGS@$<$XYQZ5RXVP_!6.<C;#;
M:^99&QPB+?')/L*]8U&UU&**V.A#3X7211*MQ$=K1<Y52OW3DY'!'7BF>'=
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M;:%#]NF@M(M,O8(&!,T4@ 0$^JR$?BU7M2AM]%^(_P .K.XO(6ND_M"2ZD+
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MR3PWK=ZI"G[3:0QM%S[EP>._% '04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &?HFC6?A_28M,T]&2VB+LH9BQRS%CR?=C6A110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exc_compmins2-9x23v1x202005.jpg
<TEXT>
begin 644 exc_compmins2-9x23v1x202005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI(HKF+RV.<E1N&=O?N#CG-=--XQT."Y,,ET^U;H633"%S$LYP!&7 V@Y('7
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M(+&%W%5(1,D\G SGWK2UIVL?BOH=]+;W+6TFFW%LLD4+2#S2Z,%)4';D \G
MXZUS)._P/\3(1%*9;O4+MK=/*;=,&B15*#'S D'!'I0!Z;?ZW9:>461I99'C
M,JQ6T+S.4'5MJ G'/6I=+U6QUO38-1TVY2XM)UW1RIT/.#UY!!!!!Y%>937T
M>A>)+#5=7MM2DT:_T>VMUNK03'[/-&6)1UC^89WGJ.OXUZ!X6M;*UT1!IVFO
MIUI([21P2 J^"<[F4\J6ZX///.#D4 ,U'Q=HNE&8WETR16\BQ7$ZPNT4#MC
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MO)[-8;F&X@C21TGA*?*Y8*0>A^ZW0\8YQ2WVKVUC<PVK++-<RHTB0PH7;8I
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M")$^2U7&(1U"\<9'?'&<UYWHEK=:=KVE3>');];"\NF.H:)?0,5LLJQ:6-F
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M@01D&-MP'S,Q VCL">E6/AR'1/$JRVUS 9==NKB/SH'CWQN1M8;@,@XKMJ*
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M/NBDJ,S%,%MH4<%L9P>V,^KT4 </\16:ZT?0VMK>YGQK%G.1%;N[+&D@9F(
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MUD=5[OERV/<U2UA+75O OB6XT7PI>64EW8FW4O8&.YN7(.%V %MH]3QSQTH
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MO(8.Y*M@C/W1D#./0@T :^J:P]W\3O!:1)J=I'.+MFBG+)',@@)4[,XR">A
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M%,_V6ZO#8P7GE_N9)P2-@.<]58 D8)'!J[X7#KX4TA)(I8I$LXD>.6,HRL$
M(((!'(KR^ZDU?4M-T6YO-#UE=1LO$,4]W;0VCK!!$LK']VHP) 00=XW').2
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MA/,(;G(.T>E &W17'S?$?2(K/4[M++59H=,N&@O#':']UM +.02/E ;Z\'C
MS5V'QKID^L6.GK#>JNH*QL[MX"L%P57<0K'G..1D 'L30!T=%<X/&FG'1]9U
M+[/=B+1YI(;U-B[T**&8CYL$ $'@UC:Y<BY\?^ ;NWFG$-W]J8Q^8P5E^S%E
MRF<9YZXS0!WE%<S<>.=*MY)6:*Z:SAOAITUXJ*8HYR0NT_-NP&(!(7&>]1P^
M*[B;Q]>Z!_9ER+>TM8Y3, IW%V;YL;L[<+@<9)SQTH ZJBN(L?%7A_1O#&K:
MU:6^IM80:C,+PNK.Z2[AO.UVR%!(&.WH.:Z=]7C2YT^W^SSL]ZI9-NTA  "2
MWS=!D<C(R1ZB@#0HKFYO&NF6\ED\T5TEA>W MK?4"B^0\A) &=VX D$!BNT^
MN,&H_B.&_P"%=:_(DLT4D5E)(CQ2LC!@I(Y4CCVZ4 =117&Z)XXTPSZ1HMQ#
M?VTUU;J+6XN;9DAN6" D(YZGZ@9[9R,W&\<Z4LL9\JZ-I)?_ -FB]"+Y7VC.
MW;][=C=\N[;C/>@#IJ*Q+OQ/:VLUXB6MW<I8NL=U+ JE8F8*P!!8,>&4D@$
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ML^[;Y13KOW$#'OZ<USEC?2W'QM:-X+^U_P") [M;W,FY<^>@#*%9EZ<<>G-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8F<1QKDD@=_0>I]* -BBL.W\2VITO3[BX2=;F] 6*W$#"25]NYMJGG &3D\
M=ZM:1KMAK7VE;21Q-:R>5<02H4DA?&<,I]1R#T/8F@#2HK%U/Q3I6D:M:Z9=
MR3K=W2.\,:6[OY@09.T@8)Z<#)Y'%9G_  L;0/[.N;T?;V%I(T=W$MC*9+;;
MRQD4+E!@YR>O..AH ZVBL>X\2Z=#)9Q1/)=SWL!N+>*V3>SQ  E_0#YAUZYX
MS7+>+-<AU71O"FL:-J%P+:YURTCW1.\8D0R$,CKQGE<$$=J /0:*S8=<LI[V
M]MD,O^A'%Q*T9$2';N(WGY20#S@\=\54@\6Z7/JEGIY-Q#+?(SV;3P,B7 49
M.PD=<<X.#CF@#=HK+UWQ!IOANP6]U29X;<R+&'$;, S' R0..3U.!5/2O&FB
MZQK4VD6\L\=]''YJQ7-N\)ECSC>FX#<ON* .@HK _P"$QT@7=E"\DR1W\GDV
MERT+"&>3LJOTR<''9NQ-5XO'VA3Z@UC"][).EW]CD"V4I\N3&?F^7Y1Z$]<'
M'0T =/17+Z#K>A6^@ZCJ5OJ5Y)8QWLWG2WI<LDF[!158;L!B%"XZ\"M&R\1V
M%YJS:4?/MK\1>>MO<Q%&>/.-RYX89ZX.1W H UZ*\V^)'B>&7P;<2Z7<ZA&R
M7D4,=Y;;TB9Q,JNF\=1C<,_=SQG/%=3]MTN3Q^MF+R^&JIIS/]E.];<Q>8OS
MX(VLV2!D$G&10!T%%8$GC+1HI[5'FE$%U<_8X+KRCY,DV2-@?Z@C/0D8S6_0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<
M!X^\U_%7@QXK2\F2UU$S3O!;22+$A0C+%00.37?T4 </?.__  M[2K@6MVUL
MFE30O.MM(8U=G0JI;;@'"GO70:1XCM=9U+5+"*VO()].E$<@N83&) 2P#H?X
ME)1L'VK8JO!9PV\T\Z@F:<@R.QR2!T'L!DX ]3W)H Y+7[ZXC\=VEG-8WRZ?
M)8'9=V-LS232[_\ 4M*HS&H #=5!)Y( KC-,M[ZW^&G@GS=*U)6TG6XY+N/[
M(YD1 TN6" ;F W+R >M>T44 1QOY]NK['3>F=KC##(Z$=C7C,,=X/@OH^CMI
M.J+?65[;+-";&7(*7&YL87D!1G(XYZYXKVJB@#SK6;.YU3XCWR6T-U''=>%Y
M;..Z-O((UF:3(!?& <'-5/"4]E?V^D:5?^$;^/7-.:(2FZMV\F!X\ S+(?EZ
M E<<DG'3FO4** .3^(MAJ%]X4+:;;-=W%I=07GV53@SK'(&*#W('Z5E6-YI&
MKVU]J>G>&]0MIH["6*2XN[-TE!(XA0'+/SDG;D#'O7H-% 'D:PW*> OAS;G3
M[_S[+4;-[F/['+NA5$<,6&W@ D<FK-C=7.@CQMHFI6%^UQ?W5U>V,T-K)*EQ
M'*@"J&4$ K@ AL8XKU.B@#G/ "RQ_#_089[>>":&QABDCGB:-E94 /! /45R
M>C"YT7PUXG\-:I8W<M[)<7;VVRW=UO4FR5*L!C.6(()^7OQ7I]% 'E]WI=YH
MEG\.-,FANKF739T-U)!;O*D8$+(264$ !B!]*]+F!EM9%3JZ$#/'45+10!XQ
M$MV?A#X<TPZ5JBWEC?VBSQ&QEROES;G.-N2 !G/3G@YR!OZW8W6K?$+5XK6&
MYC2\\+/91736\BQ"9I&(7?C&<,#UKTBB@#S+PG<V.IQ:3I][X1OX=;T\Q^<;
MNW80V[IP95D/R\X.W;R<CMDUU7C[>_@'78(H9YIKBQFABB@B:1G=D(  4$]:
MZ.B@#E? ^CZ;;^&=&NDTB&VU".QABED>S\J96" ,"2H;KFN1M/(TK5-<T'Q#
MX9U+4&N]0GN+.6&W:6&ZBE;<%)SM4@G!W8 ]:]8HH X+3X9(/BV6^PSQ6Z^'
MX;19$MW\A9%E9C&K[<< BI+7S&^+NKR_9[R."72H;=+DVT@C,BR.2 ^-I(#
M]:[FB@#R.PM;V/X0WO@B[TZY.N1QS621^2Q28LY*2J^-NSY@2Q/&#GFMS3+2
M:P^*EJDD-W+%#X<CLC=FW?RVE67)&_&,D<]:] HH \]TXR1>*OB#/):7JQ7"
MV_D.;23$VV#8VSY?FPW'&:Q!#=)\./A];'3]0^T6>IV+W,0LY2\*QD[RPVY
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MR[+>!Y2%2568D*#C !H U;;Q;97<.8K34!.9W@CM9;9HI92@!+*KX^7!'S'
MYQUXJF_Q#\/Q:6U_-+<1(EY]AFC>!MT$^0-LG9>HY)P>Q-97CB*XMO$.@^(A
MHMQK&F0PS6UW;0P>9+&LFQED6,\G!3!'4"L?Q:;1/!*ZA9>'VTN";6+*01&V
M$4\Y$JY9D'()Z 'GCWH [72/&NDZQK5QI$:WEK?0Q><(;VV> RQ9QO0,!E<T
M?\)KI(%I._VA+"\E$%M?M'^XD<G &<Y )'#$!3V)R*P=<T:;Q=XLM[NP2>VA
MM-*N[=[J:%XMTDZA44!@"=OS,3C X'6L>6QO]<^$MKX*ETR\MM91;>RDWV[B
M.(1.N91+C85VIN&#R3CK0!V%[X]T>RU6\TPPZC/=V9B\Z."RD<@.2 PXY48Y
M8<<CK5;1O'<5\/$-Q?6=Q96>E7;P^9(G\*(F<X)^8LQP!VQWJ/14GC^*GB2=
M[.\2WN+2UCAN'MG6-VC#[@'(QQN'?GM6196[VL/CC3=4\/ZA>6]WJ<ESL2!B
ML\$BQK\C#[S<-PO(([4 =W8:NE[>W%FUI=6UQ!&DK).@ *N6"D%20?N'OQWI
MMWKUG8Z[I^CSB5;G4!)]F(3*.47<PSVP/6N8\%66IZ9KM[8Q7VH7_AT6R/;2
MZE"RS0R;CF(,P#.H7GD<<#UJ3QFL]IXL\(ZV+.[N;.QGN4N?LL#3/'YL)56V
M*"2,]<"@#2N/'&CVECK%W<?:D31Y!'>*+=F9&*AA]W.1@CGISUI]EXRTN^UJ
MVTM$NXIKJ%IK62:W9([A5 +;&/WL @_3D9%<#?P:E<Z/\2D&BZFKZDRFT0VS
M,9<PJH VYSR.?3O6]>K/-XN\ W$=C?F&UAN1<2?8Y,0EX0JA_E^7+#'- $?Q
M*\1PR^ =?-@=0_T8&$WMHS(D<P(!4LK!B,G!P"H/!/''62ZY#8PPP+!=7ETM
MLL[P6J!W5.FXY(')!P,Y.#@'!KR_9JMC\)-;\%76C:I)K$ G2)XK1Y([I7E+
MB19 -O\ %T)SQTS6Q?&71_%XU?4O#-]J>E:GI]O$##:>?+:2Q[OE9!R P;.?
M6@#J&^(7AX6NDW,4]Q/%JVX6C0VSMO*@Y7I][*D;>N>U;6F:K%JNCQ:E#;W4
M<<BEA%/"8Y1@D8*'D'BN%U&T,&I>"7LO#T]C:6]_-<26]K9L5MXWC=5+^6"J
ML2P)';)],UZ30!Y/XD\5W'B7X1^(]22"^TZ6W>58720QD!)=F"RMR< Y'3GO
M7<Z?XLTZ]UM=&5+N*Z: SPM/ R)<(I 8QL?O8R/SR,BO.KFSU-?A)XHT#^QM
M3-^;NY\M5M'82[YRZE"!\P*G.1P,<D<9ZG5%FN_B-X5NH;2^^S1V5W'+/]DD
M"Q-(J; Q*\'Y3UZ=Z -JX\9Z5:RVQF%PEG=7'V6&^,?[AI<D!=V<@$@@-C:?
M6KWB*;4;?PUJ<VD1^9J26LC6R8SF0*=O'?GM7F_A2V2TTRU\+:QX'FGU:R81
M+=R60>TE53\LWFGCI@X^]D<<UZ9K=U=V6AWUU8V[7%W#"SPPJ,F1@,A1]>E
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ML;^T:V>Y8R;BH1Q]TA2!C/W.I- 'HFG^);*_UFXT=HKBTU*"(3FVN4"LT1.
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M*[EBVQ3L1E0#G(+#IN W=LUS^J:@=:^(\OAN\MM0.G+I>\+%E/WCRE/-R".
M%X/;)JC=6][XH\!:'X=.FWMIJD$UHMUYMNZ);>2REW#D;6!"G;M)SN'OC9B\
MX?&.YNS9WHM#HT=J+C[+)Y1E$S,5W8QT8'/3WH ZJRL39:3!8"\N9C#$(A<S
M,'E; QN8D8+>^*Y/P%J5[_PANIW5W<7%_/;7UZJM,^YW$<C!1^0 P.*[9W$:
M,Y#$*,G:I)_ #DUQOPUCGMM!OXKJTNK:0ZG=3!;BW>,E'E9E(W 9R#0!S-QK
MEY;?">Q\?0ZE<RZBABNKA3<,890TH1X?+SM  8@8&05'.<YZ#XB6\$>A7FJ7
M'B6^TR=(3_9ZPWOV9/-Q\H(R Y+8SNX /;DUGZEX(TW7K^WT[2]+EL]&%V+S
M4)'\Q(Y64Y$<43' W'!9U4# P"22!TNLZIIE])?Z%J&B:C> 1XV'3W>*?<O1
M),; ><9)&#],T 7!J5QIOAFRGOBEWJ+PQ1[(2,7$Y4<+VP3DYZ 9/05A?#NY
MU.>7Q1'JM\UW<0:R\6[)V(/*C.U ?NJ"3@?US46F>!-0B\.>';5_$-]8WNEV
MAA)MA&Z[FQG[Z-T V@C'&?4U1\%Z5JOAB?Q?J>H7&KWL27DSQVQMTW7>(XSY
MJ *"S'!48(7VS0!Z37.7'C?2+:28O]H:U@O!83W:Q@Q13D@;#SNZL 2 0">M
M:FB:M%KFCV^HPPSP),#F&X39)&P)5E8=B""#]*\J\3?VQJVAZ[!<:)JYOX-6
M1X8+:V80&W6=")%VX$K,HR3\S ]@!0!Z5J'B:ST^2]4P75P+%!)=M;H&$((R
M,C()..> <#DXK8ED2&)Y9&"1HI9F)X '4UYCXJL9[G4]1UC0X]9TKQ%%%&(@
MEL\D&HKL!6.08*$@DH22-O4G'3T*[DODT&>6.VCEU!;5F6#/R/+MX7/H6XH
MS+#QGI>H7>G0(ES&-3B>:PEECPERBC)*X)(X.<, 2*I3?$?0XK*_O%BU*2#3
M[EK>[9+)_P!R5 +,P(!"C=]>#QQ7(6!U"YUSP)JLFCZXTMOY\=^9;5HT@D:
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M([%>NU>.3U)XZ<]/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<AB02'4X8 XSZ&JC>.-+C@M;R2*Z32[J80PZDR+Y#,3A?XMP4G@,5"GCG!%
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M(Y 8+GZUT- $'V.'[;]L*EIPA168D[5."0!T&<#/K@>@J>BB@ HHHH ****
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MH-_8W"7=CJ$3A+"1EPGDLXS]XG(4D<$YZ5&VF:GJWPFA\#7&EW4&K(D-D[-
MWD*D<B_OA+C81M7=@'.>,5ZM10!Q4<%Q%\79;TVEV;(:&MJ+GR6*&43%RN<=
M=ISGIVZUR?\ 8FN2>#)I;33+HWFG^*&U=;.6,QM<PB8N N[@D@YQ[>N*]AHH
M \[>\U#5?B'I6L6.A:HENFE7$.Z[MS"$E9D(5MQ!'W?\,UAP1ZW>R>#M2N]
MUE]0M+\G4-\85(R8W7$:;@JQ@D?, !C&237L%% 'E]QH&JWP^(.AK8W$3ZM(
M9[2Z90(7!A0 ;L]=RX([9J]X>D&M>1"_@5]&U.%&%Q>3V4<:0MM()A<<L2<8
MQQC.3T!]"HH \6F@UM/@[+X.E\.ZFVKV+10_N;<M#,JSJP=).A! Z=1SD8R:
M]E27= )6C=,KN*,,L/; SS]*DHH \Z\.0W<'A/QA#/IU]%-=7]_/!&]LX:5)
M3\A48[YZ=1WJC#97\>B?#6%M-OO,TR2(WB_9GS"%@:,YX_O$=/K7J=% 'F-^
MNO6FL?$&^TC2YY;FZ@M/L)EMSLF*(5DV[A@D9. >I]14FDQ7,7Q(M-831M;%
MC+HKP/<7B%I/,\U7.\$DKP#A0![#%>E44 >/1:9J:_!K3=*;2K\:A%J22O;_
M &9]RJ+LRD].FSG].M;D%WJGA7QKKKR:#J>IZ;K4D5U:SV4(<HXC5&CD!(V?
M=&"<#^GHM% '#:O#J$WCGP3=R6$VVU6Z-VT$3/' 9(@JJ6 YYXS[9.!7+:Y%
MKVK:3="\T'5I-2M=;CE"11X@6!9P5,0! <E>2V"V2<D#%>Q44 <5%'=/\75U
M%K"[CM&T(6QE:$[%E\[?L+#(SM[YQVS5_P ;:?9:IIMG9ZCI]Y=6TET"9;)7
M,MHP1BLR[/F&" .,_>Z5TU% 'E%]I?B63P%<V]R+[5?L6LP36;RPXNI[6.2-
MB64X)888<@$@9QTK6UBYU?4?$5Q;7&BZH=-GTT?9%MU"AY26W"=PPQ@8PI..
M3D$XKT&B@#R33K'5K7P[\.KF31-1SI$ICNH!$#*N860-MSG;N/4X]>E6O(ET
M/Q5K<.K>"[C6K35;@7=I=6]I'.5+(JM%(6.% *\$G'->HT4 <&ME<V_Q&T&?
M^RW@M;?1Y;>0VMNWD0R,R$(I Q@!3[?2L86-^W@7X@V8TV^^TZC?WDEI&;9P
M9ED50A''<@]>G?%>JT4 >5W=M=:3K^FZW=>%[G6M+NM)@LYHH[02SVDT98@^
M6W.T[B#CT^F;NL64S?\ ")26?AV2P@AUD7DEM;6O^HBV.NZ0("H8E@2!GKWQ
MFO1Z* /-[O3+^\U[XB)%8W.W4M+B@LY'B94F=89%(#$8ZLH]^U,DT^#6O"OA
MJRU;1M;LWMK8+'>VT3K<6<R(BY 3+ -EAR.=O3&#7I=% '/>"EUI/#4<>NRO
M-=)+*L<TD>R26(.?+=U[,5P2.O//.:RXX[@?&&>^-E=BR.C):"X^SOY9E$S,
M5SCT8'/3WKM:* /-+*TO5\._$2)M.OEDU"[NY+1#;.#,KPJBE>.[ _3J:IW5
MA?Z=:^#=:D\.7&K6MGI8T_4+#[-OGA)6/YTC;[Q#(0<=J]7HH \PUO3KR6PT
M?7]%\+-:16&JI>2:;' D5Q/%L*,Y1>-XW'"GG'N<#2TZ:[U#XK_VNFD:E#I\
MFAK;B>XMS$ XF9L$-@@X[8S[8(-=[10!S_C;1)-?\)7UG;';>JHGM''59XSO
M0C_@0 ^A-<?/X<U^YU72-<$#17>MQ/9ZW$&.+>!U#+CT**A3/]YO>O4** .+
M\66T[^+?!TEM97$EO9W<LD[PPLRQ(8F09('J15*U@O\ 3_$7CE)=+O6BU I-
M;SQQ;HW7[.$P".2VX8P!GOTYKT&B@#RA;#4$\#?#VS.F7_VG3M1M)+N,6SYA
M2-'5R>.@+#IU[5Z#XHM)]1\(ZS96R;[BXL)XHDZ;F:-@!^9K6HH \OG2_N]"
M\ )_8VIQ/IU];M<H]LVZ-$A9&8@9P-S8]3UQCFDUC0-2UO6/B!;6UM/%_:5C
M:)9S2Q,L<LD08LNXC&,D#GU[UZC10!PGA:YBU2]LW;P&^CWUL";BYN;*.-8S
MM((A<<MD]QQC.>P/2Z]J%]IL5G-96$]ZIN0EQ% H+B(JV6&2.AVGWZ=ZUJ*
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M(Q1WH@?(*9  # 9QP01C XKU&B@#D1KMWK^AZC*OA_4[&+[%(A6\M]LTDI&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#%-$FPHRC+ $<@]!T)H O3?$+1(](TK5(UNY[74KI;2,Q0$M'*21M=>H((/
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M%)-++:2QQQQKEF9E( 'XFN&;3=5M] ^'4ZZ3=S2:.8X[RWC4"1#]G,9.&(!
M;OGWH ZZ;Q5!'+=K%87EPEE,D%T\/ED1.P5L$%P3@.I) ('O@XN>(H=2G\/W
ML>CLBW[)^YWN4!.1D;ARN1D9'3.:X/Q%HM[=:O>:OH=GJ6E>)TFC6.6$$VU^
M@V_Z[^# !8$G!^7C/ KT^@#DX(/$S:WH[W-C8#36L?+O8EG;_19<-G8,8<'Y
M%R>@!]>?/+66QB\.>/[F[UN[M+[3]7O([!UU"17C"A3$BKNY&[(Q@YSBO;F8
M(C,02 ,\#)_(5P?P\TZXM+KQ,=1TR:W>ZURXOK5YX?O1/M"D'L>#QUH M^%?
M%=W/;:#I6NV=S'K=[IWVMF**J-MP&R,Y5OF'! Y-8?CW7K37OAWJUU;QW=O)
MIFJQ6DJR':1(L\8?A&(88;%;/B2&^LO'^@ZY#IEW?6D=K<6DHM%#/&SE"I()
M'!VD9[=ZYB;0-?O/!/C"S_L6X2ZN=?-_!&73][&)HF.WYN3A&ZX!XP30!VUA
MXTL=0\0G0+BPU+3[N6)I;;[9#Y8N4'4H02<CK@X(]*Y'1+G3=/\ A[XP;6(+
MNZTR+6+^.:.)F:0Q!\8SN!X ZYKHY[2;Q'XQT'6$M+FVL]'CN)&>YB,;R22H
M$"*IYP!DD].@&><<VFEZHWPW\:Z?_9=X+S4+^]DM83$<R+*Q*$=A[YZ=Z .[
M.N6EJMA8VEM<7-S/;>=#:Q%=ZQ* -S%F  &5')Y)XSS4WA_7K3Q'I2W]FDT:
M>8\3QSIM>-T)5E(Y&01V)%<7=IK.A>)=&\36VC7NHV4FD+IUY:VZ#SX&5MZN
M$8C(R2#S[^E=WI=S>7EG]HO+0V;R,62W<@O&G8.02-W<@'C..<9H XS2;M_&
MWC;Q!%=R2?V/HDRV<-HCE5FFP3(\F/O8(P%/'?&:Z*+0H-)UM-4MKJ2WL([2
M6.:U:9O)4ED8.JDX7 1@<8Z_6N=L].U#P5XUUJ^BT^YO]#UN1;EFM%WRVLX!
M#;DZLK9SE<XZ8[UOZFESXIT'4].@@FL[>[LY8!-<H4<LZE1A.H SSD#V'>@"
M+_A-[!$TZYGM+VWT[4I%CM;Z5%$3LWW,@-N4-V+*/?%,G\<VR:CK&GVVD:K=
MW>E"-IXX85^97#,"I9@#PO?!.> ><<U-IFJ>(?AWIGA&ZTNZM-0A:U@NI73]
MU&D+J6D63HVX)P <Y;D#DUKZ7#=VOCOQE?S6%V+6[AM1;2"$D2F.-U<#\6'7
MKVH L1?$32YX](NH[+43IVJ21PPWQA B65_NHV6W9SQD KGC-+>_$&RM=0U6
MP@TC6+V[TS89XK:V#':RE@PRPXP/8G/ /..2ATC5HOA9X1TMM*O/MUCJ%K)<
M0"(Y1(Y=S'/0C&,8//YUKZ/J:V/Q/\;EK2\F#I8,OD0,YR(3\I ^Z3GJ<#KD
MB@#?@\<:5?6FC3Z:L]ZVL)(]I%$%#$1C+[BQ 7:>#SUZ9J"7XA:3#X;BUQ[>
M^^SM=?8WC$0+PR[_ "R' ..&]"?;-<QI>C:_X9T_PYI<NG7<^G2&YFOXM.==
M\<TC[XXRVX80;B"00"1SQUSQHNM1^ +W2?[ O(YQX@^TQQHJL&B^TB0E<'H%
M'MGMF@#T"S\807>KWNE'2]2AOK>V%W'!-&BM<19V[D^;UXPVT\]*2R\:6.H>
M$E\1V]G>FV>3RE@*H)BWF>7C;NP#NXP3FJ(@NG^+D6IBSN?L!T0VOV@Q$*)3
M,'"G//W1UZ=NM4=/T"YM/B/J%E$Z'0F=-:,0/*7+[DVX_NEE,GLRB@#N;F&.
M[LGBFC.QT^92<$?B#U^AKR'P#=>'M6^'>D6^K:M<2:S?,]N2E_)]HWM*P4\-
MQA<'Z"O7[J406LLA21]JGY8T+,?8 5QOPMTNYL/ASI>DZM836]W:,QDBF3&&
M\UG4@]#V/% %];S28O'T=D]K>/K<.D,XN<'RW@#J" -V"Q;';MUJDOQ-TM],
MCU/^S-6&G_:C:S7+0*$MV\SRP7^;.-W]T'&><=*DGM[I?BY#J7V.Y-BFBO;-
M<+$2HD,JN%XY/RCKT[=:Y.71]7?X/:KHXTF]_M&;47ECM_*Y9#="4'/3[H]?
M:@#O-5\86FEW.I0+9WEXVF6RW5Z;<)B&-@Q'WF7<<(QP,\#Z4R\\;Z;:7FCV
MR6U]<MJ\+36;00[@ZJ@?')'."/IGD@9-<WXDCUS5M0\1V,VCW]U93Z:%TGRL
M)#N:-MYER0=X8C (. .!GDLL+/4SJ7PYEETB]A33+*:&\+Q@^26@2-<X)ZLI
MZ=!UQ0!U%CXVTR[T?4-0GBNK'^SK@VUU;W*#S4EXPH"DABVY<8)SFI;?Q5!-
MK%QH]QIU_:W\5I]L6&1%;S8MVW*E&89!XP2#S7"W_A[7-0MO%[6-E-'=MK$&
MIV"SKL2Y$0CXR>F2AZX[5V^B^(=0U=#<3^']0TNWBC)E6\0>8\G'RQJI)('/
MS$#/&!UP 9OA_P 2:!8>"]#FTBSO%LK^<VUA:L=TK.6<D$LQ ^ZS9+=/RIGB
M#7+7Q#\/O%PBCNK:XTZWN89HI&V/'*D18<HQ!'*D8.#7/:);^)-&^'OA73QI
M6H*D-TZ:K#;@"X6,LY78<C@DKDJ<XXR.:DM-)U2WT+XAV(T&\@_M'S7LU^5O
M,\R!451ACDYSD]!ZT =]X6.?"&BD_P#/A!_Z+6O/+76=)'BO6-%\:R75AJ\U
MY(VGWDD[Q1M;DXB\F0$!"!UZ9/7)R*]$\,))%X5TF&:&2&:*TBCDCD7#*RH
M0?Q%<WJ;0Z]HM]IGBKPO?71$\ZVXCMO-$J!V$;HZ_P"K;;MY8K^5 #M1UK4O
M"5OX1T5;2?4);EX[6>Y61"7*1DG&]AEFVYR<#&><U?U/QS8Z9_:;/8WTT>E+
M&U^\2H1!O4, 06!8A2"=N?QKE4\/:_H_A?P$MS:SZC=:1>![M(&5W1&210!D
M@';N5>O;TIGBNU\1:W;>+=/NM#OYVDM_^)6(G7[.$\L9S\PW2;LCD$],8'-
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M^5>IV+^98P,4="8QE74JP..A!H GHHHH **** "BBB@ HHHH **** "BBB@
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M*S(4) )4XR/;CBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<SXU;6UL; Z1;W%Q#]MC^W
MQ6CA)VM\'<$)(P<[<X(.,X(ZUTU% 'CVJ:9?Z;H/Q*DET22PL;VT6:W8NA7
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M^PD <@ 9SP3WK$\5V6HW/Q"\(7]MIMS<6>FO=-=3)MPHDB"K@$@GGK@5W-%
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M8).,'G('X\X-6LM2@^)>E:S;Z=+=V9TZ:SD>)T'E.TB,"VX@[<*>F3[5V-%
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MS<7#(%_=H8V7G)&3EAP,UV-% '!Z)::IX4U3Q-:OIES?VNHWTFHV4T&TAFD
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M6L6&H7TE[:7@GC3R3*=S)*&YP#DY /'8]!Z GFV]BNY/.ECC&5B 7>P'\()
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M9<'SA*S;P2I+8?N.1C &*V+.'6[KXEQ:_+H5Q;6#:,;7$DT1D1_.W@, Q&2
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M2]%_Y 6G_P#7M'_Z"*O51T5)X]#L8[J P3I B21E@VT@ $9!(/2KU !1110
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M,65)(;9G:6!)(...O45R_G_\)9\5]4T6^'F:1H-K$QM&_P!7//* P=QT8*O
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M;\# &/K7JU% 'GFNZ5XCU76=92;2%O+"[T]8].\ZY14LY"C!]Z9.7)(PP!Z
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M;R:[MY$LDN(V,21R*Y+N2 6.T\#(''N:[BUM8+*V2WMHEBA085%' _SUS4U
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M,-P@P0Z.RC<AR.=N<]JV+W7;JVNX;&PTH2?Z";MI9I3#;QJ" $WA&&[GI@8
MS63XEL/$?B3P!K%G-I\,-_?Q>5!9I<*PA'J\AP"3SG' X SR:2]TWQ!/XGTZ
MY;3(;S2ET\1"VN+E56UN0V3(R@$/\N ",D<XQDT 9'BG5[3Q3X+\):_#;;//
MUFQ>,2 %X\R@,,_48]Z])N4EDM9D@D$<S(P1R,[6QP?SKS"V\*>)(/ASX<T2
M338C>:;J4-Q(([E2#''*7)R<<G/ Y]R*],NQ-)I\X@#+.T3;!D AB..?K0!X
M[I-YH?\ 94?@CQGI:Z-KZ@K%?3H"EU+GB9)N[,>3D\Y(SSBNZN]<UI?BC:Z)
M!;VQL#IDER=T[*S?O(U+'Y#RO.%[Y.2.E9_B/2M:\6>#&T#5/#T+:C+&J&],
M\;6\,G&95.?,R.3@)[9QS5V;0=6LO'6CZK9Q)>6L6E-IT\DLVQD.]&\PC!W9
MVG@=_2@!T_CF6UDL9;G1W@L;W5/[,B:68K/N+% _E%?N%AUW9P0<4S3O$>JR
M>/?$UE>Q6L>EZ9!;-O$[9C1EE<OC9R3@9&1@*.37-S>%_%MSI]J+K2[2YU2T
MUN*]EOGO!NNXDE+*%X^10I VG&,< YKH#X;U63Q=XD>:WA.F:]80027"3_-
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M=%>:6;+4M,1XKFSF82>5(!E65@,$$=#QWKJ#XDETS6?#^C2V"_9]2AQ%>&?
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MNI].\/ZQ_8@31]7GAMO-:Z'G122' .P+@H&XSN![XJUXC\;77A^VU>^?2/\
M0-,>-&DN)C$USN +&$%2&P&]>2".,4 =E17.7'B>>U\9Z=H<VGQK:ZC \MM>
MFX/SL@!:/9L^]@Y^]T_*M#2=3FU.;4-ULD=O;W+6\,JREO.V\,<;1MPV5ZGE
M3^(!<6]M7O'LTN86ND4.\(<%U4]"5Z@5/7FUU-?V'Q=U=M%TF*\NI-%@8H\P
M@3/FR9+-@G/0=#^%:EA\1;2]T2VN9+46>HS7LFGR6=U,$6&>,%I SX^Z ,Y
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M"'_DFNGYC\H^?=?N_P"[_I$G'X4 =S17%:?X@U9OB#XEL[U;1-+TVVMWSY[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZW:VUB[ +'9P3>=LQG+,^!DGC@#  ZG/&;J.DZE-\1M(UF&V1K"TM)K>5S*
MV9"I!"]P-O/UKJJ* .$FTOQ7X?\ %VJ7^@VECJ6F:NZ32PW%R8&MI@@0L#M;
M<I"@D8SQ^=GQ!HVMWVH>%IXXXKIM-N_M5W)O$8;*,I"+_P "XSV Y-=E5=+^
MSDOY;!+J%KN)%DD@#@NBMG!(Z@'!H XR?3/%>@^+]2U/0;.RU'3M7\N2>WN;
MDP-;3*@3<&"ME2 ,CKQ^=F[T;6Y?&GAO59(XKB*PM[B.[E5PF6E"_<7^Z"O<
MYQZFNCGUO2K;4(K"?4K2*\E8+' \RAV8C( &<YQVJ_0!RMKI.I1_$N^UI[9!
MI\^GQVBOYHWAD=FR5]#NQUSQTK*T[2O&/AK5=2L-+MM.O='OKN2[M[F><H]F
M9&W.K( =X!)( (SW(SQW]59-2L8;^&PDO($O)P3%;M(!(X ))"]2  : .1BT
M37] \<ZEJVFP0:G8ZQ% +E99Q#)#-$FP/]T@J1UQSGMQS?\ A[HVI^'_  G%
MINJQVZ3QSS./)E+@AY6?G@8/S8[UU-% '%R>&=1D\9>(9GB@?2-<L8K>67SB
MLD6Q74@+CG(?KD8_2LU/">N7O@&'P/J4,/D1>5;OJ*2C;);1N&&U/O!RJA<'
M@=<GI7>7>HV-@T"WEY!;M<2+%"LL@4R.3@*H/4DD<"K5 %+5899=&O(+:,/+
M) \<:;@H)(P.>PKA1X6UQ?"?@K3!:1&XT2]MY[H^>-K+$K*=A[D[N,XZ5Z/1
M0!P-GI?C#PWKNJP:1:Z??Z1J5V]Y'+<W!C>SDDY<,H!WKGD 8^HK0@T;58OB
M2FLR1K+9#2%T]IC(H=I!)O+[1Q@_S[5U<TT5O"\T\B11(,L[L%51ZDGI3+2[
MMK^UCNK2>.>WE&Z.6)@RL/4$=10!P]MI?B_PWX@U6/1[73]0TC5+MKQ'N;@Q
M/:2/C?D!3O7/( P?<5H7.C:JWCW1=6\M9[6RL);::8NJN[OM.X+TQ\O/(ZUU
MU,EEC@A>6:1(XT!9G<X"@=R3TH \UF\(Z]-\/_%6B?9(5O-6O[BX@/GC8J2N
M&&X]01CL#V_#T+;<R:243%M=-"54G#"-\8!]\&DT_5M.U9)'T^^M[I8GV2&&
M0/L;T..AJY0!Y;8^%?%2#PM--IVG+=Z7=M)>3&\9GNRT;(9F;9GOG!R><< 5
MH7WA*]U/Q!9:K_9L6G:Q:ZCYC:I;3 ">T#GY'4<LS)A<$8'][M7H554U*QEU
M"33X[R![R--[P+("Z+TR5Z@4 4/%FDS:[X1U?2K9T2>[M)(8V<X4,5(&?;-<
MY/HWB&\N_!US/I]O&=)D9[E([D-@&(Q@*2!DY)/88XR:[2]O[/3;?[1?74-M
M#N5/,F<*NYC@#)[DG%6* /.;_P %:KK%QXU20I9KK#VLUC.) QCD@5=N\#IE
MD!XSQFNA\/3^+[N2,>(;&PL$@7#FUN#*;E\8R 5&Q>^,DYQT&<]+10 5C>++
M*[U/PGJNG6,2R7-Y:2VZ!G"JI="N2?09[5LT4 8OA2QNM.\*:3I]_ L=S96L
M5NVU@ZDH@7<I]#SZ&L)-#U>/Q'XRO_L:-#JUM#%:XF&=T<;(=P[ EL]^!^%=
MO10!YS_PB^N+X5\$Z:+.(SZ)>6\UT?/&UEB1E.P]R=V1G'2J6N^$?%6J:9XH
MLFM;"YGOKL36E]+<D/Y D1T@"[?E"[?7&3G!)S7J=% '(0Z7K ^(IU^>RB%L
M='6R98IPQ\T2&3C(&5YQG@Y["N;A\$^)+;PWITEHMK%K>DZM/?VZ22[HIXY6
M<M&6 R"5?&<=O?(]3HH Y.\M_$FM^$M9AOK*VM;N]LY+:WLHKCS%C+*R[GDV
MC.2PX X [DUE_P!@^(XCX4'V.TO+33[$6UU8SW.Q%G"J%F!"D.!M.,C(SD#-
M=C>ZWI6G7$5O>ZE:6TTI"HDLRJ6)Z  GO@X]:OT >6OX-\2'X9ZGX;:WLVNY
M]0:>%UN"%9#<><2<CY>!@#GWKU"-F>-69"C$9*D@X]N*KP:E8W5Y<6=O>02W
M-MCSXHY S19SC<!TS@]?2K5 '#7=AXCU/P5+X?U?1;2]NI[8P?:3= PYQ@2/
MD;PPX)V@\C@^C6\)ZMI>H^#IM-,%ZFC64MC.UQ*8R0R(HD'!S@H>/<5W=4KC
M6-+M)C#<ZE9PRCJDDZJP_ F@#SC5O"/BO4-+UVT>UL+FZGU)+F"^EN2'D@69
M'2+&WY H7'7'H#DFNC;0]8'C]M8-O:/97NEQV=U^_(,+*[,=HV_,"&P#Q[UU
MT4L<\2RPR))&PRK(P(/T(I] ' >%=,\:Z!:P>&I8M/ETNT/EP:L)SYGD \+Y
M6W[^.,YP/?',]KH6L0WWC6=K--NL;3: 3+GB$1_/Z<C/&>*[BJ$6MZ5/J3:=
M%J5H]ZH)-NLRE\ X/RYSP>OI0!Q+^&-<_P"$4\$Z:MG$;C1+NUFNOWXVLL2,
MIV'N3G(SBI[/2_&'AO7=5@TBUT^_TC4[Q[V.6YN#&]I)(<N&4 [USR ,?45W
MU% '(Q:/JL/Q&_MMX1/9KHZV!D\Q1(\@D+[MO0 ].O7MBN>C\&Z^G@>&P%O;
M?VA::X-3CC,_R2IYYEV[L<'!QTKT^B@#@O%7AJ]\3PW$.HZ';2SB$-I][;W
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MOF1S$I)N'3@KM7N?O=NE)H7B74;&X\*:3>Z9!'9:I9A+:9+@M(KQPA_G7;@
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MG686FCCG<[(@@&\D@9."0!@<Y[<T^PT76K3QCXAUB2"T>'4+6WBA"SD-NB#
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M:(38Q^_'W21@\XZXXS]* *>I^/M8U#PD)K2SBT[4[?6HM,U&"24L8V\Q00C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY*JB@+M/"'(8L .G&3CBO,M7U74_$'P(U+4M8AMGD:Y+1R1R%FR+W;@*5&T
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MM"PW1%QD%AU!;DY/6M&@#A[?1-<_X2SP[JEQ9VZQ6.FR6MP([C<0[[<;<@9
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MJAQC.-V.<5VM% ' :MX3U+4[;Q9J @C34=:L5L+>W:48AC"L,NPXR2Q) S@
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MJWG$RYC9CN*[<<[O7M0!F2^-M>D@\2O::'9%M"F991+>L!*BQB0[2$^\0>A
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MW-H@$DL0>)9\K@D9 ;N/>N+L]#\8>'=:U.#1FTNXT;4;M[Q'NW=9+-Y#EQM
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M&Y:,N1*3-!#(0$E88P>JY4=,]3BM.S\1W=YXD\0:,+.!7TR&"6*7S21*)0Q
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M\*ZY_9?C>U,5B'UZ25K8BX;"!XA'\_R<8QGC- &K=>,HFFLK6Q\E;BZL5O\
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M'RW.TJR/CD!E8C(JCJFE^+/$7@W5[+4(M-M[R]M6MH;>&=C''N!!=W*Y)Z8
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M965) SA5EB+*-ZG=T.,>M:GBS0M;FUK2_$7AN6U_M&Q22"6VNR5CN(7P2NX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJEF(  R2>U</+XVOY/"EQXNT^RMY]&@>1O)+$32P1N5:56^Z#\K,%(Y Z@G
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MBD^0$*P3G&>N*]'HH X6#PUXB3Q/?ZNPTA([S2DL_L\;R 1.I?"AMO*_-][
MZ8V]ZJIX+UV/P?X2T<'3C/HE];W,KFX<+(L6>%_=YR<]^GO7HE% '"6WASQ5
MH/B#57T*YTM])U:Y-XZWGF>9:S,!O*A1AP<9P2OX=2_4/#GB73/%)USPS=V,
M_P!KMHK>_MM39U$ACR$E#(#\V"01C'].XHH JZ=#=06,:7TZSW7+2NB[5W$D
MX4=E&<#/. ,UR-AX7UO0H-=TO3&LI=-U*>6XMY)Y65[1I1\ZE0I#J#R.0>Q]
M:[BB@#A9O!E_H]WX6N/#OV28:+:R63Q7DC1^8CJHWAE5OF!7.,<Y[51E\!:W
M=>$_%VD3W=AYVLW[WMO(@<*I)0@,,<#]WVSU[UZ110!PNJ^'O%)U_3O%.ERZ
M6NKI:FRO;.9Y/(EB+;P%<#=E2>NT9]NAGUCPMK.I)HVK?;+4Z_IEVURBG<MN
MRNNUX0>6 *X^;!.<G'.!V=% '(S>&]0OM5U+7;B.TCU";3#IMK LS,B(6+,S
M/LSDDCHO 7OGC,;P=KO_  BGA#25_LXS:'=VT\SFX<+(L((PO[O.3GOT]Z]!
MHH XC4/!M[K'B77KB]-JFFZKI2Z?^[E8RH06._!0#^+IGM5CPS8>-;9;:RUZ
M\TN2SM %%Q:[_.N@HPN\, %[$XSG&.]=?10!PEKX.O[CQ%HNN7UOI]IJEEN^
MV7MC*Q:]4H5VLNQ>"2&).<8P.N1K^-=%U/7-)M8=+EMQ)!>Q7$L%TS"*YC0D
MF)RH)P>#T/0<5TE% 'GTGA'Q')<^,)FDTK&OV4<"*KR#RG$31X)VG@;LY[XZ
M+GBQ)X6UMHO!:@:?G0BIN/\ 2'_>8B,?R?N_?/./3WKN:* /-O\ A#/$FG:'
MXD\-Z<^FSZ3J8N7M9KB5TEMS,#E"H0AAD\'(QDG!Z5W.A6=S8:!865XT33V]
MND3F+.TE5 R,\]JT** //K'P9K.F>$M1\'6\MFVD7'G16UV\C"6""4DLICVX
M9AN;!W '(SC%:)\+7^G^,-+U32&L_L5MI7]ER17#,&1 ZLK+@88_+C!(]>>E
M=A10!YS+X)UZ7P5XJT0G35N-9O[BZB<7#E8UE8-AOW><C';K[5;O?#OBFP\1
M1Z_X?ETPSW-I':ZA97COY3%,[71U7.1N(Y'2N[HH XW5/#VOWVH>&;PS6,\N
MFW3W5TSR/&&+JR[(P%;  ;C)SQSUS5_QCX;G\165C]BN_L=_97D=Q!<CJ@SM
MD ^J,W'KBNCHH Y*R\%1Z=XX;6;618]/-I$GV0=//C5HUD_")BM+)H&L?\)Y
MJ&NPM9I!/I0L8?WK>8KJS.'(V8QEL8SV[]*ZRB@#@X? \MYXCAUB]L[#3YGL
MYK;43I\K$7QD4+\P*K@#ELG)S@<XS3_"^B>,]&@M=$O;_3)='LBJ0W<8?[5)
M$I^5"I&T<  G)X]^:[FB@#)\3Z?=:MX7U33;/R1/>6LENC3.55=ZE<D@$\9S
MTKG1X7UH7O@J?&GXT&)TN!]H?]X6A\KY/W?X\X]/>NXHH YCPYH>I:9XD\1Z
MA>"T\C5+B.:(0RLS)MC"88%0.<9X-&NZ'J6H>,/#>K6OV3[-I3SM*LLK*[^9
M&4^4!2.,YY//2NGHH XRT\/>(M+U+Q--I\^G>5J<_P!KMGE+[UDV*NUP!@+\
MO4$G';TD\/\ A$Z7XNN]=CL[33$NK00S6=G*7CEEW;O-(VJ 0.!@9.23COU]
M% ')>)_#NJ7/B+1_$>A26WV_3Q)#);W3,D=Q"^,KN4$J01D'!JC;>&/$(O/&
M-W/_ &8&UV&-(8TFD(C98?+^9MG(YZ@<XZ#/'=T4 <5!X;U6/PQH>AWMAI.H
MV5K8_9;VVFE;;(RA!&Z$QGIM?@@8W#!XK*3X?:UI&F^'[G1+^V.K:,\X2&Z=
MV@>"5LF'=C=A1M"MCMT';TJB@#B/$?A[Q+XB\(36,\VF_P!HW%Q#*5$CK! L
M<BN%4[26)VG)('7V%6O%?A_6M1NM'UO0[BTM]:TPOB*X+-!-'( 'C8@9_A!!
MQV_+K:* .+UWP[XB\2^";^PO[FPBU2X>&2*.+?\ 9XO+D5PNXC<<[3EL=QQQ
MS-J&AZYJ'B?POJ\BZ<HTS[0URBS.,F5-F$^3G:.YQGT%==10!PUAX6UO0[77
M-(TUK*73=1FEGMY9Y65[0RCYU*A2' /(Y&>AQUI]OX-N],\0>%Y=/^RG3-$L
M9;,^;*PEDWA1NP$(_@SUYSVKMJ* .*TK0_$^B6/B9[(:2;_4=2>^M/-ED:-0
MP12KX4'A4)R.YKM%SM&[&<<XI:* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<13&&0Q2B-PVQQU5L=",C@U-7#Z=XQT^ST7Q)JDVD)8?8-5DM98H"K-=3_(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8VWAJYN-';3K)MD6JK>C>\ .0OE8X?'RY)P.O..>R_X1?P]_T M,_P# 2/\
MPH_X1?P]_P! +3/_  $C_P * .&O+'4H+CQI9V3:7/::ZCRPW+WRJ8V: 1E"
MG<Y'!R!SSZ5*;&\$?@4,^G,VAX^U^7>J0<0F+Y<XR><]OJ:[3_A%_#W_ $ M
M,_\  2/_  H_X1?P]_T M,_\!(_\* /-]=T76M3TSQ-9/)H]S<7EZ)[2^EOP
M&\@2(Z0A<?(%"XZXSSR3FND9+M/B);:^DVE/;S:6ME<C[: 86$I<E>/G&#@=
M.1SBND_X1?P]_P! +3/_  $C_P */^$7\/?] +3/_ 2/_"@#S^3PS+JGAWQ5
MIT]]8V=Q?ZNVJ6$WVE'"D%"@< \<ISC/7C-;DP?Q%J^@WVJBSLETEWN7C%Y'
M(9IBA50A!^X,DY.#T&.M=)_PB_A[_H!:9_X"1_X4?\(OX>_Z 6F?^ D?^% '
MGDVBWTWP^\4Z)OL%O-5O[BX@/VU-@260,-Q[$ <\'M^'H,MSIVHZ))97=W;Q
MBXMS#*HG0E0RX."#[T[_ (1?P]_T M,_\!(_\*/^$7\/?] +3/\ P$C_ ,*
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M7N0Y2,N2B%C][:I S[5I_P#"+^'O^@%IG_@)'_A1_P (OX>_Z 6F?^ D?^%
M',6T4L?Q4O/$#O9C3IM.2R5OM:;PRONW%<].3WS[5G:?HR_\)+I6O)'8Z/J<
M:O\ VM+;7B>3?90C 13R=Y#98#&._%=Q_P (OX>_Z 6F?^ D?^%'_"+^'O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8998[B_C=,0AKAP"(\[F49 )X_&NF6.WB^.!GC6-/-\-EW=0!N_T@<D]^.]
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MMI;W":;9B\N)))/*4J=QVQG:0S80\<#ISS0!TE%<E<^.HX[GP[%:Z5>72Z[
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MK^W]0T?3O#EY?7%DD,I*S1HKQR$_,"3C@#(!Y/H,4 =:DT4DDD:2(SQD!U#
ME21D9';BGUQUAXDT:SO_ !?>3:;_ &:VF/&VH7#;2T_[O<K?+G/RX YSSZU:
M?Q;)8W^DPZMIC64&K.(K683!]LI&5CE&!M8C.,%AD8S0!TS,J*69@J@9))P
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M37_PDO=>\1Z(E_:L9S);QRJ0Z"9QM(;& N%&>2<9Q0!Z6\B1QM([JJ*,EF.
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M#.F^>)$R&,@;INW8QQG'7\Z[2JUQJ-C:7$5O<WEO#-,<11R2JK.?]D$Y/X4
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MW$;RJ+JY$$:HI )9L'NP  !SSV!HT"[\0WY:XUO3(-*54VK:I<B=G;NY8
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M/6NKV\,L"S9#12CYHV4D$'UY'7N,5R7A)T\8^+_$VJZFBW$.EW[:;86\HW)
M(Q\[A3QN8D?-UQQTKNM-^W&Q1M2\H7;Y9TA.4CR>%!P"V!@9QR<G Z#D;;0M
M7\)>*]6U'1[)=2TG6)1<7%JDJQS03_Q,F\A65NI!((- &U/I.D:#J5SXGQ'9
MQPV4JW6Q<*R@J^\@=P%/.,G(]!5&7QI+90Z1?:EI?V;2]4DCBBN!/O>%I!F/
MS4V@*#TR&;!Z^M6]4TV]\5:#J6G7L1TZVO+5X%C9E>0,PQO;:2HQZ G/<U@M
MH&MZ[X8T;P[J]BMO]BGMVN[M9E:.9(2"/+ .[+;1]X+C)ZX&0"[-XVU%[[Q#
M96/AUYY]%*&027:QB163?P<'!QC Y]R.[(OB!)+%X?OSHLJ:1K4L5O%<O.OF
M))("5!C ^[D8SN_#U++2=6M_$'C2]?3V,6JK#]DQ+'EBD/EG/S<9/(]O?BLK
M_A&==7P1X,TH:<3=:/?6L]T/.CV[(LYVG/).>.GOB@#4N/'.J-J&N6.E^%;B
M]N-(=!*INTC#JR;P1P<L01A1GWQQFQ;_ !"TS4-*TB[L6@$FJ0O/$EY<"!8U
M0A7WM@X(8A< ')]@2,G0KR^MOB%X[^RZ9)=EIK0KLE1-K_9UP&W$8'N,]^*K
M0^"M?\(VGAR]\/K;:C>Z;;S6U]:22>4MPDSB1MC'A</TSVQ]* - _$Z,:"^H
M+H\LDL.IKIMQ%%.K*KLP4.CX^=3N!! &?:M2U\8RKKNI:5JVDO8RVEC_ &C&
M4G$WFP9*G. -K CIS]:SO$NG>)?$'AJV273HDO#J-O<_9([A66"*-U8@N<;F
M.#T&.0.V3/=Z9K3?$"YURUL,0G0VLHFDD3_7^89!E<_=Z#/K[<T :.C^)KC5
M8+>\6PB;3KBS>ZCN+6Y\_!7;^[9=HPY#'@$\J152R\:SS:MH=C>Z3]D.MP23
M6H,^98]B[]LJ%1L)7T+<@CWK'L?!]_9ZY+J>@6)\.M<6,Z7=OYRO;RW+ >4Z
M(I(&ULDG"\8XY-5=.\-^)4U+PAJ$VBVL5QIK3+J$CWH>2=WBV&9FP2>><9)Y
MQP!0!HZ'XEU>^TKQ;=:MIEM<V]C>W,'V>*XW96-$!C 90"I&XEB>23\M:6F^
M*+1="\,0Z=IL<5QK%JLEG8*X2.&,1AVRP7A5! X7DD<>E#3=#US3K/QC8M8Q
M21:C=W5U:RI.,R><H"J5.-N.<DGZ U3MO"NMV%CX)U."U5]1T"U^QW5F95'G
MQM&J,4;.,@J",D9[XH V)?'1M;?Q#'=:6ZZGH<'VF:UCF#++#M+"1'(&1@'/
M&01C%)9>-[F;4] @N]$>UM-;B+6MP;A7(<1^9M9 . 1G!SGU JEJGAG4=3/B
MK5_L9CO=4TK^S+2U:1-R+M;+2$$J,L_0$X"^IP"70]9=O A&G-_Q)L&\_?1\
M?N3%\OS<\G/T]^* -#XF^([GPKX U+4[(XO %BA;&=C.P7=^ )/U%:&E>$M)
ML-$CL);*"Z9D'VB:= [W#X^9W8\DD\YJ3Q9X<MO%OA>^T2Z<I'=)@2 9*.""
MK>^"!Q5#1K[Q3:V$-AJNA_:+R%1&;VWNH_(FQQO.XAUSU("F@!8+B'PJFE>%
M[!#=WDPE:W264J$A4Y+.^&/&Y5S@DD_4BI<>/Q::9XA>XTJ0:EH*A[JS28$,
MA7<LB.0,J0#VR,8Q1K&A:Q'XGT/Q-:*E[=6<4MM>VRL(S)%(<_NRV!E2!PQ&
M1WS6?J_A34M1L_&.H):;;_7+-+*VM6E7,2*A4,[9VY)8D@$X '7F@#0?QQ?0
MZII%K-X>E$6L1,UDZ72EFD5-Y5UP HQDYR>G(!XI!X\GATGQ)/>:(\=_H'S7
M-K%<JZLAC\Q65R!P5]LU%=Z/J\VJ^";E-.?9I(<W8,L>5W0F+"_-SR<_3WXJ
ME?\ AW6[B3X@^7IQQKUND5F3-'U$'E$M\W'//?CWXH TF\=7L5_HT,WAV40:
MS$39R)=*S&01[]K*0 H(SAL]N0.E2VWBV2]LO$EMJ.A[+W1UQ<V:SK*DT;Q[
MU(8A005SD$?G5.ZT76);GP/*NG-C2"6NQYL?'[DQX7YN>3GZ>_%$>BZNFM^.
M+O\ L]C%J\$*6?[U,L4A,9W?-\N2<_3WXH J7'B>_CTGP*="TVSM+'5WB'V<
MS%/+7RBXB&$("\=<=L8YS6EI_B'69?B!K>GWD%G%IUA:6\A*W+'8&\PE_N<D
MX QQ@#J:S3X:UV'POX'2&QCDOM!FB^T6[3JH=5B:,E6Y'<'Z5H'P_JK>-=9N
M9;:%M.UG3H;>:9)\&%D#A@%QEL[^#Q[T -7XD6IN='?[/ ]AJLRPPR0W8DGB
M+C*&6(+\JGN=QVY&:-6^)-IIMM<WT,%O=6-K<FWF"7@%R=K['9(<'< V>K D
M D<8RSPG#XVTNTL_#VH:?9"UL0L0U=+D'S84P !%C(<J ,D@#D\]##HVG^,O
M#%W>Z+9:?97NDSW4L]GJ$EUL-JLC%RKQX)?!8D8QGU&> #M[S4(++2I]2?<U
MO# T[;!DE0N[@>N!6+I^L2>(;2/SM.M)=,O;)IUGAN?/C/*CRV!0 'YO?[IK
M:OQ=+I-R+,++>"!A")< -)M.W/;!.,UQ&C>%9])\2R:MI.D3:1:36<@O=.6=
M#%<3DKL,:AMJXPV6.WJ..30!D> O%-SH?@+P=%/I#MIMXZ67VSSU#+([L%/E
MXY7/&<@^V.O4:_XWFT*WU>];1W;3]*DC2:668Q-+N"DF)2I#@!A_$,D$5ST'
MA77H?AYX4T4Z=F]TK4;>XN )X]I2.0L=ISR2#P/KT[IXD\+^*-:M?%EG)IUM
M=O?#_B77DUR!Y,6U?W*I@[3D')X!SDG@4 ;&KQP_\+?\*W$<:!Y;"]W.%P6
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M'^DG;.'C\P<[,KQQT/-1V'C/^U+#0#9V2_VAK-J;M+>2;"0Q@ LS,%SP64#
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MKD[7QA/)J>NZ7)8P/>Z5;I<8M[K<DJL&^4DJ"K J<@@]JHZ?\0+R?0(-?O\
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M?UJS7B5G:Z/+I_Q'M;K2'O+F35[E;9+>R:63>4&S8RJ=I#'/48ZUV&AZ[?\
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MQ* H2;.SYB ",8.,Y&>M57\&^)3\,]3\-M;6;7<^H&>%UN,*R&Y$Q+9'R\#
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MG\5ZG>7^IQ&P2329=,@BWAW4R_?D;;QQP ,G/.<5D2Z#XSO/#OAW2+G3=/\
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M$D1!\M&VDL3CJ0.2>V!5WQCHVJZV=!_L^*V/V#5(+^;SIBN53=E5PIR3N]J
M$M]08>(=1TS1M-T]-42&*ZU.8L0GF."$7(7+$A"<G&!C@YQ67-\2)?\ A'[3
M4;?1]]P=672;VU:XPUO-O"D*=N'Z\<KU'O6@="U72O'%YXBTV&&Y@U2VBBO;
M5YMC))&,(ZM@@C!((X]>>E9%[X%U5=$BBLQ9R7\^OKK=YOF9(PPD#;$.TD\!
M5R0.F>^* -"?Q9XCT_5]&TR_\/V:W&ISW$49AORR@1H74G*#@\9/48/&<"H8
MO&/B.9=>M(]#L/[2T5P9\WK"&1#&)%V'9N+$<8( 'KVK3U[1M4U'Q7X8U.VB
MM_L^F2327 DF*L?,C*84!2#C.>2*J6N@:S!K'C&\:"T*:RL?V91<'*E(O+^?
MY.,]>,T 6HO%ESJ.F:'>Z?IX2WU.T-W+=7+$0VBA5.UR.I); Z=">V*RC\1K
MAO!MAKT&DQRM/J(L)HEN>%;S?+W(=N'!QD9V]15?3_"GB;38/"49BTZ[ATFT
M:VGM);EEC$F%"SJ=AR0 1@CC)QUS59/!/B5/"2Z.PTUY(M;&H+()W4-&)S*<
M_*<$YP!SCUH Z*W\875KK^J:9K]E;V8L]/\ [32:WG,JF %E;=E5PP*]N*GL
M_$&M7$VC7!T0-IVIKN+Q2[I+0%=R-(,8.1P<'@\<U1U+PK?ZQXQO[VZC@32[
M[0FTJ3;,3*I9F8L!MQC#8ZTOA2P\9:?:V6CZNVF_8K!5C%[;R,TMRB\(-A&$
M. -QR>X YR "M>?$5H[-=4LK&.]T_P"T^2T,3.URT>_8954*01D9VY^[SD'@
M=X0&4@C((K@-!T'QCX<\W0+.339="\YVMKZ1V%Q;1.Q8ILQAF!)P<@>OI7>3
MM*L#F"-9)0/E1FV@GW.#C\J / M*L%U?X$:;INEZ3=7&O-<,;.>&U=?)<7+'
M?YV J@*",[O:O4+WQ7<V,ESIEN;2XU#3K:-KEKB1D$LK+NV+M4\D<Y/3<.#S
MB7X<:!J7A;P9::+JBVQFMFD(DMY2ZN'D9^Z@C&[%4]0T7Q1I'C*]UOPXNGWE
MKJB1+>6E[*T1CDC7:LB, >-N 1CM^0!&WC[4KB7PW%8Z!^\UR"=TCNIS$T,D
M2Y*N-G S_%Z#ITJY9Z]>/XTT[2]5T2SMKV72GNFN8Y_,:/#H&C!VCC)SU.<"
MDOM!UVX\4^%M49K2==,%R;MS(8RS3*!B-=IX7MDYQCOS4]YH6HW'Q&M-:$=N
M=.BTZ2R<&4B0EW5LA=N,?+CKWH I3^.[I?"S^++;38Y]"1V) E(G:!7*&4#&
M.Q;:3]WN#Q6I_P )(^J:Q+I>B1V]PT%K'<SSSN1&HDR8T  ))8 G/88ZYQ7.
MV7@[7++P1>>" ;:33Y/,@M]0,IW);NQ)#)CEP&(&#@\<BK<7AG6/#?C&?5/#
M\-I=Z=?VL%M<VUQ<&)HFA79&ZL%;(V\$8S0 OPD+GP/F2(1/]ON]T8.0A\]^
M,]\5W-</X9T?Q3X<\,BRC@TN6Z;4WF;=.^WR))69C]T88 \#D?RKN* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *" 1@\BBB@
M#-T;0-(\/6SVVD:?;V4+N7=84V[F]3ZUI444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHI9XXY)CMC1W +G&< =SCTH EHHHH **8\T41 DD1,]-S 4J.LB[D8,/4'-
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M>."%?O22N%4?4FI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3L-82)KBUFNA!);3(@3=NPP*E0,XR<C\^TL5NELHA>O&]T1F0QC"@GG"^PZ
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MCR<9W[>.3@=><<]_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ;=V&3GGUKJ]6^(:V5O?7EC:VUY;V-RT$L(NMMS*5;:YCCVG.#G@D9VGIQD
M[BJE_JNG:5$LFHW]K9QL<*UQ,L8/XDCUKE;OQIJS>(;G1M(\/+>S1V,=]$TE
MX(A(CL5YRORG@\?RJA!)J%_\5=:L[ZRL9;,:5!%)')<LRK"SR9.#'@D]UX'
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MIG! V+U.,DDXZ8YJ?$?0]3\2>%CI>E0Q/,\\4I::78JA'#>A.3C'2NOHH B
M-Q:E9HC'YBD.A(.,^XKA?"VE>-- M8?#4B:?+I5JVR#5?./FB 'A?*VX+XXS
MG Z\XY[^B@#E/#>DZGI_BGQ-?W=M&EMJ<\4T!64,P"1A"&'8G&>]<^_@35M2
M\-^)=/G,-G=WNLOJMA,)-ZJV4*!P!Q]S!QGKQFO2Z* .0N-%U#Q+J^B7FL64
M=C%I?F2O&LPD,LS)L&TCH@!8Y."3CBN5D\'>+HOAM>^!H[6QN(8R$L]0:ZV;
MXO-#@,FTD,.AYQCU[^LT4 9B3:T=8MXWL[1=.:V+3RK.6=)LC"J-HRN,\\?A
MWTZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU<:SJYE<N"1=D='(';T%:7_"-K_T%]8_\##2^$O^19M?]Z3_ -&-6U0!B?\
M"-K_ -!?6/\ P,-'_"-K_P!!?6/_  ,-7=9TR+6M&N],G9EANHFBD*]=IX./
MPKQ3QMH6DV'QM\%Z;::9:0V,L:B6W2%0DGSN/F&,-T'6@#U[_A&U_P"@OK'_
M (&&C_A&U_Z"^L?^!AK&U&XT7X8:7<W=O:%8-2U&,1VT*[425U5.P.U?DW'
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M\+1V,_PIUY8H))O$?]HJ-.-K&S7*_<^Z5&X+C=[?C0!](_\ "-K_ -!?6/\
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MTB2S.GB'6=7'GWD<+YNR<J0<]O:NMK%\1?>TC_L)1?R:@!/^$;7_ *"^L?\
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M-C!9L8YP<'%+KG@WQ-?^&?A]:1:3FXT22%[Q!<Q_*(P@X)89)VD\<>]>QT4
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MDGVO)\S$E1@CH>YH PO!D5YX3U_QKXIN;*[TOPEM>6"UFB,32,&R&2(X*\9
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M/7@?>&,GL*R='^(_BKQ#-JUKH_AFUN;C3-0%M,QNMB%-Q4L-W4_*3CL/7@4
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M2VFG5=/):."$R.W[F3HHY-=G%K-O8>$KOQ[I_AZ:2^NH0AL;>+;)(%E94W@
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M(_\ K]C_ /2:&MJL71O^0WXC_P"OV/\ ])H: -JBBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGN<UV- !1110 4444 %%%% !1110 4444 8OA+_D6;7_ 'I/_1C5M5B^$O\
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M@ "YR,5U-<1_P@UQ_:2H+F+^SAKIUO//F^9C_5XQC&\YW9Z<8[UV] !1110
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M(_M$&@ZQJEG%;;PI,4A&TJ3Q\K#'T)QTP=G3[:+P]X0M-#U6Z0Z?H\*OJLR
MLLCL=RVZCJ1EAD=QM&/G..IT;03X<\,_V;IDB27(#OY]P.))G)9G8#_:).!V
MXJOK'A*/4?!TVA17#)([+,+B0;B\RR"3>^.N6'/UXH U=,U>UU1KJ.'?'<6D
M@BN()1AXF*A@#U'*D$$$CFK]8.@Z'<6&K:UJUX\7VK5)HW:*%BR1+'&$4 D
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M_0SW_P#X#V__ ,;K;HH Q/['U7_H9[__ ,![?_XW1_8^J_\ 0SW_ /X#V_\
M\;K;HH Q/['U7_H9[_\ \![?_P"-T?V/JO\ T,]__P" ]O\ _&ZVZ* ,3^Q]
M5_Z&>_\ _ >W_P#C=']CZK_T,]__ . ]O_\ &ZVZ* ,3^Q]5_P"AGO\ _P !
M[?\ ^-T?V/JO_0SW_P#X#V__ ,;K;HH Q/['U7_H9[__ ,![?_XW1_8^J_\
M0SW_ /X#V_\ \;K;HH Q/['U7_H9[_\ \![?_P"-T?V/JO\ T,]__P" ]O\
M_&ZVZ* ,3^Q]5_Z&>_\ _ >W_P#C=']CZK_T,]__ . ]O_\ &ZVZ* .=LO#5
M]I]HEM;^);]8DS@&"W/4DG_EGZFI_P"Q]5_Z&>__ / >W_\ C=;=% &)_8^J
M_P#0SW__ (#V_P#\;H_L?5?^AGO_ /P'M_\ XW6W10!B?V/JO_0SW_\ X#V_
M_P ;H_L?5?\ H9[_ /\  >W_ /C=;=% &)_8^J_]#/?_ /@/;_\ QNC^Q]5_
MZ&>__P# >W_^-UMT4 8G]CZK_P!#/?\ _@/;_P#QNC^Q]5_Z&>__ / >W_\
MC=;=% &)_8^J_P#0SW__ (#V_P#\;H_L?5?^AGO_ /P'M_\ XW6W10!B?V/J
MO_0SW_\ X#V__P ;H_L?5?\ H9[_ /\  >W_ /C=;=% &)_8^J_]#/?_ /@/
M;_\ QNC^Q]5_Z&>__P# >W_^-UMT4 8G]CZK_P!#/?\ _@/;_P#QNC^Q]5_Z
M&>__ / >W_\ C=;=% &)_8^J_P#0SW__ (#V_P#\;H_L?5?^AGO_ /P'M_\
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MW_\ X#V__P ;K;HH Q/['U7_ *&>_P#_  'M_P#XW1_8^J_]#/?_ /@/;_\
MQNMNB@#$_L?5?^AGO_\ P'M__C=']CZK_P!#/?\ _@/;_P#QNMNB@#$_L?5?
M^AGO_P#P'M__ (W1_8^J_P#0SW__ (#V_P#\;K;HH Q/['U7_H9[_P#\![?_
M .-T?V/JO_0SW_\ X#V__P ;K;HH Q/['U7_ *&>_P#_  'M_P#XW1_8^J_]
M#/?_ /@/;_\ QNMNB@#$_L?5?^AGO_\ P'M__C=']CZK_P!#/?\ _@/;_P#Q
MNMNB@#$_L?5?^AGO_P#P'M__ (W1_8^J_P#0SW__ (#V_P#\;K;HH Q/['U7
M_H9[_P#\![?_ .-U9TG26TQKR22]GO)KN83223*BG(14  4 8P@K2HH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA'C<*S_W"Q8'!Z$X[&JU];SWO_"UH;6WFD>[MT^S*(V_?8M@IV<?-\PQQWH
M](T74AJVD6UZ$D1I8U9E>%X_F(!. P!QSP:J:AXJTC3&NA<32E+3'VJ2*!Y$
MM\C/SLH(7@@GT!!.!S3_  O>1WWAK3Y8DF11!&G[Z)HSD*,\, >O'X5QNA7'
M]@1^+M&UR"8SW-_<W=MB)G%[#*/E"8'S-_"5'(XH U?&OB@:>N@6UK)<&+4[
M^&.2:UAD?= 0S'8Z _,=H&%.[!)'K6UI%D-$TVZF^W:G>VTCFYBCN@\LL*$
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MLZ!JCZ]IK1Q&VF$[0!HS@3A\^6%Q\V?P .1GTGQ'*D7AO4B^>;610 "2Q*G
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MH"_,.O(R/4UGZK\0+"WT70]3TV*>]M]7O8;:*2.%B%#/A\CKN # +UR.G!H
M[&BH&ND6Q-V8YM@C\S8(FWXQG&W&<^V,UA#QWH3:1INJK-<-9:E.+>UD6VD.
M^0MM"D8RN2".<=* .DHK(U#6K"!KZSN'NHS!:?:)GBAD.R-L@,&4'GY6X'/R
MD]JXW7;N-?"?@FZT;4]1:TEU:PC262=P]Q"SCB3INS@=: /2:*XR*:XC^,TU
MK]JN&M7T$3^0TK&-7\_:6"YP#@ <4SXDW<FGV6@WB7L]JBZW:),8Y616C+_,
M' ZC [T ;FNZ+?:Q^YBU=[6QE@DM[JV$"OYJN,9#'E6 SCJ.>0:U+2UAL;."
MTMT"001K%&@_A51@#\A6-H_C+1M;U"[T^WEGAO+5/,D@N[=X'\OLX#@$K[TZ
M+Q?I,NH65F7GB-^";.66%ECN,#.$8C'3D9QD<C- &[17+_$:2:#X>:Y<6US/
M;3PVCR1RP2&-E8#(Y'-,EO\ 31?>$[>]OK^*_F4M;1Q%Q'.WE'<)"!M; R<$
MYSB@#JZ*Y6Y^(?A^U_M'+WLATY]EVL5E*QAXR68;>% YW'CTS6Q/KMC%#:O&
MTERUW'YMO';H7:1, E@!_#\R\G Y ZD4 :5%8$/C30[C3+:_@N7D6YN#:10B
M-A*9QG,90C(88.<XP!GI3)?&^AP:'?ZO--/';:?,T%VIMW+PR#&590">XYZ<
MCF@#HJ*\W\<^)X-2\(WLVD7>H6\UE>V:M(JR0"19)4'!XWJ5)Z9'YBNR3Q'I
MS^)7\/!IAJ*P?:"C0L%,><;@Q&TC)QP>M &M15*PU2VU)[I;?S?]&F,$A>,J
M-XZ@$]?J.*RO[0TK_A.IH/ME^=3ATTN]IB3R?)\P?.%QAGR<97)P"* .BHKD
MX?B/X;GM[2YBN+IK6YG^SK<?9)!'')O* .Q7"$D< X/(/ -31^+EE\>7'AL6
M=R!!:I*TWDL0S,Q P>RC!^8\$_3D Z:BL&3QCH\-U:122S)#=S_9K>Z:%O(D
MEY 0/C&3@X/0XX)JJOQ T![Y[.)[V2:.Z^R2+'8S-Y<F,X;Y<@'L3UYQG!H
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M/M<LK6X-I)^^!MU0;/E^;YACBO3J* /+)UG_ .$=^&<?V*^,EE<6K72BTDS
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MQ_&9KIK>Z^RKH/D&<6[F/S//W[=V,9V\XKMZ* /%S;W?_"D'T_\ L[4/MO\
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MO=W:Z> ;U[6,.+?C=@Y(+';R0H8@$<<BH;OQOHEK-I$8EGG&K(SV;V\#R+(
MA;@@=2!T'.2.*PM ^U^%=7\4V6HZ??7$-_J$FHV<]O;/,LRR* 8R5!"LI7'S
M8&.>E8VD^'-1\.M\-[">UN9FTUKJ2\DAA>1(/-C?"EE!'#/M_#/2@#M;/QKI
M5WIM]>%;JW:QN%MKBWN(MDJRL5"+MS_$67!SCFH->\9_V/X>UF_&E7OVK381
M(T$BJ,[@=K;@Q!7@Y()].O%<T]DD]_X[74]"U&[T[4+RTVHMM*#+&%C1G3 R
M2A!;CGY<BH)-%\0/X0\8Z+#<:AJFG-8A=,DOXBERSE6W198!G ^7!(ZG [T
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MF177VR6&!Y$A:6,@ L!C&X[?PSTKHBDZ?&&2^-I=_8QH8M_M MW,9D$Q?:&
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MVL+B2,".XV#)Q@DKP"1N R*QM2^W'XH0:C9Z?=2QKH,T*2/;NL9F:171&8C
MR%YST[\USEF-5N[_ ,$:I/H>N-=6MQ(+\/;F-(7:%EVI'D*L8) #  8QEB:
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M'(@RQ92W"@=_IZBG#4-'_P"%@W$ M[W^V8M+WL^'\MH/,Z*N<,V[/(&>,9H
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M&*2.0JH4';*C!3@ <8Z5TE% %33]/CTZ!HTDEE=VWRS3-N>5L ;F/3H .
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M?9EG0J8QN =BH))P6Y.<#BNIL!=+\3]3U2;3[V&TETJ")9&@8CS%9V9<KG)
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M==JB)B&4_-][ )]/?((%@?$&S%QI22Z3JL4&JQ;K.X,*E97V;_+P&+ XZ$@
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MK*C;@2I(RIR1Q]?3.QX M=1M)?$K7^F7%DMWK,UW 9BAW(P4#[K'GY3[>A-
M'9T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'('+#Y2#U&WG('4=:XWQ+-_9OQ9T*\M[">[N9-,NU\FW WR$&/ RQ"@#)Y)
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M<SFVN5)4.,,I!(*D>H((H U**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE/B'I
M=_JOA81Z=;-=7$%Y;W(@5@K.L<JLP!8@9P#U-=710!Q)M]4G^)FGZR^CW,5F
MFDRV\CEXSLD:17"D!NN%YQD9[GK7-?\ ",>(F\/74\&D_P#$PL_$LVKV]G<N
MFV[A<L-F02 2KGKT(KUNB@#G?#5Q>7S/=3^'1HD03:(I?+,LC9Y/R<!1CC/)
MST&.<GQ-::WI7C?3_%.E:;)JMO\ 8GT^\M(75954N'5TW$ \\$9_^MW%1RSP
MP;?.ECCWG:N]@-Q]!F@#B/%5IKVK^'],U :4WVJRU>WU#^SDD0RB&,\KNSM+
M\DXSCMDXR8;>WUJ7QOK.L2:#=Q6EWH\<$69(BX=6<[6&[@G=V) XR1V]!HH
M\K70M<3X=^#-,_L>Y-[INH6DUU$'C^1(FRQSNP>.F#6^VF:C<?$R_OS831V%
MQHBV2W+%-OF"1V(QNW8PPYQ7:T4 >16VE^)3X/\ "&CGPW=K/H>J6SW+--$!
M(L9;+1_-R,<Y.WJ ,]NA>QUZ/QMXHU*PT]XVN=*CAL+B5D,;3H'(!&[(&67J
M/6N\HH \LT_2M=D\1>#M7E\.7B3VL=Q%J4]S<1-*TCQA=Y.X_N]P.,=!T4<9
MOZ;I>LV&D>-M-DT>=C>W=[<VLJR1[9Q,/D"_-D'KG. /4UZ)10!PI\,7>K?"
M&RT*>%[35+:PA6+<5S%<Q*I4@@D?>4<@]#3M1\-:MK?PUO+*8Q0Z]J"K=RY^
MXLX975#[ (J9]!7<44 <AX8N]6U">%KWPBFB/"I^T2NT;;VQC;%L.<9.=QQP
M,<YR(OBIIFI:WX$O-*TJPEO+NXDA*JC(H 25'))8@=%-=F"#G!!QUQ2;T\SR
M]R[R-VW/./7% '#ZMI.J:9XFMO%OA[3Y97N@L&KZ;O1&GC'W9!D[?,3Z\CC-
M4[^VUG2/&MYK4/AA]9TW5X81)$&B$]I-&"O1C@J1CD'J/S]$DD2)"\CJB#JS
M' IU '(>)- OM;\!O;I!#:ZO 1>V:0XVP3HV]%!Z$_PD]\DU7UWPSJNJ?#R6
MTB\E=<DECU!E<YC:X619-A/=1MV#/8"NWHH XW1KS5;^"6:?P>=':*%A(K-$
MSRR$8VQ[3]WON;';CJ1S<&@Z[%\.O!FEG1KDWNF:E:SW40>/Y$B<LQSNP>#Q
M@UZH9$618RZAV!*J3R<=<"G4 >?2V>LZ?XO\620Z+<7<&MVT!MYXY$$<;)"8
MV63+9'.", YS6+;:#XCTC1O!VJ)X?^VSZ78M87^F221EV1MAWQG)7(*#C.>U
M>MT4 9'A]KF:S>XN=*32A*V8[7Y2ZKCJY7C<>> 3@8YSG''^*-.\0ZKJ'B>P
MFT>:_L[BP\O2'$T:P1,8B'+J6!\S>>#@]L;>37H]-5T9F574LO# 'D?6@#S"
M"Q\2Z%>^'/$5OH4]V(]&32K_ $])8_.C"D,LB_-M/S \9Z8_#5\46VO:SI_A
M^8Z/+YT.MVU[);1R1EK>",\[F+ ,W?"YZXYQD]Y37=(UW.RJO3+' H XZUM-
M1A^)FK:LVF7/V&73(8(Y04^=T9V( W9_B'45RMEX8\1V/@'PK+%HXEU70;F6
M2;3;B1,7$;EPP5LE<[7!&?\ ZU>MET$@C+*'()"YY('4X_$4.Z1KN=U5?5C@
M4 8.@&?4K>XEO/#ZZ3;2H(Q;2A#+)UW%]F0%Y  SGKG'%9G@/PYJ6A1W%MJ3
M!X;!WL],8G)^R[MX8^YRBX_Z9"NSHH \P\*Z?K^@6B>%[GPK#<FV=H[;62T9
MA:$L2KN#\VX XV@<D=1UJS966N^'=2\5Z<-&N=0L]7N9;ZTN[=X\*TB -'(&
M8%<$#!&<C\J]&HR#T- '.> ;.]T[P)HUAJ-H]K=VUJD,D3LK'*C&<J2*P+73
MM3AOO&\T_AZ2[M]1N(7@MY6CVW401(W7[W!P&QNQVKT+(R1GD49YQ0!P_@OP
M_=:#KE]'8?;X/#3VZ&"SOGW&&?<=PCR20@7'7C)XS5C7[*_A\>Z'KL-A-=V5
MM:W%O/\ 9]I>,N4*G:2"1\IZ9/M7844 >8ZQX,UG4;?7-=M;>)-5NM1M;ZVL
M)V7:R6RA520@XRXW'K@9 SUQT>A7FHWL<UU-X3;1UC@93$YB:6:0XX3:<;1@
M\G&<CCBNKHH \FTOPOK]AX3\$7:Z=)_:7AV9_M%@9$W2Q."KE#NVE@#D D9Y
MKK;'2KC4/B"_BB6VEM8(M,%A#'-@/(3)O9B 3@#  SR3GC&,]4CI(NY&5ADC
M*G/(.#3J /*Y?A]J<VC:_I652WLIY+CP\5/,;L5F!]MKC8#Z%_6N_P##MI<V
MNBPF_"B_N,W%WMZ"5^64>R_='LHK31TD7<CJRY(RIR..#1YB>:8]Z^8!NVYY
MQZXH R/%L-S=>$=7M+.VDN;FYLYH(HXRH)9D('+$ #)JOX-AN]-\":1:7ME-
M#=V5E%!+ 2I8LB '!!P>1QS70T4 >26_A[7HOA1X?T5M&N?[0L]1BFFA#Q_*
MB7!D)SNP?E/KUKJM&L]0B^)7B#49M.N(K&]MK6.&=BF"T8?<,!LC[PQQVKL:
M* /,M#L-?\.S7?A]_"D6H1&ZEDL=5+Q^6(Y'+_O@?FRI8] 2>@]:=XG\-WNH
M:I>:CI.G7NF^)()(TLM2M758KJ,!?]<-V"H^8$,,X48STKTNB@#C-.M-1M/B
M+XBU273+@V=S9VT4,JE,2-'OW #=D?>&,XKEM"\+^(-(T+P-J)TR4WN@&X@O
M+#>F]XIN"Z'=M)'!QD9KURF[T\SR]R[\;MN><>N* .+&CWEUXFUOQ,;*>(2Z
M4NGVMLVT22X+,S$9PO)4#)SP<XXKG;7P_P"(=*T/P'JD6DS37?A^.2"\TX2)
MYCI(@1F0[MI(QD#/->L4UW2, NZJ"0HR<9)Z"@#B_#MOJC?$+7]6N='NK2QO
M[6U2&29X\@QA\@JK$@_,.F??'2D\?:?J>HZGX6;3]-GNH[#5HKRX=&0!(U!!
M^\PR>>@KMZ* ,KQ%I1U_PMJ>E(_DM>VDD*LP^X64@9_$US/A6?7I$M++4_!\
M>GW-HH%S?;HFCDVCK$%.XEL=\ 9//8]P)8R'(D7"'#G/W3UY]*<K!E#*05(R
M"#P10!Q_@&SU#2],UA-0TZ>V>75+J[B5BC%XY'++C:QYQV-<U#X2UO4OACJN
MBM9R6&IG49;ZV6=T*O\ O_-0$JQZCCV->J*Z.6"LK%3M;!S@^AIU '%7MG?>
M*M8\-W<^EW.GQZ7.UY<"<KGS-A58TP3NY.2>F!ZFE\%6>I:9I_B(7VEW,+W&
MK7=Y A9"98Y&RN,,0#['%=I10!Y/#X?UV+X5>&-&.C7)U"QOK>6XA#Q_*D<N
M]CG=@\=,&MW4;+76^(=YJVG:?(JGP\UI;7$I38+GS"ZAANSCISC%=W10!Y58
M:7KTFO>#=7F\.7HN;-9X]3GN;B)I7D>+;OSN/[O=G '0'A>F7/H>MR>!?'6G
M#1[D7>JZC=36<9>/]XDFW:<[L#H<YKU.B@#SAK?Q#X>\5P:]9Z'<:C97^FPV
MEW:Q21K/;RQYVG#,%*D,1P??ZS>);#Q$][H/B:+1H=0GM!/%=Z4)%+>3+M(V
MLWREUV+GU.<<5W\<B2KNC=77)&5.1D'!IU ''S:YJFC^&;G6E\*-'AU/]GQR
MQI*D0^]([#Y<]?E&> .>3CK%;S[<, 5WKD!A@C([TD]O#<H$GC61 P;:W()'
M3([U+0!Y%#H7B)?A1I/AY] N1?6%Y;[P)8B'6.;>S*=_W< 8S@D]NYZ#5=#U
M#6/'M[*;*XATZ\\.2::;HE,)*[ENF[/ /7'6N]IKND:EG=54=V.!0!Y_X0&O
MPP6&CZEX1AM;FQ"1S:INB:&1$P-R8^8LP'3 P3D],5O>/;2\U'P-K&GZ?:27
M5W=VSPQ1H5'S,,<EB !7244 97AJ.>'PUID%S;26]Q#:Q121R8)#*@!Y!(/(
M]:\XU_2/%&L:5JL-YH%S>:E%JJ36UQY\7E&V6965806^5MHYR!GG+$X%>MLR
MHI9B%4#)). !0K*ZAE(92,@@Y!% '$>.].U":/1-:TEDM-=M[E;>,/\ ,&2?
M".AQUVY#_P# ":7Q'X:N[27PIJ.AV[7/_"/RE6M X#RP/'Y;E22 7 YY(SSS
M6Y!X;TN/Q/<:UYEQ+?/AO+DN6>.$[=NY8R<*2 1G'KCJ:VZ .'F\/W>N^*-3
MUTV\EG')HC:5;I/@.[.S.SD G"CY0,\_>XZ9Y^"P\1SZ!X&LCX:O(Y-#O;<7
M>^:$;A'$Z%D^?!7ODD=0 #SCUBB@#C_#]AJ>F^._$[S:=)]BU&>&XAO!(FS"
MPJA7&=V[</3&.<],P?$73M3U/_A'$TW39[O[%K5M?3F-D4+%'NW?>89/(XKM
MZ* *&H)=-I5[/ID:)J;VK" R@??"DH&]@Q_4UYUI^E:])K_@W5YO#EXMS:+/
M'J4]S<1-*TCQ!=^=Q_=[LX Z \+TSZD'1G9 ZEEQN /(SZTZ@#SGPG'XI\,6
MDGA0Z&\\4,\OV/5A,GD^2[E@T@SNW+N/R@<X[#FK4V@ZE+XS\61/92_V?KUA
M# E\CIMA*QR(VX9W9^88P#]17>4WS$\WR]Z^9C=MSSCUQZ4 >9MH6M:Q\,[;
MP/?:9+;W48@M)KO<I@$,3J?-5LY)*H,+C.X\@#FM[1K'4+?XE>(K^;3YX[&\
MM[6."X9D*LT8?=P&W#[PQD5V%% &-XN@N;OP?K%I9VTES<W-E-!%$A )9D*C
MDD #)KD;C0]973/ ^K6^GRM>^'U6.ZL&= [HT(CD*'.TL,9'//->CT4 <'?:
M->ZGX@UCQ(MA<1[M#;2[6W?:))F9F<L1G"@$J!DC^(],9W?!%K=V'@C1K&^M
M9+:ZM;.*"6)RI(95 /*D@CBM^B@#CKZQU.V^*5KK,&FRW5C+I)LGDCD0>2_G
M!\L&(.,9Z G/:N9N- UV;X;^,M*71KD7NI:E<SVL1>/YTDD#*<[L#@<Y->KT
M4 ><7]IK.C^+WUR#PT^LZ?J=G#%/;AHQ/:RQY (#'!4AN<'K^O=:2MPNFQ&Z
MM8;69LL;>'!6($DA<C@D#&2.,YQ5VB@ HJ-IX4F2%Y8UE?[J%@"WT'>I* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KA_B_%&_PNUN5D4R11*T;XY0[UY![5W%<G\2
MM,U'6_ 6IZ3I=D]U=W:*B*KH@'S*<DLP[ T <E(EM!XU\(KX+*AVS_:R6)S!
M]GVCF4#Y0V<XSSG\*Z35/B3IFF6[7[1K)I<=S]FEN$N$\Q3OV%Q%U*!N,]>X
M!')ZK3#*=,MA/;O;RB-0T3E25('JI(_6N"\/67BOPVLWAM= @O+19Y&LM7-P
M@1(G<L/,0_,67<> .>G'6@#:F\;S_P#"0:EHUEX=U"\N+ P&0H\0!27/S@EN
M@ SCJ>>!@FL&%1XD\<^+].\0:5'/IT-O:PL)IEQ;1E'<D'J"3SD8(P/05NZ+
MI^I6WQ'\1ZC/ITL=A?06L<%P9(R&,0<-E0VX9W#''Y54L]#U&Z\5>-#>:?/;
M:?K4$$$%SYD9X6%D8D!B1RW''Y4 6?\ A-[6PT73]6DT^>+P]<,D45ZTF61&
M.U)'0\A&XYR3R,@4^[\;3Q^(-1T6R\.:A>W5BL,C^6\2ADD)&X$MT&.AY/IP
M36!_PCNNZE\-8? NH::T4L8BM)+]9$,!@C=3YB_-NR44 *5'S=<#FM[2=.U*
MV^)6N:C+ITJ:?=VEO##<&2,@M'OS\H;< =PQQV[4 5YOB'(+'7+N#PY?RIHM
MP\5V#+$I544,S#YB#P20!GISC(JY%XW235](MY-*NX;'6 197KLF';9O * [
ME!4'!/Y"L.#1=;70O'ULVCSB;6+BXDLU\Z'YQ)"L:Y._CD9.>U27&CZT\'@)
M5TB<MI+HUZ/-A_=@0F,X^?YN3GC/'Y4 :UWXY2SWW,FF3C38]2&F/<,VU_,+
M!-X0CE-QQG.>^*?<^,9U\1:AH5EH%[=WMI;I. )(T216) (8M@#COS[=37':
MSH'BO5-,OX[O0C>:G%JR7$-VUU%M>W6965(06^3"CD';G!.2>*ZBPLM6A^(N
MJZQ/I,RVEQIL$".DT39D0LS #<#CYL D#IVH N6/C:RU/0]&O[.WF>?5RR6M
MJQ"MN4'?N/0!=IR?RR2!0GC."&RU"74K&XLI[&Z6T:-\;9G?&SRW. RG<.3C
M'.<"N*TWPOXIT?PSX3OK;2M^K:#/=>=I\D\8^T0S,V[:X8KN *D9QW_'HO$.
MG^)?%'AG[3'8Q:?J5K=P7EC8SRJ^YHFR1(R_*-V2, D# YY. #4T;QE;:GXD
MN= EB2*_BMQ=(8IUFCEB)VY##&"#P00/QK(\7:C<:AX]\.>#TEDALKQ);N^,
M;%6EC0';'D<A2P^;U''K6WX=O=;U&0S:EX?718TCVF)YTE>1R1R"G 48/7DY
MZ#'-/Q5X;O+K7]%\3Z2J2:EI3.K6[MM%S XPZ!N@8=5SQGK0!F_$'3+?PSX3
MN/$7AZVM].U+2RDR-;QB-94W -'(%QN4@G@]#@C%9JZHZ?% :KI6BRWEQ?\
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MX>!KFV:Y>-DGC7[QW(2 PZE<]*KCXC:<+O2/,A L=6F6"UG6=&<.PRGF1CE
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M(&<=?SH U=%\22:R+">*P(L;^W-Q!<I,'  QA7 'RL=W0$C@\U<UK6/[(CM
MMK+<SWERMM"B#C<P)RS?PJ I)//TKC_#OA>YTWQ79:EI6F76AV<T4AU:P:9&
MMWD(&WRU5B =V3D8&!V)Q6WXTAUR6'3/[)MI;NU6\4ZA:P3+%++#@\*S$#&[
M!(R,CCIF@""7QVL.AZ[?MI,[SZ',T5[;12*QP%#%T8X##:0><'@\5;?Q<B:]
MHFEFS)76(&FMKE908SM4,R^I.""/6LKP?H-]8:MXHAO]%AM--U&=98525&1D
M,2H4VKTZ'.0!Z9ZUA+X#U^'PG'MDCEUO1+M?[%9VX\B*1MH;G^-&((]%3TH
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MC<J2K*H!Y4D=NQH \T\.>()?"=CXLDM?#MY>V%KK]Y)</:F-5@C&W.U206P
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M@9(U11;JS'+$9)Y.!DGVKL)O&-@;;3'M3')+J5K]LMTGF6%1%A3N9CG'WE&
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M2Z1.&5CMD^8' SGW .:]"H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M).>@[]* .IHKE)/'5O%H^M7S:7?M+HLQBO;6((SJ H;>OS ,NT@]<]>*TO\
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MS2(K9I%D3%O(LK,P?YL]&'W<Y/YUVE% '*?$33+[5?"ABTZV:ZN(;NWN! C
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MA.U1$R9^_P G+9P,\>_%;&O6.N:1XX/B#3-%76[&]M$M;JV61$EB=&8JZ[\
MC#D$?C0!?TWQ_IVM6.D2Z;$7N-4,JQ03N(RK1?ZP,>>1D8 SG.>F370Z9>OJ
M%@EQ+:RVLA9T:&4@LI5BO;@],\>M<GKFC/KMA86NN^&A/;2>;*XLY%$MA)E?
M+VMN4DXW9*YY]16SX+L=6TWPS!::S<S7%S&\@1YW#R^5O/EAV'!<+C)'?N:
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M#YSCO70ZA\1],TZ%+YXM^E&Y^S/=).FY3NV;_+SDINXSU[XQS766;O)9Q-+
M\#E1NCD*EE/H=I(_(UYYX:L?$_AZ!O##^'(+J"&5Q::R9H_+$+,2#(A^8LN>
M@'. ,CK0!N2>-Y6\0:CHUGX=U*ZN-/D@68HT8 27.'!W=  #CKUX&#6!"D?B
M;QGXQL/$6E++IT$=K$3-*N+6/RC(2"#D$DYRO(X]*WM"L-2MOB'XHU"XTZ6*
MQOTM1;SEXR&,2,K9 8L.2,9'Y52L]!U&\\1>.$O+">UL=<BBA@N2\;<" QL<
M!B1R>./RH N_\)O:V>EZ;J<UA<0Z%>/'%#>LX)0-Q&\BGE4;C!R3R,@4MSXW
ME37]2T:S\.ZE>75AY#2>6T8#)(3\X);H,=.I]!@FL%O#^N:O\-K7P1J&F/!-
M$(+6:]$B&$PQ.I\Q>=Q)5  , Y/.!S6[H^GZE;?$CQ%J,VG31V%[;VT<%P9(
MR&,0?=P&W#.X8R* *\WQ%*Z=K5[#X=U&6+1KF2&\&^)2BHJLS#YL-P2< G@<
MXR*O1>-8Y-:TFSDTN[AL]6#?8;V0IMD8)OP4SN7*YQD?A7/Q:)K8\->/[-M'
MG$^L7-U)9+YL7[Q9(51<G?QR,G/:K%SI.LR'P$5TB<_V4P:]_>Q?NOW)C_O\
M\G/&>* -2Y\<Q6I-P^FW TY=2&F-<$A6$I;9N"'JFXXSG/?&*?<^,I4\0:CH
M=EH-_=WUG D^%>-%D5B<$,6P!\O?GVZFN.U?0_%6J:;=+>Z!)>:I!K$=Q%=-
M<Q;'MUF#*L(+?)\H&0=N<$DD\5U&GV>JP_$75]8GTF9;2XTZ"&-UEC;=(A8L
M -P/\6 2!T[4 7;'QM8ZGHVC7UE!-+/K&X6MJV%;*@[]QZ +@Y//;&20*(O&
M=NEA>S7]E<V<]I>"R:&0#$LC$;?+<X#*<@Y.,#).,5P^E^&O%.B>'O".HV^D
M&34M"DNH[G3FGC!FAG8DE'#%<C"G!([UT?B/3_$GB;PU'>0Z?%9:C9WL-[9Z
M?<2JV_R\Y61A\H+!B, D# YY. #7T;QA;:KXAN]!EA$&H6\"W("3++'+$3MW
M*P]#P00.HZUSOQ;AM/L_A::Y6)5;Q!:PS2/@ Q'?N5C_ '3CD'BND\.7>K:A
M(;B_\.KHD:Q[?*>5)))')'(*<!1@]>3GH,<YGQ#TS5-6'AU-,TV6[^Q:S;WT
MY62- L<>[<!N89/(XH Q=(N(K+XIW9\/SG_A%HM,,FHF-RUI%.&.-A^Z&VXR
M%[9SS6^OQ!L1J&DP36S);ZLWEVDRS(QWD959$!RFX=.OH<5T.K6']LZ!?:<Q
M:'[;:R0$GDIO4KV],UR/A-O%$-O9:/JGAB"VEL@D<NIK-&\<R)T**/FW,!WQ
MC)/M0!>TSQQ-J]]/;V?AO4W2VOI;&YE+1 1.BYR?GP<GC@D#C)Y%0Z!XGT.S
M\'IJ%CIDMC;SZA);0V0"^9)<-*5P.<9+9/7 &><"I? ]AJ6F?\)']OTV:W^U
M:O<7MONDC;S(WV[?NL<'Y3P<5S%OX0\0-X(LD6P,&K:5KK:M#;2S)MN%\UVV
M;E8@$JYZ]_SH [BV\41CQ VAZG:M87QMS=0EI \4T8.&*MQRO<$#UY%<5X^U
ME=>\)Z9J$&ENUA+JEJ;6\9EW8\Y?GV]0K <'.>1D#-;>I^'[KQ?X@M=0N+6X
MTVWM-.NK9/.*>8\DZA#PK'A5!ZGDGCUKG9M,\63?#O3_  O+X;F:]TRXM5\]
M+B+R9HHI%(926W9*J."!W^E 'K=%9UM?:A+K,]I-I3PV:0))'>&96$CG.Y-H
MY&/7H:T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/J7A
MV'4M3@U W^I6LT49B*VMTT:.I.<,O0_7@^];%% $%G9V]A:I;6T8CB3.!DG)
M)R22>22222>23DU/110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
? %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exc_compmins2-9x23v1x202006.jpg
<TEXT>
begin 644 exc_compmins2-9x23v1x202006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K&O] >^O'N%UO5K8-C]U;S*J+@8X!4_7K6S10!SW_"*R_P#0RZ]_X$)_
M\11_PBLO_0RZ]_X$)_\ $5T-% '/?\(K+_T,NO?^!"?_ !%'_"*R_P#0RZ]_
MX$)_\170T4 <]_PBLO\ T,NO?^!"?_$4?\(K+_T,NO?^!"?_ !%=#10!SW_"
M*R_]#+KW_@0G_P 11_PBLO\ T,NO?^!"?_$5T-% '/?\(K+_ -#+KW_@0G_Q
M%'_"*R_]#+KW_@0G_P 170T4 <]_PBLO_0RZ]_X$)_\ $4?\(K+_ -#+KW_@
M0G_Q%=#10!SW_"*R_P#0RZ]_X$)_\11_PBLO_0RZ]_X$)_\ $5T-% '/?\(K
M+_T,NO?^!"?_ !%'_"*R_P#0RZ]_X$)_\170T4 <]_PBLO\ T,NO?^!"?_$4
M?\(K+_T,NO?^!"?_ !%=#10!SW_"*R_]#+KW_@0G_P 11_PBLO\ T,NO?^!"
M?_$5T-% '/?\(K+_ -#+KW_@0G_Q%'_"*R_]#+KW_@0G_P 170T4 <]_PBLO
M_0RZ]_X$)_\ $4?\(K+_ -#+KW_@0G_Q%=#10!SW_"*R_P#0RZ]_X$)_\11_
MPBLO_0RZ]_X$)_\ $5T-% '/?\(K+_T,NO?^!"?_ !%4]0\':E<11K8^,M<M
M'#@NS-')N7N "HP??]*ZVB@#F+7P6ME:QVUOXAUV.*,851<)_P#$4L/@T6[2
MM%XAUU6E?S)#]H3+-@#)^3T 'T KIJ* .>_X167_ *&77O\ P(3_ .(H_P"$
M5E_Z&77O_ A/_B*Z&B@#GO\ A%9?^AEU[_P(3_XBC_A%9?\ H9=>_P# A/\
MXBNAHH Y[_A%9?\ H9=>_P# A/\ XBC_ (167_H9=>_\"$_^(KH:* .>_P"$
M5E_Z&77O_ A/_B*/^$5E_P"AEU[_ ,"$_P#B*Z&B@#GO^$5E_P"AEU[_ ,"$
M_P#B*/\ A%9?^AEU[_P(3_XBNAHH Y[_ (167_H9=>_\"$_^(K3TS3FTV!XV
MO[R\+-NWW3AF''08 XJ]10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7$^.-2U73M=\+0Z?J<UK#J&HBUN(TCC8,FTG@LI(/%=M7G?Q'N
M[>+Q)X)5YD4Q:NLD@+?<3:1N/H,D<F@"[XA\2*OC'3/#1N;N""6WFEN98(W$
MA90@0*RKT^8DD=P >X.AJ.JMX%\#2WNKWMQJDMG&W[_R</,<G8&"\#C +=.,
MFLG5;ZU7XQ:!FXB 73+E2=PP"S(5!/J0"1ZXK1^)L$MQ\-/$$4,;22&T8A4&
M2<8)X^@H S=:\220^+/!]PFIS6^EWANOM4,B>6C;(2P)W*&ZGUP>.*ZK3O$F
MCZMIL^H6=_$]I;LR3R-E/*9>6#!L%<#GFN)U75M.U'QC\/;F"=)( UTV]A@#
M,&%//8MP#W/2L34O/NHOB$-+1KJ2/5;.[^SP.0T\48B,@7'/\##CN,=: /4K
M#Q!I>I7TMC;7)^V1()'@EB>)]AX#!7 )7/<<5SOQ)U/5-(TS2I]+U*:S>XU.
MWM)-D<;Y21B#]]3@^E1>&+[PEXCUZWU?1$O;N^AMVCDN9Y;@_9T/_+-O,."Q
M/\(ST)^M7XOS6_\ 8FC0RR*"=9M79-W.P,=S<<@ =Z +,6N:MHWQ/M/#%U?M
MJ=C?V+W*2S1HDULR$YW%%52IQZ9SW]>CM/%.BWUY!:V]\KRW*NUN2C*LX7[Q
MC8@*^/\ 9)XJ)=(TG2[:_P!6L-.2ZN9;=BT@8RRW"@9";V))![#.*\RT_6+.
MZU'X>7\<S"*.6:.2TM[5EALF:W8"$87)8'@Y))QG !H ](;QYX7%P(!K-N\I
MN&M@D89R90NXJ, Y.#^)XZUE1^-=)\0^!;S5'U2?1+=C+&+LH4>,"1T5E+#!
M8A,X&2,XZU#\/9;2;6/&6QHGD?6Y)5(P2R>6@##U&=PS]:Y*"[A7]GW6=+<L
MM[;"[AEA9""LC7$A5>1RQ!!P.: /6I]5LM.@MA<7#NTJ?NE6-I)90 "2$0$G
ML3@<9K)U37M%O]'TV[A\2?8[>ZNXA;SV[#,[!P/*P03R>",9'>N8O-?MO#?C
MO2]:U1V70KW1$M(;U5+QQ3"3<58KG&X8Y[[1Z<)XPFTM?!^DR:?9I8V<FNVT
M\2>5Y1D7S@SR[, @'D\]L'O0!V&H^-?#>DS74-[K%M%+:A3-&"69,YP, $YX
M)QUP,U9'B31VTNTU*._BEM+Q@ML\67,S'/RJJ@ECP> ,C!]*Y&'4=,LOC)K,
MM[<VT ?1[;RY9F"J1O<D!CQSP<=\>U<[IC)X9TK2/M-HMG8W^O7D]G>SP$_V
M? P;R\*1A6<<#/ W9(- 'I4GB_P_#HTVKS:I#%8P2&&623*E) <%"I&X-_LX
MS3[7Q3HE[J<^FVVHQ2WD$9E>)0<E <$J<88 \'&<&O(K^YA'P[^)5F7N'GEU
M5Y(Q/$RO(&$.TX*CDX)Q@=#Q@5VVIW=DWQ3\'M;SPF/[#=H"C#&&$>P<>N#@
M>U &_P"%O%EGXJ@NIK6.9%AN)(E$D3J2$;;DY&,D@\=1WK1U#5K+3V2&XG=9
MIE8QQPQM+(0.K!%!.!D<XQR/6N3^&-S&FGZOIK;UN[?5KQI8V0C8&E)7)QCD
M'(]:KW&K1>'?BY>W&N2_9['4-.ABL+J7B(,C,7BW= Q+;L=^/:@"KH?B)+WX
M?:M=ZOXJGM(O[4GAAU,%1($64; HVXY Q@+W-=]J.L6.E ?:YG#%2X2.)I7V
MCJVU 3@9&3C S7CEW=02?!KQC$@96?6IS&C1LI;-RK# (YX!.!TQS72ZYK.G
MZ%\1)+_79KN+1M3T^&.SO[>:41*Z,Y*,8SWW@C- '=#Q#I3V5I>0WBW$-V"U
MN;=&E,H'4JJ D@=^..]6[&_MM3LX[NSE$L$F=K@$9P2#U]P:\VO-*T.WL="C
MT/4+CPO,GVJ?2[F8DHREDWK(LIZ/D,%)!XSP>*Z_P1?WVI>%;:YU*UAM[II)
M0_D B.7$C#S5!YP_WAZYS0!<O_$VCZ9)*EW>B,0E1.^QF2$GIYC@%4SD?>(Z
MBF:GXKT'1YT@U#5+>"5XFF5"V24 R3@?Y/:N'T2]M]+T;QCH/B%@E_+>W<JQ
M2?>O8I1\C1C^/(^7 R00!573;632/$'PQT_5I$^VV>FW4<P=@3$[1QA%)['@
MJ/7!Q0!ZA;:G97>EQ:G!<QM8RQ"9)\X4H1D'GIQ61H6K:;;^%[*Y77)M5MY9
M'CAO)%WR7#;VX"JN6QAAP.BYZ<UON\=O"7=DCB1<DD@*H'\A7CWAZ+3KOX4^
M&;>XU:;2+N*_G-K?1$#[--NF(W@\;60D8.,[AZT >LZ?J5IJD#S6<ID1)#&V
M492K#JI# $$52UG6["QBGMI;Z2WN!"9&:"(R-"G(#MA6"KP>6&.#Z5F^ [_4
M[_2KW^U1:R3P7KPB]M5VQWJJ%Q*![_=..,J<5@:5K-OH7CCQ=8:_(8+C4)TN
M+%Y%)%S#Y84(G'S%2"-HYR3Q0!)X:UP7_@#PC<ZQXCFM+^\N(B'5EWWC[R/*
M(P?E;(!QC&.HKL;WQ#I>GS217-RRF(J)66)W6,MC:&900I.1@$@\CU%>2V%W
M OPJ^'2N^QHM:M&<."I55D8LW/\ " 1STYK8\43R:;K6MZIX=U:-[SS8EO\
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M7+W<?V%-1M)I H=4+F-T8@ '# $'&<'G-4?&GC&\\/:_I/D(#I,%Q&-7E/\
MRR2;<D7X!@6/_ ?6H?#6FM8ZSK7C;69KF&"2!;:T-\W[U;9#DNXP-I=N0@ Q
MQQDTD/AS_A+?!NH7%UK,D4&NJUS/&J1,D60 BDE20454!YZJ>E '<W\%Q<6;
MK:7'V>Y'S128RH;MN'=3W'Y$'!JCX8UV/Q)H%OJ21^5(VZ.:$G)BE1BKK^#
M_48-87PP\1G7O!]K#=R@ZG8C[+=*3RQ3Y0X]0P .>F<U%\+(G70M8NB#Y%YK
M=[<6_O&9-H(]LJ: ->_\>>%M,:Z6[UJV1K5U2=5)<HQ!(!"@]ASZ=\59N?%O
MA^S2R>?5[55OD,EL=^?-4*6W#'; /-<CI>H:18_$WQX-3GM8?,2R'[\@;T\C
MY@,]>W'TKG-,L?[#TKX;V>I 0-'J<]QY,_#0Q.)3'N!Z8W)UZ'CM0!Z%;^(=
M%UO6M$GT_P 1D^=%,\-E$?ENEQ@LX(R-I4XZ<UHWGBC1M/FDCNKY8Q$XCEDV
M,8XG.,*\@&U#R.&(ZCUKF_$,T$?Q7\&)OC4I#?!AD#:61-H/ID@X]<5@:3=0
MV?@#Q1X9UL@:UYMZIMG'[R\,I9HWC'5]VX $=QVH ] U3Q=H&BW+VVHZK;P3
MI"9VC))81C'.!GU'UJS<ZW8VN@-K9E:2P$ N!)"A<LA&00 ,G(KSW3(#IOCG
MP18:G-&][:Z!);S%F!VRD1C&?4@-CUYKT+7H7E\-ZG#"A9WLY41%'))0@ "@
M"CHWBRPU/PO9:W,QMH[B.-BCHP.]P"$7(RYYP-N<]JT-.UG3]6:X2SN-\MNP
M2>)T9)(B1D;D8!AD=,CFO++74-OAKX;ZNGF2:5I!2'4L1MB%S!Y8=N.B,3D]
MLUU6FQ+J7Q8N=<TR5)=-71DM9YX6#1RS&4LH!'#%5')'3<!0!KZ[XNLM"UO1
M]+GCF:749'&Y(78(BHS$\ Y.0!@<\D]JY^R\6Q:-XR\7Q:[K,GV"U-H;995R
M8U>(LV%1<XSU..!C)J?QO/'8>,O!.H7.Y+2&[N4DE"%@K/ RJ#@=SP*SK"[L
MCXS^(TKRQ!7MK4*SD#($#!ASZ$@$=CQ0!WLNLZ?#96]V;D/#<@& Q*9#,"-P
MV*H);CG@'CFETO5[#6K/[7IUREQ#O*$KD%6'!5@>5([@C->0:=J,6C:)X"UC
M5/M?]B1:7)8W,UL\BFTF;RR"_ED,!\FVO2/!\.B?9KZ]T"VF2TO;@S-<2O*?
MM,A W2 2'..V>Y!^I -#5/$6E:-O^W71C$:"24K&[B)#T9]H.Q>#RV!P?2HK
MKQ9H%E<1V\^K6RRRP_:$0/N+1\888SUR,>N>,UP=WJ6D:-XT\2Z=XN-]!!JD
MB36<R23B*YB,*QM%B,\L"I&,9.?I5E(M.T_XA^#+6WMQ96]OI=RD5O,Y9H V
MS8K%B2&(!X)]10!W%EXCT?4-&?6+;4(6T^/=YD[':$V_>#9P5(]#7,+XBDO/
MBOI^GVNH71LI-,FFELY83$%8,@5L,H8@@GDY'7%<7<S2G0/$-S9HUS;6GC,7
M]Y!"-S26JLC,0H^\N1GT^4^E=.->TK6/BUH%YIMTMU;OI5S&)H49EW%T(!('
M!X.0>G?% 'I%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%5[V^MM.M'NKR988$QEF]2< #U)
M)  '))Q0!8HK+M/$6F7UQ<VT,TGVJV022V\EO)'*$/1@C*&(.,9 //%<?H6H
M7'C2^U*9-3U73[BPU>2.#RHI$B,$14%'5@$);YB0WSC/8#% 'HE%<YKGB^VT
M3Q%H^CR6]U))J!D)>.VDD"HB,W&T'<V=O S@$DXXKGK#Q;!H7BSQC'KFK7+V
MEI/;^0KQM*8D:$.Q"QKPH+<G&!QDT >B45GSZWI\%K;7!G,D=TN^ 01M*TJX
MSE50$D8YR!3M)UBPURQ%YIMRL\&YD) *E6!P592 5([@@&@"]17 ZI<:I-\6
M+30X=:OK6PGTJ2[:.$1DB02;0060\8/3VIW@KQ9>7!\2VFN7D<\>B7QMDU#8
M$\Y3T!"C&\' (4<D@8]0#O**Q$\7:&POM]Z87L$$ES'<0R0O&AZ-M=02ON!B
MLRZ^(F@MI-_=:9=M>3V]A]M5([:4AD*DJ20O3(P?[O?% '745P?AN]1M,TKQ
M->:YJ2">TCCNK6XCD,=Q<2*K Q(PSG)( C&"/I72P^*-&F@OIA>",6'-VDT;
MQ/"",@LC , 1T..>U &O17*GXD^$1;R7!UE!#';+=,YADQY;' (^7DYXP.1W
M%6CXW\.B_>Q;4@MPL9E"M$X$B@X_=DKB0Y(&%).: .@HK$M?%VA7FC7.KQ:@
MHLK60Q3O)&\;1."!M9& 8-DCC&3D8ZU)#XHT><WP%TT3V**]S'/"\3QJPR&*
MNH.#@\@4 :]%<[:>._#5]<V$%MJ:N]__ ,>S>5($D.,[=Y7:&QSM)!]JM:GX
MIT;1VF%[=L@MPIG=(7D6#=T\QE4A,]?F(XYZ4 ;%%9E_K^FZ:@:>9WS%YV+>
M%YV$?]\B,$A??I5NPO[74["&^L;B.XM9T#QRQG*L#0!B6GAV[M_'-_X@>\@>
M&[MH[;[.(2&0(6(.[=R?F/:NCKSNSDUG4_B%XKT<>([^UM;""VDM?+2%O+:1
M"6SN0[AD=#5SP#XTFUKP1!JNMLBW'VE[4201DBZ93@,B*"22 > #T/;H =Q1
M7/R>./#D.DW>IS:DL5M9R^3<>9$Z/$_]UHRN\'\*H:KXK\.:C:/"OB*>R\B^
MAA:6U#*S2;@50$J=RMP"1D$'K0!U]%9U_KFGZ;/Y%Q+(T_EF4Q0023.$SC<5
M120,\9-(/$&DMHT6KI?126$VWRIHR6\PDX"J!R6)XV@9SQB@#2HKA=#UN74/
MBGK-G'?7DME%IT,@MKB-HA#(7;.$95/0*<D<YZUW5 !UHKDH_%L.LZKX@T2V
M6^M9=/C5!<?9G4[RC,3EE*J,;<;L9Y(SP:SO ?C;3Y_"_ARTU35'DU:^@ WR
MH["23D[3)C;NQ_"3GVH [ZBL?5/%&CZ,9?MUT\:P[?.D2"21(<]/,95(3J#\
MQ'!!J.[\8Z!8Z@UA-J*?:Q;_ &D0QHTC-'D#*A0=Q.1@#)/IP: -RBJ.D:O8
M:[ID6HZ9<K<6DN=D@!'0X(((!!!!&",UD?\ "6V\WC.X\,I#>)+%:K*TXMG(
M#,V%P=I&!@_,?ESQG@T =+17G'@GQM96N@11:]K$LEY+J-Q;K+,K/_RV94#L
MHVIG  S@>E=IJGB#3='W_;)I08X_-D$,$DQC3GYF"*=J\'DX'!]#0!IT5#:7
M=O?V<-W:3)-;S('CEC.593R"#7GFGRZUJ?B_QKIP\3WUI#I1M_LC;(66/S(B
MYW[D.X CUZ=^] 'I-'6O(+?XCZA>>"/"NK:O(^F6>H7<EOJ.H6T?"A-P0C(.
MT.P&3CC!QCMWFEV=X=1,T&N37^B7%IF!BZ.8WW#D2*,L".F<XP>>: .CHKB?
MACJ&I:MH%Y=ZIJ$]Y,FH7%NK2!0%1&V@84#\ZT=/NVL]6\1SZAJ<S65E*@19
MBNR)3"CGH,GECUS0!TM%4+'6;+4;J>UMVF$\"(\D<UO)$P5]P4X=1D':W3TI
MU[JUGI\L4,[R&:56=(H87E<JN,MM0$X&0,].1ZT )JFEP:K;QQREDDAE6:"9
M/O12+T8?F01T()!X-7(PXC42,K. -Q5< GV&3C\ZX/Q!XB6/Q3X+O[;5IDTB
M^:Y,J#Y8Y5$#,I(QN)SC /?'&:Z.T\7:%>Z1>:I%J"K9V3M'<O*C1&)AC(96
M 8'D<8YR,4 ;=%9=GKFGZO<75A:W,T=Y#&K21R0/%(BMG:P611D<'G!&17FC
MZSK)^ LFKC6+P:C%<R*;D.-[C[88\$XX&WCC'04 >OT4UW$<;.P8A02=JEC^
M ')_"LBT\5:-?:+<:Q;7;26%MN$LP@D&W;][@KDX[X'&* -FBLF_\2:7ID1D
MNI9@%A$[K';2R-'&?XG55)0<'[P'0^AIS>(M+$-M+'<FX6ZB,\/V6)YR\8Q\
M^$!.WD<^] &I17*WWCO3K;5- M(([JXCU='FCFBM977RA&6!&%R23MX R 23
MCBNCO+RVT^RFO+R9(+:%"\DLAPJJ.I- $]%95CXCTO4;V2S@N'6YCA%PT4\$
MD+>63@. ZC*YXR*6R\1:9J%U#;6TTK23Q&:$M;R(LJ#&65F4!A\R\@]Q0!J4
M5S_BOQ3!X6M;*26">9[N\BM4$<+N!O< DE0<8!) ZD\ &KMQX@TZU\H2/.99
M8C,L$=K*\NP?Q&-5+*,\<@<\4 :=%5=.U*RU>PBOM/N8[BUE&4EC.0>Q_$'@
MCM5#4O%>BZ3+<QWEVRM:HLER8X))! K?=,A52$!P3SCCGI0!LT4T2(T0E5U,
M97<&!X(]<US3_$/PI'$96U9/*6<V[R"&0K&X('SD+A1DXW' SGGB@#IZ@O;8
MWEA<6HFE@,T31B6(X=,C&Y3V(ZBJPUO3SK,FD><WV^.W-R8?*?)BR%W XPPR
M<<9J@_C7P['IB:E)J2):/<&U#M&X/FAMI7:1D$'CI0!0L?#.OQZ:FCW^NV5Q
MI:PB B/3O+G>/&-I;S"HXXR$^F*ZU%5$5% "J, #L*YY?'/AQKBYMAJ!^T6Z
MAVB^SR;W4G ,:[<R XZIFL'QCXGBN_".F:YH6L21VK:I;QO)$?+#*90KJ^X!
MEQSD<>] 'H%%8FC^+]!UZ_N;'3=06:ZMQNDA:-XVV_W@& W+[C(Y%*GBS19+
M^VLA>%9;HL+=GA=8YR.H20KL?\": -J@ #I7.P>.O#5U?QV,&J))<2736:HL
M;G]\HW%2=N!P>IX." <@ULWVH6NFVWVB[F$4>X(."2S$X"J!RQ)X ')H LT5
MEVGB+3+XWBV\TC368!N(&MY%F0$9!\LJ'.1TP.>U<CX5OKGQEC5AJFIV=S;Z
ME,3$L<BP26Z2%!$58;"2 ,D?,#GIT !Z%17"^+_$JZ7XOT?2]3U&72M&O()&
M-Y&0@DG!4+&TA'R+@DYXR<<XS5C48-9T[P[XFF_MRYG@6Q,^GW.(]\>(W)&0
MN&Y .[&<$<Y&: .RHKC_  EXPTN[TOP_IEQJ+2:M=:?$_P"\1SYSB(,^)"-K
M,.21G/7-:LOB[0X+HV\EZ01<BS,@A<Q+,?\ EF9 NP-R!@GKQUH VZ*YW4_'
M7AK1[JYM;[5$CGM0K3((W<H&.!]T'O\ EWJSJ/BO1=)9Q>W;1I&ZQRS"&1HH
M6;& \@4JG4?>(ZCU% &S163J'B32M+,_VJ>0"WC$LS1022B)#G!8HI"\ GGM
MS6M0 45C)XKT5[^VLA>$2W3%;=VA=8YR.H20KL8^P)I-1\5Z-I9N/M=TZI;<
M7$D=O))'"<9P[JI53@@X)'4>M &E>V\MU:O!%<-;F0;6D098*>NWT/H><>E+
M965MIUC!96D*PVT""..->BJ!@"J47B+2Y]0M[".Y)N;FW^U0H8G'F18!W D8
M/4<=>:B3Q5HDFG75^+X"WM;@VLQ:-U99@0/+VD;BV6 P!DDT 5='\.W>F^*]
M=UF:\@ECU4PGR5A*F+RDV#YMQSD>PKHZPVUNSUBPU:#3KV:*[M(RLP,312PL
M5W*=LBY&1R#C![56^'M[<ZC\/M#O+R>2>YFM%>260Y9B>Y- '2T5SFF>+[;4
M_%NJZ%';W2-8")3(]M( SL&8Y.,*N N"<;LG&>*LQ^+-$DN;:!;TC[5(8K>5
MH76*9Q_"DA78QX. "<XXH VJ*J:GJ,.DZ9<ZA<+*T-O&9'6&,R.0/11R:\_U
MKQ=/J/AKPAKMK=W6G1W6JV2W494Q(T<GS,"S*-RX[@X//6@#TNBLG2O$VCZW
M+>16-WODLB!<))$\31@@D$AP#@@'!Z'UIMMXIT>[U*#3XKIA<W"&2W$D$D:S
MJ.28V90K\<_*3QSTH V**KWU_:Z992WE[.D%O$,O(YX'8?B3@ =R:S4\6Z(^
MHMIYO3%>JF\P3PO$^W&=V&4''!Y]C0!M45SNG^._#.JS0Q66JQRM-%+*AV.J
M[8R0Y+$ #&.YZ<]#FK=IXGTB]U)=.BN76[>(S1QS021>:@ZLA=0''^[F@#7H
MK$L_%NB7UY:VMO>EI+S?]F8PR*D^S[WEN5"O@<\$\<U5T/QG9ZWJ6LVRPW$$
M>G3F$R3V\D:D*BLS,S#"\G@$@X&>] '2T8K&@\5Z+<7RV2W;1W#PF>-9X)(A
M+&.K(74!P.ORYJ#3/&_AS6;VVM-.U-;B>Y61HE6)P&\LD/R1@$$=">1R.* .
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KB_B1#>_P!GZ+J-K#+/!IFKV]Y>0Q*69H5R&(4<
MG;D-CVSVKM** .%<0ZY\3-'UO2ITEL;'3KA;NZC.8VWE=D>[H2"&8CMCG&11
M\-;B)X_$J!OF?7KR9%(P6C9AM< ]5/KTKNJ* .&\92BR\=>"]1FCF-I#+>1R
M21Q-)M9X<(,*"<DC K*MKB#^W/B9(S*%FBA\LM_RTQ;;"%_O8;Y>._%>G44
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MA0 2.><@8YKU>B@#A?AU)"U[XO"D;Y->GF3C&^,J@##U7(;!'%/^("7=M?\
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MG2Z>%=,YO%NH7@:$8W LK@$ CD''->>)%K$'A;X?0ZV+J:]M]96:5I8V:1(
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M9/F)4LQSC &,8!P3VSD4[0-8T6T\&V5]!J]W?:>[%(+J[+23SL9" ,8W,<Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%<KX_\3S^%_#T<MBB/J5]<QV-F)/NB60\$^P
M)_"@#JJ*Y]?#$BV!4:YJO]I%/^/TW+'Y\?>\HGRL9_AVX_G4D.JC2;'3=.OV
MENM6:T5GA@4R.Y4 .Y]!N/4XR3ZT :&I:;;ZI;I%/N5HY%EBE0X>*1>C*?7]
M""0<@D5:4.(@&8&0+@MMP"?7&:YZ?QUX?M_#YUM[N3[$LWD.P@<M'+NVE'7&
M4.2!\V.M)_PG6BC4IM.8WJW:1>='$UE*&N$SC,0VY<9]/KTYH U]/TV'3_/D
M4F2XN9/-GF;[TC8 'T    [ 5=KF6\?: GAN37I)YTLHIC;R[K9]\4H;:4=<
M94Y('.!R*<?'.BKJ<NG,;Q;M8O.BC:SE!N4SC,0VYDY]/KTYH Z2BN1U'Q5H
M&J^!]2U&:\O[;3XR]O=/#%)'<6[KPRD ;D8<=1CFG7WB^+3?$>A:'%:7DR7L
M#S&?RF?*(HP!CDMEE)/;\> #K**Y;1?&<.JZOKMM+;3VMOI<WEF::(JN @9F
M9CPO7@'G S5ZW\5Z9<:M;:8WVB"YNXVEM!<0-&+A5&6V$CJ 0<'!QSB@#;HK
M E\8Z/#<VL<LDR0W<_V:"[,+>1)+D@('Z<D$ ]#C@FM>_OK;3+&:]NY/+@A7
M<[8)_(#DGL .M "WMJE]87%G(\B)/$T3/$VUU# C*GL>>#7.6'A75;>R33;O
MQ-/=:8D8A$/V2..1HP,;6D';'!( /N*K^+=9%WX-\31VS7]C?V&G/<YPT+KE
M7*%6!YY0]#VP:E\-^+]-N(M%TB26Y^VW-BCQ22P.([@J@+A)",.1U.#0!UBJ
M%4*H  & !VI:YX^--&%Q''YLIADO?L"W(B)B-QG'E[O7/&>F>,UEV\D__"X-
M1LC=W+6KZ)',(6F8HCF9E)49PIPHZ4 =K17&_#.XN+CPS=&YN9[ETU.[C$D\
MA=MJRL ,GG@"M[4=9M+2Y&GD7$]W)$9?(M4+.L?0N<=!G@<Y)Z9Q0!J45P'P
M[UU!X'^VWUY<W'F:E<Q0M,7DED_>L$4 _,3@=.P!S@ UHZI\0-.L=!UN^A@N
M9;S2%_TBR>(K(C%<J6!Z(1SNZ8]^* .NHK%@\16[:;93RQ7/VFZ3,=NL#"1R
M "Q"G^$9ZGCD<\BJ3_$#P[%I*ZE)=RI;_:OL3[K=PT,^0"D@Q\A!/\6!0!T]
M%<LOQ!T'S;>*1KZ&2XN)+:))K&9"SHNX@97TZ#J<\"D7XA:&T%ZRIJ+3V3[;
MBT%C*9XQC=N9-N0N.=QX_&@#JJ*Y;5M<T*]M_#ES)J-XD-]>PO8/:>8JSN0=
MJ.0,;2"25;'3VJ2[\=:+:7VHV)-[-=Z<J-<00V<KN P)! "\C R6Z<CGD4 =
M+162GB/3)M,L;^VF:XBOU#6BPH6>8$;N%ZC ZYQCOBGZ+KUAK\$\EC(Y:WF:
M">*1"DD,@ZJRGD&@#3HKGKB^TL>.;:U>[OUU-+&1UME$@@>+<N6(QM9@< 8R
M>M4S\2?#8M3=>?=FU2Y-M-/]CEV0.&V_O#M^3YCCG% '6T4C,%4L<X R<#)_
M*N G\8:9X?\  NJZWI+ZCJ2)>RI_I(=BDS/M(.[!5%8@8X]!0!Z!161)XBM(
MVCC$%X\[Q&<P+;MYB1@[=S+U'/0=3V!K0LKR'4+"WO;<DP7$2RQDC!*L 1P>
MG!H GHK'@\36%Q=6\,2W#)<S/!!.(3Y4CH&+ -VQL;DX!QQFH+WQCI%@MQ+-
M)-]DMIO(N+M(6:&%\@$,P]"0"1D ]2* -^BN+UJXFC^*/A)8;R?[-=6]X9(5
MF/E/M1"IVYQGYCS[UJW_ (QT?327NI)EM5G%M)>"%C!')G;M9^@^;Y2>@/!(
M- &_12,RHA=V"JHR23@ 5YSXM\21WMWX0ETV?48HKK6K=%E4/'#=0G.1Z,#A
M2,]1R,C- '?W]C;:G8S65W$)8)EVNI./Q!'((/((Y!%/MHI(;=(I9FG91CS&
M #-Z$XXS^7T%<_::KHR^)_$#KJ%X+FSMXFOHK@NL$" .0R!@!R 22,@X%:%G
MX@M+NY%OY=S [6YN5-Q"45H@0-P)X_B'!Y'<"@#2E5WB98Y/+<C ?&=OOBH-
M/T^WTNS6VME(0,SLS'+.[$EF8]R222?>LJ'QCH\U]8VOF3I_:"LUE*\+!+D*
M,G8<<\<CID=,U!8^/=!U*^2TM9;IW:>6W9S:2*D<D8RP=BH"=#UQTH Z:BL&
M/QAI+W]G:,UQ$;X,;.62!ECN<#)"-CDXY .,CIFLC3_&MIKFC^(I;V#4+&SL
MII[9Y$@D#HB*%9LJ#AP2QP.0,>E ':T5@V&M:79>'=%:&XN;B.\@C6R$FZ2>
MX&S<">Y.WDD\#OBFGQGHJZ7J-_)--&FF$K>Q- _FP'&?F0 G&.0>A'.: .@H
MKGK'QKHVH:K9Z?"]PLM[$9;5Y+9TCG  9@CD88@')P:V;V]M].M'NKJ01PI@
M$X))).  !R220 !R20!0!8HK"A\6Z;-=WMF4NX[ZSA$\EH]NWFM$3@.BC[XS
MQQGGCK3=,\8Z/K$.FRV$L\Z:CYAMRL#\A#ARW'R@$@9..M &_16%JGB[2M'6
M>2Z:?[/;.([FXCA9XX&.,!V XZC.,XSSBJVI^/=!TJ^GLII;J2YAMQ<M'!:2
M2$QDX#+A?F'7D9 P>: .FHK U'QEH^EQ7,UQ).;>T*BZGCA9DMRV" Y X.&!
M(&2 03C-,;4-)F\<6=NM]>_VC]@>2.!2XMWB++E^FUCG !!/>@#HJ*Q[7Q-8
M7ES:Q0K<&.[=TMI_)/E2E0Q.&^BG&<9QQD5!<>,=(M9[=9I)DM[BX^RQW9A;
MR&ER1LW].H(STR,9H WZ*YCQ1X@LX=*UFTBDO&GM;5FGELU;-L2I*DLO0]#@
M9(')&#4O@*>:Y^'_ (?GN)7EFDT^%GDD8LS$H,DD]30!T5%<K::[H=IJ'B>^
M6^U%S9F-K^.6.5DM\)QY:;<@%1N)48/6IK'QUH>H7NFVL,ER#J4?F6DLELZQ
M2G;O*AR-I8#J,]B.O% '245#>7=OI]E->7<R0VT"&261S@*H&236,GC'2CJ-
MGI\HO(;J]026J/:2'S4/\0V@[0,C.[!&1G% &_16!>>,M'L5FFFEF^QP3?9Y
M[Q86,,4F<$,P]"<$] >"15V]URTLKJ.T EN+N2(S+!;(7?RP<%CC@#/')Y[9
MH TJ*QH?%6C3Z%_;,=X&LM_EYV-O\S=M\O9C=OW<;<9SVKFM/U66[^,TULLF
MH10C0C(]I<E@BOYZ@.JD[>5P,CW'7- '?45R?Q'\07/ASP3J%[9^:MT4"12I
M&6$99E7<3C QNXSWJ.SN-,T76#)!<ZU+/J,)=-+F,DA41G#2A9.5SD Y(!XP
M": .PHKD=9\1^'M2\)6>IR:C?1:==W$0AGLQ(CEQ( %8@97YAM(;'<5/+XL4
M^/#X8^QW0 LO/>=8FP2SA5P1T4?-ECQG'I0!T]%>9>$?&5EHNC7ZZS>7\RIK
M5S;FYD22=85\W8@DDP0HZ 9->E2QB:%XRSJ&&"48JP^A'(H ?17EW@/Q_IMA
MX+T2'6[Z]>XGDDB>]FBD>,2&9]JO,1M#$8X)X&,XKL]3\8:3I,U]'.\[_P!G
MQI+>M#"7%LC9*E\>P)P,G'/2@#>HK+N=?LK>6.)!-<R/!]IV6T9D(B_O\=CV
M Y/. <&FOXBL?LMG-")[AKR#[1!##$6D:/ .[;V'S#KCD@=: -:BL.#Q=HMU
MHL&JP71DMYY?(B58V\QI<D>7LQNW9!R,<8)Z<US_ (:U.6]^*/B:#S;X0Q6=
MJ?LUTS8A<E]VU2< $8.5X- &Y9^')[7QGJ'B!K]'%Y!' UN("-JH25(;=U^8
MYX_*N@K-O==L=.U;3]-N6D2XU!F2VQ&Q5V52Q&X# . 3S5&?QGHMK'K#SS3Q
MC1ROVT&VD)CW+N!P <@CG(XH Z"BN9LO'V@7VLVNEQSSI/=H7M7EMW2.XP,D
M(Y&UB/8U8OO&&D:>MS+,\[6MI+Y-U=1PL\4#\9#,!VR,D9"]\4 ;U%8-_P",
M=&T_5(M-EEG>[F@-Q#'#;R2>:@Q]PJ"&//1<U<T+7K#Q%IWV[3W<QB1HG22,
MH\<BG#*RGD$'M0!I45S$WBQ1X\7PP+.ZP;(W#SK$Q&2ZHN".BCYLMTSCWKF/
M"GC*RT+3-7&LWE_,D.NW5N;ATDG6!!)L3S),$*.@&30!Z=169J.NVNFR-"T=
MQ<3I%YSPVT)D=8\D;B!TS@X[G!P#@U/I6J66MZ7;ZEIUPMQ9W";XI5Z,/QY!
M[8[4 7**Y"[^)?AJS2\=YKQULIS#=&.QE;R" "6?Y?E7D<GKSC.*NW_CC0=/
MFLHI+B:5[V!KBU$%O)()D"ALH5&&.".!SS0!T5%82^+--EAA>W2[N))+9;LP
M0V[&2.)NC,N,KG!P.IP< XJAK?B#P]?^&;#4)-4NUT^[N8?(N+'S%+/O&%8J
M/E!;@AL=QUH ZRBLG4_$-EI33)(EQ/)!%YTR6T+2&*/GYFQTZ' ZG!P#BFCQ
M/I<MI8W%K.;L7Z&2U2W4NTJ@9) [ 9&2<8) ZG% &Q17%ZI\1-/@TC3+_38I
M[Q;W4XM/.V%LPL9 L@<=0P&<#J3CM6Y>^)+*R0EHKN618!<20PV[-)%&<X9E
M[=#QU.#@'!H V**QAXHTF6PT^\M;@W2:B,V:0*6>;C)P.V!U)P!WQ7/> -0D
MO]?\8 W%[)##J")%'=LY:(>4I90&Z#=GIQZ4 =U1110 4444 %%%% !1110
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MU?;C@$5WM% 'F>CZE/X;U7Q#H&KZ%J-Z;[4I[RRD@M3+%=1RG(0M]U2O0[B
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MRY@"VY1M_P ORX8@<UZG10!@>.(+>Y\"ZY%=033P&SD+1P$!VPN?E)XSD?\
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M:[6,&*.<D#8>=W4@$XP">M6M3\2V>F27,9BN+J2TA^T7*6R!C#'SAFR1UVG
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M1#:/*J0J&#%L COTZ^U=%JV@6]UX0U;2])MH+)K^SEB3RXA$-SH0"0 /7ZT
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M2)MNUE!7+9P>!S[5R4%CJ$?P5T'3&TK4A?07\+2V_P!BE+HJW.]B1MZ;><T
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M?_V='>A%\HS[BNW[V[&X%=VW&>],NO'NFV^L7VE1V&K75Y9-")H[>S9R!(2
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M9+(P9<[E/&10!BW-JVL>/])UV*VNHK+2+.X$DLML\;2O+M 148!FP QR!C)
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MXQG)Z \W.FM'X1Q^%)?#FJ?VMI\MM$PBMRT4BQSH=Z2=&!4=N1SD8&:]FHH
MKS![C3Y (V5Y(B C8R"1T/:O+[71[_5OA1IG@I]-O;?4%,$-T\]NR1VZQRAV
M<2$;7X7 VDDDCMG'K%% 'DGC&WUW6M.\9:;/HNIS3G_D&BV3%N\6U?G)!&^3
M(/!R1P !S6AXCTW^UKA+^&TUW1]<M]/0V5_:0NQ<_,?)E5=RD @'#8^]U'->
MET4 >67=OJVD>([/6M=\+OK<-_I5O;WBV=LMP]I<Q[B<(?X#O/(]/SGU*QO]
M+UCPOXDLO#;Q:?:-<QW&F64*F6!)@ LFQ."WRY8+G&<<XS7IE% '#^%1>2?$
M'Q7J$FEWUM9WR69MYKB+RP^R,@\$YSR.,?7!I^OVE]IWQ$TCQ-';3W>GBSEL
M+I+>,R/!N8.L@09+ D8. 2*[6B@#RGQ#H%_>Z9X_U:VL;IFUN&"VL[80MYLG
MEIMWE,97)) W8.%YZUM7\5S<>-_!-W'8WAM[6WNEN)/LS@1&2-%4-QQDJ1[=
MZ[RB@#D_B7I]YJGP_P!3M;"VDN;DF%UAC&6<),CD =SA3Q5&]>ZO_B+X7U-=
M,U"*UBM+I)6DMV_=F39L#8SC.T_3OBNZHH \@GT/6+K1?$<EKI,LMQ%XG_M:
M"TN8BBWD "#:-PQSAN#SP..179>%9K34;PWUKX/DT0+"8Y);NR2"9F)!V*!R
M5&"23@9QC/..MHH X/QO<BT\<^!9VCED5;JZRL2%VP8",A1R<=>.>*QO$OA#
M4O%1\7ZAI\,ENU[:VMO9I.AB:X:%_,8E6P5!("#=CH3TP:[K5O#4>K:YI.JO
M?74,NF.[P1Q!-A+KM;=E23P<=16W0!P>IQW'C*\\+21Z=?63:??+J%X;FW>/
MR=B,/+!8#>2S ?+D8!.>F;/@"&YMIO$XN;.ZM_M.MW%U"9H6021,$"L,C_9/
M'6NSHH \>73=7'P&O/#;:+J"ZG"C0"+R<^:QG+?)CJNW!W=.>M=--%>:7\1H
M?$9L[RXTJ_TM;.0Q6[O);2(Y9=T8&[:02.!P>N*[NB@#R/7?#NHMX6\5W4-A
M=O/K>K6]Q;VB1$N(HY(\NP'W20C-@\] >>*ZB>.>7XLZ=J"6=V;-=(E@:<V[
MA%D:1&"DD<<*?IT-=I10!QWCW3=1G?0=7TZWDNVTC45N9K6/[\D14JQ4=V .
M0._--BLWU7XAP>)8[>ZAL;+3'M]TUN\3S.[AL!& 8A0/3DL,9YKLZ* .,^&\
M-S:Z-J$%W9W5K*^IW4ZK/"R;D>0LI&1CD'IUH\2P7L/Q \+ZK!I]U=VL$-W!
M*;=0QC:0)LW9(P#M//0=Z[.B@#S-+2]^P_$A#IU\&U%I39@VS_O\VXC&WC^\
M,?KTJB]E>Z1/X9UJZ\,W.L6 T2+3;RT2U$D]K*F"'$;<D9)4X],^F?6J* ,?
MPW%&FF-)#HL>D13RF5+41+&X! &Z15X#'&?I@'G-<M-I[7?QI>^N=*GFTPZ(
M+,3RVC-%YPG+XR1_=/WNGO7H-% '&_$+2;VZT/3I]*TZ.^;2[^*[;3R!B>-5
M960 \9P^1]*S+D0ZMX1\0S:9X-N-*DN-+FM4$M@L5S/(Z$*@5,G:#U)XR1Z$
MUZ+10!PVIPW4WP7EL([*[:^DT?[(ML(&\SS?*V[2,<<]^GO5*_LM1BN/ _B&
MWL;N:+28GM[ZT$+><BRQ*A<(1EMI7D#)(Z9KT:B@#SC5=)NM1U/Q7X@@M+M8
M;G0CIEK$8'62XD.\EMA&X %E4$@=^W-1^(+*^NO@;:Z7!IUX^H"TLX3:B!MX
M>-HRX(QQC:W/0XXKTNB@#BM12>?XG^'[^*SO&LXK&YCDF^S.%1I"A4'CC[I^
MG?%<[&=?TW2_$LECI5^6N?$GVD[;4F4VC>6&DB5A@O\ *<#J.N*]7HH \LMK
M.]M];\:RQZ'JR6VI:5"MM),ID:1ECD4@DL6W$L..H[XIS6=\/#7PWM_[-OO.
MTVXMFO$%L^80D#(Q/'9B.GUKU&B@#S?0;O6?"NH:SH-SX=U"_%SJ$]W8W=N@
M,$B2MNQ*Y/R$$G.>W0'C,6H6]QH7CK4[S5/"DVO:?JT<#QSV=HL[02I&$9&5
MN0IP"#G'ZX]-HH H:- +72+>,6$.G@*2+2!0%B!).W"\9YYQQG.*XOPKIGF^
M//%]UJ&D3""\N8)+.6ZM#M<)'M8@L..1WQFO0Z* .#\=V5W;Z_H?B"+1&UNQ
MM$FMKRRCB620))L(D1#]X@IR.N#6;XEM'U#P-<'2?"L^GFYOK65+6.S"3R+'
M*C,\BIPO . >>/? ].HH XOQ[%<7L7AEK2SNK@0ZW:W<HC@<F.),EF88R,9'
M'7VJ#24O/#'C3Q(]Y97MQ8:M+'>6MS;6[S?,$"M&X4$J1@8)XQWKNZ* /(+/
MPSK7A)/"6L'3[B[CLKB]>^LK4>9) MR<J54?>V< @9[XKIO"_P!LE^(GBC49
M-+O[>ROH;/R)KB+RPVQ&!X)SGYAQC/KBNYHH X7Q/%J.E?$#1?$L5A=7^G):
M2V-S':QF22#>P82!!RPRH!QT K NM*U?6+#XDPPZ1>PG4U1[,SH$\[$"C R<
MY)']#@\5ZS10!YLUSJ&J>+O!.HQ:!JT5K9PW27#3V^PQLT2+R"<@9'X\XSBM
M7P!'<65MXB^UV=W;^;K-W=QB6!U,D3ME648YR.W7VKM** /'8=,U-?A1IFFM
MI6H"]BUE9W@^S/N6,71EW=.FP@_IUKK'AEE^++W[V5R=/?0?LIG:!EC,GG;]
MA)''R^O';K7;57OK*#4=/N;&Z4O;W,312J&()5A@C(Y'!H \>T2^M8-"T*UU
M?2/$D6E:5<"^@_XEIDCBP6*;YD)WQH&SD*,X!/I7M *NN1@J1^8KF;'P;]DB
M6UF\0:S>Z>J[!9W,L90K_=9E0.P[8+<C@YKIZ /))/!&M/X?UC245HX]#N7N
M?#S \NY83)_WSS&#_M-Z5M>*=-U*Y^$FJ0&RFEUC4XO-DMX4+L)7(.SCLJ@+
MD]D%>@T4 <-J"7%Q\0?"%]%97AM;:TNDGE-LX$9D6,(&R.,E3].]<Y)H6M7O
MAGQ8EC8SI??\)$=5LXKB-HQ<HK1LH!..NP\>H&<5ZY10!REEXBN]<T^YF_X1
M[4]/B2V<2"]M]LK2$<)&H)+#KEL8Z8SDXY"+3M1C^'O@*R;3+_[5I^IVDMW$
M+9]T21EM['CH,CIU[5ZU10!F>(;6:_\ #&JVENF^:XLIHXUZ99D( Y]S7G\L
M>H7/A7X?P?V-J<<NF7]FUTCVS91(H61V(&>-Q '<]0,5ZG10!Y?K6@:CKFN^
M.[:WMKB(:EIEO#:3RPLL<DD8<E=Q&,9(&??O6IX6N8]4N[,R> FTC4+8$W-S
M<64<:1MM(/DN.6R>XXQG)Z ]Y10!QWQ2M;K4/AWJVGV-I<75W<QJD44$9<L=
MZGMTX!ZUOZ);6D6G03062VTCQ*) 8/*?('(8$ UI44 >.:A'K^J:=937^@:L
M^J67B"*XG2./$"0K.2/)7(#97!+8)SG)QBNNT".Z7XE^)[N:QNX;>\M[-899
M(6",T:N'&[IP6'L>V:[6B@#SO1[>_P!.M_'-C<:5>AKF^NKJ"58MR2I)&H0*
M1RQ)!X XQSBLJWL];T32/ 6MQ:/>W?\ 9%D]EJ-A'$?/0.B LB'&[#)VZC\Z
M]9HH X#QG+J7B/X9ZXMOHM[#)>1B.UM7A_?N<C+.HSMZ=#V'/7 BU"_2V^*_
MA^X>"Z9'T6X!"6[LZ?/'R4 W=1CIWKT2L2?PU'/XMMO$1OKI;BWMVMD@4)Y9
M1B"P.5W9) YS0!Q%S8Z[IL6N:[I^G76S5]9MWD@BA#7$=HBA6E1#TD8@D C(
M!SP>D<-C?07_ (^,6AZJD&J:9"+1I5,C2,(9$P3N+%BS#@\COBO5J* /,GM+
MW^R_AO'_ &=?%].DA-X!;/F$+;F,[N/[Q_KTK9\)P7NG>+/%5O<Z==)'=ZA]
MKAN2H\ID,2+PV>3E2,5VE% '!^-KD6GCSP+.T<LBK<W>5AC+M@P$9"CDXZ\<
MUD>(/"FI^(I?%NK:?;-&]U!:16<-RAC-RT#B1BRM@@$@(-V,X/;!KN-5\-1Z
MMKNDZL]]=0RZ6SO!'$$V$NNUMV5)/''45MT </X;O;6_N8[U/ L^C36T;&>:
MXL$1U)&-D)7YGR>X&,#U-)\/8;K2OA796=]97<%W:P2));M V_)9B,#'.01T
MKN:* /)+;0]9_P"%7^$/(T^Z_M'0+V"[N+"2,H\JH6#*N< MALCG]:Z:2V?6
MO'FE>(HK:\@LM+L9U=IK:2-Y7DV@($8!CM ))QC) &><=K10!YGH%C?V_P "
MKK29M.O(]1%C=P"V:!MY=S)M &.<[AST&>:?=6UXUI\.P-/OB=/DC:[ MGS"
M! 4.[C^\<?KTKTFB@#RS6= U36M5^(5O:VL\;:C;68LI9H66.9X0Q9=Q&,9P
M.>N?2M#2 GB* PQ^"'T+4%MY8YKRYLDC$+,A7]RX^9LD]0 -H.><"O0Z* /&
MYQK4GPKLO#$GAO51JNFSVL4BQVY,3K%,AWI)]U@0.W(YSQS7L2,7C5BC(2 2
MK8R/8XIU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !5#5=7@TB*W:97DDN9UMX(DP&DD;)
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MGC:6T>\@\M+I5ZE#DG('." <=J\^\26UY:> /B"]S97$(N]72ZMS*FWS8S)
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M2KDL$) '( R<]>G% '6VOCNPG\1IHD]AJ5G<3QO+9R7-OL2[51EO+Y)SCG!
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M;75M,M[ZU<36EU$LL;8X9&&1P?8UXY;G1(8/B =0U%K.YM=1F6Q:.[:.6+"
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M\EAX)\'Z9%:S75]>::)(XT(4!45=Q9B<#[P'<Y/XT =ZB)%&L<:A44!551@
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M.2%VG=URIZXH VJ"0!DG KF;#QOI^IZ#I>IVUO=%]4E>&TM&"B5V4L&S\VT
M!&).<8'KQ7+_ !#UF#7?AKXK@DLKFUN],*)+',.C%E(96!PP(/\ B* /3J*Y
MRQ\613^(X]#N--OK.6:W:XM99U0+<(I ; #%E(R#A@#CL*Z.@ HHHH ****
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M6;'H,9SGC![75=-M]8TF\TVZ7=;W4+PR#V88/\ZMT4 >4#PEXJ.@Z+JQ:/\
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MC;ZBL\D0GAP$%R9<[M^/NGUZUZ-K^E_V_P"&=1THN8#>VLD&X\E"RD9./3-
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M\94B #B/:Q+%BHP>, G//! -G3+C2-3\5>*;!=&:&\B2W2^EF"D72LC;.A/
M4=\'GI7(>';_ $VP^"7AEM6TJ34+1Y8DVKMPDAG(1FR0<!L=,UU&D6.J6?CO
MQ;J<VESBTO8[46L@DB/FF)&5AC?D9)&,X_"N:C\->(8_@[HV@'19CJ=K=0M+
M")X>%2<2$[M^#Q[YS0!U#^)-5_X63+H,>G;K2+31<@B507+2;=QST VD8Z\Y
MJ?3_ !K#?^'-5U<Z?<0'3)989K61E\W?'U7@D9/&.><CUJO+8:K!\48M9BTU
MYK"YTE+-Y1*B^0ZRESN!.2-K<;0>?SJE=>'IO^%G@VLR#3+^&.^U*WQR9H&
MB;VW$K]?*- '<P.\D$;R1&)V4%HR02I],CBI*S_MM]_PD'V'^S&_L_[-YOV_
MS5QYF['E;.N<<YZ=JT* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!'4.C*<X88.#BLCP_X9TWPS:O!IR3?O""\D\S2NV,X&YB3@9.!T&3ZFMBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KS_ ,?JR^*_!:QSW$2W.I&*=8IW194"$[6 (!&1WKT"N%\<
MV]Y<^)_",UK87=Q%8Z@9[F2*$L(T*%<^_)Z#)XH T[GQK9VVL7VC0:9JEW?6
M4*2M%;P [U;.-I9@.QZX]LFM?0]9L_$.B6FK6#,UK=)O3>N&'8@CU!!!^E<U
M8I<0?$_6]2DLKL64VG6\4<WD,0[H7+ <9Z,/K4WPPL[O3?A_IMA?VLUK=0&4
M213)M(S(S#Z\$=* $L?$5UK7BSQ%H$^EW45I8I#'YJRH,%U=BQ*ON 8;0 ,D
M8YQG Y[X>>,+?3? OA2UOK74&6](MA?&,&'SG=MJLQ.XDGC(!&>,]:VK"*^T
MKXB>*KF;3+N2SU&*UDAN8D#)B.(JP/.=V<   ]<].:YBUTG58?A;X.TQ]*OO
MMUAJ=M+<PB!B8TCE+,WH1@CIU_.@#O\ 5O%EKI45_,+*]O(-.&;V6V5"(/E#
M'.Y@20I#$*#@&MBSO+?4+&"]M91+;W$:RQ2+T96&0?R->;?9;C0O%>M1W_@V
M;7;+5+G[79W<%O'(R%E4-%)O(V %>">.:]%M+9ETB*V>*&W;R0C1VXPD9QC"
M^P[4 8EQXXTZU-E--;W:Z=>W MH-1VH86<DA?XMP4D$!BN#US@@U;TSQ/;:I
MJNK:;':7<-SI943K,$&=P)7;ACD$#.>!7"^$;&[TVQM?#.I>!5DU&R(A75#;
M1-:R1J?EE+D[MVW^'&2?3)QN^)_#NHR^,;#4-*7]QJ4#:9JI!QMA^^LG^\ '
M0'U<4 ;<7B>&XM;*2WL+V6XO(3<0V@$8D\H8^<Y<*!\R]6SS]<9I^(^B#2[.
M_P#*OBES?C36C$&7@N-VTI( >"/;.>V:S/%^GW6G>,=/U]/#QUS2_L1L;BTA
MB226#Y]ZR(C=>X.*AUZRN;G2-!DLO#<EBBZ_;7S6D%N \<*$;GE"97=WP"3C
M Z@T =#!XT@N6UBW32M1CO\ 3(1.UG.J(\J,#M9#NVX.#U((]*G\%:[=>(_"
MMAJEW:26\MQ"LGS%=K;N<K@DX[<X/M6+]BO+CXCZY<K9W*VMUHT=K%.\3*C2
M!G)&2..&'/2K_P .8[VU\#Z7I]_IUS97%E;K;NLX +,HP2,$\>_>@#1O/$<,
M%[=65K97FH7%G&LES':!"8@P)4'<RY8@$[1DXQZC/,^-/%XG^'*:MH!GF@OI
M(8UN82JF-6F1&4Y8,&.67@<'KCK4^G07WACQQXCGN;*[N=.U=HKJWN+:%I2C
MJFQHW"Y*] 03QCO6!?\ AC4]-^%2Z4EA<3ZA=:FMZUM N_R0;D2E<CCY5&.O
M)SC- '>:'H=CI<MYJ%E8W%B]Z%,MD778K+D95%8HK,.I!YXSSFN(U?Q)>>)_
MAQXUDN-/NK+[$UU#$PE4;3$ NTE'R6SDG@KVR:]0BD6:-9%# ,,@.I4_B#R*
M\L?3=7A\%^/-%;1KTW%Y>WTMLZH&283-F/;@YZ$Y[#'- '4Z%XMM&N='T2:S
MOX);JS#VMQ-$%BN-B*7"G.[(!SR!D<C-3ZAXXT[385O)[>[_ ++^T_9FU%50
MPH^[9S\V[;N^7<%QGOCFL6YM[R7Q+X N4L+PPV,4XNW\AAY)> (H;C^\,<?7
MI61X=TZ[T:*3PQJ/@<7]W%/(+;53;1/;2QLY97E<G((!Y&">..: /4YX8[B%
MX902CC! )!_,<UX/I>I(?@U:WUOKNH-XN>23[*D-_++/+()V"J8MQW+M SE<
M8YKWB>5;>!I65V"C.V-"S'Z <FO(O#?@S5'^&>D^1:RZ;XLT.::>U:>/;NW2
MNWEL>C(ZD \\4 >E#59;#2--;4HF;4[I4C^S0 %GFV;F5<D# PQR2  .M<YK
MOQ$2R\->(KJRTZZ&J:, MQ9S[%:$N,I(Q#$,AZ_*23Z50\2-JVNZ=X?\01^&
MKB:YTR<O>Z-=1C<Z.A1MF?E<KU'].E+K.G3^(?A[XB32?"K:5)=VH2&"6".&
MXG93D[E4D =@"<YSTXR ;6IZKIDE_P"&5U?3=0CO9[O_ $/D!8Y=C<N4?:05
MSQS]*D/CRR;6KO2;?2]7N;FTN(8+CR;7<(_,&5<\\)C!)_0X.,K7C?:I=^#+
MN/2-0C6VOQ/<(\.6AC\IDRP7..6''7':KOAF"ZA\?>+[F:SN8K:]DMFMII(B
MJR!(@C8/L1WZ]J +EYXXTZP2"ZGM[L:9-<BU740J&$.6VC/S;]NX$;MN/?&#
M4=QX[LX[W6+*#2M6N[G20AN(X(%R592P*[F (P,\X)SP#S7(^%M.N]'LT\+:
MCX'%W?6TC1PZJUM$]M+'N)65W)R" >5P2<=L\;VFPW5MXS\;WDMA>+;WD=L+
M:3R&(F,<15@O'J0/?J.* +L7Q"TJ;^R)H[74#8:J\<5O?& "'S''RH<G=D],
M@$9XS5W5_%MKI,-_/]BO;NWT[_C]FME0K!\H8YW,"<*0Q"@X!KA8]+U./X9^
M"]..EWOVRPU&TENH1 V8TC?+D]B,8Z=>W>K2VEQH7BG6H;_P9+KMGJET;RSO
M(+>*0J750T4F\C8 1P3ZT =3+XZTP:K;Z=:VU_>SW-C]OMS;0Y6:,E0-I) R
M=PZX [D5EZQ\0PO@I=<TG3[J1WO%LGCF"(]M)Y@C8."W4$\ 9&2,X'-$5G=V
MWQ+TN[?3GCM(-#>TD>V@;R8Y3(C!%P.F%/;'05SLNBZO-X UZ"/2KPW1\1-J
M$<!CVO+#]I60%<\$[0>.O% 'K$$S2VRRR0R6[$9,<I7<OUVDC\B:Y/PUX@AU
M'P[>^--0D*6;&>2 $$B"UC8@$ =VV%B>IR!T KIXV:_T[,D,MN9D(,<F-Z@\
M<X)&<5P/A!=8T_X,RZ?IL"/KNFQW-H(' (\Y'; P>#D$$9X.1ZT =3IOBVUU
M#5K?37L[RTN+JT^VV_V@)B6+(!P59L$;AP<'FG:=XHM]3:P>WLKS[)?[C;79
M"&-P%+9X8L,@$C(%<=I=KJ#>.O#VKC0]76(Z?-;W-Q>%3()&*'+Y;Y5X. ,?
M[(Q1X:T6[T_Q!I-WH5MJ>EV=UO?6-(ND86T!*$[HBW ;?@80G(] ,4 >@:MJ
MUKHMB;N[9@F]8T1!N>1V(544=V)( KB;6]>7XVYFM;RRQX?D=X[F0%3^_C^9
M=K,HX&#C'3FM/XB:9J=[INDWVE6S7<^DZI#?M:*0&G1-P95SQNPV1]*R)X;_
M ,1>/?MD>CZG:6-UX?GL#<7$0C,4CR C(+9XP??\.: .C/C;3X[G2UGM;R&S
MU60165](J^5,[#*#AMR[@.-RC-<RS#Q9XU\4:3K&E7SV=I!:I 5>,-:%E=S(
MNU\AF.,%<GY0#CI3?!\5U%;:=HFH^ U@U2P,<<NHO;Q&V*I@>:LF=Q<@9  Z
MGG S6QH"7-O\1/%M[/8WD=I>+:?9YF@;;)Y4;!\<=B>_7MF@"MI'BKPWX<\"
M#4[*UU1=,2\>%A*&DE\TR[&9BS' +GN>_2M_3_%MI?Z_/HKV=]9W4=O]JC^U
MQ!%FAW;2Z\DC!QD, >>E>?2:3JK?":^TH:3??;Y-8,Z0>0=QC-V)=WIC:/7V
MKI-5T^YU/XCQSI;7:64V@SV1NO(8*DDCJP!R/0$^W3K0!KMXWT^*?3/.MKR*
MRU24065\ZIY,KL,H.&W#=C@E0#61X[\0077@SQ/#9VM_<+9VTT4MU;,%2*8(
M3C.X,VTE=V 0._0@9G@^"ZM[73M"U'P&L6J6!CBDU)K>(VS*F!YJR?>+D#(
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M520BXRWL,D#/U->=^%KW5/"'@2ZAN?#FI3W%A=SDQQ!/WRO.S!DYY4*V2?\
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MU"_^'_B70;RVFT^XO[F],33 8VRLQ1N">.>1UKT*&-HH41I7E91@N^,M[G
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M=PVY<L!Y8=U7.#U)S@=NYZ<]37*_$+2[_5O"PBTVV-S<PWEO<B!652ZQRJS
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MRH(W!5W$;FV\X]".>14=OXTMM3&G#1K2:^>_LFOH\D1JL:D*0S'HVYL8]CG
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MCN4F#&/:&/[Q<?+G;C&3C/.#Q0!T=%<C'XY4OI4TVESPV&J7K6-M*[XD$@+
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MZC)C<X&U\=.H/.#6--\2FCTK5=33PY?M:Z3>26UZQEC!C"$!F S\QYZ#L.M
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MZXSVH V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'5=PQD>XZ_A6A10!Q?A>7Q%X>T>VT+5-#N+YK&,00WUE+#Y<T:C"E@[JRMC
M(P1QUI/$^B:W>W.@:_:Q13:AI-X\QLDD #PR+L=%9L N!R"<#.>G%=K10!Q-
MQHM_J/B34/$C:?-"PT=M-M;5WC\V1F8NS'#%0/N@9;^]TXSC_P#"/:\O@?P3
MI@TB8W>DW]I-=H)H<*D6=Q!WX.<\?TKTN::*WA>::1(XD4L[NP"J!U))Z"G*
MRNH92&4C((.010!Q$VFZO_PGNLZJNDSO9W&D):1.)8LM(K.V,%\@?,.3Z5CK
MX=U]/A_X-TK^QY3>:5J%I/=()H<*D398@[\'/;]<5ZA10!Q\5CJ:?$^\UHZ7
M/]@?24M4D$D66D61GQC?GD-C/K^=<U;>%?$$?PJTO2SI9&IZ=J:7AMC/'^]5
M;DRX5@VW.UNY'(KU&:>&VC\R>6.),@;G8*,G@#)J2@#C)K#6A\1=.U]-+#V\
MNE/8SJ+A ;9C*K@MG[PP,?*#S[<UF>&K/Q=X;A;PP-$M[FRBE?[)K!N4"I$S
M%AOC/S%EST'!X&1UKT:B@#SZ*U\4>&/%&L+8:#%K.E:K<_;(I1=)"UM*RJKJ
M^[DK\H(*@X]#7=VJS):0K<,C3A )&084MCG [#-344 >;^*?"]]K&J75_8:3
M/I_B"&9!8:Q;3HB21?+_ *X;LL!\P(*G( QZ5V?B;1SX@\+ZGH_FB)KRV>%9
M,<*Q& 3[9Q6C#/#<Q"6"5)8R2 Z,&!P<'D>X(J2@#CO#-SXMN;2UTS6]$CL!
M;1B.YO!=)(MP N!Y:KR-W!.[&!D=>F7X2M?%^@V4'A>XT2WDM[0^5!K0N$V&
M '@F/[V\+QCIGJ<<UZ+10!R/AK3M2M/&?BN]N]/E@M-1F@DMI6DC;<$B"'(5
MB1R,CCI6-9Z%K]IX.\8:&VDEWO);YK25;B/$PG+;, D;<;N=V/;/;T>HXYX9
M9)(XY8W>(@2*K E#UP1VH X#5M'UNX\)^#;.#2)GN=-O+*>ZC\Z(;%A&&P2^
M"?3'Z5J7VG:E<?$K1]6339?L$%A-!+*9(_D>0J1QNR<;3G ^F:Z^B@#SOPC9
M^+O#5BOA0Z1%+9VTKK;:Q]I39Y!8L"T?WBX!(QC!..<<UE^*?#GBG7--\5V,
M^C+>W,\^[3+Q[J,1I;@H5C12<H_!R<#.>6X KUBB@#C);#6U^(VGZ^NEA[:;
M2393@7"#[,YE#Y;/WAC(^4'GVYK"N?!FL:UH?C;3I;9K"74]2%]8RR2(RMM$
M94-M8D9,?/'0UZA10!Q=WI^J>*K[PY-J&E2Z:NEW0OKCS)8VWRJA54CVL<C<
MV<G' '<\8;^'=?D\#^-],_L>87>K:A=3VB&>'#)+C:2=^!C'(_G7ICW$,<T4
M,DT:RRY\M&8!GP,G [X%24 4K*%Y-%@@N87A<P".2,L"RG;@C()'Y&O/[/PW
MK\'PWN? <U@7;:]I#J0D3R6@9B1(1NWA@I(V[>H'.#D>FT4 <3=Z-J%OX[\-
MW-GIL\VF:98S6KS^;&/OA O!8$XV<\=ZZ#Q1IT^K^$]8TVVV_:+NRF@CW' W
M,A R?J:UJ* /.9],\07=GX(WZ%+&^DW,<ET@N86*JL)C)^\ 22<@#/'OQ3-3
M\):OK6I>.HC;/9Q:O!:"QNGD0KYD*G[P5BP!;';IFO0;:_L[R26.UNX)WA.V
M18I Q0^A Z5.S*BEF("@9))X H Y;PW?^*;^2%-9\.PZ3Y /GS"Y243MC'[M
M5Y4$_-DGC&.<Y#?B-I>HZUX/FT_2[-KJYDG@<*)$0 )*KDDL1V4UU,4L<\*3
M0R))$X#*Z,"&![@CK3Z .!U&U\2:)XTN==TK1!J]CJMO"ES:FXCBEMY8P0K
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M=X7A8CF-RI9?KM)'Y&I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_:3;W8D5Q;%8R6"D@-EEP#P.O?%%SXQE^PZIJ6G:6;[3M+EDBN)%GVR.8_\
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M(KNUAN86W13(LB-C&5(R#^52TR)72%%DD\QU4!GQC<>YQVI] !1110 4444
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M">*:<AE8;R4W!3\N8R"V.G;F@#L]5\/:=K5S97%\DS2V4OG6Y2=XPC\C=A2
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M12%Y;W8DJNC/V0D-@8 QCKDCC-FV\;1:C8>'GT^UWWNN0F>&"63:(D50SL[
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MVWRO/^S[QYGEYV[]O7&>,U9H \WUE-7N?%=@VD:;:W5]INFA+I%OS;RQ&0\
MN%8,I"$A<<=>.*Z/P9*\6G3:7)H:Z/)8N%,"7(N$;?\ -N\SJ6)))W<\YYS5
MO5?"6A:U>I>WVG(]VB[!.C-')M]"R$$CV-:5C86FFVJVUE;QP0KR$08&>Y/J
M?>@#G?%_ABZUR\T>\T^Y%M=6D[QRR]";:52LJC_:QM(]" :BT3P>^C^,]4OX
MG1=)FVSVUJHP([AE"2MCM\J+C_?:NOJ"XOK2T>%+FZAA>=_+A620*9&_NKGJ
M?84 <7%H&LI<^.)39Q8UH#[)B<<8A$7S^G//&>*@7PUKBZ=X$@^R0E]":,W?
M[\8.V$Q_)QSUSSBO0J:[I%&SR,J(HRS,< #WH X.PT?Q;X:U[5X-(M]/O-)U
M2\>]CFN)VC:SDD^^"H4[USR "/J*T$T;58?B.-;,(FLDT<6'F&51(\@DW[MO
M3!Z=>O;%;T6O://((X=6L9)&. J7*$D_0&M"@#E_ >CZAH6@S66I0QQRM>3S
MKY<F\%9)"X].1G%1C1]7LOB+>ZU;06\]A>V,4+EIBLD;1LQP%QALAO48_GUE
M5KR_L]/2)[RZAMUEE6&,RN%#.QPJC/4GTH \X_X0[Q!_PJW_ (1O[);_ &_[
M?]HW?:!Y>W[3YW7&<XXZ=:U)-,\6:%XLU'4]"L[&_P!/UCRY9[:ZN3"UM,J!
M"P8*VY2 ,CKQQ[]Y10!!:)<164:W4JS7(7,C(NT%N^!V'I[5RGA+1=6TOQ1X
MFO[ZUCCM]5NDG@*3!BH5=N&'8].F:[*B@#D_$VEZU=^(]&O+*WM;_3;<2"XL
MKB<Q+YAQLE^ZP;;@\$<9R.>G,-X-\3#P==Z,;:Q>=M;^WQNMP0K)Y_FG.5XS
MT Y]Z]3HH Y3Q7H^J:E>>'=2TV""2?3;WSY+>>;RP5:-D/S -R-WI56;PWJ&
MH>-M4O+R&-=-O]&&FL\<HW!MSEFV^GSX'.>*[6B@#A_"5CXSTNRLM!U*+3Q9
M:>%C74HIRSSQ)]U1$5^4D  DGIG'/-9NKZ1J6GZ+\2[^\MTCM]3LY)H"LH8@
M);%"&'8G&>]>E50U.VT[5=.N[&_9'M2A6Y3SB@"D<AB"" 1Z]J ./L=(O_$N
M@>#X+NT2UM-.-M?2R^:'\UHX_D5 .<$D$EL8QCG.:RM0\(>++S2]0MI+73KB
M\.K)>)?271#W$2S!TCQL^0*HQC.!C@'.:[Z&^T+0[>+3EU&TMT@0*D4UV"RK
MC@?,V<8Z5I03PW,2RV\L<L;='C8,#^(H Y2QTO6+?Q[JFN36<1M[FPAMT$<P
M)WQEB>#C@[L ^W(KG[+P;XAL_!7A:R%O:/J&B:K]K>(W&$E0F7[K[3@XD'4=
MC7I]% %.]\S^Q;CS0HD^SMO"'(SM.<>U>:^&M(O_ !3\)/#NAS6J063I;R3W
M)E!#0HX<!1UW': <@ 9)R>,^D1S:=K^E,UO<I=64X9/,MYCAL$A@&4^H(X-+
MI6DV6B:=%I^G1&&UB&(XS(SA!Z#<20/:@#CX]*\7>'/$NJMHEMI^H:3JMQ]K
MQ<W#1/:3, ')PIW*< X'/T[WET75T^(EAK#I'/:0Z2UA-.7"N\C.KEPGI\O3
M/>NOHH Y-M*U3_A9ZZZ+5#IPTO[!N\X;]QE#[MO]W'OGVK)T[POKFB^&M9\*
M6L,$]C=-.+&\:7 ACFR2)%QDE2S$;<[N/NUZ%10!Q%IX6O=*\8:!-9P*^E:7
MI)TTR-* YR4PVWN/DYY[U:T_2M5LO'7B+6&M$:TOK>WC@VS#<3$&!R.P.[CG
MM76U#=75O8VSW-W<16\$8R\LKA%4>Y/ H \VB\'Z_%\,-%\._9;<WUC>132'
M[0/+*I-YG!QG)''2M-M+\6:!XJU.^T*TL;_3=8=)Y8+JY,+6LX0(S9"MN4A1
MP.>/S[-=0LFNH[5;RW-S)'YR0B4;V3^\!G)7WZ59H X:[T'Q#IOC.T\2Z>+?
M4WEL!8ZA;O)Y!)#%Q)&<$8!)&T]O4\U=\$:/J^CMKQU2&UC%_JDU[%Y$YD(5
MPHP<J/[O7WZ"NLHH X?QEX8F\3&\MKG1H+D"('3+Y)A%-:S8ZEN"%#8/&<\\
M=*K/H7BWP[X@75M'^R:P+RR@M]1ANIS S31+M$RM@]03D8_^MZ#10!Q>IZ-K
M]WKWA34)(K>X;39IYKPI)L \Q&0+&",G;NZG&0/4U>\;>'KO7=,M9-*F2WU>
MPNX[JSF<<*P.&!]04+ COQ7344 <AXS\-7>H_#R;P[HT2/*R0QQF:3: $=6)
M8X.20OIU-5=2TGQ)IOC,^)=!M+6[2^M$MKZPN;CRBK(24=7 (X#$$8_GQW-%
M '"ZYH?BD7VC>(],DLKC6;-)8KJTD<I%-#(02BMC(*E5P2.<9/I6A=6VO:EH
M\8U32M.NA<3@7>F>8'1;?8W =E 9]VUN@';C&3U5% '+>"/#<OAFRU"V&^&P
MENS+963R^8;6,JHV;LGJP8X!(&>IYI/&'AFZURZT>\T^Y%M=V<[))+W^S2J4
ME4?[6,$>A KH;W4+/3H5EO;J&WC>18E:5PH+L<*HSW)JS0!R&B^#FT?QIJ=_
M"Z)I$P6>VM%&!'<,NR1L=OE1<?[[466A:DOC3Q1?S0QI9:I;000N) 6!C5U)
M9>P._CGM77T4 >8IX5\3?\()X=T.2RL_M&E7MK*Q2ZR'CA?).2HP6XP.W<]J
MZ.WTG4A\3+C77MD2PETM+('S07#K(SY*^GS8Z]JZNB@#E_&FC:CJJ:)<:7'!
M+/INJ17C0S2F,2(%92 V#@_-GIVJ"RTK6(/'^HZY/9Q&WN-.AME$<PSYB%F/
M!Q\IW8'?CD5U]% 'EECX+\3Z7X5\.26(LUUW0;BX<0R2DPW,4S,73<!D'!&"
M1U%=[H;ZW/#)<ZW!;VDKX"6EO+YHB SDE\#+'/88  ]ZUJ* ./U_PUJ">+;/
MQ;H'D-J$-N;2ZM9W*)=0$[@ P!VL#R#@@\9Z5M6MQK%[)&9[%=.B4YDW3+*[
MX_A 7@ ]R3G'&.<B>TUS2KZ]DLK34K2>ZC7>\,<RLP7.,X!Z9XS5^@#S[3O#
M&N:)X=UKPM:P03V-V\_V&\:7 @CFSE9%QDE2S$;<[N/NU9M?"MYI7BOP[+90
M+)I>DZ4VGEVE =B=F&V_\ YY[UW%% 'G2>&-<_X13QMIIM(1/K=W<S6Q\\;5
M65%4;SC@C;DXS4!%_I_Q%\*Q?8A+<0Z#-%-"DJYX:,$J3@'D#J1Q[\5Z96;+
MH&FS:Y%K4D+G4(D,:3>>XVH>J[=V,''(QS0!QFH>$=>>RU/4+/R/[0U/58;N
MZLC,426UC 40%P.I498XQR1R.HGAGQ#'?^+IET_3XX=9TZ*""*&X.(G2-XPO
MW0,?/DGCIP#7?6U[:W@<VMS#.$.UC%(&VGT..E-L]1L=0#FRO+>Y$9VOY,JO
MM/H<'B@#AW\-ZV=+\#6PLXB^A20M=?OQA@D)C.SUSG/.*G\1Z#'JGCS1;BSN
M@C30R1:G$O(FMHV5P#_VTVK[AV'8UW596C^&]&T"2ZDTK3H+5[N0R3M&.7;)
M/)/;D\=!F@#5KS[P[H_C+PW&WARWCT^;1DE<VNIM,1+!"S%MICVG<XR0.0.F
M?2O0:@O+VUTZU>ZO;F&VMT&7EF<(J_4GB@#D[31M7MO%'B[46LXV@U6&!+4"
M8;LQQLAW#MDMGOQ6%8>#O$>C6/A#4+."VEU/0[=[.ZLWGVI<1.!DH^."" >1
M_P#7]-BECGA2:)P\<BAD93D,#R"*?0!P-KH/B'^TO&E[/8VB#6H(DMXTNBS*
MRP^7AOE QSR?8X!X-0Q^&-<CTKP);?9(2^@NAN\3C#!8C'\G'.<YYQ7HE% '
MGM_97NCWGCK6KZ"S2RU.UACMOM$FY&=(S&%D4=F9@,#/6JFCP:UH$^D2:MX4
M1HK-4LH;M=8\]K=9"J92-E'4[0<'..!QQ7HM]8VFI64MG?6\5S;3+MDBE4,K
M#W!K,TOPAH.C3K-8Z>L<B?<9Y'D\OM\NXG;QQQB@#;HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *Q_$.O)H5O:8B\ZZOKJ.TM82VT/(_J<'"@ DG!X%;%<UXS\.7.OV6
MGS:?-'%J6F7L=]:F;/ENRY!1L<@$$C(H 8GB:]M_$[^';^SMQ>RVC75C+'*1
M%<!3AD.02C#@]\@Y]JPK'XB:K<Z%H&O3:);1:7J=VEK)BZ+2QL\A16"[<%00
M,Y()]!6X-&U#4/%%OXBOK6""6QLY(+6U6??EY"-S,VW@84 8!ZD^U<Y#X)\0
M0_#K0/#VS3VN].OHKB1_M#!&6.4R<'9G)SCI0!WVM7-U9Z)?7-DL37,,#O&)
MB=F0,\XY_P ]J\OU"^U'4/AWX$U'4(TGNI-6TZ561\O*3SSD  D^^/>O5;VW
M:]TVXMB0C3PM'GKM+#']:\_7PEXF;P=X7TB2+3!-HU]:S,5N7Q)'!W!V?>;T
MQQZG/ !LV_C.XL]2UZS\0V=O:'2K-=0\RUF,JO =V>JJ=P*$=.<TRU\:7CZY
MI5I-I\<EKJ08>9:L[M:.!D"3*@$'IN'0_G46H^#[[6?$^O3W8MX]-U32!IVY
M)2TJ$%SNV[0/X_7M5CPQ;>-H$M=/UU]+^RV8"F\MG=I;H*,+E2 $SP6.3GH!
MSD &SXBUV/0-/BG,7G7%Q<1VEK &V^;-(<*N>PZDGL >M<FK7Z_&FT-]!;[Q
MH,Q5[8D[QYT?!!&<CZ\Y[=*W/'/AR[\1Z/:C3;B*#4M/O8K^T:8'RS)'G"MC
MG!!(K+_L;Q3J'C"VUV>#3]/VZ7-9,L=TTK1N[!@X^0 X*]/U[4 2VOC:]&LZ
M!9:CI\-JVL^8!;&4_:+0JA=?,4CG(4^F#ZU3T;Q9J5JWC+4M<\@V6EWKQA87
M8LH6*,JB C!SGJ2.3T JG8>$/%4,?A5I8=(2?1[IWN9!<2.UT6C9&F8[ =QS
MG!SD_P 0J_)X(U&[3QAI=Q):IIFN3-<Q7*.QEC<HJ@%, 8#(#G=STQSD &A9
M^+[Q_$UAI=Q8QR07T;LMQ:%W6W=1G9(2H&".C<9(QBM?Q!KR:'%9(L0FN[^Z
M2TM8BVT,[9.6.#A0 23@]/>LWPXGC4O!#XB.F)%;##36<C.]V<8!(( 0=SUR
M1V%2>,_#EUKMMIUSITT46I:7>I>VWG$B.0KD%&(R0&!(R!Q0 D'B6\C\42^&
M]0M8$OI+0W=E-'(?*G4'#*<C*L#CUX.?:L+X?6\VL66L'6+.RN(EUVZF5G8R
M,LR2X4@%<87'!SG@<5NPZ+>WWBR#Q'J%O%;R6=D]M;6R3;R6<@NS-@ ?=  &
M>I)]*;X(T75-"L]1@U*.U!N=1N+Q#;S%P!(^X*<J.1F@"KXBU;6[;X@^&M,L
MOLWV.ZCN961W92[1H/O$ \#?D#G)^@KGK34]4T36?B%>Z5IMK<K:W:7$HGG,
M0*K;JQ5<*<L<'K@>]=7XCT35;OQ7X>UK3!:/_9XN8IH[B1D^655&X84Y(V].
M,^HZUFQ^&=;5?&V8K+.NY^S8N&^7,(B^?Y..F>,T :$WC2&9=+BLA$D^H6 O
MP;DMMBB.-N=H)));&..A.>@-[PGX@F\1Z1)<W-A)97$-P]O+&V2K,O\ $A(!
M9"""#C^5<M_PBOBC2%\.:KHQT]]3T[3$TN]M)Y6\JXB7&"KA<@AAGD=_S[?2
M$U(66_5G@-W(V]H[?)CB&  JD\GIDDXR2> ,"@#@]3DLX/CL'O+9YXSX9(*Q
MVKSDG[1_=52>F>U1^"H=<\-:)JTL.BW0M;_6C_9FGRY4VL$C@;W')1!U*XXQ
MVSFM\Z#K!^*@\2^5:?V>-+_L_;Y[>;GS=^_&S'MC-6_&VD:KK&D6L.E- SPW
MD4\]M<.4CNHE)W1,0#@'CL0<8- &;%XZG:T\5[+2TNKCP^@E+07)$5PAC,G!
MP2K#:P(YY'6L?Q'XM\6'P#-K,.G65C;W$%H\,PN6>3$S*K#:%^4_,,'/ /KP
M+;>%/$;7/C&0Q:6J:]8QPQ(D[@0NL+1[3\G0;L[L<X^Z,\7M6\+:KJ?PIA\.
M VL>I0V]M&#YC-$S0LA^]M!P=GIQF@"YJ&M7-IXN\,Z9>Z59/)J!N=MTDI9H
M"D98A04!^88&<COQ44WBO5+G3[S5-$TA=0L[2[:V\I9")KC8^R1HQC  .[ )
MYVGIQ1J.C:[J/BCPKJ[P6*+IAN&NHUN&/^M38 GR?-CU.W/H*S](\/\ BWPW
M>ZAIFF2:;+HEW=27,%S,[":S\P[F4(!A\$DCD>_I0!KG6I/^%B2Z*-*MO.&D
MF[BO#)\[KYH7RS\N5&<GJ>U<T/B7K8\)0>*V\-0_V.DKI>;;S=,BB4QED7;A
M@,#.2"3G@ 9KI!H>I+\2UU[;;G3QI7V#F8^;N\S?NV[<8[=:XWPAI>I^(OA$
MFA)#!%:7D]Q&]V9<E8C<OO\ DQ]_[P'..0<]J .J\0>,+W2;?5;V&Q@%CI]J
MEPD]W*8Q>EE+%(CCJ .O/) QWHO/&5\NL>'[&PTF*=-:M)+B&26YV;"J*V&&
MTX'SCD9/7BLW5O".OW%_XDBMAITUEJ6G"TLIKB5P]DOE%&C50IX9CG((]3G
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MNO\ A'6+/4HM-MKN\LI+2&W@G9HU+J09'<KGZ*!QSR<\ "6GC#5#K7A^VO\
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MTCV]P1&^2P*-P2C K[]>@JMJVE^,M?\ "=]#/+86.H2^6(K6"9S&45P75Y,
M_./EX' ]<FH[/P]XA@\6W&L?8])@MY](2S%K#.W[EE9B%!V $?-UP,=,'J0"
M"Q^(.JW&E^&M8N-%MHM,UFYBM25NBTL;R$A6V[<%<C'7//05K+XMGO-<U#3=
M.CLY)]/NHX)K268K.T;;"TRC'W0&.!WV]1TK#B\&:_%X'\*:*$L#<Z/?V]S,
MWVA@CK$Q;"G9G)SW'%6?$?A"_P#$<Y>>RLX-1@NUDL-8@F*S01!P2& 4$G&X
M 9(.1D@T =KJ=W)8:5=WD5K+=R00M(EO",O*0,A5]STKFM/\6WDWBE?#]U;V
M7VN73VO%\F<GR7!4&*08R#\P^;Z\5L^)[#4-4\,:E8Z5>?8[Z>!DAGR1L8^X
MY'ID<C.:Y?3/#6OP^*M#U9[+2+.VM=/DLIK:WF=MFYD;<IV#<3M/'&.N6H Y
M^7Q7XI_X4[K.MF2T%T)[A!.KON0>>T9VKCC P%Y[9-=Y?ZQJ]I<V]LUE:P[H
M))Y[Z65OLT.U@%3=@'<V<\XP >M<O_P@VNR?#K7?"CO8+YTTTEG.)&/F;YO-
M&\;1L].-WZ<ZMWI7BFY\4Z5K$D&ERPQVCQ26<EP^RUF+9\Y#L^=MOR]%/7!&
M2: *DWCK[?X%T/Q!_8MO/%?7L4$D,TVX0.9O+WK\IW88$CIV-:5UXGUIO&%[
MX<T_2;1YH;)+N*>>[948,Q7Y@$)'W3P,_45ST'@CQ)%\/M-\/,--:XLM36ZW
MB=PK1K.9?[AP3G&.V,Y/0=)#HVK1_$.\U\PVIM)M,CM$03G?O5V?)&W&#NQU
M[4 9B_$2ZE\*^'=9AT=6.J:@EA-";C!A<R,AV_+AAE&QDCJ*M1>*/$<GB+4/
M#QT;3QJ,-O'=P2?;6,!B8LOS'9NW KC 7GV[XUMX)\10>$= TDQZ>9]-UH:C
M(PN7VL@E>3:/W><_/CICBNCBT;58_B)=Z^8;4V<NFI9HHG/F;E=GR1MQ@[L=
M>U %2P^($=YX:TB_>U2"^U&XEM1 \A*1O&7$A+ 9*C8<8&3D#C.13N_B'J%C
MH?B.Z?1DEGT8(XD61T@N8V&0R,4SD="OZU1MO OB2S\,:7]DGL(==TC49[RV
M)D9X9DE9RT;':",J^,@=O?C6US1O%?B;P1J]A>IIMO?7T(ABMXYF,4(SDLS[
M<DGT P,#WH N0^*=5C\5V&D:AI=O#%J=M+-9O'<EW#1A25D&W R&'W2V/>HO
MA]JVLZQ:ZK/JIMVV:E<P!HG;C8^P*%(X4 >N34EYH>L77B[PQJPAM%@TR">.
MX7[0Q8F557Y?DP0-O<CK4O@[1-5T!]6M;L6C6<^H7%W;RQ2,782ONPRE0%QR
M.IS[8Y +E]KTO_"21^'].CB>^-J;R5YF(2*/=M7@<DLV>.. 3GH#SFI^++S5
M/ OBU8;:.SU?28;B"[C,Q(3$3,)(V"Y((P1D#WK4U/0-1M_'-OXITE89RUF;
M&\M)9-F^/=O5T;!&X'L>H[U3G\(Z@V@>+2@MCJWB(2*RF4B*%3%Y2#=MR<#D
MG'))H TO!U@K^'M$OKNQLUO(=/BA@FB^9EB*(<9*@C..0.*SO$WC>]\.VNJ:
MA-IL4=EI\R1*MS*4DO 0I9HN,8&[WSM/2NE\/6MU8^'M/LKU(EN+:WCA?RG+
MJ2J@9!('IZ5P>O>"_$^J6?BZQ4Z;,-6DWVM[/,_FQQC;M@V[<!05/(..2<$F
M@#KKSQ!,?%4?ARPBB-V;%K]Y9R=BIOV*H Y))S] .^<5C:;\0GO/#EMJ=UIT
M-K-=WK6-O#]I+@R*7#ECL&  C'@'(QW-4-:CUK4O&%N=-M=+N=0T[3]MW&M]
M+;/$TK9 $BKEUPG0@#O@$C#7T75M8\/066G6%GH6L^';Y)[1%G,]O(VTDJS
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M,T,R-'\ZVY@51#SQN.5RW3[Q Z9K270[_5O%.EZWJ\5O;_V5!*L$,,IDW32
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M+>-$98T8^=:Q2D!)&/1OO+E0!C/!.*KW#ZH_QJAA5K5H5T.1E5]V C7"!O\
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MZ;#N'^_6MK5WX4U.\MM(UK[%=2&X @BN8MZ>>!PH)&W?@_=SGGIS70@!5
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MX!Z>_&SJGAO7?$_A>[MM7O;6RU&1HI+3[%N>.VDC;>K9;!8ENO X QZGLZ*
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MH1C)KK+$W9L(#?B(790&98L[ W<#)/ Z9KB[VPTKQ+\0]*U#3-1BG%M;O_:
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MXA$D8CP?DYP!GCK[4VX\)>)+*\TC6="O=.BU2VT]-.O+>ZWM;W$:G*D%0&#
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M>JQP+#'YS H8D*C=\G?=GCICO6,G@?6H_ GAWP^LM@9])O(+AI3*X618GW@
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ME0HZ\$XS6;>^.=5DT^?5=$TR2_MX;IH19I8SO+<(DAC=TE4; <AB!@\#D@G
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M ?=7/J>!GUH U:S-6\0:7H<;/J%R8PL9E?9$\A1 <%V"@E5_VCQ7/7_B;6-
M;0KO54LI;#4[B.UF6WC97M9)!\AW%B'7/RDX7U]JI:9'J4WQ?\0)+=VCQ+I]
MJ'0VK',1:4A1^\X/)R<$'/04 =[;W$-W;17%O*DL,J!XY$.592,@@]P14E-1
M$BC6.-%1% 5548  Z "N;;7+[5/$NJZ+I$EK VEQ1&>:YB:4-)*"RJ%5EP H
M!)S_ !8QQ0!TU%>;O\0]5FT#3+NUT^T6^;7$T:_MY78A)=^UMA';H03G&>AQ
M7<:.-7%B1K;637?F-@V0<(4S\O#9(..M &A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=P )!)') /'2M.7P%=ZCJ6O3:MJD$UMK=C';7,4%L4*,@8*4)8X W9YR21U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "LW4]$M=3N;2[<R0WEFS-;W,) >/<,,.0001U!!' [@5I44
M 4]-TNVTN&5+=6W32&::1SEY9#U9CW/ 'H  !@ "KE%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492184403456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EMERGENT BIOSOLUTIONS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">14-1902018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Professional Drive Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">631-3200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EBS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,447,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001367644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492185470048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 430.2<span></span>
</td>
<td class="nump">$ 642.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">155.9<span></span>
</td>
<td class="nump">158.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">367.9<span></span>
</td>
<td class="nump">351.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">57.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">225.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,221.3<span></span>
</td>
<td class="nump">1,210.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">716.8<span></span>
</td>
<td class="nump">817.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">608.9<span></span>
</td>
<td class="nump">728.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">218.2<span></span>
</td>
<td class="nump">218.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">184.6<span></span>
</td>
<td class="nump">191.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,949.8<span></span>
</td>
<td class="nump">3,166.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">124.2<span></span>
</td>
<td class="nump">103.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">21.3<span></span>
</td>
<td class="nump">34.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">56.8<span></span>
</td>
<td class="nump">88.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Debt, current portion</a></td>
<td class="nump">950.7<span></span>
</td>
<td class="nump">957.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities held for sale</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,215.7<span></span>
</td>
<td class="nump">1,229.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, net of current portion</a></td>
<td class="nump">447.7<span></span>
</td>
<td class="nump">448.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">59.7<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,747.2<span></span>
</td>
<td class="nump">1,783.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200.0 shares authorized, 56.0 and 55.7 shares issued; 50.4 and 50.1 shares outstanding, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 5.6 and 5.6 common shares, respectively</a></td>
<td class="num">(227.7)<span></span>
</td>
<td class="num">(227.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">878.2<span></span>
</td>
<td class="nump">873.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income, net</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">551.0<span></span>
</td>
<td class="nump">734.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,202.6<span></span>
</td>
<td class="nump">1,383.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,949.8<span></span>
</td>
<td class="nump">$ 3,166.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492184245808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">56,000,000.0<span></span>
</td>
<td class="nump">55,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">50,400,000<span></span>
</td>
<td class="nump">50,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492180596288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 165.1<span></span>
</td>
<td class="nump">$ 307.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">155.1<span></span>
</td>
<td class="nump">155.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">40.6<span></span>
</td>
<td class="nump">46.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">100.5<span></span>
</td>
<td class="nump">84.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">313.2<span></span>
</td>
<td class="nump">301.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(148.1)<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(17.9)<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(13.0)<span></span>
</td>
<td class="num">(10.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(161.1)<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">21.9<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (183.0)<span></span>
</td>
<td class="num">$ (3.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (3.65)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (3.65)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">50.2<span></span>
</td>
<td class="nump">50.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">50.2<span></span>
</td>
<td class="nump">50.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Services</a></td>
<td class="nump">$ 143.4<span></span>
</td>
<td class="nump">$ 237.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">102.9<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">CDMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total CDMO</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">52.2<span></span>
</td>
<td class="nump">75.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Services</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">51.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Services</a></td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492181854400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (183.0)<span></span>
</td>
<td class="num">$ (3.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on hedging activities</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss), net of tax</a></td>
<td class="num">$ (185.1)<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492179019424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (183.0)<span></span>
</td>
<td class="num">$ (3.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">34.6<span></span>
</td>
<td class="nump">30.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent obligations, net</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(8.4)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(29.6)<span></span>
</td>
<td class="num">(50.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">31.0<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(14.7)<span></span>
</td>
<td class="num">(51.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(25.3)<span></span>
</td>
<td class="num">(32.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable', window );">Income taxes receivable and payable, net</a></td>
<td class="nump">12.9<span></span>
</td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(184.0)<span></span>
</td>
<td class="num">(37.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(15.1)<span></span>
</td>
<td class="num">(32.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(15.1)<span></span>
</td>
<td class="num">(32.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(57.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfMediumTermNotes', window );">Principal payments on term loan facility</a></td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from stock-based compensation activity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid for stock-based compensation activity</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities:</a></td>
<td class="num">(10.5)<span></span>
</td>
<td class="num">(70.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash excluding cash classified within assets held for sale</a></td>
<td class="num">(209.8)<span></span>
</td>
<td class="num">(140.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Cash and cash equivalents included in assets held for sale</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">642.6<span></span>
</td>
<td class="nump">576.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">430.2<span></span>
</td>
<td class="nump">436.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental information on non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment unpaid at period end</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">13.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NoncashPurchasesOfTreasuryStock', window );">Purchases of treasury stock unpaid at period end</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and cash equivalents and restricted cash at March&#160;31, 2023 and December&#160;31, 2022:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">430.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Cash and cash equivalents included in assets held for sale</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total</a></td>
<td class="nump">$ 432.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NoncashPurchasesOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Purchases Of Treasury Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NoncashPurchasesOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492185469200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>$0.001 Par Value Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.1<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,619.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (152.2)<span></span>
</td>
<td class="nump">$ 829.4<span></span>
</td>
<td class="num">$ (16.1)<span></span>
</td>
<td class="nump">$ 957.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(52.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (52.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net of tax</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 1,575.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (204.4)<span></span>
</td>
<td class="nump">834.8<span></span>
</td>
<td class="num">(9.3)<span></span>
</td>
<td class="nump">954.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">55.7<span></span>
</td>
<td class="nump">55.7<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,383.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">873.5<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">734.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(183.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(183.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net of tax</a></td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">56.0<span></span>
</td>
<td class="nump">56.0<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 1,202.6<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">$ 878.2<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 551.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492186420880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492187302736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the business and organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the business and organization</a></td>
<td class="text">Nature of the business and organization<div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc., including its consolidated subsidiaries (&#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats ("PHTs"). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following five PHT categories: chemical, biological, radiological, nuclear and explosives ("CBRNE"); emerging infectious diseases ("EID"); travel health, which we have agreed to sell to Bavarian Nordic; emerging health crises; and acute/emergency care. The Company has a product portfolio of thirteen products (vaccines, therapeutics, and drug-device combination products). The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company has one product candidate that is procured under special circumstances by the United States government ("USG"), although it is not approved by the United States Food and Drug Administration ("FDA"). The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures ("MCM") Products, NARCAN, Smallpox - MCM Products and CDMO Services. The Company operates as two operating segments: (1) a products segment ("Products") consisting of the Anthrax - MCM products, NARCAN products, Smallpox - MCM products and Other products and (2) a services segment ("Services") focused on CDMO services (Note 17, "Segment information</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anthrax - MCM Products</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Anthrasil&#174; (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">AV7909 (Anthrax vaccine adsorbed (AVA), adjuvanted) procured product candidate being developed as a next-generation anthrax vaccine for post-exposure prophylaxis. AV7909 has not been approved by the FDA, but is procured by certain authorized government buyers for their use;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BioThrax&#174; (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">NARCAN</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">NARCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone approved by the FDA (including in over-the-counter form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Smallpox - MCM Products</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">ACAM2000&#174;, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">CNJ-016&#174; (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">TEMBEXA&#174;, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Products</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">BAT&#174; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; </span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Ebanga&#8482; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics ("Ridgeback"), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#8482;;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">RSDL&#174; (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA that is intended to remove or neutralize chemical warfare agents from the skin, including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Trobigard&#174; atropine sulfate, obidoxime chloride auto-injector, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It was approved in Belgium in 2021 but has not been approved by the FDA. Trobigard is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure outside of the U.S.;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Vaxchora</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the first vaccine approved by the FDA for the prevention of cholera, which we have agreed to sell as part of our travel health business (Note 3, "Assets and liabilities held for sale"); and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt">Vivotif</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), a live attenuated vaccine for oral administration for the prevention of typhoid fever, which we have agreed to sell as part of our travel health business (Note 3, "Assets and liabilities held for sale").</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services - Contract Development and Manufacturing</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's services line focused on CDMO offerings cover development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided to customers from across the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale.&#160;Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492187408480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation and consolidation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of March&#160;31, 2023. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there is $598.0&#160;million outstanding on the Revolving Credit Facility (defined below) and $354.4&#160;million on the Term Loan Facility (defined below) that matures in October 2023, which is within one year of the date that the consolidated financial statements are issued for the quarter ended March&#160;31, 2023. The Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation considered the potential mitigating effect of management&#8217;s plans that have not been fully implemented. Management may evaluate the mitigating effect of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's plan to alleviate the substantial doubt includes amending its existing Revolving Credit Facility and Term Loan Facility that are due October 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company is in the process of and expects to replace the current credit facility before it matures, management cannot make the assumption that it is probable that the Company will be able to obtain such debt refinancing on commercially reasonable terms or at all until the new credit facility is in place. The Company is currently working with its lenders and expects to refinance the credit facility with revised terms and conditions. The extent to which the Company will be able to affect such refinancing, replacement or maturity extension on terms that are favorable or at all is dependent on a number of uncertain factors, including then-prevailing credit and other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, disruptions or volatility caused by factors such as COVID-19, regional conflicts, inflation, and supply chain disruptions. In addition, rising interest rates could limit our ability to refinance our existing credit facility when it matures or cause us to pay higher interest rates upon refinancing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the replacement of the Company&#8217;s current debt facility is conditional upon the execution of agreements with new or existing third parties, which are considered outside of the Company&#8217;s control, until such time as they are completed, the refinancing cannot be considered to be probable to occur as of the date of this report. The Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pre-launch inventory</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our Products segment, costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, we consider a number of specific facts and circumstances, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a CDMO contract as CDMO pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of the policy on pre-launch inventory discussed above, there have been no significant changes to the Company's summary of significant accounting policies during the three months ended March&#160;31, 2023, contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC that have materially impacted the presentation of the Company's financial statements.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:</span></div><div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable inputs for identical assets or liabilities such as quoted prices in active markets;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs other than quoted prices in active markets that are either directly or indirectly observable; and</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company&#8217;s long-term variable interest rate debt arrangements (Level 2) approximate their fair values.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board that the Company adopts as of the pronouncement's specified effective date. There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#8217;s 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492180570832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and liabilities held for sale<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Assets and liabilities held for sale</a></td>
<td class="text">Assets and liabilities held for sale<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the Company entered into a definitive agreement with Bavarian Nordic, under which we agreed to sell our travel health business, including rights to Vaxchora and Vivotif, as well as our development-stage chikungunya vaccine candidate CHIKV VLP, the Company&#8217;s manufacturing site in Bern, Switzerland and certain of its development facilities in San Diego, California. Additionally,  approximately 280 employees are expected to join Bavarian Nordic as a result of the transaction. The transaction is expected to close in the second quarter of 2023, subject to certain customary closing conditions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the accompanying Condensed Consolidated Balance Sheet as of March 31, 2023, the assets and liabilities of our travel health business are classified as held for sale and are measured at the lower of (i) the carrying value of the disposal group and (ii) the fair value of the disposal group, less costs to sell. Effective with the designation of the travel health business as held for sale on February 15, 2023, we suspended recording depreciation of property, plant and equipment and amortization of finite-lived intangible assets and right-of-use assets while these assets are classified as held for sale. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of sale. Gains and losses recognized from a sale of a disposal group will be recognized in income (loss) from operating activities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities classified as held for sale in the Condensed Consolidated Balance Sheets as of March&#160;31, 2023 consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;March&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets held for sale:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97.1&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets held for sale</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities held for sale:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities held for sale</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492195245184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring costs</a></td>
<td class="text">Restructuring costs<div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2023 Organizational Restructuring Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company initiated an organizational restructuring plan (the &#8220;2023 Plan&#8221;) intended to reduce operating costs, improve operating margins, and continue advancing the Company&#8217;s ongoing commitment to profitable growth. As part of the 2023 Plan, the Company eliminated approximately five percent of its total headcount. The Company incurred approximately $9.7&#160;million in charges in connection with the 2023 Plan during the three months ended March&#160;31, 2023. These charges consist primarily of charges related to employee transition, severance payments and employee benefits. All activities related to the 2023 Plan were substantially completed during the first quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs associated with the Company&#8217;s segments as well as unallocated corporate and research and development ("R&amp;D") charges for the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.216%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs by segment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs, by function, for the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.216%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee transition</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of and changes in the Company's restructuring accrual during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.997%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492187408480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories, net</a></td>
<td class="text">Inventories, net<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.148%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143.4&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367.9&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is stated at the lower of cost or net realizable value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182443696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text">Property, plant and equipment, net<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.148%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land and improvements</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.9&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">327.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">515.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">567.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,092.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,201.4&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation &amp; amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(375.2)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(383.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property, plant and equipment, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">716.8&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">817.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, construction-in-progress primarily included costs incurred related to construction to advance the Company's CDMO capabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. During the year ended December&#160;31, 2022, the Company recorded accelerated depreciation of $12.7&#160;million reflecting a shortening of the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement with Janssen (the "Agreement"). For additional information related to the termination of the Agreement, refer to Note 13, "Revenue recognition".</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182510736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible assets and goodwill</a></td>
<td class="text">Intangible assets and goodwill<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the Company's Intangible assets, net:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:14.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Weighted Average Useful Life in Years</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.6</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">849.1&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240.2&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">608.9&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">982.1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">253.3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">728.8&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">883.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">274.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">608.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,016.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">728.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The net carrying value of intangible assets as of March&#160;31, 2023 excluded $102.9&#160;million of assets related to our travel health business, which were reclassified as assets held for sale in anticipation of the sale of the travel health business to Bavarian Nordic (see Note 3, "Assets and liabilities held for sale").</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, the Company recorded amortization expense for intangible assets of $17.0 million, $14.0 million, respectively, which is included in "Amortization of intangible assets" on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the changes in the carrying amount of goodwill by reportable segment:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Products </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Services </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218.2&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218.2&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts for the Company's Products segment include gross carrying values of $259.9&#160;million as of March&#160;31, 2023 and December&#160;31, 2022 and accumulated impairment losses of $41.7&#160;million.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts for the Company's Services segment include gross carrying values of $6.7&#160;million as of March&#160;31, 2023, December&#160;31, 2022, and accumulated impairment losses of $6.7&#160;million.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has $218.2&#160;million of total goodwill which is attributable to our Products segment. There is the risk of future impairments in our reporting units as any further deterioration in their performance compared to forecast, changes in order volumes or delivery schedules for major customers, as well as any changes in economic forecasts and expected recovery in the biopharmaceutical industry, may require the Company to complete additional impairment tests in future quarters and could result in the reporting unit&#8217;s fair value falling below carrying value in subsequent quarters. In the event the Company experiences factors that it believes indicate a decline in fair value, including negative changes to long-term growth rates or if discount rates increase, we may be required to record impairments of goodwill and other identified intangible assets. Further, if the composition of the Company&#8217;s reporting unit&#8217;s assets and liabilities were to change and result in an increase in the reporting unit&#8217;s carrying value, it could lead to additional impairment testing and further impairment losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182549280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">Fair value measurements<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.313%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.670%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.387%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">320.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">320.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">308.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">500.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">320.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.6&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.6&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contingent consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#8217;s products are classified in the Company's statement of operations as cost of product sales. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a reconciliation of the beginning and ending balance of the Company's contingent consideration liability: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.6&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the current portion of the contingent consideration liability was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $3.1&#160;million, respectively, and was included in "Other current liabilities" on the Condensed Consolidated Balance Sheets. The non-current portion of the contingent consideration liability is included in "Other liabilities" on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurement for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:18.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.066%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Contingent Consideration Liability</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Fair Value as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Range</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty based</span></td><td colspan="3" rowspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.6 million</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounted cash flow</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25% - 50%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projected year of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 - 2028</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative instruments</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9, "Derivative instruments and hedging activities</span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information about the Company's derivative instruments.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Non-variable rate debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2022, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he fair value of the Company's 3.875% Senior Unsecured Notes was $220.6&#160;million and $225.1&#160;million, respectively. The fair value was determined through market sources, which are Level 2 inputs and directly observable. The carrying amounts of the Company&#8217;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 10, "Debt").</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182520320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative instruments and hedging activities</a></td>
<td class="text">Derivative instruments and hedging activities<div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risk management objective of using derivatives</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from payments of variable interest rate debt associated with the Company's senior secured credit agreements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If current fair values of designated interest rate swaps&#160;remained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;$5.9&#160;million of net deferred gains from&#160;accumulated other comprehensive income&#160;into the Condensed Consolidated Statement of Operations over the next&#160;twelve-month period. All outstanding cash flow hedges mature in October 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Number of Instruments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Notional</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$350.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.143%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Fair Value of Asset Derivatives</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:15.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.162%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivatives</span></td><td colspan="3" rowspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Location of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)</span></td><td colspan="9" style="background-color:#19415e;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Amount of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)</span></td></tr><tr style="height:15pt"><td colspan="9" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182678368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the components of the Company&#8217;s debt:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.831%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.148%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement - Term loan due 2023</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">354.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">362.8&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement - Revolver loan due 2023</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">598.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">598.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.875% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">450.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">450.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,405.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,413.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion of long-term debt, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(950.7)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of debt, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">447.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">448.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the Company reclassified the debt issuance costs associated with the revolver loan to a contra account to directly offset the loan balance in other current liabilities on the Company's consolidated balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the Company had $0.9&#160;million and $1.3&#160;million of debt issuance costs associated with the revolver loan that were classified as an offset to other current liabilities, respectively. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">3.875% Senior Unsecured Notes due 2028 </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company completed its offering of $450.0&#160;million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the 2028 Notes) of which the majority of the net proceeds were used to pay down the Revolving Credit Facility. Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related Indenture, plus accrued and unpaid interest. Prior to August 15, 2023 the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to 100% of the principal amount of the 2028 Notes plus a &#8220;make-whole&#8221; premium and accrued and unpaid interest. Prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the 2028 Notes using the net cash proceeds of certain equity offerings at the redemption price set forth in the related Indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of 101% of the principal amount of such 2028 Notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative covenants in the Indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior secured credit agreement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on August 7, 2020, the Company entered into a Second Amendment (the &#8220;Credit Agreement Amendment&#8221;) to its senior secured credit agreement, dated October 15, 2018, with multiple lending institutions relating to the Company&#8217;s senior secured credit facilities (the &#8220;Credit Agreement,&#8221; and as amended, the &#8220;Amended Credit Agreement&#8221;), consisting of a senior revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and senior term loan facility (the &#8220;Term Loan Facility,&#8221; and together with the Revolving Credit Facility, the &#8220;Senior Secured Credit Facilities&#8221;).  The Credit Agreement Amendment amended, among other things, the definition of incremental facilities limit, the consolidated net leverage ratio financial covenant by increasing the maximum level, increased the permissible applicable margins based on the Company&#8217;s consolidated net leverage ratio and increased the commitment fee that the Company is required to pay in respect of the average daily unused commitments under the Revolving Credit Facility, depending on the Company&#8217;s consolidated net leverage ratio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement includes (i) a Revolving Credit Facility of $600.0&#160;million and (ii) a Term Loan Facility with a principal amount of $450.0&#160;million. The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as certain requirements involving the Company's net leverage ratio will be maintained on a pro forma basis. Borrowings under the Revolving Credit Facility and the Term Loan Facility bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from 1.25% to 2.25% per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus 0.50%, and a eurocurrency rate for an interest period of one month plus 1% plus a margin ranging from 0.25% to 1.25%, depending on the Company's consolidated net leverage ratio). The Company is required to make quarterly payments on the last business day of each calendar quarter under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from 0.15% to 0.35% per annum, depending on the Company's consolidated net leverage ratio, for the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments on the last business day of each calendar quarter based on an annual percentage equal to 2.5% of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, 5% of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and 7.5% of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature on October 13, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of $100.0&#160;million during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights. The financial covenants under the Amended Credit Agreement currently require the quarterly presentation of a minimum consolidated 12-month rolling debt service coverage ratio of 2.50 to 1.00, and a maximum consolidated net leverage ratio of 4.50 to 1.00 (subject to an increase to 5.00 to 1.00 for an applicable four quarter period, at the election of the Company, in connection with a permitted acquisition having an aggregate consideration in excess of $75.0&#160;million). Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2023, the Company entered into a Consent, Limited Waiver, and Third Amendment (the "Third Credit Agreement Amendment") to the Amended Credit Agreement relating to the Senior Secured Credit Facilities. Pursuant to the Third Credit Agreement Amendment, the requisite lenders consented to our sale of our travel health business to Bavarian Nordic substantially in accordance with the terms of the Purchase and Sale Agreement with Bavarian Nordic (the "Sale Agreement"). The proceeds from the transaction will be deposited into a cash collateral account with the Administrative Agent and will, unless otherwise agreed to by the Company and the requisite lenders, be used to repay the outstanding Term Loan Facility on the expiration of the Limited Waiver (as described below). We currently expect the transaction to close in the second quarter of 2023, but we can provide no assurance that the transaction will close prior to the October 2023 maturity of the Term Loan Facility, or at all.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Third Credit Agreement Amendment the requisite lenders have agreed to a limited waiver of any defaults or events of default that was extended on April 17, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Company entered into a First Amendment (the &#8220;Waiver Amendment&#8221;) to the Third  Credit Agreement Amendment. The lenders agreed to extend the limited waiver (the &#8220;Extended Limited Waiver&#8221;) of any defaults or events of default that result from (a) any violation of the financial covenants set forth in the Amended Credit Agreement with respect to the fiscal quarters ending December&#160;31, 2022 and March&#160;31, 2023 and (b) any going concern qualification or exception contained in the audited financial statements for the fiscal year ending December&#160;31, 2022. The Extended Limited Waiver expires on the earlier to occur of (i) any other event of default under the Amended Credit Agreement and (ii) May 17, 2023. During the period of the Limited Waiver, the Company is working with lenders under the Amended Credit Agreement in connection with replacing the current credit facility before it matures with revised terms and conditions. The Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to the Amended Credit Agreement. See Note 2, "Summary of significant accounting policies" for Going Concern considerations related to noncompliance with our debt covenants and the limited waiver.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182549280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation and stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stock-based compensation and stockholders' equity</a></td>
<td class="text">Stock-based compensation and stockholders' equity<div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock-based compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company granted stock options to purchase 0.3&#160;million shares of common stock, 0.6&#160;million restricted stock units and 0.1&#160;million performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Performance stock units are presented at the target payout percentage of 100% of target shares granted. Typically, the stock options and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria. During the three months ended March&#160;31, 2023 0.2&#160;million shares of restricted stock units and 0.2&#160;million of stock options were forfeited prior to the completion of the applicable vesting requirements or expiration. Additionally, an immaterial amount of performance stock units were forfeited during the three months ended March&#160;31, 2023, as the award targets were not achieved. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense, net of forfeitures was recorded in the following financial statement line items:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.861%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 Share Repurchase Program</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2021, the Company announced that its Board of Directors authorized a stock repurchase program of up to an aggregate of $250.0&#160;million of Common Stock ("the Share Repurchase Program"). The Share Repurchase Program expired on November 11, 2022. The Company utilized $187.9&#160;million to purchase 4.4&#160;million shares as of the program's expiration date. During the three months ended March&#160;31, 2022, the Company utilized $52.2&#160;million to purchase 1.1 million shares. Repurchased shares are available for use in connection with the Company's stock plans and for other corporate purposes.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Accumulated other comprehensive income (loss), net of tax</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.193%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.110%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Defined Benefit Pension Plan</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2022</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net current period other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.7)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net current period other comprehensive income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the tax effects related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.210%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="33" style="background-color:#19415e;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.6)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182443696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (loss) per common share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (loss) per common share</a></td>
<td class="text">Earnings (loss) per common share<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share adjusts basic loss per common share for the effects of potentially dilutive common shares and is calculated using the treasury stock method. Potentially dilutive common shares include the dilutive effect of shares issuable under our equity compensation plans, including stock options, restricted stock units, and performance stock units. Diluted loss per share excludes anti-dilutive securities, which represent the number of potential common shares related to shares issuable under our equity compensation plan that were excluded from diluted loss per common share because their effect would have been antidilutive.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted loss per share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.287%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(183.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-diluted</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per common share - basic</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.65)</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per common share - diluted</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.65)</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492179526560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue recognition</a></td>
<td class="text">Revenue recognition <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as two operating segments (see Note 17, "Segment information"). The Company's revenues disaggregated by the major sources were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.1&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103.4&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133.7&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237.1&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total CDMO</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.0&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/><br/></span><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2020, the Company, through its wholly-owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into the Agreement with Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, for large-scale drug substance manufacturing of Johnson &amp; Johnson&#8217;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#8220;Product&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, the Company provided to Janssen a notice (the &#8220;Notice&#8221;) of material breach of the Agreement for, among other things, failure by Janssen (i) to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Agreement and (ii) to confirm Janssen&#8217;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Agreement and instead, wind-down the Agreement ahead of fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#8220;Janssen Notice&#8221;) of the Agreement for asserted material breaches of the Agreement by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices ("cGMP") or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the Company&#8217;s breaches were not curable and that, therefore, termination of the Agreement would be effective as of July 6, 2022. The Company disputes </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result of the Company's alleged failure to perform under the Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process through arbitration.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, there were no impacts on previously recognized revenue or depreciation related to the conclusion of the Agreement. As of March&#160;31, 2023, the Company has no billed or unbilled net accounts receivable related to the Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the fourth quarter of 2022, because the arbitration process may extend longer than one year, the Company reclassified amounts related to the Janssen Agreement from "Inventories, net" and from "Prepaid expenses and other current assets" to "Other assets", resulting in $152.7&#160;million in long-term assets related to the Janssen Agreement on the Condensed Consolidated Balance Sheet as of December&#160;31, 2022. The long-term asset balance within "Other Assets" related to the Agreement as of March&#160;31, 2023 was $153.9&#160;million. These assets include termination penalties, certain inventory related items and raw materials inventory representing materials purchased for the Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of the inventory as of March&#160;31, 2023, concluding that because the Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for any reason, the Company is entitled to payment from Janssen for these raw materials. Additionally, the Company has $5.4&#160;million of non-cancelable orders as of March&#160;31, 2023 which have not been received and Janssen has not reimbursed.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CDMO operating leases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain multi-year CDMO service arrangements with commercial customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates 2.5 years. The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components. Excluding future amounts related to the Agreement as discussed above, the Company estimates future operating lease revenues to be $3.3&#160;million in the remainder of 2023, $0.9&#160;million in 2024, $0.9&#160;million in 2025, $0.9&#160;million in 2026, $0.9&#160;million in 2027 and $0.9&#160;million in years beyon</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d 2027.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction price allocated to remaining performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company has future contract value on unsatisfied performance obligations of approximately $331.1&#160;million associated with all arrangements entered into by the Company. The Company expects to recognize a majority of the $331.1&#160;million of unsatisfied performance obligations within the next 24 months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associated with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#8217;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of March&#160;31, 2023 and December&#160;31, 2022, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had $27.1 million an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$34.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, of contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded within "Accounts receivable, net" on the Condensed Consolidated Balance Sheets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the Condensed Consolidated Balance Sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the roll forward of the contract liability balances:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18.7)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the current portion of contract liabilities was $12.8&#160;million and $26.4&#160;million, respectively, and was included in "Other current liabilities" on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts receivable and allowance for expected credit losses</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:61.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billed</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for expected credit losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155.9&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492179526560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the lessee for operating leases for offices, R&amp;D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets and liabilities. For a discussion of lessor activities, see Note 13, "Revenue recognition".</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.149%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are reflected as components of cost of product sales, cost of contract development and manufacturing, R&amp;D expense and selling, general and administrative expense.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.863%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Leases</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_2bbfbc2c-d247-4e2c-8c4a-1c01ee6c8aa2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_7baa0cdf-0d92-4228-afaa-c3228f02be7a">Other assets</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.4&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_1145e4f7-1aec-4074-98e1-3ac124493f0e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_d44d3959-2bf6-46da-bfab-b74e748a5df1">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_3c68e61a-e113-4e32-8721-bdace66fd926"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_9da09783-cbaa-40ca-9a98-b6bc1f730f8f">Other liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182522752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated effective annual tax rate for the years ended December&#160;31, 2023 and 2022, excluding the impact of discrete adjustments, was (13)% and 25%, respectively. The decrease in the estimated effective annual tax rate is primarily due to a valuation allowance charge. The Company recorded a discrete tax expense of $0.0&#160;million for the three months ended March&#160;31, 2023, and $0.4&#160;million for the three months ended March&#160;31, 2022. The discrete tax expense in 2023 was due to share-based compensation activity which was entirely offset by a valuation allowance charge. The net discrete expense in 2022 was primarily due to share-based compensation activity and return to provision adjustments.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. At each reporting period, the Company considers the scheduled reversal of deferred tax liabilities and assets, available taxes in carryback periods, tax planning strategies and projected future taxable income in making this assessment.</span></div>In 2022, the Company determined that it was more likely than not that certain deferred tax assets would not be realized due to reductions in estimates of future profitability and disclosure related to substantial doubt about the Company's ability to continue as a going concern. Accordingly, the Company recorded an additional valuation allowance charge of $65.2 million in calculating the estimated annual tax rate for the year ended December&#160;31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492184052288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text">Litigation<div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities and shareholder litigation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock, seeking to pursue remedies under the Securities Exchange Act of 1934. These complaints were filed by Palm Tran, Inc. &#8211; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth; and Stephen M. Weiss, respectively. The complaints allege, among other things, that the defendants made false and misleading statements about the Company's manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as "CDMO Manufacturing Capabilities"). These cases were consolidated on December 23, 2021, under the caption In re Emergent BioSolutions Inc. Securities Litigation, No. 8:21-cv-00955-PWG (the "Federal Securities Class Action"). The Lead Plaintiffs in the consolidated matter are Nova Scotia Health Employees&#8217; Pension Plan and The City of Fort Lauderdale Police &amp; Firefighters&#8217; Retirement System. The defendants filed a motion to dismiss on May 19, 2022 and the Lead Plaintiff filed an opposition to that motion on July 19, 2022. A hearing on the motion to dismiss was conducted on April 19, 2023 and a decision on the motion is expected in the coming months. The defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the consolidated action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, Lincolnshire Police Pension Fund (&#8220;Lincolnshire&#8221;), and on August 16, 2021, Pooja Sayal, filed putative shareholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, the cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-PWG. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022 the Court approved the parties joint stipulation to and stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action. The defendants believe that the allegations in the complaints are without merit and intend to defend the matter vigorously.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, September 16, 2021 and November 12, 2021, putative shareholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp; Police Officers Pension Fund, respectively, in The Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption In re Emergent BioSolutions, Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#8217; filed a motion to dismiss the complaint. Ruling on this motion is stayed pursuant to a March 29, 2022 order staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, December 22, 2021 and January 18, 2022, putative shareholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the federal securities laws, each allegation related to the CDMO Manufacturing Capabilities. The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings and Discovery, pursuant to which the parties agreed to stay all proceedings until 30 calendar days after a ruling on the defendants&#8217; motion to dismiss the Federal Securities Class Action. The Court approved the Joint Stipulation on March 14, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above actions, the Company has received inquiries and subpoenas to produce documents related to these matters from the Department of Justice, the SEC, the Maryland Attorney General&#8217;s Office, and the New York Attorney General&#8217;s Office. The Company produced or is producing documents as required in response and will continue to cooperate with these government inquiries. The Company also received inquiries and subpoenas from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis and Senator Murray of the Committee on Health, Education, Labor and Pensions. The Company produced documents and provided testimony and briefings as requested in response to these inquiries.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182014048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment informationThe Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. We manage our business with a focus on two reportable segments. Our Products segment, which includes the Anthrax - MCM products, NARCAN products, Smallpox - MCM products and Other products, and our Services segment consisting of our CDMO services. The Company evaluates the performance of these reportable segments based on revenue and Adjusted Gross Margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but it does not include inter-segment services. The Company defines Adjusted Gross Margin as segment revenue less segment cost of sales reduced for significant events, inventory step-up provisions and changes in fair value of contingent consideration. The Company does not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the chief operating decision maker ("CODM"). The accounting policies for segment reporting are the same as for the Company as a whole.<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its assets on a total company basis, not by operating segment, as the Company's operating assets are shared or commingled. Therefore, the Company's CODM does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes segment revenues and a reconciliation of the Company's segment adjusted gross margin to the consolidated statement of operations for each of the Company's reporting segments:</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"/><td style="width:63.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#ededed;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total segment revenues</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">297.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants revenues</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Less: Cost of sales:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.2&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost of sales</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.5&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated gross margin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments to gross margin:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value of contingent consideration</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated adjusted gross margin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt;text-indent:-9pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other reconciling items</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants revenue</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to gross margin</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40.6)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(46.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(84.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17.9)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(161.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 10pt 0 1pt;text-indent:-9pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total segment revenues less total cost of sales.</span></div></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consolidated gross margin plus adjustments to gross margin.</span></div></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each segment:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"/><td style="width:61.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.361%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation:</span></td><td colspan="3" style="background-color:#ededed;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492185467984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of March&#160;31, 2023. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Pre-launch inventory</a></td>
<td class="text">Within our Products segment, costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, we consider a number of specific facts and circumstances, including the product candidate&#8217;s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a CDMO contract as CDMO pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:</span></div><div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Observable inputs for identical assets or liabilities such as quoted prices in active markets;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs other than quoted prices in active markets that are either directly or indirectly observable; and</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company&#8217;s long-term variable interest rate debt arrangements (Level 2) approximate their fair values.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">The Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. We manage our business with a focus on two reportable segments. Our Products segment, which includes the Anthrax - MCM products, NARCAN products, Smallpox - MCM products and Other products, and our Services segment consisting of our CDMO services. The Company evaluates the performance of these reportable segments based on revenue and Adjusted Gross Margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but it does not include inter-segment services. The Company defines Adjusted Gross Margin as segment revenue less segment cost of sales reduced for significant events, inventory step-up provisions and changes in fair value of contingent consideration. The Company does not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the chief operating decision maker ("CODM"). The accounting policies for segment reporting are the same as for the Company as a whole.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182487008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and liabilities held for sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities classified as held for sale in the Condensed Consolidated Balance Sheets as of March&#160;31, 2023 consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;March&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets held for sale:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97.1&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets held for sale</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities held for sale:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities held for sale</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182513632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of and changes in the Company's restructuring accrual during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.997%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Transition</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Severance Payments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Employee Benefits</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Restructuring and Related Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs associated with the Company&#8217;s segments as well as unallocated corporate and research and development ("R&amp;D") charges for the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.216%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs by segment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the total restructuring costs, by function, for the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.216%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee transition</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severance payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total restructuring costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182485008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.148%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143.4&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367.9&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492179526560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.148%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land and improvements</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.9&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">327.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">515.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">567.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,092.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,201.4&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation &amp; amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(375.2)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(383.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property, plant and equipment, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">716.8&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">817.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182495104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table summarizes the Company's Intangible assets, net:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:14.195%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Weighted Average Useful Life in Years</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.6</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">849.1&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240.2&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">608.9&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">982.1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">253.3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">728.8&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">883.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">274.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">608.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,016.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">728.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The net carrying value of intangible assets as of March&#160;31, 2023 excluded $102.9&#160;million of assets related to our travel health business, which were reclassified as assets held for sale in anticipation of the sale of the travel health business to Bavarian Nordic (see Note 3, "Assets and liabilities held for sale").</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the changes in the carrying amount of goodwill by reportable segment:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Products </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Services </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218.2&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218.2&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts for the Company's Products segment include gross carrying values of $259.9&#160;million as of March&#160;31, 2023 and December&#160;31, 2022 and accumulated impairment losses of $41.7&#160;million.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amounts for the Company's Services segment include gross carrying values of $6.7&#160;million as of March&#160;31, 2023, December&#160;31, 2022, and accumulated impairment losses of $6.7&#160;million.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492177255264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.313%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.670%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.387%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">320.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">320.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">308.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">500.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">320.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.6&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.6&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a reconciliation of the beginning and ending balance of the Company's contingent consideration liability: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Contingent Consideration</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.6&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurement for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:18.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.066%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Contingent Consideration Liability</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Fair Value as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Range</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty based</span></td><td colspan="3" rowspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.6 million</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounted cash flow</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25% - 50%</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projected year of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 - 2028</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492185230864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Number of Instruments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Notional</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$350.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the Condensed Consolidated Balance Sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.143%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Fair Value of Asset Derivatives</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Derivative Instruments, Gain (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:15.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.162%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivatives</span></td><td colspan="3" rowspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Location of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)</span></td><td colspan="9" style="background-color:#19415e;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Amount of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)</span></td></tr><tr style="height:15pt"><td colspan="9" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182493184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the components of the Company&#8217;s debt:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.831%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.148%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement - Term loan due 2023</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">354.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">362.8&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement - Revolver loan due 2023</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">598.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">598.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.875% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">450.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">450.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,405.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,413.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion of long-term debt, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(950.7)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(957.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion of debt, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">447.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">448.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492186294288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation and stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense, net of forfeitures was recorded in the following financial statement line items:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.861%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.193%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.110%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Defined Benefit Pension Plan</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2022</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net current period other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.7)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December&#160;31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net current period other comprehensive income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the tax effects related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.210%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="33" style="background-color:#19415e;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.6)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e526-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182014048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (loss) per common share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Income per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted loss per share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.287%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(183.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average number of shares outstanding-diluted</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per common share - basic</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.65)</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per common share - diluted</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.65)</span></td><td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492185486464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The Company's revenues disaggregated by the major sources were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Non-USG</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.1&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103.4&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133.7&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237.1&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total CDMO</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.0&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Rollforward of Contract Liabilities</a></td>
<td class="text">The following table presents the roll forward of the contract liability balances:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Contract Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18.7)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance at March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ScheduleOfAccountsReceivableNetTableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:61.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billed</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for expected credit losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155.9&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ScheduleOfAccountsReceivableNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Accounts Receivable, Net [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ScheduleOfAccountsReceivableNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182422224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.149%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Leases Supplemental Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.583%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.863%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Leases</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_2bbfbc2c-d247-4e2c-8c4a-1c01ee6c8aa2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_7baa0cdf-0d92-4228-afaa-c3228f02be7a">Other assets</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.4&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_1145e4f7-1aec-4074-98e1-3ac124493f0e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_d44d3959-2bf6-46da-bfab-b74e748a5df1">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_3c68e61a-e113-4e32-8721-bdace66fd926"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_9da09783-cbaa-40ca-9a98-b6bc1f730f8f">Other liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492178988416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes segment revenues and a reconciliation of the Company's segment adjusted gross margin to the consolidated statement of operations for each of the Company's reporting segments:</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"/><td style="width:63.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#ededed;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total segment revenues</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">297.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants revenues</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Less: Cost of sales:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.2&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost of sales</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.5&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated gross margin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjustments to gross margin:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in fair value of contingent consideration</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated adjusted gross margin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt;text-indent:-9pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other reconciling items</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants revenue</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to gross margin</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40.6)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(46.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(84.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17.9)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(161.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 10pt 0 1pt;text-indent:-9pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Total segment revenues less total cost of sales.</span></div></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consolidated gross margin plus adjustments to gross margin.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each segment:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"/><td style="width:61.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.361%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation:</span></td><td colspan="3" style="background-color:#ededed;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.6&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492184074864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the business and organization (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>category </div>
<div>product </div>
<div>segment </div>
<div>productCandidate </div>
<div>Category</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfCategoriesOfPublicHealthThreats', window );">Number of categories of public health threats | category</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfRevenueGeneratingProducts', window );">Number of revenue generating products | product</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfProductCandidates', window );">Number of product candidates | productCandidate</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfProductAndServiceCategories', window );">Number of product and service categories | Category</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfCategoriesOfPublicHealthThreats">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of categories of public health threats.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfCategoriesOfPublicHealthThreats</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfProductAndServiceCategories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product And Service Categories</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfProductAndServiceCategories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfRevenueGeneratingProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of revenue generating products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfRevenueGeneratingProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492185153296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,405.4<span></span>
</td>
<td class="nump">$ 1,413.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">598.0<span></span>
</td>
<td class="nump">598.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 354.4<span></span>
</td>
<td class="nump">$ 362.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492187239616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and liabilities held for sale - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>employee</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember', window );">Travel Health Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated', window );">Number of employees expected to join Bavarian Nordic</a></td>
<td class="nump">280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Expected Number Of Positions Eliminated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492185574608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and liabilities held for sale - Schedule of Assets and Liabilities Held for Sale (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Assets held for sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total assets held for sale</a></td>
<td class="nump">$ 225.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Liabilities held for sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total liabilities held for sale</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Assets held for sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventories, net</a></td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Property, plant and equipment, net</a></td>
<td class="nump">97.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent', window );">Intangible assets, net</a></td>
<td class="nump">102.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total assets held for sale</a></td>
<td class="nump">225.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Liabilities held for sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total liabilities held for sale</a></td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Accrued Compensation, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182634144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs - Narrative (Details) - 2023 Restructuring Plan<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated, percent</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlan2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlan2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492180262096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs - Restructuring and Related Costs (Details) - 2023 Restructuring Plan<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total restructuring costs by segment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total restructuring costs by segment | Products</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total restructuring costs by segment | Services</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_UnallocatedResearchAndDevelopmentMember', window );">R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember', window );">Employee transition</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance payments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlan2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlan2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_UnallocatedResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_UnallocatedResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492185563920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring costs - Schedule of Restructuring Reserve by Type of Cost (Details) - 2023 Restructuring Plan<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">9.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember', window );">Employee transition</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance payments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember', window );">Employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Accruals</a></td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ebs_RestructuringPlan2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ebs_RestructuringPlan2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeTransitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=ebs_EmployeeBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492207241792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, net - Schedule of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 148.9<span></span>
</td>
<td class="nump">$ 143.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">122.1<span></span>
</td>
<td class="nump">116.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">96.9<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories, net</a></td>
<td class="nump">$ 367.9<span></span>
</td>
<td class="nump">$ 351.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492180558800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,092.0<span></span>
</td>
<td class="nump">$ 1,201.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation &amp; amortization</a></td>
<td class="num">(375.2)<span></span>
</td>
<td class="num">(383.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">716.8<span></span>
</td>
<td class="nump">817.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">31.9<span></span>
</td>
<td class="nump">54.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings, building improvements and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">305.7<span></span>
</td>
<td class="nump">327.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">515.5<span></span>
</td>
<td class="nump">567.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">64.8<span></span>
</td>
<td class="nump">65.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 174.1<span></span>
</td>
<td class="nump">$ 185.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492207249472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">$ 155.1<span></span>
</td>
<td class="nump">$ 155.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember', window );">Jansen Pharmaceuticals, Inc. | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492180386416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 883.2<span></span>
</td>
<td class="nump">$ 1,016.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">274.3<span></span>
</td>
<td class="nump">287.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">608.9<span></span>
</td>
<td class="nump">728.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Travel Health Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent', window );">Intangible assets held for sale</a></td>
<td class="nump">$ 102.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life in Years</a></td>
<td class="text">13 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 849.1<span></span>
</td>
<td class="nump">982.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">240.2<span></span>
</td>
<td class="nump">253.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 608.9<span></span>
</td>
<td class="nump">728.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life in Years</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 28.6<span></span>
</td>
<td class="nump">28.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">28.6<span></span>
</td>
<td class="nump">28.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">CDMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life in Years</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ebs_TravelHealthBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractDevelopmentAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractDevelopmentAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492186260048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets and goodwill - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 17.0<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 218.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492179781920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible assets and goodwill - Goodwill Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 218.2<span></span>
</td>
<td class="nump">$ 218.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">218.2<span></span>
</td>
<td class="nump">218.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">259.9<span></span>
</td>
<td class="nump">259.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, impaired, accumulated impairment loss</a></td>
<td class="nump">41.7<span></span>
</td>
<td class="nump">41.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, impaired, accumulated impairment loss</a></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492179775424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">308.3<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">176.9<span></span>
</td>
<td class="nump">320.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">131.4<span></span>
</td>
<td class="nump">179.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">176.9<span></span>
</td>
<td class="nump">320.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">176.9<span></span>
</td>
<td class="nump">320.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">125.5<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">125.5<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492179702400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Contingent Consideration Roll Forward (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">$ 7.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492185547824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Business combination, contingent consideration, liability, current</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="nump">$ 220.6<span></span>
</td>
<td class="nump">$ 225.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492180378704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value</a></td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value</a></td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Level 3 | Fair Value, Recurring | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Level 3 | Fair Value, Recurring | Probability of payment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Level 3 | Fair Value, Recurring | Probability of payment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ebs_MeasurementInputProbabilityOfPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ebs_MeasurementInputProbabilityOfPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492195224688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swaps</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Net deferred losses from accumulated other comprehensive loss</a></td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182435760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details) - Designated as Hedging Instrument - Interest Rate Swaps<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>instrument</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Instruments | instrument</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional | $</a></td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492183981024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swaps | Designated as Hedging Instrument | Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair Value of Asset Derivatives</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492184269856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details) - Interest Rate Swaps - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492179582368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 1,405.4<span></span>
</td>
<td class="nump">$ 1,413.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt, net</a></td>
<td class="num">(950.7)<span></span>
</td>
<td class="num">(957.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of debt, net</a></td>
<td class="nump">447.7<span></span>
</td>
<td class="nump">448.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Term Loan | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">354.4<span></span>
</td>
<td class="nump">362.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 598.0<span></span>
</td>
<td class="nump">$ 598.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492181178672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance costs, current, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,405.4<span></span>
</td>
<td class="nump">$ 1,413.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod', window );">Debt instrument, covenant, net leverage ratio rolling period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod', window );">Debt instrument, covenant, net leverage ratio adjustment period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Prior to August 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Maximum | Prior to August 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Maximum | Upon the occurrence of a change in control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio', window );">Debt covenant, consolidated debt service coverage ratio, minimum</a></td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioOne', window );">Debt instrument, covenant, net leverage ratio, maximum</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioTwo', window );">Debt instrument, covenant, net leverage ratio, adjustment</a></td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Federal Funds Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Base Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember', window );">Term Loan Facility | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears', window );">Percentage of original principal amount required to repay in the first two years</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear', window );">Percentage of original principal amount required to repay during the third year</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears', window );">Percentage of original principal amount required to repay remaining year</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight', window );">Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantConsiderationThreshold', window );">Debt instrument, covenant, consideration threshold</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantConsiderationThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Consideration Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantConsiderationThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Service Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantDebtServiceCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in the third year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in the first two years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in remaining years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492180993520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation and stockholders' equity - Narrative (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Nov. 11, 2022</div></th>
<th class="th"><div>Nov. 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted (in shares)</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Nonvested options forfeited (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="nump">$ 187.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity instruments other than options granted (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Equity instruments other than options, forfeited in period (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity instruments other than options granted (in shares)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage', window );">Target payout percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Target Payout Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492184239840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product sales | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product sales | CDMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492180250368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 1,383.0<span></span>
</td>
<td class="nump">$ 1,619.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive loss before reclassifications</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">1,202.6<span></span>
</td>
<td class="nump">1,575.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(9.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember', window );">Defined Benefit Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive loss before reclassifications</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive loss before reclassifications</a></td>
<td class="num">(4.4)<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive loss before reclassifications</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">$ (6.7)<span></span>
</td>
<td class="num">$ (7.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492179842608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="num">$ (2.7)<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Expense</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Expense</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492186421648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (loss) per common share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (183.0)<span></span>
</td>
<td class="num">$ (3.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares outstanding-basic (in shares)</a></td>
<td class="nump">50.2<span></span>
</td>
<td class="nump">50.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares outstanding-diluted (in shares)</a></td>
<td class="nump">50.2<span></span>
</td>
<td class="nump">50.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (3.65)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (3.65)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492177970480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 184.6<span></span>
</td>
<td class="nump">$ 191.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">331.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Contract with customer, asset, noncurrent</a></td>
<td class="nump">27.1<span></span>
</td>
<td class="nump">34.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of contract liabilities</a></td>
<td class="nump">$ 12.8<span></span>
</td>
<td class="nump">26.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear', window );">Lessor, operating lease, payment to be received, remainder of fiscal year</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">Lessor, operating lease, payment to be received, year one</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">Lessor, operating lease, payment to be received, year two</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">Lessor, operating lease, payment to be received, year three</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">Lessor, operating lease, payment to be received, year four</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour', window );">Lessor, operating lease, payment to be received, after year four</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember', window );">Jansen Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Increase in other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">153.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Non-cancelable orders</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Payment To Be Received, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492180991792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 165.1<span></span>
</td>
<td class="nump">$ 307.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember', window );">USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">31.0<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember', window );">Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">134.1<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">143.4<span></span>
</td>
<td class="nump">237.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">103.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">117.3<span></span>
</td>
<td class="nump">133.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">Contract Development And Manufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total CDMO</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">Contract Development And Manufacturing [Member] | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total CDMO</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">Contract Development And Manufacturing [Member] | Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total CDMO</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">51.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">51.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases | Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | Non-USG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_UnitedStatesGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_NonUnitedStatesGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492185466592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Contract Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ChangeinContractWithCustomerLiabilityRollForward', window );"><strong>Change in Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning of period</a></td>
<td class="nump">$ 31.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ContractWithCustomerLiabilityAdditions', window );">Deferral of revenue</a></td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ContractWithCustomerLiabilityDeductions', window );">Revenue recognized</a></td>
<td class="num">(18.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">End of period</a></td>
<td class="nump">$ 18.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ChangeinContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ChangeinContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492180179984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed</a></td>
<td class="nump">$ 106.5<span></span>
</td>
<td class="nump">$ 102.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled</a></td>
<td class="nump">49.8<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for expected credit losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 155.9<span></span>
</td>
<td class="nump">$ 158.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492186313664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492179865600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="nump">$ 19.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="nump">$ 20.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492179884736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective annual tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Discrete tax expense (benefits)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective annual tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, deferred tax asset, increase, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492195178032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492180584512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 165.1<span></span>
</td>
<td class="nump">$ 307.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Less: Cost of sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">155.1<span></span>
</td>
<td class="nump">155.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Consolidated gross profit</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">142.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ProductsSegmentAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Adjusted Gross Margin</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">142.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Other reconciling items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_GrossProfitAdjustments', window );">Adjustments to gross margin</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(40.6)<span></span>
</td>
<td class="num">(46.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="num">(100.5)<span></span>
</td>
<td class="num">(84.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="num">(17.0)<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(17.9)<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(161.1)<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsAndServicesSegmentsMember', window );">Products And Services Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">158.6<span></span>
</td>
<td class="nump">297.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">143.4<span></span>
</td>
<td class="nump">237.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Less: Cost of sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">102.9<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Consolidated gross profit</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">156.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ProductsSegmentAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Adjusted Gross Margin</a></td>
<td class="nump">44.0<span></span>
</td>
<td class="nump">157.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Less: Cost of sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">52.2<span></span>
</td>
<td class="nump">75.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Consolidated gross profit</a></td>
<td class="num">(37.0)<span></span>
</td>
<td class="num">(14.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ProductsSegmentAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Adjusted Gross Margin</a></td>
<td class="num">$ (37.0)<span></span>
</td>
<td class="num">$ (14.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AdjustedGrossMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Gross Margin</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AdjustedGrossMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_GrossProfitAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Profit, Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_GrossProfitAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ProductsSegmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Products Segment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ProductsSegmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsAndServicesSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsAndServicesSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492185537456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">$ 17.6<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140492182607792">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
<td class="nump">$ 642,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>ebs-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ebs="http://emergentbiosolutions.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ebs-20230331.xsd" xlink:type="simple"/>
    <context id="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i88874a031ee64129abddf35ef51b22ec_I20230502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="i5a596f9ce817474386ba6f96f2eb24e5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i960cf41acb8b4188a01129fbd602dc88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8bac9a933b6d4e1f906de2a6a7325d62_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i96983ae20d1a4fd892a5f1444783a570_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i18e052da12c34e0e91cf56a39cd08cd1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i513c1b52eb2e4d47828f3ec0440d9a1a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i79e134d107e94e148da24dade40b12b6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8373489620694e8096c4d7cb76a601a2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i282b3d80373a44448dcd835b4ec3dd02_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6fcbd10db46849358e569878c1ae8ae0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0e5222cf971340bab0614a17ebbf5ed8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0d4fc9a55e4b49afb88321e52246a468_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7a099fddd1d84c7d879062f83fca8e8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i953f447150654f76b7cc01b3726027f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if638389216994724b23bca4d31679eb8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e44cdd29cc9499e9a66348b41656de5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i849666feb2a44d2fa12bc7967461f166_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8b4fd4e61c64973a212a85c54c0ebfd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if51069b7c708450e883968233c7b1100_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i082e5f03a9d2471da47571c1adea47c0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9e9d567e96ac4140ac247d74d68d020a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i497afa8d2afd4248a986014e9fa76586_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7692443ac57041479453a23b16bf3759_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8d0eaabe911a4ba4b4d72bc7370d9dc9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i613917f0ad0b475e99daeb4f7102a659_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1d83f154114044a1bbe6ae3c214f52d4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i54a6e4454a964795b8edeb5a00bdfc7a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0c1de96d7b3145dfbc133d2bb6a68cf5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie210714807324475943299c21e7d8fbc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife892d5886074c32ab62a900867615d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id730fb1f570643e09406bfe6aebe15ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0c52e66b26e4a1896b467cc5a122d9f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdfa38102e80436a8a1a8bf7681229d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2ce03bb85346406d822354b0c6ab920f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf01802184ad4612ab0690e8efff37c0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i31244a3a054948c88dabb06cdf5a93c8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i03aa139c772549d8844c18ac3d48d451_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie4912cf676c54fd1a8050521892e67c6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1caaf133e6f74cabaebe862b712e4d3f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i974ccd2c2487469c941cfc01885a5b62_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9426132f4f814179b20fee2cb4d853f7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i92b10b20be474bf0bb98ab88bd4310f2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i822b4db8d3a940d2a307f01f1a9c52ed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9b4a69b4f7e640dc9de146fd74f4ac6a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7237bcbb75b9405287fe50d45561e97f_D20230401-20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ebs:TravelHealthBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i81c28e226ee545b286e49388a057533c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i73c9842bc063446586bea2405cf33206_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icff2f736d0b84c82b69da3ae149c3877_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i90160f3d0ce54037a7e491254512bf65_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie4f9663fd12b4d8484ab91cd3165ab5f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:UnallocatedResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d94d342fe9f478da83d206f54833e08_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i624499c702f2496996732d4f547a1882_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic516a1f410604d7db3e1ff143e87a7b1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icd5bdd8d49c244448c14a689d71f1025_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i84af060aae1748fbbaa67887f4b7dbcd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3d2e8509aab4186a3c6aa464c1d4d74_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i469c99f1aa3e49068c75ef98b7a985dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75626974e4ff4354ae25be0a61b75c46_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeTransitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iad162e2c548e417d957ea777b298e0d2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i32b120655ff64d55a24337355f419f4f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">ebs:EmployeeBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i89d77487aec94b21a79a891c0bdda7bc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ebs:RestructuringPlan2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4331c0bdb2464807b4afa3f5612e3dad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib52346ef764e49d7ae1d0de332535d80_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0029254369834e77ba355f9f9212091d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i04382820c4b94237b445c43c5180113d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib46720b3fc2644378640e7ecb3eaff6c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if6246980b9314b79820f3539a51fe388_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4e4c69e4ac943b990497e0161be6d0a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia0622ee9b0854a68821bf3319e45908f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id84508c19f22426e8d7a7d283878a833_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i338e967572ba42808fef537a31e71be4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f4212f3132341cf84f6c7de6e063ded_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if4232914f6124a5e9828197daee03b72_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i95ad12ca119f497ab07833d15fda564a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie47c273b662b4a1892d60f7abfa2f3ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id2f1b2dc03074501a7307fb35e98698e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib2cfce5e9fe14623a73853fac221b591_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i949bce8b04694470a4528f867f0e10cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa639b8052ec4dfd86c079463f947791_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i941ca3dc089c4dac89d3aced14c53f5b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2fa7094242a244a5b9b80db78bdbc0d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d248c38e3394ed5bd6f6e4cda0f9c56_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb147a1d8ee745288cc6b591771da65f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7db14af93756495bb396ad2850eb791d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iced1288bc5d94738bdeb41c7ef631b5a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2678670ef0614327a8e6d3ba7f775ffe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i312fc4d3fa3d40a8b8d40b165fac9f23_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0fe6faf4ab404b7eaeb1185f253fdc6d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i237d46bcc69045b68b66b29364f7c338_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i575796b9fe234a88851410d4452a2542_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b9542ada7984655be665a722b9ac8b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c9b39689c8b4daabd9ce8b4ca48f1fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i087f2351596c4d7aaa0c69f2847ad606_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4a4bf125ea1426898eefe90abf2468b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0b76ca7b5a934284bb3f69ae4eac313f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i63a4559b34534083bbc78a87767ff732_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib6de70121c46438aa85618bf326f814d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i676d5ac2770d4880b80e8f9affcc0405_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab0b615be15c41e492c20d99095ebd67_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i846c202a9d2c465a8eaa59bba8fb61d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa141f63b241430bb8414182bb967b11_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iecb9b277674f497f94bb0ad15086a2d1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9da03b4151704bc0b9cd5c7932118c29_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i07bc53a7e37d4103b284a544dfaee08f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i10bc8bb2a2354813ac6212066587b081_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i28872533ff2f45f8afc92cc4728820d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8dd4d6dd4734137a3740ddea65d8249_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20c6e639de504e66bd14ca1b9f011604_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifba6b2f3fd2d4feba5acceb8d159572c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2adc9adb687d4dc4a6c4288252be0818_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityOfPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6a1c5f04948a4ba69680ad3fa0b5fe08_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityOfPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i542cdb35121f4951af58b7c4d099cc0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib979976208634b5c8e0a9ae50b18d4cb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8751da105fac4730bbdbaffce144fb47_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8c80cc2623ec43ee87f691cd40d2b03c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1f157297decc4c27a1eb9955ddfbb47b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i48a3c046c3a04962bc32bb21e900d52f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i263ac071f3a94b6cb410cb5275bfd042_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa715f99b2c046f29b82294c4c8cf1bd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id194daf24cf04654893b13c8dd06a8ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i52702739ed104778bc9a6b44dbd6a56c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iacaf8ffa11674dc59342790fd0bd5b42_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb39b7b0e50a41899b13e8e7a176cb73_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1b6cd7196060498f8905b788318223e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a4e68384fff4fba80f54b1741dcdea3_I20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="i2b6c423aa64e4e4896e0475d47d5f2cb_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i78876bbef2be40f0b38c6232f78ff57d_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="iacf16d55ed5643cb9ac1bebbf0f1c165_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i4b04150f100345e5b7d1dba860fc021b_I20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="ic3e55eef26f54a4894de8f45425d8253_I20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="i4918ce9801c5412b8cd5dd6bf028c13e_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i254adee00af34c94bbc5984b0bfbe52e_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="iedb6ef8e0b6b46208f6e01be5daa2b80_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i8d8a56f631634a619610a599c7700384_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="if513d33ee9754a8db7bc70bffe5355a8_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i2890fd9ac6bc4bceb48adb41f2e0e88c_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="ide27297d8c9443f09185ce0447397db4_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="id5c8865dca0b4780ad587e383427e48b_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="icaeda5c9c6b540f5bb7a60baecd1d9b2_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="ib1dc2e31750040a4aeea787dbc908607_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3cc418bd58f7472abd99705c9a2a8c70_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7c48770f38cc4b868dfb8e4164c70c6d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6f2abaf2d65647afabbaad4036b4002b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4a17055fb3844751ba1ee5905c41696a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c648afc26c64c1cb1d06fba7976dd3e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i052a8c8b494f4d23ba4683eec555cd78_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie7b2c1680b344a52a7479ff1cb61e234_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i352e9c64d26145bd8c991621254ab36d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2f4af96e200044a4bde5f4e7858cea4c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3820b0b0d3c345288eeffbe32298f81f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5a35abf804794f0cb7a12ca90e436e2b_I20211111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-11-11</instant>
        </period>
    </context>
    <context id="i6a932e200f934b2e8d7602dfc0339fbe_D20211111-20221111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-11</startDate>
            <endDate>2022-11-11</endDate>
        </period>
    </context>
    <context id="ib39593e9eeaa410eb010f609006439d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i571387e1e87d4c0ca79fba6168341392_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8456a4beddae4620b224ffe90a753930_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38e2cc2fa38f451983e4495ebddf4541_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i96351882c9cf4a119573f21d2fd9c69c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia07411d977084f2bb9e23d05b7a3e72f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id8cf4c3b78864ea8b78309b616ed410d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i004ed59fdb204528af83813c202f2349_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied3e0a962bf84f89a49887476428ac94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f133842273b47d8a0e0c8008c0debc9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1df6434f4c741debcb5c66e3f358e12_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iecaf90f0f80546248e7c187071884007_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i691f830478c747349de4e41c45528d98_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4eb60b9b64b04e06af66a990c3c77632_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7bb83926187b4279b16006f3f7fb2ab1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2f45a7313b224629804838fb75fad240_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1fad61803b4d40fbab45263d09fa943a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2b14f3e18ba4492ba6a39464c8dbffda_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i147235e355704bc1902c80160146ae9b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i72844a727a4940a0a5b4f18cc4afb0ec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6f98df3f96494ca3af0b6134b79f6e6c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i732a446dfeda451387df581fcd0cfb6e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id50de4745d3a466eafedae511bbe57f3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1ed128aa8d4847bd8d098b42c1c2112a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4a7228c4c4da4a3daa277c2e60ff556d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifc9f8df6d25942899d6f3695ef5c6172_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i987753cf494a4b45ace898c7942aef7c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5383a292c962418f9b059d0b06839b4e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie421a9cb2b954cbca8c8c507c55fd2bd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i95813f0ec62d4d0c9fcc5789b0837330_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d187bce987143dc92586a3d08ecacd6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id10f475f516846bcae44f6b46b3bbd0b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iab03b11d81254786a5977fced794e6b1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i871dc7a154524d879334cb879c7ddfd0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia3379cc28cb04ee5bececd01664b6872_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4efd920943c8420a8281d18b9639ad0e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib83a1dda4ddc4ccdad92792fb6b17c46_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2c77354994dd4d71ac100d180641d494_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9415e748067844bfbe9ef3caeb28bad0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id3f4207af8e54989a266f7659a215b5e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff58dd309a0441e3b97192aae2d95c4f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idd7432d9b0914c74aee8b459bf887d15_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i04f3699777f34efe88b689e5c3e48b90_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:UnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i39d08b46e2f94f58a5f1e2935eeece69_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:NonUnitedStatesGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4294703259534cdcbbf6f3c0f104718b_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id18cb2b8881b4956ac5446f313a06aa4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iae2ab95b86444d45b4d488934aae7ce6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ide9ab2059eb245668f1987b63208f7e7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib40925538fdf41e1b15aa28d2dffd833_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i92e936994b3b439dae281f549affd0f1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4dd32b195d7e4239a60662ca51d6ee42_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsAndServicesSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i918438631165446c9ba9921f135d6a33_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsAndServicesSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81a432e8a0bd409aabe9374107df1be3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i994e594bda11477a97c710abd0cf5e86_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="category">
        <measure>ebs:category</measure>
    </unit>
    <unit id="product">
        <measure>ebs:product</measure>
    </unit>
    <unit id="productcandidate">
        <measure>ebs:productCandidate</measure>
    </unit>
    <unit id="category2">
        <measure>ebs:Category</measure>
    </unit>
    <unit id="segment">
        <measure>ebs:segment</measure>
    </unit>
    <unit id="employee">
        <measure>ebs:employee</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="instrument">
        <measure>ebs:instrument</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80L2ZyYWc6NjIzNTdjZjQ5MzAwNDBlZGEwZTQ3NjdjOWYwMDQ4MzAvdGFibGU6OTUyYzg0MTY5OGJlNGQ4OGE0MmFmNmExMzc4Mjc0MDYvdGFibGVyYW5nZTo5NTJjODQxNjk4YmU0ZDg4YTQyYWY2YTEzNzgyNzQwNl8zLTEtMS0xLTE3NDA5MA_4e6be801-969e-4031-97e0-fb751bbba7f9">0001367644</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80L2ZyYWc6NjIzNTdjZjQ5MzAwNDBlZGEwZTQ3NjdjOWYwMDQ4MzAvdGFibGU6OTUyYzg0MTY5OGJlNGQ4OGE0MmFmNmExMzc4Mjc0MDYvdGFibGVyYW5nZTo5NTJjODQxNjk4YmU0ZDg4YTQyYWY2YTEzNzgyNzQwNl80LTEtMS0xLTE3NDA5MA_b1574acf-4f73-4a58-a0a6-320ba05a1c22">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80L2ZyYWc6NjIzNTdjZjQ5MzAwNDBlZGEwZTQ3NjdjOWYwMDQ4MzAvdGFibGU6OTUyYzg0MTY5OGJlNGQ4OGE0MmFmNmExMzc4Mjc0MDYvdGFibGVyYW5nZTo5NTJjODQxNjk4YmU0ZDg4YTQyYWY2YTEzNzgyNzQwNl8xMC0xLTEtMS0xNzQwOTA_207dabbb-f7b4-4983-813d-bfee17679a9f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80L2ZyYWc6NjIzNTdjZjQ5MzAwNDBlZGEwZTQ3NjdjOWYwMDQ4MzAvdGFibGU6OTUyYzg0MTY5OGJlNGQ4OGE0MmFmNmExMzc4Mjc0MDYvdGFibGVyYW5nZTo5NTJjODQxNjk4YmU0ZDg4YTQyYWY2YTEzNzgyNzQwNl8xMi0xLTEtMS0xNzQwOTA_7e2eaf7b-d491-486c-8300-6582a6ce2f4e">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80L2ZyYWc6NjIzNTdjZjQ5MzAwNDBlZGEwZTQ3NjdjOWYwMDQ4MzAvdGFibGU6OTUyYzg0MTY5OGJlNGQ4OGE0MmFmNmExMzc4Mjc0MDYvdGFibGVyYW5nZTo5NTJjODQxNjk4YmU0ZDg4YTQyYWY2YTEzNzgyNzQwNl8xMy0xLTEtMS0xNzQwOTA_c8920cb3-0219-43f5-bb31-09fb8a0114ca">Q1</dei:DocumentFiscalPeriodFocus>
    <ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod
      contextRef="icaeda5c9c6b540f5bb7a60baecd1d9b2_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82MS9mcmFnOjUyNjNkM2U4ZmNhNzQ2YjhhN2MzMmFhYTFmYjBkMDUzL3RleHRyZWdpb246NTI2M2QzZThmY2E3NDZiOGE3YzMyYWFhMWZiMGQwNTNfMzIx_94f7ee9f-d39f-4471-866a-c9cf1baa9a9e">P12M</ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i7bb83926187b4279b16006f3f7fb2ab1_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMS0xLTEtMS0xNzQwOTA_ee155303-6849-458c-bc9a-064105f232e8"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2f45a7313b224629804838fb75fad240_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMS0yLTEtMS0xNzQwOTA_a833e2e6-4527-4de4-8c37-aa1d810060d2"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i1fad61803b4d40fbab45263d09fa943a_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMi0xLTEtMS0xNzQwOTA_ac4f06c7-9998-43a5-8151-9b36b165dc9c"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2b14f3e18ba4492ba6a39464c8dbffda_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMi0yLTEtMS0xNzQwOTA_9bceb940-1c10-4600-95c7-7d1a14cf1da1"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i147235e355704bc1902c80160146ae9b_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMy0xLTEtMS0xNzQwOTA_fb817a40-687a-4aa9-b42e-6a53fcad4690"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i72844a727a4940a0a5b4f18cc4afb0ec_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83OS9mcmFnOmUwMzIxOTA2NDZhYjQzMmVhMWY5YzVjNTYyZGNiNDE5L3RhYmxlOjRiMmI5MjU4YWNlZDQ3ODVhYWMxMzdjYjJkOTE2MGYzL3RhYmxlcmFuZ2U6NGIyYjkyNThhY2VkNDc4NWFhYzEzN2NiMmQ5MTYwZjNfMy0yLTEtMS0xNzQwOTA_b4356db1-881d-4671-87bd-afada4e061e4"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_2bbfbc2c-d247-4e2c-8c4a-1c01ee6c8aa2">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_7baa0cdf-0d92-4228-afaa-c3228f02be7a">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_1145e4f7-1aec-4074-98e1-3ac124493f0e">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_d44d3959-2bf6-46da-bfab-b74e748a5df1">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_3c68e61a-e113-4e32-8721-bdace66fd926">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_9da09783-cbaa-40ca-9a98-b6bc1f730f8f">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODMz_8f142fad-fbe7-461b-9d0a-a3885510031b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NjgwNjIzMWM5M2ViNDA2NWEwNDZmMjk0ZWU1Mzk1YmMvdGFibGVyYW5nZTo2ODA2MjMxYzkzZWI0MDY1YTA0NmYyOTRlZTUzOTViY18wLTAtMS0xLTE3NDA5MA_95dbc491-53b2-4711-a5a2-13c9bde6ab1e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8yMTk5MDIzMjYxMjc5_700ae287-09b9-4702-bc15-82e47f4a744a">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NzhkZmUwMWI4MDRkNDUwZGJiZWU0ZGNmN2I0ODU5NDMvdGFibGVyYW5nZTo3OGRmZTAxYjgwNGQ0NTBkYmJlZTRkY2Y3YjQ4NTk0M18wLTAtMS0xLTE3NDA5MA_acde85d3-331d-4812-8a52-e383ce6c7713">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM2_18289c08-917c-4e49-8087-e879c123deed">001-33137</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM3_01d17204-9280-4089-93d3-95e5523f1a2a">EMERGENT BIOSOLUTIONS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF8wLTAtMS0xLTE3NDA5MA_265e3fb2-8a80-46c8-898d-b35dbc3e2263">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF8wLTItMS0xLTE3NDA5MA_e0e4c2c0-863d-47bf-9b36-8d39fc5d4118">14-1902018</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF8zLTAtMS0xLTE3NDA5MA_4f78440f-9e3f-44f1-a060-f5a49ed33403">400 Professional Drive Suite 400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF80LTAtMS0xLTE3NDA5MA_3da4fa25-b438-419f-8e4b-fb4f9f86e782">Gaithersburg,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF80LTEtMS0xLTE3NDA5MA_e4d9ba2f-bbdc-47ea-aa8f-8355f3fc11af">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NmZiNzdmOGM1NWQzNGViYTkwYjk5YTRlYTBmNmMyNjQvdGFibGVyYW5nZTo2ZmI3N2Y4YzU1ZDM0ZWJhOTBiOTlhNGVhMGY2YzI2NF80LTItMS0xLTE3NDA5MA_644d2057-25d0-469f-ad85-093ca15af9a0">20879</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM0_f85cbc3c-c58b-4770-9a27-13f77781423d">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM4_84cb19af-f607-4716-8909-d82338cdbd97">631-3200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6MWJhNjAzYjMwNzEwNGRlMGE1N2EyMTViNzcwMGYxZDEvdGFibGVyYW5nZToxYmE2MDNiMzA3MTA0ZGUwYTU3YTIxNWI3NzAwZjFkMV8yLTAtMS0xLTE3NDA5MA_b100b3e5-a250-453d-a08a-aecb1020b023">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6MWJhNjAzYjMwNzEwNGRlMGE1N2EyMTViNzcwMGYxZDEvdGFibGVyYW5nZToxYmE2MDNiMzA3MTA0ZGUwYTU3YTIxNWI3NzAwZjFkMV8yLTEtMS0xLTE3NDA5MA_1f2fa359-2ab9-47d8-aebd-54c60e7a6f7a">EBS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6MWJhNjAzYjMwNzEwNGRlMGE1N2EyMTViNzcwMGYxZDEvdGFibGVyYW5nZToxYmE2MDNiMzA3MTA0ZGUwYTU3YTIxNWI3NzAwZjFkMV8yLTItMS0xLTE3NDA5MA_7f3c3179-1690-40f5-8e2e-efd2e6d0f9b6">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM1_9eeeb979-cdb3-4f02-b9d1-a44cbb874fff">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODM5_b77c30fd-f44f-453a-be02-b4235d71a912">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NzA2NGYxZDkzMjVlNGI4NGI2ZGMyMGFhNGJmNzJmMWYvdGFibGVyYW5nZTo3MDY0ZjFkOTMyNWU0Yjg0YjZkYzIwYWE0YmY3MmYxZl8wLTAtMS0xLTE3NDA5MA_89315657-22a2-4965-991a-ad0e22bc0e61">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NzA2NGYxZDkzMjVlNGI4NGI2ZGMyMGFhNGJmNzJmMWYvdGFibGVyYW5nZTo3MDY0ZjFkOTMyNWU0Yjg0YjZkYzIwYWE0YmY3MmYxZl8xLTMtMS0xLTE3NDA5MA_7b1b445c-0058-459e-9e45-447913a07b41">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGFibGU6NzA2NGYxZDkzMjVlNGI4NGI2ZGMyMGFhNGJmNzJmMWYvdGFibGVyYW5nZTo3MDY0ZjFkOTMyNWU0Yjg0YjZkYzIwYWE0YmY3MmYxZl8yLTMtMS0xLTE3NDA5MA_cf73bf73-6ee2-45ff-a071-cb216c9d94c0">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml8xODQw_3525ff26-c2f1-46db-b1d1-207f5b617b7a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i88874a031ee64129abddf35ef51b22ec_I20230502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xL2ZyYWc6MTFjYmRmOGQ5NGUxNDg2ZDk0MTJjYmY3MjNhOTJiNzIvdGV4dHJlZ2lvbjoxMWNiZGY4ZDk0ZTE0ODZkOTQxMmNiZjcyM2E5MmI3Ml81NDk3NTU4MTU3NTE_defe86b8-81cd-4365-b6e9-0005e6064b8b"
      unitRef="shares">50447918</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNC0yLTEtMS0xNzQwOTA_3ed92bbe-effa-49fe-993f-4b7ad70f070f"
      unitRef="usd">430200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNC00LTEtMS0xNzQwOTA_a3d7392a-ae95-4329-a2eb-9ff18ee9f7cb"
      unitRef="usd">642600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNi0yLTEtMS0xNzQwOTA_75db1f84-7253-4620-8e75-e04c5fa4c193"
      unitRef="usd">155900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNi00LTEtMS0xNzQwOTA_8227d196-ae95-411f-ac2c-2976787296df"
      unitRef="usd">158400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNy0yLTEtMS0xNzQwOTA_56983838-b673-4fc8-9179-ffe8b853fa2e"
      unitRef="usd">367900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfNy00LTEtMS0xNzQwOTA_dd72abd6-01da-428c-9de2-4a6a921e1528"
      unitRef="usd">351800000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOC0yLTEtMS0xNzQwOTA_43dafef6-ce77-400b-81c1-d7ee699394cd"
      unitRef="usd">41700000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOC00LTEtMS0xNzQwOTA_d5f4c01a-3656-4147-8b62-aed1fb335fc1"
      unitRef="usd">57900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOS0yLTEtMS0xNzcyNDQ_c510561c-1ec5-4cb1-af58-0419714b0d03"
      unitRef="usd">225600000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOS00LTEtMS0xNzcyMzA_03a138f2-c7ac-407e-bf0d-d189e947f09d"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOS0yLTEtMS0xNzQwOTA_2477c057-46c5-4703-b0c1-a676ee264975"
      unitRef="usd">1221300000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfOS00LTEtMS0xNzQwOTA_f8b2a541-b203-4f63-bbda-96f96af281bc"
      unitRef="usd">1210700000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTEtMi0xLTEtMTc0MDkw_7d1268b6-48f0-43a7-9ffe-ed2d576e7ae7"
      unitRef="usd">716800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTEtNC0xLTEtMTc0MDkw_b4d17c15-27c7-4c91-8644-6cca1a8e3bab"
      unitRef="usd">817600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTItMi0xLTEtMTc0MDkw_d1bc11e0-97e6-4ba8-ae16-8e01e1c518b0"
      unitRef="usd">608900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTItNC0xLTEtMTc0MDkw_0406c878-8273-47ea-b452-842bd0b79b81"
      unitRef="usd">728800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTMtMi0xLTEtMTc0MDkw_d6b924e3-92a7-4b38-a990-f3f6f4778f55"
      unitRef="usd">218200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTMtNC0xLTEtMTc0MDkw_6c54423c-f7df-4892-a38c-5a26ec50bddd"
      unitRef="usd">218200000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTQtMi0xLTEtMTc0MDkw_e258ef54-fdd0-4f33-8aee-7ab0b9a5c9fc"
      unitRef="usd">184600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTQtNC0xLTEtMTc0MDkw_3d5b8ad2-d144-4a1d-aa2b-81be1af3f90f"
      unitRef="usd">191300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTUtMi0xLTEtMTc0MDkw_1ced4ea9-5a29-42bd-8925-c2cbe37687ac"
      unitRef="usd">2949800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTUtNC0xLTEtMTc0MDkw_7a7cbe54-21df-4c67-8e12-228ad2d91e5d"
      unitRef="usd">3166600000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTktMi0xLTEtMTc0MDkw_f1da97a6-1622-4006-93bb-182aea691271"
      unitRef="usd">124200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMTktNC0xLTEtMTc0MDkw_7a71e13c-5905-40ad-bdcc-5afdec09bffe"
      unitRef="usd">103500000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjAtMi0xLTEtMTc0MDkw_6110cf3a-e45f-4c3b-ae0b-42a9b523b0ad"
      unitRef="usd">21300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjAtNC0xLTEtMTc0MDkw_4099e514-8f26-44ac-b787-660e05489191"
      unitRef="usd">34900000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjEtMi0xLTEtMTc0MDkw_2035c0b0-389a-4da1-9bf9-c6ab1075a3ab"
      unitRef="usd">56800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjEtNC0xLTEtMTc0MDkw_19079e65-2cb4-4fb9-9369-35d232428d51"
      unitRef="usd">88300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjItMi0xLTEtMTc0MDkw_13963a58-9629-427e-ab81-fa58d6d5a905"
      unitRef="usd">950700000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjItNC0xLTEtMTc0MDkw_a3781426-e3bf-4bf0-8136-3dea5534816a"
      unitRef="usd">957300000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjMtMi0xLTEtMTc0MDkw_2ef8f9cd-9ac0-43f6-bd47-472065314808"
      unitRef="usd">25200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjMtNC0xLTEtMTc0MDkw_cfe90234-0cd0-4a7d-bbe3-2e6b306b467d"
      unitRef="usd">45900000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjUtMi0xLTEtMTgzNzIy_8151f9a7-e18c-4fc2-9757-f7f4ade18f5e"
      unitRef="usd">37500000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjUtNC0xLTEtMTgzNzIy_942a568d-8d9b-4e94-b20d-7c627786e7db"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjQtMi0xLTEtMTc0MDkw_31a1f323-f5bb-45a8-86d4-b42bf99cfece"
      unitRef="usd">1215700000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjQtNC0xLTEtMTc0MDkw_0878c9e8-c1a4-4758-8e89-51fb83cb4e80"
      unitRef="usd">1229900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjYtMi0xLTEtMTc0MDkw_e99f557f-5fa4-4137-9f4e-561e97e0dd93"
      unitRef="usd">447700000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjYtNC0xLTEtMTc0MDkw_7693c437-48b5-4bef-a97f-86cd84ebffde"
      unitRef="usd">448500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjctMi0xLTEtMTc0MDkw_e56914a4-5e4b-43d3-abc4-7c1896cf3acc"
      unitRef="usd">59700000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjctNC0xLTEtMTc0MDkw_9b7e7b29-5c2e-4a58-8567-a6f7a4361c24"
      unitRef="usd">71800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjgtMi0xLTEtMTc0MDkw_96f70e8d-6b13-4719-a0eb-867068dcaa11"
      unitRef="usd">24100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjgtNC0xLTEtMTc0MDkw_24635fcd-8137-4c05-9528-4198c2152b66"
      unitRef="usd">33400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjktMi0xLTEtMTc0MDkw_253c026c-0216-4256-8205-84330b233296"
      unitRef="usd">1747200000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMjktNC0xLTEtMTc0MDkw_f5124eba-e8d8-48cd-a10c-676416ba1f2e"
      unitRef="usd">1783600000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg2NQ_29f9a2d1-37dd-4c9a-814e-1e293d1e0ae5"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg2NQ_653c9e94-a11b-4ca9-beba-1cfab4892871"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg2OQ_01113c94-5ac1-4106-9331-b05b41b944df"
      unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg2OQ_f2cabb4b-8362-4625-9214-f4677c9cf75b"
      unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg3Mw_0915c235-3524-4f97-8429-749488ff2751"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg3Mw_587e9d34-c625-4b66-938a-aaf07518da36"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg3Mw_74884d0a-d863-4e32-a90d-d4869ac1c866"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZWM0M2E3ZWFmYjE3NGUxN2JiNjAwODU2ZTM1YTI5Y2FfMTA5OTUxMTYyNzg3Mw_edd7eb33-6d26-45bb-a60e-1b49a55a9091"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItMi0xLTEtMTc0MDkw_1b1ea12c-c14b-4b52-89ea-b36f1e53f32a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzItNC0xLTEtMTc0MDkw_761f8042-0cda-4956-9425-e27f3558a7f5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzg5OQ_29b78270-a5a6-48ec-a186-48a2660fed16"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzg5OQ_aa6bdcaa-58c6-4ee0-9b78-3885bb58a109"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkwMw_a8561c9b-5aef-429b-a27a-99796c8baefb"
      unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkwMw_b2fde3b6-813b-46bc-bd52-6ffdbd4ea9b4"
      unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkxNQ_702d2e9b-4133-414e-87dd-761a0970b59b"
      unitRef="shares">56000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkwNw_473f4723-32a7-4761-9daa-54e23ada144d"
      unitRef="shares">55700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkxOQ_cf0b6d8f-279a-4c05-89f0-8328bddc87d3"
      unitRef="shares">50400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246Y2IzNTc2YTZjYTdhNGZhYWJkM2VjMjdmYzBhNmM5YWRfMTA5OTUxMTYyNzkxMQ_0e574fd8-7b18-4810-93e7-f1520192a1ec"
      unitRef="shares">50100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtMi0xLTEtMTc0MDkw_64dc9ecb-f505-4d3c-8ff1-804dfbc7d090"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzMtNC0xLTEtMTc0MDkw_31e57edb-45f2-4fc2-bb45-6836987096a2"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzQtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZThiMTcwNjZlYWIzNGU5NDllYjEwYTBjY2FlNDY1YjBfMTA5OTUxMTYyNzg0Mw_21b1155e-078c-4a93-97d2-bbadd8767538"
      unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzQtMC0xLTEtMTc0MDkwL3RleHRyZWdpb246ZThiMTcwNjZlYWIzNGU5NDllYjEwYTBjY2FlNDY1YjBfMTA5OTUxMTYyNzg1MQ_3c3715ed-f058-4389-89a1-a86f1462e3e2"
      unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzQtMi0xLTEtMTc0MDkw_73e2f59b-82b4-4e17-b17b-53fd0d708f69"
      unitRef="usd">227700000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzQtNC0xLTEtMTc0MDkw_58ac306c-9c36-4e6c-bb92-c5f68bf5a014"
      unitRef="usd">227700000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzUtMi0xLTEtMTc0MDkw_afd49b66-ded6-4ac2-9455-96c96b845f24"
      unitRef="usd">878200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzUtNC0xLTEtMTc0MDkw_8f7e0857-6d62-4610-a78c-83880bda3e8a"
      unitRef="usd">873500000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzYtMi0xLTEtMTc0MDkw_625fb869-125f-43c4-aa6d-d4657e912e47"
      unitRef="usd">1000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzYtNC0xLTEtMTc0MDkw_6a027b05-d61e-41d1-a411-25a89356c18b"
      unitRef="usd">3100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzctMi0xLTEtMTc0MDkw_273a2ab0-68be-4a0d-ac65-3e638aadeeac"
      unitRef="usd">551000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzctNC0xLTEtMTc0MDkw_ce4a9b3d-af14-439f-b058-a04f3f31e2c3"
      unitRef="usd">734000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzgtMi0xLTEtMTc0MDkw_b37ede72-1bc2-4252-9608-617122023c08"
      unitRef="usd">1202600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzgtNC0xLTEtMTc0MDkw_08f42409-7cc0-4ba5-96f8-52c0d7559587"
      unitRef="usd">1383000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzktMi0xLTEtMTc0MDkw_4bb9f49e-b254-461d-b90d-f41c849b8d14"
      unitRef="usd">2949800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNi9mcmFnOjlkMzcxMmE2YTljYzQ3Mzg5OTgzMWViYzZhMzRlM2Q3L3RhYmxlOjc3YWJiY2VkOTczODQwOWI4NjI3MzNhMWJlN2QyY2VmL3RhYmxlcmFuZ2U6NzdhYmJjZWQ5NzM4NDA5Yjg2MjczM2ExYmU3ZDJjZWZfMzktNC0xLTEtMTc0MDkw_8c93e810-6278-45c9-a1c7-5e4f8a0d11e1"
      unitRef="usd">3166600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bac9a933b6d4e1f906de2a6a7325d62_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMy0xLTEtMS0xNzQwOTA_47f1d220-02fb-40c4-a5a5-364a7adb4ba2"
      unitRef="usd">143400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96983ae20d1a4fd892a5f1444783a570_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMy0zLTEtMS0xNzQwOTA_220d741f-af4d-4c3c-aa7a-ff740b026ef9"
      unitRef="usd">237100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18e052da12c34e0e91cf56a39cd08cd1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNS0xLTEtMS0xNzQwOTA_89376ba8-f089-49c4-bcd6-8a3b8091a3da"
      unitRef="usd">13400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i513c1b52eb2e4d47828f3ec0440d9a1a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNS0zLTEtMS0xNzQwOTA_47754fce-5f19-4c93-93e6-0a8df75ef925"
      unitRef="usd">51800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i79e134d107e94e148da24dade40b12b6_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNi0xLTEtMS0xNzQwOTA_bb9292b7-733e-488e-ae5c-fdbb2229ec8a"
      unitRef="usd">1800000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i8373489620694e8096c4d7cb76a601a2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNi0zLTEtMS0xNzQwOTA_86dad9c2-80b9-4f22-af2b-0dd5c71d26a2"
      unitRef="usd">9000000.0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i282b3d80373a44448dcd835b4ec3dd02_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNy0xLTEtMS0xNzQwOTA_d186d78f-8167-4346-9987-e2f3f1cecba5"
      unitRef="usd">15200000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fcbd10db46849358e569878c1ae8ae0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfNy0zLTEtMS0xNzQwOTA_5ddaf273-1da8-4610-9a20-e87b8da47dab"
      unitRef="usd">60800000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e5222cf971340bab0614a17ebbf5ed8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfOC0xLTEtMS0xNzQwOTA_856608bd-1b52-4468-a6f7-f2469fe8e3c9"
      unitRef="usd">6500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d4fc9a55e4b49afb88321e52246a468_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfOC0zLTEtMS0xNzQwOTA_05117b5e-7fab-46c0-a363-f3d5b0427568"
      unitRef="usd">9600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfOS0xLTEtMS0xNzQwOTA_df516f92-db37-42ea-90a0-b2abd3e3cc61"
      unitRef="usd">165100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfOS0zLTEtMS0xNzQwOTA_79fe4717-b7a1-49de-8c56-17bae9a49637"
      unitRef="usd">307500000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8bac9a933b6d4e1f906de2a6a7325d62_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTItMS0xLTEtMTc0MDkw_219d70c1-470a-4aec-85ae-1ce7f22be030"
      unitRef="usd">102900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i96983ae20d1a4fd892a5f1444783a570_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTItMy0xLTEtMTc0MDkw_4c266433-ce12-47ce-9b02-b3e4e129d787"
      unitRef="usd">80300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i282b3d80373a44448dcd835b4ec3dd02_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTMtMS0xLTEtMTc0MDkw_fbb3cbad-fa86-472f-bf39-14b7e16b930c"
      unitRef="usd">52200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6fcbd10db46849358e569878c1ae8ae0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTMtMy0xLTEtMTc0MDkw_2b3251b8-4166-4e5e-8a44-2aaa9bdcd110"
      unitRef="usd">75600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTQtMS0xLTEtMTc0MDkw_14628469-53cb-4309-b566-067c3ae1c8f2"
      unitRef="usd">40600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTQtMy0xLTEtMTc0MDkw_cabd71cf-2412-4d62-bdf2-1fd271809532"
      unitRef="usd">46400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTUtMS0xLTEtMTc0MDkw_b798cafd-3d9d-41c4-82d8-3285c5c063af"
      unitRef="usd">100500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTUtMy0xLTEtMTc0MDkw_0becac56-44d1-478e-b6a2-d1bc041709f1"
      unitRef="usd">84800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTYtMS0xLTEtMTc0MDkw_c905d190-f8c2-44b8-8ec5-1441158a0291"
      unitRef="usd">17000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTYtMy0xLTEtMTc0MDkw_b873614f-01bd-4c91-bd29-26e904e6db38"
      unitRef="usd">14000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTctMS0xLTEtMTc0MDkw_e6f62788-5538-458b-ab77-9bd3366827be"
      unitRef="usd">313200000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTctMy0xLTEtMTc0MDkw_9be15efe-3cdb-4f14-930f-64479e6b1469"
      unitRef="usd">301100000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTktMS0xLTEtMTc0MDkw_80ce2ea8-f4bb-44ad-be72-5e276a88aafb"
      unitRef="usd">-148100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMTktMy0xLTEtMTc0MDkw_3481de83-e918-46e0-b071-8da477ebf33a"
      unitRef="usd">6400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjItMS0xLTEtMTc0MDkw_2d0352d0-8342-4383-b5fa-8678a9f600b8"
      unitRef="usd">17900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjItMy0xLTEtMTc0MDkw_340b0204-a869-4bcb-b5e9-6dc3181b38fb"
      unitRef="usd">8200000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjMtMS0xLTEtMTc0MDkw_1dc2e9e5-4fc5-4261-a4df-3af55624026b"
      unitRef="usd">4900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjMtMy0xLTEtMTc0MDkw_27758d59-e55d-4987-b965-91c3f630ad7f"
      unitRef="usd">-2000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjQtMS0xLTEtMTc0MDkw_52cde439-391b-4b29-8e9f-0bf8753e1ee0"
      unitRef="usd">-13000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjQtMy0xLTEtMTc0MDkw_94733124-186b-474b-b840-7b39dbabe835"
      unitRef="usd">-10200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjYtMS0xLTEtMTc0MDkw_2ae179df-b78f-46cd-9921-e0f01d49de64"
      unitRef="usd">-161100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjYtMy0xLTEtMTc0MDkw_db419477-a718-42b1-87e4-c3839dfa05f6"
      unitRef="usd">-3800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjctMS0xLTEtMTc0MDkw_622a8cf8-4470-45d8-a3f7-ffa009ecfea0"
      unitRef="usd">21900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjctMy0xLTEtMTc0MDkw_0556864f-299a-4b77-9fb8-33056a391b86"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjgtMS0xLTEtMTc0MDkw_b9d147c4-e9cd-49bb-8e39-4aef3a15b632"
      unitRef="usd">-183000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMjgtMy0xLTEtMTc0MDkw_d88b4ef6-53c7-435b-bc59-7e028c5909a3"
      unitRef="usd">-3700000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzEtMS0xLTEtMTc0MDkw_9ec1226c-99d0-41b5-93dd-1803f5de3eb3"
      unitRef="usdPerShare">-3.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzEtMy0xLTEtMTc0MDkw_698382dc-c236-4c26-8f88-a1b0a5b7c617"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzItMS0xLTEtMTc0MDkw_dd3e9f52-16e1-4f96-bdc6-cb239c04030d"
      unitRef="usdPerShare">-3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzItMy0xLTEtMTc0MDkw_52c24f6c-16a4-4004-8061-3a390d717c1e"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzUtMS0xLTEtMTc0MDkw_e026564f-26cf-4b05-8d8a-a9809fce1e2e"
      unitRef="shares">50200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzUtMy0xLTEtMTc0MDkw_a1321d9d-aff7-4c91-89c9-e41a4ec4ddbf"
      unitRef="shares">50700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzYtMS0xLTEtMTc0MDkw_d72d0325-c113-4175-8265-6cf149410704"
      unitRef="shares">50200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xOS9mcmFnOjFmOTQ4YzVjMWZiZjQ2ZGVhZDQxODBlYTI4MmU0NWY0L3RhYmxlOmFiNjQ1ODhjNTExYzQ2OGY4NDAwMjdjNWNmMjk3NjExL3RhYmxlcmFuZ2U6YWI2NDU4OGM1MTFjNDY4Zjg0MDAyN2M1Y2YyOTc2MTFfMzYtMy0xLTEtMTc0MDkw_ec35f0de-e6de-4622-a82d-b7e553fb2b4b"
      unitRef="shares">50700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfMi0xLTEtMS0xNzQwOTA_df104032-7d34-4670-8046-d6c357ddb78d"
      unitRef="usd">-183000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfMi0zLTEtMS0xNzQwOTA_e0ce7220-39f1-447f-b468-d7f22ea03887"
      unitRef="usd">-3700000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNC0xLTEtMS0xNzQwOTA_d9c3cc8a-eaf5-4558-ba70-7d29311e1867"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNC0zLTEtMS0xNzQwOTA_87b37586-8f18-4c2f-9014-828b00b76150"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNS0xLTEtMS0xNzQwOTA_c46e0275-e807-45c9-9d58-15a7310f1305"
      unitRef="usd">-2000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNS0zLTEtMS0xNzQwOTA_cb0682b6-b025-4389-8e4f-49ac0ff73cb9"
      unitRef="usd">6300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNy0xLTEtMS0xNzQwOTA_f4dd3ef1-f661-4ea9-b073-1de3a0be2dfe"
      unitRef="usd">-2100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfNy0zLTEtMS0xNzQwOTA_50f98a87-bb7a-4966-8e67-fd60428a68de"
      unitRef="usd">6800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfOC0xLTEtMS0xNzQwOTA_fef392f5-9035-4b64-866d-31f9523af979"
      unitRef="usd">-185100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yMi9mcmFnOjUyNjQ4YmQ1YjMzNjQyNGViYjVlNTI0ODBiZjFkNGQwL3RhYmxlOjkxMjFiYjQ0NzFmMTQ4ODk4ZGE4MzllNzFjODNiNjI1L3RhYmxlcmFuZ2U6OTEyMWJiNDQ3MWYxNDg4OThkYTgzOWU3MWM4M2I2MjVfOC0zLTEtMS0xNzQwOTA_bc9954ec-fe95-4fc6-a19e-d80445a6e7bb"
      unitRef="usd">3100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMy0xLTEtMS0xNzQwOTA_459e0bf4-3819-4f61-a393-2416c5b11df4"
      unitRef="usd">-183000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMy0zLTEtMS0xNzQwOTA_53ac25be-3e7d-4b07-8125-61b33459c9e3"
      unitRef="usd">-3700000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNS0xLTEtMS0xNzQwOTA_8d018c1a-bbe6-48ec-b8c1-c6d2a819fcf9"
      unitRef="usd">6800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNS0zLTEtMS0xNzQwOTA_baefcc11-6e40-4a3a-a4d7-901ea756278f"
      unitRef="usd">9900000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNi0xLTEtMS0xNzQwOTA_79269be5-9e58-4346-a121-1bab48ce348e"
      unitRef="usd">34600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNi0zLTEtMS0xNzQwOTA_27914552-03ff-4957-89ef-2e492b3a2978"
      unitRef="usd">30900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfOC0xLTEtMS0xNzQwOTA_ba69ecde-a56d-4e52-b45a-8a454e2bbcfa"
      unitRef="usd">1500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfOC0zLTEtMS0xNzQwOTA_b744ae5f-b243-4835-9238-939b6fdd1e2a"
      unitRef="usd">500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfOS0xLTEtMS0xNzQwOTA_01ce6143-3c57-458e-afb8-81e3679ce644"
      unitRef="usd">1000000.0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfOS0zLTEtMS0xNzQwOTA_b113ebd0-1ca1-41ba-afe2-2c67620ca27a"
      unitRef="usd">1000000.0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTAtMS0xLTEtMTc0MDkw_7e7e19a8-a6b8-4a9b-be58-612e468551d7"
      unitRef="usd">-8400000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTAtMy0xLTEtMTc0MDkw_7a235d39-7133-4612-98a4-3e17a8044303"
      unitRef="usd">1900000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTEtMS0xLTEtMTc0MDkw_0e5752e9-7669-4d37-a661-d22b61794c56"
      unitRef="usd">-300000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTEtMy0xLTEtMTc0MDkw_273220b5-7b6d-4f9a-8eba-a0e9ca6cf5f9"
      unitRef="usd">-600000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTMtMS0xLTEtMTc0MDkw_706f97a0-03f4-472c-8f23-894bdfcf3d25"
      unitRef="usd">-1800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTMtMy0xLTEtMTc0MDkw_1300a881-92b3-4a53-ab13-02bdcfee3675"
      unitRef="usd">-93700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTQtMS0xLTEtMTc0MDkw_fcccd691-551f-4123-80c9-63f0228a8eaf"
      unitRef="usd">29600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTQtMy0xLTEtMTc0MDkw_75e9239a-78db-479c-8211-2b28b274df06"
      unitRef="usd">50100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTUtMS0xLTEtMTc0MDkw_fbc9c76f-0fef-46d0-a990-dd84a67752d7"
      unitRef="usd">4500000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTUtMy0xLTEtMTc0MDkw_eb14b6c3-a2cb-4ceb-891f-dc3d46914c98"
      unitRef="usd">16600000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTYtMS0xLTEtMTc0MDkw_8494490b-9415-4b1a-a755-c34e06f537a2"
      unitRef="usd">31000000.0</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTYtMy0xLTEtMTc0MDkw_6ebe8ced-69e9-4c5d-8cae-d736e20e6ddd"
      unitRef="usd">-14700000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTctMS0xLTEtMTc0MDkw_53f8bb59-b386-41d9-9474-b9792695be31"
      unitRef="usd">-14700000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTctMy0xLTEtMTc0MDkw_50ba7e38-8e6f-4985-8b86-2ced9109ba8d"
      unitRef="usd">-51000000.0</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTctMS0xLTEtMTgyODQ0_98b5f773-42d0-4e7c-a6ea-7aedb7e69a66"
      unitRef="usd">-25300000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTctMy0xLTEtMTgyODQ0_9c7d5913-dadf-4cd4-beac-247dcced242b"
      unitRef="usd">-32200000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTgtMS0xLTEtMTc0MDkw_c6dce842-ed1a-48ad-a312-b6a097b9e04c"
      unitRef="usd">12900000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTgtMy0xLTEtMTc0MDkw_0d16dd7f-7528-42d6-babc-5b150931c6b7"
      unitRef="usd">-5500000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTktMS0xLTEtMTc0MDkw_bcac86cb-be88-4706-a33d-56df92ab5f81"
      unitRef="usd">-8400000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMTktMy0xLTEtMTc0MDkw_3e427445-4f65-4a7b-8d53-ca129fd0401b"
      unitRef="usd">-2000000.0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjAtMS0xLTEtMTc0MDkw_b83ceb2f-f9a6-4bfc-9eab-84917647aa61"
      unitRef="usd">-184000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjAtMy0xLTEtMTc0MDkw_89c2fc09-e742-420f-9e2d-1d68a318cf26"
      unitRef="usd">-37300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjItMS0xLTEtMTc0MDkw_f66caa83-bb1d-4db0-9a6b-690e780d8ec5"
      unitRef="usd">15100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjItMy0xLTEtMTc0MDkw_a82854ef-8ede-4641-a7df-b11691ed7bdd"
      unitRef="usd">32200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjQtMS0xLTEtMTc0MDkw_cb7b7e45-5f1d-45f0-9982-e06a3b24743d"
      unitRef="usd">-15100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjQtMy0xLTEtMTc0MDkw_5085e114-2a82-423b-8664-222ab95d0364"
      unitRef="usd">-32200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjctMS0xLTEtMTc0MDkw_c4ff27c5-c847-43e1-8030-b5d9cf3b7591"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjctMy0xLTEtMTc0MDkw_e4132bc7-4696-46e9-8c22-52a00bf597e7"
      unitRef="usd">57500000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjgtMS0xLTEtMTc0MDkw_9d6ff9dd-0a01-4287-b835-a97d84b3f6b1"
      unitRef="usd">8400000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMjgtMy0xLTEtMTc0MDkw_861ed073-270d-4424-9574-a539256de58d"
      unitRef="usd">8500000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzAtMS0xLTEtMTc0MDkw_5aa6fb6a-c8dd-4cbf-a7bc-dce74a5b315d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzAtMy0xLTEtMTc0MDkw_3f2e5b17-52fa-4abb-82d8-0f1d82255678"
      unitRef="usd">500000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzEtMS0xLTEtMTc0MDkw_b82558de-083e-4536-9be6-ee1733eb3118"
      unitRef="usd">2100000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzEtMy0xLTEtMTc0MDkw_538c0f62-23a1-45e8-ae14-b06f367be520"
      unitRef="usd">5000000.0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzMtMS0xLTEtMTc0MDkw_eb68c2b1-8940-4edc-9f74-c1d4da680aa6"
      unitRef="usd">-10500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzMtMy0xLTEtMTc0MDkw_5bce7b44-4867-4e2e-9cac-74988562b839"
      unitRef="usd">-70500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzQtMS0xLTEtMTc0MDkw_795988de-1d6d-407f-8e3a-98c81912893d"
      unitRef="usd">-200000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzQtMy0xLTEtMTc0MDkw_018227da-164b-4be9-aac4-8a0cef32e7ff"
      unitRef="usd">-300000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzUtMS0xLTEtMTc0MDkw_bb63a328-da2e-4dd1-b6b3-1960354e3096"
      unitRef="usd">-209800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzUtMy0xLTEtMTc0MDkw_32ef88b8-86de-4ca9-bfb3-502844d5ca10"
      unitRef="usd">-140300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzYtMS0xLTEtMjAwMjMw_4619f1fd-25ec-445e-b864-5839a458602c"
      unitRef="usd">2600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzYtMy0xLTEtMjAwMjM5_18a3c769-b7ec-4426-9d73-483ab716d080"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzYtMS0xLTEtMTc0MDkw_951b2a9f-c8b0-4052-99ef-4f4275c32cd1"
      unitRef="usd">642600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7a099fddd1d84c7d879062f83fca8e8e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzYtMy0xLTEtMTc0MDkw_c899160e-85c8-427b-90e9-94839fbe6458"
      unitRef="usd">576300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzctMS0xLTEtMTc0MDkw_c70a1a82-164a-4c3c-b5bc-b3f89884bf0d"
      unitRef="usd">430200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzctMy0xLTEtMTc0MDkw_8d0abbcb-4c87-4b8a-af7c-8210261fb093"
      unitRef="usd">436000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzktMS0xLTEtMTc0MDkw_188108a0-a44a-4426-b0ab-0f4db7434500"
      unitRef="usd">21600000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfMzktMy0xLTEtMTc0MDkw_a88987df-f76e-431c-8e83-654a78c8118b"
      unitRef="usd">11700000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDAtMS0xLTEtMTc0MDkw_b45bcae9-d633-4cb4-a9f6-a259c8ab24db"
      unitRef="usd">16700000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDAtMy0xLTEtMTc0MDkw_c6d2f692-187f-439d-8867-506f9f1f193e"
      unitRef="usd">4800000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDItMS0xLTEtMTc0MDkw_45fb7a6b-9972-4cb2-bf96-1d60fbb5f21f"
      unitRef="usd">7800000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDItMy0xLTEtMTc0MDkw_bec5d681-0f3d-4f25-ac74-beba4e8d19dd"
      unitRef="usd">13300000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <ebs:NoncashPurchasesOfTreasuryStock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDMtMS0xLTEtMTgyOTc1_17d399e6-37d9-4e18-867d-ed2dbc168064"
      unitRef="usd">0</ebs:NoncashPurchasesOfTreasuryStock>
    <ebs:NoncashPurchasesOfTreasuryStock
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDMtMy0xLTEtMTgyOTc1_7442e80f-722f-47b6-8ab9-8d730b394956"
      unitRef="usd">1300000</ebs:NoncashPurchasesOfTreasuryStock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDQtMS0xLTEtMTc0MDkw_dd31dfd9-39f9-46f0-9859-3822d818ddb1"
      unitRef="usd">430200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDQtMy0xLTEtMTc0MDkw_b43b1785-ae4e-42e4-85fa-f6de3d643fd7"
      unitRef="usd">642600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDYtMS0xLTEtMTkzNDQ3_71537194-c3d6-4060-9a76-869be4484c41"
      unitRef="usd">2600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDYtMy0xLTEtMTkzNDU1_44cd4275-e1fb-47f7-a98f-a747119c6506"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDYtMS0xLTEtMTc0MDkw_7931fa71-ba0d-4c08-b1a3-9049c5cebe53"
      unitRef="usd">432800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yNS9mcmFnOjk4Y2IyYmIxMDZiZDRlY2E4OTEzYTY0M2U3YzE0MjMyL3RhYmxlOjQwMWY5MmQxNmFlZDRkNGFhMGRlMDk4MDQ1YzQwNmY4L3RhYmxlcmFuZ2U6NDAxZjkyZDE2YWVkNGQ0YWEwZGUwOTgwNDVjNDA2ZjhfNDYtMy0xLTEtMTc0MDkw_1f419a45-8ce9-4b05-af05-778468acabbd"
      unitRef="usd">642600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMC0yLTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjphMmY2NDNlMjUzNjQ0NDlkOTQ3MmE5MWU0MmZkNTZiNV81_9466289d-8f0c-4276-9d09-703111df8758"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMC0yLTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjphMmY2NDNlMjUzNjQ0NDlkOTQ3MmE5MWU0MmZkNTZiNV81_b904d2af-6ace-4437-b0a7-03cf8cab6595"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i953f447150654f76b7cc01b3726027f2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi0yLTEtMS0xNzQwOTA_3d72b3b7-132a-4cef-8c59-19165bcd9dc9"
      unitRef="shares">55700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i953f447150654f76b7cc01b3726027f2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi00LTEtMS0xNzQwOTA_53d9642b-7a11-4c90-9ec0-a80c872378a6"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="if638389216994724b23bca4d31679eb8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi02LTEtMS0xNzQwOTA_3a433911-6b95-4db5-a34d-2c21d1f402ff"
      unitRef="shares">5600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="if638389216994724b23bca4d31679eb8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi04LTEtMS0xNzQwOTA_fa74bc3d-df51-4d0f-9bcf-bd57ccb8a9e3"
      unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e44cdd29cc9499e9a66348b41656de5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi0xMC0xLTEtMTc0MDkw_e7b2110d-86af-4b3e-8976-f27dd43e803d"
      unitRef="usd">873500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i849666feb2a44d2fa12bc7967461f166_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi0xMi0xLTEtMTc0MDkw_2cc47609-0994-4237-bbd3-566af4428ca6"
      unitRef="usd">3100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8b4fd4e61c64973a212a85c54c0ebfd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi0xNC0xLTEtMTc0MDkw_18706970-6dd2-4ce9-a8e4-5cd5deeb8ee9"
      unitRef="usd">734000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMi0xNi0xLTEtMTc0MDkw_17201e07-0203-48f1-8f9a-9ea6ae28d6ec"
      unitRef="usd">1383000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if51069b7c708450e883968233c7b1100_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMy0xNC0xLTEtMTk1MzIw_05791a84-badc-4ee6-8c39-add1b7a0f0bb"
      unitRef="usd">-183000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMy0xNi0xLTEtMTk1MzIw_16975cbb-d541-48fa-b947-0265d34f5493"
      unitRef="usd">-183000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i082e5f03a9d2471da47571c1adea47c0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMy0yLTEtMS0xNzQwOTA_6a82ff62-0058-4539-b7cc-4b3d1651c829"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9e9d567e96ac4140ac247d74d68d020a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMy0xMC0xLTEtMTc0MDkw_b01b0412-422e-428e-b3ee-a05ab38bae5c"
      unitRef="usd">4700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfMy0xNi0xLTEtMTc0MDkw_cd713548-0487-47da-a990-97f79d97ed5d"
      unitRef="usd">4700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i497afa8d2afd4248a986014e9fa76586_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNi0xMi0xLTEtMTc0MDkw_c5853f77-24b6-459b-982d-9713503f0f60"
      unitRef="usd">-2100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNi0xNi0xLTEtMTc0MDkw_179599aa-55ea-4fc9-9cdd-604f85ba86ad"
      unitRef="usd">-2100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7692443ac57041479453a23b16bf3759_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy0yLTEtMS0xNzQwOTA_7f435787-eb8b-4629-9d66-1217b849778f"
      unitRef="shares">56000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i7692443ac57041479453a23b16bf3759_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy00LTEtMS0xNzQwOTA_3ddd3c5c-739c-47a2-8a32-cd307a4987d8"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8d0eaabe911a4ba4b4d72bc7370d9dc9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy02LTEtMS0xNzQwOTA_6457213f-7da4-475c-ae94-71fce469ea9c"
      unitRef="shares">5600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i8d0eaabe911a4ba4b4d72bc7370d9dc9_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy04LTEtMS0xNzQwOTA_a89b70ba-7002-41f5-9a24-aaf8a3017258"
      unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i613917f0ad0b475e99daeb4f7102a659_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy0xMC0xLTEtMTc0MDkw_6917c70c-c242-4e97-923d-6cdbf88d3f87"
      unitRef="usd">878200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1d83f154114044a1bbe6ae3c214f52d4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy0xMi0xLTEtMTc0MDkw_6d3ed94d-87ff-4194-b0e4-9441adbc3def"
      unitRef="usd">1000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54a6e4454a964795b8edeb5a00bdfc7a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy0xNC0xLTEtMTc0MDkw_2f919d30-29f7-4ca2-b07b-e67364d48f46"
      unitRef="usd">551000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmEwZjAwNjZlNzIyMjQ1NzJiZDQwZjJkYTE2YzhmYWZkL3RhYmxlcmFuZ2U6YTBmMDA2NmU3MjIyNDU3MmJkNDBmMmRhMTZjOGZhZmRfNy0xNi0xLTEtMTc0MDkw_f3f66e58-5449-4872-922e-9a419e6f5159"
      unitRef="usd">1202600000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMC0yLTEtMS0xODU2NjIvdGV4dHJlZ2lvbjpjOWRlM2RjNTFmMmQ0MDEwYjk4YmViYmVjMmViNjQ0MF81_9466289d-8f0c-4276-9d09-703111df8758"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMC0yLTEtMS0xODU2NjIvdGV4dHJlZ2lvbjpjOWRlM2RjNTFmMmQ0MDEwYjk4YmViYmVjMmViNjQ0MF81_b904d2af-6ace-4437-b0a7-03cf8cab6595"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0c1de96d7b3145dfbc133d2bb6a68cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi0yLTEtMS0xODU2OTE_79c51dfe-be3b-4fa7-9140-6330254e2b64"
      unitRef="shares">55100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0c1de96d7b3145dfbc133d2bb6a68cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi00LTEtMS0xODU2OTE_e1e78158-3bc5-4163-a719-8ff2064c5b9b"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie210714807324475943299c21e7d8fbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi02LTEtMS0xODU2OTQ_22d3d722-1c0b-42cb-a536-b04e1762898f"
      unitRef="shares">3800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ie210714807324475943299c21e7d8fbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi04LTEtMS0xODU2OTQ_ade6aa72-581b-45b3-ae20-ace29229eec6"
      unitRef="usd">-152200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife892d5886074c32ab62a900867615d9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi0xMC0xLTEtMTg1Njk3_f9ec8ad8-29c3-48c5-b4ce-18af91611897"
      unitRef="usd">829400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id730fb1f570643e09406bfe6aebe15ba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi0xMi0xLTEtMTg1NzAw_29133cc8-5260-4241-80ef-60366c66ab09"
      unitRef="usd">-16100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0c52e66b26e4a1896b467cc5a122d9f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi0xNC0xLTEtMTg1NzAw_7861c6ad-bcd8-4346-bbcf-e75c57a2877d"
      unitRef="usd">957800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a099fddd1d84c7d879062f83fca8e8e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMi0xNi0xLTEtMTg1NzAw_66b031e1-c2ad-4a34-ae14-4a96bd3d6939"
      unitRef="usd">1619000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icdfa38102e80436a8a1a8bf7681229d4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMy0xNC0xLTEtMTk1MzEw_27c0b7c2-836b-40d4-8321-5c0c4cf428cc"
      unitRef="usd">-3700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMy0xNi0xLTEtMjAwMDkx_f72b62ba-2384-4c6c-aabe-8611495e851e"
      unitRef="usd">-3700000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2ce03bb85346406d822354b0c6ab920f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMy0yLTEtMS0xODU3MDM_1dd2f4fd-d323-473d-a2d5-6f2e861306ef"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaf01802184ad4612ab0690e8efff37c0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMy0xMC0xLTEtMTg1NzE3_862955f3-8ee0-4e41-abca-148260c2426c"
      unitRef="usd">5400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfMy0xNi0xLTEtMTg1NzEw_ba28cc62-18b0-4544-91b8-327e325a5208"
      unitRef="usd">5400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i31244a3a054948c88dabb06cdf5a93c8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNS02LTEtMS0xODU3MDc_d8ce2f90-0a62-46aa-b8a5-0e7d74e8fbd6"
      unitRef="shares">1100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i31244a3a054948c88dabb06cdf5a93c8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNS04LTEtMS0xODU3MDc_78a5c9c4-383c-48f0-b50d-49f5fe305ff3"
      unitRef="usd">52200000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNS0xNi0xLTEtMTg1NzEw_abce7a09-c339-4753-9460-f9be718161bf"
      unitRef="usd">52200000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i03aa139c772549d8844c18ac3d48d451_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNi0xMi0xLTEtMTg1NzEw_b11b0c84-6745-40c3-b1cb-5f92991c53b1"
      unitRef="usd">6800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNi0xNi0xLTEtMTg1NzEw_e024e49d-6d26-45a2-894b-a4b32f98c8f4"
      unitRef="usd">6800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie4912cf676c54fd1a8050521892e67c6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy0yLTEtMS0xODU2NzA_f65e9a81-82ec-4e18-9ae2-9170e02f790c"
      unitRef="shares">55300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ie4912cf676c54fd1a8050521892e67c6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy00LTEtMS0xODU3MDM_b74c52e5-edd4-450c-b35a-3dd7ed5a6890"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1caaf133e6f74cabaebe862b712e4d3f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy02LTEtMS0xODU3MDc_f4d97ade-bc3c-4960-8822-d24439861ce3"
      unitRef="shares">4900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i1caaf133e6f74cabaebe862b712e4d3f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy04LTEtMS0xODU3MDc_121bb979-e413-4449-b5d8-c9521db94d6c"
      unitRef="usd">-204400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i974ccd2c2487469c941cfc01885a5b62_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy0xMC0xLTEtMTg1NzE3_d4ef5700-f38e-42f1-875d-b0a32ea54fcf"
      unitRef="usd">834800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9426132f4f814179b20fee2cb4d853f7_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy0xMi0xLTEtMTg1NzEw_62617511-e8c0-44b0-82cc-3788bf4b3875"
      unitRef="usd">-9300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92b10b20be474bf0bb98ab88bd4310f2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy0xNC0xLTEtMTg1NzEw_2bffc073-2237-4166-b0db-6adffcd9de4c"
      unitRef="usd">954100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8yOC9mcmFnOmRlZmJhOTIwNzRiODRhZGE5NDhlZTEwODA1OWE5N2U2L3RhYmxlOmU2NmFkYjAwZjNmNzQzMDBiYTZkMzUxNDc3NmUxMWJiL3RhYmxlcmFuZ2U6ZTY2YWRiMDBmM2Y3NDMwMGJhNmQzNTE0Nzc2ZTExYmJfNy0xNi0xLTEtMTg1NzEw_11bd7ccf-7873-4c21-b7cb-d458a5b39732"
      unitRef="usd">1575300000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfNzYwNw_bb02f848-d884-4a5b-8d84-9bb2c1586bb5">Nature of the business and organization&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization and business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Emergent BioSolutions Inc., including its consolidated subsidiaries (&#x201c;Emergent,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats ("PHTs"). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ("CDMO") services portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is focused on the following five PHT categories: chemical, biological, radiological, nuclear and explosives ("CBRNE"); emerging infectious diseases ("EID"); travel health, which we have agreed to sell to Bavarian Nordic; emerging health crises; and acute/emergency care. The Company has a product portfolio of thirteen products (vaccines, therapeutics, and drug-device combination products). The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company has one product candidate that is procured under special circumstances by the United States government ("USG"), although it is not approved by the United States Food and Drug Administration ("FDA"). The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following four product and service categories: Anthrax - Medical Countermeasures ("MCM") Products, NARCAN, Smallpox - MCM Products and CDMO Services. The Company operates as two operating segments: (1) a products segment ("Products") consisting of the Anthrax - MCM products, NARCAN products, Smallpox - MCM products and Other products and (2) a services segment ("Services") focused on CDMO services (Note 17, "Segment information&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Company's products and services include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Anthrax - MCM Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;Anthrasil&#xae; (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;AV7909 (Anthrax vaccine adsorbed (AVA), adjuvanted) procured product candidate being developed as a next-generation anthrax vaccine for post-exposure prophylaxis. AV7909 has not been approved by the FDA, but is procured by certain authorized government buyers for their use;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;BioThrax&#xae; (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;Raxibacumab injection, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;NARCAN&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone approved by the FDA (including in over-the-counter form) and Health Canada for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Smallpox - MCM Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;ACAM2000&#xae;, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;CNJ-016&#xae; (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;TEMBEXA&#xae;, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks which has been approved by the FDA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients, including neonates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;BAT&#xae; (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of symptomatic botulism; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;Ebanga&#x2122; (ansuvimab-zykl), a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics ("Ridgeback"), Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#x2122; in the U.S. and Canada, and Ridgeback will serve as the global access partner for Ebanga&#x2122;;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;RSDL&#xae; (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA that is intended to remove or neutralize chemical warfare agents from the skin, including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;Trobigard&#xae; atropine sulfate, obidoxime chloride auto-injector, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It was approved in Belgium in 2021 but has not been approved by the FDA. Trobigard is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure outside of the U.S.;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;Vaxchora&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Cholera Vaccine, Live, Oral), the first vaccine approved by the FDA for the prevention of cholera, which we have agreed to sell as part of our travel health business (Note 3, "Assets and liabilities held for sale"); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Source Sans Pro',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.66pt"&gt;Vivotif&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Typhoid Vaccine Live Oral Ty21a), a live attenuated vaccine for oral administration for the prevention of typhoid fever, which we have agreed to sell as part of our travel health business (Note 3, "Assets and liabilities held for sale").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Services - Contract Development and Manufacturing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's services line focused on CDMO offerings cover development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided to customers from across the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale.&#160;Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ebs:NumberOfCategoriesOfPublicHealthThreats
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfMTY0OTI2NzQ2NzA1Nw_b2dd703d-c0f8-4fe5-9fa2-d2cdf05223f7"
      unitRef="category">5</ebs:NumberOfCategoriesOfPublicHealthThreats>
    <ebs:NumberOfRevenueGeneratingProducts
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfMTY0OTI2NzQ2NzA2MQ_cb7167d2-4f09-49e1-8d3b-c12193c27b5c"
      unitRef="product">13</ebs:NumberOfRevenueGeneratingProducts>
    <ebs:NumberOfProductCandidates
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfMTA5OTUxMTY0MjYzMQ_f57f5272-1ec5-46d7-a52f-64218d271e7d"
      unitRef="productcandidate">1</ebs:NumberOfProductCandidates>
    <ebs:NumberOfProductAndServiceCategories
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfNDk0NzgwMjM2Mjc4Ng_775d5c05-4970-4395-8092-2235af9e6fec"
      unitRef="category2">4</ebs:NumberOfProductAndServiceCategories>
    <us-gaap:NumberOfReportableSegments
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfMTA5OTUxMTY0MjY1Nw_25904a2e-c7fd-4897-92f6-57fb9e4dbb42"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNC9mcmFnOjI2M2E0MTA4MmY0ZDRkM2JhYjFjNjEyZmRlOTYxMzVkL3RleHRyZWdpb246MjYzYTQxMDgyZjRkNGQzYmFiMWM2MTJmZGU5NjEzNWRfMTA5OTUxMTY0MjY1Nw_e1785b3d-d453-4476-864e-65e5ac7806fb"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfODI3Ng_3de520fd-c78d-4bf2-8678-6793369d9b73">Summary of significant accounting policies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of March&#160;31, 2023. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, there is $598.0&#160;million outstanding on the Revolving Credit Facility (defined below) and $354.4&#160;million on the Term Loan Facility (defined below) that matures in October 2023, which is within one year of the date that the consolidated financial statements are issued for the quarter ended March&#160;31, 2023. The Company determined that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation considered the potential mitigating effect of management&#x2019;s plans that have not been fully implemented. Management may evaluate the mitigating effect of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's plan to alleviate the substantial doubt includes amending its existing Revolving Credit Facility and Term Loan Facility that are due October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company is in the process of and expects to replace the current credit facility before it matures, management cannot make the assumption that it is probable that the Company will be able to obtain such debt refinancing on commercially reasonable terms or at all until the new credit facility is in place. The Company is currently working with its lenders and expects to refinance the credit facility with revised terms and conditions. The extent to which the Company will be able to affect such refinancing, replacement or maturity extension on terms that are favorable or at all is dependent on a number of uncertain factors, including then-prevailing credit and other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, disruptions or volatility caused by factors such as COVID-19, regional conflicts, inflation, and supply chain disruptions. In addition, rising interest rates could limit our ability to refinance our existing credit facility when it matures or cause us to pay higher interest rates upon refinancing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the replacement of the Company&#x2019;s current debt facility is conditional upon the execution of agreements with new or existing third parties, which are considered outside of the Company&#x2019;s control, until such time as they are completed, the refinancing cannot be considered to be probable to occur as of the date of this report. The Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pre-launch inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within our Products segment, costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, we consider a number of specific facts and circumstances, including the product candidate&#x2019;s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a CDMO contract as CDMO pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the exception of the policy on pre-launch inventory discussed above, there have been no significant changes to the Company's summary of significant accounting policies during the three months ended March&#160;31, 2023, contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC that have materially impacted the presentation of the Company's financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Observable inputs for identical assets or liabilities such as quoted prices in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inputs other than quoted prices in active markets that are either directly or indirectly observable; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company&#x2019;s long-term variable interest rate debt arrangements (Level 2) approximate their fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board that the Company adopts as of the pronouncement's specified effective date. There were no new accounting pronouncements that were issued or became effective since the issuance of the Company&#x2019;s 2022 Annual Report on Form 10-K that had, or are expected to have, a material impact on its consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfODI4Nw_d99eb0f6-44db-48a5-b438-2d0b20d5c208">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2022, as filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of March&#160;31, 2023. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i822b4db8d3a940d2a307f01f1a9c52ed_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfMTY0OTI2NzQ2MjEwNA_14b02ab2-a098-4840-b71f-6249911e591c"
      unitRef="usd">598000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9b4a69b4f7e640dc9de146fd74f4ac6a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfMTY0OTI2NzQ2MjExMQ_3018234d-f860-456c-98fb-1563e7e4cfd8"
      unitRef="usd">354400000</us-gaap:LongTermDebt>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfMjE5OTAyMzI4MTkzNg_7869a1b0-9455-42ee-b27b-460dd8d9d240">Within our Products segment, costs relating to raw materials and production of inventory in preparation for product launch prior to regulatory approval are capitalized when the review process has progressed to a point where objective and persuasive evidence exists that regulatory approval is probable, the future economic benefit is expected to be realized, and we believe that material uncertainties related to the ultimate regulatory approval have been significantly reduced. Pre-launch inventory is recorded to research and development expense unless these criteria are met. For pre-launch inventory that is capitalized, we consider a number of specific facts and circumstances, including the product candidate&#x2019;s current status in the drug development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, historical experience, viability of commercialization and market trends. This policy is not applicable to pre-launch inventory purchased to satisfy a performance obligation related to a CDMO contract as CDMO pre-launch inventory may be capitalized if it has future economic benefit based on the terms of the contract.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8zNy9mcmFnOmU2NzkxODEyNzUxMTQyOTRiOGU5YjExYjU1MThmODJhL3RleHRyZWdpb246ZTY3OTE4MTI3NTExNDI5NGI4ZTliMTFiNTUxOGY4MmFfNDk0NzgwMjM0MjQxOQ_8f11fbfe-467b-40b0-b728-a8e7b551764e">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Observable inputs for identical assets or liabilities such as quoted prices in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inputs other than quoted prices in active markets that are either directly or indirectly observable; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a recurring basis, the Company measures and records money market funds (Level 1), interest-rate swap arrangements and time deposits (Level 2) and contingent purchase consideration (Level 3) using fair value measurements in the accompanying financial statements. The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. The carrying amounts of the Company&#x2019;s long-term variable interest rate debt arrangements (Level 2) approximate their fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGV4dHJlZ2lvbjoyOWExMjNmZjA2ZDg0YjczOGZlZTAxYjhkMjY4MDQ1Ml80OTQ3ODAyMzQ3ODQy_f9bcfae0-fcdd-4ba4-ba0b-0b44d7751961">Assets and liabilities held for sale&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 15, 2023, the Company entered into a definitive agreement with Bavarian Nordic, under which we agreed to sell our travel health business, including rights to Vaxchora and Vivotif, as well as our development-stage chikungunya vaccine candidate CHIKV VLP, the Company&#x2019;s manufacturing site in Bern, Switzerland and certain of its development facilities in San Diego, California. Additionally,  approximately 280 employees are expected to join Bavarian Nordic as a result of the transaction. The transaction is expected to close in the second quarter of 2023, subject to certain customary closing conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the accompanying Condensed Consolidated Balance Sheet as of March 31, 2023, the assets and liabilities of our travel health business are classified as held for sale and are measured at the lower of (i) the carrying value of the disposal group and (ii) the fair value of the disposal group, less costs to sell. Effective with the designation of the travel health business as held for sale on February 15, 2023, we suspended recording depreciation of property, plant and equipment and amortization of finite-lived intangible assets and right-of-use assets while these assets are classified as held for sale. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of sale. Gains and losses recognized from a sale of a disposal group will be recognized in income (loss) from operating activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities classified as held for sale in the Condensed Consolidated Balance Sheets as of March&#160;31, 2023 consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets held for sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;97.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;225.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities held for sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <ebs:DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated
      contextRef="i7237bcbb75b9405287fe50d45561e97f_D20230401-20230630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGV4dHJlZ2lvbjoyOWExMjNmZjA2ZDg0YjczOGZlZTAxYjhkMjY4MDQ1Ml8yMTk5MDIzMjg1ODM4_7897e4eb-bf6a-476d-8088-04fa5b3a98d3"
      unitRef="employee">280</ebs:DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGV4dHJlZ2lvbjoyOWExMjNmZjA2ZDg0YjczOGZlZTAxYjhkMjY4MDQ1Ml8yMTk5MDIzMjg0Mzc5_824fb1df-0197-4cf5-ac62-e9a28e73bc42">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities classified as held for sale in the Condensed Consolidated Balance Sheets as of March&#160;31, 2023 consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets held for sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;97.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;225.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities held for sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xLTEtMS0xLTE5MjI1Mw_3d97f6c7-35fd-4a23-b489-6278b8e9c587"
      unitRef="usd">2600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8zLTEtMS0xLTE5NDc0OA_8ab52129-4274-400a-a6f4-261bc364c3c7"
      unitRef="usd">1700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV80LTEtMS0xLTE5NDc0OA_784f8f40-6352-40db-b7d5-d6e9f685be79"
      unitRef="usd">13800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV81LTEtMS0xLTE5NDc0OA_079db1f3-6790-432b-b13b-0bd95ea1cddb"
      unitRef="usd">4100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV82LTEtMS0xLTE5NDc0OA_ae4884ba-2b1e-46db-84c8-718c5768e80f"
      unitRef="usd">97100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV83LTEtMS0xLTE5NDc0OA_0d828002-5ca5-4c14-ab53-8df8d93546de"
      unitRef="usd">102900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV84LTEtMS0xLTE5NDc0MA_90e76648-5d2b-4f89-9ac5-6c9ac22282a8"
      unitRef="usd">3400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV85LTEtMS0xLTIwMDM2MA_a4790c3b-17c1-4bf6-9f31-ae79c14643ff"
      unitRef="usd">225600000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xMi0xLTEtMS0xOTQ3NjQ_5617d978-02b8-47a9-a0ce-c741434635dc"
      unitRef="usd">9700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xMy0xLTEtMS0xOTQ3NjQ_404b893e-3118-4c99-aba1-d173d2794052"
      unitRef="usd">5900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <ebs:DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xNC0xLTEtMS0xOTQ3NjQ_cc65dca8-9c2c-44b0-b45f-6a8f6a6676ce"
      unitRef="usd">6900000</ebs:DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xNS0xLTEtMS0xOTQ3NjQ_f6501364-eed9-4037-9ae3-432a3cca19fd"
      unitRef="usd">2400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xNi0xLTEtMS0xOTQ3NjQ_2ef93252-ba2d-418c-a197-e148d6befd75"
      unitRef="usd">3900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xNy0xLTEtMS0xOTQ3NjQ_d733ca4e-bffc-43e0-bf03-1ddeb37361fd"
      unitRef="usd">8700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTYwL2ZyYWc6MjlhMTIzZmYwNmQ4NGI3MzhmZWUwMWI4ZDI2ODA0NTIvdGFibGU6MTY3ZDJjNTU1ZWZjNGJmOGI4MDc5NDBiMTdjMmE0MjEvdGFibGVyYW5nZToxNjdkMmM1NTVlZmM0YmY4YjgwNzk0MGIxN2MyYTQyMV8xOC0xLTEtMS0yMDAzNjE_aaaa5ad1-4ca6-490f-9a57-f4725856f67b"
      unitRef="usd">37500000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGV4dHJlZ2lvbjpkY2NkZDk2NWI2ZDk0MTEyYjI5YTgwZTEwMDJjNDYyM180OTQ3ODAyMzI2Nzcw_2335c064-53b7-4d9e-81d6-16cba082d2ab">Restructuring costs&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2023 Organizational Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company initiated an organizational restructuring plan (the &#x201c;2023 Plan&#x201d;) intended to reduce operating costs, improve operating margins, and continue advancing the Company&#x2019;s ongoing commitment to profitable growth. As part of the 2023 Plan, the Company eliminated approximately five percent of its total headcount. The Company incurred approximately $9.7&#160;million in charges in connection with the 2023 Plan during the three months ended March&#160;31, 2023. These charges consist primarily of charges related to employee transition, severance payments and employee benefits. All activities related to the 2023 Plan were substantially completed during the first quarter of 2023. Restructuring costs are recognized as an operating expense within the Condensed Consolidated Statement of Operations and are classified based on the Company's classification policy for each category of operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs associated with the Company&#x2019;s segments as well as unallocated corporate and research and development ("R&amp;amp;D") charges for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs, by function, for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of and changes in the Company's restructuring accrual during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.336%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGV4dHJlZ2lvbjpkY2NkZDk2NWI2ZDk0MTEyYjI5YTgwZTEwMDJjNDYyM18xMDk5NTExNjI4MTU0_86c4a2ba-1f1f-4746-a1fe-9262201282c6"
      unitRef="number">0.05</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGV4dHJlZ2lvbjpkY2NkZDk2NWI2ZDk0MTEyYjI5YTgwZTEwMDJjNDYyM18xMDk5NTExNjMyMjIw_196bb922-6b4c-48ad-b397-0e59a8a32b56"
      unitRef="usd">9700000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGV4dHJlZ2lvbjpkY2NkZDk2NWI2ZDk0MTEyYjI5YTgwZTEwMDJjNDYyM18yMTk5MDIzMjYwMDA2_78f8eb6c-add0-4129-ad63-153f1cea03f4">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs associated with the Company&#x2019;s segments as well as unallocated corporate and research and development ("R&amp;amp;D") charges for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the total restructuring costs, by function, for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Severance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i81c28e226ee545b286e49388a057533c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV8xLTMtMS0xLTE5NTUwMw_24f168bd-77c6-491a-b012-4c47d53dd59e"
      unitRef="usd">2000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i73c9842bc063446586bea2405cf33206_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV8yLTMtMS0xLTE5NTUwMw_45f74f2e-9b76-4643-9a5e-9546eef4984a"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="icff2f736d0b84c82b69da3ae149c3877_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV8zLTMtMS0xLTE5NTUwMw_0ec952a9-3c07-4d91-9a1f-9544ca049bd5"
      unitRef="usd">2000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i90160f3d0ce54037a7e491254512bf65_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV80LTMtMS0xLTE5NTUwMw_5854298e-2d26-444b-8099-5f40afbf0616"
      unitRef="usd">5000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie4f9663fd12b4d8484ab91cd3165ab5f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV81LTMtMS0xLTE5NTUyNw_e727ed04-9275-40bf-86ec-b40b51b1b27d"
      unitRef="usd">2700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6NTRjNzdmMmM0ZDI5NGI4NGEyZTk3M2MyZjY1MWY4MmUvdGFibGVyYW5nZTo1NGM3N2YyYzRkMjk0Yjg0YTJlOTczYzJmNjUxZjgyZV82LTMtMS0xLTE5NTUwMw_196bb922-6b4c-48ad-b397-0e59a8a32b56"
      unitRef="usd">9700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i8d94d342fe9f478da83d206f54833e08_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6MDk4ZDcyOTFiMGNhNDc1NDlhODc4YjY2NGZjNzhlNDgvdGFibGVyYW5nZTowOThkNzI5MWIwY2E0NzU0OWE4NzhiNjY0ZmM3OGU0OF8xLTMtMS0xLTE5NTU0MQ_1e4b431b-1274-4ade-9d02-3c35e87935fa"
      unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i624499c702f2496996732d4f547a1882_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6MDk4ZDcyOTFiMGNhNDc1NDlhODc4YjY2NGZjNzhlNDgvdGFibGVyYW5nZTowOThkNzI5MWIwY2E0NzU0OWE4NzhiNjY0ZmM3OGU0OF8yLTMtMS0xLTE5NTU0MQ_57a15749-80c7-436b-ac8f-d34efd000373"
      unitRef="usd">8700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ic516a1f410604d7db3e1ff143e87a7b1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6MDk4ZDcyOTFiMGNhNDc1NDlhODc4YjY2NGZjNzhlNDgvdGFibGVyYW5nZTowOThkNzI5MWIwY2E0NzU0OWE4NzhiNjY0ZmM3OGU0OF8zLTMtMS0xLTE5NTU0MQ_ab959174-9bb8-4f29-865e-3677923c2066"
      unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6MDk4ZDcyOTFiMGNhNDc1NDlhODc4YjY2NGZjNzhlNDgvdGFibGVyYW5nZTowOThkNzI5MWIwY2E0NzU0OWE4NzhiNjY0ZmM3OGU0OF80LTMtMS0xLTE5NTU1Mg_ec7ec4f8-5594-4a78-af90-f8089c491436"
      unitRef="usd">9700000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGV4dHJlZ2lvbjpkY2NkZDk2NWI2ZDk0MTEyYjI5YTgwZTEwMDJjNDYyM18yMTk5MDIzMjYwMDA1_85557146-9d28-497c-8a41-5067055b50db">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of and changes in the Company's restructuring accrual during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.336%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Transition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Severance Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Employee Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="icd5bdd8d49c244448c14a689d71f1025_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8xLTEtMS0xLTE5NTY0Nw_0e346128-7938-4d2b-8fdb-234eacb68b65"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i84af060aae1748fbbaa67887f4b7dbcd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8xLTMtMS0xLTE5NTY0Nw_d3eeac5d-623e-4b91-9f44-5a6321a4b040"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ia3d2e8509aab4186a3c6aa464c1d4d74_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8xLTUtMS0xLTE5NTY0Nw_5007e520-006b-4a36-944c-db762f11d64f"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i469c99f1aa3e49068c75ef98b7a985dc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8xLTEtMS0xLTE5MjI5NQ_20e5c72f-d857-4fcf-843c-78f544f8efca"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i8d94d342fe9f478da83d206f54833e08_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8yLTEtMS0xLTE5NTY0Nw_2f91ff4a-0437-4d09-8ef9-504d063344a2"
      unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i624499c702f2496996732d4f547a1882_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8yLTMtMS0xLTE5NTY0Nw_489d938b-5842-4eea-986d-1389a334040f"
      unitRef="usd">8700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ic516a1f410604d7db3e1ff143e87a7b1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8yLTUtMS0xLTE5NTY0Nw_717057c0-ded9-4073-9558-df15dc6e08ac"
      unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8yLTEtMS0xLTE5MjI5NQ_a193fa1a-3210-437c-ab3f-440e87af5e1d"
      unitRef="usd">9700000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i8d94d342fe9f478da83d206f54833e08_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8zLTEtMS0xLTE5NTY0Nw_c68e61a9-8182-483a-a0ee-d8ef3fcb6b84"
      unitRef="usd">200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i624499c702f2496996732d4f547a1882_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8zLTMtMS0xLTE5NTY0Nw_a3e2dae4-4626-471e-aa41-92011e77b20d"
      unitRef="usd">2000000.0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ic516a1f410604d7db3e1ff143e87a7b1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8zLTUtMS0xLTE5NTY0Nw_a2e21926-3e79-44a5-ab0f-33b9cb18b708"
      unitRef="usd">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl8zLTEtMS0xLTE5MjI5NQ_38c470f3-5f10-4ec8-a6ff-f0454b88870a"
      unitRef="usd">2300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i75626974e4ff4354ae25be0a61b75c46_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl81LTEtMS0xLTE5NTY0Nw_1f5b6288-20fa-45b4-8f4b-c300c898225f"
      unitRef="usd">100000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iad162e2c548e417d957ea777b298e0d2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl81LTMtMS0xLTE5NTY0Nw_a3bce0d5-4313-4373-b656-68aa4b0a88bb"
      unitRef="usd">6700000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i32b120655ff64d55a24337355f419f4f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl81LTUtMS0xLTE5NTY0Nw_e468d030-5137-45d2-bce0-12e1c456b232"
      unitRef="usd">600000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i89d77487aec94b21a79a891c0bdda7bc_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV8xNTk0L2ZyYWc6ZGNjZGQ5NjViNmQ5NDExMmIyOWE4MGUxMDAyYzQ2MjMvdGFibGU6YTQ2NWQwMDRmNTE0NGNmZjgxMDI2ZjlhYzMwZTFjOGYvdGFibGVyYW5nZTphNDY1ZDAwNGY1MTQ0Y2ZmODEwMjZmOWFjMzBlMWM4Zl81LTEtMS0xLTE5MjI5NQ_c26f3f84-e247-4ed9-86e9-99e2d4e906f1"
      unitRef="usd">7400000</us-gaap:RestructuringReserve>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RleHRyZWdpb246YmI3MTgwZTM1YjliNGNlOWI5ODcwZDY3YTMxMmMwYjNfMzc0_b735f9f0-d1d3-4693-8583-ca77de60b4e4">Inventories, net&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;148.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;116.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;351.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is stated at the lower of cost or net realizable value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RleHRyZWdpb246YmI3MTgwZTM1YjliNGNlOWI5ODcwZDY3YTMxMmMwYjNfMzcy_81cffc2e-99a0-41a9-9f09-d2e853773c55">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;148.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;116.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;96.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;351.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMS0xLTEtMS0xNzQwOTA_e14fd035-2542-49a2-839c-9784705a44bd"
      unitRef="usd">148900000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMS0zLTEtMS0xNzQwOTA_675cd823-229a-4a63-83ff-1b95593e39e3"
      unitRef="usd">143400000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMi0xLTEtMS0xNzQwOTA_17d22196-4300-453c-8c1c-46dbadd34246"
      unitRef="usd">122100000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMi0zLTEtMS0xNzQwOTA_2d2b9ac6-cca3-4733-8129-35994380eb4f"
      unitRef="usd">116200000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMy0xLTEtMS0xNzQwOTA_78ced56d-5962-4c45-9910-79a4f6b0d81e"
      unitRef="usd">96900000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfMy0zLTEtMS0xNzQwOTA_716b6178-27ae-4ee7-a87d-76fccf0bc4d0"
      unitRef="usd">92200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfNC0xLTEtMS0xNzQwOTA_cc9c7c4a-28be-412d-8991-c2bd65282806"
      unitRef="usd">367900000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80MC9mcmFnOmJiNzE4MGUzNWI5YjRjZTliOTg3MGQ2N2EzMTJjMGIzL3RhYmxlOjNkN2IxZjM4OTE4OTQwMDRhMGE0MDAwYTFmZTM5Njc2L3RhYmxlcmFuZ2U6M2Q3YjFmMzg5MTg5NDAwNGEwYTQwMDBhMWZlMzk2NzZfNC0zLTEtMS0xNzQwOTA_9bedf4aa-bc60-4aec-b3b6-dc2a3e9eb795"
      unitRef="usd">351800000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RleHRyZWdpb246NWFkY2RkZjg4MzE1NDU4YThkY2EyYzU5M2NhZTgwNjNfNzAw_152937f2-1890-452c-9f75-bbd9a8c83fa3">Property, plant and equipment, net&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;327.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;515.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;567.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,092.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,201.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Accumulated depreciation &amp;amp; amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(375.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(383.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;716.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;817.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, construction-in-progress primarily included costs incurred related to construction to advance the Company's CDMO capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. During the year ended December&#160;31, 2022, the Company recorded accelerated depreciation of $12.7&#160;million reflecting a shortening of the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement with Janssen (the "Agreement"). For additional information related to the termination of the Agreement, refer to Note 13, "Revenue recognition".&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RleHRyZWdpb246NWFkY2RkZjg4MzE1NDU4YThkY2EyYzU5M2NhZTgwNjNfNzAx_557aa7c6-56be-492c-acd2-b470cee1a894">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;327.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;515.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;567.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,092.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,201.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Accumulated depreciation &amp;amp; amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(375.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(383.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;716.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;817.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4331c0bdb2464807b4afa3f5612e3dad_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMS0xLTEtMS0xNzQwOTA_b6b79082-ced6-4fd8-8d06-a76ab92ddced"
      unitRef="usd">31900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib52346ef764e49d7ae1d0de332535d80_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMS0zLTEtMS0xNzQwOTA_289a7b5b-6e92-4b31-a19e-61a849eb2f17"
      unitRef="usd">54900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0029254369834e77ba355f9f9212091d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMi0xLTEtMS0xNzQwOTA_f4784736-5667-4a11-a3ef-4d531d36ec9e"
      unitRef="usd">305700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i04382820c4b94237b445c43c5180113d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMi0zLTEtMS0xNzQwOTA_03c04164-33e6-463d-a6cb-613897c5a059"
      unitRef="usd">327900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib46720b3fc2644378640e7ecb3eaff6c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMy0xLTEtMS0xNzQwOTA_03b18bdc-d9b5-4721-b4ff-35893b23e5bb"
      unitRef="usd">515500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if6246980b9314b79820f3539a51fe388_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfMy0zLTEtMS0xNzQwOTA_4b2df4c2-594b-45bd-9983-1046de121e74"
      unitRef="usd">567500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia4e4c69e4ac943b990497e0161be6d0a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNC0xLTEtMS0xNzQwOTA_af5a70f8-766f-49ba-9a92-e6cd66370e2e"
      unitRef="usd">64800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia0622ee9b0854a68821bf3319e45908f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNC0zLTEtMS0xNzQwOTA_fb77e182-c490-4414-a8e8-3302b5ea1db9"
      unitRef="usd">65600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id84508c19f22426e8d7a7d283878a833_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNS0xLTEtMS0xNzQwOTA_feddb399-6618-4dee-9808-c6615ebabcd9"
      unitRef="usd">174100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i338e967572ba42808fef537a31e71be4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNS0zLTEtMS0xNzQwOTA_9243ab6b-f843-41d5-b544-ebb783f2d9a0"
      unitRef="usd">185500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNi0xLTEtMS0xNzQwOTA_61402ad2-d713-4465-b84f-1e218464566f"
      unitRef="usd">1092000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNi0zLTEtMS0xNzQwOTA_273b29c1-b073-4d55-b038-c603d40d83ae"
      unitRef="usd">1201400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNy0xLTEtMS0xNzQwOTA_904f17c3-4fa3-4426-a199-4ead9ddab02f"
      unitRef="usd">375200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfNy0zLTEtMS0xNzQwOTA_760bbf76-5748-467b-a444-7fd328d840ed"
      unitRef="usd">383800000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfOC0xLTEtMS0xNzQwOTA_3f077017-3eab-4004-b647-b928b5cc3112"
      unitRef="usd">716800000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RhYmxlOjdiYmQzNTUzYzRlNjRjNDk5MDk5MzNiOTMwNjcxYzcwL3RhYmxlcmFuZ2U6N2JiZDM1NTNjNGU2NGM0OTkwOTkzM2I5MzA2NzFjNzBfOC0zLTEtMS0xNzQwOTA_10fe1a15-60ed-4843-95a8-7f4b161e36a9"
      unitRef="usd">817600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3f4212f3132341cf84f6c7de6e063ded_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80My9mcmFnOjVhZGNkZGY4ODMxNTQ1OGE4ZGNhMmM1OTNjYWU4MDYzL3RleHRyZWdpb246NWFkY2RkZjg4MzE1NDU4YThkY2EyYzU5M2NhZTgwNjNfNDEy_5d67a234-d300-44d2-a7f4-9bee3ee80bc4"
      unitRef="usd">12700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTcxMw_67222899-ce40-4b8c-b4cf-40f76b1ad387">Intangible assets and goodwill&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the Company's Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Weighted Average Useful Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;849.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;240.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;608.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;982.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;253.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;883.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;608.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,016.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;287.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="42" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The net carrying value of intangible assets as of March&#160;31, 2023 excluded $102.9&#160;million of assets related to our travel health business, which were reclassified as assets held for sale in anticipation of the sale of the travel health business to Bavarian Nordic (see Note 3, "Assets and liabilities held for sale").&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023 and 2022, the Company recorded amortization expense for intangible assets of $17.0 million, $14.0 million, respectively, which is included in "Amortization of intangible assets" on the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the changes in the carrying amount of goodwill by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Products &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amounts for the Company's Products segment include gross carrying values of $259.9&#160;million as of March&#160;31, 2023 and December&#160;31, 2022 and accumulated impairment losses of $41.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amounts for the Company's Services segment include gross carrying values of $6.7&#160;million as of March&#160;31, 2023, December&#160;31, 2022, and accumulated impairment losses of $6.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has $218.2&#160;million of total goodwill which is attributable to our Products segment. There is the risk of future impairments in our reporting units as any further deterioration in their performance compared to forecast, changes in order volumes or delivery schedules for major customers, as well as any changes in economic forecasts and expected recovery in the biopharmaceutical industry, may require the Company to complete additional impairment tests in future quarters and could result in the reporting unit&#x2019;s fair value falling below carrying value in subsequent quarters. In the event the Company experiences factors that it believes indicate a decline in fair value, including negative changes to long-term growth rates or if discount rates increase, we may be required to record impairments of goodwill and other identified intangible assets. Further, if the composition of the Company&#x2019;s reporting unit&#x2019;s assets and liabilities were to change and result in an increase in the reporting unit&#x2019;s carrying value, it could lead to additional impairment testing and further impairment losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTcyMA_96e8d888-5499-4c1a-9f31-fdfbe09f172e">The following table summarizes the Company's Intangible assets, net:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.454%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Weighted Average Useful Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;849.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;240.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;608.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;982.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;253.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;883.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;608.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,016.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;287.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;728.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="42" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The net carrying value of intangible assets as of March&#160;31, 2023 excluded $102.9&#160;million of assets related to our travel health business, which were reclassified as assets held for sale in anticipation of the sale of the travel health business to Bavarian Nordic (see Note 3, "Assets and liabilities held for sale").&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if4232914f6124a5e9828197daee03b72_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi0xLTEtMS0xNzQwOTA_79b6da73-d932-4d2d-a9b1-124a5e91d803">P13Y7M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i95ad12ca119f497ab07833d15fda564a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi0zLTEtMS0xNzQwOTA_6f72234b-75b7-4cb7-9219-ac53e4de6e5f"
      unitRef="usd">849100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i95ad12ca119f497ab07833d15fda564a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi00LTEtMS0xNzQwOTA_9de99303-35fe-46d8-85c1-9db399a0a880"
      unitRef="usd">240200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i95ad12ca119f497ab07833d15fda564a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi01LTEtMS0xNzQwOTA_7527921c-5e54-44d4-ae26-c559ae054f92"
      unitRef="usd">608900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie47c273b662b4a1892d60f7abfa2f3ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi03LTEtMS0xNzQwOTA_4fdef5ae-8fa7-4f33-aa21-cc378e132cc3"
      unitRef="usd">982100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie47c273b662b4a1892d60f7abfa2f3ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi04LTEtMS0xNzQwOTA_f60dd355-b8e4-464a-84fc-35855e954aaa"
      unitRef="usd">253300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie47c273b662b4a1892d60f7abfa2f3ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMi05LTEtMS0xNzQwOTA_f8c46b42-3126-48b1-ba91-eaccea13f2af"
      unitRef="usd">728800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id2f1b2dc03074501a7307fb35e98698e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy0xLTEtMS0xODQwNDU_633cf24d-44d0-4d25-a82a-8a578176ab51">P0Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib2cfce5e9fe14623a73853fac221b591_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy0zLTEtMS0xODQwMjQ_738924a5-a9e1-4229-b406-fa5f25efea32"
      unitRef="usd">28600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib2cfce5e9fe14623a73853fac221b591_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy00LTEtMS0xODQwMzA_2d998b38-e016-4a35-92bb-97f2d6ae50ed"
      unitRef="usd">28600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib2cfce5e9fe14623a73853fac221b591_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy01LTEtMS0xODQwMzk_9ee86a37-9dde-46d0-b725-29aa8e66e039"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i949bce8b04694470a4528f867f0e10cd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy03LTEtMS0xODM5Nzk_d90b4e60-fea8-4021-81ce-cb3790b89927"
      unitRef="usd">28600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i949bce8b04694470a4528f867f0e10cd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy04LTEtMS0xODQwMDg_2c0d1adb-3d66-4113-a967-0bb8b120ddb3"
      unitRef="usd">28600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i949bce8b04694470a4528f867f0e10cd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy05LTEtMS0xODM5Nzk_4f18d56e-c56c-44fe-a341-2bc404645100"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ifa639b8052ec4dfd86c079463f947791_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy0xLTEtMS0xNzQwOTA_1f1ad782-2524-4338-89ff-91d060cc6274">P0Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i941ca3dc089c4dac89d3aced14c53f5b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy0zLTEtMS0xNzQwOTA_2f7ef425-9a5a-498d-89de-057062cf2181"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i941ca3dc089c4dac89d3aced14c53f5b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy00LTEtMS0xNzQwOTA_36139904-514f-4273-ae7d-55e18303f8dc"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i941ca3dc089c4dac89d3aced14c53f5b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy01LTEtMS0xNzQwOTA_fa8b79eb-cc3e-4049-a489-6ec8ea164a7f"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2fa7094242a244a5b9b80db78bdbc0d8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy03LTEtMS0xNzQwOTA_e44f6c06-1250-4f05-a983-2aadc5ee9bc9"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2fa7094242a244a5b9b80db78bdbc0d8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy04LTEtMS0xNzQwOTA_b4f011fd-e722-4638-a8b5-6ce8804ebbbc"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2fa7094242a244a5b9b80db78bdbc0d8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfMy05LTEtMS0xNzQwOTA_4a1aa1fc-696d-4c5f-b233-5b0c90b9ac04"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC0zLTEtMS0xNzQwOTA_6b11a530-2eeb-413c-9c7f-fd27efe8326b"
      unitRef="usd">883200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC00LTEtMS0xNzQwOTA_5f028852-6d71-42e7-b6cb-2ba099c53da5"
      unitRef="usd">274300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC01LTEtMS0xNzQwOTA_9d5afb0e-4bee-4bac-82a5-f54218b71e64"
      unitRef="usd">608900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC03LTEtMS0xNzQwOTA_16d74c6a-da08-4062-b74a-a010b05151a5"
      unitRef="usd">1016200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC04LTEtMS0xNzQwOTA_5e873476-4aec-4a63-8895-2d8d592d740a"
      unitRef="usd">287400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNC05LTEtMS0xNzQwOTA_6c0068da-e1fe-4d42-9ca5-f4b09bccf279"
      unitRef="usd">728800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent
      contextRef="i7ab9e0411d2a4204b339f74ecd3ace35_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOmJkNTE0YjA4NzQ2ODRlOTZhYjcwYWNlZTYwNGJmMWRkL3RhYmxlcmFuZ2U6YmQ1MTRiMDg3NDY4NGU5NmFiNzBhY2VlNjA0YmYxZGRfNi0wLTEtMS0xOTgwNzQvdGV4dHJlZ2lvbjphMjNjNjZhNjVjODM0YTJmYjU3YWE5YTA3ZDBhNjJhN18xNjQ5MjY3NDQ2MDIw_0d828002-5ca5-4c14-ab53-8df8d93546de"
      unitRef="usd">102900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTA5OTUxMTYzMTM2NQ_107ff77b-e155-4e38-a397-9b5e1771e2aa"
      unitRef="usd">17000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTA5OTUxMTYzMTM3MA_31c680c8-869e-4fbd-ad23-7df19f99c302"
      unitRef="usd">14000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTcxNA_ac9c0536-3a81-4c9e-9fd1-b729cb51294b">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the changes in the carrying amount of goodwill by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Products &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:6.04pt;font-weight:700;line-height:120%;position:relative;top:-3.25pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amounts for the Company's Products segment include gross carrying values of $259.9&#160;million as of March&#160;31, 2023 and December&#160;31, 2022 and accumulated impairment losses of $41.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amounts for the Company's Services segment include gross carrying values of $6.7&#160;million as of March&#160;31, 2023, December&#160;31, 2022, and accumulated impairment losses of $6.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i2d248c38e3394ed5bd6f6e4cda0f9c56_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNC0xLTEtMS0xOTMwNjg_356d2c8e-08cc-43e1-ad2e-987c9727b209"
      unitRef="usd">218200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idb147a1d8ee745288cc6b591771da65f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNC0zLTEtMS0xOTMwNjg_7897984a-c8a6-448a-9505-8d415bd71983"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNC01LTEtMS0xOTMwNjg_d34320c9-64be-4a04-9aaa-61dbeefc0e50"
      unitRef="usd">218200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7db14af93756495bb396ad2850eb791d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNy0xLTEtMS0xOTMwNjg_3ed4b941-42f5-44d4-94a4-943557f7f2cf"
      unitRef="usd">218200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iced1288bc5d94738bdeb41c7ef631b5a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNy0zLTEtMS0xOTMwNjg_4b5ea3f6-f38b-4079-a387-ab5fa0e694c9"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfNy01LTEtMS0xOTMwNjg_b59e24ef-8a8b-4298-a5bd-17a732dde857"
      unitRef="usd">218200000</us-gaap:Goodwill>
    <us-gaap:GoodwillGross
      contextRef="i7db14af93756495bb396ad2850eb791d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfOS0wLTEtMS0xNzc4OTAvdGV4dHJlZ2lvbjpiNDkwMWRlMjE0YWI0ZjA4YjJhYjVkODViZTQ2MzY2ZV84NQ_1cabbd19-d520-410a-9a11-b1a9bb0ead3e"
      unitRef="usd">259900000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross
      contextRef="i2d248c38e3394ed5bd6f6e4cda0f9c56_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfOS0wLTEtMS0xNzc4OTAvdGV4dHJlZ2lvbjpiNDkwMWRlMjE0YWI0ZjA4YjJhYjVkODViZTQ2MzY2ZV84NQ_2f78384e-c0c3-4c58-82b2-38b15604d1c2"
      unitRef="usd">259900000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i2d248c38e3394ed5bd6f6e4cda0f9c56_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfOS0wLTEtMS0xNzc4OTAvdGV4dHJlZ2lvbjpiNDkwMWRlMjE0YWI0ZjA4YjJhYjVkODViZTQ2MzY2ZV8xNTk_236dbc5e-3986-4a8d-8756-0f08fd163049"
      unitRef="usd">41700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i7db14af93756495bb396ad2850eb791d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfOS0wLTEtMS0xNzc4OTAvdGV4dHJlZ2lvbjpiNDkwMWRlMjE0YWI0ZjA4YjJhYjVkODViZTQ2MzY2ZV8xNTk_6117fff6-2087-4568-9e5c-c470618836c2"
      unitRef="usd">41700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillGross
      contextRef="iced1288bc5d94738bdeb41c7ef631b5a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfMTEtMC0xLTEtMTc3ODkwL3RleHRyZWdpb246MmM1NGRmYjA4YzlmNGE0MTlmOTZkMmNlNjRlZWMzYjhfMTA5OTUxMTYyODAzNw_8c18f10e-551e-48ec-b4bf-1d14e57dd29b"
      unitRef="usd">6700000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillGross
      contextRef="idb147a1d8ee745288cc6b591771da65f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfMTEtMC0xLTEtMTc3ODkwL3RleHRyZWdpb246MmM1NGRmYjA4YzlmNGE0MTlmOTZkMmNlNjRlZWMzYjhfMTA5OTUxMTYyODAzNw_c678415c-f3cb-4eea-8f04-0704c6c3d0de"
      unitRef="usd">6700000</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="idb147a1d8ee745288cc6b591771da65f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfMTEtMC0xLTEtMTc3ODkwL3RleHRyZWdpb246MmM1NGRmYjA4YzlmNGE0MTlmOTZkMmNlNjRlZWMzYjhfMTY0OTI2NzQ0Mjc4Nw_2d33c51f-8ed8-4a84-ad45-7a7816bdb34a"
      unitRef="usd">6700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="iced1288bc5d94738bdeb41c7ef631b5a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RhYmxlOjUxNGUxYjczODA5NDQ3N2FiYjgyOGU3MTIwOGQzNTk5L3RhYmxlcmFuZ2U6NTE0ZTFiNzM4MDk0NDc3YWJiODI4ZTcxMjA4ZDM1OTlfMTEtMC0xLTEtMTc3ODkwL3RleHRyZWdpb246MmM1NGRmYjA4YzlmNGE0MTlmOTZkMmNlNjRlZWMzYjhfMTY0OTI2NzQ0Mjc4Nw_504ffc1a-31fa-4b83-9dc2-4c90d174e812"
      unitRef="usd">6700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80OS9mcmFnOjVmNDcwMWNhZTRjOTQwMmJhMDQ5ODRjOGE2ODc5ODM1L3RleHRyZWdpb246NWY0NzAxY2FlNGM5NDAyYmEwNDk4NGM4YTY4Nzk4MzVfMTY0OTI2NzQ0Mzc1OQ_a0e875e8-0294-4478-8f8f-82cee7a9bcb0"
      unitRef="usd">218200000</us-gaap:Goodwill>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMjE4MQ_ee532109-cca2-4fca-8e61-dd4b15e6fda4">Fair value measurements&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;308.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration payments in an asset acquisition not required to be accounted for as derivatives are recognized when the contingency is resolved, and the consideration is paid or becomes payable. Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#x2019;s products are classified in the Company's statement of operations as cost of product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a reconciliation of the beginning and ending balance of the Company's contingent consideration liability: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, the current portion of the contingent consideration liability was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.4&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $3.1&#160;million, respectively, and was included in "Other current liabilities" on the Condensed Consolidated Balance Sheets. The non-current portion of the contingent consideration liability is included in "Other liabilities" on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurement for the Company's contingent consideration liability include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Fair Value as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.6 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25% - 50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Projected year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023 - 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 9, "Derivative instruments and hedging activities&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;" &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for more information about the Company's derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-variable rate debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31, 2022, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he fair value of the Company's 3.875% Senior Unsecured Notes was $220.6&#160;million and $225.1&#160;million, respectively. The fair value was determined through market sources, which are Level 2 inputs and directly observable. The carrying amounts of the Company&#x2019;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 10, "Debt").&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMjE4Mg_6218fd19-4d84-4dbe-898f-0d516cb840cd">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;308.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;131.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;320.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2678670ef0614327a8e6d3ba7f775ffe_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy0xLTEtMS0xNzQwOTA_ef6e2bd9-7839-4286-aad5-0d48c21734bc"
      unitRef="usd">176900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i312fc4d3fa3d40a8b8d40b165fac9f23_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy0yLTEtMS0xNzQwOTA_35342256-33ea-4c6e-886b-95c1f44933a6"
      unitRef="usd">176900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0fe6faf4ab404b7eaeb1185f253fdc6d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy0zLTEtMS0xNzQwOTA_866e3575-dba0-4d53-90ee-8744e6f04cd5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i237d46bcc69045b68b66b29364f7c338_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy00LTEtMS0xNzQwOTA_fc5a084a-12e2-4edc-bb68-71304ff07a0d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i575796b9fe234a88851410d4452a2542_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy02LTEtMS0xNzQwOTA_b2d54314-8946-4e3b-8b08-f928f5745a82"
      unitRef="usd">320800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9b9542ada7984655be665a722b9ac8b4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy03LTEtMS0xNzQwOTA_93fd6dc0-d4e2-4ae4-826e-f399d91a6e3d"
      unitRef="usd">320800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7c9b39689c8b4daabd9ce8b4ca48f1fc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy04LTEtMS0xNzQwOTA_b5a6af43-a11d-4d51-8a8d-6e21520bd695"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i087f2351596c4d7aaa0c69f2847ad606_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMy05LTEtMS0xNzQwOTA_02791a64-964c-4526-aa4d-51cdd890216f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia4a4bf125ea1426898eefe90abf2468b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC0xLTEtMS0xNzQwOTA_dfccbf59-d85c-4b4f-ab8b-250b1f98bddb"
      unitRef="usd">125500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0b76ca7b5a934284bb3f69ae4eac313f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC0yLTEtMS0xNzQwOTA_771b9652-40f1-4c94-85f7-a9105d36f5a8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i63a4559b34534083bbc78a87767ff732_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC0zLTEtMS0xNzQwOTA_9ac96e31-cff4-4f7f-99a9-5faa2ca9273a"
      unitRef="usd">125500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib6de70121c46438aa85618bf326f814d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC00LTEtMS0xNzQwOTA_10ff3ed6-0c8f-4b13-b56e-71220a173da8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i676d5ac2770d4880b80e8f9affcc0405_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC02LTEtMS0xNzQwOTA_eb3365eb-b31b-4711-9a5c-81b3bae05b26"
      unitRef="usd">170700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iab0b615be15c41e492c20d99095ebd67_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC03LTEtMS0xNzQwOTA_d0ac618a-0b2b-40d6-a000-9f114a8a78fd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i846c202a9d2c465a8eaa59bba8fb61d3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC04LTEtMS0xNzQwOTA_d9967170-ed10-4519-9ec4-a873c263a59e"
      unitRef="usd">170700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaa141f63b241430bb8414182bb967b11_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNC05LTEtMS0xNzQwOTA_890c2784-7225-44a3-b0d6-54228b3e3942"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS0xLTEtMS0xNzQwOTA_cab1b2da-935a-4f49-ae31-bb945b9b84c8"
      unitRef="usd">5900000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iecb9b277674f497f94bb0ad15086a2d1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS0yLTEtMS0xNzQwOTA_198673a0-e068-4280-bfe4-0f3aad71ecc3"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9da03b4151704bc0b9cd5c7932118c29_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS0zLTEtMS0xNzQwOTA_e2603b83-fd6a-4d72-a806-d1e93b94c2a3"
      unitRef="usd">5900000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i07bc53a7e37d4103b284a544dfaee08f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS00LTEtMS0xNzQwOTA_e60fb92b-7300-46d1-899a-73fd893661da"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS02LTEtMS0xNzQwOTA_ae37f93c-14b8-4bac-980d-5f26c7dd99a2"
      unitRef="usd">8500000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i10bc8bb2a2354813ac6212066587b081_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS03LTEtMS0xNzQwOTA_d3e4ef61-3f08-4a70-94a6-ec1eb2454d81"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i28872533ff2f45f8afc92cc4728820d6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS04LTEtMS0xNzQwOTA_c59eecb7-735f-4a64-9dfd-608c9f189bc5"
      unitRef="usd">8500000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if8dd4d6dd4734137a3740ddea65d8249_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNS05LTEtMS0xNzQwOTA_15975293-429c-494c-ab11-507ebee29bb1"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi0xLTEtMS0xNzQwOTA_17fb54de-145d-4c7e-a641-0958f4c6a60f"
      unitRef="usd">308300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iecb9b277674f497f94bb0ad15086a2d1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi0yLTEtMS0xNzQwOTA_22557a0b-42f2-4512-a36a-167b85a8fd7c"
      unitRef="usd">176900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9da03b4151704bc0b9cd5c7932118c29_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi0zLTEtMS0xNzQwOTA_54607e30-be06-46f4-a1a9-351f0c8edae5"
      unitRef="usd">131400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i07bc53a7e37d4103b284a544dfaee08f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi00LTEtMS0xNzQwOTA_968e8707-9d93-45ec-a25c-e691c6065069"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi02LTEtMS0xNzQwOTA_65bf5cb9-81b2-4ee6-b1da-181fd7f632b9"
      unitRef="usd">500000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i10bc8bb2a2354813ac6212066587b081_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi03LTEtMS0xNzQwOTA_2c8925ba-dd8d-4932-b1a9-640d795e115e"
      unitRef="usd">320800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i28872533ff2f45f8afc92cc4728820d6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi04LTEtMS0xNzQwOTA_5876b6a1-78f0-4f8e-bc55-93de58b66815"
      unitRef="usd">179200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if8dd4d6dd4734137a3740ddea65d8249_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfNi05LTEtMS0xNzQwOTA_23a70a3d-52bc-4e64-b87d-9d2046c8e524"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC0xLTEtMS0xNzQwOTA_21c16600-541d-463e-bdc9-13897520677d"
      unitRef="usd">7600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iecb9b277674f497f94bb0ad15086a2d1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC0yLTEtMS0xNzQwOTA_49c058a9-b5a4-4b5a-86cd-e1d7f2fc1b9d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9da03b4151704bc0b9cd5c7932118c29_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC0zLTEtMS0xNzQwOTA_3c284638-e76c-4b58-87ae-a8e320497996"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i07bc53a7e37d4103b284a544dfaee08f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC00LTEtMS0xNzQwOTA_ceb83e43-f933-4700-8ffe-2422eff72d3c"
      unitRef="usd">7600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC02LTEtMS0xNzQwOTA_043bb4b4-1577-46b3-9b4b-6b9bb5f3364d"
      unitRef="usd">6800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i10bc8bb2a2354813ac6212066587b081_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC03LTEtMS0xNzQwOTA_1fe2a7b3-ba23-4cbd-af25-d9647269cfe6"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i28872533ff2f45f8afc92cc4728820d6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC04LTEtMS0xNzQwOTA_1df2089f-4b18-41c1-9b12-e5b3c390a627"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if8dd4d6dd4734137a3740ddea65d8249_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfOC05LTEtMS0xNzQwOTA_6b6ce65a-1e9a-4252-85e2-4a5907ec04bd"
      unitRef="usd">6800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtMS0xLTEtMTc0MDkw_5ef43d63-f92b-4ac0-ac72-3916b7b1cc33"
      unitRef="usd">7600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iecb9b277674f497f94bb0ad15086a2d1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtMi0xLTEtMTc0MDkw_15fec32b-6b04-4d72-b83a-b7a8ded09bca"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9da03b4151704bc0b9cd5c7932118c29_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtMy0xLTEtMTc0MDkw_ecbd11b8-0ce1-4e17-b4b2-5c9183b48576"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i07bc53a7e37d4103b284a544dfaee08f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtNC0xLTEtMTc0MDkw_b59bfe41-6a4d-4ce1-9038-8bc0ab56d946"
      unitRef="usd">7600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtNi0xLTEtMTc0MDkw_528b376f-ce1e-4e71-9458-d60827d57a3f"
      unitRef="usd">6800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i10bc8bb2a2354813ac6212066587b081_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtNy0xLTEtMTc0MDkw_f3797ed8-38c0-4343-bd3c-7391d432c805"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i28872533ff2f45f8afc92cc4728820d6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtOC0xLTEtMTc0MDkw_3f43a170-25d8-4c1b-b232-6f2412290879"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if8dd4d6dd4734137a3740ddea65d8249_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjRiMjY0NjY1MDllMjQwMDg4ODg4ZDE4N2QyNjBjYTAxL3RhYmxlcmFuZ2U6NGIyNjQ2NjUwOWUyNDAwODg4ODhkMTg3ZDI2MGNhMDFfMTAtOS0xLTEtMTc0MDkw_7846ede3-3e15-4f6b-83f2-a8a34b7af870"
      unitRef="usd">6800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMjE4Mw_536c77ac-e172-41b7-819c-65c6a83a8caf">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a reconciliation of the beginning and ending balance of the Company's contingent consideration liability: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjlkYmI0MWM0ZjdjMjQwMWM4OWQ4MzQxYWFiYmRjM2ZmL3RhYmxlcmFuZ2U6OWRiYjQxYzRmN2MyNDAxYzg5ZDgzNDFhYWJiZGMzZmZfMS0yLTEtMS0xNzQwOTA_d90b302a-c0ed-4498-b31a-1ab93fb13e3c"
      unitRef="usd">6800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjlkYmI0MWM0ZjdjMjQwMWM4OWQ4MzQxYWFiYmRjM2ZmL3RhYmxlcmFuZ2U6OWRiYjQxYzRmN2MyNDAxYzg5ZDgzNDFhYWJiZGMzZmZfMi0yLTEtMS0xNzQwOTA_9570ec56-f746-41ee-8fb0-4ec4c14fc558"
      unitRef="usd">1500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjlkYmI0MWM0ZjdjMjQwMWM4OWQ4MzQxYWFiYmRjM2ZmL3RhYmxlcmFuZ2U6OWRiYjQxYzRmN2MyNDAxYzg5ZDgzNDFhYWJiZGMzZmZfMy0yLTEtMS0xNzQwOTA_e83ae70a-eff4-43ec-814d-b7309456c4c2"
      unitRef="usd">700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjlkYmI0MWM0ZjdjMjQwMWM4OWQ4MzQxYWFiYmRjM2ZmL3RhYmxlcmFuZ2U6OWRiYjQxYzRmN2MyNDAxYzg5ZDgzNDFhYWJiZGMzZmZfNC0yLTEtMS0xNzQwOTA_17808f0b-cb5b-4c07-9b22-c17068e74f88"
      unitRef="usd">7600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTA5OTUxMTYzMDA1MQ_59a27e95-a194-43be-86ae-637661a2f241"
      unitRef="usd">3400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTA5OTUxMTYzMDA1NQ_edf6702b-3b42-4558-8436-5e0379ffd99d"
      unitRef="usd">3100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMjE3OA_41dbcb98-a076-4051-9790-912eeef6b8d7">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurement for the Company's contingent consideration liability include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.802%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Fair Value as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.6 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25% - 50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Projected year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023 - 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i20c6e639de504e66bd14ca1b9f011604_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjhjZjcyNjhmYjJmNzQ1M2ZhZjdmNjUwOTRjMzMyNzAyL3RhYmxlcmFuZ2U6OGNmNzI2OGZiMmY3NDUzZmFmN2Y2NTA5NGMzMzI3MDJfMS0xLTEtMS0xNzQwOTA_c9f40416-989a-460e-b66e-886b423e4ba4"
      unitRef="usd">7600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ifba6b2f3fd2d4feba5acceb8d159572c_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjhjZjcyNjhmYjJmNzQ1M2ZhZjdmNjUwOTRjMzMyNzAyL3RhYmxlcmFuZ2U6OGNmNzI2OGZiMmY3NDUzZmFmN2Y2NTA5NGMzMzI3MDJfMS00LTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjowYmNhYzE1YWU0NzU0NzQwYjFiNzMxNGQyMDU0MzNkM18xMDk5NTExNjI3Nzgz_b0e2c255-f644-41da-a903-a8a88e68ae0a"
      unitRef="number">0.096</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i2adc9adb687d4dc4a6c4288252be0818_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjhjZjcyNjhmYjJmNzQ1M2ZhZjdmNjUwOTRjMzMyNzAyL3RhYmxlcmFuZ2U6OGNmNzI2OGZiMmY3NDUzZmFmN2Y2NTA5NGMzMzI3MDJfMi00LTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjoyMDg2Yzg3NjIzY2Y0YjgxODRmNjhjZTFjMmMyZjFmOV8xMDk5NTExNjI3Nzg4_5ce7e246-55a6-45a1-be12-10fd5e14a394"
      unitRef="number">0.25</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6a1c5f04948a4ba69680ad3fa0b5fe08_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RhYmxlOjhjZjcyNjhmYjJmNzQ1M2ZhZjdmNjUwOTRjMzMyNzAyL3RhYmxlcmFuZ2U6OGNmNzI2OGZiMmY3NDUzZmFmN2Y2NTA5NGMzMzI3MDJfMi00LTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjoyMDg2Yzg3NjIzY2Y0YjgxODRmNjhjZTFjMmMyZjFmOV8xMDk5NTExNjI3Nzkz_607c5748-2b18-4230-9be1-de47b268e60d"
      unitRef="number">0.50</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i542cdb35121f4951af58b7c4d099cc0e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTg3OQ_096fde69-bc82-4ef5-9ded-709772e40ba7"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib979976208634b5c8e0a9ae50b18d4cb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTg3OQ_f8e7cecd-8154-4ef9-bf67-f7fc4e558231"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib979976208634b5c8e0a9ae50b18d4cb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTA5OTUxMTYzMDA3NQ_60486a3c-434e-4b88-b725-5a71002efd24"
      unitRef="usd">220600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i542cdb35121f4951af58b7c4d099cc0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81Mi9mcmFnOjZiZWY3MWZkZThjMjQzZWE4MDU4NWY2YjdiY2E1MzM2L3RleHRyZWdpb246NmJlZjcxZmRlOGMyNDNlYTgwNTg1ZjZiN2JjYTUzMzZfMTA5OTUxMTYzMDA3OQ_24650aae-68a6-444e-89e8-f04820603eb0"
      unitRef="usd">225100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMjk4Mw_e6d08c54-d645-4589-8013-91e7f28dcf6c">Derivative instruments and hedging activities&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Risk management objective of using derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from payments of variable interest rate debt associated with the Company's senior secured credit agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If current fair values of designated interest rate swaps&#160;remained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;$5.9&#160;million of net deferred gains from&#160;accumulated other comprehensive income&#160;into the Condensed Consolidated Statement of Operations over the next&#160;twelve-month period. All outstanding cash flow hedges mature in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Number of Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$350.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Fair Value of Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Location of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Amount of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="9" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="i8751da105fac4730bbdbaffce144fb47_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMTA5OTUxMTYzMDgzOQ_34dc0212-c31a-4462-9da0-5921062ade43"
      unitRef="usd">5900000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMjk4MQ_a9066ca6-3685-497b-bbb1-fa96c276e85d">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Number of Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$350.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i8c80cc2623ec43ee87f691cd40d2b03c_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmYwYjhkMTZjYjFlZTQwYjg4YzBlNDMxZWVlOWQzZTAzL3RhYmxlcmFuZ2U6ZjBiOGQxNmNiMWVlNDBiODhjMGU0MzFlZWU5ZDNlMDNfMS0xLTEtMS0xNzQwOTA_e79f52c4-172d-47c8-9e79-1bf2ff07918f"
      unitRef="instrument">7</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8c80cc2623ec43ee87f691cd40d2b03c_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmYwYjhkMTZjYjFlZTQwYjg4YzBlNDMxZWVlOWQzZTAzL3RhYmxlcmFuZ2U6ZjBiOGQxNmNiMWVlNDBiODhjMGU0MzFlZWU5ZDNlMDNfMS0zLTEtMS0xNzQwOTA_95b897ca-a531-4a56-b193-51a1fb23d7a9"
      unitRef="usd">350000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMjk4OA_553d97a5-39d4-4164-959e-f914c96e62ba">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Fair Value of Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i1f157297decc4c27a1eb9955ddfbb47b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmEwMjA0MmZmNTVmODQxZTJiMmFiMDkzMDAzNGFiZDE4L3RhYmxlcmFuZ2U6YTAyMDQyZmY1NWY4NDFlMmIyYWIwOTMwMDM0YWJkMThfMy0yLTEtMS0xNzQwOTA_a7a223d5-ee7a-4d57-8f20-8200509ce77d"
      unitRef="usd">5900000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i48a3c046c3a04962bc32bb21e900d52f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmEwMjA0MmZmNTVmODQxZTJiMmFiMDkzMDAzNGFiZDE4L3RhYmxlcmFuZ2U6YTAyMDQyZmY1NWY4NDFlMmIyYWIwOTMwMDM0YWJkMThfMy00LTEtMS0xNzQwOTA_5ff51d8f-658d-4333-9c9b-b738fc0959b7"
      unitRef="usd">8500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMjk4NQ_68f7dffd-1610-412c-94aa-82be929b09de">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RleHRyZWdpb246ZTAyYjg0ZWIzYzc5NDJjNWE0Zjk3YzU0ZGQ1MDZmZGNfMjk5Mw_cc3bd8d3-77c4-4cba-bd22-a26a77cdd8ef">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Location of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#19415e;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Amount of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="9" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i8751da105fac4730bbdbaffce144fb47_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmFlZTIzYzc0ZDQzOTQ0NWE4MjVlYTc2MWYyOWEzYWFlL3RhYmxlcmFuZ2U6YWVlMjNjNzRkNDM5NDQ1YTgyNWVhNzYxZjI5YTNhYWVfMy0xLTEtMS0xNzQwOTA_1cc69f18-93fa-4019-ad34-23403dc049b4"
      unitRef="usd">5900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i263ac071f3a94b6cb410cb5275bfd042_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmFlZTIzYzc0ZDQzOTQ0NWE4MjVlYTc2MWYyOWEzYWFlL3RhYmxlcmFuZ2U6YWVlMjNjNzRkNDM5NDQ1YTgyNWVhNzYxZjI5YTNhYWVfMy0yLTEtMS0xNzQwOTA_ef6ae263-4a43-489a-9d20-5559b1098387"
      unitRef="usd">8500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ifa715f99b2c046f29b82294c4c8cf1bd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmFlZTIzYzc0ZDQzOTQ0NWE4MjVlYTc2MWYyOWEzYWFlL3RhYmxlcmFuZ2U6YWVlMjNjNzRkNDM5NDQ1YTgyNWVhNzYxZjI5YTNhYWVfMy00LTEtMS0xNzQwOTA_4fadf90b-1080-49a7-b69a-d8636a273a83"
      unitRef="usd">2400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="id194daf24cf04654893b13c8dd06a8ab_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81NS9mcmFnOmUwMmI4NGViM2M3OTQyYzVhNGY5N2M1NGRkNTA2ZmRjL3RhYmxlOmFlZTIzYzc0ZDQzOTQ0NWE4MjVlYTc2MWYyOWEzYWFlL3RhYmxlcmFuZ2U6YWVlMjNjNzRkNDM5NDQ1YTgyNWVhNzYxZjI5YTNhYWVfMy01LTEtMS0xNzQwOTA_294f397d-52e5-4ca1-b245-ebd3572231d4"
      unitRef="usd">1400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjg1NA_463e2ad9-047d-495f-83db-5447c6eecf6a">Debt&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the components of the Company&#x2019;s debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement - Term loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;354.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;362.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement - Revolver loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;598.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;598.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,405.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,413.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Current portion of long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(950.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(957.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;447.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the Company reclassified the debt issuance costs associated with the revolver loan to a contra account to directly offset the loan balance in other current liabilities on the Company's consolidated balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the Company had $0.9&#160;million and $1.3&#160;million of debt issuance costs associated with the revolver loan that were classified as an offset to other current liabilities, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;3.875% Senior Unsecured Notes due 2028 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2020, the Company completed its offering of $450.0&#160;million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the 2028 Notes) of which the majority of the net proceeds were used to pay down the Revolving Credit Facility. Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related Indenture, plus accrued and unpaid interest. Prior to August 15, 2023 the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to 100% of the principal amount of the 2028 Notes plus a &#x201c;make-whole&#x201d; premium and accrued and unpaid interest. Prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the 2028 Notes using the net cash proceeds of certain equity offerings at the redemption price set forth in the related Indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of 101% of the principal amount of such 2028 Notes plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Negative covenants in the Indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior secured credit agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also on August 7, 2020, the Company entered into a Second Amendment (the &#x201c;Credit Agreement Amendment&#x201d;) to its senior secured credit agreement, dated October 15, 2018, with multiple lending institutions relating to the Company&#x2019;s senior secured credit facilities (the &#x201c;Credit Agreement,&#x201d; and as amended, the &#x201c;Amended Credit Agreement&#x201d;), consisting of a senior revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) and senior term loan facility (the &#x201c;Term Loan Facility,&#x201d; and together with the Revolving Credit Facility, the &#x201c;Senior Secured Credit Facilities&#x201d;).  The Credit Agreement Amendment amended, among other things, the definition of incremental facilities limit, the consolidated net leverage ratio financial covenant by increasing the maximum level, increased the permissible applicable margins based on the Company&#x2019;s consolidated net leverage ratio and increased the commitment fee that the Company is required to pay in respect of the average daily unused commitments under the Revolving Credit Facility, depending on the Company&#x2019;s consolidated net leverage ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement includes (i) a Revolving Credit Facility of $600.0&#160;million and (ii) a Term Loan Facility with a principal amount of $450.0&#160;million. The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as certain requirements involving the Company's net leverage ratio will be maintained on a pro forma basis. Borrowings under the Revolving Credit Facility and the Term Loan Facility bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from 1.25% to 2.25% per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus 0.50%, and a eurocurrency rate for an interest period of one month plus 1% plus a margin ranging from 0.25% to 1.25%, depending on the Company's consolidated net leverage ratio). The Company is required to make quarterly payments on the last business day of each calendar quarter under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from 0.15% to 0.35% per annum, depending on the Company's consolidated net leverage ratio, for the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments on the last business day of each calendar quarter based on an annual percentage equal to 2.5% of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, 5% of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and 7.5% of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature on October 13, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of $100.0&#160;million during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights. The financial covenants under the Amended Credit Agreement currently require the quarterly presentation of a minimum consolidated 12-month rolling debt service coverage ratio of 2.50 to 1.00, and a maximum consolidated net leverage ratio of 4.50 to 1.00 (subject to an increase to 5.00 to 1.00 for an applicable four quarter period, at the election of the Company, in connection with a permitted acquisition having an aggregate consideration in excess of $75.0&#160;million). Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 14, 2023, the Company entered into a Consent, Limited Waiver, and Third Amendment (the "Third Credit Agreement Amendment") to the Amended Credit Agreement relating to the Senior Secured Credit Facilities. Pursuant to the Third Credit Agreement Amendment, the requisite lenders consented to our sale of our travel health business to Bavarian Nordic substantially in accordance with the terms of the Purchase and Sale Agreement with Bavarian Nordic (the "Sale Agreement"). The proceeds from the transaction will be deposited into a cash collateral account with the Administrative Agent and will, unless otherwise agreed to by the Company and the requisite lenders, be used to repay the outstanding Term Loan Facility on the expiration of the Limited Waiver (as described below). We currently expect the transaction to close in the second quarter of 2023, but we can provide no assurance that the transaction will close prior to the October 2023 maturity of the Term Loan Facility, or at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Third Credit Agreement Amendment the requisite lenders have agreed to a limited waiver of any defaults or events of default that was extended on April 17, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2023, the Company entered into a First Amendment (the &#x201c;Waiver Amendment&#x201d;) to the Third  Credit Agreement Amendment. The lenders agreed to extend the limited waiver (the &#x201c;Extended Limited Waiver&#x201d;) of any defaults or events of default that result from (a) any violation of the financial covenants set forth in the Amended Credit Agreement with respect to the fiscal quarters ending December&#160;31, 2022 and March&#160;31, 2023 and (b) any going concern qualification or exception contained in the audited financial statements for the fiscal year ending December&#160;31, 2022. The Extended Limited Waiver expires on the earlier to occur of (i) any other event of default under the Amended Credit Agreement and (ii) May 17, 2023. During the period of the Limited Waiver, the Company is working with lenders under the Amended Credit Agreement in connection with replacing the current credit facility before it matures with revised terms and conditions. The Company does not expect to be in compliance with debt covenants in future periods without additional sources of liquidity or future amendments to the Amended Credit Agreement. See Note 2, "Summary of significant accounting policies" for Going Concern considerations related to noncompliance with our debt covenants and the limited waiver.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjg1NQ_ccccf922-3dea-47d3-be50-1019a5dc9f6b">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the components of the Company&#x2019;s debt:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement - Term loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;354.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;362.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement - Revolver loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;598.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;598.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,405.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,413.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Current portion of long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(950.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(957.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;447.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;448.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i9b4a69b4f7e640dc9de146fd74f4ac6a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMS0xLTEtMS0xNzQwOTA_3018234d-f860-456c-98fb-1563e7e4cfd8"
      unitRef="usd">354400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i52702739ed104778bc9a6b44dbd6a56c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMS0zLTEtMS0xNzQwOTA_3ad634d1-ff9f-4c42-9969-2e07c9260584"
      unitRef="usd">362800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i822b4db8d3a940d2a307f01f1a9c52ed_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMi0xLTEtMS0xNzQwOTA_14b02ab2-a098-4840-b71f-6249911e591c"
      unitRef="usd">598000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iacaf8ffa11674dc59342790fd0bd5b42_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMi0zLTEtMS0xNzQwOTA_c76d9bf9-83f6-4d2a-8f6d-1cdb573f96d8"
      unitRef="usd">598000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib979976208634b5c8e0a9ae50b18d4cb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMy0wLTEtMS0xNzQwOTAvdGV4dHJlZ2lvbjpiODRhM2JlNmM4MWI0YWY3YWFkNGVlNTY2NDYxZDRiMV80_4f5eb469-c53c-4f1d-9ca7-0b3a04b92d0c"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib979976208634b5c8e0a9ae50b18d4cb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMy0xLTEtMS0xNzQwOTA_aa66eb08-ae83-48d5-a145-2889d4076beb"
      unitRef="usd">450000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i542cdb35121f4951af58b7c4d099cc0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfMy0zLTEtMS0xNzQwOTA_0928451c-0630-455a-ab07-9c1310b99861"
      unitRef="usd">450000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icb39b7b0e50a41899b13e8e7a176cb73_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNC0xLTEtMS0xNzQwOTA_43ff796f-8251-43ba-9029-5bd44f37995a"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1b6cd7196060498f8905b788318223e9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNC0zLTEtMS0xNzQwOTA_e056ee5e-ac3f-499b-8665-cde8164b27f0"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNS0xLTEtMS0xNzQwOTA_017927ad-24dd-4184-a881-fcf09e26a93c"
      unitRef="usd">1405400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNS0zLTEtMS0xNzQwOTA_88d80998-14c0-472d-a404-2bcd9709a854"
      unitRef="usd">1413800000</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNy0xLTEtMS0xOTcyMDQ_7e738f91-fa42-423f-b8e7-1d58096cf64d"
      unitRef="usd">7000000.0</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNy0zLTEtMS0xOTcxOTA_d2376b43-eb43-4672-8eb1-d46e77079ed9"
      unitRef="usd">8000000.0</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNy0xLTEtMS0xNzQwOTA_d2f2b919-3565-4cbe-95a3-401e2eeb963f"
      unitRef="usd">950700000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfNy0zLTEtMS0xNzQwOTA_0a69bebd-3549-4e14-b252-c2b352b06a86"
      unitRef="usd">957300000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfOS0xLTEtMS0xNzQwOTA_b6546187-ca79-4aa6-b4d1-4f6c5e5a68bc"
      unitRef="usd">447700000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RhYmxlOjk5NDhjMTYyMWI4YzRlZTA4MTZmNTFjNmJiZDc4YWJhL3RhYmxlcmFuZ2U6OTk0OGMxNjIxYjhjNGVlMDgxNmY1MWM2YmJkNzhhYmFfOS0zLTEtMS0xNzQwOTA_80881d78-ab8d-4b8d-b962-a3a61912e4fa"
      unitRef="usd">448500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMTA5OTUxMTYzNDcwOQ_2c53aa42-7784-457c-9a92-342cc1567aa2"
      unitRef="usd">900000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMTA5OTUxMTYzNTUwMw_d34a3705-8a47-475c-93ed-b20751e01a8a"
      unitRef="usd">1300000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2a4e68384fff4fba80f54b1741dcdea3_I20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjU4_b42e5a5b-e790-40d5-a75e-c0d237a5e0f2"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2a4e68384fff4fba80f54b1741dcdea3_I20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNzUx_74d1f613-1e2c-4d86-8138-d89141d23905"
      unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2a4e68384fff4fba80f54b1741dcdea3_I20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNzg0_0b88d814-0fc1-4ef5-abdf-d9ca9c394851"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i2b6c423aa64e4e4896e0475d47d5f2cb_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMTQyNw_f748de2b-4a4c-4f05-af1e-793d6504b0d0"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i78876bbef2be40f0b38c6232f78ff57d_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMTU4OA_fe315d3a-58fb-45eb-805f-5ad963b06a9a"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="iacf16d55ed5643cb9ac1bebbf0f1c165_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMTg3OA_b9cbbe3c-0392-4e19-9c66-6a7aeccb5ce6"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="i4b04150f100345e5b7d1dba860fc021b_I20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMzQxMw_7db51448-178d-4f09-b1f1-b6c2220870b1"
      unitRef="usd">600000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="ic3e55eef26f54a4894de8f45425d8253_I20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMzQ3Mw_92093dd2-4c54-4b43-ab3a-f6b078ce643d"
      unitRef="usd">450000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4918ce9801c5412b8cd5dd6bf028c13e_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMzg5Mw_74ac84df-7528-4c82-bfd5-434b022c5f0e"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i254adee00af34c94bbc5984b0bfbe52e_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfMzg5OQ_10ace0a2-d213-4f93-b75e-82e3d9c90982"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iedb6ef8e0b6b46208f6e01be5daa2b80_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDA2MA_a4d84db8-38ba-4311-b3ab-79b261c10dd3"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8d8a56f631634a619610a599c7700384_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDEyOQ_16c7ccb2-b4b6-43b1-a400-d5c3bd1386cc"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if513d33ee9754a8db7bc70bffe5355a8_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDE1OQ_55443674-1b14-4421-adfb-77e3f43329f2"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2890fd9ac6bc4bceb48adb41f2e0e88c_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDE2NQ_35c40d76-24ce-47ff-8c12-20d10f2524c6"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ide27297d8c9443f09185ce0447397db4_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDU0NA_374c7668-c847-4f18-aa0b-7e84471efc08"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="id5c8865dca0b4780ad587e383427e48b_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDU1MA_808f88aa-fab5-498e-922d-db9baddace77"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears
      contextRef="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNDkwMA_5f046927-b6fa-4f01-b242-df87821172bc"
      unitRef="number">0.025</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear
      contextRef="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNTAyNA_2b48fd26-1f7b-47c0-8fdd-d9e920635dce"
      unitRef="number">0.05</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears
      contextRef="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNTEzOA_87026b75-a356-4408-b3f4-f826caa013ce"
      unitRef="number">0.075</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears>
    <ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight
      contextRef="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNTg1Ng_baa11a6d-32d9-473d-93bc-4609277e6372"
      unitRef="usd">100000000</ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight>
    <ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod
      contextRef="icaeda5c9c6b540f5bb7a60baecd1d9b2_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjE1Nw_3a2441b9-4243-445b-bd94-c36e989a406c">P12M</ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod>
    <ebs:DebtInstrumentCovenantDebtServiceCoverageRatio
      contextRef="ide27297d8c9443f09185ce0447397db4_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjIwNQ_9097b04f-224c-4a4a-b22f-8d0c7622935a"
      unitRef="number">2.50</ebs:DebtInstrumentCovenantDebtServiceCoverageRatio>
    <ebs:DebtInstrumentCovenantNetLeverageRatioOne
      contextRef="id5c8865dca0b4780ad587e383427e48b_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjI2NA_0608e792-b150-45fb-9c1b-410c5f34bf32"
      unitRef="number">4.50</ebs:DebtInstrumentCovenantNetLeverageRatioOne>
    <ebs:DebtInstrumentCovenantNetLeverageRatioTwo
      contextRef="id5c8865dca0b4780ad587e383427e48b_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjMwMA_2538d838-d989-4dcb-b738-5d81bc4deced"
      unitRef="number">5.00</ebs:DebtInstrumentCovenantNetLeverageRatioTwo>
    <ebs:DebtInstrumentCovenantConsiderationThreshold
      contextRef="i5a6360cdd7834010aa7e8eeb1c68ac6d_D20200807-20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV81OC9mcmFnOjQ0MDJjZTIyNDUwMjQyYTM4NDdjYjEzMTZmYjQ4MDAyL3RleHRyZWdpb246NDQwMmNlMjI0NTAyNDJhMzg0N2NiMTMxNmZiNDgwMDJfNjQ3MA_fecb1840-0a45-40ab-970a-5f8f2a518db5"
      unitRef="usd">75000000</ebs:DebtInstrumentCovenantConsiderationThreshold>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTU4Nw_047264c7-3e6a-4630-861b-ff5df0a81023">Stock-based compensation and stockholders' equity&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, the Company granted stock options to purchase 0.3&#160;million shares of common stock, 0.6&#160;million restricted stock units and 0.1&#160;million performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Performance stock units are presented at the target payout percentage of 100% of target shares granted. Typically, the stock options and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria. During the three months ended March&#160;31, 2023 0.2&#160;million shares of restricted stock units and 0.2&#160;million of stock options were forfeited prior to the completion of the applicable vesting requirements or expiration. Additionally, an immaterial amount of performance stock units were forfeited during the three months ended March&#160;31, 2023, as the award targets were not achieved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense, net of forfeitures was recorded in the following financial statement line items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021 Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 11, 2021, the Company announced that its Board of Directors authorized a stock repurchase program of up to an aggregate of $250.0&#160;million of Common Stock ("the Share Repurchase Program"). The Share Repurchase Program expired on November 11, 2022. The Company utilized $187.9&#160;million to purchase 4.4&#160;million shares as of the program's expiration date. During the three months ended March&#160;31, 2022, the Company utilized $52.2&#160;million to purchase 1.1 million shares. Repurchased shares are available for use in connection with the Company's stock plans and for other corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accumulated other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Defined Benefit Pension Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the tax effects related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#19415e;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYyOTUyMA_ae6e50a7-c7dd-414d-980f-dd321247783b"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib1dc2e31750040a4aeea787dbc908607_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYyOTUxNg_736d1625-a095-45e1-89d5-2f78061e79f3"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3cc418bd58f7472abd99705c9a2a8c70_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYzNDkwNA_11d68da9-6968-4e4d-9557-75affe13b47b"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage
      contextRef="i7c48770f38cc4b868dfb8e4164c70c6d_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMjE5OTAyMzI2MjgyOA_20b2ebf7-d478-471f-8fa2-a5d67d130742"
      unitRef="number">1</ebs:ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3cc418bd58f7472abd99705c9a2a8c70_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTU4OQ_0093a074-1952-4da5-83ee-62947315f2af">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ib1dc2e31750040a4aeea787dbc908607_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYzNTAxMQ_3a698424-7548-4887-bb46-e3890a6712b7"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfNTQ5NzU1ODIxNzM0_6d23b045-b77c-496f-b982-e7f48d387e1d"
      unitRef="shares">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTU4Mg_9783b3f4-058d-46a8-b26f-5e8eb642b775">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense, net of forfeitures was recorded in the following financial statement line items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6f2abaf2d65647afabbaad4036b4002b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfMi0xLTEtMS0xNzQwOTA_b5cc5436-06fd-4887-93aa-18d9dc5518b9"
      unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4a17055fb3844751ba1ee5905c41696a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfMi0zLTEtMS0xNzQwOTA_b0ba09fa-2b28-4165-b755-d253653a615a"
      unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c648afc26c64c1cb1d06fba7976dd3e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfMy0xLTEtMS0xNzQwOTA_e4fe42ad-3681-4f5f-917d-d09072878f53"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i052a8c8b494f4d23ba4683eec555cd78_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfMy0zLTEtMS0xNzQwOTA_b595e0dd-03d8-4e3a-98bb-f0092d0f73d4"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7b2c1680b344a52a7479ff1cb61e234_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNC0xLTEtMS0xNzQwOTA_e04fccd5-0e4d-4062-9093-1d24a56ec0cb"
      unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i352e9c64d26145bd8c991621254ab36d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNC0zLTEtMS0xNzQwOTA_4b44c8e2-4652-4cf5-aed8-b573916f805b"
      unitRef="usd">1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f4af96e200044a4bde5f4e7858cea4c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNS0xLTEtMS0xNzQwOTA_ae731148-d273-471f-9965-46466a879f0c"
      unitRef="usd">4400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3820b0b0d3c345288eeffbe32298f81f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNS0zLTEtMS0xNzQwOTA_3bd76de4-25a1-4f74-b22b-26d3233757b5"
      unitRef="usd">6700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNi0xLTEtMS0xNzQwOTA_f3874ba8-0993-48f4-b36b-aea9028aeb20"
      unitRef="usd">6800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjgzMjRjYjM5NzdmOTQxYmNhY2UyZjYxZDc3ODg5Y2U2L3RhYmxlcmFuZ2U6ODMyNGNiMzk3N2Y5NDFiY2FjZTJmNjFkNzc4ODljZTZfNi0zLTEtMS0xNzQwOTA_ad7d8f7b-f9b4-460f-b0dd-10ba87d1d99b"
      unitRef="usd">9900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i5a35abf804794f0cb7a12ca90e436e2b_I20211111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfNjkzNg_8c749c8b-30e9-4a66-b18d-9c78dfd48867"
      unitRef="usd">250000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6a932e200f934b2e8d7602dfc0339fbe_D20211111-20221111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMzg0ODI5MDcwMzIxNw_8cf03ccc-1cfd-4dc7-86c2-77035a80e07d"
      unitRef="usd">187900000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6a932e200f934b2e8d7602dfc0339fbe_D20211111-20221111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMzg0ODI5MDcwMzIzMw_f6b6aad3-a7e9-48d2-be76-44cced4c2e98"
      unitRef="shares">4400000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i31244a3a054948c88dabb06cdf5a93c8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYzNDczNA_a7017509-35e3-4ea2-a61d-bb3ab43c7bb7"
      unitRef="usd">52200000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i31244a3a054948c88dabb06cdf5a93c8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTA5OTUxMTYzNDc2OQ_30029cf9-022a-492e-bc7c-654a7eb4d33e"
      unitRef="shares">1100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTU4Ng_8ebdc34a-2757-49ae-9bfa-633ddacd1aff">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Defined Benefit Pension Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="ib39593e9eeaa410eb010f609006439d3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMi0yLTEtMS0xNzQwOTA_f49b9060-99df-4728-a0b4-f64218fa6c05"
      unitRef="usd">3500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i571387e1e87d4c0ca79fba6168341392_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMi00LTEtMS0xNzQwOTA_1071e7a1-49e7-4d58-af92-a38dc5120974"
      unitRef="usd">6200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8456a4beddae4620b224ffe90a753930_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMi02LTEtMS0xNzQwOTA_611d90c3-b987-436c-84db-b1f3a38bd766"
      unitRef="usd">-6600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i849666feb2a44d2fa12bc7967461f166_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMi04LTEtMS0xNzQwOTA_52e60d9b-393a-4a54-9c28-37582edd08d2"
      unitRef="usd">3100000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i38e2cc2fa38f451983e4495ebddf4541_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMy0yLTEtMS0xNzQwOTA_bee9a092-be19-4fd5-93e3-64e37e11ae7d"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMy00LTEtMS0xNzQwOTA_4b51c467-0c6a-4823-8313-da3a60dd4a7b"
      unitRef="usd">-4400000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMy02LTEtMS0xNzQwOTA_c40e80ba-e209-4a3c-a4b4-2b2981f491d4"
      unitRef="usd">-100000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMy04LTEtMS0xNzQwOTA_8680bb34-b3f5-498f-b6c2-e49bb4dda7da"
      unitRef="usd">-4500000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i38e2cc2fa38f451983e4495ebddf4541_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNC0yLTEtMS0xNzQwOTA_c44d03e8-0ca3-4e11-b107-4a4e6fe4562d"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNC00LTEtMS0xNzQwOTA_8cc53540-fe58-4826-803a-16fe4f5202d4"
      unitRef="usd">-2400000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNC02LTEtMS0xNzQwOTA_a1e77a55-0270-4ac5-a65a-ec68765c0b5e"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNC04LTEtMS0xNzQwOTA_ba6ef5ee-629b-4509-b3fe-e433df49285b"
      unitRef="usd">-2400000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i38e2cc2fa38f451983e4495ebddf4541_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNS0yLTEtMS0xNzQwOTA_4c9d7b48-d723-49b9-bac6-bbc1c3460b87"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNS00LTEtMS0xNzQwOTA_2bf1aee5-6dde-44f9-9767-b3a44e7f6d58"
      unitRef="usd">-2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNS02LTEtMS0xNzQwOTA_09d7c775-2c8b-4933-9d78-075580e72225"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNS04LTEtMS0xNzQwOTA_740dc91c-7276-4da4-b16f-c6d527556dca"
      unitRef="usd">-2100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i96351882c9cf4a119573f21d2fd9c69c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNi0yLTEtMS0xNzQwOTA_dd8cd0e5-173e-48bf-b1c1-4c56f20ea5d1"
      unitRef="usd">3500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia07411d977084f2bb9e23d05b7a3e72f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNi00LTEtMS0xNzQwOTA_7367ba9d-d4f2-4ee3-aa55-14871572bf15"
      unitRef="usd">4200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8cf4c3b78864ea8b78309b616ed410d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNi02LTEtMS0xNzQwOTA_2f626608-33c0-474a-94c6-c7ecf89cc165"
      unitRef="usd">-6700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1d83f154114044a1bbe6ae3c214f52d4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfNi04LTEtMS0xNzQwOTA_56ff55bc-738f-4386-8565-2540d9b81d23"
      unitRef="usd">1000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i004ed59fdb204528af83813c202f2349_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTQtMi0xLTEtMTc0MDkw_2b9351aa-f510-4b79-ac53-f5c28d2605d7"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied3e0a962bf84f89a49887476428ac94_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTQtNC0xLTEtMTc0MDkw_666794b7-5807-4105-9eb0-4f1f0a8133f4"
      unitRef="usd">-4500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f133842273b47d8a0e0c8008c0debc9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTQtNi0xLTEtMTc0MDkw_6ce5d660-67cb-4fc5-b776-108747e1c06b"
      unitRef="usd">-7600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id730fb1f570643e09406bfe6aebe15ba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTQtOC0xLTEtMTc0MDkw_fbd47516-34e2-4a41-8457-c32b5c25d13a"
      unitRef="usd">-16100000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="id1df6434f4c741debcb5c66e3f358e12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTUtMi0xLTEtMTc0MDkw_a57c324c-bc64-4b72-a509-8d587d38ba85"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTUtNC0xLTEtMTc0MDkw_f3b3b30d-6fcf-4b40-a177-67e10dd2fa87"
      unitRef="usd">4900000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTUtNi0xLTEtMTc0MDkw_2f4cf8ed-df56-45e7-a023-7f176ce9664e"
      unitRef="usd">500000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTUtOC0xLTEtMTc0MDkw_a8c126af-b9e3-4311-b09d-633e644f6666"
      unitRef="usd">5400000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="id1df6434f4c741debcb5c66e3f358e12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTYtMi0xLTEtMTc0MDkw_c7fbab28-8a5a-4b3b-97b6-b85cd586b011"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTYtNC0xLTEtMTc0MDkw_e44e490e-3d91-4f55-b601-a32cca846cb9"
      unitRef="usd">-1400000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTYtNi0xLTEtMTc0MDkw_62d2792d-8ed5-4b80-a1a3-e0797490a157"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTYtOC0xLTEtMTc0MDkw_f61cf93f-a096-4b40-b6b8-f1bae69f32a0"
      unitRef="usd">-1400000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id1df6434f4c741debcb5c66e3f358e12_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTctMi0xLTEtMTkyODM1_a5a67026-f478-49e7-aabf-e97f7a6a80ed"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTctNC0xLTEtMTc0MDkw_acfc2cd6-1366-45ab-a95e-2bcbe5b09212"
      unitRef="usd">6300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTctNi0xLTEtMTc0MDkw_1bc788a1-f579-4742-bdad-7f19ab3e7bbf"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTctOC0xLTEtMTc0MDkw_0de38a40-0289-41b6-bcb8-2fe23a33e04c"
      unitRef="usd">6800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="iecaf90f0f80546248e7c187071884007_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTgtMi0xLTEtMTc0MDkw_6d291410-5c71-4b7d-b32a-7853369e9a17"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i691f830478c747349de4e41c45528d98_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTgtNC0xLTEtMTc0MDkw_fce76ee0-62b6-4244-a8ea-0f8b658b1bc8"
      unitRef="usd">1800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4eb60b9b64b04e06af66a990c3c77632_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTgtNi0xLTEtMTc0MDkw_95745bab-50a3-43d9-b890-9128e1b2f31c"
      unitRef="usd">-7100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9426132f4f814179b20fee2cb4d853f7_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjJmODRlZThkMmU3NTQzZTJiM2IyNWZlZDk4MzIzZTQ3L3RhYmxlcmFuZ2U6MmY4NGVlOGQyZTc1NDNlMmIzYjI1ZmVkOTgzMjNlNDdfMTgtOC0xLTEtMTc0MDkw_9df949a4-51eb-4ed2-b86f-d81f09fea5de"
      unitRef="usd">-9300000</us-gaap:StockholdersEquity>
    <us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RleHRyZWdpb246NTE1MDRjMmZkNDQ2NGI3OGFjY2NmYTA2NjIwOTZlYTNfMTU5MA_c7bd1d3f-3c3d-41b2-bcf2-14a600475d1a">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the tax effects related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#19415e;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS0xLTEtMS0xNzQwOTA_d06fde2f-f686-4512-bc99-533e0921213a"
      unitRef="usd">-2600000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS0zLTEtMS0xNzQwOTA_8e19494f-321c-45a9-9307-74c07b700ee2"
      unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if616e9c1242243a8a1d552cea8888cf0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS01LTEtMS0xNzQwOTA_ac45b056-cff3-45a9-a947-72c1a0c13577"
      unitRef="usd">-2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS03LTEtMS0xNzQwOTA_dd8ccbc9-a83c-402e-a955-4933c30af906"
      unitRef="usd">8600000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS05LTEtMS0xNzQwOTA_c02c8075-02c7-4441-bc3b-445db5197762"
      unitRef="usd">2300000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i513d752470bc44f18f09e80d6cb8e824_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNS0xMS0xLTEtMTc0MDkw_c8b168ce-71fc-4df9-9719-9c05e38ca8e6"
      unitRef="usd">6300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi0xLTEtMS0xNzQwOTA_6370bdf8-6e08-4315-bb33-61b6806571aa"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi0zLTEtMS0xNzQwOTA_ca983b86-35fb-48f4-a4f6-ef5448facf81"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib665f95ce7b1428ca5f9b49799759885_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi01LTEtMS0xNzQwOTA_3da0bdfe-3e64-4a1c-8bd0-c1a4ebee6b50"
      unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi03LTEtMS0xNzQwOTA_d37c0d19-a7d9-4409-a9d0-ee76dbb9b09b"
      unitRef="usd">700000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi05LTEtMS0xNzQwOTA_d9022670-469f-437f-8d79-991ee40f3a31"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5e9caa330f3e4d84a52bbf41c3f9d177_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNi0xMS0xLTEtMTc0MDkw_9f25b2fa-1707-4b6e-bc94-181d77291296"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy0xLTEtMS0xNzQwOTA_902afdbc-4ea0-44c3-ac96-7049e7dfb646"
      unitRef="usd">-2700000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy0zLTEtMS0xNzQwOTA_2abd920e-ea07-40c1-b369-adb764695c23"
      unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy01LTEtMS0xNzQwOTA_f0357417-03c9-49d3-af7e-f5d0f83fa92e"
      unitRef="usd">-2100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy03LTEtMS0xNzQwOTA_ce5b509f-cfe8-458c-94ed-7a277ee41921"
      unitRef="usd">9300000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy05LTEtMS0xNzQwOTA_0dd88ee3-9b70-4a72-ac46-2d16d605b665"
      unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83Ni9mcmFnOjUxNTA0YzJmZDQ0NjRiNzhhY2NjZmEwNjYyMDk2ZWEzL3RhYmxlOjQ4YjI1MzI2MDQyMzRjNWU4YjdmMTcyYjRjMGMxMTQ0L3RhYmxlcmFuZ2U6NDhiMjUzMjYwNDIzNGM1ZThiN2YxNzJiNGMwYzExNDRfNy0xMS0xLTEtMTc0MDkw_18bae771-172a-4f50-94be-187242bcf379"
      unitRef="usd">6800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RleHRyZWdpb246Y2Q0M2ZlNGRmODU5NGVmN2E3MTU5ZmRkNjNiZDRjZjRfMTMwNQ_5f849070-8080-418f-9230-f8cb090725f4">Earnings (loss) per common share&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per common share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share adjusts basic loss per common share for the effects of potentially dilutive common shares and is calculated using the treasury stock method. Potentially dilutive common shares include the dilutive effect of shares issuable under our equity compensation plans, including stock options, restricted stock units, and performance stock units. Diluted loss per share excludes anti-dilutive securities, which represent the number of potential common shares related to shares issuable under our equity compensation plan that were excluded from diluted loss per common share because their effect would have been antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1b51bf;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares outstanding-basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares outstanding-diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss per common share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss per common share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RleHRyZWdpb246Y2Q0M2ZlNGRmODU5NGVmN2E3MTU5ZmRkNjNiZDRjZjRfMTMwNA_c572b2a3-9292-4463-9b17-9e37aa68c590">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1b51bf;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(183.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares outstanding-basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares outstanding-diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss per common share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss per common share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMy0xLTEtMS0xNzQwOTA_0fbe4725-1c9d-45dc-8c18-24654d55d61b"
      unitRef="usd">-183000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMy0zLTEtMS0xNzQwOTA_0d567eb1-d823-4f66-a8ed-cef1a0048697"
      unitRef="usd">-3700000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfNi0xLTEtMS0xNzQwOTA_a09bf8f8-4dc8-4491-88e5-37df65ef1d0f"
      unitRef="shares">50200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfNi0zLTEtMS0xNzQwOTA_795bdb3c-137e-4654-9a1e-6a7a0f976cd6"
      unitRef="shares">50700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfOC0xLTEtMS0xNzQwOTA_3e13913d-d859-4c8d-86d2-3210fb19e5a8"
      unitRef="shares">50200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfOC0zLTEtMS0xNzQwOTA_2ba4a9b3-e266-47dc-8270-56e38f2a4976"
      unitRef="shares">50700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTAtMS0xLTEtMTc0MDkw_8713f992-7487-40aa-a5d4-371a68594f04"
      unitRef="usdPerShare">-3.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTAtMy0xLTEtMTc0MDkw_4ba25c4e-59cb-4c8e-96f9-6efde373ecd8"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTEtMS0xLTEtMTc0MDkw_82316647-8db5-4b8e-9e90-c571b7803b1b"
      unitRef="usdPerShare">-3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTEtMy0xLTEtMTc0MDkw_6d78697a-99ad-4d95-b4a3-1bcb117622ff"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTEtMS0xLTEtMTkyODUy_13201276-0b06-4f08-ab93-41af499ca966"
      unitRef="shares">3200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83My9mcmFnOmNkNDNmZTRkZjg1OTRlZjdhNzE1OWZkZDYzYmQ0Y2Y0L3RhYmxlOjE4YzQ0YTUxZjk0YTQxNmRiY2VmY2RjZjQxYTQwOGE2L3RhYmxlcmFuZ2U6MThjNDRhNTFmOTRhNDE2ZGJjZWZjZGNmNDFhNDA4YTZfMTEtMy0xLTEtMTkyODUy_d1b79200-383d-425a-8f29-224e68da7bbd"
      unitRef="shares">1600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfODIzMA_9cb55893-1dfd-4dbb-b672-4f012ca594b6">Revenue recognition &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as two operating segments (see Note 17, "Segment information"). The Company's revenues disaggregated by the major sources were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;133.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;237.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CDMO:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total CDMO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;165.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 2, 2020, the Company, through its wholly-owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into the Agreement with Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson, for large-scale drug substance manufacturing of Johnson &amp;amp; Johnson&#x2019;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#x201c;Product&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2022, the Company provided to Janssen a notice (the &#x201c;Notice&#x201d;) of material breach of the Agreement for, among other things, failure by Janssen (i) to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Agreement and (ii) to confirm Janssen&#x2019;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Agreement and instead, wind-down the Agreement ahead of fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#x201c;Janssen Notice&#x201d;) of the Agreement for asserted material breaches of the Agreement by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices ("cGMP") or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the Company&#x2019;s breaches were not curable and that, therefore, termination of the Agreement would be effective as of July 6, 2022. The Company disputes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result of the Company's alleged failure to perform under the Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process through arbitration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, there were no impacts on previously recognized revenue or depreciation related to the conclusion of the Agreement. As of March&#160;31, 2023, the Company has no billed or unbilled net accounts receivable related to the Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the fourth quarter of 2022, because the arbitration process may extend longer than one year, the Company reclassified amounts related to the Janssen Agreement from "Inventories, net" and from "Prepaid expenses and other current assets" to "Other assets", resulting in $152.7&#160;million in long-term assets related to the Janssen Agreement on the Condensed Consolidated Balance Sheet as of December&#160;31, 2022. The long-term asset balance within "Other Assets" related to the Agreement as of March&#160;31, 2023 was $153.9&#160;million. These assets include termination penalties, certain inventory related items and raw materials inventory representing materials purchased for the Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of the inventory as of March&#160;31, 2023, concluding that because the Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for any reason, the Company is entitled to payment from Janssen for these raw materials. Additionally, the Company has $5.4&#160;million of non-cancelable orders as of March&#160;31, 2023 which have not been received and Janssen has not reimbursed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CDMO operating leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain multi-year CDMO service arrangements with commercial customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates 2.5 years. The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components. Excluding future amounts related to the Agreement as discussed above, the Company estimates future operating lease revenues to be $3.3&#160;million in the remainder of 2023, $0.9&#160;million in 2024, $0.9&#160;million in 2025, $0.9&#160;million in 2026, $0.9&#160;million in 2027 and $0.9&#160;million in years beyon&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction price allocated to remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the Company has future contract value on unsatisfied performance obligations of approximately $331.1&#160;million associated with all arrangements entered into by the Company. The Company expects to recognize a majority of the $331.1&#160;million of unsatisfied performance obligations within the next 24 months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associated with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#x2019;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of March&#160;31, 2023 and December&#160;31, 2022, the Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;had $27.1 million an&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$34.8 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, of contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recorded within "Accounts receivable, net" on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the Condensed Consolidated Balance Sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the roll forward of the contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, the current portion of contract liabilities was $12.8&#160;million and $26.4&#160;million, respectively, and was included in "Other current liabilities" on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts receivable and allowance for expected credit losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Billed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowance for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0NTg1MA_25904a2e-c7fd-4897-92f6-57fb9e4dbb42"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0NTg1MA_e1785b3d-d453-4476-864e-65e5ac7806fb"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfODIzMg_101807eb-b2e0-4666-a34f-7322ac0f9237">The Company's revenues disaggregated by the major sources were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Non-USG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;117.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;133.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;237.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CDMO:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total CDMO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;165.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f98df3f96494ca3af0b6134b79f6e6c_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi0xLTEtMS0xNzQwOTA_b2c32862-3672-4443-b28c-01e794fdf6fd"
      unitRef="usd">26100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i732a446dfeda451387df581fcd0cfb6e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi0zLTEtMS0xNzQwOTA_e273f1a0-b36f-4475-9542-cce7bbf4e43d"
      unitRef="usd">117300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bac9a933b6d4e1f906de2a6a7325d62_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi01LTEtMS0xNzQwOTA_446c9ab0-462f-41d8-992e-9e725292e861"
      unitRef="usd">143400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id50de4745d3a466eafedae511bbe57f3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi03LTEtMS0xNzQwOTA_956029b1-13ef-4c31-8db8-5f8f638cdb64"
      unitRef="usd">103400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ed128aa8d4847bd8d098b42c1c2112a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi05LTEtMS0xNzQwOTA_73812005-ab6e-4e2b-b1d6-1cf519be11f8"
      unitRef="usd">133700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96983ae20d1a4fd892a5f1444783a570_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfMi0xMS0xLTEtMTc0MDkw_f3c015d2-02bb-46e3-8cfd-5319ac683b35"
      unitRef="usd">237100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a7228c4c4da4a3daa277c2e60ff556d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC0xLTEtMS0xNzQwOTA_de7fbf35-9407-4801-b55b-7378d36bf500"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc9f8df6d25942899d6f3695ef5c6172_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC0zLTEtMS0xNzQwOTA_72b08603-fc90-477a-8eaa-1f5c2df39562"
      unitRef="usd">13400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18e052da12c34e0e91cf56a39cd08cd1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC01LTEtMS0xNzQwOTA_72234573-1869-4776-beb7-098e451ca577"
      unitRef="usd">13400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i987753cf494a4b45ace898c7942aef7c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC03LTEtMS0xNzQwOTA_233c1547-00ac-4df7-b9d1-5b66b9c1dbfd"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5383a292c962418f9b059d0b06839b4e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC05LTEtMS0xNzQwOTA_6c4eb278-974a-47bf-99b1-5576a7076d07"
      unitRef="usd">51800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i513c1b52eb2e4d47828f3ec0440d9a1a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNC0xMS0xLTEtMTc0MDkw_4e0ef9e5-59b4-43c8-89bd-9530dc691504"
      unitRef="usd">51800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ie421a9cb2b954cbca8c8c507c55fd2bd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS0xLTEtMS0xNzQwOTA_94d58a35-3e7c-4805-9483-86eb0c3882b2"
      unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i95813f0ec62d4d0c9fcc5789b0837330_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS0zLTEtMS0xNzQwOTA_7fc665f4-195e-4908-a93e-41034c1c6e44"
      unitRef="usd">1800000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i79e134d107e94e148da24dade40b12b6_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS01LTEtMS0xNzQwOTA_76957a9c-7b79-42a8-b58f-cad423dabbeb"
      unitRef="usd">1800000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i8d187bce987143dc92586a3d08ecacd6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS03LTEtMS0xNzQwOTA_42ff9b75-d116-4603-85b0-db41e9629ea2"
      unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="id10f475f516846bcae44f6b46b3bbd0b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS05LTEtMS0xNzQwOTA_2e2a9439-9598-40a7-b63f-f0ea4e346930"
      unitRef="usd">9000000.0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i8373489620694e8096c4d7cb76a601a2_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNS0xMS0xLTEtMTc0MDkw_0cd08138-94e0-42e4-aaba-c260f50e7770"
      unitRef="usd">9000000.0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab03b11d81254786a5977fced794e6b1_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi0xLTEtMS0xNzQwOTA_f1c8244b-d7cd-4b49-a949-22b01e108cfa"
      unitRef="usd">0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i871dc7a154524d879334cb879c7ddfd0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi0zLTEtMS0xNzQwOTA_c1fb4172-3fdb-4c17-a274-672e8e60c9c5"
      unitRef="usd">15200000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i282b3d80373a44448dcd835b4ec3dd02_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi01LTEtMS0xNzQwOTA_c751a1eb-bd29-4ac8-8cdd-ffcf550196a3"
      unitRef="usd">15200000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3379cc28cb04ee5bececd01664b6872_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi03LTEtMS0xNzQwOTA_d23ff47d-295d-4036-9c8e-d2be38b39486"
      unitRef="usd">0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4efd920943c8420a8281d18b9639ad0e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi05LTEtMS0xNzQwOTA_9cdbb73d-5210-46dc-9db8-41498e8382a6"
      unitRef="usd">60800000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fcbd10db46849358e569878c1ae8ae0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNi0xMS0xLTEtMTc0MDkw_9ed84912-5525-4954-8c06-4d44a0ff2e9b"
      unitRef="usd">60800000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib83a1dda4ddc4ccdad92792fb6b17c46_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy0xLTEtMS0xNzQwOTA_e3cf7f73-1c3d-4cbd-a080-3587826c2ef7"
      unitRef="usd">4900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c77354994dd4d71ac100d180641d494_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy0zLTEtMS0xNzQwOTA_4bda558f-0c5e-4560-a8f7-8865a8784fad"
      unitRef="usd">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e5222cf971340bab0614a17ebbf5ed8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy01LTEtMS0xNzQwOTA_1ec0538a-f79d-4269-952e-1f112f4cd4e4"
      unitRef="usd">6500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9415e748067844bfbe9ef3caeb28bad0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy03LTEtMS0xNzQwOTA_f81e9dc0-6455-4dff-af50-77741a010d09"
      unitRef="usd">9100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3f4207af8e54989a266f7659a215b5e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy05LTEtMS0xNzQwOTA_e8940d1a-7eb4-457e-ab6c-786b5195509b"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d4fc9a55e4b49afb88321e52246a468_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfNy0xMS0xLTEtMTc0MDkw_4ad383f2-c832-47a0-b0be-0d6b8dab6d01"
      unitRef="usd">9600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="iff58dd309a0441e3b97192aae2d95c4f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC0xLTEtMS0xNzQwOTA_60a9ce6c-a76c-436f-b6d7-4810576f6352"
      unitRef="usd">31000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd7432d9b0914c74aee8b459bf887d15_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC0zLTEtMS0xNzQwOTA_662b33e9-9926-43e4-a3b9-e363232924c7"
      unitRef="usd">134100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC01LTEtMS0xNzQwOTA_9310d7b6-97cc-4d74-a12d-35d2d99f695c"
      unitRef="usd">165100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04f3699777f34efe88b689e5c3e48b90_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC03LTEtMS0xNzQwOTA_40a7f55f-9428-4d3a-a64f-434e601794e8"
      unitRef="usd">112500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39d08b46e2f94f58a5f1e2935eeece69_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC05LTEtMS0xNzQwOTA_d4622aa7-f7ee-4b19-9017-6626bb5c686f"
      unitRef="usd">195000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOjNmMjNjZDgxOTUzMjQwNWE4NTA3ODYyMDhlMjNiNjJmL3RhYmxlcmFuZ2U6M2YyM2NkODE5NTMyNDA1YTg1MDc4NjIwOGUyM2I2MmZfOC0xMS0xLTEtMTc0MDkw_8772a568-038c-40b6-acdc-3e7f306c3d35"
      unitRef="usd">307500000</us-gaap:Revenues>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i4294703259534cdcbbf6f3c0f104718b_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY2NTE3Ng_f79c8848-c8bc-4de6-bbd5-cdc850c1f3fb"
      unitRef="usd">152700000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id18cb2b8881b4956ac5446f313a06aa4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY2NTE2OA_1089175f-d1b4-47d6-a486-5620b57d398e"
      unitRef="usd">153900000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="id18cb2b8881b4956ac5446f313a06aa4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY2NjE3Nw_b1e43019-4b55-476a-97fb-20c47ba8ddb5"
      unitRef="usd">5400000</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY2NTIwMQ_d2054332-3edb-4607-bac4-118309db60bd">P2Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
      contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTQ5MQ_34c1536c-510e-4ef6-8af6-837650c64b63"
      unitRef="usd">3300000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTQ5NQ_ab3ba185-4c3f-4a6e-919f-43537d581c5e"
      unitRef="usd">900000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTQ5OQ_5ec43c44-6ec8-4b44-a0f1-881f8f0cc54e"
      unitRef="usd">900000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfNTQ5NzU1ODUyNTQ1_9930e150-ce4b-4bb1-8a8e-00c53cee9758"
      unitRef="usd">900000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears
      contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfNTQ5NzU1ODUyNTU5_b76b7011-3e68-48a3-89bf-8132976c70ea"
      unitRef="usd">900000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <ebs:LessorOperatingLeasePaymentToBeReceivedAfterYearFour
      contextRef="iae2ab95b86444d45b4d488934aae7ce6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTUwMw_3edd7ce8-d5b0-4fb3-9e33-a1d160ac2e68"
      unitRef="usd">900000</ebs:LessorOperatingLeasePaymentToBeReceivedAfterYearFour>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTY0OQ_f8d0e914-30d3-4d0e-aa69-721573932253"
      unitRef="usd">331100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTY1Mw_f8d0e914-30d3-4d0e-aa69-721573932253"
      unitRef="usd">331100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ide9ab2059eb245668f1987b63208f7e7_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfNjMyOQ_55c0679a-b10c-4e79-a0fb-ce2c69fd368c">P24M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTY3NQ_eb7a1ed4-b886-496e-8aa5-77305bb3a019"
      unitRef="usd">27100000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTY2Ng_31847546-dfa8-4037-b25c-74a7c3953bfa"
      unitRef="usd">34800000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfODIzNA_efbc1fe7-968a-4ed5-9fc9-1c0b0d4e4fc2">The following table presents the roll forward of the contract liability balances:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmNkYWUwNmIxODI5NTQ2Yjg5NWFhYzE5ZjBlMGZkOTM5L3RhYmxlcmFuZ2U6Y2RhZTA2YjE4Mjk1NDZiODk1YWFjMTlmMGUwZmQ5MzlfMS0yLTEtMS0xNzQwOTA_f560edb0-da2d-4d0a-9dff-44bd47615767"
      unitRef="usd">31700000</us-gaap:ContractWithCustomerLiability>
    <ebs:ContractWithCustomerLiabilityAdditions
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmNkYWUwNmIxODI5NTQ2Yjg5NWFhYzE5ZjBlMGZkOTM5L3RhYmxlcmFuZ2U6Y2RhZTA2YjE4Mjk1NDZiODk1YWFjMTlmMGUwZmQ5MzlfMi0yLTEtMS0xNzQwOTA_99bff6ab-e34f-4518-b7f7-d54c1e06502c"
      unitRef="usd">5000000.0</ebs:ContractWithCustomerLiabilityAdditions>
    <ebs:ContractWithCustomerLiabilityDeductions
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmNkYWUwNmIxODI5NTQ2Yjg5NWFhYzE5ZjBlMGZkOTM5L3RhYmxlcmFuZ2U6Y2RhZTA2YjE4Mjk1NDZiODk1YWFjMTlmMGUwZmQ5MzlfMy0yLTEtMS0xNzQwOTA_bb06064a-cc96-4d85-b4a0-34deb7e4334b"
      unitRef="usd">18700000</ebs:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmNkYWUwNmIxODI5NTQ2Yjg5NWFhYzE5ZjBlMGZkOTM5L3RhYmxlcmFuZ2U6Y2RhZTA2YjE4Mjk1NDZiODk1YWFjMTlmMGUwZmQ5MzlfNC0yLTEtMS0xNzQwOTA_506884c1-3965-4387-9ac0-eae3d473c89f"
      unitRef="usd">18000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTYzMw_134f70f7-a02a-4576-9934-ea57229d313e"
      unitRef="usd">12800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfMTA5OTUxMTY0OTYzNw_0dfbcab2-9778-4f1c-a9b4-8082a321594d"
      unitRef="usd">26400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ebs:ScheduleOfAccountsReceivableNetTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RleHRyZWdpb246OTE0MGQwYWViODliNGU3MTg3MjdiNTBlYTFmMTQ4YjFfODIzNQ_69a06eda-54ac-44f1-a451-c4a9f57cb694">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Billed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;106.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowance for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ebs:ScheduleOfAccountsReceivableNetTableTextBlock>
    <us-gaap:BilledContractReceivables
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMS0yLTEtMS0xNzQwOTA_4470c064-83f9-4981-bd0e-4da21fad3d67"
      unitRef="usd">106500000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMS00LTEtMS0xNzQwOTA_7296ea4f-a719-4da9-9b3c-d87639948fd2"
      unitRef="usd">102700000</us-gaap:BilledContractReceivables>
    <us-gaap:UnbilledContractsReceivable
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMi0yLTEtMS0xNzQwOTA_c6490ac5-d852-4abe-9820-610a7524589b"
      unitRef="usd">49800000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMi00LTEtMS0xNzQwOTA_4036a607-b686-4fab-8538-60b11196612c"
      unitRef="usd">56400000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMy0yLTEtMS0xODEyMzA_6f796635-5c41-4994-85f3-024c93a3771c"
      unitRef="usd">400000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMy00LTEtMS0xODEyMzA_fdc27700-5733-4a44-9500-72a95e5cf51a"
      unitRef="usd">700000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMy0yLTEtMS0xNzQwOTA_38cadded-a2c1-4138-99c3-dca3fe35279a"
      unitRef="usd">155900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV82NC9mcmFnOjkxNDBkMGFlYjg5YjRlNzE4NzI3YjUwZWExZjE0OGIxL3RhYmxlOmExMWJmOGNkNTI3NzRlYmRhZjRlNmIwY2MwMDllYzE4L3RhYmxlcmFuZ2U6YTExYmY4Y2Q1Mjc3NGViZGFmNGU2YjBjYzAwOWVjMThfMy00LTEtMS0xNzQwOTA_c96dd31a-51ba-4763-8184-d297b16fa912"
      unitRef="usd">158400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RleHRyZWdpb246ZTM1ZjU1YjdkOWJiNDBjYzllMDgzNmEyZWFkYTAyNjlfMTA2Nw_94766212-45cd-4601-83e6-b1559fc2a4a4">Leases&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is the lessee for operating leases for offices, R&amp;amp;D facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets and liabilities. For a discussion of lessor activities, see Note 13, "Revenue recognition".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are reflected as components of cost of product sales, cost of contract development and manufacturing, R&amp;amp;D expense and selling, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to lessee activities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_2bbfbc2c-d247-4e2c-8c4a-1c01ee6c8aa2"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_7baa0cdf-0d92-4228-afaa-c3228f02be7a"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_1145e4f7-1aec-4074-98e1-3ac124493f0e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_d44d3959-2bf6-46da-bfab-b74e748a5df1"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_3c68e61a-e113-4e32-8721-bdace66fd926"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_9da09783-cbaa-40ca-9a98-b6bc1f730f8f"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RleHRyZWdpb246ZTM1ZjU1YjdkOWJiNDBjYzllMDgzNmEyZWFkYTAyNjlfMTA2OQ_c126c478-8630-43e5-98b9-52ac49707f27">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfMy0xLTEtMS0xNzQwOTA_acb077ba-70e1-4580-a89e-f892f7b90c8d"
      unitRef="usd">1100000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfMy0zLTEtMS0xNzQwOTA_a97dc804-7913-478c-82fb-8ceb8aa5037c"
      unitRef="usd">1400000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfNC0xLTEtMS0xNzQwOTA_893686a7-60dd-4838-840e-39ba48c08b55"
      unitRef="usd">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfNC0zLTEtMS0xNzQwOTA_f812ee3f-4574-4b71-a47b-cdd9c06d0f30"
      unitRef="usd">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCost
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfNS0xLTEtMS0xNzQwOTA_28ff7392-5918-429f-b22b-9430d5bacd6b"
      unitRef="usd">1300000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOmJhYWIxM2VhMWQxNzQ4MDQ4ZTM2ZjFhYWQ1NDc2NzI1L3RhYmxlcmFuZ2U6YmFhYjEzZWExZDE3NDgwNDhlMzZmMWFhZDU0NzY3MjVfNS0zLTEtMS0xNzQwOTA_603ac74d-8a44-42ca-a481-7af7ef44d6b5"
      unitRef="usd">1700000</us-gaap:LeaseCost>
    <ebs:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RleHRyZWdpb246ZTM1ZjU1YjdkOWJiNDBjYzllMDgzNmEyZWFkYTAyNjlfMTA1Ng_d015f8f6-82bf-40eb-a55e-7adb14e23419">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to lessee activities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_2bbfbc2c-d247-4e2c-8c4a-1c01ee6c8aa2"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0xLTEtMS0xNzQwOTA_7baa0cdf-0d92-4228-afaa-c3228f02be7a"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_1145e4f7-1aec-4074-98e1-3ac124493f0e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0xLTEtMS0xNzQwOTA_d44d3959-2bf6-46da-bfab-b74e748a5df1"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_3c68e61a-e113-4e32-8721-bdace66fd926"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0xLTEtMS0xNzQwOTA_9da09783-cbaa-40ca-9a98-b6bc1f730f8f"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ebs:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS0zLTEtMS0xNzQwOTA_d5589068-c8f2-4d06-be6b-0a6e64999145"
      unitRef="usd">15500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMS01LTEtMS0xNzQwOTA_f1d597d4-c7b6-4f07-b75a-526ef22743b5"
      unitRef="usd">19400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy0zLTEtMS0xNzQwOTA_88a600e6-9857-40f1-aefa-118d5c81937c"
      unitRef="usd">3400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfMy01LTEtMS0xNzQwOTA_8e98b242-6681-4033-91eb-20a4ac8a06d6"
      unitRef="usd">5800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC0zLTEtMS0xNzQwOTA_56bdf365-500b-4ce0-b963-29bca834811f"
      unitRef="usd">13000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNC01LTEtMS0xNzQwOTA_ef1e491b-57a1-4e5e-a06c-8be492cd016e"
      unitRef="usd">14800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNS0zLTEtMS0xNzQwOTA_f3af4c4b-5d52-411c-828b-61601d7d514e"
      unitRef="usd">16400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfNS01LTEtMS0xNzQwOTA_2100886d-3d47-494f-9ab7-543d9ffb8272"
      unitRef="usd">20600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfOC0zLTEtMS0xNzQwOTA_a9723521-e222-4501-b732-1720d9480a5c">P6Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfOC01LTEtMS0xNzQwOTA_fb990bbe-cc93-4f0d-b65d-1843649d56d0">P5Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5a596f9ce817474386ba6f96f2eb24e5_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfOS0zLTEtMS0xNzQwOTA_6df6907d-0226-4a2e-b549-bbc32274468a"
      unitRef="number">0.041</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i960cf41acb8b4188a01129fbd602dc88_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV80Ni9mcmFnOmUzNWY1NWI3ZDliYjQwY2M5ZTA4MzZhMmVhZGEwMjY5L3RhYmxlOjYyMGRlM2E5OWM0ZTQ3MTU4MmI4Njc2ZjJmOThmNWIyL3RhYmxlcmFuZ2U6NjIwZGUzYTk5YzRlNDcxNTgyYjg2NzZmMmY5OGY1YjJfOS01LTEtMS0xNzQwOTA_60f67b4d-898b-4c87-82c5-d4c5a4a4c674"
      unitRef="number">0.041</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfMTgzMg_5afc8605-adaf-4594-8697-291351347ea5">Income taxes&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated effective annual tax rate for the years ended December&#160;31, 2023 and 2022, excluding the impact of discrete adjustments, was (13)% and 25%, respectively. The decrease in the estimated effective annual tax rate is primarily due to a valuation allowance charge. The Company recorded a discrete tax expense of $0.0&#160;million for the three months ended March&#160;31, 2023, and $0.4&#160;million for the three months ended March&#160;31, 2022. The discrete tax expense in 2023 was due to share-based compensation activity which was entirely offset by a valuation allowance charge. The net discrete expense in 2022 was primarily due to share-based compensation activity and return to provision adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. At each reporting period, the Company considers the scheduled reversal of deferred tax liabilities and assets, available taxes in carryback periods, tax planning strategies and projected future taxable income in making this assessment.&lt;/span&gt;&lt;/div&gt;In 2022, the Company determined that it was more likely than not that certain deferred tax assets would not be realized due to reductions in estimates of future profitability and disclosure related to substantial doubt about the Company's ability to continue as a going concern. Accordingly, the Company recorded an additional valuation allowance charge of $65.2 million in calculating the estimated annual tax rate for the year ended December&#160;31, 2023.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib40925538fdf41e1b15aa28d2dffd833_D20230101-20231231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfMTA5OTUxMTYzMjAwNQ_81f509f9-eb23-4cbb-9231-f0d2bfdb0328"
      unitRef="number">-0.13</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i92e936994b3b439dae281f549affd0f1_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfMTA5OTUxMTYzMjAwOQ_b934bace-efd5-4107-af61-09ee5244a85b"
      unitRef="number">0.25</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfMTA5OTUxMTYzMjAxNw_a9bd7e0a-aab1-41b3-96fa-7ef6de308da2"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfMTA5OTUxMTYzMjAxMw_576c79f9-d6b7-4740-a4d4-c453995162cd"
      unitRef="usd">400000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ib40925538fdf41e1b15aa28d2dffd833_D20230101-20231231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV83MC9mcmFnOjI3OTM4YTZmMDljMTRmYmQ4MTA3ZjY1YjcxZDJmYTc3L3RleHRyZWdpb246Mjc5MzhhNmYwOWMxNGZiZDgxMDdmNjViNzFkMmZhNzdfNTQ5NzU1ODE5Mjgz_0ba35470-aecf-430c-8dec-78aba25a8124"
      unitRef="usd">65200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84OC9mcmFnOjNiODllYzBmOWFjMDQ1NDM4NjM3OWU0ZjAwZTBmNzkxL3RleHRyZWdpb246M2I4OWVjMGY5YWMwNDU0Mzg2Mzc5ZTRmMDBlMGY3OTFfNzY0Mw_735a328c-a944-4a5f-b555-8900c08e55b9">Litigation&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Securities and shareholder litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#x2019;s common stock, seeking to pursue remedies under the Securities Exchange Act of 1934. These complaints were filed by Palm Tran, Inc. &#x2013; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth; and Stephen M. Weiss, respectively. The complaints allege, among other things, that the defendants made false and misleading statements about the Company's manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as "CDMO Manufacturing Capabilities"). These cases were consolidated on December 23, 2021, under the caption In re Emergent BioSolutions Inc. Securities Litigation, No. 8:21-cv-00955-PWG (the "Federal Securities Class Action"). The Lead Plaintiffs in the consolidated matter are Nova Scotia Health Employees&#x2019; Pension Plan and The City of Fort Lauderdale Police &amp;amp; Firefighters&#x2019; Retirement System. The defendants filed a motion to dismiss on May 19, 2022 and the Lead Plaintiff filed an opposition to that motion on July 19, 2022. A hearing on the motion to dismiss was conducted on April 19, 2023 and a decision on the motion is expected in the coming months. The defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the consolidated action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 29, 2021, Lincolnshire Police Pension Fund (&#x201c;Lincolnshire&#x201d;), and on August 16, 2021, Pooja Sayal, filed putative shareholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, the cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-PWG. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022 the Court approved the parties joint stipulation to and stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action. The defendants believe that the allegations in the complaints are without merit and intend to defend the matter vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2021, September 16, 2021 and November 12, 2021, putative shareholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp;amp; Police Officers Pension Fund, respectively, in The Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption In re Emergent BioSolutions, Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#x2019; filed a motion to dismiss the complaint. Ruling on this motion is stayed pursuant to a March 29, 2022 order staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2021, December 22, 2021 and January 18, 2022, putative shareholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the federal securities laws, each allegation related to the CDMO Manufacturing Capabilities. The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings and Discovery, pursuant to which the parties agreed to stay all proceedings until 30 calendar days after a ruling on the defendants&#x2019; motion to dismiss the Federal Securities Class Action. The Court approved the Joint Stipulation on March 14, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the above actions, the Company has received inquiries and subpoenas to produce documents related to these matters from the Department of Justice, the SEC, the Maryland Attorney General&#x2019;s Office, and the New York Attorney General&#x2019;s Office. The Company produced or is producing documents as required in response and will continue to cooperate with these government inquiries. The Company also received inquiries and subpoenas from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis and Senator Murray of the Committee on Health, Education, Labor and Pensions. The Company produced documents and provided testimony and briefings as requested in response to these inquiries.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMTg0OQ_82c03852-4682-4563-b7eb-c021a52f39ba">Segment informationThe Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. We manage our business with a focus on two reportable segments. Our Products segment, which includes the Anthrax - MCM products, NARCAN products, Smallpox - MCM products and Other products, and our Services segment consisting of our CDMO services. The Company evaluates the performance of these reportable segments based on revenue and Adjusted Gross Margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but it does not include inter-segment services. The Company defines Adjusted Gross Margin as segment revenue less segment cost of sales reduced for significant events, inventory step-up provisions and changes in fair value of contingent consideration. The Company does not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the chief operating decision maker ("CODM"). The accounting policies for segment reporting are the same as for the Company as a whole.&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages its assets on a total company basis, not by operating segment, as the Company's operating assets are shared or commingled. Therefore, the Company's CODM does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes segment revenues and a reconciliation of the Company's segment adjusted gross margin to the consolidated statement of operations for each of the Company's reporting segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;237.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;297.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contracts and grants revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;165.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Less: Cost of sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Products gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;156.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Services gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(37.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Consolidated gross margin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adjustments to gross margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Products adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Services adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(37.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Consolidated adjusted gross margin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt;text-indent:-9pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other reconciling items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(40.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(46.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(100.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(84.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(161.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Total segment revenues less total cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consolidated gross margin plus adjustments to gross margin.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes depreciation expense for each segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Depreciation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMjE5OTAyMzI2NTU5MA_1df719f6-f136-40cc-b463-0bb81910537f">The Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. We manage our business with a focus on two reportable segments. Our Products segment, which includes the Anthrax - MCM products, NARCAN products, Smallpox - MCM products and Other products, and our Services segment consisting of our CDMO services. The Company evaluates the performance of these reportable segments based on revenue and Adjusted Gross Margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but it does not include inter-segment services. The Company defines Adjusted Gross Margin as segment revenue less segment cost of sales reduced for significant events, inventory step-up provisions and changes in fair value of contingent consideration. The Company does not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the chief operating decision maker ("CODM"). The accounting policies for segment reporting are the same as for the Company as a whole.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMTA5OTUxMTYzMjk2NQ_25904a2e-c7fd-4897-92f6-57fb9e4dbb42"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMTA5OTUxMTYzMjk2NQ_e1785b3d-d453-4476-864e-65e5ac7806fb"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMTg1MQ_f43026ca-9393-4ace-9ab9-02eb12f5b8eb">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes segment revenues and a reconciliation of the Company's segment adjusted gross margin to the consolidated statement of operations for each of the Company's reporting segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;237.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;297.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contracts and grants revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;165.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;307.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Less: Cost of sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Products gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;156.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Services gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(37.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Consolidated gross margin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt;text-indent:-4.5pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adjustments to gross margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Products adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Services adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(37.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Consolidated adjusted gross margin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt 0 10pt;text-indent:-9pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other reconciling items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(40.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(46.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(100.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(84.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(161.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 10pt 0 1pt;text-indent:-9pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Total segment revenues less total cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consolidated gross margin plus adjustments to gross margin.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMy0xLTEtMS0xODEzNzM_4d29865b-18a4-4c6e-96d9-d15b528b2da2"
      unitRef="usd">143400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMy0zLTEtMS0xODEzNzM_e0773961-d651-4eb1-a2f0-4c9efa9bfc97"
      unitRef="usd">237100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNC0xLTEtMS0xODEzNzM_8232c18b-e547-4acb-aeb2-88c74b0717d2"
      unitRef="usd">15200000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNC0zLTEtMS0xODEzNzM_69d6ae88-ae2b-47bd-bfa1-31ab9ba942fa"
      unitRef="usd">60800000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dd32b195d7e4239a60662ca51d6ee42_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNS0xLTEtMS0xODEzNzM_f8c222ed-b0a1-4b23-91c2-c02764b918bb"
      unitRef="usd">158600000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i918438631165446c9ba9921f135d6a33_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNS0zLTEtMS0xODEzNzM_60d3da21-b8da-4296-bda0-5045161a9835"
      unitRef="usd">297900000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e5222cf971340bab0614a17ebbf5ed8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNi0xLTEtMS0xODEzNzM_644dfb1c-faf2-4a71-9286-86d31f2cf1f9"
      unitRef="usd">6500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d4fc9a55e4b49afb88321e52246a468_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNi0zLTEtMS0xODEzNzM_f392a211-6e64-4c0d-9e95-13d1d7c9df95"
      unitRef="usd">9600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNy0xLTEtMS0xODEzNzM_63dff80d-c83b-45fc-b157-2893a31473ba"
      unitRef="usd">165100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfNy0zLTEtMS0xODEzNzM_667e0104-65fc-4d68-af62-a372295d4018"
      unitRef="usd">307500000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTAtMS0xLTEtMTgxMzcz_61fe0bc7-30d1-4bff-bd2f-422cea89a0e5"
      unitRef="usd">102900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTAtMy0xLTEtMTgxMzcz_1cc4f77e-e81b-45e8-87b8-c04bf891719d"
      unitRef="usd">80300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTEtMS0xLTEtMTgxMzcz_a25107ad-f0da-4375-bec3-f6dc3c1907ba"
      unitRef="usd">52200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTEtMy0xLTEtMTgxMzcz_40c19f7d-8024-4c73-af6f-c83cd5ad1430"
      unitRef="usd">75600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTItMS0xLTEtMTgxMzcz_e8992f3f-eb10-4431-b1ba-a2e82e85a3e7"
      unitRef="usd">155100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTItMy0xLTEtMTgxMzcz_ff277aa5-c3b6-428b-86c1-961693f48fb9"
      unitRef="usd">155900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTQtMS0xLTEtMTgxMzcz_0ea8da0e-9d23-42f0-abe8-5e64c0e8173c"
      unitRef="usd">40500000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTQtMy0xLTEtMTgxMzcz_f4408481-9758-4d15-8f9f-1bf92b9e56e7"
      unitRef="usd">156800000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTUtMS0xLTEtMTgxMzcz_3c710224-3feb-4d40-b3f7-6a6f5190ed69"
      unitRef="usd">-37000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTUtMy0xLTEtMTgxMzcz_bb81ddc8-ffcf-4521-8217-de9ffc4c7d42"
      unitRef="usd">-14800000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTYtMS0xLTEtMTgxMzcz_62bb9c09-ef56-4b65-9262-750390bf9c17"
      unitRef="usd">3500000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMTYtMy0xLTEtMTgxMzcz_ac810ef1-29dd-4c70-b834-05c9e64e8153"
      unitRef="usd">142000000.0</us-gaap:GrossProfit>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjAtMS0xLTEtMTgxMzcz_9028b5e3-5acb-4be5-ab9d-92d40dbf2722"
      unitRef="usd">1500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjAtMy0xLTEtMTgxMzcz_adb575c0-00f1-4a8a-91b8-e5027a97090c"
      unitRef="usd">500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCosts
      contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjEtMS0xLTEtMTk2OTU1_7f25c10d-bd1d-4d05-bcf7-e518e22dffdf"
      unitRef="usd">2000000.0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjEtMy0xLTEtMTk2OTk5_8992a726-4f25-4fc0-8d2a-537031561d1b"
      unitRef="usd">0</us-gaap:RestructuringCosts>
    <ebs:AdjustedGrossMargin
      contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjMtMS0xLTEtMTgxMzcz_0cab0778-04e0-454d-b7dd-7283abe3c398"
      unitRef="usd">44000000.0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjMtMy0xLTEtMTgxMzcz_dea1d33a-e24b-4075-bbe3-57fdf63c4a26"
      unitRef="usd">157300000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjQtMS0xLTEtMTgxMzcz_7af5996a-eb01-4d39-bf15-c064681a287d"
      unitRef="usd">-37000000.0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjQtMy0xLTEtMTgxMzcz_0a96210f-0ace-4138-8500-9bd66d8b8a77"
      unitRef="usd">-14800000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjUtMS0xLTEtMTgxMzcz_cefa5ffa-1020-4168-bf9a-4eb7340e84aa"
      unitRef="usd">7000000.0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjUtMy0xLTEtMTgxMzcz_95b73068-a188-4c16-bee5-ae1ffeb8e4ba"
      unitRef="usd">142500000</ebs:AdjustedGrossMargin>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e5222cf971340bab0614a17ebbf5ed8_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjgtMS0xLTEtMTgxMzcz_7ee241f4-f875-4a2f-98f9-99113802f867"
      unitRef="usd">6500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d4fc9a55e4b49afb88321e52246a468_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjgtMy0xLTEtMTgxMzcz_abb3da47-0b32-4e48-9c37-8843ce438caf"
      unitRef="usd">9600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:GrossProfitAdjustments
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjktMS0xLTEtMTgxMzcz_65d53a15-23bf-45a8-8810-548fe7cfca0d"
      unitRef="usd">-3500000</ebs:GrossProfitAdjustments>
    <ebs:GrossProfitAdjustments
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMjktMy0xLTEtMTgxMzcz_7748c301-d0a8-4929-9630-70a7393c22ca"
      unitRef="usd">-500000</ebs:GrossProfitAdjustments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzAtMS0xLTEtMTgxMzcz_6e53c64f-0c8b-4a8c-950d-71b339f9d1ee"
      unitRef="usd">40600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzAtMy0xLTEtMTgxMzcz_cceb609e-8e56-45a1-a5de-8b74f3f75a65"
      unitRef="usd">46400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzEtMS0xLTEtMTgxMzcz_1a2245f4-7e46-483d-8e70-3e9d7f2b8a1e"
      unitRef="usd">100500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzEtMy0xLTEtMTgxMzcz_87907465-994c-46c5-a82b-c0d7bb2db802"
      unitRef="usd">84800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzMtMS0xLTEtMTgxMzcz_ad3a0303-5ad2-439f-9019-4cd047a8e786"
      unitRef="usd">17000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzMtMy0xLTEtMTgxMzcz_83d0a765-f54f-4476-b567-776615adb385"
      unitRef="usd">14000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:InterestExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzQtMS0xLTEtMTgxMzcz_2f1f5813-3cbb-4056-83c6-a0e3d7ff35bc"
      unitRef="usd">17900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzQtMy0xLTEtMTgxMzcz_ea258a52-646a-4aea-8c83-9df170d43d8c"
      unitRef="usd">8200000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzUtMS0xLTEtMTgxMzcz_692a4dbe-0687-459e-ae6a-3abf7871dde5"
      unitRef="usd">4900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzUtMy0xLTEtMTgxMzcz_307813de-0238-44c6-be63-d60c8fd1d17a"
      unitRef="usd">-2000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzYtMS0xLTEtMTgxMzcz_0e78c6d6-eb53-44ea-978c-d2490a37da60"
      unitRef="usd">-161100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjg2MWMxZThiMjNjNzRjNDg5Yjk5ZWY0NTFkOTk3Y2NlL3RhYmxlcmFuZ2U6ODYxYzFlOGIyM2M3NGM0ODliOTllZjQ1MWQ5OTdjY2VfMzYtMy0xLTEtMTgxMzcz_95c10e75-8885-4264-8da5-b1f28963cf3d"
      unitRef="usd">-3800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RleHRyZWdpb246ZjhjN2Y2Y2E3Zjg1NDhkM2FiZmUzNWIzY2RhMTA5YmRfMTg1Mg_0b502681-e2c4-40bb-8d79-7d7ac1b500a1">&lt;div style="margin-bottom:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes depreciation expense for each segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:9.3pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Depreciation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Depreciation
      contextRef="i4a70923bce874d0d9f07f7be7acf8a95_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfMy0xLTEtMS0xNzQwOTA_a198cf1f-3531-4875-9d68-983f47780356"
      unitRef="usd">8000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ib64fcbcac47343b094fff4937f28034b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfMy0zLTEtMS0xNzQwOTA_343b9279-fab0-48d8-a59f-c4942c3f831b"
      unitRef="usd">7400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id15df9b102ae4094afa00cbb0ef9215b_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNC0xLTEtMS0xNzQwOTA_89ee2d58-6b1d-445f-92fa-f1128751f939"
      unitRef="usd">7900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ifa5442da79c64997b82656635e32c2d6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNC0zLTEtMS0xNzQwOTA_92072a32-84ce-415f-b6e8-49d70603dfe4"
      unitRef="usd">7800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i81a432e8a0bd409aabe9374107df1be3_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNS0xLTEtMS0xNzQwOTA_7d5f86a9-ddb2-4395-9334-80eac87aa966"
      unitRef="usd">1700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i994e594bda11477a97c710abd0cf5e86_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNS0zLTEtMS0xNzQwOTA_179ff750-9cd8-4073-8d81-74252eb96dab"
      unitRef="usd">1400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia7c813299beb471abb99dc92b89568ef_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNi0xLTEtMS0xNzQwOTA_c1221e59-de64-40eb-9f5e-6c9f7663e330"
      unitRef="usd">17600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i873de6f9e88c4727a587671ba4e5e71f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ODFkYWNmMzBiYjQwOThhMDZiZDU0ZjNhZjVhMzRhL3NlYzo5NDgxZGFjZjMwYmI0MDk4YTA2YmQ1NGYzYWY1YTM0YV84Mi9mcmFnOmY4YzdmNmNhN2Y4NTQ4ZDNhYmZlMzViM2NkYTEwOWJkL3RhYmxlOjJkNDFiMTQ1YWIzOTQ3OGJhNzJhNDRiMjNlMGVlNDViL3RhYmxlcmFuZ2U6MmQ0MWIxNDVhYjM5NDc4YmE3MmE0NGIyM2UwZWU0NWJfNi0zLTEtMS0xNzQwOTA_0536db05-6ae6-4a15-82d5-eac21ce41896"
      unitRef="usd">16600000</us-gaap:Depreciation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>98
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MS%"Z4UJ4[6) 4.95\Y\]MHX8+,#AQ +2+B#'+J#M EH;VB"KS;IBFJW/I7A
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M:'P K:^T=D^.[P7]OR+[ U!+ P04    " !CCJE6?R##2H,,  !C'P  &
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M!Q(=OC(Z*$.E7;TTA:GG)G3%^7BJ=(04%;[K)857)15U^1L:FPAU0X2_H&3
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MVSDZU!P6'8?-MW][='STPQ-(,!<[Y%RTKC444EHMM]QW75^](!EOJGR/EJ0
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MEJ&/I85>^\"4!^O!#*5I2%O'& :(H&68@A!J*27825 Q^8!XD#@G4T%JMP]
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M\\)(8'>@9(<DHYXHD;AH><#J:^'<.,0F-\]^G)%@1--CZ:4.;2AN*@L0U,\
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M!<SGIL+BAP)U8%R=M-G+;M_(JCY[E^WW=<01?E=UGB)(-EG_ CTS$3?>86J
MYVN1#T;B#K-/*QR2 LG/Q.=OJC![7 69/*_[@-[BJ6.-G>,=$*\%-^F/9^*
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M.)R, M#=(Z!;6-7XQKM6EMJXGU;T;D+M!.A[J<C_W<(9Z%]BBW\ 4$L#!!0
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M]69Z*H'CT SDQ!;O:S+#0<!R)9V6Q@R3-_@/W4 -N[0!BI25-:B3MK@UQP&
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M<[KPRZ7@>!<B CR?:[Q%UQM2T'YKNOD34$L#!!0    ( &..J5:.88@ Q ,
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MRU*X"@/*8!*)[86(&^/82B X2C"*G=. 7QVW3QZ-BK5AH=ZU@DGSML/TW+J
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MUN7"JA!/UEGW*2'(JL,1EI 38Z$"Y0:C,CZM$+9#1KM8;3>;_24)MD,J[HA
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MT?"0)308*# G/):D<S;+1DP R*W/)2,KW<?-SPLW/]_+JC^@1@E$I*<4D=0
M<>4;H^<_+0CNQPC*I5AR,B*TJ3D#EJI$*IMM4U(I\%RN3MCC$5=*5:DCN5 K
MO> L;#(NIERG;N$G%CG-R9/Z50*?$RVJ GH$0C;0;)%B"32Y\2BJBESNWE @
M0#E<N[==/$P-&R*P) ,% [TJ5/$8$;4/7"@HTV?B5W@D@B>H:F7TUQ[9T"?
MI>7<*.0@H)^A41I3PK<XJF Q!1ZYA'F-P:Q-UR?BP2SQ8&5O'JR-HT58.:4.
M0=UNJ'&%[T2J<.EFI7.U0X_R+?9W61T;#>]$HXD$!D)2J_Q*_)UX2YP(YKC3
MU^+3 [-Y>JB)(2CI.0)^& *B'.Y_@9VOO>76F$+L8V/-%3*&P+].ZDZ+NH]1
M1^QO #/S1R(B%JE"*,V;:G0^%54F'G*VW\HY7K/CH^*SHOB7ATXG9=&C.%7
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MI]1>>$J37#>SOME85?GYNE"6IK5?%O0\HG8!Y,^5LIN-*] ]N-/_4$L#!!0
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M? XA/^[[+D-82D&JY<4*C.5!+5W^"S486I[+?,V*A]\T/*-1!PHTE_##J8(
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MPPNJ0>5?(+\PLG5=?RL-O2%N6M&CC<H*T'DII3DNK('^;\#J)U!+ P04
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MUUSI:T+1W.J+' @3H.<3SM5SQ]P5ZJMA]!=02P,$%     @ 8XZI5C"T,:'
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M*PC>ZASSQ_$Q\^[(IUORL_0@X(=:'T$_Z4&:I'W LE+F ?$ <+]SI1^ !WN
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MPX);.5I_@/>7QKCMQ"?H_APF?P%02P,$%     @ 8XZI5C-KP:J/!   3!8
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MUD(C&=4/*[H9P;@ VE]JC9N).Z"_:_._4$L#!!0    ( &..J5;1.0UDR@,
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MK:J.U?7_<[<1DBMQ_MM5:($\[D;6*_96I"C$<T,M28'Y 1N+M[]!W_[05?9
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M:T11414=Q7-;8]QRI2L6VTQU$0K"3-#/EYRK7<<L4)6UX4]02P,$%     @
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M>1EXMQE<5X!+$2,?3RRUQ07F:VQ-?_[)[3N_-$7>$E@M#]TB#UT3^O0WSH0
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MM'HN8)D+:)STKZG,U/UDK8K;$H-'@1<)!;=D@;5R^A,CWKPBS+BN![;:%0Q
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M971S+W-H965T-3$N>&ULK57?;],P$/Y7K#"A38*F^;%UE#12VS#8P]"T:?"
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M;)>%'K0@C('^ON1<;3?&03NZX]]02P,$%     @ 8XZI5FZ-@SA% P  [@X
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M]EPDQT<DI\/)(XK'-I/AS$UQ4E&</"UHDPY\CFT:^4PK/E.0ST>V9S$*78Q
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M90$X/Y?XN%0=6XW4U6KT#U!+ P04    " !CCJE6'D5#H\$#  "/$P  &0
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M6+#>@-[7QN#NX /T,SO[#5!+ P04    " !CCJE6<=#3GV "  !"!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6R%5.]/VS 0_5=.&9I VDB:%-A8
M&@FH$)6V"5&Q?9CVP4VNC85C9[;3,&E__,Y.F@546#XD_G'OW7OGG--6Z0=3
M(EIXK(0TLZ"TMCX/0Y.76#%SK&J4M+-6NF*6IGH3FEHC*SRH$F$<1:=AQ;@,
MLM2OW>HL58T57.*M!M-4%=._+U&H=A9,@MW"'=^4UBV$65JS#2[1WM>WFF;A
MP%+P"J7A2H+&]2RXF)Q?3EV\#_C&L36C,3@G*Z4>W&11S(+("4*!N74,C#Y;
MO$(A'!')^-5S!D-*!QR/=^S7WCMY63&#5TI\YX4M9\&'  I<LT;8.]7>8._G
MQ/'E2AC_AK:/C0+(&V-5U8-)0<5E]V6/?1U&@"1Y 1#W@-CK[A)YE7-F699J
MU8)VT<3F!MZJ1Y,X+MVA+*VF74XXF\U1\RUSE0$NC=4-%=P:8+* $HL-EYNN
M<-QR-/ >1O%S-'PCF<4"F($K9DJXIC.&&\)1[.$<+>/"''G4./2F)UX,"2ED
M(2UJ-!;N* R6+:M-&EIRZ'2&>>_FLG,3O^#F"]/'D$S>01S%"=POYW!X<#0R
M]I0QI%H-!8N'@L4^1?+_@BV>%6SGZ^)?P>;<Y$*9AIS!C\]$!0N+E?FYSUJ7
M=[H_KVO.<U.S'&<!=9]!O<4@>_MF<AI]>L55,KA*7F//OC;5"C6H]1-3?UXL
M7:>XXSSQG*[[M]E9&F[WR)@.,J:ORU"N59F@S ?[$G;HCZ.$R4G4/<\2AZ.6
M<+<+_1ET-@8$K@D;'9^1:MUU;#>QJO9=LE*6>LX/2[KD4+L VE\K97<3UWC#
MM9G]!5!+ P04    " !CCJE6NN3N)88"  !X!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6RM55%/VS 0_BNG#$T@L:9-6L98&@E:(2J!AJA@#],>
MW.3:6#AQ9E\:D/;C9SLA"EK+]L!+XK/O^W+?9_L2U5(]Z@R1X"D7A9YZ&5%Y
MYOLZR3!G>B!++,S*6JJ<D0G5QM>E0I8Z4"[\8#@\\7/&"R^.W-RMBB-9D> %
MWBK059XS]7R!0M93;^2]3-SQ349VPH^CDFUPB71?WBH3^1U+RG,L-)<%*%Q/
MO?/1V6QL\UW" \=:]\9@E:RD?+3!(IUZ0UL0"DS(,C#SVN(,A;!$IHQ?+:?7
M?=("^^,7]DNGW6A9,8TS*;[SE+*I=^I!BFM6";J3]16V>B:6+Y%"NR?4;>[0
M@Z32)/,6;"K(>=&\V5/K0P\P&N\!!"T@^%] V )")[2IS,F:,V)QI&0-RF8;
M-CMPWCBT4<,+NXM+4F:5&QS%<U1\RZR5P M-JC([1!I8D4*&Z887F\9I3APU
M?()+QA4\,%$AK)[A@@E6) A+=^"N9<+<WAS.D1@7^L@ [I=S.#PX@@/##S=<
M").@(Y],[;8"/VGKO&CJ#/;4></4 ,+1,03#(-P!G[T-GV/2P8/7<-\XUMD6
M=+8%CF^\AV]1$"K4!'>,C/R:E1I^PQPUWQ1F)@6FX:KU;]'Y:E*^488*9I52
M-C[7&FFG&V]^WE[M,UVR!*>>N;L:U1:]^..'T<GPZRYOWHGLE5-AYU3HV,-_
M'C!]W#\]/ZY-(BP(<_USEP'A>QKP3F2O#!AW!HS?/"H]S7+=[#CT3-FEO2$\
M<82V#6_CR>!+Y&_[DO[..1U,NIRF4K_7%VQ/-I?(G$@- M<&-1Q\GGB@FC[7
M!"1+URI6DDSC<</,_!I0V02SOI:27@+;?;J?3?P'4$L#!!0    ( &..J58N
M0(59)P,  '$+   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;,56;6_3
M,!#^*Z> T)"@:=.W,=I(7<-8)2:F3H,/B ]><FTLG+C83CLD?CSG),W:+@M,
MJL27-GYYGKM[SF??:"/5#QTC&KA/1*K'3FS,ZLQU=1ACPG1+KC"EE854"3,T
M5$M7KQ2R* <EPO7:[8&;,)XZ_BB?NU;^2&9&\!2O%>@L29CZ=8Y";L9.Q]E.
MS/DR-G;"]4<KML0;-+>K:T4CMV*)>(*IYC(%A8NQ,^F<!4.[/]_PA>-&[WR#
MC>1.RA]V,(O&3MLZA )#8QD8_:UQBD)8(G+C9\GI5"8M</=[RWZ1QTZQW#&-
M4RF^\LC$8^?4@0@7+!-F+C>76,;3MWRA%#K_A4VYM^U F&DCDQ),'B0\+?[9
M?:G##H!XZ@%>"? . ;TG -T2T#T$#)X ]$I +U>F""77(6"&^2,E-Z#L;F*S
M'[F8.9K"YZE-^XU1M,H)9_P %5\SJSWP5!N544J-!I9&$&.TY.FR2 TW'#6\
MA2G3,5S088'+<IF2-_D\G<%)@(9QH5_3KEEJ4*$V,&<&X6;#5A9[>Q/ R<O7
M\)),P147@A*O1ZZA,*PS;EBZ?%ZX[#WA<A>N9&IB#1_2"*,:?-",[W@-!"[I
M5XGH;44\]QH9KYAJ0;?S!KRVUZUQ:/KO<*\NGF9X@.%3\+UHNM61Z.9\W;\?
MB=G!D=CF?/)P) *N0R%U1NF&;Y^("F8&$_V]+J^%W5Z]77O!G>D5"W'LT VF
M4:W1\5^]Z S:[^LT/299<"2R/;U[E=Z])G9_DL@L-2 7\)&N:3CY)#45T1Q#
MP;3F"XX1+)1,2/0P2S)!%16!+3B>&KD+J5.\L#S(+=L78.WW6^]&[GI7R$;O
MGBOD8X.GK7YE<$^??J5/OU&?QU?.[X<+!N_I =18%WLCZW-/VS')@B.1[:DY
MJ-0<_*?J'AQ3[V.2!4<BV]-[6.D]_&_5/7Q4;%ZK=U#=C_=T#O<$C1$\5Q]W
MIQE)4"WSIDY#:&4HGM1JMNH;)WF[=#!_WCF;%NW? TW1C-*#20=5@\ %4;9;
M0RHH531XQ<#(5=[RW$E##53^&5-/C,INH/6%E&8[L :J+MO_ U!+ P04
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MA70E!=0/"MA7.6S8 ML#MY2(%0>_D!"'=?V^#$$9!_@>ARMH-'B+F T\]PQ
M!WH:///#U:$!CE=.BY?9\UKLS;[.;\!,"!8];01ZBC$0%-PAAHDX W_(U4T7
MX!&]@K_O:1P#F=!;Q,)_='',QQGHQTF+Q#E?HP!?6G+6.&8OV)K^^(/K.S_K
M@M"1L5I(!F5(!B;KTRN\C B)R%(NVQB1 .N\S4U,,A-I!7N9NMY8SN=+U0N-
MD.].2J$:NF&);FA$ER=_4$O^.$W^)RQK+985+X@1Y]$B"K+UI<WY?(A1!5AO
M8 ]WT#>%AO9 #]XOP?M&\+.$;HC@%9!R.2\836255>N;:ER,B'S'X"1U]53G
MDM] "RMH<X^:,FZ;1Z/2HY'1HT<J4+P?\1D@^5H2Z%6'?M2<$&B[._";0KX]
MUL,?E_#'1OBRJNU)]'$S9K+TV/X.-HW8<#2T/3V\20EOLC^Z.E1&M6.+34?&
M:AZZCNJ+SB=5X&*@CJ+2E;5Z6"ITP?W_5;BP44T[K[%L-$(]UZ^(U1%"A1!^
MQM(O1MFS]C52K8O?5<W?-3;2 Y9_86!87=B[T+RF Q/;<ZK_VH*M>K)K;LK7
M>"&_A. *$_DDP%U!\.\D<BUNH[FCUT)'UNK.JY;O#C^K1!C)Q=%AZ<A:/2R*
M3+AF-G%8B6@V?:]!=0JA:I;W6HB!JYB!:Z8&G3"U8HPJ,F<7O$FDCEW1 M?,
M"SZ0J!4C&STRB=0]4DS"/8!*=%"M)_O1FT3J>T9%$J"QVQY0J L#YCPOA [)
M<Z@Z-31WZFO,HA>4'I* &\(%VR2R+FF3V6SHV.K3E;6ZVZK]0_A)11D:><;1
M8>G(6CTLBE) ,Z4XJ"C#)F7P;;B;K!I>4=VEU@$J)@'-3**3LER,L8-M=[^I
MD1K8+?M_J-@ -)\ ?&!MALT]?W,7K1%JW49#U<RAN9EW5)^AII,W$JM)"?RV
MG2I4[1Z:V_T!);JY@1\TL[XIY+81?:CZ.33W<UE^<+0D8+YALD %;^"1(<+C
M_ 1V%OZ[X:*]:AM-'UV>.K)6#X2B 7#R656[TS.(KJS5#X$5O_#,_.*@JNTU
M*4;/;YP$Z:1&%:DZ0L4R/#/+Z*1L>YJC *>QU]9(.6U]QU-\P3,?%WQ@V2Y&
M-I%2HTC=H\K5@;G5=U2R/4V?UTQ*4ZI]4A09\,QD8'_1+@SX]:0?[:+32(T:
M1TS]RO59@MDRNU7D,G8R,?(;I/)K>7,YR^[K=KY?N>?S_/Y1F<FO0V\1DRN9
M@Q@OI$G''LD99_D-8_XBZ#J[I'NB0M D>UQA%&*6"LC?%Y2*]Y=T@/*>=_H?
M4$L#!!0    ( &..J5:_H]0"TP,  )D/   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;+U7;6^C.!#^*Q:WNMN5MN&MH6DO06K3GJ[25E>UNWL?3O?!
MA4G@"G;6-DGZ[V]L"(&$L&]1^Z'!9I['SPPS,#-><?$L$P!%UGG&Y,1*E%I<
MV+:,$LBI'/ %,+PSXR*G"I=B;LN% !H;4)[9GN,$=DY39H5CLW<OPC$O5)8R
MN!=$%GE.Q<L59'PUL5QKL_&0SA.E-^QPO*!S> 3U:7$O<&77+'&: Y,I9T3
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ME#7 ^XV4YK"Q!.U?1OH74$L#!!0    ( &..J5:WX;\%H0(   4'   9
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M4A%XK; _04%R!04SA$NMH;<RD@,M5V%'2RVX-^A(%M-6<'I:\+ZV55O;ET2
MZ1.9'EYCDOBW[U3V1=T<Y#7H-"G[@\#B7S&A"8<EXM 6FE5UTZTG1E:N;RVD
MP=ISPS7^IT#9 -Q?2FGV$]L*VS]?]@=02P,$%     @ 8XZI5F3CE%VE @
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M@(IGFI[;3%#7OFW--%(3],.2KBDP+H"^%UKC;N(2M!=?_@=02P,$%     @
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M&/N.WEH2Q1*=P9M7?N2]K2OO2& ;Q89EL>$^],?%-L#NXS,^/;N5".^D1-6
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M80+T]2GG:KTPXW/YN33X!U!+ P04    " !CCJE6P5:-,%@#  "'#P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6RMEUU/VS 4AO^*E;$))-9\M86R
M-M(@F88T) 2#74R[,.EI&^'8G>VV[-_/'R%K6;"HY)LV<?P^]GE/>YPSWC#^
M*!8 $CW5A(I)L)!R>1:&HEQ C46/+8&J)S/&:RS5+9^'8LD!3XVH)F$21<.P
MQA4-LK$9N^;9F*TDJ2A<<R16=8WYGW,@;#,)XN!YX*::+Z0>"+/Q$L_A%N3=
M\IJKN["E3*L:J*@811QFD^!S?%:,]'PSX;Z"C=BZ1CJ2!\8>]<WE=!)$>D-
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MXXN$]U3-4#)_A^(H3I .RB_P)E,-$L^;_*<&6^BE,DPTZ.>JT$;9COEU+NW
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M^6<"3 7(ZRM*Q7&B;E#\ZP1_ %!+ P04    " !CCJE6;^LS834"   X!@
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !CCJE6VAUM^K,%  !U,P
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M+FQON&H^!_>&CW&A6%:4PV*Q3:_4N[#M+_W1\/;^7R/W_W@Y^PY02P,$%
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MWTGU>+FWW!Y_77Z=1 E75YSK^XKA^2]02P,$%     @ 8XZI5BXH"M@5 @
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( &..J5;SH@.6[P   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( &..J5:97)PC$ 8  )PG   3
M      "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 8XZI
M5E3Y[-[J!0  [1X  !@              ("!#@@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( &..J58,WVX<508  -<:   8
M      " @2X.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" !CCJE6H)[P_@,#  #]"@  &               @(&Y%   >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 8XZI5HE(F,20!@  S2,  !@
M             ("!\A<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( &..J58@=3Z=+0,  +()   8              " @;@>  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !CCJE6S\E1P>8'  #3
M)0  &               @($;(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ 8XZI5II.M'LT!@  +2H  !@              ("!-RH
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( &..J5;*@KB*
M8 (  #<&   8              " @:$P  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " !CCJE6?R##2H,,  !C'P  &
M@($W,P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 8XZI
M5D _$YZ'#0  UR0  !D              ("!\#\  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " !CCJE6Y5&M^[@%  !Y#0  &0
M        @(&N30  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( &..J58L4=!#]@0  *,,   9              " @9U3  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 8XZI5OW\&J&7 @  O 4
M !D              ("!RE@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " !CCJE6*2YDJ24$  "5"0  &0              @(&86P
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( &..J5:&?6J+
MA 8  '(0   9              " @?1?  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ 8XZI5L'1#6/-!@  41(  !D
M ("!KV8  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !C
MCJE6+''C0$('  #B$@  &0              @(&S;0  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &..J5;Z($E"DPT  '@J   9
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M970R,BYX;6Q02P$"% ,4    " !CCJE6*N&F*#<$  #A"0  &0
M    @('2GP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M &..J59.0$JGGPL  " ?   9              " @4"D  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ 8XZI5E",1^R-!@  WA   !D
M             ("!%K   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " !CCJE6D]JMTI8,  #[(0  &0              @(':M@  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( &..J59RL>'R10,
M 'P'   9              " @:?#  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ 8XZI5CI%/KJL P  E D  !D              ("!
M(\<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !CCJE6
M@@A\RW\"  ![!0  &0              @($&RP  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &..J58N>YCX# ,  ,L&   9
M      " @;S-  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ 8XZI5L1>>#5C!   ! L  !D              ("!_]   'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !CCJE6WJ8%-XX$  !4#
M&0              @(&9U0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( &..J597M)'A\ ,  %T*   9              " @5[:  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 8XZI5@<3C=$!
M P  A 8  !D              ("!A=X  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " !CCJE6#<LJI=<$  "X#   &0
M@(&]X0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( &..
MJ5;=)\QVU0(  'P&   9              " @<OF  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ 8XZI5EB 6W 6!   %0H  !D
M         ("!U^D  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    " !CCJE6,;/>1U #   2"   &0              @($D[@  >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( &..J5;4Y..IO 0  *D+
M   9              " @:OQ  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ 8XZI5BH\17W= @  =0<  !D              ("!GO8
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !CCJE6J@M(
MT\H"   F"@  &0              @(&R^0  >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( &..J58PM#&AP (  "@&   9
M  " @;/\  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
M8XZI5C-KP:J/!   3!8  !D              ("!JO\  'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " !CCJE6'3-L FD"  !W!0  &0
M            @(%P! $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( &..J5;1.0UDR@,  #T4   9              " @1 ' 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ 8XZI5H%(8/FK P
M!Q   !D              ("!$0L! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " !CCJE67TA32:,"   '!P  &0              @('S
M#@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( &..J58U
M;E6K#00  '44   9              " @<T1 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ 8XZI5BK"!$?N @  X@H  !D
M     ("!$18! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M" !CCJE6ZF]Q%?$$  #/&   &0              @($V&0$ >&PO=V]R:W-H
M965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( &..J5;NOCMMJ (  ,8'   9
M              " @5X> 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L!
M A0#%     @ 8XZI5FZ-@SA% P  [@X  !D              ("!/2$! 'AL
M+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !CCJE6/>N+9=0%
M  ".*P  &0              @(&Y) $ >&PO=V]R:W-H965T<R]S:&5E=#4S
M+GAM;%!+ 0(4 Q0    ( &..J59TP9"-G0(  %8&   9              "
M@<0J 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ 8XZI
M5KU<_2(/ P  N0H  !D              ("!F"T! 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    " !CCJE6'D5#H\$#  "/$P  &0
M        @('>, $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( &..J5;+HU!A?P(  +\%   9              " @=8T 0!X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ 8XZI5G'0TY]@ @  0@4
M !D              ("!C#<! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    " !CCJE6NN3N)88"  !X!@  &0              @($C.@$
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( &..J58N0(59
M)P,  '$+   9              " @> \ 0!X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ 8XZI5C-QA<M#!   A1<  !D
M ("!/D ! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " !C
MCJE6S9=KK<D(  "-2@  &0              @(&X1 $ >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( &..J59U K"^T 8  (X^   9
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M970V-RYX;6Q02P$"% ,4    " !CCJE6MH*Z]BD%  !P&0  &0
M    @('Z90$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    (
M &..J59Z9E'&708  *HQ   9              " @5IK 0!X;"]W;W)K<VAE
M971S+W-H965T-CDN>&UL4$L! A0#%     @ 8XZI5OB&6_22 @  /@8  !D
M             ("![G$! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"
M% ,4    " !CCJE6M^&_!:$"   %!P  &0              @(&W= $ >&PO
M=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( &..J59DXY1=I0(
M  0'   9              " @8]W 0!X;"]W;W)K<VAE971S+W-H965T-S(N
M>&UL4$L! A0#%     @ 8XZI5O]B*E:4 P  .@T  !D              ("!
M:WH! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    " !CCJE6
MP5:-,%@#  "'#P  &0              @($V?@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<T+GAM;%!+ 0(4 Q0    ( &..J58.\ BK) (  *@$   9
M      " @<6! 0!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%
M  @ 8XZI5I4;MG!D!@   ",  !D              ("!((0! 'AL+W=O<FMS
M:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " !CCJE6DKE%F!D#  #W#
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M+G)E;'-02P$"% ,4    " !CCJE6VAUM^K,%  !U,P  #P
M@ 'FE $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 8XZI5GH$ UU< @
M(2X  !H              ( !QIH! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ 8XZI5BXH"M@5 @  _"P  !,              ( !
M6IT! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %8 5@"1%P  H)\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>221</ContextCount>
  <ElementCount>297</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>77</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Nature of the business and organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Natureofthebusinessandorganization</Role>
      <ShortName>Nature of the business and organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Assets and liabilities held for sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale</Role>
      <ShortName>Assets and liabilities held for sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Restructuring costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Restructuringcosts</Role>
      <ShortName>Restructuring costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Inventories, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Inventoriesnet</Role>
      <ShortName>Inventories, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Property, plant and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Propertyplantandequipmentnet</Role>
      <ShortName>Property, plant and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Intangible assets and goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill</Role>
      <ShortName>Intangible assets and goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Fairvaluemeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Derivative instruments and hedging activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities</Role>
      <ShortName>Derivative instruments and hedging activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stock-based compensation and stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Stockbasedcompensationandstockholdersequity</Role>
      <ShortName>Stock-based compensation and stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Earnings (loss) per common share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Earningslosspercommonshare</Role>
      <ShortName>Earnings (loss) per common share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Revenue recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Revenuerecognition</Role>
      <ShortName>Revenue recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Assets and liabilities held for sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables</Role>
      <ShortName>Assets and liabilities held for sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Restructuring costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RestructuringcostsTables</Role>
      <ShortName>Restructuring costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Restructuringcosts</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Inventories, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesnetTables</Role>
      <ShortName>Inventories, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Inventoriesnet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Property, plant and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables</Role>
      <ShortName>Property, plant and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Propertyplantandequipmentnet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Intangible assets and goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables</Role>
      <ShortName>Intangible assets and goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Fairvaluemeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Derivative instruments and hedging activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables</Role>
      <ShortName>Derivative instruments and hedging activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Debt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Stock-based compensation and stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTables</Role>
      <ShortName>Stock-based compensation and stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Stockbasedcompensationandstockholdersequity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Earnings (loss) per common share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EarningslosspercommonshareTables</Role>
      <ShortName>Earnings (loss) per common share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Earningslosspercommonshare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Revenue recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionTables</Role>
      <ShortName>Revenue recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Revenuerecognition</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Leases</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/SegmentInformation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Nature of the business and organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails</Role>
      <ShortName>Nature of the business and organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Natureofthebusinessandorganization</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Summary of significant accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails</Role>
      <ShortName>Summary of significant accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Assets and liabilities held for sale - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails</Role>
      <ShortName>Assets and liabilities held for sale - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Assets and liabilities held for sale - Schedule of Assets and Liabilities Held for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails</Role>
      <ShortName>Assets and liabilities held for sale - Schedule of Assets and Liabilities Held for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Restructuring costs - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails</Role>
      <ShortName>Restructuring costs - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Restructuring costs - Restructuring and Related Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails</Role>
      <ShortName>Restructuring costs - Restructuring and Related Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Restructuring costs - Schedule of Restructuring Reserve by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails</Role>
      <ShortName>Restructuring costs - Schedule of Restructuring Reserve by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Inventories, net - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails</Role>
      <ShortName>Inventories, net - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Property, plant and equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails</Role>
      <ShortName>Property, plant and equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails</Role>
      <ShortName>Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Intangible assets and goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails</Role>
      <ShortName>Intangible assets and goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Intangible assets and goodwill - Goodwill Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails</Role>
      <ShortName>Intangible assets and goodwill - Goodwill Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Fair value measurements - Contingent Consideration Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails</Role>
      <ShortName>Fair value measurements - Contingent Consideration Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Fair value measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair value measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Debt - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtScheduleDetails</Role>
      <ShortName>Debt - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Stock-based compensation and stockholders' equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails</Role>
      <ShortName>Stock-based compensation and stockholders' equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Stock-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Stock-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Stock-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Stock-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails</Role>
      <ShortName>Stock-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Earnings (loss) per common share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails</Role>
      <ShortName>Earnings (loss) per common share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/EarningslosspercommonshareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Revenue recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails</Role>
      <ShortName>Revenue recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Revenue recognition - Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails</Role>
      <ShortName>Revenue recognition - Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Revenue recognition - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails</Role>
      <ShortName>Revenue recognition - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncometaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Incometaxes</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Segment Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ebs-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - ebs-20230331.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - ebs-20230331.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  ebs-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="ebs-20230331.htm">ebs-20230331.htm</File>
    <File>a311-kramercert033123.htm</File>
    <File>a312-lindhalcert033123.htm</File>
    <File>a321-kramercert033123.htm</File>
    <File>a322-lindhalcert033123.htm</File>
    <File>ebs-20230331.xsd</File>
    <File>ebs-20230331_cal.xml</File>
    <File>ebs-20230331_def.xml</File>
    <File>ebs-20230331_lab.xml</File>
    <File>ebs-20230331_pre.xml</File>
    <File>exc_compmins2-9x23v1x202.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ebs-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="750">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>104
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ebs-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 31,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 750,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 221,
   "dts": {
    "calculationLink": {
     "local": [
      "ebs-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ebs-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ebs-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ebs-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ebs-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ebs-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 530,
   "entityCount": 1,
   "hidden": {
    "http://emergentbiosolutions.com/20230331": 1,
    "http://fasb.org/us-gaap/2022": 12,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 18
   },
   "keyCustom": 26,
   "keyStandard": 271,
   "memberCustom": 19,
   "memberStandard": 56,
   "nsprefix": "ebs",
   "nsuri": "http://emergentbiosolutions.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://emergentbiosolutions.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of significant accounting policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Assets and liabilities held for sale",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale",
     "shortName": "Assets and liabilities held for sale",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Restructuring costs",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://emergentbiosolutions.com/role/Restructuringcosts",
     "shortName": "Restructuring costs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Inventories, net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://emergentbiosolutions.com/role/Inventoriesnet",
     "shortName": "Inventories, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Property, plant and equipment, net",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://emergentbiosolutions.com/role/Propertyplantandequipmentnet",
     "shortName": "Property, plant and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Intangible assets and goodwill",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill",
     "shortName": "Intangible assets and goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Fair value measurements",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://emergentbiosolutions.com/role/Fairvaluemeasurements",
     "shortName": "Fair value measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Derivative instruments and hedging activities",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities",
     "shortName": "Derivative instruments and hedging activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://emergentbiosolutions.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stock-based compensation and stockholders' equity",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://emergentbiosolutions.com/role/Stockbasedcompensationandstockholdersequity",
     "shortName": "Stock-based compensation and stockholders' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Earnings (loss) per common share",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://emergentbiosolutions.com/role/Earningslosspercommonshare",
     "shortName": "Earnings (loss) per common share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Revenue recognition",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://emergentbiosolutions.com/role/Revenuerecognition",
     "shortName": "Revenue recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://emergentbiosolutions.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Income taxes",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://emergentbiosolutions.com/role/Incometaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Litigation",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://emergentbiosolutions.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Segment Information",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://emergentbiosolutions.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of significant accounting policies (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Assets and liabilities held for sale (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables",
     "shortName": "Assets and liabilities held for sale (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Restructuring costs (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://emergentbiosolutions.com/role/RestructuringcostsTables",
     "shortName": "Restructuring costs (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Inventories, net (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://emergentbiosolutions.com/role/InventoriesnetTables",
     "shortName": "Inventories, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Property, plant and equipment, net (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables",
     "shortName": "Property, plant and equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Intangible assets and goodwill (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables",
     "shortName": "Intangible assets and goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Fair value measurements (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables",
     "shortName": "Fair value measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Derivative instruments and hedging activities (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables",
     "shortName": "Derivative instruments and hedging activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://emergentbiosolutions.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Stock-based compensation and stockholders' equity (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTables",
     "shortName": "Stock-based compensation and stockholders' equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Earnings (loss) per common share (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://emergentbiosolutions.com/role/EarningslosspercommonshareTables",
     "shortName": "Earnings (loss) per common share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Revenue recognition (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionTables",
     "shortName": "Revenue recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://emergentbiosolutions.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Segment Information (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "reportCount": 1,
      "unique": true,
      "unitRef": "category",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Nature of the business and organization (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails",
     "shortName": "Nature of the business and organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "reportCount": 1,
      "unique": true,
      "unitRef": "category",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Summary of significant accounting policies (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails",
     "shortName": "Summary of significant accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i7237bcbb75b9405287fe50d45561e97f_D20230401-20230630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ebs:DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Assets and liabilities held for sale - Narrative (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
     "shortName": "Assets and liabilities held for sale - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i7237bcbb75b9405287fe50d45561e97f_D20230401-20230630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ebs:DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Assets and liabilities held for sale - Schedule of Assets and Liabilities Held for Sale (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
     "shortName": "Assets and liabilities held for sale - Schedule of Assets and Liabilities Held for Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i7ab9e0411d2a4204b339f74ecd3ace35_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Restructuring costs - Narrative (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails",
     "shortName": "Restructuring costs - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ib6db5262b9d7491abbc074a39ee22a48_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Restructuring costs - Restructuring and Related Costs (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
     "shortName": "Restructuring costs - Restructuring and Related Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "icff2f736d0b84c82b69da3ae149c3877_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i469c99f1aa3e49068c75ef98b7a985dc_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Restructuring costs - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails",
     "shortName": "Restructuring costs - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i469c99f1aa3e49068c75ef98b7a985dc_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Inventories, net - Schedule of Inventory (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails",
     "shortName": "Inventories, net - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Property, plant and equipment - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
     "shortName": "Property, plant and equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i3f4212f3132341cf84f6c7de6e063ded_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails",
     "shortName": "Intangible assets and goodwill - Schedule of Finite-lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Intangible assets and goodwill - Narrative (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails",
     "shortName": "Intangible assets and goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Intangible assets and goodwill - Goodwill Roll Forward (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails",
     "shortName": "Intangible assets and goodwill - Goodwill Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i7db14af93756495bb396ad2850eb791d_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
     "shortName": "Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i960cf41acb8b4188a01129fbd602dc88_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Fair value measurements - Contingent Consideration Roll Forward (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails",
     "shortName": "Fair value measurements - Contingent Consideration Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Fair value measurements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails",
     "shortName": "Fair value measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails",
     "shortName": "Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i20c6e639de504e66bd14ca1b9f011604_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i8751da105fac4730bbdbaffce144fb47_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails",
     "shortName": "Derivative instruments and hedging activities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i8751da105fac4730bbdbaffce144fb47_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i8c80cc2623ec43ee87f691cd40d2b03c_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "instrument",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
     "shortName": "Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i8c80cc2623ec43ee87f691cd40d2b03c_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "instrument",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i1f157297decc4c27a1eb9955ddfbb47b_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
     "shortName": "Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i1f157297decc4c27a1eb9955ddfbb47b_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i8751da105fac4730bbdbaffce144fb47_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
     "shortName": "Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i8751da105fac4730bbdbaffce144fb47_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Debt - Schedule (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://emergentbiosolutions.com/role/DebtScheduleDetails",
     "shortName": "Debt - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNoncurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsCurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Debt - Narrative (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsCurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Stock-based compensation and stockholders' equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails",
     "shortName": "Stock-based compensation and stockholders' equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Stock-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based compensation and stockholders' equity - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i960cf41acb8b4188a01129fbd602dc88_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Stock-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Stock-based compensation and stockholders' equity - Changes in Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Stock-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails",
     "shortName": "Stock-based compensation and stockholders' equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Earnings (loss) per common share (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails",
     "shortName": "Earnings (loss) per common share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Revenue recognition - Narrative (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
     "shortName": "Revenue recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "iff58dd309a0441e3b97192aae2d95c4f_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i0c1de96d7b3145dfbc133d2bb6a68cf5_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i0c1de96d7b3145dfbc133d2bb6a68cf5_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i960cf41acb8b4188a01129fbd602dc88_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Revenue recognition - Contract Liabilities (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails",
     "shortName": "Revenue recognition - Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i960cf41acb8b4188a01129fbd602dc88_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:ScheduleOfAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Revenue recognition - Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails",
     "shortName": "Revenue recognition - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:ScheduleOfAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Leases - Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i92e936994b3b439dae281f549affd0f1_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Income taxes (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://emergentbiosolutions.com/role/IncometaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i92e936994b3b439dae281f549affd0f1_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Segment Information - Narrative (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
     "shortName": "Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
     "shortName": "Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i5a596f9ce817474386ba6f96f2eb24e5_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i8aba6ec5a3fb46f5aef1dd10f59ffe8d_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Nature of the business and organization",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://emergentbiosolutions.com/role/Natureofthebusinessandorganization",
     "shortName": "Nature of the business and organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "ia7c813299beb471abb99dc92b89568ef_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i960cf41acb8b4188a01129fbd602dc88_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - ebs-20230331.htm",
     "menuCat": "Cover",
     "order": "78",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - ebs-20230331.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20230331.htm",
      "contextRef": "i960cf41acb8b4188a01129fbd602dc88_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 77,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ebs_AdjustedGrossMargin": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Gross Margin",
        "label": "Adjusted Gross Margin",
        "terseLabel": "Adjusted Gross Margin"
       }
      }
     },
     "localname": "AdjustedGrossMargin",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended credit agreement dated October 15, 2018.",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Leases Supplemental Balance Sheets"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.",
        "label": "Cash Proceeds Excess Amount from Dispositions of Property or Casualty Events Subject to Certain Reinvestment Right",
        "terseLabel": "Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right"
       }
      }
     },
     "localname": "CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ChangeinContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Contract With Customer, Liability [Roll Forward]",
        "label": "Change in Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Change in Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "localname": "ChangeinContractWithCustomerLiabilityRollForward",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_ContractDevelopmentAndManufacturingLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Development And Manufacturing, Leases",
        "label": "Contract Development And Manufacturing, Leases [Member]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "ContractDevelopmentAndManufacturingLeasesMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ContractDevelopmentAndManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue earned during the period arising from manufacturing sale under the terms of a contract.",
        "label": "Contract Development And Manufacturing [Member]",
        "terseLabel": "Contract Development And Manufacturing [Member]",
        "verboseLabel": "CDMO"
       }
      }
     },
     "localname": "ContractDevelopmentAndManufacturingMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.",
        "label": "Contract with Customer, Liability, Additions",
        "terseLabel": "Deferral of revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ContractWithCustomerLiabilityDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Deductions",
        "label": "Contract with Customer, Liability, Deductions",
        "negatedTerseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeductions",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ContractsAndGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.",
        "label": "Contracts and Grants [Member]",
        "terseLabel": "Contracts and grants"
       }
      }
     },
     "localname": "ContractsAndGrantsMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_DebtInstrumentCovenantConsiderationThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Consideration Threshold",
        "label": "Debt Instrument, Covenant, Consideration Threshold",
        "terseLabel": "Debt instrument, covenant, consideration threshold"
       }
      }
     },
     "localname": "DebtInstrumentCovenantConsiderationThreshold",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_DebtInstrumentCovenantDebtServiceCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Debt Service Coverage Ratio",
        "label": "Debt Instrument, Covenant, Debt Service Coverage Ratio",
        "verboseLabel": "Debt covenant, consolidated debt service coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDebtServiceCoverageRatio",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period",
        "terseLabel": "Debt instrument, covenant, net leverage ratio adjustment period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, One",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, One",
        "terseLabel": "Debt instrument, covenant, net leverage ratio, maximum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioOne",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio Rolling Period",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio Rolling Period",
        "terseLabel": "Debt instrument, covenant, net leverage ratio rolling period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioRollingPeriod",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, Two",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, Two",
        "terseLabel": "Debt instrument, covenant, net leverage ratio, adjustment"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioTwo",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Accrued Compensation, Current",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Compensation, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedCompensationCurrent",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Expected Number Of Positions Eliminated",
        "label": "Disposal Group, Including Discontinued Operation, Expected Number Of Positions Eliminated",
        "terseLabel": "Number of employees expected to join Bavarian Nordic"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationExpectedNumberOfPositionsEliminated",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_EmployeeBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Benefits",
        "label": "Employee Benefits [Member]",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "EmployeeBenefitsMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_EmployeeTransitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Transition",
        "label": "Employee Transition [Member]",
        "terseLabel": "Employee transition"
       }
      }
     },
     "localname": "EmployeeTransitionMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_GrossProfitAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Profit, Adjustments",
        "label": "Gross Profit, Adjustments",
        "terseLabel": "Adjustments to gross margin"
       }
      }
     },
     "localname": "GrossProfitAdjustments",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_JansenPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jansen Pharmaceuticals, Inc.",
        "label": "Jansen Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Jansen Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "JansenPharmaceuticalsIncMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_LessorOperatingLeasePaymentToBeReceivedAfterYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Operating Lease, Payment To Be Received, After Year Four",
        "label": "Lessor, Operating Lease, Payment To Be Received, After Year Four",
        "terseLabel": "Lessor, operating lease, payment to be received, after year four"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentToBeReceivedAfterYearFour",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_MeasurementInputProbabilityOfPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Probability Of Payment",
        "label": "Measurement Input, Probability Of Payment [Member]",
        "terseLabel": "Probability of payment"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfPaymentMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_NonUnitedStatesGovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-United States Government",
        "label": "Non-United States Government [Member]",
        "terseLabel": "Non-USG"
       }
      }
     },
     "localname": "NonUnitedStatesGovernmentMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_NoncashPurchasesOfTreasuryStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Purchases Of Treasury Stock",
        "label": "Noncash Purchases Of Treasury Stock",
        "terseLabel": "Purchases of treasury stock unpaid at period end"
       }
      }
     },
     "localname": "NoncashPurchasesOfTreasuryStock",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_NumberOfCategoriesOfPublicHealthThreats": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the number of categories of public health threats.",
        "label": "Number Of Categories Of Public Health Threats",
        "terseLabel": "Number of categories of public health threats"
       }
      }
     },
     "localname": "NumberOfCategoriesOfPublicHealthThreats",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_NumberOfProductAndServiceCategories": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Product And Service Categories",
        "label": "Number Of Product And Service Categories",
        "terseLabel": "Number of product and service categories"
       }
      }
     },
     "localname": "NumberOfProductAndServiceCategories",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Product Candidates",
        "label": "Number Of Product Candidates",
        "terseLabel": "Number of product candidates"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_NumberOfRevenueGeneratingProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the number of revenue generating products.",
        "label": "Number Of Revenue Generating Products",
        "terseLabel": "Number of revenue generating products"
       }
      }
     },
     "localname": "NumberOfRevenueGeneratingProducts",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax",
        "label": "Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "totalLabel": "Total CDMO"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_OtherLongTermDebtFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long Term Debt Facility [Member]",
        "label": "Other Long Term Debt Facility [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtFacilityMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in the third year.",
        "label": "Percentage of Original Principal Amount Required to Repay During the Third Year",
        "terseLabel": "Percentage of original principal amount required to repay during the third year"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in the first two years.",
        "label": "Percentage of Original Principal Amount Required to Repay in First Two Years",
        "terseLabel": "Percentage of original principal amount required to repay in the first two years"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in remaining years.",
        "label": "Percentage of Original Principal Amount Required to Repay Remaining Years",
        "terseLabel": "Percentage of original principal amount required to repay remaining year"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_ProductsAndServicesSegmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products And Services Segments",
        "label": "Products And Services Segments [Member]",
        "terseLabel": "Products And Services Segments"
       }
      }
     },
     "localname": "ProductsAndServicesSegmentsMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ProductsSegmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Segment",
        "label": "Products Segment [Abstract]",
        "terseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsSegmentAbstract",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_ProductsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Segment",
        "label": "Products Segment [Member]",
        "terseLabel": "Products"
       }
      }
     },
     "localname": "ProductsSegmentMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_RestructuringPlan2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Plan 2023",
        "label": "Restructuring Plan 2023 [Member]",
        "terseLabel": "2023 Restructuring Plan"
       }
      }
     },
     "localname": "RestructuringPlan2023Member",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ScheduleOfAccountsReceivableNetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accounts Receivable, Net [Table Text Block]",
        "label": "Schedule Of Accounts Receivable, Net [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsReceivableNetTableTextBlock",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ebs_SeniorUnsecuredNotesDueAugust2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due August 2028",
        "label": "Senior Unsecured Notes Due August 2028 [Member]",
        "terseLabel": "3.875% Senior Unsecured Notes due 2028"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueAugust2028Member",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services Segment",
        "label": "Services Segment [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServicesSegmentMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Target Payout Percentage",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Target Payout Percentage",
        "terseLabel": "Target payout percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTargetPayoutPercentage",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan dated December 2013.",
        "label": "Term Loan Facility [Member]",
        "verboseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_TravelHealthBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Travel Health Business",
        "label": "Travel Health Business [Member]",
        "terseLabel": "Travel Health Business"
       }
      }
     },
     "localname": "TravelHealthBusinessMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_UnallocatedResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unallocated Research And Development",
        "label": "Unallocated Research And Development [Member]",
        "terseLabel": "R&amp;D"
       }
      }
     },
     "localname": "UnallocatedResearchAndDevelopmentMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_UnitedStatesGovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States Government [Member]",
        "label": "United States Government [Member]",
        "terseLabel": "USG"
       }
      }
     },
     "localname": "UnitedStatesGovernmentMember",
     "nsuri": "http://emergentbiosolutions.com/20230331",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r242",
      "r276",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r304",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r366",
      "r368",
      "r369",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r242",
      "r276",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r304",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r366",
      "r368",
      "r369",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r309",
      "r586",
      "r651",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r438",
      "r538",
      "r554",
      "r564",
      "r565",
      "r583",
      "r596",
      "r603",
      "r649",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r438",
      "r538",
      "r554",
      "r564",
      "r565",
      "r583",
      "r596",
      "r603",
      "r649",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r309",
      "r586",
      "r651",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r306",
      "r542",
      "r584",
      "r602",
      "r645",
      "r646",
      "r651",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]",
        "verboseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r306",
      "r542",
      "r584",
      "r602",
      "r645",
      "r646",
      "r651",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r431",
      "r438",
      "r464",
      "r465",
      "r466",
      "r537",
      "r538",
      "r554",
      "r564",
      "r565",
      "r583",
      "r596",
      "r603",
      "r643",
      "r649",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r431",
      "r438",
      "r464",
      "r465",
      "r466",
      "r537",
      "r538",
      "r554",
      "r564",
      "r565",
      "r583",
      "r596",
      "r603",
      "r643",
      "r649",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r439",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r256",
      "r439",
      "r610",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r256",
      "r439",
      "r610",
      "r611",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29",
      "r601"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "auth_ref": [
      "r174",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable, Trade",
        "terseLabel": "Non-cancelable orders"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r311",
      "r312"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts receivable, net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": {
     "auth_ref": [
      "r43",
      "r47",
      "r131",
      "r224",
      "r225",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]",
        "terseLabel": "Defined Benefit Pension Plan"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r95",
      "r200"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation &amp; amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r216",
      "r224",
      "r225",
      "r493",
      "r571",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r206",
      "r550",
      "r559",
      "r560"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income, net"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r223",
      "r224",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r131",
      "r533",
      "r555",
      "r556",
      "r614",
      "r615",
      "r616",
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r42",
      "r47",
      "r131",
      "r224",
      "r225",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r601"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r622",
      "r623",
      "r624",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r207",
      "r313",
      "r316",
      "r317",
      "r318"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "negatedTerseLabel": "Allowance for expected credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r52",
      "r393",
      "r522",
      "r619"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r66",
      "r85",
      "r90"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedTerseLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r170",
      "r182",
      "r204",
      "r238",
      "r284",
      "r296",
      "r302",
      "r314",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r365",
      "r367",
      "r369",
      "r370",
      "r491",
      "r494",
      "r513",
      "r601",
      "r647",
      "r648",
      "r692"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r195",
      "r210",
      "r238",
      "r314",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r365",
      "r367",
      "r369",
      "r370",
      "r491",
      "r494",
      "r513",
      "r601",
      "r647",
      "r648",
      "r692"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r92",
      "r97",
      "r193",
      "r194"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Assets held for sale",
        "totalLabel": "Total assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]",
        "terseLabel": "Assets held for sale:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r140",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BilledContractReceivables": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.",
        "label": "Billed Contracts Receivable",
        "terseLabel": "Billed"
       }
      }
     },
     "localname": "BilledContractReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings, building improvements and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r490",
      "r618"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent obligations, net",
        "verboseLabel": "Changes in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r124",
      "r125",
      "r489"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r124",
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Business combination, contingent consideration, liability, current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business combination, contingent consideration, liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property, plant and equipment unpaid at period end"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r68",
      "r198",
      "r566"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r62",
      "r68",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash and cash equivalents and restricted cash at March\u00a031, 2023 and December\u00a031, 2022:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
     "auth_ref": [
      "r62",
      "r68",
      "r73"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations",
        "negatedTerseLabel": "Cash and cash equivalents included in assets held for sale",
        "terseLabel": "Cash and cash equivalents included in assets held for sale"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r62",
      "r68",
      "r73"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r62",
      "r163"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash excluding cash classified within assets held for sale"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months",
        "terseLabel": "Net deferred losses from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental information on non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r622",
      "r623",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "$0.001 Par Value Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r601"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200.0 shares authorized, 56.0 and 55.7 shares issued; 50.4 and 50.1 shares outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r220",
      "r222",
      "r228",
      "r546",
      "r551"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r598",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r129",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation and consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Rollforward of Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r413",
      "r415",
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Contract with customer, asset, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r413",
      "r414",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r413",
      "r414",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r80",
      "r295",
      "r296",
      "r297",
      "r298",
      "r304",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r54",
      "r542"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods and services sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold [Abstract]",
        "terseLabel": "Less: Cost of sales:"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r236",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r387",
      "r394",
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r171",
      "r172",
      "r181",
      "r242",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r523",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r35",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r36",
      "r242",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r523",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to August 15, 2023"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Upon the occurrence of a change in control"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r36",
      "r110",
      "r111",
      "r112",
      "r113",
      "r164",
      "r165",
      "r167",
      "r180",
      "r242",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r523",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Current, Net",
        "terseLabel": "Debt issuance costs, current, net"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedTerseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r472",
      "r473"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r66",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation [Abstract]",
        "terseLabel": "Depreciation:"
       }
      }
     },
     "localname": "DepreciationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r66",
      "r279"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r212",
      "r213",
      "r512",
      "r570"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r40",
      "r142",
      "r168",
      "r211",
      "r570"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Fair Value of Asset Derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r141",
      "r143",
      "r146",
      "r148",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r154",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative instruments and hedging activities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r138",
      "r141",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r135",
      "r138",
      "r139",
      "r150",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r427",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r91",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r92",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r92",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r92",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets held for sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r92",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r92",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r92",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r92",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r13",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Assets and liabilities held for sale"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Assetsandliabilitiesheldforsale"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r229",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r257",
      "r259",
      "r261",
      "r262",
      "r263",
      "r267",
      "r501",
      "r502",
      "r547",
      "r552",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per common share - basic (in dollars per share)",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r229",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r259",
      "r261",
      "r262",
      "r263",
      "r267",
      "r501",
      "r502",
      "r547",
      "r552",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per common share - diluted (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (loss) per common share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Earningslosspercommonshare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective annual tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance payments"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r109",
      "r191",
      "r223",
      "r224",
      "r225",
      "r243",
      "r244",
      "r245",
      "r247",
      "r253",
      "r255",
      "r271",
      "r315",
      "r412",
      "r469",
      "r470",
      "r471",
      "r480",
      "r481",
      "r500",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r533",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurocurrency"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r503",
      "r504",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r385",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r504",
      "r534",
      "r535",
      "r536",
      "r579",
      "r580",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r503",
      "r504",
      "r506",
      "r507",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Fairvaluemeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r385",
      "r432",
      "r437",
      "r504",
      "r534",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r385",
      "r432",
      "r437",
      "r504",
      "r535",
      "r579",
      "r580",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r385",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r504",
      "r536",
      "r579",
      "r580",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r159",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r159",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "terseLabel": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r385",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r534",
      "r535",
      "r536",
      "r579",
      "r580",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r509",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r140",
      "r145",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Weighted Average Useful Life in Years"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r202",
      "r336"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r337",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r89",
      "r544"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r86",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r89",
      "r543"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r201",
      "r322",
      "r545",
      "r577",
      "r601",
      "r630",
      "r637"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r323",
      "r330",
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "terseLabel": "Goodwill, gross"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r323",
      "r330",
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill, impaired, accumulated impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r53",
      "r238",
      "r284",
      "r295",
      "r301",
      "r304",
      "r314",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r365",
      "r367",
      "r369",
      "r370",
      "r513",
      "r576",
      "r647"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Consolidated gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit [Abstract]",
        "terseLabel": "Adjustments to gross margin:"
       }
      }
     },
     "localname": "GrossProfitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r138",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r50",
      "r169",
      "r175",
      "r189",
      "r284",
      "r295",
      "r301",
      "r304",
      "r548",
      "r576"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income taxes",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r9",
      "r10",
      "r11",
      "r12",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleNarrativeDetails",
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r339",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r239",
      "r476",
      "r477",
      "r479",
      "r482",
      "r484",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Incometaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r240",
      "r254",
      "r255",
      "r282",
      "r474",
      "r483",
      "r485",
      "r553"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r679"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Discrete tax expense (benefits)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r63",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r539",
      "r618"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": {
     "auth_ref": [
      "r618"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.",
        "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable",
        "terseLabel": "Income taxes receivable and payable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r618"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "terseLabel": "Increase in other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible assets and goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Intangibleassetsandgoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r84",
      "r87"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r166",
      "r177",
      "r226",
      "r278",
      "r521"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r231",
      "r233",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Inventoriesnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r82",
      "r568"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r209",
      "r567",
      "r601"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories, net",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r197",
      "r208",
      "r269",
      "r319",
      "r320",
      "r321",
      "r541",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Pre-launch inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r82",
      "r612"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r82",
      "r569"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held.",
        "label": "Land and Land Improvements [Member]",
        "terseLabel": "Land and improvements"
       }
      }
     },
     "localname": "LandAndLandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r529",
      "r600"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Operating lease cost:",
        "verboseLabel": "Operating leases:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails",
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lessee, operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "terseLabel": "Lessor, operating lease, payment to be received, year four"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "terseLabel": "Lessor, operating lease, payment to be received, year one"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": {
     "auth_ref": [
      "r691"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year",
        "terseLabel": "Lessor, operating lease, payment to be received, remainder of fiscal year"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "terseLabel": "Lessor, operating lease, payment to be received, year three"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "terseLabel": "Lessor, operating lease, payment to be received, year two"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r238",
      "r314",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r365",
      "r367",
      "r369",
      "r370",
      "r492",
      "r494",
      "r495",
      "r513",
      "r575",
      "r647",
      "r692",
      "r693"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r173",
      "r185",
      "r601",
      "r621",
      "r629",
      "r685"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r196",
      "r238",
      "r314",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r365",
      "r367",
      "r369",
      "r370",
      "r492",
      "r494",
      "r495",
      "r513",
      "r601",
      "r647",
      "r692",
      "r693"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r8",
      "r92",
      "r97",
      "r193",
      "r194"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Liabilities held for sale",
        "totalLabel": "Total liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]",
        "terseLabel": "Liabilities held for sale:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r172",
      "r183",
      "r384",
      "r398",
      "r579",
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Total debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Less: Current portion of long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of debt, net",
        "verboseLabel": "Debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r36",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market accounts"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r64",
      "r67"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r51",
      "r67",
      "r176",
      "r188",
      "r194",
      "r218",
      "r221",
      "r225",
      "r238",
      "r246",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r260",
      "r284",
      "r295",
      "r301",
      "r304",
      "r314",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r365",
      "r367",
      "r369",
      "r370",
      "r502",
      "r513",
      "r576",
      "r647"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Debt, current portion"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r134",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "terseLabel": "Number of Instruments"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NatureofthebusinessandorganizationDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r47",
      "r49"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive loss before reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r284",
      "r295",
      "r301",
      "r304",
      "r576"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r688"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "auth_ref": [
      "r270",
      "r532"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r528",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r527",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Total restructuring costs by segment"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r14",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the business and organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Natureofthebusinessandorganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r127",
      "r128",
      "r130"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r127",
      "r128",
      "r130"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent",
        "terseLabel": "Pretax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r214",
      "r215"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gains (losses) on hedging activities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r215",
      "r217",
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Amount of Gain (Loss) Reclassified from Accumulated OCI into Gain (Loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r127",
      "r128",
      "r130",
      "r219",
      "r222"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss, net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r127",
      "r128",
      "r130"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedTerseLabel": "Tax Expense"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r140",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r601"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r343",
      "r617"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Taxes paid for stock-based compensation activity"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r601"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r59",
      "r120"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from stock-based compensation activity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net",
        "verboseLabel": "Products"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Propertyplantandequipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r94",
      "r199"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant and Equipment Income Statement Disclosures [Abstract]",
        "terseLabel": "Property Plant and Equipment Income Statement Disclosures [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r96",
      "r186",
      "r549",
      "r601"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r47",
      "r49"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfMediumTermNotes": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.",
        "label": "Repayments of Medium-term Notes",
        "negatedTerseLabel": "Principal payments on term loan facility"
       }
      }
     },
     "localname": "RepaymentsOfMediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r122",
      "r190",
      "r700"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedTerseLabel": "Research and development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "R&amp;D"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r341",
      "r343",
      "r346",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Restructuringcosts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Number of positions eliminated, percent"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r66",
      "r347",
      "r349",
      "r644"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Accruals"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r342",
      "r343",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r343",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r114",
      "r184",
      "r558",
      "r560",
      "r601"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r191",
      "r243",
      "r244",
      "r245",
      "r247",
      "r253",
      "r255",
      "r315",
      "r469",
      "r470",
      "r471",
      "r480",
      "r481",
      "r500",
      "r555",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r275",
      "r276",
      "r294",
      "r299",
      "r300",
      "r306",
      "r307",
      "r309",
      "r426",
      "r427",
      "r542"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Services",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r424",
      "r425",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Revenuerecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r227",
      "r238",
      "r275",
      "r276",
      "r294",
      "r299",
      "r300",
      "r306",
      "r307",
      "r309",
      "r314",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r365",
      "r367",
      "r369",
      "r370",
      "r513",
      "r548",
      "r647"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility",
        "verboseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r47",
      "r686",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.",
        "label": "Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r141",
      "r146",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Derivative Instruments, Gain (Loss)"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r133",
      "r135",
      "r136",
      "r138",
      "r139",
      "r145",
      "r146",
      "r149",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r9",
      "r10",
      "r11",
      "r12",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/AssetsandliabilitiesheldforsaleTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Income per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r119",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r86",
      "r88",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r86",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r577",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r15",
      "r26",
      "r27",
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsNarrativeDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Restructuring and Related Costs"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r101",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r75",
      "r76",
      "r78",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r75",
      "r76",
      "r78",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r272",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r309",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r345",
      "r351",
      "r577",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r284",
      "r287",
      "r298",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Significant Reconciling Item, Consolidated [Abstract]",
        "terseLabel": "Other reconciling items"
       }
      }
     },
     "localname": "SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedTerseLabel": "Selling, general and administrative",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Equity instruments other than options, forfeited in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Equity instruments other than options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "terseLabel": "Nonvested options forfeited (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r74",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r192",
      "r272",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r309",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r340",
      "r345",
      "r351",
      "r577",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsandgoodwillGoodwillRollForwardDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r109",
      "r191",
      "r223",
      "r224",
      "r225",
      "r243",
      "r244",
      "r245",
      "r247",
      "r253",
      "r255",
      "r271",
      "r315",
      "r412",
      "r469",
      "r470",
      "r471",
      "r480",
      "r481",
      "r500",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r533",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r271",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r109",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r114",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r19",
      "r20",
      "r109",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchases of stock (in shares)",
        "terseLabel": "Stock repurchased during period, shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r19",
      "r20",
      "r109",
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchases of common stock",
        "terseLabel": "Stock repurchased during period, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r23",
      "r24",
      "r81",
      "r601",
      "r621",
      "r629",
      "r685"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r237",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stock-based compensation and stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Stockbasedcompensationandstockholdersequity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r38",
      "r115",
      "r116"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 5.6 and 5.6 common shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r342",
      "r343",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RestructuringcostsRestructuringandRelatedCostsDetails",
      "http://emergentbiosolutions.com/role/RestructuringcostsScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledContractsReceivable": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.",
        "label": "Unbilled Contracts Receivable",
        "terseLabel": "Unbilled"
       }
      }
     },
     "localname": "UnbilledContractsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance, deferred tax asset, increase, amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Discounted cash flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/StockbasedcompensationandstockholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r258",
      "r263"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average number of shares outstanding-diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r257",
      "r263"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares outstanding-basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EarningslosspercommonshareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e526-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r605": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r606": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r607": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r608": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r609": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>105
<FILENAME>0001367644-23-000088-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001367644-23-000088-xbrl.zip
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MCBX9MW=YS&5^_8Q_=!#^_.'T_U!+ P04    " !CCJE6UXA:Y!8$  "V#0
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M,C,P,S,Q+FAT;>R]:5L;R;(N^OW\"EW6/7MW/]?".0_N;I\' V;1VQ(V8/O
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MHC4*1<XLE@Q[YX,9Z@Q""LE9E<QBHJB"!&HBU41R$I"P*4.+&I.V7 _ [44
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M5$4?(4[%%G-CB/+$Q^@5I7?"FUGUOE>%LG9<Z!EX^R&(JD.C7][F17"FG*G
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M< "-KEHT*!IQD'QSXR04U0A0SX47#3LHH5_*$JX"#Q(.+N"95XOZ7S3B50V
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MJ>UT64G^O\?+UC_VQB\QW((G32@31-3U&]PY8^GW!7RG"]\B#"$ZG,?]%LZ
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M 1,LP&\,N72O''13U#L<32^@2<8-#44:LDB&HJ*M0Z=594)#1QZFI-UTRU3
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M\C;:OE_KA)R^464RUFD?'_IN*PDL=XQ;$*^/9G1I5"HP)@)@(>$U(FDT$O6
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ML&E/<P1G8\=HKVKQ@3,?G__AFY?Y4*URAVICJCF,XF=UG$\=)T_..'56>6M
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M$#?,6K>XUDVR0D(E<EX2X!5*+5T]! 8*!,IVKL*;0(A.70ESEELF?>LBB>=
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M!FF@!6/ $NHA#XP(C>N;))<Z/+4>5J.U9=;(I6ODI'7GWGAIO0-<>16M.W-
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M'0VPW%DO*0;>(0VHU YH@C P7$,EC/*0VOHFPO-69F=V\$+805;75:KK9+
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M0)L&H:1Q:5 ! 0E"R 4ITB"4!;;08AW.\Q9:ORUD%*0.ZP"XMAY02D3J\BH
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MW8 9V3*R961;2;.?6<@VWDZS?=X"KM,'P\_(L#<O[$W2.20P1!X* #$D@,J
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M.N:;,0U&Y]V+9YY^LQ(2TCNM/&XR>3$&VLVPJ7K1*[)6*L)H,W@T>\/N1 $
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M\8+/\"['G7-@&!$ FUF)R%$)0+>XSY7P;[9BO^<\A&SEE(&GB7ZOWJL"4N=
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M(M:C9N%'4[$T$5\S3LT8AB4VK8=-;!&;JMO',G%9FC*!N 5CD'DAD52&H]3
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MIB',1I%.>8I2H4*=DA)"ZXT/Z9MH;55B8XF-+PD;*='PG91S[U-F.5>$46!
M^)UAZ9DOL?%)L7')E>E8*FQ"$\1Q2,;EEJ  E@@3APWCJ28T)N.F)3:6V%AB
MX\-6+$B;94QDRAG)-,$JDTI(;!)MK<JT*;'QF6SJPG%L2.JI%PPYP@ ;0T:E
M2)U$4CIBF9-)ZO'&AVR+O0%LO$-+U/![H-]&>ZCB4\XVA2QX@(7^C=U.WJ3M
MMYYKPB=_N&G;QO]WOB%G\:C)]"M*PX,-!]=_Y9H>GG.MKUY(5T_,YGMHSOX=
MGBCRI60"6V4\3;1FB10J2;7ES%/EN:),'8<V"L673GM39_6)0[KGU#E2'A[Y
M-]6\4*/^QK_F]PHVJE@19[#D>^WIV; _:/C1=9OZX;]U#^ZZXD%OO$%!LRC(
MM'BYN>NCZT^MZ'_V>+YUOI5S[_+?C]P4>+_] YZ]TQOM-/JFV>D/>^Z%=/]-
MJA]ER[0^M0]:?S9J5Q&LKVK?]_GAV9>SHWJS<5 _H=4] &JR>U6M_WE6W=N_
M^HM^:;I_?QD=?;==35@*]Z#5V.6WB@_/F@T \N8!7.-@QUP<[1Q2N!<( UC+
M6<U7KTQRK,%,\-(GR&(+9GLJ*1)<4&14EEF7)IHYEDM40"1GMT-Y,'%&,P&F
M1L:!L1P'D9I(F4J"+1%2^,7NP.,];[C^9J7M!LN@-TO7"P"8G\FMMWRZ9M(3
M"OHX[/7@IWJ \U^8AD;' AOO#7$@LU6"6,B'!(J2*/;CH%E&#>>OLF/T(N$&
MJNHW^@-G0X/HP6P_Z3?:R3G%6ZFX7V/@9^DWS+%XG,7>[;)EO^$[-RN].:1>
M;MZ-FW=SE],WU_5U-3I_41>5EH*S:8#)'MOU]X?=;A/ NNSY6O;1N=$IQ!67
MJ9?&"9RQC%&1:@6_IYXXT( <OZM3:*(+ BU6QZ2XW;9?"T*LN4&</A*<12^F
MF.^^2N+I8>NR>7!6.Z^1_4NX#SNH[\*?Z#4ZK>[MPCVW+P[KGUJ@./+:F2'C
M[\"]AD?D6UHEG^GAV2=XIA,."B:L.7B-=N$[X1I_G%:_'S6K5^>D=G7D"R]1
M]!;5KL+S;Q\[S+Q-*$>$ARIYJ0@25!HD,\&RA"O&M T. ;$E7TD/G5L!>L8)
M54B5VQSFOP:4_7*()=/$>#"MC!:ANZ%0"<9$>FW3A%@CQ%T[?Y6(]8B(=;6(
M6&G&C16$(D*D0DRE%!#+>X2UY%Q21Z6C ;'HVN[M%]7<ZT5CR/=.[QR!Q=SM
M=8SK_VJEQ\^I%(6=WV__G>]["2SW!I;&LBJ$,PMH+U/$:)(@QJE!PF"#6&HU
M$"EEA*4 +(0\6"[JXZD[:Y1"O6T&?' 97S+@0S'@DF0GEFBI3(J,412QC()D
MA\-"E$L)T)DX';H68YRNJ/V_D0%+Z3W'/I\:[4;_U-G*2:=C2^']=,)[O/%[
M8=]+[+@W=HR6A7<FC+,\M0B.C"!F&$=2X@1E4C&?ZL0*[#8^R/3!W!BE['Y]
MLKODOX?BOR79G>%4IS@3B&3*A6Z;&5(BLRA+O3$^T8;9!/B/O'S1_2HZ?\6Q
MA)7&4A)(641;)OR^!DT(P+>$W#4@M_9Q6>4Q1IK,,(6(T "YF%@D0.=!AH"$
MY$00D:0;'VB:/73HY@750-PM<O,K UR)8X^I498XMC:.+:F.4COKF5)(FS1!
M3#F#--4ILH8HZJ33F>2 8QQOB7L%=%YJ6<(#Y;%?C]I%=/M9,CO'1_(<@#"C
M";^H#:HT^K 6%5)=U2"FNC8[%ZX7\EY-IS^H='HQ(;;GX-RO8C;K#]4<NN?<
MRJV%^HB5E31W+ >ADW*05UI@D3Y7@<7?O4X7P&;T=U.U!]MMN_M_PT8WM%U[
M@047HT((P36.]FKG1WN'[&"G>EFK?\8'>[L,7CNMMJKXH%X[._S^C55W#I>2
MY6O?87WDR_G1V0FK7NWBVLXWN-\IO+8[.KSZQJL$UE@_N:B=U7SM:OOB&',B
M:>8)$(<,D3MBD/091UI;J801U"NZ6'"1XHQP0K@@Q##BF:34,9 [EEENJ16+
MR?7C,]BL=,,IQ-Q(-SZ'^Y9@W+J(QR[!N):R?F%ZNCSF/%.PN2GB:;"L)-"3
M,J' G&6)<0XK(=D]BB_6$N=/A?"WTW59H5%6:)05&F6%QK-O7EFA 9OP5P#H
M\*?1ZO8Z/]S*V1]E<499G#$_Y!ATO]">(ZA#3"299@IT8L]33!RURM[5@7^M
MOKC7Z_1?4!3U?EICX0JS#;CF5:W^[>KPZDNS=O;EK+9SSJOASU6M<5"O@J9H
M+@^OS,6B*ZQ&_H3U5W$-KEO;^T9J>]7DH'X.SW9^527[\/UM4KOZ=%:[^F-E
M-89.=28309!Q-D7,6X&$35*DLE1I2:R%US<^4%P68[QUZ/KE$$IS0EGJ?)8R
MQZ3-E,,VL8Y2PBFW(KFK:[Y$J(=$J.4<32%5IKE&J9,$,4TQ4E@ZE()1S*33
MQ.-LXP-G:R-467QQ5Z;Z8]AHAL7V-RNZ^'%.&8S:8=.IOCOM-&_6$\M<SS'\
M) F1A#.:2D%9F%ND0JM'Z25 3B)QJ2 ] _RLJ-$(X_M81H-G+LT04QC@ASJ/
MF.446YHZ(QTH2 E_4:,GRSS/FWF/44$$20S3DA$*Q@GCAE'#L4@PIK84_<_!
M>TNB/Z$F83AEB%('QDE*+5*I 4T@3%3/#%<)E\![9.U\HU*^SY=G#'O *\.>
MF_?%E[+[6M.!I1E)-/6&I(S13*0L<9DSFCKE?7KG=J0E?CP<?JPHT4AHF#!G
M#;)2<\0R@I%FWB/*A:2:4,=#-WN.^18O9?=KX3V?$@8Z<Z(EQ4QG$L2XIYQ*
MQ;%W].X9=27O/23O+<ENIHGUS!#$)=-ARHY%$BP=A!.66H<)=AD#WDNS=7FO
ME-USG/.UXP<7JN=*87WMS!GFF$FE8\I(1K64"9.92W"*M4MMHDIA_>2 L:JX
M(&3M98D7*$M3,*^E5D@J29!+C4U3FB6.@*&=LK5S<DM9_7RLEZ2$."=U(CA3
MJ1 $:P^,!LS(92)\*:N?@_669+776>9P" *RD,W(,$-*. %F=T(T=PI;#79V
MRM<=;5**ZCG&^=AIY],G8..*7D8GO;*9T0WX807CB3!8>D(829VPF<HL$51D
M0@E*2]']]/BQ(HG .VLUE1*E*1:(6><0&&@"&?B=.ZVTL8 ?.&-E'Z/7PWN4
M"B?3C&=$*T;@.+WSG&:*@N4&FC,K9?=S\-YR+1MA5.E4(R\810Q;CC1G##FM
M,T$]L5(EP'MB;1]7V0?A/MGK)X&HR^3(,CGR2;H;W(:MOM-KJ5![=#GXK3UL
M(=L9H.)Z)?"N [PK$@-2S!*B+$$V"Z-R60K *YA'V!$L6,IXFH;><9N))%O)
MJTZ>+/,C?\G\R(=J75""U).!U'+R9$8UD08CG60TY"P!2"4T6&8)M2RQ@BH7
M0(HDN&Q>_7@5-*[?_ZVR;<RP-6S&:GSKNCT@\;PP]S]5J_M[1;4ZL.*K^-(O
MYA%Z]PRJT\QI[,P<!OS<=.$' *KMF1.Y%L1*B%H'HE8D:<B$>9P90"<?>O R
MDH;\;HF84U9:JW1"0(^B&5_1R.]]Z3=Z>1SZ4'I#R:'/PZ'+G3;31&N?I8AG
M3""69AHIQAC*O*5$6,&26",FZ(K0['4<^DS>)<R"JO*BE86\T6;W#LT_'K"5
M7C+?GNHMVW&/OS\O&\I?DIOJ136S>P7H?+ B;X;Z),L2G"'JE$9PY@SIE&5(
M2R(T-X:"]-WXD.'TP1)G'HQ37DYGSE\(_TJ8>W)'5PES:\/<DA**$^^PPARE
MH&TB%H*=DBL!2BC3.,6.IDIN? !!M6Z2TK.CV=,W[GPJ'MSNA_Y=L0-1?@3C
M-D11G1TWUYE[BVS&YE^KTJ1 )P;6Z\$R*XVV:0ZML[&+93_\.NSUX->>R]UK
M@\[<5<+OROY0;>-B-[&/G1;LQNB_^I6/.]6#BE%=I1O-QJ#A^@OM)U_IQM^A
MQ=I<9]"PC9N59MAD=9V7,G8!FK&WMRH[PUZH! \[.G*J5W'M<"37'>O,QL,Y
MF<!4-MS--5UO^6Y -_^Q3K**9P#0GF)**,/&"^93DUF7NB2E<*/8F)",&Q/>
M <L_PHX<^#BV(\S5=+T?#>/Z7SM-^Z8#%O?O8KBS.SKF-LT4' "R<9X=LP0I
MP&<DM7/4.1&&<H1Y=M>62@,K-,-)]YQO.G@#J$M5^J= =*X=?BFZ 0[[S@^;
ME6;#N]C*%DA=-=HWV\R5B].&.:U<N)X+<*#C52Q 1[PB<-S0PU)RBBZ&3(;/
MP7T\+&K%A_H%3504H)/+;]$8G%;^!+[MNW;E7?C*QO;XS8WW6Y5/G5XE"(SP
MQ'&81DY)^1-/D"M\;^!ZK49[P@KAI<F5-L/VN%[X:*TS<!5,-RL;7]P/UQZZ
MR%DG[7B'C8=LI2M?>RO=[+E:Z>ZW!ZI]T@#IO@UT,>B_O ZZ!U\G6-&J[9B+
MZO? UU_.8DOVUI]PG\_\8 =^W]LE!SL&?J[B9:PX3$(GTT/RJ0FJ76C)/CIL
M[5Z >LC@=[CW(:M=G0.._..K=7-9O3A.,T*(D!(9QP MM#!(,^/!A/59JK&R
M5&2+/71Y:-:."5$IY4QPI:WAB6,F,9G3F-+%'JG3S:^HN/L1%,(4N@O@ZGOT
MS[U] ?,+]D0K8M($"\>8!/;2('QLQK!SB4S5*V[C6I]3I!I+&UWT< WP!7AJ
M01,+R@7 <5#4?C1410_[<-%^^&1+%V#7#RW)XP7RS_8CDO6W*H_,I%_-J;/#
MICOP86+7P/W5^.'L(N?6@XK^"S/MJ+I]+$,2OA "<19B= 8K)$'M0MYZ#13M
M<4;<(@\D8)YID\$[!F1)PH02!F><FHP+SC1?9-KZ;,/?2M'#=]@*NO\5T.^\
M!K_$X5&]_>UFUKXKR^4]23>NP8);G^NI&Q!+N04$?Y_^PYAM8<D?OJ4OO$GN
MVV/XIO=H]@C-DI.M!+^:Q98[6RXVD@'C[+4L-NSLW19;A';''Q@K'BSOZO[P
M?:M[G8O;$ZQ>9P_K[_$7T+FV85GJQ%6^Y=;S7\%Z!O/WT*G>]26(#[&_F+^Y
M37W"KNIWV;U[MAI_B3M[IY;K"[A ^6/APE-<XPT=7LSHKGQ4O=XHJ.[;+7C<
MZ]N(/=#>E'N?!UMF'/?;=\DE?KW;?V.P?<:V6V7)/<O9U-Q@D2MNFE=W_P6E
M6PF[PXI^[W9RS\IOT>_<^.%^#V> Z!9986AJU7?A"AL?WN'W"S[E$C-+S'R]
M>_\+8>9+W/X5L/@K#MCYNW"/WX7JGNKPGRH_:Z5#WS-"B<3,IY@PQ9T41&"9
M6>5<0G5&[N#0O]Z-GYN_P?J=B^3#<YC?[+ 7,AE>IVL_3]%J_7E>J^\FAV?;
MK';U&=[_TCRH'YT>GID+6&_SJ'YX4=O[LU7]_N5\,44KK*5:_]*H[IS0VLXA
MJ^U]X[76IT;MZH_30_)/LW:VG1RV#N$YOJQLE9Y)G5J5460E)8A98I&2&J/B
M$+$5"=WX@.DT0VO).W__[,[E9%4;_O]5LCI_^O'?3C8G5Q83HS"6GLE,Z203
ME%K,O54\97=N]WA#(/!E=:YY)7"QE-&9^HP0RC3*N,X0,_"7)%@B93AU+.1N
M<;_Q03#Y %VCUF.&!YX]==UR2D@K(>VE0-J,)31K")4@MQ[()4O5S=9)"4>#
M*/<.L33,U^,&(QD;YJE$"9%L?" L65'=7()<"7(ER#T@R+VD.IQ7 FAXR<CC
M) ,US2#N. LYW@PI1U)D.)?*)9QY238^I(EX@(FA+PO0[C@M]+KO_:J MN[C
MOQE <RPSH?]2FA+-%!:2V#3Q &Q>$4_=G9N?EX;HPT(:71I5XJWS7#DDO )#
MU%.*E"(8&4,SX3 E\,/&!RG(SQNB:S)#"6DEI/UBD%8:H@\"<FRI1WN:6$M#
M_S_A0&\#A1H)YDV8A<:YDYPII< 0Y72+EB!7@EP)<H\)<J4ANC:@\25 $X:E
MFA%$,9B?3&B,M)(8N5!3KC#U1/F-#QD1/]_WYHD [0UU//TX[,/-72^O:PXE
M?*>-[ET2'-Y.$H,E'FMB34*3C/$$JPQ^\)J&=(94"E<F,3P_K,RT(SW8^7Q1
MV_EVG%)J/&$VN+:2D,3 D1($E"7%,X&S5&F.-SXDTY;N#Y##<+?VOO/^]%?4
M/'2=P<K$>.. 1;S#+"44F$9PZI4!@:NYQ&7P_GG8Y&J63:IGGX_A7&1(ZT%*
M.HP8(1)IEJ1 0-P3[KQ3E( Y(=;NQG07NG_FT%7)KD_(KJ4_X$$8.)ECX*OM
M8V*E%)H*%";A(J8H1Y)HC63FP=Y1CL>FOB4#EPS\$$'7V999OG'I++IRO4[)
MQ.LQ,9YGXO-CZ9Q(%<V0M#9FER1(9Z"Q$JF4<&GJ$BHW@%\%P>3W5\C'M[CN
M[L3'"]=XFWPLF=3&"9VP5#*6)8IQ(KQ(,Y\XG!A;QAJ?AV/IE&.KO 8<:V6B
MF4L3!!JR0"PA& EL'#*:9O"6D))D#R-V5]!]R:Z_#KN6>O.#,#";$[D[)\?$
M)!8KJQ&U*>C-&%,P@=,,)5H+#800)B&7#%PR\,/$B$J]^2&8F"]*8>:QL#P%
ML<M3@QCS#BG*,"+:L"3,[L1)\F!Z\P/R\5N*$.U4#WZI>)!7*95:))PXPZRW
M(C5))EE*O619!J9V&0]Z 5"Q5-2*/4C[3!!$.&&(42J0D-XC^?^S]^5-;21)
MWU]%0;P;.Q-!L74?LT\X@C&VUXZ5&-MX'/ /42<(ZV!U&,.G?[.Z):&+2]S0
M.[$8I.[JZJK,7]Y9)&")O9=4\2H>=']REGC+@L?: --8KTU@UL= N!<L"5?%
M@QXY'C0Y:#:IF#@5R%AA$3<Z )N$B+!06%*?*-%D[8W8$,_0"U5YDY\.MU9F
M[=V&@R:GB$G"C,$<"<(3XE2!61M50$)$HF'+D@Z^XM^*?ZMHT)/AX872O&2U
M4R:Z7+@2$1BR!EFN#9+1ZVB)Y%:E*AKT"KQ3-%F%#:><6LJY%2[;G<$I[8+S
M.%S[0+M*:[ZG:-"88R//YU1AB0@5&/&$<SZ59HA:&[R(T3AO[D3J5K[D5\VM
ME=9\M\&@,?\Z8%E"4D!148JX9!J!#!9(^J@UYM$Y=S=:<\6_KYI_*ZWY[F-!
MD^IO2ZPER2-I9$!@Z23D*&-(..P-=L9ZS)]_+*AXA%H2$YHYG\\L:?[\F%RX
M>%C?3G=0G)PX=^C373C;[[37)'D]A:(W>_D7 _O""B.3 4E/%%><:>DL_"T3
MC8[R**K0Q", ?&/)R>'2$6(%PXC&Z! GS"/C54(I4!53U(Q*M_9&:W8?+=@N
M887GTX"M K,*S*K(S=. MX7(C4B8:BTHDD'E2KRHD)/>(>HL-L8+%JQ8>T,5
MOWUCCPK>*GA[.F_]M."M:NEQ8RA;"&"9(&QR."+N8OYA/=+4"I0$IT0[1:+D
M]]9;\A&A[.XZ%+TB*+O9R[\8*#,2^\2)]4X[3K2VF!!JD@L2T^#U'<;VIOV-
MG6$;A>X C4:LD.YF2+<0^".@K'$O+0H6YS(P29%3W"+83>RP(()DI8VL8R)O
M;Y7>B%,JK*NP[A5A7665W@G +41&1=2*<94[2T0//R1#6AN!:-!!& KHAW.[
M2:TV> 5O%;Q5\'8_\%99I3>&LH4 L?082QTLBB0?X1(X1<9GJY0[;)SWB2IS
M;XTF[P'*EI^A?MD1ZG<0.KW=I5,+PN"M0W>80[\W/5*U>F#UP$L>N#2A@M.+
M,BI6.9!\- 3*U_\A9\<X&O8'S72ZD)!QUW),YM:U5PJRBT\(O^X!X8\A?&L[
MA['6B8.:'Y\J_-.VAK'638LI(_!/_KQN>_ZPA&E&UFO9#UR+OWQK&&*H_;\;
M2'-EG8F8$Q*HY11SQYA)BD=?U%"P:_N8MYI]6'O;^@"2X?AC)\\$7@0^S4]K
M=H8Q;!_'7F&ES$O[M\->#\BF<MW<F3K0Q">3W@$[!R?PK)_AP]\\_.=3:X^V
M?KJCX\/Z40/^VSML'/U]!'/$NSN?VKM'W]CN]W<"WIWM;?T)WWTZ;!#]JW'T
M6=2/=N&YGVE]Z^/)/@Z::HPI$EFCX)YP9)T 6RDD'0P37 ;@*H+IA1YOX*)6
MIDP@Y1%=%PP+Q#OHUKK#7FW0LS]CJW88;6MP6'/#/G!-O[]>.SEL^L/:2>Q%
MN,.WX.9F:L)MMC\>Z#"V0B:E&E!C! :J62! WSPN:"\_< #<5GPW^GWYH_)$
M_K0_;:\)@-  4&[ZVF_]&.'W0:RQ]=K:YH@A.Z'6:EK7; 'RQ+GGK_V^,5&C
M %&G,?M? PLL\*98H!&3%%.<7+GP^10DC_"#9UA;Q+R39A@< OH4FOW4726X
M_X'/;[$.U+3AX.);VK9WT.R@T9UF:2^#:>PG^NZQ_YHP2L3<4D_]/.R="[.#
MB%POVA_()IC]'[9U8D_[:_^:?6UXY[&*R>'I*RW/,MDXM3YO_L_U_O5FV9SG
M=KY$O$2=I5YBHB/G!COGP,@*BI,8L9$VWMW$'GKCW@.S%(QXV /^:L/UA_U:
M[&11MDS.98;+)N9Z<=/;;ANF?)K1(&M.@ 13#C&0B<>QTX\%/R[*4@" F\A*
MJ[PFC!KCHN.*6.>,"=Y0IXV0.J:EO3 N$YK3OKOM-"\77[1 ;,7_?#G=^QZ.
M'>6R\7T7-\XV?^W2]ZW&ASH\?_-TM_WNI '/A;_AV2#PSG[P^MG?J;ZS*;9W
MOOVJ[^R>U7?JM/%YGV"5DE(.3%T!XBCF>@9F%#).1*(4B30?$D/4>;>+B32J
MC031^HT(02L6HDPF:NVYHLH*K:0BSO(HHB(E(= Q(="*$!Z $%A]<Y\1+S7V
M&FEI(N+)!60#94B%1$PRQC-,@1#XI830B_WCZ+,<;9V.]8UF']!CI%V#1K$V
MO5]+U?2U&GQ1PE.&US[<![\5+I%"R_DZ@'_:@+L%"$U4X_Z<MG!)8YZ5P&B6
MZK[ZPQB&K;B=/G2[X0068 >&_[/5]3]>'2WY7XW-?>N-QX))Q*PFH-<"$9D4
M2.Y.:[P3A!KNUFH1&.X8EG'0&SYCH9MMSD(#K;G8ZI[4^L,V3!\&Z!=TZP^!
MH&,F^_+/L64*TG78&62B/1C13,UEX7L,#%&,UH\'F:[_F"7DRQ8I._#*6V<\
M(+ 0+7O<CW^,?_EW !NS94__:':*UREN^O?L<$O,_&*]RZ_/U;@-7*IR(\?)
MZ,FCKS>*K^;<GN5W7&PH9B[\&F^0"[^[;%@B-PB_^-;+AKW\.T%T-5G.KC7L
M%:5)BWYO8C@1\29^P"O'N(67;L$N6PXL(V?]"L!B-M@<LJBER/)7KQN&'B3;
M)3ZUU6<A-S"_QC0N]@32Z[H"IPSVBB)N11%?8^]GT\=G2A'TZ5/$S9M*WO^F
M%S6/,S'$*P!V+-Y!XXV7+]%SOK):A&H1KJ=O7/_<QB>24+,<!_ZT+=OQ8!@/
M:EO1Q[:+O=K(ET<O2C%X#?E$KRQMB ;*M6<Z,F9X#,(%F63D/EB<C!?RNFE#
M8U?%<_=[E1'!HV^_&A^^_=H]\F?;6YOPW,^L0=_#' ].MS]\8_6=CR?;'SZ?
M-79^B/F(8(XD[NWD"&"=P_PP/)OM?O_4W-[ZR/=V_*_ZT2;?@V=M[[1R@M#Y
MD9$[]9/&T<$^$S)0KR/"VGO$623961:1T<H;196CV*R]H43?.)7[$5(:K\I<
MK #EQ0%*<(0K2X*.4>5S#("*93[\2RD2K!37/O#Z'%!><JN:AP.:LWF@4=HH
MH[E%7EN).-<6&8$%T@',&A<4,9JMVJJF@IH*:IY/RG.ENZP&*60>4@+CC&)O
MD.0N(FXQ1\9:BR0)+L;D<13X">HNE=E;+<(J;=">B)"XTKXOLG7&QCV[157[
M19G/+T!TWO;M7XQ055F!M\DP)20WPCEF)!B@6N#HE"'ANIG'E5!=1:B>+G$(
MQ,"=X;D;3Q*@IP<0JMSF'TP(E52B/JTF5&])\\^G)T^%6R\?M_+)$E1KYT4P
M7#'M0@2CP*N8)"-.V)OC5N5WN L\6_ [<">B94FB!)N$.%8&6:95+E5(%D=I
MN+_S8\8K1*L0[6F\]B/T&:LTL=60:\&]X82)L/ ):9N1BQJ-K' !$645HR%$
M+=2STL26%V_+NRG>?O(END^C)ICH>ZL)OD:F\_W4!#-UJZ)@SJY(!;PL86WU
M>9L-?2T(WRQRK?M%\=)4J=,_^[5)BN4HVWI<G5 [R$W0YNJ(;USG=->6^6OI
MS/9 $F/[ZWEY;^/,\^V=S?GRWF9CZP?,_4NK?O0.[W[_".NRR7>//AWN'OW]
M8WOK[^;>SF=:/]NE>W]KGBNHO'4N$(."H!AQ@BTREA#DB#7.X6@#BX^:[5&1
MT%,G(9J49II'Y+%G^4 2C31U%('M183$/!!/06<19DE-^!5%XA>W/,BEH..D
MLIFO:/&5/6^35FL"=C9[!5BV@)9NCHIW3=(?BPG%,-7+[>-DCO^MR/WIDOLO
MF,\^93(X+R)B1N=^<?GH:)"7"">L4R"286X>U1]>T=>SIB])B$HI242Q5H@+
MJ9&)PB//%99$:R8SGG*RH6X(IQ<VI+@O^^S97_H YM2HBC';)45+CU=@7='?
M:T_5O)K4*]V+>777 81*-[Y3,*]G(!_G2^]XM@W /5];7F_7X=V^M',GI]VS
M5KOQX1VN[[3:VSM[/^KM1JMQ]*6U]QW@_.APND_!*<S[K'&RKSW1B>"(A" 1
M<1T]<MPE1 +A4:@0J'&/F@M;D=1S(RDOE>8$](/$O$,\1HMTPAQAA;F7G@6<
M6W+)&VL+%QM?ZQ=87NMW;WK=-7E7JO$S)OU=O+WSD3;./N/ZD>= ^C0PY@5)
M2,>@LR7&D0U<(&65)M(%Q[A]U A_16XOB=P$YBEY8A$CR2+N-$,F>)K;Q>!
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M$S(B12C%EB@6GKX,O$&="EUJ#K\\!I5*!F$]52JG?6OL-(XZ&9O _L <BRH
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M7%B"7"04$9R"B(1;9D"#I(O9T/^HH=K-:%!:XD7"W'!M03&51FIL TL6.Y&
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M) PB.9&(E&%!"LP=#CB?U+.HF/UC3!3+-+$Y8BDIM)9/NJ"@S-D?$14\4'Q
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MA0^?68$15WT=+?'LI;#$XYENU HGU<5T<[Z^RW"US*Y(S4YS;(<"BO:*(4#
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M8F>C#R081Y<RUSD[S?J4WXY>KA$'_QV9X%_RY+YT8<LZ!W\5 ; 9]@ ,]7_
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M]KVP?D7H7OSQ=RQ:RPX!G,Q-83WO]@+P_6OC@CQ(X-,WC VS./?&,((B'JQ
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M]>"I<U[TU@>4-(NR/"QN-UGT>O.IE;W-5W%J\UN-$[H]Y.'9/Q]Y;N%[V^O
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MZ&8ONJ#[@07:SVW2C-6QO@A/_S_'L7.CUV!D:@QR3*0T7'(ZX+7-7M8AY^K
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M&^*04!8T^/^?O>]N;AM)^OXJ*-WM/785P4,.]O.Z2I9DK_9,R2O)]N/]9VL
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MYA?V;!1>W5*2I*\W=].WR4?46AAB&3OC+@U?[N<^W\ZS<C?9Q0O82WB>EP>
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MIW" ?P$\#.\]SQCX/\2FE@%L^T&<)UD%?*J?X?4#,&I#?&^,Q [FO,^X)4\
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M9@F+V^O@P=/!@V([/O+- )FS/[$5G=AYB-@YFL4),E$43?<UT:0:B!U+]4
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M V21F!3H/EOJ%&E1*+"*?5T9%.!G;QT">"87W/Y%*:S?QQG(YG2$YZ9!%M\
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M@O"]%L?1N"H;4+@,V7VE'[]75Q6I39SPMHH4N$:_,I)CDDZ>O,=HTXR'MVD
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MH5"V'MD)WIF<TBSH4*::V/.^P6J).M3UMR>M.RP"M7\-KF)8/D:47\F-"ZB
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MOWQ^H*2-6 C)_C<4K#@3Y'ND:%B;2 7UI1HU@T9E.U)GPR<K7;:#ZR>1]NY
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M"B;:1&GO8BB*>0[Q^C-R@KFL=XU7Y*.+"Q.!HYE!'6^.5>%+5R'S#@J N1]
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MD0@091<>&IL: M=TB@:LN3D1B2U/S8X<%OW@4QNB>D'HE_$?R$Q)?PRR]%G
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MCA;B6>JQ@N-&*](SERO[12$GAV-A[F<4K%%41@==BW4T4R(C12>"(\ B(U>
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MZK8V@A5P-0-DP%5=!<^.&^Y#W"^44 ('6@,FHA> CCI#L<8F 4^O@8N1J0&
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M15"K1=LHV;!A&&"<?X.5@>$60VI,*3B]E-,4*"<7%[9"YB(.%MH.VGDE;%"
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MF<?10QZP(!2-C2AH>9@"#SDH<0+G@K>:,4F!F<KAG+MT1BU5X,U7!:\VT /
MP'",Q.LJEAN-+;LZB>OV?>/SUG%U()$68,'YHES>*<S4A4;T9R=*\VJ6$ 87
M2[-2;:2U@D^KO&EPBH5\D:0WD+EU$:*"N7JFZ*QKQDS[UG,J+BTJ<D\X>2.+
MNI4R-B^)5FO'B5AC5)8?8N2*FC+EWK4HG7+O%$"IL+F"GWE-?ZJY']_W**[A
M!&/P\"F'6-:.+^W).F+K?8;2"SH4(7( *J4W30Q%4!(;YXM+L)PEM93INF17
M4"-KZY%IY/336E5-VY'&J>&\5OO%$EL].*QUONINT\V.OT:@%3[56EK1AN;4
M.D6D93MPU $;(> \.C'R5'+Y\C$,.L"MKXX,%&G6&JN7 [)NVV$:CJ8Q2:!!
MI:9U5Q5:U>H+6T>Y:X.>,72K4'<G/E$VR.T-5O.D I"L\NA[6BS*#+D2@:DI
MIFI*6N>6*5ZZ$_%,@G19%B%<>.5LKI,'0T@.#AVCLU!KDQ9XZ;^O^^.V-P+[
MH @-><#.!221 ;6IL$[&.B';4%9R;N&]>$"9VXH68R/*>]XML I%BN4/ZICX
M82+&[<\X1:7E,UG>OBL_8@)+,,I#E%P,7%]CJ@1]R*4J7@"FA>Y$I((@U.LU
M/<O6OYI J#5#9.BXI(>\)X;H2_]Y(&C$0W2(OD%1-8^LQP9&/']<1-Q3,L5'
MLOS%AY^$_>*%Q I?9%92--7ZPWO2K]#',>WPT"@_J;A #=]]=J8 ;K:(^F>P
M/9TN.<&(!@6[8T2->E'790 .I_J4*55MCT'014,8J/BVPM2]4/Z?@5T2'(T8
M^JF^O0$C2^L<B-=*'T#>7^S*"%&1^W^6P+VY@:<U4HO4!TJI-:(V$KV]P.0&
M'M_C:GRD%#^K$5W@Q)--'IR&^)$9V"!.CC[Y$!S>+Y/+AH"WS1\^9+P&Z3"/
M:K1Z^0#)TK)RFI'^B@=*Y-A<<+9D/?RX]FT%,/D?/7M@F!(,+TS;6IQZB6%&
M3#YS@_!?/_P,Q.UYWSK@F<W Q0,?&R-8-4B;F_.P'8;FPQI-8QR<K_<)Q51L
MG*YI=58:E&3\^68BU('MPX.:,<)^ZZ]UJT6)"^UEY%H,$LFK\%EF!"*T>&P9
M)#+"0@Y5Y1-:G-)RKWKU0F'+]T:XQ'X+K4U^^*EIM,<(XD8Z@'_;N*1ZAWH4
M]0LXV3J;])7W1N\3D,.<YDVD*- (@2U==TN09F1J43R'P8"4LMTL-!LS@:R'
M9>_$/&\XU?H<$ \K5TI;IW0+T)VUUYJ!9Q<!)W93\U6FYC@Z?A47;ET($0[1
M@'X(JNT<V&%<KH5Q^6[+,"Z['?B%=N"O:$PVOWV-;<>G$WR#F_<9=[;RIH\Q
M@5P'HCKMZ/Z+EV]O9S*.JM^[9F4.)7FRG6RB[0A 0I$#R@>2?0PN\*!B4<A9
MUE'BAQ/A""6MV[-7]+R\I3';E /M0D57,UD>&VQ/G.K8_.$^^$G>GHZFL_K\
M[N2QOA@# N<)0MI"RV,,=DF23"&DLD2%\10(+<'86<&JD,JLAG,#-)*R:/A&
M28E650'R59P,""N-4\^8X#LS29?F , )R)EQ6JAQFD5&0_EXW6=Z.HYNQBO?
M*CS,K=L'>'H$EO -IDGSI))@)()22FB749$#B\5]5B1'E,TWV#\B<T1:#U$[
MZ^;,PW*H<A!>S6;*Y,6:NM,72ZE(F1GI_L'K=P]"DJO__$*M$I6/N9RZ[(VD
M<H9%XYF ZC15[C$!)EV!S(217D3K<2K\GW%EYLG31S\;4'3BQ/;Q\QM"-&9Q
MW!M9<?W<]=FP+YBCS H#Z:YBO(,-H)1G;.2.,7(]"H##U\<)R^6$[G!2,W6$
M9R;SHM,+/(7?FL9EJ94\GX[T/: OXPPQ:O^A%A++A-!?\13C4FH9'JFB5C_H
MM= +I/27:^IM 0%C1=[P5!I,-H92DLN;XIF7*=#3?.!XV ZK\BY*_NF"2L;T
M#/@BP1_TZW=JUJT2H?M^G9&4FX(I>JS2?)SV^,K2&Z^89""Q4NGR\#8KV!G:
M:,KZMV'?EP+>XBH:8\'^U=$:I:7J:50QNT%GVW: IL.MND$VAN]J4&_7+M/M
M:UA\O3PGSYF"E&EU\_,\K@R%).=4FM69%-Z>#+R_9%SKIF$ &FB>Z"^FRP&+
M8WE#/@*BP?:]6#JC1;[,O5'0$]NL@M)FR##RK4 '13^P9Q)F>)1[N-EMPCU+
MYZ@IVI-&O,#V[)YCFTTXKD:6XZ1DWDEZ$*"R.A=5M4$\V/;KC^I(YM+M%XD,
M<--7^!>/)$]VTN*7#B?3TIGDNE+T"XX_&C![# @(\%/Y+C%+WR9+6A0O!@Y
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M1%:)%E.:>(K*1(<U=%1^ 6'(PSQX/Z95.B%C[%V0/"I8V!,E:3;X6(?O[CW
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M^R7$;?NB@(#XJ#XQ!+NN0Q0&+5JWXO3G'F7;9EN:6<O)9 OK?]+-2M^KZ,\
M,.SE[CR8!*[H\*9]")2TX\%EM. MX_O45_IH^B"-UDMT/MZ.]GE\%JXA-J3V
M4FHL/&SI39 LRS[2![/\U/WV:I4FAY0<UO[KZ ;!]D9HUR.!\"#>@4J+Z%B(
M+IYGWG#$3K5/)WX\>_L8ZSI7V.U5>Q?-BYR)3)6QODJY,*S'=H$7,L4%-.$&
M]>>;08)PDK]L).-E\)^^HSF@8^/HOJA@0+YK*,6D3VEO2Q25:B@E@*_D2E*J
MBX+&Q%Y0$;(J0MT_:?XH'T@B(C>F:]^ EP; 2[]LP$OWVRKKO7ZN3J-[EHD_
M,X!G*HCZK1!T:-BPQ)SJ%6&111]3F:@@T!E59:*YK]'=HW9LZE7N5)W7PYGX
MPP@U,-!;@OEW8B@=@';9-@#\7-9@A3$),>S.%:TQ]U8Y-DYI?NYQ6^-Q+.@T
MGJ2.C^LA\[.V(<#0N+Q@;G7'0N6ZEE]EY?FT2C[#S=^PPW]D%R,WNQTC7X%U
M=E-K0S^4\!??>L8O^'>[3-*2N$?XD<![[[U 5KB":[@$Z9$+0/GDW99=.Q2^
MF[ P3&)+*[\&@C:2D1M(=XJZG20-BG9FJK(5H%*UZ()KV%D+6C/9N0L:4<7!
M<T&&^6S/>Z9 1"%'>F"_!7US70?-LS_06SS4T"9>P,HIY2\>MN"LV4TRHV"<
M02=I:0C<S]QCNJT9BJU#M7!?PZ5JNON.8C-;.JO0LHADXM:N&XXVX&="'ZX:
M$QR,KH'(I.;#&EGQ"-@FQ*%)XY,A85O"S98]HZ4'T>+)<"-#UFL+DYQ$H*%Z
M96ASLJ Y4Z:UN>E302LI0G'R HEE'<5Z]'A6"+X)'^*+<=^)FZZ!,O>- > ]
MGHX_C&-/LU;9QBW@4DMI?;AK:FC%^6)%EY,6L;@)HAO( OENE[:0*WM]Y!QE
M*>VV!5?1FOJ>*0+%:UA&X:(-3DIP9"? ["H6(83]<U<QC#MSI&3<3ZW /*IU
M<&P/M7(&G#J(O?'=,,$SX%#B4L*SU:0Z68!$G6#U$-#!'#@,MT,B1==XK*LY
MGN$%NINO'7J&WCFX,3!=8%-KE6Z1,JPC"X#FT:2"U%YU8>/K?P7J) 5XXHG4
MAVH[A^A?9-P@RZE5@J/:NQ#X0^[DY)+)9#0$"=)& [!6> CC)N4DD5QT+=R.
M?<P[_&=2M#!WNS'D57?I7$;",2SVP%@3P&F<:(R52HOMT]'U"+[XP_O?3I&U
M%/JO9L;W-C&Q=MW.@3T+<9RSX"9=H*F=Q[= ]QB]LG;23@-E6;@S\;"X(%_A
M;%PV.;%#I=$?V&I+IMI!QJP]B0D@9F/JXQ)[L8OH"*RDZ,=H(9K0FKG#SAZ7
MD-EN_0W0?>E>[D-5-J6=/U:1L&-!=_"KW$2_M7;FU B?*MN]M[.[%STZ.\*_
M_+3[8O?YX^@18#UGF&Q^S(/\V_O3'RA9T 04KF(R]>#2H]AOD/)MX?(1J5_6
M>K <'K1,,7/8&0)2W :M9W)JO/  W[%'GP&,O$CCB6F#S&=<0__N;_5@?T%X
M>V)8QQH"+!!':Q%S0LC>WN<#Z+<QID#[F/PZ[JI?O*I 9:C#DC4C/F!HLJAU
M>P3)1\!S&"_:CBW^2X*D_AMW>895GWV8^%#)*79T5)85>_ >9$QTR]#TW6K=
MBS (5;!-F$&[!LF9D@"4/2)<.F%)3GB6,.GGV*L[\1?OD0XKA #%::7P+<0[
MSZ69#RL "H\X=_S&^,F)\_&(+BPW"?I+/C'EL6>4!WLX,W[=<71E EO,4:ST
M68JSQ2!=CS=?/2M]F8M$,S +[S![HD+ AD24J:'24MCE7".4 .;X*JE2NR8O
M2R(9M#.$;0H4R',Z$M>4?U:!^!>&T^T\V\RF].;@ _-1?MS^^S:<?3;&6E ?
M/ &,K9T\**NJG8O7_(:=+59'.8'2$(8Y^"6_6 1?+<X9(&.W1GP#]+K97)?3
M;)0U+G'M7"XHM%UF:0O7QDTTIN> O'VR("L,I0/I=TD69);96W4\&5YVV5IF
M[-7'\4_R%N@*,B8PQG*X_"NF:5L,L(+ /?&% S(8&Y5.)ARB0E<5P*B1V0D=
M3!0*P+^X[\*/W*><(:;P#.6[;0A.T/E)WE)E#:K#-6IN5)]H^N&S<DE@_4S&
MNDP.!XKO^7!E#\AKV[E YH9S7@(4/HK(4JT*3%?8B [.>.4Y.G(Z70=#^PZV
MP;&8C3'2"P1(I-5%9NI RC:E3P&.RO*3;B.2VA-SI//Y!!3V.4JAY+#G( '0
M #MIX@'N#*&6):9K+:$I!QBWW5])E0GS#AG7C$7T%"NZ9\JH%S4S<?+%<OW&
MW&M5LRS+\,'!337];4*A/?+B8XR=7>(=[8LB30M^LB]LT+BI=3NR?^FL[G!#
M0C$.HKBF0V^0%4.)O;$W#!2M4Y+B7[XIM-/MY![*\?2HL-%3];A"8DBY;_>G
MM9) O<!L"[$C(G0/%T=VP<[AD-?4"' 7MPJFU#_!4X;J8C@)/@G3Y>),2QAK
M=6U?$=,6CR\L@0NI2DD;AS30BT61?6OG_4".?2'GATIE[T[+;S0Q"&2$5QYB
MXQO(1M%EP) H.O<4:H0N5R+60C_4@!54B=R<OHSS.]".OQY>P_O.:@N)FX&[
M)A8R0$B?<7=?7HY&BV5$_1TQ-2DKHBWQ)Z#D?YU9)D/B&*Z'Y@8-?+U$PJU9
MS&%9Y*[OP]GJ7@>G9]+5TKF,_HC#$C&K*>N<1T)>B=#'&KO/)W9/81ZMHY^\
MY&&7D,'X(OD OG ]@%+7K+=N0,#!(K+Q4#MN64FNGG"SCA>P9,R%%\L3^\X=
M5#$K73"QTR@IE!9#)XP8E8NQ'<Y::1!6FA:V%Q!YYC>=Q>P]2QB84GD.%I%0
M"8LH!ZBS8FYDAAGDC!?F359BO'PIAMP$7W,);HKQ \7X%YMB_!T.]^]R-F'?
M=5>-VWS&_#L01U7DQL"A%A@8D;>WIT-MD",6(\25P;$@"Z>8\P]#A*(LMI#\
M39QC^/PD($P8YY!X=X4)[[-3?+( _E&[-TP=(INZ:15TZLUXZLDNHE!)O$.^
M-5F1*2!/%E+]*U\\:R0S&^9L5@?\2XY'5[.6X_)V.:=8"MJ#.2>NOW29.*])
M>MS(2@N#@U>>595"4J%=#R_Q/!0FT+.(\[4LC:A(S8ANFWG8')P]Z#%><?0
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MVDT95AX<"(J&@BPM8]*8MI,NQWSJ:LSUG#,K5143_8WK+.)_VX&_-$7&=-#
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M0\X/%SF"*"J_D#(0].KX6D!/COW53B95]:K D[D<(]R5^P^ Z .1$M&!W;R
MR1MG*8&=G)<(WQ5S:Y<J? 1O#P0@$!0BC4A#5B"K9OX0I$O:*]AW-DGNU0A%
MV_@ VL6R->$W/Q?V;FGFAW'[&X^V':Y]&S3GT>X+Z 38?;$=G131:S-FSI4]
MZ0_ I899$62C;5"SKBV(@ 7LLRP"9T**!$C!ZGF5V--IGS!&1",V9JP>XJ>:
M)A>B'8T%B][8T<F 6?7<?$[L+T^GI3VSCFK?+?B'C<*BWS.8B2SA)P2T._;9
M4YH!R]LLI Y+;\L^2$VPN7-H,\! Y='[_?/'@5TJYUF9I2C6DI88.\#29A%Q
M>-(\ XUC?E.$*7) F#1XXI<UGMQY9EJ,9[P9=-WON/N+FF6B89+<.<^T'=+&
M57)-3_$'6%M@@/QF=P?NO?LL6ACKM*U)LI3-)B:REEI,\ID^F*K*+LKHX]^C
M-T?'!R?..GZPB\U^IYYF\^@1?RJV4W-E?Y,F%UGMA,G)*J*'87U#W!09VN)?
MMJ-#ZM!L>)DR#:S<U#[$&S.JJ(^&-LH.(\XD[DW$"?7IOJB=LZ>#"U:913%@
M:#7_L[5;B"B/FNX&AA_P:] #8Q,*_X!V);_2RDVY@47<8E$^W]G (NZ2T0VC
M % X#7V+VCL7$<+6L3IK'721]T17GUU-Q7;"0-!4&VCK#?"9<<DT8"X3"'6J
M"LX;N)R/2"B\4#PD<@=.*FG/1CR@0)9/ROP(L%!B PF*.%N+P>T@70%4\8Z3
M$:,<)IX&C?JRQJI5G'H6B0\(4VC310U0Q (1"(APQ_ZOC&K3A,27@7:!NPV'
MG&AJ9T2%>[WO^@$ ^3*QX>(H-QW4L7T%Z3H$1\/;-5#;Q< ?2@:08BTQ50!8
M1GA4]$XA'6Q]7V NTIV?V&8(:6)$J"BJ&3N'0S:/:T!M4]HU_@]#*69Q<YUO
MZP81G@Y3BO;UMNP/MK &#D4LN;:"I_2HZIS=]AS^ +6&KE3 "50+%FQ%)P3S
M'$./[,>\G<.;/YU13MM]-G@;_VD&N5?)K*T)V8V-F*-Q:Y>4 <@19$7IFGOV
MFL.[P*DK8S,T.-;)A"J+_D!##%!9\(HC(+J]]IUXSWMC^/]O[XS<'^FG?01<
M#&>P&%8\QC<?">V0B3W0#MG?[7K\G*3E-WG&Y]O/;D20VO-6FG+^Z]83_#9J
MR=@0F1<:)!OA DCL^O27O57$KM]\<.-N[D5;@%]F& ]WCS4NME!<^UOV:=;+
M!<36*HVWXVA_-K>!D0T[AC]@@T%W<S(D#"TFLJ]S:Y\GN?G,<50NWSD"ZT+/
M^;ZU)ZK]<]]N:$$SO":Q'[ 5_U\VFV:;=?$EF\XMB\=Z"= LH4T>7 W[J7V8
MN\E9?O,A")R(WZ#O^=25'L^]7%M-L;\[:YG'@ICLCBE\<@DNBLV>V&-O\,C5
MLC!"^8K?.3D_P&,34NM+<@3;XIZZ(I>*_L5=0K#^@ U]F$G06Z:</[B.2^1C
MQ4S\A,O],&C48$\=$TE6=0G_).W(=?U^O9>PFAK@6R,:1K,]VM=*F,@<^&"H
M?='5!0+P+X,>."N#D,F'4PU8/1$R:MYV(-R"?-S0%Y2@9P+(CYZNW]@&"1<8
M:KBYQ?FAR37%95:5!=-3G>-UY6-,%<(!%G\AN;+71U0)5WU<G9@FH9E"\@[Y
M?&:P+L"7IK;<PA#_)(!RLX2+^YBLA%>$*Q@\"X$J)D_&5&U$!B*Z!6>( :@"
MRPBIII#R&U8)EL3@UW1_?!Y35:7]ZHRJ7@CY@GH?\2=Q_R2!&^T#CHWKWY:W
M@OOS![B?$,>!.'^YH,+0!1BZK%;7B4,82W]7@4M>(Z'6(Y];[?!?]'6?'>V4
MXX1S=5G8:Z!IZ2JD".X39@_D,J48V>UA 5] N";LQ@A,[M$ (MS$PT<:S?M&
M8':(]AFH-K?;TTZC<:I9(430*571TPS3?PH2Q'%,_55*A#<_;C6VCCG<<4[M
M1.8*+>YG(R!^QSC:3@PP7=,7?6\QQ]BJ+6P[ JZ/%F+D$:($&LW=CQM3-Y&5
M%1,LU##I(H*.JEV.KRMVS_-U3H/43%C8A(KUE.Q1*5R?)'*6TZXYIHCUMN!O
M=<<:M'X1^HP"H+'\IAPG<!I>:!V5@:V+9.3=\C<F>PQ4#Q1@*AG#_1/.)L&=
MWQ^\=_:R,J.%XN%<@@-SX)1-V?V6/M ?9@6'75G-(>F&.J+FL[7;-?"(+#38
M6"/G&,7,QI,RB+(?KH#F*:;LDKZ49RPGBE9%>KB:LY$V+N6$T!8[&'@ UWLX
M$[=RFCXZTJ\3FA,JE4-4+"-&0P_6!)L9W 1A,!),939A7=6$_ETJ:)R+,N L
M1>?"GM'@9*5936U:E=\VV]%;82\E L/^JA!%Q> !Y#&SL@@+Y'S0$RYJDE5U
M,T"=Y:KD++T@<129 /MF4ZR[V[^K^\1"H"?*$$9$]0BMA3J8WBIAPY)?IF)?
MI*FN]EG9<!4*F6;PU$&T1]"B&:OS!C]9.L[\L81/!7I81UHJ]/?\#EF-&IT%
ME6('@7-K4I\]*J@;U<,F[(0 + A$/Y8N.#!O'C7F3Q L:Q"7(+(O@:ZGM6&S
MTAF74(U' (%Z4:$6*74%D-"YKP4(>:::55*RPMFF7>+[#LJYA/WV.2?&597V
M=G9B.Z@!%<30#$._1,PW=)KR:99<%"4R[<&H$.L0V5TXO.EGTID*IP%+#2!1
M";3A])^#@AWT(G"]+5EN^YYT&$R%-U>B("2#242O1:FU>XFMDR=/!AV[0PG%
MP;T[70P_QS8X_PQ"!4*:2Z)=0=(!J>VYSPT__;FRL"$OKA!T].;3VR-DNS:?
MEBY'QUR,,D<((,*@)JGL#C_TI^<-CN3$ITJ7GK-:1P@]XG&XB)E9RV>"F%O'
MP40[73XCC[ ,C9DZ) )/'DT3UJ35<>'L_I+7\Z<<W#/$5+'2G[NQ>Y/!IV&M
M*O$Q2#1#>17]^27)+;7)%8P6^42SLG+\Q72N F:X$#K/H58KHK7_!"&?_?,?
M9.N='!71EY$E %*?E_JAW9ZI_2-.RSRE-IIERV,,^4C'CHVFCJJC+*4%[,=(
M$P/W_&<+D18%-Z&"J:AQP<^P%PJ#+GI4)2:R]"![Z<6-;_+0D(]AKJ$ ,RYD
MS7XAR!-:4Q-(XVCGR%JZ\I-9NA&O&6,P_H#S(A%[_S466Q+1F*9J#174Q0@Y
MF#&D%JW-M:%,8SR'IB8T<(0(\!#!*H?#2#V,&"NXI'5W4O;?[<XR]J!V=+?+
M7I6O@LX$CJ6(7[J$T/#+;I ZMT+J[&Z0.G<K8X%5#ND2H#RJR 9\5,TBPXS^
MN+DPW8B]B)66E,I(2P0XN0OR\ 8MUI^B(;@GSH&CX_/#=^\.#\X_[K^+/IR>
M?#@\/?^?M>8;^$!NCW20M,MZ*ROX#O:T$UUF64$&TAY&9<YDXC7S/P<))I?I
M5XP?:1FA+E\'M76S3%3\4%-1UVW71!Q1Z7L7AW3E?"AH&XPALX3^K4804XC>
M9L0_?3$&#E#('U:?PI\ VT-E?./;O,H$&5U,2/N@>TQ+^QCF89GW2/.;0'D'
M.,=Q%NFQB5VB@KPR=W>Z15@@X P!84PPGUEO[5)H]=9BND\\5[HPIDI3M$]F
M7[\75W<!>LXZ&Z4GV%(+9#C,JBNM<2[BNPD/QM 2NYLI^>9X!N27#>J:]O6@
M7M<(P%RUR/.TF2(IQH/K_9IYXX9Y*,\2BE2Z<0!U"K%K*&O(OT7J2E::B3UC
M"\PI.,_T'.CQNCC&D?++-<*=I@AFI6P\ W[EBF(%&UUD*6HD^C=40=)U"S3N
M%*OKL?TUM15S1_^-+I*('F8W3*NPX:*X("FRW%Q@58@5(+NZ*R+H@[5@V&+Z
MI58^P7K@=4XH:<=N("U M<(Q@Q1'(IOI$DI^V9#FC.LI#)<_?;ZW8T#BEO*/
MOL;8P5[C'>GK\EC?&-EU2P<)2<AP):$E!9&J>X6>H>R-@1-BU0DPER 2/T3"
M'2'OW^",2=&4#R/:'LI\H#?7<1S6Y #85RR#P2[IR%PCH>_GAAF!% **SP=_
MI!.W'-J:E>=!=Q+LB+DF>:RGLPK:X$583Z?#1^N9O5$-UVQ?;,?<]%16]6/,
M #EH.966\&$">OD;/KZ6,J1F<E:A-'7#BN(+<O8@%P1<XA>94<PT*1!273"X
MA"I9].6.Q_%@//U;&IAS!Z!8 (=G1MV&$R)>@F&QSC9 <T2SI!,VW;:4WPN@
MUL.EC@YHZ$:+SN('J*E=NQ=$:+%D/!%%8P^CAGC& H3&#?WB:QA#F/S9GX-8
M1<U!!>VBQ$C *?@1P9A(V(@MMH=O3L(=HN"M>)EZU\XF > &MB"OF8!9S#<+
M!]QB@LSA9W/MDNR*5>4BR:',@LS[O4/?^7NNBU@UR0KM>F"!@N:657I*7[S(
M'\H:OZ7M.!HTS#Q=K@81:NQ5U4(Q_(3KT:X%1C<RRQT>^!G5C.IVYFG9E!6B
MNM\UV^+!S,"U>1KLL"-SC6@)3]OFMHEO"2>Z:&%-Q)0S2;TI^/G USK4AKB]
M!SY6:@5.],T50=X \:%6$9FX<Q:OH^K*HJI7+[DK']@]JQ,NG9CU206YYZQ5
MK%90 "KOBJ,.K"EML1[DZKHU*-^QX#&QFD[):?9O&%,@4MH"7D@OHPS;/6.$
MCJAK(7!9X)(H]23#J5A,U2GV<$;WVKU+/.UV7+#=ORW((S!AIM./0DS15EW+
MJI41[B@ );7B1'77";7LW)7D!&P6<\,L:\.951]MN:2L$(6*$I'*$R-9;#=W
MC B*Y9G;C%) /H6K=CF>'1WU$B7TZBA>_-G2B2_]39%\O@0LK-"]MM;XP>?S
M9HKW;9Q/ +5;*OJ1[1(?AO1P*7G%R=%^OGK9FSZ8!7Q;'K^"P!, I^BZH4."
MT 97:X^O0_J?H()' ZDXYQ[,V'WQ2$%-2U [B<.!B@OO%68]P[KC8G]]L*_]
MILK@AS- N]<()&<(L7=PEPY^P*<8768)WN&WI!E/M_Y(/H-.[3[SJ2&[R-QI
M*F.XPR^UP23<!I.P]Y? )-S3Z :\HFB'@BVA_$8;LSO22V5YW*F$SDMI%QTR
M_([RK 8F';\QA72PCCX@T_1!AP'OR!4080MQ<+*WL_-B37(?^W*,7AF&K,,
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M,X==/VOBL/S!/&4:?]*?DP4+S]D="X21-DPC(#KY!E>#O9K.0=0)5JQH(+$
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MKQRQA0^:L-6!-<Z5NA'J\##E "(RT7*+74X&US^#"<![(^9 D6?PFF).*3)
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M=E;_<O@QN2(L7RQS<<6:/SVS+YW-T1=YE%UV/BNZ$ZY1R7H'P(W]"#\XR)J
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MAZ=GOQU]B$[>1"<?3Z.#D_?O3XZCL_.3@[^O*1])T%Q44I-C/4TJ\20<8+2
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M,\6P61 X7NELA>74:T<Y8FY[T8N4Z@<B*;IUE)')D8AHZ&J9D&1F@,.KO2K
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M3*B84IL!L@UC"8R,U>2:I': T:4P]3"I1\VH=E;\%_.#J]L[3H-ZB^*RTCO
M1[W'TNBE:<1K)<)./-@J1KYXW_S: V@19@=(_LZ#'_A= ><II+!X^X(AR,"<
M4C**[4#5ZGE?%EY_4,:MZ<PZW)8\.Q7:5#O@(PZC[IMHA"6L7]X":8XARPS>
MNP^1Y7MV/)O#51*MD:,PRO_J3 5T2QM3_9&P)SC0W+LCH0X+GJNS+,HK:)+;
MU75TF[%KYP>NI<SV)0T<M=._=BX\+_&K7?);=EBU.GD:3+226378&R=OJ_EJ
M@O"7LJ?VE4M[PJ;TTV__!U!+ P04    " !CCJE6J6 @D-$?  !V.0$ %
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M"ON@FCHT(]^E U_N0]/MSM.\#@YENUTWBEGG96E5E,I74V_ >8H?F6$N453
M@VX]@78SHB$%9[U1JJ%2#C25<%;E%,YVDGVBL.'+>#+Y[G)J0+' R?ASW7?[
M8U74/C,-;>[<=B*B!VDT<L&KV[ZYZK:5M$Q$;44VP!RK?69J^WD5"N1 %DB9
M[%7S'<,W(]K7O-UP]=6S5)P1PA<'120'*K ((3,.:)#^&>Z1MVY2?ANF(<U8
M-.3+12/75#7-_.$-J#8<_0^M]H,MI2A+R3(SMA[J9L$5+\#JF+)-*A+8PU'H
M&I2#.O+^?EC50G\'<:>OPGC^N1ZT>4P>Y'2^.EJMOK@\??.?8YP3@*-O5^_;
MWMV7-KEM2T?:7@Y--ZV?(ZE+09-913B*CG,C=*+(79+-XF2]HD8/Z(3"(I06
MI?6,YK5@^CG^]ZI1&V:"8CD!DDT&);R&8 ,';E/A+#M.,6_C46\-;DC>M UO
MMCNS=U\]-3Q=:$Z8%F21UQO6>5$<+6>@=*@H:N]9$1G8C"7&4F(PS??37L P
MI"RR'U+L)?4^*OBO&F!VR86 B=R[I@%:K<#E($$XH9E4-@C3>G;A9D2'.VKW
M^Y%?RE*803C!ER) %900G144YK)HLQ>9E]9"V 'FD,QH0U;M?NSM;@H\2/SX
M83%+?\9ZBF':*$2A\*BK?SB:36@,75T76'Q;'=A+8]X(CE=EJO3).1[1A\F$
MU-.D=H\K>X73,MX\G-P:Q:&7[_C]]*_EDMW'\/5=S73H,5TLYN-XNJCU<1]G
M[\*J8%X6Y7E6% ]P\@G*I'HZ@0?*O',*P9=D6F>N>T+>^Q"--'Z&93:GIRI-
M0M>-RS@MM7Q^\RL%1:8CY43>TD5;CV6T!6+1")FYPJ.@/Y?6 >YN2(=DI@_)
MSDLG<O2OYV9!TD6(KTB23V=IO*X<7+4-O!$V)W_C&0DII5K9J$0$)Z,%BO>D
M*RP:WCR.VAOTH":D[I.JAU7_T (0&M.J4V6W/E]P,7L9TE'5Q6Q:*U'*K1YV
MI:J#Q"?-T=Y3^-*OU <2W6@5C+=% S/"K/KX.JLD&,YS]KH62;4^\.*^HYL;
M;G_SG?G(&6X5,@W<U^H#0>;$*T20G)(FLFY9\]:;$/> .ZC2DD,2]<JCQPZ@
M\K;'V%T#>!6RW2(M$6L7;LKG66)UN291XAU5 6E<#-PGFYNO4>^+>4C3C4,E
M:W/='R32>1GFT_'T4S>A$9S@G%X_IK\?$=K=XY';K]DR:KCC"!KY]C^65,?\
M]#/.PR?\[?0XXKSNZB)\F#_4VW=O3Q==K4TE="-N,@6QE(YA,0&4+@F<X &8
MS$D8SR,QH/%#?T>(^]K%:VYWZ3[/0C=.(X,6I;("2HP"*/<HX'2L37]#1JX3
MIS3V,/*X&N"0YB'ZY-I%"]>?%@]BSM[C9YR>XAS3[--TO+FU]GL'U-T-VUVN
MWM+$[3RJ5N4"E^Y63R,YZP1G1=8B,Y".')FRY$^#8PRBT;%0<"94:EXQ< .>
M?<W8[],XGDSJ%MCI8A[2#R=%2JT%>L4A9+,<JH)@Z:<D= HJE,R:]Y:Z <Z0
M3%0SAERT1ZW4T2S\?_8#G.]HNE'*+FM#QM;KB% 7M\%;D< XE9,R27#;.JZ_
M%LR0 O;>N-%&%<V8\70RF7T)TX2O9O,7L].X**>3*XZ;]5IR*ZT'HBBCI-5:
M\(:2@50=M72&\M;6D>!VR.ZX';#?*8G>2-.#E@X2V;RI9RUUYQ.<W:PL7UF?
MT[Y[3+/==5M&,SN,I%$<L[S/\UFW&)520BX"P:$D Y%DJ#M0(N00HHE"\!A:
M5\V?WWSO":BS S.75WQ?G\:WY?=N52>U61B\ENBH!.FEMP@I5RYC2G7[/%E#
M\INL9,N9:MVF^:X8AQ3+[,:22U-%?6JIW63F#RC/H' 63-'&TF@5)9"^<'#2
M, @>60VJLC"MGXXK@0PIBNF#%;O(^X#.9MF,8UFT'B;/PJ0ZS0]'B(O7TS*;
M'Z\WB>[G=^YPB_8N:-?QM5H>_($+&^5X61D39 0O:G03%!D"S8D23ME@K$/7
MO/O.-5#:6I?SR_XVFZ9U)(>I$EQ'X'Q5KQ+JJ"FC4ZXXC$8ZUWS1[C900_)%
M+3ARLPW:5RL]N:)S6&<Q?^"4[8N,(+#V=E%.0A1<U<8=G PDLT$W7PR_$=&0
MG-,!:;*+/K;T6>O7ZY=:!?*/O_T_4$L#!!0    ( &..J5:IK$JFS&\  )L5
M!0 4    96)S+3(P,C,P,S,Q7V1E9BYX;6SLO=F2&TF2)?K>7Y&3\SK::?M2
MTM4C7#*K.,(D*22K>^X3Q%8270B #2"8R?GZJX8E5B "#C=S1 0I4L5D+(0?
M4SUNIJJFR[_][S_/)C]]3?/%>#;]Z\_T7\G//Z5IF,7Q]--??_['Q]_ _/R_
M__U?_N7?_@? _WW^_O5/+V?A_"Q-ES^]F">W3/&G/\;+SS_]9TR+?_Z4Y[.S
MG_YS-O_G^*L#^/?5/WHQ^_)M/O[T>?D3(XS?_.G\+]%);11UD*B1(+S*8+RE
MD"WGTFOMC''_Z]-?B+.&6I^!1I9!V$S $Z\AI1AE$DH(HU8?.AE/__F7\H=W
MB_03+FZZ6'WYUY\_+Y=?_O+++W_\\<>__NGGDW^=S3_]P@CAOVQ_^^?-K_]Y
MZ_?_X*O?IM;:7U8_O?C5Q7C7+^+'TE_^[^^O/X3/Z<S!>+I8NFFX?  ^/BXO
M_N%5-/*7]0_Q5Q?CORQ6__[U++CE2CWW+N&GO;]1OH+MKT'Y%E &G/[KGXOX
M\[__RT\_K27GYF$^FZ3W*?^T^>L_WK^ZC70\7?X2QV>_;'[G%S>9(.+5)RR_
M?4E__7DQ/OLR2=OO?9ZGO!?]=LD%E"QP_F?YM%]Z8_J,0.;AW"? [Z9I(7A%
MC+L^O3_FB\^"F+([GRPK(K[]V57QSL[<N*: ;WUT!;2K#X*S=.;3O";4:Y][
M!><6Y$V$Z2S-/^$FZL>SQ6QR7E[NQ;^&V=DO*Y@O9M.(2T\1_X(_'L>RSWY8
MXI]EXUW,\ENDWFI'6-R_B.074'9>PM?O^O_L\NE7EH*<&4_'Y=NO\<O-(PK<
MUHM*?RX3_M/X\T_C^->?Q]ZFH*TF21(M+(UX/ @FO3(Y4]0'&75Y4%G>=H&3
M6;CVW$G9=6<7-)DXGR:K[X[.%_#)N2^CBP]%B:17^-?%2&OFA)82?.)XFNE
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MP\T3C$./TPNJC2[N8C[(ZWI8:K]C/N)06N\BV$;:_FTV3\$MMMED2=O2\$!
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M4<XX4%;6GM!C]-8*D,%(Z96TSM4> O98_>H^-&FED@?I5U\7X,I,-$1ISGT
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M-J(T.MFHE8BUC<#]:$YUWW8B=ASD<G;64@,?XGU:+.?CL$QQ-\;=W]W681V
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M@D@H#9E \-&#,#$C.J5!A\"4=R:JU+ ;SCY8/XRG!NIKT"UZUVMV 7#[<AT
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MY4 EM0S*FQ1UEF4\MRN3 T10 9R6I=3 X(G >,[5YYL/S)<CDE).1I<NVFA
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M^7'V G^*JWJ?QM.O:;%<-^_Y]'DY,M$4R4I(2>+R<D*YFEAZ![)$8^82?WH
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MA2B5Q:U)1G#&!."6D,R)%RG[1TV$[@T/F_"@BYQ/U/"0,T&EL[H,*L,M$,]
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MLE* \D;KVMT7?P#PN@V._7G1*I5H+T+<;F.:/EWZZ9UNQ7WVU,AR:;&?XQA
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MF*S^,HTG"D\85F-+PA!B-Y" KS/P\^O9/\MG#[%=W3Q[7$7CE' DZ3*0U/)
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M$<]L( F\3$@M*7CMS*U]L;Y2>3N(9?=%38\E:E__W963,;_0D3)A0R)"%C-
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MJG@Z$_$:C6/+E1,Z:$JWPWE[.0AV+CZV-_!P-G8UR5G9";3!\<=T_B?$29Y
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M(:D,9.#,&\K7,J2.KC0RSY*\!>@ #9 \V3>-L>%"N<.C"=Z%; M=HS(=\Y3
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MM5<H30!F.31(#5=?8M4(@ +Q#TL92P""DBC9,6$39F77+VZC5BXN$8#D0T'
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M@&5@K=.MMQ*)]&5'#J<+YY/HJ>YP7.K;%6H>F(R&)T7+/LIJ>?@I[+V=Z8O
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M6)GDE-)CLL'0%NI/^O(>[@O'7G]\[2B0C&2+GQA_6 '3[ !U:BO1:QEIRVL
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MUQI]%-G<]8CK9'M_VA0>>)JY/2#"1?=BY8PB7Y"T!E;;?&O*OLOGX]?J>]X
M@F-+A)O%91?<0)31S-E?6U6$N& 9LAS%55_.&"U)Q61HC$QMNVUZZ3_P:);D
MFRSWD-@HB=+N6]'W[#'0PP5I'0!QDN<0$3/Z0DZ3SD",]3]NI8T?*4;:_5_I
MX=_=];N;CYQ#*Q,HT^P!'M C_)Q3E&EI[?M^<L&OUS1\J5"UJ^%W;C'OJ3S0
MG]ZQ0'KEONQ\JS+=%!LR;_M&%)N)P /R[?4WN*%+):'+[[LM.&262E=-C<(\
MY5^P4-J3$E-=.C;X?[IA8REM%(EA71+Q2Z\0)HO=6'[RJ4^$OB_=,?Z<%'-!
MZ@#_N^!,2+#E+^FB/W,:%VC5?"06$[1ECG4[AWGB,_!SD__^D$X_QY)<YM,L
M'YN&"NV-&_#7!#TQ8P/ ]BHG0)\J[R0SLQ1I=[SB/]O!F/UQ;,-N:W.?_"*T
M_;1407!F),MMP?&7"VREX1F)?;HFUYH7E 4%&6/,Q-DB&]C&XT]_F?$&FD'V
M-E4S#KH$F([AI'D;ZK8%5*I?L&XHT!GGW(NL?^R]E?6-9O?PW%84EWCD:SYQ
M^*G,AD"8ZMAS+TT>\_>=GX<KW;")UW2E% 5%=58WX[P>NQ-$9*L.'I"@A-[4
M_,9F?#?T/ _C:CFT]A&!)>(\E<RJONO\ Z]H%R9R+^;VUC4]B7?0S))@3:)O
MF\/] 5/:B;;L1O(VB7L1/8\J<4%**2*9/_?R@_& !1[8/-"'Z/'% U.;,SHM
M23])GA-LC*&D*9 <KX,8\VW5V(<NH:H?(PKZ!ROEQ_8SSB&0*;JJ0QS4E$."
MIY+5?DK!,+]>>N%IR<WU6YGL=^O.=*F::73I.E0?D&\-UVVFRGQI\AQ7I&_6
MF=5\.UI)I=V@*]EQ&\J);GE-"SOX0*K)G/4:9P%Z+@Q2.NQU@(B[-0NS=EW@
MIT+B3YZ?#M*37[5"=1K0(#0'O?3<1*M[.&>^X?8Z;Z]C#2G1'6O4[3H1>T2U
M2B9+G.]U2>1=6LB=4JN1T!]?"\1%$B!/T\(*ZM2'O?IK%NE93E<X\4#4JZVU
MA8JX (L%*E/_Z#%;>ET%+MDI64:JU3Q7H:[NNK="HP,F\3<<5RTBXH[^"-QN
MU;60S1R.KXG?O+!.>XV&^KAJS#1UW;.+R*B"\ZD3.HSFML?2S5LZ_V8Y$;M8
M=C?C[]=B20?[R1N]\8 GXGZZ8!^,'W,*1OE2(BD^</OD!&YJ<JZ]!*:+!QY;
M-=PM0V0;ASWZP'ST*PD(<4!++DFAY88M+S\X^&B@A-S>ZSTWM (^'0E=RY)@
M5! G?TJ^[:HC1IY.*2>[HUXAMM=O\_[ PI$>FNA(6I^;K^ZIYV7I<5)R@!OU
M UQIDVCP0+867?AKQJP*2BC)U8$F5^X!E?=LSPIN.;,5"C(6GI**4&P0\@[X
M8A_[M_3C''(&SQF;,ERPLQUA/3>CN#$%S+Q3T%33O0/$ ^O0(-B>$M3A\$=7
MCK.5)2[HSQC"MOW]2,LQ+Y9/@WIXQO>, ^:!G^>[[3)A[)>8]S>@U&", $'<
M&!" 3YY"932_9+SASPB57YS,RXQ$9=?$Z-/TC'86';>8;^>,BE:?/.FO/7$U
MZ3GY5C*.MHZ@8B9?#:$A?&B-%WY?_'[1%H(V8#Z(!Y)6$,-2E2/GJN C'BZJ
M./?W>,![&0_XT^ZT/UP:@6\NBN) 33B:JZ!_\^>?.&W+H/4'S 1OP9_;$LW6
M+9H$(U3DI6VO0J2[$9:<B4J6A\GHY]G?^1,L7!HC@!57FK^^=A+LCXZMD^BY
M]T BMS-2[H 6U6U_U9MG?3184Z[M=RMH2!>,^$J0[QV45$W6*@VJ;3L?.:!0
M4)M6)@YX@L4Y4N@Y?&2@Z1\/HS"PP^WSSQ]XJ7?S/RJU<8@)QY;4ZQ;TBS'N
M2Q&=^H8@D'!+OLW]!,W5DX:8ZGYB#+/](C(#WA:#"6^GKW4,X+0/5^,!LU2B
M=<]O7!H>[[>5\$!=3"+!&)LD*$+J2/IEX6\+@'[.I3(=Z%<K)"T&W5PJ(EC]
M5%U$;7]9#;>SW0XH684@DYA\*CK@?#] _7&^@9?6-,BX^=I<A!/2_V:='YW@
M;+3AL$"8+#VQ/:DTJ?3K+,KG.YLXE,<STGG4_4:4KE&T4BE_/0L>.";ARR\+
M^)*2/+ZHKB*@K9IJF_"D087B"8=CSYF)%B8/^(/J ]:YMRX83@;,+!W$"!@Z
MSN6UKMX4$?7 >D@^W$S+D=SQ-/VC[CJY3--QFD]L<\/ ^8%KD1USZ]<GG>Y"
M6[?BHO<VMWGZ^894RL1#CNRZI-Z)2#&I\(!F=PMM1P/N;J8RU[QEJ:O6)&*/
M6O;+9<VVZZNN(E+7V!/')6YS.MR<Y1'(-'$2)X:.RY\^0,KB2T2LW2JGI*AT
M<GK.0VB$R]XV_KIB;T9KX269'Y]XF/#$5])U4Z.57EF#N#EG2*6@RQ:@48,@
M!&D&RKWXT6-PLI)QS,)Z>L+>R#(Y^SW*L\L- 7TMK%*G_YEMMHN^L=\'E&*X
M=@+T+"#(*0(2:N-3]%D:_,Q[ NKR(B/8S&,9!.'4@PL?4 ,/%?TB-/B:HK[J
M4;J;CTQ5DB'&;W8@9@L14T].T&\Q_(P'ZY=[E";U8!T1BWDK- %>23-N5L4%
M-WA#YFX(E[^A":>SE<7*@O?J&$5[F[)X7Z_Q\L+(H2A:O(L.6F]&-'N4YZ!'
M6IDO(F5Y7(GJ;#6KB*J>T$\^_\IEN!4YC'S+=Z)N)%$/=_JTSKNZA<BJ8GOW
M@S7@ FRWPBE_"_.NSAH:HAKT1NUZ$G''Y:TQB. $;TKS$=U3'9W'/*>A#X,A
M%?4YWAATCW!9)95^4^8,-;TUA]4[5=FI++@_I=%%^7TI^\X(9'ZA><2ITG]H
MY@. V"*K@ .*'"DID!<X".:4 ;@O1/FBC-.5]'$J/,#<5@)3QP,=<G0")73P
M,D9N6D,[@^>56XE\V.W*"9LS],N>GXF>OQU^VOVRE;;NB>)L<GFXQ@^SR/$#
MX>8*D3?-:*368EF/7A "=UVJ^O;.X0A+!9$ARP[#$-3YN#EGA4!0L7Q<Y)R<
MN[HQS/R+)L75ZYZE(K@3RZ_K^G@Y@E'BKT,-JN\7AK?035T@-1_XMIA[\\%Z
M]$Z44A)7UH('4MB/"XY?WW5^/*0C^0#G!:[W.I3G<E^PH&2ICLLR%\G<;/T+
MJP'"9K2]6O3Y.OG&DV5*'82+BBH3B>R5W]YE#:[)4=UZ!=-4'6#=[VU[A'Z-
M_4=91>QP.I:T32FU[;66%I#-2<?BMY.LG=Y^O<7H\6CGP[GN)[D=L!M+&]6!
M;<K7)2['\=QE'Z/G!=N[Q]S#IC4ZWD3&O^)"WU(=RD"MXPS0T Y8!^@^5W>:
M7E^&_+/D3>6F/)6Z<.T$3]*OA;[#<"7# %K%ZM5[\Z/,-\6G9Y;6M4&9VT_%
MK(.:NN0*"7AIH5)S<C-)BP_,>-6&@)?(*^4GT$\3-;9*E+MXBQXXO7IFQR/@
M:/0A-$MV0H>95.Q81=!!35HAIC:4$V=S<*)$4+L>7'.0=N;=#K_\U)/695#I
M63YY3@Y_8Z,]*4N8+!VKGPR4T4,'+;9%%*G;&M9@J&B9VWGXAO5$[!,+:?<:
MB0F!)E:8RS_>)K@'7JB-<;T.7_L(P1)-IR:?[]B%E4JT@IQGWXFB0;>V;;#4
MJ_>A3.V?HQ#MX61,J 0"6XZ89GH+>&Y?^BW2&QI=Q/(;Z.P'"W=7@[+V>$LU
MC7%@@B20VV$[8Y6%[D.3+WG_\^]D\X@>>=P6'CBE8#ZCIQ-J_O8C3>%23.+Q
M. ^8]F9:&%$%IXRDR?D->I;0X$=1* O02LM;YB.O4*&I)V.]RDSO8')@XW>\
MQ@N2IL;"!QBS@<8JA6:O+U*Y]_C*U@\3<*#&<,M;"%HQ5>_@)00Z[DK&0KKQ
M^W<*<-VTBRL;CLSF; IG9-PA=S!GS$>ND#E)RZZ?V3<)6I2$EC$:AS1/^C,2
M-9W2)'_MLSD_IDJG[])_T5,.-0]UIO.1/'K'L_/J!H[#.F<\B00(3XC^*L@#
MRT-#496-5.@'VLA/+,+!O!C6HB:(!A[@D9V"Q 7?_R D."-Q#::'?80'.J<1
MBX-X@-OMO'G#ZF>R_(_JSK0[>=66'&"PS#V=O#9-N_P8[/"S[3-__RSC?< J
M))!Y;W*=V\.^3)/"P)NQ]LAAI-2QR+HXSKUJ]O+OT%PA,BVM#[C%'*=8GQ?+
MTO ?JSO"=^X<< (J([DR^U[MGM!W:)G?J[U[(G>U*=B.,98SR:T^/Y\Y8=-\
M*%22H([B/E='JXC;;MX='MH92FZ*@C*(^5<VI)BXUQC)U13S*;UO0";,#/L(
M,=:D@@>>KA!$)IEB\.:1L-UJ4= :A( BD-R(K3%:G'>1C,&WQ_D7"4?\8SL!
MV <[-6.W\( ^!1Y(&TXEWQ;X1SK+'DHZPV4(\1&0\>0B%",HLKTF?4@0RBO\
M#/FR5KE&,B_'.'HFSB#:XZH<0\P:)Z]$74G\\O+T=$GWL,.!&VHUY<[!0P:<
MKNN>;K/9J,9EY).O'V36@WUTNY)LP#7_D_(M>+EWQ*&ZS-EB6<Q)(ND[7 K2
M-%F-]UXYSY3"T3#SY* WU;3,NI;LJ,:^O!6]GAE/X]39XJ2C15>:. Z$;,2&
M+)4X.N$.0\/IN'9Z*&D\.5+PR0\/"(^W^.3*N;B6.FG&]Q?J=<Q4CB0]+K_N
MX$]X/$K2U^-'@$W)T9;7R$+7^,E 5FSKWH6;K8P9SC&#KIL2L7<\WYGQ:X^?
M%9R8.?T_3]8WGJP^ H<@L6NX:V$MG:4%A,OS:H8"\UU65#\\,.[D?7W#\LYB
M\/V$M>5Q,>*5@OQAQD,FX"K1;HWIP@9+QQ!RE+@B50"]K@HI*\:OTTYAW_,O
M;JU;^.J!:MS)W,34^,,0AM2=>?2&\J<I &<O473@$_1\RK;KI= ^8<T@&&7#
M<[+CK-O+5%53]_P-1GG(A[\:.4.T@ =(<+3)- ,4QAIGL'$W"8B5?W1&$WX+
MG',"T<UHU+)0Z^69TE)<!1C:[B6(@_].&2WZ2GBD;.C04-UCRX8*2U6V<38+
MV&H$/_CZB1F["-NL_92D@JNLK[T@A2B5^'BK^PU0H?;P@'AUDDD;V5HJUS[O
MDXH-POFAS[[[%&38U)R*CI'T^P>L\H[:N]1K*5YCE;;5[6 Q9MOCIF[H(?^Y
MM"Y[_+$BSHEB_.Q=WD>AIJR^1T0/I#/7L:@)KFZU?Y+\8/SR]D*HB2[E5G:F
M*?S.L<RSJU_;3Z+SW 2$=?D6]E8R'I!1.F]>W[G+WBJ@<.5\S9D:HC4I-?",
MWBMN*^K3<=Q'LLC7WGB3V/DD'' Y)*/\+>KZI:YWNW0>U054CA\T)8C@&#RP
MQ<GEW?=S;^G72WPIMD5W,. B[A4# 0.^/DV_;OJYBEN"0S%"M&5KTDPB+4W*
MUB_VJ$R,,J6OJ2"[;#'PZ#O5!AM1,>7&0^]=-YW6AJ9MQ0,+B\C/;#@')RTM
MQ\8FJY1:K51SGM;T(6;<:>24@KR\I)H_=$G$Q_^+IV*"!& NN(ZXISJ8#3"2
M'8/;:T+?5!?,%@5RN=DJ2&H\X5*-APNW);@$2YU2&\\LA^I4S*Y=$9R%4[C$
MM[P]_'"F+5^>^NR'(08W?B:DIE$UY#0I])Q2SO4ZPJ>Z$'HM/C5&D_[)A9GE
M1WKS^+H<)8X,C/U(9_%>/!YT1V+C<M'.4GK4^J-MML3E?0KR=+%E\NWZF<0)
M"CF"XW+JM[/WD(H1 !J3+//SV^P[G0E;YKIV* :)O450&3)N%N8=0KOI,N Q
MMJV(J#]>AZOHQP-GRX^#ZQP_,WDAFF@.@J(/)1"AC<&6O)T,U*OK-U'%5P.#
MP01Y>P#&Z.*@@YH(F9\/UKAZ@<J2S9B%QZ..7LQ6 A"CJ77& Z@G'H2[RGR
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M[F&Z1%%&M4DW*98.#L0#U:*SE2L;1@2K514/U'+J$/Y%/O04#[0,!F+7X'B
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MW%I.QJZ22.A*"X3BBFHGJ\5)EA<^N@S8NFI.1@'^ZIWR+EDPS='DT_^#-U_
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MTVX_])P61R\_C"W]B^M7 ^?PP)A=AEYEX,E^RH]0@0^1;P:(5N3GCE^LV[8
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MZP.H8P)NX;RC72ADT*[^=6->BU;*5,72U$\#U/UJZP[G8/ONN6RLZ!L$80S
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MD8/MK]QFFH7.E77ON;KJJW+(')1?>_BJO1K)>&V*'VQ^IQDK,568/(M?J]_
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MDJ?\J1'36GWP\]J /X%B 79M^!^@L0+\8>T K2'_GQ][^7:3&XD-"/[ 7#8
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M2J$@,H98, 0Y2Q,8*<ZQ^1^3?BD33PF:&@VL];07[$TMJMY,<!);-RX(@=C
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MDN<HEI!SGD',50Y)%A,;V9@K%@FB$^Y#6B?D3(V>=M1L:[E[EKT_ :<;&P4
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MG,,XCVQ<+TL@1=R&PK LDJE41"&7$>L@:VK#UZAK_OS5;=BZ8-D]A@,C-/"
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MM@;88F5=66:I,AN[2$B8QUF=[U! S@6'C!&;,8T)1IV.J$X)F!K!-SJ"K9+
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M4E 09E<A@D*FA VPC%%*L>92>QU3G)0TM6&\C:Y>E[G\B]] /HVIVY@.@M3
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M[M")LOOQOK>2]_?EXLNJ%/^X8<M/RYIW9%WMYD8MZY(),TGL?0)/(4>),(2
M<\ACQ:# .E$1S66.O)PG'61.C1P:E4%E=;X"#VP)OM55IWXN%D"6\SE;5G;%
M#RJK_)]\KRK/=X'KC6508 ??I-:8?FDP-0I;Q^M&Y;:FEU$:U%J'O+ITABC8
M#>9YB2-?9#I#<'B?Z?YJ7V_'JMI)@U\[9K7E6JJOY2O59,Y0\IWY#/^/V757
MLTAF<1XE#"*1$8@QS^Q)&H8RCF,I"$+(+_NTMP93XZK&@"M0;OR)YM8&2UM/
MZS(67(%E:\<5>#)6 &WD^SI7^G:5&XL-V@$#<]H:^ZTOUX<&^YL][#]OL+<&
M@'==V/?PY>R)7S!W3U_Y(WN$]H3GT&FT;T/]EVI%$W1^O9"OZSJWM\KL#%5E
MZ][.R^IQJ39'&7FD*!,Q@3(R>S<<)PDD-&:0:DTD%[F(J-,NKI?TJ5'BCO*U
M8]F>^F"K?^_3);^^<5_-#8+X".NZ4&#W6M]Y@Q9PI><N>_0UGS<LQU9__HU<
M6H?D>=&D]PM=+N_K>YU73^O"2#93Q"R*B,#"K 0C'N70+ 2IV:?J!&8DD[$@
M<1IY5D#UUV%JQ+>;[O*@%!K8,>,*\*>M'TMMB^\!>X\><SQO'[8?ACY^'Z0+
M+BA-X@UB\-(D[AJ\4&D2;XA.ER;Q;ZH?87Y=FO7GX_*IWIPW^_2UAV*21MH6
M9<IP:@M#1P023',; *V(DBH2L=>MXDE)4R._M:+-$9,?FYV&TXVS@H T,#/M
MXW,%V@.Y\"')9\$(Q#"GY8S*(V?-?<X6YU_HQPF;PO7;Y5FUDR692I'$2D*,
M\P1B$6E(4Q[!B'&"LT1AF5,W'S\G>3X?_CB^?5;=]AS_ONX U2,-0C?&;F01
M#+>!":,&K#F:W]'4K%6&"#)R B40<73+&I4\G,Q^3B!N+_F["7Q=,FG6+%^>
M[GDYGV4J-\P@,YCG-(68Q88PZNU6IE$6Q9SPQ"DQY$'+TULXU,J!1COWJ_]]
MN,Y?]O<&8?"%@9/]7M?Y1VWM=8&_W])H5_9'#=B]I#_^0%_?G'?%7'U\K%><
M,8HRSF,$I:9FHLX9@31/%8S2**4,$TTB[N>0LVU\:D.O]2RQ"H)&0U_/FQW@
MSH_ 2^ 8>!!Z(-'#K^;0Y N<:78:&]F#YM",0[>9(\_T6TX_+RVZG6RW"[XX
MXXF("()$IPCBR$R4%#$.8XE3B6V(A_2Z=G&0.;4AO%-RES4E=^TMP&U9RN_%
MW'$V]8'<;8T=&,B!!_]AV>+=>Y-!UML>  5:=;M(''7M[0'!\Q6XSZO^@7L-
M?7W2;4#@:S.@ZM)TE5F3<XDD)Q#%R.SD$VK6Y%00J#,4*:$03:5S!>*34J;&
M,(VB3<J06E4@-KJZQS*=!K6;48)!-3"'M"A]TJ#5$KP.BI)[A%<0M$:*Z.J%
MFE<XUEDT.L*O3K\[6KC56?5WPZO./QSLMJ/V/JQFN<""B#R&<2XRB)'0D*&8
MP$PD*(]9C#BZ]+:CD30U4MR<YM=.RK5G<NV-7'FZ(Y^&MO?-AS]@+W+S<=4X
M&P<8YLY8#'?QT<IYZ8N/?7,=+CZ>O7!Q>NA/JSNUM+$22W6G%E7Q3;U?B/)>
MV:RM'XJ%>K]2]]6,<9+$)%:01R*'6' *B8@HI$D6$YY%BF5.1RQ]%9@:F>PF
M,ZX- 'L6@,:$-L4Q^,/: 6I#/)U&O#O*C8.&A']@:AH ^4M22'O!%SZ'M)OX
METHB[05.1Q9IOW9ZUQ94YJ6[ZX7<B75O<US.4D:P4!I!2I#A/\4BR*BFMDHH
M0E@SE3.O55.GM*F1W5K9^IQ*;M7UKB78 3!--5$RP9!S1 W 5$*6D 1JG*F8
MIA&2*9LMU&U=0VE,G&F#\X'H_]YPNTT3P;[2@>>$/<1V4[JTJ@8MV7@>D7 %
M&SMDC5VN\;S91XHU.KS4CZVW!3IVZG,80;:X0+&XO1;FGXK5GN-UU;C4YDPB
MF:4,)AFFU@DZ-9S."(Q%DA$L<9(PYL/DO369&LL?KWE2#ZG6%K UYIE_2P]W
MZ/X]Z,9=H_3+P+PV7)=X$]_%< 8BQ?YZC$J8%\/UG$PO;[#_K<IKL_*Y+9>F
M\4_ZYI'/"_%7Q>:KNZ^F3]FJFDF1L2R-4K-8XQ)BR919%R,%T]0&FDB$$(E\
M[UC.R)P:>6YO7,1&\?K^I58=W-6Z@U6CO/_EPKD><+^0"8CK:-<S6YWK:X<&
MTD9M\'4H2/UO;P)".UIV/FW&AHVYM@GV%C[?<*#4>Y[8.=S\G&MI]'L@1]..
MW0JYOMIS#5U4#V7%YK\NR\>'UW-6584N1%.:^$=1S01)98;2',:)U!#G208I
MEPHB(1B+>&YXWBM<\(R\J5'Z6EU0ZPOV%09_6)5]E[QG '=<V(:#<>CEZR4(
M^J]0W7 )M0X](VW<U::;Z0=K2L?7+MVB5\_KRZ0)T9FF]K#/EB//$(-$Y@3F
M<21PE&81XZC?'ORYJ,F1RE;3OMOE S1]]\.78#3:AK<:IU+/>52"[UL/!+W0
MQO24P:=WGB??Z)G"P-YDOV*5DO9J1RVJAGF62_-%U)%FKYZVC[2)8ZZ_LZ5\
M^\_'8O6TLP^N[X>^WK'%IX>Z3OJOIHE5]7YQ4^>8GO$DI5E$.#1[5+,_-1P#
MN6 (RC1-I!!FC9/ZY3T82?&ID5>C/BAVCJ+*^@9V92P 96,"N+4V*-G?P6:T
M[\*-.*?8VP/3<&T/K T"NT:#':OK9 P[SZT3>-6F7X'V6]D]MORT_59: *Y
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MJZ&J6B6;4_S[A6D^^;6B^*K[V2Y5AU I%&+2J%EG=9\R&L,<8)8CFJ$X$]G
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M)"K. $4HT0L8"@&&!05)+E/%9)80CF<_Y(HM;:EH@!<N#U37EY!9?*W'^^G
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M/='V2$Z/2OWC#L3AZV-DZP.32#@W_9S6W[9M-/4\NCFWGB']?E )U^\,DN0
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MMS5X;UOP/OML=&"'B2=RN6!L5&*Q"_R05"RO\B$#^*G..*J*[<R/7^E+78&
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MGJ;,: 0KP'*< 4TV7"0TD:RP6K\-=V%JJSD3A6:@-HR;B#>!U$0T;V*)JAK
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MS7-K3#O;K](>TPF6<RTRW6XRC.ZJ==IQB[U9421ZL@/U"BF)(4 Q+_2"*15
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M_ON/+%9A%>RQ9H7=9<&/.3O[\3,D)2T$%"##* :(8@DPX0@43.6<*")1XK0
M&^;&U,AH> WHP&'P?BPY$-S)G4)V3QY?Y<#Q!)#CGR]VG9CJ<>()H*XX/3QU
MMX&'A4I)OOFBWO_D#T8,_INFW2\+,[\[F.-5!74EURO'9@ZX_XO.)V>,$L8E
M)X 6F3EHC O D*  XR0AL%!I'F.G@T;_/DZ-4NL0S>ZS;(*L$][KG]<FL=VT
M<;RIFSG*SB+(K(Q6VS"K?W<\WPSP#; \&WW=<0T]T]P.:1N?Z8TCS5"^K8;R
M<#U[$^W":CYB!O?@E_M7O*VIH6[;T)"#QS=!P!'R=>0;P,-QCXO#07QTU!S0
MU."^0/I;NWDQG1XVVHZY\Y,YA_DL-S,:"UAD! ,>QWKRS6 ,6)*9);^"'*I<
M0.ST&NDS-K7W0>OK3?1DO*V(0+;^5GWHG!OQG =:LD)C;7(WJ887H9@#++,<
MY!A!3&*"],+'I>VH-Z!'Z#MZ9VQ$3V/";?=R] 5BX+?<[HOZ=8O<^QURGWN0
M&](^Z"(D_KK_G#<U=O.>BT&?Z+US^9IAC/V!EJN_T_FS_)ND1FO/W/4?Y>;A
M]\62K>7JASDY^KAX>C8OD4;6O)J4Z+\]KXP6QQNZ+M=M5?O+;[1<F!.G>KEC
M.BZ_IZN%_MAZ1C-(22$E2(D2 )%8 "+3#"1(L)2S7)+<J7IE-,^G]BYY6T\^
MRT6D- 31#X.!&YV--^AVW#C)H0Q,M";FJ KZ)NJ$'?VIXXZZ@4=UY-%^Z&9Q
MT00?5='?;)5"-'<;!-K3_!:%2EVDP<$?AX\^=)Y>"./Y/>K;9?3A.'Q5C>^
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M''(((2>QVTGI19M3FW3L7-:/]/:(;>>UZTGG9=!MSS.]0AG\U+(?Q0#*P@X
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M6%,J7FTR+#NA.Q8F^QY5NRG+:XY58/KJAG83[057C54WO'W5MEV$X?>*0@V
MK]IHW^Z-6SL="-RCVNI0=MREW=XWNF)OY$*J<K-N#J<X9[E 4@!>Q!P@F$I
M6 P!(T3!+$,\SZRVJLZ;F!I+MUY&K''37GKK#(;]C.H'F<"<N 6E]7! B\$S
MZ-@+C%V/TDA"84=H^1'XZH^_1ZCKS(6C"6[U.]X5SKKPR8')6 ]T)=^86N6W
MG5+EV]5*CUE%I6]>=A_Y2E_,KV[_I"OQY:E2XOI-?W"S_MADZ,X(U_$K/<^5
M5!4 "4( 51@"CFD",Y5+4CCUOO#KWM3HM*I]C9:UJ]&]\56*Z)=R$:U-4.M?
M'7.Z_(ZEW63W]48H,*U77H/*[:@;6M2)+6(O4?=S37Q1%>!-U(1X$]5!FHW
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M:P!LW@C,Q?;(5#8 EF-2&W*38?364:4PC5V/M&2WJJ54*J$(*0 ILAR@&'.
M!>, J106-!4H(4[3*EO#4R.U3Q]OWWS\]/'NX_OOT>WG=]'WNR]O_^]_??GT
M[OVW[_\1O?]_OW^\^V\W5K,> CM""P%L8"[KN+RMBMR\!)&7=47'$V59FQV5
MK5S!."0JY^L'[@-M'N3*["NMY(-I-?I#?ESPY:/\L%S)\G[Q]GFU,G+]=RNZ
M6-=R9]J;ZF_S^N1/_,_S>F/FB9_EYHNZHS^_FMFB_H?-9E6RYXTI3[A;?J7Z
M-IL9D0+%J:(@1T4"$"<)("C5D[F4(DIXC'#B)%$VJO=38\LFR(@W44:;76!Z
M*MA&YKAS->KWP7(_;*JC''J7S<0=[04>U9%'OWQ:KM>_WD3M=Z#%(.J 4-%]
M!X9HA\,VQ4-C<1,U:$1=.$QOVAH0CSMZKS&.OO8)1_5]W-W'UQB6HSW-5W'B
MRDY7M?RS=J3SLFZ:W8@OBV^F"L@<YN@/?%XN5NU?W]!UN;ZKJDP3EL@DHQ+@
MS+2ER3D$F.K7(Z4\91F$L6-&HC?/)O>NTX%%561&\+=QMR*XKO_1'Y7S0[MH
M73V<=J^S5QFDP*\J3^,SO$.7+RQ]]_&ZVJ_7Z?;E"\ZS/<&\&1A&X?^0IAVB
M%+<_Y(K>R[:'<WW@_N5YL][H[ZZQW^X/X)SJQ4L* 62% HCF"%"H.$ 82J;R
M(DZX<&%J5P>F1LBM_Q&M VCR@:+ESG4W%G8>$3NR#8ES8$[=0MSXWO:B-_+U
M-=@=_V^B=^7\V7PZQ,[.4!0]L:FS^5%)<R@XA]PX^#[!!>?KR7DU!=]TI<P9
MESQ/E0(R+01 2A8 \R0'J!!QP>,"<;=]Z^M=FAI-UDOX>H=F,SR?R,-8V='E
MN",0F$#==>?KX>I$<]/LK'C<!?$'\?C2\^<<FJKV_ 4 KQ"?OW3GH4)@/_3]
MEJL7T]R,QQE!,$9 9I0!E&498$))P!"!@F0BQC!Q4T_MWM[E.1U'';7UKGKL
MG+50]Z!3B"00IC'@,M$O)IS$ &<H!A337(F,(:JH2Q;K4.#&2UTM_8%G]Z88
M"DE@SM^ZY;E;WJEPO<F5=6X]LBS9<5#'\F,G/C.,W5K=LJ_TQ2SA&_:<81GC
M7!02X((E )DG%B/&@,)ZJ9TFD J"W7CNM*'I,=Y6>.^I=M3MH3T#I]WC>SU$
M@1_D+3:-AP%F8OT8>'JZSQ@9]3GO#_3PB;_PZ:$=+DVU']]4U2UO]9+VWJP?
M$PD5R3%(X[@PFVH%T ^[ E"@7&&B>(J=Y)1/&9G:BG#/QXC73KHVCSR!)>9*
M)2C.05$4!*!89( @A@&F,3)=0#(EN!N+7HOF:!RZ>J9S'Q#:,>>UL 3FS?WO
MU]L+WZ\!K2W/1^^M3>4)$R.WG#P?Y''[R)[/#N/*_Y+B7M_LFZR/MM</Y5,C
MA"XR)(I"I( +PDW]#004%A!(Q?7/.94)=Q(V.&MI:JS9.!IU/1TH.'\>7;OG
MWPMF@4E@&%S.9' 1"D^,<-[.J+1P,=Q#;KA\P54$\4Z:KGMU^LO/4D^G,BIA
MC!4@E.9&\H\"0K(8)%E*F<BQQ)G3=OQI,U.EAHZ;T1_&T6&\< BJ$RE< =5(
MC." TE Z. ."7RXX-/(:1' FT#,L<.[3[I+M[Q>;<O/RH9S+U5NZD??+U<L,
M$I'"1 J08M.9AB $C*H=D#S#20HYSZA5?L*9^T_MH:]=C"H?H]9)>]GV4PCV
M/^@>< G\A+M!XB3=WA/X(/7V4_<;3<"])YBNAGO?Q\+F')DD)R._B>(BQBE@
M*8SU YTQ@(V<;RJ+).9%+E+E>/KC9']Z"_W*K>'20V[H*TR++(,<Q(PA@ J(
M "4$ I$@2N*"$2&<"E6"83]FKA=H<[T6VT2DXZPO(QPUWCC9S<Z"H1^8TATS
MP"KWQT_ZVD-MY(ROVO8DT[WV8!F:Z[5_DRMD\?9J![>I#2=K)#YK'):+C<9$
MW_3^XT)3C%QOMGF7L5"4YS !G#*HJ3'- -,+3L#S."5"BI07REDQSYM[4^/.
M;G3_435[W;S\=8!HGK_QLZ/,UQN5P)RZ/R!U:-W4L'/%</L!1FV$0=)MPX#O
M4Y?/GW/C2_9Y!_:DFI]_*^ZM0>H2NCOZ4ZX_;35\.2)Y3!@#G*7"]+!E@*FT
M $7.]!.3)C&),]O&(*<,3(V!FXK9RLD!DLAG<>SG41_H!&;"4,#8]P6Y%J"1
MNH)T@?+3$*0O\)YV("<O&ZT92)_3W58@O9\;W"!7WW+;0>D-U>/#Y?<'*3>5
MA(\HS3> SG<29>LW+WO9O.O^=-ZF@#,G.?S_NOO:WKAQ+-WO^RL([+U[NP&S
M5Q(IB9P!%DB<9#>XZ;;A>&:QZ \&7^.:+5=Y2F5W,K_^DGJI4KVI2!4E:R]F
M)N,XDLXY#\5'A^1Y40G5D"L;1!''$>1IDD.59SB7.J)$"Q_?=B2]IT:YNX'W
MQ?G(^Z)?YNY8KX6;RSS!P1[X"S+ ./?I+SPFZN%:%(^B]=A=CL<<BB.-DD<5
MWS<0\KFJY%[<Z%^5G+T\W:O5TV_+M2H>6);F>:1S*!G.;#QD"IG(,%11%B=<
M$B9ST;1XO_<)BSPITHE,=MN[WX_P ;E=S19B]FR8I=$<F"6Y^70]@?F2+8!F
MHKO:M#?T;A1_*9)CA0!N4=.@TA.6X)6:A@P&/ M'L)C TY)&#@T\:_)AA.#Y
M6_S7]O<K]JKF_Z'8?/WXONY(7!=GC5-!4*1L,#7&9H5O_%F&9 ZIT")*,HVR
MQ"E*L%O,U)S.2E-0J0H:7=W7LAV GE_JAX%I8%XXCE"/AJ =4+DO_L- -M(6
M@.?+Y;49<!Z(CBV!CIM'VQ@X;T![>\#AZI[I9?,29R6/-TRI2_L^Q"K7*L$"
M*D9M&7$404(EA;F40A AA5:9SQK?3>SDV++,&BWL3O6Q5D^JTMHS(<UM -Q<
MK?"P#GVP=*Y9T\<SF/KGKWE!%"J?S4WHN/EM7D <Y+OYW=V/G*Y9\6C_9\^#
M7MG<>H-EYLA,&,'V'\P2=?<7K2L]ZA(4#U'&D4CR'*I$6.]/QY!D60(%0R+F
M+)*<H!Z+R-$,F.B2U%I4%K03]@>UM0W,2GO,K)\M "O+FH%'-9= +U? V.Q)
MHN.]*%+A-$5<0T%9#C%2$O*,I3##24JCF.;*[2!PFF_(B-_2__]>#;=/]"0'
M?."OO+7B"I0CWC+&%KUL[ 35)?9]V/OE[AV^U8D"[MN,/G"!?(_Q]![5?1E]
M./8]H/$5\$]Z^6IK@,[6/SY^%X_6I_[-3-('S,QBC:88)LI^PKC.(#%?-9AP
MKLT_B4@CIP("IP1,[4O3Z @:)8'5TCWOY2B(W60? IJA5UY^J'BEOG29WBOW
MY>@#1TM^Z3*GG?W2>5W/>I-J92C#-EGZ;5D=Q+U[LG5&'C3EN8XEA5@1#;$M
M(,ER6V0W8A'"69PBZM6"^Y2@J4WF1CO/4I"G8'3SV4* ,W14P4;%*] H"2HM
M U9A/(-#J-J*I\2,6S'QC+$'=1#/7=^/ 6X-IFJU4E4WH[(,^$.4QPPQR6%F
M#[JQ)@DD]M0JSG.4L%PKPKTF_Q$94YOW&Q6K[=<K\+^B7Z(H!L]L!5ZMPG\&
M<?I+U.16L9?UXW(U^X=M#+]8-K^=E<W"#?S]*VX?&PXW$KD0Y('Y8XOOUPK?
MNB]!U5\]'(5TH!"(/8Y)&)4X.DS<YXRN2WN>YY0;)C?:8X'1U,!3(D=2Z1A*
M@@RK1#9Y%E$)99KE J5)FOOE*/5796KD\^[B7:@+AD5PFDO"!4QCA(R[)SAD
M64H@IS)6-,YDBI%/6=:1AF6T(JZ7;Q%>,#B.QW*C0#ZTA^E=&+PR>X@:E!?C
M&>I<K[\BXY[U70S8P?G?Y4_L]X'[E1G&G['YG;*VS^8V^<LF2]2A-#JG+*%<
MPW*'"VN-("=Q"J7YGBE!.!7"*U"A6]S4/E1U]WG0TK9*3_(CQ#,8NY%>..0&
MWPD[ =H 7<K=0 G$3F>$C<I ;H;OLXSC77U7UDM#3>L?M^9ML,'N=GO^^:EL
M3=!DY<5Q2C$3ACX0)A!C12%'#,&(1L8U3CG7G/HMM,^)G!JC-!I?@5+G33?L
M4NL>"9 >X+LNJT-".O@J^V(T>ZRX70$*M@ _*W#D];@K (?+<^<[>U89$8]*
MOLR5\:,47Y>9,O?J^_J]4?^_'Y*,)H(B"5-!#/E(AB&/(@Y1'C'-<DZD7_>\
M+F%3HYU&5YN+8;7U+/[1!:L;K80":VC?90^G.E406%U!J6S("AL.F(2JE]$E
M:MSJ%PY&']2R<+FG;R;<JS*KJD]&SVM;_H*)]7_.UH_7+\5Z^:16'[_7*S"[
M/C/_E??L^P.6$6,TSZ#D60JQR @D$;5%[T6.A12I4EX-DWOH,#E^4:O7F?#O
M(> //LNR/,ZY@"+6"N)$"<@8CR$S#J0FG)G_:-\6 X/"/TYAPMJ(X?%WH_N!
M,1WX*U!K#RQ[@49_\(<Q #06V$CZ9K^N,<(6YPB9U]@;PF#YCOX:C)P'V1NB
MP_S(_H_RCR.[7AI6V!1#$PS+F"8QE%H8QS1%*20BU1!A+!7G"FOB7#9YY\E3
M^TJ4RKD4*SL#6#<'703#P,SBC(!7?-A1:WL%ANT^:;2(L*,&M$/!CE_0-P:,
MKS\O;,,4N_2LBJM@*:(HBV,8Q[CLK*Z,5Y%1F!*ETDRA&,=>-7>.R)C:9&PO
M=;XL%]^JY/QRT;/5O&=-G&,0NSD.%P(WXO*PQ.R^%V8] L5.HA(L1NQ0PLCA
M82=-/(P,.WUI/TKXQ&:K,EKD\^+Y95U\,<[ '-6G,U%BEGE<1C#*J&WC&N60
M6GZ(M$R4)'F48J_@L Y94Z.(4C> _.9^%Y9N'! (H8&YP&JYB>HJ%;T"-6 #
M''0Y8!*(";HDC<H(#B;O,X/++0%:1Y:9*'.;]/E.K&>O9=-MS]+&SL^;T!N_
MV]6ORBTKM09;M0<I1>P-UA!- #OEOEUG0!<X.ML%.CV@?S&,/VS]LT_+U8?E
M"U_KEWG3V/5."35[+3W#6$BB9(RAM+U%L*29<;X)@U&N4QPCC3.1]$@6=Y/N
M-+_&S_3>*%_&X-E*&&4&IU@I.5N#^=)N0_@7QG 8##?Z"HCMR)V<M]I=@5V0
MKRMLORQ#U-3I!U3 \A@.0D<OC^$.Q+'R&!YW3[7 [Y=-,$9&,(ZY31J5VG!>
M$F>01%K 2,52")R3./+J.CVB[E-;I=25L3>VVQXTI?6@-+]T5+8 @!8"@/_8
MRX!W*Q_[I6^4SIAOF!N13_2]&?AK,,U79H)EAP\&[W],Z>$O;Q,<]09#,GX)
MXD,5>JX/A'AY>BG7'A^4-@^5[]7"_+"V 6+%._FWEV)M3?A-K?]BIK-M6_(/
M)?^=S1;62:OWE%!*1::XAB0W:P8L6&Q+Z3'(M48HB[*$N)5?"*G4U#Z1M2&@
MM@3<JD5A*^Q9DSQ7$2&&S'&-,?) #+\":<P!!^-A+0);DZZ ,0I84\!/UIB?
M#SI!W;)5&>(:?*,Q).JAEC,A5!IWL1,0Q(.E4,AG]UTHO1H!R]6/_URN_OOS
MXG:U%*HHC, ;?:<*M7I5Q0-A*(T3L[;A",40<TPASU):EI'75*0XB[RR7QUD
M3HUUK:9PMH#/E:Z^2X7S&+NZ^$&1&]PUK[6] E9?6[2NUK@BQ:4&C=8A'6EG
MB((YP.<ECNRX.D-PZ'"ZW^I?8W[WM-<&@BQ8R6[V=,?V+;VS3NG-0CUPC$3.
M= 8S'1%;5)E HFPD!Q4QE3K#+'?*5?22.C72*8,19AO-KX"H=;\""S-]YK7Z
MH'3EK\ 3^SY[>GER+[ON/AS=[#08R /STUZPQQ6XWN!KZ:G1'-Q5^!KEA\#6
MO<+](!B/5/ ^(-9>Q?"],>NHC>_^K-%*Y7N;UZZ<[W_S((D9V_PCI;(XS]($
MTE0:UD=(0,++G0"E(TVPTMK+T705/#7B;X+65THLORW*/9Z@V0"^&5]#X#AX
M@,/9N'_P^R"I8+Y@C1/A_T8I8KY@>,;RATH=J^L<W*EGN\9>?/-M;G[B]@G-
MAVTEAUK'81J-GP$B5 KD*3'CIC^>,?8@]?'<]3V:=JG5TY<E6WRJ^]=M&W9E
M/*$QE)Q&$&<R@I3FU/9MT#'1FL9"N"76G1;B\VZ/DS=7!G!;1<$GKW9^'4">
M7_=<#L[ $_\0E3X-NH[#X]&<ZV*8QFK,M>D)*>OM?5&J"I(H1K\$:M#5"497
M<Z[C-X[7F*M3\9VF7-U7^C/=K3(#;$;_F[K1-ZO9M]F"S3==/:MJLG>V4\9*
MR?MEV2'Q0QD2>?^H[A]G*_E?BAE>%'E*4(:@- L,B*E*(5&(PSC*=<8I0HS'
MKKM*(12:VKIC:Y/=FUW65H'G3?=45MIEUB658?;T:F5- [(*)%X_*O,_8QWX
M8<QSYY<@HWN>K,<>LX&I?7>X&H/ MMEM91*X:PU7:17XL!VNTC#P7^,/E_O'
M8^QA&^M3\UANW9:#-UN8^:V*M1D29I:IK !<V1%Z9C-9MBHVUV[FHRSWA6WU
MX>KR6;&=B+/%WB0,],T*.08=7[@@8D;['H8$I?WU#/K<?BOB+ZHHEJLZ3FCQ
M[8MBA:J[$!;WR_>JBM0U\O]86FG%@XI8+&0L89HD&<1:99 +I&".E!!1AI7D
M3DV"^RHPM6]II?\56#86@+DUX:KI0&ZG+"^W^$HSKLK)"M9_+/UV^KS'R6U'
M8TCT!_XJ-L!OE =?*N!O=X"_VP!O#0#W'<![;X/T12_0]HBW^%&W3?J"L[^=
MTOLY(4H-W"FIGIZM?V"X>K:T0NHU<8YM#2/*((KL&0;!9HVA:0XYP\C\)8YD
MROJ7'S@I=VKT]Y?GQFL1HBQN+$H_AX&ZHY+Q4VPTJM'GDG($IX?!C>8& '?L
M,^NMTH;A2K4MEPT03>B)U2#%#$Y+?<,"!V>AZ"YZ</YV/\(J5NN'K\9]9.9A
MGY;&OV#%NIX43.,L1SJ&M.0F3 0D&>8P3F(4ISH3,7+RT4Z+F!H--=JYD4P'
M=-U\$@:0@:FC42P@-YRWNXL&S-TM"C!_VT[_C@>/,M//&]9,:H<K>W;X7A;K
M&_WORZ4LWBUD4Y7QZW(N-Z>3E,42,V[67 13FR\10<ZC',:$*:(R3*/,:3_3
M7>34YK=U O\$K-[6N[#]38H_>39!/@^SFR\1%KR!N:!!K%2WS)%K% 96XT$.
MA]T!"M7>][S <?OR.@-PT%#7_<Z>!?_KA5-=/N)^><^^VT"+1R/"+*X,L7VU
M?>+>FS66O%X^/:M%4>W;HA@C;58\D,5) G&L4LC3/+49T(I)R0F+1%/PP8V$
M^JKB-+MVJS\,?2#-OIOY5&[AEMV7;",SLPZTY45%2W' JF(=CL?5%P^9&YT-
M.@PCG8]4)ES98JZ@I?L5*%6'I>Z;;:%WJY5=F3X%;<=T*8JA^@[T56/<;@07
M@G70H^#2Y_7<.I\Q;@^];?&=1=6^T$HTWI!MDK#^\<!S)#.B<XALA@/.,@8)
MQ@QB&2MD_#;"<NG3MNZ<0"^G;;3F=/.MUJ4#4K3T_I=_)DF<_QFH4G_/'?%S
M\#ON@ <$=>@=[STD/W:CYK^=[0A%J.WK<^+&W:YV-/Y@>]KUO@OS-N_8'TTK
MJ%+0R_/SW,C<S2[$@N!(40Y3P3'$>2P@BS"'69Y21A22BG@M%+VD3VW-:'0&
M3XW2%?74:O=,ZW0: C?6&0S8@2FHE>IIX?UU!]Y&^3&R/GUP"YW_Z23[;3)!
M?6 YF1/J]9!^M/;Q9;64R_F<K9H04QEKK USZ11IB$620\ZE@CI*\@PE6$J_
MXEK[ J9&3E:_^L#,T^\Y@,Z-<2X!9&!2V:HVP''6*;L#D<+!XT>=]Z>,VY_:
M)Z_K602H*E%1+J)N]*?9@BV$66C9W2OC@^090TFD((XC:OXP2Q\BD@AF7"$6
M:^.#2*\ H2YA4YO5;5WM!U#6O>V!;M0&PNKM6<"G"VZWV1\*Q(&98!^_ZA2\
M*%[*0F_7G=#YE\UQP"14.9PN4>.6N7$P^J!\C<L]_9C$;G7_,9O/[PPY?5JN
M_F K^1#1)*.V"(2@*8<X2@R!)#&#E"B6"9W%G.0^!')$QM1XHU$1_&Z5!+66
MGI4JCV'IQ@X7(C0P*?B"XTT$'>8'FO_')(PZ[3M,W)_M79?VW"A=+K[93C5E
M)TCSB'??9\6#4G&FTX3 E$L,<:9S2+30,$&$<)IP3)C75L4Q(5.;YKL]>ZZ
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M,4]H+G+BM6OL('1JD[C2&99*@ZW6H%+[@F,^IQ%PW&L.C.O0F\X!(/7?>_;
M*-0FM(O(<7>C/4 XV);VN3=H=M0#$@D2-.$0<6PWG$D".>,4"A)EJ>293-/,
MK8_O&4D^DV2<9KY-*L]/LP6H*A15"5)E9M3/05*C'AA3/,MM+9',EL]7.8-<
M1P(F.)54QBA#D9=+%@#<-TLV Q#($2!WX_4 0 Y,Y1W99X.GG(4.>#@A90HI
M9B<#$,Y<WK>FZBZ]_Z;6'[_7D;U-]9.'5.<44V[KEG'C&]((0X+R%,8(8<*%
M0E0[52;P$3HU!FGY+JQ4NBQ(X%L]U0%L-[H(#>' W''@^56!L3]M= :-TJ=)
MMT>!5'>,@M5%=1 Y<CE4=Q .JZ!ZW.M?&N5$#-4V7._]C^TE=33?.QMO>\]6
MW]3:_&;YLM[VC7W 49I2PCB,$EMM,2<,$B4XU%JP6%.D<^7DVPR@V]38K-+2
M]F4U:EJ/I];3O=)'Z,'KIKTW'I*!V;$=M=JVK1VZ"M[_.-["PUIHVWV4 UH9
M"6XG,*#N!5[><&!'*@/S%@/L52]FH"'HJ"H36N)HM6<&@JI=H68H$?V6"">T
M*>49C<2CVK:@I3I1#*?FPYOD!.(R%R_##,K89B S'8O4:WO!0_;D/K&5?N[U
ML_K@[;98& C%$;^*1W,Y6@@/$&'2 [1 BP@?R:.N)7I LK^DZ/.(H+1UGD3+
M/^K3MRH()GY(181R9OO(<"PA3B-DTRD(C"..1400CE@(7NNEW-2(KU01O-:'
MP<^EDD$8L-_07421@P_(%%86O-/QK(:S.=N_[1[.4"Q[$>[#TG _U:; TQ>!
MZDCDE\GP[_J^4Z6G/)<LPV@2BE.D1 P300U?Z]AXI"*C4"*D>)+CF#"G*.?3
M(J;&NKN5KDHUO8*1.L#L9M P$ W,@SW0\6H(WPW !0WA3SQXM(;PW8:U&\*?
MN?+BOJ)UO.*#IBI!::HACXGMJ1-+2*@04&"2(TEM;[^L9R?16H37U!ZM=ZBH
M@V);/41[-PEML'3SC2Y#:."9W5+N"M3J#=(&=,_T\(T_&P%OU>ISS\".YI[[
M5UX\MV_T3G&I[MI2M?1M'6652Y'+##*1(8A)Q"&5.(54J5C%-(E8JKVZ9X31
M:VH.0KMC[J.:U_W9V5S]J3>-7#1LWMPSUF ,3%B[9?)L*GYS!-XV!&PLN0+'
M*&Z0$J6!P0Y/D1=I]5:\&@+*#C(.\O@>A_=J,5NN_K(HE'%,E/QMN5;%AQ=5
MI5.:,23U#G6L!(XUMZ?P-N 0804I9PFT<8A(1[G&B5..EX?,J3$O^H7DZ?\&
ME?9@HSXH]0?R1=G,4^)Q4NL(O<.1>GA A][0.@ZB4;K)Y+5JGS\.Z VJQ[%V
M>'#'.JYV CG0R;,?2ETGRHY/&N^DV,^TG1-@SUO[UHBQ:;]B_;*J6UB^6\BZ
MJ?6735I*@F,4J51!HA2&6&@$F102<J(XBZG"0GK5E781.C4&W]&Y[+U:UH^K
MU;X@,<AI!-P\Y="X#DSD(2#M45#%':-@Y5(<1(Y<#,4=A,-2)Q[W^CN5F\HI
M7Q0SD]K^8?S9Y9,JQ;PJX\O:2BK7QJ^U[NM_SM:/UX80S06K36"J#54U_Y7W
M[/L#RJ5,LBB'DDH$,<\C2)(T@SK.(LYTAK!$+GN% ^@VS4W&ZP^_WKC[3*&'
M*Y>,)+:Z6);' N(HIY!0FD*NDAQ+)2F/(M>UPEL.URA?I-*$MQNK\XN+-QR!
M@;]=VTIAI557U?^!RCKPKOR,E?8!:R!H+ 361-#8:&O1-CL_C9FV3/C;#:G[
MTN8-AW:D)=#;#+'7RFF@0>A88866.-I*;""HVBNVH43X.U$[/MJM>:OM.-:[
M%TFNM%!I#/-<9!!CPB"+\@QRG<DHCJ1$R/D+VR%G:E]+JQG877%8A=VIM@O3
M\U_"0$B-NB*S:I85\7KLI76AY?Z1"83:2!^,$^B%H7H'*#IHN^ONT2C8P80V
MG;I</D)_-?O;^;)X6:EMP=PL23(A4 +3C)E%96)6*90K!)4E5[.@C&E$!VNT
M=D2AJ9%M7=K%[N;,3YTY#]AY[=B0N>V@C3D0HQXR%^=/F8LKL+4(_#Y(.>-0
M^+Y%#[=CZDRWF5L'>!=U=>MZ;M\CB-(UOE.V55P5$6PXXHD93&[X?/:M<A,B
M%"EA.UI&*<$0$XX@T51 E.<HIS(6Q*^EA9/4J?%JK?056#5JV^2*1F^PW"A^
M!5C9R\;W*,)E)%S/(@+C.[CK6T.[T1BT5 8W+6C?=4/;XTC" ZI@9Q(N,D<^
ME/" X?!4PN?F"SON%!_4:O9J'OFJBO=L;H5\?51J_:7N_//^Q_:"9K5_;V2^
M__$?2GZSU*J*V;=%>6W9.^ !95IQ%.<P3[4MKR,3R/((01$Q(1,L2"*\3EB'
M4W5JE+AM:5. EJU7H+86E.:"QMXKF^JTO6Z[:V>-KCLY^%9V'.ZU<*/::0SV
MP/P\ZCCW;W4TV!"$[I047M&W:;0T&. G^S0-)[%O$/U"W>CKE9*S]2=FFY"L
M?UPOGYYF:[OG]4FI5D46AC,9<T)A@K7QHA.>0Z[S'"+&&&%)HHA?>V0/V5/[
M<&S5!%HI[P)(?=!WH_.!,!V8GZW6MH52I3=H%+\"+9R-[D'+UER 6+# ='?)
M(P>?>T-R&&#N_XB>=1K$HY(O<R-MRYS;?B3%=A,ORC3GF'*HDTA K-(<LE0(
MJ 6/(T4RDA.G2')?P5/CKD9O.^%:3DY+=<]J"ZX#X,9@0\ Z,'V=1W30-F^^
MB(6J;^ J=MS:!9Y@'-0E\+V_'VO]MEPLFQ/_ZIR_[BR]R6]+52(EYQ)2$5.(
MLQQ!JBB#"<DP1YPIAKSV+,]*G!I/W:P?U0K,JHB9GU2E[,^>V8;G<79CI:#H
M#4Q';5V;B*.?:G5_'B3QSQF=0-1S7MZHG.-L_C[9N-_H'\:S=;!N],UJ9M:.
M;'Z[,M-I]LSFU2[TG?K[R\RX:/?+._7,?FSV/VTWI^*!ISKC@G,HM4 0VQU%
MFN4:(LDC+G.%4IZ[QOI<JLS4N&EKC_WF+VN+P'-C4GV" E:U4;93Y,J:U3I\
M^6$,<X^)N7@XNWEN[$$:F )WQZ<Q!FRLJ8]AP%UK?$J+6B<XI4TC#I![9-.8
M S52^-/]HP*&!\OAFBW,%%;%&JP?V1K\P0K 57E:R682+!?FUVH[Y:1M(3HK
MBA=573XKMG-MMMB;;L4O8>*I0@U 1]#5Q2)&B\P*!48[?"O8,_LV0VY<_\W&
M;7L]4$8H/2BL19J*#.K4=AK2,H4L$RGD.M8H2G0BE%,LK(_0J7T'MP<K=N*6
M*K8/6'R[(3N@[N:NA\9RX,]5:].@5.T*?'WA?U-B;;GL5U:8H;3]+DJ'?J>$
M+5=ZN5+@1NNBHYE(C^[([O %:XWL('+DOLCN(!PV1?:XMV_G';&R60(?5/7_
MGQ?5"N*>?5?%+?MA]YO,.W.C6[^^4T(9%>SI<(IB1#+#60K;LK38$!=#DL),
M8KLK2F.EO*)0+U-G:KQ6KYK75DOC0S1JED&ISY4QO?KW7#1D;M0WWD ,3(J-
M(>"GQI2?K4=7#TVI-[AMQL)V S)?H)U_W%H5LB=0"'2#=0NZ2)F1^PB% .ZP
MPU"0IP;(!.B.?'TGA/59B[(0Q[N%_+)DBY8B1L6'""4\H2B!&MLH+L9RR+.(
M0<D%SE6JJ-!>#72#:C<U?FXT;G%S#SX..X".GNE;#<O0+JQW6;K&O*NZ/)#]
MMI8FMHB[)/:!,@A"@3]$.L'%NKU=;D$H6#L3#8()\6-^J68/'XVT]8]W4IK9
M4]3_9Z,=X@<IDHS21$"618EA<$4A)T3 A..<,TDEXT[Q49U2IL;$E:*@5O&J
M^0%89<'-PC$@JAO8;F8-!M? #-D;*6>:<T+B"%T52OSR;?GZK^;^BJG,#UN"
MZG[J*$3C9%A#&&X7]W/YCJ7?-[4T?SP0F?/(S':88J0A5C2%A)B?9)1D"8E3
MDD?LH6IH\G7-5FLW1ZY3IL_[O2]YN%?]O?HV6Y2[[F9-UJ>#RQF<B58BB6T1
M4$NT/%&0Q@F!*$Z,$YUSB96J<?YHV/\M4&[D#DDG<AATW?S88'@-S+J;V/T_
M=BNK;'0-YUTZ01+(6^R6-:KWYV3VOC?G=I-_/Y?;U5*^B/7-ZJM:O<Z$*AN0
M:*85US2!-*.VC!N2T/AITOAI21I%L198.H52G1(P-9^LUK%<4=5J>O=R.0ID
MBG,BI(HA3E4*,8XQ-'^74&;&OBA6G.?1PZM:\>484+8%#0YFT4;3OS7.43B[
MF38$1$.'6?B_:%YM<;K,OZ ISM''CM82I\NH=D.<SNOZN:_V(*I:(<_GRS]L
M\M$'I=5J59:,*@^EKA_MX>+G177&_H#2).)9G$,L&(58ZPP2G0N8*FH<K0QQ
ME#K%@/558&K,NM$?L,: *R!K$^QQ$6#5^>VLWICNETOO/4YN/MN0Z _,-%O@
MWVV!;[2WYSW-P?F14Z/P2?=]@0SD_'F+']4?[ O.OHO8^SG]N/$O"^-\SFT[
MPLHS;9^\YHS$G#$,HR@Q?@\B%#)&8Z@ECB75&<V)%PUVR)H:XS6J^A%8%YAN
M7!4(HH%IJ=%RDR(^S*FS QB!J*5+TJ@LXF#R/F&XW')A\8YM :-BDT!"-(T3
MEFNH=2+,RBBQZTQ;?YKE5"5$V*51K_(;1X1-C1U:\7\M;5UR3/QQ=N.-4.@-
M3!S]@>M?7J(#D= %(HZ)>IL2#QU&GRS2T'5/WV"]*J2]3N]YL(4>::8P3&.J
M(.:I<2AXG,(497FN*4ERG3\LU#>V5H[[UWL2G%YU6KWJ;3E#AG/54?UU)I]O
MZ-PN@+G0D6*:04QH8BNZ)09 HNQ9:T1BH0B+: /@O4\4XZ4HWH\2G1@22C=>
M[8/,6'&"-1H?SZ#1(]COJ,W!HO=VGSYR.-Y1TP[CZXY?=FE:12NC^MU"UJ5M
MW@GS3V6QURT!;[VL3%*I)(*1U+8/8!I!@DD"=93C*(Z3)/+;B;I EZDY82=*
M#MA-V=H:L#5GITQK3S?MDG%T8YN11F=@9AIR8"[(Z>@-:?!4#W]-WB@#I#=D
MIQ-#^C^R9^C*3BV>\OP)IX13'B>0)YF$6!DZY;$0,%$DHT@+E$38AU,/14R-
M*O<*3'D=XW4 Z49JE\$S,%=Y(N,?'''2^% 1$8<"Q@V#.&G@0>S#Z2O[KBY?
M#8TL5S^.U:Z/DI0GD48PQ_8<+R<2<IIJF,L,\RC/I%DPN9W9NXB;WOE]HVW9
M_;Q'RE8'M*XKIS!P#;Z,JM4<OI"_"R+!%ED=HD9><9TW^G#YY7!/3W> %8_V
M?Q___F(<DKEU0\J>*3.Q5M+^0]69L_6+UI7;51E-)*,DA1+'Y<$8@HSD.8Q0
MGM,DRTB:>:W*@F@U-:?C3ME7Q)!]=8"]U$ 8Q<ME0/F#VII0_G*U,;"^< U^
M->/[^"__'&?1GU%\5?55LI=^4*+L:;/S3XEGC:PPKX*C#S3V  _M-AD-KX#]
M$[04O0);&T!U2=V<N/W+]AV#+/F"@AW*30NBT[B>74@8#YS!H ^_H(][6^">
MF.._K1NR$9PH2G,"D\P6$J Q@93C"+*,\8AJK53J517Z$F6FQOS7#<\?3O</
M2UNOID^[][X#Y4;08\$_ B_W1+Y?5_@+(0O9+;ZO*N-WD;\0M*/=Y2]]9C\*
MM<\S:WD_9VCWI@G-GDJQ07R2XS8'>OWW'C[J"WW<L/U7],15P?9]-F^@%-A\
M?Q&!B' -,;;G99&@4*1YRG*:HY@CO_H^)V5-[:M[?">CYUE7%\:]]W\F..7[
M@A9B\V<@-NB2]-9;/^=XPN66OK4+[MGWS](\?:9G5=.9WUY*!U$GFNHXS2!-
M\ASB\F (R0SF3.$XH3I*H]2O?L$)25,CC#HSWV81[*H+*GU]:QB< KB;+X+"
M-K2#T!>Q'K4,SJ!Q03V#4T\>N:;!&0,/ZQJ<N^'2Z)QB$PGY9;90G]?JJ7B(
M(Q&3*.%0)91#K(2$A/$4)CB62L6Y3*5?U^HN:5,CB)V><:W0W=^MQJ!4N7<(
MS3&PW1R+8! .3!87H7=!G$L'*L$C68[)>J-8E0ZS3T>C=-WDWWO@X]/S?/E#
MJ?L56Q0SRU#U'E2484QTQ*! G!H680Q2S1)(>2X8(C'&2KOV%#@E9&KDT>@)
MUAM%W:O*GT2RFR)"X3.T&]% L]41_%YIZ<BGG1BY5]0/@=5(E?*/8!:FJ/TY
M##J*U9^\=;0B].>4;Q>7/WMM[W*@[-NWE:K:1=_HNJMTV?AK&S-"!,NU2A7D
M1&"(;<H84SJ"*%&:$R8PSY1GF<_S4J=&B;M*VQ/Q6FWO^IT.B#LZ4Z%Q'-JI
M.@7AH*WFO% *5QC30>;8!2_=83A2R-+CYKXGNN4S/QG-CU5:VNQ@9I' (LX3
MF.19;EOZVEWB#$.)LR3#L= (>[6.=Y0[-3YJIHX=Z6VW[YV*8;TWD%V'PO5X
M-CC  Q-5(&Q[G,IZ(17L -9-ZLAGK5Y0'!ZK^MU^88Y]4P9NIHI?%;,[W_)F
M<:?$RVHU6WQ[SXI9\9?%DA=J5:;V?UX\OZQW0^RNV5R\S,L?[Y;S^:?EZ@^V
MD@\I%3(GL3#LEMLR<%J;=2=14"5:4:181(33XG,TC:=&DVTC0&D%V(MM_-UJ
M#VKU^R;_#_8"N%'LI(9U8'+>[L9M*V+:7+3&7MMN;6,Q*$V^ F=? QL0N3'<
M]9WH7]=@Z'$*71QA,'W?IL+"T/"?+-,PN. WB*R_+<OY'K8UJ<O=?_PNRII7
M=VRM/FJMC-^(<Y;FG%&(HI1"+ 2"O"R+K"+"-6*:9OAAO5RSN=M7;5SUO3YQ
M&R.&(T3;1ZC2T?8:$F7HME.0OOK>]+LH_RKFK"AF>F;^V;JZYEEE8< "/*JY
M!'JY @7KJ! UA1?+[6LYW==EX$]GJ,C_*U"A<+QRX;:-2@,&L&B "HZ)I KT
M'L8IY!3X*_\_)_F@]\ $S5+HKT6_#_!7\:CDRUS9K36;8R_6+]8A,'\QGH!Z
M_^/>//9&7R^+]7:3&$<BBC%E4&=(0$PB#5DF&4QISN,L21).8I^U80\=IK;:
M:TRH]I9;1H#:"L!_ &N'O<!:XO<UZS-*;I^D@;$?^+OB#?N@&_X78!F(W/MH
M,"I#7P#1/LU>\JB@7%G2^=S6,[/"BNT,U#PF'.$8YCDGAB>5@(3(&$8Q5TAE
M<:*$5[:7I_RI<>3N!*T\O5+M<F9Z]K_V'8N+V# $PH.?''2"^Q:\=PZU83GO
MI/0I\-TY:!RY[NQC_*/1WCVIA33/*\NNO/NV4F7S]#I&"*4Y$Q%.H$I)!G&4
M)9!$N8)YBC4G24:D=HY(ZQ(T->:J=05UW9^-MNYA5YVP=G-32+ &)J%3./6(
M4^L$S#U6+11P(\6K-0"*"D"V 5"65'XCUDNC.(A36[LB)K^$"69S :DCH*WS
M]M&"VER,: >V.5W?ST]\_U+,%JHHKI=/?+:H-L_+OJO?C 3S4S&3=?/531>O
M>D_>JE!NO3\@3%@F(@(%LL5B*-*04(2@$)E.&2<12;R*Q030:6JLW)@$Q-:F
M*R V5MD?MV9=@7ECV!5XVIH&9M8V/^<SQ "[.:0C#]O WX?-B%VW1VQK$+C>
M';$OVQ%K654=HX9S7P-B',BE#:'1J&YN0 CW7=^0C^X=J^S:3/MF_;AMS3A3
MQ8/""".M<LBHD!!+1B!%%$,1(\X$Q0Q+KZW2"W29&GV7^FU(V2CH'<_<>U3<
MN'<DK ?FW,8*4)K1/B1K6P(VIER!:F"^. Q,GY#H2R$-%RC=6Y.QPZ<OA>Q(
M4/7%C^R;3W^M;%#D_+/QO;__7_7C >6,9RB)8,YMN]E4Q9"C6,(\-P099RPE
MV*GTQDD)4Z.].AN\UA*4:@*CIV_>_#Z0W9P6!)Z!F<H;F1[Y\2>LOR O?O^)
M(^?#GS#H, _^U(47!B"_;WM;GU;J[R]J(:I"WRP5C.0T@@E69FI+FD'.(FT6
MLY+PB BSNO7*EW"0.;7)WEZU;!3M54C=!7 WMR8PC .30B\$^X?'GL<D=(!K
MA\2W"5$]#\')(%.'6WO2S6PQ6ZLOLU<E/R_6YOV8\;DJVYH61B;[VW)U;6,(
MRUF0I0*+*#%++IS%$"=Y9)9<<0()81E%(LU0ZE5\PT/VU.BG4AV6NH.M\E7[
MW\+&1I3Z@]* ?K3D,3".]#0,W /35%"D_>G+'[-0-.8A>5PZ\X?D@-9Z/.+2
MP)*OCVREWK/"GN@^V39B55/GU<H&_97];][_V%YSRW[8W[VS@?CE^?X#$I2D
M-$JA0E)"G&$&N40,TBB22. XI;G7L4$PS:9&C>W(L5)MXYL69;3$UCC0ML[.
MX?:%M86@-+$.K_ DSW##[D:M;S*8 Q/OX3B^=QW']SW&\8+8F$"8!X^:N52O
M-XJG"03GZ4B;4 +\8W ^+\3R2=VS[ZJH69V1"*,L@5E$;1T43B#5.(4DDQG%
M*4Y9[M0U^]C#IT;,E7Z@5-"/5H]"U\V,EP(R,+D%QL(];.823$8*E6EC$R8,
MYI31':$O![>,%NYR2MEVB,O):R[U4BTAKM2CX<2R-Z.5\F59%'NUA#07L5 Y
M@3C2 F+!%20)DC#-$A5G"3'>J>CGBSK)GQJQ[2@-ZM?W)ZOWSWW=1K=Q\'4.
M@Z,[,$MV #M2V+,78L$=.#?I;^2F>4%SVAGS>TP_?ML/&[$)).7&%<(<BS11
MQOWBN2&RB$(6LP@2*BA#$4.<>@5QG!(T-<8ZB+FJ4JGZ[!.>Q-:-G$(@-N)!
MA3M8WJ1S#HE [')2S*@T<L[8?;XX>[U_U,*U[4"R4NQZ*>TZC+(XRQ1$V/:
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M8P*CA)@E(F(4<ENU(\X3G<0RX=BM:W-/^5.COM*?F+7\"5%;<0469O;.:T-
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M+^SI^<\?_!C%!5LW4@F,V,"\TFA;NC8M?9NCF_/-2[VIQ0.@0.SB(G%4@O&
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M+J3_%C_,*Q.6V]_#)])IR+Q4,D%*Y#NI6.AL4XD#"R)8CJ:Z80T0</NM>Z'
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M;LZR4R(E%$4!)B33)^D(D0<#9 ,YX1"SU:W;FSU!TI_JAK U"(\570=(O)'
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M&+1H7O%^!)E3=ZD8'Y!CRVY">-*)=]LQK[T2-V\QX7S(/OT=[X;OO1(^6VG
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M4!?ZW*)H78:VBXYIL7*J;!^%RA&,[@ L;_'+:O&%M.WMQ?P-JR$W4T1PD,4
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MP=&46""(VE2WCO/Q'AUD;[SV7/OVEYLGDCSM55 /\'Y.F3>+I(_4CNLMULF
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M\R8DIERR RZ9 U58 J=5!,Z4+[2MC(VM4U ?)&::HVHT[+1A>@?HN>[V<3$
MY'(S##J9R4*^G8A@4AW5EQ.'H$*!K,E@,W4X6FG=?OQ1@J;UD)XK#-Q.)CT
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MBLR<Y!9$;?I5(63P)=65+L&SY$3$V#I+_B1!G<+K4/7/AM)%!\!Z?4FR7)=
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M.V=-Y!!KP40BJ=%Q<T*)[@9A=-C.VSHB/$@_76'M@<+4)(-A2FK(V9"S*)D
M.BD"8LQ,>^^UCL,U2[ZH*O"]M+Y/%?@^*N@ 3H]-9" [ZUF4(&36H$K(X+..
MP*P(Q6L*CWWK-X075P6^EZ9W'(2QA]@[ ,]Q+<DI&<&Y(8NNZK2K.IW-"Z]!
M<V84#]9GWKI3</A!&(.5"?1S<PZCX0[@O*Z^F7VC[W\E9W3%=/5[ZVOA@W.J
MKV=4;RHTL,SF^"7\<V:\,]S* C:E:AN,(;,@ T1B/VN-T6+K(2_MJ._%Y@X.
MN0>KKTZN__[K%N+R<_J*^?+BJ&UT]W]*XYJ"9\AL5B$0EP^E6Y,Q180(0;@(
M%*5Z"EXEJUL*>4*53&[>]_XP)<=?ZG%Y??+65PB7S*:(##B/&93@Q)<J]6T[
M9F%]Y-&VCV'OD3&V73I:[_=OU^-$W<&=>9N%]8LB63Y4J,%P5IU8LKXQ<#*
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M>X24D2_UWM#70F$=X.[W;]\O9C\15T?HPZJC=SM*!T-ADOQ>H6I-,VH%P:
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MJOK,UB8UES5$4>H6028@$/_ O$\.-4/.FA>MMB!\W,Z#07!Y>H7V/OKV$_[
MZ27.U_.$ZQ^^#_/U-IK#'YQW^*%-7YSW9:+1D_/FLVO8K$??_\=D^?7-Y6(Y
M(WJO$!MXR;DX#9QD1#Z=,Q P.LC1:.^,0"5:]Q'M2-JQ!I*\V'!^/J_9OLU8
MZM5GUU4F42>1@I9@7-1UC8"%6 <-\EPB3]%RPUJS_10]XX:S0V#EKG5KIHV1
M%_[\&?YS-M]*9ET8+ V/5KH,PFH*53!'B-X4T Z+"Q1?.[/3S+MG-OW<__*X
MJ&FGT5DS\8X,CO?A&WXHMWC8E%E&ABRJK "]E_5:5N!#S0I3Q&(31A/53K70
MSV#D40+&V_=SK$9GK<4[(D;J(IK_$Z8D^X_DLGT+"<E;2.&BMN9MAY;EX",7
M&H(WY$%B6%4^!A#<%!^\+J[LLN/GZ:^,AX9&*IP-(L\^=LG=WIMF8W$^! Z2
M61(+5P9BW4O$LA7HH_<8?\T]A8-<+T>+N ^(/+ 7J^ZXYH4.#<DB5)L:P%OF
M@964N-)9E;Q3PN8763>XETYW6C>XCX!'OF)VV'7V#L/U+E?M<\W@&Z C5(?Z
MNGH?D]B$US((XMDSN\.=L^=G1T?,L4K>;[O<P1+OX*UQ8WL_8142\?(1YV5&
M]^TTX8=X,3F_6KZ4:F'MY!O]E;H5?3E95/8GM:PDS)>_A>7Z<)9,QS#5[H[H
M*8Z4]*MH?8%8&,^LE"ACZV*(MAR,FT]I?C-VH.8.0/Z(6-]=E1'K2 ZJKNV1
MM8I7*9*OBR[4-).TC(?H>>MBS>=H&C<],Q@0FZJB VAML]T?OF-]^9V>?\;S
M>D<0(XXX$$2Y#B*#$HR#4W5Q74Y2V5)D8JU[I!\EILOGI -U?K< L8D".D 2
M!;;SZDC\ANO__6.Z:E!X/YNF]2B_5XL%$ELVR[IF48#G+M>PMT#0QH"6HIC(
MDN"V=09Y1]*ZC"K;H&P(Y72 N143:]*O63FS3BD18YVI[^B*MX'LNW;T#Y&C
MU1Q5-H-T+=TEI$M?K V>CA=\!^AYE5)-3"\^AI^K0O-YR+@9.THAT@V^F.9:
M%I4@R=J;I<)J1!]Q*#D3&9-0OOE4]QUIZ]+-:H.Q0=33 >S>(9T;O+KO5]'W
M56"S^K<O./]VQC*B=R0U=)X"<<X0O)1U6TAR*A99R(=M#+K=*!NWP&50R V@
MFDX -YO?YHH.U<K+_#)[76>'X^0'YC6GN7JC;R>+%"[^+X;YF=0\.^L\,%]J
MX6)FX(5>KS"BX%KS:-( .#R8X)W@:5XL/$^CR!>$VO?XS_++WWCQ _^<39=?
M%V>LI"*80V!:UUJ0XB%P%R%C4)FDJZ1HW;9Y**T[8=7^TE@]2GTO"*9?_I[5
M4[@X,XEQZ6(&J6J(I5. P+B"B#8Y+-*S,A8\MS3N!$OW2\/R('6])#@2M'#-
MH; NLII/TL75&13,@I/(R+E)"8/AP8;6LUOWIW(G2/I?&Y*'J>P%@?+M['*^
M9C!:F977-9HK=8H]<B )<_ F<^<22]K&D3!Y1>1NC]+LE\;D81H;N0CA">9N
M\O:JT.<J<Y7),RD3<RQ("(;5O1RACM?E= +1\\(R%T[L4OUVR+=W ]K+2G^<
M1 \=F+Z=$M=G47+A61*0'+=UA9& D,GQ==F8XJ4-VK7.M>U$V&[(>YDID?::
M>2EP>ZI.8KUOBY\EK;/WS #SDCP,'2D*LW4_++/:Z"RM4ZW[UEO1OAMH7V;>
M913]=H#K!YM_:OKI/?W?=2:@:).<UPHP1SJM112(40@HF*71P@=66J-V-\IV
MP^3+S-,,H)M.$?=N$N+DHHXJW_ 4>9$I6P/6>PXJ&D].;W&@+,^%QQR*;)VC
MV86NW=#V,E,TS?7R\EN-S^[,)&O4;'S&3]UN?)>1JX;C_Z^]$&^#=+8%:<ON
M[6<^,;!P]V'PQ)W=(FH5HA7 !-9,E&#@<36+(%ONE0W"#.1<CMK972SY528%
MR,QY\KF<!B\4I]"BIN"84"&W?OE_^9W=^V!EK\[N?;311V_5[3XB[DVD*#0!
M=XZ!HHN-[K@<@-6):9[X8:%%W^[![7?C='?OI=7GVN_V$?'!$/F!\S@;M '/
M<*:)#0W%Y+I[(27P7EK0@OQO5!S)WVJ'E.X;\/;2ZDX->/L(N(/09L/(IN$K
M"^-E" 4X'0V*RZP'KTR!("6YRRS[(%JG_VX1,#HZCE7HK)5T^^_-W/8(JB12
M*@J8BPJ4CPY\\A:B*\RG8$)T[!EO>:\/CE.8WQXBPTFY ZNRD<^&^&)LXC)9
M\%E08%]T ._H6K8D*8R!:]Z\>^@6 >-8E0$5?'?SZ\'2[M_*W.I')NJ#X(F#
M+3*"DM%#Y!PA6:^#T]FZN]N43M8!WMSB# ^?H370";BJO?[7/$R75UWMS+B8
M(QT+;TE6B<AWP2FP6BO/%9:2]D'1W9\_3J?/L!?443+L;Q0:'10=K'7@E"(3
MF4R@7Y%?I@S#^L3@W&[[;(89A3;.K)I#@^4CQ=OM*+1 \&:Y%BTQ2Z0S5>41
M+%@612DV".5W:G7X)4:A[:71G4:A[2/>D2^2OZ:3.ON];EU?_&OV ^?3&UN#
MG5-12\'K8F(!2AD.49&A59I+95!X;M4.E\E3W^AQ#-I>ZIL-(,N1,?%^-GV2
M%>5R$9@3",YX/28)7,U!:J>,\Z&VU^SB8SSSF?%BX?;(:"G1#B+@9_/>0:1
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M7$M]<19U1!3106&AUKU+!U&2P=;6:Z]<#*'YGO!'B7D9,>0^*+EKSMKHH8.
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M7OVG+6,W)563=C%K!3DURB-=6#<4#"39?/^FK-C[(M!)@<;ZR' OM/6WU>7
MBR_ 6Y:G33M6Q^/ZN>GK:UGRX?#,*_M"OR^6BZ:M1A6Q6YR0.E@O'?O^0&W^
MFX)8^"C0U@1I+2ET_>\GGR/96)7C>R-R NN- \W]*>,/]9]LUN53&_VRH9]A
M1\]9&*(OX&QI57%V])%*A%"-=L6GB+IW2?FT1&-5E^\-Q8[6&@>"O(S"=GSU
M\62L""HI2+%->1"JT91* 4%6EWB3D<B]FS4/1!@K7[XWR&ZQQSBHVFCM7ZOE
M:I>0O31:O7IK32&IYJ,S-4I3JP"%)U A"LF_?;*]VTM.2S168GMOS'6TU@#Y
MQHOPN]S_&%OE3Z6NUF6/4>[O_V,ELI472US_N2D*M*%8K0]PM8D^=IOR44<O
M154.9/"ZJ=I!:+%PTIJ,<"6ZU/OSR(3+F7<ZU8CEG%&P\^.Q=_V:?ROTQW-9
MU4.[[OVC].>.WJ C7==U;YZ8GZN#.J8FY'(M+$W90JP*.672C<\2-=A SF!2
M(:0?A9!KI^V'4]K^::?MEYM>I@C4-G*D7IUC-U%Y^>W>NS6V9NV),=?[J^ 5
M8HY5_+P*.Q\R^HF--4 (<IK?QT4.Y:M&J&$S9;,@8$0^%VS%*!0ZK7-OY(W+
ML34Y'"XBU;K$-B, [1U;4(PV.?X%A#*V[Z@>HLT$UA?>K=Y$KWIWN/XPI%H7
M&?8DJ=8E6AZK>7![ZSYFS$YZ">0:OYA4 E+& #Y[KYU*'LL/QIS4P5#?94JZ
M1&M#,B4E[5S1E=51A0?C5!M5YA,$7D\1/EIT\0RS#\24U-?LMVMM9D*;MW28
M];[)1#>>CV0,5CD$$I3:V 3..UU0X%TA,IPI2^HQ?NOXVV<&QIUBBT[:'PX_
MVQWE9/5>!@*=DFQG9VOMLRW:C[+*4KV,9Z5*%R-H;CJD'C8]"9$K%#Q U/D+
M!UKK!3X?5.QVK#ZVNHJNN4Q'BAUP)4B)O;"DU,:,84+?N[!P6J*1 '2-Q5>3
MJ7\ ,)WPS&\U7>5J2$4E2,&V:7A.0<C60TA!^EBE<;)WW?T<N69NS;AWYMS;
M4@.@[^?";\XOA%&OU2U3O1/15Z"L..;+*4!"3ABURR8Z1TET1]LQ.8;(I3I:
M>]59]8/!Y[')S4X<H2;7OI-J3A6JMB!"-HE2C$7WYM78?_^\<+G=FB?@<9%J
MI_]VMOU!^R/AM_+7O_P?4$L#!!0    ( &..J5;4QO_-[Q,  ,!%   <
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M81?HA3 1/'@);YFG@?CC\0A"FP"6Q;W,*H5ZY<$#OXTWS]@P+GD5,B#/)6I
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M 6&:RHT XP$9LS72.FZ+*?M<9[(1$-Q(*A#R3X]!FQO;(RCVF>D1R)[RGYA
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M(50+$4&MI.LX40IPO8&.L-!CW7@"P$)K1C-@"?NFQ::==^+) Y);7]W%5!/
M[2*]!^V' \?60=D$N\$5T .9;%YES', !B,D9WAZJ(\.SXXHM?XT$N^TA2P
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M';KAMJ4W;'_Y0C%P:) ]:.Q'WS" N63@J!36N1MJ>&+<9XZZ-[Z>K;-@=P6
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M U!+ 0(4 Q0    ( &..J5;02H2"!P<  !@A   9              "  0
M  !A,S$Q+6MR86UE<F-E<G0P,S,Q,C,N:'1M4$L! A0#%     @ 8XZI5L2,
M$OP'!P  62$  !H              ( !/@<  &$S,3(M;&EN9&AA;&-E<G0P
M,S,Q,C,N:'1M4$L! A0#%     @ 8XZI5M>(6N06!   M@T  !D
M     ( !?0X  &$S,C$M:W)A;65R8V5R=# S,S$R,RYH=&U02P$"% ,4
M" !CCJE6C(UL0@X$   I#0  &@              @ '*$@  83,R,BUL:6YD
M:&%L8V5R=# S,S$R,RYH=&U02P$"% ,4    " !CCJE6<<PT#WC4 @#8;AL
M$               @ $0%P  96)S+3(P,C,P,S,Q+FAT;5!+ 0(4 Q0    (
M &..J59WF%M3LQ$  !O(   0              "  ;;K @!E8G,M,C R,S S
M,S$N>'-D4$L! A0#%     @ 8XZI5JE@()#1'P  =CD! !0
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M2P$"% ,4    " !CCJE6'W6^;*FF  #FAP< %               @ &W# 4
M96)S+3(P,C,P,S,Q7W!R92YX;6Q02P$"% ,4    " !CCJE6U,;_S>\3  #
M10  '               @ &2LP4 97AC7V-O;7!M:6YS,BTY>#(S=C%X,C R
:+FAT;5!+!08     #  , "T#  "[QP4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
